<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2016-01-02T02:00:21Z</responseDate><request verb="ListRecords" from="2016-01-01" metadataPrefix="pmc" until="2016-01-02">http://www.ncbi.nlm.nih.gov/oai/oai.cgi</request><ListRecords><record><header><identifier>oai:pubmedcentral.nih.gov:4257895</identifier><datestamp>2016-01-01</datestamp><setSpec>nihpa</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="http://jats.nlm.nih.gov/ns/archiving/1.0/ http://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-journal-id">9815831</journal-id>
      <journal-id journal-id-type="pubmed-jr-id">22061</journal-id>
      <journal-id journal-id-type="nlm-ta">Genet Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">Genet. Med.</journal-id>
      <journal-title-group>
        <journal-title>Genetics in medicine : official journal of the American College of Medical Genetics</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1098-3600</issn>
      <issn pub-type="epub">1530-0366</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4257895</article-id>
      <article-id pub-id-type="pmcid">PMC4257895</article-id>
      <article-id pub-id-type="pmc-uid">4257895</article-id>
      <article-id pub-id-type="pmid">24901347</article-id>
      <article-id pub-id-type="doi">10.1038/gim.2014.70</article-id>
      <article-id pub-id-type="manuscript">nihpa595045</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Neurofibromatosis Type 1 and Chronic Neurological Conditions in the United States: An Administrative Claims Analysis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Madubata</surname>
            <given-names>Chinwe C.</given-names>
          </name>
          <degrees>BA</degrees>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Olsen</surname>
            <given-names>Margaret A.</given-names>
          </name>
          <degrees>PhD, MPH</degrees>
          <xref ref-type="aff" rid="A2">2</xref>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Stwalley</surname>
            <given-names>Dustin L.</given-names>
          </name>
          <degrees>MA</degrees>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gutmann</surname>
            <given-names>David H.</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref ref-type="aff" rid="A4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Johnson</surname>
            <given-names>Kimberly J.</given-names>
          </name>
          <degrees>MPH, PhD</degrees>
          <xref ref-type="aff" rid="A5">5</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>School of Medicine, Washington University, St. Louis, Missouri 63110</aff>
      <aff id="A2"><label>2</label>Department of Medicine, School of Medicine, Washington University, St. Louis, Missouri 63110</aff>
      <aff id="A3"><label>3</label>Department of Surgery, School of Medicine, Washington University, St. Louis, Missouri 63110</aff>
      <aff id="A4"><label>4</label>Department of Neurology, School of Medicine, Washington University, St. Louis, Missouri 63110</aff>
      <aff id="A5"><label>5</label>Brown School, Washington University, St. Louis, Missouri 63130</aff>
      <author-notes>
        <corresp id="FN1">Corresponding author: Kimberly J. Johnson, MPH, PhD, Brown School, 237 Goldfarb Hall, Campus Box 1196, Washington University in St. Louis, One Brookings Drive, St. Louis, MO 63130, Phone: 1-314-935-9154. Fax: 1-314-935-8511, <email>kijohnson@wustl.edu</email></corresp>
      </author-notes>
      <pub-date pub-type="nihms-submitted">
        <day>3</day>
        <month>6</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>05</day>
        <month>6</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>01</day>
        <month>1</month>
        <year>2016</year>
      </pub-date>
      <volume>17</volume>
      <issue>1</issue>
      <fpage>36</fpage>
      <lpage>42</lpage>
      <!--elocation-id from pubmed: 10.1038/gim.2014.70-->
      <abstract>
        <sec id="S1">
          <title>Purpose</title>
          <p id="P1">Neurofibromatosis Type 1 (NF1) has been linked to several neurological conditions including: epilepsy, Parkinson's disease, headache, multiple sclerosis, and sleep disturbances, predominantly through case reports and series that lack comparison groups. Our objective was to assess whether specific neurological conditions occur more frequently in individuals with NF1 vs. those without NF1.</p>
        </sec>
        <sec id="S2">
          <title>Methods</title>
          <p id="P2">We used the 2006-2010 MarketScan <italic>Commercial Claims and Encounters</italic> database to examine associations between neurological conditions and NF1. The NF1 group was identified through ≥2 ICD-9-CM NF codes (237.70, 237.71) occurring ≥30 days apart or one inpatient NF code. A non-NF1 comparison group was frequency-matched to the NF1 group on age and enrollment length at a 10:1 ratio. Unconditional logistic regression was employed to calculate adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for associations between NF and neurological conditions.</p>
        </sec>
        <sec id="S3">
          <title>Results</title>
          <p id="P3">Compared to the non-NF1 group (n=85,790), the NF1 group (n=8,579) had a significantly higher odds of health insurance claims for epilepsy (OR=7.3; 95% CI 6.4-8.3), Parkinson's disease (OR=3.1; 95% CI 1.3-7.5), headache (OR=2.9, 95% CI 2.6-3.1), multiple sclerosis (OR=1.9, 95% CI 1.2-2.9), and sleep disturbances/disorder (OR=1.4, 95% CI 1.2-3.6).</p>
        </sec>
        <sec id="S4">
          <title>Conclusion</title>
          <p id="P4">This large study provides strong evidence for positive associations between several neurological conditions and NF1.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>Neurofibromatosis Type 1</kwd>
        <kwd>multiple sclerosis</kwd>
        <kwd>Parkinson's disease</kwd>
        <kwd>epilepsy</kwd>
        <kwd>headache</kwd>
        <kwd>migraine</kwd>
        <kwd>sleep disorders</kwd>
        <kwd>diabetes</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="S5">
      <title>Introduction</title>
      <p id="P5">Neurofibromatosis Type 1 (NF1) is one of the most common autosomal dominant genetic disorders with an estimated birth prevalence of 1 in 3,000<sup><xref rid="R1" ref-type="bibr">1</xref></sup>. While individuals with NF1 are prone to the development of both benign and malignant nervous system tumors, numerous non-malignant neurological conditions including learning disabilities<sup><xref rid="R2" ref-type="bibr">2</xref></sup> and attention deficits<sup><xref rid="R2" ref-type="bibr">2</xref>-<xref rid="R5" ref-type="bibr">5</xref></sup> have been reported to occur more frequently in people with NF1. In addition, NF1 has been linked to other chronic neurological problems, including epilepsy<sup><xref rid="R6" ref-type="bibr">6</xref>-<xref rid="R9" ref-type="bibr">9</xref></sup>, sleep disorders<sup><xref rid="R10" ref-type="bibr">10</xref>-<xref rid="R12" ref-type="bibr">12</xref></sup>, multiple sclerosis<sup><xref rid="R13" ref-type="bibr">13</xref>-<xref rid="R17" ref-type="bibr">17</xref></sup>, headaches<sup><xref rid="R18" ref-type="bibr">18</xref>, <xref rid="R19" ref-type="bibr">19</xref></sup>, and Parkinson's disease<sup><xref rid="R20" ref-type="bibr">20</xref>, <xref rid="R21" ref-type="bibr">21</xref></sup>. Most of the latter NF1 associations are derived from case reports and small patient series that are limited by the lack of a non-NF1 comparison group that is needed to assess whether the complications observed in NF1 occur at significantly higher frequencies than in the general population or whether they represent random co-occurrences.</p>
      <p id="P6">To identify potential associations between NF1 and several chronic neurological conditions in a large population of individuals, we employed administrative claims data from the Truven Health Analytics MarketScan <italic>Commercial Claims and Encounters</italic> database<sup><xref rid="R22" ref-type="bibr">22</xref></sup>. This database includes de-identified health insurance claims on 88 million Americans from 2006-2010, allowing information to be assembled on the healthcare of thousands of individuals with and without NF1. Using this unique epidemiologic resource, we identified an NF1 group and a comparison group without NF1 to perform the first large-scale study to assess whether specific chronic neurological conditions in individuals with NF1 occur more frequently than in those without NF1.</p>
    </sec>
    <sec sec-type="materials|methods" id="S6">
      <title>Materials and Methods</title>
      <sec id="S7">
        <title>Data source</title>
        <p id="P7">The study dataset was assembled from the Truven Health Analytics <italic>MarketScan Commercial Claims and Encounters</italic> database that includes de-identified patient-level claims data for healthcare encounters of privately-insured individuals from 2006-2010. The MarketScan database is the largest claims database and represents “real world” healthcare encounters of the privately insured U.S. population<sup><xref rid="R22" ref-type="bibr">22</xref></sup>. Variables available through MarketScan include demographic data (sex, birth year), enrollment dates, dates of specific claims, 3-digit zip codes, patient age, and <italic>International Classification of Diseases, Ninth Revision, Clinical Modification</italic> (ICD-9-CM) diagnosis codes for healthcare claims. Race/ethnicity information is not available using MarketScan data. The database differentiates between inpatient and outpatient claims, facility and professional claims, and includes information on health care plan type to identify capitated plans (health maintenance organization (HMO)). All individuals in the commercial database are privately insured and covered by dozens of different health plans across the United States.</p>
      </sec>
      <sec id="S8">
        <title>Study population</title>
        <p id="P8">The NF1 cohort was defined using two ICD-9-CM<sup><xref rid="R23" ref-type="bibr">23</xref></sup> diagnosis codes specific for Neurofibromatosis (NF) (NF1; 237.71) or NF unspecified (237.70). Patients with claims for the ICD-9-CM code 237.72 (Neurofibromatosis Type 2; NF2) were excluded from the study. Subjects were required to have at least two outpatient claims 30 days or more apart or one inpatient claim for the NF ICD-9-CM codes (237.70 or 237.71) to be included in the NF1 cohort. A non-NF1 cohort of individuals was selected from individuals without any ICD-9-CM diagnosis codes for NF (237.70, 237.71, 237.72). The non-NF1 comparison group was frequency-matched to the NF1 group at a 10:1 ratio by one year age group on 1/1/2006 or first enrollment if born after 1/1/2006 and enrollment length in months. Specifically, the sample of NF1 patients and the pool of potential control patients were divided into five subgroups based on 12 month periods of total health insurance enrollment in the database. Within each subgroup of enrollment duration for potential controls, we randomly selected ten patients without replacement so that the age distribution within the control subgroup matched that of the corresponding NF1 subgroup. We matched on enrollment length to control for differences in the number of medical claims due imbalances in enrollment length between the NF1 and non-NF1 groups.</p>
      </sec>
      <sec id="S9">
        <title>Variables</title>
        <p id="P9">Healthcare claims related to neurological and other conditions were identified by the following ICD-9-CM codes using the clinical classification software coding schema (<ext-link ext-link-type="uri" xlink:href="http://www.hcup-us.ahrq.gov/toolssoftware/ccs/AppendixASingleDX.txt">http://www.hcup-us.ahrq.gov/toolssoftware/ccs/AppendixASingleDX.txt</ext-link>) or the 2009 ICD-9-CM manual<sup><xref rid="R23" ref-type="bibr">23</xref></sup>: epilepsy (345.0-345.91, 780.33, 780.39), migraine headache (346.0-346.93), headache (784.0), multiple sclerosis (340), Parkinson's disease (332.0), sleep disturbances/disorder (780.5×, 327.3×). Of note, we excluded febrile convulsions (780.31) from the epilepsy case definition. Acute urinary infection (UTI) (590.0-590.9, 595.0, 595.89, 595.9, 597.0, 598.0×, 599.0) and diabetes types 1 and 2 (250.01-250.09) were included as negative controls, based on expert knowledge and literature reviews suggesting that these conditions are not related to NF1. For neurological conditions and diabetes, individuals were required to have any combination of at least two outpatient or inpatient claims ≥30 days apart to be classified as having the condition. For UTIs, we required only one claim for classification as having the condition since this is an acute condition.</p>
        <p id="P10">Variables for conditions specifically linked to NF2 were used for sensitivity analyses to evaluate the robustness of the results when individuals with any evidence of healthcare claims for NF2-related conditions (who were not identified as such by 237.72 ICD-9-CM coded claims) were excluded from analyses. The following diagnosis codes were used for these analyses: benign neoplasm of brain and other parts of nervous system: 225.1 (cranial nerves, acoustic neuroma), 225.2 (cerebral meninges), 225.4 (spinal meninges); malignant neoplasm of other and unspecified parts of the nervous system: 192.1 (cerebral meninges), 192.3 (spinal meninges), 192.0 (cranial nerves); secondary malignant neoplasm of other specified sites: 198.4 (other parts of the nervous system, meninges (cerebral) (spinal)); neoplasm of uncertain behavior of endocrine glands and nervous system: 237.6 (neoplasm of uncertain behavior of endocrine glands and nervous system: meninges), 237.9 (other and unspecified parts of nervous system: cranial nerves); and disorders of the acoustic nerve: 388.5. In addition, we used the following brain tumor codes to assess whether associations between NF1 and neurological conditions (epilepsy, headache, migraine) remained when individuals with healthcare encounters related to brain tumor diagnoses were excluded (malignant neoplasm of brain: 191.0-191.9; benign neoplasm of brain and other parts of nervous system: 225.0-225.9; neoplasms of unspecified nature: 239.6 (brain)).</p>
        <p id="P11">Healthcare utilization was estimated from the number of outpatient visits using the CPT<sup><xref rid="R24" ref-type="bibr">24</xref></sup> codes 99201-99205, 99211-99215, and 99241-99245. Approximate age in years at first administrative claim for comorbidities (non-NF1 neurological conditions, diabetes, and UTIs) was determined by taking the difference between the visit year for the first claim for the comorbidity from 2006-2010 and the subject's birth year.</p>
      </sec>
      <sec id="S10">
        <title>Statistical analysis</title>
        <p id="P12">Statistical Analysis Software (SAS) (version 9.2; SAS Institute Inc., Cary, NC) was used for all study analyses. Unconditional logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) to determine associations between NF1 group membership and each medical condition, adjusting for the frequency matching variables (enrollment time in months and age), sex, and number of healthcare visits. The latter was used to control for differences in healthcare utilization between the two study groups since there would be increased opportunity for medical condition claims in the NF1 group vs. the non-NF1 group due to their increased utilization of the healthcare system. Chi-square and Fisher's exact tests were used to evaluate the statistical significance of differences in the frequency of medical condition claims by sex between the NF1 and non-NF1 groups. The Wilcoxon two sample test (T approximation) was used to test the null hypothesis of no significant difference between the two groups in the age at first healthcare claim during the study period (2006-2010) for specific medical conditions. P-values were considered significant at the p≤0.05 level.</p>
      </sec>
    </sec>
    <sec sec-type="results" id="S11">
      <title>Results</title>
      <p id="P13">A total of 8,579 people that met our selection criteria comprised the NF1 group. The non-NF1 comparison group consisted of 85,790 individuals. Subject ages ranged from 0-64 years, with a mean age of 24.4 years (SD= 19.3) for both groups (<xref rid="T1" ref-type="table">Table 1</xref>). The mean enrollment time, percentage of individuals receiving healthcare through HMO plans, and geographical distribution did not differ appreciably between the two groups. In contrast, the mean healthcare visit number during the study period for the NF1 group was more than twice as high (17.6 ± 17.1 claims) as the comparison group (8.8 ± 11.7 claims). In addition, there was a slightly higher percentage of females in the NF1 group relative to the comparison group (52.3% vs. 50.5%).</p>
      <p id="P14">In general, subjects in the NF1 group had significantly higher odds of health insurance claims for all neurological conditions evaluated (<xref rid="T2" ref-type="table">Table 2</xref>). This finding was also observed when we adjusted for HMO membership; for this reason, this variable was not included in the final model. Individuals in the NF1 group had a higher odds of health insurance claims related to epilepsy (OR=7.3; 95% CI 6.4-8.3), migraine (OR=2.6; 95% CI 2.2-2.9), headache (including migraine) (OR=2.9; 95% CI 2.6-3.1), multiple sclerosis (OR=1.9; 95% CI 1.2-2.9), Parkinson's disease (OR=3.1; 95% CI 1.3-7.5), and sleep disturbances/disorder (OR=1.4; 95% CI 1.2-2.6). While there was no association between NF1 and healthcare claims for acute UTIs (OR=1.0; 95% CI 0.96-1.1), individuals in the NF1 vs. the non-NF1 group exhibited a significantly lower odds of diabetes claims (OR=0.4, 95% CI 0.3-0.4). When individuals with claims for conditions that could indicate NF2 (but who did not have claims for this condition) were excluded, the results were not materially different (data not shown).</p>
      <p id="P15">To address the possibility that associations between NF1 and epilepsy, migraine, or headaches were mediated by brain tumors, we conducted analyses that excluded individuals with brain tumor claims. For epilepsy, the overall association was slightly weaker, but still significant (OR=6.7; 95% CI 5.8-7.8). Associations for headache (including migraine) and migraine were similar to the analyses that did not exclude these individuals (headache (including migraine): OR=2.7, 95% CI 2.4-2.9; migraine: OR=2.6, 95% CI 2.3-3.0).</p>
      <p id="P16">We also sought to determine whether there were any differences in the health insurance claims patterns for each medical condition as a function of age. As expected, there were no individuals in the younger age category in the NF1 group with claims for Parkinson's disease or multiple sclerosis. For other neurological conditions, the magnitude of the association was stronger for migraines, headache (includes migraine), and sleep disturbances/disorders in the younger vs. older age group, while the opposite was true for epilepsy.</p>
      <p id="P17">For each medical condition category, we also assessed whether there was any evidence for differences in the sex distribution and the mean age at first healthcare claim between the NF1 vs. the non-NF1 group (<xref rid="T3" ref-type="table">Table 3</xref>). Among those identified with two or more healthcare claims for epilepsy, migraine, Parkinson's disease, sleep disturbances, or diabetes, there was no significant difference in the percentage of females between the NF1 and non-NF1 groups. In contrast, there was a significantly lower percentage of females among those with claims for headache (including migraine) (64.6% vs. 73.2%), multiple sclerosis (60% and 78.7%), and UTIs (77.5% and. 84.5%) in the NF1 vs. the non-NF1 group, respectively. Individuals in the NF1 group were on average younger at their first administrative claim for headache (including migraine) (29.9 vs. 34.2 years, p&lt;0.0001), migraine (31.1 vs. 36.4 years, p&lt;0.0001), and sleep disturbances/disorders (41.2 vs. 44.5 years, P=0.0113), and older for UTIs than those in the non-NF1 group (35.2 vs. 32.4 years, p&lt;0.0001).</p>
    </sec>
    <sec sec-type="discussion" id="S12">
      <title>Discussion</title>
      <p id="P18">We observed a significantly higher odds of healthcare claims related to epilepsy, migraine, headache (including migraine), sleep disorders, multiple sclerosis, and Parkinson's disease in individuals with NF1 than in those without NF1 who were identified using administrative claims data. These findings substantiate prior evidence from case reports and clinical series that have suggested causative associations between these neurological problems and NF1.</p>
      <p id="P19">An increased prevalence of epilepsy or unprovoked seizures in individuals with NF1 has been described in previous smaller studies, where the prevalence has been estimated between 5.9% and 9.5%<sup><xref rid="R6" ref-type="bibr">6</xref>-<xref rid="R8" ref-type="bibr">8</xref></sup>. In the current study, we found that the prevalence of two or more epilepsy related claims thirty days or more apart was 5.6% in the NF1 group vs. 0.6% in the non-NF1 group with evidence suggesting that both children and adults with NF1 are at risk for developing epilepsy. The propensity for individuals with NF1 to seek medical attention for seizures may be partially due to the presence of central nervous system tumors, as we have recently reported<sup><xref rid="R8" ref-type="bibr">8</xref></sup>. However, the observation that the positive association between NF1 and epilepsy persisted after exclusion of individuals with brain tumor healthcare claims suggests that other etiologies may account for epilepsy in this at-risk population<sup><xref rid="R6" ref-type="bibr">6</xref>-<xref rid="R8" ref-type="bibr">8</xref></sup>.</p>
      <p id="P20">NF1 has been evaluated as a risk factor for headache in studies surveying NF1 patients about headaches<sup><xref rid="R18" ref-type="bibr">18</xref>, <xref rid="R19" ref-type="bibr">19</xref></sup>, with mixed results. We observed a significantly higher odds of healthcare claims related to headaches and migraines in individuals in the NF1 vs. non-NF1 group. Consistent with studies demonstrating that headaches in NF1 do not necessarily result from intracranial tumors<sup><xref rid="R18" ref-type="bibr">18</xref>, <xref rid="R19" ref-type="bibr">19</xref></sup>, the association between headaches/migraines and NF1 did not change following the exclusion of individuals with brain tumor claims. Since headaches can severely compromise quality of life, further research is warranted to examine the etiology and impact of headaches in people with NF1.</p>
      <p id="P21">Previous case reports have also revealed a potential association between NF1 and multiple sclerosis (MS)<sup><xref rid="R13" ref-type="bibr">13</xref>-<xref rid="R17" ref-type="bibr">17</xref></sup>. However, our study suggests that MS is a rare complication of NF1 (&lt;1.0% individuals with NF1), with a two-fold increased odds of MS-related health insurance claims in people with NF1. While it is not clear why MS should be over-represented in people with NF1, several lines of evidence suggest that this association has a biological basis. First, the <italic>OMG</italic> (oligodendrocyte-myelin glycoprotein) gene<sup><xref rid="R25" ref-type="bibr">25</xref></sup> lies within an intron of the <italic>NF1</italic> gene, raising the intriguing possibility that impaired <italic>OMG</italic> function could affect myelination, predisposing some individuals with NF1 to MS<sup><xref rid="R15" ref-type="bibr">15</xref></sup>. However, <italic>OMG</italic> mutations are neither necessary nor sufficient for primary progressive MS<sup><xref rid="R25" ref-type="bibr">25</xref></sup>. Second, the <italic>NF1</italic> gene is highly expressed in oligodendrocytes, the primary cell type affected in MS<sup><xref rid="R26" ref-type="bibr">26</xref></sup>. Third, <italic>Nf1</italic> gene inactivation results in increased oligodendrocyte precursor numbers in mice<sup><xref rid="R27" ref-type="bibr">27</xref></sup> and zebrafish<sup><xref rid="R28" ref-type="bibr">28</xref></sup>, and leads to deregulated nitric oxide-mediated blood-brain barrier defects in <italic>Nf1</italic> genetically-engineered mouse models<sup><xref rid="R29" ref-type="bibr">29</xref></sup>. Further investigation will be required to establish a mechanistic connection between NF1 and MS pathogenesis.</p>
      <p id="P22">To our knowledge, there are only two published case reports of Parkinson's disease (PD) in individuals with NF1<sup><xref rid="R20" ref-type="bibr">20</xref>, <xref rid="R21" ref-type="bibr">21</xref></sup>. PD results from insufficient striatal dopamine production resulting in a variety of movement abnormalities<sup><xref rid="R30" ref-type="bibr">30</xref></sup>. While we observed a three-fold increased odds of PD claims in people in the NF1 group vs. the non-NF1 group, there were only seven individuals in the NF1 group who had repeated claims for PD, suggesting that PD occurs very rarely in individuals with NF1. However, the potential association between NF1 and PD is intriguing in light of recent studies demonstrating that the <italic>Nf1</italic> protein, neurofibromin, regulates striatal dopamine levels in genetically-engineered mouse (GEM) models<sup><xref rid="R31" ref-type="bibr">31</xref></sup>. In this regard, <italic>Nf1</italic> GEM strains exhibit attention and learning deficits that are responsive to dopamine restoration<sup><xref rid="R31" ref-type="bibr">31</xref>-<xref rid="R33" ref-type="bibr">33</xref></sup>. Additional research will be required to establish a biological basis for this interesting association.</p>
      <p id="P23">An increased prevalence of abnormal sleep patterns in people with NF1 has also been reported<sup><xref rid="R10" ref-type="bibr">10</xref>-<xref rid="R12" ref-type="bibr">12</xref></sup>. In the current study, we observed a two-fold higher odds of claims for sleep disturbances/disorder in individuals with NF1. While little is known about the mechanism underlying sleep disturbances in mammals using <italic>Nf1</italic> genetically engineered models, elegant studies in <italic>Drosophila</italic> have demonstrated that the <italic>Nf1</italic> gene is critical for maintaining fruit fly circadian rhythm <sup><xref rid="R34" ref-type="bibr">34</xref></sup>.</p>
      <p id="P24">Unexpectedly, we observed a significantly lower odds of diabetes-related healthcare claims in people with NF1 vs. the non-NF1 group. This inverse relationship is intriguing, and has been noted in an anecdotal expert report<sup><xref rid="R35" ref-type="bibr">35</xref></sup>. While two prior studies have reported diabetes cases in individuals with NF1, the authors of both papers indicated that this is a rare occurrence<sup><xref rid="R36" ref-type="bibr">36</xref>, <xref rid="R37" ref-type="bibr">37</xref></sup>. It is not clear why NF1 would be associated with lower risk of diabetes; however, it is possible that this reflects de-regulated Protein Kinase B (AKT)/mammalian target of rapamycin (mTOR) activity, resulting from defective neurofibromin AKT/mTOR control<sup><xref rid="R38" ref-type="bibr">38</xref>, <xref rid="R39" ref-type="bibr">39</xref></sup>. Further studies will be required to establish a mechanistic connection between these two conditions.</p>
      <p id="P25">Strengths of this study include its large size and the use of an age- and length of enrollment-matched comparison group that allows for more accurate estimation of relative differences in the prevalence of chronic neurological conditions in individuals with vs. without NF1. In addition, we controlled for healthcare utilization to minimize the concern that associations were confounded by this factor. The lack of an association between acute urinary tract infections and NF1 and the inverse association between diabetes and NF1 reinforces the concept that the positive associations detected between neurological conditions and NF1 were not due to increased surveillance for medical conditions in this population.</p>
      <p id="P26">There are also limitations to the use of administrative claims data. Using health insurance claims as markers of medical diagnoses (NF1 and comorbidities), rather than physical examinations and laboratory tests, may result in misclassification of individuals with respect to NF1. Misclassification can result from coding errors, coding to rule-out conditions, and under- and over-coding. We attempted to minimize misclassification through the application of strict selection criteria that are used in administrative data analyses by only considering individuals to have the chronic medical conditions if they had ≥2 codes for the condition in the outpatient/inpatient setting 30 or more days apart. However, we note that this approach could miss cases of NF1. In addition, it was recently recommended as a result of a systematic review of ICD codes for the study of neurological conditions that fewer than three ICD codes can be used with sufficient accuracy for identifying cases of epilepsy and MS in administrative data; insufficient data was found for PD to make recommendations<sup><xref rid="R40" ref-type="bibr">40</xref></sup>. Further, although we excluded people with NF2 and NF2-related healthcare claims from analyses, it is possible that some individuals with NF2 were not identifiable by ICD-9-CM codes. NF2 is estimated to be ten-fold less common than NF1<sup><xref rid="R41" ref-type="bibr">41</xref></sup>, and therefore, failure to exclude all subjects with NF2 is unlikely to materially impact on our findings. Finally, the generalizability of this study is limited to privately insured working adults and dependent children with NF1. In addition, since MarketScan predominantly assembles claims data from larger U.S. employers, these results may not be generalizable to individuals who are privately insured through small to medium size employers<sup><xref rid="R22" ref-type="bibr">22</xref></sup>.</p>
      <p id="P27">In conclusion, this large administrative health insurance claims study strengthens existing evidence from uncontrolled studies that individuals with NF1 are at significantly elevated risk for a number of neurological conditions compared to the general population. In addition, our results suggest that individuals with NF1 are at lower risk for diabetes. Additional research will be required to validate these results, mechanistically study these associations, and identify the specific factors that distinguish individuals with NF1 who are at risk for these neurological complications.</p>
    </sec>
  </body>
  <back>
    <ack id="S13">
      <p><bold>Grant Support:</bold> This work was funded in part by Washington University Institute of Clinical and Translational Sciences grant UL1 TR000448 from the National Center for Advancing Translational Sciences (NIH) and by grant number R24 HS19455 (PI: V. Fraser) from the Agency for Healthcare Research and Quality (AHRQ).</p>
    </ack>
    <ref-list>
      <ref id="R1">
        <label>1</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Crowe</surname>
              <given-names>FW</given-names>
            </name>
          </person-group>
          <source>A clinical, pathological, and genetic study of multiple neurofibromatosis</source>
          <publisher-loc>Springfield, Ill.</publisher-loc>
          <publisher-name>Thomas</publisher-name>
          <year>1956</year>
        </element-citation>
      </ref>
      <ref id="R2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hyman</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Arthur Shores</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>North</surname>
              <given-names>KN</given-names>
            </name>
          </person-group>
          <article-title>Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile, and attention-deficit-hyperactivity disorder</article-title>
          <source>Dev Med Child Neurol</source>
          <year>2006</year>
          <volume>48</volume>
          <fpage>973</fpage>
          <lpage>977</lpage>
          <pub-id pub-id-type="pmid">17109785</pub-id>
        </element-citation>
      </ref>
      <ref id="R3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Walsh</surname>
              <given-names>KS</given-names>
            </name>
            <name>
              <surname>Velez</surname>
              <given-names>JI</given-names>
            </name>
            <name>
              <surname>Kardel</surname>
              <given-names>PG</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Symptomatology of autism spectrum disorder in a population with neurofibromatosis type 1</article-title>
          <source>Dev Med Child Neurol</source>
          <year>2013</year>
          <volume>55</volume>
          <fpage>131</fpage>
          <lpage>138</lpage>
          <pub-id pub-id-type="pmid">23163951</pub-id>
        </element-citation>
      </ref>
      <ref id="R4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lidzba</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Granstrom</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lindenau</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Mautner</surname>
              <given-names>VF</given-names>
            </name>
          </person-group>
          <article-title>The adverse influence of attention-deficit disorder with or without hyperactivity on cognition in neurofibromatosis type 1</article-title>
          <source>Dev Med Child Neurol</source>
          <year>2012</year>
          <volume>54</volume>
          <fpage>892</fpage>
          <lpage>897</lpage>
          <pub-id pub-id-type="pmid">22881119</pub-id>
        </element-citation>
      </ref>
      <ref id="R5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pride</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Payne</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>North</surname>
              <given-names>KN</given-names>
            </name>
          </person-group>
          <article-title>The impact of ADHD on the cognitive and academic functioning of children with NF1</article-title>
          <source>Dev Neuropsychol</source>
          <year>2012</year>
          <volume>37</volume>
          <fpage>590</fpage>
          <lpage>600</lpage>
          <pub-id pub-id-type="pmid">23066937</pub-id>
        </element-citation>
      </ref>
      <ref id="R6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vivarelli</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Grosso</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Calabrese</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Epilepsy in neurofibromatosis 1</article-title>
          <source>J Child Neurol</source>
          <year>2003</year>
          <volume>18</volume>
          <fpage>338</fpage>
          <lpage>342</lpage>
          <pub-id pub-id-type="pmid">12822818</pub-id>
        </element-citation>
      </ref>
      <ref id="R7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hsieh</surname>
              <given-names>HY</given-names>
            </name>
            <name>
              <surname>Fung</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Chin</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Epileptic seizures in neurofibromatosis type 1 are related to intracranial tumors but not to neurofibromatosis bright objects</article-title>
          <source>Seizure</source>
          <year>2011</year>
          <volume>20</volume>
          <fpage>606</fpage>
          <lpage>611</lpage>
          <pub-id pub-id-type="pmid">21621428</pub-id>
        </element-citation>
      </ref>
      <ref id="R8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ostendorf</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Gutmann</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Weisenberg</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>Epilepsy in individuals with neurofibromatosis type 1</article-title>
          <source>Epilepsia</source>
          <year>2013</year>
          <volume>54</volume>
          <fpage>1810</fpage>
          <lpage>1814</lpage>
          <pub-id pub-id-type="pmid">24032542</pub-id>
        </element-citation>
      </ref>
      <ref id="R9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barba</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Jacques</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kahane</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Epilepsy surgery in Neurofibromatosis Type 1</article-title>
          <source>Epilepsy Res</source>
          <year>2013</year>
          <volume>105</volume>
          <fpage>384</fpage>
          <lpage>395</lpage>
          <pub-id pub-id-type="pmid">23597854</pub-id>
        </element-citation>
      </ref>
      <ref id="R10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Johnson</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wiggs</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Stores</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Huson</surname>
              <given-names>SM</given-names>
            </name>
          </person-group>
          <article-title>Psychological disturbance and sleep disorders in children with neurofibromatosis type 1</article-title>
          <source>Dev Med Child Neurol</source>
          <year>2005</year>
          <volume>47</volume>
          <fpage>237</fpage>
          <lpage>242</lpage>
          <pub-id pub-id-type="pmid">15832546</pub-id>
        </element-citation>
      </ref>
      <ref id="R11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leschziner</surname>
              <given-names>GD</given-names>
            </name>
            <name>
              <surname>Golding</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Ferner</surname>
              <given-names>RE</given-names>
            </name>
          </person-group>
          <article-title>Sleep disturbance as part of the neurofibromatosis type 1 phenotype in adults</article-title>
          <source>Am J Med Genet A</source>
          <year>2013</year>
          <volume>161</volume>
          <fpage>1319</fpage>
          <lpage>1322</lpage>
          <pub-id pub-id-type="pmid">23636844</pub-id>
        </element-citation>
      </ref>
      <ref id="R12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Licis</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Vallorani</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prevalence of Sleep Disturbances in Children With Neurofibromatosis Type 1</article-title>
          <source>J Child Neurol</source>
          <year>2013</year>
        </element-citation>
      </ref>
      <ref id="R13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pipatpajong</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Phanthumchinda</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Neurofibromatosis type I associated multiple sclerosis</article-title>
          <source>J Med Assoc Thai</source>
          <year>2011</year>
          <volume>94</volume>
          <fpage>505</fpage>
          <lpage>510</lpage>
          <pub-id pub-id-type="pmid">21591539</pub-id>
        </element-citation>
      </ref>
      <ref id="R14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Spinicci</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cherchi</surname>
              <given-names>MV</given-names>
            </name>
            <name>
              <surname>Murru</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Conti</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Marrosu</surname>
              <given-names>MG</given-names>
            </name>
          </person-group>
          <article-title>A case of neurofibromatosis and multiple sclerosis</article-title>
          <source>Neurol Sci</source>
          <year>2010</year>
          <volume>31</volume>
          <fpage>631</fpage>
          <lpage>634</lpage>
          <pub-id pub-id-type="pmid">20424878</pub-id>
        </element-citation>
      </ref>
      <ref id="R15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Etemadifar</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fatehi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Sahraian</surname>
              <given-names>MA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Multiple sclerosis and neurofibromatosis type 1: report of seven patients from Iran</article-title>
          <source>Mult Scler</source>
          <year>2009</year>
          <volume>15</volume>
          <fpage>1126</fpage>
          <lpage>1130</lpage>
          <pub-id pub-id-type="pmid">19692435</pub-id>
        </element-citation>
      </ref>
      <ref id="R16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Perini</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gallo</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>The range of multiple sclerosis associated with neurofibromatosis type 1</article-title>
          <source>J Neurol Neurosurg Psychiatry</source>
          <year>2001</year>
          <volume>71</volume>
          <fpage>679</fpage>
          <lpage>681</lpage>
          <pub-id pub-id-type="pmid">11606684</pub-id>
        </element-citation>
      </ref>
      <ref id="R17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ferner</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Hughes</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>Neurofibromatosis 1 and multiple sclerosis</article-title>
          <source>J Neurol Neurosurg Psychiatry</source>
          <year>1995</year>
          <volume>58</volume>
          <fpage>582</fpage>
          <lpage>585</lpage>
          <pub-id pub-id-type="pmid">7745407</pub-id>
        </element-citation>
      </ref>
      <ref id="R18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Clementi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Battistella</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Rizzi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Boni</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tenconi</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Headache in patients with neurofibromatosis type 1</article-title>
          <source>Headache</source>
          <year>1996</year>
          <volume>36</volume>
          <fpage>10</fpage>
          <pub-id pub-id-type="pmid">8666529</pub-id>
        </element-citation>
      </ref>
      <ref id="R19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>DiMario</surname>
              <given-names>FJ</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Langshur</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Headaches in patients with neurofibromatosis-1</article-title>
          <source>J Child Neurol</source>
          <year>2000</year>
          <volume>15</volume>
          <fpage>235</fpage>
          <lpage>238</lpage>
          <pub-id pub-id-type="pmid">10805189</pub-id>
        </element-citation>
      </ref>
      <ref id="R20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>D'Ambrosio</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Vizioli</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Recklinghausen disease and Parkinson disease: an unusual association</article-title>
          <source>Acta Neurol (Napoli)</source>
          <year>1984</year>
          <volume>6</volume>
          <fpage>274</fpage>
          <lpage>279</lpage>
          <pub-id pub-id-type="pmid">6435406</pub-id>
        </element-citation>
      </ref>
      <ref id="R21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Toshima</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nagashima</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hirose</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tanabe</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tsubaki</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>A case of neurofibromatosis associated with Parkinson disease showing myokymia-like movement and hypertrophy of the lower extremities</article-title>
          <source>Rinsho Shinkeigaku</source>
          <year>1987</year>
          <volume>27</volume>
          <fpage>288</fpage>
          <lpage>291</lpage>
          <pub-id pub-id-type="pmid">3111771</pub-id>
        </element-citation>
      </ref>
      <ref id="R22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hansen</surname>
              <given-names>LG</given-names>
            </name>
            <name>
              <surname>C</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <source>White Paper Health Research Data fro the Real World: The MarketScan Databases</source>
          <year>2013</year>
        </element-citation>
      </ref>
      <ref id="R23">
        <label>23</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Buck</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <source>2009 ICD-9-CM, Standard ed</source>
          <publisher-name>Saunders Elsevier</publisher-name>
          <year>2009</year>
        </element-citation>
      </ref>
      <ref id="R24">
        <label>24</label>
        <element-citation publication-type="journal">
          <collab>American Medical Association</collab>
          <source>CPT 2010 Professional Edition (Current Procedural Terminology, Professional Ed (Spiral)) (Cpt / Current Procedural Terminology (Professional Edition)) Professional Edition ed</source>
          <year>2010</year>
        </element-citation>
      </ref>
      <ref id="R25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Johnson</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Ferner</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Bobrow</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hughes</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Detailed analysis of the oligodendrocyte myelin glycoprotein gene in four patients with neurofibromatosis 1 and primary progressive multiple sclerosis</article-title>
          <source>J Neurol Neurosurg Psychiatry</source>
          <year>2000</year>
          <volume>68</volume>
          <fpage>643</fpage>
          <lpage>646</lpage>
          <pub-id pub-id-type="pmid">10766898</pub-id>
        </element-citation>
      </ref>
      <ref id="R26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Daston</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Scrable</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nordlund</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sturbaum</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Nissen</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Ratner</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytes</article-title>
          <source>Neuron</source>
          <year>1992</year>
          <volume>8</volume>
          <fpage>415</fpage>
          <lpage>428</lpage>
          <pub-id pub-id-type="pmid">1550670</pub-id>
        </element-citation>
      </ref>
      <ref id="R27">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bennett</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Rizvi</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Karyala</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>McKinnon</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Ratner</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Aberrant growth and differentiation of oligodendrocyte progenitors in neurofibromatosis type 1 mutants</article-title>
          <source>J Neurosci</source>
          <year>2003</year>
          <volume>23</volume>
          <fpage>7207</fpage>
          <lpage>7217</lpage>
          <pub-id pub-id-type="pmid">12904481</pub-id>
        </element-citation>
      </ref>
      <ref id="R28">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Padmanabhan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Shin</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Oligodendrocyte progenitor cell numbers and migration are regulated by the zebrafish orthologs of the NF1 tumor suppressor gene</article-title>
          <source>Hum Mol Genet</source>
          <year>2010</year>
          <volume>19</volume>
          <fpage>4643</fpage>
          <lpage>4653</lpage>
          <pub-id pub-id-type="pmid">20858602</pub-id>
        </element-citation>
      </ref>
      <ref id="R29">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mayes</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Rizvi</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Titus-Mitchell</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Nf1 loss and Ras hyperactivation in oligodendrocytes induce NOS-driven defects in myelin and vasculature</article-title>
          <source>Cell Rep</source>
          <year>2013</year>
          <volume>4</volume>
          <fpage>1197</fpage>
          <lpage>1212</lpage>
          <pub-id pub-id-type="pmid">24035394</pub-id>
        </element-citation>
      </ref>
      <ref id="R30">
        <label>30</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Kumar</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Abbas</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Aster</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Robbins</surname>
              <given-names>SL</given-names>
            </name>
          </person-group>
          <source>Robbins basic pathology</source>
          <edition>9th</edition>
          <publisher-loc>Philadelphia, PA</publisher-loc>
          <publisher-name>Elsevier/Saunders</publisher-name>
          <year>2013</year>
        </element-citation>
      </ref>
      <ref id="R31">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brown</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Emnett</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>White</surname>
              <given-names>CR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice</article-title>
          <source>Hum Mol Genet</source>
          <year>2010</year>
          <volume>19</volume>
          <fpage>4515</fpage>
          <lpage>4528</lpage>
          <pub-id pub-id-type="pmid">20826448</pub-id>
        </element-citation>
      </ref>
      <ref id="R32">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brown</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Diggs-Andrews</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Wozniak</surname>
              <given-names>DF</given-names>
            </name>
            <name>
              <surname>Mach</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Gutmann</surname>
              <given-names>DH</given-names>
            </name>
          </person-group>
          <article-title>PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice</article-title>
          <source>Exp Neurol</source>
          <year>2011</year>
          <volume>232</volume>
          <fpage>333</fpage>
          <lpage>338</lpage>
          <pub-id pub-id-type="pmid">21963652</pub-id>
        </element-citation>
      </ref>
      <ref id="R33">
        <label>33</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Diggs-Andrews</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Tokuda</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Izumi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zorumski</surname>
              <given-names>CF</given-names>
            </name>
            <name>
              <surname>Wozniak</surname>
              <given-names>DF</given-names>
            </name>
            <name>
              <surname>Gutmann</surname>
              <given-names>DH</given-names>
            </name>
          </person-group>
          <article-title>Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice</article-title>
          <source>Ann Neurol</source>
          <year>2013</year>
          <volume>73</volume>
          <fpage>309</fpage>
          <lpage>315</lpage>
          <pub-id pub-id-type="pmid">23225063</pub-id>
        </element-citation>
      </ref>
      <ref id="R34">
        <label>34</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Williams</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Su</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Bernards</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Field</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sehgal</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>A circadian output in Drosophila mediated by neurofibromatosis-1 and Ras/MAPK</article-title>
          <source>Science</source>
          <year>2001</year>
          <volume>293</volume>
          <fpage>2251</fpage>
          <lpage>2256</lpage>
          <pub-id pub-id-type="pmid">11567138</pub-id>
        </element-citation>
      </ref>
      <ref id="R35">
        <label>35</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Riccardi</surname>
              <given-names>VM</given-names>
            </name>
          </person-group>
          <source>Neurofibromatosis : phenotype, natural history, and pathogenesis</source>
          <edition>2nd</edition>
          <publisher-loc>Baltimore</publisher-loc>
          <publisher-name>Johns Hopkins University Press</publisher-name>
          <year>1992</year>
        </element-citation>
      </ref>
      <ref id="R36">
        <label>36</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ozhan</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Ozguven</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Ersoy</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Neurofibromatosis Type 1 and Diabetes Mellitus: An Unusual Association</article-title>
          <source>Case Rep Endocrinol</source>
          <year>2013</year>
          <volume>2013</volume>
          <fpage>689107</fpage>
          <pub-id pub-id-type="pmid">24286013</pub-id>
        </element-citation>
      </ref>
      <ref id="R37">
        <label>37</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zaka-ur-Rab</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Chopra</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Diabetes melliitus in neurofibromatosis I: an unusual presentation</article-title>
          <source>Indian Pediatr</source>
          <year>2005</year>
          <volume>42</volume>
          <fpage>185</fpage>
          <lpage>186</lpage>
          <pub-id pub-id-type="pmid">15767722</pub-id>
        </element-citation>
      </ref>
      <ref id="R38">
        <label>38</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dasgupta</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Yi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>DY</given-names>
            </name>
            <name>
              <surname>Weber</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Gutmann</surname>
              <given-names>DH</given-names>
            </name>
          </person-group>
          <article-title>Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors</article-title>
          <source>Cancer Res</source>
          <year>2005</year>
          <volume>65</volume>
          <fpage>2755</fpage>
          <lpage>2760</lpage>
          <pub-id pub-id-type="pmid">15805275</pub-id>
        </element-citation>
      </ref>
      <ref id="R39">
        <label>39</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Laplante</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sabatini</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
          <article-title>mTOR signaling in growth control and disease</article-title>
          <source>Cell</source>
          <year>2012</year>
          <volume>149</volume>
          <fpage>274</fpage>
          <lpage>293</lpage>
          <pub-id pub-id-type="pmid">22500797</pub-id>
        </element-citation>
      </ref>
      <ref id="R40">
        <label>40</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>St Germaine-Smith</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Metcalfe</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pringsheim</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Recommendations for optimal ICD codes to study neurologic conditions: a systematic review</article-title>
          <source>Neurology</source>
          <year>2012</year>
          <volume>79</volume>
          <fpage>1049</fpage>
          <lpage>1055</lpage>
          <pub-id pub-id-type="pmid">22914826</pub-id>
        </element-citation>
      </ref>
      <ref id="R41">
        <label>41</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Uhlmann</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Plotkin</surname>
              <given-names>SR</given-names>
            </name>
          </person-group>
          <article-title>Neurofibromatoses</article-title>
          <source>Adv Exp Med Biol</source>
          <year>2012</year>
          <volume>724</volume>
          <fpage>266</fpage>
          <lpage>277</lpage>
          <pub-id pub-id-type="pmid">22411249</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <table-wrap id="T1" position="float" orientation="portrait">
      <label>Table 1</label>
      <caption>
        <p>Demographics of 2006-2010 MarketScan sample population.</p>
      </caption>
      <table frame="box" rules="all">
        <thead>
          <tr>
            <th valign="middle" align="left" rowspan="1" colspan="1">Characteristic</th>
            <th valign="top" align="center" rowspan="1" colspan="1">NF1 group (n=8579)</th>
            <th valign="top" align="center" rowspan="1" colspan="1">Non-NF1 group n=85790)</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">
              <bold>Age category years (No., %)</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1"> 0-9</td>
            <td align="center" valign="top" rowspan="1" colspan="1">2,668 (31.1)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">26,680 (31.1)</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1"> 10-19</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1,816 (21.2)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">18,160 (21.2)</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1"> 20-29</td>
            <td align="center" valign="top" rowspan="1" colspan="1">762 (8.9)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">7,620 (8.9)</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1"> 30-39</td>
            <td align="center" valign="top" rowspan="1" colspan="1">889 (10.4)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">8,890 (10.4)</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1"> 40-49</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1,105 (12.9)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">11,050 (12.9)</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1"> 50-59</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1,113 (13.0)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">11,130 (13.0)</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1"> 60-69</td>
            <td align="center" valign="top" rowspan="1" colspan="1">226 (2.6)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">2,260 (2.6)</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">
              <bold>Enrollment, months</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Mean (SD)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">35.3 (17.1)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">34.6 (17.8)</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Median</td>
            <td align="center" valign="top" rowspan="1" colspan="1">36</td>
            <td align="center" valign="top" rowspan="1" colspan="1">36</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">
              <bold>Number of visits</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Mean (SD)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">17.6 (17.2)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">8.8 (11.7)</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Median</td>
            <td align="center" valign="top" rowspan="1" colspan="1">13</td>
            <td align="center" valign="top" rowspan="1" colspan="1">5</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">
              <bold>Sex (No., %)</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Female</td>
            <td align="center" valign="top" rowspan="1" colspan="1">4,486 (52.3)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">43,365 (50.6)</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Male</td>
            <td align="center" valign="top" rowspan="1" colspan="1">4,093 (47.7)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">42,425 (49.5)</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">
              <bold>HMO membership (No., %)</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Yes</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1,507 (17.6)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">15,122 (17.6)</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">No</td>
            <td align="center" valign="top" rowspan="1" colspan="1">7,072 (82.4)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">70,668 (82.4)</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">
              <bold>Region (No., %)</bold>
              <xref rid="TFN2" ref-type="table-fn">a</xref>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">New England</td>
            <td align="center" valign="top" rowspan="1" colspan="1">468 (5.5)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">3,473 (4.1)</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Middle Atlantic</td>
            <td align="center" valign="top" rowspan="1" colspan="1">903 (10.5)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">7,840 (9.1)</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">East North Central</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1,677 (19.6)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">16,356 (19.1)</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">West North Central</td>
            <td align="center" valign="top" rowspan="1" colspan="1">593 (6.9)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">5,958 (6.9)</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">South Atlantic</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1,684 (19.6)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">17,328 (20.2)</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">East South Central</td>
            <td align="center" valign="top" rowspan="1" colspan="1">365 (4.3)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">4,622 (5.4)</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">West South Central</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1,284 (15.0)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">14,352 (16.7)</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Mountain</td>
            <td align="center" valign="top" rowspan="1" colspan="1">419 (4.9)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">4,470 (5.2)</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Pacific</td>
            <td align="center" valign="top" rowspan="1" colspan="1">838 (9.8)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">10,277 (12.0)</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Missing</td>
            <td align="center" valign="top" rowspan="1" colspan="1">342 (4.0)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1,051 (1.2)</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Other</td>
            <td align="center" valign="top" rowspan="1" colspan="1">6 (0.1)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">63 (0.1)</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="TFN1">
          <p>NF1, neurofibromatosis type 1; SD, standard deviation; HMO, Health Maintenance Organization</p>
        </fn>
        <fn id="TFN2">
          <label>a</label>
          <p>New England (Maine, New Hampshire, Vermont, Massachusetts, and Connecticut); Middle Atlantic (New York, New Jersey, and Pennsylvania); East North Central (Wisconsin, Michigan, Illinois, Indiana, and Ohio); West North Central (North Dakota, South Dakota, Minnesota, Nebraska, Iowa, Kansas, and Missouri), South Atlantic (Maryland, Delaware, District of Columbia, West Virginia, Virginia, North Carolina, South Carolina, Georgia, and Florida); East South Central (Kentucky, Tennessee, Mississippi, Alabama); West South Central (Oklahoma, Arkansas, Texas, and Louisiana); Mountain (Montana, Idaho, Wyoming, Nevada, Utah, Colorado, Arizona, and New Mexico); Pacific (Washington, Oregon, California, Alaska, and Hawaii); Other (includes military regions, Puerto Rico, and Guam)</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="T2" position="float" orientation="landscape">
      <label>Table 2</label>
      <caption>
        <p>Associations between NF1 and medical conditions overall and by age group.</p>
      </caption>
      <table frame="box" rules="all">
        <thead>
          <tr>
            <th align="left" valign="top" rowspan="1" colspan="1"/>
            <th colspan="4" align="center" valign="top" rowspan="1">All subjects</th>
            <th colspan="4" align="center" valign="top" rowspan="1">&lt;18 years<xref rid="TFN4" ref-type="table-fn">a</xref></th>
            <th colspan="4" align="center" valign="top" rowspan="1">≥18 years<xref rid="TFN4" ref-type="table-fn">a</xref></th>
          </tr>
          <tr>
            <th align="left" valign="top" rowspan="1" colspan="1">Condition<xref rid="TFN5" ref-type="table-fn">b</xref></th>
            <th align="center" valign="top" rowspan="1" colspan="1">NF1 group N (%)</th>
            <th align="center" valign="top" rowspan="1" colspan="1">Non-NF1 group N (%)</th>
            <th align="center" valign="top" rowspan="1" colspan="1">OR<xref rid="TFN5" ref-type="table-fn">b</xref></th>
            <th align="center" valign="top" rowspan="1" colspan="1">95% CI</th>
            <th align="center" valign="top" rowspan="1" colspan="1">NF1 group N (%)</th>
            <th align="center" valign="top" rowspan="1" colspan="1">Non-NF1 group N (%)</th>
            <th align="center" valign="top" rowspan="1" colspan="1">OR<xref rid="TFN6" ref-type="table-fn">c</xref></th>
            <th align="center" valign="top" rowspan="1" colspan="1">95% CI</th>
            <th align="center" valign="top" rowspan="1" colspan="1">NF1 group N (%)</th>
            <th align="center" valign="top" rowspan="1" colspan="1">Non-NF1 group No (%)</th>
            <th align="center" valign="top" rowspan="1" colspan="1">OR<xref rid="TFN6" ref-type="table-fn">c</xref></th>
            <th align="center" valign="top" rowspan="1" colspan="1">95% CI</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
              <bold>Epilepsy</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"> No</td>
            <td align="center" valign="top" rowspan="1" colspan="1">7,837 (94.4)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">84,644 (99.4)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.0</td>
            <td align="center" valign="top" rowspan="1" colspan="1">Ref.</td>
            <td align="center" valign="top" rowspan="1" colspan="1">3,943 (95.1)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">42,308 (99.4)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.0</td>
            <td align="center" valign="top" rowspan="1" colspan="1">Ref.</td>
            <td align="center" valign="top" rowspan="1" colspan="1">3,894 (93.7)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">42,336 (99.4)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.0</td>
            <td align="center" valign="top" rowspan="1" colspan="1">Ref.</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"> Yes</td>
            <td align="center" valign="top" rowspan="1" colspan="1">467 (5.6)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">536 (0.6)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">7.3</td>
            <td align="center" valign="top" rowspan="1" colspan="1">6.4-8.3</td>
            <td align="center" valign="top" rowspan="1" colspan="1">204 (4.9)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">259 (0.6)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">5.6</td>
            <td align="center" valign="top" rowspan="1" colspan="1">4.6-6.9</td>
            <td align="center" valign="top" rowspan="1" colspan="1">263 (6.3)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">277 (0.7)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">8.4</td>
            <td align="center" valign="top" rowspan="1" colspan="1">7.1-10.1</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
              <bold>Migraine</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"> No</td>
            <td align="center" valign="top" rowspan="1" colspan="1">7,843 (95.8)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">83,233 (98.8)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.0</td>
            <td align="center" valign="top" rowspan="1" colspan="1">Ref.</td>
            <td align="center" valign="top" rowspan="1" colspan="1">4,033 (97.4)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">42,284 (99.5)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.0</td>
            <td align="center" valign="top" rowspan="1" colspan="1">Ref.</td>
            <td align="center" valign="top" rowspan="1" colspan="1">3,810 (94.1)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">40,949 (98.1)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.0</td>
            <td align="center" valign="top" rowspan="1" colspan="1">Ref.</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"> Yes</td>
            <td align="center" valign="top" rowspan="1" colspan="1">345 (4.2)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1010 (1.2)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">2.6</td>
            <td align="center" valign="top" rowspan="1" colspan="1">2.2-2.9</td>
            <td align="center" valign="top" rowspan="1" colspan="1">108 (2.6)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">207 (0.5)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">3.9</td>
            <td align="center" valign="top" rowspan="1" colspan="1">3.0-5.1</td>
            <td align="center" valign="top" rowspan="1" colspan="1">237 (5.9)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">803 (1.9)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">2.1</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.8-2.5</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
              <bold>Headache (including migraine)</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"> No</td>
            <td align="center" valign="top" rowspan="1" colspan="1">6,505 (87.6)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">77,586 (96.8)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.0</td>
            <td align="center" valign="top" rowspan="1" colspan="1">Ref.</td>
            <td align="center" valign="top" rowspan="1" colspan="1">3,446 (90.9)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">39,894 (98.2)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.0</td>
            <td align="center" valign="top" rowspan="1" colspan="1">Ref.</td>
            <td align="center" valign="top" rowspan="1" colspan="1">3,059 (84.2)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">37,692 (95.3)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.0</td>
            <td align="center" valign="top" rowspan="1" colspan="1">Ref.</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"> Yes</td>
            <td align="center" valign="top" rowspan="1" colspan="1">921 (12.4)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">2,592 (3.2)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">2.9</td>
            <td align="center" valign="top" rowspan="1" colspan="1">2.6-3.1</td>
            <td align="center" valign="top" rowspan="1" colspan="1">347 (9.2)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">751(1.9)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">3.4</td>
            <td align="center" valign="top" rowspan="1" colspan="1">2.9-3.9</td>
            <td align="center" valign="top" rowspan="1" colspan="1">574 (15.8)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1,841 (4.7)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">2.5</td>
            <td align="center" valign="top" rowspan="1" colspan="1">2.3-2.8</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
              <bold>Multiple sclerosis</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"> No</td>
            <td align="center" valign="top" rowspan="1" colspan="1">8,527 (99.7)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">85,615 (99.9)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.0</td>
            <td align="center" valign="top" rowspan="1" colspan="1">Ref.</td>
            <td align="center" valign="top" rowspan="1" colspan="1">4,291 (100)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">42,916 (100)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">ND</td>
            <td align="center" valign="top" rowspan="1" colspan="1">ND</td>
            <td align="center" valign="top" rowspan="1" colspan="1">4,236 (99.4)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">42,699 (99.8)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.0</td>
            <td align="center" valign="top" rowspan="1" colspan="1">Ref.</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"> Yes</td>
            <td align="center" valign="top" rowspan="1" colspan="1">25 (0.3)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">108 (0.1)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.9</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.2-2.9</td>
            <td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">5 (0.01)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">ND</td>
            <td align="center" valign="top" rowspan="1" colspan="1">ND</td>
            <td align="center" valign="top" rowspan="1" colspan="1">25 (0.6)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">103 (0.2)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.9</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.2-3.0</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
              <bold>Parkinson's disease</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"> No</td>
            <td align="center" valign="top" rowspan="1" colspan="1">8,562 (99.9)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">85,762 (100.0)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.0</td>
            <td align="center" valign="top" rowspan="1" colspan="1">Ref.</td>
            <td align="center" valign="top" rowspan="1" colspan="1">4,292 (100)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">42,927 (100)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">ND</td>
            <td align="center" valign="top" rowspan="1" colspan="1">ND</td>
            <td align="center" valign="top" rowspan="1" colspan="1">4,270 (99.8)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">42,835 (100)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.0</td>
            <td align="center" valign="top" rowspan="1" colspan="1">Ref.</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"> Yes</td>
            <td align="center" valign="top" rowspan="1" colspan="1">7 (0.08)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">19 (0.02)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">3.1</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.3-7.5</td>
            <td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1 (0.0)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">ND</td>
            <td align="center" valign="top" rowspan="1" colspan="1">ND</td>
            <td align="center" valign="top" rowspan="1" colspan="1">7 (0.2)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">18 (0.04)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">3.3</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.4-7.9</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
              <bold>Sleep disturbances/disorder</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"> No</td>
            <td align="center" valign="top" rowspan="1" colspan="1">7,842 (96.2)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">82,029 (98.2)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.0</td>
            <td align="center" valign="top" rowspan="1" colspan="1">Ref.</td>
            <td align="center" valign="top" rowspan="1" colspan="1">4,139 (98.8)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">42,298 (99.6)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.0</td>
            <td align="center" valign="top" rowspan="1" colspan="1">Ref.</td>
            <td align="center" valign="top" rowspan="1" colspan="1">3,703 (93.4)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">39,731 (96.7)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.0</td>
            <td align="center" valign="top" rowspan="1" colspan="1">Ref.</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"> Yes</td>
            <td align="center" valign="top" rowspan="1" colspan="1">311 (3.8)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1,499 (1.8)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.4</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.2-2.6</td>
            <td align="center" valign="top" rowspan="1" colspan="1">49 (1.2)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">155 (0.4)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.8</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.2-2.5</td>
            <td align="center" valign="top" rowspan="1" colspan="1">262 (6.6)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1,344 (3.3)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.4</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.2-1.6</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
              <bold>Acute urinary infection</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"> No</td>
            <td align="center" valign="top" rowspan="1" colspan="1">7,408 (86.4)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">77,735 (90.6)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.0</td>
            <td align="center" valign="top" rowspan="1" colspan="1">Ref.</td>
            <td align="center" valign="top" rowspan="1" colspan="1">3,964 (92.3)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">40,136 (93.5)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.0</td>
            <td align="center" valign="top" rowspan="1" colspan="1">Ref.</td>
            <td align="center" valign="top" rowspan="1" colspan="1">3,444 (80.4)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">37,599 (87.7)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.0</td>
            <td align="center" valign="top" rowspan="1" colspan="1">Ref.</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"> Yes</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1,171 (13.7)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">8,055 (9.4)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.0</td>
            <td align="center" valign="top" rowspan="1" colspan="1">0.96-1.1</td>
            <td align="center" valign="top" rowspan="1" colspan="1">329 (7.7)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">2794 (6.5)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">0.7</td>
            <td align="center" valign="top" rowspan="1" colspan="1">0.6-0.8</td>
            <td align="center" valign="top" rowspan="1" colspan="1">842 (19.7)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">5,261 (12.3)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.2</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.1-1.3</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
              <bold>Diabetes</bold>
              <xref rid="TFN7" ref-type="table-fn">d</xref>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"> No</td>
            <td align="center" valign="top" rowspan="1" colspan="1">8,220 (97.6)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">81,473 (96.3)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.0</td>
            <td align="center" valign="top" rowspan="1" colspan="1">Ref.</td>
            <td align="center" valign="top" rowspan="1" colspan="1">4268 (99.8)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">42714 (99.7)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.0</td>
            <td align="center" valign="top" rowspan="1" colspan="1">Ref.</td>
            <td align="center" valign="top" rowspan="1" colspan="1">3,952 (95.3)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">38,759 (92.7)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.0</td>
            <td align="center" valign="top" rowspan="1" colspan="1">Ref.</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"> Yes</td>
            <td align="center" valign="top" rowspan="1" colspan="1">201 (2.4)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">3,167 (3.7)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">0.4</td>
            <td align="center" valign="top" rowspan="1" colspan="1">0.3-0.4</td>
            <td align="center" valign="top" rowspan="1" colspan="1">7 (0.2)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">126 (0.3)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">0.3</td>
            <td align="center" valign="top" rowspan="1" colspan="1">0.1-0.6</td>
            <td align="center" valign="top" rowspan="1" colspan="1">194 (4.7)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">3,041 (7.3)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">0.4</td>
            <td align="center" valign="top" rowspan="1" colspan="1">0.3-0.4</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="TFN3">
          <p>OR, odds ratio; CI, confidence interval; NF1, Neurofibromatosis Type 1; ND, Not Determined</p>
        </fn>
        <fn id="TFN4">
          <label>a</label>
          <p>Age on 1/1/2006 or at enrollment if birth occurred after 1/1/2006</p>
        </fn>
        <fn id="TFN5">
          <label>b</label>
          <p>Individuals with only one ICD-9-CM code for the medical condition during the study period were excluded from the analysis</p>
        </fn>
        <fn id="TFN6">
          <label>c</label>
          <p>Adjusted for age, enrollment time, number of healthcare visits, and sex</p>
        </fn>
        <fn id="TFN7">
          <label>d</label>
          <p>Includes Diabetes types I and II</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="T3" position="float" orientation="landscape">
      <label>Table 3</label>
      <caption>
        <p>Differences in sex and mean age at for first healthcare claim between the NF1 and non-NF1 groups by medical condition.</p>
      </caption>
      <table frame="box" rules="all">
        <thead>
          <tr>
            <th valign="top" align="center" rowspan="1" colspan="1"/>
            <th colspan="3" valign="top" align="center" rowspan="1">Females with medical condition</th>
            <th colspan="3" valign="top" align="center" rowspan="1">Age at first healthcare claim for condition<xref rid="TFN9" ref-type="table-fn">a</xref></th>
          </tr>
          <tr>
            <th valign="top" align="left" rowspan="1" colspan="1">Medical condition (Number of cases in NF1/non-NF1 group, respectively)</th>
            <th valign="top" align="center" rowspan="1" colspan="1">NF1 group (% female)<xref rid="TFN10" ref-type="table-fn">b</xref></th>
            <th valign="top" align="center" rowspan="1" colspan="1">Non-NF1 group (% female)<xref rid="TFN10" ref-type="table-fn">b</xref></th>
            <th valign="top" align="center" rowspan="1" colspan="1">P-value<xref rid="TFN11" ref-type="table-fn">c</xref></th>
            <th valign="top" align="center" rowspan="1" colspan="1">NF1 group mean (SD)</th>
            <th valign="top" align="center" rowspan="1" colspan="1">Non-NF1 group mean (SD)</th>
            <th valign="top" align="center" rowspan="1" colspan="1">P-value<xref rid="TFN13" ref-type="table-fn">e</xref></th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
              <bold>Epilepsy (467, 536)</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">48.8</td>
            <td align="center" valign="top" rowspan="1" colspan="1">50.8</td>
            <td align="center" valign="top" rowspan="1" colspan="1">0.5433</td>
            <td align="center" valign="top" rowspan="1" colspan="1">27.1 (18.5)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">27.6 (19.7)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">0.9806</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
              <bold>Headache (including migraine) (921, 2592)</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">64.6</td>
            <td align="center" valign="top" rowspan="1" colspan="1">73.2</td>
            <td align="center" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
            <td align="center" valign="top" rowspan="1" colspan="1">29.9 (17.3)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">34.2 (16.7)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
              <bold>Migraine (345, 1010)</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">71.2</td>
            <td align="center" valign="top" rowspan="1" colspan="1">74.5</td>
            <td align="center" valign="top" rowspan="1" colspan="1">0.1324</td>
            <td align="center" valign="top" rowspan="1" colspan="1">31.0 (15.5)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">36.4 (15.4)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
              <bold>Multiple sclerosis (25, 108)</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">60.0</td>
            <td align="center" valign="top" rowspan="1" colspan="1">78.7</td>
            <td align="center" valign="top" rowspan="1" colspan="1">0.0510</td>
            <td align="center" valign="top" rowspan="1" colspan="1">45.2 (10.4)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">44.9 (12.4)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">0.9039</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
              <bold>Parkinson's disease (7, 19)</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">42.9</td>
            <td align="center" valign="top" rowspan="1" colspan="1">47.4</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.0<xref rid="TFN12" ref-type="table-fn">d</xref></td>
            <td align="center" valign="top" rowspan="1" colspan="1">56.0 (5.2)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">53.9 (12.5)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">0.9771</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
              <bold>Sleep disturbances/disorder (311, 1499)</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">47.3</td>
            <td align="center" valign="top" rowspan="1" colspan="1">46.4</td>
            <td align="center" valign="top" rowspan="1" colspan="1">0.7715</td>
            <td align="center" valign="top" rowspan="1" colspan="1">41.2 (17.4)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">44.4 (15.4)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">0.0416</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
              <bold>UTI (1171, 8055)</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">77.5</td>
            <td align="center" valign="top" rowspan="1" colspan="1">84.5</td>
            <td align="center" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
            <td align="center" valign="top" rowspan="1" colspan="1">35.2 (19.4)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">32.4 (19.4)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
              <bold>Diabetes (201, 3167)</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">50.3</td>
            <td align="center" valign="top" rowspan="1" colspan="1">48.9</td>
            <td align="center" valign="top" rowspan="1" colspan="1">0.7194</td>
            <td align="center" valign="top" rowspan="1" colspan="1">50.4 (12.0)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">50.2 (11.8)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">0.6566</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="TFN8">
          <p>N, number; NF1, neurofibromatosis type 1; SD, standard deviation</p>
        </fn>
        <fn id="TFN9">
          <label>a</label>
          <p>Age was estimated as the difference between the year of the healthcare claim for the condition during 2006-2010 and the patient's birth year</p>
        </fn>
        <fn id="TFN10">
          <label>b</label>
          <p>Percent female in NF1/non-NF1 group in those with medical condition listed in column 1.</p>
        </fn>
        <fn id="TFN11">
          <label>c</label>
          <p>Chi-square test p-value</p>
        </fn>
        <fn id="TFN12">
          <label>d</label>
          <p>Fisher's exact test two-sided p-value</p>
        </fn>
        <fn id="TFN13">
          <label>e</label>
          <p>Based on Wilcoxon Two-sample Test (T-approximation)</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:4272688</identifier><datestamp>2016-01-01</datestamp><setSpec>sportshealth</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="http://jats.nlm.nih.gov/ns/archiving/1.0/ http://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Sports Health</journal-id>
      <journal-id journal-id-type="iso-abbrev">Sports Health</journal-id>
      <journal-id journal-id-type="publisher-id">SPH</journal-id>
      <journal-id journal-id-type="hwp">spsph</journal-id>
      <journal-title-group>
        <journal-title>Sports Health</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1941-7381</issn>
      <issn pub-type="epub">1941-0921</issn>
      <publisher>
        <publisher-name>SAGE Publications</publisher-name>
        <publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4272688</article-id>
      <article-id pub-id-type="pmcid">PMC4272688</article-id>
      <article-id pub-id-type="pmc-uid">4272688</article-id>
      <article-id pub-id-type="pmid">25553209</article-id>
      <article-id pub-id-type="doi">10.1177/1941738113501984</article-id>
      <article-id pub-id-type="publisher-id">10.1177_1941738113501984</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Focus Topic: Controversies in Sports Medicine</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>The Curveball as a Risk Factor for Injury</article-title>
        <subtitle>A Systematic Review</subtitle>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Grantham</surname>
            <given-names>W. Jeffrey</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="aff1-1941738113501984">†</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Iyengar</surname>
            <given-names>Jaicharan J.</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="aff1-1941738113501984">†</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Byram</surname>
            <given-names>Ian R.</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="aff2-1941738113501984">‡</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ahmad</surname>
            <given-names>Christopher S.</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="corresp" rid="corresp1-1941738113501984">*</xref>
          <xref ref-type="aff" rid="aff1-1941738113501984">†</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1-1941738113501984"><label>†</label>Department of Orthopaedic Surgery, Columbia University Medical Center, New York, New York</aff>
      <aff id="aff2-1941738113501984"><label>‡</label>Vanderbilt Bone and Joint Clinic, Franklin, Tennessee</aff>
      <author-notes>
        <corresp id="corresp1-1941738113501984"><label>*</label>Christopher S. Ahmad, MD, Department of Orthopaedic Surgery, Columbia University Medical Center, 622 West 168th Street, PH 11th Floor, New York, NY 10032 (e-mail: <email>csa4@columbia.edu</email>)</corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>1</day>
        <month>1</month>
        <year>2016</year>
      </pub-date>
      <!-- PMC Release delay is 12 months and 0 days and was based on the <pub-date pub-type="ppub"/>. -->
      <volume>7</volume>
      <issue>1</issue>
      <fpage>19</fpage>
      <lpage>26</lpage>
      <permissions>
        <copyright-statement>© 2013 The Author(s)</copyright-statement>
        <copyright-year>2013</copyright-year>
        <copyright-holder content-type="sage">American Orthopaedic Society for Sports Medicine</copyright-holder>
      </permissions>
      <abstract>
        <sec id="section1-1941738113501984">
          <title>Context:</title>
          <p>The curveball is regarded by many as a potential risk factor for injury in youth baseball pitchers.</p>
        </sec>
        <sec id="section2-1941738113501984">
          <title>Objective:</title>
          <p>To critically evaluate the scientific evidence regarding the curveball and its impact on pitching biomechanics and the overall risk of arm injuries in baseball pitchers.</p>
        </sec>
        <sec id="section3-1941738113501984">
          <title>Study Type:</title>
          <p>Systematic review.</p>
        </sec>
        <sec id="section4-1941738113501984">
          <title>Level of Evidence:</title>
          <p>Level 3.</p>
        </sec>
        <sec id="section5-1941738113501984">
          <title>Data Sources:</title>
          <p>Ovid MEDLINE from 1946 to 2012.</p>
        </sec>
        <sec id="section6-1941738113501984">
          <title>Study Selection:</title>
          <p>Ten biomechanical studies on kinematic or electromyographic analysis of pitching a curveball were included, as well as 5 epidemiologic studies that assessed pain or injury incidence in pitchers throwing the curveball.</p>
        </sec>
        <sec id="section7-1941738113501984">
          <title>Data Extraction:</title>
          <p>When possible, demographic, methodology, kinetics, and kinematics variables and pain/injury incidence were compiled.</p>
        </sec>
        <sec id="section8-1941738113501984">
          <title>Results:</title>
          <p>Two biomechanical studies found greater horizontal adduction of the shoulder at ball release and less shoulder internal torque during the curveball pitching motion. Two studies demonstrated less proximal force and less torque at the elbow as the arm accelerated when throwing a curveball compared with a fastball, as well as greater supination of the forearm and less wrist extension. Electromyographic data suggested increased activity of extensor and supinator muscles for curveballs. No studies found increased force or torque about the elbow or shoulder. Three epidemiologic studies showed no significant association between pitching a curveball and upper extremity pain or injury. One retrospective epidemiologic study reported a 52% increase in shoulder pain in pitchers throwing a curveball, although this may have been due to confounders.</p>
        </sec>
        <sec id="section9-1941738113501984">
          <title>Conclusion:</title>
          <p>Despite much debate in the baseball community about the curveball’s safety in youth pitchers, limited biomechanical and most epidemiologic data do not indicate an increased risk of injury when compared with the fastball.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>curveball</kwd>
        <kwd>throwing injuries</kwd>
        <kwd>baseball</kwd>
        <kwd>pitching</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>January/February 2015</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <p>The growing popularity of competitive baseball among adolescents has been accompanied by a rise in the incidence of unique throwing-related injuries.<sup><xref rid="bibr8-1941738113501984" ref-type="bibr">8</xref></sup> Notably, there has been an increase in the number of medial ulnar collateral ligament reconstruction (“Tommy John”) procedures being performed on injured throwers.<sup><xref rid="bibr5-1941738113501984" ref-type="bibr">5</xref>,<xref rid="bibr9-1941738113501984" ref-type="bibr">9</xref>,<xref rid="bibr17-1941738113501984" ref-type="bibr">17</xref></sup> Many factors have been cited as proximate causes for the increasing prevalence of throwing-related injuries, including overuse, high pitch counts, poor throwing mechanics, and the curveball. Many upper extremity injuries occurring in baseball may be preventable with improvements in pitching mechanics and pitch selection.<sup><xref rid="bibr2-1941738113501984" ref-type="bibr">2</xref>,<xref rid="bibr4-1941738113501984" ref-type="bibr">4</xref>,<xref rid="bibr13-1941738113501984" ref-type="bibr">13</xref></sup> While recommendations regarding global overuse are supported by the available evidence, data regarding curveballs at a young age—a commonly accepted risk factor for injury—are unclear. A critical review to evaluate whether curveballs put pitchers at increased risk has not been performed. We hypothesized that the current evidence does not support increased injury risk from the curveball, despite widespread acceptance of this idea among baseball trainers, coaches, and physicians.</p>
    <sec sec-type="methods" id="section10-1941738113501984">
      <title>Methods</title>
      <sec id="section11-1941738113501984">
        <title>Literature Search</title>
        <p>A systematic review of the published English language literature assessing the impact of pitching a curveball in baseball was performed using the Ovid MEDLINE database from 1946 to March 1, 2012. The search included the terms <italic>curveball</italic> and <italic>baseball pitching injuries</italic>. All studies with a cohort of athletes (youth through professional levels) who were followed to determine the risk of pitching a curveball were included. Studies were divided into 2 categories: biomechanical and epidemiologic. Biomechanical studies analyzed the muscle activation, kinematics, and/or kinetics of pitching a curveball in comparison to a fastball, while epidemiologic studies attempted to correlate curveball use to pain/injury. The references of all included studies were reviewed to incorporate all relevant articles. Review articles and case reports were not included.</p>
      </sec>
      <sec id="section12-1941738113501984">
        <title>Data Abstraction</title>
        <p>Two reviewers independently extracted relevant data from the studies. Comparisons were organized by impact on the torso, shoulder, elbow, forearm, and wrist.</p>
        <p>The data by Glousman et al<sup><xref rid="bibr10-1941738113501984" ref-type="bibr">10</xref></sup> on muscle activity in healthy versus medial collateral ligament–insufficient pitchers were aggregated to compare results in healthy (n = 30) and injured pitchers (n = 10) separately. Only provided with sample size, mean, and standard deviations from the study, a paired <italic>t</italic> test assuming a small correlation value (<italic>r</italic> = 0.1) was used to determine statistical significance (<italic>P</italic> &lt; 0.05).</p>
      </sec>
    </sec>
    <sec sec-type="results" id="section13-1941738113501984">
      <title>Results</title>
      <sec id="section14-1941738113501984">
        <title>Literature Search</title>
        <p>A total of 10 biomechanical and 6 epidemiologic studies met the inclusion criteria. Of these, that by Lyman et al<sup><xref rid="bibr14-1941738113501984" ref-type="bibr">14</xref></sup> was excluded because the data collection period coincided with a larger study<sup><xref rid="bibr15-1941738113501984" ref-type="bibr">15</xref></sup> at the same institution.</p>
        <p>Five epidemiologic studies published between 2001 and 2011 were identified for inclusion: 1 case-control, 1 retrospective cohort, and 3 prospective cohort studies (<xref ref-type="table" rid="table1-1941738113501984">Table 1</xref>). Three studies included athletes aged 8 to 14 years, and the other 2 used high school and college athletes aged 14 to 20 years. Ten biomechanical laboratory studies comparing the stresses and kinematics of the curveball to the fastball were included (<xref ref-type="table" rid="table2-1941738113501984">Table 2</xref>). Three studies included electromyographic data; 7, kinematic measures; and 4, throwing kinetics. Youth athletes were included in 1 study, high school–aged pitchers in another, and college and/or professional athletes in the remaining 8. The dates of publication range from 1979<sup><xref rid="bibr11-1941738113501984" ref-type="bibr">11</xref></sup> to 2009.<sup><xref rid="bibr16-1941738113501984" ref-type="bibr">16</xref></sup></p>
        <table-wrap id="table1-1941738113501984" position="float">
          <label>Table 1.</label>
          <caption>
            <p>Epidemiologic studies</p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="left" rowspan="1" colspan="1">Study</th>
                <th align="center" rowspan="1" colspan="1">Data Collection Period</th>
                <th align="center" rowspan="1" colspan="1">Participants, n<sup><xref ref-type="table-fn" rid="table-fn1-1941738113501984"><italic>a</italic></xref></sup></th>
                <th align="center" rowspan="1" colspan="1">Mean Age, y (Range)</th>
                <th align="center" rowspan="1" colspan="1">Level of Competition</th>
                <th align="center" rowspan="1" colspan="1">Method</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">Lyman et al<sup><xref rid="bibr15-1941738113501984" ref-type="bibr">15</xref></sup></td>
                <td rowspan="1" colspan="1">1997-1998</td>
                <td rowspan="1" colspan="1">298 (99, 33.2%)</td>
                <td rowspan="1" colspan="1">10.8 (8.1-12.4)</td>
                <td rowspan="1" colspan="1">Youth</td>
                <td rowspan="1" colspan="1">Baseline and postgame telephone interviews of pitchers</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Lyman et al<sup><xref rid="bibr13-1941738113501984" ref-type="bibr">13</xref></sup></td>
                <td rowspan="1" colspan="1">1999</td>
                <td rowspan="1" colspan="1">476 (252, 52.9%)</td>
                <td rowspan="1" colspan="1">12 (9-14)</td>
                <td rowspan="1" colspan="1">Youth</td>
                <td rowspan="1" colspan="1">Baseline and postgame telephone interviews of pitchers</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Petty et al<sup><xref rid="bibr18-1941738113501984" ref-type="bibr">18</xref></sup></td>
                <td rowspan="1" colspan="1">1995-2000</td>
                <td rowspan="1" colspan="1">24</td>
                <td rowspan="1" colspan="1">17.4 (15.9-19)</td>
                <td rowspan="1" colspan="1">High school</td>
                <td rowspan="1" colspan="1">Telephone survey of pitchers following ulnar collateral ligament reconstructive surgery</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Olsen et al<sup><xref rid="bibr17-1941738113501984" ref-type="bibr">17</xref></sup></td>
                <td rowspan="1" colspan="1">2003-2004</td>
                <td rowspan="1" colspan="1">140<sup><xref ref-type="table-fn" rid="table-fn2-1941738113501984"><italic>b</italic></xref></sup></td>
                <td rowspan="1" colspan="1">18.5 ± 1.6 (14-20)</td>
                <td rowspan="1" colspan="1">High school and college</td>
                <td rowspan="1" colspan="1">Survey given to pitchers with a serious pitching-related injury and healthy pitchers</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Fleisig et al<sup><xref rid="bibr8-1941738113501984" ref-type="bibr">8</xref></sup></td>
                <td rowspan="1" colspan="1">1999-2008</td>
                <td rowspan="1" colspan="1">481 (290, 60.3%)</td>
                <td rowspan="1" colspan="1">12.0 ± 1.7 (9-14)<sup><xref ref-type="table-fn" rid="table-fn3-1941738113501984"><italic>c</italic></xref></sup></td>
                <td rowspan="1" colspan="1">Youth</td>
                <td rowspan="1" colspan="1">Annual survey of pitchers</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="table-fn1-1941738113501984">
              <label>a</label>
              <p>Parentheses indicate the number and percentage that pitched a curveball.</p>
            </fn>
            <fn id="table-fn2-1941738113501984">
              <label>b</label>
              <p>Injured, n = 95; healthy, n = 45.</p>
            </fn>
            <fn id="table-fn3-1941738113501984">
              <label>c</label>
              <p>At beginning of study in 1999.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <table-wrap id="table2-1941738113501984" position="float">
          <label>Table 2.</label>
          <caption>
            <p>Biomechanical studies<sup><xref ref-type="table-fn" rid="table-fn4-1941738113501984"><italic>a</italic></xref></sup></p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="left" rowspan="1" colspan="1">Study</th>
                <th align="center" rowspan="1" colspan="1">Participants, n</th>
                <th align="center" rowspan="1" colspan="1">Mean Age, y</th>
                <th align="center" rowspan="1" colspan="1">Level of Competition</th>
                <th align="center" rowspan="1" colspan="1">Method</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">Hang et al<sup><xref rid="bibr11-1941738113501984" ref-type="bibr">11</xref></sup></td>
                <td rowspan="1" colspan="1">10</td>
                <td rowspan="1" colspan="1">Not reported</td>
                <td rowspan="1" colspan="1">College and professional</td>
                <td rowspan="1" colspan="1">Accelerometers, EMG telemetry, stroboscopic photography</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Elliott et al<sup><xref rid="bibr6-1941738113501984" ref-type="bibr">6</xref></sup></td>
                <td rowspan="1" colspan="1">6</td>
                <td rowspan="1" colspan="1">25</td>
                <td rowspan="1" colspan="1">International</td>
                <td rowspan="1" colspan="1">2 cameras at 200 Hz and 1 camera at 300 Hz, painted landmarks</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Sisto et al<sup><xref rid="bibr20-1941738113501984" ref-type="bibr">20</xref></sup></td>
                <td rowspan="1" colspan="1">8</td>
                <td rowspan="1" colspan="1">19-22</td>
                <td rowspan="1" colspan="1">College</td>
                <td rowspan="1" colspan="1">EMG telemetry, cameras at 450 Hz</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Sakurai et al<sup><xref rid="bibr19-1941738113501984" ref-type="bibr">19</xref></sup></td>
                <td rowspan="1" colspan="1">6</td>
                <td rowspan="1" colspan="1">21 ± 1</td>
                <td rowspan="1" colspan="1">College</td>
                <td rowspan="1" colspan="1">2 cameras at 200 Hz, reflective markers, reference sticks</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Barrentine et al<sup><xref rid="bibr3-1941738113501984" ref-type="bibr">3</xref></sup></td>
                <td rowspan="1" colspan="1">8</td>
                <td rowspan="1" colspan="1">20 ± 0.6</td>
                <td rowspan="1" colspan="1">College</td>
                <td rowspan="1" colspan="1">4 cameras at 200Hz, markers, reference stick</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Escamilla et al<sup><xref rid="bibr7-1941738113501984" ref-type="bibr">7</xref></sup></td>
                <td rowspan="1" colspan="1">16</td>
                <td rowspan="1" colspan="1">19.9 ± 1.8</td>
                <td rowspan="1" colspan="1">College</td>
                <td rowspan="1" colspan="1">4 cameras at 200 Hz and 1 camera at 500 Hz, reflective markers, wrist band</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Glousman et al<sup><xref rid="bibr10-1941738113501984" ref-type="bibr">10</xref></sup></td>
                <td rowspan="1" colspan="1">40<sup><xref ref-type="table-fn" rid="table-fn4-1941738113501984"><italic>a</italic></xref></sup></td>
                <td rowspan="1" colspan="1">22</td>
                <td rowspan="1" colspan="1">College and professional</td>
                <td rowspan="1" colspan="1">EMG telemetry, cameras at 400 Hz</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Fleisig et al<sup><xref rid="bibr9-1941738113501984" ref-type="bibr">9</xref></sup></td>
                <td rowspan="1" colspan="1">20</td>
                <td rowspan="1" colspan="1">20 ± 1</td>
                <td rowspan="1" colspan="1">College</td>
                <td rowspan="1" colspan="1">6 cameras at 240 Hz, reflective markers</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Dun et al<sup><xref rid="bibr5-1941738113501984" ref-type="bibr">5</xref></sup></td>
                <td rowspan="1" colspan="1">29</td>
                <td rowspan="1" colspan="1">12.5 ± 1.7</td>
                <td rowspan="1" colspan="1">Youth</td>
                <td rowspan="1" colspan="1">8 cameras at 240 Hz, reflective markers</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Nissen et al<sup><xref rid="bibr16-1941738113501984" ref-type="bibr">16</xref></sup></td>
                <td rowspan="1" colspan="1">33</td>
                <td rowspan="1" colspan="1">16.6 ± 1.5</td>
                <td rowspan="1" colspan="1">High school</td>
                <td rowspan="1" colspan="1">12 cameras at 250 Hz, reflective markers</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="table-fn4-1941738113501984">
              <label>a</label>
              <p>Medial collateral ligament injury, n = 10; healthy, n = 30.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>All comparisons between curveball and fastball pitches were significant (<italic>P</italic> &lt; 0.05) unless otherwise stated.</p>
      </sec>
      <sec id="section15-1941738113501984">
        <title>Epidemiologic Studies</title>
        <p>A 2001 study utilizing postgame telephone interviews with 298 youth pitchers revealed no significant association between pitching a curveball and shoulder or elbow pain (<xref ref-type="table" rid="table3-1941738113501984">Table 3</xref>).<sup><xref rid="bibr15-1941738113501984" ref-type="bibr">15</xref></sup> With a similar study design in 2002, there was a 52% increase in shoulder pain in 476 pitchers when pitching a curveball.<sup><xref rid="bibr13-1941738113501984" ref-type="bibr">13</xref></sup> In a retrospective cohort of pitchers who underwent elbow ulnar collateral ligament reconstruction, 67% reported throwing a curveball before the age of 14 years.<sup><xref rid="bibr18-1941738113501984" ref-type="bibr">18</xref></sup> In a comparison of adolescent pitchers who had elbow or shoulder surgery and healthy pitchers without an arm injury, there was no significant association between the age that a pitcher began throwing a breaking ball and arm injury.<sup><xref rid="bibr17-1941738113501984" ref-type="bibr">17</xref></sup> Additionally, there was no association of arm injury with the number of years throwing a breaking ball before shaving (a measure of developmental maturity). A 10-year prospective study that utilized annual surveys of arm pain or injury found no relationship between throwing a curveball before 13 years of age and arm injury in the 481 youth pitchers.<sup><xref rid="bibr8-1941738113501984" ref-type="bibr">8</xref></sup></p>
        <table-wrap id="table3-1941738113501984" position="float">
          <label>Table 3.</label>
          <caption>
            <p>Epidemiologic data</p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="left" rowspan="1" colspan="1">Study</th>
                <th align="center" rowspan="1" colspan="1">Curveball Risk</th>
                <th align="center" rowspan="1" colspan="1">Other Factors Increasing Risk of Pain/Injury</th>
                <th align="center" rowspan="1" colspan="1">Other Factors Decreasing Risk of Pain/Injury</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">Lyman et al<sup><xref rid="bibr15-1941738113501984" ref-type="bibr">15</xref></sup></td>
                <td rowspan="1" colspan="1">No significant association between pitching a curveball and shoulder/elbow pain</td>
                <td rowspan="1" colspan="1">Increased odds of elbow and shoulder pain when pitching with arm fatigue and lower self-satisfaction with performance; increased odds of elbow pain in older, heavier, and shorter pitchers, pitchers playing baseball outside of the league, weight lifting, and pitching a split-finger pitch; increased odds of shoulder pain with the greater number of pitches per game</td>
                <td rowspan="1" colspan="1">Decreased odds of elbow and shoulder pain when pitching 300 to 599 cumulative pitches in the season; decreased odds of elbow pain when pitching a changeup; decreased odds of shoulder pain with a greater number of pitches during the season and each additional game pitched in the season</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Lyman et al<sup><xref rid="bibr13-1941738113501984" ref-type="bibr">13</xref></sup></td>
                <td rowspan="1" colspan="1">52% increased risk of shoulder pain</td>
                <td rowspan="1" colspan="1">Increased odds of elbow and shoulder pain with a greater number of cumulative pitches in a season; increased odds of elbow pain when pitching a slider; increased odds of shoulder pain with a greater number of pitches per game</td>
                <td rowspan="1" colspan="1">Decreased odds of elbow and shoulder pain when pitching a changeup</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Petty et al<sup><xref rid="bibr18-1941738113501984" ref-type="bibr">18</xref></sup></td>
                <td rowspan="1" colspan="1">67% of ulnar collateral ligament reconstruction patients reported throwing curveballs before age 14 years</td>
                <td rowspan="1" colspan="1">Overuse, high velocity</td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Olsen et al<sup><xref rid="bibr17-1941738113501984" ref-type="bibr">17</xref></sup></td>
                <td rowspan="1" colspan="1">No significant association between the age at which pitchers began throwing a breaking ball and arm injury; no significant association between the number of years throwing a breaking ball before shaving and arm injury</td>
                <td rowspan="1" colspan="1">Increased risk of injury in starting pitchers, taller and heavier pitchers, and those with a higher self-rating of pitching skill; increased risk of injury with pitching more months per year, games per year, innings per game, pitches per game, pitches per year, and warm-up pitches before a game; increased risk of injury with pitching with arm pain, fatigue, and higher velocity; increased risk of injury with more aerobic activity, use of nonsteroidal anti-inflammatory drugs, and use of ice</td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Fleisig et al<sup><xref rid="bibr8-1941738113501984" ref-type="bibr">8</xref></sup></td>
                <td rowspan="1" colspan="1">No significant association between throwing a curveball before 13 years of age and injury</td>
                <td rowspan="1" colspan="1">Increased risk of injury when pitching more than 100 innings per season</td>
                <td rowspan="1" colspan="1"/>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>While 3 of the 5 epidemiologic studies found no significant association between pitching a curveball and elbow or shoulder pain,<sup><xref rid="bibr8-1941738113501984" ref-type="bibr">8</xref>,<xref rid="bibr15-1941738113501984" ref-type="bibr">15</xref>,<xref rid="bibr17-1941738113501984" ref-type="bibr">17</xref></sup> other factors were noted that may increase risk of pain and/or injury. All 5 studies implicated an increased amount of pitching as a significant risk factor for arm pain or injury (<xref ref-type="table" rid="table3-1941738113501984">Table 3</xref>).<sup><xref rid="bibr8-1941738113501984" ref-type="bibr">8</xref>,<xref rid="bibr13-1941738113501984" ref-type="bibr">13</xref>,<xref rid="bibr15-1941738113501984" ref-type="bibr">15</xref>,<xref rid="bibr17-1941738113501984" ref-type="bibr">17</xref>,<xref rid="bibr18-1941738113501984" ref-type="bibr">18</xref></sup></p>
      </sec>
      <sec id="section16-1941738113501984">bo
        <title>Torso Kinematics</title>
        <p>Significantly less maximum pelvis angular velocity was found while pitching a curveball as compared with a fastball (560-590 vs 600-640 deg/s, respectively) (<xref ref-type="table" rid="table4-1941738113501984">Table 4</xref>).<sup><xref rid="bibr5-1941738113501984" ref-type="bibr">5</xref>,<xref rid="bibr7-1941738113501984" ref-type="bibr">7</xref>,<xref rid="bibr9-1941738113501984" ref-type="bibr">9</xref></sup> Less upper trunk angular velocity with the curveball was also shown.<sup><xref rid="bibr5-1941738113501984" ref-type="bibr">5</xref>,<xref rid="bibr7-1941738113501984" ref-type="bibr">7</xref>,<xref rid="bibr9-1941738113501984" ref-type="bibr">9</xref></sup> While 1 of the collegiate studies and the youth study found no difference in forward and lateral trunk tilt between pitches,<sup><xref rid="bibr5-1941738113501984" ref-type="bibr">5</xref>,<xref rid="bibr7-1941738113501984" ref-type="bibr">7</xref></sup> Fleisig et al found 4° greater forward and 3° greater lateral trunk tilt at ball release; this is of unknown clinical significance.<sup><xref rid="bibr9-1941738113501984" ref-type="bibr">9</xref></sup></p>
        <table-wrap id="table4-1941738113501984" position="float">
          <label>Table 4.</label>
          <caption>
            <p>Biomechanical data</p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th rowspan="1" colspan="1"/>
                <th align="center" colspan="2" rowspan="1">Pitch Velocity, m/s</th>
                <th colspan="3" rowspan="1"/>
              </tr>
              <tr>
                <th align="center" rowspan="1" colspan="1">Study</th>
                <th align="center" rowspan="1" colspan="1">Fastball</th>
                <th align="center" rowspan="1" colspan="1">Curveball</th>
                <th align="center" rowspan="1" colspan="1">Torso Kinematics</th>
                <th align="center" rowspan="1" colspan="1">Shoulder Kinematics</th>
                <th align="center" rowspan="1" colspan="1">Shoulder Kinetics</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">Hang et al<sup><xref rid="bibr11-1941738113501984" ref-type="bibr">11</xref></sup></td>
                <td rowspan="1" colspan="1">Not reported</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Elliott et al<sup><xref rid="bibr6-1941738113501984" ref-type="bibr">6</xref></sup></td>
                <td rowspan="1" colspan="1">35.1 ± 1.5</td>
                <td rowspan="1" colspan="1">28.2 ± 1.0</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Sisto et al<sup><xref rid="bibr20-1941738113501984" ref-type="bibr">20</xref></sup></td>
                <td rowspan="1" colspan="1">32.2</td>
                <td rowspan="1" colspan="1">26.8</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Glousman et al<sup><xref rid="bibr10-1941738113501984" ref-type="bibr">10</xref></sup></td>
                <td rowspan="1" colspan="1">29.1</td>
                <td rowspan="1" colspan="1">23.7</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Sakurai et al<sup><xref rid="bibr19-1941738113501984" ref-type="bibr">19</xref></sup></td>
                <td rowspan="1" colspan="1">35.0 ± 1.8</td>
                <td rowspan="1" colspan="1">28.6 ± 1.0</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">ND</td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Barrentine et al<sup><xref rid="bibr3-1941738113501984" ref-type="bibr">3</xref></sup></td>
                <td rowspan="1" colspan="1">34 ± 2</td>
                <td rowspan="1" colspan="1">28 ± 2</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Escamilla et al<sup><xref rid="bibr7-1941738113501984" ref-type="bibr">7</xref></sup></td>
                <td rowspan="1" colspan="1">35 ± 2</td>
                <td rowspan="1" colspan="1">28 ± 2</td>
                <td rowspan="1" colspan="1">Less maximum pelvis and upper torso angular velocity at arm cocking</td>
                <td rowspan="1" colspan="1">Greater maximum horizontal adduction at arm cocking and ball release, greater average abduction at arm acceleration</td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Fleisig et al<sup><xref rid="bibr9-1941738113501984" ref-type="bibr">9</xref></sup></td>
                <td rowspan="1" colspan="1">35.1 ± 1</td>
                <td rowspan="1" colspan="1">29.1 ± 1</td>
                <td rowspan="1" colspan="1">Less pelvis and upper trunk angular velocity, greater forward and lateral trunk tilt at ball release</td>
                <td rowspan="1" colspan="1">ND</td>
                <td rowspan="1" colspan="1">ND</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Dun et al<sup><xref rid="bibr5-1941738113501984" ref-type="bibr">5</xref></sup></td>
                <td rowspan="1" colspan="1">26.3 ± 3.8</td>
                <td rowspan="1" colspan="1">22.1 ± 3.2</td>
                <td rowspan="1" colspan="1">Less pelvis and upper trunk angular velocity</td>
                <td rowspan="1" colspan="1">Greater horizontal adduction at arm cocking and ball release, greater abduction at ball release, less maximum external rotation at arm cocking</td>
                <td rowspan="1" colspan="1">Less internal rotation torque at arm cocking, less proximal force at arm acceleration</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Nissen et al<sup><xref rid="bibr16-1941738113501984" ref-type="bibr">16</xref></sup></td>
                <td rowspan="1" colspan="1">29.5 ± 2.1</td>
                <td rowspan="1" colspan="1">25.9 ± 2.8</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Less overall arc of motion, less maximum internal rotation angular velocity</td>
                <td rowspan="1" colspan="1">Less maximum internal rotation moment, less maximum flexion moment</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="table-fn5-1941738113501984">
              <p>ND, study found no difference between curveballs and fastballs.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="section17-1941738113501984">
        <title>Shoulder Kinematics and Kinetics</title>
        <p>Five of the 10 biomechanical studies described the kinematics of the shoulder during the delivery of a curveball and fastball.<sup><xref rid="bibr5-1941738113501984" ref-type="bibr">5</xref>,<xref rid="bibr7-1941738113501984" ref-type="bibr">7</xref>,<xref rid="bibr9-1941738113501984" ref-type="bibr">9</xref>,<xref rid="bibr16-1941738113501984" ref-type="bibr">16</xref>,<xref rid="bibr19-1941738113501984" ref-type="bibr">19</xref></sup> Two studies of collegiate athletes (n = 26) found no difference between the 2 pitches with respect to shoulder abduction, horizontal adduction, and external rotation.<sup><xref rid="bibr9-1941738113501984" ref-type="bibr">9</xref>,<xref rid="bibr19-1941738113501984" ref-type="bibr">19</xref></sup> Two studies found greater shoulder abduction at arm acceleration<sup><xref rid="bibr7-1941738113501984" ref-type="bibr">7</xref></sup> and ball release<sup><xref rid="bibr5-1941738113501984" ref-type="bibr">5</xref></sup> while noting greater horizontal adduction at arm cocking and ball release with the curveball. Youth pitchers also had less maximum external rotation at arm cocking when pitching a curveball versus a fastball (176.2° vs 178.2°, respectively).<sup><xref rid="bibr5-1941738113501984" ref-type="bibr">5</xref></sup> However, the other 4 studies that included high school and collegiate pitchers did not find a difference in maximum external rotation.<sup><xref rid="bibr7-1941738113501984" ref-type="bibr">7</xref>,<xref rid="bibr9-1941738113501984" ref-type="bibr">9</xref>,<xref rid="bibr16-1941738113501984" ref-type="bibr">16</xref>,<xref rid="bibr19-1941738113501984" ref-type="bibr">19</xref></sup> Nissen et al described less overall arc of motion at the glenohumeral joint (117° vs 124°) and less maximum internal rotation angular velocity (3409 vs 3619 deg/s).<sup><xref rid="bibr16-1941738113501984" ref-type="bibr">16</xref></sup> The internal rotation velocity results were duplicated in youth but not collegiate pitchers.<sup><xref rid="bibr5-1941738113501984" ref-type="bibr">5</xref>,<xref rid="bibr7-1941738113501984" ref-type="bibr">7</xref></sup></p>
        <p>One of the 4 kinetics studies found no differences at the shoulder joint in collegiate pitchers.<sup><xref rid="bibr9-1941738113501984" ref-type="bibr">9</xref></sup> However, studies of youth and high school pitchers revealed less internal rotation torque (31.9 vs 34.8 Nm and 52.0 vs 56.8 Nm, respectively).<sup><xref rid="bibr5-1941738113501984" ref-type="bibr">5</xref>,<xref rid="bibr16-1941738113501984" ref-type="bibr">16</xref></sup> Less proximal force at arm acceleration was also seen in youth pitchers<sup><xref rid="bibr5-1941738113501984" ref-type="bibr">5</xref></sup> and reduced shoulder flexion moments in high school pitchers.<sup><xref rid="bibr16-1941738113501984" ref-type="bibr">16</xref></sup> No studies indicated increased force or torque at the glenohumeral joint when throwing a curveball compared with a fastball.</p>
      </sec>
      <sec id="section18-1941738113501984">
        <title>Elbow Kinematics and Kinetics</title>
        <p>Elbow kinematics in 4 studies involving collegiate pitchers (n = 6-40) show no significant differences between curveballs and fastballs (<xref ref-type="table" rid="table5-1941738113501984">Table 5</xref>).<sup><xref rid="bibr7-1941738113501984" ref-type="bibr">7</xref>,<xref rid="bibr9-1941738113501984" ref-type="bibr">9</xref>,<xref rid="bibr10-1941738113501984" ref-type="bibr">10</xref>,<xref rid="bibr19-1941738113501984" ref-type="bibr">19</xref></sup> In high school pitchers, less overall arc of motion was demonstrated in the curveball (81° ± 14° vs 83° ± 14°).<sup><xref rid="bibr16-1941738113501984" ref-type="bibr">16</xref></sup> Dun et al<sup><xref rid="bibr5-1941738113501984" ref-type="bibr">5</xref></sup> found greater elbow flexion at ball release and less extension velocity in youth pitchers. Elbow flexion at other phases of the throwing motion was similar for both types of pitches. Six international athletes showed increased mean elbow peak angular velocity just before release (985.5 vs 968.3 deg/s), but this study was not powered adequately for statistical analysis.<sup><xref rid="bibr6-1941738113501984" ref-type="bibr">6</xref></sup></p>
        <table-wrap id="table5-1941738113501984" position="float">
          <label>Table 5.</label>
          <caption>
            <p>Biomechanical data</p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th rowspan="1" colspan="1"/>
                <th align="center" colspan="2" rowspan="1">Elbow</th>
                <th align="center" colspan="2" rowspan="1">Forearm</th>
                <th align="center" colspan="2" rowspan="1">Wrist</th>
              </tr>
              <tr>
                <th align="center" rowspan="1" colspan="1">Study</th>
                <th align="center" rowspan="1" colspan="1">Kinematics</th>
                <th align="center" rowspan="1" colspan="1">Kinetics</th>
                <th align="center" rowspan="1" colspan="1">Kinematics</th>
                <th align="center" rowspan="1" colspan="1">Kinetics</th>
                <th align="center" rowspan="1" colspan="1">Kinematics</th>
                <th align="center" rowspan="1" colspan="1">Kinetics</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">Hang et al<sup><xref rid="bibr11-1941738113501984" ref-type="bibr">11</xref></sup></td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">No difference in normalized elbow force</td>
                <td rowspan="1" colspan="1">Greater supination<sup><xref ref-type="table-fn" rid="table-fn7-1941738113501984"><italic>a</italic></xref></sup></td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Elliott et al<sup><xref rid="bibr6-1941738113501984" ref-type="bibr">6</xref></sup></td>
                <td rowspan="1" colspan="1">Less sagittal velocity at ball release<sup><xref ref-type="table-fn" rid="table-fn8-1941738113501984"><italic>b</italic></xref></sup></td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Greater supination<sup><xref ref-type="table-fn" rid="table-fn7-1941738113501984"><italic>a</italic></xref></sup></td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Greater flexion,<sup><xref ref-type="table-fn" rid="table-fn8-1941738113501984"><italic>b</italic></xref></sup> ulnar deviation at ball release,<sup><xref ref-type="table-fn" rid="table-fn7-1941738113501984"><italic>a</italic></xref></sup> angular velocity<sup><xref ref-type="table-fn" rid="table-fn8-1941738113501984"><italic>b</italic></xref></sup></td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Sisto et al<sup><xref rid="bibr20-1941738113501984" ref-type="bibr">20</xref></sup></td>
                <td rowspan="1" colspan="1">Less brachioradialis activity at early cocking<sup><xref ref-type="table-fn" rid="table-fn8-1941738113501984"><italic>b</italic></xref></sup></td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Greater supination at late cocking<sup><xref ref-type="table-fn" rid="table-fn7-1941738113501984"><italic>a</italic></xref></sup></td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Greater ECRL/ECRB activity at late cocking, acceleration, follow-through<sup><xref ref-type="table-fn" rid="table-fn8-1941738113501984"><italic>b</italic></xref></sup></td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Glousman et al<sup><xref rid="bibr10-1941738113501984" ref-type="bibr">10</xref></sup></td>
                <td rowspan="1" colspan="1">Less brachioradialis at acceleration (injured pitchers) and follow-through (healthy)</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Less pronator teres activity at acceleration (healthy pitchers) and follow-through (injured)</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Less FCR activity at late cocking and acceleration (healthy pitchers); less ECRL (injured)/ECRB (healthy) activity at acceleration</td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Sakurai et al<sup><xref rid="bibr19-1941738113501984" ref-type="bibr">19</xref></sup></td>
                <td rowspan="1" colspan="1">ND</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Greater supination at max external rotation and ball release</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Less extension at max external rotation</td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Barrentine et al<sup><xref rid="bibr3-1941738113501984" ref-type="bibr">3</xref></sup></td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Greater max supination at arm cocking</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Less extension at arm cocking; greater ulnar deviation at ball release<sup><xref ref-type="table-fn" rid="table-fn7-1941738113501984"><italic>a</italic></xref></sup></td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Escamilla et al<sup><xref rid="bibr7-1941738113501984" ref-type="bibr">7</xref></sup></td>
                <td rowspan="1" colspan="1">ND</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Fleisig et al<sup><xref rid="bibr9-1941738113501984" ref-type="bibr">9</xref></sup></td>
                <td rowspan="1" colspan="1">ND</td>
                <td rowspan="1" colspan="1">Less proximal force at arm acceleration</td>
                <td rowspan="1" colspan="1">ND</td>
                <td rowspan="1" colspan="1">ND</td>
                <td rowspan="1" colspan="1">Less extension at arm cocking</td>
                <td rowspan="1" colspan="1">ND</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Dun et al<sup><xref rid="bibr5-1941738113501984" ref-type="bibr">5</xref></sup></td>
                <td rowspan="1" colspan="1">Greater elbow flexion at ball release; less extension velocity</td>
                <td rowspan="1" colspan="1">Less varus torque at arm cocking; less flexion torque and proximal force at arm acceleration</td>
                <td rowspan="1" colspan="1">Greater supination at arm cocking</td>
                <td rowspan="1" colspan="1">Greater supination torque at arm acceleration</td>
                <td rowspan="1" colspan="1">Less extension at arm cocking</td>
                <td rowspan="1" colspan="1">Greater wrist flexion torque at arm acceleration</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Nissen et al<sup><xref rid="bibr16-1941738113501984" ref-type="bibr">16</xref></sup></td>
                <td rowspan="1" colspan="1">Less overall arc of motion</td>
                <td rowspan="1" colspan="1">Less max varus moment</td>
                <td rowspan="1" colspan="1">Greater supination and max pronation angular velocity; less ROM</td>
                <td rowspan="1" colspan="1">ND</td>
                <td rowspan="1" colspan="1">Less extension; greater ulnar deviation at ball release and max internal rotation, radioulnar ROM, and ulnar angular velocity at ball release</td>
                <td rowspan="1" colspan="1">Less max flexion moment; greater max ulnar moment</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="table-fn6-1941738113501984">
              <p>ECRL, extensor carpi radialis longus; ECRB, extensor carpi radialis brevis; FCR, flexor carpi radialis; ND, study found no difference between curveballs and fastballs; max, maximum; ROM, range of motion.</p>
            </fn>
            <fn id="table-fn7-1941738113501984">
              <label>a</label>
              <p>Observational statement.</p>
            </fn>
            <fn id="table-fn8-1941738113501984">
              <label>b</label>
              <p><italic>P</italic> value not given.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>Electromyographic studies of pitchers’ elbows examined the biceps, brachioradialis, and triceps maximum muscle activity during 4 phases of the pitching motion. Sisto et al<sup><xref rid="bibr20-1941738113501984" ref-type="bibr">20</xref></sup> found less brachioradialis activity in the earlier phases—early cocking, late cocking, and acceleration—in curveball pitches, but statistical significance analysis was not provided. Glousman et al<sup><xref rid="bibr10-1941738113501984" ref-type="bibr">10</xref></sup> also found less brachioradialis activity at acceleration and follow-through but no difference in the activities of the biceps or triceps.</p>
        <p>The first kinetic study in 1979 demonstrated inconsistent measures of normalized elbow forces, with 2 adult pitchers showing increased forces at the elbow and 2 others showing decreased forces when throwing a curveball.<sup><xref rid="bibr11-1941738113501984" ref-type="bibr">11</xref></sup> Since then, less proximal elbow force at arm acceleration has been seen with the curveball (934 vs 988 Nm in collegiate pitchers and 428.2 vs 461.9 Nm in youth pitchers).<sup><xref rid="bibr9-1941738113501984" ref-type="bibr">9</xref></sup> These 3 studies of elbow flexion torque disagree; the 29 youth pitchers had less elbow flexion torque at arm acceleration,<sup><xref rid="bibr5-1941738113501984" ref-type="bibr">5</xref></sup> but the 20 collegiate athletes did not show a difference.<sup><xref rid="bibr5-1941738113501984" ref-type="bibr">5</xref>,<xref rid="bibr9-1941738113501984" ref-type="bibr">9</xref></sup> In addition, 2 studies examining elbow varus torque both found reduced moments when throwing curveballs (54.1 vs 59.6 Nm in collegiate pitchers and 31.6 vs 34.8 Nm in youth pitchers).<sup><xref rid="bibr5-1941738113501984" ref-type="bibr">5</xref>,<xref rid="bibr16-1941738113501984" ref-type="bibr">16</xref></sup></p>
      </sec>
      <sec id="section19-1941738113501984">
        <title>Forearm Kinematics and Kinetics</title>
        <p>Seven of 8 studies of forearm position in pitching found greater supination with the curveball than the fastball, with differences ranging from 7.3° to 19.8° particularly at arm-cocking and acceleration phases.<sup><xref rid="bibr3-1941738113501984" ref-type="bibr">3</xref>,<xref rid="bibr5-1941738113501984" ref-type="bibr">5</xref>,<xref rid="bibr6-1941738113501984" ref-type="bibr">6</xref>,<xref rid="bibr11-1941738113501984" ref-type="bibr">11</xref>,<xref rid="bibr16-1941738113501984" ref-type="bibr">16</xref>,<xref rid="bibr19-1941738113501984" ref-type="bibr">19</xref>,<xref rid="bibr20-1941738113501984" ref-type="bibr">20</xref></sup> One study noted greater forearm supination when throwing a curveball but did not quantify the differences between the pitches.<sup><xref rid="bibr6-1941738113501984" ref-type="bibr">6</xref></sup> In an electromyographic study, greater supinator muscle activity was found in the late cocking phase when a curveball was thrown.<sup><xref rid="bibr20-1941738113501984" ref-type="bibr">20</xref></sup> Decreased pronator teres activation (47% vs 85% maximum muscle strength test at acceleration) has also been shown.<sup><xref rid="bibr10-1941738113501984" ref-type="bibr">10</xref></sup></p>
        <p>Collegiate pitchers did not demonstrate a difference in forearm pronation torque.<sup><xref rid="bibr9-1941738113501984" ref-type="bibr">9</xref></sup> However, in youth pitchers, increased forearm supination torque at arm acceleration was recorded when pitchers threw a curveball compared with a fastball (1.2 ± 0.9 vs 0.9 ± 0.7 Nm).<sup><xref rid="bibr5-1941738113501984" ref-type="bibr">5</xref></sup></p>
      </sec>
      <sec id="section20-1941738113501984">
        <title>Wrist Kinematics and Kinetics</title>
        <p>Elliott et al was the first to report greater wrist flexion, ulnar deviation, and angular velocity when releasing a curveball, which allows the pitcher to command the appropriate spin necessary for the ball to curve.<sup><xref rid="bibr6-1941738113501984" ref-type="bibr">6</xref></sup> Five other studies show less wrist extension, ranging from 6° to 13°, when the arm is cocking, but the ulnar deviation was not significant in 4 of them.<sup><xref rid="bibr3-1941738113501984" ref-type="bibr">3</xref>,<xref rid="bibr5-1941738113501984" ref-type="bibr">5</xref>,<xref rid="bibr9-1941738113501984" ref-type="bibr">9</xref>,<xref rid="bibr16-1941738113501984" ref-type="bibr">16</xref>,<xref rid="bibr19-1941738113501984" ref-type="bibr">19</xref></sup> Nissen et al<sup><xref rid="bibr16-1941738113501984" ref-type="bibr">16</xref></sup> found slightly greater ulnar deviation of the wrist at ball release and maximum internal rotation. The wrist demonstrated greater curveball radioulnar range of motion (17° vs 14°) and greater ulnar angular velocity (360 vs 154 deg/s) at ball release with the curveball than the fastball.<sup><xref rid="bibr16-1941738113501984" ref-type="bibr">16</xref></sup></p>
        <p>Electromyographic data are inconsistent, as Sisto et al<sup><xref rid="bibr20-1941738113501984" ref-type="bibr">20</xref></sup> found greater wrist extension associated with the curveball since the extensor carpi radialis longus and extensor carpi radialis brevis had greater activity in the late cocking, acceleration, and follow-through of the curveball than with the fastball. While other researchers found decreased flexor carpi radialis muscle activation at late cocking and acceleration, they also found decreased extensor carpi radialis longus and extensor carpi radialis brevis activity at acceleration.<sup><xref rid="bibr10-1941738113501984" ref-type="bibr">10</xref></sup></p>
        <p>Mixed results are also found with wrist kinetics. Fleisig et al<sup><xref rid="bibr9-1941738113501984" ref-type="bibr">9</xref></sup> found no difference in the forces and torques about the wrist in collegiate pitchers. Nissen et al<sup><xref rid="bibr16-1941738113501984" ref-type="bibr">16</xref></sup> saw reduced maximum flexion moments (7.8 vs 8.3 Nm) but greater wrist ulnar moments (4.9 vs 3.2 Nm).<sup><xref rid="bibr9-1941738113501984" ref-type="bibr">9</xref></sup> Contradicting this were youth pitchers who demonstrated greater wrist flexion torques at arm acceleration (2.3 vs 1.5 Nm).<sup><xref rid="bibr5-1941738113501984" ref-type="bibr">5</xref></sup></p>
      </sec>
    </sec>
    <sec sec-type="discussion" id="section21-1941738113501984">
      <title>Discussion</title>
      <p>Overuse has been implicated as a risk factor for upper extremity injuries in baseball pitchers, prompting Little League Baseball to institute maximum pitch counts.<sup><xref rid="bibr12-1941738113501984" ref-type="bibr">12</xref></sup> Most youth and high school leagues have similar restrictions, usually limiting the number of innings pitched.<sup><xref rid="bibr1-1941738113501984" ref-type="bibr">1</xref>,<xref rid="bibr21-1941738113501984" ref-type="bibr">21</xref></sup> While there are currently no rules in baseball restricting the use of the curveball, many suggest that it is a potential risk factor for injury. USA Baseball recommends that breaking pitches (curveballs, sliders, etc) not be thrown until after bone maturity.<sup><xref rid="bibr22-1941738113501984" ref-type="bibr">22</xref></sup> These recommendations are primarily based on baseball expert opinion.<sup><xref rid="bibr22-1941738113501984" ref-type="bibr">22</xref></sup></p>
      <p>One of the studies cited in support of current curveball guidelines is confounded by pitch counts, which increases the odds of arm pain in a game and season.<sup><xref rid="bibr13-1941738113501984" ref-type="bibr">13</xref></sup> Youth pitchers with the highest pitch counts are likely the better pitchers on the team and therefore more inclined to throw a curveball earlier in their careers, further emphasizing overuse as a confounding variable. Additionally, a prior study using identical methods found no difference in the incidence of arm pain.<sup><xref rid="bibr15-1941738113501984" ref-type="bibr">15</xref></sup></p>
      <p>A retrospective review of pitchers who underwent ulnar collateral ligament reconstruction supporting USA Baseball’s recommendation did not compare with a healthy age-matched control group to determine statistical significance.<sup><xref rid="bibr18-1941738113501984" ref-type="bibr">18</xref></sup> A more recent study attempted to mitigate the lack of a study control group by comparing injured with uninjured pitchers and found no correlation of injury with the age at which the curveball was first thrown.<sup><xref rid="bibr17-1941738113501984" ref-type="bibr">17</xref></sup> As such, the epidemiologic evidence to support limitations on the curveball is lacking rigor in study design. Two studies found that throwing a changeup pitch reduced the incidence of elbow and/or shoulder pain.<sup><xref rid="bibr13-1941738113501984" ref-type="bibr">13</xref>,<xref rid="bibr15-1941738113501984" ref-type="bibr">15</xref></sup></p>
      <p>Consistent kinematic differences were increased horizontal adduction of the shoulder, increased forearm supination, and decreased wrist extension. Kinetics were not increased at the shoulder or elbow.<sup><xref rid="bibr5-1941738113501984" ref-type="bibr">5</xref>,<xref rid="bibr9-1941738113501984" ref-type="bibr">9</xref>,<xref rid="bibr11-1941738113501984" ref-type="bibr">11</xref>,<xref rid="bibr16-1941738113501984" ref-type="bibr">16</xref>,<xref rid="bibr19-1941738113501984" ref-type="bibr">19</xref></sup> Two studies found less proximal force and less varus torque at the elbow, with no data suggesting greater kinetic forces.<sup><xref rid="bibr5-1941738113501984" ref-type="bibr">5</xref>,<xref rid="bibr9-1941738113501984" ref-type="bibr">9</xref>,<xref rid="bibr16-1941738113501984" ref-type="bibr">16</xref></sup> Youth pitchers, the population of greatest concern, were the subjects in 1 of these studies.<sup><xref rid="bibr5-1941738113501984" ref-type="bibr">5</xref></sup> In addition, 2 studies on kinetics found decreased proximal forces and internal rotation torques at the shoulder,<sup><xref rid="bibr5-1941738113501984" ref-type="bibr">5</xref>,<xref rid="bibr16-1941738113501984" ref-type="bibr">16</xref></sup> highlighting the disconnect between biomechanical and epidemiologic studies. Whether these differences are due to pitchers’ discomfort with the grip, decreased arm speed for a slower pitch, or the minor mechanical differences required to produce the ball spin for a curveball, it does not appear that the curveball places additional strain on an athlete’s arm. The current biomechanical evidence does not support limiting the use of curveballs at any level of baseball.</p>
      <p>While the curveball does not appear to put additional biomechanical strain on a pitcher’s arm, electromyographic and kinematic studies consistently found that the curveball requires greater supination of the forearm.<sup><xref rid="bibr3-1941738113501984" ref-type="bibr">3</xref>,<xref rid="bibr5-1941738113501984" ref-type="bibr">5</xref>,<xref rid="bibr6-1941738113501984" ref-type="bibr">6</xref>,<xref rid="bibr10-1941738113501984" ref-type="bibr">10</xref>,<xref rid="bibr11-1941738113501984" ref-type="bibr">11</xref>,<xref rid="bibr16-1941738113501984" ref-type="bibr">16</xref>,<xref rid="bibr19-1941738113501984" ref-type="bibr">19</xref>,<xref rid="bibr20-1941738113501984" ref-type="bibr">20</xref></sup> This is consistent with the widespread technique of imparting spin onto the curveball with a strong “over the top” wrist supination snap. In addition to strengthening the rotator cuff muscles, the forearm muscles should be trained for the curveball.<sup><xref rid="bibr10-1941738113501984" ref-type="bibr">10</xref>,<xref rid="bibr20-1941738113501984" ref-type="bibr">20</xref></sup> We support USA Baseball’s recommendation to teach proper mechanics and use of the changeup to prevent arm injuries.<sup><xref rid="bibr22-1941738113501984" ref-type="bibr">22</xref></sup></p>
    </sec>
    <sec sec-type="conclusions" id="section22-1941738113501984">
      <title>Conclusion</title>
      <p>Despite much debate in the baseball community about the safety of the curveball, biomechanical and most epidemiologic studies do not demonstrate an increased risk of pain and/or injury when compared with the fastball. Current recommendations to discourage throwing curveballs at a young age, while well intentioned, are based on observational data and expert opinion that have not been validated by biomechanical studies. However, there is limited biomechanical and electromyographic evidence suggesting that youth pitchers throwing curveballs may benefit from conditioning programs focused on forearm supination.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="conflict">
        <p>The following author declared potential conflicts of interest: Christopher S. Ahmad, MD, received consulting fee(s) or honorarium from Acumed, LLC and Arthrex, Inc, and received payment to his institution from Stryker.<?release-delay 12|0?></p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="bibr1-1941738113501984">
        <label>1.</label>
        <mixed-citation publication-type="webpage">
<collab>AAU baseball rule book and regulations</collab>. <ext-link ext-link-type="uri" xlink:href="http://image.aausports.org/handbooks/baseball/Baseball_Handbook.pdf">http://image.aausports.org/handbooks/baseball/Baseball_Handbook.pdf</ext-link>
<date-in-citation>Accessed December 12, 2012</date-in-citation>.</mixed-citation>
      </ref>
      <ref id="bibr2-1941738113501984">
        <label>2.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aguinaldo</surname><given-names>AL</given-names></name><name><surname>Buttermore</surname><given-names>J</given-names></name><name><surname>Chambers</surname><given-names>H</given-names></name></person-group>
<article-title>Effects of upper trunk rotation on shoulder joint torque among baseball pitchers of various levels</article-title>. <source>J Appl Biomech</source>. <year>2007</year>;<volume>23</volume>:<fpage>42</fpage>-<lpage>51</lpage>.<pub-id pub-id-type="pmid">17585177</pub-id></mixed-citation>
      </ref>
      <ref id="bibr3-1941738113501984">
        <label>3.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barrentine</surname><given-names>SW</given-names></name><name><surname>Matsui</surname><given-names>T</given-names></name><name><surname>Escamilla</surname><given-names>RF</given-names></name><name><surname>Fleisig</surname><given-names>GS</given-names></name><name><surname>Andrews</surname><given-names>JR</given-names></name></person-group>
<article-title>Kinematic analysis of the wrist and forearm during baseball pitching</article-title>. <source>J Appl Biomech</source>. <year>1998</year>;<volume>14</volume>:<fpage>24</fpage>-<lpage>39</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr4-1941738113501984">
        <label>4.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Davis</surname><given-names>JT</given-names></name><name><surname>Limpisvasti</surname><given-names>O</given-names></name><name><surname>Fluhme</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>The effect of pitching biomechanics on the upper extremity in youth and adolescent baseball pitchers</article-title>. <source>Am J Sports Med</source>. <year>2009</year>;<volume>37</volume>:<fpage>1484</fpage>-<lpage>1491</lpage>.<pub-id pub-id-type="pmid">19633301</pub-id></mixed-citation>
      </ref>
      <ref id="bibr5-1941738113501984">
        <label>5.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dun</surname><given-names>S</given-names></name><name><surname>Loftice</surname><given-names>J</given-names></name><name><surname>Fleisig</surname><given-names>GS</given-names></name><name><surname>Kingsley</surname><given-names>D</given-names></name><name><surname>Andrews</surname><given-names>JR</given-names></name></person-group>
<article-title>A biomechanical comparison of youth baseball pitches: is the curveball potentially harmful?</article-title>
<source>Am J Sports Med</source>. <year>2008</year>;<volume>36</volume>:<fpage>686</fpage>-<lpage>692</lpage>.<pub-id pub-id-type="pmid">18055920</pub-id></mixed-citation>
      </ref>
      <ref id="bibr6-1941738113501984">
        <label>6.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Elliott</surname><given-names>B</given-names></name><name><surname>Grove</surname><given-names>RJ</given-names></name><name><surname>Gibson</surname><given-names>B</given-names></name><name><surname>Thurston</surname><given-names>B</given-names></name></person-group>
<article-title>A three-dimensional cinematographic analysis of the fastball and curveball pitches in baseball</article-title>. <source>J Appl Biomech</source>. <year>1986</year>;<volume>2</volume>:<fpage>20</fpage>-<lpage>28</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr7-1941738113501984">
        <label>7.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Escamilla</surname><given-names>RF</given-names></name><name><surname>Fleisig</surname><given-names>GS</given-names></name><name><surname>Barrentine</surname><given-names>SW</given-names></name><name><surname>Andrews</surname><given-names>JR</given-names></name></person-group>
<article-title>Kinematic comparisons of throwing different types of baseball pitches</article-title>. <source>J Appl Biomech</source>. <year>1998</year>;<volume>14</volume>:<fpage>1</fpage>-<lpage>23</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr8-1941738113501984">
        <label>8.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fleisig</surname><given-names>GS</given-names></name><name><surname>Andrews</surname><given-names>JR</given-names></name><name><surname>Cutter</surname><given-names>GR</given-names></name><etal/></person-group>
<article-title>Risk of serious injury for young baseball pitchers: a 10-year prospective study</article-title>. <source>Am J Sports Med</source>. <year>2011</year>;<volume>39</volume>:<fpage>253</fpage>-<lpage>257</lpage>.<pub-id pub-id-type="pmid">21098816</pub-id></mixed-citation>
      </ref>
      <ref id="bibr9-1941738113501984">
        <label>9.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fleisig</surname><given-names>GS</given-names></name><name><surname>Kingsley</surname><given-names>DS</given-names></name><name><surname>Loftice</surname><given-names>JW</given-names></name><etal/></person-group>
<article-title>Kinetic comparison among the fastball, curveball, change-up, and slider in collegiate baseball pitchers</article-title>. <source>Am J Sports Med</source>. <year>2006</year>;<volume>34</volume>:<fpage>423</fpage>-<lpage>430</lpage>.<pub-id pub-id-type="pmid">16260466</pub-id></mixed-citation>
      </ref>
      <ref id="bibr10-1941738113501984">
        <label>10.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Glousman</surname><given-names>RE</given-names></name><name><surname>Barron</surname><given-names>J</given-names></name><name><surname>Jobe</surname><given-names>FW</given-names></name><name><surname>Perry</surname><given-names>J</given-names></name><name><surname>Pink</surname><given-names>M</given-names></name></person-group>
<article-title>An electromyographic analysis of the elbow in normal and injured pitchers with medial collateral ligament insufficiency</article-title>. <source>Am J Sports Med</source>. <year>1992</year>;<volume>20</volume>:<fpage>311</fpage>-<lpage>317</lpage>.<pub-id pub-id-type="pmid">1636862</pub-id></mixed-citation>
      </ref>
      <ref id="bibr11-1941738113501984">
        <label>11.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hang</surname><given-names>YS</given-names></name><name><surname>Lippert</surname><given-names>FG</given-names><suffix>3rd</suffix></name><name><surname>Spolek</surname><given-names>GA</given-names></name><name><surname>Frankel</surname><given-names>VH</given-names></name><name><surname>Harrington</surname><given-names>RM</given-names></name></person-group>
<article-title>Biomechanical study of the pitching elbow</article-title>. <source>Int Orthop</source>. <year>1979</year>;<volume>3</volume>:<fpage>217</fpage>-<lpage>223</lpage>.<pub-id pub-id-type="pmid">528089</pub-id></mixed-citation>
      </ref>
      <ref id="bibr12-1941738113501984">
        <label>12.</label>
        <mixed-citation publication-type="webpage">
<collab>Little League tournament and regular season pitching rules made the same by adoption of new rule</collab>. <ext-link ext-link-type="uri" xlink:href="http://www.littleleague.org/media/newsarchive/2009/Sep-Dec/LLTournamentRegularSeasonPitchingRulesMadeSame.htm">http://www.littleleague.org/media/newsarchive/2009/Sep-Dec/LLTournamentRegularSeasonPitchingRulesMadeSame.htm</ext-link>
<date-in-citation>Accessed December 12, 2012</date-in-citation>.</mixed-citation>
      </ref>
      <ref id="bibr13-1941738113501984">
        <label>13.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lyman</surname><given-names>S</given-names></name><name><surname>Fleisig</surname><given-names>GS</given-names></name><name><surname>Andrews</surname><given-names>JR</given-names></name><name><surname>Osinski</surname><given-names>ED</given-names></name></person-group>
<article-title>Effect of pitch type, pitch count, and pitching mechanics on risk of elbow and shoulder pain in youth baseball pitchers</article-title>. <source>Am J Sports Med</source>. <year>2002</year>;<volume>30</volume>:<fpage>463</fpage>-<lpage>468</lpage>.<pub-id pub-id-type="pmid">12130397</pub-id></mixed-citation>
      </ref>
      <ref id="bibr14-1941738113501984">
        <label>14.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lyman</surname><given-names>S</given-names></name><name><surname>Fleisig</surname><given-names>GS</given-names></name><name><surname>Andrews</surname><given-names>JR</given-names></name><name><surname>Osinski</surname><given-names>ED</given-names></name></person-group>
<article-title>Youth pitching injuries: first-ever examination sheds light on arm injuries in youth baseball</article-title>. <source>Sports Med Update</source>. <year>1998</year>;<volume>13</volume>:<fpage>4</fpage>-<lpage>9</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr15-1941738113501984">
        <label>15.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lyman</surname><given-names>S</given-names></name><name><surname>Fleisig</surname><given-names>GS</given-names></name><name><surname>Waterbor</surname><given-names>JW</given-names></name><etal/></person-group>
<article-title>Longitudinal study of elbow and shoulder pain in youth baseball pitchers</article-title>. <source>Med Sci Sports Exerc</source>. <year>2001</year>;<volume>33</volume>:<fpage>1803</fpage>-<lpage>1810</lpage>.<pub-id pub-id-type="pmid">11689728</pub-id></mixed-citation>
      </ref>
      <ref id="bibr16-1941738113501984">
        <label>16.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nissen</surname><given-names>CW</given-names></name><name><surname>Westwell</surname><given-names>M</given-names></name><name><surname>Ounpuu</surname><given-names>S</given-names></name><name><surname>Patel</surname><given-names>M</given-names></name><name><surname>Solomito</surname><given-names>M</given-names></name><name><surname>Tate</surname><given-names>J</given-names></name></person-group>
<article-title>A biomechanical comparison of the fastball and curveball in adolescent baseball pitchers</article-title>. <source>Am J Sports Med</source>. <year>2009</year>;<volume>37</volume>:<fpage>1492</fpage>-<lpage>1498</lpage>.<pub-id pub-id-type="pmid">19448049</pub-id></mixed-citation>
      </ref>
      <ref id="bibr17-1941738113501984">
        <label>17.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Olsen</surname><given-names>SJ</given-names><suffix>2nd</suffix></name><name><surname>Fleisig</surname><given-names>GS</given-names></name><name><surname>Dun</surname><given-names>S</given-names></name><name><surname>Loftice</surname><given-names>J</given-names></name><name><surname>Andrews</surname><given-names>JR</given-names></name></person-group>
<article-title>Risk factors for shoulder and elbow injuries in adolescent baseball pitchers</article-title>. <source>Am J Sports Med</source>. <year>2006</year>;<volume>34</volume>:<fpage>905</fpage>-<lpage>912</lpage>.<pub-id pub-id-type="pmid">16452269</pub-id></mixed-citation>
      </ref>
      <ref id="bibr18-1941738113501984">
        <label>18.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Petty</surname><given-names>DH</given-names></name><name><surname>Andrews</surname><given-names>JR</given-names></name><name><surname>Fleisig</surname><given-names>GS</given-names></name><name><surname>Cain</surname><given-names>EL</given-names></name></person-group>
<article-title>Ulnar collateral ligament reconstruction in high school baseball players: clinical results and injury risk factors</article-title>. <source>Am J Sports Med</source>. <year>2004</year>;<volume>32</volume>:<fpage>1158</fpage>-<lpage>1164</lpage>.<pub-id pub-id-type="pmid">15262637</pub-id></mixed-citation>
      </ref>
      <ref id="bibr19-1941738113501984">
        <label>19.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sakurai</surname><given-names>S</given-names></name><name><surname>Ikegami</surname><given-names>Y</given-names></name><name><surname>Okamoto</surname><given-names>A</given-names></name><name><surname>Yabe</surname><given-names>K</given-names></name><name><surname>Toyoshima</surname><given-names>S</given-names></name></person-group>
<article-title>A three-dimensional cinematographic analysis of upper limb movement during fastball and curveball baseball pitches</article-title>. <source>J Appl Biomech</source>. <year>1993</year>;<volume>9</volume>:<fpage>47</fpage>-<lpage>65</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr20-1941738113501984">
        <label>20.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sisto</surname><given-names>DJ</given-names></name><name><surname>Jobe</surname><given-names>FW</given-names></name><name><surname>Moynes</surname><given-names>DR</given-names></name><name><surname>Antonelli</surname><given-names>DJ</given-names></name></person-group>
<article-title>An electromyographic analysis of the elbow in pitching</article-title>. <source>Am J Sports Med</source>. <year>1987</year>;<volume>15</volume>:<fpage>260</fpage>-<lpage>263</lpage>.<pub-id pub-id-type="pmid">3618877</pub-id></mixed-citation>
      </ref>
      <ref id="bibr21-1941738113501984">
        <label>21.</label>
        <mixed-citation publication-type="webpage">
<collab>USSA baseball rules and bylaws</collab>. <ext-link ext-link-type="uri" xlink:href="http://www.usssabaseball.org/2011_rules.htm">http://www.usssabaseball.org/2011_rules.htm</ext-link>
<date-in-citation>Accessed December 12, 2012</date-in-citation>.</mixed-citation>
      </ref>
      <ref id="bibr22-1941738113501984">
        <label>22.</label>
        <mixed-citation publication-type="webpage">
<collab>Youth baseball pitching injuries</collab>. <ext-link ext-link-type="uri" xlink:href="http://web.usabaseball.com/news/article.jsp?ymd=20090813&amp;content_id=6409508&amp;vkey=news">http://web.usabaseball.com/news/article.jsp?ymd=20090813&amp;content_id=6409508&amp;vkey=news</ext-link>
<date-in-citation>Accessed December 12, 2012</date-in-citation>.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:4272689</identifier><datestamp>2016-01-01</datestamp><setSpec>sportshealth</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="http://jats.nlm.nih.gov/ns/archiving/1.0/ http://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Sports Health</journal-id>
      <journal-id journal-id-type="iso-abbrev">Sports Health</journal-id>
      <journal-id journal-id-type="publisher-id">SPH</journal-id>
      <journal-id journal-id-type="hwp">spsph</journal-id>
      <journal-title-group>
        <journal-title>Sports Health</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1941-7381</issn>
      <issn pub-type="epub">1941-0921</issn>
      <publisher>
        <publisher-name>SAGE Publications</publisher-name>
        <publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4272689</article-id>
      <article-id pub-id-type="pmcid">PMC4272689</article-id>
      <article-id pub-id-type="pmc-uid">4272689</article-id>
      <article-id pub-id-type="pmid">25553210</article-id>
      <article-id pub-id-type="doi">10.1177/1941738114523387</article-id>
      <article-id pub-id-type="publisher-id">10.1177_1941738114523387</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Focus Topic: Controversies in Sports Medicine</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Cell Therapy in Joint Disorders</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Counsel</surname>
            <given-names>Peter D.</given-names>
          </name>
          <degrees>MBBS (Hons), DCH, FRANZCR</degrees>
          <xref ref-type="corresp" rid="corresp1-1941738114523387">*</xref>
          <xref ref-type="aff" rid="aff1-1941738114523387">†</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bates</surname>
            <given-names>Daniel</given-names>
          </name>
          <degrees>BSc (Hons), BMed</degrees>
          <xref ref-type="aff" rid="aff2-1941738114523387">‡</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Boyd</surname>
            <given-names>Richard</given-names>
          </name>
          <degrees>BSc (Hons), PhD</degrees>
          <xref ref-type="aff" rid="aff3-1941738114523387">§</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Connell</surname>
            <given-names>David A.</given-names>
          </name>
          <degrees>MBBS (Hons), MMed, FRANZCR, FFSEM (UK)</degrees>
          <xref ref-type="aff" rid="aff4-1941738114523387">‖</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1-1941738114523387"><label>†</label>Imaging at Olympic Park, Melbourne, Victoria, Australia</aff>
      <aff id="aff2-1941738114523387"><label>‡</label>Lakeside Sports Medicine Centre, Melbourne, Victoria, Australia</aff>
      <aff id="aff3-1941738114523387"><label>§</label>Monash Immunology and Stem Cell Laboratories (MISCL), Monash University, Clayton, Victoria, Australia</aff>
      <aff id="aff4-1941738114523387"><label>‖</label>Faculty of Medicine, Nursing &amp; Healthcare, Monash University, Clayton, Victoria, Australia</aff>
      <author-notes>
        <corresp id="corresp1-1941738114523387"><label>*</label>Peter D. Counsel, MBBS (Hons), DCH, FRANZCR, Imaging at Olympic Park, 60 Olympic Boulevard, Melbourne, Victoria 3004, Australia (e-mail: <email>p.counsel@iop.net.au</email>).</corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>1</day>
        <month>1</month>
        <year>2016</year>
      </pub-date>
      <!-- PMC Release delay is 12 months and 0 days and was based on the <pub-date pub-type="ppub"/>. -->
      <volume>7</volume>
      <issue>1</issue>
      <fpage>27</fpage>
      <lpage>37</lpage>
      <permissions>
        <copyright-statement>© 2014 The Author(s)</copyright-statement>
        <copyright-year>2014</copyright-year>
        <copyright-holder content-type="sage">American Orthopaedic Society for Sports Medicine</copyright-holder>
      </permissions>
      <abstract>
        <sec id="section1-1941738114523387">
          <title>Context:</title>
          <p>Articular cartilage possesses poor natural healing mechanisms, and a variety of non-cell-based and cell-based treatments aim to promote regeneration of hyaline cartilage.</p>
        </sec>
        <sec id="section2-1941738114523387">
          <title>Data Sources:</title>
          <p>A review of the literature to December 2013 using PubMed with search criteria including the keywords <italic>stem cell, cell therapy, cell transplantation, cartilage, chondral</italic>, and <italic>chondrogenic</italic>.</p>
        </sec>
        <sec id="section3-1941738114523387">
          <title>Study Selection:</title>
          <p>Forty-five articles were identified that employed local mesenchymal stem cell (MSC) therapy for joint disorders in humans. Nine comparative studies were identified, consisting of 3 randomized trials, 5 cohort studies, and 1 case-control study.</p>
        </sec>
        <sec id="section4-1941738114523387">
          <title>Study Type:</title>
          <p>Clinical review.</p>
        </sec>
        <sec id="section5-1941738114523387">
          <title>Level of Evidence:</title>
          <p>Level 4.</p>
        </sec>
        <sec id="section6-1941738114523387">
          <title>Data Extraction:</title>
          <p>Studies were assessed for stem cell source, method of implantation, comparison groups, and concurrent surgical techniques.</p>
        </sec>
        <sec id="section7-1941738114523387">
          <title>Results:</title>
          <p>Two studies comparing MSC treatment to autologous chondrocyte implantation found similar efficacy. Three studies reported clinical benefits with intra-articular MSC injection over non-MSC controls for cases undergoing debridement with or without marrow stimulation, although a randomized study found no significant clinical difference at 2-year follow-up but reported better 18-month magnetic resonance imaging and histologic scores in the MSC group. No human studies have compared intra-articular MSC therapy to non-MSC techniques for osteoarthritis in the absence of surgery.</p>
        </sec>
        <sec id="section8-1941738114523387">
          <title>Conclusion:</title>
          <p>Mesenchymal stem cell–based therapies appear safe and effective for joint disorders in large animal preclinical models. Evidence for use in humans, particularly, comparison with more established treatments such as autologous chondrocyte implantation and microfracture, is limited.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>stem cells</kwd>
        <kwd>cell therapy</kwd>
        <kwd>cartilage</kwd>
        <kwd>osteoarthritis</kwd>
        <kwd>cell transplantation</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>January/February 2015</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <p>Articular surface injury is a frequent problem, with recovery limited by incomplete natural healing mechanisms complicated by progression to osteoarthritis (OA), which leads to further pain and dysfunction.</p>
    <p>This lack of effective healing of chondral defects has led to a need to develop therapies to restore the articular surface to near normal. Broadly, these may be considered as non-cell-based and cell-based.<sup><xref rid="bibr55-1941738114523387" ref-type="bibr">55</xref>,<xref rid="bibr63-1941738114523387" ref-type="bibr">63</xref></sup> Cell-based therapies may be further subdivided into non–stem cell therapy or stem cell therapy.</p>
    <p>For non–stem cells, the most frequently employed technique is autologous chondrocyte implantation (ACI), with further advancements employing a collagen rather than periosteal cover and third generation approaches utilizing cells seeded within bioscaffolds rather than injection as a cell suspension.<sup><xref rid="bibr11-1941738114523387" ref-type="bibr">11</xref></sup></p>
    <p>The isolation of mesenchymal stem cells (MSCs) from a variety of tissues and their promise in in vitro and in animal models has led to their relatively recent implementation in humans.<sup><xref rid="bibr119-1941738114523387" ref-type="bibr">119</xref></sup> This review will focus on localized joint abnormalities such as chondral injury and OA.<sup><xref rid="bibr95-1941738114523387" ref-type="bibr">95</xref></sup></p>
    <sec sec-type="methods" id="section9-1941738114523387">
      <title>Methods</title>
      <p>A search was conducted through PubMed using various combinations of the terms <italic>stem cell, cell therapy, cell transplantation, cartilage, chondral</italic>, and <italic>chondrogenic</italic> to December 2013 with no earlier limit. Only 9 comparative studies (<xref ref-type="table" rid="table1-1941738114523387">Table 1</xref>) were identified among a total of 45 human reports of local stem cell therapy for joint disorders (see the Appendix, available at <ext-link ext-link-type="uri" xlink:href="http://sph.sagepub.com/content/suppl">http://sph.sagepub.com/content/suppl</ext-link>).</p>
      <table-wrap id="table1-1941738114523387" position="float">
        <label>Table 1.</label>
        <caption>
          <p>Comparative human studies involving the use of MSCs for cartilage repair<sup><xref ref-type="table-fn" rid="table-fn1-1941738114523387"><italic>a</italic></xref><xref ref-type="table-fn" rid="table-fn2-1941738114523387"><italic>b</italic></xref></sup></p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th align="left" rowspan="1" colspan="1">Study</th>
              <th align="center" rowspan="1" colspan="1">Cell Type</th>
              <th align="center" rowspan="1" colspan="1">Level/Design</th>
              <th align="center" rowspan="1" colspan="1">Number of Patients</th>
              <th align="center" rowspan="1" colspan="1">Comparison/Controls</th>
              <th align="center" rowspan="1" colspan="1">Disorder/Grade</th>
              <th align="center" rowspan="1" colspan="1">Surgical Approach/Method of Stem Cell Implantation</th>
              <th align="center" rowspan="1" colspan="1">Follow-up</th>
              <th align="center" rowspan="1" colspan="1">Outcomes</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">Giannini et al (2010),<sup><xref rid="bibr39-1941738114523387" ref-type="bibr">39</xref></sup> Italy</td>
              <td rowspan="1" colspan="1">BMC</td>
              <td rowspan="1" colspan="1">Level 3 (cohort)</td>
              <td rowspan="1" colspan="1">25 MSC</td>
              <td rowspan="1" colspan="1">10 open ACI, 46 arthroscopic ACI</td>
              <td rowspan="1" colspan="1">Talar osteochondral lesions, average 2.18 ± 0.5 cm<sup>2</sup></td>
              <td rowspan="1" colspan="1">Arthroscopic: Debridement, platelet gel + collagen powder or HA membrane</td>
              <td rowspan="1" colspan="1">36 months</td>
              <td rowspan="1" colspan="1">• In all groups AOFAS improved at 12 and 36 months<break/>• No significant difference between groups<break/>• Intact cartilage in all cases at arthroscopy<break/>• One-step BMC technique less than half the cost of 2-step arthroscopic ACI and less than one third of open</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Kim et al (2013),<sup><xref rid="bibr61-1941738114523387" ref-type="bibr">61</xref></sup> South Korea</td>
              <td rowspan="1" colspan="1">SVF</td>
              <td rowspan="1" colspan="1">Level 3 (cohort)</td>
              <td rowspan="1" colspan="1">31 MSC injection + surgery</td>
              <td rowspan="1" colspan="1">37 only surgery</td>
              <td rowspan="1" colspan="1">Talar osteochondral lesions, 118.9 ± 47.9 mm<sup>2</sup> in MSC group, 102.7 ± 31.4 mm<sup>2</sup> surgery only</td>
              <td rowspan="1" colspan="1">Intra-articular injection—supplement to arthroscopic debridement and microfracture</td>
              <td rowspan="1" colspan="1">Mean 21.8 months (range, 12-44 months)</td>
              <td rowspan="1" colspan="1">• Significantly greater improvement in MSC group compared with non-MSC for VAS, AOFAS, Roles and Maudsley score and Tegner activity scale at final follow-up</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Koh and Choi (2012),<sup><xref rid="bibr64-1941738114523387" ref-type="bibr">64</xref></sup> South Korea</td>
              <td rowspan="1" colspan="1">Infrapatellar fat SVF</td>
              <td rowspan="1" colspan="1">Level 4 (case-control)</td>
              <td rowspan="1" colspan="1">25 MSC injection + surgery and PRP</td>
              <td rowspan="1" colspan="1">25 surgery and PRP only</td>
              <td rowspan="1" colspan="1">OA—knee, ICRS grade 3.7 ± 0.4 MSC and 2.8 ± 0.8 control</td>
              <td rowspan="1" colspan="1">Intra-articular injection of MSC and PRP following arthroscopic debridement. Marrow stimulation procedures not performed</td>
              <td rowspan="1" colspan="1">1 year</td>
              <td rowspan="1" colspan="1">• Suggestion of greater benefit from MSC as groups similar at final follow-up, but preoperative clinical scores (VAS, Tegner, Lysholm) and ICRS grade significantly worse for MSC group</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Lee et al (2012),<sup><xref rid="bibr69-1941738114523387" ref-type="bibr">69</xref></sup> Singapore</td>
              <td rowspan="1" colspan="1">BM-MSC (culture expanded)</td>
              <td rowspan="1" colspan="1">Level 3 (cohort)</td>
              <td rowspan="1" colspan="1">35 group 1 (arthro-scopic surgery + MSC injection)</td>
              <td rowspan="1" colspan="1">35 group 2 (open MSC implantation)</td>
              <td rowspan="1" colspan="1">Full-thickness chondral defects—knee</td>
              <td rowspan="1" colspan="1">1: Arthroscopic debridement and microfracture, outpatient injection BM-MSC and HA2: Open debridement, cultured MSC sheet implantation beneath sutured periosteal patch, fibrin glue</td>
              <td rowspan="1" colspan="1">24.5 months</td>
              <td rowspan="1" colspan="1">• Both groups significantly improved IKDC, Lysholm, VAS, and SF-36 scores<break/>• Injected group more improvement in IKDC and Lysholm scores than open, while improvement in VAS and SF-36 scores were similar</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Nejadnik et al (2010),<sup><xref rid="bibr84-1941738114523387" ref-type="bibr">84</xref></sup> Singapore</td>
              <td rowspan="1" colspan="1">BM-MSC (culture expanded)</td>
              <td rowspan="1" colspan="1">Level 3 (cohort)</td>
              <td rowspan="1" colspan="1">36 MSC</td>
              <td rowspan="1" colspan="1">36 ACI (periosteal cover)</td>
              <td rowspan="1" colspan="1">Chondral defects/OA, ICRS grade III-IV, MSC average 4.6 cm<sup>2</sup> (SD 3.53), ACI average 3.6 cm<sup>2</sup> (SD 2.84)</td>
              <td rowspan="1" colspan="1">Open surgical: debridement, subchondral bone intact, periosteal patch, cells implanted beneath patch, fibrin glue seal</td>
              <td rowspan="1" colspan="1">2 years</td>
              <td rowspan="1" colspan="1">• No significant difference in IKDC, Tegner activity, and Lysholm scores<break/>• Physical role functioning significantly improved in stem cell group</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Saw et al (2013),<sup><xref rid="bibr102-1941738114523387" ref-type="bibr">102</xref></sup> Malaysia</td>
              <td rowspan="1" colspan="1">PBSC</td>
              <td rowspan="1" colspan="1">Level 2 (RCT)</td>
              <td rowspan="1" colspan="1">25 PBPC + HA</td>
              <td rowspan="1" colspan="1">25 HA only</td>
              <td rowspan="1" colspan="1">Knee—chondral defects, ICRS grade III-IV</td>
              <td rowspan="1" colspan="1">Intra-articular injection of PBPC + HA (group 1) or HA alone (group 2) × 8 injections following arthroscopic subchondral drilling</td>
              <td rowspan="1" colspan="1">24 months</td>
              <td rowspan="1" colspan="1">• Biopsy at 18 months, 16 patients from each group, better histology PBSC (1066 vs 957)<break/>• MRI scores better at 18 months (9.9 vs 8.5)<break/>• No significant clinical difference with IKDC scores at 24 months</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Skowroński and Rutka (2013),<sup><xref rid="bibr105-1941738114523387" ref-type="bibr">105</xref></sup> Poland</td>
              <td rowspan="1" colspan="1">BMC/PBSC</td>
              <td rowspan="1" colspan="1">Level 3 (cohort)</td>
              <td rowspan="1" colspan="1">21 BMC</td>
              <td rowspan="1" colspan="1">25 PBSC</td>
              <td rowspan="1" colspan="1">Osteochondral defects medial femoral condyle, &gt;4 cm<sup>2</sup>, &gt;6 mm deep</td>
              <td rowspan="1" colspan="1">Open surgical: BMC or PBSC suspension injected under collagen membrane + fibrin glue following debridement and autologous iliac graft of osseous defect</td>
              <td rowspan="1" colspan="1">5 years</td>
              <td rowspan="1" colspan="1">• KOOS, Lysholm, and VAS scales significantly better in PBSC group at 6 months and 1 year<break/>• Slight decrease in clinical scores at 5 years in both groups</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Varma et al (2010),<sup><xref rid="bibr117-1941738114523387" ref-type="bibr">117</xref></sup> India</td>
              <td rowspan="1" colspan="1">BMC</td>
              <td rowspan="1" colspan="1">Level 2 (RCT)</td>
              <td rowspan="1" colspan="1">25 MSC + surgery</td>
              <td rowspan="1" colspan="1">25 surgery only</td>
              <td rowspan="1" colspan="1">OA—knee</td>
              <td rowspan="1" colspan="1">Intra-articular injection following arthroscopic debridement</td>
              <td rowspan="1" colspan="1">6 months</td>
              <td rowspan="1" colspan="1">• Significant improvements in ADLs, sports and recreational activity, and quality of life scores at 6 months MSC compared with controls</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Wakitani et al (2002, 2008),<sup><xref rid="bibr119-1941738114523387" ref-type="bibr">119</xref>,<xref rid="bibr122-1941738114523387" ref-type="bibr">122</xref></sup> Japan</td>
              <td rowspan="1" colspan="1">BM-MSC (culture expanded)</td>
              <td rowspan="1" colspan="1">Level 2 (RCT)</td>
              <td rowspan="1" colspan="1">12 MSC</td>
              <td rowspan="1" colspan="1">12 non-MSC controls</td>
              <td rowspan="1" colspan="1">OA—knee, Outerbridge IV, mean 14 × 35 mm</td>
              <td rowspan="1" colspan="1">Open surgical: subchondral abrasion and drilling, collagen gel-sheet implant and periosteal cover + high tibial osteotomy</td>
              <td rowspan="1" colspan="1">64 months</td>
              <td rowspan="1" colspan="1">• Arthroscopic and histologic scores better in MSC group at 28-95 weeks<break/>• No clinical difference then or at 64-month follow-up</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="table-fn1-1941738114523387">
            <label>a</label>
            <p>BM-MSC, bone marrow–derived mesenchymal stem cells; ACI, autologous chondrocyte implantation; SVF, stromal vascular fraction; PBSC, peripheral blood stem cells; RCT, randomized controlled trial; BMC, bone marrow concentrate; OA, osteoarthritis; HA, hyaluronic acid; PRP, platelet-rich plasma; SD, standard deviation; ADLs, activities of daily living; ICRS, International Cartilage Repair Society; MFC, medial femoral condyle; VAS, visual analog scale; AOFAS, American Orthopaedic Foot and Ankle Society; KOOS, Knee Injury and Osteoarthritis Outcome Score; IKDC, International Knee Documentation Committee; SF-36, Short Form-36.</p>
          </fn>
          <fn id="table-fn2-1941738114523387">
            <label>b</label>
            <p>All studies utilized autologous cells. BM-MSCs represent culture-expanded cells. Non-BM-MSC studies utilized non–culture expanded cells from a variety of sources. Levels of evidence are as per the Oxford 2011 Levels of Evidence.<sup><xref rid="bibr85-1941738114523387" ref-type="bibr">85</xref></sup></p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>Three randomized trials,<sup><xref rid="bibr102-1941738114523387" ref-type="bibr">102</xref>,<xref rid="bibr117-1941738114523387" ref-type="bibr">117</xref>,<xref rid="bibr119-1941738114523387" ref-type="bibr">119</xref></sup> 3 nonrandomized cohort studies,<sup><xref rid="bibr39-1941738114523387" ref-type="bibr">39</xref>,<xref rid="bibr61-1941738114523387" ref-type="bibr">61</xref>,<xref rid="bibr84-1941738114523387" ref-type="bibr">84</xref></sup> and 1 case-control study<sup><xref rid="bibr64-1941738114523387" ref-type="bibr">64</xref></sup> compared stem cell with non–stem cell procedures. A further 2 cohort studies compared different stem cells or implantation methods.<sup><xref rid="bibr69-1941738114523387" ref-type="bibr">69</xref>,<xref rid="bibr105-1941738114523387" ref-type="bibr">105</xref></sup> Statistical analysis was not performed because of differences in study populations and methods.</p>
    </sec>
    <sec id="section10-1941738114523387">
      <title>Non-Cell-Based Treatment of Chondral Injury</title>
      <p>Non-cell-based surgical treatment includes debridement, marrow stimulation by microfracture, abrasion or drilling of the subchondral bone plate, and osteochondral grafting (mosaicplasty).<sup><xref rid="bibr55-1941738114523387" ref-type="bibr">55</xref>,<xref rid="bibr63-1941738114523387" ref-type="bibr">63</xref>,<xref rid="bibr83-1941738114523387" ref-type="bibr">83</xref></sup></p>
      <p>Abnormal cartilage in defects produces detrimental effects on adjacent and opposing cartilage, and debridement can improve symptoms and potentially minimize further chondral loss.<sup><xref rid="bibr28-1941738114523387" ref-type="bibr">28</xref>,<xref rid="bibr55-1941738114523387" ref-type="bibr">55</xref></sup> Activation of the innate repair mechanism by injuries involving the subchondral bone plate, as opposed to partial-thickness chondral injury, provides the rationale for marrow stimulation techniques where multiple small holes are placed in the subchondral bone of the defect.<sup><xref rid="bibr55-1941738114523387" ref-type="bibr">55</xref></sup> The mechanism of action is thought to be due to the influx of chondroprogenitor cells.<sup><xref rid="bibr63-1941738114523387" ref-type="bibr">63</xref></sup></p>
    </sec>
    <sec id="section11-1941738114523387">
      <title>Cell-Based Therapy</title>
      <p>The first report describing ACI in humans was by Brittberg et al<sup><xref rid="bibr10-1941738114523387" ref-type="bibr">10</xref></sup> in 1994, involving debridement, covering of the defect with a periosteal flap from the proximal medial tibia sutured to surrounding normal cartilage, and cultured chondrocyte injection beneath the periosteal flap.</p>
      <p>Autologous chondrocyte implantation utilizes cultured, mature, autologous chondrocytes suspended in an injectable medium with newer variants using a collagen type I/III membrane (ACI-C, CACI, second generation) rather than periosteal cover (ACI-P, first generation).<sup><xref rid="bibr11-1941738114523387" ref-type="bibr">11</xref></sup> Third generation techniques such as matrix-induced autologous chondrocyte implantation (MACI) use cells seeded onto the rough side of a collagen type I/III membrane with a smoother side facing the articular cavity, usually fixed with fibrin glue and sometimes sutures.<sup><xref rid="bibr11-1941738114523387" ref-type="bibr">11</xref></sup></p>
      <p>Characterized chondrocyte implantation (CCI) maximizes chondrogenic capacity through a controlled ex vivo process that produces clinically significant improvement with up to 4 years follow-up.<sup><xref rid="bibr115-1941738114523387" ref-type="bibr">115</xref></sup> Comparing CCI with microfracture in a randomized trial, Saris et al<sup><xref rid="bibr98-1941738114523387" ref-type="bibr">98</xref>,<xref rid="bibr99-1941738114523387" ref-type="bibr">99</xref></sup> found improved tissue regeneration, although similar clinical outcomes, at 1 year but improved clinical outcome for CCI at 3 years.</p>
      <p>These procedures can result in improved clinical, arthroscopic, and histologic features, with hyaline-like cartilage or fibrocartilage present in 43.9% of ACI-C and 36.4% of MACI grafts in 1 prospective, randomized study by Bartlett et al.<sup><xref rid="bibr4-1941738114523387" ref-type="bibr">4</xref></sup> In a randomized trial comparing ACI-P to MACI, Zeifang et al<sup><xref rid="bibr128-1941738114523387" ref-type="bibr">128</xref></sup> found better Lysholm and Gillquist scores at 12 and 24 months in the ACI-P group but no significant difference in International Knee Documentation Committee (IKDC), Tegner Activity Score, or Short Form–36 scores.</p>
      <p>In a systematic review of cell-based therapy for chondral lesions from 1994 to 2009, Nakamura et al<sup><xref rid="bibr83-1941738114523387" ref-type="bibr">83</xref></sup> concluded that there was insufficient evidence to indicate superiority of cell-based therapy to non-cell-based treatments with relatively short-term follow-up and most studies demonstrating no convincing differences. Variable results have been obtained comparing ACI with microfracture, with some studies showing no significant difference and others suggesting superiority of ACI.<sup><xref rid="bibr83-1941738114523387" ref-type="bibr">83</xref></sup> Second and third generation techniques offer potential advantages, but longer term follow-up is required.<sup><xref rid="bibr11-1941738114523387" ref-type="bibr">11</xref>,<xref rid="bibr83-1941738114523387" ref-type="bibr">83</xref></sup></p>
      <p>Basad et al<sup><xref rid="bibr5-1941738114523387" ref-type="bibr">5</xref></sup> demonstrated significantly improved Lysholm, Tegner, patient ICRS (International Cartilage Repair Society), and surgeon ICRS scores with MACI compared with microfracture at 2 years in a randomized study. For patients undergoing ACI after failed microfracture, significantly higher failure rates were observed.<sup><xref rid="bibr91-1941738114523387" ref-type="bibr">91</xref></sup></p>
      <p>The chondral defect site as well as level of sports activity and physical training may influence outcome.<sup><xref rid="bibr83-1941738114523387" ref-type="bibr">83</xref></sup> Surgical technique and experience also play a role. Disadvantages of ACI/MACI include healthy cartilage damage at the donor site and lack of suitable donor cartilage in elderly patients with degenerative changes.<sup><xref rid="bibr11-1941738114523387" ref-type="bibr">11</xref>,<xref rid="bibr83-1941738114523387" ref-type="bibr">83</xref></sup></p>
    </sec>
    <sec id="section12-1941738114523387">
      <title>Stem Cell Therapy</title>
      <sec id="section13-1941738114523387">
        <title>Sources of Stem Cells</title>
        <p>The stem cells with the greatest capacity for differentiation are embryonic stem cells (ESCs). In addition to ethical concerns, questions of safety have arisen because of the risk of teratoma formation.<sup><xref rid="bibr51-1941738114523387" ref-type="bibr">51</xref></sup> These concerns have prompted the search for alternative stem cell sources including adult cells and, more recently, induced pluripotential stem cells (iPSCs), although the teratoma risk currently persists with iPSCs.<sup><xref rid="bibr51-1941738114523387" ref-type="bibr">51</xref>,<xref rid="bibr108-1941738114523387" ref-type="bibr">108</xref></sup> IPSCs from osteoarthritic cartilage undergo chondrogenic differentiation in vitro and show chondrogenesis after subcutaneous implantation in mice, but have not yet been used in in vivo articular surface repair.<sup><xref rid="bibr126-1941738114523387" ref-type="bibr">126</xref></sup></p>
        <p>Mesenchymal stem cells are multipotential cells originally isolated from bone marrow but naturally existing in many tissues, often around blood vessels. They are defined by the expression of various cell surface molecules (eg, CD73, CD90, CD105), the capacity for self-renewal, and the ability to differentiate into osteogenic, chondrogenic, or adipogenic lineages.<sup><xref rid="bibr48-1941738114523387" ref-type="bibr">48</xref>,<xref rid="bibr93-1941738114523387" ref-type="bibr">93</xref></sup> While this capacity already signifies their applicability to musculoskeletal conditions, they also possess potent anti-inflammatory/immunosuppressive properties,<sup><xref rid="bibr79-1941738114523387" ref-type="bibr">79</xref></sup> which may predict efficacy in OA.<sup><xref rid="bibr48-1941738114523387" ref-type="bibr">48</xref>,<xref rid="bibr71-1941738114523387" ref-type="bibr">71</xref></sup></p>
        <p>Mesenchymal stem cells are being isolated from an increasingly wider variety of human tissues, including bone marrow,<sup><xref rid="bibr93-1941738114523387" ref-type="bibr">93</xref></sup> adipose tissue,<sup><xref rid="bibr130-1941738114523387" ref-type="bibr">130</xref></sup> skeletal muscle,<sup><xref rid="bibr70-1941738114523387" ref-type="bibr">70</xref></sup> synovial membrane<sup><xref rid="bibr26-1941738114523387" ref-type="bibr">26</xref>,<xref rid="bibr47-1941738114523387" ref-type="bibr">47</xref></sup> and synovial fluid,<sup><xref rid="bibr47-1941738114523387" ref-type="bibr">47</xref></sup> periosteum,<sup><xref rid="bibr27-1941738114523387" ref-type="bibr">27</xref></sup> peripheral blood,<sup><xref rid="bibr88-1941738114523387" ref-type="bibr">88</xref></sup> umbilical cord blood,<sup><xref rid="bibr124-1941738114523387" ref-type="bibr">124</xref></sup> endometrium,<sup><xref rid="bibr37-1941738114523387" ref-type="bibr">37</xref></sup> amniotic fluid,<sup><xref rid="bibr53-1941738114523387" ref-type="bibr">53</xref></sup> and placenta.<sup><xref rid="bibr54-1941738114523387" ref-type="bibr">54</xref></sup> The potential therapeutic value for MSCs in the treatment of joint disorders is multifactorial, including paracrine effects on regenerating native tissue and immunomodulatory effects.<sup><xref rid="bibr14-1941738114523387" ref-type="bibr">14</xref>,<xref rid="bibr48-1941738114523387" ref-type="bibr">48</xref></sup></p>
        <p>The cytokine-based immunosuppressive properties of MSCs potentially induce immune tolerance, prompting investigation in multiple sclerosis, foreign graft rejection, and rheumatoid arthritis.<sup><xref rid="bibr48-1941738114523387" ref-type="bibr">48</xref>,<xref rid="bibr95-1941738114523387" ref-type="bibr">95</xref></sup> These immunomodulatory effects may help slow the progression of OA by targeting the inflammatory processes in its pathogenesis.<sup><xref rid="bibr79-1941738114523387" ref-type="bibr">79</xref></sup></p>
        <p>So far, in the musculoskeletal system, MSCs derived from autologous bone marrow, subcutaneous adipose tissue, infrapatellar fat, and peripheral blood have been utilized in humans in treating osteochondral injury, OA, and rheumatoid arthritis.<sup><xref rid="bibr64-1941738114523387" ref-type="bibr">64</xref>,<xref rid="bibr88-1941738114523387" ref-type="bibr">88</xref>,<xref rid="bibr101-1941738114523387" ref-type="bibr">101</xref>,<xref rid="bibr119-1941738114523387" ref-type="bibr">119</xref></sup></p>
      </sec>
      <sec id="section14-1941738114523387">
        <title>Bone Marrow–Derived Mesenchymal Stem Cells and Bone Marrow Concentrate</title>
        <p>Hematopoietic stem cells (HSCs) and bone marrow–MSCs (BM-MSCs) represent different cells lines, with only BM-MSCs used for chondral regeneration. HSCs renew blood elements while MSCs can differentiate into mesenchymal elements, including cartilage.<sup><xref rid="bibr93-1941738114523387" ref-type="bibr">93</xref></sup> Most animal and human stem cell studies for cartilage repair used BM-MSCs. Initial human reports employed culture-expanded BM-MSCs,<sup><xref rid="bibr119-1941738114523387" ref-type="bibr">119</xref></sup> but subsequent publications utilized bone marrow concentrate (BMC) without expansion, allowing a same-day procedure.<sup><xref rid="bibr15-1941738114523387" ref-type="bibr">15</xref>,<xref rid="bibr38-1941738114523387" ref-type="bibr">38</xref></sup> BMC contains nucleated cells with a small stem cell component derived from marrow aspirates after removal of most red cells and plasma by centrifugation.<sup><xref rid="bibr38-1941738114523387" ref-type="bibr">38</xref></sup> Both show benefits compared with controls in small, human studies.<sup><xref rid="bibr39-1941738114523387" ref-type="bibr">39</xref>,<xref rid="bibr84-1941738114523387" ref-type="bibr">84</xref>,<xref rid="bibr117-1941738114523387" ref-type="bibr">117</xref>,<xref rid="bibr119-1941738114523387" ref-type="bibr">119</xref>,<xref rid="bibr123-1941738114523387" ref-type="bibr">123</xref></sup></p>
        <p>Technique-related differences in aspirate yields include site (anterior vs posterior iliac crest) and syringe size.<sup><xref rid="bibr92-1941738114523387" ref-type="bibr">92</xref></sup> Substantial variability also exists for MSC counts between patients.<sup><xref rid="bibr92-1941738114523387" ref-type="bibr">92</xref></sup> For these reasons, comparison between studies or patients within a study is difficult unless the sample is analyzed prior to implantation. Although cell numbers may be counted, characterization with surface markers is required to assess true stem cell counts.<sup><xref rid="bibr18-1941738114523387" ref-type="bibr">18</xref>,<xref rid="bibr105-1941738114523387" ref-type="bibr">105</xref></sup> Reported transplanted BM-MSC counts range from 8 million<sup><xref rid="bibr25-1941738114523387" ref-type="bibr">25</xref></sup> to 45.6 million<sup><xref rid="bibr17-1941738114523387" ref-type="bibr">17</xref></sup> cells.</p>
        <p>Outcome for femoral head osteonecrosis and tibial nonunion is proportionate to the number of transplanted progenitor cells.<sup><xref rid="bibr49-1941738114523387" ref-type="bibr">49</xref>,<xref rid="bibr50-1941738114523387" ref-type="bibr">50</xref></sup> This remains to be shown in humans for cartilage, but the principle of improved healing with greater cell numbers is important. In vitro work shows that increasing initial seeding density of BM-MSC enhances chondrogenesis.<sup><xref rid="bibr52-1941738114523387" ref-type="bibr">52</xref></sup> Government regulation forms a barrier to using culture-expanded cells in some countries, including the United States, as the degree of ex vivo manipulation classifies the treatment in the same manner as a drug.<sup><xref rid="bibr20-1941738114523387" ref-type="bibr">20</xref></sup> Geographic locations of human studies are listed (see the Appendix, available at <ext-link ext-link-type="uri" xlink:href="http://sph.sagepub.com/content/suppl">http://sph.sagepub.com/content/suppl</ext-link>). The US Food and Drug Administration has currently not approved any stem cell products for use in the United States other than cord blood–derived hematopoietic stem cells for certain indications.<sup><xref rid="bibr114-1941738114523387" ref-type="bibr">114</xref></sup> While the use of culture-expanded cells is prohibited, some clinics offer same day procedures using minimally manipulated cells such as BMC, concentrated at the point of care.<sup><xref rid="bibr20-1941738114523387" ref-type="bibr">20</xref></sup> The issue of stem cell regulation continues to be a subject of active debate.</p>
        <p>An apparent disadvantage of BM-MSCs is that cell numbers diminish with age and exhibit reduced proliferative capacity and increased rates of apoptosis compared with BM-MSC from younger patients.<sup><xref rid="bibr106-1941738114523387" ref-type="bibr">106</xref></sup></p>
      </sec>
      <sec id="section15-1941738114523387">
        <title>Adipose-Derived Stem Cells and Stromal Vascular Fraction</title>
        <p>Mesenchymal stem cells in adipose tissue arise from or form perivascular cells.<sup><xref rid="bibr13-1941738114523387" ref-type="bibr">13</xref>,<xref rid="bibr130-1941738114523387" ref-type="bibr">130</xref>,<xref rid="bibr131-1941738114523387" ref-type="bibr">131</xref></sup> Adipose tissue contains proportionally higher numbers of MSCs (approximately 10% of nucleated cells) than bone marrow and is amenable to liposuction without significant morbidity. In contrast to BM-MSCs, numbers do not decline with age but do decline with obesity.<sup><xref rid="bibr3-1941738114523387" ref-type="bibr">3</xref></sup> Stem cells may differ in numbers from abdominal adipose tissue compared with the hip or thigh, but proliferation and differentiation do not appear influenced by harvest site.<sup><xref rid="bibr56-1941738114523387" ref-type="bibr">56</xref></sup></p>
        <p>As with bone marrow, adipose stem cells may be utilized in 2 major forms. Stromal vascular fraction (SVF) is a heterogeneous population of cells that may contain MSCs, fibroblasts, endothelial cells, leukocytes (lymphocytes and macrophages), and pericytes.<sup><xref rid="bibr8-1941738114523387" ref-type="bibr">8</xref></sup> Stem cells from SVF may be separated and expanded in vitro (adipose-derived stem cells [ADSCs]).</p>
        <p>An advantage of SVF and BMC is elimination of the time lag between harvest and implantation, minimizing exposure to risks, reducing cost and logistical difficulties.<sup><xref rid="bibr39-1941738114523387" ref-type="bibr">39</xref>,<xref rid="bibr88-1941738114523387" ref-type="bibr">88</xref>,<xref rid="bibr95-1941738114523387" ref-type="bibr">95</xref></sup> However, the lack of cellular content identification of SVF is a major problem in evaluating clinical efficacy and patient responses. SVF contains large numbers of T regulatory (Treg) cells that may assist in immunosuppression and tolerance induction.<sup><xref rid="bibr95-1941738114523387" ref-type="bibr">95</xref></sup></p>
        <p>Intra-articular SVF has been successfully utilized in dogs with elbow or hip OA but with suboptimal results in horses.<sup><xref rid="bibr8-1941738114523387" ref-type="bibr">8</xref>,<xref rid="bibr9-1941738114523387" ref-type="bibr">9</xref>,<xref rid="bibr35-1941738114523387" ref-type="bibr">35</xref></sup> Co-administration of non-infrapatellar fat-derived SVF showed superior clinical results at mean 21.8-month follow-up compared with non-MSC controls in a human study.<sup><xref rid="bibr61-1941738114523387" ref-type="bibr">61</xref></sup></p>
        <p>Improved cartilage repair was seen with culture-expanded ADSCs compared with controls in rabbit full-thickness chondral defects with better integration and more hyaline cartilage formation, but their use in humans has not been reported.<sup><xref rid="bibr31-1941738114523387" ref-type="bibr">31</xref></sup></p>
      </sec>
      <sec id="section16-1941738114523387">
        <title>Infrapatellar Fat Pad–Derived Stem Cells</title>
        <p>Infrapatellar fat differs in composition to subcutaneous adipose tissue, containing a large amount of collagenous tissue and possibly synoviocytes.<sup><xref rid="bibr127-1941738114523387" ref-type="bibr">127</xref></sup> While exhibiting characteristics of ADSCs,<sup><xref rid="bibr57-1941738114523387" ref-type="bibr">57</xref></sup> they have more similarities with fibrous synovium-derived cells than subcutaneous fat–derived cells, and possibly greater chondrogenic potential.<sup><xref rid="bibr78-1941738114523387" ref-type="bibr">78</xref></sup> In rabbits, cells cultured from infrapatellar fat showed promising results compared with controls.<sup><xref rid="bibr110-1941738114523387" ref-type="bibr">110</xref></sup></p>
        <p>Infrapatellar SVF (not culture-expanded) has shown similar clinical findings in humans at 1 year compared with MSC free controls undergoing arthroscopic debridement, implying a potential benefit from MSC because of poorer preoperative clinical scores and ICRS grades.<sup><xref rid="bibr64-1941738114523387" ref-type="bibr">64</xref></sup></p>
      </sec>
      <sec id="section17-1941738114523387">
        <title>Peripheral Blood Mesenchymal Stem Cells/Progenitor Cells</title>
        <p>Peripheral blood presents another source of MSCs, obtained with relative ease and no significant donor site morbidity.<sup><xref rid="bibr21-1941738114523387" ref-type="bibr">21</xref></sup> MSCs derived from human peripheral blood cells (PBSCs) exhibit similar in vitro chondrogenic potential to BM-MSCs, although they are far less concentrated in blood than in marrow.<sup><xref rid="bibr23-1941738114523387" ref-type="bibr">23</xref></sup> Use of granulocyte–colony stimulating factor (G-CSF) increases MSC numbers in peripheral blood.<sup><xref rid="bibr21-1941738114523387" ref-type="bibr">21</xref>,<xref rid="bibr101-1941738114523387" ref-type="bibr">101</xref></sup> While generally well tolerated, rare risks of G-CSF in healthy donors include splenic rupture and adult respiratory distress syndrome, although the theoretical risk of hematologic malignancy remains to be proven in the healthy donor population.<sup><xref rid="bibr32-1941738114523387" ref-type="bibr">32</xref></sup></p>
        <p>Following an initial pilot report,<sup><xref rid="bibr101-1941738114523387" ref-type="bibr">101</xref></sup> PBSCs have been assessed in a randomized study augmenting arthroscopic subchondral drilling with postprocedural injections of either PBSC and hyaluronic acid (HA) or HA alone, reporting improved histologic and MRI scores at 18 months but no significant clinical difference at 24 months.<sup><xref rid="bibr102-1941738114523387" ref-type="bibr">102</xref></sup></p>
        <p>Other stem cell sources trialed in animals, but not humans, include periosteum, synovium, and skeletal muscle.<sup><xref rid="bibr73-1941738114523387" ref-type="bibr">73</xref>,<xref rid="bibr76-1941738114523387" ref-type="bibr">76</xref>,<xref rid="bibr90-1941738114523387" ref-type="bibr">90</xref>,<xref rid="bibr118-1941738114523387" ref-type="bibr">118</xref></sup></p>
      </sec>
    </sec>
    <sec id="section18-1941738114523387">
      <title>Methods of Stem Cell Transplantation</title>
      <sec id="section19-1941738114523387">
        <title>Open Surgical Implantation of MSCs</title>
        <p>Surgical implantation may be similar to ACI, with MSCs beneath a periosteal<sup><xref rid="bibr119-1941738114523387" ref-type="bibr">119</xref></sup> or collagen<sup><xref rid="bibr43-1941738114523387" ref-type="bibr">43</xref></sup> cover instead of cultured chondrocytes.<sup><xref rid="bibr45-1941738114523387" ref-type="bibr">45</xref>,<xref rid="bibr60-1941738114523387" ref-type="bibr">60</xref>,<xref rid="bibr67-1941738114523387" ref-type="bibr">67</xref>,<xref rid="bibr74-1941738114523387" ref-type="bibr">74</xref>,<xref rid="bibr84-1941738114523387" ref-type="bibr">84</xref>,<xref rid="bibr103-1941738114523387" ref-type="bibr">103</xref>,<xref rid="bibr104-1941738114523387" ref-type="bibr">104</xref>,<xref rid="bibr109-1941738114523387" ref-type="bibr">109</xref>,<xref rid="bibr119-1941738114523387" ref-type="bibr">119</xref><xref rid="bibr120-1941738114523387" ref-type="bibr"/><xref rid="bibr121-1941738114523387" ref-type="bibr"/><xref rid="bibr122-1941738114523387" ref-type="bibr"/>-<xref rid="bibr123-1941738114523387" ref-type="bibr">123</xref></sup> A cell-seeded construct (analogous to MACI) may be used rather than suspended cells.<sup><xref rid="bibr11-1941738114523387" ref-type="bibr">11</xref></sup> An ideal scaffold is nontoxic, absorbable, mechanically sound, and promotes cell growth.<sup><xref rid="bibr46-1941738114523387" ref-type="bibr">46</xref></sup></p>
        <p>Wakitani et al<sup><xref rid="bibr118-1941738114523387" ref-type="bibr">118</xref></sup> found that osteochondral progenitor cells from bone marrow or periosteum in type I collagen gel produced superior repair of full-thickness rabbit medial femoral condylar defects compared with empty defects or a cell-free collagen gel with hyaline cartilage formation and mechanically superior repair tissue. Macroscopic appearance at 24 weeks and histologic appearance at 12 and 24 weeks was less favorable than at 4 weeks postimplantation.<sup><xref rid="bibr118-1941738114523387" ref-type="bibr">118</xref></sup></p>
        <p>Wakitani et al<sup><xref rid="bibr119-1941738114523387" ref-type="bibr">119</xref></sup> used culture-expanded BM-MSCs in collagen gel in medial femoral condylar defects of humans with OA at the time of high tibial osteotomy, with 12 patients randomized to each group. Subchondral abrasion was performed to facilitate bleeding. A BM-MSC–collagen gel sheet composite was applied to the defect and covered with autologous periosteum. The control group received the same treatment without BM-MSCs. BM-MSC patients demonstrated improved arthroscopic and histologic scores 28 to 95 weeks following treatment, with no clinical difference, including on repeat assessment at 64 months.<sup><xref rid="bibr119-1941738114523387" ref-type="bibr">119</xref>,<xref rid="bibr123-1941738114523387" ref-type="bibr">123</xref></sup></p>
        <p>Gobbi et al<sup><xref rid="bibr43-1941738114523387" ref-type="bibr">43</xref></sup> applied a 1-step open approach with BMC (nonexpanded) following debridement of knee chondral lesions in 15 patients using a collagen membrane cover. Most underwent associated procedures. Significant clinical improvement was noted at 6, 12, and 24 months (visual analog scale [VAS], Knee Injury and Osteoarthritis Outcome Score [KOOS], IKDC, SF-36, Tegner, Marx, Lysholm). Defect filling at MRI was complete in 12 cases and incomplete in 3 cases. Arthroscopic evaluation in 4 knees was normal to nearly normal, and histology in 3 patients showed hyaline-like features.<sup><xref rid="bibr43-1941738114523387" ref-type="bibr">43</xref></sup></p>
        <p>Skowroński and Rutka<sup><xref rid="bibr105-1941738114523387" ref-type="bibr">105</xref></sup> showed significantly better KOOS, Lysholm, and VAS scores for PBSC over nonexpanded BMC in conjunction with autologous iliac bone grafting of medial femoral condylar osteochondral lesions at 6 months and 1 year, but commented that it could reflect double the transplanted cell numbers compared with the BMC group, with possible contribution from more stem cells provided by marrow stimulation in the G-CSF–treated PBSC group.</p>
        <p>Regarding open foot and ankle chondral defect repairs, implantation of nonexpanded BMC-impregnated collagen matrix was reported by Richter and Zech<sup><xref rid="bibr94-1941738114523387" ref-type="bibr">94</xref></sup> in 25 patients who were followed up with at 2 years with significant improvements in VAS foot and ankle scores.</p>
      </sec>
      <sec id="section20-1941738114523387">
        <title>Arthroscopic Implantation of Stem Cells</title>
        <p>Giannini et al<sup><xref rid="bibr38-1941738114523387" ref-type="bibr">38</xref>,<xref rid="bibr40-1941738114523387" ref-type="bibr">40</xref></sup> followed 49 patients, aged 14 to 50 years, for 4 years after 1-step arthroscopic implantation of nonexpanded BMC for talar osteochondral lesions, with either collagen powder/platelet gel or HA membrane/platelet gel scaffolds. American Orthopaedic Foot and Ankle Society (AOFAS) scores improved, with best results at 24 months, but deteriorating at 36 and 48 months.</p>
      </sec>
      <sec id="section21-1941738114523387">
        <title>Stem Cell Versus Autologous Chondrocyte Implantation</title>
        <p>Few studies directly compare stem cell treatment to ACI. Adachi et al<sup><xref rid="bibr1-1941738114523387" ref-type="bibr">1</xref></sup> showed similar results of B-galactosidase gene–transfected muscle-derived stem cells (MDSCs) with similarly transfected chondrocytes in rabbits. Testing a gellan gum hydrogel in rabbits, Oliveira et al<sup><xref rid="bibr86-1941738114523387" ref-type="bibr">86</xref></sup> noted improved hyaline cartilage formation with chondrogenically predifferentiated ADSCs compared with chondrocytes, but similar results between undifferentiated ADSCs and chondrocytes.</p>
        <p>Autologous, cultured BM-MSCs were compared with matrix-associated autologous chondrocyte transplantation in sheep, both suspended in collagen gel, with superior results for BM-MSCs at 1 year, particularly regarding integration with adjacent native cartilage.<sup><xref rid="bibr72-1941738114523387" ref-type="bibr">72</xref></sup></p>
        <p>Arthroscopic, nonexpanded BMC implantation was retrospectively compared with open field and arthroscopic ACI.<sup><xref rid="bibr39-1941738114523387" ref-type="bibr">39</xref></sup> Significant clinical improvement was found in all 3 groups at 36 months, with no significant difference between them. Second-look arthroscopies demonstrated intact cartilage in all cases, with components of hyaline cartilage at biopsy. The 1-step arthroscopic BMC technique was less than half the cost of the 2-step arthroscopic ACI technique.<sup><xref rid="bibr39-1941738114523387" ref-type="bibr">39</xref></sup></p>
        <p>Nejadnik et al<sup><xref rid="bibr84-1941738114523387" ref-type="bibr">84</xref></sup> matched 36 patients undergoing ACI-P with 36 patients receiving autologous, culture-expanded BM-MSCs, with cultured chondrocytes or BM-MSCs implanted beneath a sutured periosteal patch in similar techniques. No significant difference was shown between the 2 groups in terms of clinical outcome up to 24 months except for physical role functioning, which was better improved for the BM-MSC group. The BM-MSC therapy required only 1 surgery, reduced costs, and caused less donor site morbidity. In contrast to the ACI group, an age-related response was not evident with BM-MSCs.<sup><xref rid="bibr84-1941738114523387" ref-type="bibr">84</xref></sup></p>
      </sec>
      <sec id="section22-1941738114523387">
        <title>Intra-Articular Injection of MSCs</title>
        <sec id="section23-1941738114523387">
          <title>Rationale</title>
          <p>Intra-articular injection holds several potential advantages, including reduced recovery time and less cost.<sup><xref rid="bibr15-1941738114523387" ref-type="bibr">15</xref>,<xref rid="bibr25-1941738114523387" ref-type="bibr">25</xref>,<xref rid="bibr33-1941738114523387" ref-type="bibr">33</xref>,<xref rid="bibr58-1941738114523387" ref-type="bibr">58</xref>,<xref rid="bibr64-1941738114523387" ref-type="bibr">64</xref>,<xref rid="bibr101-1941738114523387" ref-type="bibr">101</xref></sup> Same day intra-articular administration of cells surgically obtained from the infrapatellar fat pad has been used to augment arthroscopic debridement.<sup><xref rid="bibr64-1941738114523387" ref-type="bibr">64</xref></sup> From a therapeutic perspective, intra-articular injection may be better matched to the pathogenesis of OA,<sup><xref rid="bibr79-1941738114523387" ref-type="bibr">79</xref>,<xref rid="bibr100-1941738114523387" ref-type="bibr">100</xref></sup> although it may increase the risk of synovial proliferation.<sup><xref rid="bibr63-1941738114523387" ref-type="bibr">63</xref></sup></p>
        </sec>
        <sec id="section24-1941738114523387">
          <title>Cartilage Defects</title>
          <p>In animal studies involving surgically created injuries to anterior cruciate ligaments, menisci, and articular cartilage, intra-articularly administered labeled BM-MSCs migrated to sites of injury.<sup><xref rid="bibr68-1941738114523387" ref-type="bibr">68</xref>,<xref rid="bibr80-1941738114523387" ref-type="bibr">80</xref>,<xref rid="bibr81-1941738114523387" ref-type="bibr">81</xref></sup> To enhance migration to the desired location, Kobayashi et al<sup><xref rid="bibr62-1941738114523387" ref-type="bibr">62</xref></sup> utilized an external magnetic force to direct magnetically labeled, intra-articularly injected BM-MSCs to experimentally created osteochondral defects in rabbit and swine patellae. In a further laboratory study, the magnetic force improved cell adhesion with no deleterious effects on cell proliferation for up to 3 weeks.<sup><xref rid="bibr82-1941738114523387" ref-type="bibr">82</xref></sup></p>
        </sec>
        <sec id="section25-1941738114523387">
          <title>Osteoarthritis</title>
          <p>The anti-inflammatory and immunomodulatory effects of MSCs may retard the progression of OA. Intra-articular injections of stem cells slowed progression of surgically induced OA in goats following a single intra-articular dose of cultured BM-MSCs,<sup><xref rid="bibr81-1941738114523387" ref-type="bibr">81</xref></sup> in rabbits using infrapatellar fat pad–derived MSCs,<sup><xref rid="bibr110-1941738114523387" ref-type="bibr">110</xref></sup> and in rats using MDSCs with transduced genes.<sup><xref rid="bibr73-1941738114523387" ref-type="bibr">73</xref></sup> BM-MSCs may also prevent the onset of posttraumatic OA in mice when injected at the same time as experimentally created closed tibial plateau fracture.<sup><xref rid="bibr30-1941738114523387" ref-type="bibr">30</xref></sup></p>
          <p>Studies of animals with spontaneous OA, as well as experimental OA, have also reported improvement following MSC injection.<sup><xref rid="bibr8-1941738114523387" ref-type="bibr">8</xref>,<xref rid="bibr9-1941738114523387" ref-type="bibr">9</xref>,<xref rid="bibr44-1941738114523387" ref-type="bibr">44</xref>,<xref rid="bibr100-1941738114523387" ref-type="bibr">100</xref></sup> Cell labeling shows incorporation into damaged cartilage and partial cartilage regeneration in guinea pigs using cultured human BM-MSCs.<sup><xref rid="bibr100-1941738114523387" ref-type="bibr">100</xref></sup> Black et al<sup><xref rid="bibr8-1941738114523387" ref-type="bibr">8</xref></sup> reported significant clinical improvement in dogs with spontaneous OA of the coxofemoral joint following intra-articular SVF compared with placebo in a randomized, double-blinded, placebo-controlled trial. Improvements were also noted following a single humeroradial SVF injection for dogs with elbow OA, although with no control group in this study.<sup><xref rid="bibr9-1941738114523387" ref-type="bibr">9</xref></sup> Guercio et al<sup><xref rid="bibr44-1941738114523387" ref-type="bibr">44</xref></sup> found improved clinical benefit following ADSC injection in 4 dogs with lameness due humeroradial OA that had previously failed to respond to anti-inflammatory drugs. While most investigations appear to focus on restoration of articular cartilage, stem cell therapy may also benefit meniscal defects in animals and humans.<sup><xref rid="bibr17-1941738114523387" ref-type="bibr">17</xref>,<xref rid="bibr81-1941738114523387" ref-type="bibr">81</xref></sup></p>
          <p>Orozco et al<sup><xref rid="bibr87-1941738114523387" ref-type="bibr">87</xref></sup> followed 12 patients receiving intra-articular, autologous-expanded BM-MSCs (40 × 10<sup>6</sup> cells) for 1 year, demonstrating significantly improved VAS, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Lequesne scores, with no significant difference in SF-36 and reduction in pain occurring within 3 months. Decreased poor quality cartilage on T2 mapping was seen in 11 patients. No human studies have yet compared MSC injection with other treatments in the absence of concurrent surgery.</p>
        </sec>
        <sec id="section26-1941738114523387">
          <title>Augmenting Surgery</title>
          <p>Mesenchymal stem cell injection has been utilized as an adjunct to surgical techniques in humans<sup><xref rid="bibr64-1941738114523387" ref-type="bibr">64</xref>,<xref rid="bibr69-1941738114523387" ref-type="bibr">69</xref>,<xref rid="bibr101-1941738114523387" ref-type="bibr">101</xref></sup> and animals.<sup><xref rid="bibr75-1941738114523387" ref-type="bibr">75</xref>,<xref rid="bibr107-1941738114523387" ref-type="bibr">107</xref></sup> In goats, BM-MSCs in alginate applied between osteochondral plugs during mosaicplasty was superior at 24 weeks compared with mosaicplasty alone, and better still using transforming growth factor-β1–transduced BM-MSCs.<sup><xref rid="bibr107-1941738114523387" ref-type="bibr">107</xref></sup> Comparing intra-articular BM-MSCs and HA to intra-articular HA alone following microfracture of full-thickness chondral defects in horses, McIlwraith et al<sup><xref rid="bibr75-1941738114523387" ref-type="bibr">75</xref></sup> noted significantly increased firmness and a non-significant trend for better overall repair quality with BM-MSCs.</p>
          <p>The location of the infrapatellar fat pad makes it an attractive harvest target. Koh and Choi<sup><xref rid="bibr64-1941738114523387" ref-type="bibr">64</xref></sup> utilized intra-articular injection of nonexpanded infrapatellar fat cells combined with arthroscopic debridement and PRP in humans with knee OA, with similar 1-year clinical findings compared with controls receiving only PRP post-debridement but significantly worse preoperative clinical (Tegner, Lysholm, and VAS) scores and ICRS grades in the MSC group, favoring a benefit from MSC injection. Of the 25 MSC patients, 18 were reassessed at 2 years, with significantly improved clinical features (WOMAC, Lysholm, and VAS scores) as well as MRI scores compared with preoperative, including significant clinical improvement in patients with grade 3 compared with grade 4 OA.<sup><xref rid="bibr65-1941738114523387" ref-type="bibr">65</xref></sup> The fat pad was acquired at surgery, but the 3- to 4-hour processing necessitated a separate procedure that day.<sup><xref rid="bibr64-1941738114523387" ref-type="bibr">64</xref></sup></p>
          <p>Kim et al<sup><xref rid="bibr61-1941738114523387" ref-type="bibr">61</xref></sup> used non-expanded buttock adipose cells (SVF) as an intra-articular supplement to arthroscopic debridement and microfracture of talar osteochondral lesions. Significantly better clinical scores were obtained with MSC (31 ankles) compared with arthroscopic surgery alone (37 ankles).</p>
          <p>In a randomized trial, Varma et al<sup><xref rid="bibr117-1941738114523387" ref-type="bibr">117</xref></sup> compared 25 patients with mild to moderate knee OA undergoing arthroscopic debridement alone with 25 patients undergoing arthroscopic debridement followed by intra-articular, nonexpanded BMC injection. Significant improvements in activities of daily living, sports and recreational activity, and quality of life scores were seen at 6 months.<sup><xref rid="bibr117-1941738114523387" ref-type="bibr">117</xref></sup></p>
          <p>Saw et al<sup><xref rid="bibr102-1941738114523387" ref-type="bibr">102</xref></sup> randomized 50 patients with ICRS grade 3-4 chondral defects undergoing arthroscopic debridement and subchondral drilling to a series of 8 injections of either non-expanded PBSC and HA or HA alone. Significantly better histologic scores (1066 vs 957) and MRI scores (9.9 vs 8.5) were reported at 18 months, with blinding of the reporting radiologist and pathologist, although no significant difference in IKDC scores at 24 months (74.8 vs 71.1).<sup><xref rid="bibr102-1941738114523387" ref-type="bibr">102</xref></sup></p>
          <p>Lee et al<sup><xref rid="bibr69-1941738114523387" ref-type="bibr">69</xref></sup> compared 35 knee full-thickness chondral defects undergoing arthroscopic debridement and microfracture, followed by outpatient injection of culture-expanded BM-MSC and HA, with 35 matched patients receiving open implantation of BM-MSC sheets beneath a sutured periosteal cover. Both groups showed significantly improved IKDC, Lysholm, VAS, and SF-36 scores at up to 2 years. The arthroscopic-injected group experienced more improvement in IKDC and Lysholm scores compared with the open group but similar improvement in VAS and SF-36 scores. MRI at 1 year showed good defect filling and integration.<sup><xref rid="bibr69-1941738114523387" ref-type="bibr">69</xref></sup></p>
        </sec>
      </sec>
    </sec>
    <sec id="section27-1941738114523387">
      <title>Growth Factors, Platelet-Rich Plasma, Gene Therapy, and Hyaluronic ACID</title>
      <p>Platelet-rich plasma (PRP) is a source of autologous growth factors and an effective treatment for elbow tendinopathy.<sup><xref rid="bibr24-1941738114523387" ref-type="bibr">24</xref></sup> A systematic review of intra-articular PRP injection for cartilage repair has shown safety in humans with potential pain reduction and improved function.<sup><xref rid="bibr36-1941738114523387" ref-type="bibr">36</xref></sup> Longer term follow-up is required before it can be recommended for OA therapy.<sup><xref rid="bibr36-1941738114523387" ref-type="bibr">36</xref></sup> After chemical induction of OA in rat knee joints, Mifune et al<sup><xref rid="bibr76-1941738114523387" ref-type="bibr">76</xref></sup> compared MDSCs expressing bone morphogenetic protein 4 (BMP-4) and sFlt-1 with and without PRP. Improved articular cartilage repair was seen at 4 and 12 weeks with the addition of PRP.</p>
      <p>Hyaluronic acid, a glycosaminoglycan extracellular matrix constituent, has been used for human OA with MRI evaluation up to 24 months showing beneficial effects on cartilage preservation.<sup><xref rid="bibr125-1941738114523387" ref-type="bibr">125</xref></sup> Multiple animal studies have shown the combined use of stem cells and HA to produce better results than HA alone.<sup><xref rid="bibr68-1941738114523387" ref-type="bibr">68</xref>,<xref rid="bibr75-1941738114523387" ref-type="bibr">75</xref>,<xref rid="bibr79-1941738114523387" ref-type="bibr">79</xref>,<xref rid="bibr81-1941738114523387" ref-type="bibr">81</xref></sup></p>
      <p>Following in vitro expansion, stem cells may be induced via transforming growth factor-β1 or BMP-2 to undergo chondrogenic differentiation<sup><xref rid="bibr22-1941738114523387" ref-type="bibr">22</xref>,<xref rid="bibr72-1941738114523387" ref-type="bibr">72</xref></sup> or can be uninduced.<sup><xref rid="bibr93-1941738114523387" ref-type="bibr">93</xref>,<xref rid="bibr129-1941738114523387" ref-type="bibr">129</xref></sup> Encouraging results have been achieved with both approaches compared with controls.<sup><xref rid="bibr22-1941738114523387" ref-type="bibr">22</xref>,<xref rid="bibr129-1941738114523387" ref-type="bibr">129</xref></sup> Comparing induced with uninduced cells in animal studies shows mixed results.<sup><xref rid="bibr22-1941738114523387" ref-type="bibr">22</xref>,<xref rid="bibr72-1941738114523387" ref-type="bibr">72</xref></sup></p>
    </sec>
    <sec id="section28-1941738114523387">
      <title>Safety of Mesenchymal Stem Cell–Related Procedures</title>
      <p>In vitro manipulation creates the opportunity for infection, necessitating antibiotic administration above the minimum inhibitory concentration for relevant organisms while not impeding MSC proliferation and differentiation.<sup><xref rid="bibr59-1941738114523387" ref-type="bibr">59</xref></sup></p>
      <p>Malignancy has been flagged as a potential risk of MSC implantation but has not yet been shown in clinical practice.<sup><xref rid="bibr18-1941738114523387" ref-type="bibr">18</xref>,<xref rid="bibr19-1941738114523387" ref-type="bibr">19</xref>,<xref rid="bibr123-1941738114523387" ref-type="bibr">123</xref></sup> Miura et al<sup><xref rid="bibr77-1941738114523387" ref-type="bibr">77</xref></sup> found that fibrosarcoma developed from murine BM-MSCs after numerous in vitro passages. Tolar et al<sup><xref rid="bibr111-1941738114523387" ref-type="bibr">111</xref></sup> also identified sarcomatous transformation from mouse BM-MSCs expanded in vitro.</p>
      <p>In 2005, Rubio et al<sup><xref rid="bibr97-1941738114523387" ref-type="bibr">97</xref></sup> reported that after long-term in vitro culture of 4 to 5 months, human ADSCs exhibited malignant transformation. The group retracted this article in 2010, unable to reproduce the findings, proposing potential cross-contamination.<sup><xref rid="bibr29-1941738114523387" ref-type="bibr">29</xref></sup> Another group described spontaneous transformation of BM-MSCs due to cross-contamination by immortalized cell lines, emphasizing the need for DNA fingerprinting.<sup><xref rid="bibr96-1941738114523387" ref-type="bibr">96</xref>,<xref rid="bibr112-1941738114523387" ref-type="bibr">112</xref></sup></p>
      <p>Bernardo et al<sup><xref rid="bibr7-1941738114523387" ref-type="bibr">7</xref></sup> found that human BM-MSCs did not demonstrate malignant transformation after long-term culture, showing telomeric shortening with progressive decline in proliferation until reaching senescence.</p>
    </sec>
    <sec sec-type="discussion" id="section29-1941738114523387">
      <title>Discussion</title>
      <p>Cell therapy represents promising treatment for many conditions, including joint disorders. The most widely practiced form, ACI and its newer variants, is capable of promoting cartilage repair and providing clinical benefit, although there is insufficient evidence to recommend these procedures over marrow stimulation techniques and osteochondral grafting.<sup><xref rid="bibr83-1941738114523387" ref-type="bibr">83</xref></sup> Only limited human data exist for use of MSCs, but both surgical implantation and intra-articular injection appear to be safe and exhibit reasonable efficacy. There is currently a paucity of randomized human trials.</p>
      <p>Cell sources that do not require in vitro expansion, such as BMC or SVF, provide the opportunity for same day therapy by reducing the turnaround time from cell harvest to treatment.<sup><xref rid="bibr38-1941738114523387" ref-type="bibr">38</xref>,<xref rid="bibr64-1941738114523387" ref-type="bibr">64</xref></sup> Intra-articular injection offers a reduction in postoperative recovery time.<sup><xref rid="bibr8-1941738114523387" ref-type="bibr">8</xref>,<xref rid="bibr64-1941738114523387" ref-type="bibr">64</xref>,<xref rid="bibr117-1941738114523387" ref-type="bibr">117</xref></sup> For chondral injury, MSC therapy may improve symptom control through anti-inflammatory and immunomodulatory effects.<sup><xref rid="bibr19-1941738114523387" ref-type="bibr">19</xref></sup></p>
    </sec>
    <sec sec-type="conclusions" id="section30-1941738114523387">
      <title>Conclusion</title>
      <p>At present, there is no conclusive evidence to recommend cell therapy over non-cell-based procedures, but both treatments appear to offer beneficial results. Non–stem cell therapy such as ACI, mosaicplasty, and microfracture at present possesses more clinical evidence than MSC treatments.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="conflict">
        <p>The following authors declared potential conflicts of interest: Daniel Bates, BSc (Hons), BMed, is a consultant for Bio Stem Cell, Hong Kong and has stock/stock options with Prostem and Cell Medicine Australia; Richard Boyd, BSc (Hons), PhD, is a board member of and has stock options with Magellan.<?release-delay 12|0?></p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="bibr1-1941738114523387">
        <label>1.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Adachi</surname><given-names>N</given-names></name><name><surname>Sato</surname><given-names>K</given-names></name><name><surname>Usas</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Muscle derived, cell based ex vivo gene therapy for treatment of full thickness articular cartilage defects</article-title>. <source>J Rheumatol</source>. <year>2002</year>;<volume>29</volume>:<fpage>1920</fpage>-<lpage>1930</lpage>.<pub-id pub-id-type="pmid">12233887</pub-id></mixed-citation>
      </ref>
      <ref id="bibr2-1941738114523387">
        <label>2.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Adachi</surname><given-names>N</given-names></name><name><surname>Ochi</surname><given-names>M</given-names></name><name><surname>Deie</surname><given-names>M</given-names></name><name><surname>Ito</surname><given-names>Y</given-names></name></person-group>
<article-title>Transplant of mesenchymal stem cells and hydroxyapatite ceramics to treat severe osteochondral damage after septic arthritis of the knee</article-title>. <source>J Rheumatol</source>. <year>2005</year>;<volume>32</volume>:<fpage>1615</fpage>-<lpage>1618</lpage>.<pub-id pub-id-type="pmid">16078345</pub-id></mixed-citation>
      </ref>
      <ref id="bibr3-1941738114523387">
        <label>3.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aust</surname><given-names>L</given-names></name><name><surname>Devlin</surname><given-names>B</given-names></name><name><surname>Foster</surname><given-names>SJ</given-names></name><etal/></person-group>
<article-title>Yield of human adipose-derived stem cells from liposuction aspirates</article-title>. <source>Cytotherapy</source>. <year>2004</year>;<volume>6</volume>:<fpage>7</fpage>-<lpage>14</lpage>.<pub-id pub-id-type="pmid">14985162</pub-id></mixed-citation>
      </ref>
      <ref id="bibr4-1941738114523387">
        <label>4.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bartlett</surname><given-names>W</given-names></name><name><surname>Skinner</surname><given-names>JA</given-names></name><name><surname>Gooding</surname><given-names>CR</given-names></name><etal/></person-group>
<article-title>Autologous chondrocyte implantation versus matrix-induced autologous chondrocyte implantation for osteochondral defects of the knee</article-title>. <source>J Bone Joint Surg Br</source>. <year>2005</year>;<volume>87</volume>:<fpage>640</fpage>-<lpage>645</lpage>.<pub-id pub-id-type="pmid">15855365</pub-id></mixed-citation>
      </ref>
      <ref id="bibr5-1941738114523387">
        <label>5.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Basad</surname><given-names>E</given-names></name><name><surname>Ishaque</surname><given-names>B</given-names></name><name><surname>Bachmann</surname><given-names>G</given-names></name><name><surname>Stürz</surname><given-names>H</given-names></name><name><surname>Steinmeyer</surname><given-names>J</given-names></name></person-group>
<article-title>Matrix-induced autologous chondrocyte implantation versus microfracture in the treatment of cartilage defects of the knee: a 2-year randomised study</article-title>. <source>Knee Surg Sports Traumatol Arthrosc</source>. <year>2010</year>;<volume>18</volume>:<fpage>519</fpage>-<lpage>527</lpage>.<pub-id pub-id-type="pmid">20062969</pub-id></mixed-citation>
      </ref>
      <ref id="bibr6-1941738114523387">
        <label>6.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Battaglia</surname><given-names>M</given-names></name><name><surname>Rimondi</surname><given-names>E</given-names></name><name><surname>Monti</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Validity of T2 mapping in characterization of the regeneration tissue by bone marrow derived cell transplantation in osteochondral lesions of the ankle</article-title>. <source>Eur J Radiol</source>. <year>2011</year>;<volume>80</volume>:<fpage>e132</fpage>-<lpage>e139</lpage>.<pub-id pub-id-type="pmid">20801594</pub-id></mixed-citation>
      </ref>
      <ref id="bibr7-1941738114523387">
        <label>7.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bernardo</surname><given-names>ME</given-names></name><name><surname>Zaffaroni</surname><given-names>N</given-names></name><name><surname>Novara</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Human bone marrow–derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms</article-title>. <source>Cancer Res</source>. <year>2007</year>;<volume>67</volume>:<fpage>9142</fpage>-<lpage>9149</lpage>.<pub-id pub-id-type="pmid">17909019</pub-id></mixed-citation>
      </ref>
      <ref id="bibr8-1941738114523387">
        <label>8.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Black</surname><given-names>LL</given-names></name><name><surname>Gaynor</surname><given-names>J</given-names></name><name><surname>Gahring</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Effect of adipose-derived mesenchymal stem and regenerative cells on lameness in dogs with chronic osteoarthritis of the coxofemoral joints: a randomized, double-blinded, multicentre, controlled trial</article-title>. <source>Vet Ther</source>. <year>2007</year>;<volume>8</volume>:<fpage>272</fpage>-<lpage>284</lpage>.<pub-id pub-id-type="pmid">18183546</pub-id></mixed-citation>
      </ref>
      <ref id="bibr9-1941738114523387">
        <label>9.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Black</surname><given-names>LL</given-names></name><name><surname>Gaynor</surname><given-names>J</given-names></name><name><surname>Adams</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Effect of intraarticular injection of autologous adipose-derived mesenchymal stem and regenerative cells on clinical signs of chronic osteoarthritis of the elbow joint in dogs</article-title>. <source>Vet Ther</source>. <year>2008</year>;<volume>9</volume>:<fpage>192</fpage>-<lpage>200</lpage>.<pub-id pub-id-type="pmid">19003780</pub-id></mixed-citation>
      </ref>
      <ref id="bibr10-1941738114523387">
        <label>10.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brittberg</surname><given-names>M</given-names></name><name><surname>Lindahl</surname><given-names>A</given-names></name><name><surname>Nilsson</surname><given-names>A</given-names></name><name><surname>Ohlsson</surname><given-names>C</given-names></name><name><surname>Isaksson</surname><given-names>O</given-names></name><name><surname>Peterson</surname><given-names>L</given-names></name></person-group>
<article-title>Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation</article-title>. <source>N Eng J Med</source>. <year>1994</year>;<volume>331</volume>:<fpage>889</fpage>-<lpage>895</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr11-1941738114523387">
        <label>11.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brittberg</surname><given-names>M</given-names></name></person-group>
<article-title>Cell carriers as the next generation of cell therapy for cartilage repair: a review of the matrix-induced autologous chondrocyte implantation procedure</article-title>. <source>Am J Sports Med</source>. <year>2010</year>;<volume>38</volume>:<fpage>1259</fpage>-<lpage>1271</lpage>.<pub-id pub-id-type="pmid">19966108</pub-id></mixed-citation>
      </ref>
      <ref id="bibr12-1941738114523387">
        <label>12.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Buda</surname><given-names>R</given-names></name><name><surname>Vannini</surname><given-names>F</given-names></name><name><surname>Cavallo</surname><given-names>M</given-names></name><name><surname>Grigolo</surname><given-names>B</given-names></name><name><surname>Cenacchi</surname><given-names>A</given-names></name><name><surname>Giannini</surname><given-names>S</given-names></name></person-group>
<article-title>Osteochondral lesions of the knee: a new one-step repair technique with bone-marrow derived cells</article-title>. <source>J Bone Joint Surg Am</source>. <year>2010</year>;<volume>92</volume>(<issue>suppl 2</issue>):<fpage>2</fpage>-<lpage>11</lpage>.<pub-id pub-id-type="pmid">21123588</pub-id></mixed-citation>
      </ref>
      <ref id="bibr13-1941738114523387">
        <label>13.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cai</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Hauschka</surname><given-names>PV</given-names></name><name><surname>Grottkau</surname><given-names>BE</given-names></name></person-group>
<article-title>Adipose stem cells originate from perivascular cells</article-title>. <source>Biol Cell</source>. <year>2011</year>;<volume>103</volume>:<fpage>435</fpage>-<lpage>447</lpage>.<pub-id pub-id-type="pmid">21679159</pub-id></mixed-citation>
      </ref>
      <ref id="bibr14-1941738114523387">
        <label>14.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Caplan</surname><given-names>AI</given-names></name><name><surname>Dennis</surname><given-names>JE</given-names></name></person-group>
<article-title>Mesenchymal stem cells as trophic mediators</article-title>. <source>J Cell Biochem</source>. <year>2006</year>;<volume>98</volume>:<fpage>1076</fpage>-<lpage>1084</lpage>.<pub-id pub-id-type="pmid">16619257</pub-id></mixed-citation>
      </ref>
      <ref id="bibr15-1941738114523387">
        <label>15.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Centeno</surname><given-names>CJ</given-names></name><name><surname>Kisiday</surname><given-names>J</given-names></name><name><surname>Freeman</surname><given-names>M</given-names></name><name><surname>Schultz</surname><given-names>JR</given-names></name></person-group>
<article-title>Partial regeneration of the human hip via autologous bone marrow nucleated cell transfer: a case study</article-title>. <source>Pain Physician</source>. <year>2006</year>;<volume>9</volume>:<fpage>253</fpage>-<lpage>256</lpage>.<pub-id pub-id-type="pmid">16886034</pub-id></mixed-citation>
      </ref>
      <ref id="bibr16-1941738114523387">
        <label>16.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Centeno</surname><given-names>CJ</given-names></name><name><surname>Busse</surname><given-names>D</given-names></name><name><surname>Kisiday</surname><given-names>J</given-names></name><name><surname>Keohan</surname><given-names>C</given-names></name><name><surname>Freeman</surname><given-names>M</given-names></name><name><surname>Karli</surname><given-names>D</given-names></name></person-group>
<article-title>Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells</article-title>. <source>Pain Physician</source>. <year>2008</year>;<volume>11</volume>:<fpage>343</fpage>-<lpage>353</lpage>.<pub-id pub-id-type="pmid">18523506</pub-id></mixed-citation>
      </ref>
      <ref id="bibr17-1941738114523387">
        <label>17.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Centeno</surname><given-names>CJ</given-names></name><name><surname>Busse</surname><given-names>D</given-names></name><name><surname>Kisiday</surname><given-names>J</given-names></name><name><surname>Keohan</surname><given-names>C</given-names></name><name><surname>Freeman</surname><given-names>M</given-names></name><name><surname>Karli</surname><given-names>D</given-names></name></person-group>
<article-title>Regeneration of meniscus cartilage in a knee treated with percutaneously implanted autologous mesenchymal stem cells</article-title>. <source>Med Hypotheses</source>. <year>2008</year>;<volume>71</volume>:<fpage>900</fpage>-<lpage>908</lpage>.<pub-id pub-id-type="pmid">18786777</pub-id></mixed-citation>
      </ref>
      <ref id="bibr18-1941738114523387">
        <label>18.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Centeno</surname><given-names>CJ</given-names></name><name><surname>Schultz</surname><given-names>JR</given-names></name><name><surname>Cheever</surname><given-names>M</given-names></name><name><surname>Robinson</surname><given-names>B</given-names></name><name><surname>Freeman</surname><given-names>M</given-names></name><name><surname>Marasco</surname><given-names>W</given-names></name></person-group>
<article-title>Safety and complications reporting on the re-implantation of culture-expanded mesenchymal stem cells using autologous platelet lysate technique</article-title>. <source>Curr Stem Cell Res Ther</source>. <year>2010</year>;<volume>5</volume>:<fpage>81</fpage>-<lpage>93</lpage>.<pub-id pub-id-type="pmid">19951252</pub-id></mixed-citation>
      </ref>
      <ref id="bibr19-1941738114523387">
        <label>19.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Centeno</surname><given-names>CJ</given-names></name><name><surname>Schultz</surname><given-names>JR</given-names></name><name><surname>Cheever</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Safety and complications reporting update on the re-implantation of culture-expanded mesenchymal stem cells using autologous platelet lysate technique</article-title>. <source>Curr Stem Cell Res Ther</source>. <year>2011</year>;<volume>6</volume>:<fpage>368</fpage>-<lpage>378</lpage>.<pub-id pub-id-type="pmid">22023622</pub-id></mixed-citation>
      </ref>
      <ref id="bibr20-1941738114523387">
        <label>20.</label>
        <mixed-citation publication-type="gov">
<collab>Center for Biologics Evaluation and Research, Food and Drug Administration, US Department of Health and Human Services</collab>. <article-title>Guidance for industry regulation of human cells, tissues, and cellular and tissue-based products (HCT/Ps): small entity compliance guide</article-title>. <month>8</month>
<year>2007</year>
<ext-link ext-link-type="uri" xlink:href="http://permanent.access.gpo.gov/LPS112358/LPS112358_ucm062592.pdf">http://permanent.access.gpo.gov/LPS112358/LPS112358_ucm062592.pdf</ext-link>
<date-in-citation>Accessed January 29, 2014</date-in-citation>.</mixed-citation>
      </ref>
      <ref id="bibr21-1941738114523387">
        <label>21.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cesselli</surname><given-names>D</given-names></name><name><surname>Beltrami</surname><given-names>AP</given-names></name><name><surname>Rigo</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Multipotent progenitor cells are present in human peripheral blood</article-title>. <source>Circ Res</source>. <year>2009</year>;<volume>104</volume>:<fpage>1225</fpage>-<lpage>1234</lpage>.<pub-id pub-id-type="pmid">19390058</pub-id></mixed-citation>
      </ref>
      <ref id="bibr22-1941738114523387">
        <label>22.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chang</surname><given-names>CH</given-names></name><name><surname>Kuo</surname><given-names>TF</given-names></name><name><surname>Lin</surname><given-names>FH</given-names></name><etal/></person-group>
<article-title>Tissue engineering-based cartilage repair with mesenchymal stem cells in a porcine model</article-title>. <source>J Orthop Res</source>. <year>2011</year>;<volume>29</volume>:<fpage>1874</fpage>-<lpage>1880</lpage>.<pub-id pub-id-type="pmid">21630328</pub-id></mixed-citation>
      </ref>
      <ref id="bibr23-1941738114523387">
        <label>23.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chong</surname><given-names>PP</given-names></name><name><surname>Selvaratnam</surname><given-names>L</given-names></name><name><surname>Abbas</surname><given-names>AA</given-names></name><name><surname>Kamarul</surname><given-names>T</given-names></name></person-group>
<article-title>Human peripheral blood derived mesenchymal stem cells demonstrate similar characteristics and chondrogenic differentiation potential to bone marrow derived mesenchymal stem cells</article-title>. <source>J Orthop Res</source>. <year>2012</year>;<volume>30</volume>:<fpage>634</fpage>-<lpage>642</lpage>.<pub-id pub-id-type="pmid">21922534</pub-id></mixed-citation>
      </ref>
      <ref id="bibr24-1941738114523387">
        <label>24.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Creaney</surname><given-names>L</given-names></name><name><surname>Wallace</surname><given-names>A</given-names></name><name><surname>Curtis</surname><given-names>M</given-names></name><name><surname>Connell</surname><given-names>D</given-names></name></person-group>
<article-title>Growth factor-based therapies provide additional benefit beyond physical therapy in resistant elbow tendinopathy: a prospective, single-blind, randomised trial of autologous blood injections versus platelet-rich plasma injections</article-title>. <source>Br J Sports Med</source>. <year>2011</year>;<volume>45</volume>:<fpage>966</fpage>-<lpage>971</lpage>.<pub-id pub-id-type="pmid">21406450</pub-id></mixed-citation>
      </ref>
      <ref id="bibr25-1941738114523387">
        <label>25.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Davatchi</surname><given-names>F</given-names></name><name><surname>Abdollahi</surname><given-names>BS</given-names></name><name><surname>Mohyeddin</surname><given-names>M</given-names></name><name><surname>Shahram</surname><given-names>F</given-names></name><name><surname>Nikbin</surname><given-names>B</given-names></name></person-group>
<article-title>Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients</article-title>. <source>Int J Rheum Dis</source>. <year>2011</year>;<volume>14</volume>:<fpage>211</fpage>-<lpage>215</lpage>.<pub-id pub-id-type="pmid">21518322</pub-id></mixed-citation>
      </ref>
      <ref id="bibr26-1941738114523387">
        <label>26.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Bari</surname><given-names>C</given-names></name><name><surname>Dell’Accio</surname><given-names>F</given-names></name><name><surname>Luyten</surname><given-names>FP</given-names></name></person-group>
<article-title>Failure of in vitro–differentiated mesenchymal stem cells from the synovial membrane to form ectopic stable cartilage in vivo</article-title>. <source>Arthritis Rheum</source>. <year>2004</year>;<volume>50</volume>:<fpage>142</fpage>-<lpage>150</lpage>.<pub-id pub-id-type="pmid">14730610</pub-id></mixed-citation>
      </ref>
      <ref id="bibr27-1941738114523387">
        <label>27.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Bari</surname><given-names>C</given-names></name><name><surname>Dell’Accio</surname><given-names>F</given-names></name><name><surname>Vanlauwe</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Mesenchymal multipotency of adult human periosteal cells demonstrated by single-cell lineage analysis</article-title>. <source>Arthritis Rheum</source>. <year>2006</year>;<volume>54</volume>:<fpage>1209</fpage>-<lpage>1221</lpage>.<pub-id pub-id-type="pmid">16575900</pub-id></mixed-citation>
      </ref>
      <ref id="bibr28-1941738114523387">
        <label>28.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dean</surname><given-names>DD</given-names></name><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name><name><surname>Pelletier</surname><given-names>JP</given-names></name><name><surname>Howell</surname><given-names>DS</given-names></name><name><surname>Woessner</surname><given-names>JF</given-names><suffix>Jr.</suffix></name></person-group>
<article-title>Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage</article-title>. <source>J Clin Invest</source>. <year>1989</year>;<volume>84</volume>:<fpage>678</fpage>-<lpage>685</lpage>.<pub-id pub-id-type="pmid">2760206</pub-id></mixed-citation>
      </ref>
      <ref id="bibr29-1941738114523387">
        <label>29.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de</surname><given-names>la</given-names></name><name><surname>Fuente</surname><given-names>R</given-names></name><name><surname>Bernad</surname><given-names>A</given-names></name><name><surname>Garcia-Castro</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>MC</given-names></name><name><surname>Ciqudosa</surname><given-names>JC</given-names></name></person-group>
<article-title>Retraction: spontaneous human adult stem cell transformation</article-title>. <source>Cancer Res</source>. <year>2010</year>;<volume>70</volume>:<fpage>6682</fpage>.<pub-id pub-id-type="pmid">20710046</pub-id></mixed-citation>
      </ref>
      <ref id="bibr30-1941738114523387">
        <label>30.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Diekman</surname><given-names>BO</given-names></name><name><surname>Wu</surname><given-names>CL</given-names></name><name><surname>Louer</surname><given-names>CR</given-names></name><etal/></person-group>
<article-title>Intra-articular delivery of purified mesenchymal stem cells from C57BL/6 or MRL/MpJ superhealer mice prevents post-traumatic arthritis</article-title>. <source>Cell Transplant</source>. <year>2013</year>;<volume>22</volume>:<fpage>1395</fpage>-<lpage>1408</lpage>.<pub-id pub-id-type="pmid">22889498</pub-id></mixed-citation>
      </ref>
      <ref id="bibr31-1941738114523387">
        <label>31.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dragoo</surname><given-names>JL</given-names></name><name><surname>Carlson</surname><given-names>G</given-names></name><name><surname>McCormick</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Healing full-thickness cartilage defects using adipose-derived stem cells</article-title>. <source>Tissue Eng</source>. <year>2007</year>;<volume>13</volume>:<fpage>1615</fpage>-<lpage>1621</lpage>.<pub-id pub-id-type="pmid">17518742</pub-id></mixed-citation>
      </ref>
      <ref id="bibr32-1941738114523387">
        <label>32.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>D’Souza</surname><given-names>A</given-names></name><name><surname>Jaiyesimi</surname><given-names>I</given-names></name><name><surname>Trainor</surname><given-names>L</given-names></name><name><surname>Venuturumili</surname><given-names>P</given-names></name></person-group>
<article-title>Granulocyte colony-stimulating factor administration: adverse events</article-title>. <source>Transfus Med Rev</source>. <year>2008</year>;<volume>22</volume>:<fpage>280</fpage>-<lpage>290</lpage>.<pub-id pub-id-type="pmid">18848155</pub-id></mixed-citation>
      </ref>
      <ref id="bibr33-1941738114523387">
        <label>33.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Emadedin</surname><given-names>M</given-names></name><name><surname>Aghdami</surname><given-names>N</given-names></name><name><surname>Taghiyar</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Intra-articular injection of autologous mesenchymal stem cells in six patients with knee osteoarthritis</article-title>. <source>Arch Iran Med</source>. <year>2012</year>;<volume>15</volume>:<fpage>422</fpage>-<lpage>428</lpage>.<pub-id pub-id-type="pmid">22724879</pub-id></mixed-citation>
      </ref>
      <ref id="bibr34-1941738114523387">
        <label>34.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Enea</surname><given-names>D</given-names></name><name><surname>Cecconi</surname><given-names>S</given-names></name><name><surname>Calcagno</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Single-stage cartilage repair in the knee with microfracture covered with a resorbable polymer-based matrix and autologous bone marrow concentrate</article-title>. <source>Knee</source>. <year>2013</year>;<volume>20</volume>:<fpage>562</fpage>-<lpage>569</lpage>.<pub-id pub-id-type="pmid">23642661</pub-id></mixed-citation>
      </ref>
      <ref id="bibr35-1941738114523387">
        <label>35.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Frisbie</surname><given-names>DD</given-names></name><name><surname>Kisiday</surname><given-names>JD</given-names></name><name><surname>Kawcak</surname><given-names>CE</given-names></name><name><surname>Werpy</surname><given-names>NM</given-names></name><name><surname>McIlwraith</surname><given-names>CW</given-names></name></person-group>
<article-title>Evaluation of adipose-derived stromal vascular fraction or bone marrow–derived mesenchymal stem cells for treatment of osteoarthritis</article-title>. <source>J Orthop Res</source>. <year>2009</year>;<volume>27</volume>:<fpage>1675</fpage>-<lpage>1680</lpage>.<pub-id pub-id-type="pmid">19544397</pub-id></mixed-citation>
      </ref>
      <ref id="bibr36-1941738114523387">
        <label>36.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Frizziero</surname><given-names>A</given-names></name><name><surname>Giannotti</surname><given-names>E</given-names></name><name><surname>Ferraro</surname><given-names>C</given-names></name><name><surname>Masiero</surname><given-names>S</given-names></name></person-group>
<article-title>Platelet rich plasma intra-articular injections: a new therapeutic strategy for the treatment of knee osteoarthritis in sport rehabilitation. A systematic review</article-title>. <source>Sport Sci Health</source>. <year>2012</year>;<volume>8</volume>:<fpage>15</fpage>-<lpage>22</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr37-1941738114523387">
        <label>37.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gargett</surname><given-names>CE</given-names></name><name><surname>Masuda</surname><given-names>H</given-names></name></person-group>
<article-title>Adult stem cells in the endometrium</article-title>. <source>Mol Hum Reprod</source>. <year>2010</year>;<volume>16</volume>:<fpage>818</fpage>-<lpage>834</lpage>.<pub-id pub-id-type="pmid">20627991</pub-id></mixed-citation>
      </ref>
      <ref id="bibr38-1941738114523387">
        <label>38.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Giannini</surname><given-names>S</given-names></name><name><surname>Buda</surname><given-names>R</given-names></name><name><surname>Vannini</surname><given-names>F</given-names></name><name><surname>Cavallo</surname><given-names>M</given-names></name><name><surname>Grigolo</surname><given-names>B</given-names></name></person-group>
<article-title>One-step bone marrow–derived cell transplantation in talar osteochondral lesions</article-title>. <source>Clin Orthop Relat Res</source>. <year>2009</year>;<volume>467</volume>:<fpage>3307</fpage>-<lpage>3320</lpage>.<pub-id pub-id-type="pmid">19449082</pub-id></mixed-citation>
      </ref>
      <ref id="bibr39-1941738114523387">
        <label>39.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Giannini</surname><given-names>S</given-names></name><name><surname>Buda</surname><given-names>R</given-names></name><name><surname>Cavallo</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Cartilage repair evolution in post-traumatic osteochondral lesions of the talus: from open field autologous chondrocyte to bone-marrow–derived cells transplantation</article-title>. <source>Injury</source>. <year>2010</year>;<volume>41</volume>:<fpage>1196</fpage>-<lpage>1203</lpage>.<pub-id pub-id-type="pmid">20934692</pub-id></mixed-citation>
      </ref>
      <ref id="bibr40-1941738114523387">
        <label>40.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Giannini</surname><given-names>S</given-names></name><name><surname>Buda</surname><given-names>R</given-names></name><name><surname>Battaglia</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>One-step repair in talar osteochondral lesions. 4-year clinical results and T2-mapping capability in outcome prediction</article-title>. <source>Am J Sports Med</source>. <year>2013</year>;<volume>41</volume>:<fpage>511</fpage>-<lpage>518</lpage>.<pub-id pub-id-type="pmid">23221772</pub-id></mixed-citation>
      </ref>
      <ref id="bibr41-1941738114523387">
        <label>41.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gigante</surname><given-names>A</given-names></name><name><surname>Calcagno</surname><given-names>S</given-names></name><name><surname>Cecconi</surname><given-names>S</given-names></name><name><surname>Ramazzotti</surname><given-names>D</given-names></name><name><surname>Manzotti</surname><given-names>S</given-names></name><name><surname>Enea</surname><given-names>D</given-names></name></person-group>
<article-title>Use of collagen scaffold and autologous bone marrow concentrate as a one-step cartilage repair in the knee: histological results of second-look biopsies at 1 year follow-up</article-title>. <source>Int J Immunopathol Pharmacol</source>. <year>2011</year>;<volume>24</volume>(<issue>suppl 2</issue>):<fpage>69</fpage>-<lpage>72</lpage>.<pub-id pub-id-type="pmid">21669141</pub-id></mixed-citation>
      </ref>
      <ref id="bibr42-1941738114523387">
        <label>42.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gigante</surname><given-names>A</given-names></name><name><surname>Cecconi</surname><given-names>S</given-names></name><name><surname>Calcagno</surname><given-names>S</given-names></name><name><surname>Busilacchi</surname><given-names>A</given-names></name><name><surname>Enea</surname><given-names>D</given-names></name></person-group>
<article-title>Arthroscopic knee cartilage repair with covered microfracture and bone marrow concentrate</article-title>. <source>Arthrosc Tech</source>. <year>2012</year>;<volume>1</volume>:<fpage>e175</fpage>-<lpage>e180</lpage>.<pub-id pub-id-type="pmid">23766992</pub-id></mixed-citation>
      </ref>
      <ref id="bibr43-1941738114523387">
        <label>43.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gobbi</surname><given-names>A</given-names></name><name><surname>Karnatzikos</surname><given-names>G</given-names></name><name><surname>Scotti</surname><given-names>C</given-names></name><name><surname>Mahajan</surname><given-names>V</given-names></name><name><surname>Mazzucco</surname><given-names>L</given-names></name><name><surname>Grigolo</surname><given-names>B</given-names></name></person-group>
<article-title>One-step cartilage repair with bone marrow aspirate concentrated cells and collagen matrix in full-thickness knee cartilage lesions: results at 2-year follow-up</article-title>. <source>Cartilage</source>. <year>2011</year>;<volume>2</volume>:<fpage>286</fpage>-<lpage>299</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr44-1941738114523387">
        <label>44.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guercio</surname><given-names>A</given-names></name><name><surname>Di Marco</surname><given-names>P</given-names></name><name><surname>Casella</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Production of canine mesenchymal stem cells from adipose tissue and their application in dogs with chronic osteoarthritis of the humeroradial joints</article-title>. <source>Cell Biol Int</source>. <year>2012</year>:<volume>36</volume>:<fpage>189</fpage>-<lpage>194</lpage>.<pub-id pub-id-type="pmid">21936851</pub-id></mixed-citation>
      </ref>
      <ref id="bibr45-1941738114523387">
        <label>45.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haleem</surname><given-names>AM</given-names></name><name><surname>Singergy</surname><given-names>AA</given-names></name><name><surname>Sabry</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>The clinical use of human culture-expanded autologous bone marrow mesenchymal stem cells transplanted on platelet-rich fibrin glue in the treatment of articular cartilage defects: a pilot study and preliminary results</article-title>. <source>Cartilage</source>. <year>2010</year>;<volume>1</volume>:<fpage>253</fpage>-<lpage>261</lpage>.<pub-id pub-id-type="pmid">21170288</pub-id></mixed-citation>
      </ref>
      <ref id="bibr46-1941738114523387">
        <label>46.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name></person-group>
<article-title>Cartilage regeneration using adipose-derived stem cells and the controlled-release hybrid microspheres</article-title>. <source>Joint Bone Spine</source>. <year>2010</year>;<volume>77</volume>:<fpage>27</fpage>-<lpage>31</lpage>.<pub-id pub-id-type="pmid">20022784</pub-id></mixed-citation>
      </ref>
      <ref id="bibr47-1941738114523387">
        <label>47.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Harvanová</surname><given-names>D</given-names></name><name><surname>Táthová</surname><given-names>T</given-names></name><name><surname>Sarišsky</surname><given-names>M</given-names></name><name><surname>Amrichová</surname><given-names>J</given-names></name><name><surname>Rosocha</surname><given-names>J</given-names></name></person-group>
<article-title>Isolation and characterization of synovial mesenchymal stem cells</article-title>. <source>Folia Biol (Praha)</source>. <year>2011</year>;<volume>57</volume>:<fpage>119</fpage>-<lpage>124</lpage>.<pub-id pub-id-type="pmid">21888835</pub-id></mixed-citation>
      </ref>
      <ref id="bibr48-1941738114523387">
        <label>48.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Heng</surname><given-names>TS</given-names></name><name><surname>Dudakov</surname><given-names>JA</given-names></name><name><surname>Khong</surname><given-names>DM</given-names></name><name><surname>Chidgey</surname><given-names>AP</given-names></name><name><surname>Boyd</surname><given-names>RL</given-names></name></person-group>
<article-title>Stem cells—meet immunity</article-title>. <source>J Mol Med (Berl)</source>. <year>2009</year>;<volume>87</volume>:<fpage>1061</fpage>-<lpage>1069</lpage>.<pub-id pub-id-type="pmid">19841876</pub-id></mixed-citation>
      </ref>
      <ref id="bibr49-1941738114523387">
        <label>49.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hernigou</surname><given-names>P</given-names></name><name><surname>Beaujean</surname><given-names>F</given-names></name></person-group>
<article-title>Treatment of osteonecrosis with autologous bone marrow grafting</article-title>. <source>Clin Orthop Relat Res</source>. <year>2002</year>;(<issue>405</issue>):<fpage>14</fpage>-<lpage>23</lpage>.<pub-id pub-id-type="pmid">12461352</pub-id></mixed-citation>
      </ref>
      <ref id="bibr50-1941738114523387">
        <label>50.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hernigou</surname><given-names>P</given-names></name><name><surname>Poignard</surname><given-names>A</given-names></name><name><surname>Beaujean</surname><given-names>F</given-names></name><name><surname>Rouard</surname><given-names>H</given-names></name></person-group>
<article-title>Percutaneous autologous bone-marrow grafting for nonunions. Influence of the number and concentration of progenitor cells</article-title>. <source>J Bone Joint Surg Am</source>. <year>2005</year>;<volume>87</volume>:<fpage>1430</fpage>-<lpage>1437</lpage>.<pub-id pub-id-type="pmid">15995108</pub-id></mixed-citation>
      </ref>
      <ref id="bibr51-1941738114523387">
        <label>51.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ho</surname><given-names>PJ</given-names></name><name><surname>Yen</surname><given-names>ML</given-names></name><name><surname>Yet</surname><given-names>SF</given-names></name><name><surname>Yen</surname><given-names>BL</given-names></name></person-group>
<article-title>Current applications of human pluripotent stem cells: possibilities and challenges</article-title>. <source>Cell Transplant</source>. <year>2012</year>;<volume>21</volume>:<fpage>801</fpage>-<lpage>814</lpage>.<pub-id pub-id-type="pmid">22449556</pub-id></mixed-citation>
      </ref>
      <ref id="bibr52-1941738114523387">
        <label>52.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>CY</given-names></name><name><surname>Reuben</surname><given-names>PM</given-names></name><name><surname>D’Ippolito</surname><given-names>G</given-names></name><name><surname>Schiller</surname><given-names>PC</given-names></name><name><surname>Cheung</surname><given-names>HS</given-names></name></person-group>
<article-title>Chondrogenesis of human bone marrow-derived mesenchymal stem cells in agarose culture</article-title>. <source>Anat Rec A Discov Mol Cell Evol Biol</source>. <year>2004</year>;<volume>278</volume>:<fpage>428</fpage>-<lpage>436</lpage>.<pub-id pub-id-type="pmid">15103737</pub-id></mixed-citation>
      </ref>
      <ref id="bibr53-1941738114523387">
        <label>53.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>in ‘t Anker</surname><given-names>PS</given-names></name><name><surname>Scherjon</surname><given-names>SA</given-names></name><name><surname>Kleijburg-van der</surname><given-names>Keur</given-names></name><etal/></person-group>
<article-title>Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation</article-title>. <source>Blood</source>. <year>2003</year>;<volume>102</volume>:<fpage>1548</fpage>-<lpage>1549</lpage>.<pub-id pub-id-type="pmid">12900350</pub-id></mixed-citation>
      </ref>
      <ref id="bibr54-1941738114523387">
        <label>54.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>in ‘t Anker</surname><given-names>PS</given-names></name><name><surname>Scherjon</surname><given-names>SA</given-names></name><name><surname>Kleijburg-van</surname><given-names>der</given-names></name><name><surname>Keur</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta</article-title>. <source>Stem Cells</source>. <year>2004</year>;<volume>22</volume>:<fpage>1338</fpage>-<lpage>1345</lpage>.<pub-id pub-id-type="pmid">15579651</pub-id></mixed-citation>
      </ref>
      <ref id="bibr55-1941738114523387">
        <label>55.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jaiswal</surname><given-names>PK</given-names></name><name><surname>Wong</surname><given-names>K</given-names></name><name><surname>Khan</surname><given-names>WS</given-names></name></person-group>
<article-title>Operative treatment of knee cartilage injuries: a review of the current literature on non-cell-based and cell-based therapies</article-title>. <source>Br J Med Med Res</source>. <year>2011</year>;<volume>1</volume>:<fpage>516</fpage>-<lpage>537</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr56-1941738114523387">
        <label>56.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jurgens</surname><given-names>WJ</given-names></name><name><surname>Oedayrajsingh-Varma</surname><given-names>MJ</given-names></name><name><surname>Helder</surname><given-names>MN</given-names></name><etal/></person-group>
<article-title>Effect of tissue-harvesting site on yield of stem cells derived from adipose tissue: implications for cell-based therapies</article-title>. <source>Cell Tissue Res</source>. <year>2008</year>;<volume>332</volume>:<fpage>415</fpage>-<lpage>426</lpage>.<pub-id pub-id-type="pmid">18379826</pub-id></mixed-citation>
      </ref>
      <ref id="bibr57-1941738114523387">
        <label>57.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jurgens</surname><given-names>WJ</given-names></name><name><surname>van Dijk</surname><given-names>A</given-names></name><name><surname>Doulabi</surname><given-names>BZ</given-names></name><etal/></person-group>
<article-title>Freshly isolated stromal cells from the infrapatellar fat pad are suitable for a one-step surgical procedure to regenerate cartilage tissue</article-title>. <source>Cytotherapy</source>. <year>2009</year>;<volume>11</volume>:<fpage>1052</fpage>-<lpage>1064</lpage>.<pub-id pub-id-type="pmid">19929469</pub-id></mixed-citation>
      </ref>
      <ref id="bibr58-1941738114523387">
        <label>58.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jurgens</surname><given-names>WJ</given-names></name><name><surname>Kroeze</surname><given-names>RJ</given-names></name><name><surname>Bank</surname><given-names>RA</given-names></name><name><surname>Ritt</surname><given-names>MJ</given-names></name><name><surname>Helder</surname><given-names>MN</given-names></name></person-group>
<article-title>Rapid attachments of adipose stromal cells on resorbable polymeric scaffolds facilitates the one-step surgical procedure for cartilage and bone tissue engineering purposes</article-title>. <source>J Orthop Res</source>. <year>2011</year>;<volume>29</volume>:<fpage>853</fpage>-<lpage>860</lpage>.<pub-id pub-id-type="pmid">21246614</pub-id></mixed-citation>
      </ref>
      <ref id="bibr59-1941738114523387">
        <label>59.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kagiwada</surname><given-names>H</given-names></name><name><surname>Fukuchi</surname><given-names>T</given-names></name><name><surname>Machida</surname><given-names>H</given-names></name><name><surname>Yamashita</surname><given-names>K</given-names></name><name><surname>Ohgushi</surname><given-names>H</given-names></name></person-group>
<article-title>Effect of gentamicin on growth and differentiation of human mesenchymal stem cells</article-title>. <source>J Toxicol Pathol</source>. <year>2008</year>;<volume>21</volume>:<fpage>61</fpage>-<lpage>67</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr60-1941738114523387">
        <label>60.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kasemkijwattana</surname><given-names>C</given-names></name><name><surname>Hongeng</surname><given-names>S</given-names></name><name><surname>Kesprayura</surname><given-names>S</given-names></name><name><surname>Rungsinaporn</surname><given-names>V</given-names></name><name><surname>Chaipinyo</surname><given-names>K</given-names></name><name><surname>Chansiri</surname><given-names>K</given-names></name></person-group>
<article-title>Autologous bone marrow mesenchymal stem cells implantation for cartilage defects: two case reports</article-title>. <source>J Med Assoc Thai</source>. <year>2011</year>;<volume>94</volume>:<fpage>395</fpage>-<lpage>400</lpage>.<pub-id pub-id-type="pmid">21560849</pub-id></mixed-citation>
      </ref>
      <ref id="bibr61-1941738114523387">
        <label>61.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Park</surname><given-names>EH</given-names></name><name><surname>Kim</surname><given-names>YC</given-names></name><name><surname>Koh</surname><given-names>YG</given-names></name></person-group>
<article-title>Clinical outcomes of mesenchymal stem cell injection with arthroscopic treatment in older patients with osteochondral lesions of the talus</article-title>. <source>Am J Sports Med</source>. <year>2013</year>;<volume>41</volume>:<fpage>1090</fpage>-<lpage>1099</lpage>.<pub-id pub-id-type="pmid">23460335</pub-id></mixed-citation>
      </ref>
      <ref id="bibr62-1941738114523387">
        <label>62.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Ochi</surname><given-names>M</given-names></name><name><surname>Yanada</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>A novel cell delivery system using magnetically labelled mesenchymal stem cells and an external magnetic device for clinical cartilage repair</article-title>. <source>Arthroscopy</source>. <year>2008</year>;<volume>24</volume>:<fpage>69</fpage>-<lpage>76</lpage>.<pub-id pub-id-type="pmid">18182205</pub-id></mixed-citation>
      </ref>
      <ref id="bibr63-1941738114523387">
        <label>63.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koga</surname><given-names>H</given-names></name><name><surname>Engebretsen</surname><given-names>L</given-names></name><name><surname>Brinchmann</surname><given-names>JE</given-names></name><name><surname>Muneta</surname><given-names>T</given-names></name><name><surname>Sekiya</surname><given-names>I</given-names></name></person-group>
<article-title>Mesenchymal stem cell-based therapy for cartilage repair: a review</article-title>. <source>Knee Surg Sports Traumatol Arthrosc</source>. <year>2009</year>;<volume>17</volume>:<fpage>1289</fpage>-<lpage>1297</lpage>.<pub-id pub-id-type="pmid">19333576</pub-id></mixed-citation>
      </ref>
      <ref id="bibr64-1941738114523387">
        <label>64.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koh</surname><given-names>YG</given-names></name><name><surname>Choi</surname><given-names>YJ</given-names></name></person-group>
<article-title>Infrapatellar fat pad–derived mesenchymal stem cell therapy for knee osteoarthritis</article-title>. <source>Knee</source>. <year>2012</year>;<volume>19</volume>:<fpage>902</fpage>-<lpage>907</lpage>.<pub-id pub-id-type="pmid">22583627</pub-id></mixed-citation>
      </ref>
      <ref id="bibr65-1941738114523387">
        <label>65.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koh</surname><given-names>YG</given-names></name><name><surname>Jo</surname><given-names>SB</given-names></name><name><surname>Kwon</surname><given-names>OR</given-names></name><etal/></person-group>
<article-title>Mesenchymal stem cell injections improve symptoms of knee osteoarthritis</article-title>. <source>Arthroscopy</source>. <year>2013</year>;<volume>29</volume>:<fpage>748</fpage>-<lpage>755</lpage>.<pub-id pub-id-type="pmid">23375182</pub-id></mixed-citation>
      </ref>
      <ref id="bibr66-1941738114523387">
        <label>66.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kon</surname><given-names>E</given-names></name><name><surname>Vannini</surname><given-names>F</given-names></name><name><surname>Buda</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>How to treat osteochondritis dissecans of the knee: surgical techniques and new trends</article-title>. <source>J Bone Joint Surg Am</source>. <year>2012</year>;<volume>94</volume>:<issue>e1</issue>(<fpage>1</fpage>-<lpage>8</lpage>).</mixed-citation>
      </ref>
      <ref id="bibr67-1941738114523387">
        <label>67.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kuroda</surname><given-names>R</given-names></name><name><surname>Ishida</surname><given-names>K</given-names></name><name><surname>Matsumoto</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Treatment of a full-thickness articular cartilage defect in the femoral condyle of an athlete with autologous bone-marrow stromal cells</article-title>. <source>Osteoarthritis Cartilage</source>. <year>2007</year>;<volume>15</volume>:<fpage>226</fpage>-<lpage>231</lpage>.<pub-id pub-id-type="pmid">17002893</pub-id></mixed-citation>
      </ref>
      <ref id="bibr68-1941738114523387">
        <label>68.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>KB</given-names></name><name><surname>Hui</surname><given-names>JH</given-names></name><name><surname>Song</surname><given-names>IC</given-names></name><name><surname>Ardany</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>EH</given-names></name></person-group>
<article-title>Injectable mesenchymal stem cell therapy for large cartilage defects—a porcine model</article-title>. <source>Stem Cells</source>. <year>2007</year>;<volume>25</volume>:<fpage>2964</fpage>-<lpage>2971</lpage>.<pub-id pub-id-type="pmid">17656639</pub-id></mixed-citation>
      </ref>
      <ref id="bibr69-1941738114523387">
        <label>69.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>KB</given-names></name><name><surname>Wang</surname><given-names>VT</given-names></name><name><surname>Chan</surname><given-names>YH</given-names></name><name><surname>Hui</surname><given-names>JH</given-names></name></person-group>
<article-title>A novel, minimally invasive technique of cartilage repair in the human knee using arthroscopic microfracture and injections of mesenchymal stem cells and hyaluronic acid—a prospective comparative study on safety and short-term efficacy</article-title>. <source>Ann Acad Med Singapore</source>. <year>2012</year>;<volume>41</volume>:<fpage>511</fpage>-<lpage>517</lpage>.<pub-id pub-id-type="pmid">23235728</pub-id></mixed-citation>
      </ref>
      <ref id="bibr70-1941738114523387">
        <label>70.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lu</surname><given-names>SH</given-names></name><name><surname>Yang</surname><given-names>AH</given-names></name><name><surname>Wei</surname><given-names>CF</given-names></name><name><surname>Chiang</surname><given-names>HS</given-names></name><name><surname>Chancellor</surname><given-names>MB</given-names></name></person-group>
<article-title>Multi-potent differentiation of human purified muscle-derived cells: potential for tissue regeneration</article-title>. <source>BJU Int</source>. <year>2010</year>;<volume>105</volume>:<fpage>1174</fpage>-<lpage>1180</lpage>.<pub-id pub-id-type="pmid">19712114</pub-id></mixed-citation>
      </ref>
      <ref id="bibr71-1941738114523387">
        <label>71.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Manferdini</surname><given-names>C</given-names></name><name><surname>Maumus</surname><given-names>M</given-names></name><name><surname>Gabusi</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Adipose-derived mesenchymal stem cells exert antiinflammatory effects on chondrocytes and synoviocytes from osteoarthritis patients through prostaglandin E2</article-title>. <source>Arthritis Rheum</source>. <year>2013</year>;<volume>65</volume>:<fpage>1271</fpage>-<lpage>1281</lpage>.<pub-id pub-id-type="pmid">23613363</pub-id></mixed-citation>
      </ref>
      <ref id="bibr72-1941738114523387">
        <label>72.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marquass</surname><given-names>B</given-names></name><name><surname>Schulz</surname><given-names>R</given-names></name><name><surname>Hepp</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Matrix-associated implantation of predifferentiated mesenchymal stem cells versus articular chondrocytes: in vivo results of cartilage repair after 1 year</article-title>. <source>Am J Sports Med</source>. <year>2011</year>;<volume>39</volume>:<fpage>1401</fpage>-<lpage>1412</lpage>.<pub-id pub-id-type="pmid">21527412</pub-id></mixed-citation>
      </ref>
      <ref id="bibr73-1941738114523387">
        <label>73.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>T</given-names></name><name><surname>Cooper</surname><given-names>GM</given-names></name><name><surname>Gharaibeh</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>Cartilage repair in a rat model of osteoarthritis through intraarticular transplantation of muscle-derived stem cells expressing bone morphogenetic protein 4 and soluble Flt-1</article-title>. <source>Arthritis Rheum</source>. <year>2009</year>;<volume>60</volume>:<fpage>1390</fpage>-<lpage>1405</lpage>.<pub-id pub-id-type="pmid">19404941</pub-id></mixed-citation>
      </ref>
      <ref id="bibr74-1941738114523387">
        <label>74.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>T</given-names></name><name><surname>Okabe</surname><given-names>T</given-names></name><name><surname>Ikawa</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Articular cartilage repair with autologous bone marrow mesenchymal cells</article-title>. <source>J Cell Physiol</source>. <year>2010</year>;<volume>225</volume>:<fpage>291</fpage>-<lpage>295</lpage>.<pub-id pub-id-type="pmid">20458744</pub-id></mixed-citation>
      </ref>
      <ref id="bibr75-1941738114523387">
        <label>75.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McIlwraith</surname><given-names>CW</given-names></name><name><surname>Frisbie</surname><given-names>DD</given-names></name><name><surname>Rodkey</surname><given-names>WG</given-names></name><etal/></person-group>
<article-title>Evaluation of intra-articular mesenchymal stem cells to augment healing of microfractured chondral defects</article-title>. <source>Arthroscopy</source>. <year>2011</year>;<volume>27</volume>:<fpage>1552</fpage>-<lpage>1561</lpage>.<pub-id pub-id-type="pmid">21862278</pub-id></mixed-citation>
      </ref>
      <ref id="bibr76-1941738114523387">
        <label>76.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mifune</surname><given-names>Y</given-names></name><name><surname>Matsumoto</surname><given-names>T</given-names></name><name><surname>Takayama</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>The effect of platelet-rich plasma on the regenerative therapy of muscle derived stem cells for articular cartilage repair</article-title>. <source>Osteoarthritis Cartilage</source>. <year>2013</year>;<volume>21</volume>:<fpage>175</fpage>-<lpage>185</lpage>.<pub-id pub-id-type="pmid">23041435</pub-id></mixed-citation>
      </ref>
      <ref id="bibr77-1941738114523387">
        <label>77.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miura</surname><given-names>M</given-names></name><name><surname>Miura</surname><given-names>Y</given-names></name><name><surname>Padilla-Nash</surname><given-names>HM</given-names></name><etal/></person-group>
<article-title>Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation</article-title>. <source>Stem Cells</source>. <year>2006</year>;<volume>24</volume>:<fpage>1095</fpage>-<lpage>1103</lpage>.<pub-id pub-id-type="pmid">16282438</pub-id></mixed-citation>
      </ref>
      <ref id="bibr78-1941738114523387">
        <label>78.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mochizuki</surname><given-names>T</given-names></name><name><surname>Muneta</surname><given-names>T</given-names></name><name><surname>Sakaguchi</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Higher chondrocyte potential of fibrous synovium– and adipose synovium–derived cells compared with subcutaneous fat-derived cells: distinguishing properties of mesenchymal stem cells in humans</article-title>. <source>Arthritis Rheum</source>. <year>2006</year>;<volume>54</volume>:<fpage>843</fpage>-<lpage>853</lpage>.<pub-id pub-id-type="pmid">16508965</pub-id></mixed-citation>
      </ref>
      <ref id="bibr79-1941738114523387">
        <label>79.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mokbel</surname><given-names>AN</given-names></name><name><surname>El-Tookhy</surname><given-names>OS</given-names></name><name><surname>Shamaa</surname><given-names>AA</given-names></name><name><surname>Rashed</surname><given-names>LA</given-names></name><name><surname>Sabry</surname><given-names>D</given-names></name><name><surname>El Sayed</surname><given-names>AM</given-names></name></person-group>
<article-title>Homing and reparative effect of intra-articular injection of autologous mesenchymal stem cells in osteoarthritic animal model</article-title>. <source>BMC Musculoskelet Disord</source>. <year>2011</year>;<volume>12</volume>:<fpage>259</fpage>.<pub-id pub-id-type="pmid">22085445</pub-id></mixed-citation>
      </ref>
      <ref id="bibr80-1941738114523387">
        <label>80.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mokbel</surname><given-names>A</given-names></name><name><surname>El-Tookhy</surname><given-names>O</given-names></name><name><surname>Shamaa</surname><given-names>AA</given-names></name><name><surname>Sabry</surname><given-names>D</given-names></name><name><surname>Rashed</surname><given-names>L</given-names></name><name><surname>Mostafa</surname><given-names>A</given-names></name></person-group>
<article-title>Homing and efficacy of intra-articular injection of autologous mesenchymal stem cells in experimental chondral defects in dogs</article-title>. <source>Clin Exp Rheumatol</source>. <year>2011</year>;<volume>29</volume>:<fpage>275</fpage>-<lpage>284</lpage>.<pub-id pub-id-type="pmid">21385540</pub-id></mixed-citation>
      </ref>
      <ref id="bibr81-1941738114523387">
        <label>81.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Murphy</surname><given-names>JM</given-names></name><name><surname>Fink</surname><given-names>DJ</given-names></name><name><surname>Hunziker</surname><given-names>EB</given-names></name><name><surname>Barry</surname><given-names>FP</given-names></name></person-group>
<article-title>Stem cell therapy in a caprine model of osteoarthritis</article-title>. <source>Arthritis Rheum</source>. <year>2003</year>;<volume>48</volume>:<fpage>3464</fpage>-<lpage>3474</lpage>.<pub-id pub-id-type="pmid">14673997</pub-id></mixed-citation>
      </ref>
      <ref id="bibr82-1941738114523387">
        <label>82.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nakamae</surname><given-names>T</given-names></name><name><surname>Adachi</surname><given-names>N</given-names></name><name><surname>Kobayashi</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>The effect of an external magnetic force on cell adhesion and proliferation of magnetically labelled mesenchymal stem cells</article-title>. <source>Sports Med Arthrosc Rehab Ther Technol</source>. <year>2010</year>;<volume>2</volume>:<fpage>5</fpage>.</mixed-citation>
      </ref>
      <ref id="bibr83-1941738114523387">
        <label>83.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>N</given-names></name><name><surname>Miyama</surname><given-names>T</given-names></name><name><surname>Engebretsen</surname><given-names>L</given-names></name><name><surname>Yoshikawa</surname><given-names>H</given-names></name><name><surname>Shino</surname><given-names>K</given-names></name></person-group>
<article-title>Cell-based therapy in articular cartilage lesions of the knee</article-title>. <source>Arthroscopy</source>. <year>2009</year>;<volume>25</volume>:<fpage>531</fpage>-<lpage>552</lpage>.<pub-id pub-id-type="pmid">19409312</pub-id></mixed-citation>
      </ref>
      <ref id="bibr84-1941738114523387">
        <label>84.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nejadnik</surname><given-names>H</given-names></name><name><surname>Hui</surname><given-names>JH</given-names></name><name><surname>Feng Choong</surname><given-names>EP</given-names></name><name><surname>Tai</surname><given-names>BC</given-names></name><name><surname>Lee</surname><given-names>EH</given-names></name></person-group>
<article-title>Autologous bone marrow-derived mesenchymal stem cells versus autologous chondrocyte implantation: an observational cohort study</article-title>. <source>Am J Sports Med</source>. <year>2010</year>;<volume>38</volume>:<fpage>1110</fpage>-<lpage>1116</lpage>.<pub-id pub-id-type="pmid">20392971</pub-id></mixed-citation>
      </ref>
      <ref id="bibr85-1941738114523387">
        <label>85.</label>
        <mixed-citation publication-type="book">
<collab>OCEBM Levels of Evidence Working Group</collab>. <source>The Oxford 2011 Levels of Evidence</source>. <publisher-loc>Oxford, England</publisher-loc>: <publisher-name>Oxford Centre for Evidence-Based Medicine</publisher-name>; <year>2011</year>.</mixed-citation>
      </ref>
      <ref id="bibr86-1941738114523387">
        <label>86.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>JT</given-names></name><name><surname>Gardel</surname><given-names>LS</given-names></name><name><surname>Rada</surname><given-names>T</given-names></name><name><surname>Martins</surname><given-names>L</given-names></name><name><surname>Gomes</surname><given-names>ME</given-names></name><name><surname>Reis</surname><given-names>RL</given-names></name></person-group>
<article-title>Injectable gellan gum hydrogels with autologous cells for the treatment of rabbit articular cartilage defects</article-title>. <source>J Orthop Res</source>. <year>2010</year>;<volume>28</volume>:<fpage>1193</fpage>-<lpage>1199</lpage>.<pub-id pub-id-type="pmid">20187118</pub-id></mixed-citation>
      </ref>
      <ref id="bibr87-1941738114523387">
        <label>87.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Orozco</surname><given-names>L</given-names></name><name><surname>Munar</surname><given-names>A</given-names></name><name><surname>Soler</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Treatment of knee osteoarthritis with autologous mesenchymal stem cells: a pilot study</article-title>. <source>Transplantation</source>. <year>2013</year>;<volume>95</volume>:<fpage>1535</fpage>-<lpage>1541</lpage>.<pub-id pub-id-type="pmid">23680930</pub-id></mixed-citation>
      </ref>
      <ref id="bibr88-1941738114523387">
        <label>88.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pak</surname><given-names>J</given-names></name></person-group>
<article-title>Regeneration of human bones in hip osteonecrosis and human cartilage in knee osteoarthritis with autologous adipose-tissue-derived stem cells: a case series</article-title>. <source>J Med Case Rep</source>. <year>2011</year>;<volume>5</volume>:<fpage>296</fpage>.<pub-id pub-id-type="pmid">21736710</pub-id></mixed-citation>
      </ref>
      <ref id="bibr89-1941738114523387">
        <label>89.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pak</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name></person-group>
<article-title>A novel biological approach to treat chondromalacia patellae</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>:<fpage>e64569</fpage>.<pub-id pub-id-type="pmid">23700485</pub-id></mixed-citation>
      </ref>
      <ref id="bibr90-1941738114523387">
        <label>90.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pei</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>F</given-names></name><name><surname>Boyce</surname><given-names>BM</given-names></name><name><surname>Kish</surname><given-names>VL</given-names></name></person-group>
<article-title>Repair of full-thickness femoral condyle cartilage defects using allogeneic synovial cell-engineered tissue constructs</article-title>. <source>Osteoarthritis Cartilage</source>. <year>2009</year>;<volume>17</volume>:<fpage>714</fpage>-<lpage>722</lpage>.<pub-id pub-id-type="pmid">19128988</pub-id></mixed-citation>
      </ref>
      <ref id="bibr91-1941738114523387">
        <label>91.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pestka</surname><given-names>JM</given-names></name><name><surname>Bode</surname><given-names>G</given-names></name><name><surname>Salzmann</surname><given-names>G</given-names></name><name><surname>Südkamp</surname><given-names>NP</given-names></name><name><surname>Niemeyer</surname><given-names>P</given-names></name></person-group>
<article-title>Clinical outcome of autologous chondrocyte implantation for failed microfracture treatment of full-thickness cartilage defects of the knee joint</article-title>. <source>Am J Sports Med</source>. <year>2012</year>;<volume>40</volume>:<fpage>325</fpage>-<lpage>331</lpage>.<pub-id pub-id-type="pmid">22056348</pub-id></mixed-citation>
      </ref>
      <ref id="bibr92-1941738114523387">
        <label>92.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pierini</surname><given-names>M</given-names></name><name><surname>Di Bella</surname><given-names>C</given-names></name><name><surname>Dozza</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>The posterior iliac crest outperforms the anterior iliac crest when obtaining mesenchymal stem cells from bone marrow</article-title>. <source>J Bone Joint Surg Am</source>. <year>2013</year>;<volume>95</volume>:<fpage>1101</fpage>-<lpage>1107</lpage>.<pub-id pub-id-type="pmid">23783207</pub-id></mixed-citation>
      </ref>
      <ref id="bibr93-1941738114523387">
        <label>93.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pittenger</surname><given-names>MF</given-names></name><name><surname>Mackay</surname><given-names>AM</given-names></name><name><surname>Beck</surname><given-names>SC</given-names></name><etal/></person-group>
<article-title>Multilineage potential of adult human mesenchymal stem cells</article-title>. <source>Science</source>. <year>1999</year>;<volume>284</volume>:<fpage>143</fpage>-<lpage>147</lpage>.<pub-id pub-id-type="pmid">10102814</pub-id></mixed-citation>
      </ref>
      <ref id="bibr94-1941738114523387">
        <label>94.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Richter</surname><given-names>M</given-names></name><name><surname>Zech</surname><given-names>S</given-names></name></person-group>
<article-title>Matrix-associated stem cell transplantation (MAST) in chondral defects of foot and ankle is effective</article-title>. <source>Foot Ankle Surg</source>. <year>2013</year>;<volume>19</volume>:<fpage>84</fpage>-<lpage>90</lpage>.<pub-id pub-id-type="pmid">23548448</pub-id></mixed-citation>
      </ref>
      <ref id="bibr95-1941738114523387">
        <label>95.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>JP</given-names></name><name><surname>Murphy</surname><given-names>MP</given-names></name><name><surname>Hong</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Autologous stromal vascular fraction therapy for rheumatoid arthritis: rationale and clinical safety</article-title>. <source>Int Arch Med</source>. <year>2012</year>;<volume>5</volume>:<fpage>5</fpage>.<pub-id pub-id-type="pmid">22313603</pub-id></mixed-citation>
      </ref>
      <ref id="bibr96-1941738114523387">
        <label>96.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rosland</surname><given-names>GV</given-names></name><name><surname>Svendsen</surname><given-names>A</given-names></name><name><surname>Torsvik</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation</article-title>. <source>Cancer Res</source>. <year>2009</year>;<volume>69</volume>:<fpage>5331</fpage>-<lpage>5339</lpage>.<pub-id pub-id-type="pmid">19509230</pub-id></mixed-citation>
      </ref>
      <ref id="bibr97-1941738114523387">
        <label>97.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rubio</surname><given-names>D</given-names></name><name><surname>Garcia-Castro</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>MC</given-names></name><etal/></person-group>
<article-title>Spontaneous human adult stem cell transformation</article-title>. <source>Cancer Res</source>. <year>2005</year>;<volume>65</volume>:<fpage>3035</fpage>-<lpage>3039</lpage>.<pub-id pub-id-type="pmid">15833829</pub-id></mixed-citation>
      </ref>
      <ref id="bibr98-1941738114523387">
        <label>98.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Saris</surname><given-names>DB</given-names></name><name><surname>Vanlauwe</surname><given-names>J</given-names></name><name><surname>Victor</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Characterized chondrocyte implantation results in better structural repair when treating symptomatic cartilage defects of the knee in a randomized controlled trial versus microfracture</article-title>. <source>Am J Sports Med</source>. <year>2008</year>;<volume>36</volume>:<fpage>235</fpage>-<lpage>246</lpage>.<pub-id pub-id-type="pmid">18202295</pub-id></mixed-citation>
      </ref>
      <ref id="bibr99-1941738114523387">
        <label>99.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Saris</surname><given-names>DB</given-names></name><name><surname>Vanlauwe</surname><given-names>J</given-names></name><name><surname>Victor</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Treatment of symptomatic cartilage defects of the knee: characterized chondrocyte implantation results in better clinical outcome at 36 months in a randomized trial compared to microfracture</article-title>. <source>Am J Sports Med</source>. <year>2009</year>;<volume>37</volume>(<issue>suppl 1</issue>):<fpage>10S</fpage>-<lpage>19S</lpage>.<pub-id pub-id-type="pmid">19846694</pub-id></mixed-citation>
      </ref>
      <ref id="bibr100-1941738114523387">
        <label>100.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Uchida</surname><given-names>K</given-names></name><name><surname>Nakajima</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Direct transplantation of mesenchymal stem cells into the knee joints of Hartley strain guinea pigs with spontaneous osteoarthritis</article-title>. <source>Arthritis Res Ther</source>. <year>2012</year>;<volume>14</volume>:<fpage>R31</fpage>.<pub-id pub-id-type="pmid">22314040</pub-id></mixed-citation>
      </ref>
      <ref id="bibr101-1941738114523387">
        <label>101.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Saw</surname><given-names>KY</given-names></name><name><surname>Anz</surname><given-names>A</given-names></name><name><surname>Merican</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Articular cartilage regeneration with autologous peripheral blood progenitor cells and hyaluronic acid after arthroscopic subchondral drilling: a report of 5 cases with histology</article-title>. <source>Arthroscopy</source>. <year>2011</year>;<volume>27</volume>:<fpage>493</fpage>-<lpage>506</lpage>.<pub-id pub-id-type="pmid">21334844</pub-id></mixed-citation>
      </ref>
      <ref id="bibr102-1941738114523387">
        <label>102.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Saw</surname><given-names>KY</given-names></name><name><surname>Anz</surname><given-names>A</given-names></name><name><surname>Siew-Yoke Jee</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Articular cartilage regeneration with autologous peripheral blood stem cells versus hyaluronic acid: a randomized controlled trial</article-title>. <source>Arthroscopy</source>. <year>2013</year>;<volume>29</volume>:<fpage>684</fpage>-<lpage>694</lpage>.<pub-id pub-id-type="pmid">23380230</pub-id></mixed-citation>
      </ref>
      <ref id="bibr103-1941738114523387">
        <label>103.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Skowroński</surname><given-names>J</given-names></name><name><surname>Skowroński</surname><given-names>R</given-names></name><name><surname>Rutka</surname><given-names>M</given-names></name></person-group>
<article-title>Cartilage lesions of the knee treated with blood mesenchymal stem cells - results</article-title>. <source>Ortop Traumatol Rehabil</source>. <year>2012</year>;<volume>14</volume>:<fpage>569</fpage>-<lpage>577</lpage>.<pub-id pub-id-type="pmid">23382284</pub-id></mixed-citation>
      </ref>
      <ref id="bibr104-1941738114523387">
        <label>104.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Skowroński</surname><given-names>J</given-names></name><name><surname>Skowroński</surname><given-names>R</given-names></name><name><surname>Rutka</surname><given-names>M</given-names></name></person-group>
<article-title>Large cartilage lesions of the knee treated with bone marrow concentrate and collagen membrane—results</article-title>. <source>Ortop Traumatol Rehabil</source>. <year>2013</year>;<volume>15</volume>:<fpage>69</fpage>-<lpage>76</lpage>.<pub-id pub-id-type="pmid">23510816</pub-id></mixed-citation>
      </ref>
      <ref id="bibr105-1941738114523387">
        <label>105.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Skowroński</surname><given-names>J</given-names></name><name><surname>Rutka</surname><given-names>M</given-names></name></person-group>
<article-title>Osteochondral lesions of the knee reconstructed with mesenchymal stem cells—results</article-title>. <source>Ortop Traumatol Rehabil</source>. <year>2013</year>;<volume>15</volume>:<fpage>195</fpage>-<lpage>204</lpage>.<pub-id pub-id-type="pmid">23897996</pub-id></mixed-citation>
      </ref>
      <ref id="bibr106-1941738114523387">
        <label>106.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stolzing</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>E</given-names></name><name><surname>McGonagle</surname><given-names>D</given-names></name><name><surname>Scutt</surname><given-names>A</given-names></name></person-group>
<article-title>Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies</article-title>. <source>Mech Ageing Dev</source>. <year>2008</year>;<volume>129</volume>:<fpage>163</fpage>-<lpage>173</lpage>.<pub-id pub-id-type="pmid">18241911</pub-id></mixed-citation>
      </ref>
      <ref id="bibr107-1941738114523387">
        <label>107.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Hou</surname><given-names>XK</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>Mosaicplasty associated with gene enhanced tissue engineering for the treatment of acute osteochondral defects in a goat model</article-title>. <source>Arch Orthop Trauma Surg</source>. <year>2009</year>;<volume>129</volume>:<fpage>757</fpage>-<lpage>771</lpage>.<pub-id pub-id-type="pmid">18839189</pub-id></mixed-citation>
      </ref>
      <ref id="bibr108-1941738114523387">
        <label>108.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Tanabe</surname><given-names>K</given-names></name><name><surname>Ohnuki</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Induction of pluripotent stem cells from adult human fibroblasts by defined factors</article-title>. <source>Cell</source>. <year>2007</year>;<volume>131</volume>:<fpage>861</fpage>-<lpage>872</lpage>.<pub-id pub-id-type="pmid">18035408</pub-id></mixed-citation>
      </ref>
      <ref id="bibr109-1941738114523387">
        <label>109.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Teo</surname><given-names>BJ</given-names></name><name><surname>Buhary</surname><given-names>K</given-names></name><name><surname>Tai</surname><given-names>BC</given-names></name><name><surname>Hui</surname><given-names>JH</given-names></name></person-group>
<article-title>Cell-based therapy improves function in adolescents and young adults with patellar osteochondritis dissecans</article-title>. <source>Clin Orthop Relat Res</source>. <year>2013</year>;<volume>471</volume>:<fpage>1152</fpage>-<lpage>1158</lpage>.<pub-id pub-id-type="pmid">22476898</pub-id></mixed-citation>
      </ref>
      <ref id="bibr110-1941738114523387">
        <label>110.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Toghraie</surname><given-names>FS</given-names></name><name><surname>Chenari</surname><given-names>N</given-names></name><name><surname>Gholipour</surname><given-names>MA</given-names></name><etal/></person-group>
<article-title>Treatment of osteoarthritis with infrapatellar fat pad–derived mesenchymal stem cells in rabbit</article-title>. <source>Knee</source>. <year>2011</year>;<volume>18</volume>:<fpage>71</fpage>-<lpage>75</lpage>.<pub-id pub-id-type="pmid">20591677</pub-id></mixed-citation>
      </ref>
      <ref id="bibr111-1941738114523387">
        <label>111.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tolar</surname><given-names>J</given-names></name><name><surname>Nauta</surname><given-names>AJ</given-names></name><name><surname>Osborn</surname><given-names>MJ</given-names></name><etal/></person-group>
<article-title>Sarcoma derived from cultured mesenchymal stem cells</article-title>. <source>Stem Cells</source>. <year>2007</year>;<volume>25</volume>:<fpage>371</fpage>-<lpage>379</lpage>.<pub-id pub-id-type="pmid">17038675</pub-id></mixed-citation>
      </ref>
      <ref id="bibr112-1941738114523387">
        <label>112.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Torsvik</surname><given-names>A</given-names></name><name><surname>Rosland</surname><given-names>GV</given-names></name><name><surname>Svendsen</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track [letter]</article-title>. <source>Cancer Res</source>. <year>2010</year>;<volume>70</volume>:<fpage>6393</fpage>-<lpage>6396</lpage>.<pub-id pub-id-type="pmid">20631079</pub-id></mixed-citation>
      </ref>
      <ref id="bibr113-1941738114523387">
        <label>113.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Turajane</surname><given-names>T</given-names></name><name><surname>Chaweewannakorn</surname><given-names>U</given-names></name><name><surname>Larbpaiboonpong</surname><given-names>V</given-names></name><etal/></person-group>
<article-title>Combination of intra-articular autologous activated peripheral blood stem cells with growth factor addition/preservation and hyaluronic acid in conjunction with arthroscopic microdrilling mesenchymal cell stimulation Improves quality of life and regenerates articular cartilage in early osteoarthritic knee disease</article-title>. <source>J Med Assoc Thai</source>. <year>2013</year>;<volume>96</volume>:<fpage>580</fpage>-<lpage>588</lpage>.<pub-id pub-id-type="pmid">23745314</pub-id></mixed-citation>
      </ref>
      <ref id="bibr114-1941738114523387">
        <label>114.</label>
        <mixed-citation publication-type="gov">
<collab>US Food and Drug Administration</collab>. <article-title>Consumer information on stem cells</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/newsevents/publichealthfocus/ucm286218.htm">http://www.fda.gov/newsevents/publichealthfocus/ucm286218.htm</ext-link>
<date-in-citation>Accessed December 3, 2013</date-in-citation>.</mixed-citation>
      </ref>
      <ref id="bibr115-1941738114523387">
        <label>115.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vanlauwe</surname><given-names>JJ</given-names></name><name><surname>Claes</surname><given-names>T</given-names></name><name><surname>Van Assche</surname><given-names>D</given-names></name><name><surname>Bellemans</surname><given-names>J</given-names></name><name><surname>Luyten</surname><given-names>FP</given-names></name></person-group>
<article-title>Characterized chondrocyte implantation in the patellofemoral joint: an up to 4 year follow-up of a prospective cohort of 38 patients</article-title>. <source>Am J Sports Med</source>. <year>2012</year>;<volume>40</volume>:<fpage>1799</fpage>-<lpage>1807</lpage>.<pub-id pub-id-type="pmid">22785604</pub-id></mixed-citation>
      </ref>
      <ref id="bibr116-1941738114523387">
        <label>116.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vannini</surname><given-names>F</given-names></name><name><surname>Battaglia</surname><given-names>M</given-names></name><name><surname>Buda</surname><given-names>R</given-names></name><name><surname>Cavallo</surname><given-names>M</given-names></name><name><surname>Giannini</surname><given-names>S</given-names></name></person-group>
<article-title>“One step” treatment of juvenile osteochondritis dissecans in the knee: clinical results and T2 mapping characterization</article-title>. <source>Orthop Clin North Am</source>. <year>2012</year>;<volume>43</volume>:<fpage>237</fpage>-<lpage>244</lpage>.<pub-id pub-id-type="pmid">22480472</pub-id></mixed-citation>
      </ref>
      <ref id="bibr117-1941738114523387">
        <label>117.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Varma</surname><given-names>HS</given-names></name><name><surname>Dadarya</surname><given-names>B</given-names></name><name><surname>Vidyarthi</surname><given-names>A</given-names></name></person-group>
<article-title>The new avenues in the management of osteo-arthritis of knee—stem cells</article-title>. <source>J Indian Med Assoc</source>. <year>2010</year>;<volume>108</volume>:<fpage>583</fpage>-<lpage>585</lpage>.<pub-id pub-id-type="pmid">21510531</pub-id></mixed-citation>
      </ref>
      <ref id="bibr118-1941738114523387">
        <label>118.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wakitani</surname><given-names>S</given-names></name><name><surname>Goto</surname><given-names>T</given-names></name><name><surname>Pineda</surname><given-names>SJ</given-names></name><etal/></person-group>
<article-title>Mesenchymal cell-based repair of large, full thickness defects of articular cartilage</article-title>. <source>J Bone Joint Surg Am</source>. <year>1994</year>;<volume>76</volume>:<fpage>579</fpage>-<lpage>592</lpage>.<pub-id pub-id-type="pmid">8150826</pub-id></mixed-citation>
      </ref>
      <ref id="bibr119-1941738114523387">
        <label>119.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wakitani</surname><given-names>S</given-names></name><name><surname>Imoto</surname><given-names>K</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Saito</surname><given-names>M</given-names></name><name><surname>Murata</surname><given-names>N</given-names></name><name><surname>Yoneda</surname><given-names>M</given-names></name></person-group>
<article-title>Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees</article-title>. <source>Osteoarthritis Cartilage</source>. <year>2002</year>;<volume>10</volume>:<fpage>199</fpage>-<lpage>206</lpage>.<pub-id pub-id-type="pmid">11869080</pub-id></mixed-citation>
      </ref>
      <ref id="bibr120-1941738114523387">
        <label>120.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wakitani</surname><given-names>S</given-names></name><name><surname>Mitsuoka</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>N</given-names></name><name><surname>Toritsuka</surname><given-names>Y</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Horibe</surname><given-names>S</given-names></name></person-group>
<article-title>Autologous bone marrow stromal cell transplantation for repair of full-thickness articular cartilage defects in human patellae: two case reports</article-title>. <source>Cell Transplant</source>. <year>2004</year>;<volume>13</volume>:<fpage>595</fpage>-<lpage>600</lpage>.<pub-id pub-id-type="pmid">15565871</pub-id></mixed-citation>
      </ref>
      <ref id="bibr121-1941738114523387">
        <label>121.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wakitani</surname><given-names>S</given-names></name><name><surname>Nawata</surname><given-names>M</given-names></name><name><surname>Tensho</surname><given-names>K</given-names></name><name><surname>Okabe</surname><given-names>T</given-names></name><name><surname>Machida</surname><given-names>H</given-names></name><name><surname>Ohgushi</surname><given-names>H</given-names></name></person-group>
<article-title>Repair of articular cartilage defects in the patello-femoral joint with autologous bone marrow mesenchymal cell transplantation: three case reports involving nine defects in five knees</article-title>. <source>J Tissue Eng Regen Med</source>. <year>2007</year>;<volume>1</volume>:<fpage>74</fpage>-<lpage>79</lpage>.<pub-id pub-id-type="pmid">18038395</pub-id></mixed-citation>
      </ref>
      <ref id="bibr122-1941738114523387">
        <label>122.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wakitani</surname><given-names>S</given-names></name><name><surname>Kawaguchi</surname><given-names>A</given-names></name><name><surname>Tokuhara</surname><given-names>Y</given-names></name><name><surname>Takaoka</surname><given-names>K</given-names></name></person-group>
<article-title>Present status of and future direction for articular cartilage repair</article-title>. <source>J Bone Miner Metab</source>. <year>2008</year>;<volume>26</volume>:<fpage>115</fpage>-<lpage>122</lpage>.<pub-id pub-id-type="pmid">18301966</pub-id></mixed-citation>
      </ref>
      <ref id="bibr123-1941738114523387">
        <label>123.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wakitani</surname><given-names>S</given-names></name><name><surname>Okabe</surname><given-names>T</given-names></name><name><surname>Horibe</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Safety of autologous bone marrow–derived mesenchymal stem cell transplantation for cartilage repair in 41 patients with 45 joints followed for up to 11 years and 5 months</article-title>. <source>J Tissue Eng Regen Med</source>. <year>2011</year>;<volume>5</volume>:<fpage>146</fpage>-<lpage>150</lpage>.<pub-id pub-id-type="pmid">20603892</pub-id></mixed-citation>
      </ref>
      <ref id="bibr124-1941738114523387">
        <label>124.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>JF</given-names></name><name><surname>Wang</surname><given-names>LJ</given-names></name><name><surname>Wu</surname><given-names>YF</given-names></name><etal/></person-group>
<article-title>Mesenchymal stem/progenitor cells in human umbilical cord blood as support for ex vivo expansion of CD34(+) hematopoietic stem cells and for chondrogenic differentiation</article-title>. <source>Haematologica</source>. <year>2004</year>;<volume>89</volume>:<fpage>837</fpage>-<lpage>844</lpage>.<pub-id pub-id-type="pmid">15257936</pub-id></mixed-citation>
      </ref>
      <ref id="bibr125-1941738114523387">
        <label>125.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Hall</surname><given-names>S</given-names></name><name><surname>Hanna</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Effects of Hylan G-F 20 supplementation on cartilage preservation detected by magnetic resonance imaging in osteoarthritis of the knee: a two-year single-blind clinical trial</article-title>. <source>BMC Musculoskelet Disord</source>. <year>2011</year>;<volume>12</volume>:<fpage>195</fpage>.<pub-id pub-id-type="pmid">21861935</pub-id></mixed-citation>
      </ref>
      <ref id="bibr126-1941738114523387">
        <label>126.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Zeng</surname><given-names>W</given-names></name><name><surname>Wan</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Chondrogenic differentiation of induced pluripotent stem cells from osteoarthritic chondrocytes in alginate matrix</article-title>. <source>Eur Cell Mater</source>. <year>2012</year>;<volume>23</volume>:<fpage>1</fpage>-<lpage>12</lpage>.<pub-id pub-id-type="pmid">22241609</pub-id></mixed-citation>
      </ref>
      <ref id="bibr127-1941738114523387">
        <label>127.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wickham</surname><given-names>MQ</given-names></name><name><surname>Erickson</surname><given-names>GR</given-names></name><name><surname>Gimble</surname><given-names>JM</given-names></name><name><surname>Vail</surname><given-names>TP</given-names></name><name><surname>Guilak</surname><given-names>F</given-names></name></person-group>
<article-title>Multipotent stromal cells derived from the infrapatellar fat pad of the knee</article-title>. <source>Clin Orthop Relat Res</source>. <year>2003</year>;<volume>412</volume>:<fpage>196</fpage>-<lpage>212</lpage>.<pub-id pub-id-type="pmid">12838072</pub-id></mixed-citation>
      </ref>
      <ref id="bibr128-1941738114523387">
        <label>128.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zeifang</surname><given-names>F</given-names></name><name><surname>Oberle</surname><given-names>D</given-names></name><name><surname>Nierhoff</surname><given-names>C</given-names></name><name><surname>Richter</surname><given-names>W</given-names></name><name><surname>Moradi</surname><given-names>B</given-names></name><name><surname>Schmitt</surname><given-names>H</given-names></name></person-group>
<article-title>Autologous chondrocyte implantation using the original periosteum-cover technique versus matrix-associated autologous chondrocyte implantation: a randomized clinical trial</article-title>. <source>Am J Sports Med</source>. <year>2010</year>;<volume>38</volume>:<fpage>924</fpage>-<lpage>933</lpage>.<pub-id pub-id-type="pmid">19966102</pub-id></mixed-citation>
      </ref>
      <ref id="bibr129-1941738114523387">
        <label>129.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>HN</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Leng</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>YZ</given-names></name><name><surname>Lv</surname><given-names>CY</given-names></name></person-group>
<article-title>Uninduced adipose-derived stem cells repair the defect of full-thickness hyaline cartilage</article-title>. <source>Chin J Traumatol</source>. <year>2009</year>;<volume>12</volume>:<fpage>92</fpage>-<lpage>97</lpage>.<pub-id pub-id-type="pmid">19321053</pub-id></mixed-citation>
      </ref>
      <ref id="bibr130-1941738114523387">
        <label>130.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zuk</surname><given-names>PA</given-names></name><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Ashjian</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Human adipose tissue is a source of multipotent stem cells</article-title>. <source>Mol Biol Cell</source>. <year>2002</year>;<volume>13</volume>:<fpage>4279</fpage>-<lpage>4295</lpage>.<pub-id pub-id-type="pmid">12475952</pub-id></mixed-citation>
      </ref>
      <ref id="bibr131-1941738114523387">
        <label>131.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zuk</surname><given-names>PA</given-names></name><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Mizuno</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Multilineage cells from human adipose tissue: implications for cell based therapies</article-title>. <source>Tissue Eng</source>. <year>2001</year>;<volume>7</volume>:<fpage>211</fpage>-<lpage>228</lpage>.<pub-id pub-id-type="pmid">11304456</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:4272690</identifier><datestamp>2016-01-01</datestamp><setSpec>sportshealth</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="http://jats.nlm.nih.gov/ns/archiving/1.0/ http://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Sports Health</journal-id>
      <journal-id journal-id-type="iso-abbrev">Sports Health</journal-id>
      <journal-id journal-id-type="publisher-id">SPH</journal-id>
      <journal-id journal-id-type="hwp">spsph</journal-id>
      <journal-title-group>
        <journal-title>Sports Health</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1941-7381</issn>
      <issn pub-type="epub">1941-0921</issn>
      <publisher>
        <publisher-name>SAGE Publications</publisher-name>
        <publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4272690</article-id>
      <article-id pub-id-type="pmcid">PMC4272690</article-id>
      <article-id pub-id-type="pmc-uid">4272690</article-id>
      <article-id pub-id-type="pmid">25553211</article-id>
      <article-id pub-id-type="doi">10.1177/1941738114529727</article-id>
      <article-id pub-id-type="publisher-id">10.1177_1941738114529727</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Focus Topic: Controversies in Sports Medicine</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Current Concepts</article-title>
        <subtitle>The Role of Mesenchymal Stem Cells in the Management of Knee Osteoarthritis</subtitle>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Wolfstadt</surname>
            <given-names>Jesse I.</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="aff1-1941738114529727">†</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cole</surname>
            <given-names>Brian J.</given-names>
          </name>
          <degrees>MD, MBA</degrees>
          <xref ref-type="aff" rid="aff2-1941738114529727">‡</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ogilvie-Harris</surname>
            <given-names>Darrell J.</given-names>
          </name>
          <degrees>MD, FRCSC</degrees>
          <xref ref-type="aff" rid="aff1-1941738114529727">†</xref>
          <xref ref-type="aff" rid="aff3-1941738114529727">§</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Viswanathan</surname>
            <given-names>Sowmya</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref ref-type="aff" rid="aff4-1941738114529727">‖</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chahal</surname>
            <given-names>Jaskarndip</given-names>
          </name>
          <degrees>MD, MSc, FRCSC</degrees>
          <xref ref-type="corresp" rid="corresp1-1941738114529727">*</xref>
          <xref ref-type="aff" rid="aff1-1941738114529727">†</xref>
          <xref ref-type="aff" rid="aff3-1941738114529727">§</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1-1941738114529727"><label>†</label>University Health Network Arthritis Program, University of Toronto, Toronto, Ontario, Canada</aff>
      <aff id="aff2-1941738114529727"><label>‡</label>Rush University Medical Centre, Chicago, Illinois</aff>
      <aff id="aff3-1941738114529727"><label>§</label>University of Toronto Orthopaedic Sports Medicine Program, Women’s College Hospital, Toronto, Ontario, Canada</aff>
      <aff id="aff4-1941738114529727"><label>‖</label>Cell Therapy Program, University Health Network, Toronto, Ontario, Canada</aff>
      <author-notes>
        <corresp id="corresp1-1941738114529727"><label>*</label>Jaskarndip Chahal, MD, MSc, FRCSC, University of Toronto Orthopaedic Sports Medicine Program, Women’s College Hospital, 1 East 447, 399 Bathurst Street, Toronto, Ontario M5T 2S8, Canada (e-mail: <email>jchahal@utosm.com</email>).</corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>1</day>
        <month>1</month>
        <year>2016</year>
      </pub-date>
      <!-- PMC Release delay is 12 months and 0 days and was based on the <pub-date pub-type="ppub"/>. -->
      <volume>7</volume>
      <issue>1</issue>
      <fpage>38</fpage>
      <lpage>44</lpage>
      <permissions>
        <copyright-statement>© 2014 The Author(s)</copyright-statement>
        <copyright-year>2014</copyright-year>
        <copyright-holder content-type="sage">American Orthopaedic Society for Sports Medicine</copyright-holder>
      </permissions>
      <abstract>
        <sec id="section1-1941738114529727">
          <title>Context:</title>
          <p>The number of adults with osteoarthritis in the United States is expected to nearly double from 21.4 million in 2005 to 41.1 million by 2030. As a result, medical costs and associated comorbidity will exponentially increase in the coming decades. In the past decade, mesenchymal stem cells (MSCs) have emerged as a novel treatment for degenerative joint disease.</p>
        </sec>
        <sec id="section2-1941738114529727">
          <title>Evidence Acquisition:</title>
          <p>PubMed (from 1990 to 2013) was searched to identify relevant studies. Reference lists of included studies were also reviewed.</p>
        </sec>
        <sec id="section3-1941738114529727">
          <title>Study Design:</title>
          <p>Clinical review.</p>
        </sec>
        <sec id="section4-1941738114529727">
          <title>Level of Evidence:</title>
          <p>Level 3.</p>
        </sec>
        <sec id="section5-1941738114529727">
          <title>Results:</title>
          <p>We identified 9 animal and 7 human studies investigating the use of MSCs in the treatment of osteoarthritis, with varying levels of support for this therapy.</p>
        </sec>
        <sec id="section6-1941738114529727">
          <title>Conclusion:</title>
          <p>While MSCs have shown potential for improving function and decreasing inflammation in animal studies, translation to patients is still in question. There is a great deal of heterogeneity in treatment methods. Standardizing the manufacturing and characterization of MSCs will allow for better comparisons.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>mesenchymal stem cells</kwd>
        <kwd>osteoarthritis</kwd>
        <kwd>treatment</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>January/February 2015</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <p>Osteoarthritis (OA) is a disease process resulting from the failure of chondrocytes to repair damaged articular cartilage in synovial joints.<sup><xref rid="bibr2-1941738114529727" ref-type="bibr">2</xref></sup> Increased synthesis of tissue-destructive proteinases such as matrix metalloproteinases, increased chondrocyte apoptosis, and insufficient extracellular matrix generation result in a cartilage matrix that is unable to withstand normal mechanical stresses.<sup><xref rid="bibr5-1941738114529727" ref-type="bibr">5</xref></sup> This leads to progressive cartilage loss, subchondral bone remodeling, osteophyte formation, and synovial inflammation.<sup><xref rid="bibr20-1941738114529727" ref-type="bibr">20</xref>,<xref rid="bibr34-1941738114529727" ref-type="bibr">34</xref></sup> These degenerative changes can ultimately result in significant disability and chronic pain. The number of adults in the United States with osteoarthritis is expected to nearly double from 21.4 million in 2005 to 41.1 million by 2030.<sup><xref rid="bibr31-1941738114529727" ref-type="bibr">31</xref></sup> Direct and indirect medical costs relating to arthritis and associated comorbidities are estimated to exponentially increase in the coming decades.<sup><xref rid="bibr6-1941738114529727" ref-type="bibr">6</xref></sup> In 1997, the total medical expenditures for arthritis and other rheumatic conditions were $233.5 billion. These costs increased to $321.8 billion by 2003 and have continued to rise on an annual basis.<sup><xref rid="bibr31-1941738114529727" ref-type="bibr">31</xref></sup></p>
    <p>The prevalent strategy for managing OA is to exhaust conservative measures in an effort to delay major reconstructive joint surgery, particularly in younger adults. The goals of treatment are to decrease joint pain and improve function resulting in improved quality of life metrics for patients.</p>
    <p>Low-impact, aerobic exercise significantly reduces pain and improves function in patients with early OA.<sup><xref rid="bibr64-1941738114529727" ref-type="bibr">64</xref></sup> More specifically, strengthening exercises seem to be superior in reducing pain and impairment, and aerobic exercise leads to improved long-term functional outcomes.<sup><xref rid="bibr64-1941738114529727" ref-type="bibr">64</xref></sup></p>
    <p>In patients with medial unicompartmental OA, valgus unloader braces reduce external varus moments and medial compartment load and improve pain and function when compared with simple neoprene sleeves.<sup><xref rid="bibr8-1941738114529727" ref-type="bibr">8</xref></sup> However, there is limited high-level evidence to suggest that valgus- or varus-directing knee braces for medial or lateral unicompartmental knee OA, respectively, are more effective than a placebo.<sup><xref rid="bibr8-1941738114529727" ref-type="bibr">8</xref>,<xref rid="bibr25-1941738114529727" ref-type="bibr">25</xref></sup></p>
    <p>Pharmacological pain control remains the mainstay of treatment for symptomatic knee OA. Nonsteroidal anti-inflammatory drugs have a statistically significant pain-reducing effect when compared with placebo and acetaminophen, although this effect is not clinically significant.<sup><xref rid="bibr64-1941738114529727" ref-type="bibr">64</xref></sup> Other options include nonselective oral nonsteroidal anti-inflammatory drugs plus a gastroprotective agent or cyclooxygenase-2 inhibitors. For patients with marked pain who are not good candidates for surgery, opioid analgesics may be considered in spite of physician and patient concerns regarding side effects and improper use.<sup><xref rid="bibr29-1941738114529727" ref-type="bibr">29</xref></sup> Intra-articular corticosteroid treatment, although popular, only relieves pain in the short term, with its greatest effect after 1 week and diminishing thereafter.<sup><xref rid="bibr29-1941738114529727" ref-type="bibr">29</xref></sup> In addition, intra-articular corticosteroid injections combined with lidocaine can be cytotoxic for chondrocytes. Its frequency and patient selection must be carefully considered.<sup><xref rid="bibr7-1941738114529727" ref-type="bibr">7</xref>,<xref rid="bibr48-1941738114529727" ref-type="bibr">48</xref></sup></p>
    <p>Intra-articular viscosupplementation has become increasingly common for the treatment of symptomatic knee OA. However, its efficacy remains controversial. In several clinical studies, exogenous hyaluronic acid (HA) reduced the production and activity of pro-inflammatory mediators and matrix metalloproteinases, while enhancing native chondrocyte HA and proteoglycan synthesis, and even altering the behavior of immune cells.<sup><xref rid="bibr15-1941738114529727" ref-type="bibr">15</xref></sup> HA is also important for modulating tissue hydration and osmotic balance.<sup><xref rid="bibr15-1941738114529727" ref-type="bibr">15</xref></sup> A meta-analysis published in the <italic>Journal of the American Medical Association</italic> in 2003 suggests that intra-articular HA knee injections for OA may not result in a clinically significant difference when compared with placebo.<sup><xref rid="bibr32-1941738114529727" ref-type="bibr">32</xref></sup> However, a Cochrane review<sup><xref rid="bibr3-1941738114529727" ref-type="bibr">3</xref></sup> concluded that viscosupplementation, when used in specific clinical settings, is an effective treatment for knee OA and may provide longer term benefits when compared with intra-articular corticosteroids.<sup><xref rid="bibr22-1941738114529727" ref-type="bibr">22</xref></sup> The results of HA therapy may be related to variations in the molecular weights of HA products as well as varying degrees of heterogeneity of HA (viscosity and elasticity).</p>
    <p>Platelet-rich plasma (PRP) is autologous blood, minus red blood cells, with higher-than-baseline concentrations of platelets prepared by centrifugal separation. Various growth factors, such as platelet-derived growth factor, vascular endothelial growth factor, and transforming growth factor β1 (TGF-β1), among others, are present. Current evidence suggests that PRP stimulates chondrogenesis and regeneration while increasing HA production and stabilizing angiogenesis.<sup><xref rid="bibr18-1941738114529727" ref-type="bibr">18</xref>,<xref rid="bibr30-1941738114529727" ref-type="bibr">30</xref></sup> Compared with intra-articular HA or placebo controls, PRP injections in the knee appear to be superior for pain control and functional improvement during the first 6 months in the treatment of OA.<sup><xref rid="bibr23-1941738114529727" ref-type="bibr">23</xref>,<xref rid="bibr41-1941738114529727" ref-type="bibr">41</xref>,<xref rid="bibr49-1941738114529727" ref-type="bibr">49</xref></sup> At this time, more substantiated clinical data are required to determine the efficacy of PRP in the treatment of symptomatic OA. Certainly, there are less data to suggest that PRP can influence the natural history of an osteoarthritic knee. Rather, its mechanism of action is likely anti-inflammatory, which can alter the local intra-articular milieu of catabolic and anabolic growth factors and cytokines.<sup><xref rid="bibr33-1941738114529727" ref-type="bibr">33</xref></sup></p>
    <p>Appropriate surgical management of OA is determined by specific patient symptoms, clinical and radiographic findings, circumstances, and expectations. While younger patients with isolated unicompartmental OA may benefit from a high tibial osteotomy or unicompartmental knee arthroplasty, patients with advanced, multiple compartmental OA are more likely to benefit from total knee arthroplasty. The routine use of arthroscopic debridement for the treatment of OA has been challenged recently by several randomized control studies demonstrating no significant difference between arthroscopic management and placebo in the treatment of knee OA.<sup><xref rid="bibr24-1941738114529727" ref-type="bibr">24</xref>,<xref rid="bibr35-1941738114529727" ref-type="bibr">35</xref></sup></p>
    <p>Although many nonsurgical and surgical treatment modalities improve pain and function in OA patients, none alter the natural history of the disease process. Recently, there has been increased focus on the potential role of stem cells in the management of OA. The following sections provide a brief overview on the different types of stem cells that can be used, with particular emphasis on the potential role of mesenchymal stem cells (MSCs), also known as mesenchymal stromal cells.</p>
    <sec id="section7-1941738114529727">
      <title>Role of Mesenchymal Stem Cells in the Management of Osteoarthritis</title>
      <sec id="section8-1941738114529727">
        <title>Rationale</title>
        <p>In the past decade, MSCs have emerged as an option in the armamentarium for the treatment of OA. MSCs, derived from bone marrow, can differentiate into cells of chondrogenic lineage.<sup><xref rid="bibr19-1941738114529727" ref-type="bibr">19</xref></sup> MSCs are abundant in many adult tissue types and are precursors to the mesodermal lineage of cells/tissues including bone, cartilage, fat, and connective tissues (including tendon and ligament).<sup><xref rid="bibr9-1941738114529727" ref-type="bibr">9</xref>,<xref rid="bibr16-1941738114529727" ref-type="bibr">16</xref></sup> MSCs can be isolated from bone marrow, adipose tissue, and umbilical cord tissue/blood as well as synovium and periosteum.<sup><xref rid="bibr16-1941738114529727" ref-type="bibr">16</xref>,<xref rid="bibr40-1941738114529727" ref-type="bibr">40</xref>,<xref rid="bibr57-1941738114529727" ref-type="bibr">57</xref></sup> Since MSCs are somatic (adult) stem cells, they have limited replicative potential and, importantly, are non-transformative.<sup><xref rid="bibr26-1941738114529727" ref-type="bibr">26</xref>,<xref rid="bibr51-1941738114529727" ref-type="bibr">51</xref></sup></p>
        <p>Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) are 2 other stem cell types that can differentiate into multiple lineages of cell/tissue types, including chondrogenic cells. However, among all potential allogeneic stem cell sources, MSCs seem to hold the most promise at present.<sup><xref rid="bibr11-1941738114529727" ref-type="bibr">11</xref>,<xref rid="bibr38-1941738114529727" ref-type="bibr">38</xref>,<xref rid="bibr50-1941738114529727" ref-type="bibr">50</xref>,<xref rid="bibr55-1941738114529727" ref-type="bibr">55</xref></sup> There are also unresolved safety concerns with potential tumorigenicity and immunologic compatibility with ESCs and/or iPSCs as allogeneic cell sources, as well as ethical/religious considerations.<sup><xref rid="bibr4-1941738114529727" ref-type="bibr">4</xref>,<xref rid="bibr37-1941738114529727" ref-type="bibr">37</xref>,<xref rid="bibr58-1941738114529727" ref-type="bibr">58</xref>,<xref rid="bibr61-1941738114529727" ref-type="bibr">61</xref></sup></p>
      </sec>
      <sec id="section9-1941738114529727">
        <title>Regulatory Pathways</title>
        <p>A cartilage product may be defined as a tissue, non-tissue biologic, device, drug, or a combination of these terms as per Section 361 of the Public Health Service Act.<sup><xref rid="bibr53-1941738114529727" ref-type="bibr">53</xref></sup> Tissues that are minimally manipulated (autologous bone marrow aspirate concentrate), intended for homologous use, and do not have a systemic effect are categorized as human cells, tissues, and cellular- and tissue-based products and do not require a formal clinical trial for Food and Drug Administration (FDA) approval and market release. Cartilage products regulated as biological drugs require an investigational new drug application for clinical evaluation and premarket demonstration. The product must be safe, pure, potent, and effective. Finally, for cartilage products regulated as devices, associated clinical studies must be conducted under an investigational device exemption, and a premarket approval is required.</p>
        <p>Products such as Orthokine, an autologous PRP procedure (Orthogen, Düsseldorf, Germany; known as Regenokine in the United States) or ex vivo expanded autologous/allogeneic MSCs would be regulated as biological drugs by the FDA but may be regulated differently depending on the country and regulatory jurisdiction.<sup><xref rid="bibr53-1941738114529727" ref-type="bibr">53</xref>,<xref rid="bibr56-1941738114529727" ref-type="bibr">56</xref></sup> While the use of minimally manipulated (eg, not ex vivo culture–expanded) autologous bone marrow cell aspirates (of which the exact number and/or proportion of MSCs may not be known at the time of administration) may pose some potential clinical merit, any significant benefit of autologous or allogeneic MSC treatment will likely be associated with ex vivo culture expansion that in turn will require standardized and quality controlled manufacturing processes. A key point to consider is that the autologous MSC therapy (eg, bone marrow aspirate concentrate) with un-expanded cells can be performed at the discretion of a physician without a formal approval/registration status of “a device or biological drug” in most regulatory jurisdictions, including Canada and the United States. The downside of this is 2-fold: (1) There may be no quality control measure that can be applied for each preparation and patient and (2) because of decreases in quality of the MSCs with increases in patient age, older patients may not get significant clinical benefits from autologous MSC procedures aside from a potential placebo effect. The evidence for procedures such as bone marrow aspirate concentrate, however, remains quite limited at the present time.</p>
      </sec>
      <sec id="section10-1941738114529727">
        <title>Mechanism of Action</title>
        <p>The most important hallmark of MSCs, regardless of their tissue sources of origin, is that the MSCs do not express major histocompatibility complex class II antigens (human leukocyte antigen, DR receptors), thereby not provoking the host’s T-cell response on implantation.<sup><xref rid="bibr47-1941738114529727" ref-type="bibr">47</xref></sup> Furthermore, the MSCs can modulate and control inflammation, inhibit apoptosis, stimulate endogenous cell proliferation and repair, and improve blood flow in joints.<sup><xref rid="bibr57-1941738114529727" ref-type="bibr">57</xref></sup> MSCs can hone to injured tissue and secrete a milieu of proteins via a paracrine effect leading to a healing or trophic effect, thus contributing to endogenous tissue repair.<sup><xref rid="bibr16-1941738114529727" ref-type="bibr">16</xref></sup> The mechanism of action is related to the secretion of cytokines, chemokines, and growth factors from the MSCs.<sup><xref rid="bibr9-1941738114529727" ref-type="bibr">9</xref></sup></p>
        <p>One of the attractive features of MSCs is the ability to readily harvest from the patient’s own tissue source such as bone marrow, although the quantity and quality of MSCs decrease with age.<sup><xref rid="bibr2-1941738114529727" ref-type="bibr">2</xref>,<xref rid="bibr21-1941738114529727" ref-type="bibr">21</xref></sup> While minimally manipulated (ie, not ex vivo culture–expanded) autologous cell aspirates may pose some potential clinical merit, the immune-privileged nature of the MSCs allows development of allogeneic MSC products for the treatment of OA with standardized and quality-controlled manufacturing process.</p>
      </sec>
      <sec id="section11-1941738114529727">
        <title>Clinical Use of Mesenchymal Stem Cells in Osteoarthritis</title>
        <p>The optimal source of MSCs has yet to be determined.<sup><xref rid="bibr16-1941738114529727" ref-type="bibr">16</xref>,<xref rid="bibr50-1941738114529727" ref-type="bibr">50</xref>,<xref rid="bibr57-1941738114529727" ref-type="bibr">57</xref></sup> There are various advantages and disadvantages associated with bone marrow, synovium, adipose tissue, and umbilical cord (<xref ref-type="table" rid="table1-1941738114529727">Table 1</xref>).<sup><xref rid="bibr45-1941738114529727" ref-type="bibr">45</xref>,<xref rid="bibr63-1941738114529727" ref-type="bibr">63</xref></sup></p>
        <table-wrap id="table1-1941738114529727" position="float">
          <label>Table 1.</label>
          <caption>
            <p>Sources for mesenchymal stem cells</p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="left" span="1"/>
              <col align="left" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="left" rowspan="1" colspan="1">Tissue Type</th>
                <th align="center" rowspan="1" colspan="1">Advantages</th>
                <th align="center" rowspan="1" colspan="1">Disadvantages</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">Bone marrow<sup><xref rid="bibr45-1941738114529727" ref-type="bibr">45</xref></sup></td>
                <td rowspan="1" colspan="1">• Good chondrogenic and osteogenic potential<break/>• Easy to harvest and exist in large numbers<break/>• High proliferative activity</td>
                <td rowspan="1" colspan="1">• Risks of harvesting, such as infection and pain</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Synovium<sup><xref rid="bibr45-1941738114529727" ref-type="bibr">45</xref></sup></td>
                <td rowspan="1" colspan="1">• Best chondrogenic potential<break/>• High proliferative activity</td>
                <td rowspan="1" colspan="1">• Poor osteogenic potential<break/>• Only preclinical studies available</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Adipose tissue<sup><xref rid="bibr45-1941738114529727" ref-type="bibr">45</xref></sup></td>
                <td rowspan="1" colspan="1">• Easily harvested<break/>• Available in large numbers</td>
                <td rowspan="1" colspan="1">• Lower chondrogenic potential, but may be improved through the use of growth factors</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Umbilical cord<sup><xref rid="bibr63-1941738114529727" ref-type="bibr">63</xref></sup></td>
                <td rowspan="1" colspan="1">• No morbidity with collection<break/>• Large capacity for ex vivo expansion<break/>• Full potential to differentiate into chondrogenic, adipogenic, and osteogenic lineages</td>
                <td rowspan="1" colspan="1">• Allogenic source<break/>• Less well studied</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>At the present time, administration usually involves placing the MSCs via intra-articular injection. The ideal approach remains to be determined as the intra-articular microenvironment can be influenced by local pro- and anti-inflammatory actions from the cells. Alternatively, MSCs can be implanted in a scaffold, encapsulated, or injected in combination with other factors such as transforming growth factor-β.<sup><xref rid="bibr50-1941738114529727" ref-type="bibr">50</xref></sup> They can be engineered to express anti-inflammatory or pro-chondrogenic factors. Another option is to inject bone marrow concentrate,<sup><xref rid="bibr57-1941738114529727" ref-type="bibr">57</xref></sup> which does not require ex vivo culture expansion.<sup><xref rid="bibr2-1941738114529727" ref-type="bibr">2</xref></sup></p>
        <p>A systematic review of the safety of intra-articular autologous bone marrow MSC injections in humans found 22 adverse events and 4 serious adverse events following 844 procedures (mean follow-up, 21 months).<sup><xref rid="bibr42-1941738114529727" ref-type="bibr">42</xref></sup> Two serious adverse events were related to the procedure (pulmonary embolism and infection at the iliac crest harvest site) and 2 were unrelated (tumors in areas not involving the cell collection or implantation site). The mild adverse events were related to transient pain or swelling, with a rate comparable with other injectable joint therapies. Nevertheless, controversy still exists about the relative risks of MSC injections. MSCs not cultured in an authorized good manufacturing practice facility using approved culture protocols may risk bacterial contamination, cellular transformation, and/or premature differentiation of cells.<sup><xref rid="bibr16-1941738114529727" ref-type="bibr">16</xref></sup> There have been no reported adverse events associated with MSC transformation,<sup><xref rid="bibr43-1941738114529727" ref-type="bibr">43</xref>,<xref rid="bibr44-1941738114529727" ref-type="bibr">44</xref></sup> but there remains a theoretical concern that cells may differentiate/transform into unwanted cell types or become tumorigenic, especially over the long term. To date, there are no long-term safety problems following either allogeneic or autologous MSC use.</p>
        <p>The recent identification of subtypes of MSCs that may demonstrate pro-inflammatory versus anti-inflammatory responses based on activation of toll-like receptors 4 and 3, respectively,<sup><xref rid="bibr62-1941738114529727" ref-type="bibr">62</xref></sup> is particularly relevant for choosing appropriate treatment strategies targeting inflammatory diseases.</p>
      </sec>
    </sec>
    <sec id="section12-1941738114529727">
      <title>Summary of Animal Models Using Mesenchymal Stem Cells in the Treatment of Osteoarthritis</title>
      <p>A full summary of animal models using MSCs to treat OA is provided in Appendix 1 (available at <ext-link ext-link-type="uri" xlink:href="http://sph.sagepub.com/content/suppl">http://sph.sagepub.com/content/suppl</ext-link>). Knees of mice injected with adipose-derived MSCs with collagenase-induced OA were protected against synovial thickening, formation of enthesophytes, and cartilage destruction when compared with the control group.<sup><xref rid="bibr52-1941738114529727" ref-type="bibr">52</xref></sup> However, knees injected on post-OA day 14 did not show the same protective effect, suggesting that early intervention is important in mitigating OA progression.</p>
      <p>Diekman et al<sup><xref rid="bibr13-1941738114529727" ref-type="bibr">13</xref></sup> used a closed tibial plateau fracture model to induce posttraumatic arthritis (PTA) in the knees of C57BL/6 mice. A single intra-articular injection of MSCs at the time of fracture prevented the development of PTA. Control mice showed evidence of PTA 8 weeks after the induced fracture. An increase in the cytokine levels of the MSC-treated mice included elevated systemic IL-10 levels, suggesting an anti-inflammatory effect from MSC injections. However, the immune mechanisms of murine and human MSCs differ, and clinical applications in humans may result in different outcomes.</p>
      <p>A hemimeniscectomy model in 12-week-old rats was used to evaluate single, intra-articular injections of rat- (rMSCs) and human-derived MSCs (hMSCs).<sup><xref rid="bibr19-1941738114529727" ref-type="bibr">19</xref></sup> At 2 and 4 weeks, there was regeneration of the meniscus in a similar manner with both rMSCs and hMSCs. At 8 weeks, hMSCs appeared to inhibit osteoarthritis progression compared with controls.</p>
      <p>In a second study, hMSCs were injected into 7-month-old guinea pigs with spontaneous knee arthritis that occurs naturally as early as 3 months of age.<sup><xref rid="bibr46-1941738114529727" ref-type="bibr">46</xref></sup> This study had 4 groups: a control group with phosphate-buffered saline (PBS), a control group with HA injection, a PBS + hMSC group, and an HA + hMSC group. Single injections of HA + hMSCs resulted in significantly lower OA scores and partial cartilage repair. These changes were found neither in the control groups injected with PBS or HA only nor in the group injected with PBS + hMSCs.</p>
      <p>The potential benefits of MSCs in the treatment of OA were shown using a model of induced subchondral defects in the knees of adult white New Zealand rabbits.<sup><xref rid="bibr59-1941738114529727" ref-type="bibr">59</xref></sup> Bone marrow– or periosteum-derived MSCs injected into the knees showed an improvement in the macroscopic appearance and histologic scores (with hyaline-like cartilage) compared with control knees.</p>
      <p>Adipose-derived stem cells injected into the medial compartment of rabbit anterior cruciate ligament (ACL)–transected knees showed improved radiologic and histologic scores compared with controls.<sup><xref rid="bibr54-1941738114529727" ref-type="bibr">54</xref></sup></p>
      <p>Goat knees injected with MSCs 6 weeks after complete excision of the medial meniscus and resection of the ACL demonstrated marked regeneration of the medial meniscus and less cartilage damage when compared with control knees.<sup><xref rid="bibr36-1941738114529727" ref-type="bibr">36</xref></sup></p>
      <p>Sheep knees were injected 6 weeks post–ACL transection with either a control (basal media without cells), chondrogenic media–induced bone marrow MSCs, or basal media–induced bone marrow MSCs.<sup><xref rid="bibr1-1941738114529727" ref-type="bibr">1</xref></sup> Chondrogenic media–induced bone marrow MSCs resulted in better repair of cartilage lesions as well as repair of some of the meniscal lesions with meniscus-like tissue. This suggests that predifferentiation might be an effective strategy compared with the use of undifferentiated MSCs.</p>
      <p>Intra-articular injections 14 days after surgery of an adipose-derived stromal vascular fraction and bone marrow–derived MSCs were compared with controls for the treatment of knee OA induced arthroscopically in horses (placebo, adipose-derived stromal vascular fraction, and bone marrow–derived MSCs).<sup><xref rid="bibr17-1941738114529727" ref-type="bibr">17</xref></sup> There were no significant treatment effects in pain scores, radiographic evaluations, or histologic examinations. The only significant beneficial effect was a decrease in the PGE2 levels in the synovial fluid of bone marrow–MSC horses on day 35.</p>
      <p>In summary, most animal studies are based on histologic evidence rather than functional evaluation, making preclinical work difficult to translate to symptomatic OA patients. Results may vary with severity of the model/injury, timing, type of MSCs, culture method, or dose.</p>
    </sec>
    <sec id="section13-1941738114529727">
      <title>Clinical Studies in Humans Using Mesenchymal Stem Cells in the Treatment of Osteoarthritis</title>
      <p>A full summary of clinical studies using MSCs in the treatment of OA in humans is provided in Appendix 2 (available at <ext-link ext-link-type="uri" xlink:href="http://sph.sagepub.com/content/suppl">http://sph.sagepub.com/content/suppl</ext-link>). Regeneration of extensive unicompartmental articular cartilage defects in OA knees was promoted by the implantation of autologous MSCs in 12 patients compared with a cell-free control group.<sup><xref rid="bibr60-1941738114529727" ref-type="bibr">60</xref></sup> There was improvement in the histologic and arthroscopic scores as well as clinical outcome scores in the treatment group, but no significant difference between the clinical outcome scores.</p>
      <p>Bone marrow–derived MSCs were evaluated in 6 female patients with radiographic and magnetic resonance imaging (MRI) evidence of Kellgren-Lawrence grade IV knee OA.<sup><xref rid="bibr10-1941738114529727" ref-type="bibr">10</xref></sup> Patients were injected with bone marrow–MSCs that were cultured for 7 days. At 1-year follow-up, there were no local or systemic adverse events. Patients all had statistically significant improvements in their visual analog scale (VAS) and Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain scores, improved function (increased range of motion, increased walking distance to pain, and decreased patellar crepitus), and MRI evidence of increased cartilage repair, extension of repair tissue, and decreased subchondral edema.</p>
      <p>A pilot study in 4 patients with moderate to severe knee OA who received bone marrow–MSC injections and were followed for 6 months were found to have improvements in walking time for onset of pain, stair climbing, knee crepitus, and swelling.<sup><xref rid="bibr12-1941738114529727" ref-type="bibr">12</xref></sup> There were no adverse events noted. There were no radiographic changes noted on postinjection knee radiography.</p>
      <p>Emadedin et al<sup><xref rid="bibr14-1941738114529727" ref-type="bibr">14</xref></sup> evaluated the use of bone marrow–MSCs in 6 female patients with radiographic and MRI evidence of Kellgren-Lawrence grade IV knee OA. At 1-year follow-up, there were no local or systemic adverse events. The patients all had improvements in their VAS and WOMAC pain scores, improved function (increased range of motion, increased walking distance to pain, and decreased patellar crepitus), and MRI evidence of increased cartilage repair, extension of repair tissue, and decreased subchondral edema.</p>
      <p>Pain scores improved following the injection of infrapatellar fat pad derived–MSCs into knees following arthroscopic procedures.<sup><xref rid="bibr27-1941738114529727" ref-type="bibr">27</xref>,<xref rid="bibr28-1941738114529727" ref-type="bibr">28</xref></sup> The improvements correlated with the number of MSCs injected. Both studies suggested a better response in knees affected by International Cartilage Repair Society grade 3 OA compared with grade 4 OA.<sup><xref rid="bibr27-1941738114529727" ref-type="bibr">27</xref>,<xref rid="bibr28-1941738114529727" ref-type="bibr">28</xref></sup> The first study reported no significant adverse events associated with the injections, although some patients reported a slight increase in their knee pain for 2 to 3 days postinjection.<sup><xref rid="bibr27-1941738114529727" ref-type="bibr">27</xref></sup></p>
      <p>Eighty to 90 mL of bone marrow was extracted from the iliac bone in an ambulatory setting from 12 patients with knee OA using local anesthesia and slight sedation.<sup><xref rid="bibr39-1941738114529727" ref-type="bibr">39</xref></sup> After a mean cell expansion period of approximately 3 weeks, the MSC concentrate was injected into the affected knee and the patients were followed for a minimum of 1 year. Patients tolerated the procedures well (both bone marrow aspiration and knee injection), and there was a statistically significant improvement in pain scores and function, measured by VAS and WOMAC scores, at 12-month follow-up.</p>
      <p>CARTISTEM (MEDIPOST, Seoul, Korea) is the only commercially available MSC product for OA using allogeneic, umbilical cord blood as the cell source. CARTISTEM is approved in Korea and is undergoing US FDA investigational new drug cleared phase I/IIa clinical trials in the United States for the treatment of cartilage defects in combination with an HA scaffold.</p>
    </sec>
    <sec id="section14-1941738114529727">
      <title>Further Areas of Investigation</title>
      <p>Despite recent advancements, the use of MSCs for the treatment of OA needs to be better defined. Barry and Murphy<sup><xref rid="bibr2-1941738114529727" ref-type="bibr">2</xref></sup> list 13 ongoing studies investigating the use of MSCs in knee, hip, or ankle OA in humans. However, there are several important hurdles that must be addressed before reliable conclusions from the body of literature regarding the role of MSCs in the treatment of knee OA can be drawn:</p>
      <list list-type="simple" id="list1-1941738114529727">
        <list-item>
          <p>(1) Is the role of MSCs predominantly symptom management or as a disease-modifying osteoarthritis drug? Human studies have shown that intra-articular injections of MSCs improve pain and function scores in knee OA.<sup><xref rid="bibr10-1941738114529727" ref-type="bibr">10</xref>,<xref rid="bibr27-1941738114529727" ref-type="bibr">27</xref>,<xref rid="bibr28-1941738114529727" ref-type="bibr">28</xref>,<xref rid="bibr39-1941738114529727" ref-type="bibr">39</xref>,<xref rid="bibr60-1941738114529727" ref-type="bibr">60</xref></sup> However, there is very little evidence to support MSCs having a disease-modifying effect.</p>
        </list-item>
        <list-item>
          <p>(2) The optimal method of MSC administration remains unknown. Specific studies have not compared MSC injections in suspension versus scaffold media.<sup><xref rid="bibr2-1941738114529727" ref-type="bibr">2</xref>,<xref rid="bibr46-1941738114529727" ref-type="bibr">46</xref></sup></p>
        </list-item>
        <list-item>
          <p>(3) The optimal dose, frequency, timing, and number of injections remains unclear (see Appendix 1). There is a distinct lack of homogeneity among animal studies investigating the use of MSCs in the treatment of OA. Although animal and clinical studies have suggested dose ranges anywhere from 1 × 10<sup>6</sup> to 4 × 10<sup>7</sup> cells per injection, there is no clear indication of what the initial dose should be.</p>
        </list-item>
        <list-item>
          <p>(4) The optimal source of MSCs (bone marrow, adipose tissue, synovium, umbilical cord blood/tissue) is yet to be identified.<sup><xref rid="bibr45-1941738114529727" ref-type="bibr">45</xref></sup> The majority of clinical studies use bone marrow– or adipose-derived MSCs.</p>
        </list-item>
        <list-item>
          <p>(5) There is a need for clinical imaging studies to determine where the MSCs end up after injection.</p>
        </list-item>
        <list-item>
          <p>(6) Knee OA may be associated with malalignment, specifically varus and valgus knee deformities. It is possible that patients who also have a mechanical axis deformity in addition to OA would benefit from a concurrent procedure to correct the deformity in addition to treatment with MSCs. Other mechanical factors to consider include the stability of the knee as well as the integrity of the meniscus. Certainly, the health of the surrounding musculotendinous structures also contributes to the structure and function of the knee joint.</p>
        </list-item>
      </list>
    </sec>
    <sec sec-type="conclusions" id="section15-1941738114529727">
      <title>Conclusion</title>
      <p>Mesenchymal stem cells are an exciting and relatively novel treatment for osteoarthritis. MSCs may improve symptoms and function in osteoarthritic joints but also decrease inflammation and induce cartilage healing. This is likely related to the secretion of cytokines, chemokines, and growth factors from MSCs.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>We would like to thank several individuals for their contribution to this article, including Dr Venhiah Tjong, Dr Ofir Chechik, Dr John Townley, Dr Nizar Mahomed, Dr Wayne Marshall, and Dr Antonio Lee. In particular, we would like to recognize Dr Tjong’s important role in the preparation of our article.</p>
    </ack>
    <fn-group>
      <fn fn-type="conflict">
        <p>The following authors declared potential conflicts of interest: Sowmya Viswanathan, PhD, is a paid consultant for Centre for Commercialization of Regenerative Medicine and CEO of Cellulead. Brian J. Cole, MD, MBA, is a paid consultant for DePuy, Arthrex, Regentis, Zimmer, and Carticept; has grants/grant pending from S&amp;N; receives royalties from Arthrex, DePuy, Elsevier, WB Saunders; and hold stock/stock options in Carticept and Regentis.<?release-delay 12|0?></p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="bibr1-1941738114529727">
        <label>1.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Al Faqeh</surname><given-names>H</given-names></name><name><surname>Nor Hamdan</surname><given-names>BM</given-names></name><name><surname>Chen</surname><given-names>HC</given-names></name><name><surname>Aminuddin</surname><given-names>BS</given-names></name><name><surname>Ruszymah</surname><given-names>BH</given-names></name></person-group>
<article-title>The potential of intra-articular injection of chondrogenic-induced bone marrow stem cells to retard the progression of osteoarthritis in a sheep model</article-title>. <source>Exp Gerontol</source>. <year>2012</year>;<volume>47</volume>:<fpage>458</fpage>-<lpage>464</lpage>.<pub-id pub-id-type="pmid">22759409</pub-id></mixed-citation>
      </ref>
      <ref id="bibr2-1941738114529727">
        <label>2.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barry</surname><given-names>F</given-names></name><name><surname>Murphy</surname><given-names>M</given-names></name></person-group>
<article-title>Mesenchymal stem cells in joint disease and repair</article-title>. <source>Nat Rev Rheumatol</source>. <year>2013</year>;<volume>9</volume>:<fpage>584</fpage>-<lpage>594</lpage>.<pub-id pub-id-type="pmid">23881068</pub-id></mixed-citation>
      </ref>
      <ref id="bibr3-1941738114529727">
        <label>3.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bellamy</surname><given-names>N</given-names></name><name><surname>Campbell</surname><given-names>J</given-names></name><name><surname>Robinson</surname><given-names>V</given-names></name><name><surname>Gee</surname><given-names>T</given-names></name><name><surname>Bourne</surname><given-names>R</given-names></name><name><surname>Wells</surname><given-names>G</given-names></name></person-group>
<article-title>Viscosupplementation for the treatment of osteoarthritis of the knee</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2006</year>;(<issue>2</issue>):<fpage>CD005321</fpage>.<pub-id pub-id-type="pmid">16625635</pub-id></mixed-citation>
      </ref>
      <ref id="bibr4-1941738114529727">
        <label>4.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ben-David</surname><given-names>U</given-names></name><name><surname>Benvenisty</surname><given-names>N</given-names></name></person-group>
<article-title>The tumorigenicity of human embryonic and induced pluripotent stem cells</article-title>. <source>Nat Rev Cancer</source>. <year>2011</year>;<volume>11</volume>:<fpage>268</fpage>-<lpage>277</lpage>.<pub-id pub-id-type="pmid">21390058</pub-id></mixed-citation>
      </ref>
      <ref id="bibr5-1941738114529727">
        <label>5.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bijlsma</surname><given-names>JW</given-names></name><name><surname>Berenbaum</surname><given-names>F</given-names></name><name><surname>Lafeber</surname><given-names>FP</given-names></name></person-group>
<article-title>Osteoarthritis: an update with relevance for clinical practice</article-title>. <source>Lancet</source>. <year>2011</year>;<volume>377</volume>:<fpage>2115</fpage>-<lpage>2126</lpage>.<pub-id pub-id-type="pmid">21684382</pub-id></mixed-citation>
      </ref>
      <ref id="bibr6-1941738114529727">
        <label>6.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bitton</surname><given-names>R</given-names></name></person-group>
<article-title>The economic burden of osteoarthritis</article-title>. <source>Am J Manag Care</source>. <year>2009</year>;<volume>15</volume>(<issue>suppl</issue>):<fpage>S230</fpage>-<lpage>S235</lpage>.<pub-id pub-id-type="pmid">19817509</pub-id></mixed-citation>
      </ref>
      <ref id="bibr7-1941738114529727">
        <label>7.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bjordal</surname><given-names>JM</given-names></name><name><surname>Klovning</surname><given-names>A</given-names></name><name><surname>Ljunggren</surname><given-names>AE</given-names></name><name><surname>Slørdal</surname><given-names>L</given-names></name></person-group>
<article-title>Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: a meta-analysis of randomised placebo-controlled trials</article-title>. <source>Eur J Pain</source>. <year>2007</year>;<volume>11</volume>:<fpage>125</fpage>-<lpage>138</lpage>.<pub-id pub-id-type="pmid">16682240</pub-id></mixed-citation>
      </ref>
      <ref id="bibr8-1941738114529727">
        <label>8.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brouwer</surname><given-names>RW</given-names></name><name><surname>van Raaij</surname><given-names>TM</given-names></name><name><surname>Verhaar</surname><given-names>JA</given-names></name><name><surname>Coene</surname><given-names>LN</given-names></name><name><surname>Bierma-Zeinstra</surname><given-names>SM</given-names></name></person-group>
<article-title>Brace treatment for osteoarthritis of the knee: a prospective randomized multi-centre trial</article-title>. <source>Osteoarthritis Cartilage</source>. <year>2006</year>;<volume>14</volume>:<fpage>777</fpage>-<lpage>783</lpage>.<pub-id pub-id-type="pmid">16563810</pub-id></mixed-citation>
      </ref>
      <ref id="bibr9-1941738114529727">
        <label>9.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Caplan</surname><given-names>AI</given-names></name></person-group>
<article-title>Review: mesenchymal stem cells: cell-based reconstructive therapy in orthopedics</article-title>. <source>Tissue Eng</source>. <year>2005</year>;<volume>11</volume>:<fpage>1198</fpage>-<lpage>1211</lpage>.<pub-id pub-id-type="pmid">16144456</pub-id></mixed-citation>
      </ref>
      <ref id="bibr10-1941738114529727">
        <label>10.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Centeno</surname><given-names>CJ</given-names></name><name><surname>Busse</surname><given-names>D</given-names></name><name><surname>Kisiday</surname><given-names>J</given-names></name><name><surname>Keohan</surname><given-names>C</given-names></name><name><surname>Freeman</surname><given-names>M</given-names></name><name><surname>Karli</surname><given-names>D</given-names></name></person-group>
<article-title>Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells</article-title>. <source>Pain Physician</source>. <year>2008</year>;<volume>11</volume>:<fpage>343</fpage>-<lpage>353</lpage>.<pub-id pub-id-type="pmid">18523506</pub-id></mixed-citation>
      </ref>
      <ref id="bibr11-1941738114529727">
        <label>11.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Craft</surname><given-names>AM</given-names></name><name><surname>Ahmed</surname><given-names>N</given-names></name><name><surname>Rockel</surname><given-names>JS</given-names></name><etal/></person-group>
<article-title>Specification of chondrocytes and cartilage tissues from embryonic stem cells</article-title>. <source>Development</source>. <year>2013</year>;<volume>140</volume>:<fpage>2597</fpage>-<lpage>2610</lpage>.<pub-id pub-id-type="pmid">23715552</pub-id></mixed-citation>
      </ref>
      <ref id="bibr12-1941738114529727">
        <label>12.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Davatchi</surname><given-names>F</given-names></name><name><surname>Abdollahi</surname><given-names>BS</given-names></name><name><surname>Mohyeddin</surname><given-names>M</given-names></name><name><surname>Shahram</surname><given-names>F</given-names></name><name><surname>Nikbin</surname><given-names>B</given-names></name></person-group>
<article-title>Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients</article-title>. <source>Int J Rheum Dis</source>. <year>2011</year>;<volume>14</volume>:<fpage>211</fpage>-<lpage>215</lpage>.<pub-id pub-id-type="pmid">21518322</pub-id></mixed-citation>
      </ref>
      <ref id="bibr13-1941738114529727">
        <label>13.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Diekman</surname><given-names>BO</given-names></name><name><surname>Wu</surname><given-names>CL</given-names></name><name><surname>Louer</surname><given-names>CR</given-names></name><etal/></person-group>
<article-title>Intra-articular delivery of purified mesenchymal stem cells from C57BL/6 or MRL/MpJ superhealer mice prevents posttraumatic arthritis</article-title>. <source>Cell Transplant</source>. <year>2013</year>;<volume>22</volume>:<fpage>1395</fpage>-<lpage>1408</lpage>.<pub-id pub-id-type="pmid">22889498</pub-id></mixed-citation>
      </ref>
      <ref id="bibr14-1941738114529727">
        <label>14.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Emadedin</surname><given-names>M</given-names></name><name><surname>Aghdami</surname><given-names>N</given-names></name><name><surname>Taghiyar</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Intra-articular injection of autologous mesenchymal stem cells in six patients with knee osteoarthritis</article-title>. <source>Arch Iran Med</source>. <year>2012</year>;<volume>15</volume>:<fpage>422</fpage>-<lpage>428</lpage>.<pub-id pub-id-type="pmid">22724879</pub-id></mixed-citation>
      </ref>
      <ref id="bibr15-1941738114529727">
        <label>15.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fakhari</surname><given-names>A</given-names></name><name><surname>Berkland</surname><given-names>C</given-names></name></person-group>
<article-title>Applications and emerging trends of hyaluronic acid in tissue engineering, as a dermal filler and in osteoarthritis treatment</article-title>. <source>Acta Biomater</source>. <year>2013</year>;<volume>9</volume>:<fpage>7081</fpage>-<lpage>7092</lpage>.<pub-id pub-id-type="pmid">23507088</pub-id></mixed-citation>
      </ref>
      <ref id="bibr16-1941738114529727">
        <label>16.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Filardo</surname><given-names>G</given-names></name><name><surname>Madry</surname><given-names>H</given-names></name><name><surname>Jelic</surname><given-names>M</given-names></name><name><surname>Roffi</surname><given-names>A</given-names></name><name><surname>Cucchiarini</surname><given-names>M</given-names></name><name><surname>Kon</surname><given-names>E</given-names></name></person-group>
<article-title>Mesenchymal stem cells for the treatment of cartilage lesions: from preclinical findings to clinical application in orthopaedics</article-title>. <source>Knee Surg Sports Traumatol Arthrosc</source>. <year>2013</year>;<volume>21</volume>:<fpage>1717</fpage>-<lpage>1729</lpage>.<pub-id pub-id-type="pmid">23306713</pub-id></mixed-citation>
      </ref>
      <ref id="bibr17-1941738114529727">
        <label>17.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Frisbie</surname><given-names>DD</given-names></name><name><surname>Kisiday</surname><given-names>JD</given-names></name><name><surname>Kawcak</surname><given-names>CE</given-names></name><name><surname>Werpy</surname><given-names>NM</given-names></name><name><surname>McIlwraith</surname><given-names>CW</given-names></name></person-group>
<article-title>Evaluation of adipose-derived stromal vascular fraction or bone marrow-derived mesenchymal stem cells for treatment of osteoarthritis</article-title>. <source>J Orthop Res</source>. <year>2009</year>;<volume>27</volume>:<fpage>1675</fpage>-<lpage>1680</lpage>.<pub-id pub-id-type="pmid">19544397</pub-id></mixed-citation>
      </ref>
      <ref id="bibr18-1941738114529727">
        <label>18.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hall</surname><given-names>MP</given-names></name><name><surname>Band</surname><given-names>PA</given-names></name><name><surname>Meislin</surname><given-names>RJ</given-names></name><name><surname>Jazrawi</surname><given-names>LM</given-names></name><name><surname>Cardone</surname><given-names>DA</given-names></name></person-group>
<article-title>Platelet-rich plasma: current concepts and application in sports medicine</article-title>. <source>J Am Acad Orthop Surg</source>. <year>2009</year>;<volume>17</volume>:<fpage>602</fpage>-<lpage>608</lpage>.<pub-id pub-id-type="pmid">19794217</pub-id></mixed-citation>
      </ref>
      <ref id="bibr19-1941738114529727">
        <label>19.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Horie</surname><given-names>M</given-names></name><name><surname>Choi</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>RH</given-names></name><etal/></person-group>
<article-title>Intra-articular injection of human mesenchymal stem cells (MSCs) promote rat meniscal regeneration by being activated to express Indian hedgehog that enhances expression of type II collagen</article-title>. <source>Osteoarthritis Cartilage</source>. <year>2012</year>;<volume>20</volume>:<fpage>1197</fpage>-<lpage>1207</lpage>.<pub-id pub-id-type="pmid">22750747</pub-id></mixed-citation>
      </ref>
      <ref id="bibr20-1941738114529727">
        <label>20.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hunter</surname><given-names>DJ</given-names></name></person-group>
<article-title>Osteoarthritis</article-title>. <source>Best Pract Res Clin Rheumatol</source>. <year>2011</year>;<volume>25</volume>:<fpage>801</fpage>-<lpage>814</lpage>.<pub-id pub-id-type="pmid">22265262</pub-id></mixed-citation>
      </ref>
      <ref id="bibr21-1941738114529727">
        <label>21.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jones</surname><given-names>E</given-names></name><name><surname>English</surname><given-names>A</given-names></name><name><surname>Churchman</surname><given-names>SM</given-names></name><etal/></person-group>
<article-title>Large-scale extraction and characterization of CD271+ multipotential stromal cells from trabecular bone in health and osteoarthritis: implications for bone regeneration strategies based on uncultured or minimally cultured multipotential stromal cells</article-title>. <source>Arthritis Rheum</source>. <year>2010</year>;<volume>62</volume>:<fpage>1944</fpage>-<lpage>1954</lpage>.<pub-id pub-id-type="pmid">20222109</pub-id></mixed-citation>
      </ref>
      <ref id="bibr22-1941738114529727">
        <label>22.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jüni</surname><given-names>P</given-names></name><name><surname>Rutjes</surname><given-names>AW</given-names></name><name><surname>da Costa</surname><given-names>BR</given-names></name><name><surname>Reichenbach</surname><given-names>S</given-names></name></person-group>
<article-title>Viscosupplementation for osteoarthritis of the knee</article-title>. <source>Ann Intern Med</source>. <year>2013</year>;<volume>158</volume>:<fpage>75</fpage>.<pub-id pub-id-type="pmid">23277909</pub-id></mixed-citation>
      </ref>
      <ref id="bibr23-1941738114529727">
        <label>23.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Khoshbin</surname><given-names>A</given-names></name><name><surname>Leroux</surname><given-names>T</given-names></name><name><surname>Wasserstein</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>The efficacy of platelet-rich plasma in the treatment of symptomatic knee osteoarthritis: a systematic review with quantitative synthesis</article-title>. <source>Arthroscopy</source>. <year>2013</year>;<volume>29</volume>:<fpage>2037</fpage>-<lpage>2048</lpage>.<pub-id pub-id-type="pmid">24286802</pub-id></mixed-citation>
      </ref>
      <ref id="bibr24-1941738114529727">
        <label>24.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kirkley</surname><given-names>A</given-names></name><name><surname>Birmingham</surname><given-names>TB</given-names></name><name><surname>Litchfield</surname><given-names>RB</given-names></name><etal/></person-group>
<article-title>A randomized trial of arthroscopic surgery for osteoarthritis of the knee</article-title>. <source>N Engl J Med</source>. <year>2008</year>;<volume>359</volume>:<fpage>1097</fpage>-<lpage>1107</lpage>.<pub-id pub-id-type="pmid">18784099</pub-id></mixed-citation>
      </ref>
      <ref id="bibr25-1941738114529727">
        <label>25.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kirkley</surname><given-names>A</given-names></name><name><surname>Webster-Bogaert</surname><given-names>S</given-names></name><name><surname>Litchfield</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>The effect of bracing on varus gonarthrosis</article-title>. <source>J Bone Joint Surg Am</source>. <year>1999</year>;<volume>81</volume>:<fpage>539</fpage>-<lpage>548</lpage>.<pub-id pub-id-type="pmid">10225800</pub-id></mixed-citation>
      </ref>
      <ref id="bibr26-1941738114529727">
        <label>26.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Knoepfler</surname><given-names>PS</given-names></name></person-group>
<article-title>Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine</article-title>. <source>Stem Cells</source>. <year>2009</year>;<volume>27</volume>:<fpage>1050</fpage>-<lpage>1056</lpage>.<pub-id pub-id-type="pmid">19415771</pub-id></mixed-citation>
      </ref>
      <ref id="bibr27-1941738114529727">
        <label>27.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koh</surname><given-names>YG</given-names></name><name><surname>Choi</surname><given-names>YJ</given-names></name></person-group>
<article-title>Infrapatellar fat pad-derived mesenchymal stem cell therapy for knee osteoarthritis</article-title>. <source>Knee</source>. <year>2012</year>;<volume>19</volume>:<fpage>902</fpage>-<lpage>907</lpage>.<pub-id pub-id-type="pmid">22583627</pub-id></mixed-citation>
      </ref>
      <ref id="bibr28-1941738114529727">
        <label>28.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koh</surname><given-names>YG</given-names></name><name><surname>Jo</surname><given-names>SB</given-names></name><name><surname>Kwon</surname><given-names>OR</given-names></name><etal/></person-group>
<article-title>Mesenchymal stem cell injections improve symptoms of knee osteoarthritis</article-title>. <source>Arthroscopy</source>. <year>2013</year>;<volume>29</volume>:<fpage>748</fpage>-<lpage>755</lpage>.<pub-id pub-id-type="pmid">23375182</pub-id></mixed-citation>
      </ref>
      <ref id="bibr29-1941738114529727">
        <label>29.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kon</surname><given-names>E</given-names></name><name><surname>Filardo</surname><given-names>G</given-names></name><name><surname>Drobnic</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Non-surgical management of early knee osteoarthritis</article-title>. <source>Knee Surg Sports Traumatol Arthrosc</source>. <year>2012</year>;<volume>20</volume>:<fpage>436</fpage>-<lpage>449</lpage>.<pub-id pub-id-type="pmid">22037809</pub-id></mixed-citation>
      </ref>
      <ref id="bibr30-1941738114529727">
        <label>30.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Krüger</surname><given-names>JP</given-names></name><name><surname>Hondke</surname><given-names>S</given-names></name><name><surname>Endres</surname><given-names>M</given-names></name><name><surname>Pruss</surname><given-names>A</given-names></name><name><surname>Siclari</surname><given-names>A</given-names></name><name><surname>Kaps</surname><given-names>C</given-names></name></person-group>
<article-title>Human platelet-rich plasma stimulates migration and chondrogenic differentiation of human subchondral progenitor cells</article-title>. <source>J Orthop Res</source>. <year>2012</year>;<volume>30</volume>:<fpage>845</fpage>-<lpage>852</lpage>.<pub-id pub-id-type="pmid">22058056</pub-id></mixed-citation>
      </ref>
      <ref id="bibr31-1941738114529727">
        <label>31.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leveille</surname><given-names>SG</given-names></name></person-group>
<article-title>Musculoskeletal aging</article-title>. <source>Curr Opin Rheumatol</source>. <year>2004</year>;<volume>16</volume>:<fpage>114</fpage>-<lpage>118</lpage>.<pub-id pub-id-type="pmid">14770095</pub-id></mixed-citation>
      </ref>
      <ref id="bibr32-1941738114529727">
        <label>32.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lo</surname><given-names>GH</given-names></name><name><surname>LaValley</surname><given-names>M</given-names></name><name><surname>McAlindon</surname><given-names>T</given-names></name><name><surname>Felson</surname><given-names>DT</given-names></name></person-group>
<article-title>Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis</article-title>. <source>JAMA</source>. <year>2003</year>;<volume>290</volume>:<fpage>3115</fpage>-<lpage>3121</lpage>.<pub-id pub-id-type="pmid">14679274</pub-id></mixed-citation>
      </ref>
      <ref id="bibr33-1941738114529727">
        <label>33.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mazzocca</surname><given-names>AD</given-names></name><name><surname>McCarthy</surname><given-names>MB</given-names></name><name><surname>Intravia</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>An in vitro evaluation of the anti-inflammatory effects of platelet-rich plasma, ketorolac, and methylprednisolone</article-title>. <source>Arthroscopy</source>. <year>2013</year>;<volume>29</volume>:<fpage>675</fpage>-<lpage>683</lpage>.<pub-id pub-id-type="pmid">23395471</pub-id></mixed-citation>
      </ref>
      <ref id="bibr34-1941738114529727">
        <label>34.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Michael</surname><given-names>JW</given-names></name><name><surname>Schlüter-Brust</surname><given-names>KU</given-names></name><name><surname>Eysel</surname><given-names>P</given-names></name></person-group>
<article-title>The epidemiology, etiology, diagnosis, and treatment of osteoarthritis of the knee</article-title>. <source>Dtsch Arztebl Int</source>. <year>2010</year>;<volume>107</volume>:<fpage>152</fpage>-<lpage>162</lpage> [erratum <italic>Dtsch Arztebl Int</italic>. 2010;107:294].<pub-id pub-id-type="pmid">20305774</pub-id></mixed-citation>
      </ref>
      <ref id="bibr35-1941738114529727">
        <label>35.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moseley</surname><given-names>JB</given-names></name><name><surname>O’Malley</surname><given-names>K</given-names></name><name><surname>Petersen</surname><given-names>NJ</given-names></name><etal/></person-group>
<article-title>A controlled trial of arthroscopic surgery for osteoarthritis of the knee</article-title>. <source>N Engl J Med</source>. <year>2002</year>;<volume>347</volume>:<fpage>81</fpage>-<lpage>88</lpage>.<pub-id pub-id-type="pmid">12110735</pub-id></mixed-citation>
      </ref>
      <ref id="bibr36-1941738114529727">
        <label>36.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Murphy</surname><given-names>JM</given-names></name><name><surname>Fink</surname><given-names>DJ</given-names></name><name><surname>Hunziker</surname><given-names>EB</given-names></name><name><surname>Barry</surname><given-names>FP</given-names></name></person-group>
<article-title>Stem cell therapy in a caprine model of osteoarthritis</article-title>. <source>Arthritis Rheum</source>. <year>2003</year>;<volume>48</volume>:<fpage>3464</fpage>-<lpage>3474</lpage>.<pub-id pub-id-type="pmid">14673997</pub-id></mixed-citation>
      </ref>
      <ref id="bibr37-1941738114529727">
        <label>37.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nakajima</surname><given-names>M</given-names></name><name><surname>Wakitani</surname><given-names>S</given-names></name><name><surname>Harada</surname><given-names>Y</given-names></name><name><surname>Tanigami</surname><given-names>A</given-names></name><name><surname>Tomita</surname><given-names>N</given-names></name></person-group>
<article-title>In vivo mechanical condition plays an important role for appearance of cartilage tissue in ES cell transplanted joint</article-title>. <source>J Orthop Res</source>. <year>2008</year>;<volume>26</volume>:<fpage>10</fpage>-<lpage>17</lpage>.<pub-id pub-id-type="pmid">17676607</pub-id></mixed-citation>
      </ref>
      <ref id="bibr38-1941738114529727">
        <label>38.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oldershaw</surname><given-names>RA</given-names></name></person-group>
<article-title>Cell sources for the regeneration of articular cartilage: the past, the horizon and the future</article-title>. <source>Int J Exp Pathol</source>. <year>2012</year>;<volume>93</volume>:<fpage>389</fpage>-<lpage>400</lpage>.<pub-id pub-id-type="pmid">23075006</pub-id></mixed-citation>
      </ref>
      <ref id="bibr39-1941738114529727">
        <label>39.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Orozco</surname><given-names>L</given-names></name><name><surname>Munar</surname><given-names>A</given-names></name><name><surname>Soler</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Treatment of knee osteoarthritis with autologous mesenchymal stem cells: a pilot study</article-title>. <source>Transplantation</source>. <year>2013</year>;<volume>95</volume>:<fpage>1535</fpage>-<lpage>1541</lpage>.<pub-id pub-id-type="pmid">23680930</pub-id></mixed-citation>
      </ref>
      <ref id="bibr40-1941738114529727">
        <label>40.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pastides</surname><given-names>P</given-names></name><name><surname>Chimutengwende-Gordon</surname><given-names>M</given-names></name><name><surname>Maffulli</surname><given-names>N</given-names></name><name><surname>Khan</surname><given-names>W</given-names></name></person-group>
<article-title>Stem cell therapy for human cartilage defects: a systematic review</article-title>. <source>Osteoarthritis Cartilage</source>. <year>2013</year>;<volume>21</volume>:<fpage>646</fpage>-<lpage>654</lpage>.<pub-id pub-id-type="pmid">23485933</pub-id></mixed-citation>
      </ref>
      <ref id="bibr41-1941738114529727">
        <label>41.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Dhillon</surname><given-names>MS</given-names></name><name><surname>Aggarwal</surname><given-names>S</given-names></name><name><surname>Marwaha</surname><given-names>N</given-names></name><name><surname>Jain</surname><given-names>A</given-names></name></person-group>
<article-title>Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: a prospective, double-blind, randomized trial</article-title>. <source>Am J Sports Med</source>. <year>2013</year>;<volume>41</volume>:<fpage>356</fpage>-<lpage>364</lpage>.<pub-id pub-id-type="pmid">23299850</pub-id></mixed-citation>
      </ref>
      <ref id="bibr42-1941738114529727">
        <label>42.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peeters</surname><given-names>CM</given-names></name><name><surname>Leijs</surname><given-names>MJ</given-names></name><name><surname>Reijman</surname><given-names>M</given-names></name><name><surname>van Osch</surname><given-names>GJ</given-names></name><name><surname>Bos</surname><given-names>PK</given-names></name></person-group>
<article-title>Safety of intra-articular cell-therapy with culture-expanded stem cells in humans: a systematic literature review</article-title>. <source>Osteoarthritis Cartilage</source>. <year>2013</year>;<volume>86</volume>:<fpage>1465</fpage>-<lpage>1473</lpage>.<pub-id pub-id-type="pmid">23831631</pub-id></mixed-citation>
      </ref>
      <ref id="bibr43-1941738114529727">
        <label>43.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Prockop</surname><given-names>DJ</given-names></name><name><surname>Brenner</surname><given-names>M</given-names></name><name><surname>Fibbe</surname><given-names>WE</given-names></name><etal/></person-group>
<article-title>Defining the risks of mesenchymal stromal cell therapy</article-title>. <source>Cytotherapy</source>. <year>2010</year>;<volume>12</volume>:<fpage>576</fpage>-<lpage>578</lpage>.<pub-id pub-id-type="pmid">20735162</pub-id></mixed-citation>
      </ref>
      <ref id="bibr44-1941738114529727">
        <label>44.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Prockop</surname><given-names>DJ</given-names></name><name><surname>Keating</surname><given-names>A</given-names></name></person-group>
<article-title>Relearning the lessons of genomic stability of human cells during expansion in culture: implications for clinical research</article-title>. <source>Stem Cells</source>. <year>2012</year>;<volume>30</volume>:<fpage>1051</fpage>-<lpage>1052</lpage>.<pub-id pub-id-type="pmid">22495826</pub-id></mixed-citation>
      </ref>
      <ref id="bibr45-1941738114529727">
        <label>45.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sakaguchi</surname><given-names>Y</given-names></name><name><surname>Sekiya</surname><given-names>I</given-names></name><name><surname>Yagishita</surname><given-names>K</given-names></name><name><surname>Muneta</surname><given-names>T</given-names></name></person-group>
<article-title>Comparison of human stem cells derived from various mesenchymal tissues: superiority of synovium as a cell source</article-title>. <source>Arthritis Rheum</source>. <year>2005</year>;<volume>52</volume>:<fpage>2521</fpage>-<lpage>2529</lpage>.<pub-id pub-id-type="pmid">16052568</pub-id></mixed-citation>
      </ref>
      <ref id="bibr46-1941738114529727">
        <label>46.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Uchida</surname><given-names>K</given-names></name><name><surname>Nakajima</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Direct transplantation of mesenchymal stem cells into the knee joints of Hartley strain guinea pigs with spontaneous osteoarthritis</article-title>. <source>Arthritis Res Ther</source>. <year>2012</year>;<volume>14</volume>:<fpage>R31</fpage>.<pub-id pub-id-type="pmid">22314040</pub-id></mixed-citation>
      </ref>
      <ref id="bibr47-1941738114529727">
        <label>47.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schu</surname><given-names>S</given-names></name><name><surname>Nosov</surname><given-names>M</given-names></name><name><surname>O’Flynn</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Immunogenicity of allogeneic mesenchymal stem cells</article-title>. <source>J Cell Mol Med</source>. <year>2012</year>;<volume>16</volume>:<fpage>2094</fpage>-<lpage>2103</lpage>.<pub-id pub-id-type="pmid">22151542</pub-id></mixed-citation>
      </ref>
      <ref id="bibr48-1941738114529727">
        <label>48.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Seshadri</surname><given-names>V</given-names></name><name><surname>Coyle</surname><given-names>CH</given-names></name><name><surname>Chu</surname><given-names>CR</given-names></name></person-group>
<article-title>Lidocaine potentiates the chondrotoxicity of methylprednisolone</article-title>. <source>Arthroscopy</source>. <year>2009</year>;<volume>25</volume>:<fpage>337</fpage>-<lpage>347</lpage>.<pub-id pub-id-type="pmid">19341919</pub-id></mixed-citation>
      </ref>
      <ref id="bibr49-1941738114529727">
        <label>49.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Spaková</surname><given-names>T</given-names></name><name><surname>Rosocha</surname><given-names>J</given-names></name><name><surname>Lacko</surname><given-names>M</given-names></name><name><surname>Harvanová</surname><given-names>D</given-names></name><name><surname>Gharaibeh</surname><given-names>A</given-names></name></person-group>
<article-title>Treatment of knee joint osteoarthritis with autologous platelet-rich plasma in comparison with hyaluronic acid</article-title>. <source>Am J Phys Med Rehabil</source>. <year>2012</year>;<volume>91</volume>:<fpage>411</fpage>-<lpage>417</lpage>.<pub-id pub-id-type="pmid">22513879</pub-id></mixed-citation>
      </ref>
      <ref id="bibr50-1941738114529727">
        <label>50.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tang</surname><given-names>QO</given-names></name><name><surname>Carasco</surname><given-names>CF</given-names></name><name><surname>Gamie</surname><given-names>Z</given-names></name><name><surname>Korres</surname><given-names>N</given-names></name><name><surname>Mantalaris</surname><given-names>A</given-names></name><name><surname>Tsiridis</surname><given-names>E</given-names></name></person-group>
<article-title>Preclinical and clinical data for the use of mesenchymal stem cells in articular cartilage tissue engineering</article-title>. <source>Expert Opin Biol Ther</source>. <year>2012</year>;<volume>12</volume>:<fpage>1361</fpage>-<lpage>1382</lpage>.<pub-id pub-id-type="pmid">22784026</pub-id></mixed-citation>
      </ref>
      <ref id="bibr51-1941738114529727">
        <label>51.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tarte</surname><given-names>K</given-names></name><name><surname>Gaillard</surname><given-names>J</given-names></name><name><surname>Lataillade</surname><given-names>JJ</given-names></name><etal/></person-group>
<article-title>Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation</article-title>. <source>Blood</source>. <year>2010</year>;<volume>115</volume>:<fpage>1549</fpage>-<lpage>1553</lpage>.<pub-id pub-id-type="pmid">20032501</pub-id></mixed-citation>
      </ref>
      <ref id="bibr52-1941738114529727">
        <label>52.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>ter Huurne</surname><given-names>M</given-names></name><name><surname>Schelbergen</surname><given-names>R</given-names></name><name><surname>Blattes</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Antiinflammatory and chondroprotective effects of intra-articular injection of adipose-derived stem cells in experimental osteoarthritis</article-title>. <source>Arthritis Rheum</source>. <year>2012</year>;<volume>64</volume>:<fpage>3604</fpage>-<lpage>3613</lpage>.<pub-id pub-id-type="pmid">22961401</pub-id></mixed-citation>
      </ref>
      <ref id="bibr53-1941738114529727">
        <label>53.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thomas</surname><given-names>JT</given-names></name><name><surname>Schneider</surname><given-names>BS</given-names></name><name><surname>Frank</surname><given-names>EL</given-names></name><name><surname>Krizan</surname><given-names>SJ</given-names></name></person-group>
<article-title>Cartilage repair and replacement in the knee: a regulatory perspective</article-title>. <source>Trends Biotechnol</source>. <year>2013</year>;<volume>31</volume>:<fpage>665</fpage>-<lpage>667</lpage>.<pub-id pub-id-type="pmid">24268060</pub-id></mixed-citation>
      </ref>
      <ref id="bibr54-1941738114529727">
        <label>54.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Toghraie</surname><given-names>F</given-names></name><name><surname>Razmkhah</surname><given-names>M</given-names></name><name><surname>Gholipour</surname><given-names>MA</given-names></name><etal/></person-group>
<article-title>Scaffold-free adipose-derived stem cells (ASCs) improve experimentally induced osteoarthritis in rabbits</article-title>. <source>Arch Iran Med</source>. <year>2012</year>;<volume>15</volume>:<fpage>495</fpage>-<lpage>499</lpage>.<pub-id pub-id-type="pmid">22827787</pub-id></mixed-citation>
      </ref>
      <ref id="bibr55-1941738114529727">
        <label>55.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tuan</surname><given-names>RS</given-names></name><name><surname>Chen</surname><given-names>AF</given-names></name><name><surname>Klatt</surname><given-names>BA</given-names></name></person-group>
<article-title>Cartilage regeneration</article-title>. <source>J Am Acad Orthop Surg</source>. <year>2013</year>;<volume>21</volume>:<fpage>303</fpage>-<lpage>311</lpage>.<pub-id pub-id-type="pmid">23637149</pub-id></mixed-citation>
      </ref>
      <ref id="bibr56-1941738114529727">
        <label>56.</label>
        <mixed-citation publication-type="book">
<collab>US Food and Drug Administration</collab>. <article-title>Guidance for industry: regulation of human cells, tissues, and cellular and tissue-based products (HCT/Ps)—small entity compliance guide</article-title>. <publisher-name>Center for Biologics Evaluation and Research</publisher-name>
<ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/ucm073366.htm">http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/ucm073366.htm</ext-link>
<date-in-citation>Accessed December 12, 2013</date-in-citation>.</mixed-citation>
      </ref>
      <ref id="bibr57-1941738114529727">
        <label>57.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Veronesi</surname><given-names>F</given-names></name><name><surname>Giavaresi</surname><given-names>G</given-names></name><name><surname>Tschon</surname><given-names>M</given-names></name><name><surname>Borsari</surname><given-names>V</given-names></name><name><surname>Nicoli Aldini</surname><given-names>N</given-names></name><name><surname>Fini</surname><given-names>M</given-names></name></person-group>
<article-title>Clinical use of bone marrow, bone marrow concentrate, and expanded bone marrow mesenchymal stem cells in cartilage disease</article-title>. <source>Stem Cells Dev</source>. <year>2013</year>;<volume>22</volume>:<fpage>181</fpage>-<lpage>192</lpage>.<pub-id pub-id-type="pmid">23030230</pub-id></mixed-citation>
      </ref>
      <ref id="bibr58-1941738114529727">
        <label>58.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wakitani</surname><given-names>S</given-names></name><name><surname>Aoki</surname><given-names>H</given-names></name><name><surname>Harada</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Embryonic stem cells form articular cartilage, not teratomas, in osteochondral defects of rat joints</article-title>. <source>Cell Transplant</source>. <year>2004</year>;<volume>13</volume>:<fpage>331</fpage>-<lpage>336</lpage>.<pub-id pub-id-type="pmid">15468674</pub-id></mixed-citation>
      </ref>
      <ref id="bibr59-1941738114529727">
        <label>59.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wakitani</surname><given-names>S</given-names></name><name><surname>Goto</surname><given-names>T</given-names></name><name><surname>Pineda</surname><given-names>SJ</given-names></name><etal/></person-group>
<article-title>Mesenchymal cell-based repair of large, full-thickness defects of articular cartilage</article-title>. <source>J Bone Joint Surg Am</source>. <year>1994</year>;<volume>76</volume>:<fpage>579</fpage>-<lpage>592</lpage>.<pub-id pub-id-type="pmid">8150826</pub-id></mixed-citation>
      </ref>
      <ref id="bibr60-1941738114529727">
        <label>60.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wakitani</surname><given-names>S</given-names></name><name><surname>Imoto</surname><given-names>K</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Saito</surname><given-names>M</given-names></name><name><surname>Murata</surname><given-names>N</given-names></name><name><surname>Yoneda</surname><given-names>M</given-names></name></person-group>
<article-title>Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees</article-title>. <source>Osteoarthritis Cartilage</source>. <year>2002</year>;<volume>10</volume>:<fpage>199</fpage>-<lpage>206</lpage>.<pub-id pub-id-type="pmid">11869080</pub-id></mixed-citation>
      </ref>
      <ref id="bibr61-1941738114529727">
        <label>61.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wakitani</surname><given-names>S</given-names></name><name><surname>Takaoka</surname><given-names>K</given-names></name><name><surname>Hattori</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Embryonic stem cells injected into the mouse knee joint form teratomas and subsequently destroy the joint</article-title>. <source>Rheumatology (Oxford)</source>. <year>2003</year>;<volume>42</volume>:<fpage>162</fpage>-<lpage>165</lpage>.<pub-id pub-id-type="pmid">12509630</pub-id></mixed-citation>
      </ref>
      <ref id="bibr62-1941738114529727">
        <label>62.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Waterman</surname><given-names>RS</given-names></name><name><surname>Tomchuck</surname><given-names>SL</given-names></name><name><surname>Henkle</surname><given-names>SL</given-names></name><name><surname>Betancourt</surname><given-names>AM</given-names></name></person-group>
<article-title>A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype</article-title>. <source>PLoS One</source>. <year>2010</year>;<volume>5</volume>:<fpage>e10088</fpage>.<pub-id pub-id-type="pmid">20436665</pub-id></mixed-citation>
      </ref>
      <ref id="bibr63-1941738114529727">
        <label>63.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yoshimura</surname><given-names>H</given-names></name><name><surname>Muneta</surname><given-names>T</given-names></name><name><surname>Nimura</surname><given-names>A</given-names></name><name><surname>Yokoyama</surname><given-names>A</given-names></name><name><surname>Koga</surname><given-names>H</given-names></name><name><surname>Sekiya</surname><given-names>I</given-names></name></person-group>
<article-title>Comparison of rat mesenchymal stem cells derived from bone marrow, synovium, periosteum, adipose tissue, and muscle</article-title>. <source>Cell Tissue Res</source>. <year>2007</year>;<volume>327</volume>:<fpage>449</fpage>-<lpage>462</lpage>.<pub-id pub-id-type="pmid">17053900</pub-id></mixed-citation>
      </ref>
      <ref id="bibr64-1941738114529727">
        <label>64.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Nuki</surname><given-names>G</given-names></name><name><surname>Moskowitz</surname><given-names>RW</given-names></name><etal/></person-group>
<article-title>OARSI recommendations for the management of hip and knee osteoarthritis: part III. Changes in evidence following systematic cumulative update of research published through January 2009</article-title>. <source>Osteoarthritis Cartilage</source>. <year>2010</year>;<volume>18</volume>:<fpage>476</fpage>-<lpage>499</lpage>.<pub-id pub-id-type="pmid">20170770</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:4272691</identifier><datestamp>2016-01-01</datestamp><setSpec>sportshealth</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="http://jats.nlm.nih.gov/ns/archiving/1.0/ http://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Sports Health</journal-id>
      <journal-id journal-id-type="iso-abbrev">Sports Health</journal-id>
      <journal-id journal-id-type="publisher-id">SPH</journal-id>
      <journal-id journal-id-type="hwp">spsph</journal-id>
      <journal-title-group>
        <journal-title>Sports Health</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1941-7381</issn>
      <issn pub-type="epub">1941-0921</issn>
      <publisher>
        <publisher-name>SAGE Publications</publisher-name>
        <publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4272691</article-id>
      <article-id pub-id-type="pmcid">PMC4272691</article-id>
      <article-id pub-id-type="pmc-uid">4272691</article-id>
      <article-id pub-id-type="pmid">25553217</article-id>
      <article-id pub-id-type="doi">10.1177/1941738114534813</article-id>
      <article-id pub-id-type="publisher-id">10.1177_1941738114534813</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Current Research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Life Span Exercise Among Elite Intercollegiate Student Athletes</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Sorenson</surname>
            <given-names>Shawn C.</given-names>
          </name>
          <degrees>PhD, CSCS</degrees>
          <xref ref-type="corresp" rid="corresp1-1941738114534813">*</xref>
          <xref ref-type="aff" rid="aff1-1941738114534813">†</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Romano</surname>
            <given-names>Russell</given-names>
          </name>
          <degrees>MA, ATC</degrees>
          <xref ref-type="aff" rid="aff2-1941738114534813">‡</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Azen</surname>
            <given-names>Stanley P.</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref ref-type="aff" rid="aff3-1941738114534813">§</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schroeder</surname>
            <given-names>E. Todd</given-names>
          </name>
          <degrees>PhD, FACSM</degrees>
          <xref ref-type="aff" rid="aff1-1941738114534813">†</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Salem</surname>
            <given-names>George J.</given-names>
          </name>
          <degrees>PhD, FACSM</degrees>
          <xref ref-type="aff" rid="aff1-1941738114534813">†</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1-1941738114534813"><label>†</label>Division of Biokinesiology and Physical Therapy, University of Southern California, Los Angeles, California</aff>
      <aff id="aff2-1941738114534813"><label>‡</label>Department of Athletic Medicine, University of Southern California, Los Angeles, California</aff>
      <aff id="aff3-1941738114534813"><label>§</label>Department of Preventive Medicine, University of Southern California, Los Angeles, California</aff>
      <author-notes>
        <corresp id="corresp1-1941738114534813"><label>*</label>Shawn C. Sorenson, PhD, CSCS, Division of Biokinesiology and Physical Therapy, University of Southern California, 1540 Alcazar Street, CHP 155, Los Angeles, CA 90089-9006 (e-mail: <email>sorenson@usc.edu</email>).</corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>1</day>
        <month>1</month>
        <year>2016</year>
      </pub-date>
      <!-- PMC Release delay is 12 months and 0 days and was based on the <pub-date pub-type="ppub"/>. -->
      <volume>7</volume>
      <issue>1</issue>
      <fpage>80</fpage>
      <lpage>86</lpage>
      <permissions>
        <copyright-statement>© 2014 The Author(s)</copyright-statement>
        <copyright-year>2014</copyright-year>
        <copyright-holder content-type="sage">American Orthopaedic Society for Sports Medicine</copyright-holder>
      </permissions>
      <abstract>
        <sec id="section1-1941738114534813">
          <title>Background:</title>
          <p>Despite prominent public attention, data on life span health and exercise outcomes among elite, competitive athletes are sparse and do not reflect the diversity of modern athletes.</p>
        </sec>
        <sec id="section2-1941738114534813">
          <title>Hypothesis:</title>
          <p>Life span exercise behavior differs between National Collegiate Athletic Association (NCAA) student athletes and a nonathlete control group. Sustained exercise is associated with improved cardiopulmonary health outcomes.</p>
        </sec>
        <sec id="section3-1941738114534813">
          <title>Study Design:</title>
          <p>Cross-sectional, descriptive epidemiology study.</p>
        </sec>
        <sec id="section4-1941738114534813">
          <title>Level of Evidence:</title>
          <p>Level 3.</p>
        </sec>
        <sec id="section5-1941738114534813">
          <title>Methods:</title>
          <p>A total of 496 students and alumni (age range, 17-84 year) at a large, NCAA Division I university, including student athletes and an age- and sex-matched nonathlete control group, completed anonymous, self-report health and exercise questionnaires. Age-stratified, cross-sectional analysis evaluated previous week’s total exercise volume (ExVol), self-rated exercise importance (ExImp), and compliance with American College of Sports Medicine (ACSM) exercise guidelines for healthy adults. The association of ACSM guideline compliance with lifetime cardiopulmonary health outcomes was also assessed.</p>
        </sec>
        <sec id="section6-1941738114534813">
          <title>Results:</title>
          <p>Current student athletes reported significantly greater ExVol (<italic>P</italic> &lt; 0.001. Cohen <italic>d</italic> = 0.99, probability of clinically important difference [pCID] &gt;99.5%), ExImp (<italic>P</italic> &lt; 0.001, <italic>d</italic> = 1.96, pCID = 96%), and likelihood of compliance with ACSM guidelines (odds ratio [OR], 95% confidence interval [CI] = 30.6, 11.0-84.6) compared with nonathletes. No significant differences were found between alumni student athletes and nonathletes. Alumni student athletes demonstrated substantially lower ExVol (<italic>P</italic> &lt; 0.001, <italic>d</italic> = –0.94, pCID &gt;99.5%) and guideline compliance (OR = 0.09, 95% CI = 0.05-0.19) compared with current student athletes, whereas nonathletes had similar exercise behavior across the life span. Among alumni, ACSM guideline compliance was associated with significant attenuation of cardiopulmonary health concerns (<italic>P</italic> = 0.02, <italic>d</italic> = –0.50, pCID = 14%) independent of intercollegiate athletic participation.</p>
        </sec>
        <sec id="section7-1941738114534813">
          <title>Conclusion:</title>
          <p>Although current NCAA Division I student athletes demonstrated significant, clinically important differences in exercise behavior compared with nonathletes, no group differences were evident later in life. Irrespective of collegiate athletic status, healthy exercise behavior among alumni was associated with cardiopulmonary health benefits.</p>
        </sec>
        <sec id="section8-1941738114534813">
          <title>Clinical Relevance:</title>
          <p>To realize life span health benefits, it is imperative that student athletes maintain consistent patterns of healthy exercise beyond retirement from competitive sports.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>athletes</kwd>
        <kwd>cardiopulmonary</kwd>
        <kwd>questionnaires</kwd>
        <kwd>NCAA</kwd>
        <kwd>life span exercise</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>January/February 2015</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <p>The long-term health impact of elite competitive sports participation is receiving increasing public attention and scrutiny. Accounts of joint injury,<sup><xref rid="bibr30-1941738114534813" ref-type="bibr">30</xref></sup> cardiopulmonary disease,<sup><xref rid="bibr3-1941738114534813" ref-type="bibr">3</xref></sup> head injury,<sup><xref rid="bibr25-1941738114534813" ref-type="bibr">25</xref></sup> and related psychosocial health concerns<sup><xref rid="bibr1-1941738114534813" ref-type="bibr">1</xref></sup> have prompted investigations from the US Congress,<sup><xref rid="bibr14-1941738114534813" ref-type="bibr">14</xref>,<xref rid="bibr15-1941738114534813" ref-type="bibr">15</xref></sup> compelled organizations such as the National Collegiate Athletic Association (NCAA) to make far-reaching policy changes,<sup><xref rid="bibr35-1941738114534813" ref-type="bibr">35</xref></sup> and brought about legal accountability.<sup><xref rid="bibr7-1941738114534813" ref-type="bibr">7</xref></sup> Enhanced understanding and promotion of athletes’ health has emerged as an imminent priority, yet scientific data concerning life span health and exercise among elite athletes remain surprisingly sparse.</p>
    <p>Regular exercise provides well-established health benefits, including reduced all-cause mortality and cardiovascular disease (CVD), increased muscle strength, preserved bone mass, reduced fall risk, and improved measures of integrated and psychosocial health, including depression, anxiety, cognitive function, overall well-being, and quality of life.<sup><xref rid="bibr8-1941738114534813" ref-type="bibr">8</xref></sup> Elite competitive athletes participate in routine, organized exercise training and have greater cardiorespiratory fitness, strength, and power compared with the general population, all of which are positively associated with health.<sup><xref rid="bibr6-1941738114534813" ref-type="bibr">6</xref>,<xref rid="bibr10-1941738114534813" ref-type="bibr">10</xref></sup> At the same time, competitive sports also carry well-recognized health risks.<sup><xref rid="bibr11-1941738114534813" ref-type="bibr">11</xref>,<xref rid="bibr16-1941738114534813" ref-type="bibr">16</xref></sup></p>
    <p>Importantly, it is unclear whether young adult athletes maintain their exercise behavior and attitudes across their life spans or how those factors relate to long-term health. Data from the Finnish former athlete cohort demonstrated that athletes had greater lifetime physical activity and reduced risk of CVD.<sup><xref rid="bibr18-1941738114534813" ref-type="bibr">18</xref></sup> Similarly, Lynch et al<sup><xref rid="bibr19-1941738114534813" ref-type="bibr">19</xref></sup> reported higher levels of physical activity from ages 20 to 64 years among retired National Football League (NFL) players, along with reduction of select CVD risk factors. In contrast, other investigators have reported no association between high school and college sports participation and later physical activity patterns<sup><xref rid="bibr2-1941738114534813" ref-type="bibr">2</xref>,<xref rid="bibr5-1941738114534813" ref-type="bibr">5</xref></sup> and a higher risk of CVD among former athletes no longer involved in sports.<sup><xref rid="bibr23-1941738114534813" ref-type="bibr">23</xref></sup> Additional research is needed to understand the overall balance of risks versus rewards.</p>
    <p>The increasingly intensive, structured, and specialized nature of modern sports brings into question the generalizability of previous studies.<sup><xref rid="bibr17-1941738114534813" ref-type="bibr">17</xref></sup> Additionally, the sexes and racial diversities of modern athletes are not reflected by research studies to date. NCAA intercollegiate athletics include more than 440,000 active participants in 23 sports<sup><xref rid="bibr22-1941738114534813" ref-type="bibr">22</xref></sup>—one of the broadest representations of today’s elite competitive athletes. We are unaware of any studies to date evaluating life span exercise among current and former NCAA athletes compared with a representative control group.</p>
    <p>Therefore, as part of a collaborative research and education program—Trojan Lifetime Champions (TLC)—we assessed life span health, exercise, and health-related quality of life (HRQoL) among current and former university students, including NCAA intercollegiate student athletes. The primary objective of the present study was to document life span exercise behaviors and attitudes. A secondary goal was to evaluate the association between exercise behavior and cardiopulmonary health.</p>
    <sec sec-type="methods" id="section9-1941738114534813">
      <title>Methods</title>
      <sec id="section10-1941738114534813">
        <title>Study Design</title>
        <p>This cross-sectional epidemiological study included students and alumni of the University of Southern California, a large, NCAA Division I university. Current and former varsity student athletes and nonathletes completed anonymous questionnaires documenting lifetime physical, mental, and emotional health; HRQoL; and exercise behaviors and attitudes. Each participant provided informed consent, and the experimental protocol was approved by the University of Southern California Health Sciences Institutional Review Board.</p>
      </sec>
      <sec id="section11-1941738114534813">
        <title>Participants</title>
        <p>Participants included a convenience sample of student athletes and nonathletes. Student athletes must have practiced or competed in Division I intercollegiate athletics at the University of Southern California. Nonathletes were current and former undergraduate University of Southern California students who never practiced or competed in Division I intercollegiate athletics or organized club sports at any university.</p>
        <p>Study participants were recruited using athletic department and university records, student and alumni organizations, and personal referrals. The study population was selected to provide a representative cross-section of the University of Southern California student athlete source population<sup><xref rid="bibr27-1941738114534813" ref-type="bibr">27</xref></sup> and a control group of similar age and sex distribution.</p>
      </sec>
      <sec id="section12-1941738114534813">
        <title>Data Collection</title>
        <p>Participants anonymously completed the TLC survey (see Appendix 1, available at <ext-link ext-link-type="uri" xlink:href="http://sph.sagepub.com/content/suppl">http://sph.sagepub.com/content/suppl</ext-link>). Details of the survey, including a formal validity and reliability assessment, have been described elsewhere.<sup><xref rid="bibr27-1941738114534813" ref-type="bibr">27</xref></sup> Briefly, the questionnaire recorded basic demographic information (age, sex, ethnicity, height, and weight), history of intercollegiate sports participation, a standard HRQoL measure (Short Form–12 [SF-12v2]),<sup><xref rid="bibr31-1941738114534813" ref-type="bibr">31</xref></sup> a health inventory including 6 domains (joint, bone and muscle, cardiopulmonary, neurological, other clinical, and psychosocial), recent (previous week’s) exercise, and perceptions of exercise and health. All participants received a $5 coffeehouse gift card incentive, as approved by the University of Southern California Office of Athletic Compliance.</p>
        <p>Previous week’s exercise was compared with guidelines for healthy adults published by the American College of Sports Medicine (ACSM).<sup><xref rid="bibr10-1941738114534813" ref-type="bibr">10</xref></sup> The survey did not distinguish between formally organized, structured, supervised exercise (eg, sports training) and informal and/or unsupervised recreational physical activity. Self-reported exercise importance was measured using a 4-point ordinal scale.</p>
        <p>Current student athletes represented all 20 varsity sports and approximately 74% of the student athlete population. This sample was considered representative of the overall source population. The survey response rate among alumni recruited for the study was 79%, including 76% of student athletes and 82% of nonathletes. Responders and nonresponders were similar in sex, age, intercollegiate sports participation, and survey type (ie, paper vs electronic).<sup><xref rid="bibr27-1941738114534813" ref-type="bibr">27</xref></sup> Thirty-four surveys containing incomplete or illegible data (27 current student athletes, 6 nonathlete current students, and 1 nonathlete alumnus) were excluded.</p>
      </sec>
      <sec id="section13-1941738114534813">
        <title>Data Analysis</title>
        <p>Descriptive statistics (mean [standard deviation] or number [percentage]) were calculated to compare demographic characteristics of student athletes and nonathletes. Primary independent variables included intercollegiate athletic participation (ie, student athlete vs nonathlete) and age. Participants were classified into age groups as follows: current students, younger alumni, and older alumni. Younger and older alumni were stratified based on the median age (43 years) of alumni participants.</p>
        <p>Primary dependent variables included total exercise volume, exercise importance, and rate of compliance with ACSM healthy exercise guidelines.<sup><xref rid="bibr10-1941738114534813" ref-type="bibr">10</xref></sup> Exercise importance was modeled as a continuous variable. Compliance with ACSM exercise guidelines was computed as a dichotomous outcome, where compliant participants reported total exercise volume of ≥150 minutes and ≥2 resistance exercise sessions.</p>
        <p>Our secondary interest was the association between cardiopulmonary domain summary scores and ACSM exercise guideline compliance. The summary score reflected a study participant’s cumulative lifetime experience with cardiopulmonary health concerns, with a score of 0 indicating “perfect” health and higher scores indicating greater evidence of concerns.<sup><xref rid="bibr27-1941738114534813" ref-type="bibr">27</xref></sup> The maximum possible score was 24.</p>
        <p>All data were screened for integrity, including identification of spurious and outlier values.<sup><xref rid="bibr27-1941738114534813" ref-type="bibr">27</xref></sup> All spurious and outlier data—including exercise data for 4 student athletes (0.9% of sample)—were excluded from subsequent statistical analysis.</p>
        <p>For the primary analysis, stratified assessment of age and athletic participation effects on exercise volume and exercise importance was conducted using independent-samples <italic>t</italic> tests and magnitude-based methods.<sup><xref rid="bibr12-1941738114534813" ref-type="bibr">12</xref>,<xref rid="bibr13-1941738114534813" ref-type="bibr">13</xref></sup> Magnitude-based assessments include probabilistic interpretation of effects relative to a priori threshold values of substantial clinical meaning and may be a preferred alternative to traditional hypothesis testing versus the null value.<sup><xref rid="bibr13-1941738114534813" ref-type="bibr">13</xref></sup> Threshold values were as follows: total weekly exercise volume (150 minutes, corresponding to the minimum ACSM guidelines for healthy adults)<sup><xref rid="bibr10-1941738114534813" ref-type="bibr">10</xref></sup> and self-reported exercise importance (1 unit, corresponding to the minimum precision for the 4-point TLC exercise importance scale). The TLC survey has demonstrated adequate precision to detect effects of this magnitude.<sup><xref rid="bibr27-1941738114534813" ref-type="bibr">27</xref></sup> A significance level of α = 0.05 was used for the traditional statistical tests. Probabilistic interpretation of magnitude-based tests utilized the following scale, based on the guidelines of Hopkins et al<sup><xref rid="bibr13-1941738114534813" ref-type="bibr">13</xref></sup>: &lt;0.5%, most unlikely; 0.5% to 5%, very unlikely; 5% to 25%, unlikely; 25% to 75%, possibly; 75% to 95%, likely; 95% to 99.5%, very likely; and &gt;99.5%, most likely.</p>
        <p>In the secondary analysis, relative odds of ACSM exercise guideline compliance were evaluated using unconditional logistic regression (odds ratios with 95% confidence intervals) stratified across the primary independent variables. The Tarone test of homogeneity was used to assess the validity of Mantel-Haenszel common odds ratios across strata. Common odds are reported where the Tarone test indicated homogeneity (<italic>P</italic> &gt; 0.05), and crude odds are reported otherwise.</p>
        <p>Finally, we conducted an age-stratified analysis of cardiopulmonary health, with ACSM exercise guideline compliance as an independent factor. Independent-samples <italic>t</italic> tests and magnitude-based methods were utilized, with a 2-unit a priori threshold for substantial clinical meaning.</p>
        <p>Sex, ethnicity, height, body mass, and body mass index (BMI) were evaluated as potential analysis covariates. Sex and ethnicity were excluded because of small sample size (n &lt; 10) in selected combinations of the independent variables. Following assessment of confounding criteria,<sup><xref rid="bibr24-1941738114534813" ref-type="bibr">24</xref></sup> analysis of covariance model assumptions (eg, homogeneity of variance and regression), and covariate effect magnitudes, the influence of each covariate was deemed minimal. Therefore, unadjusted values are reported throughout.</p>
        <p>Statistical analyses were conducted using SPSS version 16 (SPSS, Inc, Chicago, Illinois), Intercooled STATA version 10 (StataCorp, College Station, Texas), and Hopkins’ spreadsheet for magnitude-based inferences.<sup><xref rid="bibr12-1941738114534813" ref-type="bibr">12</xref></sup></p>
      </sec>
    </sec>
    <sec sec-type="results" id="section14-1941738114534813">
      <title>Results</title>
      <p>Age and sex distributions were similar between the student athlete alumni source and study populations. There was a statistically significant difference in sport distribution between the alumni source and study populations (see Appendix 2, available at <ext-link ext-link-type="uri" xlink:href="http://sph.sagepub.com/content/suppl">http://sph.sagepub.com/content/suppl</ext-link>). Subsequent to outlier screening, data from 4 participants (3 current and 1 alumni student athlete) were excluded from analysis.</p>
      <p>Student athletes (SAs) were similar to nonathletes (NAs) in age and sex distribution (<xref ref-type="table" rid="table1-1941738114534813">Table 1</xref>). SAs were taller and heavier but had similar BMI. The SAs had a lower proportion of Asian participants and a higher proportion of White participants than the NAs.</p>
      <table-wrap id="table1-1941738114534813" position="float">
        <label>Table 1.</label>
        <caption>
          <p>Demographic characteristics for participants in the Trojan Lifetime Champions study, 2008-2011<sup><xref ref-type="table-fn" rid="table-fn2-1941738114534813"><italic>a</italic></xref></sup></p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th rowspan="1" colspan="1"/>
              <th align="center" colspan="3" rowspan="1">Current Students</th>
              <th align="center" colspan="3" rowspan="1">Alumni</th>
            </tr>
            <tr>
              <th align="center" rowspan="1" colspan="1">Characteristics</th>
              <th align="center" rowspan="1" colspan="1">Student Athletes (n = 380)</th>
              <th align="center" rowspan="1" colspan="1">Nonathletes (n = 31)</th>
              <th align="center" rowspan="1" colspan="1"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn2-1941738114534813"><italic>a</italic></xref></sup></th>
              <th align="center" rowspan="1" colspan="1">Student Athletes (n = 44)</th>
              <th align="center" rowspan="1" colspan="1">Nonathletes (n = 41)</th>
              <th align="center" rowspan="1" colspan="1"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn2-1941738114534813"><italic>a</italic></xref></sup></th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">Demographics, mean (SD)</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Age, y</td>
              <td rowspan="1" colspan="1">19.6 (1.3)</td>
              <td rowspan="1" colspan="1">19.8 (1.3)</td>
              <td rowspan="1" colspan="1">0.34</td>
              <td rowspan="1" colspan="1">45.6 (16.2)</td>
              <td rowspan="1" colspan="1">46.2 (16.7)</td>
              <td rowspan="1" colspan="1">0.88</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Age range, y</td>
              <td rowspan="1" colspan="1">17-23</td>
              <td rowspan="1" colspan="1">18-22</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">24-77</td>
              <td rowspan="1" colspan="1">24-84</td>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Height, cm</td>
              <td rowspan="1" colspan="1">180.7 (11.2)</td>
              <td rowspan="1" colspan="1">169.8 (9.2)</td>
              <td rowspan="1" colspan="1">&lt;0.001</td>
              <td rowspan="1" colspan="1">180.8 (10.0)</td>
              <td rowspan="1" colspan="1">172.2 (11.3)</td>
              <td rowspan="1" colspan="1">&lt;0.001</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Mass, kg</td>
              <td rowspan="1" colspan="1">79.0 (18.0)</td>
              <td rowspan="1" colspan="1">66.8 (12.0)</td>
              <td rowspan="1" colspan="1">&lt;0.001</td>
              <td rowspan="1" colspan="1">86.7 (17.1)</td>
              <td rowspan="1" colspan="1">75.3 (17.6)</td>
              <td rowspan="1" colspan="1">0.004</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">BMI, kg/m<sup>2</sup></td>
              <td rowspan="1" colspan="1">24.1 (3.5)</td>
              <td rowspan="1" colspan="1">23.1 (3.6)</td>
              <td rowspan="1" colspan="1">0.12</td>
              <td rowspan="1" colspan="1">26.3 (4.2)</td>
              <td rowspan="1" colspan="1">25.1 (3.5)</td>
              <td rowspan="1" colspan="1">0.18</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Intercollegiate athletic experience, y</td>
              <td rowspan="1" colspan="1">1.5 (1.3)</td>
              <td rowspan="1" colspan="1">n/a</td>
              <td rowspan="1" colspan="1">n/a</td>
              <td rowspan="1" colspan="1">3.0 (1.3)</td>
              <td rowspan="1" colspan="1">n/a</td>
              <td rowspan="1" colspan="1">n/a</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Sex, n (%)</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> Male</td>
              <td rowspan="1" colspan="1">208 (55)</td>
              <td rowspan="1" colspan="1">15 (48)</td>
              <td rowspan="1" colspan="1">0.58</td>
              <td rowspan="1" colspan="1">32 (73)</td>
              <td rowspan="1" colspan="1">25 (61)</td>
              <td rowspan="1" colspan="1">0.36</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> Female</td>
              <td rowspan="1" colspan="1">171 (45)</td>
              <td rowspan="1" colspan="1">16 (52)</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">12 (27)</td>
              <td rowspan="1" colspan="1">16 (39)</td>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Ethnicity, n (%)<sup><xref ref-type="table-fn" rid="table-fn3-1941738114534813"><italic>b</italic></xref></sup></td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> White</td>
              <td rowspan="1" colspan="1">240 (64)</td>
              <td rowspan="1" colspan="1">12 (39)</td>
              <td rowspan="1" colspan="1">&lt;0.001</td>
              <td rowspan="1" colspan="1">38 (88)</td>
              <td rowspan="1" colspan="1">28 (68)</td>
              <td rowspan="1" colspan="1">0.01</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> Black</td>
              <td rowspan="1" colspan="1">52 (14)</td>
              <td rowspan="1" colspan="1">4 (13)</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">3 (7)</td>
              <td rowspan="1" colspan="1">2 (5)</td>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> Hispanic</td>
              <td rowspan="1" colspan="1">21 (6)</td>
              <td rowspan="1" colspan="1">5 (16)</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">0 (0)</td>
              <td rowspan="1" colspan="1">0 (0)</td>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> Asian</td>
              <td rowspan="1" colspan="1">22 (6)</td>
              <td rowspan="1" colspan="1">8 (26)</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">0 (0)</td>
              <td rowspan="1" colspan="1">9 (22)</td>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> Other</td>
              <td rowspan="1" colspan="1">42 (11)</td>
              <td rowspan="1" colspan="1">2 (7)</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">2 (5)</td>
              <td rowspan="1" colspan="1">2 (5)</td>
              <td rowspan="1" colspan="1"/>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="table-fn1-1941738114534813">
            <p>BMI, body mass index (calculated as mass in kilograms divided by height in meters squared); n/a, not applicable; SD, standard deviation.</p>
          </fn>
          <fn id="table-fn2-1941738114534813">
            <label>a</label>
            <p><italic>P</italic> values are for independent-samples <italic>t</italic> tests for age, height, mass, and BMI, and χ<sup>2</sup> proportion tests for sex and ethnicity.</p>
          </fn>
          <fn id="table-fn3-1941738114534813">
            <label>b</label>
            <p>Because of rounding, percentages may not total 100. Four student-athletes responded “Prefer Not to Answer” to ethnicity. One student athlete did not provide sex data.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>On average, current SAs reported more than 15 hours of exercise (Appendix 3 [available at <ext-link ext-link-type="uri" xlink:href="http://sph.sagepub.com/content/suppl">http://sph.sagepub.com/content/suppl</ext-link>], <xref ref-type="fig" rid="fig1-1941738114534813">Figure 1</xref>), substantially more than the approximate 4 hours reported by NAs (<italic>P</italic> &lt; 0.001, Cohen <italic>d</italic> = 0.99, probability of clinically important difference [pCID] &gt;99.5% [most likely]). A large majority (86%) of current SAs met the ACSM recommended weekly exercise guidelines. Current SAs were more than 30 times as likely as current NAs to do so. Current SAs reported significantly higher exercise importance than NAs (<italic>P</italic> &lt; 0.001, Cohen <italic>d</italic> = 1.96, pCID = 96% [very likely]).</p>
      <fig id="fig1-1941738114534813" position="float">
        <label>Figure 1.</label>
        <caption>
          <p>Life span exercise behavior for participants in the Trojan Lifetime Champions study, 2008-2011: Age-stratified comparison of previous week’s total exercise volume, intercollegiate student athletes versus nonathletes. Error bars indicate 1 standard deviation. *Statistically significant difference between student athletes and nonathletes (<italic>P</italic> ≤ 0.05).</p>
        </caption>
        <graphic xlink:href="10.1177_1941738114534813-fig1"/>
      </fig>
      <p>In contrast, no appreciable differences in exercise behavior or perceptions were found between alumni SAs and NAs, with comparable weekly exercise volumes between groups, small effect sizes, and little evidence of clinically relevant differences (see Appendices 3 and 4, available at <ext-link ext-link-type="uri" xlink:href="http://sph.sagepub.com/content/suppl">http://sph.sagepub.com/content/suppl</ext-link>). SAs and NAs were equally likely (~40%) to meet ACSM exercise guidelines and had similar self-rated exercise importance. While NAs demonstrated consistent exercise patterns across the 3 age strata, alumni SAs reported significantly lower exercise volume compared with current SAs (see Appendix 4) and were approximately 10% as likely as current SAs to meet ACSM exercise guidelines.</p>
      <p>Collapsed across intercollegiate athletic participation groups, alumni demonstrated differences in cardiopulmonary health associated with exercise behavior (<xref ref-type="table" rid="table2-1941738114534813">Table 2</xref>, <xref ref-type="fig" rid="fig2-1941738114534813">Figure 2</xref>). Participants who were compliant with ACSM exercise guidelines reported significantly better cardiopulmonary health. Effect sizes were moderate. The probability of clinically relevant differences was most unlikely (&lt;0.5%) among younger alumni and possible (48%) among older alumni.</p>
      <table-wrap id="table2-1941738114534813" position="float">
        <label>Table 2.</label>
        <caption>
          <p>Cardiopulmonary health and exercise behavior for participants in the TLC Study, 2008-2011: Age-stratified comparison of cardiopulmonary health concerns, according to compliance with ACSM weekly exercise guidelines for healthy adults<sup><xref ref-type="table-fn" rid="table-fn5-1941738114534813"><italic>a</italic></xref></sup></p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th rowspan="1" colspan="1"/>
              <th align="center" colspan="6" rowspan="1">Age Group</th>
            </tr>
            <tr>
              <th rowspan="1" colspan="1"/>
              <th align="center" colspan="2" rowspan="1">Current Students</th>
              <th align="center" colspan="2" rowspan="1">Younger Alumni</th>
              <th align="center" colspan="2" rowspan="1">Older Alumni</th>
            </tr>
            <tr>
              <th align="center" rowspan="1" colspan="1">Measure</th>
              <th align="center" rowspan="1" colspan="1">ACSM Compliant</th>
              <th align="center" rowspan="1" colspan="1">Not ACSM Compliant</th>
              <th align="center" rowspan="1" colspan="1">ACSM Compliant</th>
              <th align="center" rowspan="1" colspan="1">Not ACSM Compliant</th>
              <th align="center" rowspan="1" colspan="1">ACSM Compliant</th>
              <th align="center" rowspan="1" colspan="1">Not ACSM Compliant</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">Cardiopulmonary summary score, mean (SD)</td>
              <td rowspan="1" colspan="1">0.33 (0.77)</td>
              <td rowspan="1" colspan="1">0.53 (1.04)</td>
              <td rowspan="1" colspan="1">0.33 (0.62)</td>
              <td rowspan="1" colspan="1">1.04 (1.43)</td>
              <td rowspan="1" colspan="1">2.12 (2.85)</td>
              <td rowspan="1" colspan="1">4.07 (3.27)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Difference in mean summary scores</td>
              <td colspan="2" rowspan="1">–0.20</td>
              <td colspan="2" rowspan="1">–0.71</td>
              <td colspan="2" rowspan="1">–1.95</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn6-1941738114534813"><italic>b</italic></xref></sup></td>
              <td colspan="2" rowspan="1">0.15<sup><xref ref-type="table-fn" rid="table-fn7-1941738114534813"><italic>c</italic></xref></sup></td>
              <td colspan="2" rowspan="1">0.04<sup><xref ref-type="table-fn" rid="table-fn7-1941738114534813"><italic>c</italic></xref></sup></td>
              <td colspan="2" rowspan="1">0.05</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Effect size<sup><xref ref-type="table-fn" rid="table-fn8-1941738114534813"><italic>d</italic></xref></sup></td>
              <td colspan="2" rowspan="1">–0.24</td>
              <td colspan="2" rowspan="1">–0.71</td>
              <td colspan="2" rowspan="1">–0.64</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Probability of CID,<sup><xref ref-type="table-fn" rid="table-fn9-1941738114534813"><italic>e</italic></xref></sup> %</td>
              <td colspan="2" rowspan="1">&lt;0.5</td>
              <td colspan="2" rowspan="1">&lt;0.5</td>
              <td colspan="2" rowspan="1">48</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="table-fn4-1941738114534813">
            <p>ACSM, American College of Sports Medicine; CID, clinically important difference; SD, standard deviation; TLC, Trojan Lifetime Champions.</p>
          </fn>
          <fn id="table-fn5-1941738114534813">
            <label>a</label>
            <p>ACSM weekly exercise guidelines: ≥150 minutes of exercise volume and ≥2 sessions of resistance exercise.</p>
          </fn>
          <fn id="table-fn6-1941738114534813">
            <label>b</label>
            <p><italic>P</italic> values are for 2-sided, independent-samples <italic>t</italic> tests.</p>
          </fn>
          <fn id="table-fn7-1941738114534813">
            <label>c</label>
            <p>Levene test for equality of variances <italic>P</italic> ≤ 0.05. <italic>t</italic> test for unequal variances is reported.</p>
          </fn>
          <fn id="table-fn8-1941738114534813">
            <label>d</label>
            <p>Effect sizes are Cohen <italic>d</italic>.</p>
          </fn>
          <fn id="table-fn9-1941738114534813">
            <label>e</label>
            <p>Clinically important difference: 2 units.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <fig id="fig2-1941738114534813" position="float">
        <label>Figure 2.</label>
        <caption>
          <p>Cardiopulmonary health and exercise behavior for participants in the Trojan Lifetime Champions study, 2008-2011: Age-stratified comparison of cardiopulmonary health concerns, according to compliance with American College of Sports Medicine weekly exercise guidelines for healthy adults. *Statistically significant difference between participants who met ACSM guidelines versus those who did not (<italic>P</italic> ≤ 0.05). <sup><italic>a</italic></sup>ACSM weekly exercise guidelines: ≥150 minutes of exercise volume and ≥2 sessions of resistance exercise. Cardiopulmonary domain summary score reflects a study participant’s cumulative lifetime experience with cardiopulmonary health concerns. A summary score of 0 indicates “perfect” health, while progressively higher scores indicate greater evidence of concerns.</p>
        </caption>
        <graphic xlink:href="10.1177_1941738114534813-fig2"/>
      </fig>
    </sec>
    <sec sec-type="discussion" id="section15-1941738114534813">
      <title>Discussion</title>
      <p>In this cross-sectional epidemiological study, current NCAA Division I intercollegiate student athletes reported substantially higher clinically relevant volumes of weekly exercise, perceived exercise importance, and likelihood of compliance with ACSM healthy exercise guidelines compared to an age- and sex-matched nonathlete control group of university students. However, no significant differences were found between alumni student athletes and nonathletes, suggesting that former student athletes fail to maintain elevated levels of exercise across their life spans compared with their nonathlete peers. Compliance with ACSM exercise guidelines was associated with a significant attenuation of age-dependent cardiopulmonary health concerns independent of intercollegiate athletic participation.</p>
      <p>As anticipated, the currently competitive elite athletes in our study exemplified high exercise levels and a strong self-rated value of exercise. Student athletes were more than 30 times as likely to meet ACSM healthy exercise guidelines, reported exercise volume nearly 4 times that of nonathlete controls, and 77% described exercise as “very important” in their lives (versus just 16% of nonathletes). Student athlete alumni demonstrated striking reductions in exercise volume and guideline compliance compared with current student athletes. Meanwhile, nonathletes had similar exercise behavior across their life spans. Accordingly, younger and older alumni demonstrated similar exercise behavior and perceptions irrespective of intercollegiate athletic participation.</p>
      <p>Our findings contrast with previous investigations conducted in the 1980s and 1990s showing higher levels of life span exercise among elite athletes compared with referent groups.<sup><xref rid="bibr18-1941738114534813" ref-type="bibr">18</xref>,<xref rid="bibr19-1941738114534813" ref-type="bibr">19</xref></sup> In 1985, former internationally competitive Finnish athletes with a mean age of 57 years reported approximately twice the weekly exercise volume of age-matched controls.<sup><xref rid="bibr18-1941738114534813" ref-type="bibr">18</xref></sup> In a retrospective study conducted in 1998, Lynch et al<sup><xref rid="bibr19-1941738114534813" ref-type="bibr">19</xref></sup> reported approximately 5, 3, and 3 times the weekly exercise volume for retired NFL players (mean age, 66 years) compared with controls at ages 20 to 34, 35 to 49, and 50 to 64 years, respectively. In our study, current student athletes (mean age, 20 years) reported 4 times the volume of age-matched controls, with no significant group difference among younger (mean age, 33 years) or older (mean age, 58 years) alumni. This discrepancy may in part be because of differences in the experience of our more contemporary population of athletes. The age of athletes in both the Finnish and NFL cohorts at the time of investigation suggests that the average participant’s peak competitive years (age range, 20-40 years) occurred in the 1950s to 1960s, whereas the average alumnus in the TLC study was of comparable age in the 1980s and 1990s. Year-round, specialized, structured, and supervised training for a single sport or position/event has become more commonplace in recent years, with dedicated training patterns routinely adopted in youth sports. This could make transition from sports training to sustainable lifetime physical activity more difficult.</p>
      <p>Sex differences in the study populations may also contribute to discrepancies. Several studies<sup><xref rid="bibr4-1941738114534813" ref-type="bibr">4</xref>,<xref rid="bibr34-1941738114534813" ref-type="bibr">34</xref></sup> have reported a positive association between athletic participation in the college years and physical activity in middle-aged women. The larger proportion of women in our study would imply greater lifetime exercise participation, opposite the observed effect. The experience of recent NCAA student athletes may differ from previous generations.</p>
      <p>Alumni in our study reported lower rates of compliance with ACSM exercise guidelines (38%) compared with US adults in general (49%).<sup><xref rid="bibr10-1941738114534813" ref-type="bibr">10</xref></sup> This is likely attributable to a 2007 update to the guidelines, which for the first time explicitly included muscle strengthening (ie, resistance training) as a core recommendation.</p>
      <p>Beyond retirement from competitive sports, lifestyle and exercise behavior play important roles in long-term health. For instance, trained distance runners who continue high-intensity training maintain higher aerobic capacity (V<sc>o</sc><sub>2</sub>max) across their life spans compared with sedentary controls.<sup><xref rid="bibr6-1941738114534813" ref-type="bibr">6</xref></sup> However, V<sc>o</sc><sub>2</sub>max regressed to sedentary levels up cessation of training. Comparable findings have been reported among retired NFL players.<sup><xref rid="bibr19-1941738114534813" ref-type="bibr">19</xref></sup> Similarly, although bone mineral density accrued in youth is believed to reduce osteoporosis risk throughout life,<sup><xref rid="bibr20-1941738114534813" ref-type="bibr">20</xref></sup> continued physical activity may be necessary to preserve these gains.<sup><xref rid="bibr9-1941738114534813" ref-type="bibr">9</xref></sup> Equivocal findings to date regarding cardiovascular health outcomes in former elite athletes<sup><xref rid="bibr17-1941738114534813" ref-type="bibr">17</xref>,<xref rid="bibr19-1941738114534813" ref-type="bibr">19</xref>,<xref rid="bibr21-1941738114534813" ref-type="bibr">21</xref>,<xref rid="bibr26-1941738114534813" ref-type="bibr">26</xref>,<xref rid="bibr28-1941738114534813" ref-type="bibr">28</xref>,<xref rid="bibr33-1941738114534813" ref-type="bibr">33</xref></sup> may in part be explained by differences in life span exercise behavior.</p>
      <p>Valid and reliable measurement of exercise behavior is notoriously difficult and the subject of ongoing discussions in the literature.<sup><xref rid="bibr29-1941738114534813" ref-type="bibr">29</xref>,<xref rid="bibr32-1941738114534813" ref-type="bibr">32</xref></sup> Our study assessed exercise behavior in the previous week using a self-report questionnaire, which may not reflect life span exercise patterns. Its acute validity against actual behavior may also be reasonably questioned.</p>
      <p>This study has several strengths. Our study employed a survey instrument that has undergone rigorous validation of its psychometric properties<sup><xref rid="bibr27-1941738114534813" ref-type="bibr">27</xref></sup> and a statistical approach blending traditional methods with progressive, probabilistic interpretations of clinical effect. There are also important limitations. Although our survey response rate (79%) was high,<sup><xref rid="bibr27-1941738114534813" ref-type="bibr">27</xref></sup> we did not have adequate sample size to evaluate sex or ethnicity effects. University of Southern California student athletes do not necessarily represent the overall NCAA student-athlete population or those of professional and Olympic sports. We also found significant differences in sport distribution between the source and study populations but had insufficient sample size to evaluate sport-specific results. In this exploratory study, we performed numerous pairwise statistical tests, raising the possibility that some results occurred by chance. Finally, our cross-sectional study design provides less causative evidence than a longitudinal study.</p>
      <p>In summary, current NCAA Division I student athletes demonstrated significant, clinically meaningful differences in exercise behavior and perceptions compared with nonathlete students, whereas alumni student athletes and nonathletes demonstrated similar involvement and interest.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>The authors thank Doyle Lee, DPT, for substantial contributions to data processing; Won Lee, PhD, for statistical guidance; and Gina Battaglia, PhD, for assistance in review and revision of the final manuscript. This study was supported by the US Air Force Office of Scientific Research through a National Defense Science and Engineering Graduate Fellowship to S.C. Sorenson, by the USC Division of Biokinesiology and Physical Therapy Jacquelin Perry Scholarship to S.C. Sorenson, and by the USC Department of Athletics.</p>
    </ack>
    <fn-group>
      <fn fn-type="conflict">
        <p>The following author declared potential conflicts of interest: Russell Romano, MA, ATC, is employed by the University of Southern California, Department of Athletics.<?release-delay 12|0?></p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="bibr1-1941738114534813">
        <label>1.</label>
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><name><surname>Agostino</surname><given-names>J.</given-names></name></person-group>
<article-title>Once an athletic star, now an unheavenly body</article-title>. <source>New York Times</source>. <month>7</month>
<day>6</day>, <year>2006</year>
<ext-link ext-link-type="uri" xlink:href="http://www.nytimes.com/2006/07/06/fashion/06Fitness.html?pagewanted=all&amp;_r=0">http://www.nytimes.com/2006/07/06/fashion/06Fitness.html?pagewanted=all&amp;_r=0</ext-link>
<date-in-citation>Accessed April 20, 2014</date-in-citation>.</mixed-citation>
      </ref>
      <ref id="bibr2-1941738114534813">
        <label>2.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brill</surname><given-names>PA</given-names></name><name><surname>Burkhalter</surname><given-names>HE</given-names></name><name><surname>Kohl</surname><given-names>HW</given-names></name><name><surname>Blair</surname><given-names>SN</given-names></name><name><surname>Goodyear</surname><given-names>NN</given-names></name></person-group>
<article-title>The impact of previous athleticism on exercise habits, physical fitness, and coronary heart disease risk factors in middle-aged men</article-title>. <source>Res Q Exerc Sport</source>. <year>1989</year>;<volume>60</volume>:<fpage>209</fpage>-<lpage>215</lpage>.<pub-id pub-id-type="pmid">2489845</pub-id></mixed-citation>
      </ref>
      <ref id="bibr3-1941738114534813">
        <label>3.</label>
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><name><surname>Brown</surname><given-names>C</given-names></name></person-group>
<article-title>Former players dealing with lingering health issues</article-title>. <source>New York Times</source>. <month>2</month>
<day>1</day>, <year>2007</year>
<ext-link ext-link-type="uri" xlink:href="http://www.nytimes.com/2007/02/01/sports/football/01disability.html">http://www.nytimes.com/2007/02/01/sports/football/01disability.html</ext-link>
<date-in-citation>Accessed April 20, 2014</date-in-citation>.</mixed-citation>
      </ref>
      <ref id="bibr4-1941738114534813">
        <label>4.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Conroy</surname><given-names>MB</given-names></name><name><surname>Cook</surname><given-names>NR</given-names></name><name><surname>Manson</surname><given-names>JE</given-names></name><name><surname>Buring</surname><given-names>JE</given-names></name><name><surname>Lee</surname><given-names>IM</given-names></name></person-group>
<article-title>Past physical activity, current physical activity, and risk of coronary heart disease</article-title>. <source>Med Sci Sports Exerc</source>. <year>2005</year>;<volume>37</volume>:<fpage>1251</fpage>-<lpage>1256</lpage>.<pub-id pub-id-type="pmid">16118569</pub-id></mixed-citation>
      </ref>
      <ref id="bibr5-1941738114534813">
        <label>5.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dishman</surname><given-names>RK</given-names></name></person-group>
<article-title>Supervised and free-living physical activity: no differences in former athletes and nonathletes</article-title>. <source>Am J Prev Med</source>. <year>1988</year>;<volume>4</volume>:<fpage>153</fpage>-<lpage>160</lpage>.<pub-id pub-id-type="pmid">3395501</pub-id></mixed-citation>
      </ref>
      <ref id="bibr6-1941738114534813">
        <label>6.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Faulkner</surname><given-names>JA</given-names></name><name><surname>Davis</surname><given-names>CS</given-names></name><name><surname>Mendias</surname><given-names>CL</given-names></name><name><surname>Brooks</surname><given-names>SV</given-names></name></person-group>
<article-title>The aging of elite male athletes: age-related changes in performance and skeletal muscle structure and function</article-title>. <source>Clin J Sport Med</source>. <year>2008</year>;<volume>18</volume>:<fpage>501</fpage>-<lpage>507</lpage>.<pub-id pub-id-type="pmid">19001883</pub-id></mixed-citation>
      </ref>
      <ref id="bibr7-1941738114534813">
        <label>7.</label>
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><name><surname>Fendrich</surname><given-names>H</given-names></name></person-group>
<article-title>NFL concussion saga moves to new phase: litigation</article-title>. <source>Washington Times</source>. <month>10</month>
<day>20</day>, <year>2011</year>
<ext-link ext-link-type="uri" xlink:href="http://www.washingtontimes.com/news/2011/oct/20/nfl-concussion-saga-moves-to-new-phase-litigation/?page=all">http://www.washingtontimes.com/news/2011/oct/20/nfl-concussion-saga-moves-to-new-phase-litigation/?page=all</ext-link>
<date-in-citation>Accessed April 20, 2014</date-in-citation>.</mixed-citation>
      </ref>
      <ref id="bibr8-1941738114534813">
        <label>8.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Garber</surname><given-names>CE</given-names></name><name><surname>Blissmer</surname><given-names>B</given-names></name><name><surname>Deschenes</surname><given-names>MR</given-names></name><etal/></person-group>
<article-title>American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise</article-title>. <source>Med Sci Sports Exerc</source>. <year>2011</year>;<volume>43</volume>:<fpage>1334</fpage>-<lpage>1359</lpage>.<pub-id pub-id-type="pmid">21694556</pub-id></mixed-citation>
      </ref>
      <ref id="bibr9-1941738114534813">
        <label>9.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gustavsson</surname><given-names>A</given-names></name><name><surname>Olsson</surname><given-names>T</given-names></name><name><surname>Nordstrom</surname><given-names>P</given-names></name></person-group>
<article-title>Rapid loss of bone mineral density of the femoral neck after cessation of ice hockey training: a 6-year longitudinal study in males</article-title>. <source>J Bone Miner Res</source>. <year>2003</year>;<volume>18</volume>:<fpage>1964</fpage>-<lpage>1969</lpage>.<pub-id pub-id-type="pmid">14606508</pub-id></mixed-citation>
      </ref>
      <ref id="bibr10-1941738114534813">
        <label>10.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haskell</surname><given-names>WL</given-names></name><name><surname>Lee</surname><given-names>IM</given-names></name><name><surname>Pate</surname><given-names>RR</given-names></name><etal/></person-group>
<article-title>Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association</article-title>. <source>Med Sci Sports Exerc</source>. <year>2007</year>;<volume>39</volume>:<fpage>1423</fpage>-<lpage>1434</lpage>.<pub-id pub-id-type="pmid">17762377</pub-id></mixed-citation>
      </ref>
      <ref id="bibr11-1941738114534813">
        <label>11.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hootman</surname><given-names>JM</given-names></name><name><surname>Dick</surname><given-names>R</given-names></name><name><surname>Agel</surname><given-names>J</given-names></name></person-group>
<article-title>Epidemiology of collegiate injuries for 15 sports: summary and recommendations for injury prevention initiatives</article-title>. <source>J Athl Train</source>. <year>2007</year>;<volume>42</volume>:<fpage>311</fpage>-<lpage>319</lpage>.<pub-id pub-id-type="pmid">17710181</pub-id></mixed-citation>
      </ref>
      <ref id="bibr12-1941738114534813">
        <label>12.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hopkins</surname><given-names>WG</given-names></name></person-group>
<article-title>A spreadsheet for deriving a confidence interval, mechanistic inference and clinical inference from a p value</article-title>. <source>Sportscience</source>. <year>2007</year>;<volume>11</volume>:<fpage>16</fpage>-<lpage>20</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr13-1941738114534813">
        <label>13.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hopkins</surname><given-names>WG</given-names></name><name><surname>Marshall</surname><given-names>SW</given-names></name><name><surname>Batterham</surname><given-names>AM</given-names></name><name><surname>Hanin</surname><given-names>J</given-names></name></person-group>
<article-title>Progressive statistics for studies in sports medicine and exercise science</article-title>. <source>Med Sci Sports Exerc</source>. <year>2009</year>;<volume>41</volume>:<fpage>3</fpage>-<lpage>13</lpage>.<pub-id pub-id-type="pmid">19092709</pub-id></mixed-citation>
      </ref>
      <ref id="bibr14-1941738114534813">
        <label>14.</label>
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><name><surname>Jensen</surname><given-names>M</given-names></name></person-group>
<article-title>Congressional panel hears testimony on concussions</article-title>. <source>Philadelphia Inquirer</source>. <month>9</month>
<day>24</day>, <year>2010</year>
<ext-link ext-link-type="uri" xlink:href="http://articles.philly.com/2010-09-24/sports/24977128_1_effects-of-multiple-concussions-mild-concussions-cte">http://articles.philly.com/2010-09-24/sports/24977128_1_effects-of-multiple-concussions-mild-concussions-cte</ext-link>
<date-in-citation>Accessed April 20, 2014</date-in-citation>.</mixed-citation>
      </ref>
      <ref id="bibr15-1941738114534813">
        <label>15.</label>
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><name><surname>Johnson</surname><given-names>G</given-names></name></person-group>
<article-title>NFL is focus of Senate hearing</article-title>. <source>Los Angeles Times</source>. <month>9</month>
<day>18</day>, <year>2007</year>
<ext-link ext-link-type="uri" xlink:href="http://articles.latimes.com/2007/sep/18/sports/sp-nflhearing18">http://articles.latimes.com/2007/sep/18/sports/sp-nflhearing18</ext-link>
<date-in-citation>Accessed April 20, 2014</date-in-citation>.</mixed-citation>
      </ref>
      <ref id="bibr16-1941738114534813">
        <label>16.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kujala</surname><given-names>U</given-names></name><name><surname>Orava</surname><given-names>S</given-names></name><name><surname>Parkkari</surname><given-names>J</given-names></name><name><surname>Kaprio</surname><given-names>J</given-names></name><name><surname>Sarna</surname><given-names>S</given-names></name></person-group>
<article-title>Sports career-related musculoskeletal injuries: long-term health effects on former athletes</article-title>. <source>Sports Med</source>. <year>2003</year>;<volume>33</volume>:<fpage>869</fpage>-<lpage>875</lpage>.<pub-id pub-id-type="pmid">12974655</pub-id></mixed-citation>
      </ref>
      <ref id="bibr17-1941738114534813">
        <label>17.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kujala</surname><given-names>UM</given-names></name><name><surname>Marti</surname><given-names>P</given-names></name><name><surname>Kaprio</surname><given-names>J</given-names></name><name><surname>Hernelahti</surname><given-names>M</given-names></name><name><surname>Tikkanen</surname><given-names>H</given-names></name><name><surname>Sarna</surname><given-names>S</given-names></name></person-group>
<article-title>Occurrence of chronic disease in former top-level athletes. Predominance of benefits, risks or selection effects?</article-title>
<source>Sports Med</source>. <year>2003</year>;<volume>33</volume>:<fpage>553</fpage>-<lpage>561</lpage>.<pub-id pub-id-type="pmid">12797837</pub-id></mixed-citation>
      </ref>
      <ref id="bibr18-1941738114534813">
        <label>18.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kujala</surname><given-names>UM</given-names></name><name><surname>Sarna</surname><given-names>S</given-names></name><name><surname>Kaprio</surname><given-names>J</given-names></name><name><surname>Tikkanen</surname><given-names>HO</given-names></name><name><surname>Koskenvuo</surname><given-names>M</given-names></name></person-group>
<article-title>Natural selection to sports, later physical activity habits, and coronary heart disease</article-title>. <source>Br J Sports Med</source>. <year>2000</year>;<volume>34</volume>:<fpage>445</fpage>-<lpage>449</lpage>.<pub-id pub-id-type="pmid">11131233</pub-id></mixed-citation>
      </ref>
      <ref id="bibr19-1941738114534813">
        <label>19.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lynch</surname><given-names>NA</given-names></name><name><surname>Ryan</surname><given-names>AS</given-names></name><name><surname>Evans</surname><given-names>J</given-names></name><name><surname>Katzel</surname><given-names>LI</given-names></name><name><surname>Goldberg</surname><given-names>AP</given-names></name></person-group>
<article-title>Older elite football players have reduced cardiac and osteoporosis risk factors</article-title>. <source>Med Sci Sports Exerc</source>. <year>2007</year>;<volume>39</volume>:<fpage>1124</fpage>-<lpage>1130</lpage>.<pub-id pub-id-type="pmid">17596780</pub-id></mixed-citation>
      </ref>
      <ref id="bibr20-1941738114534813">
        <label>20.</label>
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>McArdle</surname><given-names>WD</given-names></name><name><surname>Katch</surname><given-names>FI</given-names></name><name><surname>Katch</surname><given-names>VL</given-names></name></person-group>
<source>Exercise Physiology: Energy, Nutrition, &amp; Human Performance</source>. <publisher-loc>Baltimore, MD</publisher-loc>: <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>; <year>2007</year>.</mixed-citation>
      </ref>
      <ref id="bibr21-1941738114534813">
        <label>21.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miller</surname><given-names>MA</given-names></name><name><surname>Croft</surname><given-names>LB</given-names></name><name><surname>Belanger</surname><given-names>AR</given-names></name><etal/></person-group>
<article-title>Prevalence of metabolic syndrome in retired National Football League players</article-title>. <source>Am J Cardiol</source>. <year>2008</year>;<volume>101</volume>:<fpage>1281</fpage>-<lpage>1284</lpage>.<pub-id pub-id-type="pmid">18435958</pub-id></mixed-citation>
      </ref>
      <ref id="bibr22-1941738114534813">
        <label>22.</label>
        <mixed-citation publication-type="book">
<collab>National Collegiate Athletic Association</collab>. <source>1981-82–2010-11 NCAA Sports Sponsorship and Participation Rates Report</source>. <publisher-loc>Indianapolis, IN</publisher-loc>: <publisher-name>National Collegiate Athletic Association</publisher-name>; <year>2011</year>.</mixed-citation>
      </ref>
      <ref id="bibr23-1941738114534813">
        <label>23.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Paffenbarger</surname><given-names>RS</given-names><suffix>Jr</suffix></name><name><surname>Hyde</surname><given-names>RT</given-names></name><name><surname>Wing</surname><given-names>AL</given-names></name><name><surname>Steinmetz</surname><given-names>CH</given-names></name></person-group>
<article-title>A natural history of athleticism and cardiovascular health</article-title>. <source>JAMA</source>. <year>1984</year>;<volume>252</volume>:<fpage>491</fpage>-<lpage>495</lpage>.<pub-id pub-id-type="pmid">6737639</pub-id></mixed-citation>
      </ref>
      <ref id="bibr24-1941738114534813">
        <label>24.</label>
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Rothman</surname><given-names>KJ</given-names></name></person-group>
<source>Epidemiology: An Introduction</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Oxford University Press</publisher-name>; <year>2002</year>.</mixed-citation>
      </ref>
      <ref id="bibr25-1941738114534813">
        <label>25.</label>
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><name><surname>Schwarz</surname><given-names>A</given-names></name></person-group>
<article-title>Dark days follow hard-hitting career in N.F.L</article-title>. <source>New York Times</source>. <month>2</month>
<day>2</day>, <year>2007</year>
<ext-link ext-link-type="uri" xlink:href="http://query.nytimes.com/gst/fullpage.html?res=9501E7DE123FF931A35751C0A9619C8B63">http://query.nytimes.com/gst/fullpage.html?res=9501E7DE123FF931A35751C0A9619C8B63</ext-link>
<date-in-citation>Accessed April 0, 2014</date-in-citation>.</mixed-citation>
      </ref>
      <ref id="bibr26-1941738114534813">
        <label>26.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sorenson</surname><given-names>SC</given-names></name><name><surname>Romano</surname><given-names>R</given-names></name><name><surname>Scholefield</surname><given-names>RM</given-names></name><etal/></person-group>
<article-title>Holistic lifespan health outcomes among elite intercollegiate student-athletes</article-title>. <source>J Athl Train</source>. <year>In press</year>.</mixed-citation>
      </ref>
      <ref id="bibr27-1941738114534813">
        <label>27.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sorenson</surname><given-names>SC</given-names></name><name><surname>Romano</surname><given-names>R</given-names></name><name><surname>Scholefield</surname><given-names>RM</given-names></name><name><surname>Schroeder</surname><given-names>ET</given-names></name><name><surname>Azen</surname><given-names>SP</given-names></name><name><surname>Salem</surname><given-names>GJ</given-names></name></person-group>
<article-title>The Trojan Lifetime Champions health survey: development, validity, and reliability</article-title>. <source>J Athl Train</source>. <year>In press</year>.</mixed-citation>
      </ref>
      <ref id="bibr28-1941738114534813">
        <label>28.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tucker</surname><given-names>AM</given-names></name><name><surname>Vogel</surname><given-names>RA</given-names></name><name><surname>Lincoln</surname><given-names>AE</given-names></name><etal/></person-group>
<article-title>Prevalence of cardiovascular disease risk factors among National Football League players</article-title>. <source>JAMA</source>. <year>2009</year>;<volume>301</volume>:<fpage>2111</fpage>-<lpage>2119</lpage>.<pub-id pub-id-type="pmid">19470988</pub-id></mixed-citation>
      </ref>
      <ref id="bibr29-1941738114534813">
        <label>29.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>van Poppel</surname><given-names>MN</given-names></name><name><surname>Chinapaw</surname><given-names>MJ</given-names></name><name><surname>Mokkink</surname><given-names>LB</given-names></name><name><surname>van Mechelen</surname><given-names>W</given-names></name><name><surname>Terwee</surname><given-names>CB</given-names></name></person-group>
<article-title>Physical activity questionnaires for adults: a systematic review of measurement properties</article-title>. <source>Sports Med</source>. <year>2010</year>;<volume>40</volume>:<fpage>565</fpage>-<lpage>600</lpage>.<pub-id pub-id-type="pmid">20545381</pub-id></mixed-citation>
      </ref>
      <ref id="bibr30-1941738114534813">
        <label>30.</label>
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><name><surname>Vecsey</surname><given-names>G</given-names></name></person-group>
<article-title>Accepting the costs of a life in football</article-title>. <source>New York Times</source>. <month>5</month>
<day>12</day>, <year>2008</year>
<ext-link ext-link-type="uri" xlink:href="http://www.nytimes.com/2008/05/12/sports/football/12vecsey.html">http://www.nytimes.com/2008/05/12/sports/football/12vecsey.html</ext-link>
<date-in-citation>Accessed April 20, 2014</date-in-citation>.</mixed-citation>
      </ref>
      <ref id="bibr31-1941738114534813">
        <label>31.</label>
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Ware</surname><given-names>JE</given-names></name><name><surname>Kosinski</surname><given-names>M</given-names></name><name><surname>Turner-Bowker</surname><given-names>DM</given-names></name><name><surname>Gandeck</surname><given-names>B</given-names></name></person-group>
<source>User’s Manual for the SF-12v2 Health Survey With a Supplement Documenting SF-12 Health Survey</source>. <publisher-loc>Lincoln, RI</publisher-loc>: <publisher-name>QualityMetric</publisher-name>; <year>2002</year>.</mixed-citation>
      </ref>
      <ref id="bibr32-1941738114534813">
        <label>32.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Warren</surname><given-names>JM</given-names></name><name><surname>Ekelund</surname><given-names>U</given-names></name><name><surname>Besson</surname><given-names>H</given-names></name><name><surname>Mezzani</surname><given-names>A</given-names></name><name><surname>Geladas</surname><given-names>N</given-names></name><name><surname>Vanhees</surname><given-names>L</given-names></name></person-group>
<article-title>Assessment of physical activity—a review of methodologies with reference to epidemiological research: a report of the exercise physiology section of the European Association of Cardiovascular Prevention and Rehabilitation</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source>. <year>2010</year>;<volume>17</volume>:<fpage>127</fpage>-<lpage>139</lpage>.<pub-id pub-id-type="pmid">20215971</pub-id></mixed-citation>
      </ref>
      <ref id="bibr33-1941738114534813">
        <label>33.</label>
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Weir</surname><given-names>DR</given-names></name><name><surname>Jackson</surname><given-names>JS</given-names></name><name><surname>Sonnega</surname><given-names>A</given-names></name></person-group>
<source>National Football League Player Care Foundation: Study of Retired NFL Players</source>. <publisher-loc>Ann Arbor</publisher-loc>: <publisher-name>University of Michigan</publisher-name>; <year>2009</year>.</mixed-citation>
      </ref>
      <ref id="bibr34-1941738114534813">
        <label>34.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wyshak</surname><given-names>G</given-names></name><name><surname>Frisch</surname><given-names>RE</given-names></name></person-group>
<article-title>Breast cancer among former college athletes compared to non-athletes: a 15-year follow-up</article-title>. <source>Br J Cancer</source>. <year>2000</year>;<volume>82</volume>:<fpage>726</fpage>-<lpage>730</lpage>.<pub-id pub-id-type="pmid">10682689</pub-id></mixed-citation>
      </ref>
      <ref id="bibr35-1941738114534813">
        <label>35.</label>
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><name><surname>Zarda</surname><given-names>B</given-names></name></person-group>
<article-title>Lawsuit prompts NCAA to screen athletes for sickle cell</article-title>. <source>USA Today</source>. <month>7</month>
<day>2</day>, <year>2010</year>
<ext-link ext-link-type="uri" xlink:href="http://usatoday30.usatoday.com/sports/college/2010-06-30-sickle-cell-ncaa-cover_N.htm">http://usatoday30.usatoday.com/sports/college/2010-06-30-sickle-cell-ncaa-cover_N.htm</ext-link>
<date-in-citation>Accessed April 20, 2014</date-in-citation>.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:4272692</identifier><datestamp>2016-01-01</datestamp><setSpec>sportshealth</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="http://jats.nlm.nih.gov/ns/archiving/1.0/ http://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Sports Health</journal-id>
      <journal-id journal-id-type="iso-abbrev">Sports Health</journal-id>
      <journal-id journal-id-type="publisher-id">SPH</journal-id>
      <journal-id journal-id-type="hwp">spsph</journal-id>
      <journal-title-group>
        <journal-title>Sports Health</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1941-7381</issn>
      <issn pub-type="epub">1941-0921</issn>
      <publisher>
        <publisher-name>SAGE Publications</publisher-name>
        <publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4272692</article-id>
      <article-id pub-id-type="pmcid">PMC4272692</article-id>
      <article-id pub-id-type="pmc-uid">4272692</article-id>
      <article-id pub-id-type="pmid">25553212</article-id>
      <article-id pub-id-type="doi">10.1177/1941738114540445</article-id>
      <article-id pub-id-type="publisher-id">10.1177_1941738114540445</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Focus Topic: Controversies in Sports Medicine</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Ability of Preseason Body Composition and Physical Fitness to Predict the Risk of Injury in Male Collegiate Hockey Players</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Grant</surname>
            <given-names>John A.</given-names>
          </name>
          <degrees>PhD, MD, FRCSC, Dip Sport Med</degrees>
          <xref ref-type="corresp" rid="corresp1-1941738114540445">*</xref>
          <xref ref-type="aff" rid="aff1-1941738114540445">†</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bedi</surname>
            <given-names>Asheesh</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="aff2-1941738114540445">‡</xref>
          <xref ref-type="aff" rid="aff3-1941738114540445">§</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kurz</surname>
            <given-names>Jennifer</given-names>
          </name>
          <degrees>BS, ATC</degrees>
          <xref ref-type="aff" rid="aff4-1941738114540445">||</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bancroft</surname>
            <given-names>Richard</given-names>
          </name>
          <degrees>MS, ATC</degrees>
          <xref ref-type="aff" rid="aff3-1941738114540445">§</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gagnier</surname>
            <given-names>Joel J.</given-names>
          </name>
          <degrees>ND, MSc, PhD</degrees>
          <xref ref-type="aff" rid="aff2-1941738114540445">‡</xref>
          <xref ref-type="aff" rid="aff5-1941738114540445">¶</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Miller</surname>
            <given-names>Bruce S.</given-names>
          </name>
          <degrees>MD, MS</degrees>
          <xref ref-type="aff" rid="aff2-1941738114540445">‡</xref>
          <xref ref-type="aff" rid="aff3-1941738114540445">§</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1-1941738114540445"><label>†</label>Department of Surgery, Dalhousie University, Saint John Regional Hospital, Saint John, New Brunswick, Canada</aff>
      <aff id="aff2-1941738114540445"><label>‡</label>MedSport, Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, Michigan</aff>
      <aff id="aff3-1941738114540445"><label>§</label>Department of Athletics, University of Michigan, Ann Arbor, Michigan</aff>
      <aff id="aff4-1941738114540445"><label>||</label>School of Physical Therapy, Washington University School of Medicine, St. Louis, Missouri</aff>
      <aff id="aff5-1941738114540445"><label>¶</label>Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan</aff>
      <author-notes>
        <corresp id="corresp1-1941738114540445"><label>*</label>John A. Grant, PhD, MD, FRCSC, Dip Sport Med, Saint John Regional Hospital, 555 Somerset Street, Suite 200, Saint John, New Brunswick, E2K 4X2, Canada (e-mail: <email>jgrantorthosports@gmail.com</email>).</corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>1</day>
        <month>1</month>
        <year>2016</year>
      </pub-date>
      <!-- PMC Release delay is 12 months and 0 days and was based on the <pub-date pub-type="ppub"/>. -->
      <volume>7</volume>
      <issue>1</issue>
      <fpage>45</fpage>
      <lpage>51</lpage>
      <permissions>
        <copyright-statement>© 2014 The Author(s)</copyright-statement>
        <copyright-year>2014</copyright-year>
        <copyright-holder content-type="sage">American Orthopaedic Society for Sports Medicine</copyright-holder>
      </permissions>
      <abstract>
        <sec id="section1-1941738114540445">
          <title>Background:</title>
          <p>Injuries in collegiate ice hockey can result in significant time lost from play. The identification of modifiable risk factors relating to a player’s physical fitness allows the development of focused training and injury prevention programs targeted at reducing these risks.</p>
        </sec>
        <sec id="section2-1941738114540445">
          <title>Purpose:</title>
          <p>To determine the ability of preseason fitness outcomes to predict in-season on-ice injury in male collegiate ice hockey players.</p>
        </sec>
        <sec id="section3-1941738114540445">
          <title>Study Design:</title>
          <p>Prognostic cohort study.</p>
        </sec>
        <sec id="section4-1941738114540445">
          <title>Level of Evidence:</title>
          <p>Level 3.</p>
        </sec>
        <sec id="section5-1941738114540445">
          <title>Methods:</title>
          <p>Athlete demographics, percentage body fat, aerobic capacity (300-m shuttle run; 1-, 1.5-, 5-mile run), and strength assessment (sit-ups, push-ups, grip strength, bench press, Olympic cleans, squats) data were collected at the beginning of 8 successive seasons for 1 male collegiate ice hockey team. Hockey-related injury data and player-level practice/game athlete exposure (AE) data were also prospectively collected. Seventy-nine players participated (203 player-years). Injury was defined as any event that resulted in the athlete being unable to participate in 1 or more practices or games following the event. Multivariable logistic regression was performed to determine the ability of the independent variables to predict the occurrence of on-ice injury.</p>
        </sec>
        <sec id="section6-1941738114540445">
          <title>Results:</title>
          <p>There were 132 injuries (mean, 16.5 per year) in 55 athletes. The overall injury rate was 4.4 injuries per 1000 AEs. Forwards suffered 68% of the injuries. Seventy percent of injuries occurred during games with equal distribution between the 3 periods. The mean number of days lost due to injury was 7.8 ± 13.8 (range, 1-127 days). The most common mechanism of injury was contact with another player (54%). The odds of injury in a forward was 1.9 times (95% CI, 1.1-3.4) that of a defenseman and 3 times (95% CI, 1.2-7.7) that of a goalie. The odds of injury if the player’s body mass index (BMI) was ≥25 kg/m<sup>2</sup> was 2.1 times (95% CI, 1.1-3.8) that of a player with a BMI &lt;25 kg/m<sup>2</sup>. The odds ratios for bench press, maximum sit-ups, and Olympic cleans were statistically significant but close to 1.0, and therefore the clinical relevance is unknown.</p>
        </sec>
        <sec id="section7-1941738114540445">
          <title>Conclusion:</title>
          <p>Forwards have higher odds of injury relative to other player positions. BMI was predictive of on-ice injury. Aerobic fitness and maximum strength outcomes were not strongly predictive of on-ice injury.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>hockey</kwd>
        <kwd>prediction</kwd>
        <kwd>risk of injury</kwd>
        <kwd>fitness parameters</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>January/February 2015</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <p>Multiple studies have reported ice hockey injury rates across different age groups, skill levels, and countries.<sup><xref rid="bibr7-1941738114540445" ref-type="bibr">7</xref>,<xref rid="bibr13-1941738114540445" ref-type="bibr">13</xref>,<xref rid="bibr14-1941738114540445" ref-type="bibr">14</xref>,<xref rid="bibr17-1941738114540445" ref-type="bibr">17</xref>,<xref rid="bibr18-1941738114540445" ref-type="bibr">18</xref>,<xref rid="bibr20-1941738114540445" ref-type="bibr">20</xref>,<xref rid="bibr24-1941738114540445" ref-type="bibr">24</xref>,<xref rid="bibr29-1941738114540445" ref-type="bibr">29</xref><xref rid="bibr30-1941738114540445" ref-type="bibr"/>-<xref rid="bibr31-1941738114540445" ref-type="bibr">31</xref>,<xref rid="bibr34-1941738114540445" ref-type="bibr">34</xref>,<xref rid="bibr35-1941738114540445" ref-type="bibr">35</xref>,<xref rid="bibr37-1941738114540445" ref-type="bibr">37</xref>,<xref rid="bibr38-1941738114540445" ref-type="bibr">38</xref></sup> While a consensus on injury rate is difficult to determine, given the use of different definitions of injury and athlete exposure, a trend for a higher risk of injury during games compared with practices is consistent across all studies.<sup><xref rid="bibr7-1941738114540445" ref-type="bibr">7</xref>,<xref rid="bibr14-1941738114540445" ref-type="bibr">14</xref>,<xref rid="bibr17-1941738114540445" ref-type="bibr">17</xref>,<xref rid="bibr18-1941738114540445" ref-type="bibr">18</xref>,<xref rid="bibr20-1941738114540445" ref-type="bibr">20</xref>,<xref rid="bibr30-1941738114540445" ref-type="bibr">30</xref>,<xref rid="bibr37-1941738114540445" ref-type="bibr">37</xref>,<xref rid="bibr38-1941738114540445" ref-type="bibr">38</xref></sup> Whether the risk of injury depends on the player position, however, has not been agreed on.<sup><xref rid="bibr7-1941738114540445" ref-type="bibr">7</xref>,<xref rid="bibr14-1941738114540445" ref-type="bibr">14</xref>,<xref rid="bibr17-1941738114540445" ref-type="bibr">17</xref>,<xref rid="bibr18-1941738114540445" ref-type="bibr">18</xref>,<xref rid="bibr20-1941738114540445" ref-type="bibr">20</xref>,<xref rid="bibr29-1941738114540445" ref-type="bibr">29</xref><xref rid="bibr30-1941738114540445" ref-type="bibr"/>-<xref rid="bibr31-1941738114540445" ref-type="bibr">31</xref>,<xref rid="bibr37-1941738114540445" ref-type="bibr">37</xref></sup> Injuries in collegiate ice hockey can result in time lost from play ranging from minutes to a month or more. On average, the combined lost time for all players on 1 team injured in 1 year is equal to the loss of 1 player for almost the complete season.<sup><xref rid="bibr13-1941738114540445" ref-type="bibr">13</xref></sup> The identification of the risk factors for these injuries is therefore paramount to the prevention of future injuries, the reduction of player morbidity and lost time, and the success of the team.</p>
    <p>A history of previous injury has been the most consistent risk factor for future muscular injury in multiple sports and physical activities.<sup><xref rid="bibr4-1941738114540445" ref-type="bibr">4</xref>,<xref rid="bibr6-1941738114540445" ref-type="bibr">6</xref>,<xref rid="bibr11-1941738114540445" ref-type="bibr">11</xref>,<xref rid="bibr19-1941738114540445" ref-type="bibr">19</xref>,<xref rid="bibr40-1941738114540445" ref-type="bibr">40</xref></sup> Previous injury is a nonmodifiable risk factor, and therefore, prevention strategies cannot change that risk. Inadequate rehabilitation, however, may be a modifiable risk factor that is related to previous injury.<sup><xref rid="bibr19-1941738114540445" ref-type="bibr">19</xref>,<xref rid="bibr42-1941738114540445" ref-type="bibr">42</xref></sup> Modifiable risk factors such as body composition, aerobic and anaerobic fitness, muscular strength, and flexibility are physical properties that are modifiable with time and are modifiable relative to the type, intensity, and volume of training. The identification of risk factors relating to a player’s physical fitness allows the development of focused training and injury prevention programs targeted at reducing these risks.<sup><xref rid="bibr13-1941738114540445" ref-type="bibr">13</xref>,<xref rid="bibr19-1941738114540445" ref-type="bibr">19</xref>,<xref rid="bibr41-1941738114540445" ref-type="bibr">41</xref>,<xref rid="bibr42-1941738114540445" ref-type="bibr">42</xref></sup></p>
    <p>Two previous studies have evaluated predictive factors associated with injury in hockey. Ferrara and Schurr<sup><xref rid="bibr13-1941738114540445" ref-type="bibr">13</xref></sup> found that the body part injured and the injury type were both independent risk factors for lost time. In high school–level ice hockey, among the history of injury, anthropometric measures, and multiple psychosocial outcomes, only self-reported preseason fatigue was predictive of in-season injury.<sup><xref rid="bibr35-1941738114540445" ref-type="bibr">35</xref></sup> Other studies report conflicting results regarding the role of fatigue in injury risk. The occurrence of injury may be higher near the end of each period and the end of the game.<sup><xref rid="bibr11-1941738114540445" ref-type="bibr">11</xref>,<xref rid="bibr18-1941738114540445" ref-type="bibr">18</xref>,<xref rid="bibr30-1941738114540445" ref-type="bibr">30</xref>,<xref rid="bibr31-1941738114540445" ref-type="bibr">31</xref>,<xref rid="bibr35-1941738114540445" ref-type="bibr">35</xref>,<xref rid="bibr37-1941738114540445" ref-type="bibr">37</xref></sup> The incidence of groin injury in National Hockey League (NHL) players is higher during preseason than during in-season play.<sup><xref rid="bibr11-1941738114540445" ref-type="bibr">11</xref></sup> The associations between injury and fatigue, early season activity, and the high-energy shock absorption of contact with the boards/players/ice surface may be related to physical fitness levels.</p>
    <p>Previous studies evaluating the role of strength in sports injury have primarily focused on hamstrings and groin strains.<sup><xref rid="bibr6-1941738114540445" ref-type="bibr">6</xref>,<xref rid="bibr11-1941738114540445" ref-type="bibr">11</xref>,<xref rid="bibr26-1941738114540445" ref-type="bibr">26</xref>,<xref rid="bibr42-1941738114540445" ref-type="bibr">42</xref></sup> The relationship between hamstring strength and hamstring strains in Australian rules football players is conflicting.<sup><xref rid="bibr6-1941738114540445" ref-type="bibr">6</xref>,<xref rid="bibr26-1941738114540445" ref-type="bibr">26</xref></sup> In NHL players, groin injury has been associated with weak hip adductor muscles and a low hip adductor to abductor muscle strength ratio.<sup><xref rid="bibr11-1941738114540445" ref-type="bibr">11</xref>,<xref rid="bibr42-1941738114540445" ref-type="bibr">42</xref></sup></p>
    <p>While body composition was not related to injury in elite female soccer players, it is associated with groin strain in elite male players.<sup><xref rid="bibr4-1941738114540445" ref-type="bibr">4</xref>,<xref rid="bibr27-1941738114540445" ref-type="bibr">27</xref></sup> Aerobic power (VO<sub>2</sub> max) was not associated with injury in elite female soccer but is predictive of overuse injury during the basic training of army recruits.<sup><xref rid="bibr16-1941738114540445" ref-type="bibr">16</xref>,<xref rid="bibr27-1941738114540445" ref-type="bibr">27</xref></sup></p>
    <p>A player’s conditioning level, strength, and/or body composition may be related to risk of on-ice injury.<sup><xref rid="bibr13-1941738114540445" ref-type="bibr">13</xref>,<xref rid="bibr18-1941738114540445" ref-type="bibr">18</xref></sup> Once the burden of disease and the factors affecting that burden have been identified, the appropriate injury prevention programs can be developed and tested. The purpose of this study was to determine the overall and seasonal injury rates for male collegiate ice hockey and to explore whether various measures of preseason fitness (eg, body composition, cardiovascular fitness, strength) play a role in the odds of sustaining an in-season on-ice injury in this group.</p>
    <sec sec-type="materials|methods" id="section8-1941738114540445">
      <title>Materials and Methods</title>
      <p>All male ice hockey athletes from a single Division I university varsity team over 8 successive hockey seasons were included in this study. These athletes were identified from rosters and SIMS (Sports Injury Monitoring System V5.2; Flantech, Inc) database entries maintained by the team’s head athletic trainer. Athletes were excluded if they did not participate in the preseason fitness assessments. Athletes were included as cases if they had a diagnosis of a hockey-related injury during the collegiate hockey season, including the preseason and postseason. All injuries were assessed by the team’s head athletic trainer in consultation with the team physician as necessary. Athletes were excluded if they were injured during non-hockey-related activity or during off-ice hockey activity. An injury was defined as any event that directly resulted in the athlete being unable to participate in on-ice activity for at least 1 day following the event.<sup><xref rid="bibr2-1941738114540445" ref-type="bibr">2</xref>,<xref rid="bibr5-1941738114540445" ref-type="bibr">5</xref>,<xref rid="bibr9-1941738114540445" ref-type="bibr">9</xref>,<xref rid="bibr14-1941738114540445" ref-type="bibr">14</xref>,<xref rid="bibr18-1941738114540445" ref-type="bibr">18</xref>,<xref rid="bibr25-1941738114540445" ref-type="bibr">25</xref>,<xref rid="bibr29-1941738114540445" ref-type="bibr">29</xref>,<xref rid="bibr38-1941738114540445" ref-type="bibr">38</xref></sup> An athlete exposure (AE) was defined as an officially scheduled on-ice practice or game in which the athlete at least partially participated (eg, 1 game in which 17 players participated for any period of time during the actual game = 17 AEs).<sup><xref rid="bibr5-1941738114540445" ref-type="bibr">5</xref>,<xref rid="bibr21-1941738114540445" ref-type="bibr">21</xref></sup> Detailed hockey-related injury data as well as player-level practice and game exposure data had been collected in the SIMS computerized database by the team athletic trainer, who attended all practices and games over the 8 seasons. Additional injury information, if needed, was obtained from the athletic department’s medical records for those athletes with injuries of interest. Ethical approval was obtained from the medical institutional review board.</p>
      <p>Individual tracking of athlete participation at each session allowed for a direct calculation of athlete exposure.<sup><xref rid="bibr21-1941738114540445" ref-type="bibr">21</xref></sup> The total number of AEs per season from all players was tabulated from the athlete-level tracking data. The total number of qualifying injuries was then related to the total number of AEs for all players, resulting in an injury rate per 1000 AEs over the entire study period (8 seasons) and for each individual season.<sup><xref rid="bibr5-1941738114540445" ref-type="bibr">5</xref></sup></p>
      <p>The following athlete demographic and injury variables were collected: (1) age, (2) year of eligibility, (3) mechanism of injury, (4) player position (forward, defense, goaltender), (5) whether injury occurred during a game (including period) or practice session, and (6) time lost before return to play.</p>
      <p>The mechanism of injury was categorized has having occurred by impact with another player, impact with the puck/stick, impact with the ice/boards/goal, a noncontact acute injury, or an overuse injury. The type of injury was categorized as fracture/dislocation, sprain, strain, laceration, contusion, concussion/closed head injury, or bursitis/synovitis. The body part injured was categorized as follows: leg/foot, knee, hip/thigh, arm/hand, shoulder, thorax, or head/neck.</p>
      <p>Body composition, aerobic endurance, and strength assessment data had been routinely collected on all varsity hockey athletes over the 8 seasons. These data were collected by the same strength and conditioning coach during standardized testing of all players during training camp each year. Some of the specific fitness variables assessed were exchanged after the first 4 years of the study period. As such, all variables were not available for all years. Three separate sets of data were therefore available for analysis (<xref ref-type="table" rid="table1-1941738114540445">Table 1</xref>). Percentage body fat was measured using bioimpedance (Quantum II Bioelectrical Body Composition Analyzer; RJL Sciences, Inc). The 300-m shuttle run involved 6 laps of a 25-m course. Lower extremity power was measured using a maximal countermovement vertical jump (centimeters). While a complete review of the reported reliability of these outcomes is beyond the scope of this manuscript, intraclass correlation coefficients (ICCs) range from 0.94 to 0.99 for grip strength, maximum bench press and squats, Olympic cleans, and the shuttle run.<sup><xref rid="bibr1-1941738114540445" ref-type="bibr">1</xref>,<xref rid="bibr8-1941738114540445" ref-type="bibr">8</xref>,<xref rid="bibr33-1941738114540445" ref-type="bibr">33</xref>,<xref rid="bibr39-1941738114540445" ref-type="bibr">39</xref></sup></p>
      <table-wrap id="table1-1941738114540445" position="float">
        <label>Table 1.</label>
        <caption>
          <p>Variables used for injury modeling</p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th align="left" rowspan="1" colspan="1">Model 1 (8 Years)</th>
              <th align="center" rowspan="1" colspan="1">Model 2 (4 Years)<sup><xref ref-type="table-fn" rid="table-fn2-1941738114540445"><italic>a</italic></xref></sup></th>
              <th align="center" rowspan="1" colspan="1">Model 3 (4 Years)<sup><xref ref-type="table-fn" rid="table-fn2-1941738114540445"><italic>a</italic></xref></sup></th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">Age, y</td>
              <td rowspan="1" colspan="1">1.5-mile run</td>
              <td rowspan="1" colspan="1">1-mile run</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Height, m</td>
              <td rowspan="1" colspan="1">5-mile run</td>
              <td rowspan="1" colspan="1">300-m shuttle run</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Weight, kg</td>
              <td rowspan="1" colspan="1">Maximum sit-ups</td>
              <td rowspan="1" colspan="1">Vertical jump, cm</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Body mass index, kg/m<sup>2</sup></td>
              <td rowspan="1" colspan="1">Maximum chin-ups</td>
              <td rowspan="1" colspan="1">Olympic cleans</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Player position</td>
              <td rowspan="1" colspan="1">Grip strength, kg</td>
              <td rowspan="1" colspan="1">3 RM bench press</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Body composition</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">3 RM squats</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Maximum bench press at 84.1 kg</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Stair run</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="table-fn1-1941738114540445">
            <p>RM, repetition maximum.</p>
          </fn>
          <fn id="table-fn2-1941738114540445">
            <label>a</label>
            <p>Model 2 variables were assessed in the first 4 years of the study period, and model 3 variables were assessed in the later 4 years of the study period.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>Statistical analyses were performed using Stata 6.0 (Stata Corp). Athlete demographic, injury, and fitness data were described with measures of central tendency, variance, and boxplots. The difference in the frequency of injury by player position was assessed with a chi-square analysis. Single-variable logistic regression analyses were employed to assess the ability of each independent variable to predict the probability of the occurrence of an on-ice injury (<xref ref-type="table" rid="table1-1941738114540445">Table 1</xref>). In addition to the fitness variables, player position and the number of years of play in collegiate hockey were also assessed. Significant predictor variables from the single-variable modeling were then entered into a multivariable regression model, and a backward stepwise regression was performed. Variables with the highest nonsignificant <italic>P</italic> values were dropped from the model until only significant variables remained. To assess the model fit, analyses of residuals were performed. Odds ratios for the significant predictor variables were determined from the logistic regression analyses. Logistic regression was performed both including and excluding reinjuries to control for the possibility of confounding. Given the retrospective nature of this study, our sample size was set. Previous epidemiological studies involving logistic regression have determined that 5 to 10 subjects per variable is acceptable for multiple logistic regression analysis.<sup><xref rid="bibr3-1941738114540445" ref-type="bibr">3</xref>,<xref rid="bibr28-1941738114540445" ref-type="bibr">28</xref></sup></p>
      <p>While data from the same player over multiple seasons are not mutually exclusive, the modifiable risk factors that may have confounded injury risk year to year would be included in the analysis, and therefore controlled for. Also, an individual’s anthropometric, cardiovascular, body composition, and strength variables may have changed from year to year, potentially modifying their risk for injury. In this manner, the independent variables associated with specific individuals could be paired with their injury history for the same year. To account for multiple observations for individual players across several years, the variables “player,” “year,” and the interaction term “player × year” were modeled on the probability of injury using logistic regression. This modeling of both the “player” and “year” variables account for the clustering associated with multiple years and having the same player present in multiple years.</p>
    </sec>
    <sec sec-type="results" id="section9-1941738114540445">
      <title>Results</title>
      <p>Seventy-nine different players participated on the team over the 8 seasons (<xref ref-type="table" rid="table2-1941738114540445">Table 2</xref>). This resulted in 203 player-years. There were 132 injuries in 55 players over the 8 seasons, with a mean of 16.5 injuries per season (range, 12-21 injuries). Fourteen (10.6%) of these were reinjuries. Appendix 1 lists the total number of injuries, AEs, and injury rates for each year and the cumulative results for the 8 seasons (available at <ext-link ext-link-type="uri" xlink:href="http://sph.sagepub.com/content/suppl">http://sph.sagepub.com/content/suppl</ext-link>). For reference, there were usually 5 practices and 2 games per week during the season.</p>
      <table-wrap id="table2-1941738114540445" position="float">
        <label>Table 2.</label>
        <caption>
          <p>Subject anthropometric data (mean ± SD)</p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th align="left" rowspan="1" colspan="1">Measure</th>
              <th align="center" rowspan="1" colspan="1">Mean</th>
              <th align="center" rowspan="1" colspan="1">Range</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">Age, y</td>
              <td rowspan="1" colspan="1">20.2 ± 1.6</td>
              <td rowspan="1" colspan="1">17-24</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Height, m</td>
              <td rowspan="1" colspan="1">1.82 ± 0.06</td>
              <td rowspan="1" colspan="1">1.65-1.93</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Weight, kg</td>
              <td rowspan="1" colspan="1">85.6 ± 7.0</td>
              <td rowspan="1" colspan="1">67.7-106.8</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Body mass index, kg/m<sup>2</sup></td>
              <td rowspan="1" colspan="1">25.7 ± 1.6</td>
              <td rowspan="1" colspan="1">20.2-30.5</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>Forwards sustained a significantly higher proportion of injuries (68.2%, χ<sup>2</sup> = 19.91, <italic>P</italic> &lt; 0.001) compared with defensemen (25.8%) and goaltenders (6.1%). Given the differential in the number of players per position on the ice at one time, the expected frequency of injury under the null hypothesis would be 50% for forwards (3 of 6 players), 33.3% for defensemen (2 of 6 players), and 16.7% for goaltenders (1 of 6 players). Thirty-four percent of injuries occurred during practice sessions, while the remaining 66% occurred in games and were equally distributed across the 3 periods of play (21%, 21%, and 19%, respectively). One injury occurred in overtime, and the period of injury was not reported in 5 cases (3.8%).</p>
      <p>The various mechanisms of injury, the frequency of injury by body region, and the types of injuries sustained are shown in <xref ref-type="table" rid="table3-1941738114540445">Tables 3</xref> through <xref ref-type="table" rid="table5-1941738114540445">5</xref>. The mean lost time per injury was 7.8 ± 13.8 days (median, 3 days; range, 1-127 days). This equated to 5.4 ± 10.7 practices or games missed (median, 2; range, 0-99). Those players missing zero events (practices or games) would have had a scheduled “off” day following the day of injury and were able to return to play by the next on-ice event. Five players had injuries or surgery at the end of the season and therefore did not miss any practices or games. These players were included in the regression analyses, but their data were not included in the calculation of lost time.</p>
      <table-wrap id="table3-1941738114540445" position="float">
        <label>Table 3.</label>
        <caption>
          <p>Mechanism of injury</p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th align="left" rowspan="1" colspan="1">Mechanism of Injury</th>
              <th align="center" rowspan="1" colspan="1">Number of Injuries</th>
              <th align="center" rowspan="1" colspan="1">Frequency (%)</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">Impact with another player</td>
              <td rowspan="1" colspan="1">71</td>
              <td rowspan="1" colspan="1">53.8</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Impact with the ice/boards</td>
              <td rowspan="1" colspan="1">19</td>
              <td rowspan="1" colspan="1">14.4</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Noncontact acute</td>
              <td rowspan="1" colspan="1">15</td>
              <td rowspan="1" colspan="1">11.4</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Not specified</td>
              <td rowspan="1" colspan="1">15</td>
              <td rowspan="1" colspan="1">11.4</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Impact with the puck/stick</td>
              <td rowspan="1" colspan="1">10</td>
              <td rowspan="1" colspan="1">7.5</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Overuse</td>
              <td rowspan="1" colspan="1">2</td>
              <td rowspan="1" colspan="1">1.5</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Total</td>
              <td rowspan="1" colspan="1">132</td>
              <td rowspan="1" colspan="1">100.0</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <table-wrap id="table4-1941738114540445" position="float">
        <label>Table 4.</label>
        <caption>
          <p>Frequency of injury to specific areas of the body</p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th align="left" rowspan="1" colspan="1">Body Part</th>
              <th align="center" rowspan="1" colspan="1">Number of Injuries</th>
              <th align="center" rowspan="1" colspan="1">Frequency (%)</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">Thigh/hip</td>
              <td rowspan="1" colspan="1">28</td>
              <td rowspan="1" colspan="1">21.2</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Shoulder</td>
              <td rowspan="1" colspan="1">27</td>
              <td rowspan="1" colspan="1">20.5</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Head/neck</td>
              <td rowspan="1" colspan="1">21</td>
              <td rowspan="1" colspan="1">15.9</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Knee</td>
              <td rowspan="1" colspan="1">18</td>
              <td rowspan="1" colspan="1">13.6</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Arm/hand</td>
              <td rowspan="1" colspan="1">16</td>
              <td rowspan="1" colspan="1">12.1</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Leg/foot</td>
              <td rowspan="1" colspan="1">13</td>
              <td rowspan="1" colspan="1">9.9</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Thorax/spine</td>
              <td rowspan="1" colspan="1">5</td>
              <td rowspan="1" colspan="1">3.8</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Abdomen</td>
              <td rowspan="1" colspan="1">4</td>
              <td rowspan="1" colspan="1">3.0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Total</td>
              <td rowspan="1" colspan="1">132</td>
              <td rowspan="1" colspan="1">100.0</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <table-wrap id="table5-1941738114540445" position="float">
        <label>Table 5.</label>
        <caption>
          <p>Frequency of the types of injuries sustained</p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th align="left" rowspan="1" colspan="1">Injury Type</th>
              <th align="center" rowspan="1" colspan="1">Number of Injuries</th>
              <th align="center" rowspan="1" colspan="1">Frequency (%)</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">Sprain</td>
              <td rowspan="1" colspan="1">49</td>
              <td rowspan="1" colspan="1">37.1</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Strain</td>
              <td rowspan="1" colspan="1">24</td>
              <td rowspan="1" colspan="1">18.2</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Fracture/dislocation</td>
              <td rowspan="1" colspan="1">17</td>
              <td rowspan="1" colspan="1">12.9</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Contusion</td>
              <td rowspan="1" colspan="1">14</td>
              <td rowspan="1" colspan="1">10.6</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Concussion/closed head injury</td>
              <td rowspan="1" colspan="1">14</td>
              <td rowspan="1" colspan="1">10.6</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Laceration</td>
              <td rowspan="1" colspan="1">5</td>
              <td rowspan="1" colspan="1">3.8</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Bursitis/synovitis</td>
              <td rowspan="1" colspan="1">5</td>
              <td rowspan="1" colspan="1">3.8</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Other<sup><xref ref-type="table-fn" rid="table-fn3-1941738114540445"><italic>a</italic></xref></sup></td>
              <td rowspan="1" colspan="1">4</td>
              <td rowspan="1" colspan="1">3.0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Total</td>
              <td rowspan="1" colspan="1">132</td>
              <td rowspan="1" colspan="1">100.0</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="table-fn3-1941738114540445">
            <label>a</label>
            <p>Two inguinal hernias, pneumothorax, cervical rib syndrome.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>Four variables were identified as significant predictors of the odds of on-ice injury in the 8-year data set (model 1, Appendix 2; available at <ext-link ext-link-type="uri" xlink:href="http://sph.sagepub.com/content/suppl">http://sph.sagepub.com/content/suppl</ext-link>). These variables were body weight, body mass index (BMI), player position, and the maximum number of bench press repetitions with an 84.1-kg (185 lbs) load. The “player” and “year of play” variables were not significant, nor was the interaction term “player × year.” Therefore, these 3 variables were excluded from the models. Given that body weight is a component of BMI, the 2 variables were assessed for collinearity. The tolerance (0.956) and the variance inflation factor (1.61) for this relationship demonstrated that these variables were not collinear. The odds of injury increased 1.3 times for each increase of 5 kg in body weight (<italic>P</italic> = 0.03). Similarly, the odds of injury increased by 1.3 times for each increase of 1 kg/m<sup>2</sup> in BMI (<italic>P</italic> = 0.002). Players with BMI ≥25 kg/m<sup>2</sup> had an odds of injury 2.1 times higher than players with a BMI of &lt;25 kg/m<sup>2</sup> (<italic>P</italic> = 0.02). The odds of injury in a forward was 1.9 times that of a defenseman (<italic>P</italic> = 0.03) and 3 times the odds of injury in a goaltender (<italic>P</italic> = 0.02). The only strength variable to be predictive of injury was the maximum number of barbell bench press repetitions performed with a standard load of 84.1 kg (185 lbs). The odds of an in-season on-ice injury was 1.3 times higher for every increase of 5 repetitions (<italic>P</italic> = 0.02). There were no significant multivariable models. The exclusion of reinjuries did not change the variables that were significant predictors, and the associated odds ratios were minimally changed (Appendix 3, available at <ext-link ext-link-type="uri" xlink:href="http://sph.sagepub.com/content/suppl">http://sph.sagepub.com/content/suppl</ext-link>).</p>
      <p>The analysis of the 4-year data in model 2 demonstrated that only the maximal number of sit-ups was a significant predictor of on-ice injury. The odds of injury increased 1.3 times for each increase of 5 sit-ups (<italic>P</italic> = 0.034). In the analysis of the 4 years of data in model 3, both the 300-m shuttle run and the maximum weight used for an Olympic clean were the only 2 significant predictor variables for on-ice injury. With every 1-second increase in shuttle run time, the odds of injury decreased by 28% (<italic>P</italic> = 0.014). The odds of injury increased 1.1 times for each 4.5-kg increase in maximum Olympic clean (<italic>P</italic> = 0.011). There were no significant multivariable regression models in either model 2 or 3. Given the potential for BMI to confound the relationship of strength variables with injury, a post hoc logistic regression analysis was performed. There was no significant interaction, nor any sign of confounding, between BMI and either bench press, sit-ups, or maximum Olympic cleans. Regression summaries for each of the significant predictor variables for single-variable modeling are listed in Appendix 2. The exclusion of reinjuries did not change the variables that were significant predictors and the associated odds ratios were minimally changed (Appendix 3).</p>
    </sec>
    <sec sec-type="discussion" id="section10-1941738114540445">
      <title>Discussion</title>
      <p>The injury rate of 4.4 injuries per 1000 AEs is consistent with the rates found by 2 previous studies of US collegiate hockey (2.69/1000 AEs and 6.4/1000 AEs)<sup><xref rid="bibr2-1941738114540445" ref-type="bibr">2</xref>,<xref rid="bibr5-1941738114540445" ref-type="bibr">5</xref></sup> and further supports that the majority of injuries occur during games.<sup><xref rid="bibr2-1941738114540445" ref-type="bibr">2</xref>,<xref rid="bibr5-1941738114540445" ref-type="bibr">5</xref>,<xref rid="bibr7-1941738114540445" ref-type="bibr">7</xref>,<xref rid="bibr14-1941738114540445" ref-type="bibr">14</xref>,<xref rid="bibr17-1941738114540445" ref-type="bibr">17</xref>,<xref rid="bibr18-1941738114540445" ref-type="bibr">18</xref>,<xref rid="bibr20-1941738114540445" ref-type="bibr">20</xref>,<xref rid="bibr30-1941738114540445" ref-type="bibr">30</xref>,<xref rid="bibr37-1941738114540445" ref-type="bibr">37</xref>,<xref rid="bibr38-1941738114540445" ref-type="bibr">38</xref></sup> Two controversies in the hockey injury literature involve whether players in a certain position (eg, forward) are more likely to sustain injury<sup><xref rid="bibr2-1941738114540445" ref-type="bibr">2</xref>,<xref rid="bibr5-1941738114540445" ref-type="bibr">5</xref>,<xref rid="bibr7-1941738114540445" ref-type="bibr">7</xref>,<xref rid="bibr14-1941738114540445" ref-type="bibr">14</xref>,<xref rid="bibr17-1941738114540445" ref-type="bibr">17</xref>,<xref rid="bibr18-1941738114540445" ref-type="bibr">18</xref>,<xref rid="bibr20-1941738114540445" ref-type="bibr">20</xref>,<xref rid="bibr29-1941738114540445" ref-type="bibr">29</xref><xref rid="bibr30-1941738114540445" ref-type="bibr"/>-<xref rid="bibr31-1941738114540445" ref-type="bibr">31</xref>,<xref rid="bibr37-1941738114540445" ref-type="bibr">37</xref></sup> and whether more injuries occur later in the game, suggestive of fatigue being a factor related to the risk of injury.<sup><xref rid="bibr2-1941738114540445" ref-type="bibr">2</xref>,<xref rid="bibr14-1941738114540445" ref-type="bibr">14</xref>,<xref rid="bibr18-1941738114540445" ref-type="bibr">18</xref>,<xref rid="bibr24-1941738114540445" ref-type="bibr">24</xref>,<xref rid="bibr29-1941738114540445" ref-type="bibr">29</xref>,<xref rid="bibr31-1941738114540445" ref-type="bibr">31</xref>,<xref rid="bibr37-1941738114540445" ref-type="bibr">37</xref>,<xref rid="bibr38-1941738114540445" ref-type="bibr">38</xref></sup> This study demonstrated that forwards do suffer a higher percentage of injuries, even after adjusting for the increased number of players in that position on the ice at any one time.<sup><xref rid="bibr2-1941738114540445" ref-type="bibr">2</xref></sup> Published data on impacts to the head during hockey demonstrate that forwards sustain either the same or more hits compared with defensemen.<sup><xref rid="bibr23-1941738114540445" ref-type="bibr">23</xref>,<xref rid="bibr32-1941738114540445" ref-type="bibr">32</xref></sup> It is unknown how these data relate to receiving body checks in general. Players delivering body checks are more likely to be prepared and brace for the impact compared with those who are trying to escape the body check and play the puck. In youth hockey, 97% of injuries related to body checking were sustained by the player receiving the check.<sup><xref rid="bibr12-1941738114540445" ref-type="bibr">12</xref></sup> Video and kinetic data show that accelerations due to head impacts are significantly less when players anticipate the impact with good body positioning compared with unanticipated impacts.<sup><xref rid="bibr22-1941738114540445" ref-type="bibr">22</xref></sup> Injury rates are higher in leagues that allow body checking,<sup><xref rid="bibr10-1941738114540445" ref-type="bibr">10</xref>,<xref rid="bibr44-1941738114540445" ref-type="bibr">44</xref></sup> and the majority of injuries that occur in those leagues are caused by player contact.<sup><xref rid="bibr2-1941738114540445" ref-type="bibr">2</xref>,<xref rid="bibr7-1941738114540445" ref-type="bibr">7</xref>,<xref rid="bibr14-1941738114540445" ref-type="bibr">14</xref>,<xref rid="bibr18-1941738114540445" ref-type="bibr">18</xref>,<xref rid="bibr20-1941738114540445" ref-type="bibr">20</xref>,<xref rid="bibr24-1941738114540445" ref-type="bibr">24</xref>,<xref rid="bibr37-1941738114540445" ref-type="bibr">37</xref></sup></p>
      <p>Fatigue has been suggested as a possible factor related to injuries in ice hockey. Three studies show that more injuries occur in the third period than either of the first 2 periods.<sup><xref rid="bibr24-1941738114540445" ref-type="bibr">24</xref>,<xref rid="bibr31-1941738114540445" ref-type="bibr">31</xref>,<xref rid="bibr37-1941738114540445" ref-type="bibr">37</xref></sup> Forty-five percent of the injuries in Junior A hockey occurred in the last 5 minutes of the period.<sup><xref rid="bibr31-1941738114540445" ref-type="bibr">31</xref></sup> Injuries later in the period or later in the game could also be related to an increased urgency to score or protect a lead, which may lead to increased physical intensity and aggression.<sup><xref rid="bibr24-1941738114540445" ref-type="bibr">24</xref>,<xref rid="bibr37-1941738114540445" ref-type="bibr">37</xref></sup> This study found an equal distribution of injuries across all 3 periods of play, in line with other previous studies.<sup><xref rid="bibr2-1941738114540445" ref-type="bibr">2</xref>,<xref rid="bibr14-1941738114540445" ref-type="bibr">14</xref>,<xref rid="bibr18-1941738114540445" ref-type="bibr">18</xref>,<xref rid="bibr29-1941738114540445" ref-type="bibr">29</xref>,<xref rid="bibr38-1941738114540445" ref-type="bibr">38</xref></sup> There may be a relationship between the amount of an NHL player’s ice time per game and his risk of concussion.<sup><xref rid="bibr36-1941738114540445" ref-type="bibr">36</xref></sup> It is not clear, however, whether the increased risk of concussion was related more to an increase in exposure time or to fatigue.</p>
      <p>An increase in body weight and BMI were related to an increased likelihood of injury. Superficially, those players who weighed more and potentially had an increase in body fat were less fit and were therefore more likely to be injured. Body composition, however, was an independently assessed variable and was not a significant predictor of injury. It is therefore difficult to fully explain the relationship between body weight or BMI and injury. Given the relative increase in lean muscle mass in athletes compared with the general population, it is important to note that BMI in this athletic population is regarded as a general measure of the body mass to height ratio and not specifically a measure of body composition or body fat percentage.</p>
      <p>The fact that better scores in the tests of physical fitness (ie, bench press, sit-ups, Olympic cleans, shuttle run) were related to an increased odds of injury further clouds the result. While the relationship between groin strains and adductor muscle strength and hip adductor to abductor muscle imbalance varies among studies,<sup><xref rid="bibr11-1941738114540445" ref-type="bibr">11</xref>,<xref rid="bibr42-1941738114540445" ref-type="bibr">42</xref></sup> an increased volume of preseason sport-specific training and a focused functional adductor strengthening program have both been shown to reduce the rate of groin strain in NHL players.<sup><xref rid="bibr11-1941738114540445" ref-type="bibr">11</xref>,<xref rid="bibr41-1941738114540445" ref-type="bibr">41</xref></sup> A small pilot study in junior hockey players also demonstrated a reduction in the number and severity of injuries following a hockey-specific 12-week preseason training program.<sup><xref rid="bibr15-1941738114540445" ref-type="bibr">15</xref></sup></p>
      <p>The findings of this study present 2 possible explanations: (1) preseason fitness levels are not strongly predictive of on-ice injury or (2) the general fitness measures included in this study are not sufficiently specific to hockey to strongly predict those players who have an increased likelihood of on-ice injury.</p>
      <p>As with any retrospective study, there are limitations. There were 203 player-years and 19 variables assessed in the logistic regression analyses. While this sample size is within the 10 samples per variable rule of thumb,<sup><xref rid="bibr3-1941738114540445" ref-type="bibr">3</xref>,<xref rid="bibr43-1941738114540445" ref-type="bibr">43</xref></sup> the study may be underpowered to detect other variables that are predictive of in-season injury. Given the retrospective nature of the study, our sample size was set, and as such, we did not perform an a priori sample size calculation. Confounding of the relationship between injury and player fitness by unknown risk factors is a possibility. An attempt was made to control for the influence of player-specific and team factors by including the “player” and “year” variables in the modeling. We did not assess for any change in intraplayer fitness variables in cases where players competed in multiple years. The variable number of players who played multiple years made the inclusion of these data in the analysis difficult.</p>
    </sec>
    <sec sec-type="conclusions" id="section11-1941738114540445">
      <title>Conclusion</title>
      <p>Division I male collegiate ice hockey teams can expect approximately 17 lost-time injuries per season, with a median of 2 practices or games missed per injury. Forwards are more likely to be injured than are those playing other positions. Injuries tend to occur in games, and involved sprains or strains to the hip, thigh, or shoulder regions. Players with higher body weight and BMI are more likely to be injured.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="conflict">
        <p>The following author declared potential conflicts of interest: Asheesh Bedi, MD, is a paid consultant for Smith &amp; Nephew.<?release-delay 12|0?></p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="bibr1-1941738114540445">
        <label>1.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aandstad</surname><given-names>A</given-names></name><name><surname>Holme</surname><given-names>I</given-names></name><name><surname>Berntsen</surname><given-names>S</given-names></name><name><surname>Anderssen</surname><given-names>SA</given-names></name></person-group>
<article-title>Validity and reliability of the 20 meter shuttle run test in military personnel</article-title>. <source>Mil Med</source>. <year>2011</year>;<volume>176</volume>:<fpage>513</fpage>-<lpage>518</lpage>.<pub-id pub-id-type="pmid">21634295</pub-id></mixed-citation>
      </ref>
      <ref id="bibr2-1941738114540445">
        <label>2.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Agel</surname><given-names>J</given-names></name><name><surname>Dompier</surname><given-names>TP</given-names></name><name><surname>Dick</surname><given-names>R</given-names></name><name><surname>Marshall</surname><given-names>SW</given-names></name></person-group>
<article-title>Descriptive epidemiology of collegiate men’s ice hockey injuries: National Collegiate Athletic Association Injury Surveillance System, 1988-1989 through 2003-2004</article-title>. <source>J Athl Train</source>. <year>2007</year>;<volume>42</volume>:<fpage>241</fpage>-<lpage>248</lpage>.<pub-id pub-id-type="pmid">17710172</pub-id></mixed-citation>
      </ref>
      <ref id="bibr3-1941738114540445">
        <label>3.</label>
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Altman</surname><given-names>DG</given-names></name></person-group>
<article-title>Multiple regression</article-title>. In: <source>Practical Statistics for Medical Research</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Chapman &amp; Hall/CRC Press</publisher-name>; <year>1990</year>:<fpage>336</fpage>-<lpage>350</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr4-1941738114540445">
        <label>4.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arnason</surname><given-names>A</given-names></name><name><surname>Sigurdsson</surname><given-names>SB</given-names></name><name><surname>Gudmundsson</surname><given-names>A</given-names></name><name><surname>Holme</surname><given-names>I</given-names></name><name><surname>Engebretsen</surname><given-names>L</given-names></name><name><surname>Bahr</surname><given-names>R</given-names></name></person-group>
<article-title>Risk factors for injuries in football</article-title>. <source>Am J Sports Med</source>. <year>2004</year>;<volume>32</volume>(<issue>suppl</issue>):<fpage>5S</fpage>-<lpage>16S</lpage>.<pub-id pub-id-type="pmid">14754854</pub-id></mixed-citation>
      </ref>
      <ref id="bibr5-1941738114540445">
        <label>5.</label>
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Bancroft</surname><given-names>RW</given-names></name></person-group>
<article-title>Type, location, and severity of hockey injuries occurring during competition and practice</article-title>. In: <person-group person-group-type="editor"><name><surname>Castaldi</surname><given-names>CR</given-names></name><name><surname>Bishop</surname><given-names>PJ</given-names></name><name><surname>Hoerner</surname><given-names>EF</given-names></name></person-group>, eds. <source>Safety in Ice Hockey: Volume 2, ASTM STP 1212</source>. <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>American Society for Testing and Materials</publisher-name>; <year>1993</year>:<fpage>31</fpage>-<lpage>43</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr6-1941738114540445">
        <label>6.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bennell</surname><given-names>K</given-names></name><name><surname>Wajswelner</surname><given-names>H</given-names></name><name><surname>Lew</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Isokinetic strength testing does not predict hamstring injury in Australian Rules footballers</article-title>. <source>Br J Sports Med</source>. <year>1998</year>;<volume>32</volume>:<fpage>309</fpage>-<lpage>314</lpage>.<pub-id pub-id-type="pmid">9865403</pub-id></mixed-citation>
      </ref>
      <ref id="bibr7-1941738114540445">
        <label>7.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bjorkenheim</surname><given-names>JM</given-names></name><name><surname>Syvahuoko</surname><given-names>I</given-names></name><name><surname>Rosenberg</surname><given-names>PH</given-names></name></person-group>
<article-title>Injuries in competitive junior ice-hockey. 1437 players followed for one season</article-title>. <source>Acta Orthop Scand</source>. <year>1993</year>;<volume>64</volume>:<fpage>459</fpage>-<lpage>461</lpage>.<pub-id pub-id-type="pmid">8213128</pub-id></mixed-citation>
      </ref>
      <ref id="bibr8-1941738114540445">
        <label>8.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Comfort</surname><given-names>P</given-names></name></person-group>
<article-title>Within and between session reliability of power, force and rate of force development during the power clean</article-title>. <source>J Strength Cond Res</source>. <year>2013</year>;<volume>27</volume>:<fpage>1210</fpage>-<lpage>1214</lpage>.<pub-id pub-id-type="pmid">22843043</pub-id></mixed-citation>
      </ref>
      <ref id="bibr9-1941738114540445">
        <label>9.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dick</surname><given-names>R</given-names></name><name><surname>Agel</surname><given-names>J</given-names></name><name><surname>Marshall</surname><given-names>SW</given-names></name></person-group>
<article-title>National Collegiate Athletic Association Injury Surveillance System commentaries: introduction and methods</article-title>. <source>J Athl Train</source>. <year>2007</year>;<volume>42</volume>:<fpage>173</fpage>-<lpage>182</lpage>.<pub-id pub-id-type="pmid">21714302</pub-id></mixed-citation>
      </ref>
      <ref id="bibr10-1941738114540445">
        <label>10.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Emery</surname><given-names>CA</given-names></name><name><surname>Kang</surname><given-names>J</given-names></name><name><surname>Shrier</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>Risk of injury associated with body checking among youth ice hockey players</article-title>. <source>JAMA</source>. <year>2010</year>;<volume>303</volume>:<fpage>2265</fpage>-<lpage>2272</lpage>.<pub-id pub-id-type="pmid">20530780</pub-id></mixed-citation>
      </ref>
      <ref id="bibr11-1941738114540445">
        <label>11.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Emery</surname><given-names>CA</given-names></name><name><surname>Meeuwisse</surname><given-names>WH</given-names></name></person-group>
<article-title>Risk factors for groin injuries in hockey</article-title>. <source>Med Sci Sports Exerc</source>. <year>2001</year>;<volume>33</volume>:<fpage>1423</fpage>-<lpage>1433</lpage>.<pub-id pub-id-type="pmid">11528328</pub-id></mixed-citation>
      </ref>
      <ref id="bibr12-1941738114540445">
        <label>12.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Emery</surname><given-names>CA</given-names></name><name><surname>Meeuwisse</surname><given-names>WH</given-names></name></person-group>
<article-title>Injury rates, risk factors, and mechanisms of injury in minor hockey</article-title>. <source>Am J Sports Med</source>. <year>2006</year>;<volume>34</volume>:<fpage>1960</fpage>-<lpage>1969</lpage>.<pub-id pub-id-type="pmid">16861577</pub-id></mixed-citation>
      </ref>
      <ref id="bibr13-1941738114540445">
        <label>13.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ferrara</surname><given-names>MS</given-names></name><name><surname>Schurr</surname><given-names>KT</given-names></name></person-group>
<article-title>Intercollegiate ice hockey injuries: a causal analysis</article-title>. <source>Clin J Sport Med</source>. <year>1999</year>;<volume>9</volume>:<fpage>30</fpage>-<lpage>33</lpage>.<pub-id pub-id-type="pmid">10336049</pub-id></mixed-citation>
      </ref>
      <ref id="bibr14-1941738114540445">
        <label>14.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Flik</surname><given-names>K</given-names></name><name><surname>Lyman</surname><given-names>S</given-names></name><name><surname>Marx</surname><given-names>RG</given-names></name></person-group>
<article-title>American collegiate men’s ice hockey: an analysis of injuries</article-title>. <source>Am J Sports Med</source>. <year>2005</year>;<volume>33</volume>:<fpage>183</fpage>-<lpage>187</lpage>.<pub-id pub-id-type="pmid">15701603</pub-id></mixed-citation>
      </ref>
      <ref id="bibr15-1941738114540445">
        <label>15.</label>
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Gilder</surname><given-names>KA</given-names></name><name><surname>Grogan</surname><given-names>J</given-names></name></person-group>
<article-title>Prevention of ice hockey injuries by strength and conditioning</article-title>. In: <person-group person-group-type="editor"><name><surname>Castaldi</surname><given-names>CR</given-names></name><name><surname>Bishop</surname><given-names>PJ</given-names></name><name><surname>Hoerner</surname><given-names>EF</given-names></name></person-group>, eds. <source>Safety in Ice Hockey: Volume 2, ASTM STP 1212</source>. <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>American Society for Testing and Materials</publisher-name>; <year>1993</year>:<fpage>56</fpage>-<lpage>68</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr16-1941738114540445">
        <label>16.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Knapik</surname><given-names>JJ</given-names></name><name><surname>Sharp</surname><given-names>MA</given-names></name><name><surname>Canham-Chervak</surname><given-names>M</given-names></name><name><surname>Hauret</surname><given-names>K</given-names></name><name><surname>Patton</surname><given-names>JF</given-names></name><name><surname>Jones</surname><given-names>BH</given-names></name></person-group>
<article-title>Risk factors for training-related injuries among men and women in basic combat training</article-title>. <source>Med Sci Sports Exerc</source>. <year>2001</year>;<volume>33</volume>:<fpage>946</fpage>-<lpage>954</lpage>.<pub-id pub-id-type="pmid">11404660</pub-id></mixed-citation>
      </ref>
      <ref id="bibr17-1941738114540445">
        <label>17.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kuzuhara</surname><given-names>K</given-names></name><name><surname>Shimamoto</surname><given-names>H</given-names></name><name><surname>Mase</surname><given-names>Y</given-names></name></person-group>
<article-title>Ice hockey injuries in a Japanese elite team: a 3-year prospective study</article-title>. <source>J Athl Train</source>. <year>2009</year>;<volume>44</volume>:<fpage>208</fpage>-<lpage>214</lpage>.<pub-id pub-id-type="pmid">19295967</pub-id></mixed-citation>
      </ref>
      <ref id="bibr18-1941738114540445">
        <label>18.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lorentzon</surname><given-names>R</given-names></name><name><surname>Wedren</surname><given-names>H</given-names></name><name><surname>Pietila</surname><given-names>T</given-names></name></person-group>
<article-title>Incidence, nature, and causes of ice hockey injuries. A three-year prospective study of a Swedish elite ice hockey team</article-title>. <source>Am J Sports Med</source>. <year>1988</year>;<volume>16</volume>:<fpage>392</fpage>-<lpage>396</lpage>.<pub-id pub-id-type="pmid">3189665</pub-id></mixed-citation>
      </ref>
      <ref id="bibr19-1941738114540445">
        <label>19.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maffey</surname><given-names>L</given-names></name><name><surname>Emery</surname><given-names>C</given-names></name></person-group>
<article-title>What are the risk factors for groin strain injury in sport? A systematic review of the literature</article-title>. <source>Sports Med</source>. <year>2007</year>;<volume>37</volume>:<fpage>881</fpage>-<lpage>894</lpage>.<pub-id pub-id-type="pmid">17887812</pub-id></mixed-citation>
      </ref>
      <ref id="bibr20-1941738114540445">
        <label>20.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McKnight</surname><given-names>CM</given-names></name><name><surname>Ferrara</surname><given-names>MS</given-names></name><name><surname>Czerwinska</surname><given-names>JM</given-names></name></person-group>
<article-title>Intercollegiate ice hockey injuries: a three-year analysis</article-title>. <source>J Athl Train</source>. <year>1992</year>;<volume>27</volume>:<fpage>338</fpage>-<lpage>343</lpage>.<pub-id pub-id-type="pmid">16558189</pub-id></mixed-citation>
      </ref>
      <ref id="bibr21-1941738114540445">
        <label>21.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meeuwisse</surname><given-names>WH</given-names></name><name><surname>Love</surname><given-names>EJ</given-names></name></person-group>
<article-title>Development, implementation, and validation of the Canadian Intercollegiate Sport Injury Registry</article-title>. <source>Clin J Sport Med</source>. <year>1998</year>;<volume>8</volume>:<fpage>164</fpage>-<lpage>177</lpage>.<pub-id pub-id-type="pmid">9762475</pub-id></mixed-citation>
      </ref>
      <ref id="bibr22-1941738114540445">
        <label>22.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mihalik</surname><given-names>JP</given-names></name><name><surname>Blackburn</surname><given-names>JT</given-names></name><name><surname>Greenwald</surname><given-names>RM</given-names></name><name><surname>Cantu</surname><given-names>RC</given-names></name><name><surname>Marshall</surname><given-names>SW</given-names></name><name><surname>Guskiewicz</surname><given-names>KM</given-names></name></person-group>
<article-title>Collision type and player anticipation affect head impact severity among youth ice hockey players</article-title>. <source>Pediatrics</source>. <year>2010</year>;<volume>125</volume>:<fpage>e1394</fpage>-<lpage>1401</lpage>.<pub-id pub-id-type="pmid">20478933</pub-id></mixed-citation>
      </ref>
      <ref id="bibr23-1941738114540445">
        <label>23.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mihalik</surname><given-names>JP</given-names></name><name><surname>Guskiewicz</surname><given-names>KM</given-names></name><name><surname>Marshall</surname><given-names>SW</given-names></name><name><surname>Blackburn</surname><given-names>JT</given-names></name><name><surname>Cantu</surname><given-names>RC</given-names></name><name><surname>Greenwald</surname><given-names>RM</given-names></name></person-group>
<article-title>Head impact biomechanics in youth hockey: comparisons across playing position, event types, and impact locations</article-title>. <source>Ann Biomed Eng</source>. <year>2012</year>;<volume>40</volume>:<fpage>141</fpage>-<lpage>149</lpage>.<pub-id pub-id-type="pmid">22012083</pub-id></mixed-citation>
      </ref>
      <ref id="bibr24-1941738114540445">
        <label>24.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Molsa</surname><given-names>J</given-names></name><name><surname>Airaksinen</surname><given-names>O</given-names></name><name><surname>Nasman</surname><given-names>O</given-names></name><name><surname>Torstila</surname><given-names>I</given-names></name></person-group>
<article-title>Ice hockey injuries in Finland. A prospective epidemiologic study</article-title>. <source>Am J Sports Med</source>. <year>1997</year>;<volume>25</volume>:<fpage>495</fpage>-<lpage>499</lpage>.<pub-id pub-id-type="pmid">9240983</pub-id></mixed-citation>
      </ref>
      <ref id="bibr25-1941738114540445">
        <label>25.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Noyes</surname><given-names>FR</given-names></name><name><surname>Lindenfeld</surname><given-names>TN</given-names></name><name><surname>Marshall</surname><given-names>MT</given-names></name></person-group>
<article-title>What determines an athletic injury (definition)? Who determines an injury (occurrence)?</article-title>
<source>Am J Sports Med</source>. <year>1988</year>;<volume>16</volume>(<issue>suppl 1</issue>):<fpage>S65</fpage>-<lpage>S68</lpage>.<pub-id pub-id-type="pmid">3414890</pub-id></mixed-citation>
      </ref>
      <ref id="bibr26-1941738114540445">
        <label>26.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Orchard</surname><given-names>J</given-names></name><name><surname>Marsden</surname><given-names>J</given-names></name><name><surname>Lord</surname><given-names>S</given-names></name><name><surname>Garlick</surname><given-names>D</given-names></name></person-group>
<article-title>Preseason hamstring muscle weakness associated with hamstring muscle injury in Australian footballers</article-title>. <source>Am J Sports Med</source>. <year>1997</year>;<volume>25</volume>:<fpage>81</fpage>-<lpage>85</lpage>.<pub-id pub-id-type="pmid">9006698</pub-id></mixed-citation>
      </ref>
      <ref id="bibr27-1941738114540445">
        <label>27.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ostenberg</surname><given-names>A</given-names></name><name><surname>Roos</surname><given-names>H</given-names></name></person-group>
<article-title>Injury risk factors in female European football. A prospective study of 123 players during one season</article-title>. <source>Scand J Med Sci Sports</source>. <year>2000</year>;<volume>10</volume>:<fpage>279</fpage>-<lpage>285</lpage>.<pub-id pub-id-type="pmid">11001395</pub-id></mixed-citation>
      </ref>
      <ref id="bibr28-1941738114540445">
        <label>28.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peduzzi</surname><given-names>P</given-names></name><name><surname>Concato</surname><given-names>J</given-names></name><name><surname>Kemper</surname><given-names>E</given-names></name><name><surname>Holford</surname><given-names>TR</given-names></name><name><surname>Feinstein</surname><given-names>AR</given-names></name></person-group>
<article-title>A simulation study of the number of events per variable in logistic regression analysis</article-title>. <source>J Clin Epidemiol</source>. <year>1996</year>;<volume>49</volume>:<fpage>1373</fpage>-<lpage>1379</lpage>.<pub-id pub-id-type="pmid">8970487</pub-id></mixed-citation>
      </ref>
      <ref id="bibr29-1941738114540445">
        <label>29.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pelletier</surname><given-names>RL</given-names></name><name><surname>Montelpare</surname><given-names>WJ</given-names></name><name><surname>Stark</surname><given-names>RM</given-names></name></person-group>
<article-title>Intercollegiate ice hockey injuries. A case for uniform definitions and reports</article-title>. <source>Am J Sports Med</source>. <year>1993</year>;<volume>21</volume>:<fpage>78</fpage>-<lpage>81</lpage>.<pub-id pub-id-type="pmid">8427373</pub-id></mixed-citation>
      </ref>
      <ref id="bibr30-1941738114540445">
        <label>30.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pettersson</surname><given-names>M</given-names></name><name><surname>Lorentzon</surname><given-names>R</given-names></name></person-group>
<article-title>Ice hockey injuries: a 4-year prospective study of a Swedish elite ice hockey team</article-title>. <source>Br J Sports Med</source>. <year>1993</year>;<volume>27</volume>:<fpage>251</fpage>-<lpage>254</lpage>.<pub-id pub-id-type="pmid">8130963</pub-id></mixed-citation>
      </ref>
      <ref id="bibr31-1941738114540445">
        <label>31.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pinto</surname><given-names>M</given-names></name><name><surname>Kuhn</surname><given-names>JE</given-names></name><name><surname>Greenfield</surname><given-names>ML</given-names></name><name><surname>Hawkins</surname><given-names>RJ</given-names></name></person-group>
<article-title>Prospective analysis of ice hockey injuries at the Junior A level over the course of one season</article-title>. <source>Clin J Sport Med</source>. <year>1999</year>;<volume>9</volume>:<fpage>70</fpage>-<lpage>74</lpage>.<pub-id pub-id-type="pmid">10442620</pub-id></mixed-citation>
      </ref>
      <ref id="bibr32-1941738114540445">
        <label>32.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reed</surname><given-names>N</given-names></name><name><surname>Taha</surname><given-names>T</given-names></name><name><surname>Keightley</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Measurement of head impacts in youth ice hockey players</article-title>. <source>Int J Sports Med</source>. <year>2010</year>;<volume>31</volume>:<fpage>826</fpage>-<lpage>833</lpage>.<pub-id pub-id-type="pmid">20830655</pub-id></mixed-citation>
      </ref>
      <ref id="bibr33-1941738114540445">
        <label>33.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ritti-Dias</surname><given-names>RM</given-names></name><name><surname>Avelar</surname><given-names>A</given-names></name><name><surname>Salvador</surname><given-names>EP</given-names></name><name><surname>Cyrino</surname><given-names>ES</given-names></name></person-group>
<article-title>Influence of previous experience on resistance training on reliability of one-repetition maximum test</article-title>. <source>J Strength Cond Res</source>. <year>2011</year>;<volume>25</volume>:<fpage>1418</fpage>-<lpage>1422</lpage>.<pub-id pub-id-type="pmid">21522076</pub-id></mixed-citation>
      </ref>
      <ref id="bibr34-1941738114540445">
        <label>34.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sim</surname><given-names>FH</given-names></name><name><surname>Simonet</surname><given-names>WT</given-names></name><name><surname>Melton</surname><given-names>LJ</given-names><suffix>3rd</suffix></name><name><surname>Lehn</surname><given-names>TA</given-names></name></person-group>
<article-title>Ice hockey injuries</article-title>. <source>Am J Sports Med</source>. <year>1987</year>;<volume>15</volume>:<fpage>30</fpage>-<lpage>40</lpage>.<pub-id pub-id-type="pmid">3812859</pub-id></mixed-citation>
      </ref>
      <ref id="bibr35-1941738114540445">
        <label>35.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smith</surname><given-names>AM</given-names></name><name><surname>Stuart</surname><given-names>MJ</given-names></name><name><surname>Wiese-Bjornstal</surname><given-names>DM</given-names></name><name><surname>Gunnon</surname><given-names>C</given-names></name></person-group>
<article-title>Predictors of injury in ice hockey players. A multivariate, multidisciplinary approach</article-title>. <source>Am J Sports Med</source>. <year>1997</year>;<volume>25</volume>:<fpage>500</fpage>-<lpage>507</lpage>.<pub-id pub-id-type="pmid">9240984</pub-id></mixed-citation>
      </ref>
      <ref id="bibr36-1941738114540445">
        <label>36.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stevens</surname><given-names>ST</given-names></name><name><surname>Lassonde</surname><given-names>M</given-names></name><name><surname>de Beaumont</surname><given-names>L</given-names></name><name><surname>Keenan</surname><given-names>JP</given-names></name></person-group>
<article-title>In-game fatigue influences concussions in national hockey league players</article-title>. <source>Res Sports Med</source>. <year>2008</year>;<volume>16</volume>:<fpage>68</fpage>-<lpage>74</lpage>.<pub-id pub-id-type="pmid">18373290</pub-id></mixed-citation>
      </ref>
      <ref id="bibr37-1941738114540445">
        <label>37.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stuart</surname><given-names>MJ</given-names></name><name><surname>Smith</surname><given-names>A</given-names></name></person-group>
<article-title>Injuries in Junior A ice hockey. A three-year prospective study</article-title>. <source>Am J Sports Med</source>. <year>1995</year>;<volume>23</volume>:<fpage>458</fpage>-<lpage>461</lpage>.<pub-id pub-id-type="pmid">7573657</pub-id></mixed-citation>
      </ref>
      <ref id="bibr38-1941738114540445">
        <label>38.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tegner</surname><given-names>Y</given-names></name><name><surname>Lorentzon</surname><given-names>R</given-names></name></person-group>
<article-title>Ice hockey injuries: incidence, nature and causes</article-title>. <source>Br J Sports Med</source>. <year>1991</year>;<volume>25</volume>:<fpage>87</fpage>-<lpage>89</lpage>.<pub-id pub-id-type="pmid">1751895</pub-id></mixed-citation>
      </ref>
      <ref id="bibr39-1941738114540445">
        <label>39.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tsigilis</surname><given-names>N</given-names></name><name><surname>Douda</surname><given-names>H</given-names></name><name><surname>Tokmakidis</surname><given-names>SP</given-names></name></person-group>
<article-title>Test-retest reliability of the Eurofit test battery administered to university students</article-title>. <source>Percept Mot Skills</source>. <year>2002</year>;<volume>95</volume>(<issue>3 pt 2</issue>):<fpage>1295</fpage>-<lpage>1300</lpage>.<pub-id pub-id-type="pmid">12578274</pub-id></mixed-citation>
      </ref>
      <ref id="bibr40-1941738114540445">
        <label>40.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Turbeville</surname><given-names>SD</given-names></name><name><surname>Cowan</surname><given-names>LD</given-names></name><name><surname>Owen</surname><given-names>WL</given-names></name><name><surname>Asal</surname><given-names>NR</given-names></name><name><surname>Anderson</surname><given-names>MA</given-names></name></person-group>
<article-title>Risk factors for injury in high school football players</article-title>. <source>Am J Sports Med</source>. <year>2003</year>;<volume>31</volume>:<fpage>974</fpage>-<lpage>980</lpage>.<pub-id pub-id-type="pmid">14623666</pub-id></mixed-citation>
      </ref>
      <ref id="bibr41-1941738114540445">
        <label>41.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tyler</surname><given-names>TF</given-names></name><name><surname>Nicholas</surname><given-names>SJ</given-names></name><name><surname>Campbell</surname><given-names>RJ</given-names></name><name><surname>Donellan</surname><given-names>S</given-names></name><name><surname>McHugh</surname><given-names>MP</given-names></name></person-group>
<article-title>The effectiveness of a preseason exercise program to prevent adductor muscle strains in professional ice hockey players</article-title>. <source>Am J Sports Med</source>. <year>2002</year>;<volume>30</volume>:<fpage>680</fpage>-<lpage>683</lpage>.<pub-id pub-id-type="pmid">12239001</pub-id></mixed-citation>
      </ref>
      <ref id="bibr42-1941738114540445">
        <label>42.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tyler</surname><given-names>TF</given-names></name><name><surname>Nicholas</surname><given-names>SJ</given-names></name><name><surname>Campbell</surname><given-names>RJ</given-names></name><name><surname>McHugh</surname><given-names>MP</given-names></name></person-group>
<article-title>The association of hip strength and flexibility with the incidence of adductor muscle strains in professional ice hockey players</article-title>. <source>Am J Sports Med</source>. <year>2001</year>;<volume>29</volume>:<fpage>124</fpage>-<lpage>128</lpage>.<pub-id pub-id-type="pmid">11292035</pub-id></mixed-citation>
      </ref>
      <ref id="bibr43-1941738114540445">
        <label>43.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vittinghoff</surname><given-names>E</given-names></name><name><surname>McCulloch</surname><given-names>CE</given-names></name></person-group>
<article-title>Relaxing the rule of ten events per variable in logistic and Cox regression</article-title>. <source>Am J Epidemiol</source>. <year>2007</year>;<volume>165</volume>:<fpage>710</fpage>-<lpage>718</lpage>.<pub-id pub-id-type="pmid">17182981</pub-id></mixed-citation>
      </ref>
      <ref id="bibr44-1941738114540445">
        <label>44.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Warsh</surname><given-names>JM</given-names></name><name><surname>Constantin</surname><given-names>SA</given-names></name><name><surname>Howard</surname><given-names>A</given-names></name><name><surname>Macpherson</surname><given-names>A</given-names></name></person-group>
<article-title>A systematic review of the association between body checking and injury in youth ice hockey</article-title>. <source>Clin J Sport Med</source>. <year>2009</year>;<volume>19</volume>:<fpage>134</fpage>-<lpage>144</lpage>.<pub-id pub-id-type="pmid">19451769</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:4272693</identifier><datestamp>2016-01-01</datestamp><setSpec>sportshealth</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="http://jats.nlm.nih.gov/ns/archiving/1.0/ http://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Sports Health</journal-id>
      <journal-id journal-id-type="iso-abbrev">Sports Health</journal-id>
      <journal-id journal-id-type="publisher-id">SPH</journal-id>
      <journal-id journal-id-type="hwp">spsph</journal-id>
      <journal-title-group>
        <journal-title>Sports Health</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1941-7381</issn>
      <issn pub-type="epub">1941-0921</issn>
      <publisher>
        <publisher-name>SAGE Publications</publisher-name>
        <publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4272693</article-id>
      <article-id pub-id-type="pmcid">PMC4272693</article-id>
      <article-id pub-id-type="pmc-uid">4272693</article-id>
      <article-id pub-id-type="pmid">25553214</article-id>
      <article-id pub-id-type="doi">10.1177/1941738114548413</article-id>
      <article-id pub-id-type="publisher-id">10.1177_1941738114548413</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Current Research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>A Double-Blinded Placebo Randomized Controlled Trial Evaluating Short-term Efficacy of Platelet-Rich Plasma in Reducing Postoperative Pain After Arthroscopic Rotator Cuff Repair</article-title>
        <subtitle>A Pilot Study</subtitle>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Hak</surname>
            <given-names>Alisha</given-names>
          </name>
          <degrees>MSc (cand)</degrees>
          <xref ref-type="aff" rid="aff1-1941738114548413">†</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rajaratnam</surname>
            <given-names>Krishan</given-names>
          </name>
          <degrees>BSc, MD, FRCSC</degrees>
          <xref ref-type="aff" rid="aff1-1941738114548413">†</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ayeni</surname>
            <given-names>Olufemi R.</given-names>
          </name>
          <degrees>MD, MSc, FRCSC</degrees>
          <xref ref-type="aff" rid="aff1-1941738114548413">†</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Moro</surname>
            <given-names>Jaydeep</given-names>
          </name>
          <degrees>MD, FRCSC</degrees>
          <xref ref-type="aff" rid="aff1-1941738114548413">†</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Peterson</surname>
            <given-names>Devin</given-names>
          </name>
          <degrees>MD, FRCSC</degrees>
          <xref ref-type="aff" rid="aff1-1941738114548413">†</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sprague</surname>
            <given-names>Sheila</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref ref-type="aff" rid="aff1-1941738114548413">†</xref>
          <xref ref-type="aff" rid="aff2-1941738114548413">‡</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bhandari</surname>
            <given-names>Mohit</given-names>
          </name>
          <degrees>MD, PhD, FRCSC</degrees>
          <xref ref-type="corresp" rid="corresp1-1941738114548413">*</xref>
          <xref ref-type="aff" rid="aff1-1941738114548413">†</xref>
          <xref ref-type="aff" rid="aff2-1941738114548413">‡</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1-1941738114548413"><label>†</label>Division of Orthopaedic Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada</aff>
      <aff id="aff2-1941738114548413"><label>‡</label>Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada</aff>
      <author-notes>
        <corresp id="corresp1-1941738114548413"><label>*</label>Mohit Bhandari, MD, PhD, FRCSC, 293 Wellington Street North, Suite 110, Hamilton, Ontario, L8L 8E7, Canada (e-mail: <email>bhandam@mcmaster.ca</email>).</corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>1</day>
        <month>1</month>
        <year>2016</year>
      </pub-date>
      <!-- PMC Release delay is 12 months and 0 days and was based on the <pub-date pub-type="ppub"/>. -->
      <volume>7</volume>
      <issue>1</issue>
      <fpage>58</fpage>
      <lpage>66</lpage>
      <permissions>
        <copyright-statement>© 2014 The Author(s)</copyright-statement>
        <copyright-year>2014</copyright-year>
        <copyright-holder content-type="sage">American Orthopaedic Society for Sports Medicine</copyright-holder>
      </permissions>
      <abstract>
        <sec id="section1-1941738114548413">
          <title>Background:</title>
          <p>We aimed to determine whether patients with arthroscopically repaired rotator cuff (RC) tears would have reduced pain and improved function after ultrasound-guided platelet-rich plasma (PRP) injections compared with placebo injection.</p>
        </sec>
        <sec id="section2-1941738114548413">
          <title>Hypothesis:</title>
          <p>PRP compared with placebo (saline) was more effective in reducing pain at the site of an RC injury that has undergone arthroscopic repair.</p>
        </sec>
        <sec id="section3-1941738114548413">
          <title>Study Design:</title>
          <p>Randomized controlled trial.</p>
        </sec>
        <sec id="section4-1941738114548413">
          <title>Level of Evidence:</title>
          <p>Level 2.</p>
        </sec>
        <sec id="section5-1941738114548413">
          <title>Methods:</title>
          <p>We conducted a 2-centered, blinded, randomized controlled trial comparing the level of pain in patients undergoing arthroscopic repair. Patients were randomized to either PRP or saline (placebo). They received 2 ultrasound-guided injections of the randomized product: 1 intraoperatively and 1 at 4 weeks postoperatively. The primary outcome measure was shoulder pain demonstrated using a visual analog scale (VAS) at 6 weeks postoperatively. Secondary outcomes included the EuroQol-5 Dimensions (EQ-5D); the Western Ontario Rotator Cuff Index (WORC); and the Disabilities of the Arm, Shoulder, and Hand Score (DASH), as well as adverse events and revision surgeries. Patients were assessed clinically preoperatively and at 2, 4, and 6 weeks postsurgery. A prespecified interim analysis was conducted after 50% of patients were recruited and followed.</p>
        </sec>
        <sec id="section6-1941738114548413">
          <title>Results:</title>
          <p>We recruited 25 patients when interim power analysis led to an early trial termination. Follow-up was 96%. The mean difference between groups was not statistically significant (–1.81; 95% CI, –4.3 to 1.2; <italic>P</italic> = 0.16). The EQ-5D, WORC, and DASH scores also did not show significant differences between groups at week 6 (<italic>P</italic> = 0.5, 0.99, and 0.9, respectively). There were no revision surgeries, and 4 adverse events (3 PRP, 1 saline).</p>
        </sec>
        <sec id="section7-1941738114548413">
          <title>Conclusion:</title>
          <p>There was no statistical difference in outcome measures when augmenting arthroscopically repaired RC tears with PRP.</p>
        </sec>
        <sec id="section8-1941738114548413">
          <title>Clinical Relevance:</title>
          <p>Identifying therapies that improve outcomes in patients with RC tears remains a challenge and deserves ongoing investigation.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>platelet-rich plasma</kwd>
        <kwd>arthroscopy</kwd>
        <kwd>rotator cuff</kwd>
        <kwd>pain</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>January/February 2015</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <p>Rotator cuff (RC) tears are a common cause of shoulder pain.<sup><xref rid="bibr4-1941738114548413" ref-type="bibr">4</xref>,<xref rid="bibr18-1941738114548413" ref-type="bibr">18</xref></sup> With a rapidly aging population, degenerative RC tears will become an increasingly prevalent clinical problem.<sup><xref rid="bibr15-1941738114548413" ref-type="bibr">15</xref></sup> Surgery can improve patient outcome, but impaired healing, surgical site infection, shoulder stiffness, and iatrogenic tendon injury have a relatively high prevalence at approximately 6% to 11%.<sup><xref rid="bibr20-1941738114548413" ref-type="bibr">20</xref></sup> Postoperative RC re-tears have been shown to occur in 11% to 94% of RC repairs, depending on the size of the tear and the level of tendon degeneration.<sup><xref rid="bibr9-1941738114548413" ref-type="bibr">9</xref>,<xref rid="bibr21-1941738114548413" ref-type="bibr">21</xref></sup> There is a recent trend in using whole blood and its derivatives to promote the healing process and decreased pain associated with tendon tears.<sup><xref rid="bibr2-1941738114548413" ref-type="bibr">2</xref>,<xref rid="bibr8-1941738114548413" ref-type="bibr">8</xref></sup></p>
    <p>Platelet-rich plasma (PRP) contains high concentrations of platelets that, once activated, undergo degranulation to release growth factors with healing properties.<sup><xref rid="bibr1-1941738114548413" ref-type="bibr">1</xref></sup> These growth factors include, but are not limited to, platelet-derived growth factor, which stimulates cell mitosis; transforming growth factor β, which is implicated in collagen synthesis and morphogenesis; and vascular endothelial growth factor, which helps induce endothelial cell proliferation and migration, thus initiating the angiogenic response.<sup><xref rid="bibr11-1941738114548413" ref-type="bibr">11</xref>,<xref rid="bibr19-1941738114548413" ref-type="bibr">19</xref>,<xref rid="bibr22-1941738114548413" ref-type="bibr">22</xref></sup> Furthermore, platelets have been identified to have analgesic properties by releasing protease-activated receptor 4 peptides.<sup><xref rid="bibr2-1941738114548413" ref-type="bibr">2</xref></sup> In 2010, at the beginning of the current study, no randomized controlled trial had been completed examining the effect of PRP on arthroscopic RC repair surgery.</p>
    <p>The primary objective of the current study was to determine whether patients treated with arthroscopic RC repair receiving either PRP or normal saline (placebo) intraoperatively and postoperatively at 4 weeks experienced less perioperative pain, as measured by the visual analog scale (VAS). Secondary objectives aimed to evaluate the effect of PRP versus normal saline on function and health-related quality of life metrics in the perioperative period and compare the rates of adverse events and revision surgeries. The primary hypothesis for this study is that PRP compared with placebo was more effective in reducing pain at the site of a RC injury that has undergone arthroscopic repair.</p>
    <sec sec-type="methods" id="section9-1941738114548413">
      <title>Methods</title>
      <sec id="section10-1941738114548413">
        <title>Study Overview</title>
        <p>We conducted a prospective, randomized, controlled, double-blind trial comparing PRP and normal saline (placebo) in patients undergoing arthroscopic RC repair. In this study, “double-blind” includes study patients and data analyzers, including the Central Adjudication Committee (CAC). Prior to the initiation of this study, approval (REB #10-403) was obtained from the McMaster University / Hamilton Health Sciences Research Ethics Board. Two surgeons (K.R. and O.A.) at 2 clinical centres within Hamilton Health Sciences (McMaster University Medical Center and Hamilton General Site) participated in this study. Briefly, patients with RC tears who provided informed consent were randomized to receive either PRP or normal saline during their arthroscopic RC repair surgery and at 4 weeks after their arthroscopy procedure. Patients completed demographic and baseline questionnaires prior to their surgery. Patients were assessed at 2, 4, and 6 weeks postoperatively (<xref ref-type="fig" rid="fig1-1941738114548413">Figure 1</xref>). The study aimed to include 50 patients based on an initial power calculation; however, a prespecified interim analysis was conducted after 50% recruitment to evaluate efficacy and statistical power. At the time of the interim analysis, it was determined that for a statistically significant difference in VAS pain score between the treatment and control groups, based on the current scores, a much larger sample would be required. The study stopped because of futility.</p>
        <fig id="fig1-1941738114548413" position="float">
          <label>Figure 1.</label>
          <caption>
            <p>Flow diagram of study methodology. PRP, platelet-rich plasma; VAS, visual analog scale.</p>
          </caption>
          <graphic xlink:href="10.1177_1941738114548413-fig1"/>
        </fig>
      </sec>
      <sec id="section11-1941738114548413">
        <title>Patient Recruitment and Eligibility Criteria</title>
        <p>All patients scheduled for arthroscopic RC repair surgery with the participating surgeons during the recruitment period, from October 2010 to July 2012, were screened for eligibility. Reasons for ineligibility were documented. Patients were enrolled in the study if they met the criteria outlined in <xref ref-type="table" rid="table1-1941738114548413">Table 1</xref>. A blinded CAC, composed of 3 orthopaedic surgeons (M.B., J.M., and D.P.), independently assessed patients whose eligibility was in doubt to confirm their eligibility.</p>
        <table-wrap id="table1-1941738114548413" position="float">
          <label>Table 1.</label>
          <caption>
            <p>Inclusion and exclusion criteria</p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" span="1"/>
            </colgroup>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">Inclusion criteria<break/> Men or women between 18 and 70 years of age<break/> Primary, traumatic, or degenerative rotator cuff tears measuring 3 cm or less<break/> Rotator cuff tears requiring arthroscopic repair within 18 months of initial diagnosis<break/> Provision of informed consent</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Exclusion criteria<break/> Rotator cuff tears secondary to fracture<break/> Patients with an associated dislocation at the time of randomization<break/> Rotator cuff tears that underwent prior surgical repair or revision arthroscopy<break/> Nonsurgical rotator cuff–associated treatment in the 1 month prior to randomization including corticosteroid injection and anti-inflammatory treatment<break/> Prior platelet-rich plasma injection<break/> Preexisting conditions associated with upper extremity pain, including arthritis, ongoing infection, carpal tunnel syndrome, cervical neuropathy or other nerve pathology, local malignancy, and systemic disorders (eg, uncontrolled diabetes, hypothyroidism)<break/> Gross shoulder instability<break/> Active infection<break/> Pregnant or plan to become pregnant in the next 12 months<break/> Preoperative platelet count less than 125,000 and preoperative hemoglobin of 7.5 g/dL or less<break/> Likely problems with follow-up (eg, patients with no fixed address, report a plan to move out of town, or intellectually challenged patients without adequate family support)<break/> Do not read and speak English<break/> In another ongoing trial that would interfere with the assessment of the primary or secondary outcomes<break/> Any other reason (in the judgment of the surgeon)</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="section12-1941738114548413">
        <title>Randomization</title>
        <p>Eligible patients providing informed consent were randomized prior to surgery using an Internet-based randomization system to ensure concealment of patient allocation. Random variable block sizes were used to avoid an imbalance in the number of patients assigned to each treatment group. Patients were randomized to have their RC tear repairs augmented with either PRP or normal saline (placebo), receiving injections intraoperatively and again at 4 weeks postoperatively.</p>
      </sec>
      <sec id="section13-1941738114548413">
        <title>Operative Technique</title>
        <p>All operations were performed under general anesthesia, with patients positioned in the beach chair position. Surgery commenced with a diagnostic arthroscopy of the glenohumeral joint. The cuff tear size was evaluated using a calibrated probe. A full subacromial bursectomy was performed. An acromioplasty was performed with release of the coracoacromial ligament and bony overhang of the acromion. The greater tuberosity was then further prepared. Next, a small awl was hand-tapped to make the pilot hole in the greater tuberosity for an Arthrex 5.5-mm BioCorkscrew suture anchor insertion. The anchor was then inserted in the mid-greater tuberosity footprint area. Each anchor was double loaded with number 2 Fibrewire sutures. One anchor was inserted for each centimeter of the supraspinatus and/or infraspinatus tear that required repair. The repair incorporated any delaminated areas. A single row repair was performed.</p>
      </sec>
      <sec id="section14-1941738114548413">
        <title>Platelet-Rich Plasma Preparation and Trial Interventions</title>
        <p>PRP was prepared using the Arthrex Autologous Conditioned Plasma (ACP) Double Syringe System (Arthrex, Inc). This system allows for rapid and efficient concentration of platelets and growth factors from autologous blood for use at the treatment site.</p>
        <p>The surgeon performed the intraoperative injection of either the prepared PRP or normal saline under direct visualization. Patients randomized to the normal saline group received a normal saline injection (6-9 mL). For patients randomized to the PRP group, half of the PRP volume (6-9 mL total volume) was injected directly into the RC tendon under direct visualization in several positions along the repair site (articular side). The injecting needle was then placed in the subacromial space, and all instrumentation was removed before performing the skin closure. After the skin closure, the subacromial space was suctioned of residual fluid, and the remaining PRP (3-4.5 mL) was injected into the subacromial space.</p>
        <p>At the 4-week visit, under ultrasound guidance, the second PRP or normal saline injection (depending on randomization) was administered by the attending surgeon, trained to use a SonoSite Ultrasound (Bothwell). Blood draw was performed using an 18- to 20-gauge needle for all patients to maintain blinding. A 3-mL lidocaine skin injection was first administered to raise a skin wheal. Using a 22- to 25-gauge needle, 1 to 2 mL of the randomized product was injected at the supraspinatus tendon–bone interface, and the rest was injected on top of the supraspinatus tissue in the subacromial space (2-3 mL).</p>
      </sec>
      <sec id="section15-1941738114548413">
        <title>Postoperative Care</title>
        <p>Patients were all discharged home on the day of surgery. The use of an ice pack was recommended, and Percocet was permitted for the first 48 hours postoperatively. All other postoperative pain management methods were avoided, including regional nerve blocks, pain pumps, and injections of any pain medication. Standard physiotherapy guidelines were followed.</p>
      </sec>
      <sec id="section16-1941738114548413">
        <title>Patient Follow-up</title>
        <p>Patients were assessed in the perioperative period by their attending surgeon at 2, 4, and 6 weeks postsurgery. The patients completed the VAS for pain and quality of life and functional questionnaires at each of these clinic visits. They were also asked about adverse events and reoperations, and this information was verified by their surgeon and by a review of their medical records.</p>
      </sec>
      <sec id="section17-1941738114548413">
        <title>Outcome Measures</title>
        <p>The primary outcome was change in pain severity, measured using a VAS at 6 weeks postsurgery. Patients were asked to rate their worst pain in their shoulder for the previous 24 hours on a 10-cm vertical scale, with “0” indicating no pain at all and “10” indicating the worst pain the patient could imagine. The VAS is considered to be a sensitive measure that is able to detect small changes in an individual’s perception of pain severity.<sup><xref rid="bibr5-1941738114548413" ref-type="bibr">5</xref></sup> This instrument is widely used and considered a more valid determinant of increases or decreases in pain over time than a questionnaire with a select number of responses, with good construct validity and high internal consistency.<sup><xref rid="bibr5-1941738114548413" ref-type="bibr">5</xref></sup></p>
        <p>Secondary outcome measures include the EuroQol-5 Dimensions (EQ-5D), the Western Ontario Rotator Cuff Index (WORC), and the Disabilities of the Arm, Shoulder, and Hand Score (DASH) administered prior to the surgical intervention and at 2, 4, and 6 weeks postsurgery, as well as incidence of revision surgeries and adverse events.</p>
        <p>Briefly, the EQ-5D is a comprehensive, compact health status classification and health state preference system.<sup><xref rid="bibr16-1941738114548413" ref-type="bibr">16</xref></sup> This questionnaire is widely used and has demonstrated validity and sensitivity in many populations. It is scored from −0.11 to 1.0, wherein 1.0 is perfect health and 0 is death.<sup><xref rid="bibr6-1941738114548413" ref-type="bibr">6</xref></sup></p>
        <p>The WORC is a self-administered, 21-item questionnaire that assesses 5 domains, including pain and physical symptoms, sports and recreation, work function, social function, and emotional function. This instrument is a valid, reliable, and responsive measure of outcome specific to RC injuries.<sup><xref rid="bibr12-1941738114548413" ref-type="bibr">12</xref>,<xref rid="bibr16-1941738114548413" ref-type="bibr">16</xref>,<xref rid="bibr17-1941738114548413" ref-type="bibr">17</xref></sup></p>
        <p>The DASH is a 30-item, self-reported questionnaire designed to measure physical function and symptoms in patients with musculoskeletal disorders of the upper limb. In addition to its wide use in evaluating function in orthopaedic patients, the DASH has been extensively validated and is a reliable and responsive measure.<sup><xref rid="bibr3-1941738114548413" ref-type="bibr">3</xref>,<xref rid="bibr10-1941738114548413" ref-type="bibr">10</xref>,<xref rid="bibr13-1941738114548413" ref-type="bibr">13</xref></sup></p>
        <p>Any adverse events and complications deemed related to the affected shoulder by the reporting surgeon were documented. Revision surgeries were defined as any secondary operative procedures at the affected shoulder site. Planned secondary interventions from initial surgical procedures were not considered outcome events.</p>
      </sec>
      <sec id="section18-1941738114548413">
        <title>Adjudication of Adverse Events</title>
        <p>The blinded CAC reviewed all reoperations and adverse events to see if they were related to the injected product and to be considered an outcome event. After independent assessment, consensus was reached for each decision.</p>
      </sec>
      <sec id="section19-1941738114548413">
        <title>Data Analysis</title>
        <p>Statistical analyses were completed using SPSS for Windows 20.0.<sup><xref rid="bibr14-1941738114548413" ref-type="bibr">14</xref></sup> Descriptive statistics (frequencies for dichotomous data and means and standard deviations for continuous data) were calculated to describe the demographic characteristics of the patients. A <italic>t</italic> test was completed at 6 weeks for each of the 4 outcome measures to determine whether there was a significant difference in the mean scores between the saline group and the PRP group. A Levene test was completed first to determine whether to assume variance between the groups. The results of the Levene test for equality of variances are also provided. Analysis included <italic>t</italic> values, significance (<italic>P</italic>) values, mean differences, and 95% confidence intervals. A <italic>t</italic> test was also completed for mean difference comparing scores at 2 weeks postoperatively to those at 6 weeks postoperatively to determine whether there was a significant increase or decrease in scores when comparing the 2 groups.</p>
      </sec>
    </sec>
    <sec sec-type="results" id="section20-1941738114548413">
      <title>Results</title>
      <p>Seventy-seven patients were screened from October 2010 to July 2012. Of these, 52 were excluded and 25 patients met the study inclusion criteria and agreed to participate. The 25 patients were randomized to PRP (12 patients) and normal saline (13 patients) groups. All patients received the treatment they were randomized to. At the time of the interim analysis, 24 patients were followed until 6 weeks (12 PRP, 12 saline); 1 patient was lost to follow-up after the 4-week visit (<xref ref-type="fig" rid="fig2-1941738114548413">Figure 2</xref>). The CAC assessed eligibility in a blinded manner and determined that 5 patients were treated for tears larger than 3 cm (2 PRP, 3 saline). One of these 5 patients also had prior surgical repair. These patients were included in the primary analysis according to the intention-to-treat principle. An exploratory analysis was conducted with these 5 patients excluded.</p>
      <fig id="fig2-1941738114548413" position="float">
        <label>Figure 2.</label>
        <caption>
          <p>Flow diagram of study participants. CAC, Central Adjudication Committee; PRP, platelet-rich plasma.</p>
        </caption>
        <graphic xlink:href="10.1177_1941738114548413-fig2"/>
      </fig>
      <sec id="section21-1941738114548413">
        <title>Demographics</title>
        <p>The mean age of the study participants was 55 ± 6.4 years, and that patient age range was similar across the treatment groups (<xref ref-type="table" rid="table2-1941738114548413">Table 2</xref>). There were 19 men and 6 women, and sex was also distributed similarly across the treatment groups. Fifteen patients had an RC tear in their dominant arm. All patients had either a degenerative RC tear (48%) or a traumatic tear (52%), and the type of tear was distributed evenly across the treatment arms. In 7 cases in the PRP group and 6 in the saline group, the tears affected the supraspinatus exclusively; the other cases involved both supraspinatus and infraspinatus tears.</p>
        <table-wrap id="table2-1941738114548413" position="float">
          <label>Table 2.</label>
          <caption>
            <p>Demographic data for the platelet-rich plasma (PRP) versus saline groups</p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th rowspan="1" colspan="1"/>
                <th align="center" rowspan="1" colspan="1">PRP (N = 12), n (%)</th>
                <th align="center" rowspan="1" colspan="1">Saline (N = 13), n (%)</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">Age, y (mean ± SD)</td>
                <td rowspan="1" colspan="1">55 ± 6.3</td>
                <td rowspan="1" colspan="1">55 ± 6.4</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Male</td>
                <td rowspan="1" colspan="1">9 (75)</td>
                <td rowspan="1" colspan="1">10 (77)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Dominant<sup><xref ref-type="table-fn" rid="table-fn1-1941738114548413"><italic>a</italic></xref></sup> side affected</td>
                <td rowspan="1" colspan="1">9 (75)</td>
                <td rowspan="1" colspan="1">6 (46)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Degenerative cuff tear</td>
                <td rowspan="1" colspan="1">5 (42)</td>
                <td rowspan="1" colspan="1">7 (54)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Traumatic cuff tear</td>
                <td rowspan="1" colspan="1">7 (58)</td>
                <td rowspan="1" colspan="1">6 (46)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Supraspinatus tear</td>
                <td rowspan="1" colspan="1">7 (58)</td>
                <td rowspan="1" colspan="1">6 (46)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Supraspinatus and infraspinatus tears</td>
                <td rowspan="1" colspan="1">5 (42)</td>
                <td rowspan="1" colspan="1">7 (54)</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="table-fn1-1941738114548413">
              <label>a</label>
              <p>Dominance is the number of patients whose rotator cuff tear was in their dominant arm.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="section22-1941738114548413">
        <title>Primary Outcome: VAS Pain Scores</title>
        <p>The mean difference between the groups was not statistically significant (<italic>P</italic> = 0.16). However, there was a trend toward greater numerical improvement in the difference of VAS scores between baseline and at 6 weeks for PRP compared with saline (<xref ref-type="table" rid="table3-1941738114548413">Table 3</xref>). At 6 weeks postoperatively, the mean ± SD VAS pain scores were 3.6 ± 2.2 and 3.9 ± 3.3, respectively, for the PRP and saline groups (<italic>P</italic> = 0.80) (<xref ref-type="table" rid="table3-1941738114548413">Table 3</xref>, <xref ref-type="fig" rid="fig3-1941738114548413">Figure 3</xref>). An exploratory analysis of VAS pain scores at week 6 including only eligible patients left data for 19 patients to be analyzed, as 1 patient was lost to follow-up (10 PRP, 9 saline). In this group, mean ± SD VAS pain scores were 4.0 ± 2.8 and 3.7 ± 2.8, respectively, for the PRP and saline groups (<italic>P</italic> = 0.4). Removing these patients did not change the primary outcome.</p>
        <table-wrap id="table3-1941738114548413" position="float">
          <label>Table 3.</label>
          <caption>
            <p>Patient pain, quality of life, and function</p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="left" rowspan="1" colspan="1">Outcome Measure</th>
                <th align="center" rowspan="1" colspan="1">Visit</th>
                <th align="center" rowspan="1" colspan="1">PRP Group, Mean ± SD (SE)</th>
                <th align="center" rowspan="1" colspan="1">Saline Group, Mean ± SD (SE)</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">VAS Pain scores</td>
                <td rowspan="1" colspan="1">Baseline</td>
                <td rowspan="1" colspan="1">5.6 ± 3.3 (0.9)</td>
                <td rowspan="1" colspan="1">4.1 ± 2.9 (0.8)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Week 2</td>
                <td rowspan="1" colspan="1">5.1 ± 3.0 (0.9)</td>
                <td rowspan="1" colspan="1">4.6 ± 3.1 (0.9)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Week 4</td>
                <td rowspan="1" colspan="1">4.4 ± 2.5 (0.7)</td>
                <td rowspan="1" colspan="1">4.8 ± 2.6 (0.7)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Week 6</td>
                <td rowspan="1" colspan="1">3.6 ± 2.2 (0.6)</td>
                <td rowspan="1" colspan="1">3.9 ± 3.3 (1.0)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Standardized mean difference between baseline and week 6</td>
                <td colspan="2" rowspan="1">−1.81 (95% CI = −4.3 to 1.2), <italic>P</italic> = 0.16</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Mean difference at week 6</td>
                <td colspan="2" rowspan="1">−0.32 (95% CI = −2.7 to 2.1), <italic>P</italic> = 0.8</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">EQ-5D scores</td>
                <td rowspan="1" colspan="1">Baseline</td>
                <td rowspan="1" colspan="1">0.614 ± 0.226 (0.065)</td>
                <td rowspan="1" colspan="1">0.674 ± 0.213 (0.059)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Week 2</td>
                <td rowspan="1" colspan="1">0.596 ± 0.209 (0.060)</td>
                <td rowspan="1" colspan="1">0.596 ± 0.274 (0.079)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Week 4</td>
                <td rowspan="1" colspan="1">0.703 ± 0.103 (0.031)</td>
                <td rowspan="1" colspan="1">0.647 ± 0.244 (0.068)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Week 6</td>
                <td rowspan="1" colspan="1">0.660 ± 0.139 (0.042)</td>
                <td rowspan="1" colspan="1">0.609 ± 0.237 (0.069)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Standardized mean difference between baseline and week 6</td>
                <td colspan="2" rowspan="1">0.11 (95% CI = −0.05 to 0.28), <italic>P</italic> = 0.18</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Mean difference at week 6</td>
                <td colspan="2" rowspan="1">0.051 (95% CI = −0.118 to 0.220), <italic>P</italic> = 0.5</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">WORC scores</td>
                <td rowspan="1" colspan="1">Baseline</td>
                <td rowspan="1" colspan="1">26.1 ± 15.2 (4.4)</td>
                <td rowspan="1" colspan="1">37.3 ± 16.1 (4.5)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Week 2</td>
                <td rowspan="1" colspan="1">28.2 ± 16.0 (4.6)</td>
                <td rowspan="1" colspan="1">33.1 ± 13.6 (3.9)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Week 4</td>
                <td rowspan="1" colspan="1">35.2 ± 18.5 (5.3)</td>
                <td rowspan="1" colspan="1">44.6 ± 16.1 (4.6)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Week 6</td>
                <td rowspan="1" colspan="1">41.2 ± 17.2 (5.0)</td>
                <td rowspan="1" colspan="1">41.2 ± 21.2 (6.1)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Standardized mean difference between baseline and week 6</td>
                <td colspan="2" rowspan="1">11.3 (95% CI = −4.4 to 27.4), <italic>P</italic> = 0.15</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Mean Difference at Week 6</td>
                <td colspan="2" rowspan="1">−0.005 (95% CI = −16.4 to 16.3), <italic>P</italic> &gt; 0.999</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">DASH scores</td>
                <td rowspan="1" colspan="1">Baseline</td>
                <td rowspan="1" colspan="1">73.0 ± 16.7 (4.8)</td>
                <td rowspan="1" colspan="1">65.5 ± 17.5 (4.8)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Week 2</td>
                <td rowspan="1" colspan="1">81.9 ± 22.9 (6.6)</td>
                <td rowspan="1" colspan="1">92.2 ± 19.1 (5.5)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Week 4</td>
                <td rowspan="1" colspan="1">77.6 ± 12.7 (3.7)</td>
                <td rowspan="1" colspan="1">76.3 ± 19.6 (5.4)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Week 6</td>
                <td rowspan="1" colspan="1">70.5 ± 16.1 (4.6)</td>
                <td rowspan="1" colspan="1">69.2 ± 24.0 (6.9)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Standardized mean difference between baseline and week 6</td>
                <td colspan="2" rowspan="1">−6.1 (95% CI = −21.4 to 9.2), <italic>P</italic> = 0.48</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Mean difference at week 6</td>
                <td colspan="2" rowspan="1">1.23 (95% CI = −16.1 to 18.5), <italic>P</italic> = 0.9</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="table-fn2-1941738114548413">
              <p>DASH, Disabilities of the Arm, Shoulder and Hand score; EQ-5D, EuroQol-5 Dimensions; SE, standard error; VAS, visual analog scale; WORC, Western Ontario Rotator Cuff Index.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <fig id="fig3-1941738114548413" position="float">
          <label>Figure 3.</label>
          <caption>
            <p>Mean VAS pain scores across follow-up time points for PRP and saline groups. PRP, platelet-rich plasma; VAS, visual analog scale.</p>
          </caption>
          <graphic xlink:href="10.1177_1941738114548413-fig3"/>
        </fig>
        <p>Analysis of the treatment effect for standardized mean difference between baseline and week 6 between the 2 groups (1.81 points on the VAS scale) suggested that 150 patients would be required to achieve adequate study power. Analysis of the treatment effect for difference in mean at 6 weeks (0.3 points on the VAS scale) suggested that approximately 2400 more patients would be required to achieve adequate study power for this difference. Given the sample size requirements to find a difference in standardized mean difference between baseline and week 6 between the 2 groups, the trial was stopped early as initial enrollment plans would not approach adequate power.</p>
      </sec>
      <sec id="section23-1941738114548413">
        <title>Secondary Outcomes: HRQoL</title>
        <p>The EQ-5D scores decreased in both groups from baseline to 2 weeks, showed improvement at week 4, and decreased again at week 6 (<xref ref-type="table" rid="table3-1941738114548413">Table 3</xref>). No significant difference in scores was found between the PRP and saline groups at week 6 (<italic>P</italic> = 0.2). There was also no difference in the standardized mean difference for the groups between week 2 and week 6 (<italic>P</italic> = 0.2).</p>
        <p>In the PRP group, the WORC scores increased consistently from baseline to week 6. In the saline group, scores decreased from baseline to week 2, increased at week 4, and decreased at week 6 (<xref ref-type="table" rid="table3-1941738114548413">Table 3</xref>). Mean scores at week 6 were 41.2 in both groups, demonstrating no difference (<italic>P</italic> &gt; 0.999). Standardized mean difference between week 2 and week 6 for the groups was also insignificant (<italic>P</italic> = 0.3).</p>
        <p>In both treatment groups, the DASH scores were worse from baseline to week 2 and showed improvement at weeks 4 and 6 (<xref ref-type="table" rid="table3-1941738114548413">Table 3</xref>). No significant differences were seen between the PRP and saline groups for the standardized mean difference at week 6 (<italic>P</italic> = 0.9) or between week 2 and week 6 (<italic>P</italic> = 0.2) for the DASH scores.</p>
      </sec>
      <sec id="section24-1941738114548413">
        <title>Adverse Events and Revision Surgeries</title>
        <p>The CAC reviewed 4 adverse events: 1 case in the saline group of excessive pain, and 3 cases in the PRP group—infection at the site of injection, hand swelling from an intravenous line, and nausea and dizziness immediately postoperative. Of these, the infection in the PRP group was classified as a superficial surgical site infection and determined to be a study event. No revision surgeries occurred in either group during the 6-week follow-up period. Given the sample size, no conclusion can be made regarding differences in adverse event frequency between the 2 groups.</p>
      </sec>
    </sec>
    <sec sec-type="discussion" id="section25-1941738114548413">
      <title>Discussion</title>
      <p>At interim analysis, our study overall did not show a significant change in the standardized mean difference in VAS scores between the 2 groups at baseline and 6 weeks. In addition, our interim analysis demonstrated a lack of clinically important benefit to PRP after arthroscopic RC repair using quality of life measures at 6 weeks. Given the sample size requirements to find a difference in the standardized mean difference between the groups at the designated time points, the trial was stopped early as the initial enrollment plans would not approach adequate power. While the study could not demonstrate that the injected product influenced the pain score, the overall decrease in pain from baseline for both groups demonstrates that arthroscopic surgery to repair RC tears does provide pain relief. Five patients were confirmed by the blinded CAC to have RC tears larger than 3.0 cm, and 4 of them had pain scores documented at 6 weeks; their eventual removal from the dataset did not change the primary outcome.</p>
      <p>Secondary objectives assessing function and quality of life exhibit varying patterns. The EQ-5D scores increased and decreased in both groups at each follow-up visit, and it is not clear whether there was overall improvement or not, failing to demonstrate any statistically significant findings. Of interest, the PRP group showed slightly improved scores from baseline to 6 weeks, whereas the saline group showed slightly worsened scores. The WORC scores improved in both groups at week 6 compared with baseline, demonstrating improvement in functioning after surgical repair without any specific benefit for augmentation with PRP. The DASH scores were also relatively similar between groups, worsening immediately after surgery and improving at weeks 4 and 6. The scores at 6 weeks were very similar between the 2 groups and better in the saline group; however, the PRP group showed improvement at week 6 compared with baseline, whereas the saline group’s mean score at week 6 was worsened from baseline.</p>
      <p>No revision surgeries occurred over the 6-week follow-up period; however, there were 4 adverse events. Three of these occurred in the PRP group and 1 in the saline group. The CAC determined that the infection occurring at the site of surgery after the patient’s week 4 follow-up was to be considered a study event. No other adverse events were deemed to be study-related. Because of the small sample size, no conclusion can be made regarding differences in adverse event frequency between the 2 groups.</p>
      <p>While the present study did demonstrate some slight trends in pain reduction in the PRP group, these overall findings are consistent with the mounting literature examining the use of PRP to augment arthroscopic RC repair surgeries. A randomized controlled trial by Castricini et al<sup><xref rid="bibr7-1941738114548413" ref-type="bibr">7</xref></sup> included 88 patients who underwent arthroscopic surgery to repair a torn RC with or without an intraoperative interposition of an autologous platelet-rich fibrin matrix between the RC and bone. This study reported no difference in shoulder function between the treatment and control group using the Constant score.<sup><xref rid="bibr7-1941738114548413" ref-type="bibr">7</xref></sup> A second study by Jo et al<sup><xref rid="bibr15-1941738114548413" ref-type="bibr">15</xref></sup> offered patients a choice of whether to receive an interpositional PRP gel or not (control) during surgical RC repair. Nineteen patients received PRP and 23 did not. Similar to the present study, this study reported that there was no difference in pain scores or functional scores at any point during the follow-up period.<sup><xref rid="bibr15-1941738114548413" ref-type="bibr">15</xref></sup> Both the previously mentioned studies did not use injections, but rather matrices placed between the cuff tissue and bone at the time of surgery, and this may limit comparisons with the present study. Randelli et al<sup><xref rid="bibr20-1941738114548413" ref-type="bibr">20</xref></sup> conducted a clinical trial involving 14 patients followed for 24 months. All patients were given a PRP injection along with an autologous thrombin component intraoperatively. This study demonstrated significant decreases in VAS pain scores at 6, 12, and 24 months in comparison with preoperative scores. However, no control was used for this trial, so the results cannot be attributed to the application of PRP.<sup><xref rid="bibr20-1941738114548413" ref-type="bibr">20</xref></sup> Randelli et al<sup><xref rid="bibr21-1941738114548413" ref-type="bibr">21</xref></sup> completed another study involving 53 patients, again where PRP injections were given intraoperatively in combination with an autologous thrombin component. Block randomization was implemented, and a control group was added. They reported that pain scores in the PRP group were significantly lower at 3, 7, 14, and 30 days postoperatively. Similar to our findings, however, they found no difference in outcomes at day 30. They also noted that there was no difference in the healing rate of the 2 groups when captured and analyzed via magnetic resonance imaging.<sup><xref rid="bibr21-1941738114548413" ref-type="bibr">21</xref></sup></p>
      <p>In summary, 2 of the 3 previously conducted studies that involved a control did not report any benefit to the application of PRP intraoperatively; however, each study reported on different outcome measures, and at different time points, rendering a comparison difficult. Randelli et al<sup><xref rid="bibr21-1941738114548413" ref-type="bibr">21</xref></sup> captured pain scores immediately postoperatively at days 3, 7, 14, and 30, allowing for major differences between the treatment and control groups to be recognized. Jo et al<sup><xref rid="bibr15-1941738114548413" ref-type="bibr">15</xref></sup> and Castricini et al<sup><xref rid="bibr7-1941738114548413" ref-type="bibr">7</xref></sup> did not obtain frequent functional and pain measurements postoperatively and may have missed differences between the groups. Each trial involved an individual treatment at operation; the current trial exclusively included a second injection at 4 weeks postoperatively, allowing for the exploration of further effects that PRP may have had on pain outcomes.</p>
      <p>There are several strengths in the present study. First, the patients were all randomized and blinded to their treatment groups. All study events were independently assessed by a blinded CAC. Quality of life and pain scores were collected at frequent time points postoperatively, allowing for an increased likelihood that subtle changes may be noticed; as pain is often at its highest immediately postoperatively, this is beneficial. Furthermore, the follow-up was 96% at 6 weeks.</p>
      <p>An apparent limitation of this pilot study was the short follow-up period. Although data on pain, the primary outcome measure used for assessing the effect of PRP, were intended to be analyzed shortly after surgery, 6 weeks is an insufficient time period to capture all potential RC re-tears and revision surgeries. Another limitation of the study was the inability to screen for RC tear size before recruitment, which led to 5 patients being included with tear sizes above the 3-cm limit for inclusion. In addition, our results are primarily applicable to patients with traumatic and degenerative RC tears that are repaired initially within 18 months of diagnosis. Patients with preexisting conditions associated with upper extremity pain or systemic disorders may not have outcomes similar to those included in the present study.</p>
    </sec>
    <sec sec-type="conclusions" id="section26-1941738114548413">
      <title>Conclusion</title>
      <p>The present study demonstrated no conclusive benefit for reducing postoperative pain after augmenting arthroscopically repaired RC tears with PRP compared with saline at 6 weeks; therefore, the primary hypothesis is rejected. It failed to demonstrate that patients receiving PRP injections intraoperatively and at 4 weeks postoperatively have decreased pain and superior functional outcomes than those receiving normal saline. Identifying therapies that improve outcomes in patients with RC tears remains a challenge and deserves ongoing investigation.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>The authors thank Franca Mossuto and Lilly-Ann Reynolds for all of their assistance.</p>
    </ack>
    <fn-group>
      <fn fn-type="conflict">
        <p>The following authors declared potential conflicts of interest: Alisha Hak, BSc, and Sheila Sprague, PhD, received payment for writing or reviewing the manuscript from GRS Inc; Mohit Bhandari, MD, PhD, FRCSC, is a paid consultant for Smith &amp; Nephew, Stryker, Amgen, Zimmer, Moximed, and Bioventus.<?release-delay 12|0?></p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="bibr1-1941738114548413">
        <label>1.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Anitua</surname><given-names>E</given-names></name><name><surname>Andia</surname><given-names>I</given-names></name><name><surname>Ardanza</surname><given-names>B</given-names></name><name><surname>Nurden</surname><given-names>P</given-names></name><name><surname>Nurden</surname><given-names>AT</given-names></name></person-group>
<article-title>Autologous platelets as a source of proteins for healing and tissue regeneration</article-title>. <source>Thromb Haemost</source>. <year>2004</year>;<volume>91</volume>:<fpage>4</fpage>-<lpage>15</lpage>.<pub-id pub-id-type="pmid">14691563</pub-id></mixed-citation>
      </ref>
      <ref id="bibr2-1941738114548413">
        <label>2.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Asfaha</surname><given-names>S</given-names></name><name><surname>Cenac</surname><given-names>N</given-names></name><name><surname>Houle</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Protease-activated receptor-4: a novel mechanism of inflammatory pain modulation</article-title>. <source>Br J Pharmacol</source>. <year>2007</year>;<volume>150</volume>:<fpage>176</fpage>-<lpage>185</lpage>.<pub-id pub-id-type="pmid">17179954</pub-id></mixed-citation>
      </ref>
      <ref id="bibr3-1941738114548413">
        <label>3.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beaton</surname><given-names>DE</given-names></name><name><surname>Katz</surname><given-names>JN</given-names></name><name><surname>Fossel</surname><given-names>AH</given-names></name><name><surname>Wright</surname><given-names>JG</given-names></name><name><surname>Tarasuk</surname><given-names>V</given-names></name><name><surname>Bombardier</surname><given-names>C</given-names></name></person-group>
<article-title>Measuring the whole or the parts? Validity, reliability, and responsiveness of the Disabilities of the Arm, Shoulder and Hand outcome measure in different regions of the upper extremity</article-title>. <source>J Hand Ther</source>. <year>2001</year>;<volume>14</volume>:<fpage>128</fpage>-<lpage>146</lpage>.<pub-id pub-id-type="pmid">11382253</pub-id></mixed-citation>
      </ref>
      <ref id="bibr4-1941738114548413">
        <label>4.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Breazeale</surname><given-names>NM</given-names></name><name><surname>Craig</surname><given-names>EV</given-names></name></person-group>
<article-title>Partial-thickness rotator cuff tears. Pathogenesis and treatment</article-title>. <source>Orthop Clin North Am</source>. <year>1997</year>;<volume>28</volume>:<fpage>145</fpage>-<lpage>155</lpage>.<pub-id pub-id-type="pmid">9113711</pub-id></mixed-citation>
      </ref>
      <ref id="bibr5-1941738114548413">
        <label>5.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Briggs</surname><given-names>M</given-names></name><name><surname>Closs</surname><given-names>JS</given-names></name></person-group>
<article-title>A descriptive study of the use of visual analog scales and verbal rating scales for the assessment of postoperative pain in orthopedic patients</article-title>. <source>J Pain Symptom Manage</source>. <year>1999</year>;<volume>18</volume>:<fpage>438</fpage>-<lpage>446</lpage>.<pub-id pub-id-type="pmid">10641470</pub-id></mixed-citation>
      </ref>
      <ref id="bibr6-1941738114548413">
        <label>6.</label>
        <mixed-citation publication-type="book">
<person-group person-group-type="editor"><name><surname>Brooks</surname><given-names>R</given-names></name><name><surname>Rabin</surname><given-names>RE</given-names></name><name><surname>de Charro</surname><given-names>F</given-names></name></person-group>, eds. <source>The Measurement and Valuation of Health Status Using EQ-5D: A European Perspective</source>. <publisher-loc>Dordrecht, Netherlands</publisher-loc>: <publisher-name>Kluwer Academic</publisher-name>; <year>2003</year>.</mixed-citation>
      </ref>
      <ref id="bibr7-1941738114548413">
        <label>7.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Castricini</surname><given-names>R</given-names></name><name><surname>Longo</surname><given-names>UG</given-names></name><name><surname>De Benedetto</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Platelet-rich plasma augmentation for arthroscopic rotator cuff repair</article-title>. <source>Am J Sports Med</source>. <year>2011</year>;<volume>39</volume>:<fpage>258</fpage>-<lpage>265</lpage>.<pub-id pub-id-type="pmid">21160018</pub-id></mixed-citation>
      </ref>
      <ref id="bibr8-1941738114548413">
        <label>8.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chahal</surname><given-names>J</given-names></name><name><surname>Van Thiel</surname><given-names>GS</given-names></name><name><surname>Mall</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>The role of platelet-rich plasma in arthroscopic rotator cuff repair: a systematic review with quantitative synthesis</article-title>. <source>Arthroscopy</source>. <year>2012</year>;<volume>28</volume>:<fpage>1718</fpage>-<lpage>1727</lpage>.<pub-id pub-id-type="pmid">22694941</pub-id></mixed-citation>
      </ref>
      <ref id="bibr9-1941738114548413">
        <label>9.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cheung</surname><given-names>EV</given-names></name><name><surname>Silverio</surname><given-names>L</given-names></name><name><surname>Sperling</surname><given-names>JW</given-names></name></person-group>
<article-title>Strategies in biologic augmentation of rotator cuff repair</article-title>. <source>Clin Orthop Relat Res</source>. <year>2010</year>;<volume>468</volume>:<fpage>1476</fpage>-<lpage>1484</lpage>.<pub-id pub-id-type="pmid">20352390</pub-id></mixed-citation>
      </ref>
      <ref id="bibr10-1941738114548413">
        <label>10.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gummesson</surname><given-names>C</given-names></name><name><surname>Atroshi</surname><given-names>I</given-names></name><name><surname>Ekdahl</surname><given-names>C</given-names></name></person-group>
<article-title>The disabilities of the arm, shoulder and hand (DASH) outcome questionnaire: longitudinal construct validity and measuring self-related health change after surgery</article-title>. <source>BMC Musculoskelet Disord</source>. <year>2003</year>;<volume>4</volume>:<fpage>11</fpage>.<pub-id pub-id-type="pmid">12809562</pub-id></mixed-citation>
      </ref>
      <ref id="bibr11-1941738114548413">
        <label>11.</label>
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Hollinger</surname><given-names>JO</given-names></name><name><surname>Hart</surname><given-names>C</given-names></name><name><surname>Gruber</surname><given-names>R</given-names></name><name><surname>Doll</surname><given-names>B</given-names></name></person-group>
<article-title>Protein therapeutics and bone healing</article-title>. In: <person-group person-group-type="editor"><name><surname>Lynch</surname><given-names>SE</given-names></name><name><surname>Wisner-Lynch</surname><given-names>LA</given-names></name><name><surname>Nevins</surname><given-names>M</given-names></name><name><surname>Marx</surname><given-names>RE</given-names></name></person-group>, eds. <source>Tissue Engineering: Applications in Oral and Maxillofacial Surgery and Periodontics</source>. <edition>2nd ed.</edition>
<publisher-loc>Chicago, IL</publisher-loc>: <publisher-name>Quintessence</publisher-name>; <year>2008</year>:<fpage>3</fpage>-<lpage>25</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr12-1941738114548413">
        <label>12.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Holtby</surname><given-names>R</given-names></name><name><surname>Razmjou</surname><given-names>H</given-names></name></person-group>
<article-title>Measurement properties of the Western Ontario rotator cuff outcome measure: a preliminary report</article-title>. <source>J Shoulder Elbow Surg</source>. <year>2005</year>;<volume>14</volume>:<fpage>506</fpage>-<lpage>510</lpage>.<pub-id pub-id-type="pmid">16194742</pub-id></mixed-citation>
      </ref>
      <ref id="bibr13-1941738114548413">
        <label>13.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hudak</surname><given-names>PL</given-names></name><name><surname>Amadio</surname><given-names>PC</given-names></name><name><surname>Bombardier</surname><given-names>C</given-names></name></person-group>; <collab>The Upper Extremity Collaborative Group (UECG)</collab>. <article-title>Development of an upper extremity outcome measure: the DASH (disabilities of the arm, shoulder and hand)</article-title>. <source>Am J Ind Med</source>. <year>1996</year>;<volume>29</volume>:<fpage>602</fpage>-<lpage>608</lpage>.<pub-id pub-id-type="pmid">8773720</pub-id></mixed-citation>
      </ref>
      <ref id="bibr14-1941738114548413">
        <label>14.</label>
        <mixed-citation publication-type="book">
<collab>IBM Corp. Released</collab>
<year>2011</year>
<article-title>IBM SPSS Statistics for Windows, Version 20.0</article-title>. <publisher-loc>Armonk, NY</publisher-loc>: <publisher-name>IBM Corp</publisher-name>.</mixed-citation>
      </ref>
      <ref id="bibr15-1941738114548413">
        <label>15.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jo</surname><given-names>CH</given-names></name><name><surname>Kim</surname><given-names>JE</given-names></name><name><surname>Yoon</surname><given-names>KS</given-names></name><etal/></person-group>
<article-title>Does platelet-rich plasma accelerate recovery after rotator cuff repair?</article-title>
<source>Am J Sports Med</source>. <year>2011</year>;<volume>39</volume>:<fpage>2082</fpage>-<lpage>2090</lpage>.<pub-id pub-id-type="pmid">21737832</pub-id></mixed-citation>
      </ref>
      <ref id="bibr16-1941738114548413">
        <label>16.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kirkley</surname><given-names>A</given-names></name><name><surname>Alvarez</surname><given-names>C</given-names></name><name><surname>Griffin</surname><given-names>S</given-names></name></person-group>
<article-title>The development and evaluation of a disease-specific quality-of-life questionnaire for disorders of the rotator cuff: The Western Ontario Rotator Cuff Index</article-title>. <source>Clin J Sport Med</source>. <year>2003</year>;<volume>13</volume>:<fpage>84</fpage>-<lpage>92</lpage>.<pub-id pub-id-type="pmid">12629425</pub-id></mixed-citation>
      </ref>
      <ref id="bibr17-1941738114548413">
        <label>17.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kirkley</surname><given-names>A</given-names></name><name><surname>Griffin</surname><given-names>S</given-names></name><name><surname>Dainty</surname><given-names>K</given-names></name></person-group>
<article-title>Scoring systems for the functional assessment of the shoulder</article-title>. <source>Arthroscopy</source>. <year>2003</year>;<volume>19</volume>:<fpage>1109</fpage>-<lpage>1120</lpage>.<pub-id pub-id-type="pmid">14673454</pub-id></mixed-citation>
      </ref>
      <ref id="bibr18-1941738114548413">
        <label>18.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Matava</surname><given-names>MJ</given-names></name><name><surname>Purcell</surname><given-names>DB</given-names></name><name><surname>Rudzki</surname><given-names>JR</given-names></name></person-group>
<article-title>Partial-thickness rotator cuff tears</article-title>. <source>Am J Sports Med</source>. <year>2005</year>;<volume>33</volume>:<fpage>1405</fpage>-<lpage>1417</lpage>.<pub-id pub-id-type="pmid">16127127</pub-id></mixed-citation>
      </ref>
      <ref id="bibr19-1941738114548413">
        <label>19.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mishra</surname><given-names>A</given-names></name><name><surname>Woodall</surname><given-names>J</given-names><suffix>Jr</suffix></name><name><surname>Vieira</surname><given-names>A</given-names></name></person-group>
<article-title>Treatment of tendon and muscle using platelet-rich plasma</article-title>. <source>Clin Sports Med</source>. <year>2009</year>;<volume>28</volume>:<fpage>113</fpage>-<lpage>125</lpage>.<pub-id pub-id-type="pmid">19064169</pub-id></mixed-citation>
      </ref>
      <ref id="bibr20-1941738114548413">
        <label>20.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Randelli</surname><given-names>PS</given-names></name><name><surname>Arrigoni</surname><given-names>P</given-names></name><name><surname>Cabitza</surname><given-names>P</given-names></name><name><surname>Volpi</surname><given-names>P</given-names></name><name><surname>Maffulli</surname><given-names>N</given-names></name></person-group>
<article-title>Autologous platelet rich plasma for arthroscopic rotator cuff repair: a pilot study</article-title>. <source>Disabil Rehabil</source>. <year>2008</year>;<volume>30</volume>:<fpage>1584</fpage>-<lpage>1589</lpage>.<pub-id pub-id-type="pmid">18608363</pub-id></mixed-citation>
      </ref>
      <ref id="bibr21-1941738114548413">
        <label>21.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Randelli</surname><given-names>PS</given-names></name><name><surname>Arrigoni</surname><given-names>P</given-names></name><name><surname>Ragone</surname><given-names>V</given-names></name><name><surname>Aliprandi</surname><given-names>A</given-names></name><name><surname>Cabitza</surname><given-names>P</given-names></name></person-group>
<article-title>Platelet rich plasma in arthroscopic rotator cuff repair: a prospective RCT study, 2-year follow-up</article-title>. <source>J Shoulder Elbow Surg</source>. <year>2011</year>;<volume>20</volume>:<fpage>518</fpage>-<lpage>528</lpage>.<pub-id pub-id-type="pmid">21570659</pub-id></mixed-citation>
      </ref>
      <ref id="bibr22-1941738114548413">
        <label>22.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sanchez</surname><given-names>M</given-names></name><name><surname>Anitua</surname><given-names>E</given-names></name><name><surname>Orive</surname><given-names>G</given-names></name><name><surname>Mujika</surname><given-names>I</given-names></name><name><surname>Andia</surname><given-names>I</given-names></name></person-group>
<article-title>Platelet-rich therapies in the treatment of orthopaedic sports injuries</article-title>. <source>Sports Med</source>. <year>2009</year>;<volume>35</volume>:<fpage>1</fpage>-<lpage>10</lpage>.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:4272694</identifier><datestamp>2016-01-01</datestamp><setSpec>sportshealth</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="http://jats.nlm.nih.gov/ns/archiving/1.0/ http://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="review-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Sports Health</journal-id>
      <journal-id journal-id-type="iso-abbrev">Sports Health</journal-id>
      <journal-id journal-id-type="publisher-id">SPH</journal-id>
      <journal-id journal-id-type="hwp">spsph</journal-id>
      <journal-title-group>
        <journal-title>Sports Health</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1941-7381</issn>
      <issn pub-type="epub">1941-0921</issn>
      <publisher>
        <publisher-name>SAGE Publications</publisher-name>
        <publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4272694</article-id>
      <article-id pub-id-type="pmcid">PMC4272694</article-id>
      <article-id pub-id-type="pmc-uid">4272694</article-id>
      <article-id pub-id-type="pmid">25553218</article-id>
      <article-id pub-id-type="doi">10.1177/1941738114550988</article-id>
      <article-id pub-id-type="publisher-id">10.1177_1941738114550988</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Current Research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Shoulder Arthroplasty</article-title>
        <subtitle>Return to Sport</subtitle>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Khair</surname>
            <given-names>M. Michael</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="corresp" rid="corresp1-1941738114550988">*</xref>
          <xref ref-type="aff" rid="aff1-1941738114550988">†</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dines</surname>
            <given-names>Joshua S.</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="aff1-1941738114550988">†</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dines</surname>
            <given-names>David M.</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="aff1-1941738114550988">†</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1-1941738114550988"><label>†</label>Hospital for Special Surgery, New York, New York</aff>
      <author-notes>
        <corresp id="corresp1-1941738114550988"><label>*</label>M. Michael Khair, MD, Rush University Medical Center, 1611 W Harrison, Suite 300, Chicago, IL 60612 (e-mail: <email>mahmoud_m_khair@rush.edu</email>).</corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>1</day>
        <month>1</month>
        <year>2016</year>
      </pub-date>
      <!-- PMC Release delay is 12 months and 0 days and was based on the <pub-date pub-type="ppub"/>. -->
      <volume>7</volume>
      <issue>1</issue>
      <fpage>87</fpage>
      <lpage>89</lpage>
      <permissions>
        <copyright-statement>© 2014 The Author(s)</copyright-statement>
        <copyright-year>2014</copyright-year>
        <copyright-holder content-type="sage">American Orthopaedic Society for Sports Medicine</copyright-holder>
      </permissions>
      <abstract>
        <sec id="section1-1941738114550988">
          <title>Context:</title>
          <p>Increasingly, total shoulder arthroplasty is being performed not only to treat the pain associated with glenohumeral arthritis but also to return patients to the level of activity and function they enjoyed prior to the development of arthritis. While return to sport and activity have been studied in the total knee and total hip replacement literature, it is only relatively recently that the same focus has been placed on total shoulder replacements.</p>
        </sec>
        <sec id="section2-1941738114550988">
          <title>Evidence Acquisition:</title>
          <p>PubMed database from the years 2000 to 2014. All studies relevant to shoulder arthroplasty and return to sport were included in the review.</p>
        </sec>
        <sec id="section3-1941738114550988">
          <title>Study Design:</title>
          <p>Clinical review.</p>
        </sec>
        <sec id="section4-1941738114550988">
          <title>Level of Evidence:</title>
          <p>Level 4.</p>
        </sec>
        <sec id="section5-1941738114550988">
          <title>Results:</title>
          <p>An increasing number of patients seeking total shoulder arthroplasty are doing so with the expectation of not only decreased symptoms of glenohumeral arthritis but also of return to a high level of activity. The majority of patients are able to return to their prior level of activity within 6 months of surgery. In some series, patients saw an improvement in their ability to perform their chosen activity.</p>
        </sec>
        <sec id="section6-1941738114550988">
          <title>Conclusion:</title>
          <p>Patients should be counseled that there is a high probability that they will be able to return to their preoperative activity level after total shoulder arthroplasty and, in some cases, see an improvement in their abilities to participate in sport.</p>
        </sec>
        <sec id="section7-1941738114550988">
          <title>Strength-of-Recommendation Taxonomy (SORT):</title>
          <p>C.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>total shoulder arthoplasty</kwd>
        <kwd>shoulder replacement</kwd>
        <kwd>athlete</kwd>
        <kwd>return to sport</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>January/February 2015</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <p>Shoulder replacement surgery is done for a variety of reasons. One of the most common indications is the reduction of pain in cases of advanced arthritis.<sup><xref rid="bibr2-1941738114550988" ref-type="bibr">2</xref></sup> In addition to the goal of pain reduction, most surgeons also try to achieve restoration of shoulder function and increase the patient’s quality of life.<sup><xref rid="bibr5-1941738114550988" ref-type="bibr">5</xref>,<xref rid="bibr7-1941738114550988" ref-type="bibr">7</xref></sup> Increasingly, these activities are being broadened to not only include activities of daily living, such as dressing oneself or being able to participate in household chores, but also to include sporting activities such as golfing, swimming, and dancing.</p>
    <p>Additionally, given the historically good results of total shoulder arthroplasty (TSA), patients have come to have increasingly higher expectations of their function postoperatively. It is common, both during preoperative and follow-up visits, for patients to ask the surgeon what kinds of sports they will be able to do or allowed to participate in after TSA.<sup><xref rid="bibr7-1941738114550988" ref-type="bibr">7</xref></sup> Specifically, they wonder whether they will be allowed to participate in the activities they enjoyed prior to developing shoulder problems and at what level they will be able to participate. This clinical review examines how return to sport has been studied and reported on in the shoulder arthroplasty literature.<sup><xref rid="bibr3-1941738114550988" ref-type="bibr">3</xref>,<xref rid="bibr5-1941738114550988" ref-type="bibr">5</xref><xref rid="bibr6-1941738114550988" ref-type="bibr"/><xref rid="bibr7-1941738114550988" ref-type="bibr"/>-<xref rid="bibr8-1941738114550988" ref-type="bibr">8</xref></sup></p>
    <sec id="section8-1941738114550988">
      <title>Return to Sport after Total Shoulder Arthroplasty</title>
      <p>McCarty et al<sup><xref rid="bibr5-1941738114550988" ref-type="bibr">5</xref></sup> reported on 75 patients (86 total shoulder replacements) at an average follow-up of 3.7 years. In their series, the study population received an older-generation biomodular implant (Biomet), and several patients received a hemiarthroplasty. Sixty-four percent of patients reported that return to sport was one of the reasons that they underwent TSA; 50% of patients were able to increase their participation postoperatively, and 71% showed an improvement in their ability to play sport. In their study, golfing and tennis were the most popular sports and had the most favorable return after TSA. Swimming was also popular and showed favorable return. A return to softball was least favorable, with only 2 of 10 patients able to return postoperatively. Most patients were able to partially return to sport at 3.6 months and make a full return by 5.8 months after surgery.<sup><xref rid="bibr5-1941738114550988" ref-type="bibr">5</xref></sup></p>
      <p>Zarkadas et al<sup><xref rid="bibr8-1941738114550988" ref-type="bibr">8</xref></sup> used a mailed questionnaire to investigate patient-reported activity after both TSA and hemiarthroplasty. Specific to the TSA group, 52 patients completed the survey, and 27 of 52 patients reported having high-demand use of their operative shoulder. The most frequently cited low-demand sporting activities were stationary biking, treadmill use, and horseshoes. Medium-demand activities included fishing, dancing, and swimming. The high-demand sporting activities that patients reported being able to return to included road biking, free weights, and hunting/shooting.</p>
      <p>Schumann et al<sup><xref rid="bibr7-1941738114550988" ref-type="bibr">7</xref></sup> examined 100 patients with unilateral TSA followed for a minimum of 1 year. They mailed patients a postoperative questionnaire that the authors developed to investigate postoperative sports participation. Of the patients surveyed, 55 participated in sports prior to undergoing TSA, and 49 patients (89%) were able to continue playing sports at a mean 3 years’ follow-up. Seventeen patients who had previously participated in sports prior to developing shoulder pathology had given up playing sports because of their disability; 11 of these patients were able to go back to sport after TSA. None of the patients who underwent TSA and were active in sports activities stopped participating after having surgery. The most commonly reported sporting activities in this series were swimming (20.4%), golfing (16.3%), cycling (16.3%), and fitness training (16.3%). It should be noted that 18 of 55 patients in this series reported sporting restrictions due to shoulder problems even after TSA.</p>
      <p>Schmidt-Wiethoff et al<sup><xref rid="bibr6-1941738114550988" ref-type="bibr">6</xref></sup> showed that 62 of 74 patients (84%) were able to return to sport after TSA. The other 12 patients gave up sport entirely. Nineteen of the 62 who continued to play had limitations of their sporting activity. Unfortunately, the article did not give exact details regarding the limitations or what the authors believed to be the reason.</p>
    </sec>
    <sec id="section9-1941738114550988">
      <title>Surgeon Opinion Regarding Return to Sport after Total Shoulder Arthroplasty</title>
      <p>With regard to surgeon expectations and preferences, several studies have investigated what the opinion of experienced shoulder surgeons is regarding return to sports after TSA.<sup><xref rid="bibr1-1941738114550988" ref-type="bibr">1</xref>,<xref rid="bibr2-1941738114550988" ref-type="bibr">2</xref>,<xref rid="bibr4-1941738114550988" ref-type="bibr">4</xref></sup> Golant et al<sup><xref rid="bibr1-1941738114550988" ref-type="bibr">1</xref></sup> distributed a survey to 310 members of the American Shoulder and Elbows Surgeons (ASES) inquiring into what types of activities they allow their patients to participate in after 5 types of shoulder arthroplasty. Looking specifically at TSA, 59.1% of surgeons responded that they would allow their patients to participate in low-impact sports without restrictions, 19.6% high-impact sports, and 8.2% contact sports; 27.5% said that they would allow low-impact sports with limitations, 39.7% high-impact sports with limitations, and 18.5% contact sports with limitations. With sufficient experience, 7.8% would allow low-impact activities, 16.8% high-impact sports, and 18.7% contact sports. The authors concluded that the majority of ASES surgeons would allow some return to sport after TSA. As might be expected, surgeons were more likely to allow return to sport if the sport did not involve significant contact, application of high loads to the upper extremity, or risk of fall or collision.</p>
      <p>Magnussen et al<sup><xref rid="bibr4-1941738114550988" ref-type="bibr">4</xref></sup> also submitted a survey to the surgeons within the ASES as well as the surgeons in the European Society for Surgery of the Shoulder and Elbow. The survey contained 37 activities and asked surgeons to classify their postoperative recommendation for each activity. The authors found that almost all surgeons allowed their patients to resume noncontact activities such as stationary bicycle, elliptical trainer, hiking, and low-impact aerobics. Sports with increased use of the upper extremity varied in terms of response. Eighty-one percent of surgeons stated they would allow patients to swim after undergoing TSA, 93% golf, 65% rowing, and 67% bowling. High-impact shoulder activities and those with a greater risk of contact were much less likely to be allowed. Fifty-eight percent of surgeons stated that they would not allow their patients to participate in lacrosse, 83% American football, 49% martial arts, and 39% waterskiing. Interestingly, 80% of European surgeons stated that they would not allow weight lifting, while only 29% of American surgeons stated that they would disallow it.</p>
      <p>In preparing their article, Healey et al<sup><xref rid="bibr2-1941738114550988" ref-type="bibr">2</xref></sup> surveyed 35 surgeons in the ASES as to their recommendations for athletics and sports participation after TSA. As expected, low-impact activities such as swimming, doubles tennis, bowling, and dancing were recommended and allowed. Those activities that were allowed with experience were golf, ice skating, shooting, and downhill skiing. Those activities that were not recommended included football, gymnastics, hockey, and rock climbing.</p>
    </sec>
    <sec sec-type="conclusions" id="section10-1941738114550988">
      <title>Conclusion</title>
      <p>Patients undergoing TSA for primary glenohumeral arthritis often report return to activity/sport as one motivation for having the operation. The majority of patients can expect to return to their preoperative level of activity within 6 months postoperatively. Many patients will see an improvement in their ability to participate after surgery.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="conflict">
        <p>The following authors declared potential conflicts of interest: Joshua S. Dines, MD, is a paid consultant for Arthrex and Conmed. David M. Dines, MD, receives royalties from Biomet.<?release-delay 12|0?></p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="bibr1-1941738114550988">
        <label>1.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Golant</surname><given-names>A</given-names></name><name><surname>Christoforou</surname><given-names>D</given-names></name><name><surname>Zuckerman</surname><given-names>JD</given-names></name><name><surname>Kwon</surname><given-names>YW</given-names></name></person-group>
<article-title>Return to sports after shoulder arthroplasty: a survey of surgeons’ preferences</article-title>. <source>J Shoulder Elbow Surg</source>. <year>2012</year>;<volume>21</volume>:<fpage>554</fpage>-<lpage>560</lpage>.<pub-id pub-id-type="pmid">21393018</pub-id></mixed-citation>
      </ref>
      <ref id="bibr2-1941738114550988">
        <label>2.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Healy</surname><given-names>WL</given-names></name><name><surname>Iorio</surname><given-names>R</given-names></name><name><surname>Lemos</surname><given-names>MJ</given-names></name></person-group>
<article-title>Athletic activity after joint replacement</article-title>. <source>Am J Sports Med</source>. <year>2001</year>;<volume>29</volume>:<fpage>377</fpage>-<lpage>388</lpage>.<pub-id pub-id-type="pmid">11394613</pub-id></mixed-citation>
      </ref>
      <ref id="bibr3-1941738114550988">
        <label>3.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jensen</surname><given-names>KL</given-names></name><name><surname>Rockwood</surname><given-names>CA</given-names><suffix>Jr</suffix></name></person-group>
<article-title>Shoulder arthroplasty in recreational golfers</article-title>. <source>J Shoulder Elbow Surg</source>. <year>1998</year>;<volume>7</volume>:<fpage>362</fpage>-<lpage>367</lpage>.<pub-id pub-id-type="pmid">9752645</pub-id></mixed-citation>
      </ref>
      <ref id="bibr4-1941738114550988">
        <label>4.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Magnussen</surname><given-names>RA</given-names></name><name><surname>Mallon</surname><given-names>WJ</given-names></name><name><surname>Willems</surname><given-names>WJ</given-names></name><name><surname>Moorman</surname><given-names>CT</given-names><suffix>3rd</suffix></name></person-group>
<article-title>Long-term activity restrictions after shoulder arthroplasty: an international survey of experienced shoulder surgeons</article-title>. <source>J Shoulder Elbow Surg</source>. <year>2011</year>;<volume>20</volume>:<fpage>281</fpage>-<lpage>289</lpage>.<pub-id pub-id-type="pmid">21051242</pub-id></mixed-citation>
      </ref>
      <ref id="bibr5-1941738114550988">
        <label>5.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McCarty</surname><given-names>EC</given-names></name><name><surname>Marx</surname><given-names>RG</given-names></name><name><surname>Maerz</surname><given-names>D</given-names></name><name><surname>Altchek</surname><given-names>D</given-names></name><name><surname>Warren</surname><given-names>RF</given-names></name></person-group>
<article-title>Sports participation after shoulder replacement surgery</article-title>. <source>Am J Sports Med</source>. <year>2008</year>;<volume>36</volume>:<fpage>1577</fpage>-<lpage>1581</lpage>.<pub-id pub-id-type="pmid">18539951</pub-id></mixed-citation>
      </ref>
      <ref id="bibr6-1941738114550988">
        <label>6.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schmidt-Wiethoff</surname><given-names>R</given-names></name><name><surname>Wolf</surname><given-names>P</given-names></name><name><surname>Lehmann</surname><given-names>M</given-names></name><name><surname>Habermeyer</surname><given-names>P</given-names></name></person-group>
<article-title>Physical activity after shoulder arthroplasty [in German]</article-title>. <source>Sportverletz Sportschaden</source>. <year>2002</year>;<volume>16</volume>:<fpage>26</fpage>-<lpage>30</lpage>.<pub-id pub-id-type="pmid">11951162</pub-id></mixed-citation>
      </ref>
      <ref id="bibr7-1941738114550988">
        <label>7.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schumann</surname><given-names>K</given-names></name><name><surname>Flury</surname><given-names>MP</given-names></name><name><surname>Schwyzer</surname><given-names>HK</given-names></name><name><surname>Simmen</surname><given-names>BR</given-names></name><name><surname>Drerup</surname><given-names>S</given-names></name><name><surname>Goldhahn</surname><given-names>J</given-names></name></person-group>
<article-title>Sports activity after anatomical total shoulder arthroplasty</article-title>. <source>Am J Sports Med</source>. <year>2010</year>;<volume>38</volume>:<fpage>2097</fpage>-<lpage>2105</lpage>.<pub-id pub-id-type="pmid">20616374</pub-id></mixed-citation>
      </ref>
      <ref id="bibr8-1941738114550988">
        <label>8.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zarkadas</surname><given-names>PC</given-names></name><name><surname>Throckmorton</surname><given-names>TQ</given-names></name><name><surname>Dahm</surname><given-names>DL</given-names></name><name><surname>Sperling</surname><given-names>J</given-names></name><name><surname>Schleck</surname><given-names>CD</given-names></name><name><surname>Cofield</surname><given-names>R</given-names></name></person-group>
<article-title>Patient reported activities after shoulder replacement: total and hemiarthroplasty</article-title>. <source>J Shoulder Elbow Surg</source>. <year>2011</year>;<volume>20</volume>:<fpage>273</fpage>-<lpage>280</lpage>.<pub-id pub-id-type="pmid">20951063</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:4272695</identifier><datestamp>2016-01-01</datestamp><setSpec>sportshealth</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="http://jats.nlm.nih.gov/ns/archiving/1.0/ http://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Sports Health</journal-id>
      <journal-id journal-id-type="iso-abbrev">Sports Health</journal-id>
      <journal-id journal-id-type="publisher-id">SPH</journal-id>
      <journal-id journal-id-type="hwp">spsph</journal-id>
      <journal-title-group>
        <journal-title>Sports Health</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1941-7381</issn>
      <issn pub-type="epub">1941-0921</issn>
      <publisher>
        <publisher-name>SAGE Publications</publisher-name>
        <publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4272695</article-id>
      <article-id pub-id-type="pmcid">PMC4272695</article-id>
      <article-id pub-id-type="pmc-uid">4272695</article-id>
      <article-id pub-id-type="pmid">25553216</article-id>
      <article-id pub-id-type="doi">10.1177/1941738114553165</article-id>
      <article-id pub-id-type="publisher-id">10.1177_1941738114553165</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Current Research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Muscular Activation During Plyometric Exercises in 90° of Glenohumeral Joint Abduction</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Ellenbecker</surname>
            <given-names>Todd S.</given-names>
          </name>
          <degrees>DPT, MS, SCS, OCS, CSCS</degrees>
          <xref ref-type="corresp" rid="corresp1-1941738114553165">*</xref>
          <xref ref-type="aff" rid="aff1-1941738114553165">†</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sueyoshi</surname>
            <given-names>Tetsuro</given-names>
          </name>
          <degrees>ATC</degrees>
          <xref ref-type="aff" rid="aff1-1941738114553165">†</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bailie</surname>
            <given-names>David S.</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="aff2-1941738114553165">‡</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1-1941738114553165"><label>†</label>Physiotherapy Associates Scottsdale Sports Clinic, Scottsdale, Arizona</aff>
      <aff id="aff2-1941738114553165"><label>‡</label>The Orthopaedic Clinic Association (TOCA), Scottsdale, Arizona</aff>
      <author-notes>
        <corresp id="corresp1-1941738114553165"><label>*</label>Todd S. Ellenbecker, DPT, MS, SCS, OCS, CSCS, Clinic Director, Physiotherapy Associates Scottsdale Sports Clinic, Vice President, Medical Services, ATP World Tour, 9917 North 95th Street, Scottsdale, AZ 85258 (e-mail: <email>ellenbeckerpt@cox.net</email>).</corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>1</day>
        <month>1</month>
        <year>2016</year>
      </pub-date>
      <!-- PMC Release delay is 12 months and 0 days and was based on the <pub-date pub-type="ppub"/>. -->
      <volume>7</volume>
      <issue>1</issue>
      <fpage>75</fpage>
      <lpage>79</lpage>
      <permissions>
        <copyright-statement>© 2014 The Author(s)</copyright-statement>
        <copyright-year>2014</copyright-year>
        <copyright-holder content-type="sage">American Orthopaedic Society for Sports Medicine</copyright-holder>
      </permissions>
      <abstract>
        <sec id="section1-1941738114553165">
          <title>Background:</title>
          <p>Plyometric exercises are frequently used to increase posterior rotator cuff and periscapular muscle strength and simulate demands and positional stresses in overhead athletes. The purpose of this study was to provide descriptive data on posterior rotator cuff and scapular muscle activation during upper extremity plyometric exercises in 90° of glenohumeral joint abduction.</p>
        </sec>
        <sec id="section2-1941738114553165">
          <title>Hypothesis:</title>
          <p>Levels of muscular activity in the posterior rotator cuff and scapular stabilizers will be high during plyometric shoulder exercises similar to previously reported electromyographic (EMG) levels of shoulder rehabilitation exercises.</p>
        </sec>
        <sec id="section3-1941738114553165">
          <title>Study Design:</title>
          <p>Descriptive laboratory study.</p>
        </sec>
        <sec id="section4-1941738114553165">
          <title>Methods:</title>
          <p>Twenty healthy subjects were tested using surface EMG during the performance of 2 plyometric shoulder exercises: prone external rotation (PERP) and reverse catch external rotation (RCP) using a handheld medicine ball. Electrode application included the upper and lower trapezius (UT and LT, respectively), serratus anterior (SA), infraspinatus (IN), and the middle and posterior deltoid (MD and PD, respectively) muscles. A 10-second interval of repetitive plyometric exercise (PERP) and 3 repetitions of RCP were sampled. Peak and average normalized EMG data were generated.</p>
        </sec>
        <sec id="section5-1941738114553165">
          <title>Results:</title>
          <p>Normalized peak and average IN activity ranged between 73% and 102% and between 28% and 52% during the plyometric exercises, respectively, with peak and average LT activity measured between 79% and 131% and between 31% and 61%. SA activity ranged between 76% and 86% for peak and between 35% and 37% for average activity. Muscular activity levels in the MD and PD ranged between 49% and 72% and between 12% and 33% for peak and average, respectively.</p>
        </sec>
        <sec id="section6-1941738114553165">
          <title>Conclusion:</title>
          <p>Moderate to high levels of muscular activity were measured in the rotator cuff and scapular stabilizers during these plyometric exercises with the glenohumeral joint abducted 90°.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>shoulder</kwd>
        <kwd>plyometrics</kwd>
        <kwd>EMG</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>January/February 2015</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <p>Clinical rehabilitation of the injured overhead athlete often includes exercises performed with the glenohumeral joint at 90° of abduction.<sup><xref rid="bibr12-1941738114553165" ref-type="bibr">12</xref>,<xref rid="bibr13-1941738114553165" ref-type="bibr">13</xref>,<xref rid="bibr26-1941738114553165" ref-type="bibr">26</xref>,<xref rid="bibr31-1941738114553165" ref-type="bibr">31</xref>,<xref rid="bibr32-1941738114553165" ref-type="bibr">32</xref></sup> Progression to exercises with 90° of glenohumeral joint abduction prepares the athlete for a return to the demands of overhead function.<sup><xref rid="bibr4-1941738114553165" ref-type="bibr">4</xref>,<xref rid="bibr14-1941738114553165" ref-type="bibr">14</xref>,<xref rid="bibr24-1941738114553165" ref-type="bibr">24</xref></sup> Specific levels of muscular activity during many exercises used in shoulder rehabilitation are known in normal subjects<sup><xref rid="bibr6-1941738114553165" ref-type="bibr">6</xref>,<xref rid="bibr20-1941738114553165" ref-type="bibr">20</xref>,<xref rid="bibr21-1941738114553165" ref-type="bibr">21</xref>,<xref rid="bibr25-1941738114553165" ref-type="bibr">25</xref>,<xref rid="bibr26-1941738114553165" ref-type="bibr">26</xref>,<xref rid="bibr29-1941738114553165" ref-type="bibr">29</xref></sup> as well as in certain types of pathology.<sup><xref rid="bibr2-1941738114553165" ref-type="bibr">2</xref></sup> These studies allow the clinician to select specific exercises to normalize muscle balance and improve muscular strength and local muscle endurance for rehabilitation, prevention, and performance enhancement programs.</p>
    <p>Medicine ball plyometric exercise in the 90° of glenohumeral abducted position results in improvements in internal and external rotation strength and in throwing velocity after 8 weeks of training in college baseball players.<sup><xref rid="bibr7-1941738114553165" ref-type="bibr">7</xref></sup> Proprioception, kinesthesia, and selected muscular strength have improved after a 6-week plyometric training program in swimmers.<sup><xref rid="bibr29-1941738114553165" ref-type="bibr">29</xref></sup> Despite these favorable results, little objective information is available regarding the muscular activity in plyometric shoulder exercises used in rehabilitation. The normalized muscular activity of the scapular stabilizers and glenohumeral musculature during a 2-hand plyometric chest pass exercise using a medicine ball shows moderate levels in the rotator cuff and scapular musculature.<sup><xref rid="bibr9-1941738114553165" ref-type="bibr">9</xref></sup></p>
    <sec sec-type="materials|methods" id="section7-1941738114553165">
      <title>Materials and Methods</title>
      <sec id="section8-1941738114553165">
        <title>Participants</title>
        <p>Subjects read and signed an informed consent prior to participation. This study was approved by the Institutional Review Board of Physiotherapy Associates, Exton, PA. Twenty subjects (13 men, 7 women) between 18 and 50 years of age and no history of shoulder or spinal injury in the past year prior to data collection volunteered to participate in this investigation. Subjects were free from any history of shoulder or spinal surgery. Subjects were active in recreational sports and demonstrated competence in the performance of the exercises, including catching and throwing ability.</p>
      </sec>
      <sec id="section9-1941738114553165">
        <title>Equipment and Procedures</title>
        <p>A Noraxon Myotrace Model 1400A (Noraxon) electromyography (EMG) unit was used to measure muscular activity on the subjects’ dominant upper extremity using standardized surface electrode application and technique (infraspinatus, upper trapezius, lower trapezius, serratus anterior, middle deltoid, and posterior deltoid). The application of surface electrodes followed standardized methodology.</p>
        <p>Precise locations of each surface electrode followed previous guidelines.<sup><xref rid="bibr3-1941738114553165" ref-type="bibr">3</xref>,<xref rid="bibr23-1941738114553165" ref-type="bibr">23</xref></sup></p>
        <p>The average and peak muscle activity was recorded for each exercise and was normalized to the maximum voluntary isometric contraction (MVIC) of each muscle tested. The muscular activity classification used in this study included 0% to 15% as absent to minimal, 16% to 30% as low, 31% to 60% as moderate, and greater than 60% as high.<sup><xref rid="bibr27-1941738114553165" ref-type="bibr">27</xref></sup> Two repetitions were used for each muscle with 1-minute rest given between muscles. Positions used for determination of MVIC are as follows: infraspinatus—0° of abduction with the glenohumeral joint in 45° of internal rotation with resistance applied just proximal to the wrist with force application into internal rotation,<sup><xref rid="bibr16-1941738114553165" ref-type="bibr">16</xref></sup> upper trapezius—seated position shoulder girdle shrug with resistance applied over the acromion and resistance applied in a caudal direction,<sup><xref rid="bibr17-1941738114553165" ref-type="bibr">17</xref></sup> lower trapezius—prone positioning with 135° of abduction in the coronal plane with thumb up position using an anteriorly directed force just proximal to the wrist,<sup><xref rid="bibr17-1941738114553165" ref-type="bibr">17</xref></sup> serratus anterior—standing position with 120° of flexion with force application posterior and inferior,<sup><xref rid="bibr3-1941738114553165" ref-type="bibr">3</xref></sup> middle deltoid—resisted abduction in the coronal plane in 90° of neutral humeral rotation (palm down) with force application straight downward into adduction,<sup><xref rid="bibr17-1941738114553165" ref-type="bibr">17</xref></sup> and posterior deltoid—shoulder abduction 90° in neutral rotation with resistance applied just proximal to the elbow in an anterior direction (horizontal adduction).<sup><xref rid="bibr17-1941738114553165" ref-type="bibr">17</xref></sup> Sampling occurred at 1000 HZ, with all signals bandpass filtered between 10 and 500 HZ and then full-wave rectified using the Myoresearch 1.04 version software (Noraxon Inc).</p>
        <p>The order of testing for the 2 exercises was randomized as was the load (Thera-Band Soft Weight; Hygenic Corporation): 0.5 kg and 1 kg for each subject. The MVIC and exercise data were collected in the same testing session. Electrodes were applied once and not moved between the MVIC and exercise data sampling. Subjects were allowed 5 minutes of rest between MVIC testing and performance of the exercise conditions and 2 minutes of rest between exercise conditions. Prior to application of the electrodes, subjects who were unfamiliar with the exercises were allowed time to practice with the metronome to ensure proper form, speed, and consistent performance during data collection.</p>
      </sec>
      <sec id="section10-1941738114553165">
        <title>Medicine Ball Plyometric Exercises</title>
        <sec id="section11-1941738114553165">
          <title>Prone 90/90 External Rotation Plyometric</title>
          <p>The subjects were positioned prone on a standard treatment table with 90° of external rotation and 90° of glenohumeral joint abduction in the coronal plane (90/90 position). A 0.5-kg (tan) and a 1-kg (yellow) Thera-Band Soft Weight were used to alternately catch and drop during a 10-second interval while muscular activity was sampled from the targeted muscles (<xref ref-type="fig" rid="fig1-1941738114553165">Figure 1</xref>). An internal metronome at 160 bpm was set to regulate the speed of the exercise to allow for standardization between trials and between subjects tested. Sampling was performed for 10 seconds, with the first and last 4 seconds discarded. A 2-second central interval was analyzed using full-wave rectification and root mean square smoothing with a window of 50 ms for data analysis. This central window selected for analysis was chosen to represent several movements of the exercise and to characterize the muscular performance during this repetitive exercise.</p>
          <fig id="fig1-1941738114553165" position="float">
            <label>Figure 1.</label>
            <caption>
              <p>Prone 90/90 external rotation plyometric exercise.</p>
            </caption>
            <graphic xlink:href="10.1177_1941738114553165-fig1"/>
          </fig>
        </sec>
        <sec id="section12-1941738114553165">
          <title>Reverse Catch External Rotation Plyometric</title>
          <p>Subjects were tested in an upright position with their dominant side (ipsilateral) knee flexed onto a foam pad and contralateral lower extremity in 90° of hip and knee flexion directly in front of them for stabilization (<xref ref-type="fig" rid="fig2-1941738114553165">Figure 2</xref>). From a distance of 3 feet behind the subject, 1 examiner used an underhand toss to propel the medicine ball toward the subject who caught the ball in the 90/90 position, decelerated the ball, and then rapidly tossed the ball back to the examiner maintaining the arm in 90° of abduction and 90° of elbow flexion. This was repeated for 3 trials, with the middle trial used for data collection.</p>
          <fig id="fig2-1941738114553165" position="float">
            <label>Figure 2.</label>
            <caption>
              <p>Reverse catch external rotation plyometric exercise.</p>
            </caption>
            <graphic xlink:href="10.1177_1941738114553165-fig2"/>
          </fig>
        </sec>
      </sec>
      <sec id="section13-1941738114553165">
        <title>Data Analysis</title>
        <p>SPSS (SPSS Inc) was used to generate the descriptive statistics from a Microsoft Excel spreadsheet that had transferred the peak and average normalized muscular activity data from the sampling windows from the Noraxon EMG software.</p>
      </sec>
    </sec>
    <sec sec-type="results" id="section14-1941738114553165">
      <title>Results</title>
      <p>The muscular activity results are presented in <xref ref-type="table" rid="table1-1941738114553165">Tables 1</xref> and <xref ref-type="table" rid="table2-1941738114553165">2</xref>.</p>
      <table-wrap id="table1-1941738114553165" position="float">
        <label>Table 1.</label>
        <caption>
          <p>Muscular activity during the prone 90/90 external rotation plyometric exercise<sup><xref ref-type="table-fn" rid="table-fn1-1941738114553165"><italic>a</italic></xref></sup></p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th rowspan="1" colspan="1"/>
              <th align="center" colspan="2" rowspan="1">0.5 Kilogram<hr/></th>
              <th align="center" colspan="2" rowspan="1">1 Kilogram<hr/></th>
            </tr>
            <tr>
              <th align="left" rowspan="1" colspan="1">Muscle/Load</th>
              <th align="center" rowspan="1" colspan="1">Peak</th>
              <th align="center" rowspan="1" colspan="1">Average</th>
              <th align="center" rowspan="1" colspan="1">Peak</th>
              <th align="center" rowspan="1" colspan="1">Average</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">Infraspinatus</td>
              <td rowspan="1" colspan="1">85 ± 23</td>
              <td rowspan="1" colspan="1">43 ± 13</td>
              <td rowspan="1" colspan="1">103 ± 26</td>
              <td rowspan="1" colspan="1">52 ± 14</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Upper trapezius</td>
              <td rowspan="1" colspan="1">54 ± 33</td>
              <td rowspan="1" colspan="1">27 ± 13</td>
              <td rowspan="1" colspan="1">71 ± 40</td>
              <td rowspan="1" colspan="1">35 ± 16</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Lower trapezius</td>
              <td rowspan="1" colspan="1">118 ± 35</td>
              <td rowspan="1" colspan="1">61 ± 19</td>
              <td rowspan="1" colspan="1">131 ± 37</td>
              <td rowspan="1" colspan="1">61 ± 21</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Serratus anterior</td>
              <td rowspan="1" colspan="1">96 ± 91</td>
              <td rowspan="1" colspan="1">36 ± 31</td>
              <td rowspan="1" colspan="1">76 ± 50</td>
              <td rowspan="1" colspan="1">35 ± 23</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Middle deltoid</td>
              <td rowspan="1" colspan="1">42 ± 23</td>
              <td rowspan="1" colspan="1">21 ± 10</td>
              <td rowspan="1" colspan="1">54 ± 23</td>
              <td rowspan="1" colspan="1">26 ± 13</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Posterior deltoid</td>
              <td rowspan="1" colspan="1">55 ± 25</td>
              <td rowspan="1" colspan="1">27 ± 11</td>
              <td rowspan="1" colspan="1">73 ± 24</td>
              <td rowspan="1" colspan="1">33 ± 12</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="table-fn1-1941738114553165">
            <label>a</label>
            <p>Data are expressed as percentage maximum voluntary isometric contraction (% MVIC) and presented as mean ± standard deviation.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <table-wrap id="table2-1941738114553165" position="float">
        <label>Table 2.</label>
        <caption>
          <p>Muscular activity during the reverse catch plyometric exercise<sup><xref ref-type="table-fn" rid="table-fn2-1941738114553165"><italic>a</italic></xref></sup></p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th rowspan="1" colspan="1"/>
              <th align="center" colspan="2" rowspan="1">0.5 Kilogram<hr/></th>
              <th align="center" colspan="2" rowspan="1">1.0 Kilogram<hr/></th>
            </tr>
            <tr>
              <th align="left" rowspan="1" colspan="1">Muscle/Load</th>
              <th align="center" rowspan="1" colspan="1">Peak</th>
              <th align="center" rowspan="1" colspan="1">Average</th>
              <th align="center" rowspan="1" colspan="1">Peak</th>
              <th align="center" rowspan="1" colspan="1">Average</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">Infraspinatus</td>
              <td rowspan="1" colspan="1">71 ± 24</td>
              <td rowspan="1" colspan="1">27 ± 8</td>
              <td rowspan="1" colspan="1">73 ± 22</td>
              <td rowspan="1" colspan="1">29 ± 9</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Upper trapezius</td>
              <td rowspan="1" colspan="1">56 ± 36</td>
              <td rowspan="1" colspan="1">17 ± 10</td>
              <td rowspan="1" colspan="1">53 ± 25</td>
              <td rowspan="1" colspan="1">18 ± 12</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Lower trapezius</td>
              <td rowspan="1" colspan="1">81 ± 53</td>
              <td rowspan="1" colspan="1">31 ± 16</td>
              <td rowspan="1" colspan="1">79 ± 44</td>
              <td rowspan="1" colspan="1">31 ± 13</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Serratus anterior</td>
              <td rowspan="1" colspan="1">98 ± 43</td>
              <td rowspan="1" colspan="1">39 ± 22</td>
              <td rowspan="1" colspan="1">87 ± 40</td>
              <td rowspan="1" colspan="1">37 ± 19</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Middle deltoid</td>
              <td rowspan="1" colspan="1">58 ± 33</td>
              <td rowspan="1" colspan="1">17 ± 9</td>
              <td rowspan="1" colspan="1">62 ± 31</td>
              <td rowspan="1" colspan="1">18 ± 9</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Posterior deltoid</td>
              <td rowspan="1" colspan="1">41 ± 25</td>
              <td rowspan="1" colspan="1">11 ± 6</td>
              <td rowspan="1" colspan="1">49 ± 24</td>
              <td rowspan="1" colspan="1">12 ± 6</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="table-fn2-1941738114553165">
            <label>a</label>
            <p>Data are expressed as percentage maximum voluntary isometric contraction (% MVIC) and presented as mean ± standard deviation.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec sec-type="discussion" id="section15-1941738114553165">
      <title>Discussion</title>
      <p>The 2 plyometric exercises resulted in moderate to high levels of muscular activity of the infraspinatus and scapular stabilizing musculature (lower trapezius and serratus anterior) using relatively low loads of 0.5 and 1 kg. While direct comparisons between EMG studies outlining rotator cuff and scapular muscle activity are difficult because of methodologic differences, it is worth noting that the muscular activity levels in the infraspinatus measured during these 2 exercises are similar to percentage MVIC reported for more traditional exercises such as side-lying and prone external rotation.<sup><xref rid="bibr26-1941738114553165" ref-type="bibr">26</xref>,<xref rid="bibr30-1941738114553165" ref-type="bibr">30</xref></sup> Similarly, muscular activity in the trapezius and serratus anterior force couple<sup><xref rid="bibr1-1941738114553165" ref-type="bibr">1</xref></sup> are again comparable with previously reported values for the serratus punch, push up with a plus, and resisted scapular retraction exercises such as rowing variations used in many shoulder rehabilitation programs.<sup><xref rid="bibr10-1941738114553165" ref-type="bibr">10</xref>,<xref rid="bibr11-1941738114553165" ref-type="bibr">11</xref>,<xref rid="bibr18-1941738114553165" ref-type="bibr">18</xref>,<xref rid="bibr21-1941738114553165" ref-type="bibr">21</xref></sup></p>
      <p>In a series of plyometric training investigations of upper extremity movement patterns, small increases in rotator cuff and upper extremity strength and functional improvement were encountered particularly among experienced, coordinated subjects who could optimally perform the movement patterns.<sup><xref rid="bibr15-1941738114553165" ref-type="bibr">15</xref>,<xref rid="bibr27-1941738114553165" ref-type="bibr">27</xref>,<xref rid="bibr28-1941738114553165" ref-type="bibr">28</xref></sup> One of the key components of the plyometric sequence is the use of the eccentric contraction and overload applied to the exercising muscle tendon unit.<sup><xref rid="bibr8-1941738114553165" ref-type="bibr">8</xref>,<xref rid="bibr13-1941738114553165" ref-type="bibr">13</xref>,<xref rid="bibr19-1941738114553165" ref-type="bibr">19</xref>,<xref rid="bibr22-1941738114553165" ref-type="bibr">22</xref>,<xref rid="bibr33-1941738114553165" ref-type="bibr">33</xref></sup></p>
      <p>Lower exercise intensities facilitate the relative activation of the rotator cuff compared with the deltoid musculature supporting the use of the lighter exercise intensities during plyometric exercises.<sup><xref rid="bibr5-1941738114553165" ref-type="bibr">5</xref></sup></p>
      <p>Several limitations exist in this study that must be taken into account. With the present instrumentation and methods, analysis of the specific phases of the exercises was not possible, and the data for each exercise are meant to summarize both the average and peak muscular activity which characterizes these exercises. Additionally, there can be surface EMG cross talk between electrodes, which can compromise the measurement of activity of individual muscles. Every attempt was made to standardize electrode placement and sample carefully representative data from each of the exercise trials to capture optimal windows of muscle performance. Cross talk secondary to movement artifact during these exercises may further affect the data collection from surface electrodes during scapulothoracic and glenohumeral joint movements. Finally, as the primary purpose of this study was descriptive, neither a formal analysis was performed to determine sample size nor were repeated measures performed to evaluate the reproducibility of the standardized methodology used during this investigation.</p>
    </sec>
    <sec sec-type="conclusions" id="section16-1941738114553165">
      <title>Conclusion</title>
      <p>Moderate to high levels of muscular activity were measured in the rotator cuff and scapular stabilizers during the prone 90/90 external rotation and reverse catch plyometric exercises with the glenohumeral joint abducted 90°.<sup><xref rid="bibr27-1941738114553165" ref-type="bibr">27</xref></sup></p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="conflict">
        <p>The authors report no potential conflicts of interest in the development and publication of this article.<?release-delay 12|0?></p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="bibr1-1941738114553165">
        <label>1.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bagg</surname><given-names>SD</given-names></name><name><surname>Forrest</surname><given-names>WJ</given-names></name></person-group>
<article-title>A biomechanical analysis of scapular rotation during arm abduction in the scapular plane</article-title>. <source>Arch Phys Med Rehabil</source>. <year>1988</year>;<volume>67</volume>:<fpage>238</fpage>-<lpage>245</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr2-1941738114553165">
        <label>2.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ballantyne</surname><given-names>BT</given-names></name><name><surname>O’Hare</surname><given-names>SJ</given-names></name><name><surname>Paschall</surname><given-names>JL</given-names></name><etal/></person-group>
<article-title>Electromyographic activity of selected shoulder muscles in commonly used therapeutic exercises</article-title>. <source>Phys Ther</source>. <year>1993</year>;<volume>73</volume>:<fpage>668</fpage>-<lpage>682</lpage>.<pub-id pub-id-type="pmid">8378423</pub-id></mixed-citation>
      </ref>
      <ref id="bibr3-1941738114553165">
        <label>3.</label>
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Basmajian</surname><given-names>JV</given-names></name><name><surname>Deluca</surname><given-names>CJ</given-names></name></person-group>
<source>Muscles Alive: Their Functions Revealed</source>. <edition>5th ed.</edition>
<publisher-loc>Baltimore, MD</publisher-loc>: <publisher-name>Williams &amp; Wilkins</publisher-name>; <year>1985</year>.</mixed-citation>
      </ref>
      <ref id="bibr4-1941738114553165">
        <label>4.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Basset</surname><given-names>RW</given-names></name><name><surname>Browne</surname><given-names>AO</given-names></name><name><surname>Morrey</surname><given-names>BF</given-names></name><name><surname>An</surname><given-names>KN</given-names></name></person-group>
<article-title>Glenohumeral muscle force and moment mechanics in a position of shoulder instability</article-title>. <source>J Biomech</source>. <year>1994</year>;<volume>23</volume>:<fpage>405</fpage>-<lpage>415</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr5-1941738114553165">
        <label>5.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bitter</surname><given-names>NL</given-names></name><name><surname>Clisby</surname><given-names>EF</given-names></name><name><surname>Jones</surname><given-names>MA</given-names></name><name><surname>Magarey</surname><given-names>ME</given-names></name><name><surname>Jaberzadeh</surname><given-names>S</given-names></name><name><surname>Sandow</surname><given-names>MJ</given-names></name></person-group>
<article-title>Relative contributions of infraspinatus and deltoid during external rotation in healthy shoulders</article-title>. <source>J Shoulder Elbow Surg</source>. <year>2007</year>;<volume>16</volume>:<fpage>563</fpage>-<lpage>568</lpage>.<pub-id pub-id-type="pmid">17560805</pub-id></mixed-citation>
      </ref>
      <ref id="bibr6-1941738114553165">
        <label>6.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Blackburn</surname><given-names>TA</given-names></name><name><surname>McLeod</surname><given-names>WD</given-names></name><name><surname>White</surname><given-names>B</given-names></name><name><surname>Wofford</surname><given-names>L</given-names></name></person-group>
<article-title>EMG analysis of posterior rotator cuff exercises</article-title>. <source>J Athl Train</source>. <year>1990</year>;<volume>25</volume>:<fpage>40</fpage>-<lpage>45</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr7-1941738114553165">
        <label>7.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carter</surname><given-names>AB</given-names></name><name><surname>Kaminsky</surname><given-names>TW</given-names></name><name><surname>Douex</surname><given-names>AT</given-names></name><name><surname>Knight</surname><given-names>CA</given-names></name><name><surname>Richards</surname><given-names>JG</given-names></name></person-group>
<article-title>Effects of high volume upper extremity plyometric training on throwing velocity and functional strength ratios of the shoulder rotators in collegiate baseball players</article-title>. <source>J Strength Cond Res</source>. <year>2007</year>;<volume>21</volume>:<fpage>208</fpage>-<lpage>215</lpage>.<pub-id pub-id-type="pmid">17313281</pub-id></mixed-citation>
      </ref>
      <ref id="bibr8-1941738114553165">
        <label>8.</label>
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Chu</surname><given-names>DA</given-names></name></person-group>
<source>Jumping into Plyometrics</source>. <publisher-loc>Champaign, IL</publisher-loc>: <publisher-name>Human Kinetics Publishers</publisher-name>; <year>1998</year>.</mixed-citation>
      </ref>
      <ref id="bibr9-1941738114553165">
        <label>9.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cordasco</surname><given-names>FA</given-names></name><name><surname>Wolf</surname><given-names>IN</given-names></name><name><surname>Wooten</surname><given-names>ME</given-names></name><name><surname>Bigliani</surname><given-names>LU</given-names></name></person-group>
<article-title>An electromyographic analysis of the shoulder during a medicine ball rehabilitation program</article-title>. <source>Am J Sports Med</source>. <year>1996</year>;<volume>24</volume>:<fpage>386</fpage>-<lpage>392</lpage>.<pub-id pub-id-type="pmid">8734893</pub-id></mixed-citation>
      </ref>
      <ref id="bibr10-1941738114553165">
        <label>10.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Decker</surname><given-names>MJ</given-names></name><name><surname>Hintermeister</surname><given-names>RA</given-names></name><name><surname>Faber</surname><given-names>KJ</given-names></name><name><surname>Hawkins</surname><given-names>RJ</given-names></name></person-group>
<article-title>Serratus anterior muscle activity during selected rehabilitation exercises</article-title>. <source>Am J Sports Med</source>. <year>1999</year>;<volume>27</volume>:<fpage>784</fpage>-<lpage>791</lpage>.<pub-id pub-id-type="pmid">10569366</pub-id></mixed-citation>
      </ref>
      <ref id="bibr11-1941738114553165">
        <label>11.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Donatelli</surname><given-names>RA</given-names></name><name><surname>Ekstrom</surname><given-names>RA</given-names></name></person-group>, <article-title>Surface electromyographic analysis of exercises for the trapezius and serratus anterior muscles</article-title>. <source>J Orthop Sports Phys Ther</source>. <year>2003</year>;<volume>33</volume>:<fpage>247</fpage>-<lpage>258</lpage>.<pub-id pub-id-type="pmid">12774999</pub-id></mixed-citation>
      </ref>
      <ref id="bibr12-1941738114553165">
        <label>12.</label>
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Ellenbecker</surname><given-names>TS</given-names></name></person-group>
<source>Shoulder Rehabilitation: Non-Operative Treatment</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Thieme</publisher-name>; <year>2006</year>.</mixed-citation>
      </ref>
      <ref id="bibr13-1941738114553165">
        <label>13.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ellenbecker</surname><given-names>TS</given-names></name><name><surname>Davies</surname><given-names>GJ</given-names></name><name><surname>Rowinski</surname><given-names>MJ</given-names></name></person-group>
<article-title>Concentric versus eccentric isokinetic strengthening of the rotator cuff: objective data versus functional test</article-title>. <source>Am J Sports Med</source>. <year>1988</year>;<volume>16</volume>:<fpage>64</fpage>-<lpage>69</lpage>.<pub-id pub-id-type="pmid">3344883</pub-id></mixed-citation>
      </ref>
      <ref id="bibr14-1941738114553165">
        <label>14.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fleisig</surname><given-names>GS</given-names></name><name><surname>Andrews</surname><given-names>JR</given-names></name><name><surname>Dillman</surname><given-names>CJ</given-names></name><name><surname>Escamilla</surname><given-names>RF</given-names></name></person-group>
<article-title>Kinetics of baseball pitching with implications about injury mechanisms</article-title>. <source>Am J Sports Med</source>. <year>1995</year>;<volume>23</volume>:<fpage>233</fpage>-<lpage>239</lpage>.<pub-id pub-id-type="pmid">7778711</pub-id></mixed-citation>
      </ref>
      <ref id="bibr15-1941738114553165">
        <label>15.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Heiderscheit</surname><given-names>BC</given-names></name><name><surname>Palmer-McLean</surname><given-names>Karen</given-names></name><name><surname>Davies</surname><given-names>GJ</given-names></name></person-group>
<article-title>The effects of isokinetic vs. plyometric training of the shoulder internal rotators</article-title>. <source>J Orthop Sports Phys Ther</source>. <year>1996</year>;<volume>23</volume>:<fpage>125</fpage>-<lpage>133</lpage>.<pub-id pub-id-type="pmid">8808515</pub-id></mixed-citation>
      </ref>
      <ref id="bibr16-1941738114553165">
        <label>16.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kelley</surname><given-names>BT</given-names></name><name><surname>Kadrmas</surname><given-names>WR</given-names></name><name><surname>Speer</surname><given-names>KP</given-names></name></person-group>
<article-title>The manual muscle examination for shoulder rotator cuff strength. An electromyographic investigation</article-title>. <source>Am J Sports Med</source>. <year>1996</year>;<volume>24</volume>:<fpage>581</fpage>-<lpage>588</lpage>.<pub-id pub-id-type="pmid">8883676</pub-id></mixed-citation>
      </ref>
      <ref id="bibr17-1941738114553165">
        <label>17.</label>
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Kendall</surname><given-names>FP</given-names></name><name><surname>McCreary</surname><given-names>EK</given-names></name><name><surname>Provance</surname><given-names>PG</given-names></name></person-group>
<source>Muscles: Testing and Function</source>. <publisher-loc>Baltimore, MD</publisher-loc>: <publisher-name>Williams &amp; Wilkins</publisher-name>; <year>1993</year>.</mixed-citation>
      </ref>
      <ref id="bibr18-1941738114553165">
        <label>18.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kibler</surname><given-names>WB</given-names></name><name><surname>Sascia</surname><given-names>A</given-names></name><name><surname>Uhl</surname><given-names>T</given-names></name><name><surname>Tambay</surname><given-names>N</given-names></name><name><surname>Cunningham</surname><given-names>T</given-names></name></person-group>
<article-title>Electromyographic analysis of specific exercises for scapular control in early phases of shoulder rehabilitation</article-title>. <source>Am J Sports Med</source>. <year>2008</year>;<volume>36</volume>:<fpage>1789</fpage>-<lpage>1798</lpage>.<pub-id pub-id-type="pmid">18469224</pub-id></mixed-citation>
      </ref>
      <ref id="bibr19-1941738114553165">
        <label>19.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kovacs</surname><given-names>M</given-names></name><name><surname>Roetert</surname><given-names>EP</given-names></name><name><surname>Ellenbecker</surname><given-names>TS</given-names></name></person-group>
<article-title>Efficient deceleration: the forgotten factor in tennis-specific training</article-title>. <source>Strength Cond J</source>. <year>2008</year>;<volume>30</volume>(<issue>6</issue>):<fpage>58</fpage>-<lpage>69</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr20-1941738114553165">
        <label>20.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Malanga</surname><given-names>GA</given-names></name><name><surname>Jenp</surname><given-names>YN</given-names></name><name><surname>Growney</surname><given-names>ES</given-names></name><name><surname>An</surname><given-names>KN</given-names></name></person-group>
<article-title>EMG analysis of shoulder positioning in testing and strengthening the supraspinatus</article-title>. <source>Med Sci Sports Exerc</source>. <year>1996</year>;<volume>28</volume>:<fpage>661</fpage>-<lpage>664</lpage>.<pub-id pub-id-type="pmid">8784752</pub-id></mixed-citation>
      </ref>
      <ref id="bibr21-1941738114553165">
        <label>21.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moesley</surname><given-names>JB</given-names><suffix>Jr</suffix></name><name><surname>Jobe</surname><given-names>FW</given-names></name><name><surname>Pink</surname><given-names>M</given-names></name><name><surname>Perry</surname><given-names>J</given-names></name><name><surname>Tibone</surname><given-names>J</given-names></name></person-group>
<article-title>EMG analysis of the scapular muscles during a shoulder rehabilitation program</article-title>. <source>Am J Sports Med</source>. <year>1992</year>;<volume>20</volume>:<fpage>128</fpage>-<lpage>134</lpage>.<pub-id pub-id-type="pmid">1558238</pub-id></mixed-citation>
      </ref>
      <ref id="bibr22-1941738114553165">
        <label>22.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mont</surname><given-names>MA</given-names></name><name><surname>Cohen</surname><given-names>DB</given-names></name><name><surname>Campbell</surname><given-names>KR</given-names></name><name><surname>Gravare</surname><given-names>K</given-names></name><name><surname>Mathur</surname><given-names>S</given-names></name></person-group>
<article-title>Isokinetic concentric versus eccentric training of the shoulder rotators with functional evaluation of performance enhancement in elite tennis players</article-title>. <source>Am J Sports Med</source>. <year>1994</year>;<volume>22</volume>:<fpage>513</fpage>-<lpage>517</lpage>.<pub-id pub-id-type="pmid">7943517</pub-id></mixed-citation>
      </ref>
      <ref id="bibr23-1941738114553165">
        <label>23.</label>
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Perotto</surname><given-names>AO</given-names></name></person-group>
<source>Anatomical Guide for the Electromyographer: The Limbs and Trunk</source>. <publisher-loc>Springfield, IL</publisher-loc>: <publisher-name>Charles C. Thomas</publisher-name>; <year>1994</year>.</mixed-citation>
      </ref>
      <ref id="bibr24-1941738114553165">
        <label>24.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reid</surname><given-names>M</given-names></name><name><surname>Elliott</surname><given-names>B</given-names></name><name><surname>Alderson</surname><given-names>J</given-names></name></person-group>
<article-title>Shoulder joint loading in the high performance flat and kick tennis serves</article-title>. <source>Br J Sports Med</source>. <year>2007</year>;<volume>41</volume>:<fpage>884</fpage>-<lpage>889</lpage>.<pub-id pub-id-type="pmid">17513331</pub-id></mixed-citation>
      </ref>
      <ref id="bibr25-1941738114553165">
        <label>25.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reinold</surname><given-names>MM</given-names></name><name><surname>Macrina</surname><given-names>LC</given-names></name><name><surname>Wilk</surname><given-names>KE</given-names></name><etal/></person-group>
<article-title>Electromyographic analysis of the supraspinatus and deltoid muscles during common rehabilitation exercises</article-title>. <source>J Athl Train</source>. <year>2007</year>;<volume>42</volume>:<fpage>464</fpage>-<lpage>469</lpage>.<pub-id pub-id-type="pmid">18174934</pub-id></mixed-citation>
      </ref>
      <ref id="bibr26-1941738114553165">
        <label>26.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reinold</surname><given-names>MM</given-names></name><name><surname>Wilk</surname><given-names>KE</given-names></name><name><surname>Fleisig</surname><given-names>GS</given-names></name><name><surname>Zheng</surname><given-names>N</given-names></name><name><surname>Barrentine</surname><given-names>SW</given-names></name><name><surname>Chmielewski</surname><given-names>T</given-names></name></person-group>
<article-title>Electromyographic analysis of the rotator cuff and deltoid musculature during common shoulder external rotation exercises</article-title>. <source>J Orthop Sports Phys Ther</source>. <year>2004</year>;<volume>34</volume>:<fpage>385</fpage>-<lpage>394</lpage>.<pub-id pub-id-type="pmid">15296366</pub-id></mixed-citation>
      </ref>
      <ref id="bibr27-1941738114553165">
        <label>27.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ryu</surname><given-names>KN</given-names></name><name><surname>McCormick</surname><given-names>FW</given-names></name><name><surname>Jobe</surname><given-names>FW</given-names></name><name><surname>Moynes</surname><given-names>DR</given-names></name><name><surname>Antonelli</surname><given-names>DJ</given-names></name></person-group>
<article-title>An electromyographic analysis of shoulder function in tennis players</article-title>. <source>Am J Sports Med</source>. <year>1988</year>;<volume>16</volume>:<fpage>481</fpage>-<lpage>485</lpage>.<pub-id pub-id-type="pmid">3189681</pub-id></mixed-citation>
      </ref>
      <ref id="bibr28-1941738114553165">
        <label>28.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schulte-Edelmann</surname><given-names>JA</given-names></name><name><surname>Davies</surname><given-names>GJ</given-names></name><name><surname>Kernozek</surname><given-names>TW</given-names></name><name><surname>Gerberding</surname><given-names>ED</given-names></name></person-group>
<article-title>The effects of plyometric training of the posterior shoulder and elbow</article-title>. <source>J Strength Cond Res</source>. <year>2005</year>;<volume>19</volume>:<fpage>129</fpage>-<lpage>134</lpage>.<pub-id pub-id-type="pmid">15707381</pub-id></mixed-citation>
      </ref>
      <ref id="bibr29-1941738114553165">
        <label>29.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Swanik</surname><given-names>KA</given-names></name><name><surname>Lephart</surname><given-names>SM</given-names></name><name><surname>Swanik</surname><given-names>B</given-names></name><name><surname>Lephart</surname><given-names>SP</given-names></name><name><surname>Stone</surname><given-names>DA</given-names></name><name><surname>Fu</surname><given-names>FH</given-names></name></person-group>
<article-title>The effects of shoulder plyometric training on proprioception and selected muscle performance</article-title>. <source>J Shoulder Elbow Surg</source>. <year>2002</year>;<volume>11</volume>:<fpage>579</fpage>-<lpage>586</lpage>.<pub-id pub-id-type="pmid">12469083</pub-id></mixed-citation>
      </ref>
      <ref id="bibr30-1941738114553165">
        <label>30.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Townsend</surname><given-names>H</given-names></name><name><surname>Jobe</surname><given-names>FW</given-names></name><name><surname>Pink</surname><given-names>M</given-names></name><name><surname>Perry</surname><given-names>J</given-names></name></person-group>
<article-title>Electromyographic analysis of the glenohumeral muscles during a baseball rehabilitation program</article-title>. <source>Am J Sports Med</source>. <year>1991</year>;<volume>19</volume>:<fpage>264</fpage>-<lpage>272</lpage>.<pub-id pub-id-type="pmid">1867334</pub-id></mixed-citation>
      </ref>
      <ref id="bibr31-1941738114553165">
        <label>31.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Trieber</surname><given-names>FA</given-names></name><name><surname>Lott</surname><given-names>J</given-names></name><name><surname>Duncan</surname><given-names>J</given-names></name><name><surname>Slavens</surname><given-names>G</given-names></name><name><surname>Davis</surname><given-names>H</given-names></name></person-group>
<article-title>Effects of Thera-band and lightweight dumbbell training on shoulder rotation torque and serve performance in college tennis players</article-title>. <source>Am J Sports Med</source>. <year>1998</year>;<volume>26</volume>:<fpage>510</fpage>-<lpage>515</lpage>.<pub-id pub-id-type="pmid">9689369</pub-id></mixed-citation>
      </ref>
      <ref id="bibr32-1941738114553165">
        <label>32.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wilk</surname><given-names>KE</given-names></name><name><surname>Obma</surname><given-names>P</given-names></name><name><surname>Simpson</surname><given-names>CD</given-names></name><name><surname>Cain</surname><given-names>EL</given-names></name><name><surname>Dugas</surname><given-names>J</given-names></name><name><surname>Andrews</surname><given-names>JR</given-names></name></person-group>
<article-title>Shoulder injuries in the overhead athlete</article-title>. <source>J Orthop Sports Phys Ther</source>. <year>2009</year>;<volume>39</volume>:<fpage>38</fpage>-<lpage>54</lpage>.<pub-id pub-id-type="pmid">19194026</pub-id></mixed-citation>
      </ref>
      <ref id="bibr33-1941738114553165">
        <label>33.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wilk</surname><given-names>KE</given-names></name><name><surname>Voight</surname><given-names>ML</given-names></name><name><surname>Keirns</surname><given-names>MA</given-names></name><name><surname>Gambetta</surname><given-names>V</given-names></name><name><surname>Dillman</surname><given-names>CJ</given-names></name><name><surname>Andrews</surname><given-names>JR</given-names></name></person-group>
<article-title>Stretch-shortening drills for the upper extremities: theory and clinical application</article-title>. <source>J Orthop Sports Phys Ther</source>. <year>1993</year>;<volume>17</volume>:<fpage>225</fpage>-<lpage>239</lpage>.<pub-id pub-id-type="pmid">8343780</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:4272696</identifier><datestamp>2016-01-01</datestamp><setSpec>sportshealth</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="http://jats.nlm.nih.gov/ns/archiving/1.0/ http://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Sports Health</journal-id>
      <journal-id journal-id-type="iso-abbrev">Sports Health</journal-id>
      <journal-id journal-id-type="publisher-id">SPH</journal-id>
      <journal-id journal-id-type="hwp">spsph</journal-id>
      <journal-title-group>
        <journal-title>Sports Health</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1941-7381</issn>
      <issn pub-type="epub">1941-0921</issn>
      <publisher>
        <publisher-name>SAGE Publications</publisher-name>
        <publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4272696</article-id>
      <article-id pub-id-type="pmcid">PMC4272696</article-id>
      <article-id pub-id-type="pmc-uid">4272696</article-id>
      <article-id pub-id-type="pmid">25553213</article-id>
      <article-id pub-id-type="doi">10.1177/1941738114555075</article-id>
      <article-id pub-id-type="publisher-id">10.1177_1941738114555075</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Focus Topic: Controversies in Sports Medicine</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Protracted Recovery From a Concussion</article-title>
        <subtitle>A Focus on Gender and Treatment Interventions in an Adolescent Population</subtitle>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Kostyun</surname>
            <given-names>Regina O.</given-names>
          </name>
          <degrees>MSEd, ATC</degrees>
          <xref ref-type="corresp" rid="corresp1-1941738114555075">*</xref>
          <xref ref-type="aff" rid="aff1-1941738114555075">†</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hafeez</surname>
            <given-names>Imran</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="aff1-1941738114555075">†</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1-1941738114555075"><label>†</label>Elite Sports Medicine, Connecticut Children’s Medical Center, Farmington, Connecticut</aff>
      <author-notes>
        <corresp id="corresp1-1941738114555075"><label>*</label>Regina O. Kostyun, MSEd, ATC, Elite Sports Medicine, Connecticut Children’s Medical Center, 399 Farmington Avenue, Farmington, CT 06032 (e-mail: <email>rkostyun@connecticutchildrens.org</email>).</corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>1</day>
        <month>1</month>
        <year>2016</year>
      </pub-date>
      <!-- PMC Release delay is 12 months and 0 days and was based on the <pub-date pub-type="ppub"/>. -->
      <volume>7</volume>
      <issue>1</issue>
      <fpage>52</fpage>
      <lpage>57</lpage>
      <permissions>
        <copyright-statement>© 2014 The Author(s)</copyright-statement>
        <copyright-year>2014</copyright-year>
        <copyright-holder content-type="sage">American Orthopaedic Society for Sports Medicine</copyright-holder>
      </permissions>
      <abstract>
        <sec id="section1-1941738114555075">
          <title>Background:</title>
          <p>Several studies have demonstrated that age and sex may influence concussion recovery time frames, with female athletes and adolescents being potentially more susceptible to a protracted recovery course. Currently, limited work has examined the influence sex may have on concussion management strategies and treatment interventions, especially for younger individuals suffering persistent concussion symptoms and cognitive dysfunctions.</p>
        </sec>
        <sec id="section2-1941738114555075">
          <title>Hypothesis:</title>
          <p>Female athletes are prescribed more treatment interventions than male athletes during a protracted recovery from a concussion.</p>
        </sec>
        <sec id="section3-1941738114555075">
          <title>Study Design:</title>
          <p>Descriptive epidemiology study.</p>
        </sec>
        <sec id="section4-1941738114555075">
          <title>Level of Evidence:</title>
          <p>Level 4.</p>
        </sec>
        <sec id="section5-1941738114555075">
          <title>Methods:</title>
          <p>Data were retrospectively collected for adolescent athletes presenting to a sports medicine concussion clinic between September 2010 and September 2011.</p>
        </sec>
        <sec id="section6-1941738114555075">
          <title>Results:</title>
          <p>A total of 266 adolescent athletes were evaluated and treated for concussion. Female athletes had a longer recovery course (<italic>P</italic> = 0.002) and required more treatment interventions (<italic>P</italic> &lt; 0.001) for their symptoms and dysfunction. Female athletes were more likely to require academic accommodations (<italic>P</italic> &lt; 0.001), vestibular therapy (<italic>P</italic> &lt; 0.001), or medication (<italic>P</italic> &lt; 0.001).</p>
        </sec>
        <sec id="section7-1941738114555075">
          <title>Conclusion:</title>
          <p>Medical providers should be aware that during the recovery course, adolescent female athletes may require a management plan that will most likely include additional treatment interventions beyond the standard cognitive and physical rest.</p>
        </sec>
        <sec id="section8-1941738114555075">
          <title>Clinical Relevance:</title>
          <p>Treatment interventions are more commonly prescribed for adolescent female athletes than for adolescent male athletes during a protracted recovery from a concussion. This highlights the need for identifying evidence-based clinical management guidelines that focus on sex, especially when dealing with persistent concussion symptoms and cognitive dysfunctions.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>concussion</kwd>
        <kwd>sex</kwd>
        <kwd>adolescent</kwd>
        <kwd>treatment intervention</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>January/February 2015</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <p>Sex differences among concussed athletes are well documented.<sup><xref rid="bibr5-1941738114555075" ref-type="bibr">5</xref>,<xref rid="bibr7-1941738114555075" ref-type="bibr">7</xref>,<xref rid="bibr9-1941738114555075" ref-type="bibr">9</xref>,<xref rid="bibr15-1941738114555075" ref-type="bibr">15</xref>,<xref rid="bibr40-1941738114555075" ref-type="bibr">40</xref></sup> Dissimilarities between male and female athletes range from anthropometric, neuromuscular, and strength differences to postconcussion symptoms and cognitive dysfunctions that can influence an individual’s recovery time. Over the past decade, epidemiologic studies have identified a surge in the incidence of sport-related concussions for female athletes<sup><xref rid="bibr26-1941738114555075" ref-type="bibr">26</xref></sup> as well as an increased rate of injury for female athletes when compared with male athletes in sex-equivalent sports.<sup><xref rid="bibr15-1941738114555075" ref-type="bibr">15</xref>,<xref rid="bibr26-1941738114555075" ref-type="bibr">26</xref>,<xref rid="bibr28-1941738114555075" ref-type="bibr">28</xref>,<xref rid="bibr37-1941738114555075" ref-type="bibr">37</xref></sup> Female athletes have longer cervical spine segments and may not be as efficient at transmitting impact forces from their head into their torso via their cervical musculature during a concussive event, thus potentially resulting in a higher incidence of injury.<sup><xref rid="bibr4-1941738114555075" ref-type="bibr">4</xref>,<xref rid="bibr14-1941738114555075" ref-type="bibr">14</xref>,<xref rid="bibr42-1941738114555075" ref-type="bibr">42</xref></sup> Female athletes may also be more likely to seek medical treatment for concussive symptoms and to honestly report symptoms when they suffer a concussion.<sup><xref rid="bibr5-1941738114555075" ref-type="bibr">5</xref>,<xref rid="bibr7-1941738114555075" ref-type="bibr">7</xref>,<xref rid="bibr9-1941738114555075" ref-type="bibr">9</xref>,<xref rid="bibr10-1941738114555075" ref-type="bibr">10</xref></sup> Ultimately, sex differences in injury susceptibility and recovery time frames are most likely multifactorial in etiology and reinforce the need for an individualized management approach.<sup><xref rid="bibr6-1941738114555075" ref-type="bibr">6</xref>,<xref rid="bibr8-1941738114555075" ref-type="bibr">8</xref></sup></p>
    <p>With several million concussions occurring each year in the United States, paired with a heightened public recognition of appropriate and prompt care for this injury acutely, clinicians are seeing an increase in concussion patients.<sup><xref rid="bibr3-1941738114555075" ref-type="bibr">3</xref></sup> Current clinical guidelines advocate for individualized care by recommending physical as well as cognitive rest until resolution of postconcussion symptoms and cognitive dysfunctions before reinstating exertional activities.<sup><xref rid="bibr32-1941738114555075" ref-type="bibr">32</xref>,<xref rid="bibr33-1941738114555075" ref-type="bibr">33</xref></sup> In the majority of individuals, this recovery takes only a few days<sup><xref rid="bibr32-1941738114555075" ref-type="bibr">32</xref></sup> and requires few management strategies.</p>
    <p>However, there is emerging evidence that recognizes younger individuals may experience a longer recovery course.<sup><xref rid="bibr19-1941738114555075" ref-type="bibr">19</xref>,<xref rid="bibr24-1941738114555075" ref-type="bibr">24</xref>,<xref rid="bibr31-1941738114555075" ref-type="bibr">31</xref></sup> Recent studies have estimated that adolescents may be more susceptible to a protracted recovery that requires multiple weeks or even months for the concussion to fully resolve.<sup><xref rid="bibr29-1941738114555075" ref-type="bibr">29</xref>,<xref rid="bibr37-1941738114555075" ref-type="bibr">37</xref></sup> In situations where cognitive difficulties, persistent symptoms, disrupted sleeping patterns, and emotional stressors are of concern, a combination of treatment strategies may be incorporated into the management plan. Current guidelines and consensus statements provide limited direction for managing patients with persistent symptoms and dysfunctions after a concussion<sup><xref rid="bibr6-1941738114555075" ref-type="bibr">6</xref></sup> since a comprehensive understanding of the long-term sequelae of a concussion, especially in an adolescent population, is still largely unknown. Although it is understood that attributable variables, such as age and sex, may predispose an individual to a longer recovery course,<sup><xref rid="bibr5-1941738114555075" ref-type="bibr">5</xref>,<xref rid="bibr13-1941738114555075" ref-type="bibr">13</xref>,<xref rid="bibr23-1941738114555075" ref-type="bibr">23</xref></sup> how these variables influence the association between treatment interventions and recovery length has not been established. Therefore, the purpose of this study was to describe the frequency of treatment interventions prescribed for each sex during the management of adolescent athletes with protracted postconcussion symptoms and cognitive dysfunctions. It was hypothesized that adolescent female athletes would be prescribed more treatment interventions than male athletes during their recovery from concussion.</p>
    <sec sec-type="methods" id="section9-1941738114555075">
      <title>Methods</title>
      <p>A retrospective chart review design was used in this study and approved by the institutional review board. All patients were seen at an outpatient adolescent sports medicine concussion clinic, which included 2 physicians, and 1 physician assistant. Inclusion criteria were (1) initially seen between September 2010 and September 2011, (2) diagnosed with a concussion (ICD-9 code 850.9), (3) between the ages of 11 and 18 years, and (4) managed through completion of care. A large portion of our patients were treated through a community-wide comanagement program, where community pediatricians would refer patients to our clinic who were still symptomatic 3 weeks after injury.</p>
      <p>Recovery from the concussion was determined by the medical provider once the individual and their parent or guardian expressed their symptoms were back to baseline. Signs of recovery included behaving normally at home, completing full academic activities with no restrictions or limitations, demonstrating competent scores on neurocognitive tests, and clearance for unrestricted physical activity.</p>
      <p>The primary outcomes for this study were sex and the number of treatment interventions during the management of a concussion for adolescent athletes. Treatment interventions included rest, academic accommodations, and medications as well as referrals to physical therapy, vestibular therapy, neuropsychology, neurology, speech pathology, and psychology. During the rest period, patients were asked to avoid the classroom environment and to refrain from participation in academic activities at home. The interventions of rest and academic accommodations were identified by school notes.</p>
      <p>Statistical analyses were conducted using SAS (version 9.3; SAS Institute). Descriptive analysis was conducted for age, sport, and treatment interventions. A single-factor analysis of variance was used to determine the differences between sex and recovery along with sex and number of prescribed treatment interventions. A univariate logistic regression with an alpha level set at 0.05 was used to determine sex and specific treatment intervention.</p>
    </sec>
    <sec sec-type="results" id="section10-1941738114555075">
      <title>Results</title>
      <p>A total of 266 adolescent athletes, including 102 female athletes, who were treated for concussion during the 2010-2011 sports season met the inclusion criteria for this study (<xref ref-type="fig" rid="fig1-1941738114555075">Figure 1</xref>). The average ages for female and male athletes were 14.9 ± 3.4 years and 14.3 ± 2.3 years, respectively. On average, female athletes took longer to recover from their concussions than male athletes: 75.6 ± 73.0 and 49.7 ± 62.0 days, respectively (<italic>P</italic> = 0.002). More than half the female (67.6%) and male (53%) athletes had a recovery time greater than 1 month (<xref ref-type="fig" rid="fig2-1941738114555075">Figure 2</xref>).</p>
      <fig id="fig1-1941738114555075" position="float">
        <label>Figure 1.</label>
        <caption>
          <p>Sports participation at the time of concussion.</p>
        </caption>
        <graphic xlink:href="10.1177_1941738114555075-fig1"/>
      </fig>
      <fig id="fig2-1941738114555075" position="float">
        <label>Figure 2.</label>
        <caption>
          <p>Time until recovery for each sex.</p>
        </caption>
        <graphic xlink:href="10.1177_1941738114555075-fig2"/>
      </fig>
      <p>The most commonly prescribed treatment inventions for female and male athletes were rest (95.1% and 73.2%) and academic accommodations (72.5 and 42.1%), respectively. The average number of treatment interventions prescribed during the management of a concussion was 2.2 ± 1.5 for female and 1.3 ± 1.0 for male athletes (<italic>P</italic> &lt; 0.001). The differences in treatment interventions between sexes were significant for rest (<italic>P</italic> &lt; 0.001), academic accommodations (<italic>P</italic> &lt; 0.001), vestibular therapy (<italic>P</italic> &lt; 0.001), and medications (<italic>P</italic> &lt; 0.001). Female athletes were 7 times more likely to be prescribed rest, 3 times more likely to be prescribed academic accommodations, 8 times more likely to be prescribed vestibular therapy, and 4 times more likely to be prescribed medication over male athletes (<xref ref-type="table" rid="table1-1941738114555075">Table 1</xref>).</p>
      <table-wrap id="table1-1941738114555075" position="float">
        <label>Table 1.</label>
        <caption>
          <p>Number of patients who were prescribed each treatment intervention during the management of their concussion</p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th align="left" rowspan="1" colspan="1">Intervention/Referral</th>
              <th align="center" rowspan="1" colspan="1">Male Patients (N = 164)</th>
              <th align="center" rowspan="1" colspan="1">Female Patients (N = 102)</th>
              <th align="center" rowspan="1" colspan="1">Odds</th>
              <th align="center" rowspan="1" colspan="1">CI</th>
              <th align="center" rowspan="1" colspan="1">
                <italic>P</italic>
              </th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">Rest</td>
              <td rowspan="1" colspan="1">120</td>
              <td rowspan="1" colspan="1">97</td>
              <td rowspan="1" colspan="1">7.11</td>
              <td rowspan="1" colspan="1">2.71-18.6</td>
              <td rowspan="1" colspan="1">&lt;0.001</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Academic accommodations</td>
              <td rowspan="1" colspan="1">69</td>
              <td rowspan="1" colspan="1">74</td>
              <td rowspan="1" colspan="1">3.63</td>
              <td rowspan="1" colspan="1">2.13-6.21</td>
              <td rowspan="1" colspan="1">&lt;0.001</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Vestibular therapy</td>
              <td rowspan="1" colspan="1">9</td>
              <td rowspan="1" colspan="1">33</td>
              <td rowspan="1" colspan="1">8.23</td>
              <td rowspan="1" colspan="1">3.7-18.1</td>
              <td rowspan="1" colspan="1">&lt;0.001</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Medications</td>
              <td rowspan="1" colspan="1">10</td>
              <td rowspan="1" colspan="1">22</td>
              <td rowspan="1" colspan="1">4.23</td>
              <td rowspan="1" colspan="1">1.91-9.37</td>
              <td rowspan="1" colspan="1">&lt;0.001</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Physical therapy</td>
              <td rowspan="1" colspan="1">5</td>
              <td rowspan="1" colspan="1">8</td>
              <td rowspan="1" colspan="1">2.70</td>
              <td rowspan="1" colspan="1">0.86-8.51</td>
              <td rowspan="1" colspan="1">0.080</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Neuropsychology</td>
              <td rowspan="1" colspan="1">3</td>
              <td rowspan="1" colspan="1">10</td>
              <td rowspan="1" colspan="1">5.83</td>
              <td rowspan="1" colspan="1">1.56-21.7</td>
              <td rowspan="1" colspan="1">0.009</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Neurology</td>
              <td rowspan="1" colspan="1">0</td>
              <td rowspan="1" colspan="1">6</td>
              <td align="center" rowspan="1" colspan="1">—</td>
              <td align="center" rowspan="1" colspan="1">—</td>
              <td rowspan="1" colspan="1">0.984</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Speech pathology</td>
              <td rowspan="1" colspan="1">2</td>
              <td rowspan="1" colspan="1">2</td>
              <td rowspan="1" colspan="1">1.62</td>
              <td rowspan="1" colspan="1">0.23-11.68</td>
              <td rowspan="1" colspan="1">0.632</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Psychology</td>
              <td rowspan="1" colspan="1">0</td>
              <td rowspan="1" colspan="1">1</td>
              <td align="center" rowspan="1" colspan="1">—</td>
              <td align="center" rowspan="1" colspan="1">—</td>
              <td rowspan="1" colspan="1">0.986</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
    <sec sec-type="discussion" id="section11-1941738114555075">
      <title>Discussion</title>
      <p>To enhance the understanding of the complex interaction between sex and age on concussion recovery, this study aimed to investigate the frequency of treatment interventions prescribed for each sex during the management of adolescent athletes with a protracted recovery from a concussion.</p>
      <p>The results of this study extend the understanding of persistent concussion symptoms and current management strategies in several ways. First, these results support current evidence that adolescent athletes require a greater amount of time to recover from a concussion than the traditionally quoted time frame of 7 to 10 days. The results also showed that adolescent female athletes were more likely to require additional treatment interventions beyond the standard cognitive and physical rest. This emphasizes the need for an individualized management plan for an athlete recovering from a concussion.</p>
      <p>Physical and cognitive rest is the cornerstone of concussion management.<sup><xref rid="bibr33-1941738114555075" ref-type="bibr">33</xref></sup> Those suffering from a concussion are recommended to rest from activities that exacerbate concussive symptoms. In our cohort, nearly all female athletes and the majority of male athletes were prescribed a period of rest after their concussions. Although rest was the most commonly prescribed treatment for each sex, a difference was found in the number of female athletes prescribed a period of absolute rest from academic and physical activities compared with male athletes. Female athletes often report a greater number of symptoms after a concussion and have greater declines in cognitive function than male athletes.<sup><xref rid="bibr5-1941738114555075" ref-type="bibr">5</xref></sup> Given the potential impact of these concussive symptoms and cognitive impairments on academic activities, it is possible that medical providers are more likely to initiate a period of absolute rest for female athletes as compared with male athletes.</p>
      <p>Unfortunately, there is currently no standard length of rest an individual will require after a concussion. However, in most patients, there is a point where the clinical benefits of rest are outweighed by the side effects caused by the lack of activity and social interactions. At this stage, the treating provider should alter a patient’s treatment to address the current concussive symptoms while avoiding the negative side effects that may further delay recovery.</p>
      <p>When a student is absent for an extended period of time, there may be a certain level of stress and anxiety about integrating back into the classroom environment.<sup><xref rid="bibr35-1941738114555075" ref-type="bibr">35</xref></sup> Students may become overwhelmed with trying to balance the normal workload of their classes with the additional task of completing the missed assignments during their absence. Approximately 6.3% of healthy adolescents have positive generalized anxiety disorder screens<sup><xref rid="bibr11-1941738114555075" ref-type="bibr">11</xref></sup> and may experience subclinical anxiety concerns over academics, social acceptance, and emotional difficulties,<sup><xref rid="bibr16-1941738114555075" ref-type="bibr">16</xref>,<xref rid="bibr17-1941738114555075" ref-type="bibr">17</xref>,<xref rid="bibr34-1941738114555075" ref-type="bibr">34</xref></sup> with many of these symptoms beginning as early as age 11 years.<sup><xref rid="bibr21-1941738114555075" ref-type="bibr">21</xref></sup> A disproportionate number of healthy adolescent female athletes, as compared with healthy adolescent male athletes, commonly express concerns about trouble sleeping, feeling tired, and being stressed out<sup><xref rid="bibr11-1941738114555075" ref-type="bibr">11</xref></sup> among other anxiety symptoms.<sup><xref rid="bibr16-1941738114555075" ref-type="bibr">16</xref></sup></p>
      <p>This study showed that female athletes with concussions were 3 times more likely than male athletes to be prescribed academic accommodations for their transition back into the classroom after a period of absolute rest. Therefore, it appears that female athletes may be more likely to need the security of academic accommodations to help ease potential anxiety or stress over missed assignments and incomplete grades. Although the exact accommodations prescribed were not collected as part of this study, they commonly range from simple adaptations such as assignment deadline extensions to aggressive modifications of the academic environment such as accommodations for light and noise sensitivity. In certain situations, the use of a tutor or implementation of a temporary action strategy that addresses the student’s current cognitive disabilities<sup><xref rid="bibr18-1941738114555075" ref-type="bibr">18</xref></sup> (504 plan) may be required in the event of a prolonged absence from the classroom.<sup><xref rid="bibr35-1941738114555075" ref-type="bibr">35</xref></sup></p>
      <p>Vestibular and visual dysfunctions have been identified in concussed individuals<sup><xref rid="bibr1-1941738114555075" ref-type="bibr">1</xref>,<xref rid="bibr2-1941738114555075" ref-type="bibr">2</xref></sup> with persistent symptoms of dizziness, imbalance, headaches, and nausea commonly provoked by repetitive eye movements during reading activities, note taking, or riding in a car. Although dizziness is a commonly reported symptom in the acute phase of a concussion,<sup><xref rid="bibr15-1941738114555075" ref-type="bibr">15</xref>,<xref rid="bibr28-1941738114555075" ref-type="bibr">28</xref></sup> dizziness during the on-field assessment of a concussion is an identifier of a protracted recovery course.<sup><xref rid="bibr25-1941738114555075" ref-type="bibr">25</xref></sup></p>
      <p>Vestibular therapy has been implemented in patients with chronic symptoms during activities of daily living after head injuries.<sup><xref rid="bibr1-1941738114555075" ref-type="bibr">1</xref>,<xref rid="bibr2-1941738114555075" ref-type="bibr">2</xref>,<xref rid="bibr20-1941738114555075" ref-type="bibr">20</xref></sup> In this study,<sup><xref rid="bibr1-1941738114555075" ref-type="bibr">1</xref></sup> female athletes were 8 times more likely to be prescribed vestibular therapy. Therefore, female athletes may be more susceptible than male athletes to vestibular or visual dysfunctions during their concussive episodes. These results may be limited by the lack of consideration of severity of postconcussion symptoms, which may have influenced the medical provider’s decision to prescribe such treatments. Unfortunately, little is known about the relationship of vestibular and visual dysfunctions to concussions as well as the appropriate time during the recovery course to implement therapeutic exercises. Cervical strains and whiplash injuries can present with similar symptoms of headache, dizziness, nausea, and visual dysfunction.<sup><xref rid="bibr12-1941738114555075" ref-type="bibr">12</xref>,<xref rid="bibr38-1941738114555075" ref-type="bibr">38</xref></sup></p>
      <p>To date, there has been no evidence to support medication usage to help correct the pathophysiologic processes that occur from trauma-induced biomechanical forces and thus shorten recovery times for a concussion.<sup><xref rid="bibr30-1941738114555075" ref-type="bibr">30</xref></sup> Since there is a limited role of over-the-counter medications for management of cognitive or somatic symptoms, medications are typically used to control significant or persistent symptoms. Melatonin may be a useful over-the-counter medication for sleep initiation in conjunction with sleep hygiene counseling.<sup><xref rid="bibr36-1941738114555075" ref-type="bibr">36</xref></sup> The off-label benefits of some prescription medications are options for managing somatic and cognitive symptoms<sup><xref rid="bibr22-1941738114555075" ref-type="bibr">22</xref>,<xref rid="bibr41-1941738114555075" ref-type="bibr">41</xref></sup> as well as sleep alternations.<sup><xref rid="bibr39-1941738114555075" ref-type="bibr">39</xref></sup> These medications should only be considered for those with prolonged recovery and functional deficits due to specific symptoms,<sup><xref rid="bibr41-1941738114555075" ref-type="bibr">41</xref></sup> as medications may preclude a return to physical activity. The concussed individual should be symptom free prior to progressing through a graded return to physical activity.<sup><xref rid="bibr32-1941738114555075" ref-type="bibr">32</xref></sup></p>
      <p>This study has several limitations, including the interpretation of clinical notes, missing charts, unrecorded information, and incomplete documentation. In addition, clinical outcomes were not used during the management of this injury to determine the effectiveness of each prescribed treatment intervention. It is possible that individually prescribed interventions did not improve the individual’s symptoms or dysfunctions and therefore additional interventions were applied to the management plan. Last, although statistically significant differences were found between sex and recovery as well as sex and treatment intervention, this study did not evaluate injury severity. It is possible that female athletes had more severe concussions than male athletes, which could explain the additional treatment interventions prescribed during the management of their injury.</p>
    </sec>
    <sec sec-type="conclusions" id="section12-1941738114555075">
      <title>Conclusion</title>
      <p>Adolescent athletes may be susceptible to a protracted recovery course from a concussion. Persistent symptoms and chronic cognitive dysfunctions can impact an adolescent athlete recovering from a concussion. Young female athletes may require an individualized treatment plan that will most likely contain additional treatment interventions outside of the standard cognitive and physical rest.</p>
      <graphic xlink:href="10.1177_1941738114555075-img1.jpg" id="img1-1941738114555075" position="anchor"/>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="conflict">
        <p>The authors report no potential conflicts of interest in the development and publication of this article.<?release-delay 12|0?></p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="bibr1-1941738114555075">
        <label>1.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alsalaheen</surname><given-names>BA</given-names></name><name><surname>Mucha</surname><given-names>A</given-names></name><name><surname>Morris</surname><given-names>LO</given-names></name><etal/></person-group>
<article-title>Vestibular rehabilitation for dizziness and balance disorders after concussion</article-title>. <source>J Neurol Phys Ther</source>. <year>2010</year>;<volume>34</volume>:<fpage>87</fpage>-<lpage>93</lpage>.<pub-id pub-id-type="pmid">20588094</pub-id></mixed-citation>
      </ref>
      <ref id="bibr2-1941738114555075">
        <label>2.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alsalaheen</surname><given-names>BA</given-names></name><name><surname>Whitney</surname><given-names>SL</given-names></name><name><surname>Mucha</surname><given-names>A</given-names></name><name><surname>Morris</surname><given-names>LO</given-names></name><name><surname>Furman</surname><given-names>JM</given-names></name><name><surname>Sparto</surname><given-names>PJ</given-names></name></person-group>
<article-title>Exercise prescription patterns in patients treated with vestibular rehabilitation after concussion</article-title>. <source>Physiother Res Int</source>. <year>2013</year>;<volume>18</volume>:<fpage>100</fpage>-<lpage>108</lpage>.<pub-id pub-id-type="pmid">22786783</pub-id></mixed-citation>
      </ref>
      <ref id="bibr3-1941738114555075">
        <label>3.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bakhos</surname><given-names>LL</given-names></name><name><surname>Lockhart</surname><given-names>GR</given-names></name><name><surname>Myers</surname><given-names>R</given-names></name><name><surname>Linakis</surname><given-names>JG</given-names></name></person-group>
<article-title>Emergency department visits for concussion in young child athletes</article-title>. <source>Pediatrics</source>. <year>2010</year>;<volume>126</volume>:<fpage>e550</fpage>-<lpage>e556</lpage>.<pub-id pub-id-type="pmid">20805145</pub-id></mixed-citation>
      </ref>
      <ref id="bibr4-1941738114555075">
        <label>4.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barth</surname><given-names>JT</given-names></name><name><surname>Freeman</surname><given-names>JR</given-names></name><name><surname>Broshek</surname><given-names>DK</given-names></name><name><surname>Varney</surname><given-names>RN</given-names></name></person-group>
<article-title>Acceleration-deceleration sport-related concussion: the gravity of it all</article-title>. <source>J Athl Train</source>. <year>2001</year>;<volume>36</volume>:<fpage>253</fpage>-<lpage>256</lpage>.<pub-id pub-id-type="pmid">12937493</pub-id></mixed-citation>
      </ref>
      <ref id="bibr5-1941738114555075">
        <label>5.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Broshek</surname><given-names>DK</given-names></name><name><surname>Kaushik</surname><given-names>T</given-names></name><name><surname>Freeman</surname><given-names>JR</given-names></name><name><surname>Erlanger</surname><given-names>D</given-names></name><name><surname>Webbe</surname><given-names>F</given-names></name><name><surname>Barth</surname><given-names>JT</given-names></name></person-group>
<article-title>Sex differences in outcome following sports-related concussion</article-title>. <source>J Neurosurg</source>. <year>2005</year>;<volume>102</volume>:<fpage>856</fpage>-<lpage>863</lpage>.<pub-id pub-id-type="pmid">15926710</pub-id></mixed-citation>
      </ref>
      <ref id="bibr6-1941738114555075">
        <label>6.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Broshek</surname><given-names>DK</given-names></name><name><surname>Samples</surname><given-names>H</given-names></name><name><surname>Beard</surname><given-names>J</given-names></name><name><surname>Goodkin</surname><given-names>HP</given-names></name></person-group>
<article-title>Current practices of the child neurologist in managing sports concussion</article-title>. <source>J Child Neurol</source>. <year>2014</year>;<volume>29</volume>:<fpage>17</fpage>-<lpage>22</lpage>.<pub-id pub-id-type="pmid">23143716</pub-id></mixed-citation>
      </ref>
      <ref id="bibr7-1941738114555075">
        <label>7.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Colvin</surname><given-names>AC</given-names></name><name><surname>Mullen</surname><given-names>J</given-names></name><name><surname>Lovell</surname><given-names>MR</given-names></name><name><surname>West</surname><given-names>RV</given-names></name><name><surname>Collins</surname><given-names>MW</given-names></name><name><surname>Groh</surname><given-names>M</given-names></name></person-group>
<article-title>The role of concussion history and gender in recovery from soccer-related concussion</article-title>. <source>Am J Sports Med</source>. <year>2009</year>;<volume>37</volume>:<fpage>1699</fpage>-<lpage>1704</lpage>.<pub-id pub-id-type="pmid">19460813</pub-id></mixed-citation>
      </ref>
      <ref id="bibr8-1941738114555075">
        <label>8.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Covassin</surname><given-names>T</given-names></name><name><surname>Elbin</surname><given-names>RJ</given-names></name></person-group>
<article-title>The female athlete: the role of gender in the assessment and management of sport-related concussion</article-title>. <source>Clin Sports Med</source>. <year>2011</year>;<volume>30</volume>:<fpage>125</fpage>-<lpage>131</lpage>.<pub-id pub-id-type="pmid">21074087</pub-id></mixed-citation>
      </ref>
      <ref id="bibr9-1941738114555075">
        <label>9.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Covassin</surname><given-names>T</given-names></name><name><surname>Schatz</surname><given-names>P</given-names></name><name><surname>Swanik</surname><given-names>CB</given-names></name></person-group>
<article-title>Sex differences in neuropsychological function and post-concussion symptoms of concussed collegiate athletes</article-title>. <source>Neurosurgery</source>. <year>2007</year>;<volume>61</volume>:<fpage>345</fpage>-<lpage>350</lpage>.<pub-id pub-id-type="pmid">17762747</pub-id></mixed-citation>
      </ref>
      <ref id="bibr10-1941738114555075">
        <label>10.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dick</surname><given-names>RW</given-names></name></person-group>
<article-title>Is there a gender difference in concussion incidence and outcomes?</article-title>
<source>Br J Sports Med</source>. <year>2009</year>;<volume>43</volume>(<issue>suppl 1</issue>):<fpage>i46</fpage>-<lpage>i50</lpage>.<pub-id pub-id-type="pmid">19433425</pub-id></mixed-citation>
      </ref>
      <ref id="bibr11-1941738114555075">
        <label>11.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dumont</surname><given-names>IP</given-names></name><name><surname>Olson</surname><given-names>AL</given-names></name></person-group>
<article-title>Primary care, depression, and anxiety: exploring somatic and emotional predictors of mental health status in adolescents</article-title>. <source>J Am Board Fam Med</source>. <year>2012</year>;<volume>25</volume>:<fpage>291</fpage>-<lpage>299</lpage>.<pub-id pub-id-type="pmid">22570392</pub-id></mixed-citation>
      </ref>
      <ref id="bibr12-1941738114555075">
        <label>12.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fernandez-de-Las-Penas</surname><given-names>C</given-names></name><name><surname>Simons</surname><given-names>D</given-names></name><name><surname>Cuadrado</surname><given-names>ML</given-names></name><name><surname>Pareja</surname><given-names>J</given-names></name></person-group>
<article-title>The role of myofascial trigger points in musculoskeletal pain syndromes of the head and neck</article-title>. <source>Curr Pain Headache Rep</source>. <year>2007</year>;<volume>11</volume>:<fpage>365</fpage>-<lpage>372</lpage>.<pub-id pub-id-type="pmid">17894927</pub-id></mixed-citation>
      </ref>
      <ref id="bibr13-1941738114555075">
        <label>13.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Field</surname><given-names>M</given-names></name><name><surname>Collins</surname><given-names>MW</given-names></name><name><surname>Lovell</surname><given-names>MR</given-names></name><name><surname>Maroon</surname><given-names>J</given-names></name></person-group>
<article-title>Does age play a role in recovery from sports-related concussion? A comparison of high school and collegiate athletes</article-title>. <source>J Pediatr</source>. <year>2003</year>;<volume>142</volume>:<fpage>546</fpage>-<lpage>553</lpage>.<pub-id pub-id-type="pmid">12756388</pub-id></mixed-citation>
      </ref>
      <ref id="bibr14-1941738114555075">
        <label>14.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Garces</surname><given-names>GL</given-names></name><name><surname>Medina</surname><given-names>D</given-names></name><name><surname>Milutinovic</surname><given-names>L</given-names></name><name><surname>Garavote</surname><given-names>P</given-names></name><name><surname>Guerado</surname><given-names>E</given-names></name></person-group>
<article-title>Normative database of isometric cervical strength in a healthy population</article-title>. <source>Med Sci Sports Exerc</source>. <year>2002</year>;<volume>34</volume>:<fpage>464</fpage>-<lpage>470</lpage>.<pub-id pub-id-type="pmid">11880811</pub-id></mixed-citation>
      </ref>
      <ref id="bibr15-1941738114555075">
        <label>15.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gessel</surname><given-names>LM</given-names></name><name><surname>Fields</surname><given-names>SK</given-names></name><name><surname>Collins</surname><given-names>CL</given-names></name><name><surname>Dick</surname><given-names>RW</given-names></name><name><surname>Comstock</surname><given-names>RD</given-names></name></person-group>
<article-title>Concussions among United States high school and collegiate athletes</article-title>. <source>J Athl Train</source>. <year>2007</year>;<volume>42</volume>:<fpage>495</fpage>-<lpage>503</lpage>.<pub-id pub-id-type="pmid">18174937</pub-id></mixed-citation>
      </ref>
      <ref id="bibr16-1941738114555075">
        <label>16.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grills-Taquechel</surname><given-names>AE</given-names></name><name><surname>Norton</surname><given-names>P</given-names></name><name><surname>Ollendick</surname><given-names>TH</given-names></name></person-group>
<article-title>A longitudinal examination of factors predicting anxiety during the transition to middle school</article-title>. <source>Anxiety Stress Coping</source>. <year>2010</year>;<volume>23</volume>:<fpage>493</fpage>-<lpage>513</lpage>.<pub-id pub-id-type="pmid">20711893</pub-id></mixed-citation>
      </ref>
      <ref id="bibr17-1941738114555075">
        <label>17.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grills</surname><given-names>AE</given-names></name><name><surname>Ollendick</surname><given-names>TH</given-names></name></person-group>
<article-title>Peer victimization, global self-worth, and anxiety in middle school children</article-title>. <source>J Clin Child Adolesc Psychol</source>. <year>2002</year>;<volume>31</volume>:<fpage>59</fpage>-<lpage>68</lpage>.<pub-id pub-id-type="pmid">11845651</pub-id></mixed-citation>
      </ref>
      <ref id="bibr18-1941738114555075">
        <label>18.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Halstead</surname><given-names>ME</given-names></name><name><surname>McAvoy</surname><given-names>K</given-names></name><name><surname>Devore</surname><given-names>CD</given-names></name><name><surname>Carl</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Logan</surname><given-names>K</given-names></name></person-group>
<article-title>Returning to learning following a concussion</article-title>. <source>Pediatrics</source>. <year>2013</year>;<volume>132</volume>:<fpage>948</fpage>-<lpage>957</lpage>.<pub-id pub-id-type="pmid">24163302</pub-id></mixed-citation>
      </ref>
      <ref id="bibr19-1941738114555075">
        <label>19.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Halstead</surname><given-names>ME</given-names></name><name><surname>Walter</surname><given-names>KD</given-names></name></person-group>
<article-title>American Academy of Pediatrics. Clinical report—sport-related concussion in children and adolescents</article-title>. <source>Pediatrics</source>. <year>2010</year>;<volume>126</volume>:<fpage>597</fpage>-<lpage>615</lpage>.<pub-id pub-id-type="pmid">20805152</pub-id></mixed-citation>
      </ref>
      <ref id="bibr20-1941738114555075">
        <label>20.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hoffer</surname><given-names>ME</given-names></name><name><surname>Gottshall</surname><given-names>KR</given-names></name><name><surname>Moore</surname><given-names>R</given-names></name><name><surname>Balough</surname><given-names>BJ</given-names></name><name><surname>Wester</surname><given-names>D</given-names></name></person-group>
<article-title>Characterizing and treating dizziness after mild head trauma</article-title>. <source>Otol Neurotol</source>. <year>2004</year>;<volume>25</volume>:<fpage>135</fpage>-<lpage>138</lpage>.<pub-id pub-id-type="pmid">15021772</pub-id></mixed-citation>
      </ref>
      <ref id="bibr21-1941738114555075">
        <label>21.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kessler</surname><given-names>RC</given-names></name><name><surname>Berglund</surname><given-names>P</given-names></name><name><surname>Demler</surname><given-names>O</given-names></name><name><surname>Jin</surname><given-names>R</given-names></name><name><surname>Merikangas</surname><given-names>KR</given-names></name><name><surname>Walters</surname><given-names>EE</given-names></name></person-group>
<article-title>Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication</article-title>. <source>Arch Gen Psychiatry</source>. <year>2005</year>;<volume>62</volume>:<fpage>593</fpage>-<lpage>602</lpage>.<pub-id pub-id-type="pmid">15939837</pub-id></mixed-citation>
      </ref>
      <ref id="bibr22-1941738114555075">
        <label>22.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kinnaman</surname><given-names>KA</given-names></name><name><surname>Mannix</surname><given-names>RC</given-names></name><name><surname>Comstock</surname><given-names>RD</given-names></name><name><surname>Meehan</surname><given-names>WP</given-names><suffix>3rd</suffix></name></person-group>
<article-title>Management strategies and medication use for treating paediatric patients with concussions</article-title>. <source>Acta Paediatr</source>. <year>2013</year>;<volume>102</volume>:<fpage>e424</fpage>-<lpage>e428</lpage>.<pub-id pub-id-type="pmid">23750873</pub-id></mixed-citation>
      </ref>
      <ref id="bibr23-1941738114555075">
        <label>23.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kontos</surname><given-names>AP</given-names></name><name><surname>Covassin</surname><given-names>T</given-names></name><name><surname>Elbin</surname><given-names>RJ</given-names></name><name><surname>Parker</surname><given-names>T</given-names></name></person-group>
<article-title>Depression and neurocognitive performance after concussion among male and female high school and collegiate athletes</article-title>. <source>Arch Phys Med Rehabil</source>. <year>2012</year>;<volume>93</volume>:<fpage>1751</fpage>-<lpage>1756</lpage>.<pub-id pub-id-type="pmid">22503738</pub-id></mixed-citation>
      </ref>
      <ref id="bibr24-1941738114555075">
        <label>24.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kutcher</surname><given-names>JS</given-names></name><name><surname>Eckner</surname><given-names>JT</given-names></name></person-group>
<article-title>At-risk populations in sports-related concussion</article-title>. <source>Curr Sports Med Rep</source>. <year>2010</year>;<volume>9</volume>:<fpage>16</fpage>-<lpage>20</lpage>.<pub-id pub-id-type="pmid">20071916</pub-id></mixed-citation>
      </ref>
      <ref id="bibr25-1941738114555075">
        <label>25.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lau</surname><given-names>BC</given-names></name><name><surname>Kontos</surname><given-names>AP</given-names></name><name><surname>Collins</surname><given-names>MW</given-names></name><name><surname>Mucha</surname><given-names>A</given-names></name><name><surname>Lovell</surname><given-names>MR</given-names></name></person-group>
<article-title>Which on-field signs/symptoms predict protracted recovery from sport-related concussion among high school football players?</article-title>
<source>Am J Sports Med</source>. <year>2011</year>;<volume>39</volume>:<fpage>2311</fpage>-<lpage>2318</lpage>.<pub-id pub-id-type="pmid">21712482</pub-id></mixed-citation>
      </ref>
      <ref id="bibr26-1941738114555075">
        <label>26.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lincoln</surname><given-names>AE</given-names></name><name><surname>Caswell</surname><given-names>SV</given-names></name><name><surname>Almquist</surname><given-names>JL</given-names></name><name><surname>Dunn</surname><given-names>RE</given-names></name><name><surname>Norris</surname><given-names>JB</given-names></name><name><surname>Hinton</surname><given-names>RY</given-names></name></person-group>
<article-title>Trends in concussion incidence in high school sports: a prospective 11-year study</article-title>. <source>Am J Sports Med</source>. <year>2011</year>;<volume>39</volume>:<fpage>958</fpage>-<lpage>963</lpage>.<pub-id pub-id-type="pmid">21278427</pub-id></mixed-citation>
      </ref>
      <ref id="bibr27-1941738114555075">
        <label>27.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lovell</surname><given-names>MR</given-names></name><name><surname>Collins</surname><given-names>MW</given-names></name><name><surname>Iverson</surname><given-names>GL</given-names></name><etal/></person-group>
<article-title>Recovery from mild concussion in high school athletes</article-title>. <source>J Neurosurg</source>. <year>2003</year>;<volume>98</volume>:<fpage>296</fpage>-<lpage>301</lpage>.<pub-id pub-id-type="pmid">12593614</pub-id></mixed-citation>
      </ref>
      <ref id="bibr28-1941738114555075">
        <label>28.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marar</surname><given-names>M</given-names></name><name><surname>McIlvain</surname><given-names>NM</given-names></name><name><surname>Fields</surname><given-names>SK</given-names></name><name><surname>Comstock</surname><given-names>RD</given-names></name></person-group>
<article-title>Epidemiology of concussions among United States high school athletes in 20 sports</article-title>. <source>Am J Sports Med</source>. <year>2012</year>;<volume>40</volume>:<fpage>747</fpage>-<lpage>755</lpage>.<pub-id pub-id-type="pmid">22287642</pub-id></mixed-citation>
      </ref>
      <ref id="bibr29-1941738114555075">
        <label>29.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McClincy</surname><given-names>MP</given-names></name><name><surname>Lovell</surname><given-names>MR</given-names></name><name><surname>Pardini</surname><given-names>J</given-names></name><name><surname>Collins</surname><given-names>MW</given-names></name><name><surname>Spore</surname><given-names>MK</given-names></name></person-group>
<article-title>Recovery from sports concussion in high school and collegiate athletes</article-title>. <source>Brain Inj</source>. <year>2006</year>;<volume>20</volume>:<fpage>33</fpage>-<lpage>39</lpage>.<pub-id pub-id-type="pmid">16403698</pub-id></mixed-citation>
      </ref>
      <ref id="bibr30-1941738114555075">
        <label>30.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McCrory</surname><given-names>P</given-names></name></person-group>
<article-title>Should we treat concussion pharmacologically? The need for evidence based pharmacological treatment for the concussed athlete</article-title>. <source>Br J Sports Med</source>. <year>2002</year>;<volume>36</volume>:<fpage>3</fpage>-<lpage>5</lpage>.<pub-id pub-id-type="pmid">11867481</pub-id></mixed-citation>
      </ref>
      <ref id="bibr31-1941738114555075">
        <label>31.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McCrory</surname><given-names>P</given-names></name><name><surname>Johnston</surname><given-names>K</given-names></name><name><surname>Meeuwisse</surname><given-names>W</given-names></name><etal/></person-group>; <collab>International Symposium on Concussion in Sport</collab>. <article-title>Summary and agreement statement of the 2nd International Conference on Concussion in Sport, Prague 2004</article-title>. <source>Clin J Sport Med</source>. <year>2005</year>;<volume>15</volume>:<fpage>48</fpage>-<lpage>55</lpage>.<pub-id pub-id-type="pmid">15782046</pub-id></mixed-citation>
      </ref>
      <ref id="bibr32-1941738114555075">
        <label>32.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McCrory</surname><given-names>P</given-names></name><name><surname>Meeuwisse</surname><given-names>W</given-names></name><name><surname>Aubry</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Consensus statement on Concussion in Sport—the 4th International Conference on Concussion in Sport Held in Zurich, November 2012</article-title>. <source>Clin J Sport Med</source>. <year>2013</year>;<volume>23</volume>:<fpage>89</fpage>-<lpage>117</lpage>.<pub-id pub-id-type="pmid">23478784</pub-id></mixed-citation>
      </ref>
      <ref id="bibr33-1941738114555075">
        <label>33.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McCrory</surname><given-names>P</given-names></name><name><surname>Meeuwisse</surname><given-names>W</given-names></name><name><surname>Johnston</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Consensus Statement on Concussion in Sport: the 3rd International Conference on Concussion in Sport held in Zurich, November 2008</article-title>. <source>J Athl Train</source>. <year>2009</year>;<volume>44</volume>:<fpage>434</fpage>-<lpage>448</lpage>.<pub-id pub-id-type="pmid">19593427</pub-id></mixed-citation>
      </ref>
      <ref id="bibr34-1941738114555075">
        <label>34.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McGee</surname><given-names>R</given-names></name><name><surname>Feehan</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>S</given-names></name><name><surname>Anderson</surname><given-names>J</given-names></name></person-group>
<article-title>DSM-III disorders from age 11 to age 15 years</article-title>. <source>J Am Acad Child Adolesc Psychiatry</source>. <year>1992</year>;<volume>31</volume>:<fpage>50</fpage>-<lpage>59</lpage>.<pub-id pub-id-type="pmid">1537781</pub-id></mixed-citation>
      </ref>
      <ref id="bibr35-1941738114555075">
        <label>35.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McGrath</surname><given-names>N</given-names></name></person-group>
<article-title>Supporting the student-athlete’s return to the classroom after a sport-related concussion</article-title>. <source>J Athl Train</source>. <year>2010</year>;<volume>45</volume>:<fpage>492</fpage>-<lpage>498</lpage>.<pub-id pub-id-type="pmid">20831397</pub-id></mixed-citation>
      </ref>
      <ref id="bibr36-1941738114555075">
        <label>36.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meehan</surname><given-names>WP</given-names><suffix>3rd</suffix></name></person-group>
<article-title>Medical therapies for concussion</article-title>. <source>Clin Sports Med</source>. <year>2011</year>;<volume>30</volume>:<fpage>115</fpage>-<lpage>124</lpage>.<pub-id pub-id-type="pmid">21074086</pub-id></mixed-citation>
      </ref>
      <ref id="bibr37-1941738114555075">
        <label>37.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meehan</surname><given-names>WP</given-names><suffix>3rd</suffix></name><name><surname>d’Hemecourt</surname><given-names>P</given-names></name><name><surname>Comstock</surname><given-names>RD</given-names></name></person-group>
<article-title>High school concussions in the 2008-2009 academic year: mechanism, symptoms, and management</article-title>. <source>Am J Sports Med</source>. <year>2010</year>;<volume>38</volume>:<fpage>2405</fpage>-<lpage>2409</lpage>.<pub-id pub-id-type="pmid">20716683</pub-id></mixed-citation>
      </ref>
      <ref id="bibr38-1941738114555075">
        <label>38.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Missaghi</surname><given-names>B</given-names></name></person-group>
<article-title>Sternocleidomastoid syndrome: a case study</article-title>. <source>J Can Chiropr Assoc</source>. <year>2004</year>;<volume>48</volume>:<fpage>201</fpage>-<lpage>205</lpage>.<pub-id pub-id-type="pmid">17549118</pub-id></mixed-citation>
      </ref>
      <ref id="bibr39-1941738114555075">
        <label>39.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Morin</surname><given-names>AK</given-names></name><name><surname>Jarvis</surname><given-names>CI</given-names></name><name><surname>Lynch</surname><given-names>AM</given-names></name></person-group>
<article-title>Therapeutic options for sleep-maintenance and sleep-onset insomnia</article-title>. <source>Pharmacotherapy</source>. <year>2007</year>;<volume>27</volume>:<fpage>89</fpage>-<lpage>110</lpage>.<pub-id pub-id-type="pmid">17192164</pub-id></mixed-citation>
      </ref>
      <ref id="bibr40-1941738114555075">
        <label>40.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Preiss-Farzanegan</surname><given-names>SJ</given-names></name><name><surname>Chapman</surname><given-names>B</given-names></name><name><surname>Wong</surname><given-names>TM</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Bazarian</surname><given-names>JJ</given-names></name></person-group>
<article-title>The relationship between gender and postconcussion symptoms after sport-related mild traumatic brain injury</article-title>. <source>PM R</source>. <year>2009</year>;<volume>1</volume>:<fpage>245</fpage>-<lpage>253</lpage>.<pub-id pub-id-type="pmid">19627902</pub-id></mixed-citation>
      </ref>
      <ref id="bibr41-1941738114555075">
        <label>41.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reddy</surname><given-names>CC</given-names></name><name><surname>Collins</surname><given-names>M</given-names></name><name><surname>Lovell</surname><given-names>M</given-names></name><name><surname>Kontos</surname><given-names>AP</given-names></name></person-group>
<article-title>Efficacy of amantadine treatment on symptoms and neurocognitive performance among adolescents following sports-related concussion</article-title>. <source>J Head Trauma Rehabil</source>. <year>2013</year>;<volume>28</volume>:<fpage>260</fpage>-<lpage>265</lpage>.<pub-id pub-id-type="pmid">22613947</pub-id></mixed-citation>
      </ref>
      <ref id="bibr42-1941738114555075">
        <label>42.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tierney</surname><given-names>RT</given-names></name><name><surname>Sitler</surname><given-names>MR</given-names></name><name><surname>Swanik</surname><given-names>CB</given-names></name><name><surname>Swanik</surname><given-names>KA</given-names></name><name><surname>Higgins</surname><given-names>M</given-names></name><name><surname>Torg</surname><given-names>J</given-names></name></person-group>
<article-title>Gender differences in head-neck segment dynamic stabilization during head acceleration</article-title>. <source>Med Sci Sports Exerc</source>. <year>2005</year>;<volume>37</volume>:<fpage>272</fpage>-<lpage>279</lpage>.<pub-id pub-id-type="pmid">15692324</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:4272697</identifier><datestamp>2016-01-01</datestamp><setSpec>sportshealth</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="http://jats.nlm.nih.gov/ns/archiving/1.0/ http://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Sports Health</journal-id>
      <journal-id journal-id-type="iso-abbrev">Sports Health</journal-id>
      <journal-id journal-id-type="publisher-id">SPH</journal-id>
      <journal-id journal-id-type="hwp">spsph</journal-id>
      <journal-title-group>
        <journal-title>Sports Health</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1941-7381</issn>
      <issn pub-type="epub">1941-0921</issn>
      <publisher>
        <publisher-name>SAGE Publications</publisher-name>
        <publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4272697</article-id>
      <article-id pub-id-type="pmcid">PMC4272697</article-id>
      <article-id pub-id-type="pmc-uid">4272697</article-id>
      <article-id pub-id-type="pmid">25553215</article-id>
      <article-id pub-id-type="doi">10.1177/1941738114555842</article-id>
      <article-id pub-id-type="publisher-id">10.1177_1941738114555842</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Current Research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Injury and Treatment Characteristics of Sport-Specific Injuries Sustained in Interscholastic Athletics</article-title>
        <subtitle>A Report From the Athletic Training Practice-Based Research Network</subtitle>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Lam</surname>
            <given-names>Kenneth C.</given-names>
          </name>
          <degrees>ScD, ATC</degrees>
          <xref ref-type="corresp" rid="corresp1-1941738114555842">*</xref>
          <xref ref-type="aff" rid="aff1-1941738114555842">†</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Snyder Valier</surname>
            <given-names>Alison R.</given-names>
          </name>
          <degrees>PhD, ATC</degrees>
          <xref ref-type="aff" rid="aff1-1941738114555842">†</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Valovich McLeod</surname>
            <given-names>Tamara C.</given-names>
          </name>
          <degrees>PhD, ATC, FNATA</degrees>
          <xref ref-type="aff" rid="aff1-1941738114555842">†</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1-1941738114555842"><label>†</label>Post-Professional Athletic Training Program, Department of Interdisciplinary Health Sciences, A.T. Still University, Mesa, Arizona</aff>
      <author-notes>
        <corresp id="corresp1-1941738114555842"><label>*</label>Kenneth C. Lam, ScD, ATC, Clinical Research, Department of Interdisciplinary Health Sciences, A.T. Still University, 5850 East Still Circle, Mesa, AZ 85206 (e-mail: <email>klam@atsu.edu</email>).</corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>1</day>
        <month>1</month>
        <year>2016</year>
      </pub-date>
      <!-- PMC Release delay is 12 months and 0 days and was based on the <pub-date pub-type="ppub"/>. -->
      <volume>7</volume>
      <issue>1</issue>
      <fpage>67</fpage>
      <lpage>74</lpage>
      <permissions>
        <copyright-statement>© 2014 The Author(s)</copyright-statement>
        <copyright-year>2014</copyright-year>
        <copyright-holder content-type="sage">American Orthopaedic Society for Sports Medicine</copyright-holder>
      </permissions>
      <abstract>
        <sec id="section1-1941738114555842">
          <title>Background:</title>
          <p>The inclusion of clinical practice factors, beyond epidemiologic data, may help guide medical coverage and care decisions.</p>
        </sec>
        <sec id="section2-1941738114555842">
          <title>Hypothesis:</title>
          <p>Trends in injury and treatment characteristics of sport-specific injuries sustained by secondary school athletes will differ based on sport.</p>
        </sec>
        <sec id="section3-1941738114555842">
          <title>Study Design:</title>
          <p>Retrospective analysis of electronic patient records.</p>
        </sec>
        <sec id="section4-1941738114555842">
          <title>Level of evidence:</title>
          <p>Level 4.</p>
        </sec>
        <sec id="section5-1941738114555842">
          <title>Methods:</title>
          <p>Participants consisted of 3302 boys and 2293 girls who were diagnosed with a sport-related injury or condition during the study years. Injury (sport, body part, diagnosis via ICD-9 codes) and treatment (type, amount, and duration of care) characteristics were grouped by sport and reported using summary statistics.</p>
        </sec>
        <sec id="section6-1941738114555842">
          <title>Results:</title>
          <p>Most injuries and treatments occurred in football, girls’ soccer, basketball, volleyball, and track and field. Sprain or strain of the ankle, knee, and thigh/hip/groin and concussion were the most commonly documented injuries across sports. The injury pattern for boys’ wrestling differed from other sports and included sprain or strain of the elbow and neck and general medical skin conditions. The most frequently reported service was athletic training evaluation/reevaluation treatment, followed by hot/cold pack, therapeutic exercise, manual therapy techniques, electrical stimulation, and strapping of lower extremity joints. Most sports required 4 to 5 services per injury. With the exception of boys’ soccer and girls’ softball, duration of care ranged from 10 to 14 days. Girls’ soccer and girls’ and boys’ track and field reported the longest durations of care.</p>
        </sec>
        <sec id="section7-1941738114555842">
          <title>Conclusion:</title>
          <p>Injury and treatment characteristics are generally comparable across sports, suggesting that secondary school athletic trainers may diagnose and treat similar injuries regardless of sport.</p>
        </sec>
        <sec id="section8-1941738114555842">
          <title>Clinical Relevance:</title>
          <p>Subtle sport trends, including skin conditions associated with boys’ wrestling and longer duration of care for girls’ soccer, are important to note when discussing appropriate medical coverage and care.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>medical coverage</kwd>
        <kwd>practice characteristics</kwd>
        <kwd>adolescent athletes</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>January/February 2015</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <p>Because of an increase in participation<sup><xref rid="bibr24-1941738114555842" ref-type="bibr">24</xref></sup> and the potential for sport-related injuries in interscholastic athletics,<sup><xref rid="bibr9-1941738114555842" ref-type="bibr">9</xref></sup> identifying appropriate medical coverage and care for secondary school athletes has become an important topic within the sports medicine community.<sup><xref rid="bibr10-1941738114555842" ref-type="bibr">10</xref></sup> Recommendations for medical coverage and care have historically been based primarily on injury risk data from epidemiologic investigations. However, while epidemiologic studies have provided an abundance of data regarding the incidence and rates of injury between the sexes,<sup><xref rid="bibr17-1941738114555842" ref-type="bibr">17</xref>,<xref rid="bibr19-1941738114555842" ref-type="bibr">19</xref>,<xref rid="bibr20-1941738114555842" ref-type="bibr">20</xref></sup> in different sports,<sup><xref rid="bibr1-1941738114555842" ref-type="bibr">1</xref><xref rid="bibr2-1941738114555842" ref-type="bibr"/><xref rid="bibr3-1941738114555842" ref-type="bibr"/>-<xref rid="bibr4-1941738114555842" ref-type="bibr">4</xref>,<xref rid="bibr11-1941738114555842" ref-type="bibr">11</xref><xref rid="bibr12-1941738114555842" ref-type="bibr"/>-<xref rid="bibr13-1941738114555842" ref-type="bibr">13</xref>,<xref rid="bibr15-1941738114555842" ref-type="bibr">15</xref>,<xref rid="bibr20-1941738114555842" ref-type="bibr">20</xref>,<xref rid="bibr34-1941738114555842" ref-type="bibr">34</xref></sup> and across different levels of play,<sup><xref rid="bibr18-1941738114555842" ref-type="bibr">18</xref>,<xref rid="bibr29-1941738114555842" ref-type="bibr">29</xref>,<xref rid="bibr33-1941738114555842" ref-type="bibr">33</xref></sup> these investigations often exclude many tasks performed by the athletic medicine staff, including injury prevention and rehabilitation, that are essential elements of high-quality medical coverage and care. As a result, sports medicine organizations such as the National Athletic Trainers’ Association (NATA),<sup><xref rid="bibr23-1941738114555842" ref-type="bibr">23</xref></sup> American Orthopaedic Society for Sports Medicine,<sup><xref rid="bibr6-1941738114555842" ref-type="bibr">6</xref></sup> and American Medical Society for Sports Medicine<sup><xref rid="bibr10-1941738114555842" ref-type="bibr">10</xref></sup> have recently highlighted the need to include the wide variety of tasks associated with assessing, treating, and managing sport-related injuries and illnesses when determining appropriate medical coverage for secondary school athletes, including clinician demands for the development of injury and illness strategies and the treatment and rehabilitation of time loss and non–time loss injuries in various sports.<sup><xref rid="bibr5-1941738114555842" ref-type="bibr">5</xref>,<xref rid="bibr10-1941738114555842" ref-type="bibr">10</xref>,<xref rid="bibr22-1941738114555842" ref-type="bibr">22</xref></sup></p>
    <p>The inclusion of other clinical practice factors beyond injury incidences and rates is important in determining appropriate medical coverage and care because many duties provided by the athletic medicine staff include preventative measures and treatment for non–time loss injuries (eg, overuse injuries) and may be unaccounted for, by definition, in epidemiologic studies.<sup><xref rid="bibr14-1941738114555842" ref-type="bibr">14</xref>,<xref rid="bibr28-1941738114555842" ref-type="bibr">28</xref></sup> However, without adequate clinical data of preventative, treatment, and rehabilitation efforts for all types of sports and injuries, determining appropriate medical coverage and care for secondary school athletes can be difficult. However, these investigations were broad in scope considering typical practice patterns<sup><xref rid="bibr31-1941738114555842" ref-type="bibr">31</xref></sup> and an aggregate of all documented injuries<sup><xref rid="bibr32-1941738114555842" ref-type="bibr">32</xref></sup> and did not account for injuries sustained in different sports. Specific attention toward injuries grouped by sports as well as an understanding of the treatment characteristics associated with these injuries is needed to aid in medical coverage recommendations and patient care decisions. Therefore, the purpose of this study was to describe the injury and treatment characteristics of injuries sustained by patients participating in various interscholastic sports as recorded through a national practice-based research network.</p>
    <sec sec-type="materials|methods" id="section9-1941738114555842">
      <title>Materials and Methods</title>
      <sec id="section10-1941738114555842">
        <title>Design and Setting</title>
        <p>This study was a retrospective analysis of de-identified patient records within a Web-based electronic medical record (EMR). The A.T. Still University Institutional Review Board exempted the study because the study was deemed to be a retrospective analysis of de-identified patient records. All records were created by an athletic trainer (AT) who was a member of the Athletic Training Practice-Based Research Network (AT-PBRN)<sup><xref rid="bibr32-1941738114555842" ref-type="bibr">32</xref></sup> and was providing patient care in a secondary school. The ATs practiced in 62 secondary schools across 14 different states (Arizona, California, Connecticut, Florida, Kansas, Massachusetts, Minnesota, Missouri, New Hampshire, New York, Utah, Virginia, Vermont, Wisconsin). Most schools were public (85%) and coeducational (95%) institutions, set in an urban area (71%), and employed 1 certified AT (77%). On average, ATs collected data over 16.1 ± 12.5 months (range, 1-48 months). To ensure data quality, all ATs completed a formal, 2-hour EMR training session prior to joining the AT-PBRN, and the administrative team of the AT-PBRN routinely reviewed the clinical data entered into the EMR relational database.<sup><xref rid="bibr32-1941738114555842" ref-type="bibr">32</xref></sup></p>
      </sec>
      <sec id="section11-1941738114555842">
        <title>Participants</title>
        <p>Patients who were diagnosed with a sport-related injury between October 1, 2009 and October 31, 2013 and participated in an interscholastic sport were included in this report (<xref ref-type="table" rid="table1-1941738114555842">Table 1</xref>). A sport-related injury was defined as that diagnosed by a health care provider (eg, AT, physician) and required at least 1 AT service, such as an initial evaluation. A Certification of Honest Broker System/Processes provided by the EMR developer (Essentialtalk) ensured that patient data obtained by the AT-PBRN research team were void of all federally defined personal identifiers (ie, protected health information).<sup><xref rid="bibr25-1941738114555842" ref-type="bibr">25</xref></sup></p>
        <table-wrap id="table1-1941738114555842" position="float">
          <label>Table 1.</label>
          <caption>
            <p>Injuries and athletic training services documented within the AT-PBRN grouped by sport</p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th rowspan="1" colspan="1"/>
                <th align="center" colspan="2" rowspan="1">Injuries, n (%)</th>
                <th align="center" colspan="2" rowspan="1">Athletic Training Services, n (%)</th>
              </tr>
              <tr>
                <th align="center" rowspan="1" colspan="1">Sport</th>
                <th align="center" rowspan="1" colspan="1">Boys</th>
                <th align="center" rowspan="1" colspan="1">Girls</th>
                <th align="center" rowspan="1" colspan="1">Boys</th>
                <th align="center" rowspan="1" colspan="1">Girls</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">Badminton</td>
                <td rowspan="1" colspan="1">5 (0.2)</td>
                <td rowspan="1" colspan="1">36 (1.6)</td>
                <td rowspan="1" colspan="1">4 (0.0)</td>
                <td rowspan="1" colspan="1">102 (1.2)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Baseball</td>
                <td rowspan="1" colspan="1">132 (4.0)</td>
                <td rowspan="1" colspan="1">0 (0.0)</td>
                <td rowspan="1" colspan="1">528 (4.3)</td>
                <td rowspan="1" colspan="1">0 (0.0)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Basketball</td>
                <td rowspan="1" colspan="1">302 (9.1)</td>
                <td rowspan="1" colspan="1">416 (18.1)</td>
                <td rowspan="1" colspan="1">1079 (8.8)</td>
                <td rowspan="1" colspan="1">1345 (15.4)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Cheerleading</td>
                <td rowspan="1" colspan="1">3 (0.1)</td>
                <td rowspan="1" colspan="1">121 (5.3)</td>
                <td rowspan="1" colspan="1">6 (0.0)</td>
                <td rowspan="1" colspan="1">269 (3.1)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Cross-country</td>
                <td rowspan="1" colspan="1">62 (1.9)</td>
                <td rowspan="1" colspan="1">122 (5.3)</td>
                <td rowspan="1" colspan="1">208 (1.7)</td>
                <td rowspan="1" colspan="1">421 (4.8)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Field hockey</td>
                <td rowspan="1" colspan="1">1 (0.0)</td>
                <td rowspan="1" colspan="1">23 (1.0)</td>
                <td rowspan="1" colspan="1">1 (0.0)</td>
                <td rowspan="1" colspan="1">73 (0.8)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Football</td>
                <td rowspan="1" colspan="1">1934 (58.6)</td>
                <td rowspan="1" colspan="1">33 (1.4)</td>
                <td rowspan="1" colspan="1">7340 (60.2)</td>
                <td rowspan="1" colspan="1">139 (1.6)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Golf</td>
                <td rowspan="1" colspan="1">1 (0.0)</td>
                <td rowspan="1" colspan="1">5 (0.2)</td>
                <td rowspan="1" colspan="1">0 (0.0)</td>
                <td rowspan="1" colspan="1">17 (0.2)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Gymnastics</td>
                <td rowspan="1" colspan="1">0 (0.0)</td>
                <td rowspan="1" colspan="1">4 (0.2)</td>
                <td rowspan="1" colspan="1">0 (0.0)</td>
                <td rowspan="1" colspan="1">20 (0.2)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Hockey</td>
                <td rowspan="1" colspan="1">28 (0.8)</td>
                <td rowspan="1" colspan="1">4 (0.2)</td>
                <td rowspan="1" colspan="1">104 (0.9)</td>
                <td rowspan="1" colspan="1">44 (0.5)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Lacrosse</td>
                <td rowspan="1" colspan="1">26 (0.8)</td>
                <td rowspan="1" colspan="1">67 (2.9)</td>
                <td rowspan="1" colspan="1">108 (0.9)</td>
                <td rowspan="1" colspan="1">373 (4.3)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Other</td>
                <td rowspan="1" colspan="1">49 (1.5)</td>
                <td rowspan="1" colspan="1">72 (3.1)</td>
                <td rowspan="1" colspan="1">103 (0.9)</td>
                <td rowspan="1" colspan="1">165 (1.9)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Soccer</td>
                <td rowspan="1" colspan="1">238 (7.2)</td>
                <td rowspan="1" colspan="1">484 (21.1)</td>
                <td rowspan="1" colspan="1">705 (5.8)</td>
                <td rowspan="1" colspan="1">2188 (25.1)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Softball</td>
                <td rowspan="1" colspan="1">2 (0.1)</td>
                <td rowspan="1" colspan="1">188 (8.2)</td>
                <td rowspan="1" colspan="1">5 (0.0)</td>
                <td rowspan="1" colspan="1">595 (6.8)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Swimming</td>
                <td rowspan="1" colspan="1">9 (0.3)</td>
                <td rowspan="1" colspan="1">23 (1.0)</td>
                <td rowspan="1" colspan="1">12 (0.1)</td>
                <td rowspan="1" colspan="1">68 (0.8)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Tennis</td>
                <td rowspan="1" colspan="1">5 (0.2)</td>
                <td rowspan="1" colspan="1">61 (2.7)</td>
                <td rowspan="1" colspan="1">14 (0.1)</td>
                <td rowspan="1" colspan="1">198 (2.3)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Track</td>
                <td rowspan="1" colspan="1">221 (6.7)</td>
                <td rowspan="1" colspan="1">303 (13.2)</td>
                <td rowspan="1" colspan="1">1075 (8.8)</td>
                <td rowspan="1" colspan="1">1435 (16.5)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Volleyball</td>
                <td rowspan="1" colspan="1">20 (0.6)</td>
                <td rowspan="1" colspan="1">328 (14.3)</td>
                <td rowspan="1" colspan="1">85 (0.7)</td>
                <td rowspan="1" colspan="1">1264 (14.5)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Wrestling</td>
                <td rowspan="1" colspan="1">264 (8.0)</td>
                <td rowspan="1" colspan="1">3 (0.1)</td>
                <td rowspan="1" colspan="1">816 (6.7)</td>
                <td rowspan="1" colspan="1">2 (0.0)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Total</td>
                <td rowspan="1" colspan="1">3302 (100.0)</td>
                <td rowspan="1" colspan="1">2293 (100.0)</td>
                <td rowspan="1" colspan="1">12,193 (100.0)</td>
                <td rowspan="1" colspan="1">8718 (100.0)</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="table-fn1-1941738114555842">
              <p>AT-PBRN, Athletic Training Practice-Based Research Network.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="section12-1941738114555842">
        <title>Instrumentation</title>
        <p>Clinical data were recorded in a Web-based EMR previously described by Valovich McLeod et al.<sup><xref rid="bibr32-1941738114555842" ref-type="bibr">32</xref></sup> AT services were recorded as International Classification of Diseases, Ninth Revision (ICD-9) and Current Procedural Terminology (CPT)<sup><xref rid="bibr27-1941738114555842" ref-type="bibr">27</xref></sup> codes within the EMR.</p>
      </sec>
      <sec id="section13-1941738114555842">
        <title>Statistical Analysis</title>
        <p>All variables of interest were grouped based on sport and reported using summary statistics. Patient demographics included age, sex, height, and weight of the patient, while injury characteristics were represented by sport, body part, and diagnosis (ICD-9 code). The most frequent injuries were reported for each sport. Treatment characteristics included the type (CPT code), amount (number of services for the duration of care), and duration (number of days between the initial evaluation to the last documented episode of care) of care for each injury.</p>
      </sec>
    </sec>
    <sec sec-type="results" id="section14-1941738114555842">
      <title>Results</title>
      <sec id="section15-1941738114555842">
        <title>Injury Characteristics</title>
        <p>A total of 5595 sport-related injuries (boys, 3302; age, 16.3 ± 1.5 years and girls, 2293; age, 16.0 ± 1.4 years) were documented during the study period. The 10 sports reporting the most injuries during the study years accounted for 84% of all documented injuries (<xref ref-type="table" rid="table1-1941738114555842">Table 1</xref>). In general, concussions and a sprain or strain of the ankle, knee, and thigh/hip/groin were the most documented injuries, in varying rank order, across most sports (<xref ref-type="table" rid="table2-1941738114555842">Table 2</xref>).</p>
        <table-wrap id="table2-1941738114555842" position="float">
          <label>Table 2.</label>
          <caption>
            <p>Common injuries documented for the top 10 sports reporting the most injuries in the AT-PBRN<sup><xref ref-type="table-fn" rid="table-fn3-1941738114555842"><italic>a</italic></xref></sup></p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="left" rowspan="1" colspan="1">Diagnosis</th>
                <th align="center" rowspan="1" colspan="1">ICD-9 Code</th>
                <th align="center" rowspan="1" colspan="1">Boys’ Football (n = 1934), n (%)</th>
                <th align="center" rowspan="1" colspan="1">Girls’ Soccer (n = 623), n (%)</th>
                <th align="center" rowspan="1" colspan="1">Girls’ Basketball (n = 416), n (%)</th>
                <th align="center" rowspan="1" colspan="1">Girls’ Volleyball (n = 328), n (%)</th>
                <th align="center" rowspan="1" colspan="1">Girls’ Track and Field (n = 302), n (%)</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">Concussion</td>
                <td rowspan="1" colspan="1">850.9, 850.0, 850.5</td>
                <td rowspan="1" colspan="1">
                  <bold>409 (21.1)</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>80 (12.8)</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>72 (17.3)</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>30 (9.1)</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>9 (3.0)</bold>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">General medical: skin</td>
                <td rowspan="1" colspan="1">684, 110.9, 54.9, 704.8</td>
                <td rowspan="1" colspan="1">6 (0.3)</td>
                <td rowspan="1" colspan="1">1 (0.1)</td>
                <td rowspan="1" colspan="1">0 (0.0)</td>
                <td rowspan="1" colspan="1">1 (0.3)</td>
                <td rowspan="1" colspan="1">0 (0.0)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Pain (general): knee</td>
                <td rowspan="1" colspan="1">719.46</td>
                <td rowspan="1" colspan="1">31 (1.6)</td>
                <td rowspan="1" colspan="1">
                  <bold>22 (3.5)</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>22 (5.3)</bold>
                </td>
                <td rowspan="1" colspan="1">10 (3.0)</td>
                <td rowspan="1" colspan="1">
                  <bold>25 (8.3)</bold>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Sprain/strain: ankle</td>
                <td rowspan="1" colspan="1">845, 845.01, 845.03, 845.09</td>
                <td rowspan="1" colspan="1">
                  <bold>225 (11.6)</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>87 (14.0)</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>78 (18.8)</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>75 (22.9)</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>41 (13.6)</bold>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Sprain/strain: elbow</td>
                <td rowspan="1" colspan="1">841.1, 841.9</td>
                <td rowspan="1" colspan="1">23 (1.2)</td>
                <td rowspan="1" colspan="1">4 (0.6)</td>
                <td rowspan="1" colspan="1">1 (0.2)</td>
                <td rowspan="1" colspan="1">4 (1.2)</td>
                <td rowspan="1" colspan="1">2 (0.7)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Sprain/strain: hand/finger</td>
                <td rowspan="1" colspan="1">842.1</td>
                <td rowspan="1" colspan="1">53 (2.7)</td>
                <td rowspan="1" colspan="1">6 (1.0)</td>
                <td rowspan="1" colspan="1">19 (4.6)</td>
                <td rowspan="1" colspan="1">
                  <bold>21 (6.4)</bold>
                </td>
                <td rowspan="1" colspan="1">0 (0.0)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Sprain/strain: low back</td>
                <td rowspan="1" colspan="1">846.00, 846.10, 847.90</td>
                <td rowspan="1" colspan="1">39 (2.0)</td>
                <td rowspan="1" colspan="1">13 (2.1)</td>
                <td rowspan="1" colspan="1">3 (0.7)</td>
                <td rowspan="1" colspan="1">
                  <bold>14 (4.2)</bold>
                </td>
                <td rowspan="1" colspan="1">7 (2.3)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Sprain/strain: knee</td>
                <td rowspan="1" colspan="1">844, 844.1, 844.2, 844.9</td>
                <td rowspan="1" colspan="1">
                  <bold>148 (7.7)</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>45 (7.2)</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>29 (7.0)</bold>
                </td>
                <td rowspan="1" colspan="1">12 (3.7)</td>
                <td rowspan="1" colspan="1">
                  <bold>24 (7.9)</bold>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Sprain/strain: neck</td>
                <td rowspan="1" colspan="1">847</td>
                <td rowspan="1" colspan="1">34 (1.8)</td>
                <td rowspan="1" colspan="1">6 (1.0)</td>
                <td rowspan="1" colspan="1">4 (0.6)</td>
                <td rowspan="1" colspan="1">5 (3.0)</td>
                <td rowspan="1" colspan="1">5 (1.7)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Sprain/strain: shoulder</td>
                <td rowspan="1" colspan="1">831.00, 840</td>
                <td rowspan="1" colspan="1">87 (4.5)</td>
                <td rowspan="1" colspan="1">4 (0.6)</td>
                <td rowspan="1" colspan="1">5 (1.2)</td>
                <td rowspan="1" colspan="1">5 (1.5)</td>
                <td rowspan="1" colspan="1">1 (0.3)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Sprain/strain: thigh/hip/groin</td>
                <td rowspan="1" colspan="1">843.9, 843.90</td>
                <td rowspan="1" colspan="1">94 (4.3)</td>
                <td rowspan="1" colspan="1">65 (10.4)</td>
                <td rowspan="1" colspan="1">33 (7.9)</td>
                <td rowspan="1" colspan="1">12 (3.7)</td>
                <td rowspan="1" colspan="1">47 (15.6)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Tendinitis: Anterior/posterior tibialis</td>
                <td rowspan="1" colspan="1">726.72</td>
                <td rowspan="1" colspan="1">8 (0.4)</td>
                <td rowspan="1" colspan="1">13 (2.1)</td>
                <td rowspan="1" colspan="1">5 (1.2)</td>
                <td rowspan="1" colspan="1">10 (3.0)</td>
                <td rowspan="1" colspan="1">
                  <bold>39 (12.9)</bold>
                </td>
              </tr>
              <tr>
                <th align="left" rowspan="1" colspan="1">Diagnosis</th>
                <th align="center" rowspan="1" colspan="1">ICD-9 Code</th>
                <th align="center" rowspan="1" colspan="1">Boys’ Basketball (n = 271), n (%)</th>
                <th align="center" rowspan="1" colspan="1">Boys’ Wrestling (n = 264), n (%)</th>
                <th align="center" rowspan="1" colspan="1">Boys’ Soccer (n = 238), n (%)</th>
                <th align="center" rowspan="1" colspan="1">Boys’ Track and Field (n = 221), n (%)</th>
                <th align="center" rowspan="1" colspan="1">Girls’ Softball (n = 188), n (%)</th>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Concussion</td>
                <td rowspan="1" colspan="1">850.9, 850.0, 850.5</td>
                <td rowspan="1" colspan="1">
                  <bold>33 (10.9)</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>27 (10.2)</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>30 (12.6)</bold>
                </td>
                <td rowspan="1" colspan="1">4 (1.8)</td>
                <td rowspan="1" colspan="1">
                  <bold>40 (21.3)</bold>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">General medical: skin</td>
                <td rowspan="1" colspan="1">684, 110.9, 54.9, 704.8</td>
                <td rowspan="1" colspan="1">0 (0.0)</td>
                <td rowspan="1" colspan="1">
                  <bold>12 (4.5)</bold>
                </td>
                <td rowspan="1" colspan="1">0 (0.0)</td>
                <td rowspan="1" colspan="1">0 (0.0)</td>
                <td rowspan="1" colspan="1">0 (0.0)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Pain (general): knee</td>
                <td rowspan="1" colspan="1">719.46</td>
                <td rowspan="1" colspan="1">5 (1.6)</td>
                <td rowspan="1" colspan="1">7 (2.7)</td>
                <td rowspan="1" colspan="1">9 (3.8)</td>
                <td rowspan="1" colspan="1">
                  <bold>9 (4.1)</bold>
                </td>
                <td rowspan="1" colspan="1">1 (0.5)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Sprain/strain: ankle</td>
                <td rowspan="1" colspan="1">845, 845.01, 845.03, 845.09</td>
                <td rowspan="1" colspan="1">
                  <bold>107 (35.4)</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>19 (7.2)</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>40 (16.8)</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>22 (10.0)</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>27 (14.4)</bold>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Sprain/strain: elbow</td>
                <td rowspan="1" colspan="1">841.1, 841.9</td>
                <td rowspan="1" colspan="1">0 (0.0)</td>
                <td rowspan="1" colspan="1">
                  <bold>17 (6.4)</bold>
                </td>
                <td rowspan="1" colspan="1">0 (0.0)</td>
                <td rowspan="1" colspan="1">1 (0.5)</td>
                <td rowspan="1" colspan="1">
                  <bold>9 (4.8)</bold>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Sprain/strain: hand/finger</td>
                <td rowspan="1" colspan="1">842.1</td>
                <td rowspan="1" colspan="1">14 (4.6)</td>
                <td rowspan="1" colspan="1">4 (1.5)</td>
                <td rowspan="1" colspan="1">3 (1.3)</td>
                <td rowspan="1" colspan="1">0 (0.0)</td>
                <td rowspan="1" colspan="1">5 (2.7)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Sprain/strain: knee</td>
                <td rowspan="1" colspan="1">844, 844.1, 844.2, 844.9</td>
                <td rowspan="1" colspan="1">
                  <bold>24 (7.9)</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>15 (5.7)</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>15 (6.3)</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>15 (6.8)</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>9 (4.8)</bold>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Sprain/strain: low back</td>
                <td rowspan="1" colspan="1">846.00, 846.10, 847.90</td>
                <td rowspan="1" colspan="1">
                  <bold>15 (5.0)</bold>
                </td>
                <td rowspan="1" colspan="1">10 (3.8)</td>
                <td rowspan="1" colspan="1">8 (3.4)</td>
                <td rowspan="1" colspan="1">6 (2.7)</td>
                <td rowspan="1" colspan="1">3 (1.6)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Sprain/strain: neck</td>
                <td rowspan="1" colspan="1">847</td>
                <td rowspan="1" colspan="1">3 (1.0)</td>
                <td rowspan="1" colspan="1">11 (4.2)</td>
                <td rowspan="1" colspan="1">4 (1.7)</td>
                <td rowspan="1" colspan="1">5 (2.3)</td>
                <td rowspan="1" colspan="1">2 (1.1)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Sprain/strain: shoulder</td>
                <td rowspan="1" colspan="1">831.00, 840</td>
                <td rowspan="1" colspan="1">8 (2.6)</td>
                <td rowspan="1" colspan="1">11 (4.2)</td>
                <td rowspan="1" colspan="1">
                  <bold>10 (4.2)</bold>
                </td>
                <td rowspan="1" colspan="1">6 (2.7)</td>
                <td rowspan="1" colspan="1">1 (0.5)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Sprain/strain: thigh/hip/groin</td>
                <td rowspan="1" colspan="1">843.9, 843.90</td>
                <td rowspan="1" colspan="1">
                  <bold>13 (4.3)</bold>
                </td>
                <td rowspan="1" colspan="1">0 (0.0)</td>
                <td rowspan="1" colspan="1">
                  <bold>29 (12.2)</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>47 (21.2)</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>13 (6.9)</bold>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Tendinitis: anterior/posterior tibialis</td>
                <td rowspan="1" colspan="1">726.72</td>
                <td rowspan="1" colspan="1">2 (0.7)</td>
                <td rowspan="1" colspan="1">0 (0.0)</td>
                <td rowspan="1" colspan="1">4 (1.7)</td>
                <td rowspan="1" colspan="1">
                  <bold>23 (10.4)</bold>
                </td>
                <td rowspan="1" colspan="1">4 (2.1)</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="table-fn2-1941738114555842">
              <p>AT-PBRN, Athletic Training Practice-Based Research Network; ICD-9, International Classification of Diseases, Ninth Revision.</p>
            </fn>
            <fn id="table-fn3-1941738114555842">
              <label>a</label>
              <p>Boldfaced values indicate the top 5 injuries for each sport.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="section16-1941738114555842">
        <title>Treatment Characteristics</title>
        <p>A total of 20,911 services were recorded during the study period. Across all sports, the most frequently reported service was AT evaluation or reevaluation, followed by hot or cold pack, therapeutic exercise or activities, manual therapy techniques or massage, electrical stimulation, and strapping of lower extremity joints (ankle, foot, hip knees, toes) (<xref ref-type="table" rid="table3-1941738114555842">Table 3</xref>). The only exceptions were reported for football, in which more strapping of the upper extremity was reported than manual therapy or massage; boys’ basketball, in which more whirlpool treatments were reported than electrical stimulation treatments; and boys’ wrestling, in which more strapping of the upper extremity was reported than electrical stimulation (<xref ref-type="table" rid="table4-1941738114555842">Table 4</xref>). Girls’ soccer, boys’ track and field, and girls’ track and field reported the highest number of services per injury (<xref ref-type="table" rid="table5-1941738114555842">Table 5</xref>). Boys’ track and field reported the longest average duration of care (18.1 ± 72.9 days), while girls’ softball reported the shortest average duration of care (6.2 ± 10.8 days).</p>
        <table-wrap id="table3-1941738114555842" position="float">
          <label>Table 3.</label>
          <caption>
            <p>Athletic training services recorded during study period</p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="left" rowspan="1" colspan="1">Treatment or Procedures</th>
                <th align="center" rowspan="1" colspan="1">CPT Codes</th>
                <th align="center" rowspan="1" colspan="1">n (%)</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">Athletic trainer evaluation or reevaluation</td>
                <td rowspan="1" colspan="1">97005, 97006</td>
                <td rowspan="1" colspan="1">9608 (45.9)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Hot or cold packs</td>
                <td rowspan="1" colspan="1">97010</td>
                <td rowspan="1" colspan="1">4120 (19.7)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Therapeutic activities or exercise</td>
                <td rowspan="1" colspan="1">97110, 97530</td>
                <td rowspan="1" colspan="1">3206 (15.3)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Strapping: Lower extremity (ankle/foot, hip, knee, toes)</td>
                <td rowspan="1" colspan="1">29540, 29520, 29230, 29550</td>
                <td rowspan="1" colspan="1">1278 (6.1)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Electrical stimulation</td>
                <td rowspan="1" colspan="1">97014</td>
                <td rowspan="1" colspan="1">778 (3.7)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Manual therapy techniques or massage</td>
                <td rowspan="1" colspan="1">97140, 97124</td>
                <td rowspan="1" colspan="1">746 (3.6)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Strapping: Upper extremity (elbow or wrist, hand or finger, shoulder)</td>
                <td rowspan="1" colspan="1">29280, 29260, 29240</td>
                <td rowspan="1" colspan="1">401 (1.9)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Whirlpool</td>
                <td rowspan="1" colspan="1">97022</td>
                <td rowspan="1" colspan="1">318 (1.5)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Physical performance test or measurement</td>
                <td rowspan="1" colspan="1">97750</td>
                <td rowspan="1" colspan="1">141 (0.7)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Ultrasound</td>
                <td rowspan="1" colspan="1">97035</td>
                <td rowspan="1" colspan="1">118 (0.6)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Neuromuscular re-education</td>
                <td rowspan="1" colspan="1">97112</td>
                <td rowspan="1" colspan="1">82 (0.4)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Vasopneumatic devices</td>
                <td rowspan="1" colspan="1">97016</td>
                <td rowspan="1" colspan="1">53 (0.3)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Gait training</td>
                <td rowspan="1" colspan="1">97116</td>
                <td rowspan="1" colspan="1">36 (0.2)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Contrast bath</td>
                <td rowspan="1" colspan="1">97034</td>
                <td rowspan="1" colspan="1">14 (0.1)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Infrared</td>
                <td rowspan="1" colspan="1">97026</td>
                <td rowspan="1" colspan="1">7 (0.0</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Aquatic therapy</td>
                <td rowspan="1" colspan="1">97113</td>
                <td rowspan="1" colspan="1">3 (0.0)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Iontophoresis</td>
                <td rowspan="1" colspan="1">97033</td>
                <td rowspan="1" colspan="1">2 (0.0)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Total</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">20,911 (100.0)</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="table-fn4-1941738114555842">
              <p>CPT, Current Procedural Terminology.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <table-wrap id="table4-1941738114555842" position="float">
          <label>Table 4.</label>
          <caption>
            <p>Common athletic training services documented for the top 10 sports reporting the most injuries, n (%)</p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th rowspan="1" colspan="1"/>
                <th align="center" rowspan="1" colspan="1">Boys’ Football</th>
                <th align="center" rowspan="1" colspan="1">Girls’ Soccer</th>
                <th align="center" rowspan="1" colspan="1">Girls’ Track and Field</th>
                <th align="center" rowspan="1" colspan="1">Girls’ Basketball</th>
                <th align="center" rowspan="1" colspan="1">Girls’ Volleyball</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">Athletic trainer evaluation or reevaluation</td>
                <td rowspan="1" colspan="1">3547 (48.3)</td>
                <td rowspan="1" colspan="1">882 (40.3)</td>
                <td rowspan="1" colspan="1">588 (41.0)</td>
                <td rowspan="1" colspan="1">667 (49.6)</td>
                <td rowspan="1" colspan="1">521 (41.2)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Electrical stimulation</td>
                <td rowspan="1" colspan="1">295 (4.0)</td>
                <td rowspan="1" colspan="1">100 (4.6)</td>
                <td rowspan="1" colspan="1">57 (4.0)</td>
                <td rowspan="1" colspan="1">41 (3.0)</td>
                <td rowspan="1" colspan="1">47 (3.5)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Hot or cold pack</td>
                <td rowspan="1" colspan="1">1493 (20.3)</td>
                <td rowspan="1" colspan="1">427 (19.5)</td>
                <td rowspan="1" colspan="1">306 (21.3)</td>
                <td rowspan="1" colspan="1">231 (17.2)</td>
                <td rowspan="1" colspan="1">226 (17.9)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Manual therapy or massage</td>
                <td rowspan="1" colspan="1">132 (1.8)</td>
                <td rowspan="1" colspan="1">99 (4.5)</td>
                <td rowspan="1" colspan="1">68 (4.7)</td>
                <td rowspan="1" colspan="1">59 (4.4)</td>
                <td rowspan="1" colspan="1">76 (6.0)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Therapeutic exercise or activities</td>
                <td rowspan="1" colspan="1">1041 (14.2)</td>
                <td rowspan="1" colspan="1">427 (19.5)</td>
                <td rowspan="1" colspan="1">238 (16.6)</td>
                <td rowspan="1" colspan="1">194 (14.4)</td>
                <td rowspan="1" colspan="1">246 (19.5)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Strapping of the lower extremities</td>
                <td rowspan="1" colspan="1">369 (5.0)</td>
                <td rowspan="1" colspan="1">175 (8.0)</td>
                <td rowspan="1" colspan="1">118 (8.2)</td>
                <td rowspan="1" colspan="1">86 (6.4)</td>
                <td rowspan="1" colspan="1">81 (6.4)</td>
              </tr>
              <tr>
                <th rowspan="1" colspan="1"/>
                <th align="center" rowspan="1" colspan="1">Boys’ Basketball</th>
                <th align="center" rowspan="1" colspan="1">Boys’ Track and Field</th>
                <th align="center" rowspan="1" colspan="1">Boys’ Wrestling</th>
                <th align="center" rowspan="1" colspan="1">Boys’ Soccer</th>
                <th align="center" rowspan="1" colspan="1">Girls’ Softball</th>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Athletic trainer evaluation or reevaluation</td>
                <td rowspan="1" colspan="1">489 (45.3)</td>
                <td rowspan="1" colspan="1">428 (39.8)</td>
                <td rowspan="1" colspan="1">427 (52.3)</td>
                <td rowspan="1" colspan="1">338 (47.9)</td>
                <td rowspan="1" colspan="1">259 (43.5)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Electrical stimulation</td>
                <td rowspan="1" colspan="1">18 (1.7)</td>
                <td rowspan="1" colspan="1">38 (3.5)</td>
                <td rowspan="1" colspan="1">21 (2.6)</td>
                <td rowspan="1" colspan="1">24 (3.4)</td>
                <td rowspan="1" colspan="1">28 (4.7)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Hot or cold pack</td>
                <td rowspan="1" colspan="1">186 (17.2)</td>
                <td rowspan="1" colspan="1">271 (25.2)</td>
                <td rowspan="1" colspan="1">173 (21.2)</td>
                <td rowspan="1" colspan="1">152 (21.6)</td>
                <td rowspan="1" colspan="1">118 (19.8)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Manual therapy or massage</td>
                <td rowspan="1" colspan="1">36 (3.3)</td>
                <td rowspan="1" colspan="1">60 (5.6)</td>
                <td rowspan="1" colspan="1">24 (2.9)</td>
                <td rowspan="1" colspan="1">31 (4.4)</td>
                <td rowspan="1" colspan="1">32 (5.4)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Therapeutic exercise or activities</td>
                <td rowspan="1" colspan="1">174 (16.1)</td>
                <td rowspan="1" colspan="1">177 (16.5)</td>
                <td rowspan="1" colspan="1">105 (12.9)</td>
                <td rowspan="1" colspan="1">72 (10.2)</td>
                <td rowspan="1" colspan="1">85 (14.3)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Strapping of the lower extremities</td>
                <td rowspan="1" colspan="1">75 (7.0)</td>
                <td rowspan="1" colspan="1">42 (3.9)</td>
                <td rowspan="1" colspan="1">22 (2.7)</td>
                <td rowspan="1" colspan="1">63 (8.9)</td>
                <td rowspan="1" colspan="1">40 (6.7)</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <table-wrap id="table5-1941738114555842" position="float">
          <label>Table 5.</label>
          <caption>
            <p>Amount and duration of care per injury for the top 10 sports reporting the most injuries</p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th rowspan="1" colspan="1"/>
                <th align="center" rowspan="1" colspan="1">Boys’ Football</th>
                <th align="center" rowspan="1" colspan="1">Girls’ Soccer</th>
                <th align="center" rowspan="1" colspan="1">Girls’ Track and Field</th>
                <th align="center" rowspan="1" colspan="1">Girls’ Basketball</th>
                <th align="center" rowspan="1" colspan="1">Girls’ Volleyball</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">Amount of care (number of services)</td>
                <td rowspan="1" colspan="1">4.7 ± 6.6</td>
                <td rowspan="1" colspan="1">5.4 ± 9.9</td>
                <td rowspan="1" colspan="1">5.2 ± 5.1</td>
                <td rowspan="1" colspan="1">4.1 ± 4.2</td>
                <td rowspan="1" colspan="1">4.6 ± 5.5</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Duration of care (days of service)</td>
                <td rowspan="1" colspan="1">11.8 ± 31.3</td>
                <td rowspan="1" colspan="1">14.4 ± 25.6</td>
                <td rowspan="1" colspan="1">10.1 ± 30.0</td>
                <td rowspan="1" colspan="1">14.7 ± 36.7</td>
                <td rowspan="1" colspan="1">11.5 ± 19.3</td>
              </tr>
              <tr>
                <th rowspan="1" colspan="1"/>
                <th align="center" rowspan="1" colspan="1">Boys’ Basketball</th>
                <th align="center" rowspan="1" colspan="1">Boys’ Track and Field</th>
                <th align="center" rowspan="1" colspan="1">Boys’ Wrestling</th>
                <th align="center" rowspan="1" colspan="1">Boys’ Soccer</th>
                <th align="center" rowspan="1" colspan="1">Girls’ Softball</th>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Amount of care (number of services)</td>
                <td rowspan="1" colspan="1">4.3 ± 4.3</td>
                <td rowspan="1" colspan="1">5.3 ± 5.9</td>
                <td rowspan="1" colspan="1">3.6 ± 4.1</td>
                <td rowspan="1" colspan="1">3.6 ± 3.2</td>
                <td rowspan="1" colspan="1">4.1 ± 4.1</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Duration of care (days of service)</td>
                <td rowspan="1" colspan="1">11.1 ± 27.4</td>
                <td rowspan="1" colspan="1">18.1 ± 72.9</td>
                <td rowspan="1" colspan="1">12.6 ± 18.7</td>
                <td rowspan="1" colspan="1">6.6 ± 5.8</td>
                <td rowspan="1" colspan="1">6.2 ± 10.8</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
    </sec>
    <sec sec-type="discussion" id="section17-1941738114555842">
      <title>Discussion</title>
      <p>Our findings are similar to previous epidemiologic<sup><xref rid="bibr7-1941738114555842" ref-type="bibr">7</xref>,<xref rid="bibr8-1941738114555842" ref-type="bibr">8</xref>,<xref rid="bibr16-1941738114555842" ref-type="bibr">16</xref>,<xref rid="bibr19-1941738114555842" ref-type="bibr">19</xref>,<xref rid="bibr21-1941738114555842" ref-type="bibr">21</xref>,<xref rid="bibr26-1941738114555842" ref-type="bibr">26</xref>,<xref rid="bibr29-1941738114555842" ref-type="bibr">29</xref>,<xref rid="bibr30-1941738114555842" ref-type="bibr">30</xref>,<xref rid="bibr33-1941738114555842" ref-type="bibr">33</xref>,<xref rid="bibr34-1941738114555842" ref-type="bibr">34</xref></sup> and clinical practice characteristics investigations<sup><xref rid="bibr32-1941738114555842" ref-type="bibr">32</xref></sup> and suggest that secondary school ATs tend to diagnose similar injuries and use similar methods to treat these injuries, regardless of sport. While the injury characteristics were generally similar across sports, there were a few trends noted between sports. For example, boys’ wrestling included diagnoses related to general medical skin conditions (ie, tinea, folliculitis, herpes simplex) and sprain or strain of the neck, while boys’ wrestling and girls’ softball were the only sports where sprain or strain of the elbow was documented as a common injury. It appears that the types of injuries suffered during girls’ soccer, girls’ track and field, and boys’ track and field tend to require more time and effort to provide treatment and care than other sports. Girls’ soccer and basketball required longer durations of care when compared with boys’ soccer and basketball, respectively. In contrast, boys’ track and field required longer durations of care when compared with girls’ track and field.</p>
      <p>The basis of determining appropriate medical coverage and care, as described by the NATA’s Appropriate Medical Coverage of Intercollegiate Athletics (AMCIA)<sup><xref rid="bibr22-1941738114555842" ref-type="bibr">22</xref></sup> document, is the relative workload of each sport. To calculate the relative work load for each sport, AMCIA guidelines recommend multiplying the injury risk (based on multiyear injury surveillance data) with the average number of treatments per injury. As a result, certain sports may require increased coverage because of increased risk of injury. Contact sports like football and soccer often require daily on-field practice and game coverage because of the increased risk of catastrophic injuries. In contrast, noncontact sports such as track and field may not require on-field event coverage but may require the same or greater amount of time to care for chronic, overuse, and recurrent injuries that may linger for a large portion of a season. While our inclusion of the type, amount, and duration of care offers a more comprehensive perspective on the demands on ATs, our data set likely does not provide a complete picture in terms of all of the treatments delivered in the secondary school setting. To continue the discussion related to appropriate medical coverage and care within the context of AMCIA<sup><xref rid="bibr22-1941738114555842" ref-type="bibr">22</xref></sup> and Appropriate Medical Coverage for Secondary School Athletes summary document,<sup><xref rid="bibr5-1941738114555842" ref-type="bibr">5</xref></sup> future studies should aim to capture data for services that are associated with non–time loss injuries and preventative services in the secondary school setting.</p>
      <p>This study is not without its limitations. We analyzed injuries based on ICD-9 coding which, at times, did not allow us to identify a specific diagnosis for an injury. Our analyses may have been more informative if we were able to differentiate between sprain and strain injuries, for example.</p>
    </sec>
    <sec sec-type="conclusions" id="section18-1941738114555842">
      <title>Conclusion</title>
      <p>Secondary school ATs tend to diagnose similar injuries and use similar treatment methods, regardless of sport. ATs covering wrestling should pay special attention to skin conditions and should be well prepared to prevent and treat these conditions.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>The authors would like to thank the participating members of the Athletic Training Practice-Based Research Network for their work to develop and promote the network.</p>
    </ack>
    <fn-group>
      <fn fn-type="conflict">
        <p>The following authors declared potential conflicts of interest: Alison R. Snyder Valier, PhD, ATC, has grants/grants pending from the National Athletic Trainers’ Association Research and Education Foundation. Tamara C. Valovich McLeod, PhD, ATC, FNATA, was a paid legal consultant for 2 cases this past year related to sports concussions.<?release-delay 12|0?></p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="bibr1-1941738114555842">
        <label>1.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Agel</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>TA</given-names></name><name><surname>Dick</surname><given-names>R</given-names></name><name><surname>Putukian</surname><given-names>M</given-names></name><name><surname>Marshall</surname><given-names>SW</given-names></name></person-group>
<article-title>Descriptive epidemiology of collegiate men’s soccer injuries: National Collegiate Athletic Association Injury Surveillance System, 1988-1989 through 2002-2003</article-title>. <source>J Athl Train</source>. <year>2007</year>;<volume>42</volume>:<fpage>270</fpage>-<lpage>277</lpage>.<pub-id pub-id-type="pmid">17710176</pub-id></mixed-citation>
      </ref>
      <ref id="bibr2-1941738114555842">
        <label>2.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Agel</surname><given-names>J</given-names></name><name><surname>Olson</surname><given-names>DE</given-names></name><name><surname>Dick</surname><given-names>R</given-names></name><name><surname>Arendt</surname><given-names>EA</given-names></name><name><surname>Marshall</surname><given-names>SW</given-names></name><name><surname>Sikka</surname><given-names>RS</given-names></name></person-group>
<article-title>Descriptive epidemiology of collegiate women’s basketball injuries: National Collegiate Athletic Association Injury Surveillance System, 1988-1989 through 2003-2004</article-title>. <source>J Athl Train</source>. <year>2007</year>;<volume>42</volume>:<fpage>202</fpage>-<lpage>210</lpage>.<pub-id pub-id-type="pmid">17710168</pub-id></mixed-citation>
      </ref>
      <ref id="bibr3-1941738114555842">
        <label>3.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Agel</surname><given-names>J</given-names></name><name><surname>Palmieri-Smith</surname><given-names>RM</given-names></name><name><surname>Dick</surname><given-names>R</given-names></name><name><surname>Wojtys</surname><given-names>EM</given-names></name><name><surname>Marshall</surname><given-names>SW</given-names></name></person-group>
<article-title>Descriptive epidemiology of collegiate women’s volleyball injuries: National Collegiate Athletic Association Injury Surveillance System, 1988-1989 through 2003-2004</article-title>. <source>J Athl Train</source>. <year>2007</year>;<volume>42</volume>:<fpage>295</fpage>-<lpage>302</lpage>.<pub-id pub-id-type="pmid">17710179</pub-id></mixed-citation>
      </ref>
      <ref id="bibr4-1941738114555842">
        <label>4.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Agel</surname><given-names>J</given-names></name><name><surname>Ransone</surname><given-names>J</given-names></name><name><surname>Dick</surname><given-names>R</given-names></name><name><surname>Oppliger</surname><given-names>R</given-names></name><name><surname>Marshall</surname><given-names>SW</given-names></name></person-group>
<article-title>Descriptive epidemiology of collegiate men’s wrestling injuries: National Collegiate Athletic Association Injury Surveillance System, 1988-1989 through 2003-2004</article-title>. <source>J Athl Train</source>. <year>2007</year>;<volume>42</volume>:<fpage>303</fpage>-<lpage>310</lpage>.<pub-id pub-id-type="pmid">17710180</pub-id></mixed-citation>
      </ref>
      <ref id="bibr5-1941738114555842">
        <label>5.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Almquist</surname><given-names>J</given-names></name><name><surname>Valovich McLeod</surname><given-names>TC</given-names></name><name><surname>Cavanna</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Summary statement: appropriate medical care for the secondary school-aged athlete</article-title>. <source>J Athl Train</source>. <year>2008</year>;<volume>43</volume>:<fpage>416</fpage>-<lpage>427</lpage>.<pub-id pub-id-type="pmid">18668175</pub-id></mixed-citation>
      </ref>
      <ref id="bibr6-1941738114555842">
        <label>6.</label>
        <mixed-citation publication-type="webpage">
<collab>American Orthopaedic Society for Sports Medicine</collab>. <article-title>Principles for selecting team medical coverage</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.nata.org/sites/default/files/SecondarySchool.pdf">http://www.nata.org/sites/default/files/SecondarySchool.pdf</ext-link>
<date-in-citation>Accessed January 7, 2014</date-in-citation>.</mixed-citation>
      </ref>
      <ref id="bibr7-1941738114555842">
        <label>7.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Badgeley</surname><given-names>MA</given-names></name><name><surname>McIlvain</surname><given-names>NM</given-names></name><name><surname>Yard</surname><given-names>EE</given-names></name><name><surname>Fields</surname><given-names>SK</given-names></name><name><surname>Comstock</surname><given-names>RD</given-names></name></person-group>
<article-title>Epidemiology of 10,000 high school football injuries: patterns of injury by position played</article-title>. <source>J Phys Act Health</source>. <year>2013</year>;<volume>10</volume>:<fpage>160</fpage>-<lpage>169</lpage>.<pub-id pub-id-type="pmid">22821941</pub-id></mixed-citation>
      </ref>
      <ref id="bibr8-1941738114555842">
        <label>8.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Borowski</surname><given-names>LA</given-names></name><name><surname>Yard</surname><given-names>EE</given-names></name><name><surname>Fields</surname><given-names>SK</given-names></name><name><surname>Comstock</surname><given-names>RD</given-names></name></person-group>
<article-title>The epidemiology of US high school basketball injuries, 2005-2007</article-title>. <source>Am J Sports Med</source>. <year>2008</year>;<volume>36</volume>:<fpage>2328</fpage>-<lpage>2335</lpage>.<pub-id pub-id-type="pmid">18765675</pub-id></mixed-citation>
      </ref>
      <ref id="bibr9-1941738114555842">
        <label>9.</label>
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><name><surname>Comstock</surname><given-names>RD</given-names></name><name><surname>Collins</surname><given-names>CL</given-names></name><name><surname>Currie</surname><given-names>DW</given-names></name></person-group>
<article-title>National High School Sports-Related Injury Surveillance Study: summary report (2012-2013)</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.ucdenver.edu/academics/colleges/PublicHealth/research/ResearchProjects/piper/projects/RIO/Documents/2012-13.pdf">http://www.ucdenver.edu/academics/colleges/PublicHealth/research/ResearchProjects/piper/projects/RIO/Documents/2012-13.pdf</ext-link>
<date-in-citation>Accessed January 10, 2014</date-in-citation>.</mixed-citation>
      </ref>
      <ref id="bibr10-1941738114555842">
        <label>10.</label>
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><name><surname>Courson</surname><given-names>R</given-names></name><name><surname>Goldenberg</surname><given-names>M</given-names></name><name><surname>Adams</surname><given-names>KG</given-names></name><etal/></person-group>
<article-title>Inter-association consensus statement on best practices for sports medicine management for secondary schools and colleges</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.nata.org/sites/default/files/SportsMedicineManagement.pdf">http://www.nata.org/sites/default/files/SportsMedicineManagement.pdf</ext-link>
<date-in-citation>Accessed January 7, 2014</date-in-citation>.</mixed-citation>
      </ref>
      <ref id="bibr11-1941738114555842">
        <label>11.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dick</surname><given-names>R</given-names></name><name><surname>Ferrara</surname><given-names>MS</given-names></name><name><surname>Agel</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Descriptive epidemiology of collegiate men’s football injuries: National Collegiate Athletic Association Injury Surveillance System, 1988-1989 through 2003-2004</article-title>. <source>J Athl Train</source>. <year>2007</year>;<volume>42</volume>:<fpage>221</fpage>-<lpage>233</lpage>.<pub-id pub-id-type="pmid">17710170</pub-id></mixed-citation>
      </ref>
      <ref id="bibr12-1941738114555842">
        <label>12.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dick</surname><given-names>R</given-names></name><name><surname>Hertel</surname><given-names>J</given-names></name><name><surname>Agel</surname><given-names>J</given-names></name><name><surname>Grossman</surname><given-names>J</given-names></name><name><surname>Marshall</surname><given-names>SW</given-names></name></person-group>
<article-title>Descriptive epidemiology of collegiate men’s basketball injuries: National Collegiate Athletic Association Injury Surveillance System, 1988-1989 through 2003-2004</article-title>. <source>J Athl Train</source>. <year>2007</year>;<volume>42</volume>:<fpage>194</fpage>-<lpage>201</lpage>.<pub-id pub-id-type="pmid">17710167</pub-id></mixed-citation>
      </ref>
      <ref id="bibr13-1941738114555842">
        <label>13.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dick</surname><given-names>R</given-names></name><name><surname>Putukian</surname><given-names>M</given-names></name><name><surname>Agel</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>TA</given-names></name><name><surname>Marshall</surname><given-names>SW</given-names></name></person-group>
<article-title>Descriptive epidemiology of collegiate women’s soccer injuries: National Collegiate Athletic Association Injury Surveillance System, 1988-1989 through 2002-2003</article-title>. <source>J Athl Train</source>. <year>2007</year>;<volume>42</volume>:<fpage>278</fpage>-<lpage>285</lpage>.<pub-id pub-id-type="pmid">17710177</pub-id></mixed-citation>
      </ref>
      <ref id="bibr14-1941738114555842">
        <label>14.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Difiori</surname><given-names>JP</given-names></name><name><surname>Benjamin</surname><given-names>HJ</given-names></name><name><surname>Brenner</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Overuse injuries and burnout in youth sports: a position statement from the American Medical Society for Sports Medicine</article-title>. <source>Clin J Sport Med</source>. <year>2014</year>;<volume>24</volume>:<fpage>3</fpage>-<lpage>20</lpage>.<pub-id pub-id-type="pmid">24366013</pub-id></mixed-citation>
      </ref>
      <ref id="bibr15-1941738114555842">
        <label>15.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dragoo</surname><given-names>JL</given-names></name><name><surname>Braun</surname><given-names>HJ</given-names></name><name><surname>Durham</surname><given-names>JL</given-names></name><name><surname>Chen</surname><given-names>MR</given-names></name><name><surname>Harris</surname><given-names>AH</given-names></name></person-group>
<article-title>Incidence and risk factors for injuries to the anterior cruciate ligament in National Collegiate Athletic Association football: data from the 2004-2005 through 2008-2009 National Collegiate Athletic Association Injury Surveillance System</article-title>. <source>Am J Sports Med</source>. <year>2012</year>;<volume>40</volume>:<fpage>990</fpage>-<lpage>995</lpage>.<pub-id pub-id-type="pmid">22491794</pub-id></mixed-citation>
      </ref>
      <ref id="bibr16-1941738114555842">
        <label>16.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>WG</given-names></name><name><surname>Yard</surname><given-names>EE</given-names></name><name><surname>Comstock</surname><given-names>RD</given-names></name></person-group>
<article-title>Epidemiology of lower extremity injuries among U.S. high school athletes</article-title>. <source>Acad Emerg Med</source>. <year>2007</year>;<volume>14</volume>:<fpage>641</fpage>-<lpage>645</lpage>.<pub-id pub-id-type="pmid">17513688</pub-id></mixed-citation>
      </ref>
      <ref id="bibr17-1941738114555842">
        <label>17.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Frommer</surname><given-names>LJ</given-names></name><name><surname>Gurka</surname><given-names>KK</given-names></name><name><surname>Cross</surname><given-names>KM</given-names></name><name><surname>Ingersoll</surname><given-names>CD</given-names></name><name><surname>Comstock</surname><given-names>RD</given-names></name><name><surname>Saliba</surname><given-names>SA</given-names></name></person-group>
<article-title>Sex differences in concussion symptoms of high school athletes</article-title>. <source>J Athl Train</source>. <year>2011</year>;<volume>46</volume>:<fpage>76</fpage>-<lpage>84</lpage>.<pub-id pub-id-type="pmid">21214354</pub-id></mixed-citation>
      </ref>
      <ref id="bibr18-1941738114555842">
        <label>18.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gessel</surname><given-names>LM</given-names></name><name><surname>Fields</surname><given-names>SK</given-names></name><name><surname>Collins</surname><given-names>CL</given-names></name><name><surname>Dick</surname><given-names>RW</given-names></name><name><surname>Comstock</surname><given-names>RD</given-names></name></person-group>
<article-title>Concussions among United States high school and collegiate athletes</article-title>. <source>J Athl Train</source>. <year>2007</year>;<volume>42</volume>:<fpage>495</fpage>-<lpage>503</lpage>.<pub-id pub-id-type="pmid">18174937</pub-id></mixed-citation>
      </ref>
      <ref id="bibr19-1941738114555842">
        <label>19.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ingram</surname><given-names>JG</given-names></name><name><surname>Fields</surname><given-names>SK</given-names></name><name><surname>Yard</surname><given-names>EE</given-names></name><name><surname>Comstock</surname><given-names>RD</given-names></name></person-group>
<article-title>Epidemiology of knee injuries among boys and girls in US high school athletics</article-title>. <source>Am J Sports Med</source>. <year>2008</year>;<volume>36</volume>:<fpage>1116</fpage>-<lpage>1122</lpage>.<pub-id pub-id-type="pmid">18375784</pub-id></mixed-citation>
      </ref>
      <ref id="bibr20-1941738114555842">
        <label>20.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Krajnik</surname><given-names>S</given-names></name><name><surname>Fogarty</surname><given-names>KJ</given-names></name><name><surname>Yard</surname><given-names>EE</given-names></name><name><surname>Comstock</surname><given-names>RD</given-names></name></person-group>
<article-title>Shoulder injuries in US high school baseball and softball athletes, 2005-2008</article-title>. <source>Pediatrics</source>. <year>2010</year>;<volume>125</volume>:<fpage>497</fpage>-<lpage>501</lpage>.<pub-id pub-id-type="pmid">20142288</pub-id></mixed-citation>
      </ref>
      <ref id="bibr21-1941738114555842">
        <label>21.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marar</surname><given-names>M</given-names></name><name><surname>McIlvain</surname><given-names>NM</given-names></name><name><surname>Fields</surname><given-names>SK</given-names></name><name><surname>Comstock</surname><given-names>RD</given-names></name></person-group>
<article-title>Epidemiology of concussions among United States high school athletes in 20 sports</article-title>. <source>Am J Sports Med</source>. <year>2012</year>;<volume>40</volume>:<fpage>747</fpage>-<lpage>755</lpage>.<pub-id pub-id-type="pmid">22287642</pub-id></mixed-citation>
      </ref>
      <ref id="bibr22-1941738114555842">
        <label>22.</label>
        <mixed-citation publication-type="webpage">
<collab>National Athletic Trainers’ Association</collab>. <article-title>Recommendations and guildelines for appropriate medical coverage of intercollegiate athletics</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.nata.org/sites/default/files/AMCIA-Revised-2010.pdf">http://www.nata.org/sites/default/files/AMCIA-Revised-2010.pdf</ext-link>
<date-in-citation>Accessed January 10, 2014</date-in-citation>.</mixed-citation>
      </ref>
      <ref id="bibr23-1941738114555842">
        <label>23.</label>
        <mixed-citation publication-type="webpage">
<collab>National Athletic Trainers’ Association</collab>. <article-title>Secondary school official statement</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.nata.org/sites/default/files/SecondarySchool.pdf">http://www.nata.org/sites/default/files/SecondarySchool.pdf</ext-link>
<date-in-citation>Accessed January 9, 2014</date-in-citation>.</mixed-citation>
      </ref>
      <ref id="bibr24-1941738114555842">
        <label>24.</label>
        <mixed-citation publication-type="webpage">
<collab>National Federation of State High School Associations</collab>. <article-title>2012-2013 High School Athletics Participation Survey results</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.nfhs.org/content.aspx?id=3282">http://www.nfhs.org/content.aspx?id=3282</ext-link>
<date-in-citation>Accessed January 7, 2014</date-in-citation>.</mixed-citation>
      </ref>
      <ref id="bibr25-1941738114555842">
        <label>25.</label>
        <mixed-citation publication-type="gov">
<collab>National Institutes of Health</collab>. <article-title>Research repositories, databases, and the HIPAA privacy rule</article-title>. <ext-link ext-link-type="uri" xlink:href="http://privacyruleandresearch.nih.gov/research_repositories.asp">http://privacyruleandresearch.nih.gov/research_repositories.asp</ext-link>
<date-in-citation>Accessed January 7, 2014</date-in-citation>.</mixed-citation>
      </ref>
      <ref id="bibr26-1941738114555842">
        <label>26.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nelson</surname><given-names>AJ</given-names></name><name><surname>Collins</surname><given-names>CL</given-names></name><name><surname>Yard</surname><given-names>EE</given-names></name><name><surname>Fields</surname><given-names>SK</given-names></name><name><surname>Comstock</surname><given-names>RD</given-names></name></person-group>
<article-title>Ankle injuries among United States high school sports athletes, 2005-2006</article-title>. <source>J Athl Train</source>. <year>2007</year>;<volume>42</volume>:<fpage>381</fpage>-<lpage>387</lpage>.<pub-id pub-id-type="pmid">18059994</pub-id></mixed-citation>
      </ref>
      <ref id="bibr27-1941738114555842">
        <label>27.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rindal</surname><given-names>DB</given-names></name><name><surname>Gordan</surname><given-names>VV</given-names></name><name><surname>Litaker</surname><given-names>MS</given-names></name><etal/></person-group>
<article-title>Methods dentists use to diagnose primary caries lesions prior to restorative treatment: findings from The Dental PBRN</article-title>. <source>J Dent</source>. <year>2010</year>;<volume>38</volume>:<fpage>1027</fpage>-<lpage>1032</lpage>.<pub-id pub-id-type="pmid">20884316</pub-id></mixed-citation>
      </ref>
      <ref id="bibr28-1941738114555842">
        <label>28.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Roos</surname><given-names>KG</given-names></name><name><surname>Marshall</surname><given-names>SW</given-names></name></person-group>
<article-title>Definition and usage of the term “overuse injury” in the US high school and collegiate sport epidemiology literature: a systematic review</article-title>. <source>Sports Med</source>. <year>2014</year>;<volume>44</volume>:<fpage>405</fpage>-<lpage>421</lpage>.<pub-id pub-id-type="pmid">24242858</pub-id></mixed-citation>
      </ref>
      <ref id="bibr29-1941738114555842">
        <label>29.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shankar</surname><given-names>PR</given-names></name><name><surname>Fields</surname><given-names>SK</given-names></name><name><surname>Collins</surname><given-names>CL</given-names></name><name><surname>Dick</surname><given-names>RW</given-names></name><name><surname>Comstock</surname><given-names>RD</given-names></name></person-group>
<article-title>Epidemiology of high school and collegiate football injuries in the United States, 2005-2006</article-title>. <source>Am J Sports Med</source>. <year>2007</year>;<volume>35</volume>:<fpage>1295</fpage>-<lpage>1303</lpage>.<pub-id pub-id-type="pmid">17369559</pub-id></mixed-citation>
      </ref>
      <ref id="bibr30-1941738114555842">
        <label>30.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Swenson</surname><given-names>DM</given-names></name><name><surname>Collins</surname><given-names>CL</given-names></name><name><surname>Best</surname><given-names>TM</given-names></name><name><surname>Flanigan</surname><given-names>DC</given-names></name><name><surname>Fields</surname><given-names>SK</given-names></name><name><surname>Comstock</surname><given-names>RD</given-names></name></person-group>
<article-title>Epidemiology of knee injuries among U.S. high school athletes, 2005/2006-2010/2011</article-title>. <source>Med Sci Sports Exerc</source>. <year>2013</year>;<volume>45</volume>:<fpage>462</fpage>-<lpage>469</lpage>.<pub-id pub-id-type="pmid">23059869</pub-id></mixed-citation>
      </ref>
      <ref id="bibr31-1941738114555842">
        <label>31.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Valovich McLeod</surname><given-names>TC</given-names></name><name><surname>Bliven</surname><given-names>KC</given-names></name><name><surname>Lam</surname><given-names>KC</given-names></name><name><surname>Bay</surname><given-names>RC</given-names></name><name><surname>Valier</surname><given-names>AR</given-names></name><name><surname>Parsons</surname><given-names>JT</given-names></name></person-group>
<article-title>The National Sports Safety in Secondary Schools Benchmark (N4SB) study: defining athletic training practice characteristics</article-title>. <source>J Athl Train</source>. <year>2013</year>;<volume>48</volume>:<fpage>483</fpage>-<lpage>492</lpage>.<pub-id pub-id-type="pmid">23768120</pub-id></mixed-citation>
      </ref>
      <ref id="bibr32-1941738114555842">
        <label>32.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Valovich McLeod</surname><given-names>TC</given-names></name><name><surname>Lam</surname><given-names>KC</given-names></name><name><surname>Bay</surname><given-names>RC</given-names></name><name><surname>Sauers</surname><given-names>EL</given-names></name><name><surname>Snyder Valier</surname><given-names>AR</given-names></name></person-group>
<article-title>Practice-based research networks, part II: a descriptive analysis of the athletic training practice-based research network in the secondary school setting</article-title>. <source>J Athl Train</source>. <year>2012</year>;<volume>47</volume>:<fpage>557</fpage>-<lpage>566</lpage>.<pub-id pub-id-type="pmid">23068594</pub-id></mixed-citation>
      </ref>
      <ref id="bibr33-1941738114555842">
        <label>33.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yard</surname><given-names>EE</given-names></name><name><surname>Collins</surname><given-names>CL</given-names></name><name><surname>Dick</surname><given-names>RW</given-names></name><name><surname>Comstock</surname><given-names>RD</given-names></name></person-group>
<article-title>An epidemiologic comparison of high school and college wrestling injuries</article-title>. <source>Am J Sports Med</source>. <year>2008</year>;<volume>36</volume>:<fpage>57</fpage>-<lpage>64</lpage>.<pub-id pub-id-type="pmid">17932400</pub-id></mixed-citation>
      </ref>
      <ref id="bibr34-1941738114555842">
        <label>34.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yard</surname><given-names>EE</given-names></name><name><surname>Schroeder</surname><given-names>MJ</given-names></name><name><surname>Fields</surname><given-names>SK</given-names></name><name><surname>Collins</surname><given-names>CL</given-names></name><name><surname>Comstock</surname><given-names>RD</given-names></name></person-group>
<article-title>The epidemiology of United States high school soccer injuries, 2005-2007</article-title>. <source>Am J Sports Med</source>. <year>2008</year>;<volume>36</volume>:<fpage>1930</fpage>-<lpage>1937</lpage>.<pub-id pub-id-type="pmid">18628486</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:4272699</identifier><datestamp>2016-01-01</datestamp><setSpec>sportshealth</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="http://jats.nlm.nih.gov/ns/archiving/1.0/ http://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="news">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Sports Health</journal-id>
      <journal-id journal-id-type="iso-abbrev">Sports Health</journal-id>
      <journal-id journal-id-type="publisher-id">SPH</journal-id>
      <journal-id journal-id-type="hwp">spsph</journal-id>
      <journal-title-group>
        <journal-title>Sports Health</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1941-7381</issn>
      <issn pub-type="epub">1941-0921</issn>
      <publisher>
        <publisher-name>SAGE Publications</publisher-name>
        <publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4272699</article-id>
      <article-id pub-id-type="pmcid">PMC4272699</article-id>
      <article-id pub-id-type="pmc-uid">4272699</article-id>
      <article-id pub-id-type="pmid">25553219</article-id>
      <article-id pub-id-type="doi">10.1177/1941738114563036</article-id>
      <article-id pub-id-type="publisher-id">10.1177_1941738114563036</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Society News</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Society News</article-title>
      </title-group>
      <pub-date pub-type="epub-ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>1</day>
        <month>1</month>
        <year>2016</year>
      </pub-date>
      <!-- PMC Release delay is 12 months and 0 days and was based on the <pub-date pub-type="ppub"/>. -->
      <volume>7</volume>
      <issue>1</issue>
      <fpage>90</fpage>
      <lpage>91</lpage>
      <permissions>
        <copyright-statement>© 2014 American Orthopaedic Society for Sports Medicine</copyright-statement>
        <copyright-year>2014</copyright-year>
        <copyright-holder content-type="society">American Orthopaedic Society for Sports Medicine</copyright-holder>
      </permissions>
      <custom-meta-group>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>January/February 2015</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="section1-1941738114563036">
      <title>American Medical Society for Sports Medicine (AMSSM)</title>
      <p>The American Medical Society for Sports Medicine (AMSSM) is pleased to introduce its latest position statement, “Interventional Musculoskeletal Ultrasound in Sports Medicine,” which has been published in the January 2015 <italic>Clinical Journal of Sport Medicine, British Journal of Sports Medicine</italic>, and <italic>PM&amp;R Journal</italic>. In addition, the new curriculum for sports medicine fellowship programs was also introduced. These publications serve as a major step toward achieving AMSSM’s goal of ensuring all sports medicine physicians are trained to competently perform the core competencies of diagnostic and interventional sports ultrasound in clinical practice. AMSSM is currently developing educational resources to assist sports medicine fellowships with implementing the curriculum. AMSSM looks forward to continuing to guide the development of sports ultrasound for our specialty.</p>
      <p>To view the AMSSM position statement and new curriculum, visit <ext-link ext-link-type="uri" xlink:href="http://www.amssm.org/Publications.html">http://www.amssm.org/Publications.html</ext-link>.</p>
      <sec id="section2-1941738114563036">
        <title>24th AMSSM Annual Meeting</title>
        <p>The 2015 Program Planning Committee is excited to invite you to attend the 24th AMSSM Annual Meeting in Hollywood, Florida (April 14-19, 2015). The theme of this year’s meeting is “Making the Call: Return to Play” and builds on the aspect of our profession that defines our clinical practice.</p>
        <p>Apart from the strong educational content of the meeting, we hope that you’ll be able to enjoy the scenic beach and nightlife that is characteristic of South Florida. The Diplomat Resort and Spa is truly one of the best venues for our AMSSM Annual Meeting.</p>
        <p>AMSSM is continuing with several rich traditions of the Annual Meeting, including the AMSSM Annual Meeting humanitarian service project to revitalize Broward County, preconference workshops, instructional course lectures (ICLs), research presentations, case presentations, the SMART workshop, and the CAQ (Certificate of Added Qualifications) review session.</p>
        <p>Some of the many program highlights include:</p>
        <list list-type="bullet" id="list1-1941738114563036">
          <list-item>
            <p>The NCAA/AMSSM preconference workshop</p>
          </list-item>
          <list-item>
            <p>“Is Heading Bad for My Kid?”</p>
          </list-item>
          <list-item>
            <p>“Does Exercise Induce Cardiomyopathy?”</p>
          </list-item>
          <list-item>
            <p>“Cardiovascular Mortality and Hypertension in American Football Athletes”</p>
          </list-item>
          <list-item>
            <p>“Regenerative Medicine in DJD: Is There a Role?”</p>
          </list-item>
          <list-item>
            <p>“Viscosupplementation: Indications, Controversies, and Effectiveness”</p>
          </list-item>
          <list-item>
            <p>“Reform in Medical Education: The Power of Exercise Training”</p>
          </list-item>
          <list-item>
            <p>and more!</p>
          </list-item>
        </list>
        <p>Visit <ext-link ext-link-type="uri" xlink:href="http://AMSSM.org">AMSSM.org</ext-link> and click on the Education/Conferences tab to view the program and register.</p>
      </sec>
    </sec>
    <sec id="section3-1941738114563036">
      <title>American Orthopaedic Society for Sports Medicine (AOSSM)</title>
      <sec id="section4-1941738114563036">
        <title>Nominate a Mentor for the Hall of Fame</title>
        <p>Do you know someone who deserves to be put into the AOSSM Hall of Fame? Submit their name at <ext-link ext-link-type="uri" xlink:href="http://www.sportsmed.org/apps/halloffame/">http://www.sportsmed.org/apps/halloffame/</ext-link>. Deadline for submissions is January 15, 2015. Questions, contact Camille Petrick at <email>camille@aossm.org</email>.</p>
      </sec>
      <sec id="section5-1941738114563036">
        <title>Submit Your Application for the OA Grant</title>
        <p>The deadline for the AOSSM/Sanofi Biosurgery Osteoarthritis (OA) Grant is January 15, 2015. The $50,000 grant funds investigations related to early OA and/or the prevention of OA progression, including either a clinical research study or a laboratory/basic science project. Proposed studies need not relate specifically to sports injuries and should also have broad applicability to OA in the general population. Projects involving viscosupplementation will not be considered. For more information and to apply, visit <ext-link ext-link-type="uri" xlink:href="http://www.sportsmed.org/researchgrants">http://www.sportsmed.org/researchgrants</ext-link>.</p>
      </sec>
      <sec id="section6-1941738114563036">
        <title>Get Involved in AOSSM—Join a Committee</title>
        <p>Are you looking to become more involved in the Society? Join a committee! Submit your qualifications online at <ext-link ext-link-type="uri" xlink:href="http://www.sportsmed.org">www.sportsmed.org</ext-link>. Deadline for submissions is February 2, 2015. Committee selections will be made in April, and members will be notified of their selection in May. Questions, contact Camille Petrick at <email>camille@aossm.org</email>.</p>
      </sec>
      <sec id="section7-1941738114563036">
        <title>Upcoming Meetings and Courses</title>
        <list list-type="simple" id="list2-1941738114563036">
          <list-item>
            <p>
              <bold>AOSSM 2014 Specialty Day</bold>
            </p>
            <p>March 28, 2015</p>
            <p>Las Vegas, NV</p>
          </list-item>
          <list-item>
            <p>
              <bold>Contemporary Treatment of the Young Adult Hip: Latest Research &amp; Surgical Techniques</bold>
            </p>
            <p>April 10-12, 2015</p>
            <p>Rosemont, IL</p>
          </list-item>
          <list-item>
            <p>
              <bold>AOSSM 2015 Annual Meeting</bold>
            </p>
            <p>July 9-12, 2015</p>
            <p>Orlando, FL</p>
          </list-item>
          <list-item>
            <p>
              <bold>AOSSM/AAOS Review Course for Subspecialty Certification in Orthopaedic Sports Medicine</bold>
            </p>
            <p>August 14-16, 2015</p>
            <p>Chicago, IL</p>
          </list-item>
          <list-item>
            <p>
              <bold>Keep Your Edge: Hockey Sports Medicine in 2015</bold>
            </p>
            <p>August 28-30, 2015</p>
            <p>Toronto, Ontario, Canada</p>
          </list-item>
          <list-item>
            <p>
              <bold>Consensus and Controversy: Advanced Techniques for the Athlete’s Shoulder</bold>
            </p>
            <p>October 25-27, 2015</p>
            <p>Orthopaedic Learning Center, Rosemont, IL</p>
          </list-item>
        </list>
      </sec>
    </sec>
    <sec id="section8-1941738114563036">
      <title>National Athletic Trainers’ Association (NATA)</title>
      <p>On Monday, March 2, 2015, the Youth Sports Safety Alliance, in partnership with National Athletic Trainers’ Association, will host the 6th annual Youth Sports Safety Summit in Dallas, Texas. The focus of this summit will be Navigating the Athletic Health Care System. The summit provides a unique opportunity to engage in dialogue around key issues related to health care for athletes, such as: psychological concerns, early specialization and overuse injuries, safety equipment claims (myths and facts), and nutrition. Keynote speaker James Andrews, MD, will discuss creating lifetime athletes. He will discuss strategies for the prevention and proper management of youth sports injuries. Visit <ext-link ext-link-type="uri" xlink:href="http://www.youthsportssafetysummit.org">http://www.youthsportssafetysummit.org</ext-link> for more information and to register.<?release-delay 12|0?></p>
    </sec>
  </body>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:4274773</identifier><datestamp>2016-01-01</datestamp><setSpec>diacare</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="http://jats.nlm.nih.gov/ns/archiving/1.0/ http://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Diabetes Care</journal-id>
      <journal-id journal-id-type="iso-abbrev">Diabetes Care</journal-id>
      <journal-id journal-id-type="hwp">diacare</journal-id>
      <journal-id journal-id-type="pmc">dcare</journal-id>
      <journal-id journal-id-type="publisher-id">Diabetes Care</journal-id>
      <journal-title-group>
        <journal-title>Diabetes Care</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0149-5992</issn>
      <issn pub-type="epub">1935-5548</issn>
      <publisher>
        <publisher-name>American Diabetes Association</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4274773</article-id>
      <article-id pub-id-type="pmcid">PMC4274773</article-id>
      <article-id pub-id-type="pmc-uid">4274773</article-id>
      <article-id pub-id-type="pmid">25336747</article-id>
      <article-id pub-id-type="publisher-id">1196</article-id>
      <article-id pub-id-type="doi">10.2337/dc14-1196</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Pathophysiology/Complications</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Spatial Patterns of Structural Brain Changes in Type 2 Diabetic Patients and Their Longitudinal Progression With Intensive Control of Blood Glucose</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Erus</surname>
            <given-names>Guray</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Battapady</surname>
            <given-names>Harsha</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>Tianhao</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lovato</surname>
            <given-names>James</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Miller</surname>
            <given-names>Michael E.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Williamson</surname>
            <given-names>Jeff D.</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Launer</surname>
            <given-names>Lenore J.</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bryan</surname>
            <given-names>R. Nick</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Davatzikos</surname>
            <given-names>Christos</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
        <aff id="aff1"><sup>1</sup>Center for Biomedical Image Computing and Analytics (CBICA) and Department of Radiology, University of Pennsylvania Health System, Philadelphia, PA</aff>
        <aff id="aff2"><sup>2</sup>Department of Biostatistical Sciences, Wake Forest University School of Medicine, Winston-Salem, NC</aff>
        <aff id="aff3"><sup>3</sup>Roena B. Kulynych Center for Memory and Cognition Research, Department of Internal Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC</aff>
        <aff id="aff4"><sup>4</sup>Intramural Research Program, National Institute on Aging, National Institutes of Health, Bethesda, MD</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">Corresponding author: Guray Erus, <email>guray.erus@uphs.upenn.edu</email>, or Christos Davatzikos, <email>christos.davatzikos@uphs.upenn.edu</email>.</corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>21</day>
        <month>10</month>
        <year>2014</year>
      </pub-date>
      <volume>38</volume>
      <issue>1</issue>
      <fpage>97</fpage>
      <lpage>104</lpage>
      <history>
        <date date-type="received">
          <day>9</day>
          <month>5</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>22</day>
          <month>9</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.</copyright-statement>
        <copyright-year>2015</copyright-year>
      </permissions>
      <self-uri xlink:title="pdf" xlink:type="simple" xlink:href="97.pdf"/>
      <abstract>
        <sec>
          <title>OBJECTIVE</title>
          <p>Understanding the effect of diabetes as well as of alternative treatment strategies on cerebral structure is critical for the development of targeted interventions against accelerated neurodegeneration in type 2 diabetes. We investigated whether diabetes characteristics were associated with spatially specific patterns of brain changes and whether those patterns were affected by intensive versus standard glycemic treatment.</p>
        </sec>
        <sec>
          <title>RESEARCH DESIGN AND METHODS</title>
          <p>Using baseline MRIs of 488 participants with type 2 diabetes from the Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) study, we applied a new voxel-based analysis methodology to identify spatially specific patterns of gray matter and white matter volume loss related to diabetes duration and HbA<sub>1c</sub>. The longitudinal analysis used 40-month follow-up data to evaluate differences in progression of volume loss between intensive and standard glycemic treatment arms.</p>
        </sec>
        <sec>
          <title>RESULTS</title>
          <p>Participants with longer diabetes duration had significantly lower gray matter volumes, primarily in certain regions in the frontal and temporal lobes. The longitudinal analysis of treatment effects revealed a heterogeneous pattern of decelerated loss of gray matter volume associated with intensive glycemic treatment. Intensive treatment decelerated volume loss, particularly in regions adjacent to those cross-sectionally associated with diabetes duration. No significant relationship between low versus high baseline HbA<sub>1c</sub> levels and brain changes was found. Finally, regions in which cognitive change was associated with longitudinal volume loss had only small overlap with regions related to diabetes duration and to treatment effects.</p>
        </sec>
        <sec>
          <title>CONCLUSIONS</title>
          <p>Applying advanced quantitative image pattern analysis methods on longitudinal MRI data of a large sample of patients with type 2 diabetes, we demonstrate that there are spatially specific patterns of brain changes that vary by diabetes characteristics and that the progression of gray matter volume loss is slowed by intensive glycemic treatment, particularly in regions adjacent to areas affected by diabetes.</p>
        </sec>
      </abstract>
      <counts>
        <page-count count="8"/>
      </counts>
    </article-meta>
  </front>
  <body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Findings from many cross-sectional and longitudinal population studies have shown that diabetes is associated with higher prevalence of global cognitive impairment and an increased risk of dementia (<xref rid="B1" ref-type="bibr">1</xref>–<xref rid="B4" ref-type="bibr">4</xref>). The underlying mechanisms of the relationship between diabetes and cerebral disease are still unclear (<xref rid="B5" ref-type="bibr">5</xref>). However, brain imaging studies using MRI have provided important insights into structural correlates of cognitive dysfunction in people with type 2 diabetes pointing to a convincing evidence for an association between diabetes and structural brain abnormalities such as cerebral atrophy and lacunar infarcts (<xref rid="B6" ref-type="bibr">6</xref>–<xref rid="B10" ref-type="bibr">10</xref>).</p><p>Besides studying the possible physiological contribution of diabetes to late-age brain pathology, another important research topic, which has received much less attention, is the influence of diabetes disease management strategies on brain structure. The Memory in Diabetes (MIND) substudy, embedded within the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial (<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B12" ref-type="bibr">12</xref>), was designed to test the effects of early glycemic intervention on brain outcomes in older people with type 2 diabetes. Previously published baseline results from the ACCORD-MIND trial have shown that lower levels of baseline cognitive performance are associated with higher levels of HbA<sub>1c</sub> and diabetes duration (<xref rid="B13" ref-type="bibr">13</xref>). However the primary MRI analyses of the trial showed that although people in a intensive glycemic treatment group had less longitudinal decline in total brain volume at 40 months compared with those receiving a standard treatment strategy (<italic>P</italic> = 0.0007), no significant differences were found in the cognitive outcomes between the two treatment groups (<xref rid="B14" ref-type="bibr">14</xref>). This difference in findings may reflect the effect of several factors with a basis ranging from methodological to biological. Previous analyses investigated relatively global measures of brain volume changes, and possibly these changes were relatively restricted to regions mediating cognitive functions other than those tested in the trial. Also possible is that treatment-related changes in brain volume loss precede cognitive changes and are therefore detected first.</p><p>The current study investigated whether there are spatially heterogeneous patterns of structural brain changes that vary by diabetes characteristics and by glycemic treatment strategy. Advanced computer-based imaging pattern analysis methods, including volume-preserving spatial normalization that allows for accurate quantification of very localized brain changes (regional analysis of volumes examined in normalized space [RAVENS]) (<xref rid="B15" ref-type="bibr">15</xref>–<xref rid="B17" ref-type="bibr">17</xref>) and a new voxel-based analysis framework (optimally-discriminative voxel-based analysis [ODVBA]) (<xref rid="B18" ref-type="bibr">18</xref>), were applied on longitudinal MRI data from 488 ACCORD-MIND participants to detect imaging patterns that highlight potential spatial differences in the relationship between images and subject groups.</p><p>Our general hypothesis is that specific areas of the brain are particularly more vulnerable to diabetes effects. In this report we investigate diabetes duration and HbA<sub>1c</sub> levels, two main clinical variables relevant to diabetes and shown to be related to cognition (<xref rid="B13" ref-type="bibr">13</xref>). We also hypothesize that there are spatially specific patterns of longitudinal change that differ between the intensive and standard glycemic treatment arms and that those regions displaying longitudinal treatment effects will show similarities with those vulnerable to diabetes effects.</p></sec><sec id="s2"><title>Research Design and Methods</title><sec id="s3"><title>Participants</title><p>ACCORD, described in detail elsewhere (<xref rid="B11" ref-type="bibr">11</xref>), was a randomized, multicenter, double two-by-two factorial parallel-treatment trial that tested the effect of treatment strategies to control blood glucose, blood pressure, and blood lipid concentrations on cardiovascular disease events. Participants targeted by ACCORD were aged 45–79 years and had type 2 diabetes, high HbA<sub>1c</sub> concentrations (&gt;7.5% [&gt;58 mmol/mol]), and a high risk for cardiovascular disease events suggested by significant atherosclerosis, albuminuria, left ventricular hypertrophy, or at least two additional risk factors for cardiovascular disease. Key exclusion criteria were frequent or recent serious hypoglycemic events, unwillingness to monitor glucose at home or inject insulin, BMI greater than 45 kg/m<sup>2</sup>, serum creatinine level greater than 1.5 mg/dL (133 μmol/L), or other serious illness. The exclusion criteria were applied before randomization. All ACCORD participants were randomly assigned to receive intensive glycemic treatment targeting HbA<sub>1c</sub> to less than 6.0% (42 mmol/mol) or standard glycemic treatment targeting HbA<sub>1c</sub> to 7.0–7.9% (53–63 mmol/mol).</p><p>The ACCORD-MIND study design has been described elsewhere (<xref rid="B12" ref-type="bibr">12</xref>). From within the overall ACCORD study population, 2,977 participants who had been randomly assigned to treatment groups were recruited into the ACCORD-MIND. A cognitive test battery was administered to MIND participants at baseline and at 20 months and 40 months after randomization. The cognitive battery tested for verbal memory (Rey Auditory Learning Test [RAVLT], mean number of recalled words over five trials), processing speed (Digit Symbol Substitution Test [DSST], number of cells correctly filled in), and executive function (modified Stroop Test (STROOP), time to finish the interference challenge).</p><p>The MRI substudy participants have been previously described (<xref rid="B14" ref-type="bibr">14</xref>). A total of 614 participants had a successful baseline scan, from which 503 had a successful 40-month follow-up scan. After processing of image data, 15 participants were excluded from the analysis based on visual quality control (QC) due to insufficient quality of the final image maps. Reasons for missing and excluded scans were similarly distributed across treatment groups (<ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc14-1196/-/DC1">Supplementary Table 1</ext-link>). The final sample included data from 488 ACCORD-MIND participants. The treatment groups had similar baseline characteristics and cardiovascular risk factors (<ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc14-1196/-/DC1">Supplementary Table 2</ext-link>).</p></sec><sec id="s4"><title>MRI Scan Protocol</title><p>The standardized MRI scan protocol (<xref rid="B12" ref-type="bibr">12</xref>) included axial, coronal, and sagittal gradient echo scout views that served as localizers; a three-dimensional fast spoiled gradient-echo T1-weighted sequence (repetition time [TR], 21; flip angle, 30; echo time [TE], 8) to image brain structure, and a two-dimensional axial fast spin-echo (FSE) fluid-attenuated inversion recovery (TR, 8,000; inversion time, 2,000; TE, 100) and proton-density/T2-weighted (TR, 3,200; TE1, 27; TE2, 120) sequences to image pathology. Voxel size was 1.5 × 0.9 × 0.9 mm for the three-dimensional T1 sequence and 3.0 × 0.9 × 0.9 mm for the two-dimensional sequences. Scanners at the four MRI sites had identical field strength (1.5 Tesla) but were from three different manufacturers.</p><p>Monthly MRI QC was managed by the University of Pennsylvania Department of Radiology. The procedures followed the American College of Radiology’s (ACR) MRI QC Program, which is based on the analysis of data acquired from scanning an ACR–National Electrical Manufacturers Association QC phantom. Each field center was responsible for keeping its ACCORD scanners within ACR performance specifications and for sending monthly digital images to the MRI QC center for in-house review. According to ACR phantom analyses, MRI scanner performance was stable across the MRI sites and over the duration of the study. In vivo confirmation of scanner performance over time is reflected by the stability of subject intracranial volumes (ICV) over time (baseline mean ICV, 1,132.34 cm<sup>3</sup>; follow-up mean ICV, 1,132.32 cm<sup>3</sup>; <italic>P</italic> = 0.47 by paired <italic>t</italic> test).</p></sec><sec id="s5"><title>Image Processing</title><p>The MRIs were first preprocessed using previously validated and published techniques (<xref rid="B16" ref-type="bibr">16</xref>). The preprocessing steps included <italic>1</italic>) alignment to the anterior commissure–posterior commissure plane; <italic>2</italic>) removal of extracranial material (skull-stripping) and cerebellum; <italic>3</italic>) N3 bias correction (<xref rid="B19" ref-type="bibr">19</xref>); <italic>4</italic>) tissue segmentation into gray matter (GM), white matter (WM), cerebrospinal fluid (CSF), and lateral ventricles (VN) (<xref rid="B20" ref-type="bibr">20</xref>); <italic>5</italic>) nonlinear image warping (<xref rid="B21" ref-type="bibr">21</xref>) to a common brain atlas using a Montreal Neurological Institute template, as previously described (<xref rid="B22" ref-type="bibr">22</xref>); and <italic>6</italic>) formation of regional volumetric maps, called RAVENS maps (<xref rid="B15" ref-type="bibr">15</xref>–<xref rid="B17" ref-type="bibr">17</xref>), using tissue-preserving image warping to enable comparative analysis of tissue volumes in the common template space.</p><p>RAVENS map intensity values quantify the regional distribution of GM, WM, and ventricular CSF, with one RAVENS map for each tissue type. In particular, RAVENS values in the template’s (stereotaxic) space are directly proportional to the volume of the respective structures in the original brain scan. Therefore, regional volumetric measurements and comparisons are performed by measurements and comparisons of the respective RAVENS maps. For example, patterns of relatively lower regional GM volume in the temporal lobe are quantified by patterns of RAVENS decrease in the temporal lobe in the template space. The RAVENS algorithm has been extensively validated and applied to a variety of studies (<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B23" ref-type="bibr">23</xref>).</p><p>The RAVENS maps were normalized by individual ICV to adjust for global between-person differences in intracranial size and down-sampled to 2 × 2 × 2 mm. Estimates of region-specific longitudinal volumetric change were obtained from the baseline and follow-up RAVENS maps by calculating the intensity difference at each voxel between the two time points. These rates of change are denoted as dRAVENS.</p></sec><sec id="s6"><title>Statistical Analyses</title><p>For the pattern analysis of the imaging data, we used the diabetes duration and HbA<sub>1c</sub> levels at baseline as dependent variables for the cross-sectional analysis, and the glycemic intervention arm (i.e., standard or intensive treatment) as the dependent variable for the longitudinal analysis. To investigate regional patterns of brain change associated with longitudinal change in cognition, an additional analysis was done using cognitive test scores as dependent variables.</p><p>In our initial statistical analysis on baseline data using the standard voxel-based morphometry (VBM) approach, we identified trends for diabetes duration (e.g., regions with significance <italic>P</italic> &lt; 0.01), but no regions showed significance after false discovery rate (FDR) correction (<xref rid="B24" ref-type="bibr">24</xref>) using a significance threshold of <italic>q</italic> ≤ 0.05. Accordingly, we applied a new voxel-based analysis methodology, ODVBA (<xref rid="B18" ref-type="bibr">18</xref>), taking into account the superiority of ODVBA to the classical VBM approach in sensitivity and spatial specificity, which has been demonstrated on both structural and functional MRI (<xref rid="B25" ref-type="bibr">25</xref>,<xref rid="B26" ref-type="bibr">26</xref>).</p><p>To leverage the strengths of ODVBA, which is a discriminative method, the values for diabetes duration and HbA<sub>1c</sub> were dichotomized and used in the analysis as class variables by grouping the subjects with values lower than the 20th percentile and with values higher than the 80th percentile of each variable into the “low” and “high” groups, respectively (<xref rid="B27" ref-type="bibr">27</xref>). The low diabetes duration group included subjects with 0–4 years of diabetes (average 2.5 ± 1.3), compared with 15–40 years (average 21 ± 6.3) for the high diabetes duration group. Participants in the low HbA<sub>1c</sub> group had HbA<sub>1c</sub> values between 5.5% (37 mmol/mol) and 7.4% (57 mmol/mol), with an average 7.1% ± 0.3% (54 ± 3 mmol/mol), whereas the high HbA<sub>1c</sub> group had values between 8.8% (73 mmol/mol) and 11.8% (105 mmol/mol), with an average 9.6% ± 0.7% (81 ± 8 mmol/mol).</p><p>In the cross-sectional analysis, ODVBA was applied on baseline imaging values of GM, WM, and VN RAVENS maps. Before applying ODVBA, RAVENS maps were corrected for age, sex, and systolic blood pressure by fitting a voxel-by-voxel generalized linear model to the RAVENS values against the covariates and by calculating the residual of the regression at each voxel. ODVBA constructed a voxel-by-voxel image of significance derived from the optimized spatial adaptive filtering applied to the data, which highlights potential spatial differences in the relationship between images and subject groups. Because many statistical tests (i.e., one on each individual voxel) were being conducted, the final maps were corrected for multiple comparisons using FDR correction. The clusters that exceeded a significance threshold of <italic>q</italic> ≤ 0.05 after correction for multiple comparisons are reported.</p><p>In the longitudinal analysis, ODVBA was applied on GM, WM, and VN dRAVENS maps, which capture longitudinal rate of regional change in tissue volume in a given subject’s brain at each voxel, for detecting imaging patterns of volume change associated with group differences between subjects in intensive and standard glycemic treatment arms. FDR-corrected values are reported at a significance level of <italic>q</italic> ≤ 0.05.</p><p>For the analysis of cognition, the longitudinal rate of change of each participant in each cognitive test was estimated by linear regression using baseline, 20-month, and 40-month test scores for DSST, RAVLT, and STROOP. The subjects were then stratified into “declining” and “nondeclining” cognition categories based on the 20th and 80th percentiles, similar to what was done for diabetes duration and HbA<sub>1c</sub>. ODVBA was applied using GM, WM, and VN dRAVENS maps of participants in the two groups for each test.</p></sec></sec><sec sec-type="results" id="s7"><title>Results</title><sec id="s8"><title>Patterns of Regional Volume Change Associated With Diabetes Characteristics</title><p>Regional pattern analysis using ODVBA was applied on baseline GM, WM, and VN RAVENS maps, which were corrected for age, sex, and systolic blood pressure, to identify group differences between subject categories for low and high values of diabetes duration and HbA<sub>1c</sub>.</p><p>The baseline characteristics of participants with low and high diabetes duration are given in <xref ref-type="table" rid="T1">Table 1</xref>. Longer diabetes duration (more than 14 years), compared with relatively short duration of diabetes (less than 5 years), was correlated with a relatively lower regional GM volume, particularly in the frontal lobes, left temporal lobe, right parietal lobe, and limbic cortex. The specific regions that were affected were the middle frontal gyrus, precentral gyrus, and inferior frontal gyrus left and right; middle temporal gyrus, inferior temporal gyrus, and lateral occipitotemporal gyrus left; angular gyrus right; and parietal cingulate region right and left. The areas of significant group differences between GM RAVENS maps and short versus long diabetes duration after FDR correction (<italic>q</italic> &lt; 0.05) are shown in <xref ref-type="fig" rid="F1">Fig. 1<italic>A</italic></xref>. A trend of positive association (<italic>P</italic> &lt; 0.05) of lateral ventricular enlargement and diabetes duration was detected, but no voxels survived the FDR correction (<ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc14-1196/-/DC1">Supplementary Fig. 1</ext-link>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Baseline characteristics comparing low diabetes duration and high diabetes duration groups</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th align="left" scope="col" rowspan="1" colspan="1"/><th align="center" scope="col" rowspan="1" colspan="1"/><th colspan="4" align="center" scope="colgroup" rowspan="1">Diabetes duration<hr/></th></tr><tr><th align="left" scope="col" rowspan="1" colspan="1"/><th align="left" scope="col" rowspan="1" colspan="1">Overall (<italic>N</italic> = 488)</th><th align="center" scope="col" rowspan="1" colspan="1">Short (<italic>n</italic> = 100)</th><th align="center" scope="col" rowspan="1" colspan="1">Middle (<italic>n</italic> = 288)</th><th align="center" scope="col" rowspan="1" colspan="1">Long (<italic>n</italic> = 100)</th><th align="center" scope="col" rowspan="1" colspan="1"><italic>P</italic> value<xref ref-type="table-fn" rid="t1n1">*</xref>
</th></tr></thead><tbody><tr><td align="left" scope="row" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">62.2 ± 5.6</td><td align="center" rowspan="1" colspan="1">60.7 ± 4.9</td><td align="center" rowspan="1" colspan="1">62.1 ± 5.8</td><td align="center" rowspan="1" colspan="1">63.9 ± 5.5</td><td align="center" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Women</td><td align="center" rowspan="1" colspan="1">223 (45.7)</td><td align="center" rowspan="1" colspan="1">53 (53.0)</td><td align="center" rowspan="1" colspan="1">121 (42.0)</td><td align="center" rowspan="1" colspan="1">49 (49.0)</td><td align="center" rowspan="1" colspan="1">0.1247</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Education</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.6944</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Less than high school graduate</td><td align="center" rowspan="1" colspan="1">45 (9.2)</td><td align="center" rowspan="1" colspan="1">6 (6.0)</td><td align="center" rowspan="1" colspan="1">27 (9.4)</td><td align="center" rowspan="1" colspan="1">12 (12.0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> High school graduate or GED</td><td align="center" rowspan="1" colspan="1">119 (24.4)</td><td align="center" rowspan="1" colspan="1">24 (24.0)</td><td align="center" rowspan="1" colspan="1">70 (24.3)</td><td align="center" rowspan="1" colspan="1">25 (25.0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Some college/technical school</td><td align="center" rowspan="1" colspan="1">163 (33.4)</td><td align="center" rowspan="1" colspan="1">39 (39.0)</td><td align="center" rowspan="1" colspan="1">91 (31.6)</td><td align="center" rowspan="1" colspan="1">33 (33.0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> College graduate or more</td><td align="center" rowspan="1" colspan="1">161 (33.0)</td><td align="center" rowspan="1" colspan="1">31 (31.0)</td><td align="center" rowspan="1" colspan="1">100 (34.7)</td><td align="center" rowspan="1" colspan="1">30 (30.0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Clinical Center Network</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.1374</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> 3-CCN-Minn/Iowa</td><td align="center" rowspan="1" colspan="1">230 (47.1)</td><td align="center" rowspan="1" colspan="1">40 (40.0)</td><td align="center" rowspan="1" colspan="1">145 (50.3)</td><td align="center" rowspan="1" colspan="1">45 (45.0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> 4-CCN-Ohio/Mich</td><td align="center" rowspan="1" colspan="1">68 (13.9)</td><td align="center" rowspan="1" colspan="1">13 (13.0)</td><td align="center" rowspan="1" colspan="1">39 (13.5)</td><td align="center" rowspan="1" colspan="1">16 (16.0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> 5-CCN-Northeast</td><td align="center" rowspan="1" colspan="1">64 (13.1)</td><td align="center" rowspan="1" colspan="1">13 (13.0)</td><td align="center" rowspan="1" colspan="1">32 (11.1)</td><td align="center" rowspan="1" colspan="1">19 (19.0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> 6-CCN-Southeast</td><td align="center" rowspan="1" colspan="1">126 (25.8)</td><td align="center" rowspan="1" colspan="1">34 (34.0)</td><td align="center" rowspan="1" colspan="1">72 (25.0)</td><td align="center" rowspan="1" colspan="1">20 (20.0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Race/ethnicity</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.3223</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> White only</td><td align="center" rowspan="1" colspan="1">331 (67.8)</td><td align="center" rowspan="1" colspan="1">71 (71.0)</td><td align="center" rowspan="1" colspan="1">200 (69.4)</td><td align="center" rowspan="1" colspan="1">60 (60.0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Spanish/Hispanic</td><td align="center" rowspan="1" colspan="1">31 (6.4)</td><td align="center" rowspan="1" colspan="1">5 (5.0)</td><td align="center" rowspan="1" colspan="1">15 (5.2)</td><td align="center" rowspan="1" colspan="1">11 (11.0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Black, non-Hispanic</td><td align="center" rowspan="1" colspan="1">84 (17.2)</td><td align="center" rowspan="1" colspan="1">17 (17.0)</td><td align="center" rowspan="1" colspan="1">46 (16.0)</td><td align="center" rowspan="1" colspan="1">21 (21.0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Asian, not-Hispanic or black</td><td align="center" rowspan="1" colspan="1">7 (1.4)</td><td align="center" rowspan="1" colspan="1">1 (1.0)</td><td align="center" rowspan="1" colspan="1">6 (2.1)</td><td align="center" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Other</td><td align="center" rowspan="1" colspan="1">35 (7.2)</td><td align="center" rowspan="1" colspan="1">6 (6.0)</td><td align="center" rowspan="1" colspan="1">21 (7.3)</td><td align="center" rowspan="1" colspan="1">8 (8.0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Smoking status</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.1547</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Never</td><td align="center" rowspan="1" colspan="1">226 (46.4)</td><td align="center" rowspan="1" colspan="1">41 (41.0)</td><td align="center" rowspan="1" colspan="1">131 (45.6)</td><td align="center" rowspan="1" colspan="1">54 (54.0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Former</td><td align="center" rowspan="1" colspan="1">200 (41.1)</td><td align="center" rowspan="1" colspan="1">45 (45.0)</td><td align="center" rowspan="1" colspan="1">115 (40.1)</td><td align="center" rowspan="1" colspan="1">40 (40.0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Current</td><td align="center" rowspan="1" colspan="1">61 (12.5)</td><td align="center" rowspan="1" colspan="1">14 (14.0)</td><td align="center" rowspan="1" colspan="1">41 (14.3)</td><td align="center" rowspan="1" colspan="1">6 (6.0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Blood pressure (mmHg)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Systolic</td><td align="center" rowspan="1" colspan="1">134.6 ± 17.8</td><td align="center" rowspan="1" colspan="1">137.5 ± 18.6</td><td align="center" rowspan="1" colspan="1">133.4 ± 17.9</td><td align="center" rowspan="1" colspan="1">135.3 ± 16.7</td><td align="center" rowspan="1" colspan="1">0.3878</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Diastolic</td><td align="center" rowspan="1" colspan="1">74.7 ± 10.2</td><td align="center" rowspan="1" colspan="1">78.4 ± 9.8</td><td align="center" rowspan="1" colspan="1">74.6 ± 10.3</td><td align="center" rowspan="1" colspan="1">71.3 ± 8.9</td><td align="center" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Diabetes duration (years)</td><td align="center" rowspan="1" colspan="1">10.0 ± 7.1</td><td align="center" rowspan="1" colspan="1">2.5 ± 1.3</td><td align="center" rowspan="1" colspan="1">8.8 ± 2.8</td><td align="center" rowspan="1" colspan="1">21.0 ± 6.3</td><td align="center" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">HbA<sub>1c</sub> (%)</td><td align="center" rowspan="1" colspan="1">8.1 ± 0.9 </td><td align="center" rowspan="1" colspan="1">8.0 ± 0.9</td><td align="center" rowspan="1" colspan="1">8.1 ± 0.9</td><td align="center" rowspan="1" colspan="1">8.3 ± 1.0</td><td align="center" rowspan="1" colspan="1">0.0631</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">HbA<sub>1c</sub> (mmol/mol)</td><td align="center" rowspan="1" colspan="1">65 ± 10</td><td align="center" rowspan="1" colspan="1"> 64 ± 10</td><td align="center" rowspan="1" colspan="1">65 ± 10</td><td align="center" rowspan="1" colspan="1"> 67 ± 11</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Cholesterol (mg/dL)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Total</td><td align="center" rowspan="1" colspan="1">181.6 ± 40.4</td><td align="center" rowspan="1" colspan="1">190.1 ± 40.4</td><td align="center" rowspan="1" colspan="1">180.7 ± 41.2</td><td align="center" rowspan="1" colspan="1">176.0 ± 36.9</td><td align="center" rowspan="1" colspan="1">0.0135</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> LDL</td><td align="center" rowspan="1" colspan="1">101.1 ± 32.2</td><td align="center" rowspan="1" colspan="1">104.4 ± 32.3</td><td align="center" rowspan="1" colspan="1">101.2 ± 32.8</td><td align="center" rowspan="1" colspan="1">97.5 ± 30.1</td><td align="center" rowspan="1" colspan="1">0.1266</td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1"> HDL</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">  In women</td><td align="center" rowspan="1" colspan="1">48.7 ± 12.4</td><td align="center" rowspan="1" colspan="1">47.8 ± 12.0</td><td align="center" rowspan="1" colspan="1">47.6 ± 11.8</td><td align="center" rowspan="1" colspan="1">52.6 ± 13.7</td><td align="center" rowspan="1" colspan="1">0.0570</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">  In men</td><td align="center" rowspan="1" colspan="1">40.0 ± 10.3</td><td align="center" rowspan="1" colspan="1">38.0 ± 9.3</td><td align="center" rowspan="1" colspan="1">40.2 ± 10.7</td><td align="center" rowspan="1" colspan="1">41.1 ± 9.7</td><td align="center" rowspan="1" colspan="1">0.1493</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">32.5 ± 5.1</td><td align="center" rowspan="1" colspan="1">33.4 ± 5.3</td><td align="center" rowspan="1" colspan="1">32.4 ± 5.1</td><td align="center" rowspan="1" colspan="1">31.7 ± 4.8</td><td align="center" rowspan="1" colspan="1">0.0235</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">History of cardiovascular disease</td><td align="center" rowspan="1" colspan="1">124 (25.4)</td><td align="center" rowspan="1" colspan="1">22 (22.0)</td><td align="center" rowspan="1" colspan="1">67 (23.3)</td><td align="center" rowspan="1" colspan="1">35 (35.0)</td><td align="center" rowspan="1" colspan="1">0.0458</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Total brain volume</td><td align="center" rowspan="1" colspan="1">925.5 ± 96.2</td><td align="center" rowspan="1" colspan="1">928.0 ± 97.6</td><td align="center" rowspan="1" colspan="1">928.2 ± 95.1</td><td align="center" rowspan="1" colspan="1">915.3 ± 98.4</td><td align="center" rowspan="1" colspan="1">0.3512</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Depression<xref ref-type="table-fn" rid="t1n2">**</xref>
</td><td align="center" rowspan="1" colspan="1">57 (11.7)</td><td align="center" rowspan="1" colspan="1">14 (14.0)</td><td align="center" rowspan="1" colspan="1">33 (11.5)</td><td align="center" rowspan="1" colspan="1">10 (10.0)</td><td align="center" rowspan="1" colspan="1">0.6673</td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Baseline scores</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> DSST</td><td align="center" rowspan="1" colspan="1">54.6 ± 15.6</td><td align="center" rowspan="1" colspan="1">58.0 ± 15.3</td><td align="center" rowspan="1" colspan="1">54.6 ± 15.6</td><td align="center" rowspan="1" colspan="1">51.2 ± 15.0</td><td align="center" rowspan="1" colspan="1">0.0019</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> RAVLT</td><td align="center" rowspan="1" colspan="1">7.6 ± 2.5</td><td align="center" rowspan="1" colspan="1">8.1 ± 2.6</td><td align="center" rowspan="1" colspan="1">7.6 ± 2.4</td><td align="center" rowspan="1" colspan="1">7.1 ± 2.4</td><td align="center" rowspan="1" colspan="1">0.0028</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> STROOP</td><td align="center" rowspan="1" colspan="1">30.5 ± 15.6</td><td align="center" rowspan="1" colspan="1">29.7 ± 13.1</td><td align="center" rowspan="1" colspan="1">29.5 ± 15.8</td><td align="center" rowspan="1" colspan="1">34.2 ± 17.0</td><td align="center" rowspan="1" colspan="1">0.0441</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> MMSE</td><td align="center" rowspan="1" colspan="1">27.7 ± 2.3</td><td align="center" rowspan="1" colspan="1">27.6 ± 2.2</td><td align="center" rowspan="1" colspan="1">27.8 ± 2.4</td><td align="center" rowspan="1" colspan="1">27.5 ± 2.2</td><td align="center" rowspan="1" colspan="1">0.7612</td></tr></tbody></table><table-wrap-foot><fn><p>Data are mean ± SD or <italic>n</italic> (%).</p></fn><fn><p>MMSE, Mini-Mental State Examination.</p></fn><fn id="t1n1"><p>*Between short-duration and long-duration groups.</p></fn><fn id="t1n2"><p>**Defined as patient health questionnaire score &gt;10.</p></fn></table-wrap-foot></table-wrap><fig id="F1" fig-type="figure" position="float"><label>Figure 1</label><caption><p>Three-dimensional surface renderings of ODVBA results. <italic>A</italic>: GM RAVENS maps in relationship with short vs. long diabetes duration at baseline. Subjects with long diabetes duration (<italic>n</italic> = 100) had lower RAVENS values (i.e., lower regional GM volume, in the highlighted areas) compared with subjects with short diabetes duration (<italic>n</italic> = 100). <italic>B</italic>: GM dRAVENS maps in relationship with standard vs. intensive glycemic treatment arm. Subjects in the intensive treatment arm (<italic>n</italic> = 221) had lower longitudinal decrease in GM tissue volume in the highlighted areas compared with subjects in the standard treatment arm (<italic>n</italic> = 267). The green color indicates the detected significant regions with FDR-corrected <italic>q</italic> &lt; 0.05. The hot color indicates the trends toward significance characterized by the −log (<italic>P</italic>) values shown in the color bar.</p></caption><graphic xlink:href="97fig1"/></fig><p>There was no statistically significant correlation of low versus high baseline HbA<sub>1c</sub> levels to the GM, WM, and VN RAVENS maps.</p></sec><sec id="s9"><title>Patterns of Regional Volume Change Associated With Glycemia Treatment</title><p>The longitudinal analysis using ODVBA has been applied for identifying group differences in regional volume loss patterns between subjects in the intensive glycemic treatment arm and those in the standard treatment arm. Estimates of region-specific longitudinal volumetric change were obtained from the baseline and follow-up RAVENS maps by calculating the intensity difference at each voxel between the two time points.</p><p>Intensive treatment preserved GM volume more than the standard treatment (FDR-corrected <italic>q</italic> &lt; 0.05) in certain cortical areas, specifically in the left and right superior temporal gyrus, left pre- and postcentral gyri, left and right medial front-orbital gyrus, and left and right frontal cingulate regions (<xref ref-type="fig" rid="F1">Fig. 1<italic>B</italic></xref>).</p><p>There was a partial overlap between the areas associated with treatment differences and those associated with diabetes duration. Importantly, the regions that showed longitudinal differences were mostly adjacent to regions displaying significant cross-sectional relationship with diabetes duration and tended to show just a trend at baseline.</p></sec><sec id="s10"><title>Patterns of Regional Volume Change Associated With Longitudinal Change in Cognition</title><p>Summary statistics of cognitive decline and nondecline categories for each cognitive test are given in <xref ref-type="table" rid="T2">Table 2</xref>. A positive association between higher GM volume loss in certain cortical areas of the brain and cognitive decline was detected for all three cognitive tests; however, after FDR correction, significant group differences were found only for RAVLT (<xref ref-type="fig" rid="F2">Fig. 2</xref>). ODVBA detected trends in right occipitotemporal regions for DSST, a global cortical trend for RAVLT with significant effects on frontotemporal regions, and trends mostly in parietal regions for STROOP.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Summary statistics of cognitive categories included in the pattern analysis</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th rowspan="2" align="left" scope="col" colspan="1"/><th colspan="4" align="center" scope="colgroup" rowspan="1">Declining<hr/></th><th colspan="4" align="center" scope="colgroup" rowspan="1">Nondeclining<hr/></th></tr><tr><th colspan="1" align="center" scope="colgroup" rowspan="1"><italic>N</italic></th><th align="center" scope="col" rowspan="1" colspan="1">Rate of change<xref ref-type="table-fn" rid="t2n1">*</xref></th><th align="center" scope="col" rowspan="1" colspan="1">Score at 40 months</th><th align="center" scope="col" rowspan="1" colspan="1">Age (years)</th><th align="center" scope="col" rowspan="1" colspan="1"><italic>N</italic></th><th align="center" scope="col" rowspan="1" colspan="1">Rate of change<xref ref-type="table-fn" rid="t2n1">*</xref></th><th align="center" scope="col" rowspan="1" colspan="1">Score at 40 months</th><th align="center" scope="col" rowspan="1" colspan="1">Age (years)</th></tr></thead><tbody><tr><td align="left" scope="row" rowspan="1" colspan="1">DSST</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">−0.34 ± 0.14</td><td align="center" rowspan="1" colspan="1">48.15 ± 13.76</td><td align="center" rowspan="1" colspan="1">63.6 ± 6.06</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">0.18 ± 0.09</td><td align="center" rowspan="1" colspan="1">60.76 ± 12.07</td><td align="center" rowspan="1" colspan="1">61.42 ± 5.09</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">RAVLT</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">−0.05 ± 0.02</td><td align="center" rowspan="1" colspan="1">6.80 ± 2.36</td><td align="center" rowspan="1" colspan="1">62.50 ± 5.88</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">0.08 ± 0.03</td><td align="center" rowspan="1" colspan="1">10.18 ± 2.09</td><td align="center" rowspan="1" colspan="1">60.70 ± 3.86</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">STROOP<xref ref-type="table-fn" rid="t2n2">**</xref></td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">0.36 ± 0.40</td><td align="center" rowspan="1" colspan="1">41.5 ± 21.40</td><td align="center" rowspan="1" colspan="1">62.52 ± 5.20</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">−0.29 ± 0.13</td><td align="center" rowspan="1" colspan="1">23.02 ± 7.3</td><td align="center" rowspan="1" colspan="1">62.19 ± 5.52</td></tr></tbody></table><table-wrap-foot><fn><p>Data are mean ± SD.</p></fn><fn id="t2n1"><p>*Change in score per month, estimated by linear regression to baseline, 20-month, and 40-month test scores.</p></fn><fn id="t2n2"><p>**Contrary to DSST and RAVLT, a higher score in STROOP test means lower performance.</p></fn></table-wrap-foot></table-wrap><fig id="F2" fig-type="figure" position="float"><label>Figure 2</label><caption><p>Three-dimensional surface renderings of ODVBA results for longitudinal change in cognitive test scores. Group differences on GM dRAVENS maps between the group with declining cognition (<italic>n</italic> = 100) vs. nondeclining cognition (<italic>n</italic> = 100) are shown for DSST (<italic>A</italic>), RAVLT (<italic>B</italic>), and STROOP (<italic>C</italic>) tests. For each three tests, subjects in the group with declining cognition had a higher longitudinal decrease in GM volume in the highlighted areas compared with subjects in the group with nondeclining cognition. The green color indicates the detected significant regions with FDR-corrected <italic>q</italic> &lt; 0.05. The hot color indicates the trends toward significance characterized by the −log (<italic>P</italic>) values shown in the color bar.</p></caption><graphic xlink:href="97fig2"/></fig></sec></sec><sec sec-type="conclusions" id="s11"><title>Conclusions</title><p>To the best of our knowledge, this is the first study to use pattern analysis methods to investigate the spatial specificity of patterns of brain volume loss in relation to diabetes duration and HbA<sub>1c.</sub> Moreover, this is the first study to apply these methods to investigate the spatial patterns of treatment effects on brain structure in a large diabetes clinical trial and using state-of-the-art pattern analysis methodology.</p><p>We applied a new VBM approach, ODVBA (<xref rid="B18" ref-type="bibr">18</xref>), in this analysis. In classical VBM methods, Gaussian smoothing of images, which is applied to account for registration errors and to integrate imaging signals from a region, has also become a limitation of these methods, because it is often chosen empirically and lacks spatial adaptivity to the shape and spatial extent of the region of interest, such as a region of volume loss. In contrast, ODVBA, using machine-learning techniques on local image neighborhoods, determines the spatially adaptive smoothing kernel whose coefficients define the optimally discriminative direction between two groups (e.g., patients and control subjects). Information from all neighborhoods that contain a given voxel is then composed to produce the statistic for each voxel, and permutation tests are used to obtain a statistical parametric map of group differences. Experimental results on three sets of previously published data from studies in schizophrenia, mild cognitive impairment, and Alzheimer disease suggest that ODVBA is considerably more sensitive in detecting group differences and performs better than classical VBM methods in the spatial extent of detected area and agreement of anatomical boundary (<xref rid="B25" ref-type="bibr">25</xref>).</p><p>We found, at baseline, that participants with longer diabetes duration had significantly reduced GM volumes in a number of brain regions. The frontal and temporal lobes were particularly more vulnerable to diabetes effects. The cortical patterns of decreased GM volume showed similarities with previously reported regions in MRI studies comparing diabetic and normal participants (<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B28" ref-type="bibr">28</xref>–<xref rid="B36" ref-type="bibr">36</xref>). In a similar approach, Brundel et al. (<xref rid="B9" ref-type="bibr">9</xref>) detected region-specific group differences between healthy controls and patients using cortical area and volume and thickness values, imaging measures complementary to those we used in our analysis. Consistent with our findings, they concluded that the cortical atrophy in type 2 diabetic patients was not equally distributed across the entire brain but showed spatially specific patterns. Also, detected patterns for the change, particularly in cortical area and volume, largely overlapped with those found in our analysis, showing large effects in middle temporal and frontal areas. In contrast to our findings, this study reported smaller cortical thickness values for diabetic patients in the hippocampal region. However, the authors noted that separating GM and WM in the hippocampal region with their present technique is difficult, which may affect the reliability of the cortical thickness and volume measurements.</p><p>Previous studies also reported enlarged VNs in diabetic patients compared with healthy controls (<xref rid="B37" ref-type="bibr">37</xref>,<xref rid="B38" ref-type="bibr">38</xref>). Although we lost significance after FDR correction, our uncorrected significance values (<italic>P</italic> &lt; 0.05) showed a trend of positive association of lateral VN enlargement and diabetes duration (<ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc14-1196/-/DC1">Supplementary Fig. 1</ext-link>). Detected regions showed similarities to the uncorrected group differences presented by Lee et al. (<xref rid="B37" ref-type="bibr">37</xref>).</p><p>An important finding is that intensive glycemic treatment displays relative preservation of some but not all brain regions. The finding of a differential treatment effect is consistent with previous findings (<xref rid="B14" ref-type="bibr">14</xref>) that preservation of the brain volume was significantly better in the participants in the intensive treatment arm during the 40-month follow-up period compared with the participants in the standard arm. The current analyses go beyond the volumetric measures by providing information on how the volume loss is spatially distributed and, hence, provides more information on how the disease and the intervention interact to produce the outcomes. We found a heterogeneous pattern affecting specific brain regions to a greater degree than others. In particular, the strongest treatment effects were found in brain regions around the Sylvian fissure as well in the medial-frontal cortex. Interestingly, the regions displaying a differential treatment effect of reduced GM volume loss were adjacent to but almost nonoverlapping with those regions that displayed significant association with diabetes duration at baseline. Therefore, intensive treatment appears to slow the spatial spreading of GM volume loss from regions mostly affected by diabetes duration toward adjacent brain regions. Additional studies must be performed, potentially by using individualized longitudinal analyses, to better measure this apparent “slowing of spatial progression” effect on an individual patient basis.</p><p>Interestingly, the areas that were associated to change in cognition were different from those affected from the treatment, which may explain the previous finding that there were no significant differences in the cognitive outcomes between the two treatment groups (<xref rid="B14" ref-type="bibr">14</xref>). Nonetheless, areas detected for RAVLT, although showing a global cortical effect, have also shown partial overlap with areas affected from the treatment as well as with areas affected from diabetes duration. Verbal learning tests have been considered a useful tool for the early diagnosis of cognitive decline and Alzheimer disease (<xref rid="B39" ref-type="bibr">39</xref>,<xref rid="B40" ref-type="bibr">40</xref>). As such, these overlapping regions might be particularly important for investigating the relationship between diabetes, its treatment, and dementia.</p><p>An important limitation of structural MRI is the lack of molecular specificity. Thus, interpretation of the measured volume changes in GM is challenging. Neuropathological correlates of the macroscopic volumetric reduction are heterogeneous and can include not only neuronal loss but also cortical thinning, subcortical vascular pathology, WM rarefaction, or other reasons (<xref rid="B9" ref-type="bibr">9</xref>). Results from animal models (<xref rid="B41" ref-type="bibr">41</xref>,<xref rid="B42" ref-type="bibr">42</xref>) have presented the associations of diabetes with neuronal changes in specific brain regions, with the aim of understanding underlying mechanisms of structural brain changes. However, these mechanisms are still unclear, as findings propose the involvement of multiple factors in the development of diabetes related brain changes (<xref rid="B43" ref-type="bibr">43</xref>). Consequently, the etiology of potentially relatively higher vulnerability of certain brain regions to diabetes duration cannot be elucidated by the current study and might relate to the differences in the underlying neuronal types and their sensitivity to insulin, underlying effects of diabetes in brain tissue perfusion, or might be effects of insulin resistance and its potential effect on brain connections. A growing body of work during the past decade has demonstrated that insulin-sensitive glucose transporters are localized to the same regions supporting memory, suggesting that insulin and its metabolism may contribute to normal cognitive functioning and that insulin abnormalities may exacerbate cognitive impairments, such as those associated with type 2 diabetes and even Alzheimer disease. The regional differences identified here in the cross-sectional and longitudinal analyses are similar to some of those brain regions associated with cognitive health (<xref rid="B44" ref-type="bibr">44</xref>,<xref rid="B45" ref-type="bibr">45</xref>).</p><p>No brain region was found to display significant correlation with low versus high HbA<sub>1c</sub>. That no brain region was significantly correlated with HbA<sub>1c</sub> levels was against our initial expectations, which were based on the central diagnostic/disease management role of HbA<sub>1c</sub> in diabetes and on earlier findings in the larger sample participating in the cognitive component of ACCORD-MIND (<xref rid="B13" ref-type="bibr">13</xref>). There, we found an association of increasing HbA<sub>1c</sub> and reduced performance on the cognitive tests of speed, memory, and executive function. Because the MRI sample was smaller than the cognitive sample, we may not have had enough power to detect differences in a measure such as HbA<sub>1c</sub> level, which only reflect blood glucose levels during the relatively short period of ∼3 months, whereas diabetes duration reflects the cumulative effect of the disease over years. However, we cannot rule out that other pathologic conditions associated with diabetes, such as hypertension, might have a relatively more deleterious effect on the brain than glucose levels. Finally, hypoglycemia might be associated with physiologic (e.g., perfusion) but not structural brain changes.</p><p>A limitation of this study is that the sample includes diabetic subjects only. Our findings on the relationship between diabetes duration and extent of brain volume loss are relatively conservative because they were obtained after correcting for age. Diabetes duration and age were somewhat correlated (<italic>r</italic> = 0.216), albeit not very strongly. The relationship between neurodegeneration and diabetes duration might therefore be even stronger. New studies, including nondiabetic control subjects, would be necessary to allow us to correct only for patterns of brain volume loss explained by normal aging and independently from diabetes duration.</p><p>Several factors might have contributed to the dissociation between the treatment effects on brain structure and on cognition (Launer et al. [<xref rid="B14" ref-type="bibr">14</xref>] found no treatment effects on cognition). Cognitive tests are known to be variable and subject to the learning effect; hence, imaging measurements, especially the pattern analysis adopted in this study, might be able to detect more subtle effects. Moreover, brain changes are likely to precede cognitive changes, which would further explain this dissociation. However, our results suggest a spatially heterogeneous effect of diabetes duration, as well as of its treatment, thereby pointing the way to future refinement of cognitive tests to tease out functions mediated by those brain regions that are more vulnerable to diabetes and more responsive to treatment.</p></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>Supplementary Data</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_38_1_97__index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_dc14-1196v141196_DC141196SupplementaryData.pdf"/>
</supplementary-material>
</sec>
</body>
  <back>
    <fn-group>
      <fn id="fn1" fn-type="supplementary-material">
        <p>This article contains Supplementary Data online at <ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc14-1196/-/DC1">http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc14-1196/-/DC1</ext-link>.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Article Information</title>
      <p><bold>Funding.</bold> ACCORD-MIND was funded through an intra-agency agreement between the National Institute on Aging (NIA) and the National Heart, Lung, and Blood Institute (NHLBI) (AG-0002) and the NIA Intramural Research Program. ACCORD was funded by NHLBI (N01-HC-95178, N01-HC-95179, N01-HC-95180, N01-HC-95181, N01-HC-95182, N01-HC-95183, and N01-HC-95184). The image analysis was funded by National Institute of Biomedical Imaging and Bioengineering 5R01-EB-009234.</p>
      <p><bold>Duality of Interest.</bold> No potential conflicts of interest relevant to this article were reported.</p>
      <p><bold>Author Contributions.</bold> G.E. wrote the manuscript. G.E., H.B., T.Z., and C.D. designed the imaging experiments and data analysis. H.B. and T.Z. performed the imaging experiments and data analysis. J.L., M.E.M., and J.D.W. were involved in quality control and data analysis. M.E.M., L.J.L., and R.N.B. designed the study. C.D. supervised the image analysis. All of the authors revised the manuscript. G.E. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biessels</surname><given-names>GJ</given-names></name><name><surname>van der Heide</surname><given-names>LP</given-names></name><name><surname>Kamal</surname><given-names>A</given-names></name><name><surname>Bleys</surname><given-names>RL</given-names></name><name><surname>Gispen</surname><given-names>WH</given-names></name></person-group>. <article-title>Ageing and diabetes: implications for brain function</article-title>. <source>Eur J Pharmacol</source>
<year>2002</year>;<volume>441</volume>:<fpage>1</fpage>–<lpage>14</lpage><?supplied-pmid 12007915?><pub-id pub-id-type="pmid">12007915</pub-id></mixed-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>KV</given-names></name><name><surname>Frier</surname><given-names>BM</given-names></name><name><surname>Strachan</surname><given-names>MW</given-names></name></person-group>. <article-title>The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations</article-title>. <source>Eur J Pharmacol</source>
<year>2004</year>;<volume>490</volume>:<fpage>169</fpage>–<lpage>175</lpage><?supplied-pmid 15094083?><pub-id pub-id-type="pmid">15094083</pub-id></mixed-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biessels</surname><given-names>GJ</given-names></name><name><surname>Staekenborg</surname><given-names>S</given-names></name><name><surname>Brunner</surname><given-names>E</given-names></name><name><surname>Brayne</surname><given-names>C</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name></person-group>. <article-title>Risk of dementia in diabetes mellitus: a systematic review</article-title>. <source>Lancet Neurol</source>
<year>2006</year>;<volume>5</volume>:<fpage>64</fpage>–<lpage>74</lpage><?supplied-pmid 16361024?><pub-id pub-id-type="pmid">16361024</pub-id></mixed-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation publication-type="other">Scheltens P, Fox N, Barkhof F, De Carli C. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol 2002;1:13–21</mixed-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation publication-type="other">Launer LJ. Diabetes: vascular or neurodegenerative: an epidemiologic perspective. Stroke 2009;40(3 Suppl.):S53–S55</mixed-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Harten</surname><given-names>B</given-names></name><name><surname>de Leeuw</surname><given-names>FE</given-names></name><name><surname>Weinstein</surname><given-names>HC</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><name><surname>Biessels</surname><given-names>GJ</given-names></name></person-group>. <article-title>Brain imaging in patients with diabetes: a systematic review</article-title>. <source>Diabetes Care</source>
<year>2006</year>;<volume>29</volume>:<fpage>2539</fpage>–<lpage>2548</lpage><?supplied-pmid 17065699?><pub-id pub-id-type="pmid">17065699</pub-id></mixed-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <mixed-citation publication-type="book">Biessels GJ, Strachan MW, Visseren FL, Kappelle LJ, Whitmer RA. Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions. Lancet Diabetes Endocrinol 2014;2:246–255</mixed-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <mixed-citation publication-type="other">Moran C, Phan TG, Chen J, et al. Brain atrophy in type 2 diabetes: regional distribution and influence on cognition. Diabetes Care 2013;36:4036–4042</mixed-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brundel</surname><given-names>M</given-names></name><name><surname>van den Heuvel</surname><given-names>M</given-names></name><name><surname>de Bresser</surname><given-names>J</given-names></name><name><surname>Kappelle</surname><given-names>LJ</given-names></name><name><surname>Biessels</surname><given-names>GJ</given-names></name><collab>Utrecht Diabetic Encephalopathy Study Group</collab></person-group>. <article-title>Cerebral cortical thickness in patients with type 2 diabetes</article-title>. <source>J Neurol Sci</source>
<year>2010</year>;<volume>299</volume>:<fpage>126</fpage>–<lpage>130</lpage><?supplied-pmid 20869085?><pub-id pub-id-type="pmid">20869085</pub-id></mixed-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <mixed-citation publication-type="other">Brundel M, Kappelle LJ, Biessels GJ. Brain imaging in type 2 diabetes. Eur Neuropsychopharmacol. 15 Mar 2014 [Epub ahead of print]</mixed-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buse</surname><given-names>JB</given-names></name><name><surname>Bigger</surname><given-names>JT</given-names></name><name><surname>Byington</surname><given-names>RP</given-names></name><etal/><collab>ACCORD Study Group</collab></person-group>. <article-title>Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods</article-title>. <source>Am J Cardiol</source>
<year>2007</year>;<volume>99</volume>:<fpage>21i</fpage>–<lpage>33i</lpage><?supplied-pmid 17599422?><pub-id pub-id-type="pmid">17599422</pub-id></mixed-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williamson</surname><given-names>JD</given-names></name><name><surname>Miller</surname><given-names>ME</given-names></name><name><surname>Bryan</surname><given-names>RN</given-names></name><etal/><collab>ACCORD Study Group</collab></person-group>. <article-title>The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods</article-title>. <source>Am J Cardiol</source>
<year>2007</year>;<volume>99</volume>:<fpage>112i</fpage>–<lpage>122i</lpage><?supplied-pmid 17599421?><pub-id pub-id-type="pmid">17599421</pub-id></mixed-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cukierman-Yaffe</surname><given-names>T</given-names></name><name><surname>Gerstein</surname><given-names>HC</given-names></name><name><surname>Williamson</surname><given-names>JD</given-names></name><etal/><collab>Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) Investigators</collab></person-group>. <article-title>Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) trial</article-title>. <source>Diabetes Care</source>
<year>2009</year>;<volume>32</volume>:<fpage>221</fpage>–<lpage>226</lpage><?supplied-pmid 19171735?><pub-id pub-id-type="pmid">19171735</pub-id></mixed-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Launer</surname><given-names>LJ</given-names></name><name><surname>Miller</surname><given-names>ME</given-names></name><name><surname>Williamson</surname><given-names>JD</given-names></name><etal/><collab>ACCORD MIND investigators</collab></person-group>. <article-title>Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy</article-title>. <source>Lancet Neurol</source>
<year>2011</year>;<volume>10</volume>:<fpage>969</fpage>–<lpage>977</lpage><?supplied-pmid 21958949?><pub-id pub-id-type="pmid">21958949</pub-id></mixed-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davatzikos</surname><given-names>C</given-names></name><name><surname>Genc</surname><given-names>A</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Resnick</surname><given-names>SM</given-names></name></person-group>. <article-title>Voxel-based morphometry using the RAVENS maps: methods and validation using simulated longitudinal atrophy</article-title>. <source>Neuroimage</source>
<year>2001</year>;<volume>14</volume>:<fpage>1361</fpage>–<lpage>1369</lpage><?supplied-pmid 11707092?><pub-id pub-id-type="pmid">11707092</pub-id></mixed-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldszal</surname><given-names>AF</given-names></name><name><surname>Davatzikos</surname><given-names>C</given-names></name><name><surname>Pham</surname><given-names>DL</given-names></name><name><surname>Yan</surname><given-names>MX</given-names></name><name><surname>Bryan</surname><given-names>RN</given-names></name><name><surname>Resnick</surname><given-names>SM</given-names></name></person-group>. <article-title>An image-processing system for qualitative and quantitative volumetric analysis of brain images</article-title>. <source>J Comput Assist Tomogr</source>
<year>1998</year>;<volume>22</volume>:<fpage>827</fpage>–<lpage>837</lpage><?supplied-pmid 9754125?><pub-id pub-id-type="pmid">9754125</pub-id></mixed-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>D</given-names></name><name><surname>Davatzikos</surname><given-names>C</given-names></name></person-group>. <article-title>Very high-resolution morphometry using mass-preserving deformations and HAMMER elastic registration</article-title>. <source>Neuroimage</source>
<year>2003</year>;<volume>18</volume>:<fpage>28</fpage>–<lpage>41</lpage><?supplied-pmid 12507441?><pub-id pub-id-type="pmid">12507441</pub-id></mixed-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Davatzikos</surname><given-names>C</given-names></name></person-group>. <article-title>ODVBA: optimally-discriminative voxel-based analysis</article-title>. <source>IEEE Trans Med Imaging</source>
<year>2011</year>;<volume>30</volume>:<fpage>1441</fpage>–<lpage>1454</lpage><?supplied-pmid 21324774?><pub-id pub-id-type="pmid">21324774</pub-id></mixed-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sled</surname><given-names>JG</given-names></name><name><surname>Zijdenbos</surname><given-names>AP</given-names></name><name><surname>Evans</surname><given-names>AC</given-names></name></person-group>. <article-title>A nonparametric method for automatic correction of intensity nonuniformity in MRI data</article-title>. <source>IEEE Trans Med Imaging</source>
<year>1998</year>;<volume>17</volume>:<fpage>87</fpage>–<lpage>97</lpage><?supplied-pmid 9617910?><pub-id pub-id-type="pmid">9617910</pub-id></mixed-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pham</surname><given-names>DL</given-names></name><name><surname>Prince</surname><given-names>JL</given-names></name></person-group>. <article-title>Adaptive fuzzy segmentation of magnetic resonance images</article-title>. <source>IEEE Trans Med Imaging</source>
<year>1999</year>;<volume>18</volume>:<fpage>737</fpage>–<lpage>752</lpage><?supplied-pmid 10571379?><pub-id pub-id-type="pmid">10571379</pub-id></mixed-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>D</given-names></name><name><surname>Davatzikos</surname><given-names>C</given-names></name></person-group>. <article-title>HAMMER: hierarchical attribute matching mechanism for elastic registration</article-title>. <source>IEEE Trans Med Imaging</source>
<year>2002</year>;<volume>21</volume>:<fpage>1421</fpage>–<lpage>1439</lpage><?supplied-pmid 12575879?><pub-id pub-id-type="pmid">12575879</pub-id></mixed-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <mixed-citation publication-type="confproc">Kabani NJ, Collins DL, Evans AC. A 3D neuroanatomical atlas. Fourth International Conference on Functional Mapping of the Human Brain, 7–12 June 1998, Montreal, Quebec, Canada</mixed-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <mixed-citation publication-type="other">Resnick SM, Pham DL, Kraut MA, Zonderman AB, Davatzikos C. Longitudinal magnetic resonance imaging studies of older adults: a shrinking brain. J Neurosc 2003;23:3295–2301</mixed-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Storey</surname><given-names>JD</given-names></name></person-group>
<article-title>A direct approach to false discovery rates</article-title>. <source>J Roy Stat Soc B Met</source>
<year>2002</year>;<volume>64</volume>:<fpage>479–498</fpage></mixed-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Davatzikos</surname><given-names>C</given-names></name></person-group>. <article-title>Optimally-discriminative voxel-based morphometry significantly increases the ability to detect group differences in schizophrenia, mild cognitive impairment, and Alzheimer’s disease</article-title>. <source>Neuroimage</source>
<year>2013</year>;<volume>79</volume>:<fpage>94</fpage>–<lpage>110</lpage><?supplied-pmid 23631985?><pub-id pub-id-type="pmid">23631985</pub-id></mixed-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <mixed-citation publication-type="confproc">Zhang T, Satterthwaite TD, Elliott M, Gur RC, Gur RE, Davatzikos C. Multivariate fMRI analysis using optimally-discriminative voxel-based analysis. Paper presented at the IEEE International workshop on Pattern Recognition in NeuroImaging, 2-4 July 2012, London, U.K.</mixed-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gelman</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>DK</given-names></name></person-group>
<article-title>Splitting a predictor at the upper quarter or third and the lower quarter or third</article-title>. <source>Am Stat</source>
<year>2009</year>;<volume>63</volume>:<fpage>1</fpage>–<lpage>8</lpage></mixed-citation>
      </ref>
      <ref id="B28">
        <label>28</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akisaki</surname><given-names>T</given-names></name><name><surname>Sakurai</surname><given-names>T</given-names></name><name><surname>Takata</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Cognitive dysfunction associates with white matter hyperintensities and subcortical atrophy on magnetic resonance imaging of the elderly diabetes mellitus Japanese Elderly Diabetes Intervention Trial (J-EDIT)</article-title>. <source>Diabetes Metab Res Rev</source>
<year>2006</year>;<volume>22</volume>:<fpage>376</fpage>–<lpage>384</lpage><?supplied-pmid 16506272?><pub-id pub-id-type="pmid">16506272</pub-id></mixed-citation>
      </ref>
      <ref id="B29">
        <label>29</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manschot</surname><given-names>SM</given-names></name><name><surname>Biessels</surname><given-names>GJ</given-names></name><name><surname>de Valk</surname><given-names>H</given-names></name><etal/><collab>Utrecht Diabetic Encephalopathy Study Group</collab></person-group>. <article-title>Metabolic and vascular determinants of impaired cognitive performance and abnormalities on brain magnetic resonance imaging in patients with type 2 diabetes</article-title>. <source>Diabetologia</source>
<year>2007</year>;<volume>50</volume>:<fpage>2388</fpage>–<lpage>2397</lpage><?supplied-pmid 17764005?><pub-id pub-id-type="pmid">17764005</pub-id></mixed-citation>
      </ref>
      <ref id="B30">
        <label>30</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musen</surname><given-names>G</given-names></name><name><surname>Lyoo</surname><given-names>IK</given-names></name><name><surname>Sparks</surname><given-names>CR</given-names></name><etal/></person-group>. <article-title>Effects of type 1 diabetes on gray matter density as measured by voxel-based morphometry</article-title>. <source>Diabetes</source>
<year>2006</year>;<volume>55</volume>:<fpage>326</fpage>–<lpage>333</lpage><?supplied-pmid 16443764?><pub-id pub-id-type="pmid">16443764</pub-id></mixed-citation>
      </ref>
      <ref id="B31">
        <label>31</label>
        <mixed-citation publication-type="other">Samaras K, Lutgers H, Wen W, et al. Glucose disorders exert a detrimental effect on total brain volume in the elderly: a 2-year prospective MRI study. Endocrine Abstracts 2012;29:OC3.6</mixed-citation>
      </ref>
      <ref id="B32">
        <label>32</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samaras</surname><given-names>K</given-names></name><name><surname>Lutgers</surname><given-names>HL</given-names></name><name><surname>Kochan</surname><given-names>NA</given-names></name><etal/></person-group>. <article-title>The impact of glucose disorders on cognition and brain volumes in the elderly: the Sydney Memory and Ageing Study</article-title>. <source>Age (Dordr)</source>
<year>2014</year>;<volume>36</volume>:<fpage>977</fpage>–<lpage>993</lpage><?supplied-pmid 24402401?><pub-id pub-id-type="pmid">24402401</pub-id></mixed-citation>
      </ref>
      <ref id="B33">
        <label>33</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seaquist</surname><given-names>ER</given-names></name></person-group>. <article-title>The final frontier: how does diabetes affect the brain?</article-title>
<source>Diabetes</source>
<year>2010</year>;<volume>59</volume>:<fpage>4</fpage>–<lpage>5</lpage><?supplied-pmid 20040482?><pub-id pub-id-type="pmid">20040482</pub-id></mixed-citation>
      </ref>
      <ref id="B34">
        <label>34</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiehuis</surname><given-names>AM</given-names></name><name><surname>van der Graaf</surname><given-names>Y</given-names></name><name><surname>Visseren</surname><given-names>FL</given-names></name><etal/><collab>SMART Study Group</collab></person-group>. <article-title>Diabetes increases atrophy and vascular lesions on brain MRI in patients with symptomatic arterial disease</article-title>. <source>Stroke</source>
<year>2008</year>;<volume>39</volume>:<fpage>1600</fpage>–<lpage>1603</lpage><?supplied-pmid 18369167?><pub-id pub-id-type="pmid">18369167</pub-id></mixed-citation>
      </ref>
      <ref id="B35">
        <label>35</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Elderen</surname><given-names>SG</given-names></name><name><surname>de Roos</surname><given-names>A</given-names></name><name><surname>de Craen</surname><given-names>AJ</given-names></name><etal/></person-group>. <article-title>Progression of brain atrophy and cognitive decline in diabetes mellitus: a 3-year follow-up</article-title>. <source>Neurology</source>
<year>2010</year>;<volume>75</volume>:<fpage>997</fpage>–<lpage>1002</lpage><?supplied-pmid 20837967?><pub-id pub-id-type="pmid">20837967</pub-id></mixed-citation>
      </ref>
      <ref id="B36">
        <label>36</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wessels</surname><given-names>AM</given-names></name><name><surname>Simsek</surname><given-names>S</given-names></name><name><surname>Remijnse</surname><given-names>PL</given-names></name><etal/></person-group>. <article-title>Voxel-based morphometry demonstrates reduced grey matter density on brain MRI in patients with diabetic retinopathy</article-title>. <source>Diabetologia</source>
<year>2006</year>;<volume>49</volume>:<fpage>2474</fpage>–<lpage>2480</lpage><?supplied-pmid 16703329?><pub-id pub-id-type="pmid">16703329</pub-id></mixed-citation>
      </ref>
      <ref id="B37">
        <label>37</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Yoon</surname><given-names>S</given-names></name><name><surname>Renshaw</surname><given-names>PF</given-names></name><etal/></person-group>. <article-title>Morphometric changes in lateral ventricles of patients with recent-onset type 2 diabetes mellitus</article-title>. <source>PLoS ONE</source>
<year>2013</year>;<volume>8</volume>:<fpage>e60515</fpage><?supplied-pmid 23593231?><pub-id pub-id-type="pmid">23593231</pub-id></mixed-citation>
      </ref>
      <ref id="B38">
        <label>38</label>
        <mixed-citation publication-type="other">Carmichael OT, Kuller LH, Lopez OL, et al., Acceleration of cerebral ventricular expansion in the Cardiovascular Health Study. Neurobiol Aging 2007;28:1316–1321</mixed-citation>
      </ref>
      <ref id="B39">
        <label>39</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barzotti</surname><given-names>T</given-names></name><name><surname>Gargiulo</surname><given-names>A</given-names></name><name><surname>Marotta</surname><given-names>MG</given-names></name><etal/></person-group>. <article-title>Correlation between cognitive impairment and the Rey auditory-verbal learning test in a population with Alzheimer disease</article-title>. <source>Arch Gerontol Geriatr Suppl</source>
<year>2004</year>:<fpage>57</fpage>–<lpage>62</lpage><?supplied-pmid 15207397?><pub-id pub-id-type="pmid">15207397</pub-id></mixed-citation>
      </ref>
      <ref id="B40">
        <label>40</label>
        <mixed-citation publication-type="other">Kuslansky G, Katz M, Verghese J, et al. Detecting dementia with the Hopkins Verbal Learning Test and the Mini-Mental State Examination. Arch Clin Neuropsychol 2004;19:89–104</mixed-citation>
      </ref>
      <ref id="B41">
        <label>41</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toth</surname><given-names>C</given-names></name><name><surname>Schmidt</surname><given-names>AM</given-names></name><name><surname>Tuor</surname><given-names>UI</given-names></name><etal/></person-group>. <article-title>Diabetes, leukoencephalopathy and RAGE</article-title>. <source>Neurobiol Dis</source>
<year>2006</year>;<volume>23</volume>:<fpage>445</fpage>–<lpage>461</lpage><?supplied-pmid 16815028?><pub-id pub-id-type="pmid">16815028</pub-id></mixed-citation>
      </ref>
      <ref id="B42">
        <label>42</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enhamre</surname><given-names>E</given-names></name><name><surname>Carlsson</surname><given-names>A</given-names></name><name><surname>Grönbladh</surname><given-names>A</given-names></name><name><surname>Watanabe</surname><given-names>H</given-names></name><name><surname>Hallberg</surname><given-names>M</given-names></name><name><surname>Nyberg</surname><given-names>F</given-names></name></person-group>. <article-title>The expression of growth hormone receptor gene transcript in the prefrontal cortex is affected in male mice with diabetes-induced learning impairments</article-title>. <source>Neurosci Lett</source>
<year>2012</year>;<volume>523</volume>:<fpage>82</fpage>–<lpage>86</lpage><?supplied-pmid 22750159?><pub-id pub-id-type="pmid">22750159</pub-id></mixed-citation>
      </ref>
      <ref id="B43">
        <label>43</label>
        <mixed-citation publication-type="other">Lee JH, Choi Y, Jun C, et al. Neurocognitive changes and their neural correlates in patients with type 2 diabetes mellitus. Endocrinol Metab (Seoul) 2014;29:112–121</mixed-citation>
      </ref>
      <ref id="B44">
        <label>44</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>GS</given-names></name><name><surname>Craft</surname><given-names>S</given-names></name></person-group>. <article-title>The role of insulin resistance in the pathogenesis of Alzheimer’s disease: implications for treatment</article-title>. <source>CNS Drugs</source>
<year>2003</year>;<volume>17</volume>:<fpage>27</fpage>–<lpage>45</lpage><?supplied-pmid 12467491?><pub-id pub-id-type="pmid">12467491</pub-id></mixed-citation>
      </ref>
      <ref id="B45">
        <label>45</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiöth</surname><given-names>HB</given-names></name><name><surname>Craft</surname><given-names>S</given-names></name><name><surname>Brooks</surname><given-names>SJ</given-names></name><name><surname>Frey</surname><given-names>WH</given-names><suffix>2nd</suffix></name><name><surname>Benedict</surname><given-names>C</given-names></name></person-group>. <article-title>Brain insulin signaling and Alzheimer’s disease: current evidence and future directions</article-title>. <source>Mol Neurobiol</source>
<year>2012</year>;<volume>46</volume>:<fpage>4</fpage>–<lpage>10</lpage><?supplied-pmid 22205300?><pub-id pub-id-type="pmid">22205300</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:4274774</identifier><datestamp>2016-01-01</datestamp><setSpec>diacare</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="http://jats.nlm.nih.gov/ns/archiving/1.0/ http://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Diabetes Care</journal-id>
      <journal-id journal-id-type="iso-abbrev">Diabetes Care</journal-id>
      <journal-id journal-id-type="hwp">diacare</journal-id>
      <journal-id journal-id-type="pmc">dcare</journal-id>
      <journal-id journal-id-type="publisher-id">Diabetes Care</journal-id>
      <journal-title-group>
        <journal-title>Diabetes Care</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0149-5992</issn>
      <issn pub-type="epub">1935-5548</issn>
      <publisher>
        <publisher-name>American Diabetes Association</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4274774</article-id>
      <article-id pub-id-type="pmcid">PMC4274774</article-id>
      <article-id pub-id-type="pmc-uid">4274774</article-id>
      <article-id pub-id-type="pmid">25325881</article-id>
      <article-id pub-id-type="publisher-id">0360</article-id>
      <article-id pub-id-type="doi">10.2337/dc14-0360</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Epidemiology/Health Services Research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Hemoglobin A<sub>1c</sub> and the Progression of Coronary Artery Calcification Among Adults Without Diabetes</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Carson</surname>
            <given-names>April P.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Steffes</surname>
            <given-names>Michael W.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Carr</surname>
            <given-names>J. Jeffrey</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Yongin</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gross</surname>
            <given-names>Myron D.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Carnethon</surname>
            <given-names>Mercedes R.</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">
            <sup>5</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Reis</surname>
            <given-names>Jared P.</given-names>
          </name>
          <xref ref-type="aff" rid="aff6">
            <sup>6</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Loria</surname>
            <given-names>Catherine M.</given-names>
          </name>
          <xref ref-type="aff" rid="aff6">
            <sup>6</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jacobs</surname>
            <given-names>David R.</given-names>
            <suffix>Jr.</suffix>
          </name>
          <xref ref-type="aff" rid="aff7">
            <sup>7</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lewis</surname>
            <given-names>Cora E.</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <aff id="aff1"><sup>1</sup>Department of Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL</aff>
        <aff id="aff2"><sup>2</sup>Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, MN</aff>
        <aff id="aff3"><sup>3</sup>Department of Radiology and Radiologic Sciences, Vanderbilt University, Nashville, TN</aff>
        <aff id="aff4"><sup>4</sup>Division of Preventive Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, AL</aff>
        <aff id="aff5"><sup>5</sup>Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL</aff>
        <aff id="aff6"><sup>6</sup>Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD</aff>
        <aff id="aff7"><sup>7</sup>Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, MN</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">Corresponding author: April P. Carson, <email>apcarson@uab.edu</email>.</corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>16</day>
        <month>10</month>
        <year>2014</year>
      </pub-date>
      <volume>38</volume>
      <issue>1</issue>
      <fpage>66</fpage>
      <lpage>71</lpage>
      <history>
        <date date-type="received">
          <day>7</day>
          <month>2</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>22</day>
          <month>9</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.</copyright-statement>
        <copyright-year>2015</copyright-year>
      </permissions>
      <self-uri xlink:title="pdf" xlink:type="simple" xlink:href="66.pdf"/>
      <abstract>
        <sec>
          <title>OBJECTIVE</title>
          <p>Higher levels of hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>) are associated with increased cardiovascular disease risk among individuals without diabetes and may also be positively associated with coronary artery calcification (CAC). This study investigated the association of HbA<sub>1c</sub> with CAC progression in the Coronary Artery Risk Development in Young Adults study.</p>
        </sec>
        <sec>
          <title>RESEARCH DESIGN AND METHODS</title>
          <p>We included 2,076 participants with HbA<sub>1c</sub> and noncontrast computed tomography (CT) assessed at baseline (2005–2006), and CT repeated 5 years later (2010–2011). CAC progression was defined as <italic>1</italic>) incident CAC (increase &gt;0 Agatston units among those with no CAC at baseline), <italic>2</italic>) any CAC progression (increase &gt;10 Agatston units between examinations), and <italic>3</italic>) advanced CAC progression (increase &gt;100 Agatston units between examinations).</p>
        </sec>
        <sec>
          <title>RESULTS</title>
          <p>During the 5-year follow-up period, 12.9% of participants without baseline CAC developed incident CAC; among all participants, 18.2% had any CAC progression and 5.4% had advanced CAC progression. Higher HbA<sub>1c</sub> was associated with incident CAC (risk ratio [RR] = 1.45; 95% CI 1.02, 2.06), any CAC progression (RR = 1.51; 95% CI 1.16, 1.96), and advanced CAC progression (RR = 2.42; 95% CI 1.47, 3.99) after adjustment for sociodemographic factors. Additional adjustment for cardiovascular risk factors attenuated the associations of HbA<sub>1c</sub> with incident CAC (RR = 1.05; 95% CI 0.74, 1.49) and any CAC progression (RR = 1.13; 95% CI 0.87, 1.47). In contrast, the association of HbA<sub>1c</sub> with advanced CAC progression persisted in multivariable adjusted models (RR = 1.78; 95% CI 1.08, 2.95).</p>
        </sec>
        <sec>
          <title>CONCLUSIONS</title>
          <p>Higher HbA<sub>1c</sub> was independently associated with advanced CAC progression among individuals without diabetes, while the associations with incident CAC and any CAC progression were accounted for by other established cardiovascular risk factors.</p>
        </sec>
      </abstract>
      <counts>
        <page-count count="6"/>
      </counts>
    </article-meta>
  </front>
  <body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Higher hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>) has been associated with an increased risk of cardiovascular morbidity among individuals without diabetes (<xref rid="B1" ref-type="bibr">1</xref>–<xref rid="B3" ref-type="bibr">3</xref>). A potential pathway linking HbA<sub>1c</sub> and cardiovascular events involves the development and progression of subclinical atherosclerosis. The atherosclerotic process begins early in life (<xref rid="B4" ref-type="bibr">4</xref>), and noninvasive markers of subclinical atherosclerosis, such as coronary artery calcification (CAC), can be used to identify individuals earlier in the disease process who may have an increased risk of clinical events later in life. CAC has been shown to be a predictor of incident cardiovascular events (<xref rid="B5" ref-type="bibr">5</xref>–<xref rid="B7" ref-type="bibr">7</xref>), but the association of HbA<sub>1c</sub> with CAC among individuals without diabetes is not clear.</p><p>Prior studies of the association between HbA<sub>1c</sub> and CAC were cross-sectional and reported contrasting findings for individuals without diabetes (<xref rid="B8" ref-type="bibr">8</xref>–<xref rid="B10" ref-type="bibr">10</xref>). To date, the relation of HbA<sub>1c</sub> and CAC progression among individuals without diabetes has not been reported in the literature. The purpose of this study was to investigate the prospective association of HbA<sub>1c</sub> with 5-year CAC progression among individuals without diabetes from the Coronary Artery Risk Development in Young Adults (CARDIA) Study.</p></sec><sec id="s2"><title>Research Design and Methods</title><sec id="s3"><title>Study Design and Population</title><p>CARDIA is a prospective, community-based cohort study of young adults designed to investigate trends and determinants of cardiovascular disease risk in the U.S. A detailed overview of the study design, recruitment, and objectives has been previously published (<xref rid="B11" ref-type="bibr">11</xref>).</p><p>Briefly, the baseline examination (1985–1986) included 5,115 non-Hispanic African American and white men and women aged 18–30 years from Birmingham, AL; Chicago, IL; Minneapolis, MN; and Oakland, CA. This analysis used data from in-person follow-up examinations at 20 (2005–2006) and 25 (2010–2011) years following the baseline examination. Participant retention rates were high, with 72% (<italic>n</italic> = 3,549) of surviving participants completing the year 20 examination (baseline for this analysis) and 72% (<italic>n</italic> = 3,498) of the surviving participants completing the year 25 examination (follow-up for this analysis). Centralized training and certification, standardized methods, and quality control measures were implemented to ensure high data quality for all examinations. The institutional review board at each participating site approved the protocol for each study examination, and participants provided written informed consent at each study examination.</p><p>For our analysis, we excluded participants who did not attend both the year 20 and the year 25 examinations (<italic>n</italic> = 1,993), did not have HbA<sub>1c</sub> measured at the year 20 examination (<italic>n</italic> = 367), did not have CAC measured at the year 20 (<italic>n</italic> = 225) and year 25 (<italic>n</italic> = 149) examinations, or had diabetes (<italic>n </italic>= 283). Diabetes was defined as a fasting glucose ≥126 mg/dL, 2-h postchallenge glucose ≥200 mg/dL, HbA<sub>1c</sub> ≥6.5% (48 mmol/mol), or use of antihyperglycemic therapy. Additionally, 22 participants with an estimated glomerular filtration rate &lt;30 mL/min/1.73 m<sup>2</sup> or an adjudicated myocardial infarction were excluded. The sample size for the analysis of any CAC progression and advanced CAC progression was 2,076 participants. For incident CAC, those with prevalent CAC at the year 20 examination were excluded, resulting in a sample size of 1,693 for that analysis.</p></sec><sec id="s4"><title>HbA<sub>1c</sub></title><p>HbA<sub>1c</sub> was measured from a whole-blood aliquot by ion-exchange high-performance liquid chromatography (Tosoh G7) at the University of Minnesota as part of the Young Adult Longitudinal Trends in Antioxidants ancillary study at the year 20 examination, baseline for this analysis.</p></sec><sec id="s5"><title>Ascertainment of Covariates</title><p>Data on age, sex, race, and smoking status were collected using standardized questionnaires. Height and weight were measured by certified technicians from participants wearing light clothing and no shoes and were used to calculate BMI in kg/m<sup>2</sup>. Systolic blood pressure (SBP) was measured following standardized protocols (<xref rid="B12" ref-type="bibr">12</xref>). After resting for 5 min in the seated position, blood pressure was measured three times at 1-min intervals using an appropriately sized cuff, with the average of the second and third measurements used to determine SBP. SBP was measured at year 20 using a standard automated blood pressure measurement monitor (Omron model HEM907XL) calibrated to the random zero sphygmomanometer that had been used at each earlier examination. Total cholesterol was measured enzymatically, and HDL cholesterol was determined by precipitation with dextran sulfate–magnesium chloride at the University of Washington (<xref rid="B12" ref-type="bibr">12</xref>).</p></sec><sec id="s6"><title>CAC</title><p>Electron beam computed tomography (CT; Chicago and Oakland field centers at year 20) or multidetector CT scanners (Birmingham and Minneapolis field centers at year 20 and all centers at year 25) were used to assess CAC by obtaining contiguous transverse images from the root of the aorta to the apex of the heart (<xref rid="B13" ref-type="bibr">13</xref>). The comparability of electron beam CT and multidetector CT has been demonstrated previously (<xref rid="B14" ref-type="bibr">14</xref>). Pregnant women and participants who exceeded the weight restriction for the scanner were ineligible. The CT scanning protocol included a hydroxyapatite calibration phantom to monitor image brightness and noise. A calcium score in Agatston units (<xref rid="B15" ref-type="bibr">15</xref>) was calculated for each calcified lesion, and the scores were summed across all lesions within a given artery and across all arteries (left anterior descending, left main, circumflex, and right coronary) to obtain the total calcium score. For the one participant who had coronary artery bypass graft surgery prior to the year 25 examination, only the native coronary arteries were scored for calcification. Three participants had had coronary stents at year 20 and four at year 25; stented areas were not scored, but 100 Agatston units was added to each person with any stents. All scans were read centrally with high interobserver (κ = 0.89) and intraobserver (κ = 0.95) agreement for the presence of CAC (<xref rid="B13" ref-type="bibr">13</xref>).</p><p>CAC progression was assessed as <italic>1</italic>) incident CAC defined as an increase &gt;0 Agatston units among those without CAC at baseline (i.e., from 0 at year 20 to &gt;0 Agatston units at year 25), <italic>2</italic>) any CAC progression defined as an increase &gt;10 Agatston units (i.e., from 0 at year 20 to &gt;10 at year 25 or &gt;10 unit increase in CAC score at year 25 among those with CAC at year 20), and <italic>3</italic>) advanced CAC progression defined as a change &gt;100 Agatston units between years 20 and 25 (i.e., from 0 at year 20 to &gt;100 at year 25 or &gt;100 unit increase in CAC score at year 25 among those with CAC at year 20).</p></sec><sec id="s7"><title>Statistical Analyses</title><p>The association of HbA<sub>1c</sub> with CAC progression was evaluated using Poisson regression with robust variance estimation to obtain risk ratio (RR) and 95% CI (<xref rid="B16" ref-type="bibr">16</xref>). HbA<sub>1c</sub> was evaluated as a continuous variable with a 1-unit increase defined as 1% (10.9 mmol/mol). Model 1 was unadjusted, model 2 was adjusted for sociodemographics (age, sex, race, education, and study field center), and model 3 included additional adjustments for cardiovascular risk factors (SBP, use of antihypertensive medications, total cholesterol, HDL cholesterol, current smoking, and BMI). Model 4 also included adjustment for the presence of baseline CAC for any CAC progression and advanced CAC progression analyses. Effect modification by race was investigated in fully adjusted models using interaction terms.</p><p>Secondary analyses were carried out to evaluate the association of HbA<sub>1c</sub> with CAC progression. First, an alternative definition of CAC progression, defined as a change ≥2.5 mm<sup>3</sup> between square root-transformed volumetric scores, was used (<xref rid="B17" ref-type="bibr">17</xref>). Second, because individuals with prevalent CAC are more likely to experience CAC progression, the association of HbA<sub>1c</sub> with the log-transformed quantity of CAC progression was also evaluated among individuals with CAC at the year 20 examination. Lastly, the association of HbA<sub>1c</sub> with CAC progression was evaluated using HbA<sub>1c</sub> quartiles to assess possible nonlinear associations. The α-level used for all analyses was 0.05. All statistical analyses were conducted using SAS version 9.2 (SAS Institute, Cary, NC).</p></sec></sec><sec sec-type="results" id="s8"><title>Results</title><p>Participant characteristics at baseline are presented in <xref ref-type="table" rid="T1">Table 1</xref>. The mean age of participants was 45.3 years, 40.9% were African American, and 57.3% were female. The mean HbA<sub>1c</sub> was 5.3%, and 18.4% of participants had baseline CAC at the year 20 examination.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Baseline characteristics of study participants without diabetes, the CARDIA study, 2005–2006</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" scope="row" rowspan="1" colspan="1"><italic>N</italic></td><td align="center" rowspan="1" colspan="1">2,076</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Age (years), mean (SD)</td><td align="center" rowspan="1" colspan="1">45.3 (3.6)</td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Race, <italic>n</italic> (%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> African American</td><td align="center" rowspan="1" colspan="1">848 (40.9)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> White</td><td align="center" rowspan="1" colspan="1">1,228 (59.1)</td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Sex, <italic>n</italic> (%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Female</td><td align="center" rowspan="1" colspan="1">1,189 (57.3)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Male</td><td align="center" rowspan="1" colspan="1">887 (42.7)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Education ≤high school, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">475 (22.9)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>), mean (SD)</td><td align="center" rowspan="1" colspan="1">28.7 (6.1)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Current smoker, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">371 (17.9)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">SBP (mmHg), mean (SD)</td><td align="center" rowspan="1" colspan="1">114.6 (14.1)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Use of blood pressure medications, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">283 (13.6)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Total cholesterol (mg/dL), mean (SD)</td><td align="center" rowspan="1" colspan="1">187.2 (34.3)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">HDL cholesterol (mg/dL), mean (SD)</td><td align="center" rowspan="1" colspan="1">55.0 (16.8)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Fasting glucose (mg/dL), mean (SD)</td><td align="center" rowspan="1" colspan="1">94.4 (9.4)</td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">HbA<sub>1c</sub>, mean (SD)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">  NGSP, %</td><td align="center" rowspan="1" colspan="1">5.3 (0.4)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">  IFCC, mmol/mol</td><td align="center" rowspan="1" colspan="1">34 (4.4)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">CAC present at baseline, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">383 (18.4)</td></tr></tbody></table></table-wrap><p>Any CAC progression and advanced CAC progression were more likely to occur among individuals with CAC present at the year 20 examination (<xref ref-type="fig" rid="F1">Fig. 1</xref>). Among participants with CAC at the year 20 examination, 69.7% experienced any CAC progression &gt;10 Agatston units, and 28.5% experienced advanced CAC progression &gt;100 Agatston units during the 5-year follow-up period. In contrast, among participants without CAC at the year 20 examination, 6.5% experienced any CAC progression, and 0.2% experienced advanced CAC progression. Overall, 12.9% of individuals without baseline CAC at the year 20 examination developed incident CAC &gt;0 Agatston units by the year 25 examination.</p><fig id="F1" fig-type="figure" position="float"><label>Figure 1</label><caption><p>Percentage of participants with CAC progression during the 5-year follow-up period, overall and by baseline CAC presence, in the CARDIA study. *Evaluated only among individuals without CAC at the year 20 examination. **<italic>P</italic> &lt; 0.001 comparing proportion with baseline CAC to no baseline CAC.</p></caption><graphic xlink:href="66fig1"/></fig><p>The unadjusted and adjusted effect estimates for the association of HbA<sub>1c</sub> with CAC progression are presented in <xref ref-type="table" rid="T2">Table 2</xref>. HbA<sub>1c</sub> was associated with incident CAC after adjustment for sociodemographic factors (RR = 1.45; 95% CI 1.02, 2.06), but this association was attenuated after additional adjustment for cardiovascular risk factors (RR = 1.05; 95% CI 0.74, 1.49). Similarly, higher HbA<sub>1c</sub> was associated with any CAC progression &gt;10 Agatston units after adjustment for age, sex, race, education, and study field center (RR = 1.51; 95% CI 1.16, 1.96), but this association was attenuated in the multivariable model (RR = 1.13; 95% CI 0.87, 1.47). Higher HbA<sub>1c</sub> was associated with advanced CAC progression &gt;100 Agatston units after adjustment for sociodemographics (RR = 2.42; 95% CI 1.47, 3.99), and this association remained after additional adjustment for cardiovascular risk factors (RR = 1.78; 95% CI 1.08, 2.95) and baseline CAC (RR = 1.75; 95% CI 1.09, 2.83).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>RR and 95% CI evaluating the association of a 1-unit increase in HbA<sub>1c</sub> with CAC progression over 5 years among individuals without diabetes in the CARDIA study</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th align="left" scope="col" rowspan="1" colspan="1">Model</th><th align="center" scope="col" rowspan="1" colspan="1">RR (95% CI)</th></tr></thead><tbody><tr><td align="left" scope="col" rowspan="1" colspan="1">Incident CAC<xref ref-type="table-fn" rid="t2n1">*</xref> (&gt;0 Agatston units),<italic> n</italic> = 1,693</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Model 1</td><td align="center" rowspan="1" colspan="1">1.55 (1.12, 2.14)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Model 2</td><td align="center" rowspan="1" colspan="1">1.45 (1.02, 2.06)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Model 3</td><td align="center" rowspan="1" colspan="1">1.05 (0.74, 1.49)</td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Any CAC progression (&gt;10 Agatston units),<italic> n</italic> = 2,076</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Model 1</td><td align="center" rowspan="1" colspan="1">1.57 (1.24, 1.99)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Model 2</td><td align="center" rowspan="1" colspan="1">1.51 (1.16, 1.96)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Model 3</td><td align="center" rowspan="1" colspan="1">1.13 (0.87, 1.47)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Model 4</td><td align="center" rowspan="1" colspan="1">1.09 (0.87, 1.37)</td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Advanced CAC progression (&gt;100 Agatston units),<italic> n</italic> = 2,076</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Model 1</td><td align="center" rowspan="1" colspan="1">2.69 (1.76, 4.13)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Model 2</td><td align="center" rowspan="1" colspan="1">2.42 (1.47, 3.99)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Model 3</td><td align="center" rowspan="1" colspan="1">1.78 (1.08, 2.95)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Model 4</td><td align="center" rowspan="1" colspan="1">1.75 (1.09, 2.83)</td></tr></tbody></table><table-wrap-foot><fn><p>One-unit increase in HbA<sub>1c</sub> = 1% (10.9 mmol/mol). Model 1, unadjusted; model 2, adjusted for age, race, sex, education, and study field center; model 3, adjusted for variables in model 2 plus SBP, antihypertensive medication use (yes/no), current smoking status (yes/no), total cholesterol, HDL cholesterol, and BMI; model 4, adjusted for variables in model 3 plus baseline CAC.</p></fn><fn id="t2n1"><p>*Evaluated only among individuals without CAC at the year 20 examination.</p></fn></table-wrap-foot></table-wrap><p>Effect modification by race was evaluated but was not statistically significant for any of the CAC progression measures (interaction <italic>P</italic> values &gt;0.35). Analyses stratified by race are presented in <ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc14-0360/-/DC1">Supplementary Table 1</ext-link> and show similar associations, although the CIs overlap and lack precision, particularly for advanced CAC progression. For the analysis of HbA<sub>1c</sub> with CAC progression using the change in CAC volumetric score, 311 (15.0%) participants experienced CAC volume progression ≥2.5 mm<sup>3</sup>, but the association of HbA<sub>1c</sub> with CAC progression was attenuated and not statistically significant after adjustment for demographics, cardiovascular risk factors, and baseline CAC (RR = 1.31; 95% CI 0.97, 1.76). In another analysis focused solely on progression among individuals with CAC at baseline, HbA<sub>1c</sub> was not associated with an increase in the log-transformed Agatston score (β = 0.44; 95% CI −0.08, 0.96). Additionally, the association of HbA<sub>1c</sub> with CAC progression was explored using HbA<sub>1c</sub> quartiles, and the findings were similar to the results for continuous HbA<sub>1c</sub> when comparing the highest HbA<sub>1c</sub> quartile with the lowest HbA<sub>1c</sub> quartile for incident CAC (RR = 1.06; 95% CI 0.72, 1.55), any CAC progression (RR = 1.14; 95% CI 0.85, 1.54), and advanced CAC progression (RR = 2.12; 95% CI 1.08, 4.19).</p></sec><sec sec-type="conclusions" id="s9"><title>Conclusions</title><p>In this prospective cohort study of individuals without diabetes, 18.2% of participants experienced CAC progression &gt;10 Agatston units over a 5-year follow-up period, and CAC progression was more common among those individuals with baseline CAC present compared with those without baseline CAC. Higher HbA<sub>1c</sub> was associated with incident CAC and any CAC progression, but these associations were attenuated and not independent of other cardiovascular risk factors. However, higher HbA<sub>1c</sub> was associated with advanced CAC progression &gt;100 Agatston units, and this association persisted after adjustment for cardiovascular risk factors.</p><p>Prior studies investigated the cross-sectional association of HbA<sub>1c</sub> with prevalent CAC among individuals without diabetes and reported conflicting results. No association between HbA<sub>1c</sub> and calcified plaque was reported in a study of middle-aged Korean adults (<xref rid="B8" ref-type="bibr">8</xref>). In contrast, another study of middle-aged Korean men and women participating in a health screening program (CAC prevalence = 10.9%) reported higher HbA<sub>1c</sub> was associated with prevalent CAC (<xref rid="B9" ref-type="bibr">9</xref>). In the Multi-Ethnic Study of Atherosclerosis, higher HbA<sub>1c</sub> was also associated with prevalent CAC (<xref rid="B10" ref-type="bibr">10</xref>). However, this association was present for women and not men in that community-based study of older adults (mean age = 63.2 years) that had a high prevalence of CAC (53.5%). The differences in participant characteristics and CAC prevalence may have contributed to the contrasting findings reported for the association of HbA<sub>1c</sub> with CAC prevalence. Additionally, the prior studies did not evaluate CAC progression as we did in our community-based study of middle-aged adults. In our study, HbA<sub>1c</sub> was not associated with incident CAC or any CAC progression &gt;10 Agatston units after taking into account other established cardiovascular risk factors, whereas higher HbA<sub>1c</sub> was independently associated with advanced CAC progression &gt;100 Agatston units.</p><p>The physiologic pathway linking HbA<sub>1c</sub> and cardiovascular disease outcomes is not fully understood. A recent analysis of participants without diabetes from 73 prospective studies reported higher HbA<sub>1c</sub> was associated with an increased risk of clinical cardiovascular events, although the addition of HbA<sub>1c</sub> to risk prediction models resulted in marginal improvements in cardiovascular disease risk assessment beyond traditional cardiovascular disease risk factors (<xref rid="B18" ref-type="bibr">18</xref>). As an integrated marker of glycemia, HbA<sub>1c</sub> represents a general process of enhanced posttranslational glycation of many proteins that may relate differently to the various development stages of macrovascular disease for individuals without diabetes. Prior findings from studies of HbA<sub>1c</sub> and other markers of subclinical atherosclerosis have reported contrasting findings. Cross-sectional studies have reported positive associations of HbA<sub>1c</sub> with carotid artery intima-media thickness (<xref rid="B19" ref-type="bibr">19</xref>–<xref rid="B23" ref-type="bibr">23</xref>) and echogenic carotid plaque (<xref rid="B24" ref-type="bibr">24</xref>). In contrast, no associations have been reported for HbA<sub>1c</sub> with echolucent carotid plaque (<xref rid="B24" ref-type="bibr">24</xref>) and change in intima-media thickness or new plaque development over 5 years of follow-up (<xref rid="B25" ref-type="bibr">25</xref>).</p><p>CAC represents a particular advanced stage in the atherosclerotic plaque (<xref rid="B26" ref-type="bibr">26</xref>), namely, metabolism incorporating calcium within an existing plaque, so its pathogenesis may differ from other markers of subclinical atherosclerosis. Our study did not find independent associations with incident CAC or any CAC progression &gt;10 Agatston units, but HbA<sub>1c</sub> was independently associated with advanced CAC progression &gt;100 Agatston units. Because individuals with diabetes experience greater CAC progression than those without diabetes (<xref rid="B27" ref-type="bibr">27</xref>), it is possible that the association observed for those with advanced CAC progression &gt;100 Agatston units was reflective of the development of diabetes. However, HbA<sub>1c</sub> was not independently associated with any of the CAC progression measures among individuals with diabetes at baseline in our study (data not shown), and HbA<sub>1c</sub> remained independently associated with advanced CAC progression &gt;100 Agatston units (RR = 1.80; 95% CI 1.06, 3.06) after multivariable adjustment and excluding 102 individuals who developed diabetes during the follow-up. These findings suggest HbA<sub>1c</sub> may exhibit differential associations with CAC progression measures, indicating a complex association of HbA<sub>1c</sub> with multiple markers of subclinical atherosclerosis and potentially cardiovascular events.</p><p>This study has several potential limitations. HbA<sub>1c</sub> was not measured until the year 20 examination, so participants who did not attend this examination and participants who did not have CT scans completed at the year 20 and 25 examinations were not included in these analyses. The retention of CARDIA participants is high, but participants who were excluded from this analysis differed from those who were included, and this may have affected our study’s findings. Excluded participants were more likely to be younger, African American, and current or former smokers and have higher BMI and higher SBP, while no differences were noted for sex, education, lipids, and medication use when compared with participants included in this analysis. Additionally, HbA<sub>1c</sub> values may be affected by genetic factors and certain medical conditions such as anemia and liver disease (<xref rid="B28" ref-type="bibr">28</xref>,<xref rid="B29" ref-type="bibr">29</xref>). Excluding 55 individuals who self-reported a physician diagnosis of anemia or liver disease did not alter findings. HbA<sub>1c</sub> reflects glycemic control over several months, but only a single baseline measure of HbA<sub>1c</sub> was used in this analysis, and the association of HbA<sub>1c</sub> with CAC progression may be better captured with the use of multiple HbA<sub>1c</sub> measurements. Currently, there are no standard guidelines for the assessment of CAC progression (<xref rid="B30" ref-type="bibr">30</xref>), so this study investigated several definitions of CAC progression, and the conclusions were the same using absolute change in Agatston units and change in volumetric score definitions for this relatively young population (ages 38–50 years when CAC was assessed at the year 20 examination). Additionally, although we used multiple absolute and relative definitions of CAC progression, interscan variability may have affected the CAC progression outcomes in our study. Repeat scans were performed at the year 20 examination to assess interscan variability. Interscan variability decreased as the degree of CAC increased, with the mean (SD) for the absolute differences in scans being 56.6 (53.5) for the Agatston score and 1.3 (1.4) for the volumetric score, respectively, for participants with an Agatston score &gt;100 at baseline. The majority of the participants did not have CAC at baseline, and the follow-up period was 5 years, so this study had limited power to assess associations with greater degrees of CAC progression. However, the investigation of CAC during this early stage of middle age is important given the established associations with future cardiovascular events.</p><p>In summary, CAC progression was a common occurrence among middle-aged adults without diabetes in this study. Higher HbA<sub>1c</sub> was associated with CAC progression over 5 years of follow-up, although it was only independently associated with advanced CAC progression &gt;100 Agatston units after taking into account cardiovascular risk factors. This suggests that the pathway linking HbA<sub>1c</sub> with clinical cardiovascular events among individuals without diabetes may not be evidenced at the earlier stages of subclinical atherosclerosis development. More comprehensive elucidation of the relation of glycemia, subclinical atherosclerosis, and clinical cardiovascular events among individuals without diabetes is warranted.</p></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>Supplementary Data</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_38_1_66__index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_dc14-0360v140360_DC140360SupplementaryData.pdf"/>
</supplementary-material>
</sec>
</body>
  <back>
    <fn-group>
      <fn id="fn1" fn-type="supplementary-material">
        <p>This article contains Supplementary Data online at <ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc14-0360/-/DC1">http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc14-0360/-/DC1</ext-link>.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Article Information</title>
      <p><bold>Acknowledgments.</bold> The authors thank the other investigators, the staff, and the participants of the CARDIA study for their contributions.</p>
      <p><bold>Funding.</bold> The CARDIA study is supported by contracts HHSN-268201300025C, HHSN-268201300026C, HHSN-268201300027C, HHSN-268201300028C, HHSN-268201300029C, and HHSN-268200900041C from the National Heart, Lung, and Blood Institute; the Intramural Research Program of the National Institute on Aging; and an intraagency agreement between the National Institute on Aging and the National Heart, Lung, and Blood Institute (AG0005). Additional support provided by K01-DK-095928 (A.P.C.), R01-HL-098445 (J.J.C.), and R01-HL-053560 (M.D.G. and D.R.J.).</p>
      <p><bold>Duality of Interest.</bold> No potential conflicts of interest relevant to this article were reported.</p>
      <p><bold>Author Contributions.</bold> A.P.C. conceptualized the study, designed the analysis, interpreted the data, and drafted the manuscript. M.W.S., M.R.C., J.P.R., and C.M.L. interpreted the data and critically revised the manuscript for important intellectual content. J.J.C., M.D.G., D.R.J., and C.E.L. secured funding, interpreted the data, and critically revised the manuscript for important intellectual content. Y.K. researched the data, performed the statistical analysis, and critically revised the manuscript for important intellectual content. A.P.C. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p>
      <p><bold>Prior Presentation.</bold> Results from previous analysis were presented at the American Heart Association Council on Epidemiology and Prevention Meeting, New Orleans, LA, 19–22 March 2013.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khaw</surname><given-names>KT</given-names></name><name><surname>Wareham</surname><given-names>N</given-names></name><name><surname>Bingham</surname><given-names>S</given-names></name><name><surname>Luben</surname><given-names>R</given-names></name><name><surname>Welch</surname><given-names>A</given-names></name><name><surname>Day</surname><given-names>N</given-names></name></person-group>. <article-title>Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk</article-title>. <source>Ann Intern Med</source>
<year>2004</year>;<volume>141</volume>:<fpage>413</fpage>–<lpage>420</lpage><?supplied-pmid 15381514?><pub-id pub-id-type="pmid">15381514</pub-id></mixed-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van ’t Riet</surname><given-names>E</given-names></name><name><surname>Rijkelijkhuizen</surname><given-names>JM</given-names></name><name><surname>Alssema</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>HbA1c is an independent predictor of non-fatal cardiovascular disease in a Caucasian population without diabetes: a 10-year follow-up of the Hoorn Study</article-title>. <source>Eur J Prev Cardiol</source>
<year>2012</year>;<volume>19</volume>:<fpage>23</fpage>–<lpage>31</lpage><?supplied-pmid 20517157?><pub-id pub-id-type="pmid">20517157</pub-id></mixed-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selvin</surname><given-names>E</given-names></name><name><surname>Steffes</surname><given-names>MW</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults</article-title>. <source>N Engl J Med</source>
<year>2010</year>;<volume>362</volume>:<fpage>800</fpage>–<lpage>811</lpage><?supplied-pmid 20200384?><pub-id pub-id-type="pmid">20200384</pub-id></mixed-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strong</surname><given-names>JP</given-names></name><name><surname>Malcom</surname><given-names>GT</given-names></name><name><surname>McMahan</surname><given-names>CA</given-names></name><etal/></person-group>. <article-title>Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study</article-title>. <source>JAMA</source>
<year>1999</year>;<volume>281</volume>:<fpage>727</fpage>–<lpage>735</lpage><?supplied-pmid 10052443?><pub-id pub-id-type="pmid">10052443</pub-id></mixed-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pletcher</surname><given-names>MJ</given-names></name><name><surname>Tice</surname><given-names>JA</given-names></name><name><surname>Pignone</surname><given-names>M</given-names></name><name><surname>Browner</surname><given-names>WS</given-names></name></person-group>. <article-title>Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis</article-title>. <source>Arch Intern Med</source>
<year>2004</year>;<volume>164</volume>:<fpage>1285</fpage>–<lpage>1292</lpage><?supplied-pmid 15226161?><pub-id pub-id-type="pmid">15226161</pub-id></mixed-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenland</surname><given-names>P</given-names></name><name><surname>LaBree</surname><given-names>L</given-names></name><name><surname>Azen</surname><given-names>SP</given-names></name><name><surname>Doherty</surname><given-names>TM</given-names></name><name><surname>Detrano</surname><given-names>RC</given-names></name></person-group>. <article-title>Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals</article-title>. <source>JAMA</source>
<year>2004</year>;<volume>291</volume>:<fpage>210</fpage>–<lpage>215</lpage><?supplied-pmid 14722147?><pub-id pub-id-type="pmid">14722147</pub-id></mixed-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeboah</surname><given-names>J</given-names></name><name><surname>McClelland</surname><given-names>RL</given-names></name><name><surname>Polonsky</surname><given-names>TS</given-names></name><etal/></person-group>. <article-title>Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals</article-title>. <source>JAMA</source>
<year>2012</year>;<volume>308</volume>:<fpage>788</fpage>–<lpage>795</lpage><?supplied-pmid 22910756?><pub-id pub-id-type="pmid">22910756</pub-id></mixed-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivera</surname><given-names>JJ</given-names></name><name><surname>Choi</surname><given-names>EK</given-names></name><name><surname>Yoon</surname><given-names>YE</given-names></name><etal/></person-group>. <article-title>Association between increasing levels of hemoglobin A1c and coronary atherosclerosis in asymptomatic individuals without diabetes mellitus</article-title>. <source>Coron Artery Dis</source>
<year>2010</year>;<volume>21</volume>:<fpage>157</fpage>–<lpage>163</lpage><?supplied-pmid 20308881?><pub-id pub-id-type="pmid">20308881</pub-id></mixed-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>Y</given-names></name><name><surname>Yun</surname><given-names>KE</given-names></name><name><surname>Jung</surname><given-names>H-S</given-names></name><etal/></person-group>. <article-title>A1C and coronary artery calcification in nondiabetic men and women</article-title>. <source>Arterioscler Thromb Vasc Biol</source>
<year>2013</year>;<volume>33</volume>:<fpage>2026</fpage>–<lpage>2031</lpage><?supplied-pmid 23788764?><pub-id pub-id-type="pmid">23788764</pub-id></mixed-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNeely</surname><given-names>MJ</given-names></name><name><surname>McClelland</surname><given-names>RL</given-names></name><name><surname>Bild</surname><given-names>DE</given-names></name><etal/></person-group>. <article-title>The association between A1C and subclinical cardiovascular disease: the multi-ethnic study of atherosclerosis</article-title>. <source>Diabetes Care</source>
<year>2009</year>;<volume>32</volume>:<fpage>1727</fpage>–<lpage>1733</lpage><?supplied-pmid 19549732?><pub-id pub-id-type="pmid">19549732</pub-id></mixed-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>GD</given-names></name><name><surname>Cutter</surname><given-names>GR</given-names></name><name><surname>Donahue</surname><given-names>RP</given-names></name><etal/></person-group>. <article-title>CARDIA: study design, recruitment, and some characteristics of the examined subjects</article-title>. <source>J Clin Epidemiol</source>
<year>1988</year>;<volume>41</volume>:<fpage>1105</fpage>–<lpage>1116</lpage><?supplied-pmid 3204420?><pub-id pub-id-type="pmid">3204420</pub-id></mixed-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <mixed-citation publication-type="webpage">National Heart Lung and Blood Institute. The Coronary Artery Risk Development in Young Adults manual of operations: year 20-cardia vii exam, 2006. Birmingham, AL, CARDIA Coordinating Center, Division of Preventive Medicine, The University of Alabama at Birmingham. Available from <ext-link ext-link-type="uri" xlink:href="http://www.cardia.dopm.uab.edu/exam-materials2012/manual-of-operations/year-2020">http://www.cardia.dopm.uab.edu/exam-materials2012/manual-of-operations/year-2020</ext-link>. Accessed 13 February 2013</mixed-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carr</surname><given-names>JJ</given-names></name><name><surname>Nelson</surname><given-names>JC</given-names></name><name><surname>Wong</surname><given-names>ND</given-names></name><etal/></person-group>. <article-title>Calcified coronary artery plaque measurement with cardiac CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study</article-title>. <source>Radiology</source>
<year>2005</year>;<volume>234</volume>:<fpage>35</fpage>–<lpage>43</lpage><?supplied-pmid 15618373?><pub-id pub-id-type="pmid">15618373</pub-id></mixed-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>SS</given-names></name><name><surname>Pal</surname><given-names>RS</given-names></name><name><surname>McKay</surname><given-names>CR</given-names></name><etal/></person-group>. <article-title>Comparison of coronary artery calcium scores between electron beam computed tomography and 64-multidetector computed tomographic scanner</article-title>. <source>J Comput Assist Tomogr</source>
<year>2009</year>;<volume>33</volume>:<fpage>175</fpage>–<lpage>178</lpage><?supplied-pmid 19346841?><pub-id pub-id-type="pmid">19346841</pub-id></mixed-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agatston</surname><given-names>AS</given-names></name><name><surname>Janowitz</surname><given-names>WR</given-names></name><name><surname>Hildner</surname><given-names>FJ</given-names></name><name><surname>Zusmer</surname><given-names>NR</given-names></name><name><surname>Viamonte</surname><given-names>M</given-names><suffix>Jr</suffix></name><name><surname>Detrano</surname><given-names>R</given-names></name></person-group>. <article-title>Quantification of coronary artery calcium using ultrafast computed tomography</article-title>. <source>J Am Coll Cardiol</source>
<year>1990</year>;<volume>15</volume>:<fpage>827</fpage>–<lpage>832</lpage><?supplied-pmid 2407762?><pub-id pub-id-type="pmid">2407762</pub-id></mixed-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>G</given-names></name></person-group>. <article-title>A modified poisson regression approach to prospective studies with binary data</article-title>. <source>Am J Epidemiol</source>
<year>2004</year>;<volume>159</volume>:<fpage>702</fpage>–<lpage>706</lpage><?supplied-pmid 15033648?><pub-id pub-id-type="pmid">15033648</pub-id></mixed-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hokanson</surname><given-names>JE</given-names></name><name><surname>MacKenzie</surname><given-names>T</given-names></name><name><surname>Kinney</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Evaluating changes in coronary artery calcium: an analytic method that accounts for interscan variability</article-title>. <source>AJR Am J Roentgenol</source>
<year>2004</year>;<volume>182</volume>:<fpage>1327</fpage>–<lpage>1332</lpage><?supplied-pmid 15100140?><pub-id pub-id-type="pmid">15100140</pub-id></mixed-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Angelantonio</surname><given-names>E</given-names></name><name><surname>Gao</surname><given-names>P</given-names></name><name><surname>Khan</surname><given-names>H</given-names></name><etal/><collab>Emerging Risk Factors Collaboration</collab></person-group>. <article-title>Glycated hemoglobin measurement and prediction of cardiovascular disease</article-title>. <source>JAMA</source>
<year>2014</year>;<volume>311</volume>:<fpage>1225</fpage>–<lpage>1233</lpage><?supplied-pmid 24668104?><pub-id pub-id-type="pmid">24668104</pub-id></mixed-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerstein</surname><given-names>HC</given-names></name><name><surname>Anand</surname><given-names>S</given-names></name><name><surname>Yi</surname><given-names>QL</given-names></name><etal/><collab>SHARE Investigators</collab></person-group>. <article-title>The relationship between dysglycemia and atherosclerosis in South Asian, Chinese, and European individuals in Canada: a randomly sampled cross-sectional study</article-title>. <source>Diabetes Care</source>
<year>2003</year>;<volume>26</volume>:<fpage>144</fpage>–<lpage>149</lpage><?supplied-pmid 12502671?><pub-id pub-id-type="pmid">12502671</pub-id></mixed-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Bi</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Glycated hemoglobin A1c, fasting plasma glucose, and two-hour postchallenge plasma glucose levels in relation to carotid intima-media thickness in chinese with normal glucose tolerance</article-title>. <source>J Clin Endocrinol Metab</source>
<year>2011</year>;<volume>96</volume>:<fpage>E1461</fpage>–<lpage>E1465</lpage><?supplied-pmid 21715536?><pub-id pub-id-type="pmid">21715536</pub-id></mixed-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okada</surname><given-names>M</given-names></name><name><surname>Miida</surname><given-names>T</given-names></name><name><surname>Hama</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Possible risk factors of carotid artery atherosclerosis in the Japanese population: a primary prevention study in non-diabetic subjects</article-title>. <source>Intern Med</source>
<year>2000</year>;<volume>39</volume>:<fpage>362</fpage>–<lpage>368</lpage><?supplied-pmid 10830174?><pub-id pub-id-type="pmid">10830174</pub-id></mixed-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bobbert</surname><given-names>T</given-names></name><name><surname>Mai</surname><given-names>K</given-names></name><name><surname>Fischer-Rosinsky</surname><given-names>A</given-names></name><name><surname>Pfeiffer</surname><given-names>AF</given-names></name><name><surname>Spranger</surname><given-names>J</given-names></name></person-group>. <article-title>A1C is associated with intima-media thickness in individuals with normal glucose tolerance</article-title>. <source>Diabetes Care</source>
<year>2010</year>;<volume>33</volume>:<fpage>203</fpage>–<lpage>204</lpage><?supplied-pmid 19808917?><pub-id pub-id-type="pmid">19808917</pub-id></mixed-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawson</surname><given-names>JD</given-names></name><name><surname>Sonka</surname><given-names>M</given-names></name><name><surname>Blecha</surname><given-names>MB</given-names></name><name><surname>Lin</surname><given-names>W</given-names></name><name><surname>Davis</surname><given-names>PH</given-names></name></person-group>. <article-title>Risk factors associated with aortic and carotid intima-media thickness in adolescents and young adults: the Muscatine Offspring Study</article-title>. <source>J Am Coll Cardiol</source>
<year>2009</year>;<volume>53</volume>:<fpage>2273</fpage>–<lpage>2279</lpage><?supplied-pmid 19520251?><pub-id pub-id-type="pmid">19520251</pub-id></mixed-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jørgensen</surname><given-names>L</given-names></name><name><surname>Jenssen</surname><given-names>T</given-names></name><name><surname>Joakimsen</surname><given-names>O</given-names></name><name><surname>Heuch</surname><given-names>I</given-names></name><name><surname>Ingebretsen</surname><given-names>OC</given-names></name><name><surname>Jacobsen</surname><given-names>BK</given-names></name></person-group>. <article-title>Glycated hemoglobin level is strongly related to the prevalence of carotid artery plaques with high echogenicity in nondiabetic individuals: the Tromsø study</article-title>. <source>Circulation</source>
<year>2004</year>;<volume>110</volume>:<fpage>466</fpage>–<lpage>470</lpage><?supplied-pmid 15249512?><pub-id pub-id-type="pmid">15249512</pub-id></mixed-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonora</surname><given-names>E</given-names></name><name><surname>Kiechl</surname><given-names>S</given-names></name><name><surname>Willeit</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Plasma glucose within the normal range is not associated with carotid atherosclerosis: prospective results in subjects with normal glucose tolerance from the Bruneck Study</article-title>. <source>Diabetes Care</source>
<year>1999</year>;<volume>22</volume>:<fpage>1339</fpage>–<lpage>1346</lpage><?supplied-pmid 10480780?><pub-id pub-id-type="pmid">10480780</pub-id></mixed-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stary</surname><given-names>HC</given-names></name><name><surname>Chandler</surname><given-names>AB</given-names></name><name><surname>Dinsmore</surname><given-names>RE</given-names></name><etal/></person-group>. <article-title>A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association</article-title>. <source>Circulation</source>
<year>1995</year>;<volume>92</volume>:<fpage>1355</fpage>–<lpage>1374</lpage><?supplied-pmid 7648691?><pub-id pub-id-type="pmid">7648691</pub-id></mixed-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kronmal</surname><given-names>RA</given-names></name><name><surname>McClelland</surname><given-names>RL</given-names></name><name><surname>Detrano</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Risk factors for the progression of coronary artery calcification in asymptomatic subjects: results from the Multi-Ethnic Study of Atherosclerosis (MESA)</article-title>. <source>Circulation</source>
<year>2007</year>;<volume>115</volume>:<fpage>2722</fpage>–<lpage>2730</lpage><?supplied-pmid 17502571?><pub-id pub-id-type="pmid">17502571</pub-id></mixed-citation>
      </ref>
      <ref id="B28">
        <label>28</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Little</surname><given-names>RR</given-names></name><name><surname>Sacks</surname><given-names>DB</given-names></name></person-group>. <article-title>HbA1c: how do we measure it and what does it mean</article-title>? <source>Curr Opin Endocrinol Diabetes Obes</source>
<year>2009</year>;<volume>16</volume>:<fpage>113</fpage>–<lpage>118</lpage><?supplied-pmid 19300091?><pub-id pub-id-type="pmid">19300091</pub-id></mixed-citation>
      </ref>
      <ref id="B29">
        <label>29</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soranzo</surname><given-names>N</given-names></name><name><surname>Sanna</surname><given-names>S</given-names></name><name><surname>Wheeler</surname><given-names>E</given-names></name><etal/><collab>WTCCC</collab></person-group>. <article-title>Common variants at 10 genomic loci influence hemoglobin A₁(C) levels via glycemic and nonglycemic pathways</article-title> [published correction appears in Diabetes 2011;60:1050–1051]. <source>Diabetes</source>
<year>2010</year>;<volume>59</volume>:<fpage>3229</fpage>–<lpage>3239</lpage><?supplied-pmid 20858683?><pub-id pub-id-type="pmid">20858683</pub-id></mixed-citation>
      </ref>
      <ref id="B30">
        <label>30</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McEvoy</surname><given-names>JW</given-names></name><name><surname>Blaha</surname><given-names>MJ</given-names></name><name><surname>Defilippis</surname><given-names>AP</given-names></name><etal/></person-group>. <article-title>Coronary artery calcium progression: an important clinical measurement? A review of published reports</article-title>. <source>J Am Coll Cardiol</source>
<year>2010</year>;<volume>56</volume>:<fpage>1613</fpage>–<lpage>1622</lpage><?supplied-pmid 21050970?><pub-id pub-id-type="pmid">21050970</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:4274775</identifier><datestamp>2016-01-01</datestamp><setSpec>diacare</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="http://jats.nlm.nih.gov/ns/archiving/1.0/ http://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Diabetes Care</journal-id>
      <journal-id journal-id-type="iso-abbrev">Diabetes Care</journal-id>
      <journal-id journal-id-type="hwp">diacare</journal-id>
      <journal-id journal-id-type="pmc">dcare</journal-id>
      <journal-id journal-id-type="publisher-id">Diabetes Care</journal-id>
      <journal-title-group>
        <journal-title>Diabetes Care</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0149-5992</issn>
      <issn pub-type="epub">1935-5548</issn>
      <publisher>
        <publisher-name>American Diabetes Association</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4274775</article-id>
      <article-id pub-id-type="pmcid">PMC4274775</article-id>
      <article-id pub-id-type="pmc-uid">4274775</article-id>
      <article-id pub-id-type="pmid">25414156</article-id>
      <article-id pub-id-type="publisher-id">1742</article-id>
      <article-id pub-id-type="doi">10.2337/dc14-1742</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Cardiovascular and Metabolic Risk</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Renal Function Is Associated With Peak Exercise Capacity in Adolescents With Type 1 Diabetes</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Bjornstad</surname>
            <given-names>Petter</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cree-Green</surname>
            <given-names>Melanie</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Baumgartner</surname>
            <given-names>Amy</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Maahs</surname>
            <given-names>David M.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cherney</surname>
            <given-names>David Z.</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">
            <sup>5</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pyle</surname>
            <given-names>Laura</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Regensteiner</surname>
            <given-names>Judith G.</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff6">
            <sup>6</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Reusch</surname>
            <given-names>Jane E.</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff7">
            <sup>7</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nadeau</surname>
            <given-names>Kristen J.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <aff id="aff1"><sup>1</sup>Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO</aff>
        <aff id="aff2"><sup>2</sup>Department of Pediatrics, Division of Pediatric Endocrinology, University of Colorado School of Medicine, Aurora, CO</aff>
        <aff id="aff3"><sup>3</sup>Center for Women’s Health Research, University of Colorado School of Medicine, Aurora, CO</aff>
        <aff id="aff4"><sup>4</sup>Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, CO</aff>
        <aff id="aff5"><sup>5</sup>Department of Medicine, Division of Nephrology, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada</aff>
        <aff id="aff6"><sup>6</sup>Department of Medicine, Divisions of Internal Medicine and Cardiology, University of Colorado School of Medicine, Aurora, CO</aff>
        <aff id="aff7"><sup>7</sup>Department of Medicine, Division of Internal Medicine, Denver VA Medical Center, Denver, CO</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">Corresponding author: Petter Bjornstad, <email>petter.bjornstad@childrenscolorado.org</email>.</corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>20</day>
        <month>11</month>
        <year>2014</year>
      </pub-date>
      <volume>38</volume>
      <issue>1</issue>
      <fpage>126</fpage>
      <lpage>131</lpage>
      <history>
        <date date-type="received">
          <day>19</day>
          <month>7</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>26</day>
          <month>9</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.</copyright-statement>
        <copyright-year>2015</copyright-year>
      </permissions>
      <self-uri xlink:title="pdf" xlink:type="simple" xlink:href="126.pdf"/>
      <abstract>
        <sec>
          <title>OBJECTIVE</title>
          <p>Diabetic nephropathy and cardiovascular disease are strongly related in adults with type 1 diabetes, yet little is known about this relationship in adolescents prior to the onset of detectable clinical disease. We hypothesized that cardiopulmonary fitness would be directly associated with albumin-to-creatinine ratio (ACR) and inversely related to estimated glomerular filtration rate (eGFR) in adolescents with type 1 diabetes.</p>
        </sec>
        <sec>
          <title>RESEARCH DESIGN AND METHODS</title>
          <p>Sixty-nine adolescents with type 1 diabetes and 13 nondiabetic control subjects of similar pubertal stage and BMI had insulin sensitivity (glucose infusion rate [GIR]), measured by hyperinsulinemic-euglycemic clamp, and lean body mass, measured by DEXA. Cardiopulmonary fitness was measured by cycle ergometry to obtain peak volume of oxygen (VO<sub>2</sub>peak), and renal function was measured by eGFR using the Bouvet equation (measuring creatinine and cystatin C levels) and ACR.</p>
        </sec>
        <sec>
          <title>RESULTS</title>
          <p>Adolescents (15.5 ± 2.2 years of age) with type 1 diabetes (6.3 ± 3.8 years diabetes duration) had reduced VO<sub>2</sub>peak (31.5 ± 6.3 vs. 36.2 ± 7.9 mL/kg ⋅ min, <italic>P</italic> = 0.046) and VO<sub>2</sub>peak/lean kg (43.7 ± 7.0 vs. 51.0 ± 8.6 mL/lean kg ⋅ min, <italic>P</italic> = 0.007) compared with nondiabetic control subjects. eGFR was inversely associated with VO<sub>2</sub>peak and VO<sub>2</sub>peak/lean kg after adjusting for sex, Tanner stage, GIR, HbA<sub>1c</sub> level, systolic blood pressure, and LDL cholesterol level (β ± SE, VO<sub>2</sub>peak: −0.19 ± 0.07, <italic>P</italic> = 0.02; VO<sub>2</sub>peak/lean kg: −0.19 ± 0.09, <italic>P</italic> = 0.048). Moreover, participants in the highest tertile for eGFR had significantly lower sex- and Tanner-adjusted VO<sub>2</sub>peak and VO<sub>2</sub>peak/lean kg compared with participants in the lowest tertile.</p>
        </sec>
        <sec>
          <title>CONCLUSIONS</title>
          <p>Adolescents with type 1 diabetes had reduced exercise capacity, which was strongly associated with renal health, independent of insulin sensitivity. Future studies should examine the underlying interrelated pathophysiology in order to identify probable targets for treatment to reduce cardiovascular and renal complications.</p>
        </sec>
      </abstract>
      <counts>
        <page-count count="6"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="s1">
      <title>Introduction</title>
      <p>Cardiovascular disease (CVD) and diabetic nephropathy (DN) are the major causes of mortality in individuals with type 1 diabetes (<xref rid="B1" ref-type="bibr">1</xref>–<xref rid="B3" ref-type="bibr">3</xref>), and a growing body of evidence from basic and clinical studies (<xref rid="B4" ref-type="bibr">4</xref>–<xref rid="B7" ref-type="bibr">7</xref>) supports the relationship between CVD and renal function in health and disease. CVD and DN have been proposed to be manifestations of the same underlying pathology and also exist as interrelated risk factors (<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B9" ref-type="bibr">9</xref>). The increased mesangial matrix associated with DN is similar to the pathophysiology of coronary atherosclerosis (<xref rid="B8" ref-type="bibr">8</xref>). While atherosclerosis tends to remain subclinical until adulthood in individuals with type 1 diabetes (<xref rid="B10" ref-type="bibr">10</xref>), adolescents with type 1 diabetes demonstrate reduced peak exercise capacity and decreased cardiac function compared with nondiabetic adolescents (<xref rid="B11" ref-type="bibr">11</xref>). Although the mechanisms underlying the reduced peak exercise capacity are poorly understood, we have previously shown that insulin resistance and elevated LDL cholesterol (LDL-C) were associated with low peak volume of oxygen (VO<sub>2</sub>peak) (<xref rid="B11" ref-type="bibr">11</xref>).</p>
      <p>Elevated albumin-to-creatinine ratio (ACR) and glomerular filtration rate (GFR), which are early manifestations of DN, are also increasingly recognized in children and adolescents with type 1 diabetes (<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B12" ref-type="bibr">12</xref>). Increased GFR was shown to be associated with increased cardiovascular mortality in adults (<xref rid="B13" ref-type="bibr">13</xref>). Little is known, however, about the possible associations between early renal health and exercise capacity in adolescents with type 1 diabetes, and whether this relationship is independent of insulin sensitivity. Accordingly, we sought to examine the associations between markers of renal health and peak exercise capacity in adolescents with type 1 diabetes. We hypothesized that cardiopulmonary fitness would be directly associated with ACR and inversely related to estimated GFR (eGFR) in adolescents with type 1 diabetes.</p>
    </sec>
    <sec id="s2">
      <title>Research Design and Methods</title>
      <sec id="s3">
        <title>Subjects</title>
        <p>Pubertal adolescents between the ages of 12 and 19 years were recruited for a study of diabetes and insulin resistance in youth from type 1 diabetes clinics at the Barbara Davis Center for Diabetes with advertisements. Control subjects were recruited from advertisements on the University of Colorado Anschutz Medical Campus, and in endocrine, adolescent medicine, and pediatric clinics at Children’s Hospital Colorado. Sixty-nine adolescents with type 1 diabetes and 13 nondiabetic control subjects had data available for analyses of cardiopulmonary fitness, insulin sensitivity, ACR, and eGFR, as determined by creatinine and cystatin C levels.</p>
        <p>Screening included a medical history, physical examination, Tanner staging, and fasting laboratory testing (measurement of glycosylated hemoglobin [HbA<sub>1c</sub>] and LDL-C levels). Type 1 diabetes was defined by American Diabetes Association criteria plus the presence of glutamic acid decarboxylase and islet cell or insulin autoantibodies, as well as an insulin requirement. The absence of diabetes was confirmed in control subjects by a 2-h, 75-g oral glucose tolerance test. Inclusion criteria included Tanner stage &gt;1 and sedentary status (&lt;3 h regular exercise/week) to minimize pubertal and training effects. Study exclusions included resting blood pressure &gt;140/90 mmHg or &gt;190/100 mmHg during exercise, hemoglobin level &lt;9 mg/dL, serum creatinine level &gt;1.5 mg/dL, HbA<sub>1c</sub> level &gt;11% (97 mmol/mol), smoking, medication-dependent asthma or other conditions precluding exercise testing, use of antihypertensive medications and oral contraceptives, pregnancy, breastfeeding, plans to alter exercise or diet during the study, family history of type 2 diabetes, and use of medications affecting insulin sensitivity (e.g., oral or inhaled steroids, metformin, thiazolidinediones, or atypical antipsychotic agents). Pubertal development was assessed by a single pediatric endocrinologist using the criteria established by Tanner and Marshall for pubic hair and breast development (<xref rid="B14" ref-type="bibr">14</xref>). Testicular volume was measured using an orchidometer.</p>
        <p>All subsequent tests were performed after a 12-h fast, preceded by 3 days of restricted physical activity and a fixed-macronutrient, weight-maintenance diet (55% carbohydrates, 30% fat, 15% protein). Participants with type 1 diabetes were instructed to monitor blood glucose levels at least four times per day and were excluded if large urine ketones were present on admission to the study. The study was approved by the University of Colorado Denver Institutional Review Board, and appropriate consent and assent were obtained.</p>
      </sec>
      <sec id="s4">
        <title>Activity Questionnaires and Body Composition</title>
        <p>A 3-day pediatric physical activity recall questionnaire was used to estimate habitual physical activity (<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B15" ref-type="bibr">15</xref>), reported as a 3-d average of daily metabolic equivalents. Body composition was assessed by DEXA scan, as previously reported (<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B15" ref-type="bibr">15</xref>).</p>
      </sec>
      <sec id="s5">
        <title>Exercise Testing</title>
        <p>Measurements were made during bicycle ergometer testing using a metabolic cart. For all bicycle tests, VO<sub>2</sub>, volume of carbon dioxide, and minute ventilation were measured, breath-by-breath, at rest and during exercise. Arm blood pressures (by auscultation) and heart rates (measured by 12-lead electrocardiogram) were obtained every minute during exercise. Cardiac status was continuously monitored throughout each test by 12-lead electrocardiogram. The respiratory exchange ratio was calculated as the volume of carbon dioxide-to-VO<sub>2</sub> ratio. Subjects were excluded if the peak respiratory exchange ratio was ≤1.1.</p>
        <p>To determine VO<sub>2</sub>peak in all participants, a graded bicycle riding protocol was performed until subject exhaustion, and was carried out, as previously reported (<xref rid="B11" ref-type="bibr">11</xref>), on a cycle ergometer (Medgraphics; Medical Graphics Corp., St. Paul, MN) while breathing into the mouthpiece of the metabolic cart (Medgraphics CPX/D; Medical Graphics Corp.). VO<sub>2</sub>peak was reported in milliliters per kilogram per minute and milliliters per lean kilogram determined from DEXA scan per minute, as previously reported (<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B15" ref-type="bibr">15</xref>). Blood sugar levels were closely monitored in participants with type 1 diabetes, and short-acting insulin or carbohydrates were administered to achieve a goal pre-exercise range of 100–150 mg/dL.</p>
      </sec>
      <sec id="s6">
        <title>Insulin Sensitivity</title>
        <p>Insulin sensitivity (glucose infusion rate [GIR] in milligrams per kilogram per minute) was calculated from a hyperinsulinemic-euglycemic clamp (80 mU ⋅ m<sup>−2</sup> ⋅ min<sup>−1</sup> insulin) after an overnight intravenous insulin infusion to normalize glycemia, as previously described (<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B15" ref-type="bibr">15</xref>).</p>
      </sec>
      <sec id="s7">
        <title>Renal Measurements</title>
        <p>Samples for serum creatinine and cystatin C measurements were collected after 3–4 h of euglycemia (100 mg/dL) and 16 h of bed rest, eliminating the effects of acute glycemia and exercise on eGFR (<xref rid="B16" ref-type="bibr">16</xref>–<xref rid="B18" ref-type="bibr">18</xref>). The cystatin C and creatinine samples were analyzed in batches, reducing the effects of temporal systemic shifts on the assays. Serum cystatin C levels were measured by immunoturbidimetric methodology (Kamiya Biomedical), and serum creatinine levels were measured by enzymatic methodology (Beckman Coulter). Because of the absence of chronic kidney disease and expected normal to elevated GFRs for age, we used the Bouvet equation to estimate GFR: eGFR = 63.2 ⋅ (serum creatinine/96)<sup>−0.35</sup> ⋅ (serum cystatin C/1.2)<sup>−0.56</sup> ⋅ (weight/45)<sup>0.30</sup> ⋅ (age/14)<sup>0.40</sup> (<xref rid="B19" ref-type="bibr">19</xref>). This equation has shown to have the best performance in estimating GFR in adolescents without chronic kidney disease (<xref rid="B19" ref-type="bibr">19</xref>). Spot urine samples were also collected upon study admission for measurement of urinary albumin and creatinine levels, and ACR was calculated. Albuminuria was defined as microalbuminuria or greater with ACR ≥30 mg/g.</p>
      </sec>
      <sec id="s8">
        <title>Statistical Analysis</title>
        <p>Analyses were performed in SAS (version 9.3 for Windows; SAS Institute, Cary, NC). Variables were checked for the distributional assumption of normality using normal plots. Differences between continuous parametric variables were examined with the <italic>t</italic> test, continuous nonparametric variables were examined with the Wilcoxon signed rank test, and dichotomous variables were examined with the χ<sup>2</sup> test. eGFRs determined by the Bouvet equation (low &lt;94, middle range 94–106, and high &gt;106 mL/min/1.73 m<sup>2</sup>) and ACR (low &lt;5.50, middle range 5.50–9.13, and high &gt;9.13 mg/g) were stratified into tertiles. ANOVA with a Tukey-Kramer <italic>P</italic> value adjustment was used for the comparison of continuous variables across the three groups (low, middle, and high tertiles), and least squares means (LSMs) were calculated for the tertile groups.</p>
        <p>Pearson correlation, and univariate and multivariable linear regression models were used to examine the associations between eGFR determined by Bouvet equation and the natural log of ACR (log transformed for these analyses because of skewed distribution) and VO<sub>2</sub>peak, unadjusted and adjusted for Tanner stage, sex, insulin sensitivity, HbA<sub>1c</sub> level, systolic blood pressure (SBP), and LDL-C level. Significance was based on an α-level of ≤0.05.</p>
      </sec>
    </sec>
    <sec sec-type="results" id="s9">
      <title>Results</title>
      <p><xref ref-type="table" rid="T1">Table 1</xref> shows participant characteristics stratified by diabetes status. Adolescents with type 1 diabetes had reduced peak exercise capacity compared with nondiabetic control subjects (VO<sub>2</sub>peak 31.5 ± 6.3 vs. 36.2 ± 7.9 mL/kg ⋅ min, <italic>P</italic> = 0.046; VO<sub>2</sub>peak/lean kg 43.7 ± 7.0 vs. 51.0 ± 8.6 mL/lean kg ⋅ min, <italic>P</italic> = 0.007), despite similar age, Tanner stage, BMI, and habitual level of physical activity. When adjusting for eGFR, the differences in Tanner stage and sex-adjusted means for VO<sub>2</sub>peak/kg (LSMs ± SE 32.3 ± 1.0 vs. 34.2 ± 1.5, <italic>P</italic> = 0.30) and VO<sub>2</sub>peak/lean kg (LSMs ± SE 49.0 ± 2.1 vs. 45.0 ± 1.4, <italic>P</italic> = 0.09) between adolescents with and without type 1 diabetes lost significance.</p>
      <table-wrap id="T1" position="float">
        <label>Table 1</label>
        <caption>
          <p>Characteristics for adolescents with type 1 diabetes</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead valign="bottom">
            <tr>
              <th align="left" scope="col" rowspan="1" colspan="1"/>
              <th align="center" scope="col" rowspan="1" colspan="1">Lean control subjects (<italic>n</italic> = 13)</th>
              <th align="center" scope="col" rowspan="1" colspan="1">Adolescents with type 1 diabetes (<italic>n</italic> = 69)</th>
              <th align="center" scope="col" rowspan="1" colspan="1"><italic>P</italic> value</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1">Age (years)</td>
              <td align="center" rowspan="1" colspan="1">15.1 ± 2.2</td>
              <td align="center" rowspan="1" colspan="1">15.5 ± 2.2</td>
              <td align="center" rowspan="1" colspan="1">0.55</td>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1">Type 1 diabetes duration (months)</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="center" rowspan="1" colspan="1">75 ± 46</td>
              <td align="left" rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1">Ethnicity (%)</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="center" rowspan="1" colspan="1">0.38<xref ref-type="table-fn" rid="t1n1"><sup>a</sup></xref></td>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1"> Non-Hispanic white</td>
              <td align="center" rowspan="1" colspan="1">83</td>
              <td align="center" rowspan="1" colspan="1">86</td>
              <td align="left" rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1"> Hispanic</td>
              <td align="center" rowspan="1" colspan="1">0</td>
              <td align="center" rowspan="1" colspan="1">7</td>
              <td align="left" rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1"> Black</td>
              <td align="center" rowspan="1" colspan="1">17</td>
              <td align="center" rowspan="1" colspan="1">3</td>
              <td align="left" rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1"> Other</td>
              <td align="center" rowspan="1" colspan="1">0</td>
              <td align="center" rowspan="1" colspan="1">4</td>
              <td align="left" rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1">Tanner stage (%)</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="center" rowspan="1" colspan="1">0.74<xref ref-type="table-fn" rid="t1n1"><sup>a</sup></xref></td>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1"> Tanner 2</td>
              <td align="center" rowspan="1" colspan="1">8</td>
              <td align="center" rowspan="1" colspan="1">4</td>
              <td align="left" rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1"> Tanner 3</td>
              <td align="center" rowspan="1" colspan="1">8</td>
              <td align="center" rowspan="1" colspan="1">13</td>
              <td align="left" rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1"> Tanner 4</td>
              <td align="center" rowspan="1" colspan="1">38</td>
              <td align="center" rowspan="1" colspan="1">26</td>
              <td align="left" rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1"> Tanner 5</td>
              <td align="center" rowspan="1" colspan="1">46</td>
              <td align="center" rowspan="1" colspan="1">57</td>
              <td align="left" rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td>
              <td align="center" rowspan="1" colspan="1">20.6 ± 2.4</td>
              <td align="center" rowspan="1" colspan="1">22.9 ± 4.7</td>
              <td align="center" rowspan="1" colspan="1">0.09</td>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1">GIR</td>
              <td align="center" rowspan="1" colspan="1">20.3 ± 4.1</td>
              <td align="center" rowspan="1" colspan="1">11.7 ± 4.3</td>
              <td align="center" rowspan="1" colspan="1">&lt;0.0001</td>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1">HbA<sub>1c</sub> (%)</td>
              <td align="center" rowspan="1" colspan="1">5.0 ± 0.3</td>
              <td align="center" rowspan="1" colspan="1">8.5 ± 1.4</td>
              <td align="center" rowspan="1" colspan="1">&lt;0.0001</td>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1">HbA<sub>1c</sub> (mmol/mol)</td>
              <td align="center" rowspan="1" colspan="1">31.0 ± 3.3</td>
              <td align="center" rowspan="1" colspan="1">69.0 ± 15.3</td>
              <td align="center" rowspan="1" colspan="1">&lt;0.0001</td>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1">SBP (mmHg)</td>
              <td align="center" rowspan="1" colspan="1">109 ± 6</td>
              <td align="center" rowspan="1" colspan="1">116 ± 12</td>
              <td align="center" rowspan="1" colspan="1">0.06</td>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1">DBP (mmHg)</td>
              <td align="center" rowspan="1" colspan="1">62 ± 6</td>
              <td align="center" rowspan="1" colspan="1">69 ± 8</td>
              <td align="center" rowspan="1" colspan="1">0.003</td>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1">LDL-C (mg/dL)</td>
              <td align="center" rowspan="1" colspan="1">81 ± 25</td>
              <td align="center" rowspan="1" colspan="1">82 ± 24</td>
              <td align="center" rowspan="1" colspan="1">0.84</td>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1">Serum creatinine (mg/dL)</td>
              <td align="center" rowspan="1" colspan="1">0.75 ± 0.15</td>
              <td align="center" rowspan="1" colspan="1">0.68 ± 0.15</td>
              <td align="center" rowspan="1" colspan="1">0.14</td>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1">Serum cystatin C (mg/dL)</td>
              <td align="center" rowspan="1" colspan="1">1.00 ± 0.17</td>
              <td align="center" rowspan="1" colspan="1">0.94 ± 0.16</td>
              <td align="center" rowspan="1" colspan="1">0.18</td>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1">eGFR by Bouvet equation (mL/min/1.73 m<sup>2</sup>)</td>
              <td align="center" rowspan="1" colspan="1">89 ± 14</td>
              <td align="center" rowspan="1" colspan="1">101 ± 19</td>
              <td align="center" rowspan="1" colspan="1">0.03</td>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1">ACR<xref ref-type="table-fn" rid="t1n2"><sup>b</sup></xref> (mg/g)</td>
              <td align="center" rowspan="1" colspan="1">7.3 (5.1–9.2)</td>
              <td align="center" rowspan="1" colspan="1">6.7 (4.4–12.9)</td>
              <td align="center" rowspan="1" colspan="1">0.48</td>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1">Mean habitual exercise (METS)</td>
              <td align="center" rowspan="1" colspan="1">58 ± 10</td>
              <td align="center" rowspan="1" colspan="1">64 ± 13</td>
              <td align="center" rowspan="1" colspan="1">0.15</td>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1">VO<sub>2</sub>peak/kg (mL/kg ⋅ min)</td>
              <td align="center" rowspan="1" colspan="1">36.2 ± 7.9</td>
              <td align="center" rowspan="1" colspan="1">31.5 ± 6.3</td>
              <td align="center" rowspan="1" colspan="1">0.046</td>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1">VO<sub>2</sub>peak/lean kg (mL/lean kg ⋅ min)</td>
              <td align="center" rowspan="1" colspan="1">51.0 ± 8.6</td>
              <td align="center" rowspan="1" colspan="1">43.7 ± 7.0</td>
              <td align="center" rowspan="1" colspan="1">0.007</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn>
            <p>Data are reported as LSMs ± SE, unless otherwise indicated. METS, metabolic equivalents.</p>
          </fn>
          <fn id="t1n1">
            <p><sup>a</sup>χ<sup>2</sup> test.</p>
          </fn>
          <fn id="t1n2">
            <p><sup>b</sup>Data are reported as the median (Q25–Q75).</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>In adolescents with type 1 diabetes, eGFR correlated strongly with VO<sub>2</sub>peak (<italic>r</italic> = −0.55, <italic>R</italic><sup>2</sup> = 30.22%, <italic>P</italic> = 0.002) and VO<sub>2</sub>peak/lean kg (<italic>r</italic> = −0.44, <italic>R</italic><sup>2</sup> = 19.58%, <italic>P</italic> = 0.02), and remained significantly associated with VO<sub>2</sub>peak and VO<sub>2</sub>peak/lean kg after adjusting for sex and Tanner stage (<xref ref-type="table" rid="T2">Tables 2</xref> and <xref ref-type="table" rid="T3">3</xref>). Additional adjustments for insulin sensitivity, HbA<sub>1c</sub> level, SBP, or LDL-C level did not attenuate the significance of the associations among eGFR, VO<sub>2</sub>peak, and VO<sub>2</sub>peak/lean kg; however, the association between eGFR and VO<sub>2</sub>peak/lean kg became less significant (<italic>P</italic> = 0.048; <xref ref-type="table" rid="T3">Table 3</xref>). In contrast, the associations between eGFR and VO<sub>2</sub>peak/kg and VO<sub>2</sub>peak/lean kg in adolescent control subjects were not significant in fully adjusted models (data not shown). In contrast to eGFR, LnACR did not correlate with VO<sub>2</sub>peak (β ± SE −1.42 ± 1.49, <italic>P</italic> = 0.35) and VO<sub>2</sub>peak/lean kg (β ± SE −2.24 ± 1.71, <italic>P</italic> = 0.20) when adjusted for sex and Tanner stage.</p>
      <table-wrap id="T2" position="float">
        <label>Table 2</label>
        <caption>
          <p>Associations between eGFR and VO<sub>2</sub>peak/kg</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead valign="bottom">
            <tr>
              <th align="left" scope="col" rowspan="1" colspan="1"/>
              <th align="center" scope="col" rowspan="1" colspan="1">VO<sub>2</sub>peak/kg<xref ref-type="table-fn" rid="t2n1">*</xref></th>
              <th align="center" scope="col" rowspan="1" colspan="1">VO<sub>2</sub>peak/kg<xref ref-type="table-fn" rid="t2n2">†</xref></th>
              <th align="center" scope="col" rowspan="1" colspan="1">VO<sub>2</sub>peak/kg<xref ref-type="table-fn" rid="t2n3">‡</xref></th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1">eGFR by Bouvet equation</td>
              <td align="center" rowspan="1" colspan="1">−0.18 ± 0.05; 0.002</td>
              <td align="center" rowspan="1" colspan="1">−0.18 ± 0.05; 0.002</td>
              <td align="center" rowspan="1" colspan="1">−0.19 ± 0.07; 0.02</td>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1">Tanner stage</td>
              <td align="center" rowspan="1" colspan="1">1.09 ± 1.45; 0.46</td>
              <td align="center" rowspan="1" colspan="1">0.94 ± 1.53; 0.54</td>
              <td align="center" rowspan="1" colspan="1">0.62 ± 1.62; 0.71</td>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1">Female sex</td>
              <td align="center" rowspan="1" colspan="1">−4.92 ± 2.43; 0.06</td>
              <td align="center" rowspan="1" colspan="1">−4.78 ± 2.51; 0.07</td>
              <td align="center" rowspan="1" colspan="1">−4.88 ± 2.70; 0.09</td>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1">GIR</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="center" rowspan="1" colspan="1">0.10 ± 0.24; 0.70</td>
              <td align="center" rowspan="1" colspan="1">0.22 ± 0.27; 0.42</td>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1">HbA<sub>1c</sub></td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="center" rowspan="1" colspan="1">0.66 ± 0.95; 0.49</td>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1">SBP</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="center" rowspan="1" colspan="1">−0.01 ± 0.10; 0.94</td>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1">LDL-C</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="center" rowspan="1" colspan="1">−0.08 ± 0.06; 0.21</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn>
            <p>Data are reported as β ± SE; <italic>P</italic> value. Age was not adjusted for because it is part of the Bouvet eGFR equation.</p>
          </fn>
          <fn id="t2n1">
            <p>*Adjusted for Tanner stage and sex.</p>
          </fn>
          <fn id="t2n2">
            <p>†Adjusted for Tanner stage, sex, and GIR.</p>
          </fn>
          <fn id="t2n3">
            <p>‡Adjusted for Tanner stage, sex, GIR, HbA<sub>1c</sub> level, SBP, and LDL-C level.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <table-wrap id="T3" position="float">
        <label>Table 3</label>
        <caption>
          <p>Associations between eGFR and VO<sub>2</sub>peak/lean kg</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead valign="bottom">
            <tr>
              <th align="left" scope="col" rowspan="1" colspan="1"/>
              <th align="center" scope="col" rowspan="1" colspan="1">VO<sub>2</sub>peak/lean kg<xref ref-type="table-fn" rid="t3n1">*</xref></th>
              <th align="center" scope="col" rowspan="1" colspan="1">VO<sub>2</sub>peak/lean kg<xref ref-type="table-fn" rid="t3n2">†</xref></th>
              <th align="center" scope="col" rowspan="1" colspan="1">VO<sub>2</sub>peak/lean kg<xref ref-type="table-fn" rid="t3n3">‡</xref></th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1">eGFR by Bouvet equation</td>
              <td align="center" rowspan="1" colspan="1">−0.16 ± 0.07; 0.03</td>
              <td align="center" rowspan="1" colspan="1">−0.16 ± 0.07; 0.03</td>
              <td align="center" rowspan="1" colspan="1">−0.19 ± 0.09; 0.048</td>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1">Tanner stage</td>
              <td align="center" rowspan="1" colspan="1">0.73 ± 1.92; 0.71</td>
              <td align="center" rowspan="1" colspan="1">0.70 ± 2.03; 0.73</td>
              <td align="center" rowspan="1" colspan="1">0.12 ± 2.05; 0.96</td>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1">Female sex</td>
              <td align="center" rowspan="1" colspan="1">−1.46 ± 3.22; 0.65</td>
              <td align="center" rowspan="1" colspan="1">−1.46 ± 3.33; 0.67</td>
              <td align="center" rowspan="1" colspan="1">−1.21 ± 3.43; 0.73</td>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1">GIR</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="center" rowspan="1" colspan="1">0.02 ± 0.32; 0.95</td>
              <td align="center" rowspan="1" colspan="1">0.27 ± 0.34; 0.45</td>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1">HbA<sub>1c</sub></td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="center" rowspan="1" colspan="1">1.31 ± 1.20; 0.29</td>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1">SBP</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="center" rowspan="1" colspan="1">0.04 ± 0.13; 0.78</td>
            </tr>
            <tr>
              <td align="left" scope="row" rowspan="1" colspan="1">LDL-C</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="center" rowspan="1" colspan="1">−0.14 ± 0.08; 0.09</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn>
            <p>Data are reported as β ± SE; <italic>P</italic> value. Age not adjusted for because it is part of the Bouvet eGFR equation.</p>
          </fn>
          <fn id="t3n1">
            <p>*Adjusted for Tanner stage and sex.</p>
          </fn>
          <fn id="t3n2">
            <p>†Adjusted for Tanner stage, sex, and GIR.</p>
          </fn>
          <fn id="t3n3">
            <p>‡Adjusted for Tanner stage, sex, GIR, HbA<sub>1c</sub> level, SBP, and LDL-C level.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>When stratifying eGFRs into tertiles, subjects in the highest eGFR tertile had significantly lower VO<sub>2</sub>peak (LSM ± SE 26.91 ± 1.52 vs. 35.53 ± 1.88, <italic>P</italic> = 0.002) and VO<sub>2</sub>peak/lean kg (LSM ± SE 39.65 ± 2.07 vs. 46.18 ± 2.55, <italic>P</italic> = 0.048) adjusted for sex and Tanner stage, compared with those in the lowest eGFR tertile (<xref ref-type="fig" rid="F1">Fig. 1</xref>). Stratifying ACR into tertiles demonstrated no differences in VO<sub>2</sub>peak or VO<sub>2</sub>peak/lean kg among the three groups (data not shown).</p>
      <fig id="F1" fig-type="figure" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Tanner stage– and sex-adjusted means for VO<sub>2</sub>peak/kg and VO<sub>2</sub>peak/lean kg stratified by tertiles of eGFR. Data are presented as LSMs ± SE.</p>
        </caption>
        <graphic xlink:href="126fig1"/>
      </fig>
    </sec>
    <sec sec-type="conclusions" id="s10">
      <title>Conclusions</title>
      <p>Our major observation in this study was that in adolescents with type 1 diabetes, a disease characterized by reduced exercise capacity, eGFR was independently and negatively associated with cardiopulmonary fitness, independent of insulin sensitivity and other important risk factors.</p>
      <p>We previously demonstrated reduced peak exercise capacity, and cardiac and vascular function in otherwise healthy, nonobese adolescents with type 1 diabetes, compared with well-matched nondiabetic control subjects of similar BMI, pubertal stage, and habitual level of physical activity (<xref rid="B11" ref-type="bibr">11</xref>). Furthermore, we found that insulin sensitivity correlated strongly with VO<sub>2</sub>peak in youths with type 1 diabetes, as did LDL-C level to a lesser degree (<xref rid="B11" ref-type="bibr">11</xref>). In this report, we present for the first time an independent relationship between renal health and cardiopulmonary fitness that is independent of insulin sensitivity, LDL-C level, and other important covariates. This association may represent a novel pathway of a cardiorenal connection in type 1 diabetes separate from atherosclerosis. Type 1 diabetes is associated with shortened life span, and cardiac and vascular dysfunction, independent of coronary artery disease (<xref rid="B20" ref-type="bibr">20</xref>). In fact, low fitness levels in adults with and without diabetes are associated with CVD mortality and decreased longevity (<xref rid="B21" ref-type="bibr">21</xref>,<xref rid="B22" ref-type="bibr">22</xref>). Control of conventional risk factors such as glucose level, cholesterol level, and blood pressure is important, but does not abolish the cardiovascular risk in subjects with type 1 diabetes (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B23" ref-type="bibr">23</xref>). Although not without controversy, the Finnish Diabetic Nephropathy Study (<xref rid="B24" ref-type="bibr">24</xref>) and the Pittsburgh Epidemiology of Diabetes Complications Study (<xref rid="B3" ref-type="bibr">3</xref>) demonstrated no increase in mortality in adults with type 1 diabetes compared with nondiabetic control subjects in the absence of DN. In contrast, The Coronary Artery Calcification in Type 1 Diabetes study (<xref rid="B9" ref-type="bibr">9</xref>) demonstrated strong associations among eGFR, ACR, and progression of coronary artery calcification in adults with type 1 diabetes in the absence of established DN, suggesting that renal health may be associated with early cardiovascular pathophysiology that may take years to manifest clinically. The specific mechanisms underlying the association between renal and cardiovascular health, however, remain unclear, but increasing evidence supports the importance of shared risk factors and pathogenic pathways, including atherosclerosis (<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B25" ref-type="bibr">25</xref>–<xref rid="B28" ref-type="bibr">28</xref>). Reduced exercise capacity and its association with renal health highlighted in this article, taken together with the established relationship between fitness and premature CVD mortality, may provide an alternative and novel pathway explaining the premature mortality of subjects with type 1 diabetes (<xref rid="B21" ref-type="bibr">21</xref>,<xref rid="B22" ref-type="bibr">22</xref>).</p>
      <p>There is currently no generally accepted definition for renal hyperfiltration (<xref rid="B29" ref-type="bibr">29</xref>), but it is increasingly recognized that elevated GFR is an early hemodynamic abnormality seen in diabetes that is linked with an increased risk of DN (<xref rid="B1" ref-type="bibr">1</xref>). The meta-analysis from the Chronic Kidney Disease Prognosis Consortium (<xref rid="B30" ref-type="bibr">30</xref>,<xref rid="B31" ref-type="bibr">31</xref>) demonstrated significantly greater all-cause mortality and cardiovascular mortality in individuals with the highest GFR values (&gt;105 mL/min/1.73 m<sup>2</sup>). Similarly, the Renal Iohexol Clearance Survey in Tromso 6 (RENIS-T6) recently reported (<xref rid="B13" ref-type="bibr">13</xref>) significantly greater odds of both carotid atherosclerosis and left ventricular hypertrophy in participants in the highest GFR quartile (&gt;101.2 mL/min/1.73 m<sup>2</sup>). It is, however, also plausible that the mechanisms underlying the association between renal health and exercise capacity in adolescents with type 1 diabetes differ from the link seen with atherosclerosis. The mechanisms responsible for the relationship between renal health and exercise capacity are not yet clear. Adults with type 1 diabetes and elevated GFR demonstrate cardiovascular dysfunction, including increases in arterial stiffness and altered flow-mediated dilatation (<xref rid="B32" ref-type="bibr">32</xref>,<xref rid="B33" ref-type="bibr">33</xref>). We previously demonstrated reduced forearm blood flow in youths with type 1 diabetes (<xref rid="B11" ref-type="bibr">11</xref>) as evidence of vascular dysfunction, which correlated with reduced VO<sub>2</sub>peak. Moreover, alterations in arterial stiffness have also been reported to be present in youths with type 1 diabetes (<xref rid="B34" ref-type="bibr">34</xref>). Elevated GFR is associated with endothelial dysfunction via cyclooxygenase-2 activity and nitric oxide synthase inhibition, and relatively higher blood pressures (<xref rid="B35" ref-type="bibr">35</xref>–<xref rid="B37" ref-type="bibr">37</xref>), both of which could directly impact exercise capacity. Elevated GFR is also associated with increased carotid intimal medial thickness and left ventricular hypertrophy in nondiabetic individuals, further suggesting that increased GFR potentially reflects a generalized change in vascular function rather than simply reflecting intrarenal abnormalities (<xref rid="B13" ref-type="bibr">13</xref>). Endothelial dysfunction could also contribute to elevated GFR, thus the relationships could be bidirectional. We did not observe a significant association between ACR and peak exercise capacity, potentially because increasing evidence supports the distinction of albuminuria as a risk factor for DN and not an early phenotype of DN (<xref rid="B38" ref-type="bibr">38</xref>). Furthermore, the prevalence of microalbuminuria (<italic>n</italic> = 9) was low due to the young age of our population.</p>
      <p>Our study does have important limitations. First, our sample size was relatively small. However, to minimize the effect of sample size, we used careful and detailed physiological measurements, including gold standard fitness testing and hyperinsulinemic-euglycemic clamp studies. We also chose groups similar in habitual physical activity, pubertal stage, sex, and BMI, and controlled for prestudy diet and physical activity. Another limitation to the current study included the cross-sectional design, which prevents the determination of causality, and whether the association holds true longitudinally; for that reason, the data should be viewed as hypothesis generating. The direction of the association between renal health and exercise capacity (i.e., whether renal health leads to reduced exercise capacity or vice versa) is also difficult to determine with the available data. Results from this study may also not be generalizable to older people with type 1 diabetes or to cohorts with a different ethnic distribution. Finally, we used an estimate of GFR to assess renal function; however, to estimate the GFR we used the Bouvet equation, which was shown to have the best performance in estimating GFR in children and adolescents with normal to elevated GFRs (<xref rid="B18" ref-type="bibr">18</xref>). The mean eGFR in our lean nondiabetic control subjects is slightly lower than GFRs measured by insulin level in adolescents in some studies (<xref rid="B39" ref-type="bibr">39</xref>), but is consistent with GFRs estimated by creatinine and cystatin C levels in adolescents in large-scale studies (<xref rid="B40" ref-type="bibr">40</xref>).</p>
      <p>In conclusion, in adolescents with type 1 diabetes, a disease characterized by reduced peak exercise capacity compared with nondiabetic adolescents, there was a strong relationship between eGFR and cardiopulmonary fitness, independent of directly measured insulin sensitivity and other important risk factors. This observation provides further evidence for the broad interactions observed between renal and cardiovascular function in type 1 diabetes. Further research is needed to investigate the longitudinal relationships between renal and cardiopulmonary health in adolescents with type 1 diabetes, and to elucidate the specific mechanisms underlying this relationship as potential therapeutic targets.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Article Information</title>
      <p><bold>Funding.</bold> Support for this study was provided by National Center for Research Resources grant K23-RR-020038-01, National Institutes of Health (NIH)-Building Interdisciplinary Research Careers in Women's Health grant K12-5K12-HD-057022-04, American Diabetes Association grants 7-11-CD-08 and 1-11-JF-23, JDRF Award 11-2010-343, NIH-Department of Health and Human Services grant R56-DK-088971, NIH-National Center for Advancing Translational Sciences-Colorado Clinical and Translational Sciences Institute grant UL1-TR-000154, the Center for Women’s Health Research, and a U.S. Department of Veterans Affairs Merit Review Award.</p>
      <p><bold>Duality of Interest.</bold> No potential conflicts of interest relevant to this article were reported.</p>
      <p><bold>Author Contributions.</bold> P.B. researched, wrote, and formulated the analytic plan; contributed to the discussion and analytic plan; and reviewed and edited the manuscript. M.C.-G. and A.B. contributed to the research, and reviewed and edited the manuscript. D.M.M. and D.Z.C. contributed to the discussion and analytic plan and reviewed and edited the manuscript. L.P. reviewed and edited the analytic plan and the manuscript. J.G.R. and J.E.R. contributed to the discussion and reviewed and edited the manuscript. K.J.N. contributed to the research and the discussion and helped to write, review, and edit the manuscript. P.B. and K.J.N. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bjornstad</surname><given-names>P</given-names></name><name><surname>Cherney</surname><given-names>D</given-names></name><name><surname>Maahs</surname><given-names>DM</given-names></name></person-group>. <article-title>Early diabetic nephropathy in type 1 diabetes: new insights</article-title>. <source>Curr Opin Endocrinol Diabetes Obes</source>
<year>2014</year>;<volume>21</volume>:<fpage>279</fpage>–<lpage>286</lpage><?supplied-pmid 24983394?><pub-id pub-id-type="pmid">24983394</pub-id></mixed-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bjornstad</surname><given-names>P</given-names></name><name><surname>Wadwa</surname><given-names>RP</given-names></name></person-group>. <article-title>Risks and benefits of statin use in young people with type 1 diabetes</article-title>. <source>Curr Diab Rep</source>
<year>2014</year>;<volume>14</volume>:<fpage>499</fpage><?supplied-pmid 24796934?><pub-id pub-id-type="pmid">24796934</pub-id></mixed-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orchard</surname><given-names>TJ</given-names></name><name><surname>Secrest</surname><given-names>AM</given-names></name><name><surname>Miller</surname><given-names>RG</given-names></name><name><surname>Costacou</surname><given-names>T</given-names></name></person-group>. <article-title>In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study</article-title>. <source>Diabetologia</source>
<year>2010</year>;<volume>53</volume>:<fpage>2312</fpage>–<lpage>2319</lpage><?supplied-pmid 20665208?><pub-id pub-id-type="pmid">20665208</pub-id></mixed-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bjornstad</surname><given-names>P</given-names></name><name><surname>Maahs</surname><given-names>DM</given-names></name><name><surname>Rivard</surname><given-names>CJ</given-names></name><etal/></person-group>. <article-title>Serum uric acid predicts vascular complications in adults with type 1 diabetes: the coronary artery calcification in type 1 diabetes study</article-title>. <source>Acta Diabetol</source>
<year>2014</year>;<volume>51</volume>:<fpage>783</fpage>–<lpage>791</lpage><?supplied-pmid 24929955?><pub-id pub-id-type="pmid">24929955</pub-id></mixed-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bjornstad</surname><given-names>P</given-names></name><name><surname>Maahs</surname><given-names>D</given-names></name><name><surname>Rewers</surname><given-names>M</given-names></name><name><surname>Johnson</surname><given-names>RJ</given-names></name><name><surname>Snell-Bergeon</surname><given-names>J</given-names></name></person-group>
<article-title>ABC goal achievement predicts microvascular but not macrovascular complications over 6-years in adults with type 1 diabetes: the Coronary Artery Calcification in Type 1 Diabetes Study</article-title>. <source>J Diabetes Complications</source>. 4 July <year>2014</year> [Epub ahead of print]</mixed-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>MC</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Klotho deficiency causes vascular calcification in chronic kidney disease</article-title>. <source>J Am Soc Nephrol</source>
<year>2011</year>;<volume>22</volume>:<fpage>124</fpage>–<lpage>136</lpage><?supplied-pmid 21115613?><pub-id pub-id-type="pmid">21115613</pub-id></mixed-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>K</given-names></name><name><surname>Lu</surname><given-names>TS</given-names></name><name><surname>Molostvov</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23</article-title>. <source>Circulation</source>
<year>2012</year>;<volume>125</volume>:<fpage>2243</fpage>–<lpage>2255</lpage><?supplied-pmid 22492635?><pub-id pub-id-type="pmid">22492635</pub-id></mixed-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>HC</given-names></name><name><surname>Guh</surname><given-names>JY</given-names></name><name><surname>Chang</surname><given-names>JM</given-names></name><name><surname>Hsieh</surname><given-names>MC</given-names></name><name><surname>Shin</surname><given-names>SJ</given-names></name><name><surname>Lai</surname><given-names>YH</given-names></name></person-group>. <article-title>Role of lipid control in diabetic nephropathy</article-title>. <source>Kidney Int Suppl</source>
<year>2005</year>:<fpage>S60</fpage>–<lpage>S62</lpage><?supplied-pmid 15752242?><pub-id pub-id-type="pmid">15752242</pub-id></mixed-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maahs</surname><given-names>DM</given-names></name><name><surname>Jalal</surname><given-names>D</given-names></name><name><surname>Chonchol</surname><given-names>M</given-names></name><name><surname>Johnson</surname><given-names>RJ</given-names></name><name><surname>Rewers</surname><given-names>M</given-names></name><name><surname>Snell-Bergeon</surname><given-names>JK</given-names></name></person-group>. <article-title>Impaired renal function further increases odds of 6-year coronary artery calcification progression in adults with type 1 diabetes: the CACTI study</article-title>. <source>Diabetes Care</source>
<year>2013</year>;<volume>36</volume>:<fpage>2607</fpage>–<lpage>2614</lpage><?supplied-pmid 23835686?><pub-id pub-id-type="pmid">23835686</pub-id></mixed-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGill</surname><given-names>HC</given-names><suffix>Jr</suffix></name><name><surname>McMahan</surname><given-names>CA</given-names></name><name><surname>Zieske</surname><given-names>AW</given-names></name><name><surname>Malcom</surname><given-names>GT</given-names></name><name><surname>Tracy</surname><given-names>RE</given-names></name><name><surname>Strong</surname><given-names>JP</given-names></name></person-group>. <article-title>Effects of nonlipid risk factors on atherosclerosis in youth with a favorable lipoprotein profile</article-title>. <source>Circulation</source>
<year>2001</year>;<volume>103</volume>:<fpage>1546</fpage>–<lpage>1550</lpage><?supplied-pmid 11257083?><pub-id pub-id-type="pmid">11257083</pub-id></mixed-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nadeau</surname><given-names>KJ</given-names></name><name><surname>Regensteiner</surname><given-names>JG</given-names></name><name><surname>Bauer</surname><given-names>TA</given-names></name><etal/></person-group>. <article-title>Insulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function</article-title>. <source>J Clin Endocrinol Metab</source>
<year>2010</year>;<volume>95</volume>:<fpage>513</fpage>–<lpage>521</lpage><?supplied-pmid 19915016?><pub-id pub-id-type="pmid">19915016</pub-id></mixed-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daniels</surname><given-names>M</given-names></name><name><surname>DuBose</surname><given-names>SN</given-names></name><name><surname>Maahs</surname><given-names>DM</given-names></name><etal/><collab>T1D Exchange Clinic Network</collab></person-group>. <article-title>Factors associated with microalbuminuria in 7,549 children and adolescents with type 1 diabetes in the T1D Exchange clinic registry</article-title>. <source>Diabetes Care</source>
<year>2013</year>;<volume>36</volume>:<fpage>2639</fpage>–<lpage>2645</lpage><?supplied-pmid 23610082?><pub-id pub-id-type="pmid">23610082</pub-id></mixed-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eriksen</surname><given-names>BO</given-names></name><name><surname>Løchen</surname><given-names>ML</given-names></name><name><surname>Arntzen</surname><given-names>KA</given-names></name><etal/></person-group>. <article-title>Subclinical cardiovascular disease is associated with a high glomerular filtration rate in the nondiabetic general population</article-title>. <source>Kidney Int</source>
<year>2014</year>;<volume>86</volume>:<fpage>146</fpage>–<lpage>153</lpage><?supplied-pmid 24304885?><pub-id pub-id-type="pmid">24304885</pub-id></mixed-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>WA</given-names></name><name><surname>Tanner</surname><given-names>JM</given-names></name></person-group>. <article-title>Variations in the pattern of pubertal changes in boys</article-title>. <source>Arch Dis Child</source>
<year>1970</year>;<volume>45</volume>:<fpage>13</fpage>–<lpage>23</lpage><?supplied-pmid 19584191?><pub-id pub-id-type="pmid">5440182</pub-id></mixed-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nadeau</surname><given-names>KJ</given-names></name><name><surname>Zeitler</surname><given-names>PS</given-names></name><name><surname>Bauer</surname><given-names>TA</given-names></name><etal/></person-group>. <article-title>Insulin resistance in adolescents with type 2 diabetes is associated with impaired exercise capacity</article-title>. <source>J Clin Endocrinol Metab</source>
<year>2009</year>;<volume>94</volume>:<fpage>3687</fpage>–<lpage>3695</lpage><?supplied-pmid 19584191?><pub-id pub-id-type="pmid">19584191</pub-id></mixed-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherney</surname><given-names>DZ</given-names></name><name><surname>Reich</surname><given-names>HN</given-names></name><name><surname>Miller</surname><given-names>JA</given-names></name><etal/></person-group>. <article-title>Age is a determinant of acute hemodynamic responses to hyperglycemia and angiotensin II in humans with uncomplicated type 1 diabetes mellitus</article-title>. <source>Am J Physiol Regul Integr Comp Physiol</source>
<year>2010</year>;<volume>299</volume>:<fpage>R206</fpage>–<lpage>R214</lpage><?supplied-pmid 20410477?><pub-id pub-id-type="pmid">20410477</pub-id></mixed-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bjornstad</surname><given-names>P</given-names></name><name><surname>McQueen</surname><given-names>RB</given-names></name><name><surname>Snell-Bergeon</surname><given-names>JK</given-names></name><etal/></person-group>. <article-title>Fasting blood glucose—a missing variable for GFR-estimation in type 1 diabetes</article-title>? <source>PLoS One</source>
<year>2014</year>;<volume>9</volume>:<fpage>e96264</fpage><?supplied-pmid 24781861?><pub-id pub-id-type="pmid">24781861</pub-id></mixed-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maahs</surname><given-names>DM</given-names></name><name><surname>Bushman</surname><given-names>L</given-names></name><name><surname>Kerr</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>A practical method to measure GFR in people with type 1 diabetes</article-title>. <source>J Diabetes Complications</source>
<year>2014</year>;<volume>28</volume>:<fpage>667</fpage>–<lpage>673</lpage><?supplied-pmid 25027389?><pub-id pub-id-type="pmid">25027389</pub-id></mixed-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>AP</given-names></name><name><surname>Yasin</surname><given-names>A</given-names></name><name><surname>Garg</surname><given-names>AX</given-names></name><name><surname>Filler</surname><given-names>G</given-names></name></person-group>. <article-title>Diagnostic accuracy of cystatin C-based eGFR equations at different GFR levels in children</article-title>. <source>Clin J Am Soc Nephrol</source>
<year>2011</year>;<volume>6</volume>:<fpage>1599</fpage>–<lpage>1608</lpage><?supplied-pmid 21700821?><pub-id pub-id-type="pmid">21700821</pub-id></mixed-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poirier</surname><given-names>P</given-names></name><name><surname>Garneau</surname><given-names>C</given-names></name><name><surname>Bogaty</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Impact of left ventricular diastolic dysfunction on maximal treadmill performance in normotensive subjects with well-controlled type 2 diabetes mellitus</article-title>. <source>Am J Cardiol</source>
<year>2000</year>;<volume>85</volume>:<fpage>473</fpage>–<lpage>477</lpage><?supplied-pmid 10728953?><pub-id pub-id-type="pmid">10728953</pub-id></mixed-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Church</surname><given-names>TS</given-names></name><name><surname>LaMonte</surname><given-names>MJ</given-names></name><name><surname>Barlow</surname><given-names>CE</given-names></name><name><surname>Blair</surname><given-names>SN</given-names></name></person-group>. <article-title>Cardiorespiratory fitness and body mass index as predictors of cardiovascular disease mortality among men with diabetes</article-title>. <source>Arch Intern Med</source>
<year>2005</year>;<volume>165</volume>:<fpage>2114</fpage>–<lpage>2120</lpage><?supplied-pmid 16217001?><pub-id pub-id-type="pmid">16217001</pub-id></mixed-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Booth</surname><given-names>FW</given-names></name><name><surname>Laye</surname><given-names>MJ</given-names></name><name><surname>Roberts</surname><given-names>MD</given-names></name></person-group>. <article-title>Lifetime sedentary living accelerates some aspects of secondary aging</article-title>. <source>J Appl Physiol (1985)</source>
<year>2011</year>;<volume>111</volume>:<fpage>1497</fpage>–<lpage>1504</lpage><?supplied-pmid 21836048?><pub-id pub-id-type="pmid">21836048</pub-id></mixed-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>JR</given-names></name><name><surname>Miller</surname><given-names>KM</given-names></name><name><surname>Maahs</surname><given-names>DM</given-names></name><etal/><collab>T1D Exchange Clinic Network</collab></person-group>. <article-title>Most youth with type 1 diabetes in the T1D Exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines</article-title>. <source>Diabetes Care</source>
<year>2013</year>;<volume>36</volume>:<fpage>2035</fpage>–<lpage>2037</lpage><?supplied-pmid 23340893?><pub-id pub-id-type="pmid">23340893</pub-id></mixed-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groop</surname><given-names>PH</given-names></name><name><surname>Thomas</surname><given-names>MC</given-names></name><name><surname>Moran</surname><given-names>JL</given-names></name><etal/><collab>FinnDiane Study Group</collab></person-group>. <article-title>The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes</article-title>. <source>Diabetes</source>
<year>2009</year>;<volume>58</volume>:<fpage>1651</fpage>–<lpage>1658</lpage><?supplied-pmid 19401416?><pub-id pub-id-type="pmid">19401416</pub-id></mixed-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bjornstad</surname><given-names>P</given-names></name><name><surname>Snell-Bergeon</surname><given-names>JK</given-names></name><name><surname>Rewers</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Early diabetic nephropathy: a complication of reduced insulin sensitivity in type 1 diabetes</article-title>. <source>Diabetes Care</source>
<year>2013</year>;<volume>36</volume>:<fpage>3678</fpage>–<lpage>3683</lpage><?supplied-pmid 24026551?><pub-id pub-id-type="pmid">24026551</pub-id></mixed-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Specht</surname><given-names>BJ</given-names></name><name><surname>Wadwa</surname><given-names>RP</given-names></name><name><surname>Snell-Bergeon</surname><given-names>JK</given-names></name><name><surname>Nadeau</surname><given-names>KJ</given-names></name><name><surname>Bishop</surname><given-names>FK</given-names></name><name><surname>Maahs</surname><given-names>DM</given-names></name></person-group>. <article-title>Estimated insulin sensitivity and cardiovascular disease risk factors in adolescents with and without type 1 diabetes</article-title>. <source>J Pediatr</source>
<year>2013</year>;<volume>162</volume>:<fpage>297</fpage>–<lpage>301</lpage><?supplied-pmid 22921593?><pub-id pub-id-type="pmid">22921593</pub-id></mixed-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welsh</surname><given-names>P</given-names></name><name><surname>Woodward</surname><given-names>M</given-names></name><name><surname>Hillis</surname><given-names>GS</given-names></name><etal/></person-group>. <article-title>Do cardiac biomarkers NT-proBNP and hsTnT predict microvascular events in patients with type 2 diabetes? Results from the ADVANCE trial</article-title>. <source>Diabetes Care</source>
<year>2014</year>;<volume>37</volume>:<fpage>2202</fpage>–<lpage>2210</lpage><?supplied-pmid 24879844?><pub-id pub-id-type="pmid">24879844</pub-id></mixed-citation>
      </ref>
      <ref id="B28">
        <label>28</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riphagen</surname><given-names>IJ</given-names></name><name><surname>Boertien</surname><given-names>WE</given-names></name><name><surname>Alkhalaf</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular and all-cause mortality in patients with type 2 diabetes (ZODIAC-31)</article-title>. <source>Diabetes Care</source>
<year>2013</year>;<volume>36</volume>:<fpage>3201</fpage>–<lpage>3207</lpage><?supplied-pmid 23757433?><pub-id pub-id-type="pmid">23757433</pub-id></mixed-citation>
      </ref>
      <ref id="B29">
        <label>29</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sunder-Plassmann</surname><given-names>G</given-names></name><name><surname>Horl</surname><given-names>WH</given-names></name></person-group>
<article-title>A critical appraisal for definition of hyperfiltration</article-title>. <source>Am J Kidney Dis</source>
<year>2004</year>;<volume>43</volume>:<fpage>396</fpage><pub-id pub-id-type="pmid">14750109</pub-id></mixed-citation>
      </ref>
      <ref id="B30">
        <label>30</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsushita</surname><given-names>K</given-names></name><name><surname>van der Velde</surname><given-names>M</given-names></name><name><surname>Astor</surname><given-names>BC</given-names></name><etal/><collab>Chronic Kidney Disease Prognosis Consortium</collab></person-group>. <article-title>Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis</article-title>. <source>Lancet</source>
<year>2010</year>;<volume>375</volume>:<fpage>2073</fpage>–<lpage>2081</lpage><?supplied-pmid 20483451?><pub-id pub-id-type="pmid">20483451</pub-id></mixed-citation>
      </ref>
      <ref id="B31">
        <label>31</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rognant</surname><given-names>N</given-names></name><name><surname>Laville</surname><given-names>M</given-names></name></person-group>. <article-title>To live with normal GFR: when higher is not better</article-title>. <source>Kidney Int</source>
<year>2014</year>;<volume>86</volume>:<fpage>10</fpage>–<lpage>13</lpage><?supplied-pmid 24978375?><pub-id pub-id-type="pmid">24978375</pub-id></mixed-citation>
      </ref>
      <ref id="B32">
        <label>32</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherney</surname><given-names>DZ</given-names></name><name><surname>Miller</surname><given-names>JA</given-names></name><name><surname>Scholey</surname><given-names>JW</given-names></name><etal/></person-group>. <article-title>Renal hyperfiltration is a determinant of endothelial function responses to cyclooxygenase 2 inhibition in type 1 diabetes</article-title>. <source>Diabetes Care</source>
<year>2010</year>;<volume>33</volume>:<fpage>1344</fpage>–<lpage>1346</lpage><?supplied-pmid 20332349?><pub-id pub-id-type="pmid">20332349</pub-id></mixed-citation>
      </ref>
      <ref id="B33">
        <label>33</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherney</surname><given-names>DZ</given-names></name><name><surname>Sochett</surname><given-names>EB</given-names></name><name><surname>Lai</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Renal hyperfiltration and arterial stiffness in humans with uncomplicated type 1 diabetes</article-title>. <source>Diabetes Care</source>
<year>2010</year>;<volume>33</volume>:<fpage>2068</fpage>–<lpage>2070</lpage><?supplied-pmid 20585001?><pub-id pub-id-type="pmid">20585001</pub-id></mixed-citation>
      </ref>
      <ref id="B34">
        <label>34</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaiswal</surname><given-names>M</given-names></name><name><surname>Urbina</surname><given-names>EM</given-names></name><name><surname>Wadwa</surname><given-names>RP</given-names></name><etal/></person-group>. <article-title>Reduced heart rate variability is associated with increased arterial stiffness in youth with type 1 diabetes: the SEARCH CVD study</article-title>. <source>Diabetes Care</source>
<year>2013</year>;<volume>36</volume>:<fpage>2351</fpage>–<lpage>2358</lpage><?supplied-pmid 23435158?><pub-id pub-id-type="pmid">23435158</pub-id></mixed-citation>
      </ref>
      <ref id="B35">
        <label>35</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherney</surname><given-names>DZ</given-names></name><name><surname>Reich</surname><given-names>HN</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Hyperfiltration and effect of nitric oxide inhibition on renal and endothelial function in humans with uncomplicated type 1 diabetes mellitus</article-title>. <source>Am J Physiol Regul Integr Comp Physiol</source>
<year>2012</year>;<volume>303</volume>:<fpage>R710</fpage>–<lpage>R718</lpage><?supplied-pmid 22855276?><pub-id pub-id-type="pmid">22855276</pub-id></mixed-citation>
      </ref>
      <ref id="B36">
        <label>36</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>GK</given-names></name><name><surname>Maahs</surname><given-names>DM</given-names></name><name><surname>Perkins</surname><given-names>BA</given-names></name><name><surname>Cherney</surname><given-names>DZI</given-names></name></person-group>. <article-title>Renal hyperfiltration and systemic blood pressure in patients with uncomplicated type 1 diabetes mellitus</article-title>. <source>PLoS One</source>
<year>2013</year>;<volume>8</volume>:<fpage>e68908</fpage><?supplied-pmid 23861950?><pub-id pub-id-type="pmid">23861950</pub-id></mixed-citation>
      </ref>
      <ref id="B37">
        <label>37</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pecis</surname><given-names>M</given-names></name><name><surname>Azevedo</surname><given-names>MJ</given-names></name><name><surname>Gross</surname><given-names>JL</given-names></name></person-group>. <article-title>Glomerular hyperfiltration is associated with blood pressure abnormalities in normotensive normoalbuminuric IDDM patients</article-title>. <source>Diabetes Care</source>
<year>1997</year>;<volume>20</volume>:<fpage>1329</fpage>–<lpage>1333</lpage><?supplied-pmid 9250464?><pub-id pub-id-type="pmid">9250464</pub-id></mixed-citation>
      </ref>
      <ref id="B38">
        <label>38</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakris</surname><given-names>GL</given-names></name><name><surname>Molitch</surname><given-names>M</given-names></name></person-group>. <article-title>Microalbuminuria as a risk predictor in diabetes: the continuing saga</article-title>. <source>Diabetes Care</source>
<year>2014</year>;<volume>37</volume>:<fpage>867</fpage>–<lpage>875</lpage><?supplied-pmid 24558077?><pub-id pub-id-type="pmid">24558077</pub-id></mixed-citation>
      </ref>
      <ref id="B39">
        <label>39</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>GJ</given-names></name><name><surname>Work</surname><given-names>DF</given-names></name></person-group>. <article-title>Measurement and estimation of GFR in children and adolescents</article-title>. <source>Clin J Am Soc Nephrol</source>
<year>2009</year>;<volume>4</volume>:<fpage>1832</fpage>–<lpage>1843</lpage><?supplied-pmid 19820136?><pub-id pub-id-type="pmid">19820136</pub-id></mixed-citation>
      </ref>
      <ref id="B40">
        <label>40</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chavers</surname><given-names>BM</given-names></name><name><surname>Rheault</surname><given-names>MN</given-names></name><name><surname>Foley</surname><given-names>RN</given-names></name></person-group>. <article-title>Kidney function reference values in US adolescents: National Health And Nutrition Examination Survey 1999-2008</article-title>. <source>Clin J Am Soc Nephrol</source>
<year>2011</year>;<volume>6</volume>:<fpage>1956</fpage>–<lpage>1962</lpage><?supplied-pmid 21784824?><pub-id pub-id-type="pmid">21784824</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:4274776</identifier><datestamp>2016-01-01</datestamp><setSpec>diacare</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="http://jats.nlm.nih.gov/ns/archiving/1.0/ http://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Diabetes Care</journal-id>
      <journal-id journal-id-type="iso-abbrev">Diabetes Care</journal-id>
      <journal-id journal-id-type="hwp">diacare</journal-id>
      <journal-id journal-id-type="pmc">dcare</journal-id>
      <journal-id journal-id-type="publisher-id">Diabetes Care</journal-id>
      <journal-title-group>
        <journal-title>Diabetes Care</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0149-5992</issn>
      <issn pub-type="epub">1935-5548</issn>
      <publisher>
        <publisher-name>American Diabetes Association</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4274776</article-id>
      <article-id pub-id-type="pmcid">PMC4274776</article-id>
      <article-id pub-id-type="pmc-uid">4274776</article-id>
      <article-id pub-id-type="pmid">25414154</article-id>
      <article-id pub-id-type="publisher-id">1861</article-id>
      <article-id pub-id-type="doi">10.2337/dc14-1861</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Clinical Care/Education/Nutrition/Psychosocial Research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Neuronal T-Cell Autoreactivity Is Amplified in Overweight Children With New-Onset Insulin-Requiring Diabetes</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Buryk</surname>
            <given-names>Melissa A.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dosch</surname>
            <given-names>H-Michael</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Libman</surname>
            <given-names>Ingrid</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Arena</surname>
            <given-names>Vincent C.</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Huang</surname>
            <given-names>Yihe</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cheung</surname>
            <given-names>Roy K.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Trucco</surname>
            <given-names>Massimo</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pietropaolo</surname>
            <given-names>Massimo</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Becker</surname>
            <given-names>Dorothy J.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
        <aff id="aff1"><sup>1</sup>Department of Pediatrics, Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA</aff>
        <aff id="aff2"><sup>2</sup>Neurosciences and Mental Health Program, Hospital for Sick Children, Toronto, Ontario, Canada</aff>
        <aff id="aff3"><sup>3</sup>Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA</aff>
        <aff id="aff4"><sup>4</sup>Department of Immunology, University of Michigan, Ann Arbor, MI</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">Corresponding author: Dorothy J. Becker, <email>dorothy.becker@chp.edu</email>.</corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>20</day>
        <month>11</month>
        <year>2014</year>
      </pub-date>
      <volume>38</volume>
      <issue>1</issue>
      <fpage>43</fpage>
      <lpage>50</lpage>
      <history>
        <date date-type="received">
          <day>1</day>
          <month>8</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>16</day>
          <month>10</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.</copyright-statement>
        <copyright-year>2015</copyright-year>
      </permissions>
      <self-uri xlink:title="pdf" xlink:type="simple" xlink:href="43.pdf"/>
      <abstract>
        <sec>
          <title>OBJECTIVE</title>
          <p>Disease-associated T-cell autoreactivities are seen in most type 1 diabetic patients and are thought to emerge before islet autoantibodies, but host factors that impact autoimmune elements remain uncertain. We assessed if adiposity and measures of insulin sensitivity impact T- and B-cell autoimmunity in children with insulin-requiring diabetes.</p>
        </sec>
        <sec>
          <title>RESEARCH DESIGN AND METHODS</title>
          <p>Insulin-requiring children and adolescents diagnosed between January 2004 and June 2008 were studied (<italic>n</italic> = 261): age 9.7 ± 4 years, 92% white, and 60% male. T-cell responses to 10 diabetes-associated antigens, β-cell autoantibodies (GADA, IA-2A, IAA, and ICA), BMI <italic>z</italic> score (BMIz), and waist percentile were measured at onset and 3 months later.</p>
        </sec>
        <sec>
          <title>RESULTS</title>
          <p>All but one subject had either T- or B-cell autoimmunity. Diabetes-associated T-cell autoreactivities were found in 92% of subjects. Higher amplitude T-cell autoreactivities to neuronal diabetes-associated autoantigens were seen in those with the highest BMIz quintile, BMI ≥85th percentile (<italic>P</italic> &lt; 0.05), and waist circumference ≥85th percentile (<italic>P</italic> &lt; 0.05). There were no relationships between the number of T-cell reactivities or T-cell diversity with adiposity measures or autoantibody number or type. Patients with positive T-cell reactivities but without autoantibodies had the highest BMIz (<italic>P</italic> = 0.006).</p>
        </sec>
        <sec>
          <title>CONCLUSIONS</title>
          <p>Our observations link obesity and diabetes-related autoimmunity, suggesting an amplification of neuronal T-cell autoimmunity associated with adiposity and/or insulin resistance, with obesity-related inflammation possibly enhancing islet autoimmunity.</p>
        </sec>
      </abstract>
      <counts>
        <page-count count="8"/>
      </counts>
    </article-meta>
  </front>
  <body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Type 1a diabetes is defined by autoimmune-mediated β-cell dysfunction and destruction (<xref rid="B1" ref-type="bibr">1</xref>). Immune markers of autoimmune diabetes have historically centered on the presence of serum autoantibodies to islet antigens (<xref rid="B2" ref-type="bibr">2</xref>) as markers of autoimmune destruction and physiological mediators of lesion repair (<xref rid="B3" ref-type="bibr">3</xref>). However, in 5–15% of new-onset type 1 diabetic patients, conventional islet autoantibodies are absent (<xref rid="B4" ref-type="bibr">4</xref>–<xref rid="B6" ref-type="bibr">6</xref>), similar to many first-degree relatives (FDRs) with high-risk HLA haplotypes who develop diabetes (<xref rid="B7" ref-type="bibr">7</xref>). Diabetes-selective T-cell reactivities to islet cell, neuronal, and environmental analytes are present at onset of type 1 diabetes (<xref rid="B8" ref-type="bibr">8</xref>). Similar diabetes-selective T-cell reactivities to islet cell proteins have been demonstrated in children (<xref rid="B9" ref-type="bibr">9</xref>) and adults with clinical type 2 diabetes regardless of autoantibody status (<xref rid="B10" ref-type="bibr">10</xref>) and have been associated with significantly low C-peptide levels in adults (<xref rid="B10" ref-type="bibr">10</xref>). Similar T-cell findings have been documented in type 1 diabetes–prone NOD mice (<xref rid="B11" ref-type="bibr">11</xref>) and B6 mice with diet-induced obesity, as well as in obese adults with the metabolic syndrome or clinically diagnosed type 2 diabetes (<xref rid="B12" ref-type="bibr">12</xref>). Each of these studies documents an adipose tissue–based, but ultimately systemic, autoimmune response (<xref rid="B13" ref-type="bibr">13</xref>).</p><p>The global rise of obesity is mirrored in cohorts of pediatric type 1 diabetes (<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B15" ref-type="bibr">15</xref>), contemporaneous with increasing type 1 diabetes incidence and earlier age at onset associated with enhanced weight gain (<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B17" ref-type="bibr">17</xref>). The concept of excess weight gain with associated insulin resistance as type 1 diabetes risk factors remains unproven but has been proposed by the “accelerator hypothesis” to precede and initiate β-cell damage (<xref rid="B18" ref-type="bibr">18</xref>). Our alternative hypothesis proposes environmentally (e.g., viral or toxin) induced initial autoimmune β-cell damage with progressively declining ability to meet the increased insulin demands of obesity-related insulin resistance and consequent presentation of clinical diabetes with less severe β-cell loss and fewer β-cell autoantibodies at onset (<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B20" ref-type="bibr">20</xref>). Adiposity has been recognized to generate a generalized proinflammatory milieu (<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B21" ref-type="bibr">21</xref>,<xref rid="B22" ref-type="bibr">22</xref>), which can promote progression of autoimmune processes. An example of this phenomenon is the association between obesity and earlier multiple sclerosis presentation (<xref rid="B23" ref-type="bibr">23</xref>), a classical, cognate autoimmune disorder with many analogies to type 1 diabetes (<xref rid="B24" ref-type="bibr">24</xref>).</p><p>Due to scarce mechanistic understanding of the immunometabolic interface in pediatric diabetes, our aim is to assess if adiposity and surrogate measures of insulin resistance impact T- and B-cell autoimmunity in normal and overweight children with insulin-requiring diabetes. This study demonstrates associations between enhanced neuronal T-cell autoreactivity and obesity in children with clinical type 1 diabetes.</p></sec><sec id="s2"><title>Research Design and Methods</title><sec id="s3"><title>Study Population</title><p>Children &lt;19 years of age with insulin-requiring diabetes, diagnosed consecutively from January 2004 to June 2008 at Children’s Hospital of Pittsburgh, were recruited for consent and enrollment in the study. All clinical data were obtained within 1 week of diagnosis and at initial follow-up, 2–3 months later. Blood for measures of autoimmunity was drawn 3–5 days after onset when metabolic control had been established and/or 3 months later. Of 351 patients recruited for the study, 287 had T-cell results available and 261 had sufficient serum for measurements of three to four autoantibodies (<ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc14-1861/-/DC1">Supplementary Fig. 1</ext-link>). Therefore 261 patients were analyzed: age 9.7 ± 4 years (range 1.2–18.9); 60% male; and 92% Caucasian, 6% African American, and 2% “other” (<xref ref-type="table" rid="T1">Table 1</xref>). There were no differences in mean hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>), BMI <italic>z</italic> score (BMIz), sex, race, or serum C-peptide levels between the included (<italic>n</italic> = 261) and excluded (<italic>n</italic> = 90) subjects. The excluded group was slightly younger, with a mean age of 7.7 years (<italic>P</italic> = 0.03), because of difficulty obtaining sufficient research blood volume in small patients. BMI percentiles and BMIz were calculated using the Centers for Disease Control and Prevention 2000 growth data.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Comparison of new-onset diabetic patients and control subjects</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th align="left" scope="col" rowspan="1" colspan="1"/><th align="center" scope="col" rowspan="1" colspan="1">Diabetic patients (<italic>n</italic> = 261)</th><th align="center" scope="col" rowspan="1" colspan="1">Control subjects (<italic>n</italic> = 45)</th><th align="center" scope="col" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" scope="row" rowspan="1" colspan="1">Age (years), mean (SD)</td><td align="center" rowspan="1" colspan="1">9.7 (±4.0)</td><td align="center" rowspan="1" colspan="1">10.6 (±5.1)</td><td align="center" rowspan="1" colspan="1">0.34</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Race (% white)</td><td align="center" rowspan="1" colspan="1">92</td><td align="center" rowspan="1" colspan="1">95</td><td align="center" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Sex (% male)</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">53</td><td align="center" rowspan="1" colspan="1">0.14</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">BMIz median (IQR)</td><td align="center" rowspan="1" colspan="1">0.83 (0.26–1.5)</td><td align="center" rowspan="1" colspan="1">0.86 (0.23–1.66)</td><td align="center" rowspan="1" colspan="1">0.77</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">WC (cm), median (IQR)</td><td align="center" rowspan="1" colspan="1">65 (57–73)</td><td align="center" rowspan="1" colspan="1">65 (56–77)</td><td align="center" rowspan="1" colspan="1">0.62</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Number of positive analytes, median (IQR)</td><td align="center" rowspan="1" colspan="1">10 (9–10)</td><td align="center" rowspan="1" colspan="1">0 (0–0)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">HLA DQ2 and/or DQ8 (%)</td><td align="center" rowspan="1" colspan="1">81</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr></tbody></table></table-wrap><p>Waist circumference (WC) measurement corrected for age and BMIz was used as a surrogate measure of insulin resistance (<xref rid="B25" ref-type="bibr">25</xref>). As most children with new-onset type 1 diabetes regain prediagnosis weight loss by the initial follow-up visit (2–3 month), BMI and WC measures were analyzed at that time to approximate prediagnosis habitus. Waist measurement was not available for 60 patients. There were no differences in age, race, sex, HbA<sub>1c</sub>, or BMI between the 201 subjects with and 60 subjects without available waist measurements.</p><p>We compared all parameters in the diabetic patients to a control group of 45 FDR siblings of the probands, selected to have the lowest diabetes risk biallelic Asp<sup>57</sup>/Asp<sup>57</sup> HLA genotype (<xref rid="B7" ref-type="bibr">7</xref>) and matched by age, race, sex, BMIz, and WC (<xref ref-type="table" rid="T1">Table 1</xref>).</p></sec><sec id="s4"><title>Autoantibody Assays</title><p>Anti-GAD and -IA-2 autoantibodies were assayed in triplicate using in vitro–translated/transcribed [<sup>35</sup>S]methionine-labeled human GAD65 and IA-2/BDC, the latter containing the intracellular domains (<xref rid="B26" ref-type="bibr">26</xref>). Insulin autoantibodies were measured using a <sup>125</sup>I-labeled insulin assay with precipitation of IgG by protein A (<xref rid="B27" ref-type="bibr">27</xref>) only in samples obtained within 1 week of insulin treatment (<italic>n</italic> = 93). ICA was measured using both human group O and cafeteria-fed rat pancreas substrates by immunohistochemistry (<xref rid="B28" ref-type="bibr">28</xref>). Based on the 97th percentile of controls, positive ICA was defined as ≥5 JDFU for human and ≥10 JDFU for rat substrates. ICA measured on rat pancreas (ICA-R) has been postulated to be an early marker of diabetes (<xref rid="B26" ref-type="bibr">26</xref>), and therefore data are included for subjects negative for conventional autoantibodies. In those individuals without positive classical autoantibodies, ZnT8 autoantibodies were measured (<xref rid="B29" ref-type="bibr">29</xref>).</p><p>These assays have been assessed repeatedly in proficiency workshops organized by the University of Florida, Gainesville (1995, 1996, and 1997), and the Diabetes Autoantibody Standardization Program (2000, 2003, 2005, 2007, and 2010): GAD65 76–100% sensitivity, 90–100% specificity (100% specificity three times), and 100% validity; IA-2 48–84% sensitivity, 98–100% specificity, and 87.5% validity; and ICA and ICA-R sensitivity and specificity between 80 and 100%. Sensitivity and specificities were 60 and 93% for IAA and 64 and 100% for ZnT8 autoantibodies, respectively.</p></sec><sec id="s5"><title>T-Cell Proliferation Assay</title><p>Blood samples for T-cell assays were collected in preservative-free heparin, blinded, and shipped to Toronto by overnight courier in uncooled Styrofoam boxes. A diabetic sample was sent regularly as a positive control for the assays as well as samples from nondiabetic FDRs. Viable peripheral blood mononuclear cells were enriched on Ficoll-Hypaque gradients, and 1 × 10<sup>5</sup> cells/flat-bottom microculture well were incubated in 200-μL serum- and protein-free Hybri-Max 2897 medium (Sigma-Aldrich, St. Louis, MO) with or without 0.005–10 μg/mL of the test protein and peptide antigens (see below). The various test antigens (“analytes,” 20 µL in medium) were preloaded to replicate dry wells prior to addition of other noncellular culture ingredients and stored frozen until used. Recombinant human IL2 (10 units) was added to test analytes to detect anergic T cells (<xref rid="B8" ref-type="bibr">8</xref>). After 6 days, cultures were pulsed overnight with 1 µCi [3H]thymidine, harvested, and submitted to scintillation counting. Data were calculated as average counts per minute (cpm) and mean stimulation indices (SI, cpm test/cpm unstimulated culture). A positive response was identified as SI ≥3 SD above the mean of ovalbumin-stimulated responses, which corresponded to an SI &gt;1.5 in 98 ± 1% of viable samples (<xref rid="B8" ref-type="bibr">8</xref>). Tetanus toxoid stimulation was used as a nonautoimmunity-related positive control. Positive T-cell reactivity was considered to be reactivity to four or more analytes, previously shown to reliably distinguish diabetic from unrelated control subjects (<xref rid="B8" ref-type="bibr">8</xref>) with confirmation of the efficacy of this assay in blinded, national T-cell assay workshops (<xref rid="B30" ref-type="bibr">30</xref>,<xref rid="B31" ref-type="bibr">31</xref>). This assay provides comparable results to those of the “Seattle assay,” despite rather different assay technologies or relatively lower SIs (<xref rid="B31" ref-type="bibr">31</xref>). <ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc14-1861/-/DC1">Supplementary Table 1</ext-link> lists the 10 previously identified diabetes-associated test antigens and two positive and two negative controls.</p></sec><sec id="s6"><title>Molecular Typing of HLA Alleles</title><p>Molecular HLA typing was carried out using sequence-specific priming and exonuclease-released fluorescence, as previously described (<xref rid="B32" ref-type="bibr">32</xref>). This methodology involves designing and purifying double-labeled fluorescent probes for the detection of class I and class II alleles in PCR-amplified DNA samples without the need of agarose gels for reading results.</p></sec><sec id="s7"><title>C-Peptide</title><p>Serum C-peptide levels were obtained at diabetes presentation prior to first insulin administration (measured by the clinical laboratory assay [Advia Centaur; Siemens]), with lower limit of detection of 0.5 ng/mL, and again, postprandially, 1–2 h after a nonstandard meal, at the first follow-up visit. All correlations were performed with this 2–3-month remission sample assayed in the research laboratory using a human C-peptide radioimmunoassay kit (Linco Research, St. Charles, MO) with a lower detection limit of 0.1 ng/mL and linearity to 5.0 ng/mL. Levels of &gt;5.0 ng/mL were remeasured using dilutions. Inter- and intra-assay coefficients of variation were 0.047 and 0.046, respectively. Assay results below the level of detection were replaced with the midpoint between 0 and the lower limit of detection. (e.g., 0.25 for values at diagnosis and 0.05 for values obtained at follow-up visits).</p></sec><sec id="s8"><title>Data Analyses and Statistics</title><p>Data were summarized using means and SDs or median and interquartile range for continuous variables and frequencies for discrete variables. The distributions of variables were assessed for normality. Student <italic>t</italic> tests were used to compare means of two groups of continuous variables. ANOVA was used to compare multiple means of continuous, normally distributed variables, and ANCOVA was used when controlling for other variables in the comparison. χ<sup>2</sup> Test was used to compare frequencies of categorical variables and Fisher exact test with less than five expected counts. Wilcoxon rank sum test and median tests were used to compare medians of nonparametric data with equal and unequal variance, respectively, and Kruskal-Wallis test was used when comparing multiple means of nonparametric data. Multiple linear regression analysis was performed to assess the contribution of each variable. Pearson and Spearman correlations were used for correlation studies for parametric and nonparametric data, respectively. There was no statistical difference in the immune markers collected at the 0- and 3-month time frames (see results); therefore, these samples were combined to increase the power of multivariate analyses. All statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC), and significance was set to 5%.</p></sec></sec><sec sec-type="results" id="s9"><title>Results</title><sec id="s10"><title>T-Cell Responses in Diabetic Patients</title><p>All 261 diabetic patients responded to the positive control antigens, whereas 240 (92%) demonstrated positive T-cell reactivity (four or more responses), with the vast majority of patients (217 of 261, 83%) showing positive reactivities to 9 or 10 of the test analytes (<xref ref-type="table" rid="T2">Table 2</xref>). Negative T-cell reactivities (less than four responses) were seen in 21 (8%) patients with zero (<italic>n</italic> = 19) or one (<italic>n</italic> = 2) reactivities to the analytes. There was not a significant difference in the response to control antigens in those with negative T-cell responses compared with those with positive T-cell responses. T-cell reactivities at onset were measured after diabetes was controlled, 3–5 days after diagnosis (57 patients) or at the 2–3-month follow-up visit (219 patients). T-cell responses were measured at both time points in 15 patients. There were no differences in median T-cell SI or number of positive T-cell reactivities in samples collected at diagnosis compared with the initial follow-up: median SI 1.8 (IQR 1.6–2) and median positive responses 10 (IQR 9–10) at each time. Fifteen subjects had available T-cell data at both 0 and 3 months, with median number of positive responses 10 (9–10) and 10 (9–10), respectively (<italic>P</italic> = 0.4), and no difference in median SIs at the two time points.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>BMIz, WC, and number of positive islet autoantibodies do not affect the diversity of T-cell autoreactivity (<italic>P</italic> values adjusted for age)</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th align="left" scope="col" rowspan="1" colspan="1"/><th align="center" scope="col" rowspan="1" colspan="1">Negative T-cell response (&lt;4)</th><th align="center" scope="col" rowspan="1" colspan="1">Weak positive T-cell response (4–8)</th><th align="center" scope="col" rowspan="1" colspan="1">Strong positive T-cell response (9–10)</th><th align="center" scope="col" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" scope="row" rowspan="1" colspan="1"><italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">21 (8)</td><td align="center" rowspan="1" colspan="1">23 (9)</td><td align="center" rowspan="1" colspan="1">217 (83)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">BMIz, mean (SD)</td><td align="center" rowspan="1" colspan="1">0.67 (1.1)</td><td align="center" rowspan="1" colspan="1">0.3 (0.7)</td><td align="center" rowspan="1" colspan="1">0.93 (0.9)</td><td align="center" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">WC (cm), mean (SD)</td><td align="center" rowspan="1" colspan="1">67 (8)</td><td align="center" rowspan="1" colspan="1">62 (18)</td><td align="center" rowspan="1" colspan="1">68 (15)</td><td align="center" rowspan="1" colspan="1">0.64</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Number of positive autoantibodies, median (range)</td><td align="center" rowspan="1" colspan="1">2 (0–4)</td><td align="center" rowspan="1" colspan="1">2 (0–4)</td><td align="center" rowspan="1" colspan="1">2 (0–4)</td><td align="center" rowspan="1" colspan="1">0.2</td></tr></tbody></table></table-wrap></sec><sec id="s11"><title>T-Cell Responses in Control FDRs</title><p>All FDR siblings had expected reactivities to the control antigens, with no significant difference in SIs to control antigens between the diabetic patients and control subjects (<ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc14-1861/-/DC1">Supplementary Table 1</ext-link>) but with significantly higher SI in the diabetic group for all diabetes antigens. There were significantly fewer positive T-cell reactivities to diabetes-associated analytes in FDRs compared with diabetic patients with only 5 of 45 (11%) FDRs having positive T-cell reactivities (<xref ref-type="table" rid="T1">Table 1</xref>). Islet autoantibodies were negative in these five individuals with positive T-cell reactivities (8–10 responses spanning all T-cell categories), and three of the five were obese (BMIz range +2.07 to +2.7). There were no significant correlations between T-cell SIs and age, sex, BMIz, or WC (after adjustment of WC for age and sex) in this control group. These data for age-matched FDRs with low HLA risk are similar to those previously reported in unrelated controls (<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B30" ref-type="bibr">30</xref>,<xref rid="B31" ref-type="bibr">31</xref>).</p></sec><sec id="s12"><title>Islet Autoantibody Distribution</title><p>Islet cell autoantibodies were detected in 232 (89%) diabetic patients using the conventional autoantibody assays (GAD, IA-2, ICA, and IAA). Autoantibody distribution was similar to our previous cohorts (<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B17" ref-type="bibr">17</xref>): 15% (<italic>n</italic> = 40) with one positive, 31% (<italic>n</italic> = 81) with two positive, and 43% (<italic>n</italic> = 111) with three or four positive autoantibodies. The percent of individuals positive for each autoantibody was as follows: 52% GAD, 71% IA-2, 66% IAA, and 80% ICA. Positive autoantibodies were seen in 88% of patients with positive T-cell reactivities, as well as all but 1 of 21 patients with negative T-cell responses. Of the 195 ICA-positive patients, 155 (79%) were also positive for ICA-R. An additional 37 of 66 (56%) who were ICA negative were ICA-R positive. ICA-R was positive in only one control FDR.</p></sec><sec id="s13"><title>Relationships of B- and T-Cell Autoimmunity With Adiposity in Diabetic Patients</title><p>BMIz (but not age- and sex-adjusted WC) was highest in autoantibody-negative group (1.4 [0.5–2.5]) compared with those with one or more islet autoantibodies (BMIz range 0.5–0.9) (<italic>P</italic> = 0.03). Neither parameter (BMIz nor WC) affected the diversity of the fully expanded T-cell autoreactivities to the 10 type 1 diabetes–associated test analytes (<xref ref-type="table" rid="T2">Table 2</xref>). This diversity was also unrelated to the presence or absence of four different type 1 diabetes–associated autoantibodies. Comparisons of measures of adiposity with numbers of positive T-cell reactivities grouped as negative, moderate, or strong positive revealed no differences in BMIz, WC adjusted for age and sex, or number of positive autoantibodies (<xref ref-type="table" rid="T2">Table 2</xref>). There were no significant correlations between numbers of T-cell reactivities and measures of adiposity nor was there a relationship between antibody type and measures of adiposity.</p><p>There were significant positive correlations between T-cell SI and BMIz for each of the five neuronal antigens (EX2, <italic>r</italic> = 0.14, <italic>P</italic> = 0.03; MBP, <italic>r</italic> = 0.14, <italic>P</italic> = 0.03; GFAP, <italic>r</italic> = 0.14, <italic>P</italic> = 0.03; s100, <italic>r</italic> = 0.03, <italic>P</italic> = 0.03; and Tep69, <italic>r</italic> = 0.18, <italic>P</italic> = 0.006); the latter is an epitope of both a neuronal and islet secretory antigen. When BMI was divided according to World Health Organization percentiles (&lt;25th, 25th to 85th, and &gt;85th) in order to assess the relationships with conventional assessment of obesity, significantly higher SIs were found in the BMI &gt;85th percentile subjects for EX2, MBP, GFAP, and s100 (<italic>P</italic> &lt; 0.05), but the distribution of subjects was unequal (&lt;25th percentile <italic>n</italic> = 7, 25th to 85th <italic>n</italic> = 137, and &gt;85th <italic>n</italic> = 117) (<ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc14-1861/-/DC1">Supplementary Fig. 2</ext-link>). Therefore, subjects were divided into BMIz quintiles in order to compare the leanest with the most obese groups (<italic>n</italic> = 52 per quintile, 53 in highest quintile). Similar results were obtained with the most obese quintile showing the highest T-cell SI to three neuronal antigens (EX2, MBP, and GFAP) (<italic>P</italic> = 0.03, 0.04, and 0.02, respectively) (<xref ref-type="fig" rid="F1">Fig. 1<italic>A</italic></xref>), with a trend toward higher SIs for all other test analytes.</p><fig id="F1" fig-type="figure" position="float"><label>Figure 1</label><caption><p><italic>A</italic>: T-cell SI in response to each analyte by highest and lowest BMIz quintile. Black bar, lowest quintile; white bar, top quintile (BMIz). Left axis, diabetes-related analytes; right axis, positive control analytes (note different scales). *<italic>P</italic> &lt; 0.05. <italic>B</italic>: T-cell SI comparing waist &lt;25th percentile and &gt;85th percentile. Black bar, &lt;25th percentile; white bar, &gt;85th percentile. Left axis, diabetes-related analytes; right axis, positive control analytes (note different scales). *<italic>P</italic> &lt; 0.05; **<italic>P</italic> &lt; 0.01; #<italic>P</italic> &lt; 0.001.</p></caption><graphic xlink:href="43fig1"/></fig><p>Similar results were obtained when comparing T-cell SIs according to WC percentile, comparing the highest WC to the lowest (&lt;25th <italic>n</italic> = 55 and &gt;85th <italic>n</italic> = 45) and controlling for BMIz because BMIz was higher in the highest WC group (&lt;25th 0.24 ± 6.7 and &gt;85th 1.95 ± 0.61) (<italic>P</italic> &lt; 0.001). Those with the highest WC percentile demonstrated significantly higher T-cell SIs for all five neuronal antigens (EX2, MBP, GFAP, s100, and Tep69) (<italic>P</italic> = 0.01, 0.01, &lt;0.001, 0.002, and 0.03, respectively) as well as two islet antigens (GAD and PI) (<italic>P</italic> = 0.01 and 0.02, respectively) and a trend toward higher SIs for all other islet antigens (<xref ref-type="fig" rid="F1">Fig. 1<italic>B</italic></xref>). These relationships between T-cell SI and BMIz and waist were not present in positive control analytes (<xref ref-type="fig" rid="F1">Fig. 1<italic>A</italic> and <italic>B</italic></xref>).</p><p>There were no correlations between T-cell SI and age, sex, race, C-peptide levels, or HbA<sub>1c</sub> at onset or 3 months. Age, race, sex, and HbA<sub>1c</sub> were similar across the BMIz and WC percentile groups and were not considered contributing factors to the significant differences observed.</p></sec><sec id="s14"><title>Relationships of Autoimmunity to Adiposity and C-Peptide</title><p>Patients were divided into four subgroups based on the following characteristics: autoantibody positive and T-cell positive (Ab<sup>+</sup>/T<sup>+</sup>), autoantibody positive and T-cell negative (Ab<sup>+</sup>/T<sup>−</sup>), autoantibody negative and T-cell positive (Ab<sup>−</sup>/T<sup>+</sup>), and autoantibody negative and T-cell negative (Ab<sup>−</sup>/T<sup>−</sup>). The Ab<sup>−</sup>/T<sup>−</sup> group with only one subject was not analyzed. There were no differences in C-peptide levels (<xref ref-type="fig" rid="F2">Fig. 2</xref>) or HbA<sub>1c</sub> at either onset or 3 months. Adjustments for age and BMIz were required because the Ab<sup>+</sup>/T<sup>+</sup> group was younger than the other groups (mean ages 9.6, 11.4, and 11.4 years, respectively; <italic>P</italic> = 0.007). BMIz was highest in the Ab<sup>−</sup>/T<sup>+</sup> group and statistically significant by 2–3 months (<xref ref-type="fig" rid="F2">Fig. 2</xref>).</p><fig id="F2" fig-type="figure" position="float"><label>Figure 2</label><caption><p>Comparison of BMIz and C-peptide between antibody/T-cell groups. Black bar, Ab<sup>+</sup>/T<sup>+</sup> = antibody positive, T-cell positive; white bar, Ab<sup>+</sup>/T<sup>−</sup> = antibody positive, T-cell negative; hatched bar, Ab<sup>−</sup>/T<sup>+</sup> = antibody negative, T-cell positive. ##<italic>P</italic> = 0.006, results expressed in means for BMIz and medians for C-peptide.</p></caption><graphic xlink:href="43fig2"/></fig><p>We also investigated the relationship between onset C-peptide levels and T-cell SI and number of positive T-cell autoreactivities using multiple linear regression analysis, controlling for BMIz, age, and HbA<sub>1c</sub>, which each contributed significantly to C-peptide (<italic>P</italic> &lt; 0.001 for all). There were no relationships between C-peptide and T-cell reactivity amplitudes nor number of positive reactivities to T-cell analytes (<italic>P</italic> = 0.11).</p></sec><sec id="s15"><title>Relationships Between B- and T-Cell Autoimmunity</title><p>The median number of positive T-cell responses was 10 (9–10), regardless of number of positive autoantibodies. Because most patients had positive T-cell reactivities to the majority of analytes, there were no correlations between numbers of positive B- and T-cell autoreactivities. When number of T-cell reactivities were grouped into negative (&lt;4), positive (4–8), or strongly positive (9–10) responses, there were no differences between the groups, all with a median of two positive islet autoantibodies (<xref ref-type="table" rid="T2">Table 2</xref>). There were also no relationships between the number of positive autoantibodies and the SI for any of the 10 test analytes. Of the 29 patients who were autoantibody negative, all but 1 had positive T-cell responses, with the number of responses ranging from 8 to 10. Evaluation of relationships between positivity to each type of autoantibody and the T-cell reactivities to the corresponding antigen demonstrated concordance in the majority of subjects (Gad<sup>+</sup>/GAD<sup>+</sup> 88%, Tep69<sup>+</sup>/ICA69<sup>+</sup> 90%, and PI<sup>+</sup>/IAA<sup>+</sup> 93%).</p></sec><sec id="s16"><title>Evaluation of Autoantibody-Negative Patients</title><p>Twenty-nine subjects were negative for conventionally assessed islet autoantibodies. Of the 28 patients without standard islet autoantibodies, but with positive T cells, 11 (39%) had positive ICA-R as did the 1 subject with negative T-cell responses and conventional autoantibodies, including ZnT8 autoantibodies. This Ab<sup>−</sup>/T<sup>−</sup> child was an obese Hispanic 2 year old with ketosis at onset and autoimmune hypothyroidism, with the low-risk HLA Asp<sup>57</sup>/Asp<sup>57</sup> haplotype and no clinical evidence of MODY (maturity-onset diabetes of the young).</p><p>ZnT8 was measured in these autoantibody-negative subjects. Two of 29 subjects (7%) were positive for ZnT8. Therefore, with addition of ZnT8, 27 of 261 subjects (10%) were autoantibody negative. The reclassification of these subjects as autoantibody positive did not change any of the above findings.</p></sec><sec id="s17"><title>HLA Status and Islet Autoreactivity</title><p>Patients were classified according to diabetes risk HLA DQ: 19% DQ2/DQ8, 5% DQ8/8, 6% DQ2/2, 51% either DQ2 or DQ8, and 19% neither DQ2 nor DQ8 (<xref ref-type="table" rid="T1">Table 1</xref>). There were no relationships between number, SI, or type of T-cell reactivities with HLA DQ2, 8, or 2/8 genotypes or those with Asp<sup>57</sup>/Asp<sup>57</sup>, non-Asp<sup>57</sup>/Asp<sup>57</sup>, or non-Asp<sup>57</sup>/non-Asp<sup>57</sup>. The protective HLA DQ 0602 was present in four patients, all of whom had positive (9–10) T-cell responses and two had positive islet autoantibodies. The lowest-risk DQ Asp<sup>57</sup>/Asp<sup>57</sup> alleles were present in 8 of 261 diabetic patients (3%), of whom 5 were autoantibody positive and by definition type 1. The other three Asp<sup>57</sup>/Asp<sup>57</sup> patients with negative autoantibodies were obese; two had positive T-cell responses and the other had thyroid autoimmunity and positive ICA-R.</p></sec></sec><sec sec-type="conclusions" id="s18"><title>Conclusions</title><p>All but one patient with clinical type 1 diabetes had either T- or B-cell diabetes–associated autoimmunity, regardless of clinical phenotype, and quite different from a control group of FDRs with low-risk HLA (Asp<sup>57</sup>/Asp<sup>57</sup>) haplotypes. Our investigation of relationships between adiposity and islet cell autoimmunity in this cohort, with a high prevalence of overweight and obesity, demonstrates significantly higher T-cell amplitudes, especially to neuronal antigens, in those with the greatest adiposity. The relationships between high WC, a surrogate marker for insulin resistance in children (<xref rid="B25" ref-type="bibr">25</xref>), and the amplification of reactivities to diabetes-related antigens suggests a possible mechanistic role for insulin resistance.</p><p>The mechanistic basis for the preference of recruiting autoreactivity to neuronal antigens remains unclear. The importance of neuronal elements in type 1 diabetes development has been previously identified by our group, in mice, and extended in recent ongoing studies to patients (<xref rid="B24" ref-type="bibr">24</xref>). This finding of amplified T-cell reactivities in the most obese patients is in keeping with the recent understanding of obesity-related inflammation (<xref rid="B33" ref-type="bibr">33</xref>), with adiposity creating a highly proinflammatory milieu (<xref rid="B21" ref-type="bibr">21</xref>). This environment enhances T-cell autoreactivity in overweight/obese hosts, including new-onset insulin-requiring diabetic patients, with recruitment and local expansion of the fat-resident, highly activated, and T-cell receptor–selected immunome and its secretory proinflammatory signals (<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B34" ref-type="bibr">34</xref>,<xref rid="B35" ref-type="bibr">35</xref>). Although originally considered a local adipose tissue process, a wide array of systemic cytokines are found in metabolic syndrome patients (<xref rid="B36" ref-type="bibr">36</xref>), including children (<xref rid="B37" ref-type="bibr">37</xref>).</p><p>The finding of diverse T-cell autoimmunity as well as zinc transporter autoantibodies and nonclassical islet antibodies using cafeteria (over-) fed rat pancreas as substrate provide evidence that type 1 diabetes autoimmunity targets a range of antigens and epitopes beyond those assessed by standard measurements of autoantibodies to GAD, IA-2, insulin, and classical ICA. Studies of T-cell autoreactivities in obese adults with metabolic syndrome or clinically diagnosed type 2 diabetes (<xref rid="B21" ref-type="bibr">21</xref>,<xref rid="B22" ref-type="bibr">22</xref>) as well as B6 mice with diet-induced obesity (<xref rid="B13" ref-type="bibr">13</xref>) typically demonstrate responses against wide arrays of self-proteins with impressive differences between insulin-resistant and -sensitive patients, strengthening the strong evidence for a link between the cognate (TCR-selecting) autoimmunity and progressive metabolic dysfunction.</p><p>Obese patients with higher-risk HLA genotypes and positive islet antibodies are typically defined as having type 1 diabetes, despite their insulin-resistant phenotype (<xref rid="B38" ref-type="bibr">38</xref>). We have demonstrated here that a subset of patients who may have been classified as having type 2 diabetes, due absence of conventional autoantibodies, did in fact have broad diabetes-related T-cell autoimmunity. This clinical scenario has been previously described in adults and children with clinical type 2 diabetes, using a different T-cell assay technique (<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B10" ref-type="bibr">10</xref>). Our observation leads to the suggestion that all insulin-deficient pediatric diabetes is an inflammatory process with a spectrum of clinical and autoimmune presentation. Validation studies of this T-cell proliferative assay have confirmed its robustness in differentiating type 1 diabetic patients from control subjects (<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B39" ref-type="bibr">39</xref>). We propose that the link between obesity/insulin resistance and autoimmunity is presentation earlier in the course of autoimmune progression with insulin concentrations inadequate to maintain euglycemia in an insulin-resistant patient at a point in development of diabetes where euglycemia would be maintained in an insulin-sensitive individual. Therefore, we see patients presenting with diabetes at a point in the autoimmune damage where only T cells (and not yet autoantibodies) are measurable. The inflammation of obesity may be providing an additional stress on the β-cell, resulting in more rapid damage. These hypotheses will be further investigated in an initiated prospective follow-up of new-onset patients, and in our current study of T-cell responses prior to development of diabetes in FDRs prior to the development of autoimmunity and/or diabetes. This cross-sectional study cannot address rates of development of B- or T-cell autoimmunity. There is one implication of this conclusion that eventually may alter therapeutic strategy. If future investigation demonstrates that an obesity-driven general inflammation facilitates the survival and the proliferation of autoreactive, diabetogenic T and B cells, a novel therapeutic approach could be to first suppress, in a general manner, TH1-driving processes in the inflammation, potentially deviating them toward a TH2 state. The consequence of this would be that the autoreactive T and B cells would be suppressed or suspended in their abilities to drive autoimmunity. Once this state is achieved, antigen-specific strategies could be used to eradicate the autoreactive T and B cells.</p><p>In summary, our data confirm a diabetes-related autoimmune milieu in children with insulin-requiring diabetes, irrespective of obesity or the presence or absence of conventional islet autoantibodies. Our observations link obesity and diabetes-related autoimmunity with amplification of T-cell responses, especially to type 1 diabetes–related neuronal antigens in those individuals with the greatest adiposity and/or insulin resistance. This association suggests the possibility of obesity-related inflammation driving the autoimmune process.</p></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>Supplementary Data</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_38_1_43__index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_dc14-1861v141861_DC141861SupplementaryData.pdf"/>
</supplementary-material>
</sec>
</body>
  <back>
    <fn-group>
      <fn id="fn1" fn-type="supplementary-material">
        <p>This article contains Supplementary Data online at <ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc14-1861/-/DC1">http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc14-1861/-/DC1</ext-link>.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Article Information</title>
      <p><bold>Acknowledgments. </bold>The authors express their gratitude to laboratory technicians David Groscost (University of Pittsburgh), Katie McDowell (University of Pittsburgh), and Susan Pietropaolo (University of Michigan); study coordinator Maribel Cedillo (University of Pittsburgh); Dr. Liping Yu (Barbara Davis Center for Diabetes, Denver, CO) for the zinc transporter autoantibody assay; and all the diabetes research nurses, study participants, and their parents.</p>
      <p><bold>Funding.</bold> This work was supported by Canadian Institutes of Health Research grant 231461 (H.-M.D.), National Institutes of Health (NIH) grants UL1-RR-024153 and UL1-TR-000005 (The Pediatric Clinical and Translational Research Center) and the Renziehausen Fund (I.L.), and NIH grants R01-DK-053456 (M.P.) and R01-DK-024021 (D.J.B.).</p>
      <p><bold>Duality of Interest.</bold> No potential conflicts of interest relevant to this article were reported.</p>
      <p><bold>Author Contributions.</bold> M.A.B. is a military service member. This work was prepared as part of her official duties. Title 17, USC, §105 provides that “Copyright protection under this title is not available for any work of the U.S. Government.” Title 17, USC, §101 defines a U.S. Government work as a work prepared by a military service member or employee of the U.S. Government as part of that person's official duties.</p>
      <p>M.A.B. compiled and analyzed the data and wrote the manuscript. H.-M.D. created the T-cell methodology, contributed to the concept of the study, and reviewed and edited the manuscript. I.L. contributed to the concept and design, researched data, and edited the manuscript. V.C.A. and Y.H. managed the database, assisted with statistical analysis, and reviewed and edited the manuscript. R.K.C. assayed all T-cell samples and reviewed the manuscript. M.T. assayed and interpreted HLA data. M.P. provided GAD and IA-2 data, contributed to the concept and design, contributed to the discussion, and reviewed and edited the manuscript. D.J.B. contributed to the concept and design, researched data, provided IAA and ICA data, contributed to the discussion, and reviewed and edited the manuscript. D.J.B. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p>
      <p><bold>Prior Presentation. </bold>This work was presented in abstract form at the Pediatric Academic Societies/Pediatric Endocrine Society Annual Meeting, Washington DC, 4–7 May 2013; the 73rd Scientific Sessions of the American Diabetes Association, Chicago, IL, 21–25 June 2013; the 39th International Society for Pediatric and Adolescent Diabetes Annual Conference, Gothenburg, Sweden, 16–19 October 2013; and the 13th International Congress of the Immunology of Diabetes Society, Melbourne, Australia, 7–11 December 2013.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nokoff</surname><given-names>N</given-names></name><name><surname>Rewers</surname><given-names>M</given-names></name></person-group>. <article-title>Pathogenesis of type 1 diabetes: lessons from natural history studies of high-risk individuals</article-title>. <source>Ann N Y Acad Sci</source>
<year>2013</year>;<volume>1281</volume>:<fpage>1</fpage>–<lpage>15</lpage><?supplied-pmid 23360422?><pub-id pub-id-type="pmid">23360422</pub-id></mixed-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vehik</surname><given-names>K</given-names></name><name><surname>Beam</surname><given-names>CA</given-names></name><name><surname>Mahon</surname><given-names>JL</given-names></name><etal/><collab>TrialNet Natural History Study Group</collab></person-group>. <article-title>Development of autoantibodies in the TrialNet Natural History Study</article-title>. <source>Diabetes Care</source>
<year>2011</year>;<volume>34</volume>:<fpage>1897</fpage>–<lpage>1901</lpage><?supplied-pmid 21750277?><pub-id pub-id-type="pmid">21750277</pub-id></mixed-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation publication-type="journal">Thai A-C, Eisenbarth GS.<article-title> Natural history of IDDM</article-title>. <source>Diabetes Rev</source>
<year>1993</year>;<volume>1</volume>:<fpage>1</fpage>–<lpage>14</lpage></mixed-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Miao</surname><given-names>D</given-names></name><name><surname>Babu</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Prevalence of autoantibody-negative diabetes is not rare at all ages and increases with older age and obesity</article-title>. <source>J Clin Endocrinol Metab</source>
<year>2007</year>;<volume>92</volume>:<fpage>88</fpage>–<lpage>92</lpage><?supplied-pmid 17062766?><pub-id pub-id-type="pmid">17062766</pub-id></mixed-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Libman</surname><given-names>IM</given-names></name><name><surname>Pietropaolo</surname><given-names>M</given-names></name><name><surname>Trucco</surname><given-names>M</given-names></name><name><surname>Dorman</surname><given-names>JS</given-names></name><name><surname>LaPorte</surname><given-names>RE</given-names></name><name><surname>Becker</surname><given-names>D</given-names></name></person-group>. <article-title>Islet cell autoimmunity in white and black children and adolescents with IDDM</article-title>. <source>Diabetes Care</source>
<year>1998</year>;<volume>21</volume>:<fpage>1824</fpage>–<lpage>1827</lpage><?supplied-pmid 9802728?><pub-id pub-id-type="pmid">9802728</pub-id></mixed-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietropaolo</surname><given-names>M</given-names></name><name><surname>Eisenbarth</surname><given-names>GS</given-names></name></person-group>. <article-title>Autoantibodies in human diabetes</article-title>. <source>Curr Dir Autoimmun</source>
<year>2001</year>;<volume>4</volume>:<fpage>252</fpage>–<lpage>282</lpage><?supplied-pmid 11569406?><pub-id pub-id-type="pmid">11569406</pub-id></mixed-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trucco</surname><given-names>M</given-names></name></person-group>. <article-title>To be or not to be Asp 57, that is the question</article-title>. <source>Diabetes Care</source>
<year>1992</year>;<volume>15</volume>:<fpage>705</fpage>–<lpage>715</lpage><?supplied-pmid 1355423?><pub-id pub-id-type="pmid">1355423</pub-id></mixed-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dosch</surname><given-names>H</given-names></name><name><surname>Cheung</surname><given-names>RK</given-names></name><name><surname>Karges</surname><given-names>W</given-names></name><name><surname>Pietropaolo</surname><given-names>M</given-names></name><name><surname>Becker</surname><given-names>DJ</given-names></name></person-group>. <article-title>Persistent T cell anergy in human type 1 diabetes</article-title>. <source>J Immunol</source>
<year>1999</year>;<volume>163</volume>:<fpage>6933</fpage>–<lpage>6940</lpage><?supplied-pmid 10586096?><pub-id pub-id-type="pmid">10586096</pub-id></mixed-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brooks-Worrell</surname><given-names>BM</given-names></name><name><surname>Greenbaum</surname><given-names>CJ</given-names></name><name><surname>Palmer</surname><given-names>JP</given-names></name><name><surname>Pihoker</surname><given-names>C</given-names></name></person-group>. <article-title>Autoimmunity to islet proteins in children diagnosed with new-onset diabetes</article-title>. <source>J Clin Endocrinol Metab</source>
<year>2004</year>;<volume>89</volume>:<fpage>2222</fpage>–<lpage>2227</lpage><?supplied-pmid 15126545?><pub-id pub-id-type="pmid">15126545</pub-id></mixed-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brooks-Worrell</surname><given-names>BM</given-names></name><name><surname>Reichow</surname><given-names>JL</given-names></name><name><surname>Goel</surname><given-names>A</given-names></name><name><surname>Ismail</surname><given-names>H</given-names></name><name><surname>Palmer</surname><given-names>JP</given-names></name></person-group>. <article-title>Identification of autoantibody-negative autoimmune type 2 diabetic patients</article-title>. <source>Diabetes Care</source>
<year>2011</year>;<volume>34</volume>:<fpage>168</fpage>–<lpage>173</lpage><?supplied-pmid 20855551?><pub-id pub-id-type="pmid">20855551</pub-id></mixed-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winer</surname><given-names>S</given-names></name><name><surname>Tsui</surname><given-names>H</given-names></name><name><surname>Lau</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Autoimmune islet destruction in spontaneous type 1 diabetes is not β-cell exclusive</article-title>. <source>Nat Med</source>
<year>2003</year>;<volume>9</volume>:<fpage>198</fpage>–<lpage>205</lpage><?supplied-pmid 12539039?><pub-id pub-id-type="pmid">12539039</pub-id></mixed-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winer</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>Y</given-names></name><name><surname>Paltser</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Normalization of obesity-associated insulin resistance through immunotherapy</article-title>. <source>Nat Med</source>
<year>2009</year>;<volume>15</volume>:<fpage>921</fpage>–<lpage>929</lpage><?supplied-pmid 19633657?><pub-id pub-id-type="pmid">19633657</pub-id></mixed-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winer</surname><given-names>DA</given-names></name><name><surname>Winer</surname><given-names>S</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies</article-title>. <source>Nat Med</source>
<year>2011</year>;<volume>17</volume>:<fpage>610</fpage>–<lpage>617</lpage><?supplied-pmid 21499269?><pub-id pub-id-type="pmid">21499269</pub-id></mixed-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Libman</surname><given-names>IM</given-names></name><name><surname>Pietropaolo</surname><given-names>M</given-names></name><name><surname>Arslanian</surname><given-names>SA</given-names></name><name><surname>LaPorte</surname><given-names>RE</given-names></name><name><surname>Becker</surname><given-names>DJ</given-names></name></person-group>. <article-title>Changing prevalence of overweight children and adolescents at onset of insulin-treated diabetes</article-title>. <source>Diabetes Care</source>
<year>2003</year>;<volume>26</volume>:<fpage>2871</fpage>–<lpage>2875</lpage><?supplied-pmid 14514594?><pub-id pub-id-type="pmid">14514594</pub-id></mixed-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>EURODIAB ACE Study Group</collab></person-group>. <article-title>Variation and trends in incidence of childhood diabetes in Europe</article-title>. <source>Lancet</source>
<year>2000</year>;<volume>355</volume>:<fpage>873</fpage>–<lpage>876</lpage><?supplied-pmid 10752702?><pub-id pub-id-type="pmid">10752702</pub-id></mixed-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vehik</surname><given-names>K</given-names></name><name><surname>Hamman</surname><given-names>RF</given-names></name><name><surname>Lezotte</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Increasing incidence of type 1 diabetes in 0- to 17-year-old Colorado youth</article-title>. <source>Diabetes Care</source>
<year>2007</year>;<volume>30</volume>:<fpage>503</fpage>–<lpage>509</lpage><?supplied-pmid 17327312?><pub-id pub-id-type="pmid">17327312</pub-id></mixed-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Libman</surname><given-names>IM</given-names></name><name><surname>LaPorte</surname><given-names>RE</given-names></name><name><surname>Becker</surname><given-names>D</given-names></name><name><surname>Dorman</surname><given-names>JS</given-names></name><name><surname>Drash</surname><given-names>AL</given-names></name><name><surname>Kuller</surname><given-names>L</given-names></name></person-group>. <article-title>Was there an epidemic of diabetes in nonwhite adolescents in Allegheny County, Pennsylvania</article-title>? <source>Diabetes Care</source>
<year>1998</year>;<volume>21</volume>:<fpage>1278</fpage>–<lpage>1281</lpage><?supplied-pmid 9702433?><pub-id pub-id-type="pmid">9702433</pub-id></mixed-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkin</surname><given-names>TJ</given-names></name></person-group>. <article-title>The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes</article-title>. <source>Diabetologia</source>
<year>2001</year>;<volume>44</volume>:<fpage>914</fpage>–<lpage>922</lpage><?supplied-pmid 11508279?><pub-id pub-id-type="pmid">11508279</pub-id></mixed-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Libman</surname><given-names>IM</given-names></name><name><surname>Becker</surname><given-names>DJ</given-names></name></person-group>. <article-title>Coexistence of type 1 and type 2 diabetes mellitus: “double” diabetes</article-title>? <source>Pediatr Diabetes</source>
<year>2003</year>;<volume>4</volume>:<fpage>110</fpage>–<lpage>113</lpage><?supplied-pmid 14655267?><pub-id pub-id-type="pmid">14655267</pub-id></mixed-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Libman</surname><given-names>I</given-names></name><name><surname>Arena</surname><given-names>V</given-names></name><name><surname>Cedillo</surname><given-names>M</given-names></name><name><surname>Pietropaolo</surname><given-names>M</given-names></name><name><surname>Becker</surname><given-names>DJ</given-names></name></person-group>
<article-title>β-Cell autoantibody number has no effect on C-peptide recovery or loss in children with T1D</article-title>. <source>Diabetes</source>
<year>2012</year>;<volume>61</volume>(<issue>Suppl. 1</issue>): A331</mixed-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Youm</surname><given-names>YH</given-names></name><name><surname>Vandanmagsar</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Obesity increases the production of proinflammatory mediators from adipose tissue T cells and compromises TCR repertoire diversity: implications for systemic inflammation and insulin resistance</article-title>. <source>J Immunol</source>
<year>2010</year>;<volume>185</volume>:<fpage>1836</fpage>–<lpage>1845</lpage><?supplied-pmid 20581149?><pub-id pub-id-type="pmid">20581149</pub-id></mixed-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sell</surname><given-names>H</given-names></name><name><surname>Habich</surname><given-names>C</given-names></name><name><surname>Eckel</surname><given-names>J</given-names></name></person-group>. <article-title>Adaptive immunity in obesity and insulin resistance</article-title>. <source>Nat Rev Endocrinol</source>
<year>2012</year>;<volume>8</volume>:<fpage>709</fpage>–<lpage>716</lpage><?supplied-pmid 22847239?><pub-id pub-id-type="pmid">22847239</pub-id></mixed-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langer-Gould</surname><given-names>A</given-names></name><name><surname>Brara</surname><given-names>SM</given-names></name><name><surname>Beaber</surname><given-names>BE</given-names></name><name><surname>Koebnick</surname><given-names>C</given-names></name></person-group>. <article-title>Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome</article-title>. <source>Neurology</source>
<year>2013</year>;<volume>80</volume>:<fpage>548</fpage>–<lpage>552</lpage><?supplied-pmid 23365063?><pub-id pub-id-type="pmid">23365063</pub-id></mixed-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winer</surname><given-names>S</given-names></name><name><surname>Astsaturov</surname><given-names>I</given-names></name><name><surname>Cheung</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Type I diabetes and multiple sclerosis patients target islet plus central nervous system autoantigens; nonimmunized nonobese diabetic mice can develop autoimmune encephalitis</article-title>. <source>J Immunol</source>
<year>2001</year>;<volume>166</volume>:<fpage>2831</fpage>–<lpage>2841</lpage><?supplied-pmid 11160351?><pub-id pub-id-type="pmid">11160351</pub-id></mixed-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernández</surname><given-names>JR</given-names></name><name><surname>Redden</surname><given-names>DT</given-names></name><name><surname>Pietrobelli</surname><given-names>A</given-names></name><name><surname>Allison</surname><given-names>DB</given-names></name></person-group>. <article-title>Waist circumference percentiles in nationally representative samples of African-American, European-American, and Mexican-American children and adolescents</article-title>. <source>J Pediatr</source>
<year>2004</year>;<volume>145</volume>:<fpage>439</fpage>–<lpage>444</lpage><?supplied-pmid 15480363?><pub-id pub-id-type="pmid">15480363</pub-id></mixed-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietropaolo</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Libman</surname><given-names>IM</given-names></name><etal/></person-group>. <article-title>Cytoplasmic islet cell antibodies remain valuable in defining risk of progression to type 1 diabetes in subjects with other islet autoantibodies</article-title>. <source>Pediatr Diabetes</source>
<year>2005</year>;<volume>6</volume>:<fpage>184</fpage>–<lpage>192</lpage><?supplied-pmid 16390386?><pub-id pub-id-type="pmid">16390386</pub-id></mixed-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>AJ</given-names></name><name><surname>Bingley</surname><given-names>PJ</given-names></name><name><surname>Chance</surname><given-names>RE</given-names></name><name><surname>Gale</surname><given-names>EA</given-names></name></person-group>. <article-title>Insulin autoantibodies: more specific than proinsulin autoantibodies for prediction of type 1 diabetes</article-title>. <source>J Autoimmun</source>
<year>1999</year>;<volume>13</volume>:<fpage>357</fpage>–<lpage>363</lpage><?supplied-pmid 10550223?><pub-id pub-id-type="pmid">10550223</pub-id></mixed-citation>
      </ref>
      <ref id="B28">
        <label>28</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipton</surname><given-names>RB</given-names></name><name><surname>Kocova</surname><given-names>M</given-names></name><name><surname>LaPorte</surname><given-names>RE</given-names></name><etal/></person-group>. <article-title>Autoimmunity and genetics contribute to the risk of insulin-dependent diabetes mellitus in families: islet cell antibodies and HLA DQ heterodimers</article-title>. <source>Am J Epidemiol</source>
<year>1992</year>;<volume>136</volume>:<fpage>503</fpage>–<lpage>512</lpage><?supplied-pmid 1442714?><pub-id pub-id-type="pmid">1442714</pub-id></mixed-citation>
      </ref>
      <ref id="B29">
        <label>29</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Boulware</surname><given-names>DC</given-names></name><name><surname>Beam</surname><given-names>CA</given-names></name><etal/><collab>Type 1 Diabetes TrialNet Study Group</collab></person-group>. <article-title>Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies</article-title>. <source>Diabetes Care</source>
<year>2012</year>;<volume>35</volume>:<fpage>1213</fpage>–<lpage>1218</lpage><?supplied-pmid 22446173?><pub-id pub-id-type="pmid">22446173</pub-id></mixed-citation>
      </ref>
      <ref id="B30">
        <label>30</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dosch</surname><given-names>H-M</given-names></name><name><surname>Becker</surname><given-names>DJ</given-names></name></person-group>. <article-title>Measurement of T-cell autoreactivity in autoimmune diabetes</article-title>. <source>Diabetologia</source>
<year>2000</year>;<volume>43</volume>:<fpage>386</fpage>–<lpage>387</lpage><?supplied-pmid 10768103?><pub-id pub-id-type="pmid">10768103</pub-id></mixed-citation>
      </ref>
      <ref id="B31">
        <label>31</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seyfert-Margolis</surname><given-names>V</given-names></name><name><surname>Gisler</surname><given-names>TD</given-names></name><name><surname>Asare</surname><given-names>AL</given-names></name><etal/></person-group>. <article-title>Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study</article-title>. <source>Diabetes</source>
<year>2006</year>;<volume>55</volume>:<fpage>2588</fpage>–<lpage>2594</lpage><?supplied-pmid 16936208?><pub-id pub-id-type="pmid">16936208</pub-id></mixed-citation>
      </ref>
      <ref id="B32">
        <label>32</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faas</surname><given-names>SJ</given-names></name><name><surname>Menon</surname><given-names>R</given-names></name><name><surname>Braun</surname><given-names>ER</given-names></name><name><surname>Rudert</surname><given-names>WA</given-names></name><name><surname>Trucco</surname><given-names>M</given-names></name></person-group>. <article-title>Sequence-specific priming and exonuclease-released fluorescence detection of HLA-DQB1 alleles</article-title>. <source>Tissue Antigens</source>
<year>1996</year>;<volume>48</volume>:<fpage>97</fpage>–<lpage>112</lpage><?supplied-pmid 8883299?><pub-id pub-id-type="pmid">8883299</pub-id></mixed-citation>
      </ref>
      <ref id="B33">
        <label>33</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>DL</given-names></name><name><surname>Cho</surname><given-names>KW</given-names></name><name><surname>Delproposto</surname><given-names>JL</given-names></name><etal/></person-group>. <article-title>Adipose tissue macrophages function as antigen-presenting cells and regulate adipose tissue CD4+ T cells in mice</article-title>. <source>Diabetes</source>
<year>2013</year>;<volume>62</volume>:<fpage>2762</fpage>–<lpage>2772</lpage><?supplied-pmid 23493569?><pub-id pub-id-type="pmid">23493569</pub-id></mixed-citation>
      </ref>
      <ref id="B34">
        <label>34</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caspar-Bauguil</surname><given-names>S</given-names></name><name><surname>Cousin</surname><given-names>B</given-names></name><name><surname>Bour</surname><given-names>S</given-names></name><name><surname>Casteilla</surname><given-names>L</given-names></name><name><surname>Penicaud</surname><given-names>L</given-names></name><name><surname>Carpéné</surname><given-names>C</given-names></name></person-group>. <article-title>Adipose tissue lymphocytes: types and roles</article-title> [published correction appears in J Physiol Biochem 2011;67:497]. <source>J Physiol Biochem</source>
<year>2009</year>;<volume>65</volume>:<fpage>423</fpage>–<lpage>436</lpage><?supplied-pmid 20358356?><pub-id pub-id-type="pmid">20358356</pub-id></mixed-citation>
      </ref>
      <ref id="B35">
        <label>35</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caspar-Bauguil</surname><given-names>S</given-names></name><name><surname>Cousin</surname><given-names>B</given-names></name><name><surname>Galinier</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Adipose tissues as an ancestral immune organ: site-specific change in obesity</article-title>. <source>FEBS Lett</source>
<year>2005</year>;<volume>579</volume>:<fpage>3487</fpage>–<lpage>3492</lpage><?supplied-pmid 15953605?><pub-id pub-id-type="pmid">15953605</pub-id></mixed-citation>
      </ref>
      <ref id="B36">
        <label>36</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surendar</surname><given-names>J</given-names></name><name><surname>Mohan</surname><given-names>V</given-names></name><name><surname>Rao</surname><given-names>MM</given-names></name><name><surname>Babu</surname><given-names>S</given-names></name><name><surname>Aravindhan</surname><given-names>V</given-names></name></person-group>. <article-title>Increased levels of both Th1 and Th2 cytokines in subjects with metabolic syndrome (CURES-103)</article-title>. <source>Diabetes Technol Ther</source>
<year>2011</year>;<volume>13</volume>:<fpage>477</fpage>–<lpage>482</lpage><?supplied-pmid 21355722?><pub-id pub-id-type="pmid">21355722</pub-id></mixed-citation>
      </ref>
      <ref id="B37">
        <label>37</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pham</surname><given-names>MN</given-names></name><name><surname>Hawa</surname><given-names>MI</given-names></name><name><surname>Pfleger</surname><given-names>C</given-names></name><etal/><collab>Action LADA Study Group</collab></person-group>. <article-title>Pro- and anti-inflammatory cytokines in latent autoimmune diabetes in adults, type 1 and type 2 diabetes patients: Action LADA 4</article-title> [published correction appears in Diabetologia 2012;55:534]. <source>Diabetologia</source>
<year>2011</year>;<volume>54</volume>:<fpage>1630</fpage>–<lpage>1638</lpage><?supplied-pmid 21347621?><pub-id pub-id-type="pmid">21347621</pub-id></mixed-citation>
      </ref>
      <ref id="B38">
        <label>38</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klingensmith</surname><given-names>GJ</given-names></name><name><surname>Pyle</surname><given-names>L</given-names></name><name><surname>Arslanian</surname><given-names>S</given-names></name><etal/><collab>TODAY Study Group</collab></person-group>. <article-title>The presence of GAD and IA-2 antibodies in youth with a type 2 diabetes phenotype: results from the TODAY study</article-title>. <source>Diabetes Care</source>
<year>2010</year>;<volume>33</volume>:<fpage>1970</fpage>–<lpage>1975</lpage><?supplied-pmid 20519658?><pub-id pub-id-type="pmid">20519658</pub-id></mixed-citation>
      </ref>
      <ref id="B39">
        <label>39</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadley</surname><given-names>D</given-names></name><name><surname>Cheung</surname><given-names>RK</given-names></name><name><surname>Becker</surname><given-names>DJ</given-names></name><etal/><collab>TRIGR North America Investigators</collab></person-group>. <article-title>Large-scale prospective T cell function assays in shipped, unfrozen blood samples: experiences from the multicenter TRIGR trial</article-title>. <source>Clin Vaccine Immunol</source>
<year>2014</year>;<volume>21</volume>:<fpage>203</fpage>–<lpage>211</lpage><?supplied-pmid 24334687?><pub-id pub-id-type="pmid">24334687</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:4274777</identifier><datestamp>2016-01-01</datestamp><setSpec>diacare</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="http://jats.nlm.nih.gov/ns/archiving/1.0/ http://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Diabetes Care</journal-id>
      <journal-id journal-id-type="iso-abbrev">Diabetes Care</journal-id>
      <journal-id journal-id-type="hwp">diacare</journal-id>
      <journal-id journal-id-type="pmc">dcare</journal-id>
      <journal-id journal-id-type="publisher-id">Diabetes Care</journal-id>
      <journal-title-group>
        <journal-title>Diabetes Care</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0149-5992</issn>
      <issn pub-type="epub">1935-5548</issn>
      <publisher>
        <publisher-name>American Diabetes Association</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4274777</article-id>
      <article-id pub-id-type="pmcid">PMC4274777</article-id>
      <article-id pub-id-type="pmc-uid">4274777</article-id>
      <article-id pub-id-type="pmid">25336746</article-id>
      <article-id pub-id-type="publisher-id">0886</article-id>
      <article-id pub-id-type="doi">10.2337/dc14-0886</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Epidemiology/Health Services Research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>HbA<sub>1c</sub> as a Predictor of Diabetes and as an Outcome in the Diabetes Prevention Program: A Randomized Clinical Trial</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <collab>Diabetes Prevention Program Research Group</collab>
          <xref ref-type="fn" rid="fn3">*</xref>
        </contrib>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">Corresponding author: William C. Knowler, <email>dppmail@bsc.gwu.edu</email>.</corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>21</day>
        <month>10</month>
        <year>2014</year>
      </pub-date>
      <volume>38</volume>
      <issue>1</issue>
      <fpage>51</fpage>
      <lpage>58</lpage>
      <history>
        <date date-type="received">
          <day>8</day>
          <month>4</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>22</day>
          <month>9</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.</copyright-statement>
        <copyright-year>2015</copyright-year>
      </permissions>
      <self-uri xlink:title="pdf" xlink:type="simple" xlink:href="51.pdf"/>
      <abstract>
        <sec>
          <title>OBJECTIVE</title>
          <p>Glycated hemoglobin (HbA<sub>1c</sub>), a standard measure of chronic glycemia for managing diabetes, has been proposed to diagnose diabetes and identify people at risk. The Diabetes Prevention Program (DPP) was a 3.2-year randomized clinical trial of preventing type 2 diabetes with a 10-year follow-up study, the DPP Outcomes Study (DPPOS). We evaluated baseline HbA<sub>1c</sub> as a predictor of diabetes and determined the effects of treatments on diabetes defined by an HbA<sub>1c</sub> ≥6.5% (48 mmol/mol).</p>
        </sec>
        <sec>
          <title>RESEARCH DESIGN AND METHODS</title>
          <p>We randomized 3,234 nondiabetic adults at high risk of diabetes to placebo, metformin, or intensive lifestyle intervention and followed them for the development of diabetes as diagnosed by fasting plasma glucose (FPG) and 2-h postload glucose (2hPG) concentrations (1997 American Diabetes Association [ADA] criteria). HbA<sub>1c</sub> was measured but not used for study eligibility or outcomes. We now evaluate treatment effects in the 2,765 participants who did not have diabetes at baseline according to FPG, 2hPG, or HbA<sub>1c</sub> (2010 ADA criteria).</p>
        </sec>
        <sec>
          <title>RESULTS</title>
          <p>Baseline HbA<sub>1c</sub> predicted incident diabetes in all treatment groups. Diabetes incidence defined by HbA<sub>1c</sub> ≥6.5% was reduced by 44% by metformin and 49% by lifestyle during the DPP and by 38% by metformin and 29% by lifestyle throughout follow-up. Unlike the primary DPP and DPPOS findings based on glucose criteria, metformin and lifestyle were similarly effective in preventing diabetes defined by HbA<sub>1c.</sub></p>
        </sec>
        <sec>
          <title>CONCLUSIONS</title>
          <p>HbA<sub>1c</sub> predicted incident diabetes. In contrast to the superiority of the lifestyle intervention on glucose-defined diabetes, metformin and lifestyle interventions had similar effects in preventing HbA<sub>1c</sub>-defined diabetes. The long-term implications for other health outcomes remain to be determined.</p>
        </sec>
      </abstract>
      <counts>
        <page-count count="8"/>
      </counts>
    </article-meta>
  </front>
  <body><sec sec-type="intro" id="s1"><title>Introduction</title><p>The Diabetes Prevention Program (DPP), including its long-term follow-up Diabetes Prevention Program Outcomes Study (DPPOS), was a randomized clinical trial evaluating metformin and an intensive lifestyle (ILS) weight-loss intervention to prevent or delay type 2 diabetes (<xref rid="B1" ref-type="bibr">1</xref>–<xref rid="B3" ref-type="bibr">3</xref>) defined by 1997 American Diabetes Association (ADA) criteria for fasting plasma glucose (FPG) and 2-h postload glucose (2hPG) (<xref rid="B4" ref-type="bibr">4</xref>). Current diagnostic criteria define diabetes using HbA<sub>1c</sub> ≥6.5% (48 mmol/mol) (<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref>). HbA<sub>1c</sub> &lt;6.5% but ≥6.0% (42 mmol/mol) was recommended to identify persons at high risk of developing diabetes who should be offered preventive interventions (<xref rid="B5" ref-type="bibr">5</xref>). The lower limit defining high risk has also been set at ≥5.7% (39 mmol/mol) (<xref rid="B6" ref-type="bibr">6</xref>). To compare these different diagnostic criteria and evaluate HbA<sub>1c</sub> as a risk indicator, we evaluated HbA<sub>1c</sub> as a predictor of diabetes and as an alternate outcome in the DPP and DPPOS.</p></sec><sec id="s2"><title>Research Design and Methods</title><sec id="s3"><title>Participants, Treatment, and Follow-up</title><p>The methods and primary findings have been described (<xref rid="B1" ref-type="bibr">1</xref>–<xref rid="B3" ref-type="bibr">3</xref>), and protocols are available at <ext-link ext-link-type="uri" xlink:href="https://dppos.bsc.gwu.edu/web/dppos/home">https://dppos.bsc.gwu.edu/web/dppos/home</ext-link>. The trial is registered as NCT00004992 (DPP) and NCT00038727 (DPPOS). The 3,234 nondiabetic participants had the following risk factors: BMI ≥24 kg/m<sup>2</sup>, FPG ≥5.3 mmol/L (95 mg/dL) and &lt;7.0 mmol/L (126 mg/dL), and 2hPG ≥7.8 mmol/L (140 mg/dL) and &lt;11.1 mmol/L (200 mg/dL). There were minor exceptions to these criteria: FPG &lt;7.8 mmol/L before this diagnostic level was lowered with the 1997 ADA criteria, no lower limit of FPG in the American Indian centers, and BMI ≥22 kg/m<sup>2</sup> in Asian Americans (<xref rid="B1" ref-type="bibr">1</xref>).</p><p>Participants were randomly assigned to one of three treatment groups: placebo, metformin 850 mg twice per day, or ILS (<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>). A tentative diabetes diagnosis was made if FPG was ≥7.0 mmol/L (126 mg/dL) at a semiannual examination or 2hPG during the annual 75-g oral glucose tolerance test was ≥11.1 mmol/L (200 mg/dL), according to ADA criteria (<xref rid="B4" ref-type="bibr">4</xref>). A diagnosis required confirmation on a repeat of the same test (FPG or oral glucose tolerance test) as that triggering the tentative diagnosis (<xref rid="B1" ref-type="bibr">1</xref>). Confirmed diagnoses were reported to the participants and their health-care providers, but study metformin or placebo was still provided unless hyperglycemia worsened to FPG ≥140 mg/dL (7.8 mmol/L) during DPP or HbA<sub>1c</sub> ≥7.0% (53 mmol/mol) during DPPOS. At this point, the study drug was discontinued, and diabetes management, including metformin or other drug treatment, was transferred to the participant’s own health-care provider. Otherwise, HbA<sub>1c</sub> results were not used for determining eligibility or outcomes.</p><p>Diabetes incidence rates during the DPP were 11.0 cases/100 person-years in the placebo group, 7.8 in the metformin group, and 4.8 in the ILS group, representing reductions in diabetes incidence of 31% and 58% with metformin and ILS compared with placebo (<xref rid="B1" ref-type="bibr">1</xref>). Following drug unmasking and release of these results in 2001, all participants were offered lifestyle intervention (<xref rid="B3" ref-type="bibr">3</xref>). Metformin was continued in the original metformin group, placebo was discontinued, and the original ILS group was offered additional lifestyle support. Of the original cohort, 2,766 (88% of those alive and enrolled at the end of the DPP whether or not they had developed diabetes) were enrolled in the DPPOS long-term follow-up (<xref rid="B3" ref-type="bibr">3</xref>). During the DPPOS, after all study participants had been offered lifestyle intervention, diabetes rates in the metformin and former placebo groups fell to rates similar to those of the original ILS group, which remained relatively stable (<xref rid="B3" ref-type="bibr">3</xref>).</p><p>HbA<sub>1c</sub> was measured at baseline, 6 months, and 12 months and then annually in the level 1 central laboratory at the University of Washington. The high-performance liquid chromatography method was aligned to the National Glycohemoglobin Standardization Program. At the start of the study in 1996, analyses were performed using the Variant Classic instrument (Bio-Rad Laboratories, Inc., Hercules, CA) with an overall interassay coefficient of variance (CV) of 2.3%. In 1999, the Variant Classic was replaced by the Variant II instrument from the same manufacturer with an overall interassay CV of 1.7%. In 2004, the Variant II was replaced by the Tosoh G7 analyzer (Tosoh Bioscience, Inc., San Francisco, CA), with an overall interassay CV of 0.9%. Each transition was monitored by parallel measurements of patient and quality control samples to ensure no difference in the measurements among instruments. Additionally, to monitor for possible assay drift during the course of the study, five blood pools having HbA<sub>1c</sub> levels of 5%, 6%, 7%, 8%, and 9% (31, 42, 53, 64, and 75 mmol/mol, respectively) were prepared in the laboratory. The pools were aliquotted and stored under liquid nitrogen and analyzed for several days every month, and the mean values were plotted against their assigned values. There was consistently low variation around the target values with no evidence of assay drift over time. Some HbA<sub>1c</sub> assays are sensitive to hemoglobinopathies, of which HbS and HbF are especially common in African Americans, but the results are not affected by HbS. When a suspected S variant was detected, it was confirmed by an independent method. If HbF was above the instrument threshold, HbA<sub>1c</sub> results were not reported.</p></sec><sec id="s4"><title>Analysis of HbA<sub>1c</sub> as a Predictor and as a Study Outcome</title><p>The current report includes the participants who did not have diabetes at baseline according to FPG, 2hPG, and HbA<sub>1c</sub> (2010 ADA criteria), that is, FPG &lt;7.0 mmol/L, 2hPG &lt;11.1 mmol/L, and HbA<sub>1c</sub> &lt;6.5% (48 mmol/mol). Of the 3,234 individuals randomized, we excluded 54 with FPG ≥7.0 mmol/L (enrolled before the change in ADA diagnostic criteria), 7 with missing HbA<sub>1c</sub>, and 408 with HbA<sub>1c</sub> ≥6.5%, leaving an analysis set of 2,765 participants. The participants were grouped by baseline HbA<sub>1c</sub> &lt;5.5%, 5.5% to &lt;6.0%, or 6.0% to &lt;6.5% (&lt;37, 37 to &lt;42, or 42 to &lt;48 mmol/mol, respectively) to determine the predictive value for diabetes development defined by glucose or HbA<sub>1c</sub>. <ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc14-0886/-/DC1">Supplementary Fig. 1</ext-link> shows the follow-up of these participants. HbA<sub>1c</sub> results were not confirmed with repeat tests; therefore, for these analyses, a single HbA<sub>1c</sub> ≥6.5% was considered diagnostic.</p></sec><sec id="s5"><title>Statistical Methods</title><p>The intention-to-treat analysis compared each intervention group with the placebo group on the modified product-limit life-table distribution using the log-rank test statistic. Treatment groups and study time periods were also compared with incidence rates in cases/100 person-years. Person-years were summed over all participants in a group of time to follow-up before a diagnosis or to end of follow-up if diabetes did not develop during the period of interest. Diabetes hazard rates were stratified by age, sex, and self-reported race/ethnicity, and the covariate effects were assessed by simultaneously evaluating indicator terms for each major group compared with a predefined comparison group with the likelihood ratio test. Risk reduction and interactions between treatment assignments and covariates were assessed by proportional hazards regression.</p><p>We present results for the 2,765 participants separately for the 3.0-year median (interquartile range 2.5–3.7) follow-up in the DPP before the study results were announced and the protocol was modified and for the total follow-up period (DPP and DPPOS) from each participant’s randomization until a common closing date of 27 August 2008 (median 9.9 years, interquartile range 9.0–10.5). Statistical tests evaluating both periods must be interpreted while recognizing that they are not independent of each other (the first is contained in the second). Both periods are of interest: the DPP period because intervention effects on diabetes incidence were maximal in this period and it was the only double-blind period (for placebo and metformin) and the total follow-up period to assess effects for as long as possible.</p></sec></sec><sec sec-type="results" id="s6"><title>Results</title><p>Baseline characteristics of the 2,765 participants are shown in <xref ref-type="table" rid="T1">Table 1</xref>. None of the diabetes risk factors, including HbA<sub>1c</sub> and glucose measures, differed among the treatment groups.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Baseline characteristics at DPP randomization</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th valign="middle" align="left" scope="col" rowspan="1" colspan="1"/><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">Overall</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">Placebo</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">Metformin</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">Lifestyle</th></tr></thead><tbody><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Men</td><td valign="middle" align="center" rowspan="1" colspan="1">873 (31.6)</td><td valign="middle" align="center" rowspan="1" colspan="1">289 (31.0)</td><td valign="middle" align="center" rowspan="1" colspan="1">305 (33.5)</td><td valign="middle" align="center" rowspan="1" colspan="1">279 (30.3)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Women</td><td valign="middle" align="center" rowspan="1" colspan="1">1,892 (68.4)</td><td valign="middle" align="center" rowspan="1" colspan="1">643 (69.0)</td><td valign="middle" align="center" rowspan="1" colspan="1">606 (66.5)</td><td valign="middle" align="center" rowspan="1" colspan="1">643 (69.7)</td></tr><tr><td valign="middle" align="left" scope="col" rowspan="1" colspan="1">Race/ethnicity</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1"> Caucasian</td><td valign="middle" align="center" rowspan="1" colspan="1">1,621 (58.6)</td><td valign="middle" align="center" rowspan="1" colspan="1">534 (57.3)</td><td valign="middle" align="center" rowspan="1" colspan="1">548 (60.2)</td><td valign="middle" align="center" rowspan="1" colspan="1">539 (58.5)</td></tr><tr><td valign="middle" align="left" scope="col" rowspan="1" colspan="1"> African American</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1"> Hispanic</td><td valign="middle" align="center" rowspan="1" colspan="1">422 (15.3)</td><td valign="middle" align="center" rowspan="1" colspan="1">135 (14.5)</td><td valign="middle" align="center" rowspan="1" colspan="1">147 (16.1)</td><td valign="middle" align="center" rowspan="1" colspan="1">140 (15.2)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1"> American Indian</td><td valign="middle" align="center" rowspan="1" colspan="1">150 (5.4)</td><td valign="middle" align="center" rowspan="1" colspan="1">53 (5.7)</td><td valign="middle" align="center" rowspan="1" colspan="1">47 (5.2)</td><td valign="middle" align="center" rowspan="1" colspan="1">50 (5.4)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1"> Asian American</td><td valign="middle" align="center" rowspan="1" colspan="1">125 (4.5)</td><td valign="middle" align="center" rowspan="1" colspan="1">53 (5.7)</td><td valign="middle" align="center" rowspan="1" colspan="1">30 (3.3)</td><td valign="middle" align="center" rowspan="1" colspan="1">42 (4.6)</td></tr><tr><td valign="middle" align="left" scope="col" rowspan="1" colspan="1">HbA<sub>1c</sub></td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1"> &lt;5.5%</td><td align="center" rowspan="1" colspan="1">532 (19.2)</td><td align="center" rowspan="1" colspan="1">186 (20.0)</td><td align="center" rowspan="1" colspan="1">164 (18.0)</td><td align="center" rowspan="1" colspan="1">182 (19.7)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1"> 5.5–5.9%</td><td align="center" rowspan="1" colspan="1">1,200 (43.4)</td><td align="center" rowspan="1" colspan="1">385 (41.3)</td><td align="center" rowspan="1" colspan="1">421 (46.2)</td><td align="center" rowspan="1" colspan="1">394 (42.7)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1"> 6.0–6.4%</td><td align="center" rowspan="1" colspan="1">1,033 (37.4)</td><td align="center" rowspan="1" colspan="1">361 (38.7)</td><td align="center" rowspan="1" colspan="1">326 (35.8)</td><td align="center" rowspan="1" colspan="1">346 (37.5)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">50.3 (10.6)</td><td align="center" rowspan="1" colspan="1">50.2 (11.3)</td><td align="center" rowspan="1" colspan="1">50.4 (10.2)</td><td align="center" rowspan="1" colspan="1">50.1 (10.4)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Weight (kg)</td><td align="center" rowspan="1" colspan="1">93.3 (19.8)</td><td align="center" rowspan="1" colspan="1">93.1 (20.3)</td><td align="center" rowspan="1" colspan="1">93.4 (19.4)</td><td align="center" rowspan="1" colspan="1">93.3 (19.6)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">33.7 (6.5)</td><td align="center" rowspan="1" colspan="1">33.6 (6.6)</td><td align="center" rowspan="1" colspan="1">33.6 (6.4)</td><td align="center" rowspan="1" colspan="1">33.8 (6.5)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Waist circumference (cm)</td><td align="center" rowspan="1" colspan="1">104.3 (14.1)</td><td align="center" rowspan="1" colspan="1">104.5 (14.5)</td><td align="center" rowspan="1" colspan="1">104.1 (13.9)</td><td align="center" rowspan="1" colspan="1">104.4 (13.8)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">FPG (mg/dL)</td><td align="center" rowspan="1" colspan="1">105.4 (7.4)</td><td align="center" rowspan="1" colspan="1">105.3 (7.3)</td><td align="center" rowspan="1" colspan="1">105.2 (7.4)</td><td align="center" rowspan="1" colspan="1">105.6 (7.4)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">2hPG (mg/dL)</td><td align="center" rowspan="1" colspan="1">163.9 (16.9)</td><td align="center" rowspan="1" colspan="1">163.5 (16.7)</td><td align="center" rowspan="1" colspan="1">164.3 (17.0)</td><td align="center" rowspan="1" colspan="1">163.8 (16.9)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">HbA<sub>1c</sub> (%)</td><td align="center" rowspan="1" colspan="1">5.8 (0.4)</td><td align="center" rowspan="1" colspan="1">5.8 (0.4)</td><td align="center" rowspan="1" colspan="1">5.8 (0.4)</td><td align="center" rowspan="1" colspan="1">5.8 (0.4)</td></tr></tbody></table><table-wrap-foot><fn><p>Data are <italic>n</italic> (%) or mean (SD). None of the variables differed significantly among treatment groups.</p></fn></table-wrap-foot></table-wrap><p>HbA<sub>1c</sub> at baseline was a strong predictor of the development of glucose-defined diabetes during the DPP and total follow-up periods (<xref ref-type="fig" rid="F1">Fig. 1<italic>A</italic> and <italic>B</italic></xref>). During the DPP and total follow-up periods, the incidence of glucose-defined diabetes was positively related to baseline HbA<sub>1c</sub>, and stratified by baseline HbA<sub>1c</sub>, the incidence was reduced by metformin versus placebo (<italic>P</italic> &lt; 0.001) and by lifestyle versus placebo (<italic>P</italic> &lt; 0.001), and the reduction by lifestyle was greater than that by metformin (<italic>P</italic> &lt; 0.001). These relationships were continuous, with no evidence of an HbA<sub>1c</sub> threshold. In neither period was there a significant interaction of baseline HbA<sub>1c</sub> with treatment group on incidence of diabetes; that is, treatment effect (as a percent rate reduction) was independent of baseline HbA<sub>1c</sub>. The absolute effect in reducing diabetes incidence was greater in those with higher baseline HbA<sub>1c</sub>, however, among whom the incidence rates were higher regardless of treatment assignment.</p><fig id="F1" fig-type="figure" position="float"><label>Figure 1</label><caption><p>Incidence of diabetes (new cases/100 person-years) by baseline HbA<sub>1c</sub>, where diabetes was determined by 1997 ADA criteria using FPG and 2hPG concentrations or by HbA<sub>1c</sub> ≥6.5% (48 mmol/mol). Results are shown for the original masked treatment phase (DPP with mean follow-up of 3.0 years) (<italic>A</italic> and <italic>C</italic>) and for the DPP plus long-term follow-up (total follow-up with median follow-up of 9.9 years) (<italic>B</italic> and <italic>D</italic>). Met, metformin; Plac, placebo.</p></caption><graphic xlink:href="51fig1"/></fig><p>Incidence rates by treatment are shown for diabetes defined by HbA<sub>1c</sub> ≥6.5% in <xref ref-type="fig" rid="F1">Fig. 1<italic>C</italic> and <italic>D</italic></xref>. As with glucose-defined diabetes (<xref ref-type="fig" rid="F1">Fig. 1<italic>A</italic> and <italic>B</italic></xref>), baseline HbA<sub>1c</sub> strongly predicted HbA<sub>1c</sub>-defined diabetes, and treatment effects did not differ significantly by baseline HbA<sub>1c</sub>. During the DPP and total follow-up periods, the incidence of diabetes defined by HbA<sub>1c</sub> ≥6.5% was positively related to baseline HbA<sub>1c</sub>, and stratified by baseline HbA<sub>1c</sub>, the incidence was reduced by metformin versus placebo (<italic>P</italic> &lt; 0.0001) and by lifestyle versus placebo (<italic>P</italic> &lt; 0.0001), but the reductions by metformin and lifestyle did not differ significantly from each other. There was a significant interaction (<italic>P</italic> &lt; 0.01) between baseline HbA<sub>1c</sub> and the lifestyle versus placebo effect, the effect being greater at higher baseline HbA<sub>1c</sub>. Indeed, this outcome was so infrequent in those with baseline HbA<sub>1c</sub> &lt;5.5% that treatment effects could not be estimated precisely in this group.</p><p>Incidence rates by treatment are compared for the outcomes of glucose- and HbA<sub>1c</sub>-defined diabetes (<xref ref-type="fig" rid="F2">Fig. 2</xref>). Incidence rates of glucose-defined diabetes were lower in this subset than for all participants as reported previously (<xref rid="B2" ref-type="bibr">2</xref>) because of exclusion of the highest risk group with baseline HbA<sub>1c</sub> ≥6.5%, but the treatment effects persisted, with a reduction by 29% with metformin and by 51% with ILS during the DPP and by 21% with metformin and 28% with ILS in the total follow-up period. During the DPP period, the incidence of diabetes by glucose criteria was reduced by metformin versus placebo (<italic>P</italic> = 0.0013) and by lifestyle versus placebo (<italic>P</italic> &lt; 0.0001), and lifestyle intervention reduced it more than metformin (<italic>P</italic> = 0.0023). During the total follow-up period, the incidence of diabetes by glucose criteria was reduced by metformin versus placebo (<italic>P</italic> = 0.0014) and by lifestyle versus placebo (<italic>P</italic> &lt; 0.0001), but the reductions by metformin or lifestyle intervention did not differ significantly from each other. By contrast, for incidence rates of HbA<sub>1c</sub>-defined diabetes, metformin and ILS resulted in nearly the same rate reductions as each other during the DPP period (44% and 49%, respectively) and during total follow-up (38% and 29%, respectively). During the DPP and total follow-up periods, the incidence of HbA<sub>1c</sub> ≥6.5% was reduced by metformin versus placebo (<italic>P</italic> &lt; 0.0001) and by lifestyle versus placebo (<italic>P</italic> &lt; 0.0001) but did not differ significantly between the metformin and lifestyle interventions.</p><fig id="F2" fig-type="figure" position="float"><label>Figure 2</label><caption><p>Comparison of treatment effects on the incidence of diabetes diagnosed by glucose criteria or by HbA<sub>1c</sub> ≥6.5% (48 mmol/mol). Results are shown for the original masked treatment phase (DPP) (<italic>A</italic>) and for the total follow-up period (<italic>B</italic>). Met, metformin; Plac, placebo.</p></caption><graphic xlink:href="51fig2"/></fig><p>There were significant race/ethnicity effects on the incidence of glucose-defined (during total follow-up) and HbA<sub>1c</sub>-defined diabetes (during the DPP and total follow-up periods). Across all treatment groups combined, incidence rates were highest among African Americans (<ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc14-0886/-/DC1">Supplementary Table 1</ext-link>) during the total follow-up period when defined by glucose (<italic>P</italic> = 0.005) and when defined by HbA<sub>1c</sub> during the DPP and total follow-up periods (all <italic>P</italic> &lt; 0.001) in models adjusted for sex, age, HbA<sub>1c</sub> at baseline, FPG and 2hPG at baseline, and treatment assignment.</p><p>Results are presented stratified by baseline age and sex in <xref ref-type="fig" rid="F3">Fig. 3</xref>. In each age stratum among men and for each outcome (diabetes defined by glucose or HbA<sub>1c</sub>), rates were lower in the metformin and ILS groups than in the placebo group. Among women ≥60 years old, the incidence of glucose-defined diabetes was higher in the metformin than in the placebo group, but the incidence of HbA<sub>1c</sub>-defined diabetes was lower in the metformin group. The three-way interaction of sex × age × treatment was not statistically significant, however, indicating that these disparities could be due to chance. There were no significant sex × treatment interactions for incidence of glucose-defined diabetes during DPP or the total follow-up period; however, there were several significant sex × treatment interactions in incidence of HbA<sub>1c</sub> ≥6.5%. During the DPP, risk reduction by ILS versus placebo was greater in men than in women (70% and 38%, respectively; <italic>P</italic> = 0.010 for sex × treatment interaction). Reduction in risk of reaching HbA<sub>1c</sub> ≥6.5% during total follow-up was also greater in men (52% for ILS vs. placebo and 54% for metformin vs. placebo compared with 15% and 29% risk reductions, respectively, in women; both <italic>P</italic> &lt; 0.05 for sex × treatment interaction).</p><fig id="F3" fig-type="figure" position="float"><label>Figure 3</label><caption><p>Incidence of diabetes diagnosed by glucose criteria or by HbA<sub>1c</sub> ≥6.5% (48 mmol/mol) by baseline age and treatment assignment in men (<italic>A</italic>–<italic>D</italic>) and women (<italic>E</italic>–<italic>H</italic>). Results are shown for the original masked treatment phase (DPP) and for the total follow-up period. Met, metformin; Plac, placebo.</p></caption><graphic xlink:href="51fig3"/></fig><p>There were significant (<italic>P</italic> &lt; 0.05) interactions between treatment and baseline age in the incidence of glucose-defined diabetes during the DPP and total follow-up periods, with ILS having a greater advantage over metformin at older ages. Although there was a tendency for such an age interaction on incidence of HbA<sub>1c</sub> ≥6.5%, the interaction was not as pronounced and not statistically significant in the DPP or total follow-up periods.</p><p>The coincidence of diabetes defined by glucose and HbA<sub>1c</sub> criteria was examined. At the 1,059 examinations that led to a confirmed diabetes diagnosis based on glucose criteria during the total follow-up period, HbA<sub>1c</sub> was &lt;6.5% in 779 (74%) participants, was ≥6.5% for the first time in 105 (10%), and had been ≥6.5% at a previous examination in 175 (17%). Conversely, at the first examination after baseline at which HbA<sub>1c</sub> was ≥6.5% (750 occurrences), there was no confirmed glucose-based diagnosis of diabetes in 341 (45%), a confirmed glucose-based diagnosis triggered at the same visit in 105 (14%), and a previously confirmed glucose-based diabetes diagnosis in 304 (41%).</p></sec><sec sec-type="conclusions" id="s7"><title>Conclusions</title><p>HbA<sub>1c</sub> is recommended for identifying persons at high risk of developing diabetes and as a diabetes diagnostic criterion (<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref>). In this report, we evaluated baseline HbA<sub>1c</sub> as a predictor of diabetes and analyzed the DPP and DPPOS as if HbA<sub>1c</sub> ≥6.5% had been the sole outcome. Baseline HbA<sub>1c</sub> predicted development of glucose- and HbA<sub>1c</sub>-defined diabetes during the DPP and total follow-up periods, confirming findings in other prevention trials (<xref rid="B7" ref-type="bibr">7</xref>–<xref rid="B9" ref-type="bibr">9</xref>) that HbA<sub>1c</sub> below the diagnostic level of 6.5% is directly associated with risk of developing diabetes. The risk relationship is continuous with baseline HbA<sub>1c</sub> as previously suggested (<xref rid="B5" ref-type="bibr">5</xref>), confirming that selection of high-risk cut points of 6.0% (<xref rid="B5" ref-type="bibr">5</xref>) or 5.7% (<xref rid="B6" ref-type="bibr">6</xref>) is arbitrary. The optimal selection of high-risk characteristics for individuals offered diabetes prevention interventions will depend on available resources, health benefits of preventive measures, and their comparative effectiveness and costs.</p><p>In the DPP and DPPOS, diabetes was prevented or delayed with metformin or ILS aimed at weight loss and increased physical activity. The ILS was substantially more effective than metformin in preventing glucose-defined diabetes (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>). By contrast, if HbA<sub>1c</sub> ≥6.5% had been the outcome, we would have concluded that both interventions were similarly effective. We would have also accrued fewer events, confirming that HbA<sub>1c</sub> ≥6.5% alone defines fewer persons as having diabetes than does the combination of FPG or 2hPG, as found in the National Health and Nutrition Examination Survey (<xref rid="B10" ref-type="bibr">10</xref>) and the Finnish Diabetes Prevention Study (<xref rid="B7" ref-type="bibr">7</xref>). The HbA<sub>1c</sub> diagnostic cut point was purposefully chosen to favor specificity over sensitivity, recognizing that it would usually lead to fewer diagnoses compared with the 1997 glucose-based criteria (<xref rid="B5" ref-type="bibr">5</xref>).</p><p>These results add to previous DPP reports that metformin and ILS were similar in affecting FPG, whereas ILS was more effective for 2hPG-defined diabetes (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>). Metformin lowered FPG (<xref rid="B11" ref-type="bibr">11</xref>) consistent with its suppression of endogenous glucose production by the liver (<xref rid="B12" ref-type="bibr">12</xref>).</p><p>Do these results indicate that the two interventions will have equivalent health benefits in DPP participants; that is, is preventing diabetes defined by HbA<sub>1c</sub> as clinically important as preventing diabetes defined by FPG or 2hPG? HbA<sub>1c</sub> and FPG represent usual glycemia better than does 2hPG, which measures response to a nonphysiologic challenge. All three measures, however, have similar associations with microvascular disease (<xref rid="B13" ref-type="bibr">13</xref>–<xref rid="B16" ref-type="bibr">16</xref>). Therefore, the relative importance for other health outcomes of these glycemic measures is not clear. The current analyses do not address the relative importance of reducing diabetes based on glucose or HbA<sub>1c</sub> levels. Better understanding of the relative long-term health effects of the two interventions should come from further follow-up, during which intervention effects on microvascular-neuropathic outcomes and cardiovascular disease risk factors will be assessed (<xref rid="B3" ref-type="bibr">3</xref>). The analyses performed to date of the treatment effects on other outcomes during DPP, including lipids, blood pressure, and hemostatic factors, suggest that ILS achieves better or similar results with less medication use (<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B18" ref-type="bibr">18</xref>). Weight loss per se, which was greater with ILS, might have benefits beyond diabetes prevention. Neither the metformin nor the ILS had a significant interaction with a multigene diabetes risk score in predicting glucose-defined diabetes in the DPP (<xref rid="B19" ref-type="bibr">19</xref>), providing little support for considering genetic risk in choosing one of these treatment approaches. Evidence suggests that genotype at candidate loci influences success in weight loss intervention (<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B21" ref-type="bibr">21</xref>). Such developments and more comprehensive research on the genetics of response to metformin and lifestyle interventions may ultimately lead to tools for selecting optimal interventions for diabetes prevention.</p><p>Not only did treatment effects on glucose-defined and HbA<sub>1c</sub>-defined diabetes differ, but the participants diagnosed by each criterion did not fully overlap. Only 26% of those diagnosed by FPG or 2hPG had a previous or simultaneous HbA<sub>1c</sub> ≥6.5%. Conversely, 55% of those first attaining an HbA<sub>1c</sub> ≥6.5% had a current or previous diagnosis of diabetes by glucose criteria. We cannot determine whether those diagnosed by FPG or 2hPG with HbA<sub>1c</sub> &lt;6.5% would have subsequently met this level had they not been diagnosed by glucose levels and diabetes management subsequently initiated.</p><p>There were significant treatment interactions with age and sex. We previously reported that the effects of the active DPP interventions differed by age, with ILS being exceptionally effective and metformin ineffective among participants ≥60 years old at baseline (<xref rid="B22" ref-type="bibr">22</xref>). Furthermore, among those developing diabetes during DPP, the older group was more likely than the young or middle-aged groups to be diagnosed by 2hPG, on which metformin may have less effect. In the current analysis of HbA<sub>1c</sub>-defined diabetes, the greater effect of ILS with older age was maintained, and metformin was effective in all age-groups, particularly in men. The apparent adverse effect of metformin on incidence of glucose-defined diabetes in older women was not observed for HbA<sub>1c</sub>-defined diabetes.</p><p>Racial differences in the relationships between HbA<sub>1c</sub> and FPG and 2hPG have been reported (<xref rid="B23" ref-type="bibr">23</xref>,<xref rid="B24" ref-type="bibr">24</xref>). Other studies, however, suggested that interracial differences in HbA<sub>1c</sub> parallel differences in other measures of chronic glycemia (<xref rid="B25" ref-type="bibr">25</xref>) and that the relationships of HbA<sub>1c</sub> with retinopathy (<xref rid="B26" ref-type="bibr">26</xref>) and macrovascular disease and death (<xref rid="B27" ref-type="bibr">27</xref>) are the same in American blacks and whites. Moreover, differences in HbA<sub>1c</sub> between races are not explained by ancestry-informative genetic markers (<xref rid="B28" ref-type="bibr">28</xref>) or by allele frequency differences in genes associated with HbA<sub>1c</sub> (<xref rid="B29" ref-type="bibr">29</xref>). In the current analyses over the total follow-up period, the incidence of diabetes in the African Americans was higher than in the other race/ethnicity groups whether diabetes was defined by glucose or HbA<sub>1c</sub>. In addition, treatment effects on HbA<sub>1c</sub>-defined diabetes were similar among the race/ethnicity groups. Despite potential race/ethnicity differences in HbA<sub>1c</sub>, these data suggest treatment efficacy in all the race/ethnicity groups.</p><p>There are three important limitations to these analyses. First, we cannot strictly compare the performance of the different tests for diabetes because by protocol, diagnoses made by FPG or 2hPG required confirmation and the HbA<sub>1c</sub> tests did not. Second, we cannot determine to what extent elevation of HbA<sub>1c</sub> to ≥6.5% was prevented or delayed by the diagnosis of diabetes by glucose criteria and subsequent management or behavioral changes. Third, the eligibility criteria, including adults with BMI ≥24 kg/m<sup>2</sup>, with elevated FPG and 2hPG but without limitations on HbA<sub>1c</sub>, limit generalizability. Among persons not selected by BMI and glucose criteria as in the DPP, it is not known to what extent HbA<sub>1c</sub> would predict diabetes or response to interventions. For example, persons with HbA<sub>1c</sub> in the range of 6.0–6.4% who do not meet the other criteria may be at lower risk of diabetes than indicated herein. Given the uniformity of treatment effects according to baseline FPG and 2hPG reported previously (<xref rid="B2" ref-type="bibr">2</xref>) and HbA<sub>1c</sub> in the current study, we suspect that the study interventions would reduce diabetes risk similarly regardless of these baseline factors but that the absolute risk reduction (or numbers of cases prevented per number treated) would be lower in persons with lower levels of risk factors. Because eligibility criteria in prevention trials have been so restricted, we do not know how best to select persons who should be offered preventive interventions (<xref rid="B30" ref-type="bibr">30</xref>).</p><p>In summary, HbA<sub>1c</sub> measured at DPP entry predicted incidence of diabetes, and study treatment effects were uniform with respect to baseline HbA<sub>1c</sub> (i.e., there were no significant baseline HbA<sub>1c</sub> by treatment interactions). By contrast, although ILS was superior to metformin for preventing the development of glucose-defined diabetes, the effects of the two study treatments were similar in preventing diabetes defined by HbA<sub>1c</sub>. The health implications of these treatment and diagnostic differences await further assessment of long-term health outcomes.</p></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>Supplementary Data</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_38_1_51__index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_dc14-0886v140886_DC140886SupplementaryData.pdf"/>
</supplementary-material>
</sec>
</body>
  <back>
    <fn-group>
      <fn id="fn1" fn-type="supplementary-material">
        <p>This article contains Supplementary Data online at <ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc14-0886/-/DC1">http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc14-0886/-/DC1</ext-link>.</p>
      </fn>
      <fn id="fn2">
        <p>Clinical trial reg. nos. NCT00004992, <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link>, and NCT00038727, <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link>.</p>
      </fn>
      <fn id="fn3">
        <label>*</label>
        <p>A complete list of the members of the Diabetes Prevention Program Research Group can be found in the <ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc14-0886/-/DC1">Supplementary Data</ext-link> online, and a complete list of the members of the Writing Group is available in the <xref ref-type="app" rid="app1"><sc>appendix</sc></xref>.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Article Information</title>
      <p><bold>Acknowledgments.</bold> The Research Group gratefully acknowledges the commitment and dedication of the participants of the DPP and DPPOS.</p>
      <p><bold>Funding.</bold> During the DPPOS, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health provided funding to the clinical centers and the coordinating center for the design and conduct of the study and collection, management, analysis, and interpretation of the data. The Southwestern American Indian Centers were supported directly by the NIDDK, including its Intramural Research Program, and the Indian Health Service. The General Clinical Research Center Program, National Center for Research Resources, supported data collection at many of the clinical centers. Funding was also provided by the Eunice Kennedy Shriver National Institute of Child Health and Human Development; the National Institute on Aging; the National Eye Institute; the National Heart, Lung, and Blood Institute; the Office of Research on Women’s Health; the National Institute on Minority Health and Health Disparities; the Centers for Disease Control and Prevention; and the ADA.</p>
      <p>The primary sponsor, the NIDDK, was represented on the steering committee and played a part in study design, management, and publication. The sponsors were not members of the writing group, although all members of the steering committee had input into the article’s contents and reviewed the manuscript.</p>
      <p><bold>Duality of Interest.</bold> Bristol-Myers Squibb and Parke-Davis provided additional funding and material support during the DPP, Lipha (Merck Santé) provided medication, and LifeScan Inc. donated materials during the DPP and DPPOS. No other potential conflicts of interest relevant to this article were reported.</p>
      <p>The opinions expressed are those of the investigators and do not necessarily reflect the views of the funding agencies. A complete list of centers, investigators, and staff can be found in the <ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc14-0886/-/DC1">Supplementary Data</ext-link> online.</p>
      <p><bold>Author Contributions.</bold> The Writing Group, W.C.K., S.L.E., R.B.G., R.T.A., J.P.C., J.C.F., S.E.F., W.H.H., E.S.H., S.E.K., K.J.M., and D.M.N., had access to all data. W.C.K. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p>
      <p><bold>Prior Presentation.</bold> Parts of this study were presented in abstract form at the 70th Scientific Sessions of the American Diabetes Association, Orlando, FL, 25–29 June 2010.</p>
    </ack>
    <app-group>
      <app id="app1">
        <title>Appendix</title>
        <p>This article was prepared by William C. Knowler (National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, AZ), Sharon L. Edelstein (Biostatistics Center, George Washington University, Rockville, MD), Ronald B. Goldberg (University of Miami, Miami, FL), Ronald T. Ackermann (Northwestern University, Chicago, IL), Jill P. Crandall (Albert Einstein College of Medicine, New York, NY), Jose C. Florez (Massachusetts General Hospital and Harvard Medical School, Boston, MA), Sarah E. Fowler (Biostatistics Center, George Washington University, Rockville, MD), William H. Herman (University of Michigan, Ann Arbor, MI), Edward S. Horton (Joslin Diabetes Center and Harvard Medical School, Boston, MA), Steven E. Kahn (VA Puget Sound Health Care System and University of Washington, Seattle, WA), Kieren J. Mather (Indiana University, Indianapolis, IN), and David M. Nathan (Massachusetts General Hospital and Harvard Medical School, Boston, MA).</p>
      </app>
    </app-group>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>The Diabetes Prevention Program Research Group</collab></person-group>. <article-title>The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes</article-title>. <source>Diabetes Care</source>
<year>1999</year>;<volume>22</volume>:<fpage>623</fpage>–<lpage>634</lpage><?supplied-pmid 10189543?><pub-id pub-id-type="pmid">10189543</pub-id></mixed-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knowler</surname><given-names>WC</given-names></name><name><surname>Barrett-Connor</surname><given-names>E</given-names></name><name><surname>Fowler</surname><given-names>SE</given-names></name><etal/><collab>Diabetes Prevention Program Research Group</collab></person-group>. <article-title>Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin</article-title>. <source>N Engl J Med</source>
<year>2002</year>;<volume>346</volume>:<fpage>393</fpage>–<lpage>403</lpage><?supplied-pmid 11832527?><pub-id pub-id-type="pmid">11832527</pub-id></mixed-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knowler</surname><given-names>WC</given-names></name><name><surname>Fowler</surname><given-names>SE</given-names></name><name><surname>Hamman</surname><given-names>RF</given-names></name><etal/><collab>Diabetes Prevention Program Research Group</collab></person-group>. <article-title>10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study</article-title>. <source>Lancet</source>
<year>2009</year>;<volume>374</volume>:<fpage>1677</fpage>–<lpage>1686</lpage><?supplied-pmid 19878986?><pub-id pub-id-type="pmid">19878986</pub-id></mixed-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>American Diabetes Association</collab></person-group>. <article-title>Report of the expert committee on the diagnosis and classification of diabetes mellitus</article-title>. <source>Diabetes Care</source>
<year>1997</year>;<volume>20</volume>:<fpage>1183</fpage>–<lpage>1197</lpage><?supplied-pmid 9203460?><pub-id pub-id-type="pmid">9203460</pub-id></mixed-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>International Expert Committee</collab></person-group>. <article-title>International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes</article-title>. <source>Diabetes Care</source>
<year>2009</year>;<volume>32</volume>:<fpage>1327</fpage>–<lpage>1334</lpage><?supplied-pmid 19502545?><pub-id pub-id-type="pmid">19502545</pub-id></mixed-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>American Diabetes Association</collab></person-group>. <article-title>Diagnosis and classification of diabetes mellitus</article-title>. <source>Diabetes Care</source>
<year>2010</year>;<volume>33</volume>(<issue>Suppl. 1</issue>):<fpage>S62</fpage>–<lpage>S69</lpage><?supplied-pmid 20042775?><pub-id pub-id-type="pmid">20042775</pub-id></mixed-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pajunen</surname><given-names>P</given-names></name><name><surname>Peltonen</surname><given-names>M</given-names></name><name><surname>Eriksson</surname><given-names>JG</given-names></name><etal/><collab>Finnish Diabetes Prevention Study</collab></person-group>. <article-title>HbA(1c) in diagnosing and predicting type 2 diabetes in impaired glucose tolerance: the Finnish Diabetes Prevention Study</article-title>. <source>Diabet Med</source>
<year>2011</year>;<volume>28</volume>:<fpage>36</fpage>–<lpage>42</lpage><?supplied-pmid 21166843?><pub-id pub-id-type="pmid">21166843</pub-id></mixed-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Nishida</surname><given-names>J</given-names></name><etal/><collab>Zensharen Study for Prevention of Lifestyle Diseases Group</collab></person-group>. <article-title>Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial</article-title>. <source>Arch Intern Med</source>
<year>2011</year>;<volume>171</volume>:<fpage>1352</fpage>–<lpage>1360</lpage><?supplied-pmid 21824948?><pub-id pub-id-type="pmid">21824948</pub-id></mixed-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramachandran</surname><given-names>A</given-names></name><name><surname>Snehalatha</surname><given-names>C</given-names></name><name><surname>Samith Shetty</surname><given-names>A</given-names></name><name><surname>Nanditha</surname><given-names>A</given-names></name></person-group>. <article-title>Predictive value of HbA1c for incident diabetes among subjects with impaired glucose tolerance—analysis of the Indian Diabetes Prevention Programmes</article-title>. <source>Diabet Med</source>
<year>2012</year>;<volume>29</volume>:<fpage>94</fpage>–<lpage>98</lpage><?supplied-pmid 21790773?><pub-id pub-id-type="pmid">21790773</pub-id></mixed-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cowie</surname><given-names>CC</given-names></name><name><surname>Rust</surname><given-names>KF</given-names></name><name><surname>Byrd-Holt</surname><given-names>DD</given-names></name><etal/></person-group>. <article-title>Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006</article-title>. <source>Diabetes Care</source>
<year>2010</year>;<volume>33</volume>:<fpage>562</fpage>–<lpage>568</lpage><?supplied-pmid 20067953?><pub-id pub-id-type="pmid">20067953</pub-id></mixed-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitabchi</surname><given-names>AE</given-names></name><name><surname>Temprosa</surname><given-names>M</given-names></name><name><surname>Knowler</surname><given-names>WC</given-names></name><etal/><collab>Diabetes Prevention Program Research Group</collab></person-group>. <article-title>Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin</article-title>. <source>Diabetes</source>
<year>2005</year>;<volume>54</volume>:<fpage>2404</fpage>–<lpage>2414</lpage><?supplied-pmid 16046308?><pub-id pub-id-type="pmid">16046308</pub-id></mixed-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hundal</surname><given-names>RS</given-names></name><name><surname>Krssak</surname><given-names>M</given-names></name><name><surname>Dufour</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Mechanism by which metformin reduces glucose production in type 2 diabetes</article-title>. <source>Diabetes</source>
<year>2000</year>;<volume>49</volume>:<fpage>2063</fpage>–<lpage>2069</lpage><?supplied-pmid 11118008?><pub-id pub-id-type="pmid">11118008</pub-id></mixed-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCance</surname><given-names>DR</given-names></name><name><surname>Hanson</surname><given-names>RL</given-names></name><name><surname>Charles</surname><given-names>M-A</given-names></name><etal/></person-group>. <article-title>Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes</article-title>. <source>BMJ</source>
<year>1994</year>;<volume>308</volume>:<fpage>1323</fpage>–<lpage>1328</lpage><?supplied-pmid 8019217?><pub-id pub-id-type="pmid">8019217</pub-id></mixed-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tapp</surname><given-names>RJ</given-names></name><name><surname>Tikellis</surname><given-names>G</given-names></name><name><surname>Wong</surname><given-names>TY</given-names></name><name><surname>Harper</surname><given-names>CA</given-names></name><name><surname>Zimmet</surname><given-names>PZ</given-names></name><name><surname>Shaw</surname><given-names>JE</given-names></name><collab>Australian Diabetes Obesity and Lifestyle Study Group</collab></person-group>. <article-title>Longitudinal association of glucose metabolism with retinopathy: results from the Australian Diabetes Obesity and Lifestyle (AusDiab) study</article-title>. <source>Diabetes Care</source>
<year>2008</year>;<volume>31</volume>:<fpage>1349</fpage>–<lpage>1354</lpage><?supplied-pmid 18411241?><pub-id pub-id-type="pmid">18411241</pub-id></mixed-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colagiuri</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>CMY</given-names></name><name><surname>Wong</surname><given-names>TY</given-names></name><name><surname>Balkau</surname><given-names>B</given-names></name><name><surname>Shaw</surname><given-names>JE</given-names></name><name><surname>Borch-Johnsen</surname><given-names>K</given-names></name></person-group>;<article-title>
</article-title>DETECT-2 Collaboration Writing Group. <article-title>Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes</article-title>. <source>Diabetes Care</source>
<year>2011</year>;<volume>34</volume>:<fpage>145</fpage>–<lpage>150</lpage><?supplied-pmid 20978099?></mixed-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selvin</surname><given-names>E</given-names></name><name><surname>Ning</surname><given-names>Y</given-names></name><name><surname>Steffes</surname><given-names>MW</given-names></name><etal/></person-group>. <article-title>Glycated hemoglobin and the risk of kidney disease and retinopathy in adults with and without diabetes</article-title>. <source>Diabetes</source>
<year>2011</year>;<volume>60</volume>:<fpage>298</fpage>–<lpage>305</lpage><?supplied-pmid 20978092?><pub-id pub-id-type="pmid">20978092</pub-id></mixed-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haffner</surname><given-names>S</given-names></name><name><surname>Temprosa</surname><given-names>M</given-names></name><name><surname>Crandall</surname><given-names>J</given-names></name><etal/><collab>Diabetes Prevention Program Research Group</collab></person-group>. <article-title>Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance</article-title>. <source>Diabetes</source>
<year>2005</year>;<volume>54</volume>:<fpage>1566</fpage>–<lpage>1572</lpage><?supplied-pmid 15855347?><pub-id pub-id-type="pmid">15855347</pub-id></mixed-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orchard</surname><given-names>TJ</given-names></name><name><surname>Temprosa</surname><given-names>M</given-names></name><name><surname>Barrett-Connor</surname><given-names>E</given-names></name><etal/><collab>Diabetes Prevention Program Outcomes Study Research Group</collab></person-group>. <article-title>Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study</article-title>. <source>Diabet Med</source>
<year>2013</year>;<volume>30</volume>:<fpage>46</fpage>–<lpage>55</lpage><?supplied-pmid 22812594?><pub-id pub-id-type="pmid">22812594</pub-id></mixed-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hivert</surname><given-names>MF</given-names></name><name><surname>Jablonski</surname><given-names>KA</given-names></name><name><surname>Perreault</surname><given-names>L</given-names></name><etal/><collab>DIAGRAM Consortium</collab><collab>Diabetes Prevention Program Research Group</collab></person-group>. <article-title>Updated genetic score based on 34 confirmed type 2 diabetes loci is associated with diabetes incidence and regression to normoglycemia in the Diabetes Prevention Program</article-title>. <source>Diabetes</source>
<year>2011</year>;<volume>60</volume>:<fpage>1340</fpage>–<lpage>1348</lpage><?supplied-pmid 21378175?><pub-id pub-id-type="pmid">21378175</pub-id></mixed-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franks</surname><given-names>PW</given-names></name><name><surname>Jablonski</surname><given-names>KA</given-names></name><name><surname>Delahanty</surname><given-names>LM</given-names></name><etal/><collab>Diabetes Prevention Program Research Group</collab></person-group>. <article-title>Assessing gene-treatment interactions at the FTO and INSIG2 loci on obesity-related traits in the Diabetes Prevention Program</article-title>. <source>Diabetologia</source>
<year>2008</year>;<volume>51</volume>:<fpage>2214</fpage>–<lpage>2223</lpage><?supplied-pmid 18839134?><pub-id pub-id-type="pmid">18839134</pub-id></mixed-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>Q</given-names></name><name><surname>Delahanty</surname><given-names>LM</given-names></name><name><surname>Jablonski</surname><given-names>KA</given-names></name><etal/><collab>Diabetes Prevention Program Research Group</collab></person-group>. <article-title>Variation at the melanocortin 4 receptor gene and response to weight-loss interventions in the Diabetes Prevention Program</article-title>. <source>Obesity (Silver Spring)</source>
<year>2013</year>;<volume>21</volume>:<fpage>E520</fpage>–<lpage>E526</lpage><?supplied-pmid 23512951?><pub-id pub-id-type="pmid">23512951</pub-id></mixed-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crandall</surname><given-names>J</given-names></name><name><surname>Schade</surname><given-names>D</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><etal/><collab>Diabetes Prevention Program Research Group</collab></person-group>. <article-title>The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>
<year>2006</year>;<volume>61</volume>:<fpage>1075</fpage>–<lpage>1081</lpage><?supplied-pmid 17077202?><pub-id pub-id-type="pmid">17077202</pub-id></mixed-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herman</surname><given-names>WH</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Uwaifo</surname><given-names>G</given-names></name><etal/><collab>Diabetes Prevention Program Research Group</collab></person-group>. <article-title>Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program</article-title>. <source>Diabetes Care</source>
<year>2007</year>;<volume>30</volume>:<fpage>2453</fpage>–<lpage>2457</lpage><?supplied-pmid 17536077?><pub-id pub-id-type="pmid">17536077</pub-id></mixed-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziemer</surname><given-names>DC</given-names></name><name><surname>Kolm</surname><given-names>P</given-names></name><name><surname>Weintraub</surname><given-names>WS</given-names></name><etal/></person-group>. <article-title>Glucose-independent, black-white differences in hemoglobin A1c levels: a cross-sectional analysis of 2 studies</article-title>. <source>Ann Intern Med</source>
<year>2010</year>;<volume>152</volume>:<fpage>770</fpage>–<lpage>777</lpage><?supplied-pmid 20547905?><pub-id pub-id-type="pmid">20547905</pub-id></mixed-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selvin</surname><given-names>E</given-names></name><name><surname>Steffes</surname><given-names>MW</given-names></name><name><surname>Ballantyne</surname><given-names>CM</given-names></name><name><surname>Hoogeveen</surname><given-names>RC</given-names></name><name><surname>Coresh</surname><given-names>J</given-names></name><name><surname>Brancati</surname><given-names>FL</given-names></name></person-group>. <article-title>Racial differences in glycemic markers: a cross-sectional analysis of community-based data</article-title>. <source>Ann Intern Med</source>
<year>2011</year>;<volume>154</volume>:<fpage>303</fpage>–<lpage>309</lpage><?supplied-pmid 21357907?><pub-id pub-id-type="pmid">21357907</pub-id></mixed-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsugawa</surname><given-names>Y</given-names></name><name><surname>Mukamal</surname><given-names>KJ</given-names></name><name><surname>Davis</surname><given-names>RB</given-names></name><name><surname>Taylor</surname><given-names>WC</given-names></name><name><surname>Wee</surname><given-names>CC</given-names></name></person-group>. <article-title>Should the hemoglobin A1c diagnostic cutoff differ between blacks and whites? A cross-sectional study</article-title>. <source>Ann Intern Med</source>
<year>2012</year>;<volume>157</volume>:<fpage>153</fpage>–<lpage>159</lpage><?supplied-pmid 22868832?><pub-id pub-id-type="pmid">22868832</pub-id></mixed-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selvin</surname><given-names>E</given-names></name><name><surname>Steffes</surname><given-names>MW</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults</article-title>. <source>N Engl J Med</source>
<year>2010</year>;<volume>362</volume>:<fpage>800</fpage>–<lpage>811</lpage><?supplied-pmid 20200384?><pub-id pub-id-type="pmid">20200384</pub-id></mixed-citation>
      </ref>
      <ref id="B28">
        <label>28</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maruthur</surname><given-names>NM</given-names></name><name><surname>Kao</surname><given-names>WHL</given-names></name><name><surname>Clark</surname><given-names>JM</given-names></name><etal/></person-group>. <article-title>Does genetic ancestry explain higher values of glycated hemoglobin in African Americans</article-title>? <source>Diabetes</source>
<year>2011</year>;<volume>60</volume>:<fpage>2434</fpage>–<lpage>2438</lpage><?supplied-pmid 21788574?><pub-id pub-id-type="pmid">21788574</pub-id></mixed-citation>
      </ref>
      <ref id="B29">
        <label>29</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grimsby</surname><given-names>JL</given-names></name><name><surname>Porneala</surname><given-names>BC</given-names></name><name><surname>Vassy</surname><given-names>JL</given-names></name><etal/><collab>MAGIC Investigators</collab></person-group>. <article-title>Race-ethnic differences in the association of genetic loci with HbA1c levels and mortality in U.S. adults: the third National Health and Nutrition Examination Survey (NHANES III)</article-title>. <source>BMC Med Genet</source>
<year>2012</year>;<volume>13</volume>:<fpage>30</fpage><?supplied-pmid 22540250?><pub-id pub-id-type="pmid">22540250</pub-id></mixed-citation>
      </ref>
      <ref id="B30">
        <label>30</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knowler</surname><given-names>WC</given-names></name></person-group>. <article-title>Prevention of type 2 diabetes: comment on “Lifestyle Modification and Prevention of Type 2 Diabetes in Overweight Japanese With Impaired Fasting Glucose Levels.”</article-title>
<source>Arch Intern Med</source>
<year>2011</year>;<volume>171</volume>:<fpage>1361</fpage>–<lpage>1362</lpage><?supplied-pmid 21824949?><pub-id pub-id-type="pmid">21824949</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:4274778</identifier><datestamp>2016-01-01</datestamp><setSpec>diacare</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="http://jats.nlm.nih.gov/ns/archiving/1.0/ http://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Diabetes Care</journal-id>
      <journal-id journal-id-type="iso-abbrev">Diabetes Care</journal-id>
      <journal-id journal-id-type="hwp">diacare</journal-id>
      <journal-id journal-id-type="pmc">dcare</journal-id>
      <journal-id journal-id-type="publisher-id">Diabetes Care</journal-id>
      <journal-title-group>
        <journal-title>Diabetes Care</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0149-5992</issn>
      <issn pub-type="epub">1935-5548</issn>
      <publisher>
        <publisher-name>American Diabetes Association</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4274778</article-id>
      <article-id pub-id-type="pmcid">PMC4274778</article-id>
      <article-id pub-id-type="pmc-uid">4274778</article-id>
      <article-id pub-id-type="pmid">25404659</article-id>
      <article-id pub-id-type="publisher-id">1474</article-id>
      <article-id pub-id-type="doi">10.2337/dc14-1474</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Clinical Care/Education/Nutrition/Psychosocial Research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>An Automated Internet Behavioral Weight-Loss Program by Physician Referral: A Randomized Controlled Trial</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Thomas</surname>
            <given-names>J. Graham</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Leahey</surname>
            <given-names>Tricia M.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wing</surname>
            <given-names>Rena R.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <aff id="aff1"><sup>1</sup>Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, The Miriam Hospital/Weight Control and Diabetes Research Center, Providence, RI</aff>
        <aff id="aff2"><sup>2</sup>College of Agriculture and Natural Resources Department of Allied Health Sciences, University of Connecticut, Storrs, CT</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">Corresponding author: J. Graham Thomas, <email>jthomas4@lifespan.org</email>.</corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>17</day>
        <month>11</month>
        <year>2014</year>
      </pub-date>
      <volume>38</volume>
      <issue>1</issue>
      <fpage>9</fpage>
      <lpage>15</lpage>
      <history>
        <date date-type="received">
          <day>16</day>
          <month>6</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>30</day>
          <month>9</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.</copyright-statement>
        <copyright-year>2015</copyright-year>
      </permissions>
      <self-uri xlink:title="pdf" xlink:type="simple" xlink:href="9.pdf"/>
      <abstract>
        <sec>
          <title>OBJECTIVE</title>
          <p>To evaluate 3- and 6-month weight-loss outcomes achieved when physicians refer overweight/obese patients to an automated 3-month Internet-based behavioral weight-loss intervention.</p>
        </sec>
        <sec>
          <title>RESEARCH DESIGN AND METHODS</title>
          <p>A total of 154 patients age 18–70 years with a BMI between 25 and 45 kg/m<sup>2</sup> and access to a personal computer and the Internet were randomly assigned to 3 months of Internet behavioral intervention (IBI; <italic>n</italic> = 77) with 12 weekly videos teaching behavioral weight-loss skills, a platform for submitting self-monitored data, and automated feedback or an education-only Internet-delivered eating and activity control group (IDEA; <italic>n</italic> = 77). Outcome measures were weight loss after 3 months (primary outcome) and 6 months and changes in weight-control behaviors (secondary outcomes).</p>
        </sec>
        <sec>
          <title>RESULTS</title>
          <p>In intent-to-treat analyses with baseline weight carried forward for missing data, IBI produced significantly larger mean (SD) weight losses than IDEA at 3 months (5.5 kg [4.4] vs. 1.3 kg [2.1]) and 6 months (5.4 kg [5.6] vs. 1.3 kg [4.1]) (<italic>P</italic> &lt; 0.001). Participants in IBI compared with IDEA were also more likely to achieve a clinically significant weight loss of 5% of initial body weight at 3 months (53.3 vs. 9.1%) and 6 months (48.1 vs. 15.6%) (<italic>P</italic> &lt; 0.001) and reported more frequent use of weight control–related strategies.</p>
        </sec>
        <sec>
          <title>CONCLUSIONS</title>
          <p>Physician referral to an Internet-based behavioral weight-loss intervention produced clinically significant weight loss for over half of the patients studied. Further research is needed to determine the effectiveness of implementing this intervention more broadly within diverse health care settings.</p>
        </sec>
      </abstract>
      <counts>
        <page-count count="7"/>
      </counts>
    </article-meta>
  </front>
  <body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Over two-thirds of U.S. adults are overweight or obese and therefore at increased risk of developing type 2 diabetes (<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>). Physicians are in an excellent position to identify these individuals and advise them to lose weight, which has been shown to reduce the risk of developing diabetes and to improve a variety of health outcomes (<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref>). However, few physicians provide their patients with counseling to achieve weight loss (<xref rid="B5" ref-type="bibr">5</xref>). The physician counseling literature suggests that having physicians advise their patients to lose weight, while referring them to an effective program or allied health counselors rather than trying to offer counseling themselves, may be the most effective model for obesity treatment (<xref rid="B3" ref-type="bibr">3</xref>).</p><p>Unfortunately, there are few options for reimbursed weight-loss programs to which physicians can refer their patients (<xref rid="B6" ref-type="bibr">6</xref>). Behavioral weight-loss programs (BWLs) such as the lifestyle intervention used in the Diabetes Prevention Program (DPP) produce weight losses of 7–10%, reduce the risk of developing type 2 diabetes, and improve cardiovascular disease risk factors (<xref rid="B7" ref-type="bibr">7</xref>–<xref rid="B10" ref-type="bibr">10</xref>). However, these programs typically involve frequent group or individual sessions, are costly to both patients and providers, may not appeal to large numbers of patients seeking to lose weight, and are not widely available outside of research studies (<xref rid="B8" ref-type="bibr">8</xref>). Efforts to translate the DPP for delivery by medical and allied health professionals (e.g., in primary care practices) and in community settings such as the YMCA have produced a modest mean weight loss of 3.2–4.3% of initial body weight as determined by meta-analysis (<xref rid="B11" ref-type="bibr">11</xref>). There are also continued concerns about the cost, reach, accessibility, and long-term sustainability of these programs, which have relied heavily on in-person treatment delivery that is not well financed by the current health care system (<xref rid="B11" ref-type="bibr">11</xref>).</p><p>Shortcomings associated with in-person treatment delivery may be mitigated by adapting BWLs for Internet delivery (<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B13" ref-type="bibr">13</xref>), but there have been few randomized controlled trials testing these programs as a resource for physicians to refer their overweight and obese patients. In early studies of patients recruited through health care providers, the Internet was used to provide tailored or personal advice but not a structured BWL with a clearly defined curriculum of training in empirically validated behavioral weight-loss strategies. Attrition was high in these studies, and weight losses were quite limited (<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B15" ref-type="bibr">15</xref>). More recent studies of physician referral to Internet programs have used stronger behavioral programs but have provided substantial contact with health care coaches in person, by phone, and/or via e-mail (<xref rid="B16" ref-type="bibr">16</xref>–<xref rid="B19" ref-type="bibr">19</xref>). Although weight losses have been better in some of these studies [e.g., 4.8 kg at 12 months (<xref rid="B16" ref-type="bibr">16</xref>) and 5.1 kg at 24 months (<xref rid="B18" ref-type="bibr">18</xref>)], the human interaction once again makes these programs more expensive to deliver and less easily disseminated.</p><p>The primary objective of the Rx Weight Loss Trial was to examine the weight losses produced by a nearly fully automated Internet BWL compared with a healthy eating and activity Internet newsletter control condition, after a 3-month program and at 3-month follow-up, among patients who were randomized after accepting a referral to the trial by their physicians.</p></sec><sec id="s2"><title>Research Design and Methods</title><sec id="s3"><title>Design Overview</title><p>Participants were referred to the Rx Weight Loss Trial by 35 physicians at 5 primary care and 1 endocrinology practice in Rhode Island. Physicians identified potential participants during routine care and reviewed the study and inclusion/exclusion criteria with them. Physicians were especially encouraged to refer individuals with one or more obesity-related comorbidities, such as diabetes, hypertension, or metabolic syndrome. A referral form was signed by both the physician and patient and faxed to the researchers. Interested participants were contacted by the research staff, phone screened for eligibility, and scheduled for an orientation session, at which time further information was provided about the study and informed consent completed. Participants were scheduled for a baseline assessment and randomization/program kickoff visit ∼1 week later.</p><p>Participants were randomly assigned to a 3-month Internet behavior therapy program or Internet-Delivered Eating and Activity (IDEA) control condition with information on healthy eating habits and physical activity. During both the randomization/program kickoff visit and in their lesson materials, participants in both conditions received information pertaining to a healthy rate of weight loss and safe engagement in physical activity. The importance of regular contact with the referring physician for adjustments in medications was stressed. Access to the Internet interventions ended after 12 weeks in both groups. Both groups were assessed at the end of the 3-month program (posttreatment) and after 3 additional months of follow-up and received $25 and $50, respectively, for completing the assessments. Study procedures were approved by the Institutional Review Board of The Miriam Hospital.</p></sec><sec id="s4"><title>Participants</title><p>Participants were 154 overweight or obese English-speaking individuals with a BMI of 25–45 kg/m<sup>2</sup>, age 18–70 years old, with access to a personal computer and the Internet. Exclusion criteria included a weight loss of ≥5% of initial body weight within the last 6 months, current participation in another weight-loss program or current use of weight-loss medication, participation in a weight-loss program at the study clinic within the last 2 years, living with another study participant, pregnant or breastfeeding within the last 6 months, a plan to become pregnant or move to a new geographic region within 6 months, current chemotherapy or radiation treatment for cancer, untreated serious mental illness, or hospitalization for mental illness within the last 12 months.</p></sec><sec id="s5"><title>Randomization and Interventions</title><p>Participants were randomly assigned to one of the two treatment conditions using a computer-generated permuted blocking procedure, stratified by sex. A 1:1 randomization scheme was used. The allocation sequence was concealed until a patient consented to participate and had completed the baseline assessment.</p><sec id="s6"><title>Internet Behavioral Intervention</title><p>The Internet Behavioral Intervention (IBI) program included 12 weekly multimedia behavioral lessons, a website for submitting self-monitoring data, and weekly automated feedback provided to the participant on their progress to date. Participants were introduced to the IBI program at the 60-min randomization/program kickoff visit; they were given a goal of losing 1 to 2 lbs/week and achieving a total weight loss of ≥10% of initial body weight. To accomplish this, they were prescribed a calorie goal of 1,200–1,500 kcal/day depending on initial body weight with ≤30% calories from fat (40–60 g of fat/day) and a physical activity goal that gradually increased to 200 min/week of physical activity using activities similar in intensity to brisk walking. The remainder of the randomization/program kickoff visit was used to teach skills for self-monitoring daily food intake, physical activity minutes, and body weight. Participants received paper diaries and a calorie reference book for this purpose.</p><p>Standard behavioral strategies for changing their eating and activity were taught to the participants by having them view weekly 10–15-min interactive multimedia behavioral weight-loss lessons. In contrast to previous studies using static lessons with text and graphics (<xref rid="B20" ref-type="bibr">20</xref>), interactive lessons incorporating video, animation, audio, quizzes, and exercises for goal setting, planning, and problem-solving were developed to improve patient engagement (<xref rid="B21" ref-type="bibr">21</xref>). These lessons were based on strategies used in the DPP and Look AHEAD trials and included topics such as restaurant eating, changing the home environment, and social support (<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B22" ref-type="bibr">22</xref>). Daily values for body weight, caloric intake, fat intake (g), and physical activity minutes were submitted at least weekly to the Rx Weight Loss website. In response to their submissions, participants received a weekly automated tailored feedback message. The feedback messages were generated via an algorithm that compared participants’ self-reported values to their goals for weekly and overall weight loss, caloric intake, and physical activity minutes. Participants received praise for meeting goals and, when goals were not met, received specific recommendations for behavioral strategies to implement, along with support and encouragement. Automated e-mail reminder messages were sent weekly to participants who were not using the study website. Although in our prior research we found that human feedback was associated with larger weight losses than automated messages (<xref rid="B20" ref-type="bibr">20</xref>), we used automated messages in this trial because of the cost savings and ease of dissemination.</p><p>At weeks 4, 8, and 12, a letter was sent to the referring physician (and copied to the participant) indicating the number of weeks the participant had submitted data and their weight loss at that point. The letters were intended to provide physicians with information on the outcome of their referral, facilitate communication about health behaviors between physicians and patients, and enhance patients’ sense of accountability for their health and health behaviors.</p></sec><sec id="s7"><title>IDEA</title><p>Participants in this education-only control condition were seen at the randomization/program kickoff visit and instructed to access the Rx Weight Loss website at least once weekly to view a new printable lesson with static text and graphics in the Adobe portable document format. These newsletters provided general educational information on the benefits of losing weight and healthy eating and physical activity habits. Participants were not taught behavioral weight-loss strategies and were not instructed to self-monitor their behaviors, but were encouraged to explore online resources such as choosemyplate.gov, which contains information and tools for weight loss. This condition mimicked what patients may receive during routine care: a recommendation to lose weight accompanied by general educational information. IDEA also served as a method for controlling for access to Internet-based resources.</p></sec></sec><sec id="s8"><title>Outcomes and Follow-up</title><p>The primary outcome was change in body weight (kg, percent of initial body weight). Weight was measured in the research setting at baseline, 3 months (end of treatment), and 6 months (follow-up) in light street clothing, without shoes, and on a calibrated scale by blinded research staff. A secondary outcome was engagement with the Internet-based treatment system, which was measured by the number of weeks (out of 12) that participants logged in to the website, and, in the IBI group only, the number of weeks that calories, physical activity minutes, and body weight were reported for at least 5 of the 7 days. At baseline, participants reported their demographic characteristics and physician-diagnosed medical conditions. At baseline, 3, and 6 months, participants reported the number of weeks in the past 3 months that they had: <italic>1</italic>) reduced the number of calories consumed; <italic>2</italic>) decreased fat intake; <italic>3</italic>) increased fruits and vegetables consumed; and <italic>4</italic>) increased exercise levels. These items were drawn from the Weight Control Practices questionnaire used in the Look AHEAD trial (<xref rid="B23" ref-type="bibr">23</xref>).</p></sec><sec id="s9"><title>Statistical Analysis</title><p>PASW Statistics 19 (SPSS, Inc., 2009, Chicago, IL; <ext-link ext-link-type="uri" xlink:href="http://www.spss.com">http://www.spss.com</ext-link>) was used for all analyses. Changes in weight and levels of engagement with the Internet-based treatment system were examined via separate repeated-measures ANOVA that followed the intent-to-treat (ITT) principle in which missing data were replaced by baseline weights (assuming no weight loss). A secondary ITT analysis using multiple imputation by chained equations was used to confirm the pattern of results from the initial ITT analysis given that replacing missing data with baseline values could adversely affect tests of statistical significance (<xref rid="B24" ref-type="bibr">24</xref>). Given no difference in the pattern of results, the more conservative analysis with missing data replaced by baseline weights (assuming no weight loss) was selected for detailed reporting. Correlations were used to evaluate associations between engagement with the Internet-based treatment system and change in weight. Paired and independent samples <italic>t</italic> tests, respectively, were used to evaluate within-groups changes in rates of weight-control behaviors and to compare IBI and IDEA on rates of weight-control behaviors at baseline, 3, and 6 months. Unless noted otherwise, tests of significance were conducted at α = 0.05; all tests were two-tailed. This trial was designed to have 80% power to detect significant between-groups differences in weight loss of ≥2 kg at 3 and 6 months after randomization with 250 participants. An interim analysis comparing between-groups weight loss was conducted with 150 participants (4 more were in progress at the time), which resulted in early stopping of the trial due to clear evidence of efficacy. The analysis, and decision to stop the trial, were consistent with the α spending function approach to interim data analysis in which a more stringent criterion for statistical significance is used, in this case <italic>P</italic> &lt; 0.004 (<xref rid="B25" ref-type="bibr">25</xref>).</p></sec></sec><sec sec-type="results" id="s10"><title>Results</title><sec id="s11"><title>Recruitment and Retention</title><p>The CONSORT diagram is depicted in <xref ref-type="fig" rid="F1">Fig. 1</xref>. A total of 154 participants were randomized; 84.4% completed the assessment at the end of the 3 months, and 79.2% completed the 6 month follow-up. All attrition was attributed to loss of contact with participants. Retention rates were comparable in IBI and IDEA at both 3 months (83.1% in IBI vs. 85.7% in IDEA) and 6 months (79.2% in IBI vs. 79.2% in IDEA). There were also no statistically significant differences in baseline characteristics between participants who did and did not attend a postbaseline assessment.</p><fig id="F1" fig-type="figure" position="float"><label>Figure 1</label><caption><p>Flow of participants through the trial. The CONSORT flow diagram includes data on physician referrals, patient enrollment, allocation to treatment groups, follow-up, and primary analysis.</p></caption><graphic xlink:href="9fig1"/></fig></sec><sec id="s12"><title>Sample Characteristics</title><p>Participants’ baseline characteristics are reported in <xref ref-type="table" rid="T1">Table 1</xref>. Eighty percent of the participants were women. Participants averaged 53.2 (10.9) years of age and had an entry weight of 94.9 (16.4) kg. The most commonly endorsed physician-diagnosed medical conditions were hypertension (<italic>n</italic> = 80; 51.9% of sample), arthritis (<italic>n</italic> = 53; 34.4% of sample), cancer history (<italic>n</italic> = 22; 14.3% of sample), and type 2 diabetes (<italic>n</italic> = 20; 13.0% of sample). At baseline, IDEA participants reported higher rates of decreasing fat intake as a weight-loss strategy; there were no other statistically significant baseline differences between IBI and IDEA.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Baseline characteristics of participants assigned to the IBI and IDEA control conditions</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th align="left" scope="col" rowspan="1" colspan="1"/><th align="center" scope="col" rowspan="1" colspan="1">Full sample (<italic>N</italic> = 154)</th><th align="center" scope="col" rowspan="1" colspan="1">IBI condition (<italic>n</italic> = 77)</th><th align="center" scope="col" rowspan="1" colspan="1">IDEA condition (<italic>n</italic> = 77)</th></tr></thead><tbody><tr><td align="left" scope="col" rowspan="1" colspan="1">Sex, no. (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Men</td><td align="center" rowspan="1" colspan="1">31 (20.1)</td><td align="center" rowspan="1" colspan="1">15 (19.5)</td><td align="center" rowspan="1" colspan="1">16 (20.8)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Women</td><td align="center" rowspan="1" colspan="1">123 (79.9)</td><td align="center" rowspan="1" colspan="1">62 (80.5)</td><td align="center" rowspan="1" colspan="1">61 (79.2)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Age, mean (SD), years</td><td align="center" rowspan="1" colspan="1">53.2 (10.9)</td><td align="center" rowspan="1" colspan="1">52.8 (10.2)</td><td align="center" rowspan="1" colspan="1">53.6 (11.6)</td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Race, no. (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> American Indian</td><td align="center" rowspan="1" colspan="1">4 (2.6)</td><td align="center" rowspan="1" colspan="1">1 (1.3)</td><td align="center" rowspan="1" colspan="1">3 (3.9)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Asian</td><td align="center" rowspan="1" colspan="1">2 (1.3)</td><td align="center" rowspan="1" colspan="1">1 (1.3)</td><td align="center" rowspan="1" colspan="1">1 (1.3)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Black</td><td align="center" rowspan="1" colspan="1">7 (4.6)</td><td align="center" rowspan="1" colspan="1">3 (3.9)</td><td align="center" rowspan="1" colspan="1">4 (5.2)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> White</td><td align="center" rowspan="1" colspan="1">136 (88.3)</td><td align="center" rowspan="1" colspan="1">70 (90.9)</td><td align="center" rowspan="1" colspan="1">66 (85.7)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Other</td><td align="center" rowspan="1" colspan="1">10 (6.5)</td><td align="center" rowspan="1" colspan="1">5 (6.5)</td><td align="center" rowspan="1" colspan="1">5 (6.5)</td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Ethnicity, no. (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Hispanic</td><td align="center" rowspan="1" colspan="1">8 (5.2)</td><td align="center" rowspan="1" colspan="1">5 (6.5)</td><td align="center" rowspan="1" colspan="1">3 (3.9)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Non-Hispanic</td><td align="center" rowspan="1" colspan="1">146 (94.8)</td><td align="center" rowspan="1" colspan="1">72 (93.5)</td><td align="center" rowspan="1" colspan="1">74 (96.1)</td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Marital status, no. (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Single</td><td align="center" rowspan="1" colspan="1">33 (21.4)</td><td align="center" rowspan="1" colspan="1">14 (18.2)</td><td align="center" rowspan="1" colspan="1">19 (24.7)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Married</td><td align="center" rowspan="1" colspan="1">97 (63.0)</td><td align="center" rowspan="1" colspan="1">50 (64.9)</td><td align="center" rowspan="1" colspan="1">47 (61.0)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Separated/divorced</td><td align="center" rowspan="1" colspan="1">24 (15.6)</td><td align="center" rowspan="1" colspan="1">13 (16.9)</td><td align="center" rowspan="1" colspan="1">11 (14.3)</td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Education, no. (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> High school or less</td><td align="center" rowspan="1" colspan="1">19 (12.3)</td><td align="center" rowspan="1" colspan="1">5 (6.5)</td><td align="center" rowspan="1" colspan="1">14 (18.2)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Some college</td><td align="center" rowspan="1" colspan="1">44 (28.6)</td><td align="center" rowspan="1" colspan="1">27 (35.1)</td><td align="center" rowspan="1" colspan="1">17 (22.1)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> College or university degree</td><td align="center" rowspan="1" colspan="1">32 (20.8)</td><td align="center" rowspan="1" colspan="1">14 (18.2)</td><td align="center" rowspan="1" colspan="1">18 (23.4)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Graduate degree</td><td align="center" rowspan="1" colspan="1">59 (38.3)</td><td align="center" rowspan="1" colspan="1">31 (40.2)</td><td align="center" rowspan="1" colspan="1">28 (36.3)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Weight, mean (SD), kg</td><td align="center" rowspan="1" colspan="1">94.9 (16.4)</td><td align="center" rowspan="1" colspan="1">95.5 (16.8)</td><td align="center" rowspan="1" colspan="1">94.3 (16.1)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">BMI, mean (SD), kg/m<sup>2</sup></td><td align="center" rowspan="1" colspan="1">34.9 (4.8)</td><td align="center" rowspan="1" colspan="1">34.9 (4.7)</td><td align="center" rowspan="1" colspan="1">34.9 (5.0)</td></tr></tbody></table><table-wrap-foot><fn><p>There were no statistically significant differences between IBI and IDEA at baseline.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s13"><title>ITT Analysis</title><p>Group-specific changes in weight at months 3 and 6 are depicted in <xref ref-type="table" rid="T2">Table 2</xref> and <xref ref-type="fig" rid="F2">Fig. 2</xref>. The IBI condition produced significantly greater weight loss than IDEA at 3 months, 5.5 (4.4) vs. 1.3 (2.4) kg, and at 6 months, 5.4 (5.6) vs. 1.3 (4.1) kg (<italic>P</italic> &lt; 0.0001 for the overall effect of group). Moreover, 53% of IBI lost at least 5% of their body weight at 3 months, and 48% met the 5% weight goal at 6 months. Of the individuals in IBI that lost at least 5% of their body weight at 3 months, 34% lost at least an additional 1 kg from 3 to 6 months (mean [SD] loss of 2.9 [1.7] kg), 29% gained at least 1 kg from 3 to 6 months (mean [SD] gain of 2.8 [1.2] kg), and 37% were within 1 kg of their 3-month weight at 6 months. Twenty-one percent of IBI participants lost at least 10% of their body weight at each assessment point. The proportion of IBI participants achieving clinically significant weight losses exceeded those in IDEA (<xref ref-type="table" rid="T2">Table 2</xref>). Nearly a third (25–30%) of participants in IDEA gained weight at 3 and 6 months, respectively, whereas this occurred in only 2–7% of participants assigned to IBI (<ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc14-1474/-/DC1">Supplementary Fig. 1</ext-link>). The secondary analysis using multiple imputation produced the same pattern of results and statistically significant effects (not shown).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Change in weight at months 3 and 6 (ITT) for participants assigned to the IBI and IDEA control condition</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th align="left" scope="col" rowspan="1" colspan="1"/><th align="center" scope="col" rowspan="1" colspan="1">IBI (<italic>n</italic> = 77)</th><th align="center" scope="col" rowspan="1" colspan="1">IDEA (<italic>n</italic> = 77)</th></tr></thead><tbody><tr><td align="left" scope="col" rowspan="1" colspan="1">Weight loss (kg), mean (SD)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> 3 months</td><td align="center" rowspan="1" colspan="1">5.5 (4.4)</td><td align="center" rowspan="1" colspan="1">1.3 (2.4)<xref ref-type="table-fn" rid="t2n1">***</xref></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> 6 months</td><td align="center" rowspan="1" colspan="1">5.4 (5.6)</td><td align="center" rowspan="1" colspan="1">1.3 (4.1)<xref ref-type="table-fn" rid="t2n1">***</xref></td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Weight loss (% of initial weight), mean (SD)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> 3 months</td><td align="center" rowspan="1" colspan="1">5.8 (4.4)</td><td align="center" rowspan="1" colspan="1">1.4 (2.7)<xref ref-type="table-fn" rid="t2n1">***</xref></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> 6 months</td><td align="center" rowspan="1" colspan="1">5.6 (5.6)</td><td align="center" rowspan="1" colspan="1">1.4 (4.6)<xref ref-type="table-fn" rid="t2n1">***</xref></td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Participants with no loss or weight gain, no. (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> 3 months</td><td align="center" rowspan="1" colspan="1">1 (1.3)</td><td align="center" rowspan="1" colspan="1">20 (26.0)<xref ref-type="table-fn" rid="t2n1">***</xref></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> 6 months</td><td align="center" rowspan="1" colspan="1">5 (6.5)</td><td align="center" rowspan="1" colspan="1">23 (29.9)<xref ref-type="table-fn" rid="t2n1">***</xref></td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Participants with ≥5% weight loss, no. (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> 3 months</td><td align="center" rowspan="1" colspan="1">41 (53.3)</td><td align="center" rowspan="1" colspan="1">7 (9.1)<xref ref-type="table-fn" rid="t2n1">***</xref></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> 6 months</td><td align="center" rowspan="1" colspan="1">37 (48.1)</td><td align="center" rowspan="1" colspan="1">12 (15.6)<xref ref-type="table-fn" rid="t2n1">***</xref></td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Participants with ≥10% weight loss, no. (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> 3 months</td><td align="center" rowspan="1" colspan="1">16 (20.8)</td><td align="center" rowspan="1" colspan="1">1 (1.3)<xref ref-type="table-fn" rid="t2n1">***</xref></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> 6 months</td><td align="center" rowspan="1" colspan="1">16 (20.8)</td><td align="center" rowspan="1" colspan="1">4 (5.2)<xref ref-type="table-fn" rid="t2n1">**</xref></td></tr></tbody></table><table-wrap-foot><fn id="t2n1"><p>**<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001 for comparison of IBI and IDEA.</p></fn></table-wrap-foot></table-wrap><fig id="F2" fig-type="figure" position="float"><label>Figure 2</label><caption><p>Change in weight at months 3 and 6 in the ITT population for participants assigned to the IBI and IDEA control condition. Means with 95% CI bars.</p></caption><graphic xlink:href="9fig2"/></fig></sec><sec id="s14"><title>Engagement With the Website</title><p>IBI and IDEA did not differ significantly in the number of weeks (out of 12) that the website was used during the initial 3-month program (10.0 ± 3.0 in IBI and 9.5 ± 3.1 in IDEA; <italic>P</italic> = 0.301). Using the website for a greater number of weeks was associated with larger weight loss in the IBI condition (<italic>r</italic> = 0.41; <italic>P</italic> &lt; 0.001) but not in the IDEA condition (<italic>r</italic> = 0.18; <italic>P</italic> = 0.110).</p><p>Participants in the IBI condition reported their daily caloric intake, physical activity minutes, and daily weight on the intervention website at least 5 days out of the week on 6.7 (4.7) of the 12 weeks. Frequency of reporting was correlated with weight loss (<italic>r</italic> = 0.54; <italic>P</italic> &lt; 0.001).</p></sec><sec id="s15"><title>Weight-Control Behaviors</title><p>The frequency of each weight-loss behavior increased significantly from baseline to 3 months in IBI and IDEA (<italic>P</italic> values &lt;0.001), but IBI participants reported making changes during a greater number of weeks during this 3-month period (<xref ref-type="table" rid="T3">Table 3</xref>). Although the frequency of these changes decreased over time (<xref ref-type="table" rid="T3">Table 3</xref>), at 6 months, IBI participants still reported a greater frequency of reducing calorie and fat intake than IDEA.</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>IBI and IDEA control condition participants’ reports of their weight-control behaviors</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th rowspan="2" align="left" scope="col" colspan="1"/><th colspan="3" align="center" scope="colgroup" rowspan="1">Baseline<hr/></th><th colspan="3" align="center" scope="colgroup" rowspan="1">3 months<hr/></th><th colspan="3" align="center" scope="colgroup" rowspan="1">6 months<hr/></th></tr><tr><th colspan="1" align="center" scope="colgroup" rowspan="1">IBI (<italic>n</italic> = 77)</th><th align="center" scope="col" rowspan="1" colspan="1">IDEA (<italic>n</italic> = 77)</th><th align="center" scope="col" rowspan="1" colspan="1"><italic>P</italic> value</th><th align="center" scope="col" rowspan="1" colspan="1">IBI (<italic>n</italic> = 64)</th><th align="center" scope="col" rowspan="1" colspan="1">IDEA (<italic>n</italic> = 66)</th><th align="center" scope="col" rowspan="1" colspan="1"><italic>P</italic> value</th><th align="center" scope="col" rowspan="1" colspan="1">IBI (<italic>n</italic> = 61)</th><th align="center" scope="col" rowspan="1" colspan="1">IDEA (<italic>n</italic> = 61)</th><th align="center" scope="col" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" scope="row" rowspan="1" colspan="1">Reduce calories consumed</td><td align="center" rowspan="1" colspan="1">2.1 (3.7)</td><td align="center" rowspan="1" colspan="1">2.0 (3.1)</td><td align="center" rowspan="1" colspan="1">0.942</td><td align="center" rowspan="1" colspan="1">11.0 (2.5)<xref ref-type="table-fn" rid="t3n1">*</xref></td><td align="center" rowspan="1" colspan="1">5.9 (4.7)<xref ref-type="table-fn" rid="t3n1">*</xref></td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">6.6 (5.2)<xref ref-type="table-fn" rid="t3n1">*</xref><xref ref-type="table-fn" rid="t3n2">‡</xref></td><td align="center" rowspan="1" colspan="1">4.3 (4.8)<xref ref-type="table-fn" rid="t3n1">*</xref><xref ref-type="table-fn" rid="t3n2">‡</xref></td><td align="center" rowspan="1" colspan="1">0.013</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Decrease fat intake</td><td align="center" rowspan="1" colspan="1">0.9 (2.4)</td><td align="center" rowspan="1" colspan="1">2.2 (3.6)</td><td align="center" rowspan="1" colspan="1">0.009</td><td align="center" rowspan="1" colspan="1">10.6 (2.9)<xref ref-type="table-fn" rid="t3n1">*</xref></td><td align="center" rowspan="1" colspan="1">5.9 (5.0)<xref ref-type="table-fn" rid="t3n1">*</xref></td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">7.2 (4.9)<xref ref-type="table-fn" rid="t3n1">*</xref><xref ref-type="table-fn" rid="t3n2">‡</xref></td><td align="center" rowspan="1" colspan="1">5.1 (5.2)<xref ref-type="table-fn" rid="t3n1">*</xref></td><td align="center" rowspan="1" colspan="1">0.023</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Increase fruits and vegetables</td><td align="center" rowspan="1" colspan="1">2.9 (4.0)</td><td align="center" rowspan="1" colspan="1">3.4 (4.4)</td><td align="center" rowspan="1" colspan="1">0.481</td><td align="center" rowspan="1" colspan="1">9.9 (3.9)<xref ref-type="table-fn" rid="t3n1">*</xref></td><td align="center" rowspan="1" colspan="1">7.6 (4.6)<xref ref-type="table-fn" rid="t3n1">*</xref></td><td align="center" rowspan="1" colspan="1">0.002</td><td align="center" rowspan="1" colspan="1">7.8 (5.0)<xref ref-type="table-fn" rid="t3n1">*</xref><xref ref-type="table-fn" rid="t3n2">‡</xref></td><td align="center" rowspan="1" colspan="1">6.1 (4.9)<xref ref-type="table-fn" rid="t3n1">*</xref><xref ref-type="table-fn" rid="t3n2">‡</xref></td><td align="center" rowspan="1" colspan="1">0.063</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Increase exercise levels</td><td align="center" rowspan="1" colspan="1">1.9 (3.3)</td><td align="center" rowspan="1" colspan="1">2.8 (3.7)</td><td align="center" rowspan="1" colspan="1">0.882</td><td align="center" rowspan="1" colspan="1">8.7 (4.0)<xref ref-type="table-fn" rid="t3n1">*</xref></td><td align="center" rowspan="1" colspan="1">5.5 (4.9)<xref ref-type="table-fn" rid="t3n1">*</xref></td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">4.6 (5.1)<xref ref-type="table-fn" rid="t3n1">*</xref><xref ref-type="table-fn" rid="t3n2">‡</xref></td><td align="center" rowspan="1" colspan="1">3.2 (4.6)<xref ref-type="table-fn" rid="t3n2">‡</xref></td><td align="center" rowspan="1" colspan="1">0.096</td></tr></tbody></table><table-wrap-foot><fn><p>Data represent mean (SD) number of weeks in the past 3 months that the behavior was endorsed.</p></fn><fn id="t3n1"><p>*Value is significantly different from baseline value (<italic>P</italic> &lt; 0.05).</p></fn><fn id="t3n2"><p>‡Value is significantly different from 3-month value (<italic>P</italic> &lt; 0.05).</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="conclusions" id="s16"><title>Conclusions</title><p>The Rx Weight Loss Trial found that overweight and obese patients referred by their physician to an Internet behavioral weight-loss program lost on average 5.5 kg at the end of the 3-month program and maintained this weight loss in full at 6 months. In addition, 53% achieved a clinically significant weight loss of at least 5% of initial body weight at 3 months and 48% at 6 months. These results far exceeded the weight losses achieved by the patients who were randomly assigned to an Internet newsletter control condition and provide an effective, potentially low-cost option that physicians could use with their overweight and obese patients to reduce the risk of type 2 diabetes and other weight-related diseases.</p><p>Engagement with the IBI website was quite high during treatment and correlated with weight-loss outcomes. Prior work suggests that feedback messages, perhaps to an even greater degree than online lessons, contributed to improved weight-loss outcomes in similar programs (<xref rid="B26" ref-type="bibr">26</xref>). IBI participants also reported more frequent use of key behaviors, such as reducing calorie and fat intake, than was seen in IDEA. This suggests that successful skills acquisition and implementation is at least partially responsible for the superior weight losses in IBI. The use of key strategies was greatest during the 3-month treatment and then appeared to decrease; this finding emphasizes the need to develop approaches to maintaining adherence to these behaviors longer term. Likewise, additional research could be helpful in determining the relative importance of IBI components (e.g., goal-setting, lessons, self-monitoring, feedback, and reports to referring physicians).</p><p>Weight losses in the IBI condition appear to exceed those we achieved using a similar 3-month intervention in a community setting (3.5 kg weight loss at 3 months) (<xref rid="B26" ref-type="bibr">26</xref>). This difference in outcome may reflect differences in the two study groups. For example, participants referred by physicians may have more health concerns and therefore greater motivation to lose weight compared with individuals participating in a community wellness campaign. The difference may also suggest that there are added beneficial effects from physicians’ referrals and their involvement in the process. For example, the letters sent monthly to physicians (and copied to patients) reporting weight-loss progress may have increased the patients’ sense of accountability for their weight-loss success. Further research is needed to determine whether involving the physician improves outcomes and how best to maximize this effect.</p><p>Previous studies of weight-loss interventions in primary care settings have primarily involved physician counseling, physician counseling combined with weight-loss medications, or delivery of the intervention by other office staff (<xref rid="B27" ref-type="bibr">27</xref>). In many cases, the interventions were not based on empirically tested behavioral weight-loss strategies, and the results of these studies have been variable (<xref rid="B27" ref-type="bibr">27</xref>). We are aware of few studies that used web-based approaches in primary care, and as noted above, many of these have involved substantial face-to-face (<xref rid="B27" ref-type="bibr">27</xref>,<xref rid="B28" ref-type="bibr">28</xref>) or remote counseling (<xref rid="B16" ref-type="bibr">16</xref>–<xref rid="B19" ref-type="bibr">19</xref>). Our results suggest that comparable weight losses, at least initially, can be achieved with a nearly (i.e., with the exception of the randomization/program kickoff visit) fully automated Internet program. Likewise, our findings appear consistent with efforts to translate behavioral weight-loss interventions, such as the DPP, for delivery by medical and allied health professionals and in community settings that have achieved mean weight loss of 3.2–4.3% of initial body weight after 12 months (<xref rid="B11" ref-type="bibr">11</xref>). Compared with these other efforts, the Rx Weight Loss approach may incur fewer problems with cost, reach, accessibility, and long-term sustainability that have been a cause for concern with programs delivered in-person (<xref rid="B11" ref-type="bibr">11</xref>).</p><p>There are several limitations to this study. First, the study lasted only 6 months, and thus, it is not clear if these weight losses will be maintained long term. Since participants in behavioral weight-loss programs typically lose weight for the first 3–6 months of treatment (<xref rid="B8" ref-type="bibr">8</xref>) and then gradually regain weight, our study did not follow participants through the period during which they are at greatest risk of regain. Previous studies have consistently shown that continued contact is important for maintaining weight losses (<xref rid="B8" ref-type="bibr">8</xref>); providing further ongoing intervention and tailoring of the program to specific needs of the participant may promote long-term efficacy (<xref rid="B29" ref-type="bibr">29</xref>,<xref rid="B30" ref-type="bibr">30</xref>). Second, the study required several visits to an academic medical center that may have influenced outcomes. At the randomization/program kickoff visit, both groups were seen face-to-face and introduced to the website and the key elements of the weight-loss intervention (self-monitoring and goal-setting) were reviewed with participants in IBI. In the future, this information could be presented to participants via Internet-streamed video. Third, although some physicians referred many more patients than others (data not shown), we do not know the factors that influenced this. Nor do we know why some patients who agreed to a referral decided not to enroll. An exploration of factors affecting willingness of both physicians and patients to participate in such a program could be important if the program were to be made widely available. Fourth, while weight loss has been reliably shown to improve cardiovascular disease risk factors such as glucose control (<xref rid="B31" ref-type="bibr">31</xref>), we did not measure changes in these physiological indicators. Lastly, the sample had low racial and ethnic minority representation and was generally well educated; the generalizability of the results to other populations, including older adults and those with disabilities should be tested.</p><p>Strengths of the study include the system of referrals from physicians, which required very little time on their part, and the fact that the approach we used is nearly fully automated and can thus be scaled for use with large numbers of patients at minimal additional cost. Moreover, we compared the IBI program to a control group that received weekly printable lessons via the Internet, thus controlling for engagement with the website and ongoing attention to weight control. The clinically significant weight loss in IBI but not the control group suggests that physician advice to lose weight combined with common diet and exercise information is insufficient and that behavioral strategies and feedback are also required to produce meaningful weight loss.</p><p>In conclusion, physician referral to a behavioral Internet intervention, which includes weekly behavioral lessons and weekly automated feedback to patients on their self-monitoring records, with periodic written feedback to the physician, can be an effective approach for weight loss in overweight and obese individuals. Given that ∼80% of U.S. adults use the Internet (<xref rid="B32" ref-type="bibr">32</xref>,<xref rid="B33" ref-type="bibr">33</xref>), this approach may provide a cost-effective alternative or complement to the face-to-face counseling models of obesity treatment, including that which is currently reimbursable by the Centers for Medicare &amp; Medicaid Services (<xref rid="B34" ref-type="bibr">34</xref>), and could be paired with other Internet-based resources for diabetes management and risk reduction (<xref rid="B35" ref-type="bibr">35</xref>). Additional translational research is needed to determine whether this intervention can be fully implemented within current health care settings and reimbursement models while preserving the positive weight-loss outcomes.</p></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>Supplementary Data</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_38_1_9__index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_dc14-1474v141474_DC141474SupplementaryData.pdf"/>
</supplementary-material>
<supplementary-material id="PMC_2" content-type="local-data">
<caption>
<title>Slide Set</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_38_1_9_v2_index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="vnd.ms-powerpoint" xlink:href="supp_dc14-1474_January_2015_DC13_1474.ppt"/>
</supplementary-material>
</sec>
</body>
  <back>
    <fn-group>
      <fn id="fn1">
        <p>Clinical trial reg. no. NCT01222858, <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link>.</p>
      </fn>
      <fn id="fn2" fn-type="supplementary-material">
        <p>This article contains Supplementary Data online at <ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc14-1474/-/DC1">http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc14-1474/-/DC1</ext-link>.</p>
      </fn>
      <fn id="fn3">
        <p>A slide set summarizing this article is available online.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Article Information</title>
      <p><bold>Acknowledgments.</bold> The authors thank the study participants for their contribution to the research; the physicians for referring patients to the trial; and Pam Coward, Katelyn Gettens, and Rachel Ogilvie, The Weight Control and Diabetes Research Center of The Miriam Hospital, for assistance with study implementation.</p>
      <p><bold>Funding.</bold> This study was funded by a grant from the National Heart, Lung, and Blood Institute (RC1-HL-100002).</p>
      <p><bold>Duality of Interest.</bold> No potential conflicts of interest relevant to this article were reported.</p>
      <p><bold>Author Contributions.</bold> J.G.T. researched data, conducted the statistical analysis, and cowrote the manuscript. T.M.L. contributed to the discussion and reviewed and edited the manuscript. R.R.W. researched data and cowrote the manuscript. J.G.T. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p>
      <p><bold>Prior Presentation. </bold>A portion of the findings reported in this article was presented in poster form at the 30th Annual Scientific Meeting of The Obesity Society, San Antonio, TX, 20–24 September 2012.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flegal</surname><given-names>KM</given-names></name><name><surname>Carroll</surname><given-names>MD</given-names></name><name><surname>Kit</surname><given-names>BK</given-names></name><name><surname>Ogden</surname><given-names>CL</given-names></name></person-group>. <article-title>Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010</article-title>. <source>JAMA</source>
<year>2012</year>;<volume>307</volume>:<fpage>491</fpage>–<lpage>497</lpage><?supplied-pmid 22253363?><pub-id pub-id-type="pmid">22253363</pub-id></mixed-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>GA</given-names></name></person-group>. <article-title>Obesity increases risk for diabetes</article-title>. <source>Int J Obes Relat Metab Disord</source>
<year>1992</year>;<volume>16</volume>(<issue>Suppl. 4</issue>):<fpage>S13</fpage>–<lpage>S17</lpage><?supplied-pmid 1338382?><pub-id pub-id-type="pmid">1338382</pub-id></mixed-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreuter</surname><given-names>MW</given-names></name><name><surname>Chheda</surname><given-names>SG</given-names></name><name><surname>Bull</surname><given-names>FC</given-names></name></person-group>. <article-title>How does physician advice influence patient behavior? Evidence for a priming effect</article-title>. <source>Arch Fam Med</source>
<year>2000</year>;<volume>9</volume>:<fpage>426</fpage>–<lpage>433</lpage><?supplied-pmid 10810947?><pub-id pub-id-type="pmid">10810947</pub-id></mixed-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eden</surname><given-names>KB</given-names></name><name><surname>Orleans</surname><given-names>CT</given-names></name><name><surname>Mulrow</surname><given-names>CD</given-names></name><name><surname>Pender</surname><given-names>NJ</given-names></name><name><surname>Teutsch</surname><given-names>SM</given-names></name></person-group>. <article-title>Does counseling by clinicians improve physical activity? A summary of the evidence for the U.S. Preventive Services Task Force</article-title>. <source>Ann Intern Med</source>
<year>2002</year>;<volume>137</volume>:<fpage>208</fpage>–<lpage>215</lpage><?supplied-pmid 12160371?><pub-id pub-id-type="pmid">12160371</pub-id></mixed-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galuska</surname><given-names>DA</given-names></name><name><surname>Will</surname><given-names>JC</given-names></name><name><surname>Serdula</surname><given-names>MK</given-names></name><name><surname>Ford</surname><given-names>ES</given-names></name></person-group>. <article-title>Are health care professionals advising obese patients to lose weight</article-title>? <source>JAMA</source>
<year>1999</year>;<volume>282</volume>:<fpage>1576</fpage>–<lpage>1578</lpage><?supplied-pmid 10546698?><pub-id pub-id-type="pmid">10546698</pub-id></mixed-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>AG</given-names></name><name><surname>Asch</surname><given-names>DA</given-names></name><name><surname>Wadden</surname><given-names>TA</given-names></name></person-group>. <article-title>Insurance coverage for obesity treatment</article-title>. <source>J Am Diet Assoc</source>
<year>2006</year>;<volume>106</volume>:<fpage>1651</fpage>–<lpage>1655</lpage><?supplied-pmid 17000198?><pub-id pub-id-type="pmid">17000198</pub-id></mixed-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McTigue</surname><given-names>KM</given-names></name><name><surname>Harris</surname><given-names>R</given-names></name><name><surname>Hemphill</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Screening and interventions for obesity in adults: summary of the evidence for the U.S. Preventive Services Task Force</article-title>. <source>Ann Intern Med</source>
<year>2003</year>;<volume>139</volume>:<fpage>933</fpage>–<lpage>949</lpage><?supplied-pmid 14644897?><pub-id pub-id-type="pmid">14644897</pub-id></mixed-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butryn</surname><given-names>ML</given-names></name><name><surname>Webb</surname><given-names>V</given-names></name><name><surname>Wadden</surname><given-names>TA</given-names></name></person-group>. <article-title>Behavioral treatment of obesity</article-title>. <source>Psychiatr Clin North Am</source>
<year>2011</year>;<volume>34</volume>:<fpage>841</fpage>–<lpage>859</lpage><?supplied-pmid 22098808?><pub-id pub-id-type="pmid">22098808</pub-id></mixed-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Diabetes Prevention Program (DPP) Research Group</collab></person-group>. <article-title>The Diabetes Prevention Program (DPP): description of lifestyle intervention</article-title>. <source>Diabetes Care</source>
<year>2002</year>;<volume>25</volume>:<fpage>2165</fpage>–<lpage>2171</lpage><?supplied-pmid 12453955?><pub-id pub-id-type="pmid">12453955</pub-id></mixed-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knowler</surname><given-names>WC</given-names></name><name><surname>Fowler</surname><given-names>SE</given-names></name><name><surname>Hamman</surname><given-names>RF</given-names></name><etal/><collab>Diabetes Prevention Program Research Group</collab></person-group>. <article-title>10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study</article-title>. <source>Lancet</source>
<year>2009</year>;<volume>374</volume>:<fpage>1677</fpage>–<lpage>1686</lpage><?supplied-pmid 19878986?><pub-id pub-id-type="pmid">19878986</pub-id></mixed-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>MK</given-names></name><name><surname>Echouffo-Tcheugui</surname><given-names>J</given-names></name><name><surname>Williamson</surname><given-names>DF</given-names></name></person-group>. <article-title>How effective were lifestyle interventions in real-world settings that were modeled on the Diabetes Prevention Program</article-title>? <source>Health Aff (Millwood)</source>
<year>2012</year>;<volume>31</volume>:<fpage>67</fpage>–<lpage>75</lpage><?supplied-pmid 22232096?><pub-id pub-id-type="pmid">22232096</pub-id></mixed-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neve</surname><given-names>M</given-names></name><name><surname>Morgan</surname><given-names>PJ</given-names></name><name><surname>Jones</surname><given-names>PR</given-names></name><name><surname>Collins</surname><given-names>CE</given-names></name></person-group>. <article-title>Effectiveness of web-based interventions in achieving weight loss and weight loss maintenance in overweight and obese adults: a systematic review with meta-analysis</article-title>. <source>Obes Rev</source>
<year>2010</year>;<volume>11</volume>:<fpage>306</fpage>–<lpage>321</lpage><?supplied-pmid 19754633?><pub-id pub-id-type="pmid">19754633</pub-id></mixed-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>JG</given-names></name><name><surname>Bond</surname><given-names>DS</given-names></name></person-group>. <article-title>Review of innovations in digital health technology to promote weight control</article-title>. <source>Curr Diab Rep</source>
<year>2014</year>;<volume>14</volume>:<fpage>485</fpage><?supplied-pmid 24664797?><pub-id pub-id-type="pmid">24664797</pub-id></mixed-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothert</surname><given-names>K</given-names></name><name><surname>Strecher</surname><given-names>VJ</given-names></name><name><surname>Doyle</surname><given-names>LA</given-names></name><etal/></person-group>. <article-title>Web-based weight management programs in an integrated health care setting: a randomized, controlled trial</article-title>. <source>Obesity (Silver Spring)</source>
<year>2006</year>;<volume>14</volume>:<fpage>266</fpage>–<lpage>272</lpage><?supplied-pmid 16571852?><pub-id pub-id-type="pmid">16571852</pub-id></mixed-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McConnon</surname><given-names>A</given-names></name><name><surname>Kirk</surname><given-names>SF</given-names></name><name><surname>Cockroft</surname><given-names>JE</given-names></name><etal/></person-group>. <article-title>The Internet for weight control in an obese sample: results of a randomised controlled trial</article-title>. <source>BMC Health Serv Res</source>
<year>2007</year>;<volume>7</volume>:<fpage>206</fpage><?supplied-pmid 18093289?><pub-id pub-id-type="pmid">18093289</pub-id></mixed-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McTigue</surname><given-names>KM</given-names></name><name><surname>Conroy</surname><given-names>MB</given-names></name><name><surname>Hess</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Using the internet to translate an evidence-based lifestyle intervention into practice</article-title>. <source>Telemed J E Health</source>
<year>2009</year>;<volume>15</volume>:<fpage>851</fpage>–<lpage>858</lpage><?supplied-pmid 19919191?><pub-id pub-id-type="pmid">19919191</pub-id></mixed-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bennett</surname><given-names>GG</given-names></name><name><surname>Warner</surname><given-names>ET</given-names></name><name><surname>Glasgow</surname><given-names>RE</given-names></name><etal/><collab>Be Fit, Be Well Study Investigators</collab></person-group>. <article-title>Obesity treatment for socioeconomically disadvantaged patients in primary care practice</article-title>. <source>Arch Intern Med</source>
<year>2012</year>;<volume>172</volume>:<fpage>565</fpage>–<lpage>574</lpage><?supplied-pmid 22412073?><pub-id pub-id-type="pmid">22412073</pub-id></mixed-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Appel</surname><given-names>LJ</given-names></name><name><surname>Clark</surname><given-names>JM</given-names></name><name><surname>Yeh</surname><given-names>HC</given-names></name><etal/></person-group>. <article-title>Comparative effectiveness of weight-loss interventions in clinical practice</article-title>. <source>N Engl J Med</source>
<year>2011</year>;<volume>365</volume>:<fpage>1959</fpage>–<lpage>1968</lpage><?supplied-pmid 22085317?><pub-id pub-id-type="pmid">22085317</pub-id></mixed-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Yank</surname><given-names>V</given-names></name><name><surname>Xiao</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Translating the Diabetes Prevention Program lifestyle intervention for weight loss into primary care: a randomized trial</article-title>. <source>JAMA Intern Med</source>
<year>2013</year>;<volume>173</volume>:<fpage>113</fpage>–<lpage>121</lpage><?supplied-pmid 23229846?><pub-id pub-id-type="pmid">23229846</pub-id></mixed-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tate</surname><given-names>DF</given-names></name><name><surname>Jackvony</surname><given-names>EH</given-names></name><name><surname>Wing</surname><given-names>RR</given-names></name></person-group>. <article-title>A randomized trial comparing human e-mail counseling, computer-automated tailored counseling, and no counseling in an Internet weight loss program</article-title>. <source>Arch Intern Med</source>
<year>2006</year>;<volume>166</volume>:<fpage>1620</fpage>–<lpage>1625</lpage><?supplied-pmid 16908795?><pub-id pub-id-type="pmid">16908795</pub-id></mixed-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norman</surname><given-names>GJ</given-names></name><name><surname>Zabinski</surname><given-names>MF</given-names></name><name><surname>Adams</surname><given-names>MA</given-names></name><name><surname>Rosenberg</surname><given-names>DE</given-names></name><name><surname>Yaroch</surname><given-names>AL</given-names></name><name><surname>Atienza</surname><given-names>AA</given-names></name></person-group>. <article-title>A review of eHealth interventions for physical activity and dietary behavior change</article-title>. <source>Am J Prev Med</source>
<year>2007</year>;<volume>33</volume>:<fpage>336</fpage>–<lpage>345</lpage><?supplied-pmid 17888860?><pub-id pub-id-type="pmid">17888860</pub-id></mixed-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wadden</surname><given-names>TA</given-names></name><name><surname>West</surname><given-names>DS</given-names></name><name><surname>Delahanty</surname><given-names>L</given-names></name><etal/><collab>Look AHEAD Research Group</collab></person-group>. <article-title>The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it</article-title> [published correction appears in Obesity (Silver Spring) 2007;15:1339]. <source>Obesity (Silver Spring)</source>
<year>2006</year>;<volume>14</volume>:<fpage>737</fpage>–<lpage>752</lpage><?supplied-pmid 16855180?><pub-id pub-id-type="pmid">16855180</pub-id></mixed-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raynor</surname><given-names>HA</given-names></name><name><surname>Jeffery</surname><given-names>RW</given-names></name><name><surname>Ruggiero</surname><given-names>AM</given-names></name><name><surname>Clark</surname><given-names>JM</given-names></name><name><surname>Delahanty</surname><given-names>LM</given-names></name><collab>Look AHEAD (Action for Health in Diabetes) Research Group</collab></person-group>. <article-title>Weight loss strategies associated with BMI in overweight adults with type 2 diabetes at entry into the Look AHEAD (Action for Health in Diabetes) trial</article-title>. <source>Diabetes Care</source>
<year>2008</year>;<volume>31</volume>:<fpage>1299</fpage>–<lpage>1304</lpage><?supplied-pmid 18375417?><pub-id pub-id-type="pmid">18375417</pub-id></mixed-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lachin</surname><given-names>JM</given-names></name></person-group>. <article-title>Statistical considerations in the intent-to-treat principle</article-title>. <source>Control Clin Trials</source>
<year>2000</year>;<volume>21</volume>:<fpage>167</fpage>–<lpage>189</lpage><?supplied-pmid 10822117?><pub-id pub-id-type="pmid">10822117</pub-id></mixed-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeMets</surname><given-names>DL</given-names></name><name><surname>Lan</surname><given-names>KK</given-names></name></person-group>. <article-title>Interim analysis: the alpha spending function approach</article-title>. <source>Stat Med</source>
<year>1994</year>;<volume>13</volume>:<fpage>1341</fpage>–<lpage>1352</lpage>; discussion 1353–1356<?supplied-pmid 7973215?><pub-id pub-id-type="pmid">7973215</pub-id></mixed-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wing</surname><given-names>RR</given-names></name><name><surname>Crane</surname><given-names>MM</given-names></name><name><surname>Thomas</surname><given-names>JG</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Weinberg</surname><given-names>B</given-names></name></person-group>. <article-title>Improving weight loss outcomes of community interventions by incorporating behavioral strategies</article-title>. <source>Am J Public Health</source>
<year>2010</year>;<volume>100</volume>:<fpage>2513</fpage>–<lpage>2519</lpage><?supplied-pmid 20966375?><pub-id pub-id-type="pmid">20966375</pub-id></mixed-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoong</surname><given-names>SL</given-names></name><name><surname>Carey</surname><given-names>M</given-names></name><name><surname>Sanson-Fisher</surname><given-names>R</given-names></name><name><surname>Grady</surname><given-names>A</given-names></name></person-group>. <article-title>A systematic review of behavioural weight-loss interventions involving primary-care physicians in overweight and obese primary-care patients (1999-2011)</article-title>. <source>Public Health Nutr</source>
<year>2013</year>;<volume>16</volume>:<fpage>2083</fpage>–<lpage>2099</lpage><?supplied-pmid 23101456?><pub-id pub-id-type="pmid">23101456</pub-id></mixed-citation>
      </ref>
      <ref id="B28">
        <label>28</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bennett</surname><given-names>GG</given-names></name><name><surname>Herring</surname><given-names>SJ</given-names></name><name><surname>Puleo</surname><given-names>E</given-names></name><name><surname>Stein</surname><given-names>EK</given-names></name><name><surname>Emmons</surname><given-names>KM</given-names></name><name><surname>Gillman</surname><given-names>MW</given-names></name></person-group>. <article-title>Web-based weight loss in primary care: a randomized controlled trial</article-title>. <source>Obesity (Silver Spring)</source>
<year>2010</year>;<volume>18</volume>:<fpage>308</fpage>–<lpage>313</lpage><?supplied-pmid 19696764?><pub-id pub-id-type="pmid">19696764</pub-id></mixed-citation>
      </ref>
      <ref id="B29">
        <label>29</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreuter</surname><given-names>MW</given-names></name><name><surname>Bull</surname><given-names>FC</given-names></name><name><surname>Clark</surname><given-names>EM</given-names></name><name><surname>Oswald</surname><given-names>DL</given-names></name></person-group>. <article-title>Understanding how people process health information: a comparison of tailored and nontailored weight-loss materials</article-title>. <source>Health Psychol</source>
<year>1999</year>;<volume>18</volume>:<fpage>487</fpage>–<lpage>494</lpage><?supplied-pmid 10519465?><pub-id pub-id-type="pmid">10519465</pub-id></mixed-citation>
      </ref>
      <ref id="B30">
        <label>30</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saperstein</surname><given-names>SL</given-names></name><name><surname>Atkinson</surname><given-names>NL</given-names></name><name><surname>Gold</surname><given-names>RS</given-names></name></person-group>. <article-title>The impact of Internet use for weight loss</article-title>. <source>Obes Rev</source>
<year>2007</year>;<volume>8</volume>:<fpage>459</fpage>–<lpage>465</lpage><?supplied-pmid 17716303?><pub-id pub-id-type="pmid">17716303</pub-id></mixed-citation>
      </ref>
      <ref id="B31">
        <label>31</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>DJ</given-names></name></person-group>. <article-title>Beneficial health effects of modest weight loss</article-title>. <source>Int J Obes Relat Metab Disord</source>
<year>1992</year>;<volume>16</volume>:<fpage>397</fpage>–<lpage>415</lpage><?supplied-pmid 1322866?><pub-id pub-id-type="pmid">1322866</pub-id></mixed-citation>
      </ref>
      <ref id="B32">
        <label>32</label>
        <mixed-citation publication-type="webpage">Duggan M, Smith A. Cell internet use 2013 [Internet], 2013. Available from <ext-link ext-link-type="uri" xlink:href="http://pewinternet.org/Reports/2013/Cell-Internet.aspx">http://pewinternet.org/Reports/2013/Cell-Internet.aspx</ext-link>. Accessed 31 July 2014</mixed-citation>
      </ref>
      <ref id="B33">
        <label>33</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>File</surname><given-names>T</given-names></name></person-group>
<source>Computer and Internet Use in the United States. Current Population Survey Reports</source>. <publisher-loc>Washington, D.C.</publisher-loc>, <publisher-name>U.S. Census Bureau</publisher-name>, <year>2013</year>, p. <fpage>20</fpage>–<lpage>568</lpage></mixed-citation>
      </ref>
      <ref id="B34">
        <label>34</label>
        <mixed-citation publication-type="webpage">Centers for Medicare &amp; Medicaid Services. Decision memo for intensive behavioral therapy for obesity (CAG-00423N) [article online], 2013. Available from <ext-link ext-link-type="uri" xlink:href="http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?&amp;NCAId=253">http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?&amp;NCAId=253</ext-link>. Accessed 20 August 2013</mixed-citation>
      </ref>
      <ref id="B35">
        <label>35</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufman</surname><given-names>N</given-names></name></person-group>. <article-title>Internet and information technology use in treatment of diabetes</article-title>. <source>Int J Clin Pract Suppl</source>
<year>2010</year>;<volume>166</volume>:<fpage>41</fpage>–<lpage>46</lpage><?supplied-pmid 20377663?><pub-id pub-id-type="pmid">20377663</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:4274779</identifier><datestamp>2016-01-01</datestamp><setSpec>diacare</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="http://jats.nlm.nih.gov/ns/archiving/1.0/ http://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Diabetes Care</journal-id>
      <journal-id journal-id-type="iso-abbrev">Diabetes Care</journal-id>
      <journal-id journal-id-type="hwp">diacare</journal-id>
      <journal-id journal-id-type="pmc">dcare</journal-id>
      <journal-id journal-id-type="publisher-id">Diabetes Care</journal-id>
      <journal-title-group>
        <journal-title>Diabetes Care</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0149-5992</issn>
      <issn pub-type="epub">1935-5548</issn>
      <publisher>
        <publisher-name>American Diabetes Association</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4274779</article-id>
      <article-id pub-id-type="pmcid">PMC4274779</article-id>
      <article-id pub-id-type="pmc-uid">4274779</article-id>
      <article-id pub-id-type="pmid">25392294</article-id>
      <article-id pub-id-type="publisher-id">1166</article-id>
      <article-id pub-id-type="doi">10.2337/dc14-1166</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Epidemiology/Health Services Research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Hyperglycemia Predicts Persistently Lower Muscle Strength With Aging</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Kalyani</surname>
            <given-names>Rita Rastogi</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Metter</surname>
            <given-names>E. Jeffrey</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Egan</surname>
            <given-names>Josephine</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Golden</surname>
            <given-names>Sherita H.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ferrucci</surname>
            <given-names>Luigi</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <aff id="aff1"><sup>1</sup>Division of Endocrinology, Diabetes &amp; Metabolism, Department of Medicine, Johns Hopkins University, Baltimore, MD</aff>
        <aff id="aff2"><sup>2</sup>Clinical Research Branch, National Institute on Aging, Baltimore, MD</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">Corresponding author: Rita Rastogi Kalyani, <email>rrastogi@jhmi.edu</email>.</corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>12</day>
        <month>11</month>
        <year>2014</year>
      </pub-date>
      <volume>38</volume>
      <issue>1</issue>
      <fpage>82</fpage>
      <lpage>90</lpage>
      <history>
        <date date-type="received">
          <day>7</day>
          <month>5</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>13</day>
          <month>10</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.</copyright-statement>
        <copyright-year>2015</copyright-year>
      </permissions>
      <self-uri xlink:title="pdf" xlink:type="simple" xlink:href="82.pdf"/>
      <abstract>
        <sec>
          <title>OBJECTIVE</title>
          <p>Persons with diabetes have accelerated muscle loss compared with their counterparts. The relationship of hyperglycemia per se to declines in muscle function has not been explored yet has implications for developing appropriate intervention strategies to prevent muscle loss.</p>
        </sec>
        <sec>
          <title>RESEARCH DESIGN AND METHODS</title>
          <p>We examined 984 participants aged 25–96 years in the Baltimore Longitudinal Study of Aging (2003–2011) with HbA<sub>1c</sub>, knee extensor strength (isokinetic dynamometer), and lean body mass (DEXA) measured at baseline. Participants had repeated measurements up to 7.5 years later. Muscle quality was defined as knee extensor strength/leg lean mass. Participants were categorized by HbA<sub>1c</sub> quartile (&lt;5.5, 5.5–5.79, 5.8–6.09, and ≥6.1% or &lt;37, 37–40, 40–43, and ≥43 mmol/mol). Mixed-effects regression models were used to examine the regression of muscle outcomes on HbA<sub>1c</sub>.</p>
        </sec>
        <sec>
          <title>RESULTS</title>
          <p>Muscle strength and quality were significantly lower across HbA<sub>1c</sub> quartiles (both <italic>P</italic> &lt; 0.001), without differences in muscle mass at baseline. Comparing highest versus lowest HbA<sub>1c</sub> quartiles and adjusting for age, race, sex, weight, and height, strength was significantly lower (−4.70 ± 2.30 N · m; <italic>P</italic> value trend = 0.02) and results were unchanged after adjustment for physical activity (<italic>P</italic> value trend = 0.045) but of borderline significance after additional adjustment for peripheral neuropathy (<italic>P</italic> value trend = 0.05). Adjusting for demographics, muscle quality was significantly lower (−0.32 ± 0.15 N · m/kg; <italic>P</italic> value trend = 0.02) in the highest versus lowest HbA<sub>1c</sub> quartiles, but differences were attenuated after adjusting for weight and height (−0.25 ± 0.15 N · m/kg; <italic>P</italic> value trend = 0.07). Muscle mass measures were similar across HbA<sub>1c</sub> quartiles.</p>
        </sec>
        <sec>
          <title>CONCLUSIONS</title>
          <p>Hyperglycemia is associated with persistently lower muscle strength with aging, but this effect may be mediated, at least in part, by peripheral neuropathy. Future studies should explore if better glycemic control can preserve muscle function in diabetes.</p>
        </sec>
      </abstract>
      <counts>
        <page-count count="9"/>
      </counts>
    </article-meta>
  </front>
  <body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Persons with diabetes are more likely to experience accelerated loss of muscle mass, strength, and quality over time, particularly in the lower extremities, compared with those without diabetes (<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>). Such effects of diabetes on muscle may explain why patients with diabetes are at high risk of developing functional disability and mobility limitations (<xref rid="B3" ref-type="bibr">3</xref>–<xref rid="B6" ref-type="bibr">6</xref>). However, the reason for this accelerated decline of muscle function in persons with diabetes is still unclear. As the prevalence of diabetes continues to rise, and persons with diabetes live longer (<xref rid="B7" ref-type="bibr">7</xref>–<xref rid="B9" ref-type="bibr">9</xref>), diabetes will become a major contributor to sarcopenia in the elderly, with increased burden of disability and rising health care costs (<xref rid="B10" ref-type="bibr">10</xref>). Thus, understanding factors related to the loss of muscle in persons with diabetes has implications for future preventive efforts and has broad, significant public health implications.</p><p>A possible hypothesis is that hyperglycemia, which is an early manifestation in the development of diabetes, damages muscle and results in loss of strength and mass. Previous observational studies have described the cross-sectional association of fasting and 2-h post–75-g oral glucose tolerance test levels (and insulin levels) with loss of muscle mass and strength in persons with and without diabetes (<xref rid="B11" ref-type="bibr">11</xref>–<xref rid="B14" ref-type="bibr">14</xref>). However, no studies to date have examined the relationship of hyperglycemia with longitudinal changes in muscle mass, strength, or quality. Glycemic status may also be altered in prediabetic states, and poor diabetes control may cause wide fluctuations of glycemia over time, which may further impact muscle function.</p><p>Of note, longitudinal studies of aging have shown that declines in muscle strength exceed what is expected on the basis of the decline in muscle mass alone, especially after the age of 60–70 years (<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B16" ref-type="bibr">16</xref>). This progressive mismatch probably occurs because of change in muscle composition and progressive denervation (<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B18" ref-type="bibr">18</xref>). When these age-related changes occur, it is possible that the effect of hyperglycemia or diabetes on muscle function may be moderated (<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B18" ref-type="bibr">18</xref>). Unfortunately, previous studies did not address the question of whether the association of diabetes with loss of muscle function is affected by age.</p><p>In the current study, we used data from the Baltimore Longitudinal Study of Aging (BLSA) to investigate the hypothesis that the severity of hyperglycemia (assessed by HbA<sub>1c</sub>) is associated with decreased muscle strength, mass, and quality, and these associations are not affected by age and other potential confounders such as physical activity or the presence of peripheral neuropathy. In addition, we verified whether hyperglycemia affects muscle characteristics over the entire adult and older age lifespan.</p></sec><sec id="s2"><title>Research Design And Methods</title><sec id="s3"><title>Study Population</title><p>The BLSA is a longitudinal cohort study conducted by the Intramural Research Program of the National Institutes of Health, National Institute on Aging, since 1958. BLSA participants are community-dwelling men and women recruited primarily from the Baltimore–Washington, DC, area with above-average education, income, and access to medical care (<xref rid="B19" ref-type="bibr">19</xref>). Participants underwent extensive evaluations at regular, predefined intervals (on average, intervals were every 2.5 ± 1.2 years). Participants in the BLSA currently return for evaluations based on age. Participants under age 60 years are assessed every 4 years, those aged 60–79 years are assessed every 2 years, and participants aged 80 years and older are assessed annually.</p><p>A total of 984 participants (aged 26–96 years) who had HbA<sub>1c</sub> measured at least once (baseline) and assessment of both quadriceps strength and DEXA between the years 2003 and 2011 was included in this study. The mean length of follow-up was ∼1.9 ± 2.2 years for all subjects (range 0–7.5 years).</p><p>The research protocol was approved by the Intramural Research Program of the National Institute on Aging and the institutional review board of the MedStar Health Research Institute, Baltimore, MD. All participants provided written informed consent.</p></sec><sec id="s4"><title>Assessment of HbA<sub>1c</sub></title><p>HbA<sub>1c</sub> was assessed using the automated DiaSTAT analyzer between the years 2003 and 2006 (Bio-Rad, Hercules, CA) and the Dimension Vista System (Siemens, Camberley, U.K.) from 2007 onwards. The values from both instruments were standardized such that the results were comparable.</p><p>There were 1,720 visits with a measure of HbA<sub>1c</sub>, and many participants had repeated visits where HbA<sub>1c</sub> was assessed (one visit, <italic>n</italic> = 495; two visits, <italic>n</italic> = 308; three visits, <italic>n</italic> = 124; four visits, <italic>n</italic> = 48; and five visits, <italic>n</italic> = 9). Participants also had information on both knee extensor and DEXA assessment at all of these visits. For analytical purposes, HbA<sub>1c</sub> assessments were divided into quartiles as follows: quartile 1 (HbA<sub>1c</sub> &lt;5.5% or &lt;37 mmol/mol, <italic>n</italic> = 262); quartile 2 (HbA<sub>1c</sub> 5.5–5.79% or 37–40 mmol/mol, <italic>n</italic> = 246); quartile 3 (HbA<sub>1c</sub> 5.8–6.09% or 40–43 mmol/mol, <italic>n</italic> = 216); and quartile 4 (HbA<sub>1c</sub> ≥6.1% or ≥43 mmol/mol, <italic>n</italic> = 260).</p></sec><sec id="s5"><title>Assessment of Knee Extensor Strength</title><p>Knee extensor strength was assessed using the Kinetic Communicator (Kin-Com, model 125E; Chattecx, Chattanooga, TN) isokinetic dynamometer. Maximal voluntary torque was measured in the dominant knee extensor at an angular velocity of 0.52 rad/s (30°/s). Gravity corrections to torque were performed (<xref rid="B20" ref-type="bibr">20</xref>). Three graded submaximal practice repetitions preceded the test. These were followed by three maximal efforts, separated by 30 s of rest intervals. Knee extensor strength was considered as the maximum of three trials. Peak torque was assessed by using the Kin-Com computer software (version 3.2). Reliability of strength testing by the Kin-Com dynamometer has been reported elsewhere (<xref rid="B21" ref-type="bibr">21</xref>). Mean coefficient of variation was 5% (<xref rid="B20" ref-type="bibr">20</xref>). The total number of knee extensor measurements available for 984 subjects across all visits was <italic>n </italic>= 1,720.</p></sec><sec id="s6"><title>Assessment of Muscle Mass Using DEXA</title><p>Total and leg lean body mass were assessed using DEXA (model DPX-L; Lunar Radiation, Madison, WI) to determine fat mass, fat-free mass, and bone mineral content for the total body and lower extremities (<xref rid="B22" ref-type="bibr">22</xref>). All scans were analyzed by one investigator using the Lunar version 1.2i DPX-L program for body-composition analyses. These scans were considered reliable, with &lt;1% difference between repeated scans a few weeks apart (<xref rid="B20" ref-type="bibr">20</xref>). The scanner was calibrated daily before testing. The total number of DEXA measurements available for 984 subjects across all visits was <italic>n</italic> = 1,720.</p></sec><sec id="s7"><title>Assessment of Muscle Quality</title><p>To assess muscle quality of the lower extremity, knee extensor strength was divided by DEXA-derived leg lean body mass, similar to other studies (<xref rid="B2" ref-type="bibr">2</xref>).</p></sec><sec id="s8"><title>Assessment of Thigh Cross-sectional Area by Computed Tomography</title><p>Ten-millimeter (120 kVp, 200–250 mA) cross-sectional images were obtained at the midfemur level by the Somatom Sensation 10 CT scanner (Siemens, Malvern, PA), considered to be the midpoint between the medial edge of the greater trochanter and the intercondyloid fossa in scout-view images. A single cross-sectional image of the midthigh was analyzed by BonAlyse (BonAlyse Oy, Jyväskylä, Finland), a software for processing computed tomography (CT) images that identifies muscle tissue, fat, and bone. Further details regarding assessment of CT thigh cross-sectional area (CSA) have been previously described (<xref rid="B14" ref-type="bibr">14</xref>). Overall, 726 participants had one or more measures of CT thigh CSA, distributed as follows: one visit, <italic>n</italic> = 511; two visits, <italic>n</italic> = 178; three visits, <italic>n</italic> = 29; and four visits, <italic>n</italic> = 8.</p></sec><sec id="s9"><title>Covariates</title><p>Demographics including age, sex, and race were assessed by questionnaire. Height and weight were measured objectively by standard methods. Diabetes was defined as fasting glucose ≥126 mg/dL, 2-h oral glucose tolerance test ≥200 mg/dL, self-reported history, or current use of oral hypoglycemic agents or insulin.</p><p>Physical activity level was determined using a standardized questionnaire, modeled from the well-validated Minnesota Leisure-Time Physical Activity Questionnaire (<xref rid="B23" ref-type="bibr">23</xref>). An overall physical activity score (in kcal/week) was calculated for each participant (<xref rid="B24" ref-type="bibr">24</xref>). A total of 1,327 visits had information on physical activity available; thus, 23% of visits had physical activity data imputed. Data were imputed using an expectation maximum algorithm in combination with a bootstrap approach with the assumption of missing at random and a multivariate normal distribution. Ten imputed sets of data were created using the data from all of the models being considered. The variables with missing data were then examined for distribution of these variables. Models were run on each individual imputed data set, and then separate results from these 10 data sets were averaged and variance estimated as described by Rubin (<xref rid="B25" ref-type="bibr">25</xref>).</p><p>Peripheral nerve function was evaluated by measuring peroneal motor nerve conduction velocity (NCV) using standard techniques (<xref rid="B26" ref-type="bibr">26</xref>) (Nicolet Viking Select, Madison, WI). Testing was performed on the right leg if no contraindications were present. Contraindications included amputation, ulcer, trauma, knee replacement, or surgery. Details of neuropathy assessment have been previously described (<xref rid="B14" ref-type="bibr">14</xref>). A total of 1,024 visits had information on peripheral neuropathy available; 40% of visits had peripheral neuropathy data imputed using methods similar to those described for physical activity.</p></sec><sec id="s10"><title>Statistical Analysis</title><p>Differences in baseline characteristics by quartile of HbA<sub>1c</sub> were summarized as means ± SD and tested by ANOVA for continuous variables and by χ<sup>2</sup> tests for categorical variables.</p><p>Knee extensor strength, leg lean mass, total body lean mass, thigh CSA, and knee extensor strength/leg lean mass (muscle quality) were plotted against age for each HbA<sub>1c</sub> quartile using a local regression (loess) function in figures. The loess curves represent an exploratory data analysis with smoothing lines to depict the general shape of the response data across all of the data. Data plotted in figures were truncated below 38 years of age for comparability since HbA<sub>1c</sub> quartile 4 did not have any participants younger than this age. We tested the interaction of HbA<sub>1c</sub> quartiles with slope of muscle decline using a linear regression model.</p><p>Mixed-effects regression models (<ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc14-1166/-/DC1">Supplementary Data</ext-link>) were used to examine the regression of knee extensor strength, leg lean mass, total lean mass, CT thigh CSA, and knee extensor strength/leg lean mass (muscle quality) on HbA<sub>1c</sub>. Follow-up time was entered into each regression model in addition to age at time of entry into the study as a continuous variable given the unbalanced study design of BLSA (fixed effect). In the final mixed-effects regression model used for analyses, a random parameter for intercept only was included. The maximum likelihood estimation procedure was used. Four models were fitted, which sequentially included covariates of interest: model 1 was adjusted for age, race, and sex; model 2 was model 1 + height + weight; model 3 was model 2 + physical activity; and model 4 was model 3 + peripheral NCV. We chose to use both height and weight in our models, instead of BMI, given that higher BMI can also be due to greater total body lean mass, similar to previous studies suggesting that both height and weight are independently related to muscle outcomes (<xref rid="B21" ref-type="bibr">21</xref>).</p><p>We used a likelihood ratio test comparing models with HbA<sub>1c</sub> to models without HbA<sub>1c</sub> for each muscle outcome, including variables known to be associated with muscle outcomes such as age, follow-up time, sex, and race in these models, and found results to be statistically significant (<italic>P</italic> &lt; 0.05). These results suggested that HbA<sub>1c</sub> was related to observed differences in muscle outcomes between participants even after accounting for these covariates. Differences in the rate of decline in muscle outcomes (slope) by HbA<sub>1c</sub> quartile were explored using a likelihood ratio test comparing models with an interaction term for HbA<sub>1c</sub> × time to models without an interaction term. In addition, β-coefficients ± SEs for the difference in intercept for each muscle outcome were calculated comparing each of the higher HbA<sub>1c</sub> quartiles (quartiles 2–4) to reference quartile 1 in sequential regression analyses. Tests of trend were also performed across HbA<sub>1c</sub> quartiles. Interactions of HbA<sub>1c</sub> with sex were not significant (<italic>P</italic> &gt; 0.05) for any of the muscle outcomes examined; thus, analyses for the overall study cohort are displayed.</p><p>Sensitivity analyses were performed in persons with measured (nonimputed) data only. In additional sensitivity analyses, subjects with an established clinical diagnosis of diabetes were excluded. In sensitivity analyses, we also adjusted for weight-training activities (total minutes over 2 weeks) in models 3 and 4.</p><p>A two-tailed <italic>P</italic> value &lt; 0.05 was used to indicate statistical significance. Analyses were done using packages lme4 and lmerTest in R version 3.0.2.</p></sec></sec><sec sec-type="results" id="s11"><title>Results</title><p>The participant characteristics according to HbA<sub>1c</sub> quartile at baseline are shown in <xref ref-type="table" rid="T1">Table 1</xref>. The mean HbA<sub>1c</sub> values for each quartile were as follows: quartile 1 (mean HbA<sub>1c</sub> = 5.2%), quartile 2 (mean HbA<sub>1c</sub> = 5.6%), quartile 3 (mean HbA<sub>1c</sub> = 5.9%), and quartile 4 (mean HbA<sub>1c</sub> = 6.6%). Participants in the higher HbA<sub>1c</sub> quartiles (<italic>P</italic> &lt; 0.001) were significantly older, heavier, and taller than those in the lower quartiles. There were also significant differences in race by HbA<sub>1c</sub> quartile, with less white participants in the higher HbA<sub>1c</sub> quartiles (<italic>P</italic> &lt; 0.001). There were no differences in sex by HbA<sub>1c</sub>. Physical activity levels were similar across HbA<sub>1c</sub> quartiles. NCV, a measure of peripheral nerve function, was significantly lower across HbA<sub>1c</sub> quartiles (<italic>P</italic> &lt; 0.001). Not surprisingly, the percentage of participants with known diabetes was significantly greater in the higher HbA<sub>1c</sub> quartiles compared with the lowest quartile (<italic>P</italic> &lt; 0.001).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Selected baseline characteristics of the study participants, according to HbA<sub>1c</sub> quartile at baseline</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th rowspan="2" align="left" scope="col" colspan="1"/><th colspan="4" align="center" scope="colgroup" rowspan="1">HbA<sub>1c</sub> level</th><th rowspan="1" colspan="1"/></tr><tr><th colspan="1" align="center" scope="colgroup" rowspan="1">Quartile 1 (&lt;5.5% or &lt;37 mmol/mol)</th><th align="center" scope="col" rowspan="1" colspan="1">Quartile 2 (5.5–5.79% or 37–40 mmol/mol)</th><th align="center" scope="col" rowspan="1" colspan="1">Quartile 3 (5.8–6.09% or 40–43 mmol/mol)</th><th align="center" scope="col" rowspan="1" colspan="1">Quartile 4 (≥6.1% or ≥43 mmol/mol)</th><th align="center" scope="col" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" scope="col" rowspan="1" colspan="1">Demographics</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Age (years)</td><td align="center" rowspan="1" colspan="1">58.82 ± 15.10</td><td align="center" rowspan="1" colspan="1">64.60 ± 13.98</td><td align="center" rowspan="1" colspan="1">67.75 ± 12.48</td><td align="center" rowspan="1" colspan="1">68.29 ± 10.69</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Sex (% female)</td><td align="center" rowspan="1" colspan="1">49.2</td><td align="center" rowspan="1" colspan="1">50.8</td><td align="center" rowspan="1" colspan="1">49.1</td><td align="center" rowspan="1" colspan="1">48.1</td><td align="center" rowspan="1" colspan="1">0.94</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Race (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">  White</td><td align="center" rowspan="1" colspan="1">75.3</td><td align="center" rowspan="1" colspan="1">69.5</td><td align="center" rowspan="1" colspan="1">66.6</td><td align="center" rowspan="1" colspan="1">54.9</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">  Black</td><td align="center" rowspan="1" colspan="1">21.0</td><td align="center" rowspan="1" colspan="1">24.9</td><td align="center" rowspan="1" colspan="1">26.2</td><td align="center" rowspan="1" colspan="1">35.6</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">  Other</td><td align="center" rowspan="1" colspan="1">3.7</td><td align="center" rowspan="1" colspan="1">5.6</td><td align="center" rowspan="1" colspan="1">7.2</td><td align="center" rowspan="1" colspan="1">9.5</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">History and examination</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Physical activity (kcal/day)<xref ref-type="table-fn" rid="t1n1">*</xref></td><td align="center" rowspan="1" colspan="1">2,223.46 ± 2,552.38</td><td align="center" rowspan="1" colspan="1">2,178.25 ± 2,914.55</td><td align="center" rowspan="1" colspan="1">1,789.16 ± 1,576.43</td><td align="center" rowspan="1" colspan="1">1,959.97 ± 3,002.87</td><td align="center" rowspan="1" colspan="1">0.50</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> NCV (m/s)<xref ref-type="table-fn" rid="t1n1">*</xref></td><td align="center" rowspan="1" colspan="1">46.9 ± 6.3</td><td align="center" rowspan="1" colspan="1">46.4 ± 6.3</td><td align="center" rowspan="1" colspan="1">46.1 ± 6.5</td><td align="center" rowspan="1" colspan="1">44.9 ± 6.3</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Known diabetes (%)</td><td align="center" rowspan="1" colspan="1">6.5</td><td align="center" rowspan="1" colspan="1">9.3</td><td align="center" rowspan="1" colspan="1">11.1</td><td align="center" rowspan="1" colspan="1">31.9</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Body composition</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Weight (kg)</td><td align="center" rowspan="1" colspan="1">77.27 ± 15.47</td><td align="center" rowspan="1" colspan="1">75.42 ± 16.04</td><td align="center" rowspan="1" colspan="1">76.37 ± 15.18</td><td align="center" rowspan="1" colspan="1">80.91 ± 16.06</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Height (cm)</td><td align="center" rowspan="1" colspan="1">171.04 ± 9.10</td><td align="center" rowspan="1" colspan="1">169.10 ± 9.79</td><td align="center" rowspan="1" colspan="1">168.30 ± 9.09</td><td align="center" rowspan="1" colspan="1">168.90 ± 9.15</td><td align="center" rowspan="1" colspan="1">0.007</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Knee extensor strength (N · m)</td><td align="center" rowspan="1" colspan="1">151.76 ± 51.29</td><td align="center" rowspan="1" colspan="1">142.11 ± 53.10</td><td align="center" rowspan="1" colspan="1">134.48 ± 43.27</td><td align="center" rowspan="1" colspan="1">132.30 ± 40.91</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Knee extensor/leg lean mass (N · m/kg)</td><td align="center" rowspan="1" colspan="1">9.48 ± 2.3</td><td align="center" rowspan="1" colspan="1">9.15 ± 2.2</td><td align="center" rowspan="1" colspan="1">8.82 ± 2.11</td><td align="center" rowspan="1" colspan="1">8.53 ± 2.26</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Leg lean mass (kg)</td><td align="center" rowspan="1" colspan="1">16.06 ± 3.7</td><td align="center" rowspan="1" colspan="1">15.58 ± 4.1</td><td align="center" rowspan="1" colspan="1">15.36 ± 3.7</td><td align="center" rowspan="1" colspan="1">15.78 ± 3.8</td><td align="center" rowspan="1" colspan="1">0.23</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Total lean mass (kg)</td><td align="center" rowspan="1" colspan="1">49.17 ± 3.7</td><td align="center" rowspan="1" colspan="1">47.93 ± 4.1</td><td align="center" rowspan="1" colspan="1">47.43 ± 3.7</td><td align="center" rowspan="1" colspan="1">49.03 ± 3.8</td><td align="center" rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Thigh CSA (mm<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">12,057 ± 3,030</td><td align="center" rowspan="1" colspan="1">11,446 ± 3,510</td><td align="center" rowspan="1" colspan="1">11,135 ± 3,184</td><td align="center" rowspan="1" colspan="1">11,847 ± 3,116</td><td align="center" rowspan="1" colspan="1">0.26</td></tr></tbody></table><table-wrap-foot><fn><p>Data are mean ± SD unless otherwise indicated.</p></fn><fn id="t1n1"><p>*Only original data (nonimputed) shown.</p></fn></table-wrap-foot></table-wrap><p>Muscle strength (knee extensor strength) and muscle quality (knee extensor strength/leg lean mass) were all significantly decreased from lower to higher HbA<sub>1c</sub> quartiles (both <italic>P</italic> &lt; 0.001). In contrast, measures of muscle mass including leg lean mass, total lean mass, and thigh CSA did not significantly differ by HbA<sub>1c</sub> quartiles.</p><p>We next performed analyses to examine the average decline in muscle strength, mass, and quality with aging for participants categorized according to time-varying quartile of HbA<sub>1c</sub> (<xref ref-type="fig" rid="F1">Fig. 1</xref>). In <xref ref-type="fig" rid="F1">Fig. 1<italic>A</italic></xref>, knee extensor strength generally remains lower for participants in the highest HbA<sub>1c</sub> category (quartile 4) compared with the lower HbA<sub>1c</sub> categories (quartiles 1–3) with older ages. We did not find any evidence for a statistically significant difference in linear slopes across HbA<sub>1c</sub> quartiles in <xref ref-type="fig" rid="F1">Fig. 1<italic>A</italic></xref> (<italic>P</italic> &gt; 0.05). To further examine the relationship of HbA<sub>1c</sub> with the average decline in knee extensor strength during aging, we next included a break point at age 65 years in regression models and found that results were unchanged. Of note, this model assumes that an actual break point is present at this age that we could not confirm in these exploratory data analyses.</p><fig id="F1" fig-type="figure" position="float"><label>Figure 1</label><caption><p>The relationship of age with average muscle strength, muscle quality, and muscle mass is shown for participants categorized by time-varying quartile of HbA<sub>1c</sub>. For muscle strength (<italic>A</italic>), participants in HbA<sub>1c</sub> quartile 4 generally have lower values than those in HbA<sub>1c</sub> quartiles 1–3 with older ages. For muscle quality (<italic>B</italic>), participants in HbA<sub>1c</sub> quartile 4 generally have lower values than those in HbA<sub>1c</sub> quartiles 1–3 with older ages. For muscle mass (<italic>C</italic>), there are no consistent differences in values across HbA<sub>1c</sub> quartiles with older ages. There was no significant interaction of HbA<sub>1c</sub> with slopes for any of the muscle outcomes (all <italic>P</italic> &gt; 0.05).</p></caption><graphic xlink:href="82fig1"/></fig><p>In <xref ref-type="fig" rid="F1">Fig. 1<italic>B</italic></xref>, knee extensor strength/leg lean mass generally remains lower for participants in HbA<sub>1c</sub> quartile 4 compared with all other quartiles (quartiles 1–3) with older ages. We did not find any evidence for a statistically significant difference in slopes across HbA<sub>1c</sub> quartiles in <xref ref-type="fig" rid="F1">Fig. 1<italic>B</italic></xref> (<italic>P</italic> &gt; 0.05).</p><p>In <xref ref-type="fig" rid="F1">Fig. 1<italic>C</italic></xref>, leg lean mass overall declines with older age, though less dramatically than muscle strength (<xref ref-type="fig" rid="F1">Fig. 1<italic>A</italic></xref>). However, differences by HbA<sub>1c</sub> quartile are quite variable, with no consistent patterns found for participants in higher versus lower HbA<sub>1c</sub> quartiles with older ages. We did not find any evidence for a statistically significant difference in linear slopes across HbA<sub>1c</sub> quartiles in <xref ref-type="fig" rid="F1">Fig. 1<italic>C</italic></xref> (<italic>P</italic> &gt; 0.05). To further examine the relationship of HbA<sub>1c</sub> with the average decline in leg lean mass during aging, we next included a quadratic term in regression models and found that results were unchanged in exploratory data analyses.</p><p>To further explore the relationship of HbA<sub>1c</sub> and muscle characteristics, we used mixed-effects regression models adjusting for potential confounders (<xref ref-type="table" rid="T2">Table 2</xref>). The <italic>P</italic> values for the likelihood ratio test comparing model 1 with and without an interaction term for HbA<sub>1c</sub> × time were as follows: knee extensor strength (<italic>P</italic> = 0.38); knee extensor strength/leg lean mass (<italic>P</italic> = 0.40); and leg lean mass (<italic>P</italic> = 0.55). These findings show that rates of decline (slopes) for all muscle outcomes were not significantly different across HbA<sub>1c</sub> quartiles.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Mixed-effects regression models exploring differences in muscle outcomes among BLSA participants, according to HbA<sub>1c</sub> quartile at time of visit<xref ref-type="table-fn" rid="t2n1">§</xref></p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th align="left" scope="col" rowspan="1" colspan="1"/><th align="center" scope="col" rowspan="1" colspan="1">Model 1</th><th align="center" scope="col" rowspan="1" colspan="1">Model 2</th><th align="center" scope="col" rowspan="1" colspan="1">Model 3<xref ref-type="table-fn" rid="t2n5">‡</xref></th><th align="center" scope="col" rowspan="1" colspan="1">Model 4<xref ref-type="table-fn" rid="t2n5">‡</xref></th></tr></thead><tbody><tr><td align="left" scope="col" rowspan="1" colspan="1">Knee extensor strength (N · m)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Age at first visit (years)</td><td align="center" rowspan="1" colspan="1">−1.78 ± 0.08<xref ref-type="table-fn" rid="t2n2">*</xref></td><td align="center" rowspan="1" colspan="1">−1.48 ± 0.09<xref ref-type="table-fn" rid="t2n2">*</xref></td><td align="center" rowspan="1" colspan="1">−1.47 ± 0.09<xref ref-type="table-fn" rid="t2n2">*</xref></td><td align="center" rowspan="1" colspan="1">−1.41 ± 0.09<xref ref-type="table-fn" rid="t2n2">*</xref></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Time since first visit (years)</td><td align="center" rowspan="1" colspan="1">−0.99 ± 0.32<xref ref-type="table-fn" rid="t2n2">*</xref></td><td align="center" rowspan="1" colspan="1">−0.76 ± 0.31<xref ref-type="table-fn" rid="t2n2">*</xref></td><td align="center" rowspan="1" colspan="1">−0.79 ± 0.29<xref ref-type="table-fn" rid="t2n2">*</xref></td><td align="center" rowspan="1" colspan="1">−0.72 ± 0.29<xref ref-type="table-fn" rid="t2n2">*</xref></td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1"> HbA<sub>1c</sub> quartile<xref ref-type="table-fn" rid="t2n3">**</xref></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">  Q1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1">Reference</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">  Q2</td><td align="center" rowspan="1" colspan="1">1.04 ± 2.08</td><td align="center" rowspan="1" colspan="1">0.86 ± 2.05</td><td align="center" rowspan="1" colspan="1">0.64 ± 2.05</td><td align="center" rowspan="1" colspan="1">0.69 ± 2.05</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">  Q3</td><td align="center" rowspan="1" colspan="1">0.03 ± 2.19</td><td align="center" rowspan="1" colspan="1">−0.27 ± 2.15</td><td align="center" rowspan="1" colspan="1">−0.12 ± 2.17</td><td align="center" rowspan="1" colspan="1">−0.004 ± 2.17</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">  Q4</td><td align="center" rowspan="1" colspan="1">−3.40 ± 2.33</td><td align="center" rowspan="1" colspan="1">−4.70 ± 2.30<xref ref-type="table-fn" rid="t2n4">†</xref></td><td align="center" rowspan="1" colspan="1">−4.67 ± 2.32<xref ref-type="table-fn" rid="t2n4">†</xref></td><td align="center" rowspan="1" colspan="1">−4.47 ± 2.32</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><italic> P </italic>value for trend</td><td align="center" rowspan="1" colspan="1">0.10</td><td align="center" rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">0.045</td><td align="center" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Knee extensor strength/leg lean mass (N · m/kg)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Age at first visit (years)</td><td align="center" rowspan="1" colspan="1">−0.07 ± 0.004<xref ref-type="table-fn" rid="t2n2">*</xref></td><td align="center" rowspan="1" colspan="1">−0.07 ± 0.005<xref ref-type="table-fn" rid="t2n2">*</xref></td><td align="center" rowspan="1" colspan="1">−0.07 ± 0.005<xref ref-type="table-fn" rid="t2n2">*</xref></td><td align="center" rowspan="1" colspan="1">−0.07 ± 0.005<xref ref-type="table-fn" rid="t2n2">*</xref></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Time since first visit (years)</td><td align="center" rowspan="1" colspan="1">−0.09 ± 0.02<xref ref-type="table-fn" rid="t2n2">*</xref></td><td align="center" rowspan="1" colspan="1">−0.09 ± 0.02<xref ref-type="table-fn" rid="t2n2">*</xref></td><td align="center" rowspan="1" colspan="1">−0.09 ± 0.02<xref ref-type="table-fn" rid="t2n2">*</xref></td><td align="center" rowspan="1" colspan="1">−0.09 ± 0.02<xref ref-type="table-fn" rid="t2n2">*</xref></td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1"> HbA<sub>1c</sub> quartile<xref ref-type="table-fn" rid="t2n3">**</xref></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">  Q1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1">Reference</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">  Q2</td><td align="center" rowspan="1" colspan="1">−0.01 ± 0.13</td><td align="center" rowspan="1" colspan="1">−0.002 ± 0.13</td><td align="center" rowspan="1" colspan="1">−0.001 ± 0.13</td><td align="center" rowspan="1" colspan="1">0.001 ± 0.13</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">  Q3</td><td align="center" rowspan="1" colspan="1">−0.06 ± 0.14</td><td align="center" rowspan="1" colspan="1">−0.04 ± 0.14</td><td align="center" rowspan="1" colspan="1">−0.03 ± 0.14</td><td align="center" rowspan="1" colspan="1">−0.02 ± 0.14</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">  Q4</td><td align="center" rowspan="1" colspan="1">−0.32 ± 0.15<xref ref-type="table-fn" rid="t2n4">†</xref></td><td align="center" rowspan="1" colspan="1">−0.25 ± 0.15</td><td align="center" rowspan="1" colspan="1">−0.24 ± 0.15</td><td align="center" rowspan="1" colspan="1">−0.23 ± 0.15</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><italic> P </italic>value for trend</td><td align="center" rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">0.07</td><td align="center" rowspan="1" colspan="1">0.22</td><td align="center" rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Leg lean mass (kg)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Age at first visit (years)</td><td align="center" rowspan="1" colspan="1">−0.08 ± 0.005<xref ref-type="table-fn" rid="t2n2">*</xref></td><td align="center" rowspan="1" colspan="1">−0.04 ± 0.004<xref ref-type="table-fn" rid="t2n2">*</xref></td><td align="center" rowspan="1" colspan="1">−0.04 ± 0.004<xref ref-type="table-fn" rid="t2n2">*</xref></td><td align="center" rowspan="1" colspan="1">−0.04 ± 0.004<xref ref-type="table-fn" rid="t2n2">*</xref></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Time since first visit (years)</td><td align="center" rowspan="1" colspan="1">0.02 ± 0.01</td><td align="center" rowspan="1" colspan="1">0.04 ± 0.01<xref ref-type="table-fn" rid="t2n2">*</xref></td><td align="center" rowspan="1" colspan="1">0.05 ± 0.01<xref ref-type="table-fn" rid="t2n2">*</xref></td><td align="center" rowspan="1" colspan="1">0.05 ± 0.01<xref ref-type="table-fn" rid="t2n2">*</xref></td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1"> HbA<sub>1c</sub> quartile<xref ref-type="table-fn" rid="t2n3">**</xref></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">  Q1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1">Reference</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">  Q2</td><td align="center" rowspan="1" colspan="1">0.13 ± 0.09</td><td align="center" rowspan="1" colspan="1">0.08 ± 0.08</td><td align="center" rowspan="1" colspan="1">0.08 ± 0.09</td><td align="center" rowspan="1" colspan="1">0.09 ± 0.09</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">  Q3</td><td align="center" rowspan="1" colspan="1">0.18 ± 0.10</td><td align="center" rowspan="1" colspan="1">0.09 ± 0.09</td><td align="center" rowspan="1" colspan="1">0.09 ± 0.09</td><td align="center" rowspan="1" colspan="1">0.09 ± 0.09</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">  Q4</td><td align="center" rowspan="1" colspan="1">0.20 ± 0.11</td><td align="center" rowspan="1" colspan="1">0.01 ± 0.10</td><td align="center" rowspan="1" colspan="1">0.02 ± 0.10</td><td align="center" rowspan="1" colspan="1">0.02 ± 0.10</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><italic> P </italic>value for trend</td><td align="center" rowspan="1" colspan="1">0.07</td><td align="center" rowspan="1" colspan="1">0.99</td><td align="center" rowspan="1" colspan="1">0.63</td><td align="center" rowspan="1" colspan="1">0.63</td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Total body lean mass (kg)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Age at first visit (years)</td><td align="center" rowspan="1" colspan="1">−0.18 ± 0.01<xref ref-type="table-fn" rid="t2n2">*</xref></td><td align="center" rowspan="1" colspan="1">−0.07 ± 0.009<xref ref-type="table-fn" rid="t2n2">*</xref></td><td align="center" rowspan="1" colspan="1">−0.07 ± 0.009<xref ref-type="table-fn" rid="t2n2">*</xref></td><td align="center" rowspan="1" colspan="1">−0.07 ± 0.01<xref ref-type="table-fn" rid="t2n2">*</xref></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Time since first visit (years)</td><td align="center" rowspan="1" colspan="1">−0.29 ± 0.02<xref ref-type="table-fn" rid="t2n2">*</xref></td><td align="center" rowspan="1" colspan="1">−0.23 ± 0.02<xref ref-type="table-fn" rid="t2n2">*</xref></td><td align="center" rowspan="1" colspan="1">−0.23 ± 0.02<xref ref-type="table-fn" rid="t2n2">*</xref></td><td align="center" rowspan="1" colspan="1">−0.22 ± 0.02<xref ref-type="table-fn" rid="t2n2">*</xref></td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1"> HbA<sub>1c</sub> quartile<xref ref-type="table-fn" rid="t2n3">**</xref></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">  Q1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1">Reference</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">  Q2</td><td align="center" rowspan="1" colspan="1">0.11 ± 0.17</td><td align="center" rowspan="1" colspan="1">−0.05 ± 0.16</td><td align="center" rowspan="1" colspan="1">−0.02 ± 0.16</td><td align="center" rowspan="1" colspan="1">−0.02 ± 0.16</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">  Q3</td><td align="center" rowspan="1" colspan="1">0.23 ± 0.18</td><td align="center" rowspan="1" colspan="1">0.03 ± 0.17</td><td align="center" rowspan="1" colspan="1">0.04 ± 0.17</td><td align="center" rowspan="1" colspan="1">0.04 ± 0.17</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">  Q4</td><td align="center" rowspan="1" colspan="1">0.40 ± 0.20</td><td align="center" rowspan="1" colspan="1">0.04 ± 0.18</td><td align="center" rowspan="1" colspan="1">0.06 ± 0.19</td><td align="center" rowspan="1" colspan="1">0.06 ± 0.19</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><italic> P </italic>value for trend</td><td align="center" rowspan="1" colspan="1">0.04</td><td align="center" rowspan="1" colspan="1">0.76</td><td align="center" rowspan="1" colspan="1">0.96</td><td align="center" rowspan="1" colspan="1">0.96</td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Thigh CSA (mm<sup>2</sup>)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Age at first visit (years)</td><td align="center" rowspan="1" colspan="1">−118.2 ± 5.3<xref ref-type="table-fn" rid="t2n2">*</xref></td><td align="center" rowspan="1" colspan="1">−96.7 ± 4.9<xref ref-type="table-fn" rid="t2n2">*</xref></td><td align="center" rowspan="1" colspan="1">−96.5 ± 4.9<xref ref-type="table-fn" rid="t2n2">*</xref></td><td align="center" rowspan="1" colspan="1">−93.5 ± 5.0<xref ref-type="table-fn" rid="t2n2">*</xref></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Time since first visit (years)</td><td align="center" rowspan="1" colspan="1">−113.3 ± 15.9<xref ref-type="table-fn" rid="t2n2">*</xref></td><td align="center" rowspan="1" colspan="1">−96.9 ± 14.5<xref ref-type="table-fn" rid="t2n2">*</xref></td><td align="center" rowspan="1" colspan="1">−99.3 ± 13.9<xref ref-type="table-fn" rid="t2n2">*</xref></td><td align="center" rowspan="1" colspan="1">−95.5 ± 13.8<xref ref-type="table-fn" rid="t2n2">*</xref></td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1"> HbA<sub>1c</sub> quartile<xref ref-type="table-fn" rid="t2n3">**</xref></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">  Q1</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1">Reference</td><td align="center" rowspan="1" colspan="1">Reference</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">  Q2</td><td align="center" rowspan="1" colspan="1">132.0 ± 92.5</td><td align="center" rowspan="1" colspan="1">110.4 ± 84.6</td><td align="center" rowspan="1" colspan="1">147.9 ± 83.2</td><td align="center" rowspan="1" colspan="1">148.1 ± 82.6</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">  Q3</td><td align="center" rowspan="1" colspan="1">146.4 ± 107.6</td><td align="center" rowspan="1" colspan="1">103.4 ± 98.1</td><td align="center" rowspan="1" colspan="1">126.4 ± 96.9</td><td align="center" rowspan="1" colspan="1">127.2 ± 96.3</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">  Q4</td><td align="center" rowspan="1" colspan="1">264.8 ± 116.7<xref ref-type="table-fn" rid="t2n4">†</xref></td><td align="center" rowspan="1" colspan="1">83.2 ± 106.8</td><td align="center" rowspan="1" colspan="1">142.05 ± 105.5</td><td align="center" rowspan="1" colspan="1">138.4 ± 104.9</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><italic> P </italic>value for trend</td><td align="center" rowspan="1" colspan="1">0.03</td><td align="center" rowspan="1" colspan="1">0.53</td><td align="center" rowspan="1" colspan="1">0.34</td><td align="center" rowspan="1" colspan="1">0.34</td></tr></tbody></table><table-wrap-foot><fn id="t2n1"><p>§β-Coefficients ± SE shown.</p></fn><fn id="t2n2"><p>*<italic>P</italic> &lt; 0.05.</p></fn><fn id="t2n3"><p>**Model 1: adjusted for age at first visit, race, sex, and time since first visit (only age and time coefficients are shown above). Model 2: adjusted for variables in model 1 and weight and height. Model 3: adjusted for variables in model 2 and physical activity. Model 4: adjusted for variables in model 3 and NCV.</p></fn><fn id="t2n4"><p>†<italic>P</italic> &lt; 0.05 compared with reference quartile (Q1).</p></fn><fn id="t2n5"><p>‡Physical activity and NCV were imputed.</p></fn></table-wrap-foot></table-wrap><p>Participants in HbA<sub>1c</sub> quartile 4 compared with reference (HbA<sub>1c</sub> quartile 1) had decreased knee extensor strength after accounting for age, race, and sex (−3.40 ± 2.33 N · m, model 1), with a trend across HbA<sub>1c</sub> categories approaching statistical significance (<italic>P</italic> = 0.10). After further adjustment for weight and height (model 2), knee extensor strength was significantly decreased in the highest versus lowest HbA<sub>1c</sub> quartile (−4.70 ± 2.30 N · m) with a significant trend of lower knee extensor strength across higher HbA<sub>1c</sub> quartiles (<italic>P</italic> = 0.02). In model 3, after accounting for physical activity, knee extensor strength was significantly lower in the highest versus lowest HbA<sub>1c</sub> quartile (−4.67 ± 2.32 N · m), and the trend for knee extensor strength across HbA<sub>1c</sub> categories remained significant (<italic>P</italic> value for trend = 0.045). In the fully adjusted model further accounting for peripheral neuropathy, knee extensor strength was lower in the highest versus lowest HbA<sub>1c</sub> quartile (−4.47 ± 2.32 N · m) but such difference was no longer significant, and the trend across HbA<sub>1c</sub> categories was of only borderline significant (<italic>P</italic> value for trend = 0.05). Interestingly, the difference in knee extensor strength comparing HbA<sub>1c</sub> quartile 2 to reference was positive, but such a difference was not statistically significant in any of the models.</p><p>Differences in muscle quality (knee extensor strength/leg lean mass) were also explored in mixed regression models. Participants in the highest HbA<sub>1c</sub> quartile had significantly poorer muscle quality compared with those in the lowest HbA<sub>1c</sub> quartile (−0.32 ± 0.15 N · m/kg), and the trend of decreasing muscle quality across higher HbA<sub>1c</sub> categories was statistically significant (<italic>P</italic> = 0.02) in model 1 (<xref ref-type="table" rid="T2">Table 2</xref>). After accounting for weight and height (model 2), the association of decreased muscle quality across HbA<sub>1c</sub> categories was attenuated and only approached statistical significance (<italic>P</italic> value for trend = 0.07) while in the fully adjusted model was no longer significant (model 4; <italic>P</italic> value for trend = 0.24).</p><p>In regards to leg lean mass, there were no significant differences in higher versus lower HbA<sub>1c</sub> quartiles in models 1–4. Interestingly, for total body lean mass, participants in higher versus lower quartiles had greater values after accounting for demographics (<italic>P</italic> value = 0.04 for trend, model 1). However, after further adjustment for weight and height (model 2), these differences were no longer significant (<italic>P</italic> value for trend &gt;0.05). Similar results were observed for thigh CSA with participants in HbA<sub>1c</sub> quartile 4 compared with those in reference category (quartile 1) having significantly higher values (264.8 ± 116.7 mm<sup>2</sup>) in model 1 (<italic>P</italic> value = 0.03 for trend). However, after adjusting for weight and height in model 2, this trend was not significant.</p><p>In sensitivity analysis, using only nonimputed data, participants in the highest versus lowest HbA<sub>1c</sub> quartile had significantly decreased muscle strength in model 3 (−6.74 N · m ± 2.59; <italic>P</italic> = 0.01) with a trend toward significance after further accounting for peripheral neuropathy (−5.68 ± 3.03 N · m; <italic>P</italic> = 0.06; model 4). For muscle quality, those in the highest versus lowest HbA<sub>1c</sub> quartile had significantly decreased muscle quality in model 3 (−0.40 ± 0.17 N · m/kg; <italic>P</italic> = 0.01) and also after further accounting for peripheral neuropathy (−0.41 ± 0.19 N · m/kg; <italic>P</italic> = 0.03; model 4). These results reinforce the robustness of the findings obtained including imputed data, with an even more significant association for muscle quality using only measured data.</p><p>In additional sensitivity analyses, excluding participants with history of known diabetes, participants in the highest HbA<sub>1c</sub> quartile tended to have decreased knee extensor strength than those in the lowest quartile accounting for age, race, sex, weight, and height, although the difference was not statistically significant (−3.18 ± 2.53 N · m; <italic>P</italic> = 0.20). Similarly, decreased muscle quality (knee extensor strength/leg lean mass) was observed in HbA<sub>1c</sub> quartile 4 versus quartile 1, but the difference was not statistically significant (−0.16 ± 0.16 N · m/kg; <italic>P</italic> = 0.20). We found no significant differences of muscle mass across higher HbA<sub>1c</sub> quartiles (leg lean mass, total body lean mass, and thigh CSA). The inclusion of HbA<sub>1c</sub> as a diagnostic criterion for diabetes did not change results of sensitivity analyses.</p><p>In sensitivity analyses that additionally accounted for weight-training activities, we found that results were unchanged compared with primary analyses.</p></sec><sec sec-type="conclusions" id="s12"><title>Conclusions</title><p>In this study, we found that elevated HbA<sub>1c</sub>, a marker of chronic hyperglycemia, was associated with persistently lower muscle strength compared with normoglycemia. The significant associations of hyperglycemia with lower muscle strength over time were independent of potential confounders, including demographics, anthropometrics, and physical activity, and were potentially accounted for, at least in part, by peripheral neuropathy. The robustness of these findings was confirmed in analyses that accounted for changing glycemic status during follow-up for persons with repeated HbA<sub>1c</sub> measures, which appropriately characterize the relationship of hyperglycemia with longitudinal changes in muscle outcomes.</p><p>To our knowledge, there have been no previous studies that related hyperglycemia with longitudinal changes in muscle strength or quality. Interestingly, studies looking at the effect of diabetes noted similar differences in knee extensor strength (∼4 N · m) in persons with versus without diabetes over 3 years (<xref rid="B2" ref-type="bibr">2</xref>) as those reported in our study for persons in the highest versus lowest quartile of HbA<sub>1c</sub>, which is in a range of potential clinical significance (<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B27" ref-type="bibr">27</xref>). The declines in muscle function were also greater in those with undiagnosed diabetes and more dramatic with longer diabetes duration or higher HbA<sub>1c</sub> in other studies (<xref rid="B28" ref-type="bibr">28</xref>). These findings suggested a potential role for hyperglycemia and/or insulin resistance in the accelerated loss of muscle observed in persons with diabetes. Yet previous studies were limited to a shorter follow-up period (&lt;6 years) and restricted to older adults. Further, the effects of comorbidities that may be present in both impaired glucose states and diabetes (<xref rid="B29" ref-type="bibr">29</xref>), such as peripheral neuropathy, were not consistently taken into account. Our study further adds to this literature by specifically demonstrating that high HbA<sub>1c</sub>, a marker of sustained hyperglycemia, predicts persistently lower muscle strength and, potentially, muscle quality even after accounting for age-related declines. Our participants spanned a wide range of ages and follow-up was up to 7.5 years later. We also had availability of nerve conduction velocities, a well-validated measure of peripheral neuropathy, and found that the relationship of hyperglycemia with loss of muscle strength was partially accounted for by the presence of peripheral neuropathy.</p><p>Interestingly, in our cohort, hyperglycemia was not related to decreased skeletal muscle mass over time, which is in contrast with previous cross-sectional studies (<xref rid="B21" ref-type="bibr">21</xref>). Our findings also differ from previous reports of excessive loss of skeletal muscle mass in older adults with diabetes compared with those without diabetes (<xref rid="B1" ref-type="bibr">1</xref>). It is possible that factors distinct from hyperglycemia may relate to loss of skeletal muscle mass in persons with diabetes. Of note, we did find that muscle quality was lower in persons with hyperglycemia compared with those who had normoglycemia with aging in our study, although the results were not significant after accounting for confounders. Our results are similar to previous studies that have reported accelerated decline of muscle quality in persons with diabetes compared with those without diabetes (<xref rid="B2" ref-type="bibr">2</xref>), but more specifically characterizes the role of hyperglycemia in this process.</p><p>The effects of hyperglycemia and/or insulin resistance on mitochondrial dysfunction, protein degradation, and autophagy pathways in skeletal muscle have been described by other authors (<xref rid="B30" ref-type="bibr">30</xref>–<xref rid="B32" ref-type="bibr">32</xref>) and may be related to our observations of persistently decreased muscle strength and, potentially, muscle quality in persons with elevated levels of HbA<sub>1c</sub>. Further, reduced peripheral nerve function has been related to poorer lower extremity muscle strength in older adults (<xref rid="B33" ref-type="bibr">33</xref>); in our study, the association of hyperglycemia with decreased muscle strength was in part accounted for by peripheral neuropathy.</p><p>The relationship of hyperglycemia with longitudinal impairments in muscle function may represent the initial stage in the development of clinical phenotypes such as disability, frailty, and potentially early mortality in persons with diabetes. HbA<sub>1c</sub> is a relatively long-term measure of hyperglycemia that is subject to less measurement error compared with other biomarkers of glycemia (<xref rid="B34" ref-type="bibr">34</xref>). We and others have reported an association of HbA<sub>1c</sub> with functional disability (<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B6" ref-type="bibr">6</xref>) and mortality (<xref rid="B35" ref-type="bibr">35</xref>); muscle loss may mediate this association similar to older adults (<xref rid="B27" ref-type="bibr">27</xref>). HbA<sub>1c</sub> in higher ranges is also related to the development of frailty, a geriatric condition in which muscle weakness is a key criterion (<xref rid="B3" ref-type="bibr">3</xref>). Thus, the relationship of hyperglycemia with muscle impairment has potential wide-ranging consequences on both quality of life and mortality for persons with diabetes.</p><p>Interestingly, therapies that lower blood glucose or improve insulin sensitivity have been reported to improve skeletal muscle function by some authors. In observational studies, skeletal muscle mass loss is attenuated by use of insulin sensitizers in older men with diabetes (<xref rid="B36" ref-type="bibr">36</xref>). In interventional studies of animals and humans, the use of peripheral insulin sensitizers can lead to improved mitochondrial activity and less protein degradation in skeletal muscle, with measurable increases in lean body mass (<xref rid="B30" ref-type="bibr">30</xref>,<xref rid="B37" ref-type="bibr">37</xref>–<xref rid="B40" ref-type="bibr">40</xref>). However, these are preliminary findings that need to be better investigated in future studies. Also, the role of weight-bearing physical activities that could impact both glycemic control and quadriceps strength warrants further exploration. Well-controlled exercise interventions may improve both insulin sensitivity and mitochondrial function in skeletal muscle (<xref rid="B41" ref-type="bibr">41</xref>–<xref rid="B44" ref-type="bibr">44</xref>).</p><p>The strengths of our study are the comprehensive testing that was performed in BLSA and the assessment of both skeletal muscle strength and mass, allowing for characterization of muscle quality. Whereas past studies examining the association of diabetes with accelerated loss of muscle used only baseline glucose status (<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>), we were able to update glucose status with HbA<sub>1c</sub> at successive visits using rigorous analytic methods (mixed-effects regression models), allowing more robust assessment of glycemic exposure. Given the availability of valid information on peripheral neuropathy using NCVs, we were able to account for the contribution of neuropathy to our findings. We were also able to explore effects of hyperglycemia over and above age-related declines in muscle outcomes given the wide age range of our study participants.</p><p>The limitations of our study include the use of a single measure to assess hyperglycemia. However, HbA<sub>1c</sub> has the least variability of the glucose biomarkers available (<xref rid="B34" ref-type="bibr">34</xref>). While we had repeated HbA<sub>1c</sub> measures on many participants, this measure was not available for all participants included in this study, potentially leading to misclassification of glycemic status for some participants over time. Further, muscle quality was assessed using knee extensor strength divided by leg lean body mass; the assessment of leg muscle mass was not necessarily specific to the quadriceps muscle. Yet, this has been a commonly used as a measure of muscle quality in other studies (<xref rid="B2" ref-type="bibr">2</xref>). In our cohort, information on physical activity and peripheral neuropathy was not available for all visits, but we were able to impute results on visits with missing measurements. However, this may have still led to limited power in detecting associations particularly in the fully adjusted models, yet, compared with analyses with measured data only, resulted in more conservative estimates. Further, not having this information on peripheral neuropathy and physical activity in all participants could have impacted the results of our study, particularly those regarding older individuals who are more likely to be inactive. The length of follow-up was variable among participants. It is possible that longer follow-up may have resulted in different findings, and the effect of hyperglycemia may diminish after a few years.</p><p>We chose to use HbA<sub>1c</sub> quartiles based on our study population so that we could explore potential nonlinear relationships of hyperglycemia with muscle outcomes. However, results for muscle strength were similar when we defined HbA<sub>1c</sub> quartiles using clinically defined cutoffs (&lt;5.7, 5.7–6.4, and ≥6.5%), though were limited by fewer participants in the HbA<sub>1c</sub> ≥6.5% group (data not shown). Despite moderately strong correlation, HbA<sub>1c</sub> levels may still underestimate postprandial hyperglycemia and its impact on skeletal muscle (<xref rid="B45" ref-type="bibr">45</xref>). We also could not account for the effects of glucose-lowering medications or diabetes duration on muscle outcomes given the relatively small proportion of patients with undiagnosed diabetes, particularly in lower HbA<sub>1c</sub> quartiles. It is possible that the definition of diabetes used also included participants who had prediabetes on glucose-lowering medications, but this would have likely underestimated the degree of muscle loss in participants with diabetes. The use of self-reported measures for physical activity may have led to residual confounding in our study in comparison with objective measures (<xref rid="B46" ref-type="bibr">46</xref>–<xref rid="B48" ref-type="bibr">48</xref>). Our observational study provides limited insight into possible mechanisms that could underlie the association of hyperglycemia with persistently decreased muscle strength, but this should be investigated in future studies.</p><p>In summary, our study demonstrates that hyperglycemia predicts persistently lower muscle strength after accounting for age-related effects but may be mediated, at least in part, by peripheral neuropathy. It remains unclear if hyperglycemia at different times of day (i.e., postprandial versus fasting) may have relatively greater impact on the accelerated loss of muscle; this should be explored in future studies. Further interventional studies are needed to better investigate if improving hyperglycemia and/or insulin resistance can impact loss of muscle strength or quality over time. Our findings may inform preventive efforts targeted at potentially preserving muscle function in older persons and, ultimately, can facilitate strategies to reduce the burden of disability for persons with diabetes.</p></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>Supplementary Data</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_38_1_82__index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_dc14-1166v141166_DC141166SupplementaryData.pdf"/>
</supplementary-material>
</sec>
</body>
  <back>
    <fn-group>
      <fn id="fn1" fn-type="supplementary-material">
        <p>This article contains Supplementary Data online at <ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc14-1166/-/DC1">http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc14-1166/-/DC1</ext-link>.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Article Information</title>
      <p><bold>Funding.</bold> This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (K23-DK-093583), the Johns Hopkins University Older Americans Independence Center (P30-AG-021334), and the Intramural Research Program of the National Institute on Aging.</p>
      <p><bold>Duality of Interest.</bold> No potential conflicts of interest relevant to this article were reported.</p>
      <p><bold>Author Contributions.</bold> R.R.K., J.E., S.H.G., and L.F. were responsible for study concept and design, analysis and interpretation of the data, and drafting and critical revision of the manuscript for important intellectual content. E.J.M. was responsible for study concept and design, acquisition of data, analysis and interpretation of data, and drafting and critical revision of the manuscript for important intellectual content. E.J.M. and L.F. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SW</given-names></name><name><surname>Goodpaster</surname><given-names>BH</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><etal/><collab>Health, Aging, and Body Composition Study</collab></person-group>. <article-title>Excessive loss of skeletal muscle mass in older adults with type 2 diabetes</article-title>. <source>Diabetes Care</source>
<year>2009</year>;<volume>32</volume>:<fpage>1993</fpage>–<lpage>1997</lpage><?supplied-pmid 19549734?><pub-id pub-id-type="pmid">19549734</pub-id></mixed-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SW</given-names></name><name><surname>Goodpaster</surname><given-names>BH</given-names></name><name><surname>Strotmeyer</surname><given-names>ES</given-names></name><etal/><collab>Health, Aging, and Body Composition Study</collab></person-group>. <article-title>Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: the Health, Aging, and Body Composition Study</article-title>. <source>Diabetes Care</source>
<year>2007</year>;<volume>30</volume>:<fpage>1507</fpage>–<lpage>1512</lpage><?supplied-pmid 17363749?><pub-id pub-id-type="pmid">17363749</pub-id></mixed-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalyani</surname><given-names>RR</given-names></name><name><surname>Tian</surname><given-names>J</given-names></name><name><surname>Xue</surname><given-names>QL</given-names></name><etal/></person-group>. <article-title>Hyperglycemia and incidence of frailty and lower extremity mobility limitations in older women</article-title>. <source>J Am Geriatr Soc</source>
<year>2012</year>;<volume>60</volume>:<fpage>1701</fpage>–<lpage>1707</lpage><?supplied-pmid 22882211?><pub-id pub-id-type="pmid">22882211</pub-id></mixed-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volpato</surname><given-names>S</given-names></name><name><surname>Ferrucci</surname><given-names>L</given-names></name><name><surname>Blaum</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Progression of lower-extremity disability in older women with diabetes: the Women’s Health and Aging Study</article-title>. <source>Diabetes Care</source>
<year>2003</year>;<volume>26</volume>:<fpage>70</fpage>–<lpage>75</lpage><?supplied-pmid 12502660?><pub-id pub-id-type="pmid">12502660</pub-id></mixed-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryerson</surname><given-names>B</given-names></name><name><surname>Tierney</surname><given-names>EF</given-names></name><name><surname>Thompson</surname><given-names>TJ</given-names></name><etal/></person-group>. <article-title>Excess physical limitations among adults with diabetes in the U.S. population, 1997-1999</article-title>. <source>Diabetes Care</source>
<year>2003</year>;<volume>26</volume>:<fpage>206</fpage>–<lpage>210</lpage><?supplied-pmid 12502682?><pub-id pub-id-type="pmid">12502682</pub-id></mixed-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalyani</surname><given-names>RR</given-names></name><name><surname>Saudek</surname><given-names>CD</given-names></name><name><surname>Brancati</surname><given-names>FL</given-names></name><name><surname>Selvin</surname><given-names>E</given-names></name></person-group>. <article-title>Association of diabetes, comorbidities, and A1C with functional disability in older adults: results from the National Health and Nutrition Examination Survey (NHANES), 1999-2006</article-title>. <source>Diabetes Care</source>
<year>2010</year>;<volume>33</volume>:<fpage>1055</fpage>–<lpage>1060</lpage><?supplied-pmid 20185736?><pub-id pub-id-type="pmid">20185736</pub-id></mixed-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>JE</given-names></name><name><surname>Sicree</surname><given-names>RA</given-names></name><name><surname>Zimmet</surname><given-names>PZ</given-names></name></person-group>. <article-title>Global estimates of the prevalence of diabetes for 2010 and 2030</article-title>. <source>Diabetes Res Clin Pract</source>
<year>2010</year>;<volume>87</volume>:<fpage>4</fpage>–<lpage>14</lpage><?supplied-pmid 19896746?><pub-id pub-id-type="pmid">19896746</pub-id></mixed-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wild</surname><given-names>S</given-names></name><name><surname>Roglic</surname><given-names>G</given-names></name><name><surname>Green</surname><given-names>A</given-names></name><name><surname>Sicree</surname><given-names>R</given-names></name><name><surname>King</surname><given-names>H</given-names></name></person-group>. <article-title>Global prevalence of diabetes: estimates for the year 2000 and projections for 2030</article-title>. <source>Diabetes Care</source>
<year>2004</year>;<volume>27</volume>:<fpage>1047</fpage>–<lpage>1053</lpage><?supplied-pmid 15111519?><pub-id pub-id-type="pmid">15111519</pub-id></mixed-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cowie</surname><given-names>CC</given-names></name><name><surname>Rust</surname><given-names>KF</given-names></name><name><surname>Ford</surname><given-names>ES</given-names></name><etal/></person-group>. <article-title>Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006</article-title>. <source>Diabetes Care</source>
<year>2009</year>;<volume>32</volume>:<fpage>287</fpage>–<lpage>294</lpage><?supplied-pmid 19017771?><pub-id pub-id-type="pmid">19017771</pub-id></mixed-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janssen</surname><given-names>I</given-names></name><name><surname>Shepard</surname><given-names>DS</given-names></name><name><surname>Katzmarzyk</surname><given-names>PT</given-names></name><name><surname>Roubenoff</surname><given-names>R</given-names></name></person-group>. <article-title>The healthcare costs of sarcopenia in the United States</article-title>. <source>J Am Geriatr Soc</source>
<year>2004</year>;<volume>52</volume>:<fpage>80</fpage>–<lpage>85</lpage><?supplied-pmid 14687319?><pub-id pub-id-type="pmid">14687319</pub-id></mixed-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazarus</surname><given-names>R</given-names></name><name><surname>Sparrow</surname><given-names>D</given-names></name><name><surname>Weiss</surname><given-names>ST</given-names></name></person-group>. <article-title>Handgrip strength and insulin levels: cross-sectional and prospective associations in the Normative Aging Study</article-title>. <source>Metabolism</source>
<year>1997</year>;<volume>46</volume>:<fpage>1266</fpage>–<lpage>1269</lpage><?supplied-pmid 9361683?><pub-id pub-id-type="pmid">9361683</pub-id></mixed-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barzilay</surname><given-names>JI</given-names></name><name><surname>Cotsonis</surname><given-names>GA</given-names></name><name><surname>Walston</surname><given-names>J</given-names></name><etal/><collab>Health ABC Study</collab></person-group>. <article-title>Insulin resistance is associated with decreased quadriceps muscle strength in nondiabetic adults aged &gt;or=70 years</article-title>. <source>Diabetes Care</source>
<year>2009</year>;<volume>32</volume>:<fpage>736</fpage>–<lpage>738</lpage><?supplied-pmid 19171728?><pub-id pub-id-type="pmid">19171728</pub-id></mixed-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sayer</surname><given-names>AA</given-names></name><name><surname>Dennison</surname><given-names>EM</given-names></name><name><surname>Syddall</surname><given-names>HE</given-names></name><name><surname>Gilbody</surname><given-names>HJ</given-names></name><name><surname>Phillips</surname><given-names>DI</given-names></name><name><surname>Cooper</surname><given-names>C</given-names></name></person-group>. <article-title>Type 2 diabetes, muscle strength, and impaired physical function: the tip of the iceberg</article-title>? <source>Diabetes Care</source>
<year>2005</year>;<volume>28</volume>:<fpage>2541</fpage>–<lpage>2542</lpage><?supplied-pmid 16186295?><pub-id pub-id-type="pmid">16186295</pub-id></mixed-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalyani</surname><given-names>RR</given-names></name><name><surname>Metter</surname><given-names>EJ</given-names></name><name><surname>Ramachandran</surname><given-names>R</given-names></name><name><surname>Chia</surname><given-names>CW</given-names></name><name><surname>Saudek</surname><given-names>CD</given-names></name><name><surname>Ferrucci</surname><given-names>L</given-names></name></person-group>. <article-title>Glucose and insulin measurements from the oral glucose tolerance test and relationship to muscle mass</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>
<year>2012</year>;<volume>67</volume>:<fpage>74</fpage>–<lpage>81</lpage><?supplied-pmid 21350243?><pub-id pub-id-type="pmid">21350243</pub-id></mixed-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baum</surname><given-names>K</given-names></name><name><surname>Hildebrandt</surname><given-names>U</given-names></name><name><surname>Edel</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Comparison of skeletal muscle strength between cardiac patients and age-matched healthy controls</article-title>. <source>Int J Med Sci</source>
<year>2009</year>;<volume>6</volume>:<fpage>184</fpage>–<lpage>191</lpage><?supplied-pmid 19584952?><pub-id pub-id-type="pmid">19584952</pub-id></mixed-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodpaster</surname><given-names>BH</given-names></name><name><surname>Park</surname><given-names>SW</given-names></name><name><surname>Harris</surname><given-names>TB</given-names></name><etal/></person-group>. <article-title>The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>
<year>2006</year>;<volume>61</volume>:<fpage>1059</fpage>–<lpage>1064</lpage><?supplied-pmid 17077199?><pub-id pub-id-type="pmid">17077199</pub-id></mixed-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>AZ</given-names></name><name><surname>Caturegli</surname><given-names>G</given-names></name><name><surname>Metter</surname><given-names>EJ</given-names></name><etal/></person-group>. <article-title>Difference in muscle quality over the adult life span and biological correlates in the Baltimore Longitudinal Study of Aging</article-title>. <source>J Am Geriatr Soc</source>
<year>2014</year>;<volume>62</volume>:<fpage>230</fpage>–<lpage>236</lpage><?supplied-pmid 24438020?><pub-id pub-id-type="pmid">24438020</pub-id></mixed-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Visser</surname><given-names>M</given-names></name><name><surname>Goodpaster</surname><given-names>BH</given-names></name><name><surname>Kritchevsky</surname><given-names>SB</given-names></name><etal/></person-group>. <article-title>Muscle mass, muscle strength, and muscle fat infiltration as predictors of incident mobility limitations in well-functioning older persons</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>
<year>2005</year>;<volume>60</volume>:<fpage>324</fpage>–<lpage>333</lpage><?supplied-pmid 15860469?><pub-id pub-id-type="pmid">15860469</pub-id></mixed-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <mixed-citation publication-type="book">Shock NW, Greulich RC, Andres R, et al. <italic>Normal Human Aging: The Baltimore Longitudinal Study of Aging.</italic> Washington, DC, U.S. Govt Printing Office, 1984 (publ. no. 84-2450)</mixed-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindle</surname><given-names>RS</given-names></name><name><surname>Metter</surname><given-names>EJ</given-names></name><name><surname>Lynch</surname><given-names>NA</given-names></name><etal/></person-group>
<article-title>Age and gender comparisons of muscle strength in 654 women and men aged 20-93 yr</article-title>. <source>J Appl Physiol</source>
<year>1997</year>;<volume>83</volume>:<fpage>1581</fpage>–<lpage>1587</lpage><pub-id pub-id-type="pmid">9375323</pub-id></mixed-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalyani</surname><given-names>RR</given-names></name><name><surname>Tra</surname><given-names>Y</given-names></name><name><surname>Yeh</surname><given-names>HC</given-names></name><name><surname>Egan</surname><given-names>JM</given-names></name><name><surname>Ferrucci</surname><given-names>L</given-names></name><name><surname>Brancati</surname><given-names>FL</given-names></name></person-group>. <article-title>Quadriceps strength, quadriceps power, and gait speed in older U.S. adults with diabetes mellitus: results from the National Health and Nutrition Examination Survey, 1999-2002</article-title>. <source>J Am Geriatr Soc</source>
<year>2013</year>;<volume>61</volume>:<fpage>769</fpage>–<lpage>775</lpage><?supplied-pmid 23617584?><pub-id pub-id-type="pmid">23617584</pub-id></mixed-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazess</surname><given-names>RB</given-names></name><name><surname>Barden</surname><given-names>HS</given-names></name><name><surname>Bisek</surname><given-names>JP</given-names></name><name><surname>Hanson</surname><given-names>J</given-names></name></person-group>. <article-title>Dual-energy x-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition</article-title>. <source>Am J Clin Nutr</source>
<year>1990</year>;<volume>51</volume>:<fpage>1106</fpage>–<lpage>1112</lpage><?supplied-pmid 2349926?><pub-id pub-id-type="pmid">2349926</pub-id></mixed-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>HL</given-names></name><name><surname>Jacobs</surname><given-names>DR</given-names><suffix>Jr</suffix></name><name><surname>Schucker</surname><given-names>B</given-names></name><name><surname>Knudsen</surname><given-names>J</given-names></name><name><surname>Leon</surname><given-names>AS</given-names></name><name><surname>Debacker</surname><given-names>G</given-names></name></person-group>. <article-title>A questionnaire for the assessment of leisure time physical activities</article-title>. <source>J Chronic Dis</source>
<year>1978</year>;<volume>31</volume>:<fpage>741</fpage>–<lpage>755</lpage><?supplied-pmid 748370?><pub-id pub-id-type="pmid">748370</pub-id></mixed-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ainsworth</surname><given-names>BE</given-names></name><name><surname>Haskell</surname><given-names>WL</given-names></name><name><surname>Leon</surname><given-names>AS</given-names></name><etal/></person-group>. <article-title>Compendium of physical activities: classification of energy costs of human physical activities</article-title>. <source>Med Sci Sports Exerc</source>
<year>1993</year>;<volume>25</volume>:<fpage>71</fpage>–<lpage>80</lpage><?supplied-pmid 8292105?><pub-id pub-id-type="pmid">8292105</pub-id></mixed-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Rubin</surname><given-names>DB</given-names></name></person-group>
<source>Multiple Imputation for Nonresponse in Surveys</source>. <publisher-loc>New York</publisher-loc>, <publisher-name>John Wiley &amp; Sons, Inc.</publisher-name>, <year>1987</year></mixed-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Aminoff</surname><given-names>M</given-names></name></person-group>
<source>Clinical Electromyography in Clinical Practice</source>. <edition>3rd ed.</edition>
<person-group person-group-type="editor"><name><surname>Aminoff</surname><given-names>M</given-names></name></person-group>, Ed. <publisher-loc>New York</publisher-loc>, <publisher-name>Churchill-Livingstone</publisher-name>, <year>1998</year>, p. <fpage>488</fpage>–<lpage>489</lpage></mixed-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Visser</surname><given-names>M</given-names></name><name><surname>Kritchevsky</surname><given-names>SB</given-names></name><name><surname>Goodpaster</surname><given-names>BH</given-names></name><etal/></person-group>. <article-title>Leg muscle mass and composition in relation to lower extremity performance in men and women aged 70 to 79: the Health, Aging and Body Composition Study</article-title>. <source>J Am Geriatr Soc</source>
<year>2002</year>;<volume>50</volume>:<fpage>897</fpage>–<lpage>904</lpage><?supplied-pmid 12028178?><pub-id pub-id-type="pmid">12028178</pub-id></mixed-citation>
      </ref>
      <ref id="B28">
        <label>28</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SW</given-names></name><name><surname>Goodpaster</surname><given-names>BH</given-names></name><name><surname>Strotmeyer</surname><given-names>ES</given-names></name><etal/></person-group>. <article-title>Decreased muscle strength and quality in older adults with type 2 diabetes: the Health, Aging, and Body Composition Study</article-title>. <source>Diabetes</source>
<year>2006</year>;<volume>55</volume>:<fpage>1813</fpage>–<lpage>1818</lpage><?supplied-pmid 16731847?><pub-id pub-id-type="pmid">16731847</pub-id></mixed-citation>
      </ref>
      <ref id="B29">
        <label>29</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajabally</surname><given-names>YA</given-names></name></person-group>. <article-title>Neuropathy and impaired glucose tolerance: an updated review of the evidence</article-title>. <source>Acta Neurol Scand</source>
<year>2011</year>;<volume>124</volume>:<fpage>1</fpage>–<lpage>8</lpage><?supplied-pmid 20868430?><pub-id pub-id-type="pmid">20868430</pub-id></mixed-citation>
      </ref>
      <ref id="B30">
        <label>30</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Du</surname><given-names>J</given-names></name><name><surname>Mitch</surname><given-names>WE</given-names></name></person-group>. <article-title>Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling</article-title>. <source>Endocrinology</source>
<year>2006</year>;<volume>147</volume>:<fpage>4160</fpage>–<lpage>4168</lpage><?supplied-pmid 16777975?><pub-id pub-id-type="pmid">16777975</pub-id></mixed-citation>
      </ref>
      <ref id="B31">
        <label>31</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelley</surname><given-names>DE</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Menshikova</surname><given-names>EV</given-names></name><name><surname>Ritov</surname><given-names>VB</given-names></name></person-group>. <article-title>Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes</article-title>. <source>Diabetes</source>
<year>2002</year>;<volume>51</volume>:<fpage>2944</fpage>–<lpage>2950</lpage><?supplied-pmid 12351431?><pub-id pub-id-type="pmid">12351431</pub-id></mixed-citation>
      </ref>
      <ref id="B32">
        <label>32</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaushik</surname><given-names>S</given-names></name><name><surname>Rodriguez-Navarro</surname><given-names>JA</given-names></name><name><surname>Arias</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Autophagy in hypothalamic AgRP neurons regulates food intake and energy balance</article-title>. <source>Cell Metab</source>
<year>2011</year>;<volume>14</volume>:<fpage>173</fpage>–<lpage>183</lpage><?supplied-pmid 21803288?><pub-id pub-id-type="pmid">21803288</pub-id></mixed-citation>
      </ref>
      <ref id="B33">
        <label>33</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strotmeyer</surname><given-names>ES</given-names></name><name><surname>de Rekeneire</surname><given-names>N</given-names></name><name><surname>Schwartz</surname><given-names>AV</given-names></name><etal/><collab>Health ABC Study</collab></person-group>. <article-title>Sensory and motor peripheral nerve function and lower-extremity quadriceps strength: the Health, Aging and Body Composition Study</article-title>. <source>J Am Geriatr Soc</source>
<year>2009</year>;<volume>57</volume>:<fpage>2004</fpage>–<lpage>2010</lpage><?supplied-pmid 19793163?><pub-id pub-id-type="pmid">19793163</pub-id></mixed-citation>
      </ref>
      <ref id="B34">
        <label>34</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selvin</surname><given-names>E</given-names></name><name><surname>Crainiceanu</surname><given-names>CM</given-names></name><name><surname>Brancati</surname><given-names>FL</given-names></name><name><surname>Coresh</surname><given-names>J</given-names></name></person-group>. <article-title>Short-term variability in measures of glycemia and implications for the classification of diabetes</article-title>. <source>Arch Intern Med</source>
<year>2007</year>;<volume>167</volume>:<fpage>1545</fpage>–<lpage>1551</lpage><?supplied-pmid 17646610?><pub-id pub-id-type="pmid">17646610</pub-id></mixed-citation>
      </ref>
      <ref id="B35">
        <label>35</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>ES</given-names></name><name><surname>Liu</surname><given-names>JY</given-names></name><name><surname>Moffet</surname><given-names>HH</given-names></name><name><surname>John</surname><given-names>PM</given-names></name><name><surname>Karter</surname><given-names>AJ</given-names></name></person-group>. <article-title>Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study</article-title>. <source>Diabetes Care</source>
<year>2011</year>;<volume>34</volume>:<fpage>1329</fpage>–<lpage>1336</lpage><?supplied-pmid 21505211?><pub-id pub-id-type="pmid">21505211</pub-id></mixed-citation>
      </ref>
      <ref id="B36">
        <label>36</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CG</given-names></name><name><surname>Boyko</surname><given-names>EJ</given-names></name><name><surname>Barrett-Connor</surname><given-names>E</given-names></name><etal/><collab>Osteoporotic Fractures in Men (MrOS) Study Research Group</collab></person-group>. <article-title>Insulin sensitizers may attenuate lean mass loss in older men with diabetes</article-title>. <source>Diabetes Care</source>
<year>2011</year>;<volume>34</volume>:<fpage>2381</fpage>–<lpage>2386</lpage><?supplied-pmid 21926282?><pub-id pub-id-type="pmid">21926282</pub-id></mixed-citation>
      </ref>
      <ref id="B37">
        <label>37</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mensink</surname><given-names>M</given-names></name><name><surname>Hesselink</surname><given-names>MK</given-names></name><name><surname>Russell</surname><given-names>AP</given-names></name><name><surname>Schaart</surname><given-names>G</given-names></name><name><surname>Sels</surname><given-names>JP</given-names></name><name><surname>Schrauwen</surname><given-names>P</given-names></name></person-group>. <article-title>Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus</article-title>. <source>Int J Obes (Lond)</source>
<year>2007</year>;<volume>31</volume>:<fpage>1302</fpage>–<lpage>1310</lpage><?supplied-pmid 17310221?><pub-id pub-id-type="pmid">17310221</pub-id></mixed-citation>
      </ref>
      <ref id="B38">
        <label>38</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabøl</surname><given-names>R</given-names></name><name><surname>Boushel</surname><given-names>R</given-names></name><name><surname>Almdal</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes</article-title>. <source>Diabetes Obes Metab</source>
<year>2010</year>;<volume>12</volume>:<fpage>806</fpage>–<lpage>814</lpage><?supplied-pmid 20649633?><pub-id pub-id-type="pmid">20649633</pub-id></mixed-citation>
      </ref>
      <ref id="B39">
        <label>39</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasouli</surname><given-names>N</given-names></name><name><surname>Raue</surname><given-names>U</given-names></name><name><surname>Miles</surname><given-names>LM</given-names></name><etal/></person-group>. <article-title>Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue</article-title>. <source>Am J Physiol Endocrinol Metab</source>
<year>2005</year>;<volume>288</volume>:<fpage>E930</fpage>–<lpage>E934</lpage><?supplied-pmid 15632102?><pub-id pub-id-type="pmid">15632102</pub-id></mixed-citation>
      </ref>
      <ref id="B40">
        <label>40</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skov</surname><given-names>V</given-names></name><name><surname>Glintborg</surname><given-names>D</given-names></name><name><surname>Knudsen</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Pioglitazone enhances mitochondrial biogenesis and ribosomal protein biosynthesis in skeletal muscle in polycystic ovary syndrome</article-title>. <source>PLoS ONE</source>
<year>2008</year>;<volume>3</volume>:<fpage>e2466</fpage><?supplied-pmid 18560589?><pub-id pub-id-type="pmid">18560589</pub-id></mixed-citation>
      </ref>
      <ref id="B41">
        <label>41</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishii</surname><given-names>T</given-names></name><name><surname>Yamakita</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Fujii</surname><given-names>S</given-names></name></person-group>. <article-title>Resistance training improves insulin sensitivity in NIDDM subjects without altering maximal oxygen uptake</article-title>. <source>Diabetes Care</source>
<year>1998</year>;<volume>21</volume>:<fpage>1353</fpage>–<lpage>1355</lpage><?supplied-pmid 9702447?><pub-id pub-id-type="pmid">9702447</pub-id></mixed-citation>
      </ref>
      <ref id="B42">
        <label>42</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Praet</surname><given-names>SF</given-names></name><name><surname>Jonkers</surname><given-names>RA</given-names></name><name><surname>Schep</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Long-standing, insulin-treated type 2 diabetes patients with complications respond well to short-term resistance and interval exercise training</article-title>. <source>Eur J Endocrinol</source>
<year>2008</year>;<volume>158</volume>:<fpage>163</fpage>–<lpage>172</lpage><?supplied-pmid 18230822?><pub-id pub-id-type="pmid">18230822</pub-id></mixed-citation>
      </ref>
      <ref id="B43">
        <label>43</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sigal</surname><given-names>RJ</given-names></name><name><surname>Kenny</surname><given-names>GP</given-names></name><name><surname>Boulé</surname><given-names>NG</given-names></name><etal/></person-group>. <article-title>Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial</article-title>. <source>Ann Intern Med</source>
<year>2007</year>;<volume>147</volume>:<fpage>357</fpage>–<lpage>369</lpage><?supplied-pmid 17876019?><pub-id pub-id-type="pmid">17876019</pub-id></mixed-citation>
      </ref>
      <ref id="B44">
        <label>44</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Tienen</surname><given-names>FH</given-names></name><name><surname>Praet</surname><given-names>SF</given-names></name><name><surname>de Feyter</surname><given-names>HM</given-names></name><etal/></person-group>. <article-title>Physical activity is the key determinant of skeletal muscle mitochondrial function in type 2 diabetes</article-title>. <source>J Clin Endocrinol Metab</source>
<year>2012</year>;<volume>97</volume>:<fpage>3261</fpage>–<lpage>3269</lpage><?supplied-pmid 22802091?><pub-id pub-id-type="pmid">22802091</pub-id></mixed-citation>
      </ref>
      <ref id="B45">
        <label>45</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Dijk</surname><given-names>JW</given-names></name><name><surname>Manders</surname><given-names>RJ</given-names></name><name><surname>Hartgens</surname><given-names>F</given-names></name><name><surname>Stehouwer</surname><given-names>CD</given-names></name><name><surname>Praet</surname><given-names>SF</given-names></name><name><surname>van Loon</surname><given-names>LJ</given-names></name></person-group>. <article-title>Postprandial hyperglycemia is highly prevalent throughout the day in type 2 diabetes patients</article-title>. <source>Diabetes Res Clin Pract</source>
<year>2011</year>;<volume>93</volume>:<fpage>31</fpage>–<lpage>37</lpage><?supplied-pmid 21497935?><pub-id pub-id-type="pmid">21497935</pub-id></mixed-citation>
      </ref>
      <ref id="B46">
        <label>46</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westerterp</surname><given-names>KR</given-names></name></person-group>. <article-title>Assessment of physical activity: a critical appraisal</article-title>. <source>Eur J Appl Physiol</source>
<year>2009</year>;<volume>105</volume>:<fpage>823</fpage>–<lpage>828</lpage><?supplied-pmid 19205725?><pub-id pub-id-type="pmid">19205725</pub-id></mixed-citation>
      </ref>
      <ref id="B47">
        <label>47</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamer</surname><given-names>M</given-names></name><name><surname>Stamatakis</surname><given-names>E</given-names></name><name><surname>Steptoe</surname><given-names>A</given-names></name></person-group>. <article-title>Effects of substituting sedentary time with physical activity on metabolic risk</article-title>. <source>Med Sci Sports Exerc</source>
<year>2014</year>;<volume>46</volume>:<fpage>1946</fpage>–<lpage>1950</lpage><?supplied-pmid 24674977?><pub-id pub-id-type="pmid">24674977</pub-id></mixed-citation>
      </ref>
      <ref id="B48">
        <label>48</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>James</surname><given-names>BD</given-names></name><name><surname>Boyle</surname><given-names>PA</given-names></name><name><surname>Bennett</surname><given-names>DA</given-names></name><name><surname>Buchman</surname><given-names>AS</given-names></name></person-group>. <article-title>Total daily activity measured with actigraphy and motor function in community-dwelling older persons with and without dementia</article-title>. <source>Alzheimer Dis Assoc Disord</source>
<year>2012</year>;<volume>26</volume>:<fpage>238</fpage>–<lpage>245</lpage><?supplied-pmid 21946015?><pub-id pub-id-type="pmid">21946015</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:4274787</identifier><datestamp>2016-01-01</datestamp><setSpec>mic</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="http://jats.nlm.nih.gov/ns/archiving/1.0/ http://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Microbiology</journal-id>
      <journal-id journal-id-type="iso-abbrev">Microbiology (Reading, Engl.)</journal-id>
      <journal-id journal-id-type="publisher-id">Micro</journal-id>
      <journal-id journal-id-type="hwp">mic</journal-id>
      <journal-title-group>
        <journal-title>Microbiology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1350-0872</issn>
      <issn pub-type="epub">1465-2080</issn>
      <publisher>
        <publisher-name>Society for General Microbiology</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4274787</article-id>
      <article-id pub-id-type="pmcid">PMC4274787</article-id>
      <article-id pub-id-type="pmc-uid">4274787</article-id>
      <article-id pub-id-type="pmid">25370750</article-id>
      <article-id pub-id-type="publisher-id">083386</article-id>
      <article-id pub-id-type="doi">10.1099/mic.0.083386-0</article-id>
      <article-categories>
        <subj-group subj-group-type="article-type">
          <subject>Standard</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Physiology and Biochemistry</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>A quinol oxidase, encoded by <italic>cyoABCD</italic>, is utilized to adapt to lower O<sub>2</sub> concentrations in <italic>Rhizobium etli</italic> CFN42</article-title>
        <alt-title alt-title-type="recto-page-foot">
          <ext-link ext-link-type="uri" xlink:href="http://mic.sgmjournals.org">http://mic.sgmjournals.org</ext-link>
        </alt-title>
        <alt-title alt-title-type="verso-running-head">Z. R. Lunak and K. D. Noel</alt-title>
        <alt-title alt-title-type="recto-running-head">Physiological role of quinol oxidase</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Lunak</surname>
            <given-names>Zachary R.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Noel</surname>
            <given-names>K. Dale</given-names>
          </name>
        </contrib>
        <aff id="aff1">Department of Biological Sciences, Marquette University, Milwaukee, WI, USA</aff>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Oresnik</surname>
            <given-names>I.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <corresp id="cor1"><bold>Correspondence</bold> K. Dale Noel <email xlink:href="dale.noel@marquette.edu">dale.noel@marquette.edu</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>1</day>
        <month>1</month>
        <year>2016</year>
      </pub-date>
      <!-- PMC Release delay is 12 months and 0 days and was based on the <pub-date pub-type="ppub"/>. -->
      <volume>161</volume>
      <issue>Pt 1</issue>
      <fpage>203</fpage>
      <lpage>212</lpage>
      <history>
        <date date-type="received">
          <day>12</day>
          <month>8</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>30</day>
          <month>10</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2015 The Authors</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:title="pdf" xlink:type="simple" xlink:href="203_mic083386.pdf"/>
      <abstract>
        <p>Bacteria have branched aerobic respiratory chains that terminate at different terminal oxidases. These terminal oxidases have varying properties such as their affinity for oxygen, transcriptional regulation and proton pumping ability. The focus of this study was a quinol oxidase encoded by <italic>cyoABCD</italic>. Although this oxidase (Cyo) is widespread among bacteria, not much is known about its role in the cell, particularly in bacteria that contain both cytochrome <italic>c</italic> oxidases and quinol oxidases. Using <italic>Rhizobium etli</italic> CFN42 as a model organism, a <italic>cyo</italic> mutant was analysed for its ability to grow in batch cultures at high (21 % O<sub>2</sub>) and low (1 and 0.1 % O<sub>2</sub>) ambient oxygen concentrations. In comparison with other oxidase mutants, the <italic>cyo</italic> mutant had a significantly longer lag phase under low-oxygen conditions. Using a <italic>cyo</italic> :: <italic>lacZ</italic> transcriptional fusion, it was shown that <italic>cyo</italic> expression in the wild type peaks between 1 and 2.5 % O<sub>2</sub>. In addition, it was shown with quantitative reverse transcriptase PCR that <italic>cyoB</italic> is upregulated approximately fivefold in 1 % O<sub>2</sub> compared with fully aerobic (21 % O<sub>2</sub>) conditions. Analysis of the <italic>cyo</italic> mutant during symbiosis with <italic>Phaseolous vulgaris</italic> indicated that Cyo is utilized during early development of the symbiosis. Although it is commonly thought that Cyo is utilized only at higher oxygen concentrations, the results from this study indicate that Cyo is important for adaptation to and sustained growth under low oxygen.</p>
      </abstract>
      <funding-group>
        <award-group>
          <funding-source id="sp1">NIH</funding-source>
          <award-id rid="sp1">1 R15 GM087699-01A1</award-id>
        </award-group>
      </funding-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>OpenAccessEmbargo</meta-name>
          <meta-value>12</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
    <notes>
      <def-list list-type="simple" list-content="abbreviations">
        <title>Abbreviations: </title>
        <def-item>
          <term>Cyo</term>
          <def>
            <p>cytochrome <italic>c</italic> oxidase</p>
          </def>
        </def-item>
        <def-item>
          <term>Fbc</term>
          <def>
            <p>ubiquinol–cytochrome <italic>c</italic> oxidoreductase</p>
          </def>
        </def-item>
        <def-item>
          <term>GUS</term>
          <def>
            <p>beta-glucuronidase</p>
          </def>
        </def-item>
      </def-list>
    </notes>
  </front>
  <body>
    <sec sec-type="intro" id="sec1-1">
      <title>Introduction</title>
      <p>Bacteria have remarkable adaptability to environmental changes, such as fluctuations in oxygen concentration. Presumably, an important aspect of coping with variation in oxygen concentration is that aerobic bacteria have a variety of terminal oxidases (<xref rid="r32" ref-type="bibr">Poole &amp; Cook, 2000</xref>; <xref rid="r7" ref-type="bibr">Bueno <italic>et al.</italic>, 2012</xref>; <xref rid="r28" ref-type="bibr">Morris &amp; Schmidt, 2013</xref>). Terminal oxidases are the enzymes that catalyse oxygen reduction during aerobic respiration. In many bacteria this step is achieved by cytochrome <italic>c</italic> oxidases, which catalyse electron transfer from cytochrome <italic>c</italic> to oxygen. Prior to this reaction, cytochrome <italic>c</italic> is reduced by quinol through the action of ubiquinol–cytochrome <italic>c</italic> oxidoreductase (Fbc), also known as the bc1 complex (<xref ref-type="fig" rid="f1">Fig. 1</xref>). Quinol oxidation is a key branch point in aerobic respiration. Electrons from quinol flow either through the aforementioned Fbc or directly to oxygen via terminal oxidases known as quinol oxidases (<xref ref-type="fig" rid="f1">Fig. 1</xref>). Because oxygen is a substrate for both quinol and cytochrome <italic>c</italic> oxidases, oxygen is expected to be a major factor in how each of these oxidases is regulated and utilized within bacteria.</p>
      <fig id="f1" fig-type="figure" position="float">
        <label>Fig. 1. </label>
        <caption>
          <p>Predicted aerobic respiratory chains of <italic>R. etli</italic> CFN42. Electrons from quinol to oxygen can be transferred through Fbc (square), ultimately leading to cytochrome <italic>c</italic> oxidases (circles): FixN_P, Cta and CoxM_P. Independent of the Fbc pathway, <italic>R. etli</italic> can transfer electrons directly from quinol to oxygen via Cyo (triangle). In parentheses, below each of the oxidases and Fbc complex, are the indicated operons that encode each of the oxidases followed by their NCBI reference numbers of the encoded proteins. Not included in the diagram are two putative cytochrome <italic>c</italic> oxidases, RHE_CH00981-85 and RHE_PB00063-66.</p>
        </caption>
        <graphic xlink:href="083386-f1"/>
      </fig>
      <p>The quinol oxidase encoded by <italic>cyoABCD</italic> (Cyo) is widespread among aerobic bacteria. Much of what is known about Cyo has been concluded from studies performed in <italic>Escherichia coli</italic>, where Cyo was used at high oxygen concentrations and a high-affinity quinol oxidase (Cyd), encoded by <italic>cydAB</italic>, was utilized at lower oxygen concentrations (<xref rid="r8" ref-type="bibr">D’Mello <italic>et al.</italic>, 1995</xref>, <xref rid="r9" ref-type="bibr">1996</xref>; <xref rid="r46" ref-type="bibr">Tseng <italic>et al.</italic>, 1996</xref>). However, <italic>E. coli</italic> does not contain the Fbc pathway. Therefore, the regulation and utilization of Cyo may be very different in bacteria that also contain cytochrome <italic>c</italic> oxidases. Currently, Cyo is classified as a low-affinity oxidase along with the cytochrome <italic>c</italic> aa3 oxidase (Cta), encoded by <italic>ctaCDGE</italic> (<xref rid="r14" ref-type="bibr">García-Horsman <italic>et al.</italic>, 1994</xref>, <xref rid="r28" ref-type="bibr">Morris &amp; Schmidt, 2013</xref>).</p>
      <p>In this study, <italic>Rhizobium etli</italic> CFN42 was used as a model organism. Like other rhizobia, <italic>R. etli</italic> contains both the quinol oxidase and the Fbc pathway that contains multiple cytochrome <italic>c</italic> oxidases. This enables a direct comparison between quinol oxidases and cytochrome <italic>c</italic> oxidases within the same organism. This strain of <italic>R. etli</italic> only contains one quinol oxidase, Cyo, making it an ideal organism to study this particular enzyme.</p>
      <p>Much of what is known about aerobic respiration in <italic>R. etli</italic> is limited to the necessary components involved in the symbiotic interaction with <italic>Phaseolus vulgaris</italic> (<xref rid="r10" ref-type="bibr">Delgado <italic>et al.</italic>, 1998</xref>). It has been well established that a high-affinity cbb3 cytochrome <italic>c</italic> oxidase (<xref rid="r33" ref-type="bibr">Preisig <italic>et al.</italic>, 1996</xref>), encoded by <italic>fixNOQP</italic>, is required for nitrogen fixation in <italic>P. vulgaris</italic>. For this reason, the regulation of this oxidase (FixN_P in <xref ref-type="fig" rid="f1">Fig. 1</xref>) has been studied extensively in <italic>R. etli</italic>. It is tightly regulated and expressed at low oxygen (<xref rid="r26" ref-type="bibr">Michiels <italic>et al.</italic>, 1998</xref>; <xref rid="r15" ref-type="bibr">Girard <italic>et al.</italic>, 2000</xref>; <xref rid="r24" ref-type="bibr">Lopez <italic>et al.</italic>, 2001</xref>; <xref rid="r27" ref-type="bibr">Moris <italic>et al.</italic>, 2004</xref>; <xref rid="r18" ref-type="bibr">Granados-Baeza <italic>et al.</italic>, 2007</xref>). How the other oxidases in <italic>R. etli</italic>, such as Cyo, are utilized and regulated in <italic>R. etli</italic> CFN42 is unclear. Mutants, with altered levels of Cyo, have been isolated and examined in the symbiotic interaction (<xref rid="r39" ref-type="bibr">Soberón <italic>et al.</italic>, 1989</xref>, <xref rid="r40" ref-type="bibr">1990</xref>). However, to our knowledge these mutations are either not in the <italic>cyo</italic> genes or they have not been genetically defined.</p>
      <p>In this study, the oxygen conditions in which Cyo was utilized in liquid culture were determined. Initially, the ability of a <italic>cyo</italic> mutant to grow at various oxygen concentrations in comparison to other oxidase mutants was analysed. In addition, the activity of the <italic>cyo</italic> promoter was measured at various oxygen conditions. Lastly, the impact of <italic>cyo</italic> mutation on symbiosis with <italic>P. vulgaris</italic> was examined.</p>
    </sec>
    <sec sec-type="methods" id="sec1-2">
      <title>Methods</title>
      <sec id="sec2-1">
        <title/>
        <sec id="sec3-1">
          <title>Bacterial strains and growth conditions.</title>
          <p><italic>R. etli</italic> strains were derived from strain CE3, a streptomycin-resistant derivative of wild-type strain CFN42 (<xref rid="r30" ref-type="bibr">Noel <italic>et al.</italic>, 1984</xref>), whose genome nucleotide sequence has been determined (<xref rid="r17" ref-type="bibr">González <italic>et al.</italic>, 2006</xref>). <italic>R. etli</italic> strains were grown at 30 °C on a rotating shaker in TY liquid medium [0.5 %, w/v, tryptone (Difco); 0.3 %, w/v, yeast extract (Difco); 10 mM CaCl<sub>2</sub>]. <italic>E. coli</italic> strains were grown in LB liquid medium (1.0 %, w/v, tryptone; 0.5 %, w/v, yeast extract; 0.5 %, w/v, NaCl) at 37 °C on a rotating shaker (<xref rid="r37" ref-type="bibr">Sambrook <italic>et al.</italic>, 1989</xref>). Agar medium contained 1.5 % (w/v) Bacto agar (Difco). To analyse growth at low-oxygen conditions, fully grown cultures were diluted 1 : 200 into 5 ml of TY medium resting in 60 ml serum vials. The serum vials were then capped and the headspace was flushed with nitrogen gas. Using a sterile syringe needle, ambient air (assumed 21 % O<sub>2</sub>) was injected back into the headspace to make it 1 and 0.1 % O<sub>2</sub>. For growth at 21 % O<sub>2</sub>, the vials were covered with aluminium foil. Cultures were then grown at 30 °C on a rotating shaker. To follow growth, 400 µl was removed from the cultures using a sterile syringe needle and the OD<sub>600</sub> was analysed. In addition, for some cultures the c.f.u. ml<sup>−1</sup> was enumerated. To ensure oxygen was not reintroduced into the cultures while sampling for growth, nitrogen gas was aspirated from a separate vial prior to sampling.</p>
        </sec>
        <sec id="sec3-2">
          <title>Materials and techniques for DNA isolation.</title>
          <p>Genomic DNA was isolated from <italic>R. etli</italic> strains using the GenElute Bacterial Genomic DNA kit (Sigma) for use in cloning. <italic>E. coli</italic> NEB 5-α (Invitrogen) competent cells were transformed (<xref rid="r19" ref-type="bibr">Hanahan, 1983</xref>), and plasmids were isolated using QIAprep spin miniprep kit (Qiagen). DNA was recovered from agarose gels using Gel/PCR DNA Fragments Extraction kit (IBI Scientific) and modified with restriction enzymes (NEB). Custom primers were synthesized by Eurofins MWG Operon.</p>
        </sec>
        <sec id="sec3-3">
          <title>Cloning and site-directed mutagenesis.</title>
          <p>The <italic>fixN_P</italic> mutant was generously provided by L. Girard (<xref rid="r15" ref-type="bibr">Girard <italic>et al.</italic>, 2000</xref>). Using PCR, <italic>cyoA</italic>, <italic>cyoB</italic>, <italic>ctaC</italic> and <italic>coxN</italic> were amplified separately from <italic>R. etli</italic> CE3 genomic DNA (primer sequences are listed in Table S1, available with the online Supplementary Material). PCR products were inserted into a TA cloning vector, pCR2.1. Plasmids were then digested using restriction enzymes, and DNA fragments were then inserted into plasmid pEX18Tc (<xref rid="r20" ref-type="bibr">Hoang <italic>et al.</italic>, 1998</xref>). Either the gentamicin-resistant cassette from plasmid pUCGm, the kanamycin-resistant cassette from plasmid pBSL86 or the omega chloramphenicol resistant cassette from pBSL119 was inserted (<xref rid="r38" ref-type="bibr">Schweizer, 1993</xref>; <xref rid="r1" ref-type="bibr">Alexeyev, 1995</xref>; <xref rid="r2" ref-type="bibr">Alexeyev <italic>et al.</italic>, 1995</xref>). Plasmids carrying the mutated ORFs were transferred into <italic>R. etli</italic> CE3 by using the plasmid-mobilizer strain MT616 on TY agar plates (<xref rid="r13" ref-type="bibr">Finan <italic>et al.</italic>, 1986</xref>; <xref rid="r16" ref-type="bibr">Glazebrook &amp; Walker, 1991</xref>). CE3 transconjugants containing these constructs were selected and purified as previously described (<xref rid="r31" ref-type="bibr">Ojeda <italic>et al.</italic>, 2010</xref>). Double-crossover recombinants were screened on TY agar plates supplemented with 1 µg of tetracycline ml<sup>−1</sup>. Of the recombinants that were sensitive to 1 µg tetracycline ml<sup>−1</sup> and resistant to 8 % (w/v) sucrose on TY agar, it was then verified by PCR that the colonies contained only the mutant allele and the wild-type allele was absent. The resulting strains are listed in <xref ref-type="table" rid="t1">Table 1</xref>.</p>
          <table-wrap id="t1" position="float">
            <label>Table 1. </label>
            <caption>
              <title>Strains and plasmids used in study</title>
            </caption>
            <table frame="hsides" rules="groups">
              <colgroup span="1">
                <col align="left" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Bacterial strain or plasmid</td>
                  <td align="center" rowspan="1" colspan="1">Description, genotype or phenotype</td>
                  <td align="center" rowspan="1" colspan="1">Reference or Source</td>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>Strains</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"><italic>R. etli</italic>
</td>
                  <td align="left" rowspan="1" colspan="1">
</td>
                  <td align="left" rowspan="1" colspan="1">
</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"> CE3</td>
                  <td align="left" rowspan="1" colspan="1">Wild-type strain, <italic>str-1</italic></td>
                  <td align="left" rowspan="1" colspan="1">
                    <xref rid="r30" ref-type="bibr">Noel <italic>et al.</italic> (1984)</xref>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"> CE3/pZL39</td>
                  <td align="left" rowspan="1" colspan="1">CE3 carrying pZL39; Tc<sup>R</sup></td>
                  <td align="left" rowspan="1" colspan="1">This study</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"> CE119</td>
                  <td align="left" rowspan="1" colspan="1">CE3 derivative, <italic>str-1</italic>
<italic>fbcF</italic> :: Tn<italic>5</italic></td>
                  <td align="left" rowspan="1" colspan="1">This study</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"> CE426</td>
                  <td align="left" rowspan="1" colspan="1">CE3 with mTn<italic>5</italic>SS<italic>gusA11</italic> at unknown site</td>
                  <td align="left" rowspan="1" colspan="1">
                    <xref rid="r11" ref-type="bibr">Duelli <italic>et al.</italic> (2001)</xref>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"> CE574</td>
                  <td align="left" rowspan="1" colspan="1">CE3 derivative, <italic>str-1 cyoA</italic> :: Km; Km<sup>R</sup></td>
                  <td align="left" rowspan="1" colspan="1">This study</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"> CE574/pZL34</td>
                  <td align="left" rowspan="1" colspan="1">CE574 carrying pZL34; Tc<sup>r</sup></td>
                  <td align="left" rowspan="1" colspan="1">This study</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"> CE582</td>
                  <td align="left" rowspan="1" colspan="1">CE3 derivative, <italic>str-1 coxN</italic> :: CmΩ; Cm<sup>R</sup></td>
                  <td align="left" rowspan="1" colspan="1">This study</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"> CE583</td>
                  <td align="left" rowspan="1" colspan="1">CFNX641 derivative, <italic>str-1 cyoB</italic> :: Gm <italic>fixNf</italic> :: Sp <italic>fixNd</italic> :: Km; Gm<sup>R</sup> Km<sup>R</sup></td>
                  <td align="left" rowspan="1" colspan="1">This study</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"> CE598</td>
                  <td align="left" rowspan="1" colspan="1">CE3 derivative, <italic>str-1 ctaC</italic> :: Gm; Gm<sup>R</sup></td>
                  <td align="left" rowspan="1" colspan="1">This study</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"> CE607</td>
                  <td align="left" rowspan="1" colspan="1">CE574 with mTn<italic>5</italic>SS<italic>gusA11</italic> at unknown site</td>
                  <td align="left" rowspan="1" colspan="1">This study</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"> CFNX641</td>
                  <td align="left" rowspan="1" colspan="1">CE3 derivative; <italic>str-1 fixNf</italic> :: Sp <italic>fixNd</italic> :: Km; Sp<sup>R</sup> Km<sup>R</sup></td>
                  <td align="left" rowspan="1" colspan="1">
                    <xref rid="r15" ref-type="bibr">Girard <italic>et al.</italic> (2000)</xref>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <italic>E. coli</italic>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
</td>
                  <td align="left" rowspan="1" colspan="1">
</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"> NEB-5α</td>
                  <td align="left" rowspan="1" colspan="1">Competent strain used for cloning</td>
                  <td align="left" rowspan="1" colspan="1">NEB</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"> MT616</td>
                  <td align="left" rowspan="1" colspan="1"><italic>pro thi endA hsdR supE44 recA-J6</italic> pRK2013Km :: Tn<italic>9</italic></td>
                  <td align="left" rowspan="1" colspan="1">
                    <xref rid="r13" ref-type="bibr">Finan <italic>et al.</italic> (1986)</xref>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>Plasmids</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
</td>
                  <td align="left" rowspan="1" colspan="1">
</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">pBSL86</td>
                  <td align="left" rowspan="1" colspan="1"><italic>nptII</italic> gene cassette; Km<sup>R</sup></td>
                  <td align="left" rowspan="1" colspan="1">
                    <xref rid="r1" ref-type="bibr">Alexeyev (1995)</xref>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">pBSL119</td>
                  <td align="left" rowspan="1" colspan="1">CmΩ gene cassette; Cm<sup>R</sup></td>
                  <td align="left" rowspan="1" colspan="1">
                    <xref rid="r2" ref-type="bibr">Alexeyev <italic>et al.</italic> (1995)</xref>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">pCAM111</td>
                  <td align="left" rowspan="1" colspan="1">Carries mTn<italic>5</italic>SS<italic>gusA11</italic>; Sm<sup>R</sup> Sp<sup>R</sup> Ap<sup>R</sup></td>
                  <td align="left" rowspan="1" colspan="1">
                    <xref rid="r47" ref-type="bibr">Wilson <italic>et al.</italic> (1995)</xref>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">pCR2.1</td>
                  <td align="left" rowspan="1" colspan="1">T-A cloning vector for PCR products; Ap<sup>R</sup> Km<sup>R</sup></td>
                  <td align="left" rowspan="1" colspan="1">Invitrogen</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">pEX18Tc</td>
                  <td align="left" rowspan="1" colspan="1">Suicide plasmid; Tc<sup>r</sup>
<italic>ori</italic>T <italic>sacB</italic></td>
                  <td align="left" rowspan="1" colspan="1">
                    <xref rid="r20" ref-type="bibr">Hoang <italic>et al.</italic> (1998)</xref>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">pFAJ1708</td>
                  <td align="left" rowspan="1" colspan="1">Expression vector with <italic>nptII</italic> promoter</td>
                  <td align="left" rowspan="1" colspan="1">
                    <xref rid="r50" ref-type="bibr">Dombrecht <italic>et al.</italic> (2001)</xref>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">pMP220</td>
                  <td align="left" rowspan="1" colspan="1">Transcriptional <italic>lacZ</italic> fusion vector; Tc<sup>R</sup></td>
                  <td align="left" rowspan="1" colspan="1">
                    <xref rid="r41" ref-type="bibr">Spaink <italic>et al.</italic> (1987)</xref>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">pSY6</td>
                  <td align="left" rowspan="1" colspan="1"><italic>cyoA</italic> with Km inserted at <italic>Sal</italic>I site in pEX18Tc</td>
                  <td align="left" rowspan="1" colspan="1">This study</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">pUCGm</td>
                  <td align="left" rowspan="1" colspan="1"><italic>aaC1</italic> gene cassette; Gm<sup>R</sup></td>
                  <td align="left" rowspan="1" colspan="1">
                    <xref rid="r38" ref-type="bibr">Schweizer (1993)</xref>
                  </td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">pZL3</td>
                  <td align="left" rowspan="1" colspan="1"><italic>cyoB</italic> with Gm inserted at <italic>Sal</italic>I site in pEX18Tc; Gm<sup>R</sup></td>
                  <td align="left" rowspan="1" colspan="1">This study</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">pZL12</td>
                  <td align="left" rowspan="1" colspan="1"><italic>coxN</italic> with CmΩ inserted at <italic>Pst</italic>I site; Cm<sup>R</sup></td>
                  <td align="left" rowspan="1" colspan="1">This study</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">pZL31</td>
                  <td align="left" rowspan="1" colspan="1">Gm cassette replacing 798 bp of <italic>ctaC</italic> ORF; Gm<sup>R</sup>
</td>
                  <td align="left" rowspan="1" colspan="1">This study</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">pZL22</td>
                  <td align="left" rowspan="1" colspan="1"><italic>cyoB</italic> qRT-PCR fragment cloned into pCR2.1 for standard curve</td>
                  <td align="left" rowspan="1" colspan="1">This study</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">pZL34</td>
                  <td align="left" rowspan="1" colspan="1">1.3 kb <italic>Bam</italic>HI, <italic>Pst</italic>I fragment with <italic>cyoA</italic> in pFAJ1708</td>
                  <td align="left" rowspan="1" colspan="1">This study</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">pZL39</td>
                  <td align="left" rowspan="1" colspan="1">pMP220 derived, 350 bp <italic>Kpn</italic>I, <italic>Xba</italic>I fragment upstream of <italic>cyoA</italic> fused with <italic>lacZ</italic></td>
                  <td align="left" rowspan="1" colspan="1">This study</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <p>Ap<sup>R</sup>, ampicillin resistance; Cm<sup>R</sup>, chloramphenicol resistance; Gm<sup>R</sup>, gentamicin resistance; Km<sup>R</sup>, kanamycin resistance; Sm<sup>R</sup>, streptomycin resistance; Sp<sup>R</sup>, spectinomycin resistance; Tc<sup>R</sup>, tetracycline resistance.</p>
            </table-wrap-foot>
          </table-wrap>
        </sec>
        <sec id="sec3-4">
          <title>Isolation of the <italic>fbc</italic> mutant.</title>
          <p>The <italic>fbc</italic> mutant (CE119) was isolated via random Tn<italic>5</italic> mutagenesis as a <italic>fix</italic> mutant that still developed nodules (K. D. Noel, J. Richmond &amp; P. Pachori, unpublished data). The genomic location of the transposon was determined to be in the <italic>fbcF</italic> gene of the <italic>fbcFBC</italic> operon (K. D. Noel &amp; E. Rosado, unpublished data). The cytochrome <italic>c</italic> reduction activity was deficient in this mutant, but activity was restored after the addition of the wild-type <italic>fbcFBC</italic> operon (K. D. Noel &amp; K. J. Ojeda, unpublished). In addition, an independent mutant was constructed by inserting a gentamicin cassette in the <italic>fbcB</italic> gene. This mutant (CE581) displayed the same phenotypic characteristics as CE119.</p>
        </sec>
        <sec id="sec3-5">
          <title>Quinol oxidase activity measurements.</title>
          <p>Membranes were prepared and solubilized by modifying a protocol previously described (<xref rid="r25" ref-type="bibr">Ludwig, 1986</xref>). Cells were either grown in 500 ml Erlenmeyer flasks containing 250 ml of TY medium or 120 ml serum vials containing 10 ml of TY medium. Cells in the exponential growth phase in 250 ml of TY medium were harvested and washed with 50 mM K-phosphate buffer (pH 7.5). The washed cells were suspended in 15 ml of buffer and broken by sonication. Crude extracts were obtained by centrifugation of the sonicate for 15 min at 6 000 <bold><italic>g</italic></bold>. The supernatant (crude extract) was removed and centrifuged at 75 000 <bold><italic>g</italic></bold> for 2 h 15 min. The pellet (membranes) was suspended in 3 ml of buffer. Triton-X was added to the membranes at a final concentration of 2 % and allowed to incubate on a rotator for 2 h at 4 °C to solubilize the membranes. The solubilized membranes were kept at −80 °C until tested. Measurements of quinol oxidase activity were essentially performed as previously described (<xref rid="r35" ref-type="bibr">Richter <italic>et al.</italic>, 1994</xref>). The activity of solubilized membranes was determined by measuring the change of absorbance at 275 nm. The membranes were incubated in a 1 ml reaction containing 50 mM of K-phosphate buffer (pH 7.5) and 30 µM antimycin A. The substrate, 75 µM quinol (reduced according to the method described by <xref rid="r36" ref-type="bibr">Rieske, 1967</xref>), was added to the mixture and the absorbance was immediately detected. The specific activity was then calculated by using the molar absorption coefficient of quinone (12,500 M<sup>−1</sup> cm<sup>−1</sup>) and the total protein (BCA assay; Thermo Scientific) used in the reaction. To inhibit quinol oxidase activity, 1 mM potassium cyanide was added to the reaction prior to the addition of quinol.</p>
        </sec>
        <sec id="sec3-6">
          <title><italic>lacZ</italic> fusion and beta-galactosidase measurements.</title>
          <p>To generate a <italic>cyoA</italic> :: <italic>lacZ</italic> transcriptional fusion, a 350 bp fragment of the promoter region of <italic>cyoA</italic> was amplified from <italic>R. etli</italic> CE3 genomic DNA by PCR (primer sequences in Table S1). The PCR product was then inserted into the TA cloning vector, PCR 2.1. The fragment was then inserted into the pMP220 plasmid (<xref rid="r41" ref-type="bibr">Spaink <italic>et al.</italic>, 1987</xref>) at the <italic>Kpn</italic>I, <italic>Xba</italic>I restriction sites resulting in the plasmid pZL39. The plasmid pZL39 was transferred into CE3 using the MT616 plasmid-mobilizer strain. The empty vector, pMP220, was introduced into CE3 as a negative control. At different oxygen conditions (0.1–21 % O<sub>2</sub>), 1 ml of culture was withdrawn and washed with cold Z-buffer (<xref rid="r37" ref-type="bibr">Sambrook <italic>et al.</italic>, 1989</xref>). The beta-galactosidase assay was performed as previously described (<xref rid="r37" ref-type="bibr">Sambrook <italic>et al.</italic>, 1989</xref>).</p>
        </sec>
        <sec id="sec3-7">
          <title>Quantitative reverse transcriptase PCR (qRT-PCR).</title>
          <p>Cultures were pelleted and immediately frozen in dry ice and stored at −80 °C. When ready for testing, cells were thawed on ice and RNA was extracted using NucleoSpin RNA II kit (Macherey–Nagel). The RNA concentration was measured by NanoDrop and 1 µg RNA was converted to cDNA using an EasyScript cDNA synthesis kit (MidSci) with the specific reverse primer for the gene of interest. As a negative control, water was added instead of the reverse-transcriptase. cDNA products were quantified by real-time PCR using EvaGreen qPCR Mastermix (MidSci), gene specific primers and the Bio-Rad iCycler. For analysing <italic>cyo</italic> expression, primers were designed to detect a 118 bp fragment in <italic>cyoB</italic> (Table S1). Samples were initially denatured at 95 °C for 10 min followed by a 40-cycle amplification protocol (95 °C for 15 s, 60 °C for 60 s). After the PCR, a melt curve was performed to ensure only one amplification product was present. The expression of the 16S rRNA gene was analysed using the same approach. Results for <italic>cyoB</italic> expression were normalized to the expression of the 16S rRNA gene.</p>
        </sec>
        <sec id="sec3-8">
          <title>Western blotting of BacS.</title>
          <p><italic>R. etli</italic> CE3 was grown at various oxygen concentrations (0.1–21 % O<sub>2</sub>) as described above. At full growth, 1 ml of cells were pelleted and resuspended in 100 µl 1× SDS buffer. The sample was then boiled for 6 min and stored at −20 °C until testing. The extracts were separated by SDS-PAGE (<xref rid="r22" ref-type="bibr">Laemmli, 1970</xref>) with 15 % acrylamide in the separating gel. The gel was stained with Coomassie blue (<xref rid="r12" ref-type="bibr">Dzandu <italic>et al.</italic>, 1984</xref>) to visualize protein amounts in each sample or the contents were electroblotted onto a nitrocellulose membrane. The blot was incubated with rabbit polyclonal antiserum against the BacS protein (<xref rid="r21" ref-type="bibr">Jahn <italic>et al.</italic>, 2003</xref>), and bound antibodies were detected with goat alkaline-phosphatase-conjugated anti-rabbit IgG (Sigma) that was developed with 5-bromo-4-chloro-3-indolyl phosphate.</p>
        </sec>
        <sec id="sec3-9">
          <title>Nodule assays.</title>
          <p>Inoculation of bean seeds (<italic>P. vulgaris</italic>) with <italic>R. etli</italic> was performed as described previously (<xref rid="r6" ref-type="bibr">Box &amp; Noel, 2011</xref>). For nodule staining, the wild-type and <italic>cyo</italic> mutants were tagged with beta-glucuronidase (GUS) by introducing pCAM111 via mating (<xref rid="r47" ref-type="bibr">Wilson <italic>et al.</italic>, 1995</xref>; <xref rid="r11" ref-type="bibr">Duelli <italic>et al.</italic>, 2001</xref>). Slicing and staining of the nodules were performed as previously described (<xref rid="r6" ref-type="bibr">Box &amp; Noel, 2011</xref>). Nitrogenase activity of nodules was measured as acetylene reduction. Shoots were removed, and intact roots were incubated with acetylene in serum-capped vials. The production of ethylene was measured by gas chromatography on a Porapak N column (<xref rid="r29" ref-type="bibr">Noel <italic>et al.</italic>, 1982</xref>). The ratio of ethylene : acetylene was normalized to the collective weight of the nodules on the root to give an overall specific activity.</p>
        </sec>
      </sec>
    </sec>
    <sec sec-type="results" id="sec1-3">
      <title>Results</title>
      <sec id="sec2-2">
        <title>Predicted aerobic respiratory branches of <italic>R. etli</italic> CFN42 and sequence-directed mutant construction</title>
        <p>The genome nucleotide sequence of <italic>R. etli</italic> CFN42 has been determined (<xref rid="r17" ref-type="bibr">González <italic>et al.</italic>, 2006</xref>). With <sc>blast</sc> (<xref rid="r3" ref-type="bibr">Altschul <italic>et al.</italic>, 1990</xref>) searches, the terminal oxidases encoded by the genome of this strain were predicted (<xref ref-type="fig" rid="f1">Figs 1</xref> and S1). The only quinol oxidase revealed in this way was a potential Cyo quinol oxidase, encoded by contiguous <italic>cyoABCD</italic> genes. On the other hand, the <italic>R. etli</italic> CFN42 genome revealed sequences for several cytochrome <italic>c</italic> oxidases: FixN_P (two copies), Cta and an alternative aa3-oxidase (CoxM_P), encoded by <italic>coxMNOP</italic>. Two additional operons that encode putative cytochrome <italic>c</italic> oxidases were also revealed in the genome (RHE_CH00981-85 and RHE_PB00063-66; Fig. S1).</p>
        <p>To gain insight into the physiological function of the oxidases, strains were constructed with mutations in the essential subunits I and/or II of the oxidases using antibiotic-resistance cassettes (<xref ref-type="table" rid="t1">Table 1</xref>). The <italic>fixN_P</italic> mutant, strain CFNx641, was previously constructed by <xref rid="r15" ref-type="bibr">Girard <italic>et al.</italic> (2000)</xref>. In this strain both <italic>fixNOQP</italic> operons have been mutated. An <italic>fbc</italic> mutant, carrying a Tn<italic>5</italic> in the iron–sulfur cluster gene (<italic>fbcF</italic>), was also studied. Despite repeated attempts, a double mutant (<italic>fbc</italic>, <italic>cyo</italic>) was not attained. Specific mutations in RHE_CH00981-85 and RHE_PB00063-66 putative cytochrome <italic>c</italic> oxidases were not constructed.</p>
      </sec>
      <sec id="sec2-3">
        <title>Quinol oxidase activity</title>
        <p>To confirm that the <italic>cyo</italic> genes encoded active proteins, and that Cyo was the only quinol oxidase present under aerobic conditions in <italic>R. etli</italic> CFN42, quinol oxidase activity was measured in the wild-type (CE3), <italic>fbc</italic> (CE119) and <italic>cyo</italic> (CE574) mutants during exponential growth (<xref ref-type="fig" rid="f2">Fig. 2</xref>). Quinol oxidase activity was undetectable in the <italic>cyo</italic> mutant, supporting the notion that Cyo is the only quinol oxidase present under these conditions. Addition of the wild-type <italic>cyo</italic> gene (pZL34) restored activity similar to that of the wild-type. The <italic>fbc</italic> mutant had increased quinol oxidase activity compared with the wild-type.</p>
        <fig id="f2" fig-type="figure" position="float">
          <label>Fig. 2. </label>
          <caption>
            <p>Quinol oxidase activities of solubilized membranes. Strains were grown under aerobic conditions in 250 ml of TY medium in 500 ml Erlenmeyer flasks, and solubilized membranes were prepared as described in Methods. The addition of KCN depleted activity in all strains. Reaction mixtures with no substrate (quinol) and no membranes were used as separate negative controls (data not shown) that gave no apparent quinol oxidase activity. Mean±<sc>sd</sc> values were calculated from measured activities from three separate experiments and cultures.</p>
          </caption>
          <graphic xlink:href="083386-f2"/>
        </fig>
      </sec>
      <sec id="sec2-4">
        <title>Growth at varying oxygen concentrations</title>
        <p>To determine the growth of mutants at low oxygen, the headspace in sealed batch cultures was adjusted to 1 or 0.1 % O<sub>2</sub>. To ensure that low oxygen conditions had been met, BacS (<xref rid="r21" ref-type="bibr">Jahn <italic>et al.</italic>, 2003</xref>) was used as a physiological biomarker. BacS is a protein that is regulated by NifA and is expressed only at low oxygen conditions. As the oxygen concentration was lowered, the amount of BacS increased (Fig. S2).</p>
        <p>In general, growth was monitored by measuring the OD<sub>600</sub> of the cultures. However, to assess whether OD<sub>600</sub> was a valid indicator of growth, c.f.u. were measured in some cases as well. It was determined at low oxygen (0.1 % O<sub>2</sub>) that an increase in OD<sub>600</sub> correlated with an increase in c.f.u. (Fig. S3). As expected, the growth of the high-affinity <italic>fixN_P</italic> mutant was deficient in low-oxygen conditions (<xref ref-type="fig" rid="f3">Fig. 3a, b</xref>). The <italic>fbc</italic> mutant was defective similarly to the <italic>fixN</italic>_<italic>P</italic> mutant in low-oxygen conditions.</p>
        <fig id="f3" fig-type="figure" position="float">
          <label>Fig. 3. </label>
          <caption>
            <p>Growth curves at (a) 0.1, (b) 1.0 and (c) 21 % O<sub>2</sub>. Strains were initially grown in TY liquid under a gas phase with 21 % O<sub>2</sub>. At full growth they were subcultured 1 : 200 into 5 ml of TY medium in 60 ml serum vials. As described in Methods, nitrogen and air were added to the headspaces in the vials above the liquid to give the indicated concentrations of oxygen. Growth was followed by measuring the OD<sub>600</sub>. Error bars indicate <sc>sd</sc> from at least three separate experiments.</p>
          </caption>
          <graphic xlink:href="083386-f3"/>
        </fig>
        <p>Unexpectedly, the <italic>cyo</italic> mutant was the strain that had the longest lag phase compared with the wild-type and other respiratory mutants under both 1 and 0.1 % O<sub>2</sub> conditions (<xref ref-type="fig" rid="f3">Fig. 3a, b</xref>). This effect was alleviated after transferring the wild-type copy of <italic>cyoA</italic> to the <italic>cyo</italic> background (Fig. S4). Furthermore, a <italic>cyo</italic>/<italic>fixN</italic>_<italic>P</italic> mutant (CE583) was unable to grow under the 0.1 % condition, whereas the single <italic>cyo</italic> or <italic>fixN</italic>_<italic>P</italic> mutant recovered to grow after a delay (<xref ref-type="fig" rid="f3">Fig. 3a</xref>). The <italic>fbc</italic> mutant, presumably completely dependent on Cyo activity, not only suffered less delay than <italic>cyo</italic> but sustained its growth at 0.1 % comparably to the <italic>cyo</italic>, which could use FixN_P. The <italic>cta</italic> (CE598) and the <italic>coxM_P</italic> (CE582) displayed growth similar to the wild-type at low oxygen conditions (data not shown).</p>
        <p>Under fully aerobic conditions, the <italic>cta</italic> mutant reproducibly had a slight growth defect (<xref ref-type="fig" rid="f3">Fig. 3c</xref>). The <italic>fbc</italic> mutant had a similar growth defect at high-oxygen conditions. The other oxidase mutants grew similarly to the wild-type at high-oxygen conditions (data not shown).</p>
      </sec>
      <sec id="sec2-5">
        <title><italic>cyo</italic> expression at various oxygen concentrations</title>
        <p>A transcriptional fusion containing the promoter region of <italic>cyo</italic> and the <italic>lacZ</italic> reporter (P<italic>cyo</italic> :: <italic>lacZ</italic>) was used to analyse <italic>cyo</italic> expression at various oxygen concentrations ranging from 0.1 to 21 % O<sub>2</sub> in the wild-type (<xref ref-type="fig" rid="f4">Fig. 4</xref>). Expression of <italic>cyo</italic> gradually increased as oxygen was lowered, peaking at 1–2.5 % O<sub>2</sub>. The beta-galactosidase activity was approximately 2.5-fold higher from cells grown at 1 % O<sub>2</sub> compared with 21 % O<sub>2</sub> conditions (<xref ref-type="fig" rid="f5">Fig. 5a</xref>). As the oxygen concentration was further lowered to 0.1 % O<sub>2</sub>, the expression decreased (<xref ref-type="fig" rid="f4">Fig. 4</xref>) even though analysis of mutant growth had shown a more obvious importance of Cyo at 0.1 % O<sub>2</sub> (<xref ref-type="fig" rid="f3">Fig. 3a</xref>). Expression of <italic>cyo</italic> at 1 and 21 % O<sub>2</sub> was investigated more closely using qRT-PCR, which showed that <italic>cyo</italic> expression was upregulated approximately fivefold at 1 % O<sub>2</sub> compared with fully aerobic conditions. Depicted in <xref ref-type="fig" rid="f5">Fig. 5(b)</xref> are data from one of the qRT-PCR experiments performed. Furthermore, the quinol oxidase activity in the wild-type was greatly increased at 1 % O<sub>2</sub> compared with 21 % O<sub>2</sub> (<xref ref-type="fig" rid="f5">Fig. 5c</xref>).</p>
        <fig id="f4" fig-type="figure" position="float">
          <label>Fig. 4. </label>
          <caption>
            <p>Impact of oxygen concentration on <italic>cyo</italic> promoter activity. Wild-type (CE3) cells, carrying the P<italic>cyoA</italic> :: <italic>lacZ</italic> transcriptional fusion (pZL39), were harvested from exponentially growing cultures at different oxygen concentrations (0.1–21 % O<sub>2</sub>), washed in cold Z-buffer and beta-galactosidase assay was performed. Specific activity is given in Miller units. Mean±<sc>sd</sc> values were calculated from three or more separate <italic>lacZ</italic> assays from two different cultures.</p>
          </caption>
          <graphic xlink:href="083386-f4"/>
        </fig>
        <fig id="f5" fig-type="figure" position="float">
          <label>Fig. 5. </label>
          <caption>
            <p>Comparison of <italic>cyo</italic> expression and quinol oxidase activity at low (1 %) versus high (21 %) oxygen. Wild-type cells were grown either in 21 or 1 % O<sub>2</sub>. Protein, RNA and membranes were all extracted from cells in the exponential phase. (a) Beta-galactosidase activity of wild-type cells carrying the transcriptional fusion plasmid, pZL39 (<italic>cyoA</italic> :: <italic>lacZ</italic>). Mean±<sc>sd</sc> values were calculated from three or more separate <italic>lacZ</italic> assays from two different cultures. (b) qRT-PCR of <italic>cyoB</italic>. RNA was extracted and converted to cDNA using the reverse gene-specific primer. As described in Methods, cDNA was then quantified by qPCR. The amount of <italic>cyoB</italic> cDNA (ng) was then normalized to the amount of 16S rRNA cDNA (pg) from the original RNA sample. Mean±<sc>sd</sc> values were calculated from three separate qPCR assays. (c) Specific quinol oxidase activity of wild-type solubilized membranes. Wild-type cells were grown in six separate 120 ml serum vials containing 10 ml of TY medium. These cultures were pooled together and the membranes were prepared and solubilized as described in Methods. In these experiments, growth was in serum vials rather than in Erlenmeyer flasks as described in <xref ref-type="fig" rid="f2">Fig. 2</xref>.</p>
          </caption>
          <graphic xlink:href="083386-f5"/>
        </fig>
      </sec>
      <sec id="sec2-6">
        <title>Impact of <italic>cyo</italic> on development of symbiosis</title>
        <p>To analyse the symbiotic role of Cyo, nodules harbouring the wild-type were compared to nodules harbouring the <italic>cyo</italic> mutant. Although <italic>cyo</italic> mutant and wild-type nodules displayed nitrogenase activity on the same day [8 days post-inoculation (p.i.)], nodules harbouring the <italic>cyo</italic> mutant had significantly less activity compared with the wild-type (<xref ref-type="fig" rid="f6">Fig. 6a</xref>). At 9 days p.i., the nitrogenase activity was similar to the wild-type (data not shown).</p>
        <fig id="f6" fig-type="figure" position="float">
          <label>Fig. 6. </label>
          <caption>
            <p>Symbiotic phenotype of <italic>cyo</italic>. (a) Nitrogenase activity of intact nodulated roots whose nodules harboured wild-type or <italic>cyo</italic> at 8 days p.i. Error bars indicate <sc>sd</sc> (<italic>n</italic> = 8; <italic>P</italic>&lt;0.05). Acetylene reduction activity = [(ethylene peak/acetylene peak)/nodule weight]. (b) Gus-staining of nodules harbouring <italic>gus-</italic>tagged wild-type (CE426) and <italic>gus</italic>-tagged <italic>cyo</italic> mutants (CE607) at different days p.i. The <italic>gusA</italic> gene was constitutively expressed at equivalent levels (in TY culture) in both strains under low (0.1 % O<sub>2</sub>) and high (21 % O<sub>2</sub>) oxygen conditions. Therefore, staining reflects the relative density of bacterial cells. Bars in the lower right corner of each image represent 500 µm. Samples are from 6, 7, 8 and 10 days p.i.</p>
          </caption>
          <graphic xlink:href="083386-f6"/>
        </fig>
        <p>As a more direct measure of infection, the bacterial content within nodules was examined by tagging the bacteria with the <italic>gus</italic> gene (<xref ref-type="fig" rid="f6">Fig. 6b</xref>), assuming that the intensity of GUS staining was proportional to the bacterial content within the nodule. The GUS activities of the studied <italic>gus</italic>-tagged strains were equivalent in cells grown in TY liquid at various oxygen conditions (Fig. S5). In the early days post-inoculation (6–7 days p.i.), the staining of nodules harbouring the <italic>gus</italic>-tagged wild-type (CE426) was more intense compared with the nodules harbouring the <italic>gus</italic>-tagged <italic>cyo</italic> mutant (CE607). By 8 days p.i., the <italic>cyo</italic> nodules had comparable staining to the wild-type.</p>
      </sec>
    </sec>
    <sec sec-type="discussion" id="sec1-4">
      <title>Discussion</title>
      <p>In this study we sought to determine the oxygen conditions in which Cyo is utilized in an Fbc-containing organism such as <italic>R. etli</italic> CFN42. This strain is specifically useful for studying Cyo, as inspection of the genome indicated that Cyo is the only terminal oxidase independent of the Fbc pathway. The inability to obtain a double <italic>cyo</italic>, <italic>fbc</italic> mutant under aerobic conditions supports this notion. In addition, quinol oxidase activity was undetectable in the <italic>cyo</italic> mutant under aerobic conditions. On the other hand, the quinol oxidase activity was increased in an <italic>fbc</italic> mutant, as might be predicted, given that Cyo is the only viable respiratory option in this case. These results indicate that the quinol oxidase assay is specific for Cyo in <italic>R. etli</italic> CFN42, and presumably enables measurement of the activity of Cyo directly under different physiological conditions. However, it is still possible that a cryptic quinol oxidase might be induced under conditions not yet studied.</p>
      <p>To begin to understand the oxygen condition under which Cyo is utilized, we analysed the ability of the <italic>cyo</italic> mutant to grow at low oxygen in comparison to the wild-type and other oxidase mutants. Since the inoculant is from an aerobic culture, the results can be interpreted as the bacterium’s ability to adapt to a sudden decrease in oxygen concentration. Surprisingly, the <italic>cyo</italic> mutant had the greatest growth defect under low-oxygen conditions but no growth defect at high oxygen, even though Cyo is classified as a low-affinity oxidase. This result is supported by a previously reported observation in <italic>R. etli</italic> CFN42 that <italic>cyo</italic> mutants were slow to grow on minimal medium plates under micro-aerobic conditions compared with the wild-type (<xref rid="r23" ref-type="bibr">Landeta <italic>et al.</italic>, 2011</xref>). In addition, the <italic>fbc</italic> mutant was able to reach a similar final OD<sub>600</sub> as rapidly as the <italic>cyo</italic> at 0.1 % O<sub>2</sub>. Interestingly, both <italic>fbc</italic> and <italic>cyo</italic> reproducibly reached an OD<sub>600</sub> higher than that of the wild-type. The basis for this observation is unknown. These growth results, along with the upregulation of <italic>cyo</italic> in the wild-type, indicate that Cyo is utilized and important for adapting to and sustaining growth under low oxygen.</p>
      <p>As predicted, the high-affinity <italic>fixN</italic>_P mutant had a growth defect at low oxygen and the low-affinity <italic>cta</italic> mutant had a growth defect at high oxygen. The <italic>fbc</italic> mutant had similar growth defects to the <italic>FixN_P</italic> mutant at low oxygen and similar growth defects to the <italic>cta</italic> mutant under fully aerobic conditions. This is consistent with the literature in that the Fbc pathway terminates with the aa3 oxidase under aerobic conditions and the cbb3 oxidase under micro-aerobic conditions (<xref rid="r5" ref-type="bibr">Bott <italic>et al.</italic>, 1990</xref>; <xref rid="r33" ref-type="bibr">Preisig <italic>et al.</italic>, 1996</xref>). The <italic>coxM_P</italic> mutant had no a distinct observable growth defect under any of the conditions tested. The two other putative cytochrome <italic>c</italic> oxidases (RHE_CH00981-85 and RHE_PB00063-66) were not specifically addressed in this study.</p>
      <p>The symbiotic process from infection to bacteroid differentiation requires <italic>R. etli</italic> to adapt and eventually to respire at very low oxygen concentrations. Based on the results from growth in liquid cultures, it was hypothesized that Cyo may have a role during infection, because it is required for the bacterium to grow while adapting to lower levels of oxygen. The onset of nitrogen fixation was initially tested, as it was assumed that the more efficiently the bacteria infected, the faster they would differentiate into bacteroids and fix nitrogen. Although wild-type nodules and <italic>cyo</italic> nodules started to fix nitrogen at the same time, the wild-type nodules showed significantly more nitrogenase activity compared with the <italic>cyo</italic> nodules at the earliest time investigated. A similar result was reported in <italic>Bradyrhizobium japonicum</italic>, where a mutant defective for a Cyo homologue (<italic>coxWXYZ</italic>) displayed an approximately 30 % decrease in nitrogenase activity (<xref rid="r43" ref-type="bibr">Surpin and Maier, 1999</xref>). However, in the present study there was no significant difference in nitrogenase activity after 8 days p.i. Using <italic>gus</italic>-tagged bacteria, the results show that there was significantly less bacterial content in early-developed <italic>cyo</italic> nodules (6–7 days p.i.). As nodules matured, the staining was similar between the wild-type and <italic>cyo</italic> nodules. Taken together, these results indicate that Cyo is advantageous during the early stages of symbiosis but has little role in the later stages. A logical inference is that Fbc-dependent oxidases are not sufficient to provide optimal bacterial growth during the infection phase.</p>
      <p>A potential reason for observing such gross phenotypes associated with Cyo is the fact that <italic>R. etli</italic> CFN42 does not contain the high-affinity Cyd quinol oxidase. However, studies in other rhizobial species have revealed that Cyo may be utilized at lower oxygen conditions regardless of the presence of Cyd. Two separate studies in <italic>Sinorhizobium meliloti,</italic> using DNA microarray and transcriptional fusion respectively, indicated that <italic>cyo</italic> is transcriptionally upregulated (2–4-fold) at lower oxygen concentrations (1–2 % O<sub>2</sub>) (<xref rid="r45" ref-type="bibr">Trzebiatowski <italic>et al.</italic>, 2001</xref>; <xref rid="r4" ref-type="bibr">Bobik <italic>et al.</italic>, 2006</xref>). In <italic>B. japonicum</italic>, based on cyanide inhibitor titration patterns of cell membranes, the Cyo homologue (<italic>coxWXYZ</italic>) is predicted to be expressed under micro-aerobic conditions (1 % O<sub>2</sub>) (<xref rid="r44" ref-type="bibr">Surpin <italic>et al.</italic>, 1996</xref>). In addition, a mutation in <italic>coxWXYZ</italic> had a growth defect at low oxygen levels under chemolithotrophic conditions (<xref rid="r42" ref-type="bibr">Surpin &amp; Maier, 1998</xref>). To our knowledge these organisms contain a Cyd quinol oxidase based on <sc>blast</sc> searches. It has yet to be ruled out whether the absence of Cyd has had an impact on the manner in which Cyo is utilized and expressed in <italic>R. etli</italic> CFN42. Nevertheless, our results indicate that Cyo and Cta oxidases have distinct physiological roles in regard to oxygen. Based on our growth studies, Cyo enhances the ability to respire at lower oxygen concentrations in comparison with the Cta oxidase. Furthermore, it appears that Cyo is capable of functioning in batch culture at 0.1 % O<sub>2</sub> as effectively as the FixN_P oxidase.</p>
      <p>We propose that Cyo is a versatile oxidase that can function under a broad range of oxygen concentrations based on the growth results of the <italic>fbc</italic> mutant, in which it is assumed that Cyo is the only functional oxidase. With only slight deficiency in both instances, the <italic>fbc</italic> mutant was able to grow under both fully aerobic and low oxygen conditions. On the other hand, Cta and FixN_P seem more specialized with respect to the oxygen concentrations at which they support growth. The <italic>cyo</italic>, <italic>fixN_P</italic> mutant was unable to grow at 0.1 % O<sub>2</sub>, indicating that Cta is unable to function at this oxygen concentration. Under fully aerobic conditions, a <italic>cyo</italic>, <italic>cta</italic> double mutant was unattainable indicating that other cytochrome <italic>c</italic> oxidases are in sufficient for growth under fully aerobic conditions. A recent study on the alphaproteobacterium <italic>Gluconobacter oxydans</italic> also indicates that Cyo is capable of functioning under a wide range of oxygen conditions as a <italic>cyo</italic> mutant had a defect in growth and oxygen consumption under both free oxygen and oxygen-limiting conditions (<xref rid="r34" ref-type="bibr">Richhardt <italic>et al.</italic>, 2013</xref>). This bacterium is an obligate aerobe yet it contains neither cytochrome <italic>c</italic> oxidases nor a high-affinity Cyd quinol oxidase, indicating that it may be taking advantage of the versatility of Cyo that we have shown in the present study.</p>
      <p>Although it is capable of functioning under a wide range of oxygen concentrations, Cyo may be most important at intermediate oxygen levels. Based on our results, <italic>cyo</italic> expression peaks at approximately 1–2.5 % O<sub>2</sub>. Perhaps at these concentrations, oxygen is too low for Cta to be adequately effective but not low enough to induce FixN_P. Having an oxidase such as Cyo that is capable of functioning at various oxygen concentrations would be of great benefit for many bacteria, particularly soil bacteria that frequently have to adjust to wide ranges of oxygen conditions.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgements</title>
      <p>We would like to thank Dr Lourdes Girard for providing the <italic>R. etli</italic> strain, CFNx641. We acknowledge Jodi Richmond, Pappi Pachori and Eric Rosado for the isolation and genomic identification of CE119 and Sihui Yang for the construction of pSY6. Funds from <funding-source rid="sp1">NIH</funding-source> grant no. <award-id rid="sp1">1 R15 GM087699-01A1</award-id> helped support this research.</p>
    </ack>
    <fn-group>
      <fn id="fn1" fn-type="supplementary-material">
        <p>Five supplementary figures and one supplementary table are available with the online Supplementary Material.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="r1">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexeyev</surname><given-names>M. F.</given-names></name></person-group>
<bold>(</bold><year>1995</year><bold>).</bold>
<article-title>Three kanamycin resistance gene cassettes with different polylinkers</article-title>. <source>Biotechniques</source>
<volume>18</volume>, <fpage>52</fpage>–<lpage>56, 54, 56</lpage>.<?supplied-pmid 7702853?><pub-id pub-id-type="pmid">7702853</pub-id></mixed-citation>
      </ref>
      <ref id="r2">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexeyev</surname><given-names>M. F.</given-names></name><name><surname>Shokolenko</surname><given-names>I. N.</given-names></name><name><surname>Croughan</surname><given-names>T. P.</given-names></name></person-group>
<bold>(</bold><year>1995</year><bold>).</bold>
<article-title>Improved antibiotic-resistance gene cassettes and omega elements for <italic>Escherichia coli</italic> vector construction and in vitro deletion/insertion mutagenesis</article-title>. <source>Gene</source>
<volume>160</volume>, <fpage>63</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1016/0378-1119(95)00108-I</pub-id><?supplied-pmid 7628718?><pub-id pub-id-type="pmid">7628718</pub-id></mixed-citation>
      </ref>
      <ref id="r3">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altschul</surname><given-names>S. F.</given-names></name><name><surname>Gish</surname><given-names>W.</given-names></name><name><surname>Miller</surname><given-names>W.</given-names></name><name><surname>Myers</surname><given-names>E. W.</given-names></name><name><surname>Lipman</surname><given-names>D. J.</given-names></name></person-group>
<bold>(</bold><year>1990</year><bold>).</bold>
<article-title>Basic local alignment search tool</article-title>. <source>J Mol Biol</source>
<volume>215</volume>, <fpage>403</fpage>–<lpage>410</lpage>. <pub-id pub-id-type="doi">10.1016/S0022-2836(05)80360-2</pub-id><?supplied-pmid 2231712?><pub-id pub-id-type="pmid">2231712</pub-id></mixed-citation>
      </ref>
      <ref id="r4">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bobik</surname><given-names>C.</given-names></name><name><surname>Meilhoc</surname><given-names>E.</given-names></name><name><surname>Batut</surname><given-names>J.</given-names></name></person-group>
<bold>(</bold><year>2006</year><bold>).</bold>
<article-title>FixJ: a major regulator of the oxygen limitation response and late symbiotic functions of <italic>Sinorhizobium meliloti</italic></article-title>. <source>J Bacteriol</source>
<volume>188</volume>, <fpage>4890</fpage>–<lpage>4902</lpage>. <pub-id pub-id-type="doi">10.1128/JB.00251-06</pub-id><?supplied-pmid 16788198?><pub-id pub-id-type="pmid">16788198</pub-id></mixed-citation>
      </ref>
      <ref id="r5">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bott</surname><given-names>M.</given-names></name><name><surname>Bolliger</surname><given-names>M.</given-names></name><name><surname>Hennecke</surname><given-names>H.</given-names></name></person-group>
<bold>(</bold><year>1990</year><bold>).</bold>
<article-title>Genetic analysis of the cytochrome c-aa3 branch of the <italic>Bradyrhizobium japonicum</italic> respiratory chain</article-title>. <source>Mol Microbiol</source>
<volume>4</volume>, <fpage>2147</fpage>–<lpage>2157</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2958.1990.tb00576.x</pub-id><?supplied-pmid 1965217?><pub-id pub-id-type="pmid">1965217</pub-id></mixed-citation>
      </ref>
      <ref id="r6">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Box</surname><given-names>J.</given-names></name><name><surname>Noel</surname><given-names>K. D.</given-names></name></person-group>
<bold>(</bold><year>2011</year><bold>).</bold>
<article-title>Controlling the expression of rhizobial genes during nodule development with elements and an inducer of the <italic>lac</italic> operon</article-title>. <source>Mol Plant Microbe Interact</source>
<volume>24</volume>, <fpage>478</fpage>–<lpage>486</lpage>. <pub-id pub-id-type="doi">10.1094/MPMI-07-10-0155</pub-id><?supplied-pmid 21375387?><pub-id pub-id-type="pmid">21375387</pub-id></mixed-citation>
      </ref>
      <ref id="r7">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bueno</surname><given-names>E.</given-names></name><name><surname>Mesa</surname><given-names>S.</given-names></name><name><surname>Bedmar</surname><given-names>E. J.</given-names></name><name><surname>Richardson</surname><given-names>D. J.</given-names></name><name><surname>Delgado</surname><given-names>M. J.</given-names></name></person-group>
<bold>(</bold><year>2012</year><bold>).</bold>
<article-title>Bacterial adaptation of respiration from oxic to microoxic and anoxic conditions: redox control</article-title>. <source>Antioxid Redox Signal</source>
<volume>16</volume>, <fpage>819</fpage>–<lpage>852</lpage>. <pub-id pub-id-type="doi">10.1089/ars.2011.4051</pub-id><?supplied-pmid 22098259?><pub-id pub-id-type="pmid">22098259</pub-id></mixed-citation>
      </ref>
      <ref id="r8">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D’Mello</surname><given-names>R.</given-names></name><name><surname>Hill</surname><given-names>S.</given-names></name><name><surname>Poole</surname><given-names>R. K.</given-names></name></person-group>
<bold>(</bold><year>1995</year><bold>).</bold>
<article-title>The oxygen affinity of cytochrome bo’ in <italic>Escherichia coli</italic> determined by the deoxygenation of oxyleghemoglobin and oxymyoglobin: <italic>K<sub>m</sub></italic> values for oxygen are in the submicromolar range</article-title>. <source>J Bacteriol</source>
<volume>177</volume>, <fpage>867</fpage>–<lpage>870</lpage>.<?supplied-pmid 7836332?><pub-id pub-id-type="pmid">7836332</pub-id></mixed-citation>
      </ref>
      <ref id="r9">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D’Mello</surname><given-names>R.</given-names></name><name><surname>Hill</surname><given-names>S.</given-names></name><name><surname>Poole</surname><given-names>R. K.</given-names></name></person-group>
<bold>(</bold><year>1996</year><bold>).</bold>
<article-title>The cytochrome bd quinol oxidase in <italic>Escherichia coli</italic> has an extremely high oxygen affinity and two oxygen-binding haems: implications for regulation of activity <italic>in vivo</italic> by oxygen inhibition</article-title>. <source>Microbiology</source>
<volume>142</volume>, <fpage>755</fpage>–<lpage>763</lpage>. <pub-id pub-id-type="doi">10.1099/00221287-142-4-755</pub-id><?supplied-pmid 8936304?><pub-id pub-id-type="pmid">8936304</pub-id></mixed-citation>
      </ref>
      <ref id="r10">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delgado</surname><given-names>M. J.</given-names></name><name><surname>Bedmar</surname><given-names>E. J.</given-names></name><name><surname>Downie</surname><given-names>J. A.</given-names></name></person-group>
<bold>(</bold><year>1998</year><bold>).</bold>
<article-title>Genes involved in the formation and assembly of rhizobial cytochromes and their role in symbiotic nitrogen fixation</article-title>. <source>Adv Microb Physiol</source>
<volume>40</volume>, <fpage>191</fpage>–<lpage>231</lpage>. <pub-id pub-id-type="doi">10.1016/S0065-2911(08)60132-0</pub-id><?supplied-pmid 9889979?><pub-id pub-id-type="pmid">9889979</pub-id></mixed-citation>
      </ref>
      <ref id="r50">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dombrecht</surname><given-names>B.</given-names></name><name><surname>Vanderleyden</surname><given-names>J.</given-names></name><name><surname>Michiels</surname><given-names>J.</given-names></name></person-group>
<bold>(</bold><year>2001</year><bold>).</bold>
<article-title>Stable RK2-derived cloning vectors for the analysis of gene expression and gene function in gram-negative bacteria</article-title>. <source>Mol Plant Microbe Interact</source>
<volume>14</volume>, <fpage>426</fpage>–<lpage>430</lpage>. <pub-id pub-id-type="pmid">11277442</pub-id></mixed-citation>
      </ref>
      <ref id="r11">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duelli</surname><given-names>D. M.</given-names></name><name><surname>Tobin</surname><given-names>A.</given-names></name><name><surname>Box</surname><given-names>J. M.</given-names></name><name><surname>Kolli</surname><given-names>V. S. K.</given-names></name><name><surname>Carlson</surname><given-names>R. W.</given-names></name><name><surname>Noel</surname><given-names>K. D.</given-names></name></person-group>
<bold>(</bold><year>2001</year><bold>).</bold>
<article-title>Genetic locus required for antigenic maturation of <italic>Rhizobium</italic>
<italic>etli</italic> CE3 lipopolysaccharide</article-title>. <source>J Bacteriol</source>
<volume>183</volume>, <fpage>6054</fpage>–<lpage>6064</lpage>. <pub-id pub-id-type="doi">10.1128/JB.183.20.6054-6064.2001</pub-id><?supplied-pmid 11567006?><pub-id pub-id-type="pmid">11567006</pub-id></mixed-citation>
      </ref>
      <ref id="r12">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dzandu</surname><given-names>J. K.</given-names></name><name><surname>Deh</surname><given-names>M. E.</given-names></name><name><surname>Barratt</surname><given-names>D. L.</given-names></name><name><surname>Wise</surname><given-names>G. E.</given-names></name></person-group>
<bold>(</bold><year>1984</year><bold>).</bold>
<article-title>Detection of erythrocyte membrane proteins, sialoglycoproteins, and lipids in the same polyacrylamide gel using a double-staining technique</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>81</volume>, <fpage>1733</fpage>–<lpage>1737</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.81.6.1733</pub-id><?supplied-pmid 6200882?><pub-id pub-id-type="pmid">6200882</pub-id></mixed-citation>
      </ref>
      <ref id="r13">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finan</surname><given-names>T. M.</given-names></name><name><surname>Kunkel</surname><given-names>B.</given-names></name><name><surname>De Vos</surname><given-names>G. F.</given-names></name><name><surname>Signer</surname><given-names>E. R.</given-names></name></person-group>
<bold>(</bold><year>1986</year><bold>).</bold>
<article-title>Second symbiotic megaplasmid in <italic>Rhizobium meliloti</italic> carrying exopolysaccharide and thiamine synthesis genes</article-title>. <source>J Bacteriol</source>
<volume>167</volume>, <fpage>66</fpage>–<lpage>72</lpage>.<?supplied-pmid 3013840?><pub-id pub-id-type="pmid">3013840</pub-id></mixed-citation>
      </ref>
      <ref id="r14">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>García-Horsman</surname><given-names>J. A.</given-names></name><name><surname>Barquera</surname><given-names>B.</given-names></name><name><surname>Rumbley</surname><given-names>J.</given-names></name><name><surname>Ma</surname><given-names>J.</given-names></name><name><surname>Gennis</surname><given-names>R. B.</given-names></name></person-group>
<bold>(</bold><year>1994</year><bold>).</bold>
<article-title>The superfamily of heme-copper respiratory oxidases</article-title>. <source>J Bacteriol</source>
<volume>176</volume>, <fpage>5587</fpage>–<lpage>5600</lpage>.<?supplied-pmid 8083153?><pub-id pub-id-type="pmid">8083153</pub-id></mixed-citation>
      </ref>
      <ref id="r15">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girard</surname><given-names>L.</given-names></name><name><surname>Brom</surname><given-names>S.</given-names></name><name><surname>Dávalos</surname><given-names>A.</given-names></name><name><surname>López</surname><given-names>O.</given-names></name><name><surname>Soberón</surname><given-names>M.</given-names></name><name><surname>Romero</surname><given-names>D.</given-names></name></person-group>
<bold>(</bold><year>2000</year><bold>).</bold>
<article-title>Differential regulation of fixN-reiterated genes in <italic>Rhizobium</italic>
<italic>etli</italic> by a novel <italic>fixL</italic>-<italic>fixK</italic> cascade</article-title>. <source>Mol Plant Microbe Interact</source>
<volume>13</volume>, <fpage>1283</fpage>–<lpage>1292</lpage>. <pub-id pub-id-type="doi">10.1094/MPMI.2000.13.12.1283</pub-id><?supplied-pmid 11106020?><pub-id pub-id-type="pmid">11106020</pub-id></mixed-citation>
      </ref>
      <ref id="r16">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glazebrook</surname><given-names>J.</given-names></name><name><surname>Walker</surname><given-names>G. C.</given-names></name></person-group>
<bold>(</bold><year>1991</year><bold>).</bold>
<article-title>Genetic techniques in <italic>Rhizobium meliloti</italic></article-title>. <source>Methods Enzymol</source>
<volume>204</volume>, <fpage>398</fpage>–<lpage>418</lpage>. <pub-id pub-id-type="doi">10.1016/0076-6879(91)04021-F</pub-id><?supplied-pmid 1658566?><pub-id pub-id-type="pmid">1658566</pub-id></mixed-citation>
      </ref>
      <ref id="r17">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>González</surname><given-names>V.</given-names></name><name><surname>Santamaría</surname><given-names>R. I.</given-names></name><name><surname>Bustos</surname><given-names>P.</given-names></name><name><surname>Hernández-González</surname><given-names>I.</given-names></name><name><surname>Medrano-Soto</surname><given-names>A.</given-names></name><name><surname>Moreno-Hagelsieb</surname><given-names>G.</given-names></name><name><surname>Janga</surname><given-names>S. C.</given-names></name><name><surname>Ramírez</surname><given-names>M. A.</given-names></name><name><surname>Jiménez-Jacinto</surname><given-names>V.</given-names></name></person-group>
<bold>&amp; other authors (</bold><year>2006</year><bold>).</bold>
<article-title>The partitioned <italic>Rhizobium etli</italic> genome: genetic and metabolic redundancy in seven interacting replicons</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>103</volume>, <fpage>3834</fpage>–<lpage>3839</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0508502103</pub-id><?supplied-pmid 16505379?><pub-id pub-id-type="pmid">16505379</pub-id></mixed-citation>
      </ref>
      <ref id="r18">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Granados-Baeza</surname><given-names>M. J.</given-names></name><name><surname>Gómez-Hernández</surname><given-names>N.</given-names></name><name><surname>Mora</surname><given-names>Y.</given-names></name><name><surname>Delgado</surname><given-names>M. J.</given-names></name><name><surname>Romero</surname><given-names>D.</given-names></name><name><surname>Girard</surname><given-names>L.</given-names></name></person-group>
<bold>(</bold><year>2007</year><bold>).</bold>
<article-title>Novel reiterated Fnr-type proteins control the production of the symbiotic terminal oxidase cbb3 in <italic>Rhizobium etli</italic> CFN42</article-title>. <source>Mol Plant Microbe Interact</source>
<volume>20</volume>, <fpage>1241</fpage>–<lpage>1249</lpage>. <pub-id pub-id-type="doi">10.1094/MPMI-20-10-1241</pub-id><?supplied-pmid 17918626?><pub-id pub-id-type="pmid">17918626</pub-id></mixed-citation>
      </ref>
      <ref id="r19">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D.</given-names></name></person-group>
<bold>(</bold><year>1983</year><bold>).</bold>
<article-title>Studies on transformation of <italic>Escherichia coli</italic> with plasmids</article-title>. <source>J Mol Biol</source>
<volume>166</volume>, <fpage>557</fpage>–<lpage>580</lpage>. <pub-id pub-id-type="doi">10.1016/S0022-2836(83)80284-8</pub-id><?supplied-pmid 6345791?><pub-id pub-id-type="pmid">6345791</pub-id></mixed-citation>
      </ref>
      <ref id="r20">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoang</surname><given-names>T. T.</given-names></name><name><surname>Karkhoff-Schweizer</surname><given-names>R. R.</given-names></name><name><surname>Kutchma</surname><given-names>A. J.</given-names></name><name><surname>Schweizer</surname><given-names>H. P.</given-names></name></person-group>
<bold>(</bold><year>1998</year><bold>).</bold>
<article-title>A broad-host-range Flp-FRT recombination system for site-specific excision of chromosomally-located DNA sequences: application for isolation of unmarked <italic>Pseudomonas aeruginosa</italic> mutants</article-title>. <source>Gene</source>
<volume>212</volume>, <fpage>77</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1016/S0378-1119(98)00130-9</pub-id><?supplied-pmid 9661666?><pub-id pub-id-type="pmid">9661666</pub-id></mixed-citation>
      </ref>
      <ref id="r21">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jahn</surname><given-names>O. J.</given-names></name><name><surname>Davila</surname><given-names>G.</given-names></name><name><surname>Romero</surname><given-names>D.</given-names></name><name><surname>Noel</surname><given-names>K. D.</given-names></name></person-group>
<bold>(</bold><year>2003</year><bold>).</bold>
<article-title>BacS: an abundant bacteroid protein in <italic>Rhizobium etli</italic> whose expression ex planta requires <italic>nifA</italic></article-title>. <source>Mol Plant Microbe Interact</source>
<volume>16</volume>, <fpage>65</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1094/MPMI.2003.16.1.65</pub-id><?supplied-pmid 12580283?><pub-id pub-id-type="pmid">12580283</pub-id></mixed-citation>
      </ref>
      <ref id="r22">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laemmli</surname><given-names>U. K.</given-names></name></person-group>
<bold>(</bold><year>1970</year><bold>).</bold>
<article-title>Cleavage of structural proteins during the assembly of the head of bacteriophage T4</article-title>. <source>Nature</source>
<volume>227</volume>, <fpage>680</fpage>–<lpage>685</lpage>. <pub-id pub-id-type="doi">10.1038/227680a0</pub-id><?supplied-pmid 5432063?><pub-id pub-id-type="pmid">5432063</pub-id></mixed-citation>
      </ref>
      <ref id="r23">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landeta</surname><given-names>C.</given-names></name><name><surname>Dávalos</surname><given-names>A.</given-names></name><name><surname>Cevallos</surname><given-names>M. Á.</given-names></name><name><surname>Geiger</surname><given-names>O.</given-names></name><name><surname>Brom</surname><given-names>S. C.</given-names></name><name><surname>Romero</surname><given-names>D.</given-names></name></person-group>
<bold>(</bold><year>2011</year><bold>).</bold>
<article-title>Plasmids with a chromosome-like role in rhizobia</article-title>. <source>J Bacteriol</source>
<volume>193</volume>, <fpage>1317</fpage>–<lpage>1326</lpage>. <pub-id pub-id-type="doi">10.1128/JB.01184-10</pub-id><?supplied-pmid 21217003?><pub-id pub-id-type="pmid">21217003</pub-id></mixed-citation>
      </ref>
      <ref id="r24">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez</surname><given-names>O.</given-names></name><name><surname>Morera</surname><given-names>C.</given-names></name><name><surname>Miranda-Rios</surname><given-names>J.</given-names></name><name><surname>Girard</surname><given-names>L.</given-names></name><name><surname>Romero</surname><given-names>D.</given-names></name><name><surname>Soberón</surname><given-names>M.</given-names></name></person-group>
<bold>(</bold><year>2001</year><bold>).</bold>
<article-title>Regulation of gene expression in response to oxygen in <italic>Rhizobium etli</italic>: role of FnrN in <italic>fixNOQP</italic> expression and in symbiotic nitrogen fixation</article-title>. <source>J Bacteriol</source>
<volume>183</volume>, <fpage>6999</fpage>–<lpage>7006</lpage>. <pub-id pub-id-type="doi">10.1128/JB.183.24.6999-7006.2001</pub-id><?supplied-pmid 11717256?><pub-id pub-id-type="pmid">11717256</pub-id></mixed-citation>
      </ref>
      <ref id="r25">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ludwig</surname><given-names>B.</given-names></name></person-group>
<bold>(</bold><year>1986</year><bold>).</bold>
<article-title>Cytochrome <italic>c</italic> oxidase from <italic>Paracoccus denitrificans</italic></article-title>. <source>Methods Enzymol</source>
<volume>126</volume>, <fpage>153</fpage>–<lpage>159</lpage>. <pub-id pub-id-type="doi">10.1016/S0076-6879(86)26017-6</pub-id><?supplied-pmid 2856122?><pub-id pub-id-type="pmid">2856122</pub-id></mixed-citation>
      </ref>
      <ref id="r26">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michiels</surname><given-names>J.</given-names></name><name><surname>Moris</surname><given-names>M.</given-names></name><name><surname>Dombrecht</surname><given-names>B.</given-names></name><name><surname>Verreth</surname><given-names>C.</given-names></name><name><surname>Vanderleyden</surname><given-names>J.</given-names></name></person-group>
<bold>(</bold><year>1998</year><bold>).</bold>
<article-title>Differential regulation of <italic>Rhizobium etli rpoN2</italic> gene expression during symbiosis and free-living growth</article-title>. <source>J Bacteriol</source>
<volume>180</volume>, <fpage>3620</fpage>–<lpage>3628</lpage>.<?supplied-pmid 9658006?><pub-id pub-id-type="pmid">9658006</pub-id></mixed-citation>
      </ref>
      <ref id="r27">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moris</surname><given-names>M.</given-names></name><name><surname>Dombrecht</surname><given-names>B.</given-names></name><name><surname>Xi</surname><given-names>C.</given-names></name><name><surname>Vanderleyden</surname><given-names>J.</given-names></name><name><surname>Michiels</surname><given-names>J.</given-names></name></person-group>
<bold>(</bold><year>2004</year><bold>).</bold>
<article-title>Regulatory role of <italic>Rhizobium etli</italic> CNPAF512 <italic>fnrN</italic> during symbiosis</article-title>. <source>Appl Environ Microbiol</source>
<volume>70</volume>, <fpage>1287</fpage>–<lpage>1296</lpage>. <pub-id pub-id-type="doi">10.1128/AEM.70.3.1287-1296.2004</pub-id><?supplied-pmid 15006745?><pub-id pub-id-type="pmid">15006745</pub-id></mixed-citation>
      </ref>
      <ref id="r28">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>R. L.</given-names></name><name><surname>Schmidt</surname><given-names>T. M.</given-names></name></person-group>
<bold>(</bold><year>2013</year><bold>).</bold>
<article-title>Shallow breathing: bacterial life at low O<sub>2</sub></article-title>. <source>Nat Rev Microbiol</source>
<volume>11</volume>, <fpage>205</fpage>–<lpage>212</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro2970</pub-id><?supplied-pmid 23411864?><pub-id pub-id-type="pmid">23411864</pub-id></mixed-citation>
      </ref>
      <ref id="r29">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noel</surname><given-names>K. D.</given-names></name><name><surname>Carneol</surname><given-names>M.</given-names></name><name><surname>Brill</surname><given-names>W. J.</given-names></name></person-group>
<bold>(</bold><year>1982</year><bold>).</bold>
<article-title>Nodule protein synthesis and nitrogenase activity of soybeans exposed to fixed nitrogen</article-title>. <source>Plant Physiol</source>
<volume>70</volume>, <fpage>1236</fpage>–<lpage>1241</lpage>. <pub-id pub-id-type="doi">10.1104/pp.70.5.1236</pub-id><?supplied-pmid 16662660?><pub-id pub-id-type="pmid">16662660</pub-id></mixed-citation>
      </ref>
      <ref id="r30">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noel</surname><given-names>K. D.</given-names></name><name><surname>Sanchez</surname><given-names>A.</given-names></name><name><surname>Fernandez</surname><given-names>L.</given-names></name><name><surname>Leemans</surname><given-names>J.</given-names></name><name><surname>Cevallos</surname><given-names>M. A.</given-names></name></person-group>
<bold>(</bold><year>1984</year><bold>).</bold>
<article-title><italic>Rhizobium phaseoli</italic> symbiotic mutants with transposon Tn<italic>5</italic> insertions</article-title>. <source>J Bacteriol</source>
<volume>158</volume>, <fpage>148</fpage>–<lpage>155</lpage>.<?supplied-pmid 6325385?><pub-id pub-id-type="pmid">6325385</pub-id></mixed-citation>
      </ref>
      <ref id="r31">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ojeda</surname><given-names>K. J.</given-names></name><name><surname>Box</surname><given-names>J. M.</given-names></name><name><surname>Noel</surname><given-names>K. D.</given-names></name></person-group>
<bold>(</bold><year>2010</year><bold>).</bold>
<article-title>Genetic basis for <italic>Rhizobium etli</italic> CE3 O-antigen <italic>O</italic>-methylated residues that vary according to growth conditions</article-title>. <source>J Bacteriol</source>
<volume>192</volume>, <fpage>679</fpage>–<lpage>690</lpage>. <pub-id pub-id-type="doi">10.1128/JB.01154-09</pub-id><?supplied-pmid 19948805?><pub-id pub-id-type="pmid">19948805</pub-id></mixed-citation>
      </ref>
      <ref id="r32">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poole</surname><given-names>R. K.</given-names></name><name><surname>Cook</surname><given-names>G. M.</given-names></name></person-group>
<bold>(</bold><year>2000</year><bold>).</bold>
<article-title>Redundancy of aerobic respiratory chains in bacteria? Routes, reasons and regulation</article-title>. <source>Adv Microb Physiol</source>
<volume>43</volume>, <fpage>165</fpage>–<lpage>224</lpage>. <pub-id pub-id-type="doi">10.1016/S0065-2911(00)43005-5</pub-id><?supplied-pmid 10907557?><pub-id pub-id-type="pmid">10907557</pub-id></mixed-citation>
      </ref>
      <ref id="r33">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Preisig</surname><given-names>O.</given-names></name><name><surname>Zufferey</surname><given-names>R.</given-names></name><name><surname>Thöny-Meyer</surname><given-names>L.</given-names></name><name><surname>Appleby</surname><given-names>C. A.</given-names></name><name><surname>Hennecke</surname><given-names>H.</given-names></name></person-group>
<bold>(</bold><year>1996</year><bold>).</bold>
<article-title>A high-affinity <italic>cbb3-</italic>type cytochrome oxidase terminates the symbiosis-specific respiratory chain of <italic>Bradyrhizobium japonicum</italic></article-title>. <source>J Bacteriol</source>
<volume>178</volume>, <fpage>1532</fpage>–<lpage>1538</lpage>.<?supplied-pmid 8626278?><pub-id pub-id-type="pmid">8626278</pub-id></mixed-citation>
      </ref>
      <ref id="r34">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richhardt</surname><given-names>J.</given-names></name><name><surname>Luchterhand</surname><given-names>B.</given-names></name><name><surname>Bringer</surname><given-names>S.</given-names></name><name><surname>Büchs</surname><given-names>J.</given-names></name><name><surname>Bott</surname><given-names>M.</given-names></name></person-group>
<bold>(</bold><year>2013</year><bold>).</bold>
<article-title>Evidence for a key role of cytochrome <italic>bo<sub>3</sub></italic> oxidase in respiratory energy metabolism of <italic>Gluconobacter oxydans</italic></article-title>. <source>J Bacteriol</source>
<volume>195</volume>, <fpage>4210</fpage>–<lpage>4220</lpage>. <pub-id pub-id-type="doi">10.1128/JB.00470-13</pub-id><?supplied-pmid 23852873?><pub-id pub-id-type="pmid">23852873</pub-id></mixed-citation>
      </ref>
      <ref id="r35">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richter</surname><given-names>O. M. H.</given-names></name><name><surname>Tao</surname><given-names>J. S.</given-names></name><name><surname>Turba</surname><given-names>A.</given-names></name><name><surname>Ludwig</surname><given-names>B.</given-names></name></person-group>
<bold>(</bold><year>1994</year><bold>).</bold>
<article-title>A cytochrome <italic>ba3</italic> functions as a quinol oxidase in <italic>Paracoccus denitrificans.</italic> Purification, cloning, and sequence comparison</article-title>. <source>J Biol Chem</source>
<volume>269</volume>, <fpage>23079</fpage>–<lpage>23086</lpage>.<?supplied-pmid 8083210?><pub-id pub-id-type="pmid">8083210</pub-id></mixed-citation>
      </ref>
      <ref id="r36">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rieske</surname><given-names>J. S.</given-names></name></person-group>
<bold>(</bold><year>1967</year><bold>).</bold>
<article-title>Preparation and properties of reduced coenzyme Q-cytochrome c reductase (complex III of the respiratory chain)</article-title>. <source>Methods Enzymol</source>
<volume>10</volume>, <fpage>239</fpage>–<lpage>245</lpage>
<pub-id pub-id-type="doi">10.1016/0076-6879(67)10047-5</pub-id></mixed-citation>
      </ref>
      <ref id="r37">
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sambrook</surname><given-names>J.</given-names></name><name><surname>Fritsch</surname><given-names>E. F.</given-names></name><name><surname>Maniatis</surname><given-names>T.</given-names></name></person-group>
<bold>(</bold><year>1989</year><bold>).</bold>
<source>Molecular Cloning: a Laboratory Manual</source>, <edition>2nd edn</edition>
<publisher-loc>Cold Spring Harbor, NY</publisher-loc>: <publisher-name>Cold Spring Harbor Laboratory</publisher-name>.</mixed-citation>
      </ref>
      <ref id="r38">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schweizer</surname><given-names>H. D.</given-names></name></person-group>
<bold>(</bold><year>1993</year><bold>).</bold>
<article-title>Small broad-host-range gentamycin resistance gene cassettes for site-specific insertion and deletion mutagenesis</article-title>. <source>Biotechniques</source>
<volume>15</volume>, <fpage>831</fpage>–<lpage>834</lpage>.<?supplied-pmid 8267974?><pub-id pub-id-type="pmid">8267974</pub-id></mixed-citation>
      </ref>
      <ref id="r39">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soberón</surname><given-names>M.</given-names></name><name><surname>Williams</surname><given-names>H. D.</given-names></name><name><surname>Poole</surname><given-names>R. K.</given-names></name><name><surname>Escamilla</surname><given-names>E.</given-names></name></person-group>
<bold>(</bold><year>1989</year><bold>).</bold>
<article-title>Isolation of a <italic>Rhizobium phaseoli</italic> cytochrome mutant with enhanced respiration and symbiotic nitrogen fixation</article-title>. <source>J Bacteriol</source>
<volume>171</volume>, <fpage>465</fpage>–<lpage>472</lpage>.<?supplied-pmid 2644201?><pub-id pub-id-type="pmid">2644201</pub-id></mixed-citation>
      </ref>
      <ref id="r40">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soberón</surname><given-names>M.</given-names></name><name><surname>Membrillo-Hernández</surname><given-names>J.</given-names></name><name><surname>Aguilar</surname><given-names>G. R.</given-names></name><name><surname>Sánchez</surname><given-names>F.</given-names></name></person-group>
<bold>(</bold><year>1990</year><bold>).</bold>
<article-title>Isolation of <italic>Rhizobium phaseoli</italic> Tn5-induced mutants with altered expression of cytochrome terminal oxidases <italic>o</italic> and <italic>aa3</italic></article-title>. <source>J Bacteriol</source>
<volume>172</volume>, <fpage>1676</fpage>–<lpage>1680</lpage>.<?supplied-pmid 2155209?><pub-id pub-id-type="pmid">2155209</pub-id></mixed-citation>
      </ref>
      <ref id="r41">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spaink</surname><given-names>H. P.</given-names></name><name><surname>Okker</surname><given-names>R. J. H.</given-names></name><name><surname>Wijffelman</surname><given-names>C. A.</given-names></name><name><surname>Pees</surname><given-names>E.</given-names></name><name><surname>Lugtenberg</surname><given-names>B. J. J.</given-names></name></person-group>
<bold>(</bold><year>1987</year><bold>).</bold>
<article-title>Promoters in the nodulation region of the <italic>Rhizobium</italic>
<italic>leguminosarum</italic> Sym plasmid pRL1JI</article-title>. <source>Plant Mol Biol</source>
<volume>9</volume>, <fpage>27</fpage>–<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1007/BF00017984</pub-id><?supplied-pmid 24276795?><pub-id pub-id-type="pmid">24276795</pub-id></mixed-citation>
      </ref>
      <ref id="r42">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surpin</surname><given-names>M. A.</given-names></name><name><surname>Maier</surname><given-names>R. J.</given-names></name></person-group>
<bold>(</bold><year>1998</year><bold>).</bold>
<article-title>Roles of the <italic>bradyrhizobium japonicum</italic> terminal oxidase complexes in microaerobic H<sub>2</sub>-dependent growth</article-title>. <source>Biochim Biophys Acta</source>
<volume>1364</volume>, <fpage>37</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/S0005-2728(98)00003-6</pub-id><?supplied-pmid 9554944?><pub-id pub-id-type="pmid">9554944</pub-id></mixed-citation>
      </ref>
      <ref id="r43">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surpin</surname><given-names>M. A.</given-names></name><name><surname>Maier</surname><given-names>R. J.</given-names></name></person-group>
<bold>(</bold><year>1999</year><bold>).</bold>
<article-title>Symbiotic deficiencies associated with a <italic>coxWXYZ</italic> mutant of <italic>bradyrhizobium japonicum</italic></article-title>. <source>Appl Environ Microbiol</source>
<volume>65</volume>, <fpage>339</fpage>–<lpage>341</lpage>.<?supplied-pmid 9872805?><pub-id pub-id-type="pmid">9872805</pub-id></mixed-citation>
      </ref>
      <ref id="r44">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surpin</surname><given-names>M. A.</given-names></name><name><surname>Lübben</surname><given-names>M.</given-names></name><name><surname>Maier</surname><given-names>R. J.</given-names></name></person-group>
<bold>(</bold><year>1996</year><bold>).</bold>
<article-title>The <italic>Bradyrhizobium japonicum coxWXYZ</italic> gene cluster encodes a <italic>bb3-</italic>type ubiquinol oxidase</article-title>. <source>Gene</source>
<volume>183</volume>, <fpage>201</fpage>–<lpage>206</lpage>. <pub-id pub-id-type="doi">10.1016/S0378-1119(96)00559-8</pub-id><?supplied-pmid 8996107?><pub-id pub-id-type="pmid">8996107</pub-id></mixed-citation>
      </ref>
      <ref id="r45">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trzebiatowski</surname><given-names>J. R.</given-names></name><name><surname>Ragatz</surname><given-names>D. M.</given-names></name><name><surname>de Bruijn</surname><given-names>F. J.</given-names></name></person-group>
<bold>(</bold><year>2001</year><bold>).</bold>
<article-title>Isolation and regulation of <italic>Sinorhizobium meliloti</italic> 1021 loci induced by oxygen limitation</article-title>. <source>Appl Environ Microbiol</source>
<volume>67</volume>, <fpage>3728</fpage>–<lpage>3731</lpage>. <pub-id pub-id-type="doi">10.1128/AEM.67.8.3728-3731.2001</pub-id><?supplied-pmid 11472955?><pub-id pub-id-type="pmid">11472955</pub-id></mixed-citation>
      </ref>
      <ref id="r46">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tseng</surname><given-names>C. P.</given-names></name><name><surname>Albrecht</surname><given-names>J.</given-names></name><name><surname>Gunsalus</surname><given-names>R. P.</given-names></name></person-group>
<bold>(</bold><year>1996</year><bold>).</bold>
<article-title>Effect of microaerophilic cell growth conditions on expression of the aerobic (<italic>cyoABCDE</italic> and <italic>cydAB</italic>) and anaerobic (<italic>narGHJI, frdABCD</italic>, and <italic>dmsABC</italic>) respiratory pathway genes in <italic>Escherichia coli</italic></article-title>. <source>J Bacteriol</source>
<volume>178</volume>, <fpage>1094</fpage>–<lpage>1098</lpage>.<?supplied-pmid 8576043?><pub-id pub-id-type="pmid">8576043</pub-id></mixed-citation>
      </ref>
      <ref id="r47">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>K. J.</given-names></name><name><surname>Sessitsch</surname><given-names>A.</given-names></name><name><surname>Corbo</surname><given-names>J. C.</given-names></name><name><surname>Giller</surname><given-names>K. E.</given-names></name><name><surname>Akkermans</surname><given-names>A. D. L.</given-names></name><name><surname>Jefferson</surname><given-names>R. A.</given-names></name></person-group>
<bold>(</bold><year>1995</year><bold>).</bold>
<article-title>β-Glucuronidase (GUS) transposons for ecological and genetic studies of rhizobia and other gram-negative bacteria</article-title>. <source>Microbiology</source>
<volume>141</volume>, <fpage>1691</fpage>–<lpage>1705</lpage>. <pub-id pub-id-type="doi">10.1099/13500872-141-7-1691</pub-id><?supplied-pmid 7551037?><pub-id pub-id-type="pmid">7551037</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:4274798</identifier><datestamp>2016-01-01</datestamp><setSpec>diabetes</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="http://jats.nlm.nih.gov/ns/archiving/1.0/ http://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Diabetes</journal-id>
      <journal-id journal-id-type="iso-abbrev">Diabetes</journal-id>
      <journal-id journal-id-type="hwp">diabetes</journal-id>
      <journal-id journal-id-type="pmc">diabetes</journal-id>
      <journal-id journal-id-type="publisher-id">Diabetes</journal-id>
      <journal-title-group>
        <journal-title>Diabetes</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0012-1797</issn>
      <issn pub-type="epub">1939-327X</issn>
      <publisher>
        <publisher-name>American Diabetes Association</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4274798</article-id>
      <article-id pub-id-type="pmcid">PMC4274798</article-id>
      <article-id pub-id-type="pmc-uid">4274798</article-id>
      <article-id pub-id-type="pmid">25114294</article-id>
      <article-id pub-id-type="publisher-id">0671</article-id>
      <article-id pub-id-type="doi">10.2337/db14-0671</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Complications</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Perifornical Hypothalamic Orexin and Serotonin Modulate the Counterregulatory Response to Hypoglycemic and Glucoprivic Stimuli</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Otlivanchik</surname>
            <given-names>Oleg</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Le Foll</surname>
            <given-names>Christelle</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Levin</surname>
            <given-names>Barry E.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
        <aff id="aff1"><sup>1</sup>Graduate School of Biomedical Sciences, Rutgers, Newark, NJ</aff>
        <aff id="aff2"><sup>2</sup>Department of Neurology and Neurosciences, New Jersey Medical School, Rutgers, Newark, NJ</aff>
        <aff id="aff3"><sup>3</sup>Neurology Service, Veterans Affairs Medical Center, East Orange, NJ</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">Corresponding author: Barry E. Levin, <email>levin@njms.rutgers.edu</email>.</corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>11</day>
        <month>8</month>
        <year>2014</year>
      </pub-date>
      <volume>64</volume>
      <issue>1</issue>
      <fpage>226</fpage>
      <lpage>235</lpage>
      <history>
        <date date-type="received">
          <day>28</day>
          <month>4</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>03</day>
          <month>8</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.</copyright-statement>
        <copyright-year>2015</copyright-year>
      </permissions>
      <self-uri xlink:title="pdf" xlink:type="simple" xlink:href="226.pdf"/>
      <abstract>
        <p>Previous reports suggested an important role for serotonin (5-hydroxytryptamine [5-HT]) in enhancing the counterregulatory response (CRR) to hypoglycemia. To elucidate the sites of action mediating this effect, we initially found that insulin-induced hypoglycemia stimulates 5-HT release in widespread forebrain regions, including the perifornical hypothalamus (PFH; 30%), ventromedial hypothalamus (34%), paraventricular hypothalamus (34%), paraventricular thalamic nucleus (64%), and cerebral cortex (63%). Of these, we focused on the PFH because of its known modulation of diverse neurohumoral and behavioral responses. In awake, behaving rats, bilateral PFH glucoprivation with 5-thioglucose stimulated adrenal medullary epinephrine (Epi) release (3,153%) and feeding (400%), while clamping PFH glucose at postprandial brain levels blunted the Epi response to hypoglycemia by 30%. The PFH contained both glucose-excited (GE) and glucose-inhibited (GI) neurons; GE neurons were primarily excited, while GI neurons were equally excited or inhibited by 5-HT at hypoglycemic glucose levels in vitro. Also, 5-HT stimulated lactate production by cultured hypothalamic astrocytes. Depleting PFH 5-HT blunted the Epi (but not feeding) response to focal PFH (69%) and systemic glucoprivation (39%), while increasing PFH 5-HT levels amplified the Epi response to hypoglycemia by 32%. Finally, the orexin 1 receptor antagonist SB334867A attenuated both the Epi (65%) and feeding (47%) responses to focal PFH glucoprivation. Thus we have identified the PFH as a glucoregulatory region where both 5-HT and orexin modulate the CRR and feeding responses to glucoprivation.</p>
      </abstract>
      <counts>
        <page-count count="10"/>
      </counts>
    </article-meta>
  </front>
  <body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Iatrogenic hypoglycemia is a significant clinical problem in type 1 and type 2 diabetic patients treated with exogenous insulin (<xref rid="B1" ref-type="bibr">1</xref>–<xref rid="B3" ref-type="bibr">3</xref>). The neurohumoral counterregulatory response (CRR) and awareness evoked by hypoglycemia, which typically defend against dangerously low plasma glucose levels, are progressively blunted by repeated bouts of hypoglycemia with potentially life-threatening consequences (<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref>). It has been reported that treatment with selective serotonin (5-hydroxytryptamine [5-HT]) reuptake inhibitors (SSRIs) amplifies the CRR to acute hypoglycemia and prevents the blunting of the CRR after recurrent hypoglycemia in both rats (<xref rid="B6" ref-type="bibr">6</xref>) and humans (<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B8" ref-type="bibr">8</xref>), suggesting that 5-HT plays an important role in mediating this response. However, the role of 5-HT, per se, in the central control of the CRR is currently unknown. To explore the potential brain sites at which SSRIs might act on 5-HT metabolism to enhance the CRR, we first identified forebrain regions where hypoglycemia stimulates 5-HT release and investigated the role of 5-HT signaling at one such site, the perifornical hypothalamus (PFH), in modulating the CRR to insulin-induced hypoglycemia (IIH) in awake, behaving rats. We found that the PFH regulates adrenal medullary epinephrine (Epi) release and feeding in response to local and systemic glucose deficit and contains neurons that are either excited or inhibited by low glucose and/or 5-HT, that PFH 5-HT promotes the adrenomedullary response, and that PFH orexin neurons mediate both feeding and hormonal responses induced by local PFH glucoprivation.</p></sec><sec id="s2"><title>Research Design and Methods</title><sec id="s3"><title>Animals</title><p>Male 8-week-old Sprague-Dawley rats (250–350 g; Charles River) were used for all studies, unless otherwise noted. Animals were maintained on a conventional 12-h light/dark cycle (lights off at 2000) with food (Purina rat chow #5001) and water available ad libitum. Experimental groups contained 6–8 rats each. Experiments involving hypoglycemia and/or glucoprivation were uniformly performed during the light phase (beginning at 0800 unless otherwise noted). The animal care and experimental protocols were reviewed and approved by the Institutional Animal Care and Use Committee of the East Orange Veterans Affairs Medical Center.</p></sec><sec id="s4"><title>Placement of Hypothalamic Cannulae and Vascular Catheters</title><p>For jugular venous catheters, rats were anesthetized with ketamine (60 mg/mL) and xylazine (6.5 mg/mL) at 1 mL/kg i.p. Silastic catheters (0.24 mm inner diameter) were inserted into the right jugular vein, externalized at the top of the skull, and secured with dental cement. Placement of bilateral guide cannulae for microdialysis probes or direct injection was done under isofluorane anesthesia using stereotaxic guidance (Kopf Instruments). PFH coordinates relative to bregma were A-P = −3.1, M-L = 3.0, D = 7.1–8.1 at a 15° angle. All microdialysis probe and injection cannulae placements were verified histologically.</p></sec><sec id="s5"><title>5-HT Axon Lesion Studies</title><p>Rats were pretreated with desmethylimipramine (25 mg/kg; Sigma) to prevent damage to noradrenergic axons. Then, 2 h later, 5,7-dihydroxytryptamine (5,7-DHT; Sigma; 5 μg in 0.5 μL 0.1% ascorbic acid), a neurotoxin that selectively ablates 5-HT nerve terminals (<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B10" ref-type="bibr">10</xref>), or ascorbic acid vehicle were administered by direct bilateral infusions into the PFH via stainless steel injection cannulae over 5 min (0.06 mL/h). During the same session, venous catheters were placed in the right jugular vein. One week later, rats were assessed for their responses to IIH, and brains were collected after 2 h of hypoglycemia for determination of 5-HT and 5-hydroxyindole acetic acid (5-HIAA) from frozen brain micropunches with high-performance liquid chromatography with electrochemical detection (HPLC-ED) as described below (<xref rid="B11" ref-type="bibr">11</xref>).</p></sec><sec id="s6"><title>Drugs and Dosing</title><p>The following were used: serotonin (5-HT; 10 nmol/L; Sigma), orexin 1 receptor antagonist, SB334867A (10 mg/kg; 20 mg/kg; Tocris), SSRI, sertraline (10 μmol/L for reverse microdialysis and direct injection; Toronto Biochemicals), glucose antimetabolites, 2-deoxy-<sc>d</sc>-glucose (2-DG; 200 mg/kg; Sigma), and 5-thio-<sc>d</sc>-glucose (5-TG; 60 μg in 0.5 μL per side; Sigma).</p></sec><sec id="s7"><title>IIH</title><p>On the day prior to induction of IIH, animals were semifasted overnight (∼13 g of chow). On the morning of testing, remaining food was removed, and hypoglycemia was initiated by bolus insulin (4.5 units/kg; Humulin, Lilly) injection via indwelling jugular venous catheters. Blood (0.5 mL) was collected for baseline measurements and, subsequently, at 30 min intervals over 2 h. After each blood draw, packed red blood cells were resuspended in an equal volume saline and reinfused to maintain blood volume (<xref rid="B12" ref-type="bibr">12</xref>).</p></sec><sec id="s8"><title>Assays of Blood and Brain Tissues</title><p>Plasma norepinephrine (NE) and Epi were assayed by HPLC-ED on a Coulochem III system (ESA) (<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B13" ref-type="bibr">13</xref>). Glucose was determined by an automated glucose analyzer (Analox). Glucagon was assayed by commercially available radioimmunoassay (Linco). Extracellular 5-HT obtained from microdialysis samples in a pilot study by the present authors (data not shown) was below the level of detection (at baseline) by HPLC-ED. Therefore, brain 5-HT and 5-HIAA were assayed by HPLC-ED from brain micropunches isolated from fresh frozen brain slabs after homogenization and centrifugation (10,000 rpm for 10 min). The supernatant was analyzed by HPLC-ED as previously described (<xref rid="B11" ref-type="bibr">11</xref>); protein from micropunches was quantified with a commercially available kit and the values used to normalize HPLC results (BCA Protein Assay, Thermo).</p></sec><sec id="s9"><title>Microdialysis</title><p>Bilateral reverse microdialysis studies were performed in awake, behaving rats using CMA 11, Harvard Instruments probes with 1 mm dialysis membranes as previously reported (<xref rid="B14" ref-type="bibr">14</xref>). Probes were inserted via guide cannulae, animals were rested for 2 h, and glucose (25 mmol/L), extracellular fluid (ECF), sertraline (100 μmol/L), 5-HT (100 nmol/L), or 3% DMSO/0.1% ascorbic acid were infused at a flow rate of 0.06 mL/h, and IIH was induced as described above for a total testing period of 4 h. For glucose reverse microdialysis, probe efficiency (8–12%) was calculated from glucose recovered after probe calibration in artificial ECF. For sertraline reverse microdialysis, probe efficiency was estimated as 10%.</p></sec><sec id="s10"><title>Isolation of Primary PFH Neurons and Astrocytes</title><p>Primary neuronal and astrocytic cultures were prepared from PFH micropunches using 3-week-old male Sprague-Dawley rats, as previously described (<xref rid="B15" ref-type="bibr">15</xref>–<xref rid="B17" ref-type="bibr">17</xref>). Astrocytes were cultured for 5 days and then assessed for 5-HT–induced lactate production using previously reported culture methods (<xref rid="B17" ref-type="bibr">17</xref>). Lactate levels were assessed in supernatants after 5-HT exposure using a commercially available fluorometric L-lactate assay kit (Cayman).</p></sec><sec id="s11"><title>Calcium Imaging</title><p>Calcium imaging with fura-2 calcium-sensitive dye was performed as previously described (<xref rid="B15" ref-type="bibr">15</xref>–<xref rid="B17" ref-type="bibr">17</xref>). Neurons were serially exposed to 0.5, 2.5, and 0.5 mmol/L glucose to establish their glucose responsiveness and then at 0.5 mmol/L glucose, sequentially to 50 pmol/L 5-HT, and glutamate.</p></sec><sec id="s12"><title>Feeding Studies</title><p>Rats were fed ad libitum overnight and were then bilaterally infused with either 0.5 μL 5-TG or saline at 0900 on the day of testing. Cumulative food intake was monitored 2 h after each injection.</p></sec><sec id="s13"><title>Statistical Analysis</title><p>All statistical analysis was carried out using Systat 8.0. One-way or two-way ANOVAs were used for determination of significance with post hoc corrections made using Tukey test. Areas under the curve were calculated using the trapezoidal rule.</p></sec></sec><sec sec-type="results" id="s14"><title>Results</title><sec id="s15"><title>Effect of IIH on Central 5-HT Turnover</title><p>Because others have shown that SSRIs, which alter brain 5-HT metabolism (<xref rid="B18" ref-type="bibr">18</xref>), amplify the CRR to IIH (<xref rid="B6" ref-type="bibr">6</xref>–<xref rid="B8" ref-type="bibr">8</xref>), we first evaluated 5-HT turnover (the ratio of 5-HIAA, the principal 5-HT metabolite, to 5-HT) (<xref rid="B11" ref-type="bibr">11</xref>) in response to acute IIH. Hypoglycemia significantly increased 5-HT turnover in the ventromedial hypothalamus (VMH; 34%), paraventricular hypothalamic nucleus (PVN; 34%), and PFH (30%), as well as the paraventricular thalamic nucleus (PVP; 64%) and cerebral cortex (63%) (<xref ref-type="fig" rid="F1">Fig. 1</xref>).</p><fig id="F1" fig-type="figure" position="float"><label>Figure 1</label><caption><p>5-HT turnover in selected brain regions after IIH. Rats (<italic>n</italic> = 5–6/group) were given bolus insulin (4.5 units/kg s.c.) or vehicle (saline) injections, and 5-HT turnover (ratio of 5-HIAA to 5-HT) was assessed in brain micropunches after 2 h of hypoglycemia. Bars are mean ± SEM. *<italic>P</italic> = 0.05 or less between hypoglycemia and saline groups by one-way ANOVA with Tukey post hoc correction. Ctx, cerebral cortex; DMN, dorsomedial hypothalamic nucleus; dRa, dorsal raphe nucleus; vHip, ventral hippocampus.</p></caption><graphic xlink:href="226fig1"/></fig></sec><sec id="s16"><title>Role of PFH Glucose Availability on the CRR</title><p>Of those areas in which hypoglycemia increased 5-HT turnover, we chose to further explore the potential role of the PFH in mediating the CRR and feeding responses to glucose deficit, because it contains glucosensing neurons (<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B20" ref-type="bibr">20</xref>), some of which project to the adrenal medulla (<xref rid="B21" ref-type="bibr">21</xref>). First, we used injections of 5-TG into the PFH since we (<xref rid="B22" ref-type="bibr">22</xref>) and others (<xref rid="B23" ref-type="bibr">23</xref>–<xref rid="B25" ref-type="bibr">25</xref>) have shown it to be highly effective in eliciting both counterregulatory and feeding responses when injected into various brain areas. Bilateral PFH 5-TG–induced glucoprivation (<xref rid="B24" ref-type="bibr">24</xref>,<xref rid="B26" ref-type="bibr">26</xref>,<xref rid="B27" ref-type="bibr">27</xref>) increased plasma glucose by 724%, Epi levels by 3,153%, and food intake by 400% over 2 h relative to saline-infused rats (<xref ref-type="fig" rid="F2">Fig. 2<italic>A</italic> and <italic>B</italic></xref> and <xref ref-type="table" rid="T1">Table 1</xref>). PFH 5-TG also increased 30-min peak plasma NE levels by 182%, but levels did not differ from controls when integrated over the entire 2-h test period (<xref ref-type="fig" rid="F2">Fig. 2<italic>C</italic></xref> and <xref ref-type="table" rid="T1">Table 1</xref>). Control plasma glucagon levels were below the level of detectability, but PFH 5-TG caused a significant 235% increase above baseline levels 30 min after PFH 5-TG infusion (F<sub>4,20</sub> = 15.608; <italic>P</italic> &lt; 0.001) (<xref ref-type="fig" rid="F2">Fig. 2<italic>D</italic></xref> and <xref ref-type="table" rid="T1">Table 1</xref>). To further assess the relative contribution of PFH glucoprivation-induced CRR, bilateral PFH glucose was clamped at brain levels seen following a meal (3.2 ± 0.3 mmol/L) or allowed to fall spontaneously to brain levels seen during IIH (<ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0671/-/DC1">Supplementary Fig. 1</ext-link>) (<xref rid="B22" ref-type="bibr">22</xref>,<xref rid="B28" ref-type="bibr">28</xref>,<xref rid="B29" ref-type="bibr">29</xref>). Clamping PFH glucose at ∼3 mmol/L during systemic hypoglycemia affected neither the depth nor duration of hypoglycemia but did significantly reduce the plasma Epi response by 30% over 2 h of hypoglycemia relative to PFH ECF-infused rats (<xref ref-type="fig" rid="F3">Fig. 3<italic>A</italic></xref> and <xref ref-type="table" rid="T1">Table 1</xref>). There was no effect on NE or glucagon levels (<xref ref-type="fig" rid="F3">Fig. 3<italic>B</italic> and <italic>C</italic></xref> and <xref ref-type="table" rid="T1">Table 1</xref>).</p><fig id="F2" fig-type="figure" position="float"><label>Figure 2</label><caption><p>Effects of local PFH glucoprivation on glucoregulatory hormone release. Rats (<italic>n</italic> = 4–8/group) were infused bilaterally with 5-TG (60 μg in 0.5 μL) or vehicle (saline) in the PFH. Results are shown for blood glucose (<italic>A</italic>), epinephrine (<italic>B</italic>), norepinephrine (<italic>C</italic>), and glucagon (<italic>D</italic>). Data points are mean ± SEM. *<italic>P</italic> = 0.05 or less between 5-TG and saline groups at each time point by <italic>t</italic> test after responses over 2 h were significant by one-way repeated-measures ANOVA. Glucagon levels in saline controls (2<italic>D</italic>) were below assay detection limits.</p></caption><graphic xlink:href="226fig2"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Areas under the curve values for glucose, counterregulatory hormones, and food intake in response to PFH (5-TG) or systemic glucoprivation (IIH) and/or manipulation of PFH glucose levels (by reverse dialysis) or 5-HT with 5,7-DHT or sertraline and by inhibiting orexin 1 receptors with SB334867A</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th rowspan="2" align="left" scope="col" colspan="1"/><th colspan="2" align="center" scope="colgroup" rowspan="1">PFH 5-TG 5,7-DHT<hr/></th><th colspan="3" align="center" scope="colgroup" rowspan="1">PFH Sertraline IIH<hr/></th><th colspan="2" align="center" scope="colgroup" rowspan="1">PFH 5-TG<hr/></th><th colspan="2" align="center" scope="colgroup" rowspan="1">PFH glucose IIH<hr/></th><th colspan="2" align="center" scope="colgroup" rowspan="1">PFH 5-TG SB334867A<hr/></th></tr><tr><th align="center" scope="colgroup" rowspan="1" colspan="1">0.1% AA</th><th align="center" scope="col" rowspan="1" colspan="1">5,7-DHT</th><th align="center" scope="col" rowspan="1" colspan="1">DMSO</th><th align="center" scope="col" rowspan="1" colspan="1">Sertraline</th><th align="center" scope="col" rowspan="1" colspan="1">Sertraline + 5-HT</th><th align="center" scope="col" rowspan="1" colspan="1">Saline</th><th align="center" scope="col" rowspan="1" colspan="1">5-TG</th><th align="center" scope="col" rowspan="1" colspan="1">ECF</th><th align="center" scope="col" rowspan="1" colspan="1">25 mmol/L glucose</th><th align="center" scope="col" rowspan="1" colspan="1">DMSO</th><th align="center" scope="col" rowspan="1" colspan="1">SB334867A</th></tr></thead><tbody><tr><td align="left" scope="row" rowspan="1" colspan="1">Glucose (mg/2 h)</td><td align="center" rowspan="1" colspan="1">12,078 ± 1,223</td><td align="center" rowspan="1" colspan="1">4,887 ± 628<xref ref-type="table-fn" rid="t1n1">*</xref></td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">1,548 ± 314</td><td align="center" rowspan="1" colspan="1">11,473 ± 689<xref ref-type="table-fn" rid="t1n1">*</xref></td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">20,150 ± 1,039</td><td align="center" rowspan="1" colspan="1">10,272 ± 1,024<xref ref-type="table-fn" rid="t1n1">*</xref></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Epi (pg/2 h)</td><td align="center" rowspan="1" colspan="1">165,211 ± 9,134</td><td align="center" rowspan="1" colspan="1">51,347 ± 2,309<xref ref-type="table-fn" rid="t1n1">*</xref></td><td align="center" rowspan="1" colspan="1">168,668 ± 3,103<xref ref-type="table-fn" rid="t1n2"><sup>A</sup></xref></td><td align="center" rowspan="1" colspan="1">139,217 ± 9,890<xref ref-type="table-fn" rid="t1n2"><sup>B</sup></xref></td><td align="center" rowspan="1" colspan="1">223,765 ± 12,268<xref ref-type="table-fn" rid="t1n2"><sup>C</sup></xref></td><td align="center" rowspan="1" colspan="1">2,581 ± 406</td><td align="center" rowspan="1" colspan="1">81,470 ± 5,279<xref ref-type="table-fn" rid="t1n1">*</xref></td><td align="center" rowspan="1" colspan="1">307,675 ± 16,871</td><td align="center" rowspan="1" colspan="1">215,849 ± 14,686<xref ref-type="table-fn" rid="t1n1">*</xref></td><td align="center" rowspan="1" colspan="1">160,331 ± 20,576</td><td align="center" rowspan="1" colspan="1">57,087 ± 7,688<xref ref-type="table-fn" rid="t1n1">*</xref></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">NE (pg/2 h)</td><td align="center" rowspan="1" colspan="1">23,581 ± 5,450</td><td align="center" rowspan="1" colspan="1">23,378 ± 8,365</td><td align="center" rowspan="1" colspan="1">21,659 ± 1,526</td><td align="center" rowspan="1" colspan="1">23,873 ± 3,813</td><td align="center" rowspan="1" colspan="1">19,194 ± 3,918</td><td align="center" rowspan="1" colspan="1">7,212 ± 3,519</td><td align="center" rowspan="1" colspan="1">16,486 ± 502<xref ref-type="table-fn" rid="t1n1">*</xref></td><td align="center" rowspan="1" colspan="1">28,433 ± 2,451</td><td align="center" rowspan="1" colspan="1">29,319 ± 1,909</td><td align="center" rowspan="1" colspan="1">11,796 ± 2,272</td><td align="center" rowspan="1" colspan="1">11,696 ± 931</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Glucagon (pg/2 h)</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">14,404 ± 1,080</td><td align="center" rowspan="1" colspan="1">14,881 ± 3,066</td><td align="center" rowspan="1" colspan="1">22,377 ± 3,153</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">1,807 ± 556</td><td align="center" rowspan="1" colspan="1">12,045 ± 2,289</td><td align="center" rowspan="1" colspan="1">12,486 ± 3,137</td><td align="center" rowspan="1" colspan="1">5,628 ± 659</td><td align="center" rowspan="1" colspan="1">4,872 ± 710</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Food intake (g/2 h)</td><td align="center" rowspan="1" colspan="1">6.3 ± 0.6</td><td align="center" rowspan="1" colspan="1">6.5 ± 1.0</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">1.5 ± 0.3</td><td align="center" rowspan="1" colspan="1">6.0 ± 0.3<xref ref-type="table-fn" rid="t1n1">*</xref></td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">7.4 ± 0.6</td><td align="center" rowspan="1" colspan="1">3.5 ± 0.3<xref ref-type="table-fn" rid="t1n1">*</xref></td></tr></tbody></table><table-wrap-foot><fn><p>Data are mean ± SEM. AA, ascorbic acid.</p></fn><fn id="t1n1"><p>*<italic>P</italic> = 0.05 or less compared with comparable controls.</p></fn><fn id="t1n2"><p><sup>A,B,C</sup>Data with differing superscript letters differ from each other by <italic>P</italic> = 0.05 or less.</p></fn></table-wrap-foot></table-wrap><fig id="F3" fig-type="figure" position="float"><label>Figure 3</label><caption><p>Effect of clamping PFH extracellular glucose at euglycemic levels on the CRR to IIH. Rats (<italic>n</italic> = 7–8/group) were given bolus insulin (4.5 units/kg i.v.) and reverse dialyzed with 25 mmol/L glucose or ECF. Results are shown for blood epinephrine (<italic>A</italic>), norepinephrine (<italic>B</italic>), glucagon (<italic>C</italic>), and glucose (<italic>D</italic>). Data points are mean ± SEM. *<italic>P</italic> = 0.05 or less between 25 mmol/L glucose and ECF groups at each time point by <italic>t</italic> test after responses over 2 h were significant by one-way repeated-measures ANOVA.</p></caption><graphic xlink:href="226fig3"/></fig></sec><sec id="s17"><title>Role of PFH 5-HT Availability in the CRR</title><p>Our initial studies suggested that hypoglycemia has a major stimulatory effect on 5-HT release (turnover) in the PFH. To test the hypothesis that 5-HT release is required for the full CRR, we first injected the PFH bilaterally with the selective 5-HT neurotoxin, 5,7-DHT. This reduced 5-HT levels below the limit for detection (less than 0.5 pg/mg protein) as determined postmortem. Prior PFH 5,7-DHT injections blunted the hyperglycemic response to systemic 2-DG by 39% over 2 h relative to sham-operated rats (<xref ref-type="fig" rid="F4">Fig. 4<italic>A</italic></xref>) and decreased PFH 5-TG–induced hyperglycemia by 60% and plasma Epi levels by 69% over 2 h relative to PFH saline-injected controls (<xref ref-type="fig" rid="F4">Fig. 4<italic>B</italic> and <italic>C</italic></xref> and <xref ref-type="table" rid="T1">Table 1</xref>). However, PFH 5,7-DHT lesions had no effect on plasma NE levels or food intake over 2 h after PFH 5-TG (<xref ref-type="fig" rid="F4">Fig. 4<italic>D</italic></xref>, <xref ref-type="table" rid="T1">Table 1</xref>, and <ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0671/-/DC1">Supplementary Fig. 2</ext-link>). Glucagon data could not be obtained for this study because of insufficient plasma.</p><fig id="F4" fig-type="figure" position="float"><label>Figure 4</label><caption><p>Effect of PFH ablation of 5-HT signaling on glucoregulatory hormone release after systemic and local PFH glucoprivation. Rats (<italic>n</italic> = 6–10/group), previously treated with 5,7-DHT (5 μg in 0.5 μL infused over 5 min, in combination with 25 mg/kg desmethylimipramine s.c.) or vehicle (0.1% ascorbic acid), were given systemic 2-DG (200 mg/kg) (<italic>A</italic>). In a separate group, rats (<italic>n</italic> = 5/group) with prior 5,7-DHT lesions or sham operations, were infused with 5-TG (60 μg in 0.5 μL) into the PFH (<italic>B</italic>–<italic>D</italic>). Data points are mean ± SEM. *<italic>P</italic> = 0.05 or less between 5,7-DHT and sham-operated groups at each time point by <italic>t</italic> test after responses over 2 h were significant by one-way repeated-measures ANOVA.</p></caption><graphic xlink:href="226fig4"/></fig><p>To test the hypothesis that increased PFH 5-HT levels would increase the CRR, we reverse dialyzed sertraline into the PFH during IIH. Unexpectedly, this reduced plasma Epi levels by 18% over 2 h relative to controls, and in a separate study, bilateral PFH sertraline dialysis (10 μmol/L in 0.5 μL) reduced the hyperglycemic effect of systemic 2-DG by 39% over 2 h (<ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0671/-/DC1">Supplementary Fig. 3</ext-link>). We postulated that instead of increasing synaptic 5-HT during hypoglycemia, local sertraline, by inhibiting reuptake and subsequent rerelease, actually depleted synaptic 5-HT during 2 h of hypoglycemia. For that reason, we reverse dialyzed both sertraline and 5-HT bilaterally into the PFH during hypoglycemia to increase synaptic 5-HT. This combination increased plasma Epi levels by 32% over 2 h relative to controls and by 60% over 2 h relative to the PFH sertraline-dialyzed group (<xref ref-type="fig" rid="F5">Fig. 5<italic>A</italic></xref> and <xref ref-type="table" rid="T1">Table 1</xref>). Neither of these manipulations had a significant effect on plasma glucagon, NE, or glucose levels over 2 h of hypoglycemia (<xref ref-type="fig" rid="F5">Fig. 5<italic>B</italic>–<italic>D</italic></xref> and <xref ref-type="table" rid="T1">Table 1</xref>).</p><fig id="F5" fig-type="figure" position="float"><label>Figure 5</label><caption><p>Effect of PFH sertraline reverse dialysis on the CRR to IIH. Rats (<italic>n</italic> = 5–6/group) were reverse dialyzed with sertraline (10 μmol/2 h), sertraline + 5-HT (10 μmol/2 h + 10 nmol/2 h, respectively), or vehicle (3% DMSO, 0.1% ascorbic acid) in combination with systemic IIH (4.5 units/kg bolus insulin i.v.). Results are shown for blood epinephrine (<italic>A</italic>), norepinephrine (<italic>B</italic>), glucagon (<italic>C</italic>), and glucose (<italic>D</italic>). Data points are mean ± SEM. Curves marked by different letters are significantly different by one-way repeated-measures ANOVA.</p></caption><graphic xlink:href="226fig5"/></fig><p>Given these in vivo findings, we next explored the effects of 5-HT on PFH neuronal excitability using fura-2 calcium imaging in dissociated PFH neurons (<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B30" ref-type="bibr">30</xref>). Of the PFH neurons analyzed, 11% were excited by glucose (glucose excited [GE]) and 15% were glucose inhibited (GI). When held at glucose levels comparable to those seen in the brain during hypoglycemia (0.5 mmol/L) (<xref rid="B22" ref-type="bibr">22</xref>,<xref rid="B28" ref-type="bibr">28</xref>,<xref rid="B29" ref-type="bibr">29</xref>), ∼60% of GE neurons (which are predominantly inhibited at 0.5 mmol/L glucose [<xref rid="B30" ref-type="bibr">30</xref>,<xref rid="B31" ref-type="bibr">31</xref>]) were excited by 5-HT. Among GI neurons (which are predominantly activated at 0.5 mmol/L glucose [<xref rid="B30" ref-type="bibr">30</xref>,<xref rid="B31" ref-type="bibr">31</xref>]), ∼20% were inhibited by 5-HT and ∼20% were excited by 5-HT (<xref ref-type="fig" rid="F6">Fig. 6</xref>).</p><fig id="F6" fig-type="figure" position="float"><label>Figure 6</label><caption><p>Effect of 5-HT on PFH glucosensing neurons in vitro. PFH neurons were classified as GE or GI and, at glucose levels comparable to those seen during hypoglycemia (0.5 mmol/L), were assessed for their responses to 50 pmol/L 5-HT. Bars are mean ± SEM. SerE, 5-HT excited; SerI, 5-HT inhibited; SerN, 5-HT nonresponsive.</p></caption><graphic xlink:href="226fig6"/></fig><p>To test the hypothesis that 5-HT might alter the release of lactate from astrocytes as an additional mechanism by which 5-HT might modulate the CRR, cultured hypothalamic astrocytes held at 0.5 mmol/L glucose were exposed to 50 pmol/L 5-HT. This increased lactate release into the culture medium by 37% at 10 min and by 68% at 30 min after exposure to 5-HT (<ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0671/-/DC1">Supplementary Fig. 4</ext-link>). Thus 5-HT has direct effects on PFH neuronal activity and astrocyte metabolism, both of which could potentially contribute to the observed effects on the CRR of manipulating PFH 5-HT availability during hypoglycemia in vivo.</p></sec><sec id="s18"><title>Role of Orexin Signaling in PFH Glucoprivation-Induced Glucoregulatory Hormone Release</title><p>PFH orexin neurons project polysynaptically to the adrenal medulla (<xref rid="B21" ref-type="bibr">21</xref>) and are activated during hypoglycemia (<xref rid="B32" ref-type="bibr">32</xref>–<xref rid="B37" ref-type="bibr">37</xref>). For that reason, we postulated that these neurons might contribute to the hypoglycemic CRR. Indeed, systemic administration of the brain-penetrant orexin 1 receptor antagonist, SB334867A (20 mg/kg), given just prior to PFH 5-TG infusions, reduced PFH 5-TG–induced hyperglycemia by 50% and plasma Epi levels by 65% over 2 h relative to vehicle-treated rats (<xref ref-type="fig" rid="F7">Fig. 7<italic>A </italic>and <italic>B</italic></xref> and <xref ref-type="table" rid="T1">Table 1</xref>). While a lower dose of SB334867A (10 mg/kg) had no effect on Epi levels (data not shown), it did reduce PFH 5-TG–induced feeding by 47% over 2 h relative to vehicle-treated rats (<xref ref-type="table" rid="T1">Table 1</xref>). Neither dose affected the glucagon or NE responses to PFH 5-TG (<xref ref-type="fig" rid="F7">Fig. 7<italic>C</italic> and <italic>D</italic></xref> and <xref ref-type="table" rid="T1">Table 1</xref>).</p><fig id="F7" fig-type="figure" position="float"><label>Figure 7</label><caption><p>Effect of systemically administered brain-penetrant orexin 1 receptor antagonist SB334867A on PFH glucoprivation-induced glucoregulatory hormone release. Rats (<italic>n</italic> = 5–6/group) received bilateral PFH 5-TG infusions (60 μg in 0.5 μL) in combination with systemic administration of SB334867A (20 mg/kg i.v.) or vehicle (100% DMSO). Results are shown for blood glucose (<italic>A</italic>), epinephrine (<italic>B</italic>), norepinephrine (<italic>C</italic>), and glucagon (<italic>D</italic>). Data points are mean ± SEM. *<italic>P</italic> = 0.05 or less between SB334867A and DMSO groups at each time point by <italic>t</italic> test after responses over 2 h were significant by one-way repeated-measures ANOVA.</p></caption><graphic xlink:href="226fig7"/></fig></sec></sec><sec sec-type="discussion" id="s19"><title>Discussion</title><p>This work provides the first demonstration that local bilateral PFH glucoprivation evokes an adrenomedullary and a feeding response in awake, behaving animals. Further, while hypoglycemia activates 5-HT neurons throughout much of the forebrain, the adrenomedullary, but not feeding, response to PFH and systemic glucoprivation are dependent upon PFH 5-HT innervation. Finally, both PFH-evoked CRR and feeding are dependent upon orexin signaling.</p><p>We initiated these studies based on the finding that SSRIs enhance the CRR to hypoglycemia (<xref rid="B6" ref-type="bibr">6</xref>–<xref rid="B8" ref-type="bibr">8</xref>) with the idea of discovering a central location at which 5-HT might act to regulate the CRR. Thus we first examined the effects of IIH on 5-HT turnover in various forebrain regions known to be involved in the CRR, which included the PVN (<xref rid="B38" ref-type="bibr">38</xref>,<xref rid="B39" ref-type="bibr">39</xref>), VMH (<xref rid="B40" ref-type="bibr">40</xref>–<xref rid="B44" ref-type="bibr">44</xref>), PVP (<xref rid="B45" ref-type="bibr">45</xref>), and PFH (<xref rid="B32" ref-type="bibr">32</xref>). We found that hypoglycemia elicited increases in the ratio of 5-HIAA to 5-HT in all of these regions. Since 5-HT release in vivo is primarily reuptake dependent and 5-HIAA is formed in presynaptic axon terminals by monoamine oxidase derived from 5-HT that is taken up from the synapse after release (<xref rid="B46" ref-type="bibr">46</xref>), the 5-HIAA/5-HT ratio can be used as an index of 5-HT turnover and 5-HT release (<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B11" ref-type="bibr">11</xref>). Although differences in these 5-HIAA/5-HT ratios among groups were relatively small, statistically significant differences were sufficient to identify specific areas within the brain where hypoglycemia evoked an increase, suggesting increased 5-HT release. As such, the use of this ratio served as a useful tool to identify areas where 5-HT release might modulate the CRR.</p><p>Our investigations focused on the PFH because of its known efferent connections to the adrenal medulla (<xref rid="B21" ref-type="bibr">21</xref>) and the fact that PFH orexin neurons, which are glucosensing (<xref rid="B19" ref-type="bibr">19</xref>), are activated by hypoglycemia (<xref rid="B32" ref-type="bibr">32</xref>–<xref rid="B37" ref-type="bibr">37</xref>). While this work was already in progress, Korim et al. (<xref rid="B47" ref-type="bibr">47</xref>) demonstrated that PFH glucoprivation increased adrenal sympathetic nerve activity and plasma metanephrine levels, while inhibition of PFH orexin neurons abolished the increased adrenal nerve response to systemic glucoprivation in anesthetized rats. We confirmed that local, bilateral PFH glucoprivation in awake, behaving rats was sufficient to initiate adrenal medullary Epi release but also caused feeding in satiated rats. Both of these responses were significantly attenuated by systemic administration of orexin 1 receptor antagonist SB334867A. Conversely, preventing the decline in PFH glucose during systemic hypoglycemia attenuated the adrenomedullary response. Ablation of 5-HT signaling in the PFH with 5,7-DHT attenuated, but did not completely abolish, the adrenomedullary response and had no effect on the behavioral feeding response to local PFH glucoprivation. On the other hand, increasing PFH synaptic 5-HT availability by coadministration of sertraline and 5-HT was sufficient to amplify the CRR to acute hypoglycemia.</p><p>Taken together, these results suggest that the PFH is an important mediator of the adrenomedullary response to IIH and confirm prior findings (<xref rid="B47" ref-type="bibr">47</xref>) that adrenomedullary activation induced by PFH glucoprivation is at least partially mediated by orexin signaling. Modest increments in plasma NE and glucagon after local PFH glucoprivation suggest that PFH preautonomic neurons primarily regulate (mono- or polysynaptically) adrenal medulla–projecting sympathetic preganglionic neurons (Epi release) (<xref rid="B21" ref-type="bibr">21</xref>) in response to local glucose availability, with less of an effect on generalized sympathetic activation (NE release) and glucagon release. On the other hand, clamping PFH glucose at postprandial brain levels (<xref rid="B22" ref-type="bibr">22</xref>,<xref rid="B28" ref-type="bibr">28</xref>,<xref rid="B29" ref-type="bibr">29</xref>) dampened, but did not completely abolish, the CRR. The likely reason for the only partial alteration of the CRR by focal manipulation of PFH glucose availability is that multiple sites besides the PFH are known to contribute to this response (<xref rid="B26" ref-type="bibr">26</xref>,<xref rid="B27" ref-type="bibr">27</xref>,<xref rid="B38" ref-type="bibr">38</xref>–<xref rid="B44" ref-type="bibr">44</xref>,<xref rid="B48" ref-type="bibr">48</xref>,<xref rid="B49" ref-type="bibr">49</xref>). Therefore, when hypoglycemia sensing is altered in only one of these areas, the overall CRR is not completely altered.</p><p>As a potential mechanism for the release of Epi and stimulation of feeding, we confirmed reports of others (<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B20" ref-type="bibr">20</xref>) that the PFH contains glucosensing neurons that are either excited (GE) or inhibited (GI) by rising glucose levels. Furthermore, our studies provide the first overall estimate of the relative percentages of GE versus GI neurons in the PFH. More importantly, at glucose levels comparable to those seen in the brain during hypoglycemia (<xref rid="B22" ref-type="bibr">22</xref>,<xref rid="B28" ref-type="bibr">28</xref>,<xref rid="B29" ref-type="bibr">29</xref>), we showed for the first time that GE neurons (which are largely inactivated at low glucose levels [<xref rid="B30" ref-type="bibr">30</xref>,<xref rid="B31" ref-type="bibr">31</xref>]) were predominantly activated by 5-HT, while subpopulations of GI neurons (which are largely activated at hypoglycemic levels [<xref rid="B30" ref-type="bibr">30</xref>,<xref rid="B31" ref-type="bibr">31</xref>]) were either inhibited or excited by 5-HT. Thus both glucoprivic and 5-HT activation of neighboring glutamate neurons might activate PFH orexin neurons (<xref rid="B50" ref-type="bibr">50</xref>). In addition, at similarly low glucose levels, 5-HT increased lactate release from cultured astrocytes. Such astrocyte-derived lactate activates orexin neurons (<xref rid="B51" ref-type="bibr">51</xref>), as well as PFH/lateral hypothalamic area GE (<xref rid="B50" ref-type="bibr">50</xref>) and ventromedial hypothalamic nucleus GE and GI neurons (<xref rid="B52" ref-type="bibr">52</xref>). Thus there are several ways in which local release of 5-HT in the PFH might act to alter the activity of local glucosensing and nonglucosensing neurons or astrocytes involved in the regulation of the CRR.</p><p>While the neuronal cell bodies of the 5-HT neurons in the dorsal and median raphe nuclei that innervate the PFH are not glucosensing (<xref rid="B53" ref-type="bibr">53</xref>), PFH orexin neurons that project to these raphe 5-HT neurons are glucosensing (<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B54" ref-type="bibr">54</xref>,<xref rid="B55" ref-type="bibr">55</xref>). This provides a circuitry by which hypoglycemia would activate dorsal and median raphe 5-HT neurons to provide positive feedback for promotion of a CRR within the PFH and other forebrain areas innervated by these 5-HT and orexin neurons that are also involved in the CRR. Given this reciprocal relationship between PFH orexin and dorsal and median raphe 5-HT neurons (<xref rid="B54" ref-type="bibr">54</xref>–<xref rid="B56" ref-type="bibr">56</xref>) and the fact that PFH orexin neurons are both glucosensing and project polysynaptically to the adrenal medulla (<xref rid="B21" ref-type="bibr">21</xref>), we used the orexin receptor 1 antagonist, SB334867A, to test the hypothesis that orexin signaling is involved in mounting the adrenomedullary and feeding responses to focal PFH glucoprivation. Our results in awake, behaving rats lent support to those of Korim et al. (<xref rid="B47" ref-type="bibr">47</xref>) in anesthetized animals, demonstrating a role for PFH orexin neurons in stimulating the adrenal nerve during PFH glucoprivation. In addition, antagonizing orexin 1 receptors also inhibited the feeding behavioral response evoked by PFH glucoprivation. The difference in the dose of SB334867A that inhibited feeding (10 mg/kg) versus the hyperglycemic adrenomedullary response (20 mg/kg) suggests that distinct pathways may mediate these branches of the CRR with differential orexin neuronal involvement. Alternatively, PFH glucoprivation might be a more potent stimulus for counterregulatory hormone release than for feeding and therefore require higher concentrations of SB334867A to overcome.</p><p>We originally postulated that local dialysis of sertraline into the PFH would increase synaptic 5-HT availability and enhance the CRR to glucoprivation. Instead, this inhibited the CRR, suggesting that blockade of 5-HT reuptake, the major source of presynaptic 5-HT release during activation of 5-HT neurons (<xref rid="B57" ref-type="bibr">57</xref>), had acutely depleted extracellular 5-HT due to rapid clearance of 5-HT by postsynaptic degradation and uptake by non-serotonergic transporters (<xref rid="B58" ref-type="bibr">58</xref>,<xref rid="B59" ref-type="bibr">59</xref>). We tested this hypothesis by coinfusing sertraline and 5-HT into the PFH. As predicted, this presumptive elevation in synaptic 5-HT levels enhanced the Epi response to IIH. We were unable to measure baseline levels of 5-HT by microdialysis to confirm the basic premise of this hypothesis, but taken together with the inhibition of Epi release by local PFH 5-HT depletion with 5,7-DHT, our PFH sertraline results strongly support the idea that PFH 5-HT release during IIH is required for the full CRR.</p><p>In conclusion, we have identified a novel role for the PFH in regulating adrenomedullary and feeding responses under conditions of metabolic emergency in awake, freely behaving animals. These responses are mediated, in part, by PFH orexin neurons and 5-HT signaling. Future studies are needed to elaborate the role of the PFH, orexin neurons, and 5-HT signaling in the broader glucoregulatory network and the contribution these players make to the physiology and pathophysiology of hypoglycemia counterregulation.</p></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>Supplementary Data</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_64_1_226__index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_db14-0671_DB140671SupplementaryData.pdf"/>
</supplementary-material>
</sec>
</body>
  <back>
    <fn-group>
      <fn id="fn1" fn-type="supplementary-material">
        <p>This article contains Supplementary Data online at <ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0671/-/DC1">http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0671/-/DC1</ext-link>.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Article Information</title>
      <p><bold>Acknowledgments.</bold> The authors thank Sunny Lee, Antoinette Moralishvili, Charlie Salter, and Ambrose Dunn-Meynell (all Veterans Affairs Medical Center) for technical assistance.</p>
      <p><bold>Funding.</bold> This work was supported by the Research Service of the Department of Veterans Affairs (B.E.L.) and by the National Institute for Diabetes and Digestive and Kidney Diseases grant R01-DK-30066 (B.E.L.).</p>
      <p><bold>Duality of Interest.</bold> No potential conflicts of interest relevant to this article were reported.</p>
      <p><bold>Author Contributions.</bold> O.O. performed the research, designed the experiments, and wrote the manuscript. C.L.F. performed the primary neuronal and astrocyte cultures and calcium imaging. B.E.L. helped design the experiments and write the manuscript. O.O. and B.E.L. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.</p>
      <p><bold>Prior Presentation.</bold> Parts of this study were presented at the 74th Scientific Sessions of the American Diabetes Association, San Francisco, CA, 13–17 June 2014.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cryer</surname><given-names>PE</given-names></name></person-group>. <article-title>Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes</article-title>. <source>Diabetologia</source>
<year>2002</year>;<volume>45</volume>:<fpage>937</fpage>–<lpage>948</lpage><?supplied-pmid 12136392?><pub-id pub-id-type="pmid">12136392</pub-id></mixed-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cryer</surname><given-names>PE</given-names></name></person-group>. <article-title>Severe hypoglycemia predicts mortality in diabetes</article-title>. <source>Diabetes Care</source>
<year>2012</year>;<volume>35</volume>:<fpage>1814</fpage>–<lpage>1816</lpage><?supplied-pmid 22923682?><pub-id pub-id-type="pmid">22923682</pub-id></mixed-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCoy</surname><given-names>RG</given-names></name><name><surname>Van Houten</surname><given-names>HK</given-names></name><name><surname>Ziegenfuss</surname><given-names>JY</given-names></name><name><surname>Shah</surname><given-names>ND</given-names></name><name><surname>Wermers</surname><given-names>RA</given-names></name><name><surname>Smith</surname><given-names>SA</given-names></name></person-group>. <article-title>Increased mortality of patients with diabetes reporting severe hypoglycemia</article-title>. <source>Diabetes Care</source>
<year>2012</year>;<volume>35</volume>:<fpage>1897</fpage>–<lpage>1901</lpage><?supplied-pmid 22699297?><pub-id pub-id-type="pmid">22699297</pub-id></mixed-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heller</surname><given-names>SR</given-names></name><name><surname>Cryer</surname><given-names>PE</given-names></name></person-group>. <article-title>Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans</article-title>. <source>Diabetes</source>
<year>1991</year>;<volume>40</volume>:<fpage>223</fpage>–<lpage>226</lpage><?supplied-pmid 1991573?><pub-id pub-id-type="pmid">1991573</pub-id></mixed-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cryer</surname><given-names>PE</given-names></name></person-group>. <article-title>Iatrogenic hypoglycemia as a cause of hypoglycemia-associated autonomic failure in IDDM. A vicious cycle</article-title>. <source>Diabetes</source>
<year>1992</year>;<volume>41</volume>:<fpage>255</fpage>–<lpage>260</lpage><?supplied-pmid 1551485?><pub-id pub-id-type="pmid">1551485</pub-id></mixed-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanders</surname><given-names>NM</given-names></name><name><surname>Wilkinson</surname><given-names>CW</given-names></name><name><surname>Taborsky</surname><given-names>GJ</given-names><suffix>Jr</suffix></name><etal/></person-group>. <article-title>The selective serotonin reuptake inhibitor sertraline enhances counterregulatory responses to hypoglycemia</article-title>. <source>Am J Physiol Endocrinol Metab</source>
<year>2008</year>;<volume>294</volume>:<fpage>E853</fpage>–<lpage>E860</lpage><?supplied-pmid 18334609?><pub-id pub-id-type="pmid">18334609</pub-id></mixed-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briscoe</surname><given-names>VJ</given-names></name><name><surname>Ertl</surname><given-names>AC</given-names></name><name><surname>Tate</surname><given-names>DB</given-names></name><name><surname>Davis</surname><given-names>SN</given-names></name></person-group>. <article-title>Effects of the selective serotonin reuptake inhibitor fluoxetine on counterregulatory responses to hypoglycemia in individuals with type 1 diabetes</article-title>. <source>Diabetes</source>
<year>2008</year>;<volume>57</volume>:<fpage>3315</fpage>–<lpage>3322</lpage><?supplied-pmid 18835927?><pub-id pub-id-type="pmid">18835927</pub-id></mixed-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briscoe</surname><given-names>VJ</given-names></name><name><surname>Ertl</surname><given-names>AC</given-names></name><name><surname>Tate</surname><given-names>DB</given-names></name><name><surname>Dawling</surname><given-names>S</given-names></name><name><surname>Davis</surname><given-names>SN</given-names></name></person-group>. <article-title>Effects of a selective serotonin reuptake inhibitor, fluoxetine, on counterregulatory responses to hypoglycemia in healthy individuals</article-title>. <source>Diabetes</source>
<year>2008</year>;<volume>57</volume>:<fpage>2453</fpage>–<lpage>2460</lpage><?supplied-pmid 18567822?><pub-id pub-id-type="pmid">18567822</pub-id></mixed-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunn-Meynell</surname><given-names>AA</given-names></name><name><surname>Routh</surname><given-names>VH</given-names></name><name><surname>McArdle</surname><given-names>JJ</given-names></name><name><surname>Levin</surname><given-names>BE</given-names></name></person-group>. <article-title>Low-affinity sulfonylurea binding sites reside on neuronal cell bodies in the brain</article-title>. <source>Brain Res</source>
<year>1997</year>;<volume>745</volume>:<fpage>1</fpage>–<lpage>9</lpage><?supplied-pmid 9037388?><pub-id pub-id-type="pmid">9037388</pub-id></mixed-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuxe</surname><given-names>K</given-names></name><name><surname>Ogren</surname><given-names>SO</given-names></name><name><surname>Agnati</surname><given-names>LF</given-names></name><name><surname>Jonsson</surname><given-names>G</given-names></name><name><surname>Gustafsson</surname><given-names>JA</given-names></name></person-group>. <article-title>5,7-Dihydroxytryptamine as a tool to study the functional role of central 5-hydroxytryptamine neurons</article-title>. <source>Ann N Y Acad Sci</source>
<year>1978</year>;<volume>305</volume>:<fpage>346</fpage>–<lpage>369</lpage><?supplied-pmid 280251?><pub-id pub-id-type="pmid">280251</pub-id></mixed-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassanain</surname><given-names>M</given-names></name><name><surname>Levin</surname><given-names>BE</given-names></name></person-group>. <article-title>Dysregulation of hypothalamic serotonin turnover in diet-induced obese rats</article-title>. <source>Brain Res</source>
<year>2002</year>;<volume>929</volume>:<fpage>175</fpage>–<lpage>180</lpage><?supplied-pmid 11864622?><pub-id pub-id-type="pmid">11864622</pub-id></mixed-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>BE</given-names></name><name><surname>Becker</surname><given-names>TC</given-names></name><name><surname>Eiki</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>BB</given-names></name><name><surname>Dunn-Meynell</surname><given-names>AA</given-names></name></person-group>. <article-title>Ventromedial hypothalamic glucokinase is an important mediator of the counterregulatory response to insulin-induced hypoglycemia</article-title>. <source>Diabetes</source>
<year>2008</year>;<volume>57</volume>:<fpage>1371</fpage>–<lpage>1379</lpage><?supplied-pmid 18292346?><pub-id pub-id-type="pmid">18292346</pub-id></mixed-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tkacs</surname><given-names>NC</given-names></name><name><surname>Levin</surname><given-names>BE</given-names></name></person-group>. <article-title>Obesity-prone rats have preexisting defects in their counterregulatory response to insulin-induced hypoglycemia</article-title>. <source>Am J Physiol Regul Integr Comp Physiol</source>
<year>2004</year>;<volume>287</volume>:<fpage>R1110</fpage>–<lpage>R1115</lpage><?supplied-pmid 15475504?><pub-id pub-id-type="pmid">15475504</pub-id></mixed-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>BE</given-names></name></person-group>. <article-title>Glucose-regulated dopamine release from substantia nigra neurons</article-title>. <source>Brain Res</source>
<year>2000</year>;<volume>874</volume>:<fpage>158</fpage>–<lpage>164</lpage><?supplied-pmid 10960600?><pub-id pub-id-type="pmid">10960600</pub-id></mixed-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Foll</surname><given-names>C</given-names></name><name><surname>Irani</surname><given-names>BG</given-names></name><name><surname>Magnan</surname><given-names>C</given-names></name><name><surname>Dunn-Meynell</surname><given-names>AA</given-names></name><name><surname>Levin</surname><given-names>BE</given-names></name></person-group>. <article-title>Characteristics and mechanisms of hypothalamic neuronal fatty acid sensing</article-title>. <source>Am J Physiol Regul Integr Comp Physiol</source>
<year>2009</year>;<volume>297</volume>:<fpage>R655</fpage>–<lpage>R664</lpage><?supplied-pmid 19535676?><pub-id pub-id-type="pmid">19535676</pub-id></mixed-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Foll</surname><given-names>C</given-names></name><name><surname>Dunn-Meynell</surname><given-names>A</given-names></name><name><surname>Musatov</surname><given-names>S</given-names></name><name><surname>Magnan</surname><given-names>C</given-names></name><name><surname>Levin</surname><given-names>BE</given-names></name></person-group>. <article-title>FAT/CD36: a major regulator of neuronal fatty acid sensing and energy homeostasis in rats and mice</article-title>. <source>Diabetes</source>
<year>2013</year>;<volume>62</volume>:<fpage>2709</fpage>–<lpage>2716</lpage><?supplied-pmid 23557700?><pub-id pub-id-type="pmid">23557700</pub-id></mixed-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Foll</surname><given-names>C</given-names></name><name><surname>Dunn-Meynell</surname><given-names>AA</given-names></name><name><surname>Miziorko</surname><given-names>HM</given-names></name><name><surname>Levin</surname><given-names>BE</given-names></name></person-group>. <article-title>Regulation of hypothalamic neuronal sensing and food intake by ketone bodies and fatty acids</article-title>. <source>Diabetes</source>
<year>2014</year>;<volume>63</volume>:<fpage>1259</fpage>–<lpage>1269</lpage><?supplied-pmid 24379353?><pub-id pub-id-type="pmid">24379353</pub-id></mixed-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaswani</surname><given-names>M</given-names></name><name><surname>Linda</surname><given-names>FK</given-names></name><name><surname>Ramesh</surname><given-names>S</given-names></name></person-group>. <article-title>Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry</source>
<year>2003</year>;<volume>27</volume>:<fpage>85</fpage>–<lpage>102</lpage><?supplied-pmid 12551730?><pub-id pub-id-type="pmid">12551730</pub-id></mixed-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burdakov</surname><given-names>D</given-names></name><name><surname>Gerasimenko</surname><given-names>O</given-names></name><name><surname>Verkhratsky</surname><given-names>A</given-names></name></person-group>. <article-title>Physiological changes in glucose differentially modulate the excitability of hypothalamic melanin-concentrating hormone and orexin neurons in situ</article-title>. <source>J Neurosci</source>
<year>2005</year>;<volume>25</volume>:<fpage>2429</fpage>–<lpage>2433</lpage><?supplied-pmid 15745970?><pub-id pub-id-type="pmid">15745970</pub-id></mixed-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muroya</surname><given-names>S</given-names></name><name><surname>Uramura</surname><given-names>K</given-names></name><name><surname>Sakurai</surname><given-names>T</given-names></name><name><surname>Takigawa</surname><given-names>M</given-names></name><name><surname>Yada</surname><given-names>T</given-names></name></person-group>. <article-title>Lowering glucose concentrations increases cytosolic Ca2+ in orexin neurons of the rat lateral hypothalamus</article-title>. <source>Neurosci Lett</source>
<year>2001</year>;<volume>309</volume>:<fpage>165</fpage>–<lpage>168</lpage><?supplied-pmid 11514067?><pub-id pub-id-type="pmid">11514067</pub-id></mixed-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geerling</surname><given-names>JC</given-names></name><name><surname>Mettenleiter</surname><given-names>TC</given-names></name><name><surname>Loewy</surname><given-names>AD</given-names></name></person-group>. <article-title>Orexin neurons project to diverse sympathetic outflow systems</article-title>. <source>Neuroscience</source>
<year>2003</year>;<volume>122</volume>:<fpage>541</fpage>–<lpage>550</lpage><?supplied-pmid 14614918?><pub-id pub-id-type="pmid">14614918</pub-id></mixed-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunn-Meynell</surname><given-names>AA</given-names></name><name><surname>Sanders</surname><given-names>NM</given-names></name><name><surname>Compton</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Relationship among brain and blood glucose levels and spontaneous and glucoprivic feeding</article-title>. <source>J Neurosci</source>
<year>2009</year>;<volume>29</volume>:<fpage>7015</fpage>–<lpage>7022</lpage><?supplied-pmid 19474328?><pub-id pub-id-type="pmid">19474328</pub-id></mixed-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritter</surname><given-names>RC</given-names></name><name><surname>Slusser</surname><given-names>P</given-names></name></person-group>. <article-title>5-Thio-D-glucose causes increased feeding and hyperglycemia in the rat</article-title>. <source>Am J Physiol</source>
<year>1980</year>;<volume>238</volume>:<fpage>E141</fpage>–<lpage>E144</lpage><?supplied-pmid 7361889?><pub-id pub-id-type="pmid">7361889</pub-id></mixed-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slusser</surname><given-names>PG</given-names></name><name><surname>Ritter</surname><given-names>RC</given-names></name></person-group>. <article-title>Increased feeding and hyperglycemia elicited by intracerebroventricular 5-thioglucose</article-title>. <source>Brain Res</source>
<year>1980</year>;<volume>202</volume>:<fpage>474</fpage>–<lpage>478</lpage><?supplied-pmid 6254614?><pub-id pub-id-type="pmid">6254614</pub-id></mixed-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritter</surname><given-names>S</given-names></name><name><surname>Dinh</surname><given-names>TT</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group>. <article-title>Localization of hindbrain glucoreceptive sites controlling food intake and blood glucose</article-title>. <source>Brain Res</source>
<year>2000</year>;<volume>856</volume>:<fpage>37</fpage>–<lpage>47</lpage><?supplied-pmid 10677609?><pub-id pub-id-type="pmid">10677609</pub-id></mixed-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrew</surname><given-names>SF</given-names></name><name><surname>Dinh</surname><given-names>TT</given-names></name><name><surname>Ritter</surname><given-names>S</given-names></name></person-group>. <article-title>Localized glucoprivation of hindbrain sites elicits corticosterone and glucagon secretion</article-title>. <source>Am J Physiol Regul Integr Comp Physiol</source>
<year>2007</year>;<volume>292</volume>:<fpage>R1792</fpage>–<lpage>R1798</lpage><?supplied-pmid 17218439?><pub-id pub-id-type="pmid">17218439</pub-id></mixed-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritter</surname><given-names>S</given-names></name><name><surname>Dinh</surname><given-names>TT</given-names></name><name><surname>Li</surname><given-names>AJ</given-names></name></person-group>. <article-title>Hindbrain catecholamine neurons control multiple glucoregulatory responses</article-title>. <source>Physiol Behav</source>
<year>2006</year>;<volume>89</volume>:<fpage>490</fpage>–<lpage>500</lpage><?supplied-pmid 16887153?><pub-id pub-id-type="pmid">16887153</pub-id></mixed-citation>
      </ref>
      <ref id="B28">
        <label>28</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silver</surname><given-names>IA</given-names></name><name><surname>Erecińska</surname><given-names>M</given-names></name></person-group>. <article-title>Extracellular glucose concentration in mammalian brain: continuous monitoring of changes during increased neuronal activity and upon limitation in oxygen supply in normo-, hypo-, and hyperglycemic animals</article-title>. <source>J Neurosci</source>
<year>1994</year>;<volume>14</volume>:<fpage>5068</fpage>–<lpage>5076</lpage><?supplied-pmid 8046468?><pub-id pub-id-type="pmid">8046468</pub-id></mixed-citation>
      </ref>
      <ref id="B29">
        <label>29</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Vries</surname><given-names>MG</given-names></name><name><surname>Arseneau</surname><given-names>LM</given-names></name><name><surname>Lawson</surname><given-names>ME</given-names></name><name><surname>Beverly</surname><given-names>JL</given-names></name></person-group>. <article-title>Extracellular glucose in rat ventromedial hypothalamus during acute and recurrent hypoglycemia</article-title>. <source>Diabetes</source>
<year>2003</year>;<volume>52</volume>:<fpage>2767</fpage>–<lpage>2773</lpage><?supplied-pmid 14578295?><pub-id pub-id-type="pmid">14578295</pub-id></mixed-citation>
      </ref>
      <ref id="B30">
        <label>30</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>L</given-names></name><name><surname>Routh</surname><given-names>VH</given-names></name><name><surname>Kuzhikandathil</surname><given-names>EV</given-names></name><name><surname>Gaspers</surname><given-names>LD</given-names></name><name><surname>Levin</surname><given-names>BE</given-names></name></person-group>. <article-title>Physiological and molecular characteristics of rat hypothalamic ventromedial nucleus glucosensing neurons</article-title>. <source>Diabetes</source>
<year>2004</year>;<volume>53</volume>:<fpage>549</fpage>–<lpage>559</lpage><?supplied-pmid 14988237?><pub-id pub-id-type="pmid">14988237</pub-id></mixed-citation>
      </ref>
      <ref id="B31">
        <label>31</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Z</given-names></name><name><surname>Levin</surname><given-names>BE</given-names></name><name><surname>McArdle</surname><given-names>JJ</given-names></name><name><surname>Bakhos</surname><given-names>N</given-names></name><name><surname>Routh</surname><given-names>VH</given-names></name></person-group>. <article-title>Convergence of pre- and postsynaptic influences on glucosensing neurons in the ventromedial hypothalamic nucleus</article-title>. <source>Diabetes</source>
<year>2001</year>;<volume>50</volume>:<fpage>2673</fpage>–<lpage>2681</lpage><?supplied-pmid 11723049?><pub-id pub-id-type="pmid">11723049</pub-id></mixed-citation>
      </ref>
      <ref id="B32">
        <label>32</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>XJ</given-names></name><name><surname>Evans</surname><given-names>ML</given-names></name><name><surname>Lister</surname><given-names>CA</given-names></name><etal/></person-group>. <article-title>Hypoglycemia activates orexin neurons and selectively increases hypothalamic orexin-B levels: responses inhibited by feeding and possibly mediated by the nucleus of the solitary tract</article-title>. <source>Diabetes</source>
<year>2001</year>;<volume>50</volume>:<fpage>105</fpage>–<lpage>112</lpage><?supplied-pmid 11147774?><pub-id pub-id-type="pmid">11147774</pub-id></mixed-citation>
      </ref>
      <ref id="B33">
        <label>33</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>XJ</given-names></name><name><surname>Widdowson</surname><given-names>PS</given-names></name><name><surname>Harrold</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Hypothalamic orexin expression: modulation by blood glucose and feeding</article-title>. <source>Diabetes</source>
<year>1999</year>;<volume>48</volume>:<fpage>2132</fpage>–<lpage>2137</lpage><?supplied-pmid 10535445?><pub-id pub-id-type="pmid">10535445</pub-id></mixed-citation>
      </ref>
      <ref id="B34">
        <label>34</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffond</surname><given-names>B</given-names></name><name><surname>Risold</surname><given-names>PY</given-names></name><name><surname>Jacquemard</surname><given-names>C</given-names></name><name><surname>Colard</surname><given-names>C</given-names></name><name><surname>Fellmann</surname><given-names>D</given-names></name></person-group>. <article-title>Insulin-induced hypoglycemia increases preprohypocretin (orexin) mRNA in the rat lateral hypothalamic area</article-title>. <source>Neurosci Lett</source>
<year>1999</year>;<volume>262</volume>:<fpage>77</fpage>–<lpage>80</lpage><?supplied-pmid 10203235?><pub-id pub-id-type="pmid">10203235</pub-id></mixed-citation>
      </ref>
      <ref id="B35">
        <label>35</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiss</surname><given-names>A</given-names></name><name><surname>Jezova</surname><given-names>D</given-names></name><name><surname>Mikkelsen</surname><given-names>JD</given-names></name></person-group>. <article-title>Activation of FOS in hypocretin neurons of the rat by insulin-induced hypoglycemia</article-title>. <source>Endocr Regul</source>
<year>2004</year>;<volume>38</volume>:<fpage>97</fpage>–<lpage>102</lpage><?supplied-pmid 15693287?><pub-id pub-id-type="pmid">15693287</pub-id></mixed-citation>
      </ref>
      <ref id="B36">
        <label>36</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moriguchi</surname><given-names>T</given-names></name><name><surname>Sakurai</surname><given-names>T</given-names></name><name><surname>Nambu</surname><given-names>T</given-names></name><name><surname>Yanagisawa</surname><given-names>M</given-names></name><name><surname>Goto</surname><given-names>K</given-names></name></person-group>. <article-title>Neurons containing orexin in the lateral hypothalamic area of the adult rat brain are activated by insulin-induced acute hypoglycemia</article-title>. <source>Neurosci Lett</source>
<year>1999</year>;<volume>264</volume>:<fpage>101</fpage>–<lpage>104</lpage><?supplied-pmid 10320024?><pub-id pub-id-type="pmid">10320024</pub-id></mixed-citation>
      </ref>
      <ref id="B37">
        <label>37</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briski</surname><given-names>KP</given-names></name><name><surname>Sylvester</surname><given-names>PW</given-names></name></person-group>. <article-title>Hypothalamic orexin-A-immunpositive neurons express Fos in response to central glucopenia</article-title>. <source>Neuroreport</source>
<year>2001</year>;<volume>12</volume>:<fpage>531</fpage>–<lpage>534</lpage><?supplied-pmid 11234758?><pub-id pub-id-type="pmid">11234758</pub-id></mixed-citation>
      </ref>
      <ref id="B38">
        <label>38</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>SB</given-names></name><name><surname>Wilkinson</surname><given-names>CW</given-names></name><name><surname>Gronbeck</surname><given-names>P</given-names></name><name><surname>Bennett</surname><given-names>JL</given-names></name><name><surname>Taborsky</surname><given-names>GJ</given-names><suffix>Jr</suffix></name><name><surname>Figlewicz</surname><given-names>DP</given-names></name></person-group>. <article-title>Inactivation of the PVN during hypoglycemia partially simulates hypoglycemia-associated autonomic failure</article-title>. <source>Am J Physiol Regul Integr Comp Physiol</source>
<year>2003</year>;<volume>284</volume>:<fpage>R57</fpage>–<lpage>R65</lpage><?supplied-pmid 12388440?><pub-id pub-id-type="pmid">12388440</pub-id></mixed-citation>
      </ref>
      <ref id="B39">
        <label>39</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>SB</given-names></name><name><surname>Wilkinson</surname><given-names>CW</given-names></name><name><surname>Bentson</surname><given-names>K</given-names></name><name><surname>Gronbeck</surname><given-names>P</given-names></name><name><surname>Zavosh</surname><given-names>A</given-names></name><name><surname>Figlewicz</surname><given-names>DP</given-names></name></person-group>. <article-title>PVN activation is suppressed by repeated hypoglycemia but not antecedent corticosterone in the rat</article-title>. <source>Am J Physiol Regul Integr Comp Physiol</source>
<year>2001</year>;<volume>281</volume>:<fpage>R1426</fpage>–<lpage>R1436</lpage><?supplied-pmid 11641112?><pub-id pub-id-type="pmid">11641112</pub-id></mixed-citation>
      </ref>
      <ref id="B40">
        <label>40</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borg</surname><given-names>WP</given-names></name><name><surname>During</surname><given-names>MJ</given-names></name><name><surname>Sherwin</surname><given-names>RS</given-names></name><name><surname>Borg</surname><given-names>MA</given-names></name><name><surname>Brines</surname><given-names>ML</given-names></name><name><surname>Shulman</surname><given-names>GI</given-names></name></person-group>. <article-title>Ventromedial hypothalamic lesions in rats suppress counterregulatory responses to hypoglycemia</article-title>. <source>J Clin Invest</source>
<year>1994</year>;<volume>93</volume>:<fpage>1677</fpage>–<lpage>1682</lpage><?supplied-pmid 8163668?><pub-id pub-id-type="pmid">8163668</pub-id></mixed-citation>
      </ref>
      <ref id="B41">
        <label>41</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borg</surname><given-names>WP</given-names></name><name><surname>Sherwin</surname><given-names>RS</given-names></name><name><surname>During</surname><given-names>MJ</given-names></name><name><surname>Borg</surname><given-names>MA</given-names></name><name><surname>Shulman</surname><given-names>GI</given-names></name></person-group>. <article-title>Local ventromedial hypothalamus glucopenia triggers counterregulatory hormone release</article-title>. <source>Diabetes</source>
<year>1995</year>;<volume>44</volume>:<fpage>180</fpage>–<lpage>184</lpage><?supplied-pmid 7859938?><pub-id pub-id-type="pmid">7859938</pub-id></mixed-citation>
      </ref>
      <ref id="B42">
        <label>42</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borg</surname><given-names>MA</given-names></name><name><surname>Sherwin</surname><given-names>RS</given-names></name><name><surname>Borg</surname><given-names>WP</given-names></name><name><surname>Tamborlane</surname><given-names>WV</given-names></name><name><surname>Shulman</surname><given-names>GI</given-names></name></person-group>. <article-title>Local ventromedial hypothalamus glucose perfusion blocks counterregulation during systemic hypoglycemia in awake rats</article-title>. <source>J Clin Invest</source>
<year>1997</year>;<volume>99</volume>:<fpage>361</fpage>–<lpage>365</lpage><?supplied-pmid 9006005?><pub-id pub-id-type="pmid">9006005</pub-id></mixed-citation>
      </ref>
      <ref id="B43">
        <label>43</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borg</surname><given-names>MA</given-names></name><name><surname>Borg</surname><given-names>WP</given-names></name><name><surname>Tamborlane</surname><given-names>WV</given-names></name><name><surname>Brines</surname><given-names>ML</given-names></name><name><surname>Shulman</surname><given-names>GI</given-names></name><name><surname>Sherwin</surname><given-names>RS</given-names></name></person-group>. <article-title>Chronic hypoglycemia and diabetes impair counterregulation induced by localized 2-deoxy-glucose perfusion of the ventromedial hypothalamus in rats</article-title>. <source>Diabetes</source>
<year>1999</year>;<volume>48</volume>:<fpage>584</fpage>–<lpage>587</lpage><?supplied-pmid 10078560?><pub-id pub-id-type="pmid">10078560</pub-id></mixed-citation>
      </ref>
      <ref id="B44">
        <label>44</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borg</surname><given-names>MA</given-names></name><name><surname>Tamborlane</surname><given-names>WV</given-names></name><name><surname>Shulman</surname><given-names>GI</given-names></name><name><surname>Sherwin</surname><given-names>RS</given-names></name></person-group>. <article-title>Local lactate perfusion of the ventromedial hypothalamus suppresses hypoglycemic counterregulation</article-title>. <source>Diabetes</source>
<year>2003</year>;<volume>52</volume>:<fpage>663</fpage>–<lpage>666</lpage><?supplied-pmid 12606506?><pub-id pub-id-type="pmid">12606506</pub-id></mixed-citation>
      </ref>
      <ref id="B45">
        <label>45</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arbelaez</surname><given-names>AM</given-names></name><name><surname>Powers</surname><given-names>WJ</given-names></name><name><surname>Videen</surname><given-names>TO</given-names></name><name><surname>Price</surname><given-names>JL</given-names></name><name><surname>Cryer</surname><given-names>PE</given-names></name></person-group>. <article-title>Attenuation of counterregulatory responses to recurrent hypoglycemia by active thalamic inhibition: a mechanism for hypoglycemia-associated autonomic failure</article-title>. <source>Diabetes</source>
<year>2008</year>;<volume>57</volume>:<fpage>470</fpage>–<lpage>475</lpage><?supplied-pmid 18003752?><pub-id pub-id-type="pmid">18003752</pub-id></mixed-citation>
      </ref>
      <ref id="B46">
        <label>46</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobs</surname><given-names>BL</given-names></name><name><surname>Azmitia</surname><given-names>EC</given-names></name></person-group>. <article-title>Structure and function of the brain serotonin system</article-title>. <source>Physiol Rev</source>
<year>1992</year>;<volume>72</volume>:<fpage>165</fpage>–<lpage>229</lpage><?supplied-pmid 1731370?><pub-id pub-id-type="pmid">1731370</pub-id></mixed-citation>
      </ref>
      <ref id="B47">
        <label>47</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korim</surname><given-names>WS</given-names></name><name><surname>Bou Farah</surname><given-names>L</given-names></name><name><surname>McMullan</surname><given-names>S</given-names></name><name><surname>Verberne</surname><given-names>AJ</given-names></name></person-group>. <article-title>Orexinergic activation of medullary premotor neurons modulates the adrenal sympathoexcitation to hypothalamic glucoprivation</article-title>. <source>Diabetes</source>
<year>2014</year>;<volume>63</volume>:<fpage>1895</fpage>–<lpage>1906</lpage><?supplied-pmid 24550189?><pub-id pub-id-type="pmid">24550189</pub-id></mixed-citation>
      </ref>
      <ref id="B48">
        <label>48</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanders</surname><given-names>NM</given-names></name><name><surname>Ritter</surname><given-names>S</given-names></name></person-group>. <article-title>Repeated 2-deoxy-D-glucose-induced glucoprivation attenuates Fos expression and glucoregulatory responses during subsequent glucoprivation</article-title>. <source>Diabetes</source>
<year>2000</year>;<volume>49</volume>:<fpage>1865</fpage>–<lpage>1874</lpage><?supplied-pmid 11078453?><pub-id pub-id-type="pmid">11078453</pub-id></mixed-citation>
      </ref>
      <ref id="B49">
        <label>49</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>SB</given-names></name><name><surname>Wilkinson</surname><given-names>CW</given-names></name><name><surname>Gronbeck</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Inactivation of the DMH selectively inhibits the ACTH and corticosterone responses to hypoglycemia</article-title>. <source>Am J Physiol Regul Integr Comp Physiol</source>
<year>2004</year>;<volume>286</volume>:<fpage>R123</fpage>–<lpage>R128</lpage><?supplied-pmid 14660476?><pub-id pub-id-type="pmid">14660476</pub-id></mixed-citation>
      </ref>
      <ref id="B50">
        <label>50</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burt</surname><given-names>J</given-names></name><name><surname>Alberto</surname><given-names>CO</given-names></name><name><surname>Parsons</surname><given-names>MP</given-names></name><name><surname>Hirasawa</surname><given-names>M</given-names></name></person-group>. <article-title>Local network regulation of orexin neurons in the lateral hypothalamus</article-title>. <source>Am J Physiol Regul Integr Comp Physiol</source>
<year>2011</year>;<volume>301</volume>:<fpage>R572</fpage>–<lpage>R580</lpage><?supplied-pmid 21697524?><pub-id pub-id-type="pmid">21697524</pub-id></mixed-citation>
      </ref>
      <ref id="B51">
        <label>51</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parsons</surname><given-names>MP</given-names></name><name><surname>Hirasawa</surname><given-names>M</given-names></name></person-group>. <article-title>ATP-sensitive potassium channel-mediated lactate effect on orexin neurons: implications for brain energetics during arousal</article-title>. <source>J Neurosci</source>
<year>2010</year>;<volume>30</volume>:<fpage>8061</fpage>–<lpage>8070</lpage><?supplied-pmid 20554857?><pub-id pub-id-type="pmid">20554857</pub-id></mixed-citation>
      </ref>
      <ref id="B52">
        <label>52</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Z</given-names></name><name><surname>Routh</surname><given-names>VH</given-names></name></person-group>. <article-title>Differential effects of glucose and lactate on glucosensing neurons in the ventromedial hypothalamic nucleus</article-title>. <source>Diabetes</source>
<year>2005</year>;<volume>54</volume>:<fpage>15</fpage>–<lpage>22</lpage><?supplied-pmid 15616006?><pub-id pub-id-type="pmid">15616006</pub-id></mixed-citation>
      </ref>
      <ref id="B53">
        <label>53</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fornal</surname><given-names>CA</given-names></name><name><surname>Litto</surname><given-names>WJ</given-names></name><name><surname>Morilak</surname><given-names>DA</given-names></name><name><surname>Jacobs</surname><given-names>BL</given-names></name></person-group>. <article-title>Single-unit responses of serotonergic neurons to glucose and insulin administration in behaving cats</article-title>. <source>Am J Physiol</source>
<year>1989</year>;<volume>257</volume>:<fpage>R1345</fpage>–<lpage>R1353</lpage><?supplied-pmid 2690647?><pub-id pub-id-type="pmid">2690647</pub-id></mixed-citation>
      </ref>
      <ref id="B54">
        <label>54</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>RJ</given-names></name><name><surname>van den Pol</surname><given-names>AN</given-names></name><name><surname>Aghajanian</surname><given-names>GK</given-names></name></person-group>. <article-title>Hypocretins (orexins) regulate serotonin neurons in the dorsal raphe nucleus by excitatory direct and inhibitory indirect actions</article-title>. <source>J Neurosci</source>
<year>2002</year>;<volume>22</volume>:<fpage>9453</fpage>–<lpage>9464</lpage><?supplied-pmid 12417670?><pub-id pub-id-type="pmid">12417670</pub-id></mixed-citation>
      </ref>
      <ref id="B55">
        <label>55</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peyron</surname><given-names>C</given-names></name><name><surname>Tighe</surname><given-names>DK</given-names></name><name><surname>van den Pol</surname><given-names>AN</given-names></name><etal/></person-group>. <article-title>Neurons containing hypocretin (orexin) project to multiple neuronal systems</article-title>. <source>J Neurosci</source>
<year>1998</year>;<volume>18</volume>:<fpage>9996</fpage>–<lpage>10015</lpage><?supplied-pmid 9822755?><pub-id pub-id-type="pmid">9822755</pub-id></mixed-citation>
      </ref>
      <ref id="B56">
        <label>56</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>K</given-names></name><name><surname>McCormack</surname><given-names>S</given-names></name><name><surname>España</surname><given-names>RA</given-names></name><name><surname>Crocker</surname><given-names>A</given-names></name><name><surname>Scammell</surname><given-names>TE</given-names></name></person-group>. <article-title>Afferents to the orexin neurons of the rat brain</article-title>. <source>J Comp Neurol</source>
<year>2006</year>;<volume>494</volume>:<fpage>845</fpage>–<lpage>861</lpage><?supplied-pmid 16374809?><pub-id pub-id-type="pmid">16374809</pub-id></mixed-citation>
      </ref>
      <ref id="B57">
        <label>57</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rutter</surname><given-names>JJ</given-names></name><name><surname>Auerbach</surname><given-names>SB</given-names></name></person-group>. <article-title>Acute uptake inhibition increases extracellular serotonin in the rat forebrain</article-title>. <source>J Pharmacol Exp Ther</source>
<year>1993</year>;<volume>265</volume>:<fpage>1319</fpage>–<lpage>1324</lpage><?supplied-pmid 7685386?><pub-id pub-id-type="pmid">7685386</pub-id></mixed-citation>
      </ref>
      <ref id="B58">
        <label>58</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baganz</surname><given-names>NL</given-names></name><name><surname>Horton</surname><given-names>RE</given-names></name><name><surname>Calderon</surname><given-names>AS</given-names></name><etal/></person-group>. <article-title>Organic cation transporter 3: keeping the brake on extracellular serotonin in serotonin-transporter-deficient mice</article-title>. <source>Proc Natl Acad Sci U S A</source>
<year>2008</year>;<volume>105</volume>:<fpage>18976</fpage>–<lpage>18981</lpage><?supplied-pmid 19033200?><pub-id pub-id-type="pmid">19033200</pub-id></mixed-citation>
      </ref>
      <ref id="B59">
        <label>59</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suarez-Roca</surname><given-names>H</given-names></name><name><surname>Cubeddu</surname><given-names>LX</given-names></name></person-group>. <article-title>The selective serotonin reuptake inhibitor citalopram induces the storage of serotonin in catecholaminergic terminals</article-title>. <source>J Pharmacol Exp Ther</source>
<year>2002</year>;<volume>302</volume>:<fpage>174</fpage>–<lpage>179</lpage><?supplied-pmid 12065714?><pub-id pub-id-type="pmid">12065714</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:4274799</identifier><datestamp>2016-01-01</datestamp><setSpec>diabetes</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="http://jats.nlm.nih.gov/ns/archiving/1.0/ http://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Diabetes</journal-id>
      <journal-id journal-id-type="iso-abbrev">Diabetes</journal-id>
      <journal-id journal-id-type="hwp">diabetes</journal-id>
      <journal-id journal-id-type="pmc">diabetes</journal-id>
      <journal-id journal-id-type="publisher-id">Diabetes</journal-id>
      <journal-title-group>
        <journal-title>Diabetes</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0012-1797</issn>
      <issn pub-type="epub">1939-327X</issn>
      <publisher>
        <publisher-name>American Diabetes Association</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4274799</article-id>
      <article-id pub-id-type="pmcid">PMC4274799</article-id>
      <article-id pub-id-type="pmc-uid">4274799</article-id>
      <article-id pub-id-type="pmid">25092675</article-id>
      <article-id pub-id-type="publisher-id">0316</article-id>
      <article-id pub-id-type="doi">10.2337/db14-0316</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Pathophysiology</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Impaired Macromolecular Protein Pools in Fronto-Striato-Thalamic Circuits in Type 2 Diabetes Revealed by Magnetization Transfer Imaging</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Yang</surname>
            <given-names>Shaolin</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ajilore</surname>
            <given-names>Olusola</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wu</surname>
            <given-names>Minjie</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lamar</surname>
            <given-names>Melissa</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Kumar</surname>
            <given-names>Anand</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
        <aff id="aff1"><sup>1</sup>Department of Psychiatry, University of Illinois at Chicago, Chicago, IL</aff>
        <aff id="aff2"><sup>2</sup>Department of Radiology, University of Illinois at Chicago, Chicago, IL</aff>
        <aff id="aff3"><sup>3</sup>Department of Bioengineering, University of Illinois at Chicago, Chicago, IL</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">Corresponding authors: Shaolin Yang, <email>syang@psych.uic.edu</email>, and Anand Kumar, <email>akumar@psych.uic.edu</email>.</corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>4</day>
        <month>8</month>
        <year>2014</year>
      </pub-date>
      <volume>64</volume>
      <issue>1</issue>
      <fpage>183</fpage>
      <lpage>192</lpage>
      <history>
        <date date-type="received">
          <day>23</day>
          <month>2</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>29</day>
          <month>7</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.</copyright-statement>
        <copyright-year>2015</copyright-year>
      </permissions>
      <self-uri xlink:title="pdf" xlink:type="simple" xlink:href="183.pdf"/>
      <abstract>
        <p>Previous research has shown that type 2 diabetes mellitus (T2DM) is associated with white matter microstructural changes, cognitive impairment, and decreased resting-state functional connectivity and spontaneous brain activity. This study used magnetization transfer imaging to examine, for the first time, the integrity of macromolecular protein pools in fronto-striato-thalamic circuits and its clinical and cognitive correlates in patients with T2DM. T2DM patients without mood disorders (<italic>n</italic> = 20, aged 65.05 ± 11.95 years) and healthy control subjects (HCs; <italic>n</italic> = 26, aged 62.92 ± 12.71 years) were recruited. Nodes of fronto-striato-thalamic circuits—head of the caudate nucleus (hCaud), putamen, globus pallidus, thalamus—and four cortical regions—rostral and dorsal anterior cingulate cortex, dorsolateral prefrontal cortex, and lateral orbitofrontal cortex—were examined. Compared with HCs, patients with T2DM had significantly lower magnetization transfer ratio (MTR) in bilateral anterior cingulate and hCaud. Reduced MTRs in the above regions showed correlations with T2DM-related clinical measures, including hemoglobin A<sub>1c</sub> level and vascular risk factors, and neuropsychological task performance in the domains of learning and memory, executive function, and attention and information processing. The impaired biophysical integrity of brain macromolecular protein pools and their local microenvironments in T2DM patients may provide insights into the neurological pathophysiology underlying diabetes-associated clinical and cognitive deficits.</p>
      </abstract>
      <counts>
        <page-count count="10"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="s1">
      <title>Introduction</title>
      <p>Type 2 diabetes mellitus (T2DM) is associated with metabolic and macro- and microvascular complications in multiple organ systems, including the brain (<xref rid="B1" ref-type="bibr">1</xref>). T2DM is also associated with behavioral aberrations, including mood disorders, cognitive impairment, and increased risk of dementia in the elderly (<xref rid="B2" ref-type="bibr">2</xref>–<xref rid="B5" ref-type="bibr">5</xref>). This may be due in part to neuroanatomical alterations as revealed by structural MRI, including atrophy in prefrontal cortex and the anterior cingulate (<xref rid="B6" ref-type="bibr">6</xref>–<xref rid="B8" ref-type="bibr">8</xref>). Findings from diffusion tensor imaging studies indicate reduced fractional anisotropy in the frontal white matter (<xref rid="B9" ref-type="bibr">9</xref>), cingulum bundle, uncinate fasciculus (<xref rid="B10" ref-type="bibr">10</xref>), and anterior limb of internal capsule (ALIC) (<xref rid="B11" ref-type="bibr">11</xref>) in patients with T2DM relative to nondiabetic control subjects. Moreover, recent resting-state functional MRI studies demonstrated disrupted functional connectivity within the default mode network and decreased spontaneous brain activity in the occipital lobe and postcentral gyrus in T2DM patients compared with control subjects (<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B13" ref-type="bibr">13</xref>). However, it is not clear whether macromolecular protein pools in these regions and circuits are also impaired in T2DM. Investigating the integrity of macromolecular protein pools in gray and white matter may provide complementary information and would aid in our understanding of the mechanisms underlying T2DM-related brain alterations and the neurobiology of diabetes.</p>
      <p>Magnetization transfer (MT) imaging exploits magnetization exchange between protons bound to macromolecules and free protons in tissue water. In MT imaging, an off-resonance prepulse is applied to selectively saturate bound protons, and magnetization is then transferred from saturated bound protons to free protons through chemical exchange and direct dipolar coupling. This transfer of magnetization leads to decreased magnetic resonance signal from free protons. The contrast between MT images with and without the saturation prepulse is defined as magnetization transfer ratio (MTR) (<xref rid="B14" ref-type="bibr">14</xref>), which reflects the biophysical integrity of macromolecular protein pools and their local microenvironment. Postmortem MT and histopathology studies of multiple sclerosis revealed that in white matter, lower MTR is associated with axonal loss and myelin compromise (<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B16" ref-type="bibr">16</xref>). The origins of MTR changes in gray matter are more complex and heterogeneous and may reflect multiple neurobiological aberrations (<xref rid="B17" ref-type="bibr">17</xref>–<xref rid="B20" ref-type="bibr">20</xref>). In gray matter, cell membrane proteins and phospholipids contribute to macromolecular density (<xref rid="B19" ref-type="bibr">19</xref>). Therefore, damage to cell membranes, reduction in dendritic density and neuronal size and number may independently or collectively lead to decreased MTR (<xref rid="B19" ref-type="bibr">19</xref>). Wallerian degeneration, secondary to proximal and/or distal axonal damage, has also been implicated as a mechanism contributing to lower MTR (<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B20" ref-type="bibr">20</xref>). Although lacking of specificity in its origins, MTR imaging provides an innovative way to probe the integrity of macromolecular protein pools in the brain.</p>
      <p>Despite the unique features of MT imaging, there are very few MT studies on T2DM in the literature. The only published MT study was on T2DM and major depression in combination, which focused on subcortical regions and found compromised macromolecular protein pools in the head of the caudate nucleus (hCaud) in T2DM patients (<xref rid="B4" ref-type="bibr">4</xref>). However, it is unknown whether there are accompanied changes in macromolecular protein pools in the connected cortical regions.</p>
      <p>Fronto-striato-thalamic circuits have been implicated in the pathophysiology of several mood and associated cognitive disorders (<xref rid="B21" ref-type="bibr">21</xref>,<xref rid="B22" ref-type="bibr">22</xref>). T2DM is consistently associated with disturbances in mood and cognition (<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B23" ref-type="bibr">23</xref>). Particularly, individuals with T2DM are at a greater risk for depression (<xref rid="B24" ref-type="bibr">24</xref>,<xref rid="B25" ref-type="bibr">25</xref>). However, neurosubstrates underlying the increased risk of mood disturbance and/or cognitive impairments in T2DM are unclear. In this study, we specifically evaluated the biophysical integrity of macromolecular protein pools in fronto-striato-thalamic circuits in patients with T2DM without comorbid mood or cognitive disturbances. Such a study design allows us to elucidate T2DM-specific influence on brain circuits implicated in mood and cognitive functions, which may potentially inform mechanisms underlying increased vulnerability to mood and cognitive disorders in T2DM.</p>
      <p>More specifically, this study investigated brain regions/structures associated with the dorsolateral prefrontal, lateral orbitofrontal, and anterior cingulate frontal-subcortical circuits—circuits that are neurobiologically relevant in human behavior, including cognitive control, decision making, action planning and execution, learning and working memory, attention, and emotional processing (<xref rid="B21" ref-type="bibr">21</xref>). Additionally, we were interested in examining the relationships between altered macromolecular protein pools and T2DM-related clinical measures as well as neuropsychological metrics in different cognitive domains. We hypothesized that MTR would be lower at nodes of fronto-striato-thalamic circuits in T2DM patients compared with healthy control subjects (HCs). We additionally hypothesized that MTR in these node regions in patients with T2DM would be negatively correlated with clinical measures reflecting vascular comorbidities and blood glucose regulation and positively correlated with neuropsychological performance.</p>
    </sec>
    <sec id="s2">
      <title>Research Design and Methods</title>
      <sec id="s3">
        <title>Subjects</title>
        <p>The subject population consisted of 20 T2DM patients without mood disorders (aged 65.05 ± 11.95 years) and 26 nondiabetic HCs (aged 62.92 ± 12.71 years). Subjects were selected from a larger sample of a research program on diabetes and depression at the University of Illinois at Chicago. All participants were aged 30 years and older and recruited from the greater Chicago area through flyers, local advertisements, and relevant outpatient clinics. The study was approved by the University of Illinois at Chicago Institutional Review Board, and written informed consent was obtained from all participants.</p>
        <p>The diagnosis of T2DM in patients was made by their primary care physicians and was confirmed using American Diabetes Association guidelines (<xref rid="B26" ref-type="bibr">26</xref>) (an elevated nonfasting hemoglobin A<sub>1c</sub> [HbA<sub>1c</sub>] level [&gt;6.5% (48 mmol/mol)] or the use of antidiabetic medications [oral hypoglycemic and/or insulin] when enrolled for this study). T2DM patients reported using oral hypoglycemic medications and/or insulin for glycemic control (six patients with one oral hypoglycemic medication or insulin; seven with two or more hypoglycemic medications; two with both medications and insulin; five without any hypoglycemic medication or insulin). With respect to diabetic vascular complications (<xref rid="B27" ref-type="bibr">27</xref>), 5 patients had diabetic microvascular complications (e.g., diabetic nephropathy, neuropathy, and retinopathy), 1 had diabetic macrovascular complications (e.g., coronary artery disease, peripheral arterial disease, and myocardial infarction), 2 had both, and 12 were without any vascular complications to their diabetes. HCs were free of diabetes and had HbA<sub>1c</sub> levels within normal limits. All participants received the Mini-Mental State Examination (MMSE) (<xref rid="B28" ref-type="bibr">28</xref>), the Structured Clinical Interview for DSM-IV (<xref rid="B29" ref-type="bibr">29</xref>), and the 17-item Hamilton Depression Rating Scale (HAM-D) (<xref rid="B30" ref-type="bibr">30</xref>), administered by a trained research assistant and a board-certified (A.K.) or board-eligible (O.A.) psychiatrist. Both control and patient subjects denied a history of depressed mood, obtained scores of 8 or lower on the HAM-D, were free of unstable medical conditions, and were of comparable age and sex.</p>
        <p>Exclusion criteria included any current or past history of neurological and psychiatric disorders (e.g., dementia, stroke, seizure, transient ischemic attack, or depression), learning disability or attention deficit hyperactivity disorder, psychotropic medication, current or past history of substance abuse or dependence, history of head injury or loss of consciousness, a MMSE score less than 24, or any contraindication to MRI scan such as metal in the body, surgically implanted devices containing metal, claustrophobia, and pregnancy.</p>
        <p>All participants were assessed for medical comorbidity using the Cumulative Illness Rating Scale (CIRS) (<xref rid="B31" ref-type="bibr">31</xref>) and for vascular comorbidities using the Framingham Stroke Risk Profile (FSRP) score (<xref rid="B32" ref-type="bibr">32</xref>). We also designed a modified FSRP (mFSRP) score in which the contribution of T2DM was removed to represent vascular complications only. All participants received a nonfasting blood draw to document HbA<sub>1c</sub> levels, HDL cholesterol, and LDL cholesterol and to verify diabetes status. Systolic blood pressure (SBP), diastolic blood pressure (DBP), and BMI were documented on each participant. All participants were also assessed for IQ using the Wechsler Test of Adult Reading (WTAR) (<xref rid="B33" ref-type="bibr">33</xref>). Demographic and T2DM-related clinical measures are summarized in <xref ref-type="table" rid="T1">Table 1</xref>. Obesity, hypertension, vascular diseases, and/or elevated bad cholesterol levels are often seen in patients with T2DM, and each of these comorbidities has been reported to exert their own effects on the human brain. It must be noted that in this study, these comorbidities (including the following variables: BMI, SBP, DBP, mFSRP, and LDL cholesterol) were of comparable levels between two groups (<italic>P</italic> &gt; 0.20). So the possible effects of these comorbidities on the group difference in MTR have been minimized, and the findings from this study are primarily attributable to T2DM.</p>
        <table-wrap id="T1" position="float">
          <label>Table 1</label>
          <caption>
            <p>Demographic and clinical measures across subject groups</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead valign="bottom">
              <tr>
                <th rowspan="2" align="left" scope="col" colspan="1">Measures</th>
                <th colspan="2" align="center" scope="colgroup" rowspan="1">HC (<italic>N</italic> = 26)<hr/></th>
                <th colspan="2" align="center" scope="colgroup" rowspan="1">T2DM (<italic>N</italic> = 20)<hr/></th>
                <th colspan="3" align="center" scope="colgroup" rowspan="1">Statistics<hr/></th>
              </tr>
              <tr>
                <th colspan="1" align="center" scope="colgroup" rowspan="1">Mean</th>
                <th align="center" scope="col" rowspan="1" colspan="1">SD</th>
                <th align="center" scope="col" rowspan="1" colspan="1">Mean</th>
                <th align="center" scope="col" rowspan="1" colspan="1">SD</th>
                <th align="center" scope="col" rowspan="1" colspan="1">
                  <italic>F</italic>
                </th>
                <th align="center" scope="col" rowspan="1" colspan="1">df</th>
                <th align="center" scope="col" rowspan="1" colspan="1">
                  <italic>P</italic>
                </th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">Age (years)</td>
                <td align="center" rowspan="1" colspan="1">62.92</td>
                <td align="center" rowspan="1" colspan="1">12.71</td>
                <td align="center" rowspan="1" colspan="1">65.05</td>
                <td align="center" rowspan="1" colspan="1">11.95</td>
                <td align="center" rowspan="1" colspan="1">0.333</td>
                <td align="center" rowspan="1" colspan="1">1, 44</td>
                <td align="center" rowspan="1" colspan="1">0.567</td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">Sex (<italic>n</italic>)</td>
                <td align="center" rowspan="1" colspan="1">11 M, 15 F</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1">12 M, 8 F</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1"><italic>χ</italic><sup>2</sup> = 1.415</td>
                <td align="center" rowspan="1" colspan="1">1</td>
                <td align="center" rowspan="1" colspan="1">0.234</td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">Race (<italic>n</italic>)</td>
                <td align="center" rowspan="1" colspan="1">10 B, 2 H, 1 A, 11 W, 2 O</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1">11 B, 1 H, 0 A, 8 W, 0 O</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1"><italic>χ</italic><sup>2</sup> = 3.125</td>
                <td align="center" rowspan="1" colspan="1">4</td>
                <td align="center" rowspan="1" colspan="1">0.537</td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">Handedness (<italic>n</italic>)</td>
                <td align="center" rowspan="1" colspan="1">25 R, 1 L, 0 M</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1">16 R, 3 L, 1 M</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1"><italic>χ</italic><sup>2</sup> = 3.248</td>
                <td align="center" rowspan="1" colspan="1">2</td>
                <td align="center" rowspan="1" colspan="1">0.197</td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">Education (years)</td>
                <td align="center" rowspan="1" colspan="1">14.54</td>
                <td align="center" rowspan="1" colspan="1">1.86</td>
                <td align="center" rowspan="1" colspan="1">14.80</td>
                <td align="center" rowspan="1" colspan="1">2.28</td>
                <td align="center" rowspan="1" colspan="1">0.184</td>
                <td align="center" rowspan="1" colspan="1">1, 44</td>
                <td align="center" rowspan="1" colspan="1">0.670</td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">WTAR</td>
                <td align="center" rowspan="1" colspan="1">102.52</td>
                <td align="center" rowspan="1" colspan="1">11.09</td>
                <td align="center" rowspan="1" colspan="1">99.95</td>
                <td align="center" rowspan="1" colspan="1">16.54</td>
                <td align="center" rowspan="1" colspan="1">0.387</td>
                <td align="center" rowspan="1" colspan="1">1, 43<xref ref-type="table-fn" rid="t1n1"><sup>a</sup></xref></td>
                <td align="center" rowspan="1" colspan="1">0.537</td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">MMSE</td>
                <td align="center" rowspan="1" colspan="1">28.92</td>
                <td align="center" rowspan="1" colspan="1">0.98</td>
                <td align="center" rowspan="1" colspan="1">28.35</td>
                <td align="center" rowspan="1" colspan="1">1.18</td>
                <td align="center" rowspan="1" colspan="1">3.241</td>
                <td align="center" rowspan="1" colspan="1">1, 44</td>
                <td align="center" rowspan="1" colspan="1">0.079</td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">HAM-D</td>
                <td align="center" rowspan="1" colspan="1">0.96</td>
                <td align="center" rowspan="1" colspan="1">1.311</td>
                <td align="center" rowspan="1" colspan="1">1.65</td>
                <td align="center" rowspan="1" colspan="1">1.843</td>
                <td align="center" rowspan="1" colspan="1">2.193</td>
                <td align="center" rowspan="1" colspan="1">1, 44</td>
                <td align="center" rowspan="1" colspan="1">0.146</td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td>
                <td align="center" rowspan="1" colspan="1">30.18</td>
                <td align="center" rowspan="1" colspan="1">17.54</td>
                <td align="center" rowspan="1" colspan="1">31.43</td>
                <td align="center" rowspan="1" colspan="1">5.91</td>
                <td align="center" rowspan="1" colspan="1">0.092</td>
                <td align="center" rowspan="1" colspan="1">1, 44</td>
                <td align="center" rowspan="1" colspan="1">0.763</td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">SBP (mmHg)</td>
                <td align="center" rowspan="1" colspan="1">136.38</td>
                <td align="center" rowspan="1" colspan="1">14.05</td>
                <td align="center" rowspan="1" colspan="1">139.30</td>
                <td align="center" rowspan="1" colspan="1">17.87</td>
                <td align="center" rowspan="1" colspan="1">0.384</td>
                <td align="center" rowspan="1" colspan="1">1, 44</td>
                <td align="center" rowspan="1" colspan="1">0.539</td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">DBP (mmHg)</td>
                <td align="center" rowspan="1" colspan="1">79.85</td>
                <td align="center" rowspan="1" colspan="1">10.06</td>
                <td align="center" rowspan="1" colspan="1">83.70</td>
                <td align="center" rowspan="1" colspan="1">10.30</td>
                <td align="center" rowspan="1" colspan="1">1.627</td>
                <td align="center" rowspan="1" colspan="1">1, 44</td>
                <td align="center" rowspan="1" colspan="1">0.209</td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">
                  <bold>T2DM duration (months)</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">—</td>
                <td align="center" rowspan="1" colspan="1">—</td>
                <td align="center" rowspan="1" colspan="1">115.15</td>
                <td align="center" rowspan="1" colspan="1">85.19</td>
                <td align="center" rowspan="1" colspan="1">—</td>
                <td align="center" rowspan="1" colspan="1">—</td>
                <td align="center" rowspan="1" colspan="1">—</td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">
                  <bold>HDL cholesterol</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">72.88</td>
                <td align="center" rowspan="1" colspan="1">22.21</td>
                <td align="center" rowspan="1" colspan="1">48.15</td>
                <td align="center" rowspan="1" colspan="1">13.27</td>
                <td align="center" rowspan="1" colspan="1">19.406</td>
                <td align="center" rowspan="1" colspan="1">1, 44</td>
                <td align="center" rowspan="1" colspan="1">
                  <bold>&lt;0.001</bold>
                </td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">LDL cholesterol</td>
                <td align="center" rowspan="1" colspan="1">93.27</td>
                <td align="center" rowspan="1" colspan="1">23.99</td>
                <td align="center" rowspan="1" colspan="1">88.00</td>
                <td align="center" rowspan="1" colspan="1">22.56</td>
                <td align="center" rowspan="1" colspan="1">0.574</td>
                <td align="center" rowspan="1" colspan="1">1, 44</td>
                <td align="center" rowspan="1" colspan="1">0.453</td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">
                  <bold>CIRS</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">3.69</td>
                <td align="center" rowspan="1" colspan="1">2.83</td>
                <td align="center" rowspan="1" colspan="1">7.15</td>
                <td align="center" rowspan="1" colspan="1">3.05</td>
                <td align="center" rowspan="1" colspan="1">15.812</td>
                <td align="center" rowspan="1" colspan="1">1, 44</td>
                <td align="center" rowspan="1" colspan="1">
                  <bold>&lt;0.001</bold>
                </td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">
                  <bold>FSRP</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">8.81</td>
                <td align="center" rowspan="1" colspan="1">4.61</td>
                <td align="center" rowspan="1" colspan="1">13.00</td>
                <td align="center" rowspan="1" colspan="1">4.90</td>
                <td align="center" rowspan="1" colspan="1">8.848</td>
                <td align="center" rowspan="1" colspan="1">1, 44</td>
                <td align="center" rowspan="1" colspan="1">
                  <bold>0.005</bold>
                </td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">mFSRP (T2DM removed)</td>
                <td align="center" rowspan="1" colspan="1">8.81</td>
                <td align="center" rowspan="1" colspan="1">4.61</td>
                <td align="center" rowspan="1" colspan="1">10.60</td>
                <td align="center" rowspan="1" colspan="1">5.14</td>
                <td align="center" rowspan="1" colspan="1">1.544</td>
                <td align="center" rowspan="1" colspan="1">1, 44</td>
                <td align="center" rowspan="1" colspan="1">0.221</td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">
                  <bold>HbA<sub>1c</sub> (%) (mmol/mol)</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">5.70 (39)</td>
                <td align="center" rowspan="1" colspan="1">0.36 (3.9)</td>
                <td align="center" rowspan="1" colspan="1">7.37 (57)</td>
                <td align="center" rowspan="1" colspan="1">1.67 (18.3)</td>
                <td align="center" rowspan="1" colspan="1">24.503</td>
                <td align="center" rowspan="1" colspan="1">1, 44</td>
                <td align="center" rowspan="1" colspan="1">
                  <bold>&lt;0.001</bold>
                </td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>A, Asian; B, black; F, female; H, Hispanic; L, left; M (handedness), mixed; M (sex), male; O, other; R, right; W, white.</p>
            </fn>
            <fn id="t1n1">
              <p><sup>a</sup>One control subject’s WTAR was not recorded. Measures with significant group differences are in boldface text.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="s4">
        <title>Neuropsychological Tests</title>
        <p>A neuropsychological battery was conducted on each participant across three domains: learning and memory (California Verbal Learning Test [Second Edition] immediate total recall and long-delay free recall [<xref rid="B34" ref-type="bibr">34</xref>]; Wechsler Memory Scale [Third Edition] Logical Memory I and II and Visual Reproduction I and II [<xref rid="B35" ref-type="bibr">35</xref>]); attention and information processing (Stroop Color and Word tests [<xref rid="B36" ref-type="bibr">36</xref>]; Trail Making Test A; and Wechsler Adult Intelligence Scale [Third Edition] Digit Symbol-Coding [<xref rid="B37" ref-type="bibr">37</xref>]); and executive function (Delis-Kaplan Executive Function System Category Switching [<xref rid="B38" ref-type="bibr">38</xref>]; Trail Making Test B [<xref rid="B39" ref-type="bibr">39</xref>]; Stroop Interference Score [<xref rid="B36" ref-type="bibr">36</xref>]; Wechsler Adult Intelligence Scale [Third Edition] Digit Span Backward [<xref rid="B37" ref-type="bibr">37</xref>]; and Self-Ordered Pointing Task Total Errors [<xref rid="B40" ref-type="bibr">40</xref>]). Raw scores from the neuropsychological battery were standardized using the HC sample mean and SD. Relevant scores were reversed so that high scores consistently reflected better performance. Composite Z scores were calculated for each domain, and Cronbach α suggested that each variable measured a unidimensional latent construct (learning and memory, α = 0.88; attention and information processing, α = 0.85; executive function, α = 0.76).</p>
      </sec>
      <sec id="s5">
        <title>MT Image Data Acquisition</title>
        <p>MRI was performed on a Philips Achieva 3.0T scanner (Philips Medical Systems, Best, the Netherlands) with a body coil for transmission and a Philips 8-channel SENSE Head coil for reception. Subjects were equipped with soft ear plugs, positioned comfortably in the head coil using custom-made foam pads to minimize head motion, and instructed to remain still. MT images were acquired using a three-dimensional (3D) spoiled gradient echo sequence with multishot echo-planar imaging (EPI) readout and the following parameters: repetition time (TR)/echo time (TE) = 64/15 ms, flip angle = 9°, field of view (FOV) = 24 cm, 67 axial slices, slice thickness/gap = 2.2 mm/no gap, EPI factor = 7, and reconstructed voxel size = 0.83 × 0.83 × 2.2 mm<sup>3</sup>, with a nonselective five-lobed Sinc-Gauss off-resonance MT prepulse (B<sub>1</sub>/Δf/duration = 10.5 μT/1.5 kHz/24.5 ms) optimized for maximum white matter/gray matter contrast (<xref rid="B41" ref-type="bibr">41</xref>). Image slices were parallel to the anterior commissure–posterior commissure line. Parallel imaging was used with a reduction factor of 2. Before the MT scan, high-resolution 3D T<sub>1</sub>-weighted magnetization prepared rapid acquisition gradient echo (MPRAGE) images were acquired with the following sequence parameters: TR/TE = 8.4/3.9 ms, flip angle = 8°, FOV = 24 cm, 134 axial slices/no gap, and reconstructed voxel size = 0.83 × 0.83 × 1.1 mm<sup>3</sup>. In addition, T<sub>2</sub>-weighted fluid-attenuated inversion recovery (FLAIR) images were also acquired using turbo spin echo sequence with the following sequence parameters: TR/inversion time (TI)/TE = 11,000/2,800/68 ms, FOV = 24 cm, 67 axial slices without gap, and reconstructed voxel size = 0.83 × 0.83 × 2.2 mm<sup>3</sup>, for delineation of hyperintense areas in the brain.</p>
      </sec>
      <sec id="s6">
        <title>Image Processing</title>
        <p>For each participant, T<sub>1</sub>-weighted MPRAGE image, T<sub>2</sub>-weighted FLAIR image, and MT images (with and without the off-resonance MT prepulse: M<sub>s</sub> and M<sub>0</sub>) were coregistered. MTR values were calculated on a voxel-by-voxel basis using coregistered M<sub>0</sub> and M<sub>s</sub> with the formula MTR = (M<sub>0</sub> − M<sub>s</sub>)/M<sub>0</sub>. Regions of interest (ROIs) were placed on the coregistered high-resolution T<sub>1</sub>-weighted image at the nodes of fronto-striato-thalamic circuits (<xref rid="B21" ref-type="bibr">21</xref>), including four subcortical regions (i.e., hCaud, putamen, globus pallidus, and thalamus) and four cortical regions (i.e., rostral anterior cingulate cortex [rACC], dorsal anterior cingulate cortex [dACC], dorsolateral prefrontal cortex [DLPFC], and lateral orbitofrontal cortex [lOFC]) in both hemispheres (see <xref ref-type="fig" rid="F1">Fig. 1</xref>). Care was taken to ensure consistent placement of the subcortical ROIs for the MTR analysis. The slice displaying the most anterior margin of the genu of the corpus callosum (Montreal Neurological Institute (MNI) [<italic>x</italic>, <italic>y</italic>, <italic>z</italic>] coordinates, [1, 32, 6] mm) was chosen as the reference slice for placing the subcortical ROIs hCaud, putamen, and thalamus, because this landmark could be easily and consistently identified across subjects and these ROIs are visible at this slice level (<xref rid="B4" ref-type="bibr">4</xref>) (see <xref ref-type="fig" rid="F1">Fig. 1<italic>A</italic></xref>). In the case that putamen was not completely visualized on this slice, the next inferior slice was used as the reference slice (<xref rid="B4" ref-type="bibr">4</xref>). For the ROI of globus pallidus, the slice clearly displaying the anterior commissure (MNI coordinates [0, 2, −4] mm) was chosen as the reference slice (see <xref ref-type="fig" rid="F1">Fig. 1<italic>B</italic></xref>). During the placement of the subcortical ROIs, the coregistered FLAIR image was closely examined to ensure the ROIs were not placed in hyperintense areas. Moreover, we used constant volumes of ROIs in all of the defined subcortical regions, i.e., the volume was fixed to 73.3 mm<sup>3</sup> for hCaud, putamen, and thalamus and was fixed to relatively smaller 55 mm<sup>3</sup> for globus pallidus. These two volumes were selected so that the MTR calculation in each subcortical ROI could be devoid of any partial volume effects from adjoining brain regions and/or cerebrospinal fluid on all the involved subjects. For the four cortical ROIs (i.e., rACC, dACC, DLPFC, and lOFC), we used the FreeSurfer package (<ext-link ext-link-type="uri" xlink:href="https://surfer.nmr.mgh.harvard.edu/">https://surfer.nmr.mgh.harvard.edu/</ext-link>) to parcellate these structures and evaluated MTR within cortical white matter to minimize partial volume effects from the cerebrospinal fluid. To better illustrate the anatomical location of each cortical region, both gray (green) and white (red) matter areas are displayed in <xref ref-type="fig" rid="F1">Fig. 1<italic>C</italic>–<italic>E</italic></xref> (the region of dACC is not shown for simplicity). Generation of ROI masks and calculation of MTR were performed using in-house developed programs.</p>
        <fig id="F1" fig-type="figure" position="float">
          <label>Figure 1</label>
          <caption>
            <p>ROIs for MTR analysis.</p>
          </caption>
          <graphic xlink:href="183fig1"/>
        </fig>
      </sec>
      <sec id="s7">
        <title>Statistical Analysis</title>
        <p>Clinical and demographic measures were analyzed using univariate ANOVA for continuous variables and χ<sup>2</sup> tests for categorical variables. Group differences in MTR in bilateral regions were assessed using a mixed-model analysis with diagnostic group as the between-group factor and hemisphere as a within-subject factor. Group differences in MTR in individual regions on each hemisphere were further analyzed using univariate ANCOVA controlling for age. Correlations between MTR and FSRP, mFSRP, HbA<sub>1c</sub> level, or other related clinical variables were analyzed using partial Pearson product-moment correlations controlling for age. In the correlation analysis of MTR and HbA<sub>1c</sub>, a natural log transformation was first performed on HbA<sub>1c</sub> (i.e., log-transformed HbA<sub>1c</sub>) to reduce the skewness of this variable when the sample was combined from both HC and T2DM groups. Correlations between MTR and neuropsychological task performance were also analyzed using partial Pearson product-moment correlations controlling for age and MMSE as initial covariates. Multiple comparison correction was performed using false discovery rate (FDR) approach (<xref rid="B42" ref-type="bibr">42</xref>–<xref rid="B44" ref-type="bibr">44</xref>) with the maximum acceptable FDR set at 0.15. All statistical analyses were carried out using SPSS version 18 (SPSS Inc., Chicago, IL).</p>
      </sec>
    </sec>
    <sec sec-type="results" id="s8">
      <title>Results</title>
      <sec id="s9">
        <title>Demographic and Clinical Measures</title>
        <p><xref ref-type="table" rid="T1">Table 1</xref> summarizes the demographic and clinical characteristics of the T2DM and HC groups. There were no significant group differences in age, sex, race, handedness, years of education, IQ (WTAR), MMSE, HAM-D (both groups were free of depression, with mean scales &lt;2), BMI, SBP, DBP, LDL cholesterol, and mFSRP. As expected, there were significant group differences in the diabetes-related clinical measures, HDL cholesterol (<italic>F</italic> = 19.406, df = 1, 44, <italic>P</italic> &lt; 0.001), CIRS (<italic>F</italic> = 15.812, df = 1, 44, <italic>P</italic> &lt; 0.001), FSRP (<italic>F</italic> = 8.848, df = 1, 44, <italic>P</italic> = 0.005), and HbA<sub>1c</sub> (<italic>F</italic> = 24.503, df = 1, 44, <italic>P</italic> &lt; 0.001).</p>
      </sec>
      <sec id="s10">
        <title>Neuropsychological Tests</title>
        <p>There was no significant group difference in neuropsychological task performance in the three domains: learning and memory, executive function, and attention and information processing (<italic>P</italic> &gt; 0.09) (see <xref ref-type="table" rid="T2">Table 2</xref>) (the neuropsychological data of one control subject was not recorded, one diabetic subject was color blind and did not perform the Stroop tasks, and another diabetic subject’s Trail Making Test A task was not scored).</p>
        <table-wrap id="T2" position="float">
          <label>Table 2</label>
          <caption>
            <p>Neuropsychological task performance (in composite Z score) in three domains across subject groups</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead valign="bottom">
              <tr>
                <th rowspan="2" align="left" scope="col" colspan="1">Domain</th>
                <th colspan="2" align="center" scope="colgroup" rowspan="1">HC (<italic>N</italic> = 26)<hr/></th>
                <th colspan="2" align="center" scope="colgroup" rowspan="1">T2DM (<italic>N</italic> = 20)<hr/></th>
                <th colspan="3" align="center" scope="colgroup" rowspan="1">Statistics<hr/></th>
              </tr>
              <tr>
                <th colspan="1" align="center" scope="colgroup" rowspan="1">Mean</th>
                <th align="center" scope="col" rowspan="1" colspan="1">SD</th>
                <th align="center" scope="col" rowspan="1" colspan="1">Mean</th>
                <th align="center" scope="col" rowspan="1" colspan="1">SD</th>
                <th align="center" scope="col" rowspan="1" colspan="1">
                  <italic>F</italic>
                </th>
                <th align="center" scope="col" rowspan="1" colspan="1">df</th>
                <th align="center" scope="col" rowspan="1" colspan="1">
                  <italic>P</italic>
                </th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">Learning and memory </td>
                <td align="center" rowspan="1" colspan="1">Ref<xref ref-type="table-fn" rid="t2n1"><sup>a</sup></xref></td>
                <td align="center" rowspan="1" colspan="1">0.785</td>
                <td align="center" rowspan="1" colspan="1">−0.280</td>
                <td align="center" rowspan="1" colspan="1">0.779</td>
                <td align="center" rowspan="1" colspan="1">1.217</td>
                <td align="center" rowspan="1" colspan="1">1, 43</td>
                <td align="center" rowspan="1" colspan="1">0.276</td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">Executive function</td>
                <td align="center" rowspan="1" colspan="1">Ref<xref ref-type="table-fn" rid="t2n1"><sup>a</sup></xref></td>
                <td align="center" rowspan="1" colspan="1">0.715</td>
                <td align="center" rowspan="1" colspan="1">−0.372</td>
                <td align="center" rowspan="1" colspan="1">0.673</td>
                <td align="center" rowspan="1" colspan="1">2.972</td>
                <td align="center" rowspan="1" colspan="1">1, 42</td>
                <td align="center" rowspan="1" colspan="1">0.092</td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">Attention and information processing</td>
                <td align="center" rowspan="1" colspan="1">Ref<xref ref-type="table-fn" rid="t2n1"><sup>a</sup></xref></td>
                <td align="center" rowspan="1" colspan="1">0.826</td>
                <td align="center" rowspan="1" colspan="1">−0.278</td>
                <td align="center" rowspan="1" colspan="1">0.861</td>
                <td align="center" rowspan="1" colspan="1">1.348</td>
                <td align="center" rowspan="1" colspan="1">1, 41</td>
                <td align="center" rowspan="1" colspan="1">0.252</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="t2n1">
              <p><sup>a</sup>Raw score of each specific cognitive task on each subject was standardized (called Z score) using the mean and SD of the HC group.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="s11">
        <title>Group Differences in MTR</title>
        <p>The mixed-model analysis (with diagnostic group as the between-group factor and hemisphere as a within-subject factor) showed that among the ROIs examined, MTR was significantly lower in bilateral dACC (<italic>F</italic> = 6.082, df = 1, 44, <italic>P</italic> = 0.018) and bilateral hCaud (<italic>F</italic> = 5.085, df = 1, 44, <italic>P</italic> = 0.029), and there was a trend of lower MTR in bilateral rACC (<italic>F</italic> = 2.767, df = 1, 44, <italic>P</italic> = 0.103) in T2DM patients compared with nondiabetic control subjects (see <xref ref-type="fig" rid="F2">Fig. 2</xref>). The above significant results remained significant after the FDR multiple comparison correction. There were no significant hemispheric differences in MTR in the above regions, i.e., dACC (<italic>F</italic> = 1.040, df = 1, 45, <italic>P</italic> = 0.313), hCaud (<italic>F</italic> = 0.548, df = 1, 45, <italic>P</italic> = 0.463), and rACC (<italic>F</italic> = 1.451, df = 1, 45, <italic>P</italic> = 0.235). ANCOVA analysis further revealed that the dACC MTRs in both left and right hemispheres were significantly lower in T2DM patients than in nondiabetic control subjects (left: <italic>F</italic> = 5.787, df = 1, 43, <italic>P</italic> = 0.021 and right: <italic>F</italic> = 4.847, df = 1, 43, <italic>P</italic> = 0.033), and right hCaud MTR was significantly lower in T2DM patients (<italic>F</italic> = 5.416, df = 1, 43, <italic>P</italic> = 0.025), while no significant difference was found in left hCaud MTR (<italic>F</italic> = 1.974, df = 1, 43, <italic>P</italic> = 0.167) despite a lower mean value in T2DM patients than control subjects. In the following sections, we limited our further statistical analysis to the regions showing group differences in MTR, i.e., bilateral dACC, bilateral rACC, and right hCaud.</p>
        <fig id="F2" fig-type="figure" position="float">
          <label>Figure 2</label>
          <caption>
            <p>Scatterplots of MTRs in (<italic>A</italic>) hCaud, (<italic>B</italic>) dACC, and (<italic>C</italic>) rACC. <italic>A</italic>: <italic>F</italic> = 5.085, df = 1, 44, <italic>P</italic> = 0.029. <italic>B</italic>: <italic>F</italic> = 6.082, df = 1, 44, <italic>P</italic> = 0.018. <italic>C</italic>: <italic>F</italic> = 2.767, df = 1, 44, <italic>P</italic> = 0.103.</p>
          </caption>
          <graphic xlink:href="183fig2"/>
        </fig>
      </sec>
      <sec id="s12">
        <title>Correlation Between MTR and T2DM-Related Clinical Measures</title>
        <p>When groups were combined, MTR was negatively correlated with the log-transformed HbA<sub>1c</sub> level in bilateral dACC (left: <italic>r</italic> = −0.401, df = 43, <italic>P</italic> = 0.006 and right: <italic>r</italic> = −0.412, df = 43, <italic>P</italic> = 0.005) (see <xref ref-type="fig" rid="F3">Fig. 3<italic>A</italic> and <italic>B</italic></xref>), bilateral rACC (left: <italic>r</italic> = −0.350, df = 43, <italic>P</italic> = 0.018 and right: <italic>r</italic> = −0.329, df = 43, <italic>P</italic> = 0.027), and right hCaud (<italic>r</italic> = −0.323, df = 43, <italic>P</italic> = 0.031). These results remained significant after the FDR multiple comparison correction.</p>
        <fig id="F3" fig-type="figure" position="float">
          <label>Figure 3</label>
          <caption>
            <p>Representative scatterplots of correlations between MTRs and log-transformed HbA<sub>1c</sub> level in (<italic>A</italic>) left dACC and (<italic>B</italic>) right dACC. <italic>A</italic>: <italic>r</italic> = −0.401, df = 43, <italic>P</italic> = 0.006. <italic>B</italic>: <italic>r</italic> = −0.412, df = 43, <italic>P</italic> = 0.005.</p>
          </caption>
          <graphic xlink:href="183fig3"/>
        </fig>
        <p>MTRs in bilateral rACC were negatively correlated with the FSRP score across the entire sample combining both groups (left: <italic>r</italic> = −0.344, df = 43, <italic>P</italic> = 0.021 and right: <italic>r</italic> = −0.371, df = 43, <italic>P</italic> = 0.012). If examining MTR in each group, significant correlation between right rACC MTR and FSRP was found in the T2DM group but not in the HC group (T2DM: <italic>r</italic> = −0.589, df = 17, <italic>P</italic> = 0.008 and HC: <italic>r</italic> = −0.158, df = 23, <italic>P</italic> = 0.450) (see <xref ref-type="fig" rid="F4">Fig. 4<italic>A</italic></xref>). The above significant results remained significant after the FDR multiple comparison correction. We repeated the above correlation analysis using the mFSRP score, and the results remained significant in bilateral rACC across the entire sample (left: <italic>r</italic> = −0.304, df = 43, <italic>P</italic> = 0.043 and right: <italic>r</italic> = −0.357, df = 43, <italic>P</italic> = 0.016) and in right rACC in the T2DM group (T2DM: <italic>r</italic> = −0.599, df = 17, <italic>P</italic> = 0.007 and HC: <italic>r</italic> = −0.158, df = 23, <italic>P</italic> = 0.450).</p>
        <fig id="F4" fig-type="figure" position="float">
          <label>Figure 4</label>
          <caption>
            <p>Representative scatterplots of correlations between MTRs in right rACC and (<italic>A</italic>) vascular risk factor assessed by FSRP score and (<italic>B</italic>) neuropsychological task performance (in Z score) in learning and memory. <italic>A</italic>: T2DM: <italic>r</italic> = −0.589, df = 17, <italic>P</italic> = 0.008 and HC: <italic>r</italic> = −0.158, df = 23, <italic>P</italic> = 0.450. <italic>B</italic>: T2DM: <italic>r</italic> = 0.811, df = 16, <italic>P</italic> &lt; 0.001 and HC: <italic>r</italic> = −0.100, df = 21, <italic>P</italic> = 0.651.</p>
          </caption>
          <graphic xlink:href="183fig4"/>
        </fig>
        <p>There was no significant correlation between MTR in the examined regions and the duration of T2DM (<italic>P</italic> &gt; 0.07), SBP (<italic>P</italic> &gt; 0.08), DBP (<italic>P</italic> &gt; 0.13), BMI (<italic>P</italic> &gt; 0.39), HDL cholesterol (<italic>P</italic> &gt; 0.19), and LDL cholesterol (<italic>P</italic> &gt; 0.12) in T2DM patients.</p>
      </sec>
      <sec id="s13">
        <title>Correlation Between MTR and Neuropsychological Task Performance</title>
        <p>The learning and memory Z score was positively correlated with bilateral rACC MTR in the T2DM group (left: <italic>r</italic> = 0.595, df = 16, <italic>P</italic> = 0.009 and right: <italic>r</italic> = 0.811, df = 16, <italic>P</italic> &lt; 0.001) but not in the HC group (left: <italic>r</italic> = −0.166, df = 21, <italic>P</italic> = 0.449 and right: <italic>r</italic> = −0.100, df = 21, <italic>P</italic> = 0.651). The significant correlation in right rACC remained significant after the FDR multiple comparison correction (see <xref ref-type="fig" rid="F4">Fig. 4<italic>B</italic></xref>). Furthermore, this correlation remained significant after adding the HbA<sub>1c</sub> level (<italic>r</italic> = 0.722, df = 15, <italic>P</italic> = 0.001) or mFSRP score (<italic>r</italic> = 0.648, df = 15, <italic>P</italic> = 0.005) as an additional covariate besides age and MMSE. In addition, the right rACC MTR was also positively correlated with the executive function Z score in the T2DM group (<italic>r</italic> = 0.540, df = 15, <italic>P</italic> = 0.025) but not in the HC group (<italic>r</italic> = −0.097, df = 21, <italic>P</italic> = 0.659). Finally, the attention and information processing Z score was positively correlated with right hCaud MTR in the T2DM group only (T2DM: <italic>r</italic> = 0.549, df = 14, <italic>P</italic> = 0.028 and HC: <italic>r</italic> = −0.209, df = 21, <italic>P</italic> = 0.339). While the significant correlations between right rACC MTR and the Z score of executive function and between hCaud MTR and the attention and information processing Z score remained significant after adding HbA<sub>1c</sub> or mFSRP as an additional covariate besides age and MMSE, these two correlations did not survive the FDR multiple comparison correction.</p>
      </sec>
    </sec>
    <sec sec-type="discussion" id="s14">
      <title>Discussion</title>
      <p>The primary finding of the current study is that biophysical integrity of macromolecular protein pools are compromised at node regions of frontal-subcortical circuits, i.e., bilateral anterior cingulate and head of the right caudate nucleus, in T2DM patients compared with nondiabetic control subjects. Reduced MTR in these regions correlated with T2DM-related clinical measures (including HbA<sub>1c</sub> level and increased vascular risk factors) and neuropsychological task performance in the domains of learning and memory, executive function, and attention and information processing.</p>
      <p>Our findings of reduced MTRs in bilateral anterior cingulate and the head of the right caudate nucleus are consistent with recent reports of reduced fractional anisotropy and increased radial diffusivity (suggestive of possible demyelination) in the frontal white matter and the associations between disease duration and increased radial diffusivity in the cingulate white matter gyrus and the right caudate nucleus in T2DM patients (<xref rid="B9" ref-type="bibr">9</xref>). Also in line with our findings, significantly lower concentrations of glutamate and glutamine in the caudate nucleus and higher concentrations of <italic>myo</italic>-inositol in the frontal white matter were observed in patients with T2DM relative to HCs (<xref rid="B2" ref-type="bibr">2</xref>). Further, a trend toward significant white matter impairment in the ALIC was observed in T2DM, which was associated with elevated HbA<sub>1c</sub> in a recent diffusion tensor imaging tractography study (<xref rid="B11" ref-type="bibr">11</xref>). The ALIC contains the anterior thalamic radiation, prefrontal corticopontine tracts, and thalamo-striate and striato-striate tracts, providing reciprocal connections between the frontal lobe, striatum, and thalamus (<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B45" ref-type="bibr">45</xref>,<xref rid="B46" ref-type="bibr">46</xref>). Our study extended the finding of altered white matter integrity in ALIC and demonstrated that the biophysical integrity of macromolecular protein pools in brain regions connected through these white matter tracts is also impaired in T2DM.</p>
      <p>hCaud and the anterior cingulate are important nodes of cortico-striatal-pallidal-thalamic circuits that are involved in cognitive functions such as learning and memory, attention and information processing, and executive function (<xref rid="B21" ref-type="bibr">21</xref>). Specifically, the caudate nucleus is extensively connected with cortical and subcortical structures in well-characterized circuits (<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B21" ref-type="bibr">21</xref>) that subserve the complex regulation of motor functions, cognition, and mood. Among five primary cortical-subcortical circuits (prefrontal, striatal, pallidal, thalamic, and prefrontal circuits), three circuits (i.e., the oculomotor, dorsolateral prefrontal, and lateral orbitofrontal circuits) have direct connections from the prefrontal regions to the caudate nucleus (<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B21" ref-type="bibr">21</xref>). In agreement with these circuitry functions, our results demonstrated significant association between cognition and the integrity of macromolecular protein pools in the node regions of frontal-subcortical circuits. The positive correlations between MTRs and neuropsychological task performance in distinct domains are consistent with and further expand the reported association between caudate MTR and global cognition (<xref rid="B23" ref-type="bibr">23</xref>). Changes in the caudate and prefrontal regions have been associated with a broad spectrum of behavioral aberrations (<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B21" ref-type="bibr">21</xref>). Our results demonstrated that the biophysical integrity of the cortico-striatal-pallidal-thalamic circuits was compromised in T2DM patients in the absence of significant cognitive impairments or mood disturbances. T2DM-related changes in these circuits may contribute, in part, to increased susceptibility of cognitive deficits and/or mood disorders in patients with T2DM and potentially inform the underlying substrates linking T2DM and cognitive/mood disorders.</p>
      <p>Further, MTRs in bilateral dACC, rACC, and right hCaud were significantly correlated with the HbA<sub>1c</sub> level, and reduced MTRs in bilateral rACC were associated with increased vascular risk factors. While correlations do not prove causality, these correlations may suggest that both hyperglycemia and vascular diseases may be contributing to the abnormalities observed in our clinical sample. In contrast, there was no significant association between reduced MTRs and duration of T2DM. The HbA<sub>1c</sub> is known to reflect an average level of blood glucose over the previous 3 months. A possible explanation is that reduced MTRs may, in part, reflect the intermediate or dynamic impact of T2DM on macromolecular protein pools of these regions.</p>
      <p>Several limitations of the current study should be considered. The study is limited by its relatively small sample size (20 patients with T2DM and 26 HCs), which may have limited the power to detect subtle changes in some regions of the fronto-striato-thalamic circuits in T2DM patients. Furthermore, the relatively small sample size restricted our ability to examine specific task-level cognitive processes. Thus a composite Z score approach was used to protect against multiple comparisons. In addition, a cross-sectional instead of longitudinal design was used in this study. The cross-sectional design is inherently more vulnerable to intersubject variance and cohort effects. Therefore, future studies are needed to increase the sample size and to investigate the relationship between biophysical integrity of macromolecular protein pools and specific cognitive functions.</p>
      <p>In conclusion, our study found compromised macromolecular protein pools in bilateral anterior cingulate and the head of the right caudate nucleus in T2DM patients compared with control subjects. Moreover, the compromised biophysical properties of macromolecular protein pools represented by lower MTR were correlated with T2DM-related clinical measures and neuropsychological task performance in distinct domains. This study is the first to report impaired macromolecular protein pools in frontal-subcortical circuits and its clinical and cognitive correlates in patients with T2DM. These findings contribute to the growing literature in brain alterations in T2DM and have important implications for the underlying neurobiology of diabetes.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Article Information</title>
      <p><bold>Acknowledgments.</bold> The authors thank Dr. Peter van Zijl, Joseph S. Gillen, Terri Brawner, and Seth A. Smith (Johns Hopkins University) for the MT sequence, which was developed by the support of National Center for Research Resources grant P41 RR015241.</p>
      <p><bold>Funding.</bold> This work was supported by National Institutes of Health grants R01-MH63764 and R01-MH73989.</p>
      <p><bold>Duality of Interest.</bold> No potential conflicts of interest relevant to this article were reported.</p>
      <p><bold>Author Contributions.</bold> S.Y. performed the investigations, designed the imaging protocol, acquired and analyzed the data, and wrote the manuscript. O.A. reviewed and edited the manuscript. M.W. analyzed the data and wrote the manuscript. M.L. reviewed and edited the manuscript. A.K. designed the study and wrote the manuscript. S.Y. and A.K. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.</p>
      <p><bold>Prior Presentation.</bold> Parts of this study were presented in abstract form at the Annual Meeting of the International Society for Magnetic Resonance in Medicine, Milan, Italy, 12–16 May 2014.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation publication-type="other">Harati Y. Diabetes and the nervous system. Endocrinol Metab Clin North Am 1996;25:325–359</mixed-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ajilore</surname><given-names>O</given-names></name><name><surname>Haroon</surname><given-names>E</given-names></name><name><surname>Kumaran</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Measurement of brain metabolites in patients with type 2 diabetes and major depression using proton magnetic resonance spectroscopy</article-title>. <source>Neuropsychopharmacology</source>
<year>2007</year>;<volume>32</volume>:<fpage>1224</fpage>–<lpage>1231</lpage><?supplied-pmid 17180124?><pub-id pub-id-type="pmid">17180124</pub-id></mixed-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biessels</surname><given-names>GJ</given-names></name><name><surname>Staekenborg</surname><given-names>S</given-names></name><name><surname>Brunner</surname><given-names>E</given-names></name><name><surname>Brayne</surname><given-names>C</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name></person-group>. <article-title>Risk of dementia in diabetes mellitus: a systematic review</article-title>. <source>Lancet Neurol</source>
<year>2006</year>;<volume>5</volume>:<fpage>64</fpage>–<lpage>74</lpage><?supplied-pmid 16361024?><pub-id pub-id-type="pmid">16361024</pub-id></mixed-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Gupta</surname><given-names>R</given-names></name><name><surname>Thomas</surname><given-names>A</given-names></name><name><surname>Ajilore</surname><given-names>O</given-names></name><name><surname>Hellemann</surname><given-names>G</given-names></name></person-group>. <article-title>Focal subcortical biophysical abnormalities in patients diagnosed with type 2 diabetes and depression</article-title>. <source>Arch Gen Psychiatry</source>
<year>2009</year>;<volume>66</volume>:<fpage>324</fpage>–<lpage>330</lpage><?supplied-pmid 19255382?><pub-id pub-id-type="pmid">19255382</pub-id></mixed-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luchsinger</surname><given-names>JA</given-names></name><name><surname>Reitz</surname><given-names>C</given-names></name><name><surname>Patel</surname><given-names>B</given-names></name><name><surname>Tang</surname><given-names>MX</given-names></name><name><surname>Manly</surname><given-names>JJ</given-names></name><name><surname>Mayeux</surname><given-names>R</given-names></name></person-group>. <article-title>Relation of diabetes to mild cognitive impairment</article-title>. <source>Arch Neurol</source>
<year>2007</year>;<volume>64</volume>:<fpage>570</fpage>–<lpage>575</lpage><?supplied-pmid 17420320?><pub-id pub-id-type="pmid">17420320</pub-id></mixed-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ajilore</surname><given-names>O</given-names></name><name><surname>Narr</surname><given-names>K</given-names></name><name><surname>Rosenthal</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Regional cortical gray matter thickness differences associated with type 2 diabetes and major depression</article-title>. <source>Psychiatry Res</source>
<year>2010</year>;<volume>184</volume>:<fpage>63</fpage>–<lpage>70</lpage><?supplied-pmid 20832254?><pub-id pub-id-type="pmid">20832254</pub-id></mixed-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brundel</surname><given-names>M</given-names></name><name><surname>van den Heuvel</surname><given-names>M</given-names></name><name><surname>de Bresser</surname><given-names>J</given-names></name><name><surname>Kappelle</surname><given-names>LJ</given-names></name><name><surname>Biessels</surname><given-names>GJ</given-names></name><collab>Utrecht Diabetic Encephalopathy Study Group</collab></person-group>. <article-title>Cerebral cortical thickness in patients with type 2 diabetes</article-title>. <source>J Neurol Sci</source>
<year>2010</year>;<volume>299</volume>:<fpage>126</fpage>–<lpage>130</lpage><?supplied-pmid 20869085?><pub-id pub-id-type="pmid">20869085</pub-id></mixed-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Haroon</surname><given-names>E</given-names></name><name><surname>Darwin</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Gray matter prefrontal changes in type 2 diabetes detected using MRI</article-title>. <source>J Magn Reson Imaging</source>
<year>2008</year>;<volume>27</volume>:<fpage>14</fpage>–<lpage>19</lpage><?supplied-pmid 18050330?><pub-id pub-id-type="pmid">18050330</pub-id></mixed-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>JL</given-names></name><name><surname>Chen</surname><given-names>YL</given-names></name><name><surname>Leu</surname><given-names>JG</given-names></name><etal/></person-group>. <article-title>Microstructural white matter abnormalities in type 2 diabetes mellitus: a diffusion tensor imaging study</article-title>. <source>Neuroimage</source>
<year>2012</year>;<volume>59</volume>:<fpage>1098</fpage>–<lpage>1105</lpage><?supplied-pmid 21967726?><pub-id pub-id-type="pmid">21967726</pub-id></mixed-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoogenboom</surname><given-names>WS</given-names></name><name><surname>Marder</surname><given-names>TJ</given-names></name><name><surname>Flores</surname><given-names>VL</given-names></name><etal/></person-group>. <article-title>Cerebral white matter integrity and resting-state functional connectivity in middle-aged patients with type 2 diabetes</article-title>. <source>Diabetes</source>
<year>2014</year>;<volume>63</volume>:<fpage>728</fpage>–<lpage>738</lpage><?supplied-pmid 24203723?><pub-id pub-id-type="pmid">24203723</pub-id></mixed-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>A</given-names></name><name><surname>Ajilore</surname><given-names>O</given-names></name><name><surname>Zhan</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>White matter tract integrity of anterior limb of internal capsule in major depression and type 2 diabetes</article-title>. <source>Neuropsychopharmacology</source>
<year>2013</year>;<volume>38</volume>:<fpage>1451</fpage>–<lpage>1459</lpage><?supplied-pmid 23389692?><pub-id pub-id-type="pmid">23389692</pub-id></mixed-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Jiao</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>YC</given-names></name><etal/></person-group>. <article-title>Altered spontaneous brain activity in type 2 diabetes: a resting-state functional MRI study</article-title>. <source>Diabetes</source>
<year>2014</year>;<volume>63</volume>:<fpage>749</fpage>–<lpage>760</lpage><?supplied-pmid 24353185?><pub-id pub-id-type="pmid">24353185</pub-id></mixed-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musen</surname><given-names>G</given-names></name><name><surname>Jacobson</surname><given-names>AM</given-names></name><name><surname>Bolo</surname><given-names>NR</given-names></name><etal/></person-group>. <article-title>Resting-state brain functional connectivity is altered in type 2 diabetes</article-title>. <source>Diabetes</source>
<year>2012</year>;<volume>61</volume>:<fpage>2375</fpage>–<lpage>2379</lpage><?supplied-pmid 22664957?><pub-id pub-id-type="pmid">22664957</pub-id></mixed-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolff</surname><given-names>SD</given-names></name><name><surname>Balaban</surname><given-names>RS</given-names></name></person-group>. <article-title>Magnetization transfer contrast (MTC) and tissue water proton relaxation in vivo</article-title>. <source>Magn Reson Med</source>
<year>1989</year>;<volume>10</volume>:<fpage>135</fpage>–<lpage>144</lpage><?supplied-pmid 2547135?><pub-id pub-id-type="pmid">2547135</pub-id></mixed-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Waesberghe</surname><given-names>JH</given-names></name><name><surname>Kamphorst</surname><given-names>W</given-names></name><name><surname>De Groot</surname><given-names>CJ</given-names></name><etal/></person-group>. <article-title>Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability</article-title>. <source>Ann Neurol</source>
<year>1999</year>;<volume>46</volume>:<fpage>747</fpage>–<lpage>754</lpage><?supplied-pmid 10553992?><pub-id pub-id-type="pmid">10553992</pub-id></mixed-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmierer</surname><given-names>K</given-names></name><name><surname>Scaravilli</surname><given-names>F</given-names></name><name><surname>Altmann</surname><given-names>DR</given-names></name><name><surname>Barker</surname><given-names>GJ</given-names></name><name><surname>Miller</surname><given-names>DH</given-names></name></person-group>. <article-title>Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain</article-title>. <source>Ann Neurol</source>
<year>2004</year>;<volume>56</volume>:<fpage>407</fpage>–<lpage>415</lpage><?supplied-pmid 15349868?><pub-id pub-id-type="pmid">15349868</pub-id></mixed-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steens</surname><given-names>SC</given-names></name><name><surname>Bosma</surname><given-names>GP</given-names></name><name><surname>Steup-Beekman</surname><given-names>GM</given-names></name><name><surname>le Cessie</surname><given-names>S</given-names></name><name><surname>Huizinga</surname><given-names>TW</given-names></name><name><surname>van Buchem</surname><given-names>MA</given-names></name></person-group>. <article-title>Association between microscopic brain damage as indicated by magnetization transfer imaging and anticardiolipin antibodies in neuropsychiatric lupus</article-title>. <source>Arthritis Res Ther</source>
<year>2006</year>;<volume>8</volume>:<fpage>R38</fpage><?supplied-pmid 16469116?><pub-id pub-id-type="pmid">16469116</pub-id></mixed-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Audoin</surname><given-names>B</given-names></name><name><surname>Davies</surname><given-names>G</given-names></name><name><surname>Rashid</surname><given-names>W</given-names></name><name><surname>Fisniku</surname><given-names>L</given-names></name><name><surname>Thompson</surname><given-names>AJ</given-names></name><name><surname>Miller</surname><given-names>DH</given-names></name></person-group>. <article-title>Voxel-based analysis of grey matter magnetization transfer ratio maps in early relapsing remitting multiple sclerosis</article-title>. <source>Mult Scler</source>
<year>2007</year>;<volume>13</volume>:<fpage>483</fpage>–<lpage>489</lpage><?supplied-pmid 17463071?><pub-id pub-id-type="pmid">17463071</pub-id></mixed-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagary</surname><given-names>MS</given-names></name><name><surname>Symms</surname><given-names>MR</given-names></name><name><surname>Barker</surname><given-names>GJ</given-names></name><name><surname>Mutsatsa</surname><given-names>SH</given-names></name><name><surname>Joyce</surname><given-names>EM</given-names></name><name><surname>Ron</surname><given-names>MA</given-names></name></person-group>. <article-title>Gray and white matter brain abnormalities in first-episode schizophrenia inferred from magnetization transfer imaging</article-title>. <source>Arch Gen Psychiatry</source>
<year>2003</year>;<volume>60</volume>:<fpage>779</fpage>–<lpage>788</lpage><?supplied-pmid 12912761?><pub-id pub-id-type="pmid">12912761</pub-id></mixed-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khaleeli</surname><given-names>Z</given-names></name><name><surname>Altmann</surname><given-names>DR</given-names></name><name><surname>Cercignani</surname><given-names>M</given-names></name><name><surname>Ciccarelli</surname><given-names>O</given-names></name><name><surname>Miller</surname><given-names>DH</given-names></name><name><surname>Thompson</surname><given-names>AJ</given-names></name></person-group>. <article-title>Magnetization transfer ratio in gray matter: a potential surrogate marker for progression in early primary progressive multiple sclerosis</article-title>. <source>Arch Neurol</source>
<year>2008</year>;<volume>65</volume>:<fpage>1454</fpage>–<lpage>1459</lpage><?supplied-pmid 19001163?><pub-id pub-id-type="pmid">19001163</pub-id></mixed-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexander</surname><given-names>GE</given-names></name><name><surname>DeLong</surname><given-names>MR</given-names></name><name><surname>Strick</surname><given-names>PL</given-names></name></person-group>. <article-title>Parallel organization of functionally segregated circuits linking basal ganglia and cortex</article-title>. <source>Annu Rev Neurosci</source>
<year>1986</year>;<volume>9</volume>:<fpage>357</fpage>–<lpage>381</lpage><?supplied-pmid 3085570?><pub-id pub-id-type="pmid">3085570</pub-id></mixed-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Ajilore</surname><given-names>O</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Charlton</surname><given-names>R</given-names></name><name><surname>Lamar</surname><given-names>M</given-names></name></person-group>. <article-title>Subcortical biophysical abnormalities in patients with mood disorders</article-title>. <source>Mol Psychiatry</source>
<year>2014</year>;<volume>19</volume>:<fpage>710</fpage>–<lpage>716</lpage><?supplied-pmid 23877833?><pub-id pub-id-type="pmid">23877833</pub-id></mixed-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elderkin-Thompson</surname><given-names>V</given-names></name><name><surname>Hellemann</surname><given-names>G</given-names></name><name><surname>Gupta</surname><given-names>RK</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name></person-group>. <article-title>Biophysical correlates of cognition among depressed and nondepressed type 2 diabetic patients</article-title>. <source>Diabetes Care</source>
<year>2009</year>;<volume>32</volume>:<fpage>48</fpage>–<lpage>50</lpage><?supplied-pmid 18835947?><pub-id pub-id-type="pmid">18835947</pub-id></mixed-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nouwen</surname><given-names>A</given-names></name><name><surname>Winkley</surname><given-names>K</given-names></name><name><surname>Twisk</surname><given-names>J</given-names></name><etal/><collab>European Depression in Diabetes (EDID) Research Consortium</collab></person-group>. <article-title>Type 2 diabetes mellitus as a risk factor for the onset of depression: a systematic review and meta-analysis</article-title>. <source>Diabetologia</source>
<year>2010</year>;<volume>53</volume>:<fpage>2480</fpage>–<lpage>2486</lpage><?supplied-pmid 20711716?><pub-id pub-id-type="pmid">20711716</pub-id></mixed-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Groot</surname><given-names>M</given-names></name><name><surname>Anderson</surname><given-names>R</given-names></name><name><surname>Freedland</surname><given-names>KE</given-names></name><name><surname>Clouse</surname><given-names>RE</given-names></name><name><surname>Lustman</surname><given-names>PJ</given-names></name></person-group>. <article-title>Association of depression and diabetes complications: a meta-analysis</article-title>. <source>Psychosom Med</source>
<year>2001</year>;<volume>63</volume>:<fpage>619</fpage>–<lpage>630</lpage><?supplied-pmid 11485116?><pub-id pub-id-type="pmid">11485116</pub-id></mixed-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>American Diabetes Association</collab></person-group>. <article-title>Standards of medical care in diabetes—2013</article-title>. <source>Diabetes Care</source>
<year>2013</year>;<volume>36</volume>(<issue>Suppl. 1</issue>):<fpage>S11</fpage>–<lpage>S66</lpage><?supplied-pmid 23264422?><pub-id pub-id-type="pmid">23264422</pub-id></mixed-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fowler</surname><given-names>MJ</given-names></name></person-group>
<article-title>Microvascular and macrovascular complications of diabetes</article-title>. <source>Clin Diabetes</source>
<year>2008</year>;<volume>26</volume>:<fpage>77</fpage>–<lpage>82</lpage></mixed-citation>
      </ref>
      <ref id="B28">
        <label>28</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folstein</surname><given-names>MF</given-names></name><name><surname>Folstein</surname><given-names>SE</given-names></name><name><surname>McHugh</surname><given-names>PR</given-names></name></person-group>. <article-title>“Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician</article-title>. <source>J Psychiatr Res</source>
<year>1975</year>;<volume>12</volume>:<fpage>189</fpage>–<lpage>198</lpage><?supplied-pmid 1202204?><pub-id pub-id-type="pmid">1202204</pub-id></mixed-citation>
      </ref>
      <ref id="B29">
        <label>29</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>First</surname><given-names>MB</given-names></name><name><surname>Spitzer</surname><given-names>RL</given-names></name><name><surname>Gibbon</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>JB</given-names></name></person-group>
<source>Structured Clinical Interview for Axis I DSM-IV Disorders</source>. <publisher-loc>New York</publisher-loc>, <publisher-name>Biometrics Research</publisher-name>, <year>1994</year></mixed-citation>
      </ref>
      <ref id="B30">
        <label>30</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>M</given-names></name></person-group>. <article-title>Development of a rating scale for primary depressive illness</article-title>. <source>Br J Soc Clin Psychol</source>
<year>1967</year>;<volume>6</volume>:<fpage>278</fpage>–<lpage>296</lpage><?supplied-pmid 6080235?><pub-id pub-id-type="pmid">6080235</pub-id></mixed-citation>
      </ref>
      <ref id="B31">
        <label>31</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linn</surname><given-names>BS</given-names></name><name><surname>Linn</surname><given-names>MW</given-names></name><name><surname>Gurel</surname><given-names>L</given-names></name></person-group>. <article-title>Cumulative illness rating scale</article-title>. <source>J Am Geriatr Soc</source>
<year>1968</year>;<volume>16</volume>:<fpage>622</fpage>–<lpage>626</lpage><?supplied-pmid 5646906?><pub-id pub-id-type="pmid">5646906</pub-id></mixed-citation>
      </ref>
      <ref id="B32">
        <label>32</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D’Agostino</surname><given-names>RB</given-names></name><name><surname>Wolf</surname><given-names>PA</given-names></name><name><surname>Belanger</surname><given-names>AJ</given-names></name><name><surname>Kannel</surname><given-names>WB</given-names></name></person-group>. <article-title>Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study</article-title>. <source>Stroke</source>
<year>1994</year>;<volume>25</volume>:<fpage>40</fpage>–<lpage>43</lpage><?supplied-pmid 8266381?><pub-id pub-id-type="pmid">8266381</pub-id></mixed-citation>
      </ref>
      <ref id="B33">
        <label>33</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wechsler</surname><given-names>D</given-names></name></person-group>
<source>Wechsler Test of Adult Reading: WTAR</source>. <publisher-loc>San Antonio, TX</publisher-loc>, <publisher-name>Psychological Corporation</publisher-name>, <year>2001</year></mixed-citation>
      </ref>
      <ref id="B34">
        <label>34</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Delis</surname><given-names>DC</given-names></name><name><surname>Kramer</surname><given-names>JH</given-names></name><name><surname>Kaplan</surname><given-names>E</given-names></name><name><surname>Ober</surname><given-names>BA</given-names></name></person-group>
<source>California Verbal Learning Test 2nd Edition: Adult Version</source>
<publisher-name>Manual</publisher-name>
<publisher-loc>San Antonio, TX, Psychological Corporation</publisher-loc>, <year>2000</year></mixed-citation>
      </ref>
      <ref id="B35">
        <label>35</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wechsler</surname><given-names>D</given-names></name></person-group>
<source>Wechsler Memory Scale (WMS-III)</source>. <publisher-loc>San Antonio, TX</publisher-loc>, <publisher-name>Psychological Corporation</publisher-name>, <year>1997</year></mixed-citation>
      </ref>
      <ref id="B36">
        <label>36</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Golden</surname><given-names>CJ</given-names></name></person-group>
<source>Stroop Color and Word Test: A Manual for Clinical and Experimental Uses</source>. <publisher-loc>Chicago, IL</publisher-loc>, <publisher-name>Stoelting</publisher-name>, <year>1978</year></mixed-citation>
      </ref>
      <ref id="B37">
        <label>37</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wechsler</surname><given-names>D</given-names></name></person-group>
<source>Wechsler Adult Intelligence Scale–Third Edition (WAIS-III): Administration and Scoring Manual</source>. <publisher-loc>San Antonio, TX</publisher-loc>, <publisher-name>Psychological Corporation</publisher-name>, <year>1997</year></mixed-citation>
      </ref>
      <ref id="B38">
        <label>38</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Delis</surname><given-names>DC</given-names></name><name><surname>Kaplan</surname><given-names>E</given-names></name><name><surname>Kramer</surname><given-names>JH</given-names></name></person-group>
<source>Delis-Kaplan Executive Function System (D-KEFS)</source>. <publisher-loc>San Antonio, TX</publisher-loc>, <publisher-name>Psychological Corporation</publisher-name>, <year>2001</year></mixed-citation>
      </ref>
      <ref id="B39">
        <label>39</label>
        <mixed-citation publication-type="book"><source>Army Individual Test Battery: Manual of Directions and Scoring</source>. <publisher-loc>Washington, DC</publisher-loc>, <publisher-name>War Department, Adjutant General’s Office</publisher-name>, <year>1944</year></mixed-citation>
      </ref>
      <ref id="B40">
        <label>40</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrides</surname><given-names>M</given-names></name><name><surname>Alivisatos</surname><given-names>B</given-names></name><name><surname>Frey</surname><given-names>S</given-names></name></person-group>. <article-title>Differential activation of the human orbital, mid-ventrolateral, and mid-dorsolateral prefrontal cortex during the processing of visual stimuli</article-title>. <source>Proc Natl Acad Sci U S A</source>
<year>2002</year>;<volume>99</volume>:<fpage>5649</fpage>–<lpage>5654</lpage><?supplied-pmid 11960018?><pub-id pub-id-type="pmid">11960018</pub-id></mixed-citation>
      </ref>
      <ref id="B41">
        <label>41</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>SA</given-names></name><name><surname>Farrell</surname><given-names>JA</given-names></name><name><surname>Jones</surname><given-names>CK</given-names></name><name><surname>Reich</surname><given-names>DS</given-names></name><name><surname>Calabresi</surname><given-names>PA</given-names></name><name><surname>van Zijl</surname><given-names>PC</given-names></name></person-group>. <article-title>Pulsed magnetization transfer imaging with body coil transmission at 3 Tesla: feasibility and application</article-title>. <source>Magn Reson Med</source>
<year>2006</year>;<volume>56</volume>:<fpage>866</fpage>–<lpage>875</lpage><?supplied-pmid 16964602?><pub-id pub-id-type="pmid">16964602</pub-id></mixed-citation>
      </ref>
      <ref id="B42">
        <label>42</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>Y</given-names></name><name><surname>Hochberg</surname><given-names>Y</given-names></name></person-group>
<article-title>Controlling the false discovery rate: a practical and powerful approach to multiple testing</article-title>. <source>J R Stat Soc B</source>
<year>1995</year>;<volume>57</volume>:<fpage>289</fpage>–<lpage>300</lpage></mixed-citation>
      </ref>
      <ref id="B43">
        <label>43</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>Y</given-names></name><name><surname>Hochberg</surname><given-names>Y</given-names></name></person-group>
<article-title>On the adaptive control of the false discovery rate in multiple testing with independent statistics</article-title>. <source>J Educ Behav Stat</source>
<year>2000</year>;<volume>25</volume>:<fpage>60</fpage>–<lpage>83</lpage></mixed-citation>
      </ref>
      <ref id="B44">
        <label>44</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>Y</given-names></name><name><surname>Krieger</surname><given-names>AM</given-names></name><name><surname>Yekutieli</surname><given-names>D</given-names></name></person-group>
<article-title>Adaptive linear step-up procedures that control the false discovery rate</article-title>. <source>Biometrika</source>
<year>2006</year>;<volume>93</volume>:<fpage>491</fpage>–<lpage>507</lpage></mixed-citation>
      </ref>
      <ref id="B45">
        <label>45</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>LH</given-names></name><name><surname>Zhou</surname><given-names>XJ</given-names></name><name><surname>Fitzgerald</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Microstructural abnormalities of white matter differentiate pediatric and adult-onset bipolar disorder</article-title>. <source>Bipolar Disord</source>
<year>2012</year>;<volume>14</volume>:<fpage>597</fpage>–<lpage>606</lpage><?supplied-pmid 22882719?><pub-id pub-id-type="pmid">22882719</pub-id></mixed-citation>
      </ref>
      <ref id="B46">
        <label>46</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beasley</surname><given-names>CL</given-names></name><name><surname>Dwork</surname><given-names>AJ</given-names></name><name><surname>Rosoklija</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Metabolic abnormalities in fronto-striatal-thalamic white matter tracts in schizophrenia</article-title>. <source>Schizophr Res</source>
<year>2009</year>;<volume>109</volume>:<fpage>159</fpage>–<lpage>166</lpage><?supplied-pmid 19272755?><pub-id pub-id-type="pmid">19272755</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:4274800</identifier><datestamp>2016-01-01</datestamp><setSpec>diabetes</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="http://jats.nlm.nih.gov/ns/archiving/1.0/ http://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Diabetes</journal-id>
      <journal-id journal-id-type="iso-abbrev">Diabetes</journal-id>
      <journal-id journal-id-type="hwp">diabetes</journal-id>
      <journal-id journal-id-type="pmc">diabetes</journal-id>
      <journal-id journal-id-type="publisher-id">Diabetes</journal-id>
      <journal-title-group>
        <journal-title>Diabetes</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0012-1797</issn>
      <issn pub-type="epub">1939-327X</issn>
      <publisher>
        <publisher-name>American Diabetes Association</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4274800</article-id>
      <article-id pub-id-type="pmcid">PMC4274800</article-id>
      <article-id pub-id-type="pmc-uid">4274800</article-id>
      <article-id pub-id-type="pmid">25071025</article-id>
      <article-id pub-id-type="publisher-id">1070</article-id>
      <article-id pub-id-type="doi">10.2337/db13-1070</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Metabolism</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Compartmentalized Acyl-CoA Metabolism in Skeletal Muscle Regulates Systemic Glucose Homeostasis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Lei O.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Grevengoed</surname>
            <given-names>Trisha J.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Paul</surname>
            <given-names>David S.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ilkayeva</surname>
            <given-names>Olga</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Koves</surname>
            <given-names>Timothy R.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pascual</surname>
            <given-names>Florencia</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Newgard</surname>
            <given-names>Christopher B.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Muoio</surname>
            <given-names>Deborah M.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Coleman</surname>
            <given-names>Rosalind A.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
        <aff id="aff1"><sup>1</sup>Department of Nutrition, University of North Carolina, Chapel Hill, NC</aff>
        <aff id="aff2"><sup>2</sup>Sarah W. Stedman Nutrition and Metabolism Center, and Departments of Medicine and Pharmacology and Cancer Biology, Duke University, Durham, NC</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">Corresponding author: Rosalind A. Coleman, <email>rcoleman@unc.edu</email>.</corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>28</day>
        <month>7</month>
        <year>2014</year>
      </pub-date>
      <volume>64</volume>
      <issue>1</issue>
      <fpage>23</fpage>
      <lpage>35</lpage>
      <history>
        <date date-type="received">
          <day>08</day>
          <month>7</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>23</day>
          <month>7</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.</copyright-statement>
        <copyright-year>2015</copyright-year>
      </permissions>
      <self-uri xlink:title="pdf" xlink:type="simple" xlink:href="23.pdf"/>
      <abstract>
        <p>The impaired capacity of skeletal muscle to switch between the oxidation of fatty acid (FA) and glucose is linked to disordered metabolic homeostasis. To understand how muscle FA oxidation affects systemic glucose, we studied mice with a skeletal muscle–specific deficiency of long-chain acyl-CoA synthetase (ACSL)1. ACSL1 deficiency caused a 91% loss of ACSL-specific activity and a 60–85% decrease in muscle FA oxidation. <italic>Acsl1<sup>M−/−</sup></italic> mice were more insulin sensitive, and, during an overnight fast, their respiratory exchange ratio was higher, indicating greater glucose use. During endurance exercise, <italic>Acsl1<sup>M−/−</sup></italic> mice ran only 48% as far as controls. At the time that <italic>Acsl1<sup>M−/−</sup></italic> mice were exhausted but control mice continued to run, liver and muscle glycogen and triacylglycerol stores were similar in both genotypes; however, plasma glucose concentrations in <italic>Acsl1<sup>M−/−</sup></italic> mice were ∼40 mg/dL, whereas glucose concentrations in controls were ∼90 mg/dL. Excess use of glucose and the likely use of amino acids for fuel within muscle depleted glucose reserves and diminished substrate availability for hepatic gluconeogenesis. Surprisingly, the content of muscle acyl-CoA at exhaustion was markedly elevated, indicating that acyl-CoAs synthesized by other ACSL isoforms were not available for β-oxidation. This compartmentalization of acyl-CoAs resulted in both an excessive glucose requirement and severely compromised systemic glucose homeostasis.</p>
      </abstract>
      <counts>
        <page-count count="13"/>
      </counts>
    </article-meta>
  </front>
  <body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Skeletal muscle switches between the use of glucose and lipid, depending on fuel availability and energy requirements. Metabolic inflexibility, a state of impaired capacity for fuel switching between fatty acids (FAs) and glucose (<xref rid="B1" ref-type="bibr">1</xref>), is associated with metabolic disorders such as insulin resistance, diabetes, and the cardiometabolic syndrome (<xref rid="B2" ref-type="bibr">2</xref>–<xref rid="B5" ref-type="bibr">5</xref>), whereas enhanced oxidation of FA spares glucose (<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B7" ref-type="bibr">7</xref>). Metabolic inflexibility occurs in human disorders in which β-oxidation is genetically impaired; these disorders are associated with hepatic steatosis, myopathy, cardiomyopathy, and episodes of fasting-induced nonketotic hypoglycemia (<xref rid="B8" ref-type="bibr">8</xref>). However, it remains uncertain how fuel selection is regulated in skeletal muscle and how fuel inflexibility specifically impairs exercise tolerance and leads to metabolic dysfunction (<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B9" ref-type="bibr">9</xref>).</p><p>Before FAs are used for oxidation or for the synthesis of cholesterol esters, phospholipids, or triacylglycerol (TAG), they must be activated to form acyl-CoAs by one of a family of five long-chain acyl-CoA synthetases (ACSLs), each encoded by a separate gene (<xref rid="B10" ref-type="bibr">10</xref>). We have proposed that each ACSL isoform determines whether FAs are channeled toward pathways of oxidation or complex lipid biosynthesis (<xref rid="B11" ref-type="bibr">11</xref>). Data from ACSL1 deficiencies in adipose, liver, heart, or macrophages suggest that channeling is tissue-specific, but that in highly oxidative tissues, the ACSL1 isoform directs FAs toward β-oxidation (<xref rid="B11" ref-type="bibr">11</xref>–<xref rid="B14" ref-type="bibr">14</xref>). Thus, mice deficient in brown adipose ACSL1 cannot metabolize FAs for heat production and fail to maintain a normal body temperature when placed in a cold environment (<xref rid="B13" ref-type="bibr">13</xref>). Likewise, hearts that lack ACSL1 cannot oxidize FAs for contractile energy, have an eightfold increased use of glucose, and develop mammalian target of rapamycin complex 1–mediated hypertrophy (<xref rid="B14" ref-type="bibr">14</xref>).</p><p>ACSL1 is located on the mitochondrial outer membrane, but it is unclear why its absence would block FA oxidation; acyl-CoAs are amphipathic molecules that are both soluble in water and able to integrate into membrane monolayers via their hydrophobic acyl chains. In addition, acyl-CoA binding protein and some isoforms of FA binding protein can bind and carry acyl-CoAs. Thus, an acyl-CoA should be able to enter any downstream pathway, unless the entry into one specific pathway versus another depend on the relative substrate affinities of the initiating acyltransferases.</p><p>The role of any ACSL isoform in skeletal muscle remains unknown (<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B15" ref-type="bibr">15</xref>). Given the importance of lipid metabolism in skeletal muscle and the key position of ACSL in initiating most lipid metabolic pathways, we hypothesized that a deficiency of ACSL1 would block the use of FAs for energy, thereby impairing fuel selection during exercise. To learn whether ACSL1 deficiency in skeletal muscle impairs exercise capacity or alters whole-body fuel metabolism, we studied the metabolic adaptation of skeletal muscle–specific <italic>Acsl1</italic> knockout mice (<italic>Acsl1<sup>M−/−</sup></italic>) to physiological challenges. Unexpectedly, acyl-CoA content rose markedly during exercise, revealing that acyl-CoAs synthesized by non-ACSL1 isoforms were retained in a pool that was inaccessible for mitochondrial oxidation.</p></sec><sec id="s2"><title>Research Design and Methods</title><sec id="s3"><title>Muscle-Specific <italic>Acsl1</italic> Knockout Mice</title><p>Homozygous floxed mice (<italic>Acsl1</italic><sup>loxP/loxP</sup>) (<xref rid="B12" ref-type="bibr">12</xref>) were mated with mice expressing Cre recombinase controlled by the muscle-specific human skeletal actin (HSA) promoter (catalog #006149; The Jackson Laboratory) to achieve muscle-specific deletion of <italic>Acsl1</italic>. HSA-Cre is expressed in the early embryo (<xref rid="B16" ref-type="bibr">16</xref>), and mice were born with deficient ACSL1. <italic>Acsl1<sup>M−/−</sup></italic> (<italic>Acsl1<sup>loxP/loxP</sup>-HSACre</italic>) were mated with <italic>Acsl1<sup>loxP/loxP</sup></italic> mice to obtain <italic>Acsl1<sup>M−/−</sup></italic> and littermate controls (<italic>Acsl1<sup>loxP/loxP</sup></italic>). Because most measurements were qualitatively similar in male and female <italic>Acsl1<sup>M−/−</sup></italic> mice compared with controls, we report measurements from only one sex. Procedures were approved by the University of North Carolina Institutional Animal Care and Use Committee. Mice were kept in a pathogen-free barrier facility (12-h dark/light cycle) and fed standard chow (Prolab RMH 3000; LabDiet, Richmond, IN). Between 8 and 25 weeks of age, some mice were fed a high-fat diet (45%; D12451) or a matched low-fat (10%; D12450B) standard diet (Research Diets). Oral glucose (2.5 g <sc>d</sc>-glucose/kg body wt) and intraperitoneal insulin tolerance tests (control diet 0.35 units/kg body wt; high-fat diet 0.50 units/kg body wt) (<xref rid="B12" ref-type="bibr">12</xref>) and glycerol tolerance tests (2 mg/kg body wt) (<xref rid="B17" ref-type="bibr">17</xref>) were performed.</p><p>Metabolic analysis was performed in PhenoMaster/LabMaster chambers (TSE Systems, Chesterfield, MO). After 24 h of acclimatization, measurements were acquired every 27 min for <italic>V</italic><sc>O</sc><sub>2</sub>, <italic>V</italic><sc>CO</sc><sub>2</sub>, respiratory exchange ratio (RER), food intake, and physical activity.</p></sec><sec id="s4"><title>Endurance Exercise</title><p>Mice (16–26 weeks of age) were acclimatized to a motorized, speed–controlled treadmill with an electric shock stimulus (Exer-3/6; Columbus Instruments, Columbus, OH) for 3 consecutive days, starting from 0 to 16 m/min and from 0 to 10% grade. On the study day, mice were fasted for 2 h after 10:00 <sc>a.m.</sc> (“rested” state) to prevent potential carbohydrate-induced increases in insulin with a subsequent decrease in adipose lipolysis (<xref rid="B18" ref-type="bibr">18</xref>). Speed was increased from 8 m/min by 2 m/min every 15 min until reaching 18 m/min. Mice were maintained at this speed until they refused to run. Tail blood was taken for measurement of glucose and lactate levels. For measurement of plasma metabolites and tissue glycogen, trunk blood and tissues were collected at exhaustion. Blood and tissues were taken from additional control mice after they had run for the same length of time as the exhausted <italic>Acsl1<sup>M−/−</sup></italic> mice.</p></sec><sec id="s5"><title>Metabolites, Western Blot Analysis, and Histology</title><p>Mice were fasted for 4 h (basal state) or 17 h. Plasma metabolites were measured colorimetrically (glucose, nonesterified FA; Wako, Richmond, VA; triglyceride; Stanbio Laboratory, Elkhart, IN) or enzymatically (β-hydroxybutyrate, creatine kinase; Stanbio Laboratory), with a mouse insulin ELISA kit (Millipore, Billerica, MA) or with a lactometer (Lactate Plus; Nova Biomedical, Waltham, MA). Glycogen was measured in snap-frozen tissues (<xref rid="B19" ref-type="bibr">19</xref>). TAG was measured in tissue lipid extracts (Stanbio Laboratory) (<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B21" ref-type="bibr">21</xref>). Gastrocnemius muscle was fixed and stained (<xref rid="B22" ref-type="bibr">22</xref>).</p><p>Tissue proteins were blotted with primary antibodies to detect ACSL1, Akt, and pAkt (Cell Signaling Technology, Danvers, MA); ACSL4 (Santa Cruz Biotechnology, Santa Cruz, CA); and GLUT1 and GAPDH (Abcam, Cambridge, MA).</p></sec><sec id="s6"><title>Insulin Signaling</title><p>Mice were injected with PBS or insulin (2 units/kg body wt i.p.). Glucose was measured by glucometer to ensure adequate lowering. Ten minutes later, tissue supernatants were prepared, electrophoresed, and blotted for antiphospho-Akt (Thr-308) and total Akt (Cell Signaling Technology) (<xref rid="B20" ref-type="bibr">20</xref>).</p></sec><sec id="s7"><title>Quantitative PCR</title><p>Genomic/mitochondrial DNA and total RNA were extracted from tissues (TRIzol; Invitrogen, Carlsbad, CA; AllPrep DNA/RNA kit; Qiagen, Valencia, CA). cDNA was synthesized (Applied Biosystems). Gene expression and mitochondrial DNA content were determined with Absolute QPCR Sybr Green Fluorescein Mix (Thermo Scientific, West Palm Beach, FL). Expression of target genes (<ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1070/-/DC1">Supplementary Table 1</ext-link>) was normalized to endogenous β-actin, tubulin, or H19 and calculated using the 2<sup>−ΔΔCt</sup> method (<xref rid="B23" ref-type="bibr">23</xref>).</p></sec><sec id="s8"><title>ACSL Activity, FA Oxidation, and Metabolomics</title><p>ACSL-specific activity was measured in tissue homogenates from 13- to 16-week-old mice (<xref rid="B24" ref-type="bibr">24</xref>). CO<sub>2</sub> and acid soluble metabolites (ASM) were measured from gastrocnemius homogenates incubated for 30 min in 100 mmol/L KCl, 40 mmol/L Tris-HCl, 10 mmol/L Tris base, 5 mmol/L MgCl<sub>2</sub>⋅6H<sub>2</sub>O, 1 mmol/L EDTA, and 1 mmol/L ATP, pH 7.4, and [1-<sup>14</sup>C]palmitate or [1-<sup>14</sup>C]palmitoyl-CoA (<xref rid="B25" ref-type="bibr">25</xref>). Amino acids, acyl-carnitines, acyl-CoAs, and ceramides were analyzed by flow injection tandem mass spectrometry (<xref rid="B26" ref-type="bibr">26</xref>,<xref rid="B27" ref-type="bibr">27</xref>). Organic acids were analyzed by gas chromatography–mass spectrometry (<xref rid="B27" ref-type="bibr">27</xref>).</p><p>For whole-muscle incubations, soleus and extensor digitorum longus muscles were removed (fed state) and incubated (<xref rid="B28" ref-type="bibr">28</xref>) with gassing in Krebs-Henseleit buffer, 5 mmol/L <sc>d</sc>-glucose, 1 mmol/L <sc>l</sc>-carnitine, 12.5 mmol/L HEPES, and 1% BSA. Media were changed after 30 min. Contralateral muscles were incubated with 1 mmol/L [1-<sup>14</sup>C]oleate (2 μCi/ml) or with 5 mmol/L [U-<sup>14</sup>C]glucose (2 μCi/ml), 100 nmol/L insulin, and 0.75 mmol/L palmitate for 90 min. Media were transferred to culture tubes containing 1 N NaOH CO<sub>2</sub> traps. <sup>14</sup>CO<sub>2</sub> and [<sup>14</sup>C]ASM were assessed (<xref rid="B28" ref-type="bibr">28</xref>).</p></sec><sec id="s9"><title>Statistics</title><p>Data were analyzed using a two-tailed Student <italic>t</italic> test or two-way ANOVA where appropriate (SAS, Inc.) and were expressed as means ± SE. Statistical significance was defined as <italic>P</italic> &lt; 0.05.</p></sec></sec><sec sec-type="results" id="s10"><title>Results</title><sec id="s11"><title>FA Oxidation Was Severely Diminished in <italic>Acsl1<sup>M−/−</sup></italic> Skeletal Muscle</title><p>In <italic>Acsl1<sup>M−/−</sup></italic> mice, weight and activity did not differ from those in littermate controls, and female reproduction was normal. ACSL1 protein was absent in <italic>Acsl1<sup>M−/−</sup></italic> gastrocnemius muscle but was present in the heart (<xref ref-type="fig" rid="F1">Fig. 1<italic>A</italic></xref>) and liver (<ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1070/-/DC1">Supplementary Fig. 1<italic>A</italic></ext-link>). <italic>Acsl1</italic> mRNA expression in gastrocnemius muscle was 86% lower than that in controls, with no compensatory increases in other ACSL isoforms (<xref ref-type="fig" rid="F1">Fig. 1<italic>B</italic></xref>). Compared with controls, the mRNA content of <italic>Acsl4</italic> was 30% lower in <italic>Acsl1<sup>M−/−</sup></italic> gastrocnemius muscle and 35% higher in soleus muscle (<ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1070/-/DC1">Supplementary Fig. 1<italic>B</italic></ext-link>), but ACSL4 gastrocnemius muscle protein content was unchanged (<ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1070/-/DC1">Supplementary Fig. 1<italic>C</italic></ext-link>). ACSL-specific activity was unchanged in the heart but was diminished by &gt;90% in <italic>Acsl1<sup>M−/−</sup></italic> gastrocnemius muscle (<xref ref-type="fig" rid="F1">Fig. 1<italic>C</italic></xref>). Residual ACSL activity represents the combined activities of all remaining ACSL isoforms. These data show that ACSL1 contributes the majority of total ACSL activity in skeletal muscle.</p><fig id="F1" fig-type="figure" position="float"><label>Figure 1</label><caption><p>ACSL1 deficiency decreased ACSL-specific activity and FA oxidation in skeletal muscle. <italic>A</italic>: ACSL1 protein in the gastrocnemius muscle and heart in <italic>Acsl1<sup>M−/−</sup></italic> and control mice. <italic>B</italic>: mRNA expression of <italic>Acsl1</italic> isoforms in gastrocnemius relative to tubulin (males; <italic>n</italic> = 8). <italic>C</italic>: ACSL-specific activity in homogenates from the gastrocnemius muscle and heart (<italic>n</italic> = 4). Histology (×20) of control (<italic>D</italic>) and <italic>Acsl1<sup>M−/−</sup></italic> (<italic>E</italic>) gastrocnemius. Thin arrows, central nuclei; thick arrow, macrophage infiltration. FA oxidation in homogenates from gastrocnemius and soleus muscle from [1-<sup>14</sup>C]palmitate (<italic>F</italic>) or [<sup>14</sup>C]palmitoyl-CoA (<italic>G</italic>) (<italic>n</italic> = 3–4). Oxidation (<italic>H</italic>) or incorporation (<italic>I</italic>) in isolated soleus or extensor digitorum longus with [<sup>14</sup>C]16:0, or with [<sup>14</sup>C]glucose (<italic>J</italic>) (<italic>n</italic> = 5). *<italic>P</italic> &lt; 0.05, compared with control littermates. EDL, extensor digitorum longus; Gastroc, gastrocnemius.</p></caption><graphic xlink:href="23fig1"/></fig><p>Deficiency of ACSL1 caused a mild myopathy with occasional central nuclei and cells surrounded by macrophages (<xref ref-type="fig" rid="F1">Fig. 1<italic>D</italic> and <italic>E</italic></xref>), but plasma creatine kinase activity was not statistically elevated (<xref ref-type="table" rid="T1">Table 1</xref>). Compared with controls, the sum of complete oxidation of [1-<sup>14</sup>C]palmitate to CO<sub>2</sub> plus incomplete oxidation to ASM was 83% and 63% lower, respectively, in <italic>Acsl1<sup>M−/−</sup></italic> gastrocnemius and soleus muscles (<xref ref-type="fig" rid="F1">Fig. 1<italic>F</italic></xref>). Unimpaired oxidation of [<sup>14</sup>C]palmitoyl-CoA to CO<sub>2</sub> (<xref ref-type="fig" rid="F1">Fig. 1<italic>G</italic></xref>) and the presence of normal mitochondrial DNA content (<ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1070/-/DC1">Supplementary Fig. 1<italic>D</italic></ext-link>) indicated that ACSL1 deficiency did not block the downstream FA oxidation pathway or diminish mitochondrial respiratory function. The significant decrease in FA oxidation in <italic>Acsl1<sup>M−/−</sup></italic> muscle suggests that the ACSL1 isoform is required to activate FAs before they can be converted to acyl-carnitines, enter the mitochondrial matrix, and undergo β-oxidation; in contrast, acyl-CoAs were oxidized.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Metabolic parameters of <italic>Acsl1<sup>M</sup><sup>−</sup><sup>/</sup><sup>−</sup></italic> mice before and during endurance exercise</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th align="left" scope="col" rowspan="1" colspan="1">Metabolic parameters</th><th align="center" scope="col" rowspan="1" colspan="1">Resting control mice (<italic>n</italic> = 4–6)</th><th align="center" scope="col" rowspan="1" colspan="1">Resting <italic>Acsl1<sup>M−/− </sup></italic>mice (<italic>n</italic> = 6–11)</th><th align="center" scope="col" rowspan="1" colspan="1">Running control mice (<italic>n</italic> = 5)</th><th align="center" scope="col" rowspan="1" colspan="1">Exhausted control mice (<italic>n</italic> = 6–7)</th><th align="center" scope="col" rowspan="1" colspan="1">Exhausted <italic>Acsl1<sup>M−/− </sup></italic>mice (<italic>n</italic> = 6–13)</th></tr></thead><tbody><tr><td align="left" scope="col" rowspan="1" colspan="1">Plasma</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> TAG (mg/dL)</td><td align="center" rowspan="1" colspan="1">38.0 ± 3.6</td><td align="center" rowspan="1" colspan="1">34.9 ± 2.9</td><td align="center" rowspan="1" colspan="1">75.6 ± 5.3</td><td align="center" rowspan="1" colspan="1">73.1 ± 4.4<xref ref-type="table-fn" rid="t1n2">†</xref></td><td align="center" rowspan="1" colspan="1">52.7 ± 3.9<xref ref-type="table-fn" rid="t1n1">*</xref><xref ref-type="table-fn" rid="t1n2">†</xref></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> NEFA (mmol/L)</td><td align="center" rowspan="1" colspan="1">0.17 ± 0.03</td><td align="center" rowspan="1" colspan="1">0.28 ± 0.04<xref ref-type="table-fn" rid="t1n1">*</xref></td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.28 ± 0.02<xref ref-type="table-fn" rid="t1n2">†</xref></td><td align="center" rowspan="1" colspan="1">1.32 ± 0.10<xref ref-type="table-fn" rid="t1n2">†</xref></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> β-Hydroxybutyrate (mmol/L)</td><td align="center" rowspan="1" colspan="1">0.33 ± 0.03</td><td align="center" rowspan="1" colspan="1">0.35 ± 0.05</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.99 ± 0.20<xref ref-type="table-fn" rid="t1n2">†</xref></td><td align="center" rowspan="1" colspan="1">0.83 ± 0.06<xref ref-type="table-fn" rid="t1n2">†</xref></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Creatine kinase (units/L/min)</td><td align="center" rowspan="1" colspan="1">134 ± 6</td><td align="center" rowspan="1" colspan="1">248 ± 11<xref ref-type="table-fn" rid="t1n3">‡</xref></td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2347 ± 376<xref ref-type="table-fn" rid="t1n2">†</xref></td><td align="center" rowspan="1" colspan="1">2325 ± 183<xref ref-type="table-fn" rid="t1n2">†</xref></td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Liver</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Glycogen (μmol/g wet wt)</td><td align="center" rowspan="1" colspan="1">62.2 ± 14.7</td><td align="center" rowspan="1" colspan="1">40.1 ± 12.5</td><td align="center" rowspan="1" colspan="1">8.79 ± 0.96</td><td align="center" rowspan="1" colspan="1">9.32 ± 1.52<xref ref-type="table-fn" rid="t1n2">†</xref></td><td align="center" rowspan="1" colspan="1">7.77 ± 0.52<xref ref-type="table-fn" rid="t1n2">†</xref></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> TAG (μg/mg wet wt)</td><td align="center" rowspan="1" colspan="1">15.7 ± 1.5</td><td align="center" rowspan="1" colspan="1">15.6 ± 2.1</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">36.9 ± 3.0<xref ref-type="table-fn" rid="t1n2">†</xref></td><td align="center" rowspan="1" colspan="1">22.4 ± 3.0<xref ref-type="table-fn" rid="t1n1">*</xref><xref ref-type="table-fn" rid="t1n2">†</xref></td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Muscle</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Glycogen (μmol/g wet wt)</td><td align="center" rowspan="1" colspan="1">13.7 ± 1.2</td><td align="center" rowspan="1" colspan="1">15.6 ± 1.3</td><td align="center" rowspan="1" colspan="1">BD</td><td align="center" rowspan="1" colspan="1">BD<xref ref-type="table-fn" rid="t1n2">†</xref></td><td align="center" rowspan="1" colspan="1">BD<xref ref-type="table-fn" rid="t1n2">†</xref></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> TAG (μg/mg wet wt)</td><td align="center" rowspan="1" colspan="1">4.34 ± 0.57</td><td align="center" rowspan="1" colspan="1">3.60 ± 0.35</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2.65 ± 0.54<xref ref-type="table-fn" rid="t1n2">†</xref></td><td align="center" rowspan="1" colspan="1">2.70 ± 0.44</td></tr></tbody></table><table-wrap-foot><fn><p>Data are represented as the mean ± SE.</p></fn><fn><p>BD, below detectable concentration; NEFA, nonesterified FA; Resting, data before exercise and after 2 h without food; Running control, data from control mice at the time when their <italic>Acsl1<sup>M−/−</sup></italic> littermates were exhausted.</p></fn><fn id="t1n1"><p>*<italic>P</italic> &lt; 0.05, <italic>Acsl1<sup>M−/−</sup></italic> compared with control littermates (same conditions).</p></fn><fn id="t1n2"><p>†<italic>P</italic> &lt; 0.05, compared with resting state (same genotype).</p></fn><fn id="t1n3"><p>‡<italic>P</italic> = 0.53.</p></fn></table-wrap-foot></table-wrap><p>Because the preparation of homogenates or isolated mitochondria alters normal organelle relationships, we performed additional studies in permeabilized muscle fibers. FA oxidation in permeabilized fibers was only 1% of the oxidation in homogenates (compare <xref ref-type="fig" rid="F1">Fig. 1<italic>F</italic> and <italic>H</italic></xref>), and neither glucose nor FA oxidation or FA incorporation into complex lipids was impaired (<xref ref-type="fig" rid="F1">Fig. 1<italic>I</italic> and <italic>J</italic></xref>), suggesting that maximal FA transport, similar to that of glucose, may require specific transporters or ACSL isoforms that are activated by muscle contraction. Experiments using homogenates or isolated mitochondria would eliminate the transport step and permit ACSL1 to directly activate FAs and allow them to be converted to acyl-carnitines for mitochondrial entry. Alternatively, in static muscle, perhaps only very small amounts of FA enter the mitochondria for oxidation, and these small amounts of acyl-CoAs are supplied by non–ACSL1 isoforms such as ACSL5, which is also present on the outer mitochondrial membrane (<xref rid="B10" ref-type="bibr">10</xref>).</p></sec><sec id="s12"><title>ACSL1 Deficiency in Muscle Impairs Fasting Glucose Homeostasis</title><p>To examine how the limitation in skeletal muscle FA oxidation affects whole-body energy metabolism, we challenged <italic>Acsl1<sup>M−/−</sup></italic> mice with an overnight fast, a state in which FAs released from adipose become the major fuel source for most organs. <italic>Acsl1<sup>M−/−</sup></italic> mice became mildly hypoglycemic (plasma glucose level: 82 ± 6 mg/dL vs. 137 ± 24 mg/dL in controls) (<xref ref-type="fig" rid="F2">Fig. 2<italic>A</italic></xref>). Compared with controls, basal plasma FA concentrations were 64% higher in <italic>Acsl1<sup>M−/−</sup></italic> mice and rose further after an overnight fast (0.58 ± 0.04 vs. 0.25 ± 0.05 mmol/L, respectively) (<xref ref-type="fig" rid="F2">Fig. 2<italic>B</italic></xref>). After fasting, the plasma TAG level was 46% higher in <italic>Acsl1<sup>M−/−</sup></italic> mice (<xref ref-type="fig" rid="F2">Fig. 2<italic>C</italic></xref>), and the plasma β-hydroxybutyrate level was 71% higher (<xref ref-type="fig" rid="F2">Fig. 2<italic>D</italic></xref>), consistent with increased hepatic β-oxidation of FA. Compared with fasting controls, fasting <italic>Acsl1<sup>M−/−</sup></italic> mice stored 53% more TAG in the liver (<xref ref-type="fig" rid="F2">Fig. 2<italic>E</italic> and <italic>F</italic></xref>), suggesting that the inability of <italic>Acsl1<sup>M−/−</sup></italic> muscle to metabolize FA caused adipose-derived FAs to relocate to the liver for re-esterification and storage (<xref rid="B29" ref-type="bibr">29</xref>,<xref rid="B30" ref-type="bibr">30</xref>).</p><fig id="F2" fig-type="figure" position="float"><label>Figure 2</label><caption><p><italic>Acsl1<sup>M−/−</sup></italic> mice were more vulnerable to hypoglycemia and hepatic lipid accumulation after an overnight fast and required less insulin to maintain euglycemia. Plasma glucose (<italic>A</italic>), nonesterified FAs (NEFAs) (<italic>B</italic>), TAG (<italic>C</italic>), and β-hydroxybutyrate (<italic>D</italic>) in female <italic>Acsl1<sup>M−/−</sup></italic> after food removal for 4 h (<italic>n</italic> = 9–11) or fasting overnight (O/N) (<italic>n</italic> = 7–17). <italic>E</italic>: Histology of representative liver slides from female control and <italic>Acsl1<sup>M−/−</sup></italic> mice after an overnight fast (hematoxylin-eosin staining). Measurement after an overnight fast of liver TAG (<italic>F</italic>) and glycogen (<italic>G</italic>) content (<italic>n</italic> = 4–8). <italic>H</italic>: Gene expression of glucose-6-phosphatase (G6Pase), phosphoenolpyruvate (PEPCK), and hydroxymethylglutaryl-CoA synthase-2 (HMGS2) in male mice (<italic>n</italic> = 6–10). <italic>I</italic>: Glycerol tolerance test in male mice after an overnight fast (<italic>n</italic> = 4). <italic>J</italic>: GLUT1 protein in gastrocnemius muscle (<italic>n</italic> = 4–5). In control and <italic>Acsl1<sup>M−/−</sup></italic> female mice fed a high-fat diet (HFD) or matched standard diet (SD): glucose tolerance (<italic>K</italic>); blood glucose and insulin levels before and 15 min after intraperitoneal administration of insulin (<italic>L</italic>); and insulin tolerance tests and areas above the curve (AAC) after food removal for 4 h (<italic>M</italic>). <italic>N</italic>: pAkt (T308) and total Akt in female liver and gastrocnemius muscle 10 min after intraperitoneal PBS or insulin. C, control mice; K, knockout mice. #<italic>P</italic> &lt; 0.05, vs. 4-h state (same genotype); *<italic>P</italic> &lt; 0.05, vs. control (same treatment).</p></caption><graphic xlink:href="23fig2"/></fig><p>Overnight fasting depleted liver glycogen stores in both control and knockout mice (<xref ref-type="fig" rid="F2">Fig. 2<italic>G</italic></xref>). Although mRNA abundance of glucose-6-phophatase and phosphoenolpyruvate carboxykinase increased similarly in both genotypes (<xref ref-type="fig" rid="F2">Fig. 2<italic>H</italic></xref>), which is consistent with appropriate gluconeogenic upregulation, this upregulation was insufficient to counteract hypoglycemia in <italic>Acsl1<sup>M−/−</sup></italic> mice, probably because of diminished substrate availability since a glycerol tolerance test showed enhanced gluconeogenesis (<xref ref-type="fig" rid="F2">Fig. 2<italic>I</italic></xref>). The gastrocnemius muscle of <italic>Acsl1<sup>M−/−</sup></italic> mice contained more GLUT1 protein (<xref ref-type="fig" rid="F2">Fig. 2<italic>J</italic></xref>). Weight gain, body composition (<ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1070/-/DC1">Supplementary Fig. 2</ext-link>), and glucose tolerance test results showed no genotype differences in mice fed control or high-fat diets (<xref ref-type="fig" rid="F2">Fig. 2<italic>K</italic></xref>), but less insulin was secreted by <italic>Acsl1<sup>M−/−</sup></italic> mice (<xref ref-type="fig" rid="F2">Fig. 2<italic>L</italic></xref>). Enhanced insulin sensitivity was confirmed by insulin tolerance tests (<xref ref-type="fig" rid="F2">Fig. 2<italic>M</italic></xref>), high basal pAkt (T308) levels in the liver, and increased pAkt levels in the liver and gastrocnemius muscle after insulin injection (<xref ref-type="fig" rid="F2">Fig. 2<italic>N</italic></xref>). Taken together, these data show that, during fasting, the inability of <italic>Acsl1<sup>M−/−</sup></italic> skeletal muscle to switch from glucose to FA use resulted in an overflow of FAs to plasma and liver, thereby increasing liver TAG and plasma VLDL levels, diminishing plasma glucose levels, and increasing insulin sensitivity.</p></sec><sec id="s13"><title>Metabolic Inflexibility During Fasting</title><p>The RER (<italic>V</italic><sc>CO</sc><sub>2</sub>/<italic>V</italic><sc>O</sc><sub>2</sub>) was consistent with impaired fuel switching from glucose to FA oxidation in <italic>Acsl1<sup>M−/−</sup></italic> muscle (<xref ref-type="fig" rid="F3">Fig. 3<italic>A</italic></xref>). The RER did not differ between genotypes when mice were fed chow (60% carbohydrate), suggesting that muscle FA oxidation may not be critical without exercise, but when food was removed, the responses of the two genotypes diverged. Whether or not food is available at the start of the dark cycle, the RER normally rises; this rise in RER occurred in both control and <italic>Acsl1<sup>M−/−</sup></italic> mice (<xref ref-type="fig" rid="F3">Fig. 3<italic>B</italic></xref> and <ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1070/-/DC1">Supplementary Fig. 3</ext-link>). However, although fasting decreased the total RER during both the day and night cycles, at every point during the dark cycle the RER of the <italic>Acsl1<sup>M−/−</sup></italic> mice remained higher than that of the controls, indicating increased systemic use of glucose by <italic>Acsl1<sup>M−/−</sup></italic> mice, despite the fast (<xref ref-type="fig" rid="F3">Fig. 3<italic>A</italic> and <italic>B</italic></xref>). With refeeding, the RER rose similarly in both genotypes, and the amount of food eaten and heat produced were similar (<xref ref-type="fig" rid="F3">Fig. 3<italic>C</italic> and <italic>D</italic></xref>). These data indicate that during fasting when FA is normally the major fuel source, <italic>Acsl1<sup>M−/−</sup></italic> mice relied predominantly on nonlipid fuels; this requirement was less prominent in the nonfasted state, primarily because exercise was minimal in both genotypes.</p><fig id="F3" fig-type="figure" position="float"><label>Figure 3</label><caption><p><italic>Acsl1<sup>M−/−</sup></italic> mice used more glucose as fuel source. <italic>A</italic>: Male mice (13 wk) were placed in metabolic chambers at 1:00 <sc>p.m.</sc> and measurements were taken for 2 days before overnight (O/N; 5:00 <sc>p.m.</sc> to 10:00 <sc>a.m.</sc>) fasting. Mice were then refed with chow for 24 h (<italic>n</italic> = 4); RER (<italic>V</italic><sc>CO</sc><sub>2</sub>/<italic>V</italic><sc>O</sc><sub>2</sub>) was monitored by indirect calorimetry during O/N fasting. Average RER (<italic>B</italic>), food intake (<italic>C</italic>), and heat production (<italic>D</italic>) during day and night cycles when the mice were fed, fasted, or refed. *<italic>P</italic> &lt; 0.05, compared with control.</p></caption><graphic xlink:href="23fig3"/></fig></sec><sec id="s14"><title><italic>Acsl1<sup>M−/−</sup></italic> Mice Were Exercise Intolerant</title><p>During endurance exercise, <italic>Acsl1<sup>M−/−</sup></italic> mice ran only 46–48% of the distance run by controls (1,522 ± 122 vs. 3,175 ± 327 m) (<xref ref-type="fig" rid="F4">Fig. 4<italic>A</italic></xref> and <ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1070/-/DC1">Supplementary Fig. 4<italic>A</italic></ext-link>). Blood lactate levels increased minimally (<xref ref-type="fig" rid="F4">Fig. 4<italic>B</italic></xref>), indicating that the aerobic threshold had not been exceeded, but both genotypes ceased to run when their blood glucose concentrations dropped to ∼40 mg/dL (<xref ref-type="fig" rid="F4">Fig. 4<italic>C</italic></xref>). Although glucose concentrations declined more slowly in control mice, at exhaustion, liver and muscle glycogen levels were equally depleted in both genotypes, and both were similarly hypoglycemic (<xref ref-type="table" rid="T1">Table 1</xref>). At exhaustion, plasma creatine kinase levels were similar in both genotypes.</p><fig id="F4" fig-type="figure" position="float"><label>Figure 4</label><caption><p>Muscle ACSL1 deficiency impaired endurance capacity. <italic>A</italic>: Total distance run during treadmill endurance exercise for <italic>Acsl1<sup>M−/−</sup></italic> mice (16 weeks of age, female). Blood lactate (<italic>B</italic>) and glucose (<italic>C</italic>) levels during endurance exercise. *<italic>P</italic> &lt; 0.05, glucose from exhausted <italic>Acsl1<sup>M−/−</sup></italic> mice compared with control mice that had run same distance (Run). <italic>D</italic>: mRNA expression of glucose-6-phosphatase (G6Pase), phosphoenolpyruvate carboxykinase (PEPCK), FGF21, hydroxymethylglutaryl-CoA synthase-2 (HMGS2), and liver CPT1 (LCPT1) (<italic>n</italic> = 5–13). *<italic>P</italic> &lt; 0.05, compared with exhausted controls. Run, data from control mice collected at the time their <italic>Acsl1<sup>M−/−</sup></italic> littermates were exhausted.</p></caption><graphic xlink:href="23fig4"/></fig><p>At the time point when <italic>Acsl1<sup>M−/−</sup></italic> mice refused to run further, running control mice had blood glucose values of 87 ± 7 mg/dL, despite depleted liver glycogen levels and undetectable muscle glycogen levels (<xref ref-type="table" rid="T1">Table 1</xref>). Because the basal content of liver and muscle glycogen was similar in both genotypes (<xref ref-type="fig" rid="F2">Fig. 2<italic>G</italic></xref>) and since liver glycogen stores were almost totally absent in the running controls, it appeared that gluconeogenesis in control mice was sufficient to avoid severe hypoglycemia, but <italic>Acsl1<sup>M−/−</sup></italic> mice, despite similar increases in the expression of hepatic gluconeogenic genes (<xref ref-type="fig" rid="F4">Fig. 4<italic>D</italic></xref>), were unable to produce enough glucose to compensate for the increased muscle demand.</p><p>During prolonged exercise, hydrolyzed adipose FA becomes a major fuel source for most tissues (<xref rid="B31" ref-type="bibr">31</xref>). Endurance exercise increased plasma nonesterified FA levels in both genotypes (<xref ref-type="table" rid="T1">Table 1</xref>). Although an increase in plasma FA level normally increases liver TAG content during exercise, <italic>Acsl1<sup>M−/−</sup></italic> mice accumulated less hepatic TAG than did controls, probably because more FA was used for energy in the liver (<xref ref-type="table" rid="T1">Table 1</xref>). Similarly, although plasma TAG levels increased in both genotypes, there was less of an increase in the <italic>Acsl1<sup>M−/−</sup></italic> mice (<xref ref-type="table" rid="T1">Table 1</xref>). Intramuscular TAG is believed to be a major fuel source in muscle during endurance exercise (<xref rid="B32" ref-type="bibr">32</xref>), and, at exhaustion, control muscle had lost twice as much TAG (<xref ref-type="table" rid="T1">Table 1</xref>), which is consistent with their ability to use lipid for energy.</p></sec><sec id="s15"><title>Basal Muscle and Plasma Metabolites Differed in <italic>Acsl1<sup>M−/−</sup></italic> and Control Mice</title><p>To understand how FA use differs in exercising muscle, we profiled plasma and muscle metabolites. Consistent with absent ACSL1 activity, resting <italic>Acsl1<sup>M−/−</sup></italic> muscle contained lower levels of long-chain acyl-CoAs (<xref ref-type="fig" rid="F5">Fig. 5<italic>A</italic></xref> and <ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1070/-/DC1">Supplementary Fig. 4<italic>A</italic></ext-link>). Compared with controls, acyl-CoA species of 14–18 carbons were 31–42% lower, but little difference was observed for short-chain acyl-CoAs, which are primarily products of amino acid degradation. Basal levels of long-chain acyl-carnitine species were similar in both genotypes (<xref ref-type="fig" rid="F5">Fig. 5<italic>B</italic></xref>). Acetyl-CoA is the final product of pathways of FA oxidation, glycolysis, and amino acid degradation. Basal acetyl-CoA levels were higher in <italic>Acsl1<sup>M−/−</sup></italic> muscle than in that of controls (<xref ref-type="fig" rid="F5">Fig. 5<italic>A</italic></xref>). Because FA oxidation was severely impaired in <italic>Acsl1<sup>M−/−</sup></italic> muscle and basal tricarboxylic acid (TCA) cycle intermediates were not limiting (<xref ref-type="fig" rid="F5">Fig. 5<italic>C</italic></xref>), this elevation in acetyl-CoA content, together with the lower basal content of total amino acids in <italic>Acsl1<sup>M−/−</sup></italic> muscle, suggests an increase in the use of amino acids and glucose for energy, even without exercise (<xref ref-type="fig" rid="F5">Fig. 5<italic>D</italic></xref>). Levels of amino acids and acyl-carnitines in plasma did not differ between genotypes (<ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1070/-/DC1">Supplementary Fig. 5<italic>B</italic> and <italic>C</italic></ext-link>).</p><fig id="F5" fig-type="figure" position="float"><label>Figure 5</label><caption><p>Metabolite changes in <italic>Acsl1<sup>M−/−</sup></italic> gastrocnemius muscle during endurance exercise (16–26 weeks of age, female). <italic>A</italic>: Muscle free- and acyl-CoAs. <italic>B</italic>: Muscle free- and acyl-carnitines. <italic>C</italic>: Muscle Krebs cycle intermediates. <italic>D</italic>: Muscle amino acids (<italic>n</italic> = 5–9). #<italic>P</italic> &lt; 0.05, vs. 4-h state (same genotype); *<italic>P</italic> &lt; 0.05, vs. control (same treatment). Running, data from control mice collected when their <italic>Acsl1<sup>M−/−</sup></italic> littermates were exhausted. a-KG, α-ketoglutarate; LC-AC, long-chain acyl-carnitine; LC-CoA, long-chain acyl-CoA; C, carbon number.</p></caption><graphic xlink:href="23fig5"/></fig></sec><sec id="s16"><title>Muscle and Plasma Metabolites Differed After Endurance Exercise</title><p>With endurance exercise, many acyl-CoA and acyl-carnitine metabolites increased markedly. In muscle from exhausted control mice, the levels of total acyl-CoA and long-chain acyl-CoA species each rose threefold (<xref ref-type="fig" rid="F5">Fig. 5<italic>A</italic></xref>), which is consistent with the normally enhanced influx of adipocyte-derived FA and its metabolism to acyl-CoA. Surprisingly, the increases of total acyl-CoA and long-chain acyl-CoA were even greater in <italic>Acsl1<sup>M−/−</sup></italic> muscle than in that of controls, with 4- and 10-fold increases, respectively. Total long-chain acyl-CoA levels were 89% higher in exhausted knockout muscle than in exhausted control muscle, despite the absence of ACSL1, the 79% lower ACSL-specific activity, and the absence of increases in mRNA expression of other <italic>Acsl</italic> or <italic>Fatp</italic> isoforms (<xref ref-type="fig" rid="F6">Fig. 6<italic>A</italic></xref>) (<xref rid="B33" ref-type="bibr">33</xref>).</p><fig id="F6" fig-type="figure" position="float"><label>Figure 6</label><caption><p>Muscle ACSL1 regulates fuel use and whole-body metabolism. <italic>A</italic>: mRNA expression of <italic>Acsl</italic> isoforms in gastrocnemius muscle relative to tubulin (female, <italic>n</italic> = 7–9). <italic>B</italic>: ACSL-specific activity within gastrocnemius homogenates (<italic>n</italic> = 4). <italic>C</italic>: Intramuscular TAG in gastrocnemius muscle after endurance exercise (<italic>n</italic> = 6–8). #<italic>P</italic> &lt; 0.05, vs. 4-h state (same genotype); *<italic>P</italic> &lt; 0.05, vs. control (same treatment). Exh, exhausted; Rest, resting.</p></caption><graphic xlink:href="23fig6"/></fig><p>Acyl-carnitines, which normally correspond to acyl-CoA levels, differed greatly by genotype. Endurance exercise increased total and long-chain acyl-carnitines 5.5- and 23-fold, respectively, in control muscle, but only 3- and 12-fold, respectively, in <italic>Acsl1<sup>M−/−</sup></italic> muscle. Thus, in exhausted <italic>Acsl1<sup>M−/−</sup></italic> muscle, the levels of total and individual long-chain acyl-carnitine species were 33–77% lower than in exhausted controls, consistent with impaired FA oxidation (<xref ref-type="fig" rid="F5">Fig. 5<italic>B</italic></xref>), and levels of medium-chain acyl-carnitines were 30–77% lower than those in controls (<ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1070/-/DC1">Supplementary Fig. 5</ext-link>). These data indicate that, despite the marked decrease in skeletal muscle ACSL-specific activity in <italic>Acsl1<sup>M−/−</sup></italic> mice, during endurance exercise plasma FAs taken up into muscle were converted to acyl-CoAs by other ACSL isoforms; these acyl-CoAs, however, remained in cytosolic pools that were inaccessible to carnitine palmitoyltransferase (CPT) 1 and β-oxidation enzymes in mitochondria and peroxisomes (<xref rid="B34" ref-type="bibr">34</xref>).</p><p>Exercise increases the demand for carnitine as a carrier for acyl groups (<xref rid="B18" ref-type="bibr">18</xref>). Although exercise diminished muscle carnitine content in both genotypes (<xref ref-type="fig" rid="F5">Fig. 5<italic>B</italic></xref>), free carnitine levels remained higher in <italic>Acsl1<sup>M−/−</sup></italic> than in control muscle, both in the resting state and at exhaustion, indicating that the availability of carnitine had not limited the conversion of acyl-CoAs to acyl-carnitines. Because acyl-carnitines often reflect the flux of acyl-CoAs that enter the β-oxidation pathway, the observation that muscle from exhausted <italic>Acsl1<sup>M−/−</sup></italic> mice contained higher amounts of long-chain acyl-CoAs but lower amounts of long-chain acyl-carnitines (<xref ref-type="fig" rid="F5">Fig. 5<italic>A</italic> and <italic>B</italic></xref>) strongly suggests that muscle contains separate pools of acyl-CoA. <italic>Acsl3</italic> mRNA was 40 and 30% higher, respectively, in resting and exhausted <italic>Acsl1<sup>M−/−</sup></italic> muscle, but none of the other <italic>Acsl</italic> isoforms was specifically upregulated by exercise (<xref ref-type="fig" rid="F6">Fig. 6<italic>A</italic></xref>). In control muscle, the total specific activity derived from all ACSL isoforms was unchanged by exercise; however, in muscle from exhausted <italic>Acsl1<sup>M−/−</sup></italic> mice, ACSL-specific activity more than doubled (0.06 ± 0.01 to 0.17 ± 0.04 nmol/min/mg protein), suggesting that one or more ACSL isoforms had been post-translationally activated by exercise (<xref ref-type="fig" rid="F6">Fig. 6<italic>B</italic></xref>). Lack of change in intramuscular TAG content in <italic>Acsl1<sup>M−/−</sup></italic> mice (<xref ref-type="table" rid="T1">Table 1</xref> and <xref ref-type="fig" rid="F6">Fig. 6<italic>C</italic></xref>) suggests that the accumulating long-chain-CoAs were not used for net TAG synthesis.</p><p>Intense exercise induces autophagy with the use of proteolyzed amino acids for both fuel within muscle and as a substrate for hepatic gluconeogenesis (<xref rid="B35" ref-type="bibr">35</xref>–<xref rid="B37" ref-type="bibr">37</xref>). With exercise, control muscle content of proline, valine, leucine/isoleucine, aspartate/asparagines, and tyrosine rose 57–115% (<xref ref-type="fig" rid="F5">Fig. 5<italic>D</italic></xref>); plasma branch-chain and aromatic amino acids increased two- to threefold (<ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1070/-/DC1">Supplementary Fig. 6<italic>B</italic></ext-link>); and amino acid degradation products (short-chain C3–C6 acyl-carnitines) rose 3.5-fold (<ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1070/-/DC1">Supplementary Fig. 5<italic>B</italic></ext-link>). In exhausted <italic>Acsl1<sup>M−/−</sup></italic> muscle, however, the levels of proline, alanine, aspartate/asparagines, and the branched-chain amino acids were low (<xref ref-type="fig" rid="F5">Fig. 5<italic>D</italic></xref>), probably because these amino acids were diverted toward energy production within muscle, as indicated by the marked rise in short-chain acyl-CoA amino acid degradation products (<ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1070/-/DC1">Supplementary Fig. 5<italic>A</italic></ext-link>). TCA intermediates were not depleted (<xref ref-type="fig" rid="F5">Fig. 5<italic>C</italic></xref>).</p></sec></sec><sec sec-type="discussion" id="s17"><title>Discussion</title><p>Our data show that acyl-CoAs are poorly available for β-oxidation in muscle if they have not been synthesized by ACSL1 (<xref ref-type="fig" rid="F7">Fig. 7</xref>). Endurance exercise in <italic>Acsl1<sup>M−/−</sup></italic> mice caused a marked increase in muscle content of long-chain acyl-CoAs. These acyl-CoAs, generated by other ACSL isoforms, were not in a pool that was accessible to the multiprotein CPT1-voltage-dependent anion channel-ACSL1 complex (<xref rid="B38" ref-type="bibr">38</xref>,<xref rid="B39" ref-type="bibr">39</xref>), and could not be converted to acyl-carnitines or enter the mitochondrial matrix. Thus, acyl-CoAs are located in separate and distinct pools within the cell. This is a surprising result, because amphipathic long-chain acyl-CoAs are water soluble and can interact with membranes and with lipid binding proteins that should allow them to move freely within cells.</p><fig id="F7" fig-type="figure" position="float"><label>Figure 7</label><caption><p>Skeletal muscle metabolism in control and <italic>Acsl1<sup>M−/−</sup></italic> mice. <italic>Exercising control muscle</italic>. Initial fuels include glucose hydrolyzed from hepatic and muscle glycogen and intramuscular TAG. Activation of AMPK suppresses TAG synthesis and accelerates mitochondrial FA oxidation, and autophagy releases amino acids, which are exported to provide a substrate for hepatic gluconeogenesis (<xref rid="B37" ref-type="bibr">37</xref>). As exercise continues, <italic>Acsl1</italic> mRNA increases, and epinephrine increases the supply of adipocyte-derived long-chain (LC)-FA, which are activated by ACSL1 and converted to LC-acyl-carnitines (ACs) by CPT1 and, within the mitochondria, back to LC-CoA by CPT2. Mitochondrial oxidation produces shorter-chain acyl-CoAs and their AC counterparts. Some amino acids that arise from protein hydrolysis contribute to TCA cycle intermediates and to acetyl-CoA for energy production. Hepatic glucose, now derived via amino acid–fueled gluconeogenesis, continues to enter the glycolytic pathway, but the use of LC-FA spares muscle demand for glucose. In addition to ACs of different chain lengths that move out of the mitochondria into the cytosol, ACs derived from hepatic FA oxidation are released into the blood and equilibrate across the muscle plasma membrane. <italic>Exercising Acsl1<sup>M−/−</sup> muscle</italic>. When ACSL1 is absent, other ACSL isoforms (ACSL?) activate the large amount of entering LC-FA. Most, but perhaps not all, of the LC-CoA produced by these ACSL? lack ready access to CPT1 and cannot be converted to LC-AC and enter the mitochondria. (For simplicity, we have not shown a theoretical pathway by which some FAs might be activated by ACSL? and oxidized in the absence of ACSL1 [see <xref ref-type="fig" rid="F1">Fig. 1<italic>D</italic></xref>]; these pathways <italic>1</italic>) might provide some LC-CoA at the mitochondrial surface with access to CPT1 or <italic>2</italic>) might provide medium-chain (MC)-CoA in <italic>Acsl1<sup>M−/−</sup></italic> muscle [<ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1070/-/DC1">Supplementary Fig. 4<italic>A</italic></ext-link>], which can enter the mitochondria without CPT1.) The cell content of LC-CoAs increases because of their diminished entry into both oxidative and synthetic pathways. Failure to switch to the use of LC-FA for oxidation enhances glucose entry and oxidation and increases the use of muscle protein–derived amino acid that is converted to acetyl-CoA and TCA cycle intermediates. Fewer amino acids are released by muscle to supply the substrate for hepatic gluconeogenesis. As a consequence, systemic hypoglycemia ensues and the capacity for endurance exercise is impaired.</p></caption><graphic xlink:href="23fig7"/></fig><p>Because exercise-activated AMPK downregulates lipid synthesis, lipid synthetic enzymes were apparently unable to handle the excess FA that enters muscle during endurance exercise. Exercise also enhances lipolysis (<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B40" ref-type="bibr">40</xref>). Consistent with its critical importance in facilitating acyl-CoA entry into mitochondria and in concert with other peroxisome proliferator–activated receptor α targets, <italic>Acsl1</italic> was the only <italic>Acsl</italic> mRNA upregulated by endurance exercise in control mice (<xref rid="B41" ref-type="bibr">41</xref>,<xref rid="B42" ref-type="bibr">42</xref>). No change in expression of other <italic>Acsl</italic> isoforms was observed in <italic>Acsl1<sup>M−/−</sup></italic> muscle, but exercise increased the low basal specific activity of ACSL in gastrocnemius muscle by 166%, suggesting possible post-transcriptional activation.</p><p>A second important finding was that the inability of skeletal muscle to oxidize FA made <italic>Acsl1<sup>M−/−</sup></italic> mice vulnerable to systemic hypoglycemia. The dependence of <italic>Acsl1<sup>M−/−</sup></italic> muscle on glucose limited glucose availability for other tissues, and gluconeogenesis was unable to supply sufficient glucose during fasting or exercise. The metabolic profile observed is consistent with muscle that is unable to oxidize FA and, instead, uses hydrolyzed amino acids for energy rather than releasing them as substrates for hepatic gluconeogenesis. Thus, <italic>Acsl1<sup>M−/−</sup></italic> muscle burned more glucose during exercise, and its demand for nonlipid fuel impaired systemic energy homeostasis. The increased demand for glucose during an overnight fast was accompanied by increased muscle GLUT1 protein and enhanced insulin sensitivity in both the liver and muscle.</p><p>The marked decrease in FA β-oxidation in <italic>Acsl1<sup>M−/−</sup></italic> muscle resulted in a fasting phenotype of hypoglycemia, elevated plasma FA levels, and fatty liver similar to that of humans and animals with genetic defects in FA oxidation (<xref rid="B43" ref-type="bibr">43</xref>,<xref rid="B44" ref-type="bibr">44</xref>). However, <italic>Acsl1<sup>M−/−</sup></italic> mice differed from other models of defective FA oxidation in that muscle TAG did not accumulate. Further, because the liver retained normal ACSL activity, fasting-induced hypoketonemic hypoglycemia did not occur (<xref rid="B43" ref-type="bibr">43</xref>).</p><p>Metabolic limitations on endurance exercise have been variously attributed to low intramuscular fuel stores (<xref rid="B45" ref-type="bibr">45</xref>), diminished liver glycogen stores (<xref rid="B41" ref-type="bibr">41</xref>), lack of glucose or ketone production by the liver (<xref rid="B43" ref-type="bibr">43</xref>), or an impaired ability of muscle to take up and oxidize available fuels, including glucose (<xref rid="B46" ref-type="bibr">46</xref>) and FA (<xref rid="B43" ref-type="bibr">43</xref>). Diminished endurance in rats is associated with hypoglycemia (<xref rid="B45" ref-type="bibr">45</xref>) and with low glycogen content in discrete cerebral regions (<xref rid="B47" ref-type="bibr">47</xref>), which may contribute to exhaustion (<xref rid="B48" ref-type="bibr">48</xref>).</p><p>Failure of muscle to switch to FA use rendered <italic>Acsl1<sup>M−/−</sup></italic> mice unable to run optimally, despite normal hepatic FA oxidation and comparable upregulation of mRNA for hepatic gluconeogenic genes. Although a mild myopathy was present, the most striking difference between the running genotypes was the concentration of plasma glucose. <italic>Acsl1<sup>M−/−</sup></italic> mice refused to run when their glucose concentrations dropped to ∼40 mg/dL, while the controls, with glucose concentrations of ∼90 mg/dL, continued to run, despite levels of liver and muscle glycogen, muscle TAG, and plasma ketones, FA, and amino acids equivalent to those of the knockouts. Thus, hypoglycemia, causing central fatigue and an inadequate peripheral energy supply, was the deciding feature in the refusal of both genotypes to run.</p><p>In summary, ACSL1 is essential for FA oxidation in skeletal muscle, and acyl-CoA synthesis by other ACSL isoforms cannot compensate (<xref ref-type="fig" rid="F7">Fig. 7</xref>). ACSL1 is located on both the endoplasmic reticulum and the mitochondrial outer membrane in rat liver (<xref rid="B38" ref-type="bibr">38</xref>,<xref rid="B49" ref-type="bibr">49</xref>) and 3T3-L1 adipocytes (<xref rid="B50" ref-type="bibr">50</xref>), but the subcellular location of ACSL1 in muscle has not been investigated. The absence of ACSL1 resulted in an inappropriate dependence on glucose for muscle energy, such that systemic glucose homeostasis became severely compromised. In human and animal models with defective FA oxidation, the hypoglycemia that occurs with fasting or exercise has been attributed to a lack of hepatic FA metabolism and diminished ATP production to power gluconeogenesis. In <italic>Acsl1<sup>M−/−</sup></italic> mice, however, hypoglycemia occurred despite the fact that hepatic FA oxidation was not impaired. Instead, the muscle-specific defect in FA oxidation drained the glucose supply, and the likely increased use of amino acids within muscle precluded amino acid availability as a substrate for hepatic gluconeogenesis. Thus, during both fasting and endurance exercise, the liver was unable to synthesize sufficient glucose to prevent hypoglycemia, a dramatic example of the interdependence of muscle and liver fuel metabolism.</p></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>Supplementary Data</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_64_1_23__index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_db13-1070_DB131070SupplementaryData.pdf"/>
</supplementary-material>
</sec>
</body>
  <back>
    <fn-group>
      <fn id="fn1" fn-type="supplementary-material">
        <p>This article contains Supplementary Data online at <ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1070/-/DC1">http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1070/-/DC1</ext-link>.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Article Information</title>
      <p><bold>Funding.</bold> This work was supported by National Institutes of Health grants T32HL069768 (T.J.G.), DK058398 (C.B.N.), AG028930 (D.M.M.), and DK59935 and DK59935(ARRA) (R.A.C.); the UNC Nutrition Obesity Research Center grant P30DK56350; and Ellison Medical Foundation grant AG-NS-0548-09 (T.R.K.).</p>
      <p><bold>Duality of Interest.</bold> No potential conflicts of interest relevant to this article were reported.</p>
      <p><bold>Author Contributions.</bold> L.O.L. designed and performed the research, wrote the manuscript, and contributed to the writing of the final submitted version of the manuscript. T.J.G., D.S.P., T.R.K., and F.P. performed the research and contributed to the writing of the final submitted version of the manuscript. O.I. performed the research. C.B.N. and D.M.M. contributed to the writing of the final submitted version of the manuscript. R.A.C. designed the research, wrote the manuscript, and contributed to the writing of the final submitted version of the manuscript. R.A.C. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelley</surname><given-names>DE</given-names></name><name><surname>Mandarino</surname><given-names>LJ</given-names></name></person-group>. <article-title>Fuel selection in human skeletal muscle in insulin resistance: a reexamination</article-title>. <source>Diabetes</source>
<year>2000</year>;<volume>49</volume>:<fpage>677</fpage>–<lpage>683</lpage><?supplied-pmid 10905472?><pub-id pub-id-type="pmid">10905472</pub-id></mixed-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thyfault</surname><given-names>JP</given-names></name><name><surname>Rector</surname><given-names>RS</given-names></name><name><surname>Noland</surname><given-names>RC</given-names></name></person-group>. <article-title>Metabolic inflexibility in skeletal muscle: a prelude to the cardiometabolic syndrome?</article-title>
<source>J Cardiometab Syndr</source>
<year>2006</year>;<volume>1</volume>:<fpage>184</fpage>–<lpage>189</lpage><?supplied-pmid 17679820?><pub-id pub-id-type="pmid">17679820</pub-id></mixed-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watt</surname><given-names>MJ</given-names></name><name><surname>Hoy</surname><given-names>AJ</given-names></name></person-group>. <article-title>Lipid metabolism in skeletal muscle: generation of adaptive and maladaptive intracellular signals for cellular function</article-title>. <source>Am J Physiol Endocrinol Metab</source>
<year>2012</year>;<volume>302</volume>:<fpage>E1315</fpage>–<lpage>E1328</lpage><?supplied-pmid 22185843?><pub-id pub-id-type="pmid">22185843</pub-id></mixed-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>ZX</given-names></name><name><surname>Choi</surname><given-names>CS</given-names></name><etal/></person-group>. <article-title>Mitochondrial dysfunction due to long-chain Acyl-CoA dehydrogenase deficiency causes hepatic steatosis and hepatic insulin resistance</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2007</year>;<volume>104</volume>:<fpage>17075</fpage>–<lpage>17080</lpage><?supplied-pmid 17940018?><pub-id pub-id-type="pmid">17940018</pub-id></mixed-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ukropcova</surname><given-names>B</given-names></name><name><surname>Sereda</surname><given-names>O</given-names></name><name><surname>de Jonge</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Family history of diabetes links impaired substrate switching and reduced mitochondrial content in skeletal muscle</article-title>. <source>Diabetes</source>
<year>2007</year>;<volume>56</volume>:<fpage>720</fpage>–<lpage>727</lpage><?supplied-pmid 17327442?><pub-id pub-id-type="pmid">17327442</pub-id></mixed-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahlin</surname><given-names>K</given-names></name><name><surname>Harris</surname><given-names>RC</given-names></name></person-group>. <article-title>Control of lipid oxidation during exercise: role of energy state and mitochondrial factors</article-title>. <source>Acta Physiol (Oxf)</source>
<year>2008</year>;<volume>194</volume>:<fpage>283</fpage>–<lpage>291</lpage><?supplied-pmid 18557841?><pub-id pub-id-type="pmid">18557841</pub-id></mixed-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeppesen</surname><given-names>J</given-names></name><name><surname>Jordy</surname><given-names>AB</given-names></name><name><surname>Sjøberg</surname><given-names>KA</given-names></name><etal/></person-group>. <article-title>Enhanced fatty acid oxidation and FATP4 protein expression after endurance exercise training in human skeletal muscle</article-title>. <source>PLoS One</source>
<year>2012</year>;<volume>7</volume>:<fpage>e29391</fpage><?supplied-pmid 22235293?><pub-id pub-id-type="pmid">22235293</pub-id></mixed-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baruteau</surname><given-names>J</given-names></name><name><surname>Sachs</surname><given-names>P</given-names></name><name><surname>Broué</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Clinical and biological features at diagnosis in mitochondrial fatty acid beta-oxidation defects: a French pediatric study of 187 patients</article-title>. <source>J Inherit Metab Dis</source>
<year>2013</year>;<volume>36</volume>:<fpage>795</fpage>–<lpage>803</lpage><?supplied-pmid 23053472?><pub-id pub-id-type="pmid">23053472</pub-id></mixed-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holloszy</surname><given-names>JO</given-names></name><name><surname>Kohrt</surname><given-names>WM</given-names></name></person-group>. <article-title>Regulation of carbohydrate and fat metabolism during and after exercise</article-title>. <source>Annu Rev Nutr</source>
<year>1996</year>;<volume>16</volume>:<fpage>121</fpage>–<lpage>138</lpage><?supplied-pmid 8839922?><pub-id pub-id-type="pmid">8839922</pub-id></mixed-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellis</surname><given-names>JM</given-names></name><name><surname>Frahm</surname><given-names>JL</given-names></name><name><surname>Li</surname><given-names>LO</given-names></name><name><surname>Coleman</surname><given-names>RA</given-names></name></person-group>. <article-title>Acyl-coenzyme A synthetases in metabolic control</article-title>. <source>Curr Opin Lipidol</source>
<year>2010</year>;<volume>21</volume>:<fpage>212</fpage>–<lpage>217</lpage><?supplied-pmid 20480548?><pub-id pub-id-type="pmid">20480548</pub-id></mixed-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>LO</given-names></name><name><surname>Klett</surname><given-names>EL</given-names></name><name><surname>Coleman</surname><given-names>RA</given-names></name></person-group>
<article-title>Acyl-CoA synthesis, lipid metabolism and lipotoxicity</article-title>. <source>Biochim Biophys Acta</source>
<year>2010</year>;<volume>1801</volume>:<fpage>246</fpage>–<fpage>251</fpage><pub-id pub-id-type="pmid">19818872</pub-id></mixed-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>LO</given-names></name><name><surname>Ellis</surname><given-names>JM</given-names></name><name><surname>Paich</surname><given-names>HA</given-names></name><etal/></person-group>. <article-title>Liver-specific loss of long chain acyl-CoA synthetase-1 decreases triacylglycerol synthesis and beta-oxidation and alters phospholipid fatty acid composition</article-title>. <source>J Biol Chem</source>
<year>2009</year>;<volume>284</volume>:<fpage>27816</fpage>–<lpage>27826</lpage><?supplied-pmid 19648649?><pub-id pub-id-type="pmid">19648649</pub-id></mixed-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellis</surname><given-names>JM</given-names></name><name><surname>Li</surname><given-names>LO</given-names></name><name><surname>Wu</surname><given-names>PC</given-names></name><etal/></person-group>. <article-title>Adipose acyl-CoA synthetase-1 directs fatty acids toward beta-oxidation and is required for cold thermogenesis</article-title>. <source>Cell Metab</source>
<year>2010</year>;<volume>12</volume>:<fpage>53</fpage>–<lpage>64</lpage><?supplied-pmid 20620995?><pub-id pub-id-type="pmid">20620995</pub-id></mixed-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellis</surname><given-names>JM</given-names></name><name><surname>Mentock</surname><given-names>SM</given-names></name><name><surname>Depetrillo</surname><given-names>MA</given-names></name><etal/></person-group>. <article-title>Mouse cardiac acyl coenzyme a synthetase 1 deficiency impairs fatty acid oxidation and induces cardiac hypertrophy</article-title>. <source>Mol Cell Biol</source>
<year>2011</year>;<volume>31</volume>:<fpage>1252</fpage>–<lpage>1262</lpage><?supplied-pmid 21245374?><pub-id pub-id-type="pmid">21245374</pub-id></mixed-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watt</surname><given-names>MJ</given-names></name><name><surname>Hoy</surname><given-names>AJ</given-names></name><name><surname>Muoio</surname><given-names>DM</given-names></name><name><surname>Coleman</surname><given-names>RA</given-names></name></person-group>. <article-title>Distinct roles of specific fatty acids in cellular processes: implications for interpreting and reporting experiments</article-title>. <source>Am J Physiol Endocrinol Metab</source>
<year>2012</year>;<volume>302</volume>:<fpage>E1</fpage>–<lpage>E3</lpage><?supplied-pmid 22180647?><pub-id pub-id-type="pmid">22180647</pub-id></mixed-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwander</surname><given-names>M</given-names></name><name><surname>Leu</surname><given-names>M</given-names></name><name><surname>Stumm</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Beta1 integrins regulate myoblast fusion and sarcomere assembly</article-title>. <source>Dev Cell</source>
<year>2003</year>;<volume>4</volume>:<fpage>673</fpage>–<lpage>685</lpage><?supplied-pmid 12737803?><pub-id pub-id-type="pmid">12737803</pub-id></mixed-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonardi</surname><given-names>R</given-names></name><name><surname>Rehg</surname><given-names>JE</given-names></name><name><surname>Rock</surname><given-names>CO</given-names></name><name><surname>Jackowski</surname><given-names>S</given-names></name></person-group>. <article-title>Pantothenate kinase 1 is required to support the metabolic transition from the fed to the fasted state</article-title>. <source>PLoS One</source>
<year>2010</year>;<volume>5</volume>:<fpage>e11107</fpage><?supplied-pmid 20559429?><pub-id pub-id-type="pmid">20559429</pub-id></mixed-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiens</surname><given-names>B</given-names></name></person-group>. <article-title>Skeletal muscle lipid metabolism in exercise and insulin resistance</article-title>. <source>Physiol Rev</source>
<year>2006</year>;<volume>86</volume>:<fpage>205</fpage>–<lpage>243</lpage><?supplied-pmid 16371598?><pub-id pub-id-type="pmid">16371598</pub-id></mixed-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passonneau</surname><given-names>JV</given-names></name><name><surname>Lauderdale</surname><given-names>VR</given-names></name></person-group>. <article-title>A comparison of three methods of glycogen measurement in tissues</article-title>. <source>Anal Biochem</source>
<year>1974</year>;<volume>60</volume>:<fpage>405</fpage>–<lpage>412</lpage><?supplied-pmid 4844560?><pub-id pub-id-type="pmid">4844560</pub-id></mixed-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wendel</surname><given-names>AA</given-names></name><name><surname>Li</surname><given-names>LO</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Cline</surname><given-names>GW</given-names></name><name><surname>Shulman</surname><given-names>GI</given-names></name><name><surname>Coleman</surname><given-names>RA</given-names></name></person-group>. <article-title>Glycerol-3-phosphate acyltransferase 1 deficiency in ob/ob mice diminishes hepatic steatosis but does not protect against insulin resistance or obesity</article-title>. <source>Diabetes</source>
<year>2010</year>;<volume>59</volume>:<fpage>1321</fpage>–<lpage>1329</lpage><?supplied-pmid 20200319?><pub-id pub-id-type="pmid">20200319</pub-id></mixed-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folch</surname><given-names>J</given-names></name><name><surname>Lees</surname><given-names>M</given-names></name><name><surname>Sloane Stanley</surname><given-names>GH</given-names></name></person-group>. <article-title>A simple method for the isolation and purification of total lipides from animal tissues</article-title>. <source>J Biol Chem</source>
<year>1957</year>;<volume>226</volume>:<fpage>497</fpage>–<lpage>509</lpage><?supplied-pmid 13428781?><pub-id pub-id-type="pmid">13428781</pub-id></mixed-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Engel</surname><given-names>AG</given-names></name><name><surname>Franzini-Armstrong</surname><given-names>C</given-names></name></person-group>
<source>Myology: Basic and Clinical</source>. <publisher-loc>New York</publisher-loc>, <publisher-name>McGraw-Hill</publisher-name>, <year>2004</year></mixed-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Schmittgen</surname><given-names>TD</given-names></name></person-group>. <article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method</article-title>. <source>Methods</source>
<year>2001</year>;<volume>25</volume>:<fpage>402</fpage>–<lpage>408</lpage><?supplied-pmid 11846609?><pub-id pub-id-type="pmid">11846609</pub-id></mixed-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polokoff</surname><given-names>MA</given-names></name><name><surname>Bell</surname><given-names>RM</given-names></name></person-group>. <article-title>Limited palmitoyl-CoA penetration into microsomal vesicles as evidenced by a highly latent ethanol acyltransferase activity</article-title>. <source>J Biol Chem</source>
<year>1978</year>;<volume>253</volume>:<fpage>7173</fpage>–<lpage>7178</lpage><?supplied-pmid 701242?><pub-id pub-id-type="pmid">701242</pub-id></mixed-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noland</surname><given-names>RC</given-names></name><name><surname>Woodlief</surname><given-names>TL</given-names></name><name><surname>Whitfield</surname><given-names>BR</given-names></name><etal/></person-group>. <article-title>Peroxisomal-mitochondrial oxidation in a rodent model of obesity-associated insulin resistance</article-title>. <source>Am J Physiol Endocrinol Metab</source>
<year>2007</year>;<volume>293</volume>:<fpage>E986</fpage>–<lpage>E1001</lpage><?supplied-pmid 17638705?><pub-id pub-id-type="pmid">17638705</pub-id></mixed-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrara</surname><given-names>CT</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Neto</surname><given-names>EC</given-names></name><etal/></person-group>. <article-title>Genetic networks of liver metabolism revealed by integration of metabolic and transcriptional profiling</article-title>. <source>PLoS Genet</source>
<year>2008</year>;<volume>4</volume>:<fpage>e1000034</fpage><?supplied-pmid 18369453?><pub-id pub-id-type="pmid">18369453</pub-id></mixed-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>An</surname><given-names>J</given-names></name><name><surname>Muoio</surname><given-names>DM</given-names></name><name><surname>Shiota</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance</article-title>. <source>Nat Med</source>
<year>2004</year>;<volume>10</volume>:<fpage>268</fpage>–<lpage>274</lpage><?supplied-pmid 14770177?><pub-id pub-id-type="pmid">14770177</pub-id></mixed-citation>
      </ref>
      <ref id="B28">
        <label>28</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muoio</surname><given-names>DM</given-names></name><name><surname>Noland</surname><given-names>RC</given-names></name><name><surname>Kovalik</surname><given-names>JP</given-names></name><etal/></person-group>. <article-title>Muscle-specific deletion of carnitine acetyltransferase compromises glucose tolerance and metabolic flexibility</article-title>. <source>Cell Metab</source>
<year>2012</year>;<volume>15</volume>:<fpage>764</fpage>–<lpage>777</lpage><?supplied-pmid 22560225?><pub-id pub-id-type="pmid">22560225</pub-id></mixed-citation>
      </ref>
      <ref id="B29">
        <label>29</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kersten</surname><given-names>S</given-names></name><name><surname>Seydoux</surname><given-names>J</given-names></name><name><surname>Peters</surname><given-names>JM</given-names></name><name><surname>Gonzalez</surname><given-names>FJ</given-names></name><name><surname>Desvergne</surname><given-names>B</given-names></name><name><surname>Wahli</surname><given-names>W</given-names></name></person-group>. <article-title>Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting</article-title>. <source>J Clin Invest</source>
<year>1999</year>;<volume>103</volume>:<fpage>1489</fpage>–<lpage>1498</lpage><?supplied-pmid 10359558?><pub-id pub-id-type="pmid">10359558</pub-id></mixed-citation>
      </ref>
      <ref id="B30">
        <label>30</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Ginneken</surname><given-names>V</given-names></name><name><surname>Verhey</surname><given-names>E</given-names></name><name><surname>Poelmann</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Metabolomics (liver and blood profiling) in a mouse model in response to fasting: a study of hepatic steatosis</article-title>. <source>Biochim Biophys Acta</source>
<year>2007</year>;<volume>1771</volume>:<fpage>1263</fpage>–<lpage>1270</lpage><pub-id pub-id-type="pmid">17904417</pub-id></mixed-citation>
      </ref>
      <ref id="B31">
        <label>31</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frayn</surname><given-names>KN</given-names></name></person-group>. <article-title>Fat as a fuel: emerging understanding of the adipose tissue-skeletal muscle axis</article-title>. <source>Acta Physiol (Oxf)</source>
<year>2010</year>;<volume>199</volume>:<fpage>509</fpage>–<lpage>518</lpage><?supplied-pmid 20353493?><pub-id pub-id-type="pmid">20353493</pub-id></mixed-citation>
      </ref>
      <ref id="B32">
        <label>32</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stellingwerff</surname><given-names>T</given-names></name><name><surname>Boon</surname><given-names>H</given-names></name><name><surname>Jonkers</surname><given-names>RA</given-names></name><etal/></person-group>. <article-title>Significant intramyocellular lipid use during prolonged cycling in endurance-trained males as assessed by three different methodologies</article-title>. <source>Am J Physiol Endocrinol Metab</source>
<year>2007</year>;<volume>292</volume>:<fpage>E1715</fpage>–<lpage>E1723</lpage><?supplied-pmid 17299080?><pub-id pub-id-type="pmid">17299080</pub-id></mixed-citation>
      </ref>
      <ref id="B33">
        <label>33</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watkins</surname><given-names>PA</given-names></name></person-group>. <article-title>Very-long-chain acyl-CoA synthetases</article-title>. <source>J Biol Chem</source>
<year>2008</year>;<volume>283</volume>:<fpage>1773</fpage>–<lpage>1777</lpage><?supplied-pmid 18024425?><pub-id pub-id-type="pmid">18024425</pub-id></mixed-citation>
      </ref>
      <ref id="B34">
        <label>34</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westin</surname><given-names>MA</given-names></name><name><surname>Hunt</surname><given-names>MC</given-names></name><name><surname>Alexson</surname><given-names>SE</given-names></name></person-group>. <article-title>Short- and medium-chain carnitine acyltransferases and acyl-CoA thioesterases in mouse provide complementary systems for transport of beta-oxidation products out of peroxisomes</article-title>. <source>Cell Mol Life Sci</source>
<year>2008</year>;<volume>65</volume>:<fpage>982</fpage>–<lpage>990</lpage><?supplied-pmid 18264800?><pub-id pub-id-type="pmid">18264800</pub-id></mixed-citation>
      </ref>
      <ref id="B35">
        <label>35</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rennie</surname><given-names>MJ</given-names></name><name><surname>Tipton</surname><given-names>KD</given-names></name></person-group>. <article-title>Protein and amino acid metabolism during and after exercise and the effects of nutrition</article-title>. <source>Annu Rev Nutr</source>
<year>2000</year>;<volume>20</volume>:<fpage>457</fpage>–<lpage>483</lpage><?supplied-pmid 10940342?><pub-id pub-id-type="pmid">10940342</pub-id></mixed-citation>
      </ref>
      <ref id="B36">
        <label>36</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>C</given-names></name><name><surname>Bassik</surname><given-names>MC</given-names></name><name><surname>Moresi</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis</article-title>. <source>Nature</source>
<year>2012</year>;<volume>481</volume>:<fpage>511</fpage>–<lpage>515</lpage><?supplied-pmid 22258505?><pub-id pub-id-type="pmid">22258505</pub-id></mixed-citation>
      </ref>
      <ref id="B37">
        <label>37</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dohm</surname><given-names>GL</given-names></name><name><surname>Tapscott</surname><given-names>EB</given-names></name><name><surname>Kasperek</surname><given-names>GJ</given-names></name></person-group>. <article-title>Protein degradation during endurance exercise and recovery</article-title>. <source>Med Sci Sports Exerc</source>
<year>1987</year>;<volume>19</volume>(<issue>Suppl</issue>.):<fpage>S166</fpage>–<lpage>S171</lpage><?supplied-pmid 3316916?><pub-id pub-id-type="pmid">3316916</pub-id></mixed-citation>
      </ref>
      <ref id="B38">
        <label>38</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Kerner</surname><given-names>J</given-names></name><name><surname>Hoppel</surname><given-names>CL</given-names></name></person-group>. <article-title>Mitochondrial carnitine palmitoyltransferase 1a (CPT1a) is part of an outer membrane fatty acid transfer complex</article-title>. <source>J Biol Chem</source>
<year>2011</year>;<volume>286</volume>:<fpage>25655</fpage>–<lpage>25662</lpage><?supplied-pmid 21622568?><pub-id pub-id-type="pmid">21622568</pub-id></mixed-citation>
      </ref>
      <ref id="B39">
        <label>39</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alfonso-Pecchio</surname><given-names>A</given-names></name><name><surname>Garcia</surname><given-names>M</given-names></name><name><surname>Leonardi</surname><given-names>R</given-names></name><name><surname>Jackowski</surname><given-names>S</given-names></name></person-group>. <article-title>Compartmentalization of mammalian pantothenate kinases</article-title>. <source>PLoS One</source>
<year>2012</year>;<volume>7</volume>:<fpage>e49509</fpage><?supplied-pmid 23152917?><pub-id pub-id-type="pmid">23152917</pub-id></mixed-citation>
      </ref>
      <ref id="B40">
        <label>40</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinberg</surname><given-names>GR</given-names></name></person-group>. <article-title>Role of the AMP-activated protein kinase in regulating fatty acid metabolism during exercise</article-title>. <source>Appl Physiol Nutr Metab</source>
<year>2009</year>;<volume>34</volume>:<fpage>315</fpage>–<lpage>322</lpage><?supplied-pmid 19448692?><pub-id pub-id-type="pmid">19448692</pub-id></mixed-citation>
      </ref>
      <ref id="B41">
        <label>41</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muoio</surname><given-names>DM</given-names></name><name><surname>MacLean</surname><given-names>PS</given-names></name><name><surname>Lang</surname><given-names>DB</given-names></name><etal/></person-group>. <article-title>Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) alpha knock-out mice. Evidence for compensatory regulation by PPAR delta</article-title>. <source>J Biol Chem</source>
<year>2002</year>;<volume>277</volume>:<fpage>26089</fpage>–<lpage>26097</lpage><?supplied-pmid 12118038?><pub-id pub-id-type="pmid">12118038</pub-id></mixed-citation>
      </ref>
      <ref id="B42">
        <label>42</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>G</given-names></name><name><surname>Schoonjans</surname><given-names>K</given-names></name><name><surname>Lefebvre</surname><given-names>AM</given-names></name><name><surname>Staels</surname><given-names>B</given-names></name><name><surname>Auwerx</surname><given-names>J</given-names></name></person-group>. <article-title>Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators</article-title>. <source>J Biol Chem</source>
<year>1997</year>;<volume>272</volume>:<fpage>28210</fpage>–<lpage>28217</lpage><?supplied-pmid 9353271?><pub-id pub-id-type="pmid">9353271</pub-id></mixed-citation>
      </ref>
      <ref id="B43">
        <label>43</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spiekerkoetter</surname><given-names>U</given-names></name><name><surname>Wood</surname><given-names>PA</given-names></name></person-group>. <article-title>Mitochondrial fatty acid oxidation disorders: pathophysiological studies in mouse models</article-title>. <source>J Inherit Metab Dis</source>
<year>2010</year>;<volume>33</volume>:<fpage>539</fpage>–<lpage>546</lpage><?supplied-pmid 20532823?><pub-id pub-id-type="pmid">20532823</pub-id></mixed-citation>
      </ref>
      <ref id="B44">
        <label>44</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wanders</surname><given-names>RJ</given-names></name><name><surname>Vreken</surname><given-names>P</given-names></name><name><surname>den Boer</surname><given-names>ME</given-names></name><name><surname>Wijburg</surname><given-names>FA</given-names></name><name><surname>van Gennip</surname><given-names>AH</given-names></name><name><surname>IJlst</surname><given-names>L</given-names></name></person-group>. <article-title>Disorders of mitochondrial fatty acyl-CoA beta-oxidation</article-title>. <source>J Inherit Metab Dis</source>
<year>1999</year>;<volume>22</volume>:<fpage>442</fpage>–<lpage>487</lpage><?supplied-pmid 10407780?><pub-id pub-id-type="pmid">10407780</pub-id></mixed-citation>
      </ref>
      <ref id="B45">
        <label>45</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winder</surname><given-names>WW</given-names></name><name><surname>Yang</surname><given-names>HT</given-names></name><name><surname>Jaussi</surname><given-names>AW</given-names></name><name><surname>Hopkins</surname><given-names>CR</given-names></name></person-group>. <article-title>Epinephrine, glucose, and lactate infusion in exercising adrenodemedullated rats</article-title>. <source>J Appl Physiol (1985)</source>
<year>1987</year>;<volume>62</volume>:<fpage>1442</fpage>–<lpage>1447</lpage><?supplied-pmid 3298192?><pub-id pub-id-type="pmid">3298192</pub-id></mixed-citation>
      </ref>
      <ref id="B46">
        <label>46</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacLean</surname><given-names>PS</given-names></name><name><surname>Zheng</surname><given-names>D</given-names></name><name><surname>Dohm</surname><given-names>GL</given-names></name></person-group>. <article-title>Muscle glucose transporter (GLUT 4) gene expression during exercise</article-title>. <source>Exerc Sport Sci Rev</source>
<year>2000</year>;<volume>28</volume>:<fpage>148</fpage>–<lpage>152</lpage><?supplied-pmid 11064847?><pub-id pub-id-type="pmid">11064847</pub-id></mixed-citation>
      </ref>
      <ref id="B47">
        <label>47</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsui</surname><given-names>T</given-names></name><name><surname>Soya</surname><given-names>S</given-names></name><name><surname>Okamoto</surname><given-names>M</given-names></name><name><surname>Ichitani</surname><given-names>Y</given-names></name><name><surname>Kawanaka</surname><given-names>K</given-names></name><name><surname>Soya</surname><given-names>H</given-names></name></person-group>. <article-title>Brain glycogen decreases during prolonged exercise</article-title>. <source>J Physiol</source>
<year>2011</year>;<volume>589</volume>:<fpage>3383</fpage>–<lpage>3393</lpage><?supplied-pmid 21521757?><pub-id pub-id-type="pmid">21521757</pub-id></mixed-citation>
      </ref>
      <ref id="B48">
        <label>48</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nybo</surname><given-names>L</given-names></name><name><surname>Secher</surname><given-names>NH</given-names></name></person-group>. <article-title>Cerebral perturbations provoked by prolonged exercise</article-title>. <source>Prog Neurobiol</source>
<year>2004</year>;<volume>72</volume>:<fpage>223</fpage>–<lpage>261</lpage><?supplied-pmid 15142684?><pub-id pub-id-type="pmid">15142684</pub-id></mixed-citation>
      </ref>
      <ref id="B49">
        <label>49</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewin</surname><given-names>TM</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Granger</surname><given-names>DA</given-names></name><name><surname>Vance</surname><given-names>JE</given-names></name><name><surname>Coleman</surname><given-names>RA</given-names></name></person-group>. <article-title>Acyl-CoA synthetase isoforms 1, 4, and 5 are present in different subcellular membranes in rat liver and can be inhibited independently</article-title>. <source>J Biol Chem</source>
<year>2001</year>;<volume>276</volume>:<fpage>24674</fpage>–<lpage>24679</lpage><?supplied-pmid 11319232?><pub-id pub-id-type="pmid">11319232</pub-id></mixed-citation>
      </ref>
      <ref id="B50">
        <label>50</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gargiulo</surname><given-names>CE</given-names></name><name><surname>Stuhlsatz-Krouper</surname><given-names>SM</given-names></name><name><surname>Schaffer</surname><given-names>JE</given-names></name></person-group>. <article-title>Localization of adipocyte long-chain fatty acyl-CoA synthetase at the plasma membrane</article-title>. <source>J Lipid Res</source>
<year>1999</year>;<volume>40</volume>:<fpage>881</fpage>–<lpage>892</lpage><?supplied-pmid 10224157?><pub-id pub-id-type="pmid">10224157</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:4274801</identifier><datestamp>2016-01-01</datestamp><setSpec>diabetes</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="http://jats.nlm.nih.gov/ns/archiving/1.0/ http://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Diabetes</journal-id>
      <journal-id journal-id-type="iso-abbrev">Diabetes</journal-id>
      <journal-id journal-id-type="hwp">diabetes</journal-id>
      <journal-id journal-id-type="pmc">diabetes</journal-id>
      <journal-id journal-id-type="publisher-id">Diabetes</journal-id>
      <journal-title-group>
        <journal-title>Diabetes</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0012-1797</issn>
      <issn pub-type="epub">1939-327X</issn>
      <publisher>
        <publisher-name>American Diabetes Association</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4274801</article-id>
      <article-id pub-id-type="pmcid">PMC4274801</article-id>
      <article-id pub-id-type="pmc-uid">4274801</article-id>
      <article-id pub-id-type="pmid">25125488</article-id>
      <article-id pub-id-type="publisher-id">0670</article-id>
      <article-id pub-id-type="doi">10.2337/db14-0670</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Complications</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Mineralocorticoid Receptor Blockade Improves Coronary Microvascular Function in Individuals With Type 2 Diabetes</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Garg</surname>
            <given-names>Rajesh</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rao</surname>
            <given-names>Ajay D.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Baimas-George</surname>
            <given-names>Maria</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hurwitz</surname>
            <given-names>Shelley</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Foster</surname>
            <given-names>Courtney</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shah</surname>
            <given-names>Ravi V.</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jerosch-Herold</surname>
            <given-names>Michael</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kwong</surname>
            <given-names>Raymond Y.</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">
            <sup>5</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Di Carli</surname>
            <given-names>Marcelo F.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff5">
            <sup>5</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Adler</surname>
            <given-names>Gail K.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
        <aff id="aff1"><sup>1</sup>Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA</aff>
        <aff id="aff2"><sup>2</sup>Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA</aff>
        <aff id="aff3"><sup>3</sup>Noninvasive Cardiovascular Imaging Program, Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA</aff>
        <aff id="aff4"><sup>4</sup>Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA</aff>
        <aff id="aff5"><sup>5</sup>Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">Corresponding author: Gail K. Adler, <email>gadler@partners.org</email>.</corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>14</day>
        <month>8</month>
        <year>2014</year>
      </pub-date>
      <volume>64</volume>
      <issue>1</issue>
      <fpage>236</fpage>
      <lpage>242</lpage>
      <history>
        <date date-type="received">
          <day>28</day>
          <month>4</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>10</day>
          <month>8</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.</copyright-statement>
        <copyright-year>2015</copyright-year>
      </permissions>
      <self-uri xlink:title="pdf" xlink:type="simple" xlink:href="236.pdf"/>
      <abstract>
        <p>Reduced coronary flow reserve (CFR), an indicator of coronary microvascular dysfunction, is seen in type 2 diabetes mellitus (T2DM) and predicts cardiac mortality. Since aldosterone plays a key role in vascular injury, the aim of this study was to determine whether mineralocorticoid receptor (MR) blockade improves CFR in individuals with T2DM. Sixty-four men and women with well-controlled diabetes on chronic ACE inhibition (enalapril 20 mg/day) were randomized to add-on therapy of spironolactone 25 mg, hydrochlorothiazide (HCTZ) 12.5 mg, or placebo for 6 months. CFR was assessed by cardiac positron emission tomography at baseline and at the end of treatment. There were significant and similar decreases in systolic blood pressure with spironolactone and HCTZ but not with placebo. CFR improved with treatment in the spironolactone group as compared with the HCTZ group and with the combined HCTZ and placebo groups. The increase in CFR with spironolactone remained significant after controlling for baseline CFR, change in BMI, race, and statin use. Treatment with spironolactone improved coronary microvascular function, raising the possibility that MR blockade could have beneficial effects in preventing cardiovascular disease in patients with T2DM.</p>
      </abstract>
      <counts>
        <page-count count="7"/>
      </counts>
    </article-meta>
  </front>
  <body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Individuals with type 2 diabetes mellitus (T2DM) have an increased risk of cardiovascular disease (CVD) (<xref rid="B1" ref-type="bibr">1</xref>). Diabetes accelerates coronary artery atherosclerosis and impairs coronary microvascular function (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>). In the absence of significant epicardial coronary artery disease, patients with T2DM and impaired myocardial blood flow (MBF) (coronary flow reserve [CFR] below median) have a 3.2-fold increased rate of cardiac death in comparison with those with CFR above median (<xref rid="B4" ref-type="bibr">4</xref>). Thus, CFR is a good intermediate marker of CVD.</p><p>Aldosterone plays a critical role in the pathophysiology of CVD. In heart failure patients, mineralocorticoid receptor (MR) blockade improves cardiac morbidity and mortality (<xref rid="B5" ref-type="bibr">5</xref>). MR blockade reduces coronary microvascular damage in a rodent model of angiotensin II–dependent cardiovascular injury (<xref rid="B6" ref-type="bibr">6</xref>), suggesting that excess MR activation promotes injury to the coronary microvasculature. Further, preclinical studies demonstrate that excess MR activation contributes to vascular injury in obesity and diabetes (<xref rid="B7" ref-type="bibr">7</xref>–<xref rid="B10" ref-type="bibr">10</xref>).</p><p>We hypothesized that in humans with T2DM without clinical ischemic heart disease, addition of MR blockade to chronic ACE inhibitor (ACEI) therapy would improve coronary microvascular function, as assessed by quantitative positron emission tomography (PET) measures of CFR.</p></sec><sec id="s2"><title>Research Design and Methods</title><sec id="s3"><title>Patient Population</title><p>Individuals with T2DM, aged 18–70 years, were enrolled in a double-blind, randomized, controlled study (<ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link> NCT00865124). Exclusion criteria included the following: coronary, cerebrovascular, or peripheral vascular or renal disease (estimated glomerular filtration rate &lt;60 mL/min/1.73 m<sup>2</sup>); bronchospastic lung disease; gout if not on hydrochlorothiazide (HCTZ); serum potassium &gt;5.0 mmol/L; current smoker; pregnancy; use of potassium-sparing diuretics, oral contraceptives, hormone replacement therapy, or rosiglitazone; uncontrolled hypertension (systolic blood pressure [BP] &gt;160 mmHg or diastolic BP &gt;100 mmHg); ACEI intolerance; systolic BP &lt;105 mmHg off antihypertensive therapy; and other major medical illnesses. Partners HealthCare Institutional Review Board approved the protocol, and all participants provided written informed consent.</p></sec><sec id="s4"><title>Study Procedures</title><p>Participants completed a 3-month run-in phase followed by a baseline assessment, randomization to drug treatment, and posttreatment assessment. With initiation of the 3-month run-in, participants were placed on enalapril 20 mg daily and tapered off other antihypertensive medications except amlodipine 5–10 mg daily that was added for systolic BP ≥140 mmHg. Antidiabetic medications were adjusted to achieve a goal hemoglobin A1C (HbA<sub>1c</sub>) ≤7%. Simvastatin 20 mg daily was added for direct LDL &gt;100 mg/dL if participant was statin tolerant not on a statin. Participants measured BP and blood glucose daily and communicated readings to study staff weekly.</p></sec><sec id="s5"><title>Baseline and 6-Month Assessment Protocol</title><p>Four days prior to and during the 2-day in-patient admission, participants consumed a caffeine-free, isocaloric diet (250 mmol/day Na<sup>+</sup>, 100 mmol/day K<sup>+</sup>, 1,000 mg/day Ca<sup>++</sup>, 300 mg/day Mg<sup>++</sup>, and at least 30% carbohydrate by calories). Participants stopped amlodipine 36 h prior to admission, and antidiabetic medications were adjusted to avoid hypoglycemia. Upon admission after an overnight fast, supine BP was measured every 5 min for 30 min, and the average was used for analysis. Blood samples were collected for HbA<sub>1c</sub>, glucose, and lipids, and 24-h urine collection for sodium, creatinine, and aldosterone was initiated. Participants underwent echocardiography for assessment of diastolic function, cardiac PET scan for determination of CFR (ratio of adenosine-stimulated to rest MBF), and cardiac MRI scan to determine left ventricular (LV) mass index and myocardial extracellular volume using techniques described previously (<xref rid="B11" ref-type="bibr">11</xref>). The following morning, after being supine and fasting from midnight onwards, blood was drawn for potassium, sodium, plasma renin activity, angiotensin II, and aldosterone. Assays were performed as previously described (<xref rid="B11" ref-type="bibr">11</xref>); angiotensin II was measured using ALPCO Immunoassay (Salem, NH).</p></sec><sec id="s6"><title>Drug Treatment</title><p>Participants without evidence of cardiac ischemia or prior myocardial infarction on baseline imaging were randomized 1:1:1 to 6 months of add-on daily therapy with one of three treatments: spironolactone 25 mg, HCTZ 12.5 mg with KCl 10 mEq, or matching placebo. To accommodate a funding reduction and considering the study rationale where the primary outcome was the effect of spironolactone versus HCTZ on CFR, the placebo arm was stopped after 80% of participants were randomized. All participants and study staff (except Investigational Drug Service, which was responsible for randomization) were blinded to treatment. Plasma potassium was measured at 1, 2, 4, 8, 16, and 24 weeks. A posttreatment assessment, which was identical to the baseline assessment, was completed at 6 months.</p></sec><sec id="s7"><title>Statistical Methods</title><p>Comparisons of treatment arms for demographic and other baseline variables were performed using Wilcoxon rank sum tests or χ<sup>2</sup> tests. The primary outcome was CFR, and the overall analysis framework was a repeated measures ANCOVA covering baseline and 6-month visit data. Spironolactone versus HCTZ was considered primary in the design, and HCTZ and placebo were expected to be similar. In addition to baseline CFR, covariates were selected from among those associated with vascular function (e.g., statin use, HbA<sub>1c</sub>, BMI, race, and age). All subsets were tested, retaining only those covariates contributing significantly to the multiple variable model. Diastolic function (E/e’), as a measure of the impact of CFR on cardiac function, was a secondary outcome. Data are presented as means ± SD. All statistical analyses were performed with SAS version 9.3 (SAS Institute, Cary, NC).</p></sec></sec><sec sec-type="results" id="s8"><title>Results</title><p>Prior to randomization, 24 of 93 participants who entered the run-in period were excluded. Twenty-one met the following prespecified exclusion criteria: <italic>1</italic>) evidence of ischemia or prior myocardial infarction on baseline cardiac PET and/or MRI imaging (<italic>n</italic> = 6); <italic>2</italic>) medical condition (lung mass, shortness of breath, seizures, uninephrectomy, atypical chest pain, kidney stones, or liver lesions) (<italic>n</italic> = 7); <italic>3</italic>) ACEI intolerance (<italic>n</italic> = 3); <italic>4</italic>) inability to meet blood glucose goals (<italic>n</italic> = 2); <italic>5</italic>) incarcerated (<italic>n</italic> = 1); <italic>6</italic>) enrolled in another study (<italic>n</italic> = 1); and <italic>7</italic>) illicit drug use (<italic>n</italic> = 1). Two participants withdrew consent and one was lost to follow-up. Thus, 69 participants were randomized to drug treatment. Ninety-three percent (64 participants) completed both baseline and posttreatment assessments and are included in the analysis (<ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0670/-/DC1">Supplementary Fig. 1</ext-link>).</p><p>Patient characteristics and baseline laboratory data for each treatment group are displayed in <xref ref-type="table" rid="T1">Table 1</xref>. All participants had a normal LV ejection fraction (&gt;50%), normal LV mass index (≤80 g/m<sup>2</sup>), and normal diastolic function (E/e’ ≤15). Investigational Drug Service halved the enalapril and spironolactone doses in one participant with a 4-week plasma potassium &gt;5.5 mmol/L; no further hyperkalemia was noted and study staff remained blinded as to treatment. One participant in the HCTZ group had enalapril increased to 40 mg daily for the final 4 months by his cardiologist.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Characteristics of study population at baseline assessment</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th align="left" scope="col" rowspan="1" colspan="1"/><th align="center" scope="col" rowspan="1" colspan="1">Spironolactone group</th><th align="center" scope="col" rowspan="1" colspan="1">HCTZ group</th><th align="center" scope="col" rowspan="1" colspan="1">Placebo group</th></tr></thead><tbody><tr><td align="left" scope="row" rowspan="1" colspan="1"><italic>n</italic></td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">17</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Mean age (years)</td><td align="center" rowspan="1" colspan="1">56 ± 6</td><td align="center" rowspan="1" colspan="1">53 ± 7</td><td align="center" rowspan="1" colspan="1">55 ± 10</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Male (<italic>n</italic> [%])</td><td align="center" rowspan="1" colspan="1">17 (74)</td><td align="center" rowspan="1" colspan="1">13 (54)</td><td align="center" rowspan="1" colspan="1">10 (59)</td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Race (<italic>n</italic> [%])</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Caucasian</td><td align="center" rowspan="1" colspan="1">17 (74)</td><td align="center" rowspan="1" colspan="1">17 (71)</td><td align="center" rowspan="1" colspan="1">8 (47)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> African American</td><td align="center" rowspan="1" colspan="1">4 (17)</td><td align="center" rowspan="1" colspan="1">6 (25)</td><td align="center" rowspan="1" colspan="1">7 (41)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Other</td><td align="center" rowspan="1" colspan="1">2 (9)</td><td align="center" rowspan="1" colspan="1">1 (4)</td><td align="center" rowspan="1" colspan="1">2 (12)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">31.4 ± 4.5</td><td align="center" rowspan="1" colspan="1">32.5 ± 5.4</td><td align="center" rowspan="1" colspan="1">31.3 ± 4.2</td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">BP (mmHg)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Systolic</td><td align="center" rowspan="1" colspan="1">123 ± 11</td><td align="center" rowspan="1" colspan="1">124 ± 14</td><td align="center" rowspan="1" colspan="1">125 ± 13</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Diastolic</td><td align="center" rowspan="1" colspan="1">75 ± 7</td><td align="center" rowspan="1" colspan="1">74 ± 9</td><td align="center" rowspan="1" colspan="1">77 ± 10</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Duration of diabetes (years)</td><td align="center" rowspan="1" colspan="1">9 ± 7</td><td align="center" rowspan="1" colspan="1">7 ± 6</td><td align="center" rowspan="1" colspan="1">7 ± 6</td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Diabetes medications (<italic>n</italic> [%])</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Metformin</td><td align="center" rowspan="1" colspan="1">16 (70)</td><td align="center" rowspan="1" colspan="1">20 (83)</td><td align="center" rowspan="1" colspan="1">16 (94)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Insulin</td><td align="center" rowspan="1" colspan="1">3 (13)</td><td align="center" rowspan="1" colspan="1">3 (13)</td><td align="center" rowspan="1" colspan="1">3 (18)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Sulfonylurea</td><td align="center" rowspan="1" colspan="1">7 (30)</td><td align="center" rowspan="1" colspan="1">7 (29)</td><td align="center" rowspan="1" colspan="1">7 (41)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Thiazolidinedione</td><td align="center" rowspan="1" colspan="1">1 (4)</td><td align="center" rowspan="1" colspan="1">1 (4)</td><td align="center" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> GLP-1 analog</td><td align="center" rowspan="1" colspan="1">1 (4)</td><td align="center" rowspan="1" colspan="1">1 (4)</td><td align="center" rowspan="1" colspan="1">2 (12)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Dipeptidyl peptidase-4 inhibitor</td><td align="center" rowspan="1" colspan="1">1 (4)</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Antihypertensive medications (<italic>n</italic> [%])</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Enalapril</td><td align="center" rowspan="1" colspan="1">23 (100)</td><td align="center" rowspan="1" colspan="1">24 (100)</td><td align="center" rowspan="1" colspan="1">17 (100)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Amlodipine</td><td align="center" rowspan="1" colspan="1">7 (30)</td><td align="center" rowspan="1" colspan="1">6 (25)</td><td align="center" rowspan="1" colspan="1">4 (24)</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Statin use (<italic>n</italic> [%])</td><td align="center" rowspan="1" colspan="1">17 (74)</td><td align="center" rowspan="1" colspan="1">20 (83)</td><td align="center" rowspan="1" colspan="1">11 (65)</td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Fasting laboratory data</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Blood glucose (mg/dL)</td><td align="center" rowspan="1" colspan="1">105 ± 23</td><td align="center" rowspan="1" colspan="1">106 ± 25</td><td align="center" rowspan="1" colspan="1">105 ± 24</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Total cholesterol (mg/dL)</td><td align="center" rowspan="1" colspan="1">150 ± 35</td><td align="center" rowspan="1" colspan="1">153 ± 24</td><td align="center" rowspan="1" colspan="1">139 ± 24</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> LDL cholesterol (mg/dL)</td><td align="center" rowspan="1" colspan="1">81 ± 27</td><td align="center" rowspan="1" colspan="1">82 ± 20</td><td align="center" rowspan="1" colspan="1">75 ± 21</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> HDL cholesterol (mg/dL)</td><td align="center" rowspan="1" colspan="1">47 ± 12</td><td align="center" rowspan="1" colspan="1">45 ± 12</td><td align="center" rowspan="1" colspan="1">41 ± 12</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Triglycerides (mg/dL)</td><td align="center" rowspan="1" colspan="1">113 ± 39</td><td align="center" rowspan="1" colspan="1">130 ± 77</td><td align="center" rowspan="1" colspan="1">120 ± 72</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> HbA<sub>1c</sub> (%)</td><td align="center" rowspan="1" colspan="1">6.6 ± 0.4</td><td align="center" rowspan="1" colspan="1">7.0 ± 0.9</td><td align="center" rowspan="1" colspan="1">7.0 ± 0.7</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Serum sodium (mmol/L)</td><td align="center" rowspan="1" colspan="1">139.5 ± 2.1</td><td align="center" rowspan="1" colspan="1">139.0 ± 2.1</td><td align="center" rowspan="1" colspan="1">139.2 ± 1.5</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Serum potassium (mmol/L)</td><td align="center" rowspan="1" colspan="1">4.2 ± 0.3</td><td align="center" rowspan="1" colspan="1">4.3 ± 0.3</td><td align="center" rowspan="1" colspan="1">4.2 ± 0.2</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Creatinine clearance rate (mL/min)</td><td align="center" rowspan="1" colspan="1">129 ± 30</td><td align="center" rowspan="1" colspan="1">126 ± 26</td><td align="center" rowspan="1" colspan="1">124 ± 38</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Plasma renin activity (ng/mL/h)</td><td align="center" rowspan="1" colspan="1">1.5 ± 2.2</td><td align="center" rowspan="1" colspan="1">2.3 ± 3.3</td><td align="center" rowspan="1" colspan="1">2.4 ± 3.9</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Serum angiotensin II (pg/mL)</td><td align="center" rowspan="1" colspan="1">18.01 ± 8.89</td><td align="center" rowspan="1" colspan="1">22.59 ± 6.17</td><td align="center" rowspan="1" colspan="1">19.15 ± 5.82</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Serum aldosterone (ng/dL)</td><td align="center" rowspan="1" colspan="1">3.13 ± 1.46</td><td align="center" rowspan="1" colspan="1">3.21 ± 1.19</td><td align="center" rowspan="1" colspan="1">3.84 ± 2.14</td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Echocardiography</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="col" rowspan="1" colspan="1"> Mitral inflow</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> E (m/s)</td><td align="center" rowspan="1" colspan="1">0.76 ± 0.14</td><td align="center" rowspan="1" colspan="1">0.74 ± 0.14</td><td align="center" rowspan="1" colspan="1">0.68 ± 0.13</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> A (m/s)</td><td align="center" rowspan="1" colspan="1">0.68 ± 0.17</td><td align="center" rowspan="1" colspan="1">0.66 ± 0.16</td><td align="center" rowspan="1" colspan="1">0.67 ± 0.17</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Deceleration time (ms)</td><td align="center" rowspan="1" colspan="1">220.38 ± 37.94</td><td align="center" rowspan="1" colspan="1">212.04 ± 37.36</td><td align="center" rowspan="1" colspan="1">216.88 ± 31.75</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> E/A ratio</td><td align="center" rowspan="1" colspan="1">1.15 ± 0.23</td><td align="center" rowspan="1" colspan="1">1.13 ± 0.29</td><td align="center" rowspan="1" colspan="1">1.05 ± 0.23</td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1"> Tissue Doppler imaging</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> e’ (m/s)</td><td align="center" rowspan="1" colspan="1">0.11 ± 0.02</td><td align="center" rowspan="1" colspan="1">0.11 ± 0.03</td><td align="center" rowspan="1" colspan="1">0.11 ± 0.02</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> E/e’ ratio</td><td align="center" rowspan="1" colspan="1">7.24 ± 2.00</td><td align="center" rowspan="1" colspan="1">6.92 ± 1.59</td><td align="center" rowspan="1" colspan="1">6.58 ± 1.68</td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Cardiac MRI</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> LV mass index (g/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">46.4 ± 12.2</td><td align="center" rowspan="1" colspan="1">43.6 ± 10.9</td><td align="center" rowspan="1" colspan="1">46.7 ± 11.2</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> LV ejection fraction (%)</td><td align="center" rowspan="1" colspan="1">61.4 ± 4.5</td><td align="center" rowspan="1" colspan="1">60.2 ± 7.0</td><td align="center" rowspan="1" colspan="1">60.4 ± 5.0</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Myocardial extracellular volume</td><td align="center" rowspan="1" colspan="1">0.36 ± 0.06</td><td align="center" rowspan="1" colspan="1">0.34 ± 0.04</td><td align="center" rowspan="1" colspan="1">0.38 ± 0.04</td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">24-h Urine results</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Sodium (mmol/24 h)</td><td align="center" rowspan="1" colspan="1">291 ± 74</td><td align="center" rowspan="1" colspan="1">258 ± 72</td><td align="center" rowspan="1" colspan="1">256 ± 77</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Creatinine (mg/24 h)</td><td align="center" rowspan="1" colspan="1">1,599.7 ± 407.5</td><td align="center" rowspan="1" colspan="1">1,510.4 ± 326.9</td><td align="center" rowspan="1" colspan="1">1,537.8 ± 466.1</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Potassium (mmol/24 h)</td><td align="center" rowspan="1" colspan="1">97.8 ± 15.0</td><td align="center" rowspan="1" colspan="1">91.1 ± 19.1</td><td align="center" rowspan="1" colspan="1">88.8 ± 29.1</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Aldosterone (μg/24 h)</td><td align="center" rowspan="1" colspan="1">6.49 ± 6.46</td><td align="center" rowspan="1" colspan="1">7.19 ± 5.16</td><td align="center" rowspan="1" colspan="1">6.17 ± 4.99</td></tr></tbody></table><table-wrap-foot><fn><p>Data are expressed as mean ± SD unless stated otherwise. There were no significant differences between treatment groups prerandomization.</p></fn></table-wrap-foot></table-wrap><p>Average treatment duration was 5.9 ± 0.5 months for spironolactone, 5.6 ± 0.9 months for HCTZ, and 5.7 ± 0.3 months for placebo (<italic>P</italic> = NS). <xref ref-type="table" rid="T2">Table 2</xref> shows the changes in study parameters between visits. There were significant and similar decreases in systolic BP with spironolactone and HCTZ. Serum potassium increased significantly with spironolactone but not with other treatments. There were no significant changes from baseline in HbA<sub>1c</sub>, total cholesterol, HDL, calculated LDL (cLDL), triglycerides, and BMI with any treatment. Diastolic function, LV mass index, LV ejection fraction, and myocardial extracellular volume were unaffected by treatment.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Change in study parameter with treatment<xref ref-type="table-fn" rid="t2n1">†</xref></p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th align="left" scope="col" rowspan="1" colspan="1"/><th align="center" scope="col" rowspan="1" colspan="1">Spironolactone group</th><th align="center" scope="col" rowspan="1" colspan="1">HCTZ group</th><th align="center" scope="col" rowspan="1" colspan="1">Placebo group</th><th align="center" scope="col" rowspan="1" colspan="1"><italic>P</italic> value spiro vs. HCTZ</th><th align="center" scope="col" rowspan="1" colspan="1"><italic>P</italic> value spiro vs. HCTZ + placebo</th></tr></thead><tbody><tr><td align="left" scope="row" rowspan="1" colspan="1"><italic>n</italic></td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Δ BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">0.07 ± 0.9</td><td align="center" rowspan="1" colspan="1">−0.06 ± 1.02</td><td align="center" rowspan="1" colspan="1">−0.11 ± 1.25</td><td align="center" rowspan="1" colspan="1">0.59</td><td align="center" rowspan="1" colspan="1">0.59</td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Δ BP (mmHg)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Systolic</td><td align="center" rowspan="1" colspan="1">−7 ± 13<xref ref-type="table-fn" rid="t2n2">*</xref></td><td align="center" rowspan="1" colspan="1">−5 ± 10<xref ref-type="table-fn" rid="t2n2">*</xref></td><td align="center" rowspan="1" colspan="1">−1 ± 12</td><td align="center" rowspan="1" colspan="1">0.56</td><td align="center" rowspan="1" colspan="1">0.25</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Diastolic</td><td align="center" rowspan="1" colspan="1">−5 ± 7<xref ref-type="table-fn" rid="t2n3">‡</xref></td><td align="center" rowspan="1" colspan="1">−2 ± 7</td><td align="center" rowspan="1" colspan="1">−2 ± 7</td><td align="center" rowspan="1" colspan="1">0.07</td><td align="center" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Δ Fasting laboratory data</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Glucose (mg/dL)</td><td align="center" rowspan="1" colspan="1">10.5 ± 23.9</td><td align="center" rowspan="1" colspan="1">8.3 ± 25.1</td><td align="center" rowspan="1" colspan="1">2.7 ± 11.8</td><td align="center" rowspan="1" colspan="1">0.99</td><td align="center" rowspan="1" colspan="1">0.52</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Total cholesterol (mg/dL)</td><td align="center" rowspan="1" colspan="1">3.6 ± 32.1</td><td align="center" rowspan="1" colspan="1">2.4 ± 30.2</td><td align="center" rowspan="1" colspan="1">13.8 ± 32.5</td><td align="center" rowspan="1" colspan="1">0.24</td><td align="center" rowspan="1" colspan="1">0.12</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> LDL cholesterol (mg/dL)</td><td align="center" rowspan="1" colspan="1">2.9 ± 25.4</td><td align="center" rowspan="1" colspan="1">1.6 ± 25.2</td><td align="center" rowspan="1" colspan="1">9.7 ± 30.3</td><td align="center" rowspan="1" colspan="1">0.46</td><td align="center" rowspan="1" colspan="1">0.36</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> HDL cholesterol (mg/dL)</td><td align="center" rowspan="1" colspan="1">−2.0 ± 5.6</td><td align="center" rowspan="1" colspan="1">1.6 ± 5.0</td><td align="center" rowspan="1" colspan="1">2.8 ± 6.1</td><td align="center" rowspan="1" colspan="1">0.05</td><td align="center" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Triglycerides (mg/dL)</td><td align="center" rowspan="1" colspan="1">13.4 ± 37.7</td><td align="center" rowspan="1" colspan="1">1.9 ± 46.9</td><td align="center" rowspan="1" colspan="1">11.8 ± 48.3</td><td align="center" rowspan="1" colspan="1">0.74</td><td align="center" rowspan="1" colspan="1">0.65</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> HbA<sub>1c</sub> (%)</td><td align="center" rowspan="1" colspan="1">0.16 ± 0.39</td><td align="center" rowspan="1" colspan="1">0.08 ± 0.75</td><td align="center" rowspan="1" colspan="1">0.06 ± 0.45</td><td align="center" rowspan="1" colspan="1">0.94</td><td align="center" rowspan="1" colspan="1">0.64</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Serum sodium (mmol/L)</td><td align="center" rowspan="1" colspan="1">−1.5 ± 2.6</td><td align="center" rowspan="1" colspan="1">−0.3 ± 2.1</td><td align="center" rowspan="1" colspan="1">0.0 ± 2.8</td><td align="center" rowspan="1" colspan="1">0.09</td><td align="center" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Serum potassium (mmol/L)</td><td align="center" rowspan="1" colspan="1">0.22 ± 0.3†</td><td align="center" rowspan="1" colspan="1">0.03 ± 0.3</td><td align="center" rowspan="1" colspan="1">0.04 ± 0.2</td><td align="center" rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Δ 24-h Urine sodium (mmol/24 h)</td><td align="center" rowspan="1" colspan="1">−19.6 ± 76.9</td><td align="center" rowspan="1" colspan="1">3.9 ± 78.5</td><td align="center" rowspan="1" colspan="1">16.5 ± 71.3</td><td align="center" rowspan="1" colspan="1">0.31</td><td align="center" rowspan="1" colspan="1">0.15</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Δ Creatinine clearance (mL/min)</td><td align="center" rowspan="1" colspan="1">−2.6 ± 21.4</td><td align="center" rowspan="1" colspan="1">−1.0 ± 20.4</td><td align="center" rowspan="1" colspan="1">−0.8 ± 13.0</td><td align="center" rowspan="1" colspan="1">0.96</td><td align="center" rowspan="1" colspan="1">0.98</td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Cardiac MRI</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Δ LV mass index (g/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">6.03 ± 22.50</td><td align="center" rowspan="1" colspan="1">4.81 ± 26.24</td><td align="center" rowspan="1" colspan="1">8.00 ± 24.05</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">0.91</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Δ LV ejection fraction (%)</td><td align="center" rowspan="1" colspan="1">−0.87 ± 5.83</td><td align="center" rowspan="1" colspan="1">0.32 ± 8.25</td><td align="center" rowspan="1" colspan="1">1.08 ± 5.20</td><td align="center" rowspan="1" colspan="1">0.22</td><td align="center" rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Δ Extracellular volume</td><td align="center" rowspan="1" colspan="1">0.00 ± 0.08</td><td align="center" rowspan="1" colspan="1">0.00 ± 0.04</td><td align="center" rowspan="1" colspan="1">0.00 ± 0.03</td><td align="center" rowspan="1" colspan="1">0.64</td><td align="center" rowspan="1" colspan="1">0.94</td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Echocardiography</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> Mitral inflow</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Δ E (m/s)</td><td align="center" rowspan="1" colspan="1">−0.03 ± 0.15</td><td align="center" rowspan="1" colspan="1">−0.02 ± 0.09</td><td align="center" rowspan="1" colspan="1">0.01 ± 0.09</td><td align="center" rowspan="1" colspan="1">0.87</td><td align="center" rowspan="1" colspan="1">0.66</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Δ A (m/s)</td><td align="center" rowspan="1" colspan="1">−0.02 ± 0.12</td><td align="center" rowspan="1" colspan="1">−0.02 ± 0.11</td><td align="center" rowspan="1" colspan="1">−0.01 ± 0.12</td><td align="center" rowspan="1" colspan="1">0.84</td><td align="center" rowspan="1" colspan="1">0.88</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Δ Deceleration time (ms)</td><td align="center" rowspan="1" colspan="1">−17.93 ± 60.90</td><td align="center" rowspan="1" colspan="1">8.18 ± 61.24</td><td align="center" rowspan="1" colspan="1">7.56 ± 57.34</td><td align="center" rowspan="1" colspan="1">0.49</td><td align="center" rowspan="1" colspan="1">0.53</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Δ E/A ratio</td><td align="center" rowspan="1" colspan="1">−0.02 ± 0.32</td><td align="center" rowspan="1" colspan="1">0.02 ± 0.18</td><td align="center" rowspan="1" colspan="1">0.04 ± 0.21</td><td align="center" rowspan="1" colspan="1">0.75</td><td align="center" rowspan="1" colspan="1">0.58</td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1"> Tissue Doppler imaging</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Δ e’ (m/s)</td><td align="center" rowspan="1" colspan="1">−0.01 ± 0.02</td><td align="center" rowspan="1" colspan="1">0.00 ± 0.02</td><td align="center" rowspan="1" colspan="1">0.00 ± 0.01</td><td align="center" rowspan="1" colspan="1">0.45</td><td align="center" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Secondary outcome</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Δ E/e’ ratio</td><td align="center" rowspan="1" colspan="1">0.02 ± 1.61</td><td align="center" rowspan="1" colspan="1">0.06 ± 1.35</td><td align="center" rowspan="1" colspan="1">0.64 ± 1.95</td><td align="center" rowspan="1" colspan="1">0.65</td><td align="center" rowspan="1" colspan="1">0.85</td></tr></tbody></table><table-wrap-foot><fn id="t2n1"><p>†Posttreatment study parameter minus baseline study parameter.</p></fn><fn id="t2n2"><p>*<italic>P</italic> &lt; 0.05, indicates significant change from baseline within treatment group.</p></fn><fn id="t2n3"><p>‡<italic>P</italic> &lt; 0.01, indicates significant change from baseline within treatment group. spiro, spironolactone.</p></fn></table-wrap-foot></table-wrap><sec id="s9"><title>MBF and Flow Reserve</title><p>Complete MBF and CFR data (<xref ref-type="table" rid="T3">Table 3</xref>) were available in 60 participants; four participants had technical difficulties with the dynamic PET images (spironolactone, <italic>n</italic> = 1; HCTZ, <italic>n</italic> = 2; and placebo, <italic>n</italic> = 1). There was a significantly greater increase in CFR from baseline to posttreatment in the spironolactone group as compared with the HCTZ group (0.33 vs. −0.10, <italic>P</italic> = 0.04) and as compared with the combined HCTZ and placebo groups (0.33 vs. −0.05, <italic>P</italic> = 0.047).</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Cardiac PET imaging parameters</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th align="left" scope="col" rowspan="1" colspan="1">Characteristic</th><th align="center" scope="col" rowspan="1" colspan="1">Spironolactone group</th><th align="center" scope="col" rowspan="1" colspan="1">HCTZ group</th><th align="center" scope="col" rowspan="1" colspan="1">Placebo group</th><th align="center" scope="col" rowspan="1" colspan="1"><italic>P</italic> value spiro vs. HCTZ</th><th align="center" scope="col" rowspan="1" colspan="1"><italic>P</italic> value spiro vs. HCTZ + placebo</th></tr></thead><tbody><tr><td align="left" scope="row" rowspan="1" colspan="1"><italic>n</italic></td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Primary outcome</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Change in global CFR  (posttreatment minus baseline)<xref ref-type="table-fn" rid="t3n1">*</xref></td><td align="center" rowspan="1" colspan="1">0.33 ± 0.83</td><td align="center" rowspan="1" colspan="1">−0.10 ± 0.65</td><td align="center" rowspan="1" colspan="1">0.02 ± 1.03</td><td align="center" rowspan="1" colspan="1">0.04</td><td align="center" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Additional measures</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Change in rest global MBF  (mL ⋅ g<sup>−1</sup> ⋅ min<sup>−1</sup>)<xref ref-type="table-fn" rid="t3n1">*</xref></td><td align="center" rowspan="1" colspan="1">−0.07 ± 0.16</td><td align="center" rowspan="1" colspan="1">0.01 ± 0.11</td><td align="center" rowspan="1" colspan="1">−0.07 ± 0.13</td><td align="center" rowspan="1" colspan="1">0.14</td><td align="center" rowspan="1" colspan="1">0.46</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Change in stress global MBF  (mL ⋅ g<sup>−1</sup> ⋅ min<sup>−1</sup>)<xref ref-type="table-fn" rid="t3n1">*</xref></td><td align="center" rowspan="1" colspan="1">0.06 ± 0.46</td><td align="center" rowspan="1" colspan="1">−0.02 ± 0.34</td><td align="center" rowspan="1" colspan="1">−0.08 ± 0.57</td><td align="center" rowspan="1" colspan="1">0.75</td><td align="center" rowspan="1" colspan="1">0.54</td></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Prerandomization</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Global CFR</td><td align="center" rowspan="1" colspan="1">2.77 ± 0.82</td><td align="center" rowspan="1" colspan="1">2.92 ± 0.52</td><td align="center" rowspan="1" colspan="1">2.68 ± 0.93</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Rest global MBF  (mL ⋅ g<sup>−1</sup> ⋅ min<sup>−1</sup>)</td><td align="center" rowspan="1" colspan="1">0.78 ± 0.23</td><td align="center" rowspan="1" colspan="1">0.70 ± 0.13</td><td align="center" rowspan="1" colspan="1">0.73 ± 0.20</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Stress global MBF  (mL ⋅ g<sup>−1</sup> ⋅ min<sup>−1</sup>)</td><td align="center" rowspan="1" colspan="1">2.03 ± 0.38</td><td align="center" rowspan="1" colspan="1">2.00 ± 0.37</td><td align="center" rowspan="1" colspan="1">1.81 ± 0.40</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="col" rowspan="1" colspan="1">Posttreatment</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Global CFR</td><td align="center" rowspan="1" colspan="1">3.10 ± 1.04</td><td align="center" rowspan="1" colspan="1">2.83 ± 0.55</td><td align="center" rowspan="1" colspan="1">2.69 ± 0.96</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Rest global MBF  (mL ⋅ g<sup>−1</sup> ⋅ min<sup>−1</sup>)</td><td align="center" rowspan="1" colspan="1">0.72 ± 0.20</td><td align="center" rowspan="1" colspan="1">0.71 ± 0.11</td><td align="center" rowspan="1" colspan="1">0.66 ± 0.17</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"> Stress global MBF  (mL ⋅ g<sup>−1</sup> ⋅ min<sup>−1</sup>)</td><td align="center" rowspan="1" colspan="1">2.09 ± 0.50</td><td align="center" rowspan="1" colspan="1">1.98 ± 0.41</td><td align="center" rowspan="1" colspan="1">1.73 ± 0.61</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="t3n1"><p>*Posttreatment study parameter minus baseline study parameter. spiro, spironolactone.</p></fn></table-wrap-foot></table-wrap><p>An ANCOVA model predicting CFR posttreatment revealed a significant effect of treatment (<italic>P</italic> = 0.03), taking into account race (<italic>P</italic> = 0.07), statin use (<italic>P</italic> = 0.03), baseline CFR (<italic>P</italic> &lt; 0.0001), and BMI change over the treatment period (<italic>P</italic> = 0.0002). Factors not contributing to the model included age, sex, insulin use, amlodipine use, duration of diabetes, baseline BMI, hypertensive status at screen, and either the baseline or change with treatment of HbA<sub>1c</sub>, BP, rest rate pressure product assessed during PET, potassium, TSH, total cholesterol, cLDL, and triglycerides. A priori treatment group contrasts demonstrated that CFR increased with spironolactone significantly more than with HCTZ (<italic>P</italic> = 0.02), placebo (<italic>P</italic> = 0.05), and the combined HCTZ/placebo groups (<italic>P</italic> = 0.01). HCTZ and placebo had similar effects on CFR (<italic>P</italic> = 0.79). The predicted change (95% CI) in CFR was +0.38 (0.11, 0.65) with spironolactone, −0.10 (−0.38, 0.18) with HCTZ, and −0.05 (−0.38, 0.28) with placebo after multivariable adjustment (<xref ref-type="fig" rid="F1">Fig. 1</xref>).</p><fig id="F1" fig-type="figure" position="float"><label>Figure 1</label><caption><p>An ANCOVA model predicting the change with treatment in CFR. Spironolactone treatment improved CFR as compared with HCTZ (*<italic>P</italic> = 0.02), placebo (†<italic>P</italic> = 0.05), and combined HCTZ/placebo groups (‡<italic>P</italic> = 0.01). HCTZ and placebo had similar effects on CFR (<italic>P</italic> = 0.79). The predicted adjusted change (95% CI) in posttreatment CFR was 0.38 (0.11, 0.65) with spironolactone, −0.10 (−0.38, 0.18) with HCTZ, and −0.05 (−0.38, 0.28) with placebo. Model adjusts for race, statin use, baseline CFR, and the change in BMI over the treatment period.</p></caption><graphic xlink:href="236fig1"/></fig><p>A secondary analysis to identify additional factors predicting posttreatment CFR found that both LV mass index (<italic>P</italic> = 0.03) and baseline serum aldosterone (<italic>P</italic> = 0.02), but not E/e’ (<italic>P</italic> = 0.29), contributed to the ANCOVA model, where the predicted change in CFR with spironolactone (+0.34 [0.06, 0.61]) remained significantly higher than with HCTZ (<italic>P</italic> = 0.006) and combined HCTZ/placebo (<italic>P</italic> = 0.014).</p></sec></sec><sec sec-type="discussion" id="s10"><title>Discussion</title><p>Addition of spironolactone to standard therapy, including ACEI, improved CFR in patients with well-controlled T2DM without clinical ischemic heart disease, suggesting that excess MR activation contributes to coronary microvascular dysfunction in T2DM. Our observation that MR blockade improves CFR is consistent with the current understanding of MR biology. MR is expressed in endothelium, vascular smooth muscle cells (<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B13" ref-type="bibr">13</xref>), cardiomyocytes (<xref rid="B14" ref-type="bibr">14</xref>), and circulating leukocytes (<xref rid="B15" ref-type="bibr">15</xref>). MR activation causes vascular inflammation with increased ROS production and increased expression of PAI-1 and ICAM, vascular damage, vascular dysfunction, and perivascular fibrosis (<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B15" ref-type="bibr">15</xref>–<xref rid="B17" ref-type="bibr">17</xref>). In rodents, excess MR activity is associated with a proinflammatory phenotype involving the intramural coronary circulation and myocardium (<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B19" ref-type="bibr">19</xref>).</p><p>The improvement in CFR with MR blockade in the current study is consistent with the results of our pilot study assessing effects of eplerenone in a crossover design on cardiac MRI determinations of CFR in 12 individuals with type 1 diabetes mellitus or T2DM and microalbuminuria (<xref rid="B20" ref-type="bibr">20</xref>). Additionally, we report herein that both statin use and weight loss were significant predictors of an improvement in CFR with treatment in our multivariable model; we believe the weight loss association is novel. The CFR benefits contrast with studies in diabetes showing no improvement (and in one study a detriment) with MR blockade in forearm vascular endothelial function (<xref rid="B20" ref-type="bibr">20</xref>–<xref rid="B22" ref-type="bibr">22</xref>), perhaps related to intrinsic differences in the regulation of the coronary versus peripheral vasculature.</p><p>The strengths of this physiological study include the well-controlled cardiometabolic phenotype, addition of MR blockade to standard medical therapy, comparison of MR blockade to another antihypertensive medication and to placebo, and the assessment of coronary microvascular function under highly controlled conditions that controlled for possible confounders such as dietary sodium, low or high glucose levels, lipid levels, and BP. We hypothesize that since this study excluded patients with ischemic heart disease, the improvements we saw in CFR with MR blockade reflect improvement in microvascular function. Furthermore, since 87% of our 69 participants had interpretable pre- and posttreatment CFR data, our results are likely applicable to patients with clinical characteristics similar to our study population.</p><p>Limitations include the lack of assessment of cardiovascular events, sample size, and duration of this physiological study. Further, although spironolactone improved CFR as compared with HCTZ and as compared with combined HCTZ and placebo treatments, we cannot rule out the possibility that HCTZ may have impaired CFR. We did not see an effect of MR blockade on diastolic function, possibly related to the lack of diastolic dysfunction at baseline, or on myocardial extracellular volume, possibly because cardiac remodeling takes longer than 6 months. Due to spironolactone’s effects on potassium homeostasis, we restricted this study to individuals with good renal function. Novel MR antagonists, which preserve the cardiovascular benefits of spironolactone but lack the adverse potassium effects, are currently in development and could prove to be useful in patients with diabetes (<xref rid="B23" ref-type="bibr">23</xref>). Also, selective MR antagonists, like eplerenone, may prove to be beneficial in patients who cannot tolerate the antiandrogen or antiprogesterone effects of spironolactone. Finally, CFR is an intermediate marker for cardiovascular outcomes. It remains to be determined if there is a cause and effect relationship between CFR and cardiovascular health, and whether increasing CFR through administration of an MR antagonist will lead to reductions in cardiovascular events.</p><p>This proof-of-concept study demonstrating improvement in CFR with MR blockade may have important clinical implications. Impaired CFR is associated with increased mortality in patients with no evidence for CAD (<xref rid="B4" ref-type="bibr">4</xref>). Thus, it is possible that MR antagonists over and above ACEI/angiotensin receptor blocker therapy may lead to significant cardiovascular benefits in patients with diabetes. Future studies are needed to address this possibility.</p></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>Supplementary Data</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_64_1_236__index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_db14-0670_DB140670SupplementaryData.pdf"/>
</supplementary-material>
</sec>
</body>
  <back>
    <fn-group>
      <fn id="fn1" fn-type="supplementary-material">
        <p>This article contains Supplementary Data online at <ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0670/-/DC1">http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0670/-/DC1</ext-link>.</p>
      </fn>
      <fn id="fn2">
        <p>See accompanying article, p. <related-article related-article-type="companion" id="d35e1680" vol="64" page="3" ext-link-type="pmc">3</related-article>.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Article Information</title>
      <p><bold>Funding.</bold> This work was supported by National Institutes of Health grants UL-1TR-000170 (Harvard Catalyst, Harvard Clinical and Translational Science Center), K24-HL-103845 (G.K.A.), R01-HL-087060 (G.K.A.), and T32-HL-007609 (A.D.R.).</p>
      <p><bold>Duality of Interest.</bold> No potential conflicts of interest relevant to this article were reported.</p>
      <p><bold>Author Contributions.</bold> R.G. recruited participants, conducted the study, interpreted data, and wrote the manuscript. A.D.R. recruited participants, helped in clinical management of study participants, conducted the study, and interpreted data. M.B.-G. helped in conducting the study and collected data. S.H. performed statistical analysis. C.F. helped with PET imaging analysis. R.V.S. performed and interpreted MRI scans. M.J.-H. analyzed MRI data. R.Y.K. directed MRI imaging. M.F.D.C. directed PET imaging and analysis. G.K.A. conceived the idea, procured funding, directed and conducted the study, interpreted data, and wrote the manuscript. All authors contributed to the manuscript and take full responsibility for its originality. G.K.A. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>PW</given-names></name><name><surname>D’Agostino</surname><given-names>RB</given-names></name><name><surname>Levy</surname><given-names>D</given-names></name><name><surname>Belanger</surname><given-names>AM</given-names></name><name><surname>Silbershatz</surname><given-names>H</given-names></name><name><surname>Kannel</surname><given-names>WB</given-names></name></person-group>. <article-title>Prediction of coronary heart disease using risk factor categories</article-title>. <source>Circulation</source>
<year>1998</year>;<volume>97</volume>:<fpage>1837</fpage>–<lpage>1847</lpage><?supplied-pmid 9603539?><pub-id pub-id-type="pmid">9603539</pub-id></mixed-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beckman</surname><given-names>JA</given-names></name><name><surname>Creager</surname><given-names>MA</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name></person-group>. <article-title>Diabetes and atherosclerosis: epidemiology, pathophysiology, and management</article-title>. <source>JAMA</source>
<year>2002</year>;<volume>287</volume>:<fpage>2570</fpage>–<lpage>2581</lpage><?supplied-pmid 12020339?><pub-id pub-id-type="pmid">12020339</pub-id></mixed-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Carli</surname><given-names>MF</given-names></name><name><surname>Janisse</surname><given-names>J</given-names></name><name><surname>Grunberger</surname><given-names>G</given-names></name><name><surname>Ager</surname><given-names>J</given-names></name></person-group>. <article-title>Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes</article-title>. <source>J Am Coll Cardiol</source>
<year>2003</year>;<volume>41</volume>:<fpage>1387</fpage>–<lpage>1393</lpage><?supplied-pmid 12706936?><pub-id pub-id-type="pmid">12706936</pub-id></mixed-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murthy</surname><given-names>VL</given-names></name><name><surname>Naya</surname><given-names>M</given-names></name><name><surname>Foster</surname><given-names>CR</given-names></name><etal/></person-group>. <article-title>Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus</article-title>. <source>Circulation</source>
<year>2012</year>;<volume>126</volume>:<fpage>1858</fpage>–<lpage>1868</lpage><?supplied-pmid 22919001?><pub-id pub-id-type="pmid">22919001</pub-id></mixed-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markowitz</surname><given-names>M</given-names></name><name><surname>Messineo</surname><given-names>F</given-names></name><name><surname>Coplan</surname><given-names>NL</given-names></name></person-group>. <article-title>Aldosterone receptor antagonists in cardiovascular disease: a review of the recent literature and insight into potential future indications</article-title>. <source>Clin Cardiol</source>
<year>2012</year>;<volume>35</volume>:<fpage>605</fpage>–<lpage>609</lpage><?supplied-pmid 22778046?><pub-id pub-id-type="pmid">22778046</pub-id></mixed-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oestreicher</surname><given-names>EM</given-names></name><name><surname>Martinez-Vasquez</surname><given-names>D</given-names></name><name><surname>Stone</surname><given-names>JR</given-names></name><etal/></person-group>. <article-title>Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury</article-title>. <source>Circulation</source>
<year>2003</year>;<volume>108</volume>:<fpage>2517</fpage>–<lpage>2523</lpage><?supplied-pmid 14581407?><pub-id pub-id-type="pmid">14581407</pub-id></mixed-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schäfer</surname><given-names>N</given-names></name><name><surname>Lohmann</surname><given-names>C</given-names></name><name><surname>Winnik</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity</article-title>. <source>Eur Heart J</source>
<year>2013</year>;<volume>34</volume>:<fpage>3515</fpage>–<lpage>3524</lpage><?supplied-pmid 23594590?><pub-id pub-id-type="pmid">23594590</pub-id></mixed-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pojoga</surname><given-names>LH</given-names></name><name><surname>Baudrand</surname><given-names>R</given-names></name><name><surname>Adler</surname><given-names>GK</given-names></name></person-group>. <article-title>Mineralocorticoid receptor throughout the vessel: a key to vascular dysfunction in obesity</article-title>. <source>Eur Heart J</source>
<year>2013</year>;<volume>34</volume>:<fpage>3475</fpage>–<lpage>3477</lpage><?supplied-pmid 23666249?><pub-id pub-id-type="pmid">23666249</pub-id></mixed-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bender</surname><given-names>SB</given-names></name><name><surname>McGraw</surname><given-names>AP</given-names></name><name><surname>Jaffe</surname><given-names>IZ</given-names></name><name><surname>Sowers</surname><given-names>JR</given-names></name></person-group>. <article-title>Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease</article-title>? <source>Diabetes</source>
<year>2013</year>;<volume>62</volume>:<fpage>313</fpage>–<lpage>319</lpage><?supplied-pmid 23349535?><pub-id pub-id-type="pmid">23349535</pub-id></mixed-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiffrin</surname><given-names>EL</given-names></name></person-group>. <article-title>Effects of aldosterone on the vasculature</article-title>. <source>Hypertension</source>
<year>2006</year>;<volume>47</volume>:<fpage>312</fpage>–<lpage>318</lpage><?supplied-pmid 16432039?><pub-id pub-id-type="pmid">16432039</pub-id></mixed-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>AD</given-names></name><name><surname>Shah</surname><given-names>RV</given-names></name><name><surname>Garg</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Aldosterone and myocardial extracellular matrix expansion in type 2 diabetes mellitus</article-title>. <source>Am J Cardiol</source>
<year>2013</year>;<volume>112</volume>:<fpage>73</fpage>–<lpage>78</lpage><?supplied-pmid 23597770?><pub-id pub-id-type="pmid">23597770</pub-id></mixed-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatakeyama</surname><given-names>H</given-names></name><name><surname>Miyamori</surname><given-names>I</given-names></name><name><surname>Fujita</surname><given-names>T</given-names></name><name><surname>Takeda</surname><given-names>Y</given-names></name><name><surname>Takeda</surname><given-names>R</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name></person-group>. <article-title>Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells</article-title>. <source>J Biol Chem</source>
<year>1994</year>;<volume>269</volume>:<fpage>24316</fpage>–<lpage>24320</lpage><?supplied-pmid 7929089?><pub-id pub-id-type="pmid">7929089</pub-id></mixed-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caprio</surname><given-names>M</given-names></name><name><surname>Newfell</surname><given-names>BG</given-names></name><name><surname>la Sala</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion</article-title>. <source>Circ Res</source>
<year>2008</year>;<volume>102</volume>:<fpage>1359</fpage>–<lpage>1367</lpage><?supplied-pmid 18467630?><pub-id pub-id-type="pmid">18467630</pub-id></mixed-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lombès</surname><given-names>M</given-names></name><name><surname>Alfaidy</surname><given-names>N</given-names></name><name><surname>Eugene</surname><given-names>E</given-names></name><name><surname>Lessana</surname><given-names>A</given-names></name><name><surname>Farman</surname><given-names>N</given-names></name><name><surname>Bonvalet</surname><given-names>JP</given-names></name></person-group>. <article-title>Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart</article-title>. <source>Circulation</source>
<year>1995</year>;<volume>92</volume>:<fpage>175</fpage>–<lpage>182</lpage><?supplied-pmid 7600648?><pub-id pub-id-type="pmid">7600648</pub-id></mixed-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bienvenu</surname><given-names>LA</given-names></name><name><surname>Morgan</surname><given-names>J</given-names></name><name><surname>Rickard</surname><given-names>AJ</given-names></name><etal/></person-group>. <article-title>Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis</article-title>. <source>Endocrinology</source>
<year>2012</year>;<volume>153</volume>:<fpage>3416</fpage>–<lpage>3425</lpage><?supplied-pmid 22653557?><pub-id pub-id-type="pmid">22653557</pub-id></mixed-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viel</surname><given-names>EC</given-names></name><name><surname>Benkirane</surname><given-names>K</given-names></name><name><surname>Javeshghani</surname><given-names>D</given-names></name><name><surname>Touyz</surname><given-names>RM</given-names></name><name><surname>Schiffrin</surname><given-names>EL</given-names></name></person-group>. <article-title>Xanthine oxidase and mitochondria contribute to vascular superoxide anion generation in DOCA-salt hypertensive rats</article-title>. <source>Am J Physiol Heart Circ Physiol</source>
<year>2008</year>;<volume>295</volume>:<fpage>H281</fpage>–<lpage>H288</lpage><?supplied-pmid 18487445?><pub-id pub-id-type="pmid">18487445</pub-id></mixed-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leopold</surname><given-names>JA</given-names></name><name><surname>Dam</surname><given-names>A</given-names></name><name><surname>Maron</surname><given-names>BA</given-names></name><etal/></person-group>. <article-title>Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity</article-title>. <source>Nat Med</source>
<year>2007</year>;<volume>13</volume>:<fpage>189</fpage>–<lpage>197</lpage><?supplied-pmid 17273168?><pub-id pub-id-type="pmid">17273168</pub-id></mixed-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rocha</surname><given-names>R</given-names></name><name><surname>Martin-Berger</surname><given-names>CL</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Scherrer</surname><given-names>R</given-names></name><name><surname>Delyani</surname><given-names>J</given-names></name><name><surname>McMahon</surname><given-names>E</given-names></name></person-group>. <article-title>Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart</article-title>. <source>Endocrinology</source>
<year>2002</year>;<volume>143</volume>:<fpage>4828</fpage>–<lpage>4836</lpage><?supplied-pmid 12446610?><pub-id pub-id-type="pmid">12446610</pub-id></mixed-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>SS</given-names></name><name><surname>Quinn</surname><given-names>MT</given-names></name><name><surname>Weber</surname><given-names>KT</given-names></name></person-group>. <article-title>Aldosterone-induced inflammation in the rat heart: role of oxidative stress</article-title>. <source>Am J Pathol</source>
<year>2002</year>;<volume>161</volume>:<fpage>1773</fpage>–<lpage>1781</lpage><?supplied-pmid 12414524?><pub-id pub-id-type="pmid">12414524</pub-id></mixed-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joffe</surname><given-names>HV</given-names></name><name><surname>Kwong</surname><given-names>RY</given-names></name><name><surname>Gerhard-Herman</surname><given-names>MD</given-names></name><name><surname>Rice</surname><given-names>C</given-names></name><name><surname>Feldman</surname><given-names>K</given-names></name><name><surname>Adler</surname><given-names>GK</given-names></name></person-group>. <article-title>Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus</article-title>. <source>J Clin Endocrinol Metab</source>
<year>2007</year>;<volume>92</volume>:<fpage>2552</fpage>–<lpage>2558</lpage><?supplied-pmid 17488800?><pub-id pub-id-type="pmid">17488800</pub-id></mixed-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>JI</given-names></name><name><surname>Band</surname><given-names>M</given-names></name><name><surname>Morris</surname><given-names>A</given-names></name><name><surname>Struthers</surname><given-names>AD</given-names></name></person-group>. <article-title>Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes</article-title>. <source>Diabetologia</source>
<year>2004</year>;<volume>47</volume>:<fpage>1687</fpage>–<lpage>1694</lpage><?supplied-pmid 15365622?><pub-id pub-id-type="pmid">15365622</pub-id></mixed-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swaminathan</surname><given-names>K</given-names></name><name><surname>Davies</surname><given-names>J</given-names></name><name><surname>George</surname><given-names>J</given-names></name><name><surname>Rajendra</surname><given-names>NS</given-names></name><name><surname>Morris</surname><given-names>AD</given-names></name><name><surname>Struthers</surname><given-names>AD</given-names></name></person-group>. <article-title>Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles</article-title>. <source>Diabetologia</source>
<year>2008</year>;<volume>51</volume>:<fpage>762</fpage>–<lpage>768</lpage><?supplied-pmid 18347776?><pub-id pub-id-type="pmid">18347776</pub-id></mixed-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collin</surname><given-names>M</given-names></name><name><surname>Niemann</surname><given-names>F</given-names></name><name><surname>Jaisser</surname><given-names>F</given-names></name></person-group>. <article-title>Mineralocorticoid receptor modulators: a patent review (2007–2012)</article-title>. <source>Expert Opin Ther Pat</source>
<year>2014</year>;<volume>24</volume>:<fpage>177</fpage>–<lpage>183</lpage><?supplied-pmid 24215301?><pub-id pub-id-type="pmid">24215301</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><record><header><identifier>oai:pubmedcentral.nih.gov:4274802</identifier><datestamp>2016-01-01</datestamp><setSpec>diabetes</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://jats.nlm.nih.gov/ns/archiving/1.0/" xsi:schemaLocation="http://jats.nlm.nih.gov/ns/archiving/1.0/ http://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Diabetes</journal-id>
      <journal-id journal-id-type="iso-abbrev">Diabetes</journal-id>
      <journal-id journal-id-type="hwp">diabetes</journal-id>
      <journal-id journal-id-type="pmc">diabetes</journal-id>
      <journal-id journal-id-type="publisher-id">Diabetes</journal-id>
      <journal-title-group>
        <journal-title>Diabetes</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0012-1797</issn>
      <issn pub-type="epub">1939-327X</issn>
      <publisher>
        <publisher-name>American Diabetes Association</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4274802</article-id>
      <article-id pub-id-type="pmcid">PMC4274802</article-id>
      <article-id pub-id-type="pmc-uid">4274802</article-id>
      <article-id pub-id-type="pmid">25187372</article-id>
      <article-id pub-id-type="publisher-id">0016</article-id>
      <article-id pub-id-type="doi">10.2337/db14-0016</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Complications</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Deletion of Placental Growth Factor Prevents Diabetic Retinopathy and Is Associated With Akt Activation and HIF1α-VEGF Pathway Inhibition</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Huang</surname>
            <given-names>Hu</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>He</surname>
            <given-names>Jianbo</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Johnson</surname>
            <given-names>Da’Kuawn</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wei</surname>
            <given-names>Yanhong</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>Ying</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Shuang</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lutty</surname>
            <given-names>Gerard A.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Duh</surname>
            <given-names>Elia J.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Semba</surname>
            <given-names>Richard D.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <aff id="aff1"><sup>1</sup>Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD</aff>
        <aff id="aff2"><sup>2</sup>Guangxi Tumor Hospital and Institute, Nanning, Guangxi, China</aff>
        <aff id="aff3"><sup>3</sup>Aier Eye Hospital, Changsha, Hunan, China</aff>
        <aff id="aff4"><sup>4</sup>China Japan Union Hospital, Changchun, Jilin, China</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">Corresponding author: Hu Huang, <email>hhuang27@jhmi.edu</email>.</corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>3</day>
        <month>9</month>
        <year>2014</year>
      </pub-date>
      <volume>64</volume>
      <issue>1</issue>
      <fpage>200</fpage>
      <lpage>212</lpage>
      <history>
        <date date-type="received">
          <day>05</day>
          <month>1</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>21</day>
          <month>7</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.</copyright-statement>
        <copyright-year>2015</copyright-year>
      </permissions>
      <self-uri xlink:title="pdf" xlink:type="simple" xlink:href="200.pdf"/>
      <abstract>
        <p>A new diabetic mouse strain, the Akita.PlGF knockout (<sup>−/−</sup>), was generated to study the role of placental growth factor (PlGF) in the pathogenesis of diabetic retinopathy (DR). PlGF deletion did not affect blood glucose but reduced the body weight of Akita.PlGF<sup>−/−</sup> mice. Diabetes-induced retinal cell death, capillary degeneration, pericyte loss, and blood-retinal barrier breakdown were prevented in these mice. Protein expression of PlGF was upregulated by diabetes, particularly in vascular cells. Diabetes-induced degradation of ZO-1 and VE-cadherin was reversed due to PlGF deficiency; their expression was correlated with that of sonic hedgehog and angiopoietin-1. PlGF deletion in Akita mice resulted in an increased Akt phosphorylation. Diabetes-activated hypoxia-inducible factor (HIF)1α–vascular endothelial growth factor (VEGF) pathway, including expression of HIF1α, VEGF, VEGFR1–3, and the extent of phospho (p)-VEGFR1, p-VEGFR2, and p–endothelial nitric oxide synthase, was inhibited in the retinas of diabetic PlGF<sup>−/−</sup> mice. However, expression of intercellular adhesion molecule-1, vascular cell adhesion molecule-1, CD11b, and CD18 was not inhibited by PlGF deletion, nor was retinal leukostasis. These results suggest that PlGF is critical for the development of DR, and its genetic deletion protects the retina from diabetic damage. Protective mechanisms are associated with Akt activation and HIF1α-VEGF pathway inhibition, but independent of retinal leukostasis in the retinas of diabetic PlGF<sup>−/−</sup> mice.</p>
      </abstract>
      <counts>
        <page-count count="13"/>
      </counts>
    </article-meta>
  </front>
  <body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Diabetic retinopathy (DR) is a leading cause of visual impairment and blindness. DR is characterized by increased vascular permeability; breakdown of the blood-retinal barrier (BRB); apoptotic cell death of retinal neurons, endothelial cells (ECs), and pericytes; and the appearance of microaneurysms and acellular capillaries. Several biological pathways have been implicated in the pathogenesis of DR, including vascular endothelial growth factor (VEGF) (<xref rid="B1" ref-type="bibr">1</xref>), tumor necrosis factor-α (<xref rid="B2" ref-type="bibr">2</xref>), the kallikrein-kinin system (<xref rid="B3" ref-type="bibr">3</xref>), and altered <italic>O</italic>-GlcNAc signaling (<xref rid="B4" ref-type="bibr">4</xref>). The exact mechanisms and the relationship of pathogenic changes to biochemical pathways in DR need further elucidation.</p><p>Placental growth factor (PlGF), a member of the VEGF family, was first described from a human placental cDNA library in 1991 (<xref rid="B5" ref-type="bibr">5</xref>). PlGF is expressed by a wide variety of cell types, including ECs and retinal pigment epithelial cells (RPEs) in response to hypoxia (<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B7" ref-type="bibr">7</xref>). PlGF is a homolog of VEGF and binds to fms-like tyrosine kinase-1 (FLT1; also known as VEGFR-1) and soluble FLT1, a circulating form of FLT1 that lacks the transmembrane and intracellular domains. Activation of FLT1 by PlGF augments the effects of VEGF signaling with VEGFR-2, suggesting synergistic effects of PlGF and VEGF (<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B9" ref-type="bibr">9</xref>). PlGF can also form heterodimers with VEGF (<xref rid="B8" ref-type="bibr">8</xref>). PlGF exerts a strong effect upon blood vessel growth and maturation and has direct proangiogenic effects on ECs (<xref rid="B6" ref-type="bibr">6</xref>).</p><p>Recent studies suggest that PlGF plays a role in the pathogenesis of DR (<xref rid="B10" ref-type="bibr">10</xref>). Diabetic human retinas have higher expression of PlGF mRNA compared with nondiabetic retinas (<xref rid="B11" ref-type="bibr">11</xref>). In proliferative DR, immunoreactivity for PlGF was localized to endothelial and perivascular regions of neovascular membranes (<xref rid="B12" ref-type="bibr">12</xref>). PlGF was produced in a cultured human RPE line in response to hypoxia (<xref rid="B13" ref-type="bibr">13</xref>). Other studies have shown higher concentrations of PlGF in aqueous and vitreous humor of eyes with DR compared with controls (<xref rid="B14" ref-type="bibr">14</xref>–<xref rid="B16" ref-type="bibr">16</xref>).</p><p>Mice with inactivation of the gene expressing PlGF (<italic>plgf</italic><sup>−/−</sup> or <italic>pgf<sup>−/−</sup></italic>) show little effect of PlGF absence on vascular development, but in response to hypoxia, PlGF<sup>−/−</sup> mice have reduced angiogenesis in the retina from oxygen-induced retinopathy (<xref rid="B6" ref-type="bibr">6</xref>). The findings from clinical studies, in vitro studies, and PlGF<sup>−/−</sup> mice demonstrate the PlGF may have a role in the pathogenesis of DR. To gain further insights, we compared molecular and histological changes in wild-type (WT) mice, Akita diabetic mice, and PlGF<sup>−/−</sup> mice and generated a novel Akita.PlGF<sup>−/−</sup> mouse strain. We hypothesized that DR would be less severe in Akita diabetic mice that were deficient in PlGF.</p></sec><sec id="s2"><title>Research Design and Methods</title><sec id="s3"><title>Diabetic Mice</title><p>Animal use was in accordance with the approved protocols by the Institutional Animal Care and Use Committee of The Johns Hopkins University. Akita mice were crossed with PlGF<sup>−/−</sup> mice (<xref rid="B17" ref-type="bibr">17</xref>) in a C57BL/6J background for two generations to give birth to the progeny with the genotype of Akita.PlGF<sup>−/−</sup>. Additional mating of Akita.PlGF<sup>−/−</sup> and PlGF<sup>−/−</sup> was performed to fix the PlGF mutation to homozygosity while maintaining the Akita mutation in the heterozygous state. The genotyping of PlGF gene was performed as described in the literature (<xref rid="B6" ref-type="bibr">6</xref>). The genotyping for Pde6b<sup>rd1</sup> and Crb1<sup>rd8</sup> genes was performed as described in the literature (<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B19" ref-type="bibr">19</xref>).</p></sec><sec id="s4"><title>Western Blots and Quantification</title><p>Western blot (WB) was performed as described previously (<xref rid="B20" ref-type="bibr">20</xref>). The anti-PlGF, anti–hypoxia-inducible factor (HIF)-1α, anti-VEGFR1, anti-VEGFR2, anti–intercellular adhesion molecule (ICAM)-1, anti–vascular cell adhesion molecule (VCAM)-1, anti-ZO-1, and anti-VE-cadherin antibodies are described in more detail elsewhere (<xref rid="B21" ref-type="bibr">21</xref>,<xref rid="B22" ref-type="bibr">22</xref>). Dilutions of 1:200 and 1:1,000 were used for anti-VEGF antibody (Santa Cruz, Dallas, TX) and anti-VEGFR3 antibody (eBioscience, San Diego, CA), respectively. The anti-Akt and anti-phospho (p)-Akt antibodies were bought from Cell Signaling (Indiana, IN) and used as 1:1,000 dilutions.</p><p>The optical density (OD) of protein bands in WB images was determined by ImageJ (National Institutes of Health). After normalization by dividing the OD of protein of interest with the housekeeping gene β-actin of the same sample, the percentage of the normalized OD was calculated for each protein of interest based on this equation: percentage of OD (4) = 100*OD (4) / [OD (1) + OD (2) + OD (3) + OD (4)] (each represents one retinal protein sample in the same WB membrane). The average percentage of normalized OD was designated as the relative protein expression (<italic>n</italic> = 6).</p></sec><sec id="s5"><title>Apoptotic Cell Death Assays</title><p>The methods of TUNEL assay were described previously (<xref rid="B2" ref-type="bibr">2</xref>). Apoptotic DNA cleavage was analyzed with the cell death ELISA kit (Roche, Indianapolis, IN), which was performed according to the manufacturer’s instructions with some modifications. In brief, retina was incubated with lysis buffer (0.1 mol/L citric acid buffer containing 0.5% Tween 20) for 30 min. Retinal lysates were centrifuged to sediment the cell debris and nuclei (&gt;1,500 rpm, for 10 min). The 20 μL supernatants were subjected to apoptotic DNA cleavage ELISA assay. The OD (absorbance at 405 nm with a reference at 490 nm) was normalized with retinal mass. The average OD/retinal mass indicated the level of cytoplasmic nucleosome containing fragmented DNA (<italic>n</italic> = 8).</p></sec><sec id="s6"><title>Transcardial Perfusion, Confocal Microscopy, and Retinal Leukostasis</title><p>The transcardial perfusion of fluorescein isothiocyanate (FITC)-dextran and confocal microscopy were performed as described previously (<xref rid="B21" ref-type="bibr">21</xref>). The z-series of optical sections from confocal images were made of the superficial, intermediate, and deep retinal vessel bed to examine the localization of FITC-dextran (70 kDa, TdB Consultancy, Sweden). Retinal leukostasis was performed as previously described (<xref rid="B2" ref-type="bibr">2</xref>).</p></sec><sec id="s7"><title>Quantitative BRB Assay</title><p>The quantitative BRB assay was performed as previously described (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B21" ref-type="bibr">21</xref>). The count per minute (CPM) was normalized with tissue weight (CPM/mg retina, lung, or kidney) or with serum volume (CPM/μL/h). The ratio of retina to lung, kidney, or serum was designated as retinal vascular leakage ratio.</p></sec><sec id="s8"><title>Immunofluorescence Staining and Quantification</title><p>Immunofluorescence (IF) staining was performed as described previously (<xref rid="B22" ref-type="bibr">22</xref>). The primary antibodies used for this study included anti-CD31/PECAM-1 (BD Pharmingen, San Jose, CA); anti-VEGFR1 (ImClone, Somerville, NJ); and anti-p-VEGFR1 (Y1213; R&amp;D Systems), anti-NG2, anti-GFAP, anti-p-Akt (Ser473), anti-p-VEGFR2 (Tyr1175), and anti-p-endothelial nitric oxide synthase (eNOS; Ser1177; Cell Signaling). For double labeling, two primary antibodies from the distinct host species were mixed for the same tissue section and two appropriate secondary antibodies conjugated with different chromophores (e.g., rhodamine or fluorescein) were used for detection and visualization. For the quantitative comparison of IF images, the specimens and images were prepared as described previously (<xref rid="B23" ref-type="bibr">23</xref>). The immunoreactive intensity and area were quantified by ImageJ and Image Pro, respectively.</p></sec><sec id="s9"><title>Real-Time PCR</title><p>The procedures of real-time PCR were described previously (<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B24" ref-type="bibr">24</xref>). For quantifying the relative expression of genes of interest (GOI), the threshold cycles (<italic>C</italic>t) were normalized by subtracting the Ct of housekeeping gene actin of the same sample (Δ<italic>C</italic>t = GOI <italic>C</italic>t-actin <italic>C</italic>t). The value of 2<sup>−Δ</sup><italic><sup>C</sup></italic><sup>t</sup> was calculated for each sample and average for each mouse strain. The percentage of the average 2<sup>−Δ</sup><italic><sup>C</sup></italic><sup>t</sup> from each mouse strain to the sum 2<sup>−Δ</sup><italic><sup>C</sup></italic><sup>t</sup> from the four mouse strains was designated as the relative expression of GOI (<italic>n</italic> = 6).</p></sec><sec id="s10"><title>Trypsin Digestion and Quantification</title><p>Isolation of retinal vasculature and quantification of acellular capillary were performed as previously described (<xref rid="B25" ref-type="bibr">25</xref>,<xref rid="B26" ref-type="bibr">26</xref>). The enucleated eyes were fixed with 2% paraformaldehyde for 24 h. After removing the cornea, the eye cups were fixed with 2% paraformaldehyde for 24 h and dissected to isolate the retina. The retinas were rinsed in tap water overnight and then were incubated with 40 unit/mL elastase (Calbiochem, MA) in 100 mmol/L sodium phosphate buffer with 150 mmol/L sodium chloride and 5.0 mmol/L EDTA pH 6.5 at 37°C for 2 h. Retinas were transferred to a 100 mmol/L Tris-HCl (8.5) solution at room temperature for 3 h. Nonvascular tissues were removed by gentle brushing, and the isolated vasculature was mounted on the slide. After drying overnight, the retinal blood vessels were subjected to the periodic acid–Schiff and hematoxylin stain. The retinal blood vessels of 20–25 random fields (200× magnification) were analyzed in a masked fashion for the quantification of acellular capillaries, which were identified as capillary-sized vessel tubes without nuclei along their length. The numbers were normalized by the counting area (degenerated vessels/mm<sup>2</sup>). The number of ECs and pericytes were determined by counting their respective nuclei, the differences of which were distinguished by their morphology and position in the blood vessels, as described previously (<xref rid="B27" ref-type="bibr">27</xref>). The six midzone fields of retinal digest (400× magnification) were analyzed for each retina in a masked fashion. The average number of ECs per mm<sup>2</sup> vascular bed was calculated and expressed as the density of EC. The average ratio of EC to pericyte was used to demonstrate the pericyte coverage or death.</p></sec><sec id="s11"><title>Statistical Analysis</title><p>The nonparametric Mann-Whitney <italic>U</italic> test was performed to determine the significance level between two samples: diabetic retina versus nondiabetic retina and Akita versus Akita.PlGF<sup>−/−</sup>. <italic>P</italic> &lt; 0.05 was designated as being statistically significant.</p></sec></sec><sec sec-type="results" id="s12"><title>Results</title><sec id="s13"><title>Blood Glucose Is Not Affected, but Body Weight Is Reduced in Akita.PlGF<sup>−/−</sup> Mice</title><p>We generated a genetic model of diabetes by crossing the PlGF<sup>−/−</sup> mouse and the Akita diabetic mouse. PCR genotyping analysis confirmed the deletion of the PlGF gene in Akita.PlGF<sup>−/−</sup> mice (<xref ref-type="fig" rid="F1">Fig. 1<italic>A</italic></xref>). We further performed genotyping for Pde6b<sup>rd1</sup> and Crb1<sup>rd8</sup> genes, since the two are common retinal degeneration gene mutations that are found in the C57BL/6 mouse strains (<xref rid="B18" ref-type="bibr">18</xref>). The results showed that neither was present in the four mouse strains used in this study. Further histopathological analysis indicated there was no obvious retinal degeneration, as indicated by the 10–12 nuclear layers in photoreceptors, and other retinal abnormalities (<ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0016/-/DC1">Supplementary Fig. 1</ext-link>). The level of blood glucose was equal between the offspring of WT/Akita (PlGF<sup>+/+</sup>/Akita.PlGF<sup>−/−</sup>) and PlGF<sup>−/−</sup>/Akita.PlGF<sup>−/−</sup> breeding mice (<xref ref-type="fig" rid="F1">Fig. 1<italic>B</italic> and <italic>C</italic></xref>). The Akita.PlGF<sup>−/−</sup> mice were significantly lighter in body weight than the same-aged Akita mice (<xref ref-type="fig" rid="F1">Fig. 1<italic>D</italic></xref> and <ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0016/-/DC1">Supplementary Table 1</ext-link>). Despite the loss of body weight, the double mutant Akita.PlGF<sup>−/−</sup> mice were viable, fertile, and healthy. The blood assays and histopathological assessments also suggested less severe pathology in the liver and kidney of Akita.PlGF<sup>−/−</sup> mice than Akita mice (data not shown).</p><fig id="F1" fig-type="figure" position="float"><label>Figure 1</label><caption><p>The blood glucose and body weight of Akita.PlGF<sup>−/−</sup> mice. <italic>A</italic>: The PCR genotyping results for PlGF<sup>+/+</sup> (WT), Akita.PlGF<sup>+/+</sup> (Akita), PlGF<sup>−/−</sup>, and Akita.PlGF<sup>−/−</sup>. The PCR products of PlGF heterozygous (+/−) mice indicated the amplicons of 750 bp (<sup>−/−</sup>) and 150 bp (<sup>+/+</sup>). <italic>B</italic>: The blood glucose level of the offspring of WT/Akita breeding mice or PlGF<sup>−/−</sup>/Akita.PlGF<sup>−/−</sup> breeding mice. The blood glucose of 95 ∼1-month-old male mice (diabetes just started) from WT/Akita breeding mice and 115 same-aged male mice from PlGF<sup>−/−</sup>/Akita.PlGF<sup>−/−</sup> breeding mice was measured (mg/dL), converted to the HbA<sub>1c</sub> values (mmol/mol), and then scatter plotted. <italic>C</italic>: The average body weight and blood glucose (see <ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0016/-/DC1">Supplementary Table 1</ext-link> for the values of HbA<sub>1c</sub> % and mmol/mol) of 6-month-old diabetic male mice (5-month diabetes duration) and their nondiabetic littermate male mice (<italic>n</italic> = 10). Blood glucose of 250 mg/dL was used as the cutoff for diabetic and nondiabetic mice. *<italic>P</italic> &lt; 0.05; **<italic>P</italic> &lt; 0.0001.</p></caption><graphic xlink:href="200fig1"/></fig></sec><sec id="s14"><title>Cell Death Is Decreased in the Retinas of Akita.PlGF<sup>−/−</sup> Mice</title><p>By comparing the two diabetic mouse strains (Akita and Akita.PlGF<sup>−/−</sup>) with their respective nondiabetic mouse strains of the same genetic background (C57BL6 [WT] and PlGF<sup>−/−</sup> mice), we found that PlGF deficiency prevented diabetes-caused retinal cell death in the Akita.PlGF<sup>−/−</sup> mouse retina. The number of diabetes-induced TUNEL(+) cells was significantly reduced in Akita.PlGF<sup>−/−</sup> mice compared with Akita mice of the same age (<xref ref-type="fig" rid="F2">Fig. 2<italic>A</italic>–<italic>E</italic></xref>). The number of activated caspase-3(+) cells was also significantly reduced due to PlGF deficiency in the diabetic retina (data not shown). Furthermore, apoptotic cell death was examined by cell death ELISA analysis, in which cytoplasmic nucleosomes were measured. The results showed that DNA fragmented nucleosomes were increased in Akita diabetic mice compared with nondiabetic mice, but not in Akita.PlGF<sup>−/−</sup> mice (<xref ref-type="fig" rid="F2">Fig. 2<italic>F</italic></xref>).</p><fig id="F2" fig-type="figure" position="float"><label>Figure 2</label><caption><p>Decreased cell death in the retinas of Akita.PlGF<sup>−/−</sup> mice. Cryopreserved eye sections were made from the 6-month-old diabetic male mice (∼5-month diabetes duration) and nondiabetic littermate male mice. Cell death was detected by TUNEL staining. <italic>A</italic>–<italic>D</italic>: The example results of TUNEL staining for WT (<italic>A</italic>), Akita (<italic>B</italic>), PlGF<sup>−/−</sup> (<italic>C</italic>), and Akita.PlGF<sup>−/−</sup> (<italic>D</italic>). <italic>E</italic>: Quantification of the TUNEL(+) cells. Results were shown as mean ± SD of TUNEL(+) cells per mouse strain (<italic>n</italic> = 6). <italic>F</italic>: The cell death ELISA. The results were averaged from eight measurements and expressed as mean ± SD (<italic>n</italic> = 8). *<italic>P</italic> &lt; 0.05; NS, not significant. GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; ONL, outer nuclear layer.</p></caption><graphic xlink:href="200fig2"/></fig></sec><sec id="s15"><title>Capillary Degeneration and Pericyte Death Are Abrogated in the Retinas of Akita.PlGF<sup>−/−</sup> Mice</title><p>Retinal digests were performed as described in <xref ref-type="sec" rid="s2"><sc>Research Design and Methods</sc></xref>. Intact retinal vasculatures were used for quantitative analyses of acellular capillary, EC density, and pericyte death. Firstly, acellular capillaries or capillary degeneration were significantly increased in Akita mice compared with WT controls. Genetic ablation of the PlGF gene abrogated the diabetes-induced capillary degeneration: the mean number of acellular capillary/mm<sup>2</sup> retinal vasculature was significantly increased in Akita mice compared with WT and Akita.PlGF<sup>−/−</sup> mice. Secondly, there was not a significant change in the density of vascular ECs between the mouse strains (<ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0016/-/DC1">Supplementary Fig. 2</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0016/-/DC1">Supplementary Table 2</ext-link>). Lastly, pericyte death was significantly increased in Akita mice compared with WT mice, but PlGF deletion abrogated diabetes-induced pericyte loss (<xref ref-type="fig" rid="F3">Fig. 3</xref>). Consistently, double immunostaining of NG2 and CD31 showed the pericyte coverage was decreased by diabetes (5-month diabetes duration), but PlGF deletion abrogated the pericyte loss: the average ratio of NG2(+) to CD31(+) vessel areas was significantly reduced in Akita diabetic retina compared with the nondiabetic control retina, but that of Akita.PlGF<sup>−/−</sup> retina was not (<ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0016/-/DC1">Supplementary Fig. 3</ext-link>).</p><fig id="F3" fig-type="figure" position="float"><label>Figure 3</label><caption><p>Decreased capillary degeneration and pericyte loss in the retinas of Akita.PlGF<sup>−/−</sup> mice. Six-month-old diabetic male mice (∼5-month diabetes duration) and nondiabetic littermate male mice were used for elastase digestion. <italic>A</italic>–<italic>D</italic>: Representative examples of isolated retinal vasculature for PlGF<sup>−/−</sup> (<italic>A</italic>), Akita.PlGF<sup>−/−</sup> (<italic>B</italic>), WT (<italic>C</italic>), and Akita (<italic>D</italic>) mice strains. Purple arrows indicate acellular capillaries. Green arrows indicate pericytes. <italic>E</italic>: Quantification of acellular capillaries. Results were expressed as mean ± SD number of acellular capillaries/mm<sup>2</sup>. <italic>F</italic>: Pericyte quantification. The results were expressed as the ratio of ECs to pericyte (<italic>n</italic> = 6). *<italic>P</italic> &lt; 0.05 vs. nondiabetic WT control; $<italic>P</italic> &lt; 0.05 vs. Akita diabetic mice; NS, not significant.</p></caption><graphic xlink:href="200fig3"/></fig><p>Although it is possible that PlGF, like its homolog VEGF, is produced by a variety of retinal cell types, its cellular targets appear to be vascular ECs and pericytes in diabetic retina. We investigated this question with the vascular EC markers CD31 and the pericyte marker NG2. IF staining also showed an increased expression of PlGF protein and its receptor VEGFR1 by diabetes: PlGF or VEGFR1 immunoreactivity was not present or, if present, was barely detectable in nondiabetic mouse retina but was dramatically increased in the retinas of Akita diabetic mice (3 months old with an ∼2-month diabetes duration). Double labeling of IF staining showed that the diabetes-induced increased PlGF protein colocalizes well with its receptor VEGFR1, the EC marker CD31, and the pericyte marker NG2 but does not colocalize with the astrocyte/glial marker GFAP (<ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0016/-/DC1">Supplementary Fig. 4</ext-link>). These results suggest vascular EC and pericytes are likely the cellular targets of PlGF, where it mediates DR by transmitting signaling via VEGFR1. We recently observed that diabetes-induced inflammation and vascular leakage were significantly inhibited due to VEGFR1 blockade (J.H., D. Kim, and H.H., unpublished data).</p></sec><sec id="s16"><title>Vascular Leakage Is Prevented in the Retinas of Akita.PlGF<sup>−/−</sup> Mice</title><p>Vascular leakage was determined by a quantitative BRB method, in which <sup>3</sup>H-mannitol (molecular weight 182 Da) acted as a tracer. The results showed diabetes caused a significant vascular leakage in Akita mice compared with the nondiabetic control mice, which is consistent with our previous results (<xref rid="B2" ref-type="bibr">2</xref>). However, deletion of PlGF in Akita mice prevented diabetes-related vascular leakage (<xref ref-type="fig" rid="F4">Fig. 4</xref>). Vascular leakage was further examined by the extravascularization of FITC-dextran (70 kDa) in the superficial (ganglion cell layer), intermediate (inner plexiform layer), and deep (outer plexiform layer [OPL]) retinal vasculatures. The z-series of images by scanning confocal microscopy showed that the leakage of the perfused dextran could be observed in some areas of all three layers of Akita mouse vasculature but not in those of nondiabetic mice or Akita.PlGF<sup>−/−</sup> mice (<ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0016/-/DC1">Supplementary Fig. 5</ext-link>).</p><fig id="F4" fig-type="figure" position="float"><label>Figure 4</label><caption><p>Decreased vascular leakage in the retinas of Akita.PlGF<sup>−/−</sup> mice. Six-month-old diabetic mice (∼5-month diabetes duration) and age-matched nondiabetic littermate control mice were used for the quantitative BRB assay, in which <sup>3</sup>H-mannitol acts as a tracer. CPMs were normalized by the mass of tissues: retina, lung, and kidney (CPM/mg) or serum value (CPM/h/μL). Retina-to-lung leakage ratio (<italic>A</italic>), retina-to-renal leakage ratio (<italic>B</italic>), and retina-to-serum leakage ratio (<italic>C</italic>) were used to demonstrate the degree of vascular leakage.</p></caption><graphic xlink:href="200fig4"/></fig></sec><sec id="s17"><title>Expression of ZO-1 and VE-Cadherin Is Upregulated in the Retinas of Akita.PlGF<sup>−/−</sup> Mice</title><p>We examined the expression of the tight junction protein ZO-1 and the adhesion protein VE-cadherin, both of which play critical roles in maintaining the integrity of BRB complex. The WB results showed that expression of the two proteins was significantly decreased in the Akita diabetic mice compared with the nondiabetic control mice, suggesting impaired BRB function. Protein expression was significantly increased in the Akita.PlGF<sup>−/−</sup> diabetic mouse retina compared with the nondiabetic PlGF<sup>−/−</sup> control mice, suggesting an enhanced BRB function (<xref ref-type="fig" rid="F5">Fig. 5<italic>A</italic>–<italic>D</italic></xref>). Furthermore, double labeling showed that ZO-1 colocalized with the vascular marker CD31/PECAM-1, similar to the nondiabetic PlGF<sup>−/−</sup> mice. However, the signal intensity and area of ZO-1 immunoreactivity were evidently reduced in Akita mice compared with those of CD31 (<ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0016/-/DC1">Supplementary Fig. 6</ext-link>). The mRNA expression of the two factors was consistent with their proteins: decreased in Akita mice, but increased in Akita.PlGF<sup>−/−</sup> mice (<xref ref-type="fig" rid="F5">Fig. 5<italic>E</italic> and <italic>F</italic></xref>). These results suggested PlGF deletion in Akita mice protects against diabetes-caused degradation of ZO-1 and VE-cadherin proteins and also upregulates both genes.</p><fig id="F5" fig-type="figure" position="float"><label>Figure 5</label><caption><p>Increased expression of ZO-1, VE-cadherin, SHH, and Ang-1 in the retinas of Akita.PlGF<sup>−/−</sup> mice. Protein lysates and total RNA were prepared from the retinas of the 6-month-old mice diabetic mice (∼5-month diabetes duration) and the littermate control mice. <italic>A</italic> and <italic>B</italic>: WB of ZO-1 (<italic>A</italic>) and VE-cadherin (<italic>B</italic>). Shown is the anti-β-actin antibody, which was mixed with anti-ZO-1 antibody or anti-VE-cadherin antibody and used to probe on the same protein membrane, serving as the internal control of protein loading and quantification. <italic>C</italic> and <italic>D</italic>: WB quantification of ZO-1 (<italic>C</italic>) and VE-cadherin (<italic>D</italic>). <italic>E</italic>–<italic>H</italic>: Relative mRNA expression of ZO-1 (<italic>E</italic>), VE-cadherin (<italic>F</italic>), SHH (<italic>G</italic>), and Ang-1 (<italic>H</italic>). The results were averaged from six results and expressed as the relative protein expression ± SD (<italic>n</italic> = 6). *<italic>P</italic> &lt; 0.05 (Akita diabetic mice vs. WT nondiabetic mice); #<italic>P</italic> &lt; 0.05 (Akita.PlGF<sup>−/−</sup> vs. PlGF<sup>−/−</sup>). QPCR, quantitative PCR.</p></caption><graphic xlink:href="200fig5"/></fig><p>To give insight into the mechanisms regulating the increased expression of ZO-1 and VE-cadherin in these diabetic mouse retina, we examined mRNA expression of sonic hedgehog (SHH), angiopoietin (Ang)-1, activator protein-1, Sry-related HMG-box (Sox7), T-cell acute lymphocytic leukemia-1 (TAL1 or SCL), transcription factor 3 (TCL3 or E47), and LM02, all of which were known to regulate the expression of ZO-1 and/or VE-cadherin (<xref rid="B28" ref-type="bibr">28</xref>–<xref rid="B30" ref-type="bibr">30</xref>). We found that the expression of Ang-1 and SHH was concomitantly related with that of ZO-1 and VE-cadherin: decreased in Akita diabetic mouse retina, but increased in Akita.PlGF<sup>−/−</sup> compared with their respective nondiabetic control mice (<xref ref-type="fig" rid="F5">Fig. 5<italic>G</italic> and<italic> H</italic></xref>). The corelated expression patterns suggested that Ang-1 and SHH are likely involved in the regulation of ZO-1 and VE-cadherin expression in the diabetic conditions.</p></sec><sec id="s18"><title>Akt Phosphorylation Is Increased in the Retinas of Akita.PlGF<sup>−/−</sup> Mice</title><p>Akt is a key survival factor that protects retinal cells from various impairments, including diabetes (<xref rid="B31" ref-type="bibr">31</xref>). We examined the extent and cellular localization of p-Akt, which is the activated form of Akt protein, by WB and IF staining. The WB results showed that Akt phosphorylation expressed in the WT mouse retina was abolished by diabetes (5-month diabetes duration) but was significantly increased in the retinas of Akita.PlGF<sup>−/−</sup> mice compared with its nondiabetic PlGF<sup>−/−</sup> control mouse retina (<xref ref-type="fig" rid="F6">Fig. 6<italic>A</italic></xref>). The p-Akt was not detected by IF staining in the retinas of the two nondiabetic mice or the Akita diabetic mice but was significantly increased in the retinas of Akita.PlGF<sup>−/−</sup> mice. p-Akt immunoreactivity was largely localized to the photoreceptor inner segment layer, outer nuclear layer and OPL in the PlGF<sup>−/−</sup> diabetic mouse retina (<xref ref-type="fig" rid="F6">Fig. 6<italic>B</italic>–<italic>E</italic></xref>). Interestingly, p-Akt immuoreactivity appeared to be present in the processes of Müller glial cells (<xref ref-type="fig" rid="F6">Fig. 6<italic>E</italic> and <italic>F</italic></xref>). The induction of Akt phosphorylation in these cell types suggests both autocrine and paracrine protective mechanisms may exist in the retinas of Akita.PlGF<sup>−/−</sup> mice.</p><fig id="F6" fig-type="figure" position="float"><label>Figure 6</label><caption><p>Increased Akt phosphorylation in the retinas of Akita.PlGF<sup>−/−</sup> mice. Six-month-old diabetic mice (∼5-month diabetes duration) were compared with nondiabetic littermate control mice. <italic>A</italic>: The upper panel is the WB result of p-Akt and Akt protein; the lower panel is WB quantification, which is expressed as the percentage of p-Akt to Akt protein. Quantification of WB represents the average from six mice per mouse strain (<italic>n</italic> = 6). In the blot, lane 1 is nondiabetic WT (PlGF<sup>+/+</sup>); lane 2 is Akita.PlGF<sup>+/+</sup>; lane 3 is nondiabetic PlGF<sup>−/−</sup>; and lane 4 is Akita.PlGF<sup>−/−</sup>. *<italic>P</italic> &lt; 0.05; #<italic>P</italic> &lt; 0.01. IF staining of p-AKT on PlGF<sup>+/+</sup> (<italic>B</italic>), Akita (<italic>C</italic>), PlGF<sup>−/−</sup> (<italic>D</italic>), and Akita.PlGF<sup>−/−</sup> (<italic>E</italic>) is presented. Panel <italic>F</italic> is a high magnification of the boxed area in panel <italic>E</italic>. Arrows indicate the processes of Müller glial cells. Scale bar, 100 μm. GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; ONL, outer nuclear layer.</p></caption><graphic xlink:href="200fig6"/></fig></sec><sec id="s19"><title>HIF1α-VEGF Signaling Pathway Is Inhibited in the Retinas of Akita.PlGF<sup>−/−</sup> Mice</title><p>To investigate whether the HIF1α-VEGF signaling pathway is inhibited in Akita.PlGF<sup>−/−</sup> mice, we examined the expression of HIF1α, several VEGF family proteins (PlGF, VEGF-A, VEGF-B), and the three tyrosine kinase receptors (VEGFR1–3) in the Akita and Akita.PlGF<sup>−/−</sup> diabetic mice strains and their nondiabetic mouse controls. The WB results (<xref ref-type="fig" rid="F7">Fig. 7<italic>A</italic> and <italic>B</italic></xref>) showed that <italic>1</italic>) PlGF protein expression was negative in PlGF<sup>−/−</sup> and Akita.PlGF<sup>−/−</sup>, further confirming the deletion of the PlGF gene in the PlGF<sup>−/−</sup> and Akita.PlGF<sup>−/−</sup> mouse strains; <italic>2</italic>) protein expression of HIF1α, PlGF, VEGF-A, and VEGFR1–3 was significantly upregulated in Akita mouse retina compared with the nondiabetic WT mouse retina, implicating the HIF1α-VEGF pathway in the pathogenesis of DR; <italic>3</italic>) protein expression of HIF1α, VEGF, and VEGFR1–3 was significantly downregulated in Akita.PlGF<sup>−/−</sup> mice compared with nondiabetic PlGF<sup>−/−</sup> mice, suggesting the inhibition of HIF1 α-VEGF pathway is likely one of the protective mechanisms; and <italic>4</italic>) VEGF-B protein expression was of the same level for all four mice stains, suggesting VEGF-B may not be involved in this type 1 diabetic model, although there is evidence supporting that VEGF-B is important in the type 2 diabetic model with obesity (<xref rid="B32" ref-type="bibr">32</xref>,<xref rid="B33" ref-type="bibr">33</xref>).</p><fig id="F7" fig-type="figure" position="float"><label>Figure 7</label><caption><p>Inhibition of HIF1α-VEGF signaling pathway in the retinas of Akita.PlGF<sup>−/−</sup> mice. Six-month-old diabetic mice (∼5-month diabetes duration) and nondiabetic littermate control mice were used for WB and IF. <italic>A</italic>: Example WB results for HIF1α, PlGF, VEGF-A, VEGF-B, VEGFR1, VEGFR2, and VEGFR3 are shown. The anti-β-actin antibody was used to probe the stripped protein membrane and was used as a controls for protein loading and quantification. Lane 1 is nondiabetic WT (PlGF<sup>+/+</sup>); lane 2 is Akita.PlGF<sup>+/+</sup>; lane 3 is nondiabetic PlGF<sup>−/−</sup>; and lane 4 is Akita.PlGF<sup>−/−</sup>. <italic>B</italic>: The WB quantification. The results were averaged from six independent mice and are expressed as mean relative expression ± SD (<italic>n</italic> = 6). *<italic>P </italic>&lt; 0.05 (Akita vs. WT); ¶<italic>P </italic>&lt; 0.05 (Akita.PlGF<sup>−/−</sup> vs. PlGF<sup>−/−</sup>). Double-label IF staining was done for p-VEGFR1 and CD31 (<italic>C</italic>–<italic>F</italic>), p-VEGFR2 and CD31 (<italic>G</italic>–<italic>J</italic>), or p-eNOS and CD31 (<italic>K</italic>–<italic>N</italic>). Arrows indicate colocalization of phosphorylated protein and CD31 (yellow). Arrowheads indicate the immunoreactivity only for phosphorylated protein (green). Scale bar, 50 μm. GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; ONL, outer nuclear layer.</p></caption><graphic xlink:href="200fig7"/></fig><p>In addition, we examined the extent and cellular localization of the three important elements in the VEGF signaling pathway: p-VEGFR1, p-VEGFR2, and p-eNOS. Immunoreactivity of p-VEGFR1 and p-VEGFR2 prominently localized in the OPL; the signal intensity was increased in the retinas of Akita diabetic mice compared with the other three mouse strains. Double labeling showed that p-VEGFR1-immunopositive(+) cells are either CD31(+) or CD31(−). The p-VEGFR1(+)/CD31(−) cells were present in all the four mouse strains, suggesting the constitutive expression, but the p-VEGFR1(+)/CD31(+) cells were only present in Akita diabetic mice, indicating the induced expression by diabetes (<xref ref-type="fig" rid="F7">Fig. 7<italic>C</italic>–<italic>F</italic></xref>). The expression pattern and cellular localization of p-VEGFR2 were similar to that of p-VEGFR1 (<xref ref-type="fig" rid="F7">Fig. 7<italic>G</italic>–<italic>J</italic></xref>). p-eNOS was detected only in the Akita mice, not in the others; its immunoreactivity colocalized with CD31(+) cells or CD31(−) cells. The p-eNOS(+)/CD31(+) cells and p-eNOS(+)/CD31(−) cells were localized in the neural fiber layer/ganglion cell layer (<xref ref-type="fig" rid="F7">Fig. 7<italic>K</italic>–<italic>N</italic></xref>).</p></sec><sec id="s20"><title>Expression of ICAM-1, VCAM-1, CD11b, and CD18 Is Upregulated in the Retinas of Akita.PlGF<sup>−/−</sup> Mice</title><p>ICAM-1, VCAM-1, CD11b, and CD18 play important roles in regulating leukocyte-EC adhesion. We examined the protein and/or mRNA expression of these factors. The results showed that protein and/or mRNA expression of ICAM-1, VCAM-1, CD11b, and CD18 were increased in the retinas of both Akita and Akita.PlGF<sup>−/−</sup> mice (<xref ref-type="fig" rid="F8">Fig. 8</xref>). The number of leukocytes adhering to the retinal vasculature was equal between Akita and Akita.PlGF<sup>−/−</sup> mice, both of which were significantly greater than WT or PlGF<sup>−/−</sup> nondiabetic mouse retina (<ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0016/-/DC1">Supplementary Fig. 7</ext-link>). These results suggest protection from diabetes complications due to PlGF deficiency is likely independent of suppression of leukocyte-EC adhesion or retinal leukostasis.</p><fig id="F8" fig-type="figure" position="float"><label>Figure 8</label><caption><p>Increased expression of VCAM-1, ICAM-1, CD11b, and CD18 in the retinas of Akita mice and Akita.PlGF<sup>−/−</sup> mice. Protein lysates and total RNA were made from the retinas of 6-month-old mice (∼5-month diabetes duration) and the nondiabetic littermate control mice. WB results for VCAM-1 (<italic>A</italic>) and ICAM-1 (<italic>B</italic>). The anti-β-actin antibody was mixed with anti-VCAM-1 or anti-ICAM-1 antibody and the mixture was used to probe the same protein membrane, serving as the internal control of protein loading and quantification of VCAM-1 (<italic>A</italic>) and ICAM-1 (<italic>B</italic>). WB quantification of VCAM-1 (<italic>C</italic>) and ICAM-1 (<italic>D</italic>) demonstrates a significant difference between diabetic and nondiabetic control mice. Relative mRNA expression of VCAM-1 (<italic>E</italic>), ICAM-1 (<italic>F</italic>), CD11b (<italic>G</italic>), and CD18 (<italic>H</italic>) represent the average from six independent samples and are expressed as mean ± SD (<italic>n</italic> = 6). *<italic>P</italic> &lt; 0.05 (Akita.PlGF<sup>+/+</sup>[Akita] diabetic mice vs. nondiabetic PlGF<sup>+/+</sup> [WT] mice); #<italic>P</italic> &lt; 0.05 (Akita.PlGF<sup>−/−</sup> diabetic mice vs. nondiabetic PlGF<sup>−/−</sup> mice). QPCR, quantitative PCR.</p></caption><graphic xlink:href="200fig8"/></fig></sec></sec><sec sec-type="discussion" id="s21"><title>Discussion</title><p>In the current study, we developed a novel Akita.PlGF<sup>−/−</sup> diabetic mouse strain. Investigation of the retinas from Akita.PlGF<sup>−/−</sup> mice suggests that PlGF deficiency prevents the diabetes complications of acellular capillary, retinal cell death, and BRB breakdown and also confers additional protection, as shown by the increased expression of ZO-1 and VE-cadherin. To gain further insight into the protective mechanisms, we investigated several important pathophysiological pathways and events in DR. First, we found that PlGF deletion in Akita mice led to an increased Akt phosphorylation, which is an important survival factor and may contribute to the protective mechanisms. Second, we found that the expression of SHH and Ang-1 is corelated with that of VE-cadherin and ZO-1. The findings are in agreement with the previous reports that demonstrated SHH and Ang-1 play important roles in preserving the integrity of blood-brain barrier (<xref rid="B34" ref-type="bibr">34</xref>) and BRB (<xref rid="B35" ref-type="bibr">35</xref>), respectively. Third, we found that the HIF1 α-VEGF signaling pathway, which is the key mediator of diabetic retinal complications, was inhibited due to PlGF deficiency. Last, we found that leukocyte-EC adhesion, or retinal leukostasis, which is a relatively early event and contributes to the development of DR (<xref rid="B36" ref-type="bibr">36</xref>), was not suppressed by knocking out PlGF, and therefore, it is possible that the protection is independent of this inflammatory event. It is important to note that although retinal leukostasis has been shown to occur in the early stage in the streptozotocin-induced diabetic model (<xref rid="B37" ref-type="bibr">37</xref>), it also happens in the late stages in the Akita model.</p><p>The comparisons in this study were considered fairly robust since diabetic mice were always compared with nondiabetic control mice (Akita vs. WT and Akita.PlGF<sup>−/−</sup> vs. PlGF<sup>−/−</sup>) to control for baseline differences owing to different genetic background, and nondiabetic control mice were always the male siblings of Akita diabetic mice. The four respective mouse strains were maintained by the breeding of Akita/C57 and Akita.PlGF<sup>−/−</sup>/PlGF<sup>−/−</sup>, and each breeding pair gave rise to offspring of which half were WT or PlGF<sup>−/−</sup> and half were diabetic Akita and Akita.PlGF<sup>−/−</sup>; only the male diabetic mice were used for experimental analyses. To further ascertain the effects of PlGF deletion on diabetic retinal complications, we characterized the retinal vasculatures of the two nondiabetic mouse strains. The vascular cell density and pericyte number are comparative between PlGF<sup>−/−</sup> mice and WT mice (without statistically significant difference). Similarly, histopathological assessment demonstrated the gross anatomy of the retina looks similar among the mouse strains, without showing any retinal degeneration or other abnormities. Despite the similarities, it appears that there are differences in molecular composition and function. For example, the protein expression of VEGFR1–3 was increased in the nondiabetic PlGF<sup>−/−</sup> mice compared with the WT mice. The permeability of <sup>3</sup>H-mannitol (molecular weight 182 Da) was increased in PlGF<sup>−/−</sup> mice compared with the WT mice (approximately two- to threefold), using the lung and kidney as a reference (but not serum). However, the permeability of FITC-dextran (70 kDa) did not show any increase in the knockout mice. It is possible that the differences are attributed to the effect of long-term diabetes on the lung and kidney and the different molecular weight of the two tracers.</p><p>Currently, agents targeting VEGF are widely used for the treatment of vascular disorders, including DR. However, there is concern about potential side effects after a long-standing VEGF blockade because new evidence is emerging that VEGF is a survival factor for the choriocapillaris, retinal neurons, and RPE (<xref rid="B38" ref-type="bibr">38</xref>–<xref rid="B40" ref-type="bibr">40</xref>). One possibility is to target the upstream regulators of VEGF such as prolyl hydroxylase and HIF (<xref rid="B41" ref-type="bibr">41</xref>). Because prolyl hydroxylase and HIF regulate a broad spectrum of gene expression, inhibition of their activities could potentially protect the vasculature. Another possible therapeutic intervention would be inhibition of PlGF. In a study on PlGF<sup>−/−</sup> mice, Carmeliet and colleagues (<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B42" ref-type="bibr">42</xref>) showed that PlGF regulates angiogenesis and vascular permeability in pathological conditions. The results from the current study showed that deletion of PlGF led to not only the suppression of diabetes complications, but also an increase in junction and adhesion factors. These findings suggest that inhibition of PlGF signaling most likely produces the equivalent efficacy of blocking VEGF, but activation of protective factors in PlGF deficiency may also confer additional benefits.</p><p>Future work is needed to determine whether activation of Akt survival signaling and inhibition of VEGF signaling pathway are the causes of protection due to PlGF deficiency; how PlGF coordinates the interaction of VEGF, VEGFR1, and VEGFR2 in the background of DR; and the effect of PlGF deficiency upon other biological pathways involved in protection, such as tumor necrosis factor-α, the kallikrein-kinin system, and altered <italic>O</italic>-GlcNAc signaling. The Akita.PlGF<sup>−/−</sup> mouse is a good tool to use in the study of the in vivo effect of these kinds. From this study, it is now apparent PlGF plays a critical role in the pathogenesis of DR.</p></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>Supplementary Data</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_64_1_200__index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_db14-0016_DB140016SupplementaryData.pdf"/>
</supplementary-material>
</sec>
</body>
  <back>
    <fn-group>
      <fn id="fn1" fn-type="supplementary-material">
        <p>This article contains Supplementary Data online at <ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0016/-/DC1">http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0016/-/DC1</ext-link>.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Article Information</title>
      <p><bold>Acknowledgments.</bold> The authors thank Dr. Peter Carmeliet at VIB Vesalius Research Center, K.U. Leuven, Belgium, for providing PlGF<sup>−/−</sup> mice; Dr. Zhenhua Xu, Wilmer Eye Institute, for her helpful discussions about the WB experiments; and Dr. Junsong Gong, Wilmer Eye Institute, for his technical assistance.</p>
      <p><bold>Funding.</bold> This study was supported by research grants from the National Institutes of Health EY017164 (H.H.) and EY022383 (E.J.D.), Research to Prevent Blindness, and Wilmer Pooled Professor Funds (H.H.).</p>
      <p><bold>Duality of Interest.</bold> No potential conflicts of interest relevant to this article were reported.</p>
      <p><bold>Author Contributions.</bold> H.H. designed study, performed experiments, interpreted data, and wrote the manuscript. J.H., D.J., Y.W., Y.L., S.W., and E.J.D. performed experiments and interpreted data. G.A.L. and R.D.S. discussed the study and reviewed and edited the manuscript. H.H. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonetti</surname><given-names>DA</given-names></name><name><surname>Klein</surname><given-names>R</given-names></name><name><surname>Gardner</surname><given-names>TW</given-names></name></person-group>. <article-title>Diabetic retinopathy</article-title>. <source>N Engl J Med</source>
<year>2012</year>;<volume>366</volume>:<fpage>1227</fpage>–<lpage>1239</lpage><?supplied-pmid 22455417?><pub-id pub-id-type="pmid">22455417</pub-id></mixed-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Gandhi</surname><given-names>JK</given-names></name><name><surname>Zhong</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>TNFalpha is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis</article-title>. <source>Invest Ophthalmol Vis Sci</source>
<year>2011</year>;<volume>52</volume>:<fpage>1336</fpage>–<lpage>1344</lpage><?supplied-pmid 21212173?><pub-id pub-id-type="pmid">21212173</pub-id></mixed-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>BB</given-names></name><name><surname>Clermont</surname><given-names>A</given-names></name><name><surname>Rook</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation</article-title>. <source>Nat Med</source>
<year>2007</year>;<volume>13</volume>:<fpage>181</fpage>–<lpage>188</lpage><?supplied-pmid 17259996?><pub-id pub-id-type="pmid">17259996</pub-id></mixed-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semba</surname><given-names>RD</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Lutty</surname><given-names>GA</given-names></name><name><surname>Van Eyk</surname><given-names>JE</given-names></name><name><surname>Hart</surname><given-names>GW</given-names></name></person-group>. <article-title>The role of O-GlcNAc signaling in the pathogenesis of diabetic retinopathy</article-title>. <source>Proteomics Clin Appl</source>
<year>2014</year>;<volume>8</volume>:<fpage>218</fpage>–<lpage>231</lpage><?supplied-pmid 24550151?><pub-id pub-id-type="pmid">24550151</pub-id></mixed-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maglione</surname><given-names>D</given-names></name><name><surname>Guerriero</surname><given-names>V</given-names></name><name><surname>Viglietto</surname><given-names>G</given-names></name><name><surname>Delli-Bovi</surname><given-names>P</given-names></name><name><surname>Persico</surname><given-names>MG</given-names></name></person-group>. <article-title>Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor</article-title>. <source>Proc Natl Acad Sci U S A</source>
<year>1991</year>;<volume>88</volume>:<fpage>9267</fpage>–<lpage>9271</lpage><?supplied-pmid 1924389?><pub-id pub-id-type="pmid">1924389</pub-id></mixed-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carmeliet</surname><given-names>P</given-names></name><name><surname>Moons</surname><given-names>L</given-names></name><name><surname>Luttun</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions</article-title>. <source>Nat Med</source>
<year>2001</year>;<volume>7</volume>:<fpage>575</fpage>–<lpage>583</lpage><?supplied-pmid 11329059?><pub-id pub-id-type="pmid">11329059</pub-id></mixed-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohno-Matsui</surname><given-names>K</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><name><surname>Uetama</surname><given-names>T</given-names></name><name><surname>Mochizuki</surname><given-names>M</given-names></name><name><surname>Morita</surname><given-names>I</given-names></name></person-group>. <article-title>Vascular endothelial growth factor upregulates pigment epithelium-derived factor expression via VEGFR-1 in human retinal pigment epithelial cells</article-title>. <source>Biochem Biophys Res Commun</source>
<year>2003</year>;<volume>303</volume>:<fpage>962</fpage>–<lpage>967</lpage><?supplied-pmid 12670505?><pub-id pub-id-type="pmid">12670505</pub-id></mixed-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR</article-title>. <source>J Biol Chem</source>
<year>1996</year>;<volume>271</volume>:<fpage>3154</fpage>–<lpage>3162</lpage><?supplied-pmid 8621715?><pub-id pub-id-type="pmid">8621715</pub-id></mixed-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Autiero</surname><given-names>M</given-names></name><name><surname>Waltenberger</surname><given-names>J</given-names></name><name><surname>Communi</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1</article-title>. <source>Nat Med</source>
<year>2003</year>;<volume>9</volume>:<fpage>936</fpage>–<lpage>943</lpage><?supplied-pmid 12796773?><pub-id pub-id-type="pmid">12796773</pub-id></mixed-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <mixed-citation publication-type="book">Dewerchin M, Carmeliet P. PlGF: a multitasking cytokine with disease-restricted activity. Cold Spring Harb Perspect Med 2012;2</mixed-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spirin</surname><given-names>KS</given-names></name><name><surname>Saghizadeh</surname><given-names>M</given-names></name><name><surname>Lewin</surname><given-names>SL</given-names></name><name><surname>Zardi</surname><given-names>L</given-names></name><name><surname>Kenney</surname><given-names>MC</given-names></name><name><surname>Ljubimov</surname><given-names>AV</given-names></name></person-group>. <article-title>Basement membrane and growth factor gene expression in normal and diabetic human retinas</article-title>. <source>Curr Eye Res</source>
<year>1999</year>;<volume>18</volume>:<fpage>490</fpage>–<lpage>499</lpage><?supplied-pmid 10435836?><pub-id pub-id-type="pmid">10435836</pub-id></mixed-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khaliq</surname><given-names>A</given-names></name><name><surname>Foreman</surname><given-names>D</given-names></name><name><surname>Ahmed</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Increased expression of placenta growth factor in proliferative diabetic retinopathy</article-title>. <source>Lab Invest</source>
<year>1998</year>;<volume>78</volume>:<fpage>109</fpage>–<lpage>116</lpage><?supplied-pmid 9461127?><pub-id pub-id-type="pmid">9461127</pub-id></mixed-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyamoto</surname><given-names>N</given-names></name><name><surname>de Kozak</surname><given-names>Y</given-names></name><name><surname>Jeanny</surname><given-names>JC</given-names></name><etal/></person-group>. <article-title>Placental growth factor-1 and epithelial haemato-retinal barrier breakdown: potential implication in the pathogenesis of diabetic retinopathy</article-title>. <source>Diabetologia</source>
<year>2007</year>;<volume>50</volume>:<fpage>461</fpage>–<lpage>470</lpage><?supplied-pmid 17187248?><pub-id pub-id-type="pmid">17187248</pub-id></mixed-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yonekura</surname><given-names>H</given-names></name><name><surname>Sakurai</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Placenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes. Implication in autocrine and paracrine regulation of angiogenesis</article-title>. <source>J Biol Chem</source>
<year>1999</year>;<volume>274</volume>:<fpage>35172</fpage>–<lpage>35178</lpage><?supplied-pmid 10575000?><pub-id pub-id-type="pmid">10575000</pub-id></mixed-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitamura</surname><given-names>Y</given-names></name><name><surname>Tashimo</surname><given-names>A</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Vitreous levels of placenta growth factor and vascular endothelial growth factor in patients with proliferative diabetic retinopathy</article-title>. <source>Diabetes Care</source>
<year>2002</year>;<volume>25</volume>:<fpage>2352</fpage><?supplied-pmid 12453985?><pub-id pub-id-type="pmid">12453985</pub-id></mixed-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonas</surname><given-names>JB</given-names></name><name><surname>Jonas</surname><given-names>RA</given-names></name><name><surname>Neumaier</surname><given-names>M</given-names></name><name><surname>Findeisen</surname><given-names>P</given-names></name></person-group>. <article-title>Cytokine concentration in aqueous humor of eyes with diabetic macular edema</article-title>. <source>Retina</source>
<year>2012</year>;<volume>32</volume>:<fpage>2150</fpage>–<lpage>2157</lpage><?supplied-pmid 22617833?><pub-id pub-id-type="pmid">22617833</pub-id></mixed-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van de Veire</surname><given-names>S</given-names></name><name><surname>Stalmans</surname><given-names>I</given-names></name><name><surname>Heindryckx</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease</article-title>. <source>Cell</source>
<year>2010</year>;<volume>141</volume>:<fpage>178</fpage>–<lpage>190</lpage><?supplied-pmid 20371353?><pub-id pub-id-type="pmid">20371353</pub-id></mixed-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>B</given-names></name><name><surname>Hurd</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Nishina</surname><given-names>P</given-names></name></person-group>. <article-title>Survey of common eye diseases in laboratory mouse strains</article-title>. <source>Invest Ophthalmol Vis Sci</source>
<year>2013</year>;<volume>54</volume>:<fpage>4974</fpage>–<lpage>4981</lpage><?supplied-pmid 23800770?><pub-id pub-id-type="pmid">23800770</pub-id></mixed-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattapallil</surname><given-names>MJ</given-names></name><name><surname>Wawrousek</surname><given-names>EF</given-names></name><name><surname>Chan</surname><given-names>CC</given-names></name><etal/></person-group>. <article-title>The Rd8 mutation of the Crb1 gene is present in vendor lines of C57BL/6N mice and embryonic stem cells, and confounds ocular induced mutant phenotypes</article-title>. <source>Invest Ophthalmol Vis Sci</source>
<year>2012</year>;<volume>53</volume>:<fpage>2921</fpage>–<lpage>2927</lpage><?supplied-pmid 22447858?><pub-id pub-id-type="pmid">22447858</pub-id></mixed-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Wahlin</surname><given-names>KJ</given-names></name><name><surname>McNally</surname><given-names>M</given-names></name><name><surname>Irving</surname><given-names>ND</given-names></name><name><surname>Adler</surname><given-names>R</given-names></name></person-group>. <article-title>Developmental regulation of muscleblind-like (MBNL) gene expression in the chicken embryo retina</article-title>. <source>Dev Dyn</source>
<year>2008</year>;<volume>237</volume>:<fpage>286</fpage>–<lpage>296</lpage><?supplied-pmid 18095352?><pub-id pub-id-type="pmid">18095352</pub-id></mixed-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Vinores</surname><given-names>SA</given-names></name></person-group>. <article-title>Blockade of VEGFR1 and 2 suppresses pathological angiogenesis and vascular leakage in the eye</article-title>. <source>PLoS ONE</source>
<year>2011</year>;<volume>6</volume>:<fpage>e21411</fpage><?supplied-pmid 21731737?><pub-id pub-id-type="pmid">21731737</pub-id></mixed-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Parlier</surname><given-names>R</given-names></name><name><surname>Shen</surname><given-names>JK</given-names></name><name><surname>Lutty</surname><given-names>GA</given-names></name><name><surname>Vinores</surname><given-names>SA</given-names></name></person-group>. <article-title>VEGF receptor blockade markedly reduces retinal microglia/macrophage infiltration into laser-induced CNV</article-title>. <source>PLoS ONE</source>
<year>2013</year>;<volume>8</volume>:<fpage>e71808</fpage><?supplied-pmid 23977149?><pub-id pub-id-type="pmid">23977149</pub-id></mixed-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waters</surname><given-names>JC</given-names></name></person-group>. <article-title>Accuracy and precision in quantitative fluorescence microscopy</article-title>. <source>J Cell Biol</source>
<year>2009</year>;<volume>185</volume>:<fpage>1135</fpage>–<lpage>1148</lpage><?supplied-pmid 19564400?><pub-id pub-id-type="pmid">19564400</pub-id></mixed-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Frank</surname><given-names>MB</given-names></name><name><surname>Dozmorov</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Identification of mouse retinal genes differentially regulated by dim and bright cyclic light rearing</article-title>. <source>Exp Eye Res</source>
<year>2005</year>;<volume>80</volume>:<fpage>727</fpage>–<lpage>739</lpage><?supplied-pmid 15862179?><pub-id pub-id-type="pmid">15862179</pub-id></mixed-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laver</surname><given-names>NM</given-names></name><name><surname>Robison</surname><given-names>WG</given-names><suffix>Jr</suffix></name><name><surname>Pfeffer</surname><given-names>BA</given-names></name></person-group>. <article-title>Novel procedures for isolating intact retinal vascular beds from diabetic humans and animal models</article-title>. <source>Invest Ophthalmol Vis Sci</source>
<year>1993</year>;<volume>34</volume>:<fpage>2097</fpage>–<lpage>2104</lpage><?supplied-pmid 8491560?><pub-id pub-id-type="pmid">8491560</pub-id></mixed-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Gong</surname><given-names>J</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Nrf2 has a protective role against neuronal and capillary degeneration in retinal ischemia-reperfusion injury</article-title>. <source>Free Radic Biol Med</source>
<year>2011</year>;<volume>51</volume>:<fpage>216</fpage>–<lpage>224</lpage><?supplied-pmid 21545836?><pub-id pub-id-type="pmid">21545836</pub-id></mixed-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimaio</surname><given-names>TA</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Scheef</surname><given-names>EA</given-names></name><name><surname>Sorenson</surname><given-names>CM</given-names></name><name><surname>Sheibani</surname><given-names>N</given-names></name></person-group>. <article-title>Attenuation of retinal vascular development and neovascularization in PECAM-1-deficient mice</article-title>. <source>Dev Biol</source>
<year>2008</year>;<volume>315</volume>:<fpage>72</fpage>–<lpage>88</lpage><?supplied-pmid 18206868?><pub-id pub-id-type="pmid">18206868</pub-id></mixed-citation>
      </ref>
      <ref id="B28">
        <label>28</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gamble</surname><given-names>JR</given-names></name><name><surname>Drew</surname><given-names>J</given-names></name><name><surname>Trezise</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions</article-title>. <source>Circ Res</source>
<year>2000</year>;<volume>87</volume>:<fpage>603</fpage>–<lpage>607</lpage><?supplied-pmid 11009566?><pub-id pub-id-type="pmid">11009566</pub-id></mixed-citation>
      </ref>
      <ref id="B29">
        <label>29</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>YP</given-names></name><name><surname>He</surname><given-names>QW</given-names></name><name><surname>Li</surname><given-names>YN</given-names></name><etal/></person-group>. <article-title>Recombinant human sonic hedgehog protein regulates the expression of ZO-1 and occludin by activating angiopoietin-1 in stroke damage</article-title>. <source>PLoS ONE</source>
<year>2013</year>;<volume>8</volume>:<fpage>e68891</fpage><?supplied-pmid 23894369?><pub-id pub-id-type="pmid">23894369</pub-id></mixed-citation>
      </ref>
      <ref id="B30">
        <label>30</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>G</given-names></name><name><surname>Mazan</surname><given-names>A</given-names></name><name><surname>Gandillet</surname><given-names>A</given-names></name><name><surname>Pearson</surname><given-names>S</given-names></name><name><surname>Lacaud</surname><given-names>G</given-names></name><name><surname>Kouskoff</surname><given-names>V</given-names></name></person-group>. <article-title>SOX7 regulates the expression of VE-cadherin in the haemogenic endothelium at the onset of haematopoietic development</article-title>. <source>Development</source>
<year>2012</year>;<volume>139</volume>:<fpage>1587</fpage>–<lpage>1598</lpage><?supplied-pmid 22492353?><pub-id pub-id-type="pmid">22492353</pub-id></mixed-citation>
      </ref>
      <ref id="B31">
        <label>31</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reiter</surname><given-names>CE</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Sandirasegarane</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Diabetes reduces basal retinal insulin receptor signaling: reversal with systemic and local insulin</article-title>. <source>Diabetes</source>
<year>2006</year>;<volume>55</volume>:<fpage>1148</fpage>–<lpage>1156</lpage><?supplied-pmid 16567541?><pub-id pub-id-type="pmid">16567541</pub-id></mixed-citation>
      </ref>
      <ref id="B32">
        <label>32</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagberg</surname><given-names>CE</given-names></name><name><surname>Falkevall</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Vascular endothelial growth factor B controls endothelial fatty acid uptake</article-title>. <source>Nature</source>
<year>2010</year>;<volume>464</volume>:<fpage>917</fpage>–<lpage>921</lpage><?supplied-pmid 20228789?><pub-id pub-id-type="pmid">20228789</pub-id></mixed-citation>
      </ref>
      <ref id="B33">
        <label>33</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagberg</surname><given-names>CE</given-names></name><name><surname>Mehlem</surname><given-names>A</given-names></name><name><surname>Falkevall</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes</article-title>. <source>Nature</source>
<year>2012</year>;<volume>490</volume>:<fpage>426</fpage>–<lpage>430</lpage><?supplied-pmid 23023133?><pub-id pub-id-type="pmid">23023133</pub-id></mixed-citation>
      </ref>
      <ref id="B34">
        <label>34</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvarez</surname><given-names>JI</given-names></name><name><surname>Dodelet-Devillers</surname><given-names>A</given-names></name><name><surname>Kebir</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence</article-title>. <source>Science</source>
<year>2011</year>;<volume>334</volume>:<fpage>1727</fpage>–<lpage>1731</lpage><?supplied-pmid 22144466?><pub-id pub-id-type="pmid">22144466</pub-id></mixed-citation>
      </ref>
      <ref id="B35">
        <label>35</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nambu</surname><given-names>H</given-names></name><name><surname>Nambu</surname><given-names>R</given-names></name><name><surname>Oshima</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood-retinal barrier</article-title>. <source>Gene Ther</source>
<year>2004</year>;<volume>11</volume>:<fpage>865</fpage>–<lpage>873</lpage><?supplied-pmid 15042118?><pub-id pub-id-type="pmid">15042118</pub-id></mixed-citation>
      </ref>
      <ref id="B36">
        <label>36</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lutty</surname><given-names>GA</given-names></name></person-group>. <article-title>Effects of diabetes on the eye</article-title>. <source>Invest Ophthalmol Vis Sci</source>
<year>2013</year>;<volume>54</volume>:<fpage>ORSF81-7</fpage><?supplied-pmid 24335073?><pub-id pub-id-type="pmid">24335073</pub-id></mixed-citation>
      </ref>
      <ref id="B37">
        <label>37</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adamis</surname><given-names>AP</given-names></name><name><surname>Berman</surname><given-names>AJ</given-names></name></person-group>. <article-title>Immunological mechanisms in the pathogenesis of diabetic retinopathy</article-title>. <source>Semin Immunopathol</source>
<year>2008</year>;<volume>30</volume>:<fpage>65</fpage>–<lpage>84</lpage><?supplied-pmid 18340447?><pub-id pub-id-type="pmid">18340447</pub-id></mixed-citation>
      </ref>
      <ref id="B38">
        <label>38</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saint-Geniez</surname><given-names>M</given-names></name><name><surname>Maharaj</surname><given-names>AS</given-names></name><name><surname>Walshe</surname><given-names>TE</given-names></name><etal/></person-group>. <article-title>Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors</article-title>. <source>PLoS ONE</source>
<year>2008</year>;<volume>3</volume>:<fpage>e3554</fpage><?supplied-pmid 18978936?><pub-id pub-id-type="pmid">18978936</pub-id></mixed-citation>
      </ref>
      <ref id="B39">
        <label>39</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurihara</surname><given-names>T</given-names></name><name><surname>Westenskow</surname><given-names>PD</given-names></name><name><surname>Bravo</surname><given-names>S</given-names></name><name><surname>Aguilar</surname><given-names>E</given-names></name><name><surname>Friedlander</surname><given-names>M</given-names></name></person-group>. <article-title>Targeted deletion of Vegfa in adult mice induces vision loss</article-title>. <source>J Clin Invest</source>
<year>2012</year>;<volume>122</volume>:<fpage>4213</fpage>–<lpage>4217</lpage><?supplied-pmid 23093773?><pub-id pub-id-type="pmid">23093773</pub-id></mixed-citation>
      </ref>
      <ref id="B40">
        <label>40</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>YZ</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name></person-group>. <article-title>Temporal requirement of RPE-derived VEGF in the development of choroidal vasculature</article-title>. <source>J Neurochem</source>
<year>2010</year>;<volume>112</volume>:<fpage>1584</fpage>–<lpage>1592</lpage><?supplied-pmid 20067573?><pub-id pub-id-type="pmid">20067573</pub-id></mixed-citation>
      </ref>
      <ref id="B41">
        <label>41</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Van de Veire</surname><given-names>S</given-names></name><name><surname>Dalal</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Reduced retinal neovascularization, vascular permeability, and apoptosis in ischemic retinopathy in the absence of prolyl hydroxylase-1 due to the prevention of hyperoxia-induced vascular obliteration</article-title>. <source>Invest Ophthalmol Vis Sci</source>
<year>2011</year>;<volume>52</volume>:<fpage>7565</fpage>–<lpage>7573</lpage><?supplied-pmid 21873682?><pub-id pub-id-type="pmid">21873682</pub-id></mixed-citation>
      </ref>
      <ref id="B42">
        <label>42</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luttun</surname><given-names>A</given-names></name><name><surname>Brusselmans</surname><given-names>K</given-names></name><name><surname>Fukao</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Loss of placental growth factor protects mice against vascular permeability in pathological conditions</article-title>. <source>Biochem Biophys Res Commun</source>
<year>2002</year>;<volume>295</volume>:<fpage>428</fpage>–<lpage>434</lpage><?supplied-pmid 12150967?><pub-id pub-id-type="pmid">12150967</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record><resumptionToken>oai%3Apubmedcentral.nih.gov%3A4274803!2016-01-01!2016-01-02!pmc!</resumptionToken></ListRecords></OAI-PMH>